"Id","Title","Acronym title","Source id","Source id optional","Interventions","Study type","Study results","Phase","Url","Status","Start date","Completion date","Additional data"
"1","Duvelisib to Combat COVID-19","","NCT04372602","202007009","Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04372602","Recruiting","2020-10-12","2022-04-30","{""locations"":""Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""28"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0""}"
"2","Observational Cohort of COVID-19 Patients at Raymond-Poincare","COVID-RPC","NCT04364698","20SBS-COVID-RPC","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04364698","Recruiting","2020-05-07","2020-06-01","{""locations"":""Department of Infectiology, Raymond Poincar\u00e9 Hospital, APHP, Garches, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""clinical, biological and radiological characteristics|patients' journey description|Treatments effects""}"
"3","COVID-19 Surveillance Based on Smart Wearable Device","COVID-19SWD","NCT04459637","2020055-0615","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459637","Not yet recruiting","2020-07-01","2021-03-10","{""locations"":""Peking University First Hospital, Beijing, Beijing, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Deterioration of the condition|Mortality|The information analysis degree, the proportion of signal loss, the proportion of wrong signal,""}"
"4","Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial","DART","NCT04482621","IRB00247544","Drug: Decitabine|Other: Placebo Saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04482621","Recruiting","2020-09-14","2021-07-01","{""locations"":""Johns Hopkins University, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in clinical state as assessed by a 6-point ordinal scale|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Time (days) to clinical improvement|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction (PCR) negativity|Percentage of patients with National Early Warning Score 2 of 3 or more""}"
"5","A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).","","NCT04425538","STUDY00000564","Drug: Infliximab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04425538","Completed","2020-06-01","2021-01-22","{""locations"":""Tufts Medical Center, Boston, Massachusetts, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""17"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to improvement in oxygenation|28-day mortality|Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy|Qualitative and quantitative toxicity|incidence and duration of supplemental oxygen administration|Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula|Incidence and duration of mechanical ventilation|Incidence and duration of vasopressor support|Incidence and duration of extracorporeal membrane oxygenation|Duration of fever|Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives|Duration of hospitalization|Secondary infections""}"
"6","Safety & Performance Evaluation of Seraph 100 in Treatment of Pts With COVID-19","CP022","NCT04547257","CP022","Device: Seraph 100","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04547257","Not yet recruiting","2021-02-01","2021-10-15","{""locations"":""Carla Kikken-Jussen, Vaals, Limburg, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Organ failure|Change in Organ Failure|All-cause mortality|Change in Viral load|Organ dysfunction-free days|ICU complications|Ventilator-free days (VFDs|Length of stay (LOS) at ICU|Prognosis Factors""}"
"7","Application of Desferal to Treat COVID-19","","NCT04333550","1398.1224","Drug: Deferoxamine","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04333550","Recruiting","2020-04-01","2021-03-01","{""locations"":""Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""3 Years to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay""}"
"8","Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients","","NCT04454307","TRAM/COVID19","Drug: Tramadol|Other: Standard care delivered in the isolation hospitals.","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04454307","Not yet recruiting","2020-07-01","2020-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of COVID-19 PCR negative cases""}"
"9","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","","NCT04343183","STUDY00001051","Device: Hyperbaric Oxygen Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04343183","Not yet recruiting","2020-04-01","2020-06-01","{""locations"":""Ochsner Medical Center, New Orleans, Louisiana, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decrease incidence of intubation by 30% or greater|Decrease renal injury""}"
"10","Safety and Efficacy of C21 in Subjects With COVID-19","","NCT04452435","VP-C21-006|2020-001502-38","Drug: C21|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04452435","Completed","2020-07-21","2020-10-13","{""locations"":""Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India|Infectious Disease, Metas Adventist Hospital, Surat, Gujarat, India|Clinical Research Department, Basement, Unity Trauma Centre and ICU (Unity Hospital, Surat, Gujarat, India|First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India|Internal Medicine S.L. Raheja Hospital, Mumbai, Maharashtra, India|Department of Medicine, Government Medical College and Hospital, Nagpur, Maharashtra, India|Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|Department of Medicine, Noble Hospitals Pvt. Ltd, Pune, Maharashtra, India|Respiratory Medicine, University College Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""106"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline in C-reactive protein (CRP) after treatment with C21 200 mg daily dose (100 mg b.i.d.)|Change from baseline in Body temperature|Change from baseline in IL-6|Change from baseline in IL-10|Change from baseline in TNF|Change from baseline in CA125|Change from baseline in Ferritin|Number of subjects not in need of oxygen supply|Number of subjects not in need of mechanical invasive or non-invasive ventilation|Time to need of mechanical invasive or non-invasive ventilation|Time on oxygen supply (for those not needing mechanical invasive or non-invasive ventilation)|Adverse events""}"
"11","Dornase Alpha for the Treatment of COVID-19","","NCT04432987","8820","Drug: Pulmozyme","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04432987","Recruiting","2020-05-25","2020-09-25","{""locations"":""Ac\u0131badem Altunizade Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Response|Survival""}"
"12","Study of AZD1222 for the Prevention of COVID-19 in Japan","","NCT04568031","D8111C00002","Drug: AZD1222|Drug: 0.9% (w/v) saline","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04568031","Active, not recruiting","2020-08-23","2021-11-10","{""locations"":""Research Site, Fukuoka-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Toshima-ku, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""256"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who have a post treatment seroresponse to the spike antigens of AZD1222|The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination|The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)|Biochemistry; change from baseline for blood chemistry measures|Haematology; change from baseline for hematology\/hemostasis measures|Proportion of participants who have a post treatment|Genometric mean titres and genometric mean fold rise|Proportion of participants who have a post treatment seroresponse to AZD1222 as measured by SARS-CoV-2 nAbs|The incidence of serious adverse events (SAEs) and adverse events of specisl interest (AESIs) collected from Day1 through Day365""}"
"13","A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia","","NCT04628143","A108_01CVD2013","Drug: Nafamostat Mesilate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04628143","Not yet recruiting","2020-11-20","2021-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Time to recovery|Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status|Proportion of patients with recovery as defined as the subject satisfies one of the following|Change of clinical status assessed by 7-category ordinal scale|Change in National Early Warning Score (NEWS)|Time to National Early Warning Score (NEWS) of \u2264 2 which is maintained|Duration of hospitalization|Duration of non-invasive ventilation or high flow oxygen use|Incidence of non-invasive ventilation or high flow oxygen use|Duration of supplement oxygen use|Incidence of supplement oxygen use|Duration of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|28-Day mortality""}"
"14","AZD1222 Vaccine for the Prevention of COVID-19","","NCT04540393","D8111C00001","Biological: AZD1222","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04540393","Suspended","2020-09-02","2021-05-11","{""locations"":""Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years to 130 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of SAEs following the first vaccination and throughout the study duration (Day 180) [Safety and Tolerability].|Incidence of Solicited AEs for 7 following each vaccination [Safety and Tolerability].|SARS-CoV-2 antigen-specific antibody levels|The rate of participants seroconverting from negative to positive SARS-CoV-2 S antigen|The rate of participants seroconverting from negative to positive SARS-CoV-2 N|Quantity of SARS-CoV-2 neutralizing antibodies|Count of peripheral blood mononuclear cells (PBMCs)|Quantity of seasonal coronavirus antigens|Quantity of antibodies to the ChAdOx1vector and the persistence of these antibodies over time""}"
"15","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19","","NCT04336904","HS216C17-PHASE III","Drug: Favipiravir|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04336904","Active, not recruiting","2020-03-25","2020-07-01","{""locations"":""Asst Fatebenefratelli Sacco, Milano, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration\/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality""}"
"16","Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia","","NCT04359095","76968","Drug: Emtricitabine/tenofovir|Drug: Colchicine Pill|Drug: Rosuvastatin|Other: Standard treatment","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04359095","Recruiting","2020-08-18","2021-05-31","{""locations"":""Clinica santa Maria del lago, Bogota, DC, Colombia|Hospital Universitario de Neiva, Neiva, Huila, Colombia|Cl\u00ednica Reina Sof\u00eda, Bogot\u00e1, Colombia|Fundacion Cardio Infantil, Bogot\u00e1, Colombia|Hospital Universitario San Ignacio, Bogot\u00e1, Colombia|Clinica Universitaria Colombia, Bogot\u00e1, Colombia|Hospital Universitario Nacional de Colombia, Bogot\u00e1, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection""}"
"17","CORonavirus (COVID-19) Diagnostic Lung UltraSound Study","COR-DLUS","NCT04351802","282661","Diagnostic Test: Lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351802","Recruiting","2020-05-11","2021-01-20","{""locations"":""Derriford Hospital, Plymouth, Devon, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diagnosis of COVID-19 on lung ultrasound|Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray|Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray|Ability of surveillance lung ultrasound to predict clinical trajectory \/ outcome in patients with COVID-19|Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19""}"
"18","Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia","","NCT04445272","BREATH-19 (FSG011-20)","Drug: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04445272","Completed","2020-05-22","2020-12-23","{""locations"":""Hospital Universitario de Cabue\u00f1es, Gij\u00f3n, Asturias, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Sant Joan de D\u00e9u de Manresa, Manresa, Barcelona, Spain|Hospital de Matar\u00f3, Matar\u00f3, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Hospital Universitario Marqu\u00e9s Valdecilla, Santander, Cantabria, Spain|Hospital P\u00fablico General del Tomelloso, Tomelloso, Ciudad Real, Spain|Hospital Jerez de la Frontera, Jerez De La Frontera, C\u00e1diz, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Alcorc\u00f3n, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Rey Juan Carlos, M\u00f3stoles, Madrid, Spain|Hospital Universitario Rey Juan Carlos, M\u00f3stoles, Madrid, Spain|Hospital Universitario Infanta Sof\u00eda, San Sebasti\u00e1n De Los Reyes, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Nuestra Se\u00f1ora del Prado, Talavera De La Reina, Toledo, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Cl\u00ednic i Provincial Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Dr. Josep Trueta, Gerona, Spain|Hospital Universitario Cl\u00ednico San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain|Complexo Hospitalario Universitario de Ourense, Orense, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Poliectenic La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""495"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To calulate the time of intubation|To calculate the time with oxygen therapy|To calculate the time with Non-invasive mechanical ventilation|To evaluate mortality rate|To calculate respiratory function parameters|To evaluate radiological lung extension|To evaluate radiological evolution|To describe the duration of hospitalization and ICU use|To evaluate the requirement of additional organ support|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory markers|To calculate the number of adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To assess time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory|To calculate the number of serious adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To calculate the number of adverse events of special interest in patients with COVID-19 pneumonia treated with Tocilizumab|To evaluate respiratory function""}"
"19","PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US","","NCT04582266","IMPAACT 2032|DAIDS Study ID 38746","Drug: Remdesivir","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04582266","Not yet recruiting","2020-10-15","2022-01-15","{""locations"":""USC\/Los Angeles County Medical Center NICHD CRS (5048), Los Angeles, California, United States|David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California, United States|University California, San Diego (CRS 4601), San Diego, California, United States|Childrens Hospital (U. Colorado, Denver) NICHD CRS (5052), Denver, Colorado, United States|University of Florida (5051), Jacksonville, Florida, United States|Univ of Miami Pediatric\/Perinatal HIV\/AIDS (4201), Miami, Florida, United States|Emory University School of Medicine (CRS 5030), Atlanta, Georgia, United States|Ann & Robert H Lurie Children's Hospital of Chicago (4001), Chicago, Illinois, United States|Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States|Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States|Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States|Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS (5013), Bronx, New York, United States|Stony Brook University Medical Center (CRS 5040), Stony Brook, New York, United States|St. Jude Childrens Research Hosp, Memphis (6501), Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|University of Puerto Rico Pediatric HIV\/AIDS CRS (6601), San Juan, Puerto Rico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""PK Outcome: Area under the plasma concentration-time curve (AUC) of RDV|PK Outcome: Half-life (t1\/2) of RDV|PK Outcome: Trough concentration (Ctrough) of GS-441524|Safety Outcome: Maternal renal adverse event (AE) of any grade|Safety Outcome: Maternal hepatic AE of any grade|Safety Outcome: Maternal hematologic AE of any grade|Safety Outcome: Maternal Grade 3 or higher AE|Safety Outcome: Serious AE|Safety Outcome: Maternal Grade 3 or higher AE assessed as related to RDV by the Clinical Management Committee (CMC)|Safety Outcome: Pregnancy loss|Safety Outcome: Congenital anomalies|Safety Outcome: Preterm birth, defined as < 37 weeks|Safety Outcome: Preterm birth, defined as < 34 weeks|Safety Outcome: Small for gestational age, defined as < 10th percentile|Safety Outcome: Newborn birth weight|Safety Outcome: Newborn length|Safety Outcome: Newborn head circumference|PK Outcome: AUC of RDV|PK Outcome: t1\/2 of RDV|PK Outcome: Ctrough of GS-441524|Safety Outcome: Renal AE of any grade|Safety Outcome: Hepatic AE of any grade|Safety Outcome: Hematologic AE of any grade|Safety Outcome: Grade 3 or higher AE|Safety Outcome: Grade 3 or higher AE assessed as related to RDV by the CMC""}"
"20","A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection","","NCT04354831","PRO00037712","Biological: anti-SARS-CoV-2 convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04354831","Active, not recruiting","2020-05-11","2023-05-01","{""locations"":""Froedtert Hospital, Milwaukee, Wisconsin, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""131"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall Mortality within 60 days|Length of ICU stay during current admission for COVID""}"
"21","Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults","TACKLE","NCT04723394","D8851C00001","Drug: AZD7442|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04723394","Recruiting","2021-01-28","2022-05-27","{""locations"":""Research Site, Tempe, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Huntington Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Pomona, California, United States|Research Site, Rolling Hills Estates, California, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Conyers, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, La Vista, Nebraska, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Statesville, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Berlin - Friedrichshain, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, K\u00f6ln, Germany|Research Site, Mainz, Germany|Research Site, M\u00fcnchen-Pasing, Germany|Research Site, M\u00fcnchen, Germany|Research Site, Budapest, Hungary|Research Site, Chihuahua, Mexico|Research Site, Cuautitlan Izcalli, Mexico|Research Site, M\u00e9rida, Mexico|Research Site, Tlalpan, Mexico|Research Site, Blackpool, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Connor Downs, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Rochdale, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A composite of either severe COVID-19 or death from any cause through Day 29.|A composite of either death from any cause or hospitalization for COVID-19 complications or sequelae during the 168-day post-dose period (Day 1 to Day 169).|The incidence of participants with respiratory failure, defined as requirement for mechanical ventilation, ECMO, non-invasive ventilation, or high-flow nasal cannula oxygen delivery.|COVID-19 symptom severity assessments based on symptom severity scores over time during the 28-day period from and including the day of the dose of AZD7442 or placebo.|Progression through Day 29 of one or more COVID-19-associated symptoms to a worse status than recorded in the participant-reported symptom diary at study entry, prior to start of AZD7442 or placebo.|Detection (detectable versus undetectable) from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.|Level of SARS-CoV-2 RNA from nasal swabs through Day 29.|Change from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.|Time to return to usual (pre-COVID-19) health through Day 29.|Duration of fever through Day 29.|Incidence of ADA to AZD7442 in serum over time.|Pharmacokinetics - Serum Concentration|Pharmacokinetics - Maximum Serum Concentration|Pharmacokinetics - Time to Maximum Serum Concentration|Pharmacokinetics - Area under the plasma concentration-time curve to the last measurable time point|Pharmacokinetics - Area under the plasma concentration-time curve extrapolated to infinity""}"
"22","Long-term Outcomes in Patients With COVID-19","","NCT04508712","COVID-19 Prognosis","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04508712","Recruiting","2020-08-10","2021-08-31","{""locations"":""Renji Hospital, Shanghai Jiaotong University School of Medicine, Pudong, Shanghai, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical functions|Respiratory function|Cognitive function|Depression status|Sensory functions|Heart function""}"
"23","Isotretinoin in Treatment of COVID-19","Randomized","NCT04361422","9469305c","Drug: Isotretinoin Only Product in Oral Dose Form","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04361422","Not yet recruiting","2020-12-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Clinical clearance""}"
"24","Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","","NCT04345445","TVCS-COVID19","Drug: Tocilizumab|Drug: Methylprednisolone","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04345445","Not yet recruiting","2020-04-15","2020-10-31","{""locations"":""University Malaya Medical Centre, Kuala Lumpur, Malaysia"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""310"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay""}"
"25","COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics)","","NCT04466644","IGX2-COV-JC-20-04|20201490","Diagnostic Test: ELISA|Diagnostic Test: RT-PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04466644","Completed","2020-06-08","2020-08-25","{""locations"":""Boston IVF Fertility Clinic, Boston, Massachusetts, United States|Utah Fertility Clinic, Pleasant Grove, Utah, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""340"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of contagiousness in asymptomatic individuals by PCR with nasopharyngeal swabs|Ratio of asymptomatic immunized (IgG) population|To validate saliva specimens as a biological sample for COVID-19 testing""}"
"26","Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic","","NCT04460547","COAHS","Drug: Convalescent Plasma Transfusion|Drug: Hydroxychloroquine|Drug: DAS181|Drug: Ivermectin|Drug: Interferon Beta-1A","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04460547","Not yet recruiting","2020-07-25","2020-09-20","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Geographical distribution of the interventional studies after 11th of March 2020.|Geographical distribution of the Observational studies after 11th of March 2020.|Monthly Research study completion rate as per geographic distribution of the Research.|Statistical correlation of the interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the observational studies Research with developed, developing and under developed countries.|Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.""}"
"27","COVID-19 Symptom Tracker","","NCT04331509","COVID-19 Symptom tracker","Other: No Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04331509","Recruiting","2020-03-23","2022-03-23","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical health symptoms|Lack of physical health symptoms|Fever""}"
"28","Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease","","NCT04355741","COVID19_Microbiota","Other: Exposure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355741","Completed","2020-04-20","2020-07-16","{""locations"":""Hospital CUF Infante Santo, S.A., Lisbon, Portugal|Hospital de S\u00e3o Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Oporto, Portugal"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""115"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.|Differences in gut microbiota composition between COVID-19 patients in relation to mortality.|Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.|Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.""}"
"29","Inhaled Nitric Oxide for Preventing Progression in COVID-19","NO-COVID-19","NCT04388683","STUDY00000554","Drug: Nitric Oxide","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04388683","Active, not recruiting","2020-05-12","2021-07-31","{""locations"":""Tufts Medical Center, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|Prevention of progression assessed by an alternate severity scale|Time to reaching maximal severity score|Proportion of patients in each stage at maximum severity|PaO2\/FIO2 or SaO2\/FIO2 ratio, measured daily|Length of hospital Stay (death assigned as worst case)|Frequency of Intubation, ECMO, or need to intubate with \""Do Not Resuscitate\"" order|Mortality|IL6 level|TNF-alpha level|Fibrinogen level|CRP level|Ferritin Level|D-dimer level""}"
"30","COVID-19 Endoscopy Survey","COVID-19 Endo","NCT04342637","WES-2","Other: Practice details","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04342637","Completed","2020-04-10","2020-05-01","{""locations"":""Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""163"",""age"":""30 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number""}"
"31","Impact of COVID-19 Outbreak on Non-COVID-19 Patients","NoCOVImpact","NCT04537559","2020-01017","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04537559","Enrolling by invitation","2020-03-01","2020-10-31","{""locations"":""Geneva University Hospital, Geneva, Canton De Gen\u00e8ve, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""40000"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Intra-hospital mortality|composite outcome (worsening during hospitalization)|Pathologies leading to hospitalization|overall mortality at 3 months (90 days)|Potentially avoidable readmission rate|mortality rate by pathology at 3 months|length of stay|rate of transfer to intermediate or intensive care|rate of transfer to rehabilitation care|specific gravity outcomes for patients with pneumonia : CURB 65 scale (Confusion, Urea, Respiratory rate, Blood pressure, Age [>65])|specific gravity outcomes for patients with cardiac Failure : KILLIP class|specific gravity outcomes for patients with cardiac Failure : Weight variation|specific gravity outcomes for patients with cardiac Failure or lung disease|Leukocytes serum level|Polynuclear neutrophils serum level|Lymphocytes serum level|Hemoglobin serum level|Thrombocytes serum level|Quick serum level|INR (International Normalized Ratio)|fibrinogen serum level|PTT serum level (partial Thromboplastin time)|D-Dimers serum level|glucose serum level|glycated hemoglobin serum level (HbA1C)|C-reactive protein serum level (CRP)|sodium serum level|potassium serum level|chlorides serum level|calculated osmolality serum level|Phosphates serum level|corrected calcium serum level|urea serum level|creatinine serum level|eGFR (CKD-EPI) serum level|albumin serum level|prealbumin serum level|cyanocobalamin serum level|folate serum level|25-hydroxy vitamin D (D2 + D3) serum level|proBNP (Brain Natriuretic Peptid) serum level|Ultra sensitive Troponin T serum level|ASAT (aspartate transaminase) serum level|ALAT (alanine aminotransferase) serum level|Alkaline phosphatases serum level|Gamma glutamyl transpeptidase. serum level|Total bilirubin serum level|ferritin serum level|TSH serum level|Arterial pH|Arterial pCO2 (carbon dioxide partial pressure)|Arterial pO2 (oxygen partial pressure)|Arterial lactate|Arterial HCO3 (bicarbonate)|protein serum level|Arterial pressure|cardiac rates|respiratory rates|temperature|oxygen saturation|peak flow|specific scales : VAS of pain|specific scales : FIM|specific scales : SOFA score|specific scales : MNA|specific scales : NRS|serum or urine positive bacteriologic sample|Patient questionnaire""}"
"32","Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","STORM CHASER","NCT04625972","D8850C00003","Drug: AZD7442|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04625972","Recruiting","2020-12-02","2022-01-21","{""locations"":""Research Site, Birmingham, Alabama, United States|Research Site, Guntersville, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Corona, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Huntington Park, California, United States|Research Site, Modesto, California, United States|Research Site, Coral Springs, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Mount Dora, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Winter Haven, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Buford, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Greenwood, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Kansas City, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Dakota Dunes, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Gonzales, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Waxahachie, Texas, United States|Research Site, Riverton, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Portsmouth, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Wakefield, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1125"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness|AEs, SAEs, MAAEs, and AESIs through 365 days post dose of IMP|The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP|The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARSCoV- 2 nucleocapsid antibodies|The incidence of COVID-19-related death occurring after dosing with IMP|The incidence of all-cause mortality occurring after dosing with IMP|Serum AZD7442 concentrations, PK parameters if data permit.|Incidence of ADA to AZD7442 in serum""}"
"33","Serological Surveillance for COVID-19 in Central North Carolina","","NCT04490174","200143|20-E-0143","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04490174","Recruiting","2020-01-08","2022-06-01","{""locations"":""NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anti-SARS-COV-2 antibodies|Positive SARS-CoV-2 PCR|Clinical questionnaires and ELISA antibody testing results|Detection of Anti-SARS-CoV-2 antibodies by ELISA Assay Algorithm""}"
"34","Developement and Evaluation of Serological Assays for COVID-19","SEROCOV","NCT04377763","20MWI-SEROCOV","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377763","Recruiting","2020-07-15","2021-03-01","{""locations"":""Laboratory of microbiology of hospital hygiene, Ambroise Par\u00e9 Hospital, APHP, Boulogne-Billancourt, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensibility and specificity|Delay between the first symptoms and the positive serological result""}"
"35","Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19","","NCT04578158","LUMHS/REC/894","Drug: Standard COVID-19 care|Dietary Supplement: Quercetin Phytosome","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04578158","Recruiting","2020-09-29","2021-06-28","{""locations"":""Liaquat University Hospital, J\u0101mshoro, Sindh, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of subjects with COVID-19 disease progression""}"
"36","A Trial of NT-I7 in COVID-19 (SPESELPIS)","","NCT04501796","NIT-116 (SPESELPIS)","Drug: Double-Blind NT-I7|Drug: Double-Blind Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04501796","Recruiting","2020-08-01","2021-12-01","{""locations"":""Nih\/Niaid, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion|Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients.""}"
"37","Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19","","NCT04421534","CUKA-001","Drug: Lactoferrin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04421534","Not yet recruiting","2020-06-01","2020-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Rate of virological cure""}"
"38","Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19","","NCT04428801","CTX0020-003","Biological: autologous adipose-derived stem cells","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04428801","Not yet recruiting","2021-01-10","2024-01-10","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs\/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs\/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM\/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg\/L) from the baseline|Change of D-dimer (mg\/L) from the baseline|Change of Procalcitonin (ug)\/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg\/mL) from the baseline|Change of Bilirubin (mg\/dL) from the baseline|Change of Creatinine (mg\/dL) from the baseline|Change in blood test values for cytokine panels (IL-1\u03b2, IL-6, IL-8, IL-10, TNF\u03b1) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.""}"
"39","COVID-19 Convalescent Plasma (CCP) Transfusion","","NCT04412486","2020-0137","Biological: COVID Convalescent Plasma","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04412486","Recruiting","2020-06-01","2022-05-31","{""locations"":""University of Mississippi Medical Center, Jackson, Mississippi, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in PaO2\/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU\/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.""}"
"40","Hyperimmune Plasma for Critical Patients With COVID-19","COV19-PLASMA","NCT04321421","IRCCSSanMatteoH","Other: hyperimmune plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04321421","Completed","2020-03-17","2020-05-07","{""locations"":""Catherine Klersy, Pavia, PV, Italy|Ospedale Asst Carlo Poma Mantova, Mantova, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""49"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response""}"
"41","Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects","","NCT04431908","2000028259","Device: olfactory device","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04431908","Recruiting","2020-06-15","2020-10-01","{""locations"":""Yale New Haven Hospital, New Haven, Connecticut, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""sensitivity, specificity and accuracy|repeatability|validation|asymptomatic sensitivity, specificity and accuracy""}"
"42","Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","PROVENT","NCT04625725","D8850C00002","Drug: AZD7442|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04625725","Recruiting","2020-11-21","2022-03-16","{""locations"":""Research Site, Birmingham, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Cerritos, California, United States|Research Site, Chula Vista, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Fresno, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Lancaster, California, United States|Research Site, Modesto, California, United States|Research Site, Victorville, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Middlebury, Connecticut, United States|Research Site, Norwich, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Wesley Chapel, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Noblesville, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Jamaica, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Summerville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lewisville, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Alken, Belgium|Research Site, Bruxelles, Belgium|Research Site, Goz\u00e9e, Belgium|Research Site, Namur, Belgium|Research Site, Wetteren, Belgium|Research Site, Clermont-Ferrand cedex, France|Research Site, Dijon cedex, France|Research Site, La Roche S\/ Yon Cedex 9, France|Research Site, Lille, France|Research Site, Limoges cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Nimes, France|Research Site, Paris cedex 10, France|Research Site, Paris cedex 14, France|Research Site, Saint Etienne Cedex 2, France|Research Site, Tours cedex 9, France|Research Site, Alcobendas, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Marbella (M\u00e1laga), Spain|Research Site, Pozuelo de Alarc\u00f3n, Spain|Research Site, Enfield, United Kingdom|Research Site, Hayle, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Preston, United Kingdom|Research Site, Rochdale, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Torpoint, United Kingdom|Research Site, Wakefield, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness|AEs, SAEs, MAAEs, and AESIs through 365 days post dose of IMP|The incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring after dosing with IMP through Day 366|The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARS-CoV-2 nucleocapsid antibodies|The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP|The incidence of COVID-19-related Emergency Department visits occurring after dosing with IMP|Serum AZD7442 concentrations, PK parameters if data permit.|Incidence of ADA to AZD7442 in serum.""}"
"43","Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)","","NCT04470622","HTX-019-202","Drug: Aprepitant injectable emulsion|Drug: Saline Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04470622","Recruiting","2020-07-20","2021-07-01","{""locations"":""Helen Keller Hospital, Sheffield, Alabama, United States|University of California, Irvine Medical Center, Orange, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Memorial Hermann - Memorial City Medical Center, Houston, Texas, United States|Ponce Medical School Foundation, Ponce, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects alive and discharged from the hospital.|Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).|Time to discharge from hospital.|Change from Baseline in Interleukin 6 (IL-6).|Incidence of treatment-emergent adverse events.""}"
"44","The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","","NCT04347915","BK-CLV-201","Drug: Clevudine|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04347915","Recruiting","2020-05-06","2021-03-31","{""locations"":""Korea University Guro Hospital, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)|The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load""}"
"45","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","C-19-ACS","NCT04333407","20HH5868","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04333407","Recruiting","2020-04-03","2021-03-30","{""locations"":""Charing Cross Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""3170"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate""}"
"46","VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation","VPCOVID","NCT04452669","APC-VPCOV-CLN-001","Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04452669","Recruiting","2020-09-15","2021-09-01","{""locations"":""Ohio State University, Columbus, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in Respiratory Failure|Reduction in Cardiac\/Circulatory Failure|Improvement in Oxygenation|Improved Clinical Outcomes""}"
"47","Study of COVID-19 DNA Vaccine (AG0302-COVID19)","","NCT04527081","AG0302-COVID19-JN-01","Biological: AG0302-COVID19","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04527081","Active, not recruiting","2020-08-31","2021-09-30","{""locations"":""Osaka University Hospital, Osaka, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""30"",""age"":""20 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Immunogenicity|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein receptor binding domain-specific antibody|Change in GMT of anti-SARS-CoV-2 B cell epitope antibody|Change in IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Change in the neutralizing activity against pseudovirus of SARS-CoV-2|Change in binding inhibition of SARS-CoV-2 spike (S) glycoprotein and ACE2|Change in IFN-\u03b3 production against SARS-CoV-2 spike (S) glycoprotein by T cells in peripheral blood mononuclear cells|Adverse events""}"
"48","Study of COVID-19 DNA Vaccine (AG0301-COVID19)","","NCT04463472","AG0301-COVID19-JN-01","Biological: AG0301-COVID19","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04463472","Active, not recruiting","2020-06-29","2021-07-31","{""locations"":""Osaka City University Hospital, Osaka, Japan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""30"",""age"":""20 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Immunogenicity|Change in GMT of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein receptor binding domain-specific antibody|Change in GMT of anti-SARS-CoV-2 B cell epitope antibody|Change in IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Adverse events""}"
"49","Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","IMPACT","NCT04406389","20-04021936","Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04406389","Recruiting","2020-10-13","2021-12-01","{""locations"":""Weill Cornell Medicine, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""186"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30-day mortality|Length of Intensive Care Unit (ICU) Stay in Days|Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|Number of major and clinically relevant non-major bleeding events""}"
"50","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19","","NCT04291053","TJ-IRB20200205","Drug: Huaier Granule","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04291053","Not yet recruiting","2020-04-01","2020-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""550"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2\/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function""}"
"51","A Prospective ""Universal"" Observational Database for COVID-19","","NCT04347993","Pro2020-0342","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347993","Recruiting","2020-03-27","2021-04-01","{""locations"":""Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Need for hospitalization|Duration of hospitalization|Need for ICU\/Ventilator Support|Duration of ICU\/Ventilator Support|Overall Survival""}"
"52","Pegylated Interferon Lambda for Treatment of COVID-19 Infection","","NCT04534673","0129-20-SOR|SCRC200006","Drug: Lambda 180 mcg S.C","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04534673","Recruiting","2020-08-05","2021-12-31","{""locations"":""Soroka UMC, Be'er Sheva, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral shedding in days since initial diagnosis|Rate of adverse events and severe adverse events|Time to clinical recovery|Rate of non-invasive or mechanical ventilation|Length of hospital stay|All-cause mortality|Undetectable COVID-19 virus levels""}"
"53","Expanded Access to Convalescent Plasma for Treatment of COVID-19","","NCT04472572","Pro2020-0663","Biological: Convalescent Plasma","Expanded Access:Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04472572","Available","1970-01-01","1970-01-01","{""locations"":""Hackensack University Medical Center, Hackensack, New Jersey, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"54","Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","","NCT04590586","COV-01|2020-002594-10","Drug: Standard of care|Drug: Apremilast|Drug: Apremilast placebo|Drug: Lanadelumab|Drug: Lanadelumab placebo|Drug: Zilucoplan|Drug: Zilucoplan placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04590586","Recruiting","2020-11-24","2022-01-28","{""locations"":""Research Site, Anniston, Alabama, United States|Research Site, Bakersfield, California, United States|Research Site, Chula Vista, California, United States|Research Site, El Centro, California, United States|Rsearch Site, Riverside, California, United States|Research Site, S. El Monte, California, United States|Research Site, Gainesville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Ramos Mejia, Buenos Aires, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Botucatu, Sao Paulo, Brazil|Research Site, Santo Andr\u00e9, Sao Paulo, Brazil|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Dnipro, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kremenchuk, Ukraine|Research Site, Odesa, Ukraine|Research Site, Rivne, Ukraine|Recruiting, Vinnytsia, Ukraine"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to confirmed clinical recovery|Number of participants who achieve oxygen-free recovery at Day 29|Number of participants who experience \u22652-point improvement from baseline or assessed as fit-for-discharge on the ordinal scale at Day 29|Incidence of all-cause mortality|Distribution of participants across the 8-point ordinal scale of clinical severity status scores at Day 8, Day 15 and Day 29|Worst post-baseline score on the 8-point ordinal scale of clinical severity status|Number of intensive care unit (ICU) days|Number of invasive mechanical ventilator days|Number of participants who achieve clinical recovery at Day 8, Day 15, and Day 29|Number of participants who achieve sustained clinical recovery at Day 60|Number of participants who experience one or more treatment-emergent adverse events (TEAEs)|Number of participants who experience one or more serious adverse events (SAEs)|Number of participants who experience one or more common terminology criteria for adverse events (CTCAE) grade 3 or higher|Number of participants who experience one or more adverse events (AEs) leading to dose modification|Number of participants who experience one or more adverse events (AEs) leading to discontinuation""}"
"55","Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)","","NCT04655625","AG0302-COVID19-JN-02","Biological: Group A (AG0302-COVID19)|Biological: Group A (Placebo)|Biological: Group B (AG0302-COVID19)|Biological: Group B (Placebo)","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04655625","Active, not recruiting","2020-11-23","2022-03-31","{""locations"":""UHW Narita Hospital, Narita, Chiba, Japan|Medical Corporation Heishinkai OCROM Clinic, Suita, Osaka, Japan|Medical Corporation Tsurukamekai Shinjuku Tsurukame C linic, Shibuya-ku, Tokyo, Japan|Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan|Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku, Tokyo, Japan|Sekino Clinical Pharmacology Clinic, Toshima-ku, Tokyo, Japan|NISHI-UMEDA Clinic for Asian Medical Collaboration, Osaka, Japan|Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events|Immunogenicity|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody|Change in the neutralizing activity against pseudovirus of SARS-CoV-2|Change in IFN-gamma production against SARS-CoV-2 spike (S) glycoprotein by T cells in peripheral blood mononuclear cells|IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Adverse events|Rate of SARS-CoV-2 positive and incidence rate of COVID-19 after the first vaccination""}"
"56","Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19","COVID-19","NCT04474483","UBMELCOVID19","Drug: Melatonin|Other: Placebo (Methylcellulose) capsule","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04474483","Recruiting","2020-11-06","2021-03-31","{""locations"":""University at Buffalo, Buffalo, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality""}"
"57","A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults","","NCT04552366","AMMS85-2004","Biological: Ad5-nCoV","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04552366","Active, not recruiting","2020-09-29","2021-06-30","{""locations"":""Zhongnan Hospital, Wuhan, Hubei, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""149"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of the AE in all groups|Seroconversion rate of the IgG antibody against SARS-CoV-2|Geomean titers of the IgG antibody against SARS-CoV-2|Seroconversion rate of the neutralizing antibody against SARS-CoV-2|Geomean titers of the neutralizing antibody against SARS-CoV-2|Incidence of Serious adverse events (SAE) in all groups|Cellular immune response by ELISpot|Geomean titers of neutralizing antibody response to Ad5-vector|Cellular immune response by ICS|Geomean titers of the IgA antibody against SARS-CoV-2""}"
"58","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","COVID-19","NCT04336462","JT202002LZ","Device: oxyhydrogen|Device: Oxygen","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04336462","Recruiting","2020-02-15","2020-08-01","{""locations"":""First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme""}"
"59","Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19","","NCT04619706","FSD201-03","Drug: FSD201|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04619706","Recruiting","2020-12-14","2021-12-05","{""locations"":""St. Petersburg, Florida, Saint Petersburg, Florida, United States|Idaho Falls, Idaho, Idaho Falls, Idaho, United States|Winfield, Illinois, Winfield, Illinois, United States|Mesquite, Texas, Mesquite, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants With Disease Progression at Day 28|Percentage of Participants With Disease Resolution at Day 28|Percentage of Participants Requiring Invasive Mechanical Ventilation or ExtraCorporeal Membrane Oxygenation (ECMO) or who are not Alive on Day 28|Change From Baseline in Oxygen use|Change From Baseline in Saturation of Oxygen (SpO2) percent (%)|Change From Baseline in Clinical Status Related to COVID-19|Percentage of Participants who Die (Mortality Rate) at Day 28|Percentage of Participants Testing Negative for COVID-19 at Day 28|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters, Electrocardiogram Findings and Physical Examination Findings|Plasma Concentrations of FSD201|Maximum Observed Plasma Concentration (Cmax) of FSD201|Area Under the Concentration-Time Curve (AUC) of FSD201|Elimination Half-Life (t1\/2)|Apparent Total Body Clearance (CL\/F) of FSD201|Apparent Volume of Distribution (Vz\/F) of FSD201|Average Observed Plasma Concentration at Steady State (Cav) of FSD201""}"
"60","Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)","CONDITION","NCT04389658","IGX1-COV-XS-20-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389658","Completed","2020-05-07","2020-08-25","{""locations"":""Igenomix, Paterna, Valencia, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""1526"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence of contagiousness in asymptomatic individuals by PCR|Ratio of asymptomatic immunized (IgA\/IgM and IgG) population|Description of demographic characteristics""}"
"61","Setting up a COVID-19 Care Facility at a Prison in Pakistan","","NCT04404179","CovJ","Other: COVID-19 FACILITY","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04404179","Completed","2020-03-27","2020-05-02","{""locations"":""Camp Jail \/ COVID-19 CARE FACILITY\/ SIMS, Lahore, Pakistan"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""69"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Recovery|Mortality|ICU admission""}"
"62","An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","","NCT04434248","COVID-FPR-01","Drug: Favipiravir|Drug: Standard of Care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04434248","Active, not recruiting","2020-04-23","2020-07-01","{""locations"":""Republican Clinical Hospital, Makhachkala, Russian Federation|\""K+31\"" Clinic, Moscow, Russian Federation|\""Khaven\"" Llc, Moscow, Russian Federation|Central Clinical Hospital with Polyclinic, Moscow, Russian Federation|Central Research Institute of Epidemiology, Moscow, Russian Federation|City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital named after S.S. Yudin, Moscow, Russian Federation|City Clinical Hospital No. 24, Moscow, Russian Federation|City Clinical Hospital No. 51, Moscow, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation|National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russian Federation|City Hospital \u2116 33 of the Leninsky region of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Ryazan State Medical University named after I.P. Pavlov, Ryazan, Russian Federation|Military Medical Academy named after S.M. Kirova, Saint Petersburg, Russian Federation|Saratov State Medical University named after V.I. Razumovsky, Saratov, Russian Federation|Clinical hospital No.1, Smolensk, Russian Federation|Regional Clinic Hospital, Tver, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Yakutsk City Clinical Hospital, Yakutsk, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans, Yaroslavl, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""330"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of viral elimination by Day 10 [pilot stage, dose selection]|Time to viral elimination [pivotal stage]|Time to clinical improvement [pivotal stage]|Rate of viral elimination|Time to normalization of clinical symptoms|Duration of oxygen therapy|Change in the level of lung damage according to CT|Rate of transfer to the intensive care unit|Rate of the use of non-invasive lung ventilation|Rate of the use of mechanical ventilation|Mortality|Peak plasma concentration (Cmax)|Time to peak plasma concentration (Tmax)|Area under the plasma concentration versus time curve (AUC0-t)|Trough plasma concentration (Ctrough)""}"
"63","ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19","Mir-Age","NCT04393038","ABX464-401","Drug: ABX464|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04393038","Recruiting","2020-05-01","2021-04-30","{""locations"":""Centre hospitalier Saint Pierre, Brussels, Belgium|H\u00f4pital Erasme, Brussels, Belgium|UZ Gent, Gent, Belgium|Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - Instituto de Pesquisa Cl\u00ednica Carlos Borborema, Manaus, Amazonas, Brazil|Centro Oncol\u00f3gico de Roraima - CECOR - NAP, Boa Vista, Roraima, Brazil|Hospital das Clinicas da FMUSP, S\u00e3o Paulo, Sao Paulo, Brazil|Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro, Rio De Janeiro, Brazil|Conjunto Hospitalar do Mandaqui, Sao Paulo, Brazil|H\u00f4pital Nord, Amiens, France|Centre Hospitalier D\u00e9partemental de Vend\u00e9e, La Roche-sur-Yon, France|Centre Hospitalier Universitaire de Nice, Nice, France|H\u00f4pital Saint-Antoine, Paris, France|Universit\u00e4tsmedizin Mannheim Ruprecht-Karls-Universit\u00e4t Heid, Mannheim, Baden-W\u00fcrttemberg, Germany|Universit\u00e4tsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Fondazione IRCCS C\u00e0 Granda - Ospedale Maggiore Policlinico - Infectious Diseases, Milano, Lombardia, Italy|Ospedale San Paolo, Milano, Lombardia, Italy|Ospedale Luigi Sacco, AO-PU, Milano, Lombardia, Italy|Ospedale di Vittorio Veneto - Medecina generale, Vittorio Veneto, Treviso, Italy|Ospedale A. Manzonidi Lecco - ASST Lecco, Lecco, Italy|Ospedale Niguarda, Milano, Italy|Consultorio m\u00e9dico, M\u00e9rida, Yucatan, Mexico|Centro de Prevenci\u00f3n y Rehabilitaci\u00f3n de Enfermedades Pulmon, Nuevo Le\u00f3n, Mexico|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|H.G.U. Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital de La Princesa, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Royal Free Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1034"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal\/mask oxygen supplementation, and who are alive|Rate of patients hospitalized|Percentage of patients reporting each severity rating on a 7-point ordinal scale|Change from enrolment in inflammatory markers in plasma and in immune phenotype and assessment of cell-activation markers in PBMCs|Rate of patients requiring oxygen supplementation|Time to hospitalization|Time to assisted ventilation and oxygen supplementation|Change from baseline in microRNA-124 levels|Change from baseline in CRP, Troponin I & T and D-dimer|SARS-CoV-2 viral load|Number and rates of participants with Treatment Emergent Adverse Event""}"
"64","APT™ T3X on the COVID-19 Contamination Rate","","NCT04716426","4.485.847","Drug: Tetracycline hydrochloride 3%|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04716426","Recruiting","2021-01-28","2021-04-01","{""locations"":""Santa Casa de Miseric\u00f3rdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 contamination rate.|Presence of adverse events.|Number of adverse events.|Frequency of adverse events.|Other virus or bacteria contamination rate.""}"
"65","Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19","","NCT04610554","SARS-CoV-2_DLNO","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04610554","Completed","2020-05-14","2020-10-12","{""locations"":""IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""74"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Lung diffusing capacity for nitric oxide (DLNO)|Lung diffusing capacity for carbon monoxide (DLco)""}"
"66","Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia","","NCT04363346","IDIM-2020-28708|2020LS083","Drug: FT516","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04363346","Active, not recruiting","2020-05-14","2022-01-01","{""locations"":""University of Minnesota, Minneapolis, Minnesota, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""5"",""age"":""18 Years to 76 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge""}"
"67","Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection","","NCT04456413","Pro2020-0542","Biological: Convalescent Plasma|Other: Best Supportive Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04456413","Recruiting","2020-11-06","2021-11-01","{""locations"":""Hackensack University Medical Center, Hackensack, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""306"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization Rate|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|Rate of nasopharyngeal swab positivity in donors|Rate of donor titers level|Impact of donor titers level on efficacy|Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months.""}"
"68","Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.","PLASCOSSA","NCT04372979","2020-A01166-33","Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04372979","Recruiting","2020-09-14","2021-06-01","{""locations"":""HIA Percy, Clamart, France|HIA Laveran, Marseille, France|HIA B\u00e9gin, Saint-Mand\u00e9, France|HIA Sainte Anne, Toulon, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival time without needs of a ventilator.|Morbidity|Mortality|Length of stay|Effect on viral pharyngeal specimen clearance|Effect on viral blood specimen clearance|Effect on hemostasis disorders|Kinetics of appearance of neutralizing antibodies|Transfusion endotheliopathy effect|Transfusion biological Inflammation effect|Transfusion hemovigilance|Decrease in the consumption of antibiotics""}"
"69","The Role of Resistant Starch in COVID-19 Infection","","NCT04342689","2000027887","Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04342689","Recruiting","2020-06-03","2021-06-01","{""locations"":""Yale University, New Haven, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1500"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rates of hospitalization for a COVID-19 related complication (Phase 3)|Time to clinical recovery (TTCR) (Phase 2)|Symptom Severity Score (Phase 2)""}"
"70","Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19","","NCT04514302","INOSARS-CoV-2 TecSalud","Drug: Placebo|Drug: Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04514302","Not yet recruiting","2020-10-20","2021-06-20","{""locations"":""Hospital San Jos\u00e9, Monterrey, Nuevo Leon, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""51"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with improvement in clinical status|Time to clinical improvement|Proportion of patients that reach a score of 6, 7 or 8 in the NIAID 8-point ordinal scale|Duration of hospitalization|SARS-CoV-2 PCR negativization rate|Proportion of patients with clinical improvement at day 7|Proportion of patients with immediate adverse events (< 24 hours)|Proportion of patients with late adverse events (1 - 28 days)""}"
"71","Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19","COVIDOSE-2","NCT04479358","IRB20-1179","Drug: Tocilizumab|Other: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04479358","Recruiting","2020-09-10","2021-03-01","{""locations"":""University of Chicago Medicine, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""332"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Recovery|Achievement of Recovery|Overall Survival|Hospital Length of Stay|Clinical Response: Maximum Temperature (Tmax) Response|Clinical Response: Rate of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Duration of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Time to Non-Elective Invasive Mechanical Ventilation|Clinical Response: Rate of Vasopressor\/Inotrope Utilization|Clinical Response: Duration of Vasopressor\/Inotrope Utilization|Clinical Response: Time to Vasopressor\/Inotrope Utilization|Clinical Response: Duration of Increased Supplemental Oxygen from Baseline|Biochemical Response: C-reactive Protein Response Rate|Safety: Rate of Secondary Infection""}"
"72","VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease","","NCT04587323","IRB-300005378","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04587323","Recruiting","2020-05-22","2023-05-20","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Laboratory Assays|VEGF-A|VEGF-C|VEGF-D|Tie-2|Flt-1|PlGF|FGF""}"
"73","C5a Receptor Expression - COVID-19 (C5-COV)","C5-COV","NCT04369820","2020-14|IDRCB","Other: draw blood","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04369820","Recruiting","2020-03-31","2020-11-01","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).""}"
"74","Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19","","NCT04467151","HS-20-00516","Drug: anti-SARS-CoV-2 plasma|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04467151","Withdrawn","2020-10-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease progression measured by WHO scale|Comparison of maximum WHO score per group|Comparison of decrease of median and maximum WHO score per group|Comparison of time to clinical improvement per group|Comparison of time to reach score of \""6\"" or greater on the WHO scale""}"
"75","TXA127 for the Treatment of Severe COVID-19","","NCT04401423","AAAT0535","Drug: TXA127|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04401423","Recruiting","2020-08-01","2021-12-01","{""locations"":""Columbia University Irving Medical Center, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of serum creatinine|Number of participants requiring intubation and ventilatory support|Change in number of deceased participants|Number of participants requiring dialysis|Number of participants requiring a vasopressors|Change in blood inflammatory markers|Percent change in supplemental oxygen requirements""}"
"76","Changes in Viral Load in COVID-19 After Probiotics","","NCT04666116","HdeSagunto","Dietary Supplement: Dietary supplementation in patients with covid disease admitted to hospital","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04666116","Recruiting","2020-04-01","2021-02-01","{""locations"":""Hospital de Sagunto, Sagunto, Valencia, Spain|Hospital de Sagunto, Valencia, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""96"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load during the period of admission to the nasopharyngeal smear.|Clinical indicators on admission and every 48 hours thereafter|Analytical parameters|Mobility|Microbiome analysis in feces""}"
"77","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","","NCT04343755","Pro2020-0375","Biological: Convalescent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04343755","Active, not recruiting","2020-04-09","2021-04-01","{""locations"":""Hackensack University Medical Center, Hackensack, New Jersey, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""52"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60""}"
"78","Relation Between Lab Finding and COVID-19 Severity","","NCT04470557","RLCS","Diagnostic Test: D-dimer,CBC.ESR,CRP,|Diagnostic Test: Liver function tests ,serum ferritin and PCR for COVID-19 .","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04470557","Not yet recruiting","2020-07-15","2020-12-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Estimation of severity of patients with COVID-19 in relation to Laboratory findings.""}"
"79","DAS181 for Severe COVID-19: Compassionate Use","","NCT04324489","DAS181-SARS-CoV-2","Drug: DAS181","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04324489","Completed","2020-03-06","2020-04-30","{""locations"":""Renmin Hospital of Wuhan University, Wuhan, Hubei, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""4"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death""}"
"80","Dendritic Cell Vaccine to Prevent COVID-19","","NCT04685603","CL-COV-P02-ID|U1111-1263-0568","Biological: AV-COVID-19","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04685603","Recruiting","2020-12-07","2022-01-31","{""locations"":""Rumah Sakit Umum Pusat Dr. Kariadi, Semarang, Jawa Tengah, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""27"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of solicited local and systemic reactogenicity adverse events (AEs)|Safety Laboratory Values (Serum Chemistry)|Safety Laboratory Values (Hematology)|Frequency of any serious adverse events (SAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of medically attended adverse events (MAAEs)|Frequency of Unsolicited AE and Adverse Events of Special Interest (AESIs)|Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs)|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs)|Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs)|Neutralizing Antibody Activity Expressed as GMTs|Neutralizing Antibody Activity Expressed as GMFRs|Neutralizing Antibody Activity Expressed as SCRs|Assessment of Cell-Mediated (T helper 1 [Th1]\/T helper 2 [Th2]) Pathways|Optimal dose of SARS-CoV2 antigen and GM-CSF|Duration of detection IgG and neutralizing antibody againts SARS-CoV-2in blood after vaccination""}"
"81","Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients","","NCT04464395","CPI-006-002","Drug: CPI-006|Other: Standard of Care","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04464395","Recruiting","2020-07-01","2021-08-31","{""locations"":""El Centro Regional Medical Center, El Centro, California, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19|Immunoglobulin Anti-SARS CoV-2 Levels|Negative Nasal Swab Polymerase Chain Reaction (PCR) SARS CoV-2 Viral Tests|Duration of symptoms|Time to discharge|Rate of medical procedures|Difference in changes in serum\/plasma immunoglobulin anti-SARS CoV-2 levels""}"
"82","Genosvid Diagnostic Test for Early Detection of COVID-19","","NCT04558372","1.6/2020","Other: exhaled breath sampling","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04558372","Completed","2020-04-01","2020-12-12","{""locations"":""RS Bhayangkara Tk I R.Said Soekanto, Jakarta, Indonesia|Saiful Anwar, Malang, Indonesia|Dr Sardjito Hospital, Yogyakarta, Indonesia|Bambanglipuro Hospital, Yogyakarta, Indonesia|Bhayangkara Tk III Polda DIY, Yogyakarta, Indonesia|RS Akademik UGM, Yogyakarta, Indonesia|RSPAU Hardjolukito, Yogyakarta, Indonesia|RST Tk III Dr Soetarto, Yogyakarta, Indonesia"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic"",""enrollment"":""1999"",""age"":""4 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Diagnostic accuracy of electronic nose signal in COVID-19""}"
"83","Genetic Bases of COVID-19 Clinical Variability","GEN-COVID","NCT04549831","16917","Genetic: Massive parallel sequencing of host genome","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04549831","Recruiting","2020-04-08","2026-04-08","{""locations"":""University of Siena, Siena, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To identify the genetic determinants of COVID-19 severity|To identify the genetic determinants of COVID-19 clinical trajectories.""}"
"84","Vitamin D Supplementation in Patients With COVID-19","","NCT04449718","30959620.4.0000.0068","Dietary Supplement: Vitamin D|Dietary Supplement: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04449718","Completed","2020-06-01","2020-10-07","{""locations"":""Clinical Hospital of the School of Medicine, University of Sao Paulo, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Length of hospitalization|Mortality|Number of cases admitted to Intensive Care Unit (ICU)|Length of use of mechanic ventilator|Number and severity of symptoms|Inflammatory markers|C-reactive protein|Vitamin D|Creatinine|Calcium|Physical activity""}"
"85","Colchicine Plus Phenolic Monoterpenes to Treat COVID-19","","NCT04392141","1399.062","Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04392141","Recruiting","2020-04-01","2020-11-01","{""locations"":""Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""10 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality rate|Change in patients clinical manifestation|Length of hospitalization|C-reactive protein|Lymphocyte count|Serum lactate dehydrogenase|Serum Interleukin-6|Erythrocyte sedimentation rate""}"
"86","Online Learning of Veterinary Anatomy During COVID-19 Pandemic","","NCT04418284","2-2020","Other: survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04418284","Recruiting","2020-06-05","2020-11-05","{""locations"":""South Valley University, Qin\u0101, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""400"",""age"":""17 Years to 35 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Measure the students' interest in studying anatomy on-line.|Assess the easiness of using technology during studying anatomy online|Assess the student satisfaction regarding the provided study materials""}"
"87","Multi-site Adaptive Trials for COVID-19","","NCT04370262","20-0268","Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04370262","Completed","2020-04-07","2020-09-07","{""locations"":""Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""233"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and\/or lower respiratory secretions|Clinical Severity""}"
"88","Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease","","NCT04432298","FGCL-3019-098","Drug: Pamrevlumab|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04432298","Recruiting","2020-06-20","2021-01-01","{""locations"":""Research Center, Detroit, Michigan, United States|Research Center, Greensboro, North Carolina, United States|Research Center, Philadelphia, Pennsylvania, United States|Research Center, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""130"",""age"":""40 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects who never received mechanical ventilation and\/or ECMO and alive|Proportion of subjects alive, discharged home, and not on supplemental oxygen|Time to recovery based on a Modified 8-Point Ordinal Scale|Days in ICU\/CCU (either on or off mechanical ventilation and\/or ECMO)|Days on mechanical ventilation and\/or ECMO|Time to death from any cause|Changes in PaO2\/FiO2 ratio, both as categorical and continuous variable|Change in (non-invasive) oxygen supplementation requirements""}"
"89","COVID-19 Infection in Healthcare Workers","HOP-COVID","NCT04386759","APHP200483","Other: Cohort","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386759","Not yet recruiting","2020-05-01","2020-10-01","{""locations"":""Assistance Publique H\u00f4pitaux de Paris - CHU Henri Mondor, Cr\u00e9teil, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""6000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-COV-2 infection|Individual factors|Hospital ward level""}"
"90","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","","NCT04329611","ABCOV-01 version 1.5","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04329611","Terminated","2020-04-13","2020-07-20","{""locations"":""University of Calgary\/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""148"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased (categorical)""}"
"91","Ivermectin for Severe COVID-19 Management","","NCT04646109","IVMC_03","Drug: Ivermectin","Interventional","Has Results","Phase 3","https://ClinicalTrials.gov/show/NCT04646109","Completed","2020-05-11","2020-09-02","{""locations"":""Afyonkarahisar Health Science University, Afyonkarahisar, Turkey|Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey|Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, Ankara City Hospital, Ankara, Turkey|Haydarpasa Sultan Abdulhamid Han Training and Research Hospital, \u0130stanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Gender Distribution of the Patients|Age Distribution of the Patients|Percentage of Patients With Accompanying Diseases|Percentage of Patients With Baseline Clinical Symptoms|Body Temperature Means of the Patients|Heart Rate Means of the Patients|Respiratory Rate Means of the Patients|Systolic and Diastolic Pressure Means of the Patients|Number of Participants With Clinical Response|Changes in Oxygen Saturation (SpO2) Values|Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2\/FiO2)|Changes in Serum Lymphocyte Counts|Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL\/L)|Changes in Serum Ferritin Levels|Changes in Serum D-dimer Levels|Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism|Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Mortality|Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity""}"
"92","Study of Open Label Losartan in COVID-19","","NCT04335123","STUDY00145514","Drug: Losartan","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04335123","Completed","2020-04-04","2020-08-17","{""locations"":""University of Kansas Medical Center, Kansas City, Kansas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""34"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir\/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg""}"
"93","A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia","","NCT04708236","ORTD1-COV-001","Drug: ORTD-1 low dose|Drug: ORTD-1 mid dose|Drug: ORTD-1 high dose|Other: Vehicle control","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04708236","Recruiting","2021-04-01","2021-07-01","{""locations"":""UC Irvine Medical Center, Orange, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events|Incidence of laboratory abnormalities|Incidence of anti-drug antibodies|Proportion of patients requiring intubation|Percentage of days requiring supplemental oxygen|Overall survival (OS)""}"
"94","Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19","PROVID-19","NCT04621071","2021-3700","Dietary Supplement: Probiotics (2 strains 10x10^9 UFC)|Dietary Supplement: Placebo (potato starch and magnesium stearate)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04621071","Recruiting","2021-01-05","2021-04-01","{""locations"":""CIUSSS de L'Estrie-CHUS Hospital, Sherbrooke, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""84"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of symptoms of the COVID-19|Severity of the COVID-19|Evolution of oral and fecal microbiota""}"
"95","Impact of COVID-19 on Marshallese Communities in the U.S.","","NCT04474496","261131","Other: Assessing impact of COVID19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04474496","Enrolling by invitation","2020-07-27","2020-12-15","{""locations"":""University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effects of COVID-19 on social determinants of health|Effects of COVID-19 on general health status and mental health|Effects of COVID-19 on disease management|Effects of COVID-19 on diet and physical activity behaviors|COVID-19 screening, testing, and prevention|Trusted sources of COVID-19 information|Impacts of COVID-19 on daily life|COVID-19 attitudes, fears, and beliefs""}"
"96","Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)","","NCT04582344","9026-ASI","Biological: CoronaVac|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04582344","Recruiting","2020-09-14","2021-04-15","{""locations"":""T.R. Ministry of Health Ankara City Hospital, Infectious Diseases and Clinical Microbiology Clinic, Ankara, Turkey Region, Turkey|T.R. Ministry of Health Ankara Provincial Health Directorate Ankara Training and Research Hospital, Infectious Diseases, Ankara, Turkey Region, Turkey|Ankara University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey Region, Turkey|\u00c7ukurova University Faculty of Medicine, Department of Infectious Diseases, Adana, Turkey|Hacettepe University Faculty of Medicine Department of Infections Diseases and Clinical Microbiology, Ankara, Turkey|T.C Ministry of Health Ankara Provincial Health Directorate Health Sciences University Ankara Atat\u00fcrk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey|Akdeniz University Faculty of Medicine, Department of Infectious Diseases, Antalya, Turkey|Bursa Uluda\u011f University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bursa, Turkey|Dicle University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Diyarbak\u0131r, Turkey|Gaziantep University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Gaziantep, Turkey|Ac\u0131badem Atakent Hospital, Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|Cerrahpa\u015fa Faculty of Medicine, Department of Internal Medicine - Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|Istanbul Medipol University Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey|Istanbul University Istanbul Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|T.R. Ministry of Health Istanbul Provincial Health Directorate Marmara Univesity Istanbul Pendik Education and Research Hospital, Istanbul, Turkey|T.R. Ministry of Health Istanbul Provincial Health Directorate Prof. Dr. Cemil Ta\u015f\u00e7\u0131o\u011flu City Hospital, Infectious Diseases Clinic, Istanbul, Turkey|T.R. Ministry of Health Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey|University of Health Sciences \u0130stanbul \u00dcmraniye Training and Research Hospital, Istanbul, Turkey|Ege University Faculty of Medicine Hospital, Department of Infectious Diseasesaculty of Medicine Hospital, Department of Infectious Diseases, \u0130zmir, Turkey|Republic Of Turkey Ministry Of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital, \u0130zmir, Turkey|T.R. Ministry of Health \u0130zmir Provincial Health Directorate \u0130zmir Health Sciences University Tepecik Training and Research Hospital, Infectious Diseases, \u0130zmir, Turkey|T.R. Ministry of Health Kayseri City Training and Research Hospital, Infectious Diseases and Clinical Microbiology Department, Kayseri, Turkey|Kocaeli University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Kocaeli, Turkey|Malatya \u0130n\u00f6n\u00fc University Faculty of Medicine, Department of Infectious Diseases, Malatya, Turkey|Karadeniz Technical University Medical Faculty Hospital, Department of Infectious Diseases and Clinical Microbiology, Trabzon, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""13000"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19|Protection Indexes of One Vaccine Dose For Symptomatic COVID-19|Protection Indexes of Second Vaccine Dose For Hospitalization, Disease Severity\/and Death|Protection Indexes of Two Vaccine Doses For SARS-CoV-2 infection|Safety indexes of adverse reactions in 28 days|Safety indexes of adverse reactions in 7 days|Safety indexes of serious adverse events in 1 year|Immunogenicity parameters (seroconversion rate, seropositivity rate) in 14 days|Immunogenicity parameters (seroconversion rate, seropositivity rate) in 28 days|Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 14 days|Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 28 days""}"
"97","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","ONSCOVID19","NCT04323228","ONS_COVID-19","Dietary Supplement: Oral supplement enriched in antioxidants|Dietary Supplement: cellulose-containing placebo capsules","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04323228","Recruiting","2020-09-01","2020-12-30","{""locations"":""Prince Mohamed BinAbdulaziz Hospital, Riyadh, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care"",""enrollment"":""40"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor-\u03b1 concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial""}"
"98","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","","NCT04321993","SAIL-004","Drug: Baricitinib (janus kinase inhibitor)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04321993","Recruiting","2020-04-17","2022-03-01","{""locations"":""Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events""}"
"99","Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19","","NCT04351659","COVID-T 1.0","Other: Blood donation from convalescent donor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351659","Recruiting","2020-04-14","2020-08-01","{""locations"":""National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""8"",""age"":""21 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Success rate in production of SARS-CoV-2 specific T cells from convalescent donor""}"
"100","Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children","HEART-COVID","NCT04420468","APHP200632","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04420468","Not yet recruiting","2020-06-01","2020-12-01","{""locations"":""H\u00f4pital Bic\u00eatre, Le Kremlin-Bic\u00eatre, France|H\u00f4pital Armand Trousseau, Paris, France|H\u00f4pital Necker-Enfants Malades, Paris, France|H\u00f4pital Robert Debr\u00e9, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""20"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""Acute myocarditis|Multi-systemic inflammatory syndrome|Kawasaki disease|Results of SARS-CoV-2""}"
"101","Ivermectin and Nitazoxanide Combination Therapy for COVID-19","","NCT04360356","IVR/NTZ","Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04360356","Not yet recruiting","2020-05-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNF\u03b1|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio \""INR\"" for prothrombin time|Number of patients with normalized complete blood count \""CBC\""|The Mortality rate among treated patients""}"
"102","PROLIFIC ChemoprophylaxisTrial (COVID-19)","","NCT04352933","PROLIFIC2020 (A095583)","Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04352933","Recruiting","2020-05-11","2021-04-01","{""locations"":""Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to positive COVID-19 disease|Number of COVID-19 test positive cases|Number of COVID-19 serological test positive cases|Severity of COVID-19 disease between each arm|Number of common COVID-19 complications between each arm""}"
"103","Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients","MIA-COVID-19","NCT04366882","JessaH_COVID-19_MIA","Procedure: CT-scan with minimal invasive autopsy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04366882","Recruiting","2020-04-14","2020-12-01","{""locations"":""Jessa Hospital, Hasselt, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""45"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Determination of cause of death and contributing factors based on clinical, radiological, microbiological and histopathological data of the deceased patient|Detailed description of the postmortem radiological changes induced by COVID-19|Detailed description of the postmortem histopathological changes induced by COVID-19|Postmortem quantity of viral RNA|Postmortem disease mechanisms at cellular level""}"
"104","Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19)","","NCT04664010","XianInternationalMCH_HXJ","Drug: Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04664010","Active, not recruiting","2020-02-06","2021-01-31","{""locations"":""Xi'an International Medical Center Hospital, Xi'an, Shaanxi, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recovery time|Time of disappearance of fever symptoms|The rate of conversion from COVID-19 positive to COVID-19 negative|Time of disappearance of cough|Respiratory rate|Blood oxygen saturation|PaO2|PaCO2|The time of obvious improvement as shown on chest CT scans relative to admission|The rate of obvious improvement as shown on chest CT scans relative to admission|Levels of C-reactive protein|Erythrocyte sedimentation rate|Levels of Procalcitonin|Levels of interleukin-6|Levels of interleukin-10|Levels of tumor necrosis factor-alpha""}"
"105","Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19","COVID-19","NCT04376788","FMASU P22/2020","Biological: exchange blood transfusion from normal donor|Biological: plasma from convalescent patients with COVID-19|Drug: Methylene Blue 5 MG/ML","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04376788","Recruiting","2020-05-20","2020-09-01","{""locations"":""Ain Shams University, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""improvement of condition|change in organs function with PFS and OS""}"
"106","PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19","","NCT04497324","PER-016-20|20997","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04497324","Not yet recruiting","2020-08-20","2020-12-31","{""locations"":""Hospital Nacional Hipolito Unanue, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Transfusion-related Serious Adverse Events|All-cause in-hospital mortality|Length of hospital stay|Length of ICU stay|Need of invasive mechanical ventilation|Duration of mechanical ventilation|Clinical Improvement at 14 days""}"
"107","Dapagliflozin in Respiratory Failure in Patients With COVID-19","DARE-19","NCT04350593","D1690C00081|ESR-20-20653","Drug: Dapagliflozin 10 MG|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04350593","Active, not recruiting","2020-04-22","2021-06-01","{""locations"":""Heart Group of the Eastern Shore, Fairhope, Alabama, United States|Baptist Hospital of Miami, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University, Maywood, Illinois, United States|Ascension - St. Vincent, Indianapolis, Indiana, United States|Lahey Health, Burlington, Massachusetts, United States|McLaren Health Care, Auburn Hills, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|St. Francis Hospital, Roslyn, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Clinical Trials Network of Tennessee, Memphis, Tennessee, United States|DHR Health Institute for Research and Development, Edinburg, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Sentara Healthcare, Norfolk, Virginia, United States|Fundaci\u00f3n Favaloro, Buenos Aires, Argentina|Hospital Espa\u00f1ol, Buenos Aires, Argentina|Hospital Fern\u00e1ndez, Buenos Aires, Argentina|Hospital Pirovano, Buenos Aires, Argentina|Hospital Santojanni, Buenos Aires, Argentina|Sanatorio Anchorena, Buenos Aires, Argentina|Sanatorio G\u00fcemes, Buenos Aires, Argentina|Hospital San Roque, C\u00f3rdoba, Argentina|Sanatorio Privado Duarte Quiros, C\u00f3rdoba, Argentina|Centro de Pesquisa Dr. Marco Mota, Macei\u00f3, Alagoas, Brazil|Hospital EMEC e Hospital da Cidade, Feira de Santana, Bahia, Brazil|Hospital e Cl\u00ednica S\u00e3o Roque, Ipia\u00fa, Bahia, Brazil|Hospital Regional Deputado Luis Eduardo Magalh\u00e3es, Porto Seguro, Bahia, Brazil|Hospital C\u00e1rdio Pulmonar, Salvador, Bahia, Brazil|Hospital Maternidade S\u00e3o Vicente de Paulo, Barbalha, Cear\u00e1, Brazil|Unimed de Fortaleza, Fortaleza, Cear\u00e1, Brazil|Hospital de Messejana dr Carlos Alberto Studart Gomes, Fortaleza, Cear\u00e1, Brazil|Hospital Cora\u00e7\u00e3o do Brasil, Bras\u00edlia, Distrito Federal, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, Esp\u00edrito Santo, Brazil|Liga de Hipertens\u00e3o Arterial, Goiania, Goias, Brazil|Santa Casa de Miseric\u00f3rdia de Passos, Passos, Minas Gerais, Brazil|Hospital S\u00e3o Domingos - Unimed Uberaba, Uberaba, Minas Gerais, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Associa\u00e7\u00e3o Dr. Bartholomeu Tacchini, Bento Gon\u00e7alves, Rio Grande Do Sul, Brazil|Hospital S\u00e3o Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Miseric\u00f3rdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital M\u00e3e de Deus, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital S\u00e3o Jos\u00e9 - Criciuma, Criciuma, Santa Catarina, Brazil|IPEMI- Instituto de Pesquisas M\u00e9dicas de Itaja\u00ed, Itajai, Santa Catarina, Brazil|Hospital Municipal S\u00e3o Jos\u00e9, Joinville, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Centro de Pesquisa Cl\u00ednica do Cora\u00e7\u00e3o, Aracaju, Sergipe, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, S\u00e3o Paulo, Brazil|Instituto de Pesquisa Cl\u00ednica de Campinas, Campinas, S\u00e3o Paulo, Brazil|Unimed Ribeirao Preto, Ribeir\u00e3o Preto, S\u00e3o Paulo, Brazil|Funda\u00e7\u00e3o do ABC (Hospital Estadual M\u00e1rio Covas), Santo Andr\u00e9, S\u00e3o Paulo, Brazil|Centro Integrado de Pesquisas, S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Paulo, Brazil|Santa Casa de Votuporanga, Votuporanga, S\u00e3o Paulo, Brazil|Funda\u00e7\u00e3o Pio XII, Barretos, Brazil|Hospital Naval Marc\u00edlio Dias, Rio de Janeiro, Brazil|Hospital Moriah, S\u00e3o Paulo, Brazil|Hospital Santa Paula, S\u00e3o Paulo, Brazil|InCor - Instituto do Cora\u00e7\u00e3o do Hospital das Cl\u00ednicas FMUSP, S\u00e3o Paulo, Brazil|Halton Healthcare Services, Oakville, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|CIMS Hospital Pvt. Ltd, Sola, Ahmedabad, India|All India Institute of Medical Science, New Delhi, Delhi, India|Lokmanya Tilak General Hospital, Mumbai, Maharashtra, India|Max Smart Super Speciality Hospital, Saket, New Delhi, India|Max Super Speciality Hospital (A unit of Devki Devi Foundation), Saket, New Delhi, India|Dayanand Medical College & Hospital, Ludhi\u0101na, Punjab, India|Grupo Medico del Prado, Acapulco, Mexico|Icaro, Chihuahua, Mexico|Hospital General de Cuernavaca, Cuernavaca, Mexico|JM Research, Cuernavaca, Mexico|Instituto de Investigaciones Aplicadas, Durango, Mexico|Hospital Civil, Guadalajara, Mexico|Hospital San Javier, Guadalajara, Mexico|Invesclinica Mx, Guanajuato, Mexico|CIMEZAP, Jalisco, Mexico|Medica Sur, Mexico City, Mexico|Clinica Nova, Monterrey, Mexico|Hospital San Jose, Monterrey, Mexico|Estudios Clinicos Internacionales, Puebla, Mexico|Hospital SMIQ, Queretaro, Mexico|Investigacion Medica, Sonora, Mexico|Sanatorio Santa Cruz, Toluca, Mexico|Addenbrooke's Hospital, Cambridge, Cb2 0qq, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevention of COVID-19 Complications or death: During the 30-day treatment period, time to first occurrence of new\/worsened organ dysfunction during index hospitalization or death from any cause.|Improving clinical recovery: Hierarchical composite outcome measures including time to death from any cause through Day 30, new\/worsened organ dysfunction, clinical status at day 30 and hospital discharge before Day 30 and alive at Day 30:|Time to hospital discharge|Total number of days alive and free from respiratory decompensation requiring initiation of mechanical ventilation (includes invasive or non-invasive ventilation, CPAP, or BiPAP)|Total number of days alive, not in the ICU, and free from respiratory decompensation requiring initiation of mechanical ventilation (includes invasive or non-invasive ventilation, CPAP, or BiPAP)|Time to composite of acute kidney injury or initiation of renal replacement therapy, or death from any cause|Time to death from any cause""}"
"108","COVID-19 Ozanimod Intervention Study","COZI","NCT04405102","2021-3474","Drug: Ozanimod|Other: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04405102","Recruiting","2020-09-16","2024-01-01","{""locations"":""Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec - Universit\u00e9 Laval, Qu\u00e9bec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale|The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92%|Rate of non invasive ventilation (NIV) \/ high flow nasal therapy (HFNT) use|Rate of intubation|Ventilator-free days at day 28|Rate of ICU admission\/length of stay\/mortality|Severity index measurement""}"
"109","Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support","","NCT04528368","34651120.8.0000.5249","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04528368","Recruiting","2020-12-11","2021-05-30","{""locations"":""D'Or Institute for Research and Education, Rio de Janeiro, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Area under the curve of SARS-COV-2 viral load obtained from nasopharyngeal and \/or oropharyngeal swabs.|Assessment of clinical improvement using an Ordinal Severity Scale|Evaluate oxygen saturation|Evaluate oxygen supplementation|Assess respiratory rate|Evaluate the PaO2 \/ FiO2 ratio (for patients on mechanical mechanisms)|Length of hospital stay|Length of stay in intensive care|Assess the rate of orotracheal intubation|Change in the profile of cytokines\/chemokines in both groups|Presence of antibodies against SARS-CoV-2 in serum after convalescent plasma administration|Death rate|Rate of transfusion reactions to convalescent plasma infusion""}"
"110","Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19","","NCT04361318","HCQ/NTZ","Combination Product: Hydroxychloroquine plus Nitazoxanide|Other: Standard care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04361318","Not yet recruiting","2020-05-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNF\u03b1|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio \""INR\"" for prothrombin time|Number of patients with normalized complete blood count \""CBC\""|The Mortality rate among treated patients""}"
"111","COVID-19 Household Transmission Study","CO-HOST","NCT04445233","20-0982|550KR242023","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445233","Active, not recruiting","2020-04-29","2021-06-01","{""locations"":""University of North Carolina Health Care, Chapel Hill, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""315"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of Households with New SARS-CoV-2 Infection by Day 28|Risk Factors Associated with Secondary Household Transmission|Number of Self-Swab Tests vs. NP Swabs at Day 1 with Detectable Viral Load""}"
"112","Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2","Bacterial ACE2","NCT04375046","proposed by Mahmoud kazazzaz","Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04375046","Not yet recruiting","2020-09-01","2020-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time course of body temperature (fever)|Viral load over time|P\/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-\u03b1 (TNF-\u03b1) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events""}"
"113","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","","NCT04287686","GIRH-APN01","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04287686","Withdrawn","2020-02-01","2020-04-01","{""locations"":""GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time course of body temperature (fever)|Viral load over time|P\/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-\u03b1 (TNF-\u03b1) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events""}"
"114","Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection","Anosmie-COVID","NCT04354857","IRB: 20.04.09","Other: olfactory and gustatory tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354857","Recruiting","2020-03-27","2020-11-01","{""locations"":""CHU de Nimes, N\u00eemes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""454"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection status|Olfactory and gustatory loss|Ability to detect odor|Ability to detect salty taste|Ability to detect sweet taste|Severity of infection according to hospitalization rate""}"
"115","Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19","","NCT04425629","R10933-10987-COV-2067|2020-003690-21","Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04425629","Recruiting","2020-06-16","2021-08-28","{""locations"":""Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site 1, Long Beach, California, United States|Regeneron Study Site 2, Long Beach, California, United States|Regeneron Study Site 3, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Rolling Hills Estates, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 1, Downers Grove, Illinois, United States|Regeneron Study Site 2, Downers Grove, Illinois, United States|Regeneron Study Site, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Ridgewood, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Santa Fe, New Mexico, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Durham, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Las Condes, Santiago De Chile, Chile|Regeneron Study Site, Monterrey, Nuevo Leon, Mexico|Regeneron Study Site, Merida, Yucatan, Mexico|Regeneron Study Site, Ciudad de Mexico, Mexico|Regeneron Study Site, Durango, Mexico|Regeneron Study Site, M\u00e9rida, Mexico|Regeneron Study Site, Veracruz, Mexico|Regeneron Study Site, Veracruz, Mexico|Regeneron Study Site, Bucuresti, Romania"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""6420"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral load (log10 copies\/mL), as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Cumulative incidence of patients with at least one (\u22651) COVID-19 related medically attended visit or all-cause death|Concentration of REGN10933 in serum over time|Concentration of REGN10987 in serum over time|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of ADA to REGN10987|Incidence of neutralizing antibody (NAb) to REGN10933|Incidence of NAb to REGN10987|Time-weighted average change from baseline in viral load (log10 copies\/mL), as measured by RT-qPCR in saliva samples|Time-weighted average change from baseline in viral load (log10 copies\/mL), as measured by RT-qPCR in nasal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR|Change from baseline in viral load at each visit, as measured by RT-qPCR in NP swabs|Change from baseline in viral load at each visit, as measured by RT-qPCR in saliva samples|Change from baseline in viral load at each visit, as measured by RT-qPCR in nasal swabs|Correlation of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Concordance of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Time-weighted average change from baseline in viral load (log10 copies\/mL) from day 1 to post-baseline study days|Proportion of participants with \u22651 COVID-19 related medically-attended visit|Proportion of participants with \u22652 COVID-19 related medically-attended visit|Total number of COVID-19 related medically-attended visits|Proportion of participants admitted to a hospital due to COVID-19|Proportion of participants with \u22651 outpatient or telemedicine visit due to COVID-19|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax\/dose) of REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax\/dose) of REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Proportion of participants with high viral load at each visit|Proportion of participants with viral loads below the limit of detection at each visit|Proportion of participants with viral loads below the lower limit of quantitation at each visit|Proportion of participants admitted to an intensive care unit (ICU) due to COVID-19|Proportion of participants requiring mechanical ventilation due to COVID-19|Number of days of hospitalization due to COVID-19|Proportion of participants with all-cause mortality|Time to first onset of symptoms consistent with COVID-19 (asymptomatic cohort only)|Duration of symptoms consistent with COVID-19|Cumulative incidence of participants with \u22651 COVID-19-related hospitalization, emergency room visit, or all-cause death|Proportion of participants with \u22651 COVID-19-related hospitalization, emergency room visit, or all-cause death|Cumulative incidence of participants with \u22651 COVID-19-related hospitalization or all-cause death|Proportion of participants with \u22651 COVID-19-related hospitalization or all-cause death|Proportion of participants with \u22651 COVID-19-related medically-attended visit or all-cause death|Proportion of participants with \u22651 COVID-19 related medically-attended visit by type of visit|Proportion of participants requiring supplemental oxygen due to COVID-19|Time to all-cause death|All-cause death|Viral load over time in participants with COVID-19-related medically-attended visits|Viral load over time in participants without COVID-19-related medically-attended visits""}"
"116","CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany","CORONA Germany","NCT04659187","#3871","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659187","Recruiting","2020-03-26","2021-07-01","{""locations"":""Asklepios Fachkliniken M\u00fcnchen-Gauting, Gauting, Bavaria, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Wandsbek, Hamburg, Germany|Asklepios Klinik Barmbek, Hamburg, Germany|Asklepios Kliniken GmbH & Co. KGaA, Hamburg, Germany|Asklepios Klinik Nord, Hamburg, Germany|Asklepios Westklinikum Hamburg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Composite of death and\/or need for mechanical ventilation and\/or admission to ICU|Occurrence of a clinical manifest cardiovascular event|Overall mortality and mortality rate|Risk stratification score to predict the primary endpoints""}"
"117","An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19","","NCT04527133","COVID-APR-01","Drug: Aprotinin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04527133","Active, not recruiting","2020-06-11","2020-08-31","{""locations"":""Regional State Budgetary Healthcare Institution \""Clinical Hospital \u21161\"", Smolensk, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to elimination of SARS-CoV-2 virus|Time to CRP normalization|Time to D-dimer normalization|Time to body temperature normalization|Change in absolute neutrophil count (ANC)|Change in white blood cells (WBC)|Change of CRP|Change of D-dimer|Change in fibrinogen|Change of Quick's value|Change of international normalized ratio (INR)|Changes of lung injury on CT scan|Frequency of clinical status improvement by 2 scores in accordance with the WHO-OSCI or discharge from the hospital|Frequency of deterioration of the patients' status|Frequency of AEs and SAEs""}"
"118","Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)","","NCT04668235","IGZ-1","Drug: AZVUDINE|Drug: AZVUDINE placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04668235","Not yet recruiting","2020-12-01","2021-06-01","{""locations"":""Santa Casa de Miseric\u00f3rdia de Campos, Campos Dos Goytacazes, RJ, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""342"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Negative conversion rate|Time of negative conversion|Recovery of body temperature|Improvement of respiratory signs and symptoms|Improvement of diarrhea, myalgia fatigue and other symptoms|Change in blood oxygen detection rates|Frequency of supplemental oxygenation or non-invasive ventilation|Frequency of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Frequency of adverse events|Frequency of serious adverse events|Proportion of moderate cases that progressed to severe cases|Proportion of severe cases that worsened during treatment|Mortality rate""}"
"119","Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19","","NCT04495101","GC2005|2020-001953-36","Biological: Prolastin|Drug: Standard Medical Treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04495101","Recruiting","2020-07-29","2021-05-01","{""locations"":""Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Cl\u00ednic de Barcelona, Barcelona, Spain|Hospital Universitario Valle de Hebr\u00f3n, Barcelona, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital General Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Pr\u00edncipe de Asturias, Madrid, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Subjects Dying or Requiring ICU Admission|Percentage of Subjects Who are Dependent on Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS \u2264 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Subjects in Each Severity Category of the 7-Point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Subjects who Sustained Normalization of Temperature|Number of Subjects who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression|Mortality Through Day 29""}"
"120","Favipiravir Therapy in Adults With Mild COVID-19","Avi-Mild","NCT04464408","RC 20/220/R","Drug: Favipiravir|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04464408","Recruiting","2020-07-23","2021-12-01","{""locations"":""Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah, Al Madinah, Saudi Arabia|King Fahad Hospital - Madinah, Al Mad\u012bnah, Saudi Arabia|Primary Health Care-Safiyah, Al Mad\u012bnah, Saudi Arabia|King Abdullah Medical City - Makkah, Mecca, Saudi Arabia|King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia|Primary Health Care-Al Mansoura, Riyadh, Saudi Arabia|Primary Health Care-Al Urijah, Riyadh, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""576"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PCR negative|Time from randomization to clinical recovery|Evaluate symptoms progression|Evaluate Faviparivirs effect|Evaluate Favipiravir's effect|Evaluate the safety of Favipiravir""}"
"121","Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","","NCT04381052","AAAT0142","Drug: Clazakizumab|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04381052","Not yet recruiting","2020-05-01","2020-08-01","{""locations"":""Columbia University Medical Center \/ New York Presbyerian Hospital, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative Incidence of Intubation|Time to Extubation|Length of Intensive Care Unit (ICU) stay|Number of Patients who Present a Decrease in C-reactive protein (CRP)|Number of Patients with Acute Kidney Injury (AKI)|Number of Patients with a Need for Renal Replacement Therapy (RRT)|Duration of Renal Replacement Therapy (RRT)|Patient Survival|Number of Patients with Hemodialysis|Number of Patients with Continuous Renal Replacement Therapies (CRRT)|Number of Patients with Peritoneal Dialysis""}"
"122","Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","","NCT04619628","CDX-CoV-001","Biological: COVI-VAC|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04619628","Recruiting","2020-12-11","2022-05-01","{""locations"":""hVIVO, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""48"",""age"":""18 Years to 30 Years \u00a0 (Adult)"",""outcome_measures"":""Reactogenicity|Adverse events|Serious adverse events|IgG titre|Neutralizing antibody titre""}"
"123","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","ENACOVID","NCT04325633","APHP200387","Drug: 1: Naproxen|Drug: 2: Standard of care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04325633","Terminated","2020-04-24","2020-12-15","{""locations"":""R\u00e9animation m\u00e9dico-chirurgicale, Avicenne Hospital, Bobigny, France|Urgences, Avicenne Hospital, Bobigny, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)""}"
"124","Detection of Anti-COVID-19 Antibody Levels in an Hospital Population","","NCT04387929","1374 IgG COVID-19 HUMANITAS","Diagnostic Test: Detection of anti-COVID-19 antibody level","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387929","Recruiting","2020-05-04","2021-05-30","{""locations"":""Humanitas Rozzano\/San Pio X, Rozzano, Lombardia, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""6000"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 levels of IgG antibodies|SARS-CoV-2 viral load in nasopharyngeal swab of IgG positive subjects|Epidemiology correlations""}"
"125","Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19","APLICOV-PC","NCT04382066","APL-D-002-20|2020-001993-31","Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04382066","Completed","2020-05-12","2020-12-23","{""locations"":""Hospital Universitario Hm Montepr\u00edncipe, Boadilla Del Monte, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Cl\u00ednic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Ciudad Real, Ciudad Real, Spain|Hospital Universitario de Getafe, Getafe, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital La Princesa, Madrid, Spain|Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Ram\u00f3n Y Cajal, Madrid, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hosptial Quironsalud Madrid, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""46"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of occurrence of Neutropenia \u2265 grade 3|Frequency of occurrence of Thrombocytopenia \u2265 grade 3|Frequency of occurrence of Anemia \u2265 grade 3|Frequency of occurrence of Lymphopenia \u2265 grade 3|Frequency of occurrence of CPK increase \u2265 grade 3|Frequency of occurrence of Increase ALT and \/ or AST \u2265 grade 3|Frequency of occurrence of Increase total bilirubin or direct bilirubin \u2265 grade 3|Frequency of occurrence of Neurotoxicity \u2265 grade 3|Frequency of occurrence of QT-QTc interval extension \u2265 grade 3|Frequency of occurrence of Other adverse events \u2265 grade 3|Percentage of patients in whom treatment cannot be completed.|Percentage of patients with adverse events.|Percentage of patients with serious adverse events.|Percentage of patients with ECG abnormalities.|Change in the viral load of SARS-CoV-2|Time to negative PCR test for COVID-19|Mortality|Percentage of patients requiring invasive mechanical ventilation and \/ or ICU admission|Percentage of patients requiring non-invasive mechanical ventilation|Percentage of patients requiring oxygen therapy""}"
"126","Inhaled Ivermectin and COVID-19","CCOVID-19","NCT04681053","R.20.11.1090.R1","Drug: Ivermectin Powder","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04681053","Recruiting","2021-02-25","2021-12-31","{""locations"":""Mansoura Faculty of Medicine, Mansoura, Dakahlyia, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of virological cure by Rt -PCR for COVID -19 using ivermectin when compared to standard treatment|resolution of pneumonia""}"
"127","Treatment of Patients With COVID-19 With Convalescent Plasma","COOPCOVID-19","NCT04415086","COOP-COVID-19-MCTIC","Biological: convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04415086","Recruiting","2020-06-01","2022-05-22","{""locations"":""University of Sao Paulo - General Hospital, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time elapsed until clinical improvement or hospital discharge|acute adverse events|Clinical Status|Duration of clinical events|SARS-CoV-2 in nasopharyngeal swab|IgG, IgM and IgA titers for SARS-CoV-2|Neutralizing antibodies""}"
"128","Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)","","NCT04390178","CP1","Biological: SARS-CoV-2 convalescent plasma","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04390178","Active, not recruiting","2020-04-10","2020-12-01","{""locations"":""Danderyd Hospital, Danderyd, Sweden"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease progression|Adverse events (AE)|Time ro resolution of fever and symptoms|Clearance of viraemia|Inflammatory parameters|Antibody response to SARS-CoV-2""}"
"129","TCM Differentiation and Treatment Protocol of COVID-19","TDATPOC","NCT04306497","JSZYJ202001","Drug: TCM prescriptions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04306497","Completed","2020-01-22","2020-05-30","{""locations"":""Huai'an fourth people's Hospital, Huaian, Jiangsu, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""340"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The relief of main symptoms\/ disappearance rate of time|Chest CT absorption|Evaluation standard of comprehensive curative effect|Virus antigen negative conversion rate|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score""}"
"130","Ozone Auto-hemotherapy for COVID-19 Pneumonia","COVID-OZONE","NCT04370223","COVID-19 Networking group","Biological: Ozone auto-hemotherapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04370223","Not yet recruiting","2020-05-25","2020-12-25","{""locations"":""Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Nuestra Se\u00f1ora del Rosario, Ibiza, Spain|Hospital Quir\u00f3n Rey Juan Carlos I, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Pr\u00edncipe de Asturias de Alcal\u00e1 de Henares, Madrid, Spain|Fundaci\u00f3 Althaia de Manresa, Manresa, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain|Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain|Clinica Claro, Vigo, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""208"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of patients achieving improvement in clinical condition at day 14 after recruitment|Mortality at day 28|Rate of patients achieving improvement in clinical condition at day 28 after recruitment|Rate of patients achieving improvement in clinical condition at day 7 after recruitment|Time to clinical improvement or hospital discharge|Number of ventilator-free days at 28 days|Hospital length of stay|Time to a 2-fold decrease in ferritin|Time to a 2-fold decrease in C-protein reactive|Time to a 2-fold decrease in Dimer-D|Time to a 2-fold decrease in Lactate Dehydrogenase|Time to a 2-fold decrease in Neutrophils to Lymphocytes ratio""}"
"131","Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)","","NCT04432324","GC2004|2020-001696-32","Biological: Intravenous Immune Globulin|Drug: Standard Medical Treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04432324","Completed","2020-06-02","2021-03-03","{""locations"":""Hospital Universitario Infanta Sof\u00eda, San Sebasti\u00e1n De Los Reyes, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Getafe, Getafe, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS \u2264 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Length of Time to Clinical Progression|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)""}"
"132","Colchicine in COVID-19: a Pilot Study","COLVID-19","NCT04375202","2020-001475-33","Drug: Colchicine 1 MG Oral Tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04375202","Recruiting","2020-04-18","2021-10-31","{""locations"":""Associazione Italiana Pneumologi Ospedalieri, Milan, Italy|Societ\u00e0 Italiana di Reumatologia, Milan, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""308"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of entering the critical stage|Trend of White blood cell count|Change of the \""Sequential Organ failure Assessment\"" (SOFA)|Rate of biochemical criterion (CK, ALT, ferritin) recovery|Rate of disease remission""}"
"133","Traditional Chinese Medicine for Severe COVID-19","","NCT04323332","2020XLA015-1","Drug: Traditional Chinese Medicine Prescription","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04323332","Not yet recruiting","2020-03-01","2020-04-01","{""locations"":""Hao Li, Beijing, Beijing, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""up to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events""}"
"134","Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease","","NCT04391712","2020.01","Device: MLS Laser|Other: Regular Inpatient Medical Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04391712","Completed","2020-04-30","2020-07-16","{""locations"":""Lowell General Hospital, Lowell, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Disposition Post treatment|oxygenation|IL-6 levels|Chest Xray radiographic results|Brescia-COVID Respiratory Severity Scale|SMART-COP Score|PSI Score|CRP levels""}"
"135","Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19","DOXYCOV","NCT04715295","CNO0032020","Drug: Doxycycline Tablets|Drug: Rivaroxaban 15Mg Tab|Combination Product: Hydroxychloroquine and Azithromycin","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04715295","Recruiting","2020-10-05","2021-09-05","{""locations"":""Yaounde Central Hospital, Yaounde, Centre, Cameroon"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical|Virological|Symptom remission|Hospitalisation|Mortality|Biological variables""}"
"136","Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure","TXACOVIDPREV","NCT04550338","TXA.COVID.3","Drug: Tranexamic acid|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04550338","Not yet recruiting","2021-08-01","2023-03-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Conversion from negative to positive COVID-19 test""}"
"137","Repurposing of Chlorpromazine in Covid-19 Treatment","reCoVery","NCT04366739","D20-P016","Drug: CHLORPROMAZINE (CPZ)|Combination Product: Standard of Care (SOC)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04366739","Not yet recruiting","2020-04-29","2020-09-30","{""locations"":""Centre Hospitalier Sainte-Anne, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time To Response (TTR)|Objective Response Rate (ORR)|All-cause mortality|Duration in days required for hospital discharge|Duration in days required for National Early Warning Score \u2264 2 maintained 24 hours|Number of days without oxygen therapy|Incidence of oxygen use, NIV or high flow oxygen therapy|Duration in days of oxygen prescription, NIV or high flow oxygen therapy|Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample|Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample|Biochemical response: serum viral load of SARS-CoV-2|Biochemical response: C-reactive protein (CRP)|Biochemical response: blood test for lymphocytes (lymphopenia)|Parenchymal involvement (chest CT)|Define the optimal dose of CPZ and its tolerance: rates of serious adverse events|Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects|Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale (GA-VAS)|Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation|Define the optimal dose of CPZ and its tolerance: biological anomalies|Define the optimal dose of CPZ and its tolerance: ECG abnormalities|Define the optimal dose of CPZ and its tolerance: plasma CPK assessment|Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment|Define the optimal dose of CPZ and its tolerance: CPZ dose administered""}"
"138","Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)","","NCT04547140","GC2006","Biological: Liquid Alpha1-Proteinase Inhibitor (Human)|Drug: Placebo|Drug: Standard Medical Treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04547140","Recruiting","2021-01-29","2021-09-01","{""locations"":""Birmingham VA, Birmingham, Alabama, United States|St. Joseph's Hospital, Phoenix, Arizona, United States|CHI Health Center, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|University of Utah, Salt Lake City, Utah, United States|AngioCor Blumenau, Blumenau, Santa Catarina, Brazil|Hospital Sao Jose, Crici\u00fama, Santa Catarina, Brazil|Hospital das Clinicas da Faculdade de Medicina de Botucatu, Botucatu, S\u00e3o Paulo, Brazil|Hospital Alemao Oswaldo Cruz, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS \u2264 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression""}"
"139","Hyperimmune Plasma in Patients With COVID-19 Severe Infection","COV2-CP","NCT04385043","Covid-19 convalescent plasma","Other: plasma hyperimmune|Drug: standard therapy","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04385043","Recruiting","2020-05-01","2021-05-15","{""locations"":""Azienda Ospedaliera Policlinico Mater Domini, Catanzaro, Italy|Azienda Ospedaliera Pugliese Ciaccio Catanzaro, Catanzaro, Italy|Azienda Ospedaliera Annunziata, Cosenza, Italy|Azienda Sanitaria Provinciale, Crotone, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy|Azienda Sanitaria Provinciale, Vibo Valentia, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""decrease in mortality|lymphocytes|PCR levels vs control|PCR levels vs before treatment|AB levels and clinical improvement|Inflammatory cytokines vs controls|Inflammatory cytokines vs before treatment""}"
"140","COVID-19 Plasma Collection","","NCT04344015","20D.346","Other: Plasma Donation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04344015","Recruiting","2020-04-13","2021-04-12","{""locations"":""Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures""}"
"141","Antibody Responses in Contacts of COVID-19 Patients","","NCT04444310","Assiut13","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444310","Active, not recruiting","2020-06-15","2020-09-30","{""locations"":""AssiutU, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure level of Abs in asymptomatic close contacts of COVID 19 patients.""}"
"142","COVID-19 and Vaccination Attitudes","VACAT","NCT04352582","VACAT","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04352582","Completed","2020-04-14","2020-04-30","{""locations"":""Survey, London, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1194"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""How vaccination and other attitudes are affected by COVID""}"
"143","Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being","COVIDeF","NCT04352348","APHP200382|2020-A00754-35","Other: blood samples|Other: feces samples (COVI-BIOME ancillary study)|Other: sweat samples (COVIDOG ancillary study)|Other: saliva samples|Other: 6 minutes walk test|Other: Phone call|Other: Urine samples","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04352348","Recruiting","2020-03-31","2022-03-31","{""locations"":""GH Piti\u00e9-Salp\u00eatri\u00e8re \/ Service d'Accueil des Urgences, Paris, Ile-de-France, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of prognostic factors for progression to a severe form of COVID-19 infection|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of clinical manifestations|Description of biological manifestations|Description of radiological manifestations|Description of physiological manifestations|Patient-related prognostic factors|Virus-related risk factors|Comparison of the results of different diagnosis tests""}"
"144","COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)","","NCT04595773","10000102|000102-CC","Other: Aerobic Exercise Training|Other: Education","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04595773","Recruiting","2021-01-22","2023-12-31","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""6 minute walk test distance|Patient reported outcomes and quality of life|Free-living physical activity and sleep quality""}"
"145","Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19","","NCT04465695","UW 20-463","Drug: Interferon beta-1b|Drug: Clofazimine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04465695","Recruiting","2020-07-14","2021-09-30","{""locations"":""The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""81"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical alleviation of symptoms|Hospitalisation|Time to negative viral load|Inflammatory changes|Mortality|Adverse events""}"
"146","Predictive Immune Biomarkers for COVID-19 Pathogenesis","COVIDBioToul","NCT04385108","RC31/20/0162","Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days later","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04385108","Recruiting","2020-03-04","2021-12-31","{""locations"":""Purpan University Hospital, Toulouse, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immune signature|Dosage of cytokines and chemokines in plasma samples|Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity""}"
"147","Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy","","NCT04412252","A3921377","Drug: Tofacitinib|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04412252","Withdrawn","2020-07-06","2020-10-18","{""locations"":""Hartford Hospital (HH), Hartford, Connecticut, United States|University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|LSUHSC-Shreveport, Shreveport, Louisiana, United States|Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical status using ordinal scale|Status of alive and not using mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Status of discharged or not requiring supplemental oxygen|Mortality""}"
"148","A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)","","NCT04547127","GC2003|2020-001299-14","Biological: Convalescent anti-SARS-CoV-2 MBT Plasma|Drug: Standard Medical Treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04547127","Completed","2020-04-29","2021-02-04","{""locations"":""Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Fundaci\u00f3n Jimenez Diaz, Madrid, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Complejo Hospitalario Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital Cl\u00ednico Universitario de Santiago -CHUS, Santiago, Spain|Hospital Universitari Joan XXIII, Tarragona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-Cause Mortality Rate|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by NEWS \u2264 2 Maintained for 24 hours|Time to Hospital Discharge|Time to ICU Discharge|Duration of All Oxygen Use|Duration of Mechanical Ventilation|Absolute Value Change from Baseline in Ordinal Scale|Mean Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale""}"
"149","DAS181 for STOP COVID-19","","NCT04354389","DAS181-2-08|2020-003192-17","Drug: DAS181|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04354389","Withdrawn","2020-07-25","2020-11-30","{""locations"":""Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent of subjects return to room air (RTRA)|Percent of subjects who have recovered|Improved COVID-19 Clinical Classification|Return To Room Air (RTRA)|Percent of subjects who achieve clinical stability|SARS-CoV-2 RNA undetectable|Clinical Deterioration|Percent of subjects discharged|Death (all cause)""}"
"150","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","","NCT04339660","Pr20200402","Biological: UC-MSCs|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04339660","Recruiting","2020-02-01","2020-06-30","{""locations"":""Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The immune function (TNF-\u03b1 \u3001IL-1\u03b2\u3001IL-6\u3001TGF-\u03b2\u3001IL-8\u3001PCT\u3001CRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time""}"
"151","Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)","","NCT04454372","covid-19 ICU","Other: demographic and clinical data obtained from hospital's electronic medical record.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04454372","Not yet recruiting","2020-07-15","2020-11-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""187"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Outcome 30 days after ICU admission""}"
"152","Co-infection Management in COVID-19 Critically Ill","","NCT04382092","2019/14MAR/124","Diagnostic Test: FilmArray Pneumonia","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04382092","Completed","2020-03-23","2020-04-24","{""locations"":""Cliniques Universitaires Saint-Luc, Brussels, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""32"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""% of COVID-19 co-infections|% of antibiotic switches following FA results""}"
"153","Safety and Efficacy of Ruxolitinib for COVID-19","","NCT04348071","20-0869","Drug: Ruxolitinib","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04348071","Withdrawn","2021-07-01","2021-10-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS \u22642 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)""}"
"154","Safety and Efficacy of Baricitinib for COVID-19","","NCT04340232","20-0738","Drug: Baricitinib","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04340232","Withdrawn","2021-03-01","2021-10-01","{""locations"":""University of Colorado, Denver, Aurora, Colorado, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS \u22642 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)""}"
"155","Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)","AVISA","NCT04355338","COV-01-IB","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355338","Recruiting","2020-10-25","2022-05-30","{""locations"":""Universidade Federal do Cear\u00e1, Fortaleza, CE, Brazil|Universidade de Bras\u00edlia, Brasilia, DF, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Hospital Universit\u00e1rio J\u00falio M\u00fcller da Universidade Federal de Mato Grosso, Cuiab\u00e1, Mount, Brazil|Universidade Federal de Roraima - UFRR, Boa Vista, Roraima, Brazil|Centro de Pesquisas em Medicina Tropical de Rond\u00f4nia (CEPEM), Porto Velho, RO, Brazil|Universidade Federal de Sergipe, Laranjeiras, SE, Brazil|Hospital Estadual de Serrana, Serrana, SP, Brazil|Faculdade Santa Marcelina, S\u00e3o Paulo, SP, Brazil|Faculdade de Medicina de S\u00e3o Jos\u00e9 do Rio Preto - FAMERP, S\u00e3o Jos\u00e9 Do Rio Preto, S\u00e3o Paulo, Brazil|Instituto de Infectologia Evandro Chagas - Fiocruz, Rio De Janeiro, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incidence of SARS-CoV-2 infection|Incidence of COVID-19|Incidence of hospitalization due to COVID-19|Level of neutralizing antibodies|Previous SARS-CoV-2 infection""}"
"156","Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients","","NCT04544605","HA Covid-19","Other: Individualized-Chinese herbal medicine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04544605","Recruiting","2020-09-07","2021-12-31","{""locations"":""School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in CM Diagnostic Pattern & Clinical Characteristics using CM Syndrome Differentiation Assessment|Change in Body Constitution Scores using Body Constitution Questionnaires Assessment|Lung Function Questionnaire in Lung Function Assessment|Blood Pressure in 6-minute Walk Test (6MWT)|Pulse in 6-minute Walk Test (6MWT)|SpO2 in 6-minute Walk Test (6MWT)|Distance Walked in 6-minute Walk Test (6MWT)|Number of Rests in 6-minute Walk Test (6MWT)|MRC Dyspnoea Scale in 6-minute Walk Test (6MWT)|Borg Scale of Perceived Exertion in 6-minute Walk Test (6MWT)|Peak Expiratory Flow (PEF) in Spirometry Assessment|Forced Expiratory Volume in 1 second (FEV1) in Spirometry Assessment|Force Vital Capacity (FVC) in Spirometry Assessment|FEV1\/FVC ratio (%) in Spirometry Assessment|Quality of Life (WHO-QOL BREF HK)|Assessment on Western Medicine Visit Frequency""}"
"157","Blood Types in Children With COVID-19","","NCT04682912","MersinTRH","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04682912","Recruiting","2021-01-30","2021-02-01","{""locations"":""Mersin City Training & Research Hospital, Mersi\u0307n, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""1 Month to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Patient medical files""}"
"158","Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19","","NCT04497948","D822FC00005","Drug: Acalabrutinib","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04497948","Terminated","2020-09-21","2020-11-18","{""locations"":""Research Site, Baltimore, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Porto Alegre, Brazil|Research Site, Ribeir\u00e3o Preto, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""8"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acalabrutinib and ACP-5862 plasma PK parameter: AUC12h|Acalabrutinib and ACP-5862 plasma PK parameter: AUClast|Acalabrutinib and ACP-5862 plasma PK parameter: Cmax|Type, frequency, severity, and relationship to study intervention of any treatment-emergent AEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study intervention|Proportion of participants alive and free of respiratory failure at Days 14 and 28|Percent change from baseline in CRP at Days 3, 5, 7, 14, 28|Time to improvement- clinical improvement of \u2265 2 points(from first dose date)on a 9-point category ordinal scale Or live discharge from the hospital Or considered fit for discharge(a score of 0,1,or2 on the ordinal scale)whichever comes first,by Day 28""}"
"159","Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19","EPCOvid-1","NCT04388410","3380","Biological: convalescent plasma","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04388410","Recruiting","2020-08-25","2020-12-31","{""locations"":""Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Tlalpan, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""410"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity and death|Adverse events that require study treatment interruption|Time to clinical improvement|Antibodies against SARS-CoV-2|Disease progression 1|Disease progression 2|Time on mechanical ventilation|Number of days with fever|Adverse events attributed to the study intervention""}"
"160","Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults","pVAC","NCT04546841","P-pVAC-SARS-CoV-2","Biological: multipeptide cocktail","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04546841","Recruiting","2020-11-27","2021-12-20","{""locations"":""University Hospital Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany"",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety- Eastern Cooperative Oncology Group (ECOG) Status|Safety -Vital Signs 2|Safety -Vital Signs 3|Safety-Blood Chemistry and Coagulation 1|Safety-Blood Chemistry and Coagulation 2|Safety-Hematology 1|Safety-Hematology 2|Safety-Hematology 3|Safety-Hematology 4|CoVac-1 specific T-cell response""}"
"161","Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection","","NCT04355793","INCB 18424-MA-COVID-19-301","Drug: Ruxolitinib","Expanded Access:Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04355793","Available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""""}"
"162","Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)","Mon-Covid","NCT04361916","Mon-Covid","Other: home care monitoring","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04361916","Terminated","2020-04-21","2020-06-30","{""locations"":""Asl Alessandria, Casale Monferrato, Alessandria, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""37"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SpO2 at hospital entry|in-hospital mortality|need of intubation|Percentage of hospitalized patients among those with recommendation of hospitalization""}"
"163","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","HAHPS","NCT04329832","1051355","Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04329832","Active, not recruiting","2020-03-30","2021-12-31","{""locations"":""Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""85"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score""}"
"164","Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine","COVID-19-101","NCT04497298","2020-016|2020-002973-89","Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose|Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - High dose|Biological: One COVID-19 vaccine candidate (TMV-083) administration - High dose|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04497298","Recruiting","2020-08-10","2021-10-01","{""locations"":""SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium|CIC Cochin - Pasteur, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""90"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""To assess the safety and tolerability of the COVID-19 vaccine following one or two consecutive intramuscular injections in healthy volunteers|To assess induction of SARS-CoV-2 spike protein-binding antibodies upon one or two administrations of the COVID-19 vaccine by means of ELISA up to study day 390|To assess induction of SARS-CoV-2 neutralizing antibodies upon one or two administrations of the COVID-19 vaccine by means of serum neutralization assay up to study day 390|To assess SARS-CoV-2 spike protein-specific, cell-mediated immune responses up to study day 390, induced by one or two doses of vaccine, by means of intracellular staining and flow cytometry.|To assess potential measles virus shedding by means of RT-qPCR of saliva, nasal swab, urine, or blood samples in sentinel groups on day 0 and up to day 42""}"
"165","Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population","","NCT04344145","PSY-ENCOVID19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344145","Completed","2020-04-16","2020-05-29","{""locations"":""H\u00f4pital de Warquignies, Boussu, Hainaut, Belgium|H\u00f4pital de Jolimont, Haine-Saint-Paul, Hainaut, Belgium|H\u00f4pital de Lobbes, Lobbes, Hainaut, Belgium|H\u00f4pital de Mons, Mons, Hainaut, Belgium|Erasme Hospital CUB, Brussels, Belgium"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""693"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Burnout|Emotional Distress|Insomnia|Needs and difficulties in work situations""}"
"166","Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)","","NCT04718467","JSVCT107","Biological: Recombinant COVID-19 vaccine (Sf9 cells)|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04718467","Not yet recruiting","2021-02-01","2022-03-15","{""locations"":""Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""4000"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of adverse reaction (AR)|The incidence of Adverse Events of Special Interest (AESI)|The incidence of adverse events (AE)|The incidence of grade 3 adverse events (AE)|The incidence of severe adverse events (SAE)|Geometric mean (GMT) of specific antibody|Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies|The positive conversion rate of S-RBD protein-specific antibody|Geometric mean fold increase (GMI) of S-RBD protein-specific antibody|The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody|Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies""}"
"167","Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","","NCT04542694","FAV052020","Drug: Favipiravir|Drug: Standard of care","Interventional","Has Results","Phase 3","https://ClinicalTrials.gov/show/NCT04542694","Completed","2020-05-21","2020-08-20","{""locations"":""State Clinical Hospital \u211650, Moscow, Russian Federation|Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation|City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation|Medical institute Ogarev Mordovia State university, Saransk, Russian Federation|Smolensk clinical hospital \u21161, Smolensk, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of Clinical Status Improvement|Time to Clinical Improvement|Rate of Viral Elimination by Day 10|Time Before the End of Fever|Change in the Level of Lung Damage According to CT|Rate of Transfer to the Intensive Care Unit|Rate of the Use of Non-invasive Lung Ventilation|Rate of the Use of Mechanical Ventilation|Mortality""}"
"168","Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis","PLASMA","NCT04480632","CEI-2020-01200","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04480632","Not yet recruiting","2020-08-01","2022-08-01","{""locations"":""Hospital Internacional de Colombia, Piedecuesta, Santander, Colombia"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""44"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality|Incidence of renal replacement therapy|Incidece of adverse events""}"
"169","COVID-19 Treatment in South Africa","","NCT04532931","SP-PA-COV-202","Other: Standard of care (Paracetamol)|Drug: Artesunate-amodiaquine|Drug: Pyronaridine-artesunate|Drug: Favipiravir plus Nitazoxanide|Drug: Sofosbuvir/daclatasvir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04532931","Recruiting","2020-09-03","2021-10-01","{""locations"":""Ezintsha, Wits Reproductive Health & HIV Institute University of the Witwatersrand, Johannesburg, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""250"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of SARS-CoV-2 clearance|Time to clearance of nasal SARS-CoV-2|Median quantity of SARS-CoV-2|Proportion of days with fever after randomization|Proportion of days with respiratory symptoms after randomization|FLU-PRO\u00a9 Plus|Serious adverse events|Adverse events resulting in treatment discontinuation|Adverse events considered related to the investigational products|LRTI|Maximum score on WHO Ordinal Scale for Clinical Improvement during study participation|Cumulative incidence of hospitalization|Days of hospitalization|Cumulative incidence of mortality""}"
"170","Favipiravir in Hospitalized COVID-19 Patients","FIC","NCT04359615","Favipiravir in COVID-19","Drug: Favipiravir|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04359615","Not yet recruiting","2020-04-20","2020-05-05","{""locations"":""Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Mortality|oxygen saturation by pulse oximetry (SpO2) Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events""}"
"171","Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19","","NCT04426695","R10933-10987-COV-2066|2020-002537-15","Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04426695","Recruiting","2020-06-11","2021-04-16","{""locations"":""Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Chandler, Arizona, United States|Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site 1, Tucson, Arizona, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Mission Hills, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regneron Study Site, Hartford, Connecticut, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Pensacola, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Glenview, Illinois, United States|Regeneron Study Site, Urbana, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Grand Rapids, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Chesterfield, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Englewood, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Pennington, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Albuquerque, New Mexico, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site 1, Buffalo, New York, United States|Regeneron Study Site 2, Buffalo, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Rochester, New York, United States|Regeneron Study Site, Syracuse, New York, United States|Regeneron Study Site, West Islip, New York, United States|Regeneron Study Site, White Plains, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Concord, North Carolina, United States|Regeneron Study Site, Greensboro, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site 1, Amarillo, Texas, United States|Regeneron Study Site 2, Amarillo, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Lubbock, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Sugar Land, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site 1, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Salvador, Bahia, Brazil|Regeneron Study Site, Fortaleza, Ceara, Brazil|Regeneron Study Site, Curitiba, Paran\u00e1, Brazil|Regeneron Study Site, Porto Alegre, Rio Grande Do Sul, Brazil|Regeneron Study Site, Passo Fundo, RS, Brazil|Regeneron Study Site, Chapeco, Santa Catarina, Brazil|Regeneron Study Site, Criciuma, Santa Catarina, Brazil|Regeneron Study Site, Botucatu, Sao Paolo, Brazil|Regeneron Study Site, Campinas, Sao Paolo, Brazil|Regeneron Study Site, S\u00e3o Paulo, Brazil|Regeneron Study Site, S\u00e3o Paulo, Brazil|Regeneron Study Site, S\u00e3o Paulo, Brazil|Regeneron Study Site 1, Las Condes, Santiago De Chile, Chile|Regeneron Study Site 2, Las Condes, Santiago De Chile, Chile|Regeneron Study Site, Regi\u00f3n Metropolitana, Santiago, Chile|Regeneron Study Site, Santiago de Chile, Chile|Regeneron Study Site, Guadalajara, Jalisco, Mexico|Regeneron Study Site, Monterrey, Nuevo Leon, Mexico|Regeneron Study Site, Culiacan, Mexico|Regeneron Study Site 1, M\u00e9rida, Mexico|Regeneron Study Site 2, M\u00e9rida, Mexico|Regeneron Study Site, Veracruz, Mexico|Regeneron Study Site, Zapopan, Mexico|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucuresti, Romania"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""6900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of death or required mechanical ventilation|Proportion of patients with treatment-emergent Serious Adverse Events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral load as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average change from baseline in viral load as measured by RT-qPCR in NP swab samples|Change from baseline in viral load as measured by RT-qPCR in NP swabs|Time to sustained negative RT-qPCR in NP swab samples|Incidence of deaths due to any cause|Incidence of required mechanical ventilation|Proportion of patients who died or went on mechanical ventilation|Proportion of patients who died|Proportion of patients who went on mechanical ventilation|Time to discharge|Serum concentration of REGN10933 over time|Serum concentration of REGN10987 over time|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax\/dose) for REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax\/dose) for REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10933|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10987|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf\/dose) of REGN10933|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf\/dose) of REGN10987|Assessment of PK parameter: Observed terminal half-life [t1\/2] for REGN10933|Assessment of PK parameter: Observed terminal half-life [t1\/2] of REGN10987|Assessment of PK parameter: Clearance (CL) for REGN10933|Assessment of PK parameter: Clearance (CL) of REGN10987|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10933|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10987|Assessment of PK parameter: Mean residence time (MRT) of REGN10933|Assessment of PK parameter: Mean residence time (MRT) of REGN10987|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of anti-drug antibodies (ADA) to REGN10987""}"
"172","Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients","","NCT04443270","01","Drug: Chloroquine phosphate","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04443270","Not yet recruiting","2020-07-27","2021-01-31","{""locations"":""Centro M\u00e9dico Nacional \""20 de Noviembre\"", Mexico City, Benito Ju\u00e1rez, Mexico"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Negative Polymerase Chain Reaction assay at day 0|Polymerase Chain Reaction assay at day 60|Clinical improvement related to COVID-19|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic Use|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic|COVID-19 symptomatic onset rate""}"
"173","A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)","","NCT04640402","JSVCT099","Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: Low-dose placebo (18-59 years) & Two dose regimen|Biological: Low-dose placebo (18-59 years) & Three dose regimen|Biological: High-dose placebo (18-59 years) & Two dose regimen|Biological: High-dose placebo (18-59 years) & Three dose regimen|Biological: Low-dose placebo (60-85 years) & Two dose regimen|Biological: Low-dose placebo (60-85 years) & Three dose regimen|Biological: High-dose placebo (60-85 years) & Two dose regimen|Biological: High-dose placebo (60-85 years) & Three dose regimen","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04640402","Recruiting","2020-11-17","2021-11-18","{""locations"":""Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""960"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Geometric mean (GMT) of specific antibody|The incidence of adverse reaction (AR)|The incidence of adverse events (AE)|The incidence of severe adverse events (SAE)|The incidence of serious adverse events|Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies|The positive conversion rate of S-RBD protein-specific antibody|Geometric mean fold increase (GMI) of S-RBD protein-specific antibody|The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody|Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies""}"
"174","Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection","","NCT04362865","200103|20-C-0103","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362865","Recruiting","2020-04-27","2024-12-01","{""locations"":""Medstar Washington Hospital Center, Washington, District of Columbia, United States|Medstar Franklin Square Medical Center, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Medstar Montgomery Medical Center, Olney, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""360"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characterize immune response|Immune response and outcome|B- and T-cell arm immune response""}"
"175","Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study","","NCT04384497","CP2","Biological: SARS-CoV-2 convalescent plasma","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04384497","Recruiting","2020-05-07","2020-12-01","{""locations"":""Danderyd Hospital, Danderyd, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy|Adverse events|Dose of plasma needed to clear viremia|Clearance of viremia|Fever and symptoms|Inflammatory parameters|Antibody response to SARS-CoV-2""}"
"176","Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)","","NCT04351646","2020.0075","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351646","Not yet recruiting","2020-04-15","2022-04-15","{""locations"":""St. Georges Hospital Foundation Trust, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody titres to SARS-CoV-2""}"
"177","Vitamin D and COVID-19 Trial","VIVID","NCT04536298","2020P002815","Dietary Supplement: vitamin D|Dietary Supplement: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04536298","Recruiting","2020-12-28","2021-04-30","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""2700"",""age"":""30 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization or death in index cases|Self-reported disease severity in index cases|Time to hospitalization or death in index cases|ICU admission\/ventilation support in index cases|SARS-CoV-2 infection in close household contacts|Self-reported disease severity in close household contacts""}"
"178","Azithromycin in Hospitalized COVID-19 Patients","AIC","NCT04359316","Azithromycin in COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04359316","Not yet recruiting","2020-04-20","2020-05-05","{""locations"":""Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events""}"
"179","VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection","VITACOV","NCT04370808","VITACOV","Other: Exposure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370808","Not yet recruiting","2020-06-01","2021-03-01","{""locations"":""Cardiovascular Center at Universidade de Lisboa, Lisbon, Lisboa, Portugal|Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, Lisboa, Portugal|Centro Hospitalar de S\u00e3o Jo\u00e3o, Oporto, Portugal"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.|Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.|Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.|Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.""}"
"180","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19","","NCT04324996","ChongqingPublicHMC","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04324996","Recruiting","2020-02-21","2022-08-31","{""locations"":""Chongqing Public Health Medical Center, Chongqing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical response|Side effects in the treatment group""}"
"181","Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19","","NCT04410354","VC-02-01","Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04410354","Terminated","2020-06-16","2020-12-01","{""locations"":""Mayo Clinic in Arizona, Phoenix, Arizona, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Atlantic Health System \/ Morristown Medical Center, Morristown, New Jersey, United States|Atlantic Health System \/ Overlook Medical Center, Summit, New Jersey, United States|St. David's South Austin Medical Center, Austin, Texas, United States|St. David's Medical Center, Austin, Texas, United States|HCA Houston Healthcare Medical Center, Houston, Texas, United States|HCA Houston Healthcare Mainland, Texas City, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""44"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation\/Fraction of Inspired Oxygen""}"
"182","An Observational Study of Neurologic Function After COVID-19 Infection","","NCT04564287","10000094|000094-N","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04564287","Enrolling by invitation","2020-10-28","2022-12-01","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""MRI brain abnormalities|Neurological Examination|Autonomic Testing""}"
"183","Safety in Convalescent Plasma Transfusion to COVID-19","","NCT04333355","PC-TecSalud Fase I","Biological: Convalescent Plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04333355","Terminated","2020-05-08","2020-08-20","{""locations"":""Hospital San Jos\u00e9, Monterrey, Nuevo Leon, Mexico"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Viral load of SARS-CoV-2""}"
"184","COVID-19 : Study of INFLAmmasome and PLAtelets Functions","CO-QUETTES","NCT04397822","RC31/20/0142","Biological: Blood samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397822","Recruiting","2020-04-16","2022-04-01","{""locations"":""CHU Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""110"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Activation of platelet NLRP3 inflammasome""}"
"185","A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19","","NCT04433013","IRB-2020-05-029","Drug: Lianhua Qingwen|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04433013","Not yet recruiting","2020-07-01","2021-02-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who test negative for COVID-19|Time taken in days for relief of clinical symptoms|Proportion of participants with mild symptoms of COVID-19 progressing to moderate or severe illness|Proportion of participants who test positive for COVID-19 with Ct value>30""}"
"186","Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica","RESPIRA","NCT04537338","R020-SABI-00261","Genetic: 1. Characterize the immune response after infection with SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04537338","Not yet recruiting","2020-09-14","2022-09-14","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""2000"",""age"":""6 Months to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""COVID-19 Seroconversion""}"
"187","Losmapimod Safety and Efficacy in COVID-19","LOSVID","NCT04511819","FIS-001-2020","Drug: Losmapimod oral tablet|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04511819","Recruiting","2020-08-28","2021-06-01","{""locations"":""University of California Irvine - Irvine Medical Center, Irvine, California, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Memorial Hermann Hospital South West, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|United Medical Memorial Hospital, Houston, Texas, United States|Hospital Universitario Cassiano Antonio de Moraes-HUCAM\/Hospital das Clinicas, Vit\u00f3ria, ES, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Irmandade de Santa Casa de Misericordia de Porto Alegre, Porto Alegre, SC, Brazil|Hospital Santa Paula, San Paolo, SP, Brazil|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Nuevo Hospital Civil de Guadalajara, Guadalajara, JC, Mexico|JM Research Cuernavaca, Cuernavaca, Morelos, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia M\u00e9dica Especializada, S.C., Culiac\u00e1n, Sinaloa, Mexico|Hospital Nacional Carlos Alberto Segu\u00edn Escobedo - EsSalud Arequipa, Arequipa, AR, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""410"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Day 28 Mortality|Clinical Status Assessment|Respiratory Failure Assessment|Treatment Survival|Treatment-Emergent Adverse Events""}"
"188","ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19","","NCT04583969","20-0013B","Biological: Lenzilumab|Other: Placebo|Drug: Remdesivir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04583969","Recruiting","2020-10-19","2021-12-31","{""locations"":""Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|Kern Medical Center, Bakersfield, California, United States|Hoag Hospital Newport Beach, Newport Beach, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|MedStar Washington Hospital Center - Infectious Diseases, Washington, District of Columbia, United States|Advent Health Orlando - Critical Care, Orlando, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States|Virtua Health - Virtua Voorhees Hospital - Pulmonology, Voorhees, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|The State University of New York - University at Buffalo - Department of Medicine, Buffalo, New York, United States|Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York, New York, United States|Wake Forest Baptist Health - Infectious Diseases, Winston-Salem, North Carolina, United States|University of Toledo Medical Center - Ruppert Clinic, Toledo, Ohio, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Kent County Memorial Hospital, Warwick, Rhode Island, United States|Baptist Hospitals of Southeast Texas Site, Beaumont, Texas, United States|West Virginia University - Infectious Diseases Clinic, Morgantown, West Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale.|Change from baseline in C-reactive protein (CRP) concentration|Change from baseline in d-dimer concentration|Change from baseline in ferritin concentration|Change from baseline in fibrinogen concentration|Change from baseline in lactate dehydrogenase (LDH) concentration|Change from baseline in troponin concentration|Change in alanine aminotransferase (ALT) over time|Change in aspartate aminotransferase (AST) over time|Change in creatinine over time|Change in hemoglobin over time|Change in international normalized ratio (INR) over time|Change in platelets over time|Change in total bilirubin over time|Change in white blood cell (WBC) count with differential over time|Clinical efficacy, as assessed by time to recovery|Cumulative incidence of Grade 3 and 4 clinical and\/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of study product administration|Duration of hospitalization|Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Duration of new non-invasive ventilation or high flow oxygen use during the study|Duration of new oxygen use|Duration of non-invasive ventilation\/high flow oxygen use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of ventilator\/ extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Oxygenation use|Proportion of subjects alive and without respiratory failure|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to death|Ventilator\/ extracorporeal membrane oxygenation (ECMO) use""}"
"189","AstraZeneca Vax - Sputnik V Combination Study","","NCT04684446","D8111C00003","Biological: AZD1222|Biological: rAd26-S","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04684446","Not yet recruiting","2021-03-30","2021-10-12","{""locations"":""Research Site, Vitebsk, Belarus|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years to 130 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody seroconversion rate (\u2265 4-fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination.|Incidence of local and systemic solicited AEs for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination).|Incidence of unsolicited AEs, SAEs and AESIs through 29 days post each vaccination (ie, until Day 29 following the first vaccination and Day 57 following the second vaccination).|Incidence of SAEs and AESIs after first vaccination until study end (Day 180).|Antibody seroconversion rate (\u2265 4-fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post first vaccination.|Antibody seroconversion rate (\u2265 4-fold increase from baseline) against RBD antigen.|GMT and GMFR of immunogenicity against Spike and RBD antigens (MSD serology assay) at the day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).|Antibody seroconversion rate (\u2265 4-fold increase from baseline) SARS-CoV-2 neutralising antibodies.|GMT and GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).""}"
"190","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.","CALAVI US","NCT04380688","D822FC00003","Drug: Acalabrutinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04380688","Completed","2020-06-13","2020-11-16","{""locations"":""Research Site, Anniston, Alabama, United States|Research Site, Escondido, California, United States|Research Site, Fullerton, California, United States|Research Site, Glendale, California, United States|Research Site, Newport Beach, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Loxahatchee Groves, Florida, United States|Research Site, Peoria, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""62"",""age"":""18 Years to 130 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of Adverse Events and Serious Adverse Events|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Change from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (SpO2\/FiO2)|Time to clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale|Time to SpO2 > 94% on room air|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862""}"
"191","COVID-19 Antibody Plasma Research Study in Hospitalized Patients","UNC CCP RCT","NCT04524507","20-1544","Biological: High-titer Convalescent COVID-19 Plasma (CCP1)|Biological: Standard-titer Convalescent COVID-19 plasma (CCP2)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04524507","Recruiting","2020-08-27","2021-05-01","{""locations"":""University of North Carolina Health Care, Chapel Hill, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative Incidence of Serious Adverse Events (SAEs) at study Day 14|Days to hospital discharge (or discharge equivalent) following first dose of CCP""}"
"192","Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19)","COROBIOCHIC","NCT04641988","RECHMPL20_0625","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04641988","Completed","2020-02-01","2020-06-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""111"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""hs-cTnT|NT-proBNP""}"
"193","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.","CALAVI","NCT04346199","D822FC00001","Drug: Acalabrutinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04346199","Completed","2020-06-12","2020-11-17","{""locations"":""Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Monte Grande, Argentina|Research Site, Ramos Mej\u00eda, Argentina|Research Site, Botucatu, Brazil|Research Site, Florian\u00f3polis, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeir\u00e3o Preto, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, S\u00e3o Paulo, Brazil|Research Site, Curico, Chile|Research Site, Santiago, Chile|Research Site, Talca, Chile|Research Site, Villejuif Cedex, France|Research Site, Frankfurt, Germany|Research Site, Gauting, Germany|Research Site, Hamburg, Germany|Research Site, K\u00f6ln, Germany|Research Site, Bangalore, India|Research Site, New Delhi, India|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, Shinjuku-ku, Japan|Research Site, D.F, Mexico|Research Site, Monterrey, Mexico|Research Site, M\u00e9xico, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Cape Town, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Ankara, Turkey|Research Site, Bakirkoy, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Umraniye, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""177"",""age"":""18 Years to 130 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Subject alive and free of respiratory failure|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Chnage from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (PaO2\/FiO2)|Occurrence of Adverse Events and Serious Adverse Events|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC)""}"
"194","A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19","","NCT04330586","KUMC-COVID-19","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04330586","Recruiting","2020-04-01","2021-03-31","{""locations"":""Korea University Guro Hospital, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""66"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure""}"
"195","Adaptive COVID-19 Treatment Trial 3 (ACTT-3)","","NCT04492475","20-0006 ACTT-3","Drug: Interferon beta-1a|Other: Placebo|Drug: Remdesivir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04492475","Completed","2020-08-05","2020-12-21","{""locations"":""University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Seongnam, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cos\u00edo Villegas, Mexico City, Mexico|Instituto Nacional de Ciencias Medicas y Nutrici\u00f3n Salvador Zubir\u00e1n - Departamento de Infectologia, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""969"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery for patients with baseline ordinal score 4, 5, and 6|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in C-reactive protein (CRP)|Change from baseline in creatinine|Change from baseline in d-dimer concentration|Change from baseline in hemoglobin|Change from baseline in international normalized ratio (INR)|Change from baseline in platelets|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and\/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of invasive mechanical ventilation|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of non invasive ventilation or high flow oxygen use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of study product administration|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change from baseline in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale for patients with baseline ordinal score 4 and 5|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of <\/= 2 and maintained for 24 hours, whichever occurs first|Time to recovery for patients with a baseline ordinal score of 4 and 5""}"
"196","Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management","IMMUNOMARKCOV","NCT04668170","RC31/20/0187","Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days later","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04668170","Recruiting","2020-05-05","2021-12-31","{""locations"":""University Hospital Bordeaux, Bordeau, France|University Hospital Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""340"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immune signature on admission : phenotypic profile of blood T-cells|Immune signature on admission : inflammatory cytokines|Dynamics of cellular immunity: CD4 and CD8 T cells|Dynamics of cellular immunity: gd T cells|Dynamics of cellular immunity: T cell transcriptomic analysis|Dynamics of cellular immunity: humoral immunity""}"
"197","A Longitudinal Study of COVID-19 Sequelae and Immunity","","NCT04411147","200123|20-I-0123","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04411147","Recruiting","2020-06-17","2027-12-31","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Medical Sequelae in COVID- 19 Survivors|Risk Factors for Medical Sequelae in COVID-19 Survivors|Antibody and cell-mediated immune responses to SARSCoV-2|Antibody and cell-mediated immune responses to SARSCoV-2 over time|Incidence of reinfection with COVID-19|Incidence of clinical silent infection|Mental health status in COVID-19 survivors and contacts""}"
"198","Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients","Ta1","NCT04428008","ACW-1221958-1","Drug: Thymalfasin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04428008","Recruiting","2021-01-12","2022-01-01","{""locations"":""Clinical Research Consultants, Kansas City, Kansas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""240"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in documented infection with COVID-19 Reduction in infection with COVID-19|Need for hospitalization|Hospital length of stay|Need for ICU admission|ICU length of stay|Need for mechanical ventilation|Duration of mechanical ventilation|Recovery time from COVID-19|Change in any existing comorbidities or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections|Change in lymphocyte subsets (CD4, CD8)|Mortality|Treatment-emergent adverse events|Treatment-emergent changes in vital signs|Treatment-emergent laboratory parameters""}"
"199","The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial","","NCT04364815","RGAO-2020-0339","Drug: Hydroxychloroquine plus standard preventive measures|Drug: Placebo plus standard preventive measures","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04364815","Withdrawn","2020-12-01","2021-05-01","{""locations"":""Philippine General Hospital - University of the Philippines Manila, Manila, Philippines"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""0"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection|Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms (to be reported as absolute number and frequency of events)|Time to COVID-19 infection in patients receiving study drug (in days)|Safety and tolerability of study drug (to be reported as absolute number and frequency of events)""}"
"200","Adaptive COVID-19 Treatment Trial 2 (ACTT-2)","","NCT04401579","20-0006 ACTT-2","Other: Placebo|Drug: Remdesivir|Drug: Baricitinib","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04401579","Completed","2020-05-08","2020-07-31","{""locations"":""University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Indiana University School of Medicine - Infectious Diseases, Indianapolis, Indiana, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrici\u00f3n Salvador Zubir\u00e1n - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cos\u00edo Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Catalu\u00f1a, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Catalu\u00f1a, Spain|Hospital Clinico San Carlos - Enfermedades Infecciosas, Madrid, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, City Of London, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1034"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and\/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of <\/= 2 and maintained for 24 hours, whichever occurs first|Change from baseline in C-reactive protein (CRP)|Change from baseline in d-dimer concentration""}"
"201","Hemostasis in COVID-19: an Adaptive Clinical Trial","","NCT04466670","33788820.9.0000.0068","Drug: unfractionated Heparin|Drug: Unfractionated heparin nebulized|Drug: acetylsalicylic acid|Drug: Enoxaparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04466670","Recruiting","2020-07-08","2021-04-30","{""locations"":""Vanderson Rocha, Sao Paulo, Brazil"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""310"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital discharge - alive \/ death|Length of mechanical ventilation free days|Length of renal replacement therapy free days|Number of documented venous thromboembolism or arterial thrombosis""}"
"202","NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression","COVID-19 NGS","NCT04364828","COVID-19 NGS","Genetic: Whole Genome Analysis|Genetic: T-cell receptor (TCR) repertoire|Genetic: SARS-CoV-2 viral composition","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04364828","Recruiting","2020-10-21","2022-08-01","{""locations"":""University Hospital T\u00fcbingen, T\u00fcbingen, Germany"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral evolution|Immune response|Disease severity""}"
"203","Adaptive COVID-19 Treatment Trial (ACTT)","","NCT04280705","20-0006","Other: Placebo|Drug: Remdesivir","Interventional","Has Results","Phase 3","https://ClinicalTrials.gov/show/NCT04280705","Completed","2020-02-21","2020-05-21","{""locations"":""University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie\/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universit\u00e4tsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrici\u00f3n Salvador Zubir\u00e1n - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cos\u00edo Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Catalu\u00f1a, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Catalu\u00f1a, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1062"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Recovery|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin Time (PT)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|Percentage of Participants Reporting Grade 3 and 4 Clinical and\/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics|Duration of Hospitalization|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use|Percentage of Participants Requiring New Oxygen Use|Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Mean Change in the Ordinal Scale|14-day Participant Mortality|29-day Participant Mortality|Time to an Improvement by at Least One Category Using an Ordinal Scale|Time to an Improvement of at Least Two Categories Using an Ordinal Scale|Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First""}"
"204","Cardiovascular Manifestations of COVID-19","","NCT04701515","030.CVS.2020.D","Other: Chart review","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04701515","Recruiting","2020-06-10","2022-12-31","{""locations"":""Methodist Dallas Medical Center, Dallas, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Heart failure|Tamponade|Pericardial Effusion|Myocarditis|Pericarditis|Arrythmias|Troponin I|N-terminal prohormone BNP|Stroke|Myocardial infarction|Shock|Deep venous thrombosis|Discharge disposition|Primary diagnosis|Rate of ICU admission\/transfer|Total hospital length of stay|ICU length of stay|Percentage of patients in cohort that had EKG testing or Echocardiography""}"
"205","Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance","","NCT04459520","IRB#20-000980","Behavioral: Positive COVID Test Result - Hypothetical Scenario|Behavioral: Negative COVID Test Result - Hypothetical Scenario|Behavioral: Unavailable COVID Test Result - Hypothetical Scenario","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04459520","Completed","2020-07-23","2020-07-29","{""locations"":""UCLA Health Department of Medicine, Quality Office, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""1400"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Behavioral Intentions|Personal Decisions Subscale|Social Expectations Subscale|Voting Behavior Question|Protest Question|Transportation""}"
"206","Classification of COVID-19 Infection in Posteroanterior Chest X-rays","","NCT04358536","04202002","Device: CovX","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04358536","Completed","2020-04-01","2020-04-17","{""locations"":""Dascena, Oakland, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of COVID-19""}"
"207","Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","","NCT04640168","20-0006 ACTT-4","Drug: Baricitinib|Drug: Dexamethasone|Other: Placebo|Drug: Remdesivir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04640168","Recruiting","2020-11-24","2021-06-30","{""locations"":""University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Kaiser Permanente San Diego Medical Center, San Diego, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|VA Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|Tulane University - Section of Pulmonary Diseases, Critical Care, and Environmental Medicine, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Michigan - Infectious Disease Clinic at Taubman Center, Ann Arbor, Michigan, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|CHI Health Creighton University Medical Center - Bergan Mercy - Pulmonary Medicine, Omaha, Nebraska, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|University of Oklahoma Health Science Center - Surgery, Oklahoma City, Oklahoma, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Seongnam, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cos\u00edo Villegas, Mexico City, Mexico|Instituto Nacional de Ciencias Medicas y Nutrici\u00f3n Salvador Zubir\u00e1n - Departamento de Infectologia, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National University Health System - Alexandra Hospital - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1500"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of subjects not meeting criteria for one of the following two ordinal scale categories at any time: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in C-reactive protein (CRP)|Change from baseline in creatinine|Change from baseline in d-dimer concentration|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Cumulative incidence of Grade 3 and 4 clinical and\/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Days of invasive mechanical ventilation\/ extracorporeal membrane oxygenation (ECMO) (if applicable)|Days of non-invasive ventilation\/high flow oxygen (if applicable)|Days of supplemental oxygen (if applicable)|Desirability of Outcome Ranking (DOOR)|Duration of hospitalization|Incidence of discontinuation or temporary suspension of study product administration|Subject 14-day mortality|Subject 28-day mortality|Subject clinical status|The proportion of subjects meeting criteria for one of the 8 ordinal scale categories|Time to an improvement of one category from baseline using an ordinal scale|Time to an improvement of two categories from baseline using an ordinal scale|Time to recovery""}"
"208","A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)","","NCT04504032","Gates MRI - COD-01-T01-01","Drug: Rivaroxaban|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04504032","Active, not recruiting","2020-09-02","2021-04-01","{""locations"":""Woodland Research Northwest LLC - ERG - PPDS, Rogers, Arkansas, United States|Science 37, Inc, Los Angeles, California, United States|Allergy and Asthma Medical Group and Research Center - CRN - PPDS, San Diego, California, United States|Invesclinic, LLC, Fort Lauderdale, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|LCC Medical Research - Miami - BTC - PPDS, Miami, Florida, United States|Adult Medicine of Lake County, Mount Dora, Florida, United States|Providea Health Partners LLC, Evergreen Park, Illinois, United States|Clinical Research Institute, Inc - CRN - PPDS, Minneapolis, Minnesota, United States|Encompass Care, North Las Vegas, Nevada, United States|Riverside Medical Group - Circuit- PPDS, Secaucus, New Jersey, United States|NYC Health + Hospitals\/Lincoln, Bronx, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Harlem Hospital Center, New York, New York, United States|Premier Family Physicians - Austin - Hunt - PPDS, Austin, Texas, United States|Village Health Partners - Plano - Hunt - PPDS, Plano, Texas, United States|South Texas Allergy and Asthma Medical Professionals, San Antonio, Texas, United States|Boundary House Medical Centre, Sale, Cheshire, United Kingdom|St Mary's Hospital - PPDS, London, City Of London, United Kingdom|Royal Free Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs)|Number of Participants With AEs Leading to Study Discontinuation|Number of Participants With Serious Adverse Events (SAEs)|Proportion of Participants With Disease Progression|Median Time to Disease Resolution|Proportion of Participants Who Achieve Disease Resolution|Mean Gates Medical Research Institute Ordinal Scale Score|Change From Baseline in Gates Medical Research Institute Ordinal Scale Score|Mean World Health Organization Ordinal Scale Score|Change From Baseline in World Health Organization Ordinal Scale Score|Incidence of Hospitalization|Number of Days of Hospitalization""}"
"209","Keto-diet for Intubated Critical Care COVID-19","KICC-COVID19","NCT04358835","IRB00247383","Dietary Supplement: Ketogenic diet|Other: standard of care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04358835","Withdrawn","2020-09-01","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the partial pressure of carbon dioxide (PaCO2)|Change in minute ventilation|Change in respiratory system compliance|Change in driving pressure|Change in ventilator synchrony|Change in mean arterial pressure|Change in the fraction of inspired oxygen percentage of oxygen (FiO2)|Change in the partial pressure of carbon dioxide (PaO2) to the fraction of inspired oxygen percentage of oxygen (FiO2) ratio|Change in hydrogen ion activity (pH)|Change in Bicarbonate (HCO3)|Change in red blood cell count|Change in white blood cell count|Change in white cell differential|Change in hemoglobin levels|Change in hematocrit|Change in mean cell volume|Change in mean cell hemoglobin|Change in mean cell hemoglobin concentration|Change in platelet count|Change in red cell distribution width|Change in blood albumin level|Change in serum alkaline phosphatase level|Change in serum aspartate transaminase level|Change in serum alanine aminotransferase level|Change in blood urea nitrogen levels|Change in serum calcium level|Change in serum chloride level|Change in serum potassium level|Change in serum creatinine level|Date patient is re-intubated or need mechanical ventilation for a second time|Length of intensive care unit stay|The total hospital stay|Disposition at discharge|Change in heart rate|Change in the dosage of vasopressor medication""}"
"210","Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections","REMDECO-19","NCT04365725","APHP200522","Drug: Remdesivir","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365725","Recruiting","2020-05-05","2020-06-01","{""locations"":""H\u00f4pital Cochin, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical course on Day 15.|Clinical course on Day 3.|Clinical course on Day 8|Clinical course on Day 11.|Clinical course on Day 29.|Duration of treatment|Sepsis-related Organ Failure Assessment score|Duration without mechanical ventilation|Mortality|cumulative incidence of grade 3 and 4 adverse events (AEs).""}"
"211","Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -","","NCT04647604","2020-002293-28","Drug: Omegaven®|Drug: Sodium chloride","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04647604","Recruiting","2020-06-23","2021-04-30","{""locations"":""Karolinska Universitetssjuhuset, Stockholm, Sweden|S\u00f6dersjukhuset, Stockholm, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in inflammatory biomarkers|Changes in proresolving mediators|Changes in fatty acids in the erythrocyte fraction|Changes in cardiac biomarkers|Changes in biomarkers of organ damage|Changes in thrombosis parameters|Changes in coagulation parameters|Changes in markers of infection|Changes in infection load|Changes in clinical parameters|Length of hospital stay|Complications""}"
"212","Clinical and Biological Predictors of COVID-19 Disease in Older Patients","","NCT04348396","INRCA_01_2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04348396","Recruiting","2020-04-03","2020-12-01","{""locations"":""IRCCS INRCA Hospital, Ancona, Italy|IRCCS INRCA Hospital, Casatenovo, Italy|IRCCS INRCA Hospital, Fermo, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Descriptive-epidemiological analysis of health conditions|Evaluation of frailty condition|Identification of biomarkers of inflammation|Assessment of functional capacity|Evaluation of drug consumption|Evaluation of inflamma-miRs""}"
"213","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19","","NCT04252118","2020003D","Biological: MSCs","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04252118","Recruiting","2020-01-27","2021-12-01","{""locations"":""Beijing 302 Military Hospital of China, Beijing, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase""}"
"214","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","COVIFERON","NCT04343768","Different Interferons in COVID","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04343768","Completed","2020-04-09","2020-04-27","{""locations"":""Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization""}"
"215","Cardiac Injury in COVID-19: a Pathology Study","","NCT04367792","56/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367792","Active, not recruiting","2020-04-23","2021-03-01","{""locations"":""ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cardiac pathological findings from series of 60 patients dying from COVID-19 disease|viral load in cardiac tissues and the extent of damage|Co-localize the SARS-CoV-2 using RNAscope in situ hybridization, with its entry receptor ACE2 and serine protease TMPRSS2 in different cell types found in the heart|Multi-organ involvement obtained from hystological analyses of paraffine blocks from different organs (ie kidney, spleen, bowel,....)""}"
"216","COVID-19 - Cytokine Storm","","NCT04474067","DM002","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04474067","Recruiting","2020-06-28","2021-03-01","{""locations"":""Hadassah Medical Center, Jerusalem, Israel"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Outcomes of Patients with COVID-19 using the National Early Warning Score 2 (NEWS2) system|Clinical Outcomes of Patients with COVID-19 using the new NIH Patient Classification of severity of illness|Mortality|Cytokine\/Chemokine\/Hematopoietic Growth Factors\/ Complement and Other Immune Modulators in Patients with COVID-19""}"
"217","Immunosupressive Treatment in COVID-19 Patients","SAM-COVID","NCT04382781","FIS-INM-2020-03","Drug: NO-Immunosuppressive|Drug: Immunosuppressive|Drug: Immunoglubulins","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382781","Recruiting","2020-05-01","2020-05-01","{""locations"":""Hospital Virgen Macarena, Sevilla, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Invasive ventilation or death|Ventilation|Death|Secondary infections|Digestive tract hemorrhage|Change in 7 points scale""}"
"218","COVID-19: Respiratory and Sleep Follow-up","Co-SURVIVORS","NCT04406324","38RC20.157","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406324","Recruiting","2020-06-01","2026-03-05","{""locations"":""H\u00f4pital Avicenne, Bobigny, France|Centre Hospitalier Henri Mondor, APHP, Cr\u00e9teil, France|CHU Grenoble Alpes, Grenoble, France|CHRU Nancy, Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diffusion Capacity for Carbon Monoxide (CO) 3 months after COVID diagnosis|Prevalence of Sleep Disordered Breathing (SDB) 3 months after COVID diagnosis|Prevalence of sleep disorders 3 months after COVID diagnosis|Prevalence of ventilatory muscle function impairments, 3 months after COVID diagnosis|Prevalence of cardiac impairments 3 months after COVID diagnosis|Follow-up of pulmonary diffusion capacity of carbon monoxide|Follow-up of sleep disorders treatment compliance|Follow-up of sleep disorders treatments efficacy|HLA alleles aspect of COVID clinical presentation|KIR loci aspect of COVID clinical presentation|metabolomic aspect of COVID clinical presentation""}"
"219","Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients","","NCT04603924","ANA001-001","Drug: Niclosamide|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04603924","Recruiting","2020-10-07","2022-06-01","{""locations"":""Helen Keller Hospital, Sheffield, Alabama, United States|Baptist Health Research Institute, Jacksonville, Florida, United States|AdventHealth Tampa, Tampa, Florida, United States|Therapeutic Concepts, PA, Houston, Texas, United States|Memorial Hermann Memorial City Medical Center, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""436"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety and Tolerability of ANA001 as measured by the incidence of treatment emergent adverse events (TEAE's) (Part 1 and Part 2)|Efficacy as measured by median time to hospital discharge (Part 2)|Efficacy as measured by median time to hospital discharge (Part 1)|Pharmacokinetics (PK) of ANA001 as measured by plasma concentrations (Part 1)|Efficacy of ANA001 as measured by mean change from baseline in the National Early Warning Score (NEWS 2) (Part 2)|Efficacy of ANA001 as measured by mean number of days on rescue therapy (Part 2)""}"
"220","A Clinical Trial for Hospitalized Patients With COVID-19 in Ceará: ResCOVID Study","ResCOVID","NCT04649827","3.948.100","Other: Clinical Observation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649827","Recruiting","2020-04-02","2021-12-30","{""locations"":""Hospital Leonardo Da Vinci, Fortaleza, Ceara, Brazil"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU outcome|Hospital outcome|Mechanical ventilation|Hospital complications""}"
"221","COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada","","NCT04397328","9881","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04397328","Not yet recruiting","2020-05-19","2021-04-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""336"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of symptomatic fever >37.8, dry cough, or shortness of breath (resident\/patient report or nurse observation) respiratory infection with confirmed PCR+ result for SARS-CoV-2.|Requirement for admission to acute care hospital and\/or ICU admission or death|Asymptomatic PCR+ SARS-CoV-2 test result|Time to clinical recovery (TTCR).""}"
"222","COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection","","NCT04666441","R10933-10987-COV-20145","Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04666441","Recruiting","2020-12-15","2021-04-24","{""locations"":""Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time-weighted average daily change from baseline in viral load (log10 copies\/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average daily change from baseline in viral load (log10 copies\/mL)|Time-weighted average daily change from baseline in viral load (log10 copies\/mL) in patients with high viral load|Proportion of patients with high viral load|Proportion of patients with viral loads below the limit of detection|Proportion of patients with viral loads below the lower limit of quantitation|Time-weighted average daily change from baseline in cycle threshold (Ct) as measured by RT-qPCR in NP samples|Time-weighted average daily change from baseline in Ct from day 1 to day 5, as measured by RT-qPCR in NP samples|Change from baseline in Ct as measured by RT-qPCR in NP samples|Change from baseline in viral load as measured by RT-qPCR in NP samples|Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions (grade \u22652)|Proportion of patients with injection-site reactions (grade \u22652)|Proportion of patients with hypersensitivity reactions (grade \u22652)|Concentrations of REGN10933 in serum|Concentrations of REGN10987 in serum""}"
"223","The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients","","NCT04475107","SP-PA-COV-201","Drug: Pyronaridine-Artesunate|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04475107","Recruiting","2020-07-09","2021-09-01","{""locations"":""Korea University Ansan Hospital, Ansan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyungpook national university hospital, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Sahmyook Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""76"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion (%) of patients with virological clearance of SARS-CoV-2 at day 7 post-dose*|Viral load reduction of SARS-CoV-2 at Day 3, 7, 10, and 14 post-dose compared to the baseline|Proportion (%) of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose*|Change in WHO Ordinal Scale for Clinical Improvement at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Change in NEWS score at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Time to achieve normalization of body temperature, post-dose|Time to achieve normalization of respiratory rate, post-dose|Time to achieve normalization of oxygen saturation, post-dose""}"
"224","CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","CONCOR-1","NCT04348656","CONCOR-1","Biological: Convalescent plasma","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04348656","Active, not recruiting","2020-05-14","2021-03-31","{""locations"":""Brooklyn Hospital, Brooklyn, New York, United States|Lower Manhattan Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Hospital Universit\u00e1rio Ant\u00f4nio Pedro (HUAP), Niter\u00f3i, Brazil|Hemario, Rio De Janeiro, Brazil|Peter Lougheed Center, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|University of Alberta - Royal Alexandra Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Sturgeon Community Hospital, St. Albert, Alberta, Canada|Fraser Health Authority - Abbotsford Regional Hospital and Cancer Centre, Abbotsford, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|Vitalit\u00e9 Health Network - Acadie-Bathurst, Bathurst, New Brunswick, Canada|Vitalit\u00e9 Health Network - Restigouche, Campbellton, New Brunswick, Canada|Vitalit\u00e9 Health Network- Northwest, Edmundston, New Brunswick, Canada|Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada|Lakeridge Health Ajax Pickering, Ajax, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners - Mississauga Hospital, Mississauga, Ontario, Canada|Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada|North York General Hospital, North York, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Bluewater Health, Sarnia, Ontario, Canada|Scarborough Health Network, Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, Birchmount Hospital, Scarborough, Ontario, Canada|Niagara Health System - St. Catherines, St. Catherines, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health, St. Joseph's Health Care Centre, Toronto, Ontario, Canada|Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada|Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada|L'Hopital Chicoutimi, Chicoutimi, Quebec, Canada|H\u00f4pital de la Cit\u00e9-de-la-Sant\u00e9, Laval, Quebec, Canada|H\u00f4pital Charles-Le Moyne, Longueuil, Quebec, Canada|Hotel Dieu Hospital of L\u00e9vis, L\u00e9vis, Quebec, Canada|H\u00f4pital Maisonneuve-Rosemont, Montr\u00e9al, Quebec, Canada|Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Quebec, Canada|Montr\u00e9al General Hospital, Montr\u00e9al, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montr\u00e9al, Quebec, Canada|Jewish General Hospital, Montr\u00e9al, Quebec, Canada|McGill University Health Centre, Montr\u00e9al, Quebec, Canada|H\u00f4pital du Sacr\u00e9-Coeur de Montreal, Montr\u00e9al, Quebec, Canada|Centre Hospitalier Universitaire (CHU) de Qu\u00e9bec - Universit\u00e9 Laval, Quebec City, Quebec, Canada|Institut Universitaire de cardiologie et pneumologie de Qu\u00e9bec, Quebec City, Quebec, Canada|Centre hospitalier r\u00e9gional de St-J\u00e9r\u00f4me, Saint-J\u00e9r\u00f4me, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS) - H\u00f4pital H\u00f4tel-Dieu, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS) - H\u00f4pital Fleurimont, Sherbrooke, Quebec, Canada|Centre hospitalier affili\u00e9 universitaire r\u00e9gional de Trois-Rivi\u00e8res, Trois-Rivi\u00e8res, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|St. Paul's Hospital, Saskatoon, Saskatchewan, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1200"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Intubation or death|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE)""}"
"225","ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19","","NCT04583956","20-0013A","Other: Placebo|Drug: Remdesivir|Biological: Risankizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04583956","Recruiting","2020-10-14","2021-12-31","{""locations"":""Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kern Medical Center, Bakersfield, California, United States|Hoag Hospital Newport Beach, Newport Beach, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Penrose Hospital - Emergency Medicine, Colorado Springs, Colorado, United States|St. Francis Medical Center, Colorado Springs, Colorado, United States|St. Anthony Hospital, Lakewood, Colorado, United States|St. Anthony Hospital North Health Campus, Westminster, Colorado, United States|Nuvance Health Danbury Hospital - Infectious Disease, Danbury, Connecticut, United States|Yale School of Medicine - The Anlyan Center for Medical Research & Education - Immunobiology, New Haven, Connecticut, United States|Nuvance Health - Norwalk Hospital - Asthma Pulmonary and Critical Care Medicine, Norwalk, Connecticut, United States|MedStar Washington Hospital Center - Infectious Diseases, Washington, District of Columbia, United States|Advent Health Orlando - Critical Care, Orlando, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|University of Louisville - Division of Infectious Diseases, Louisville, Kentucky, United States|Tulane University - Section of Pulmonary Diseases, Critical Care, and Environmental Medicine, New Orleans, Louisiana, United States|Louisiana State University Health Shreveport - Infectious Diseases, Shreveport, Louisiana, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Boston Medical Center - Center for Infectious Diseases - Shapiro Center, Boston, Massachusetts, United States|Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States|Englewood Hospital, Englewood, New Jersey, United States|Virtua Health - Virtua Voorhees Hospital - Pulmonology, Voorhees, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|The State University of New York - University at Buffalo - Department of Medicine, Buffalo, New York, United States|Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York, New York, United States|Nuvance Health - Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Stony Brook Medicine - Stony Brook University Hospita, Stony Brook, New York, United States|East Carolina University Brody School of Medicine - Adult Specialty Care, Greenville, North Carolina, United States|Wake Forest Baptist Health - Infectious Diseases, Winston-Salem, North Carolina, United States|University of Toledo Medical Center - Ruppert Clinic, Toledo, Ohio, United States|St. Charles Health System - St. Charles Bend Hospital, Bend, Oregon, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Kent County Memorial Hospital, Warwick, Rhode Island, United States|Monument Health - Clinical Research, Rapid City, South Dakota, United States|Hendrick Health - Hendrick Medical Center, Abilene, Texas, United States|Texas Tech University Health Science Center, Amarillo, Texas, United States|Baptist Hospitals of Southeast Texas Site, Beaumont, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at Tyler, Tyler, Texas, United States|West Virginia University - Infectious Diseases Clinic, Morgantown, West Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale.|Change from baseline in C-reactive protein (CRP) concentration|Change from baseline in d-dimer concentration|Change from baseline in ferritin concentration|Change from baseline in fibrinogen concentration|Change from baseline in troponin concentration|Change in alanine aminotransferase (ALT) over time|Change in aspartate aminotransferase (AST) over time|Change in creatinine over time|Change in hemoglobin over time|Change in international normalized ratio (INR) over time|Change in platelets over time|Change in total bilirubin over time|Change in white blood cell (WBC) count with differential over time|Clinical efficacy, as assessed by time to recovery|Cumulative incidence of Grade 3 and 4 clinical and\/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of study product administration|Duration of hospitalization|Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Duration of new non-invasive ventilation or high flow oxygen use during the study|Duration of new oxygen use|Duration of non-invasive ventilation\/high flow oxygen use|Incidence of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Mean change in the ordinal scale|Oxygenation use|Proportion of subjects alive and without respiratory failure|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to death|Ventilator\/ extracorporeal membrane oxygenation (ECMO) use""}"
"226","Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int)","COVIDiet_Int","NCT04449731","1526/CEIH/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04449731","Recruiting","2020-03-20","2021-06-30","{""locations"":""Universidad de Granada, Granada, Spain"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""30000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adherence to the Mediterranean diet before and during the COVID-19 confinement|Eating behaviours|Level of physical activity during the COVID-19 confinement|Weight gain during the COVID-19 confinement""}"
"227","Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19","","NCT04603794","2020H0346","Drug: 0.5% Povidone Iodine|Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse|Drug: 1% Hydrogen Peroxide|Drug: 0.9% Normal Saline","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04603794","Recruiting","2020-10-01","2020-11-01","{""locations"":""The Ohio State University Wexner Medical Center, Columbus, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""real time reverse transcriptase quantitative PCR|ct values""}"
"228","SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients","","NCT04521309","biotech001","Biological: SARS-CoV-2 antibody based IVIG therapy","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04521309","Completed","2020-06-19","2021-02-08","{""locations"":""Dow University of Health Sciences, Karachi, Sindh, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28 Days mortality|Requirement of supplemental oxygen support|Number of days on assisted ventilation|Days to step down|Days to Hospital Discharge|Adverse events during hospital stay|Change in C-Reactive Protein (CRP) levels|Change in neutrophil lymphocyte ratio|Change in Ferritin levels|Change in lactate dehydrogenase (LDH) levels|Change in radiological (X-ray) findings|Days to negative SARS-CoV-2 Polymerase Chain Reaction (PCR) test|Anti-SARS-CoV-2 Antibody|Change in fever|Change in Sodium levels|Change in Potassium levels|Change in Chloride levels|Change in Bicarbonate levels""}"
"229","Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).","MARACOVID","NCT04441385","MARACOVID|2020-002011-21","Drug: Maraviroc 300 mg|Other: Standard care therapy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04441385","Recruiting","2020-06-26","2020-12-20","{""locations"":""Hospital Cl\u00ednic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients developing severe ARDS.|All-cause mortality.|Percentage of patients requiring tracheal intubation, use of Non-invasive Ventilation NIV or High Flow Nasal Cannula (HFNC) devices during the study period|Percentage of patients who progress to severe ARDS, death or ICU admission.|Differences in Time to Clinical Improvement|Change in clinical status of subject on a 7-point ordinal scale.|Percentage of patients requiring immunosuppressive\/immunomodulatory treatment as a rescue medication.|Proportion of patients developing adverse effects, serious adverse reactions, laboratory or physical examination findings, EKG abnormalities acquired during the trial, death and adverse events leading to early discontinuation of treatment.""}"
"230","Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland","COPEP","NCT04364022","CCER 2020-00864","Drug: Lopinavir/ritonavir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04364022","Recruiting","2020-04-23","2021-03-01","{""locations"":""Universit\u00e4tsspital Basel and SwissTPH, Basel, Switzerland|H\u00f4pitaux Universitaires de Gen\u00e8ve, Geneva, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""300"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|Severity of clinical COVID-19 on a 7-point ordinal scale""}"
"231","Niclosamide for Mild to Moderate COVID-19","","NCT04399356","STUDY00000605","Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04399356","Recruiting","2020-10-01","2021-02-12","{""locations"":""Tufts Medical Center, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in respiratory viral clearance (by PCR)|Fecal viral clearance (by PCR)|Reduction (change) in respiratory viral shedding (by PCR)|Reduction (change) in GI viral shedding (by PCR)|Progression to severe COVID-19 Disease|Time to resolution of a fever""}"
"232","Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)","PREVENT","NCT04365257","IRB00246659|COV2001","Drug: Prazosin|Other: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04365257","Recruiting","2020-05-13","2021-06-30","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""45 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death|Hospitalized, requiring mechanical ventilation and\/or high flow nasal cannula and\/or ICU\/CCU admission (or equivalent) and\/or ECMO|Hospitalized, requiring supplemental oxygen, not requiring ICU\/CCU level care (or interventions listed under Outcome 2)|Cumulative incidence of grade 3 and 4 adverse events|Number of participants with serious adverse events|Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|Number of participants with laboratory abnormalities in peripheral blood|Duration of laboratory abnormalities in peripheral blood|Number of participants with laboratory abnormalities in plasma|Duration of laboratory abnormalities in plasma""}"
"233","The Effect of Deep Breathing Exercise on Dyspnea, Anxiety and Quality of Life in Patients Treated for COVID-19","","NCT04696562","OCengiz","Behavioral: Deep Breathing Exercise with Triflo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04696562","Not yet recruiting","2021-01-01","2021-03-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""44"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygen saturation (%)|Respiratory rate per minute|Dyspnea level|Anxiety|Quality of life level""}"
"234","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","COVID CALL 15","NCT04331171","WP-2020-02","Device: Web application users","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04331171","Recruiting","2020-03-17","2020-11-15","{""locations"":""All French Emergency services, Le Mans, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""12000000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https:\/\/www.maladiecoronavirus.fr\/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https:\/\/www.maladiecoronavirus.fr\/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population""}"
"235","Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","SEN-CoV-Fadj","NCT04390594","2020-002","Drug: Nafamostat Mesilate","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04390594","Recruiting","2020-08-13","2021-08-12","{""locations"":""Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal|Diamniadio Children Hospital, Diamniadio, Senegal|Dalal Jamm Hospital, Gu\u00e9diawaye, Senegal"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""186"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation|Clinical status on the seven-category ordinal scale""}"
"236","Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings","","NCT04568499","13736","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568499","Not yet recruiting","2020-10-01","2021-03-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Hospitalization|Mortality""}"
"237","Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms","COVIDLight","NCT04418505","VL-2020-02","Device: Vielight RX Plus","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04418505","Recruiting","2020-09-02","2021-03-01","{""locations"":""Progressive Medical Research, Port Orange, Florida, United States|Dr. Michael Zahavi, Oshawa, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""280"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery|Time to elimination of COVID-19 related symptoms|Mean number of days with mild COVID-19 related symptoms|Mean number of days with mild overall respiratory symptoms|Time to symptom reduction|Time to elimination of symptoms|Average number of days with mild respiratory symptoms|Oxygen saturation|Hospitalization rate|Mortality""}"
"238","Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)","","NCT04636333","JSVCT096","Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Biological: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Biological: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Biological: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Biological: Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Biological: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04636333","Recruiting","2020-10-30","2022-01-07","{""locations"":""Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""216"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of adverse reactions (AR) up to Day 28 after prime and boost vaccination of the recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.|The proportion of adverse events (AE) within 7 days after each dose of the recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.|The proportion of abnormal markers of hematology, blood chemistry and urine analysis within 3 days after each dose of the recombinant SARS-CoV-2 vaccine (CHO cell) or placebo|The proportion of serious adverse events up to Month 12 after prime and boost vaccination.|The proportion of neutralizing antibody positive conversion rate, positive rate, GMT and GMI at Day 14, Day 21, Day 28, Day 42 after prime vaccination of recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.#Day 0, Day 14 vaccination program#|The proportion of IgG antibody positive rate at Day 14, Day 21, Day 28, Day 42 after prime vaccination of recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.#Day 0, Day 14 vaccination program#|The proportion of neutralizing antibody positive conversion rate, positive rate, GMT and GM at Day 28, Day 35, Day 42, Day 56 after prime vaccination of recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.#Day 0, Day 14 ,Day 28 vaccination program#|The proportion of IgG antibody positive rate at Day 28, Day 35, Day 42, Day 56 after prime vaccination of recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.#Day 0, Day 14 ,Day 28 vaccination program#""}"
"239","Interferon Beta 1a in Hospitalized COVID-19 Patients","IB1aIC","NCT04350671","Interferon Beta 1a in COVID-19","Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04350671","Enrolling by invitation","2020-04-15","2020-04-24","{""locations"":""Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events""}"
"240","Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)","","NCT04394884","200114|20-I-0114","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04394884","Suspended","2021-03-09","2023-04-30","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States|Walter Reed National Medical Center, Bethesda, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To characterize the immunologic mechanisms by which BTK inhibition may ameliorate hyper- inflammatory responses in patients with COVID-19.|1. Characterization of TLR3 and TLR7\/8-dependent immunologic phenotypes in COVID-19 patients before and after BTK inhibition.|2. Evaluation of mechanisms of immune cell-specific activation, cytokine production, exhaustion and apoptosis in COVID-19 patients before and after BTK inhibition.|3. Transcriptional, chromatin, and epigenetic profiling of immune cells at the single cell level in COVID-19 patients before and after BTK inhibition.|4. Longitudinal evaluation of TCR and BCR repertoire development in COVID-19 patients before and after BTK inhibition.|5. Characterization of SARS- CoV-2 serological responses in COVID-19 patients with and without BTK inhibition.|6. Characterization of genetic variants that correlate with disease severity and\/or response to BTK inhibition treatment.|7. Evaluation of soluble biomarkers as surrogate markers of hyper- inflammation\/prognosis and of response to BTK inhibition therapy in COVID-19 patients""}"
"241","Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study","BRAINSTEM-COV","NCT04527198","APHP200644|2020-A01559-30","Diagnostic Test: Brainstem Responses Assessment Sedation Score (BRASS)|Diagnostic Test: Electroencephalogram with EKG lead","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04527198","Not yet recruiting","2020-09-01","2021-06-01","{""locations"":""H\u00f4pital Cochin, Paris, France|HEGP, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Brainstem dysfunction prevalence|Brainstem dysfunction prevalence after sedation weaning|Link between brainstem dysfunction and clinical dysautonomia|Link between brainstem dysfunction and clinical dysautonomia after sedation weaning|Characterization of brainstem dysfunction in COVID-19 patients: EEG power|Characterization of brainstem dysfunction in COVID-19 patients: EEG power after sedation weaning|Characterization of brainstem dysfunction in COVID-19 patients: EEG functional connectivity|Characterization of brainstem dysfunction in COVID-19 patients: EEG functional connectivity, after sedation weaning|Characterization of brainstem dysfunction in COVID-19 patients: EEG complexity|Characterization of brainstem dysfunction in COVID-19 patients: EEG complexity after sedation weaning|Characterization of brainstem dysfunction in COVID-19 patients: multivariate classification|Characterization of brainstem dysfunction in COVID-19 patients: multivariate classification after sedation weaning|Duration of mechanical ventilation|Mortality|Duration of hospitalisation|Duration of coma, disturbance of consciousness, delirium|Neurological functional evolution with mRankin|Neurological functional evolution with GOSE""}"
"242","Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19","","NCT04581135","2020-00799","Other: COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581135","Recruiting","2020-05-01","2023-06-01","{""locations"":""St. Claraspital AG - Department of Pulmonary Medicine, Basel, Switzerland|Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center, Bern, Switzerland|University and Hospital of Fribourg, Fribourg, Switzerland|H\u00f4pitaux Universitaires de Gen\u00e8ve - Service de Pneumologie, Gen\u00e8ve, Switzerland|CHUV - Service de Pneumologie, Lausanne, Switzerland|Clinica Moncucco, Lugano, Switzerland|H\u00f4pital du Valais - Service de Pneumologie, Sion, Switzerland|Kantonspital St. Gallen - Klinik f\u00fcr Pneumologie und Schlafmedizin Lungenzentrum, St. Gallen, Switzerland|Universit\u00e4tsspital Z\u00fcrich - Klinik f\u00fcr Pneumologie, Z\u00fcrich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pulmonary follow-up sequelae in patients after COVID-19|Evaluation of risk factors for adverse Outcome after COVID-19|Compare the functional Pulmonary outcome of COVID-19 disease|Compare the radiological Pulmonary outcome of COVID-19 disease|Quality of Life after COVID-19|Physical performance after COVID-19 using Clinical Frailty Scale|Physical performance after COVID-19 using frailty assessment tests|Microbiota and COVID-19""}"
"243","Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","PANAMO","NCT04333420","IFX-1-P2.9","Drug: SOC + IFX-1|Drug: SOC + Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04333420","Recruiting","2020-03-31","2021-08-31","{""locations"":""University of Aachen, Aachen, Germany|University Amsterdam, Amsterdam, Netherlands|University Amsterdam, Amsterdam, Netherlands|University Maastricht, Maastricht, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""390"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Treatment Emergent Adverse Events|Safety Parameters""}"
"244","Umifenovir in Hospitalized COVID-19 Patients","UAIIC","NCT04350684","Umifenovir in COVID-19","Drug: Umifenovir|Drug: Interferon-β 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04350684","Enrolling by invitation","2020-04-15","2020-04-24","{""locations"":""Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events""}"
"245","Ruxolitinib to Combat COVID-19","","NCT04354714","04-13-20-DiPersio","Drug: Ruxolitinib|Procedure: Peripheral blood draw","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04354714","Withdrawn","2020-06-30","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0|Proportion of participants with detectable virus""}"
"246","Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19","COVHYP","NCT04374695","P20/11_COVHYP","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374695","Not yet recruiting","2020-05-01","2020-07-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prior treatment by ACEi|Prior treatment by ARB|Baseline characteristics and comorbidities|Major Clinical Adverse Events""}"
"247","Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19","CRISIS","NCT04425252","CCB-CRISIS-01","Drug: Brequinar|Other: Standard of Care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04425252","Completed","2020-08-01","2020-12-29","{""locations"":""Hartford Hospital, Hartford, Connecticut, United States|Baptist Medical Center, Jacksonville, Florida, United States|University of South Florida\/Tampa General, Tampa, Florida, United States|University of New Mexico, Albuquerque, New Mexico, United States|Temple University, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""23"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety\/tolerability measured by rates of post randomization adverse events and hematology\/chemistry safety labs.|Hospitalization status|Duration of hospitalization|NEWS2 Score|Mortality|SARS-CoV-2 nasopharyngeal viral load|Inflammatory markers|DHO Concentration|Brequinar Concentration""}"
"248","Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC","ERUCOV-VAC","NCT04691947","IDEAL00420-EU01-PK537-1","Biological: ERUCOV-VAC|Other: Placebo Vaccine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04691947","Recruiting","2020-11-05","2022-03-15","{""locations"":""Erciyes University Hakan \u00c7etinsaya Iyi Klinik Uygulama ve Arastirma Merkezi, IKUM (Center for GCP), Kayseri, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""44"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""To assess the safety and tolerability of the COVID-19 vaccine|Serum IgG antibody Levels|Neutralizing Antibodies Levels|TNF-alpha Levels|Interferon Levels|Interleukine Levels""}"
"249","Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS","","NCT04449588","STS-BDB001-04","Drug: BDB-001 Injection|Other: Conventional treatment","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04449588","Recruiting","2020-07-23","2022-08-07","{""locations"":""Asgar Ali Hospital, Dhaka, Bangladesh|Bangladesh Specialized Hospital, Dhaka, Bangladesh|Southwest Hospital Chongqing, Chongqing, Chongqing, China|Noble Hospital Pvt Ltd, Nagpur, India|Government Medical College and Hospital, Pune, India|RSUP Persahabatan(Persahabatan General Hospital), East Jakarta, Jakarta, Indonesia|RSUD Pasar Minggu(Pasar Minggu General Hospital), South Jakarta, Jakarta, Indonesia|RSUD Cengkareng(Cengkareng General Hospital), West Jakrata, Jakrata, Indonesia|Hospital Universitario 12 De Octubre, Madrid, Spain|Hospital Universitario Cl\u00ednico San Carlos, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundaci\u00f3n D\u00edaz, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""368"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline|28-day all-cause mortality rate|Percentage of patients who progress to critical severe|Percentage of subjects achieving recovery in SpO2|Mean change of PaO2\/FiO2|Mechanical ventilation time|Time of oxygen therapy|Change in inflammation indicators (CRP or IL-6 etc.) from baseline|Improvement in body temperature|Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&D Blueprint during treatment period|Improvement at D3, 7, 11 & D14 based on ordinal scale recommended by the WHO R&D Blueprint during treatment period|Time to get categories 1 to 4 in the 8-points ordinal scale|Time to attain an improvement of 1 point on the ordinal scale""}"
"250","Development and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT","PREDICTCovid19","NCT04481620","CHUBX 2020/23","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04481620","Recruiting","2020-08-31","2021-01-31","{""locations"":""CHU Bordeaux, Bordeaux, France|Clinique Bordeaux Nord, Bordeaux, France|Clinique Saint Augustin, Bordeaux, France|CHU de Grenoble Alpes, Grenoble, France|H\u00f4pital Arnaud-de-Villeneuve CHU de Montpellier, Montpellier, France|H\u00f4pitaux de Brabois CHU de Nancy, Nancy, France|H\u00f4pital de la Mil\u00e9trie CHU de Poitiers, Poitiers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1315"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""occurrence of significant clinical degradation|occurrence of a severe form|occurrence of an orotracheal intubation|occurrence of an Acute Respiratory Distress Syndrom|average length of stay in hospital|mortality|evolution of the imaging parameters""}"
"251","Atovaquone for Treatment of COVID-19","","NCT04456153","STU-2020-0707","Drug: Experimental Group|Drug: Placebo Group","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04456153","Completed","2020-07-22","2021-01-31","{""locations"":""University of Texas Medical Center, Dallas, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""61"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Analysis|Secondary Between group differences in viral load|AUC comparison|Stratified|Time to viral load drop|Ordinal scale""}"
"252","Endothelial Function and COVID-19","","NCT04525443","20/451","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04525443","Completed","2020-06-03","2021-02-11","{""locations"":""Mayo Clinic, Rochester, Minnesota, United States|Hospital Cl\u00ednico San Carlos, Madrid, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""110"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Reactive hyperemia index (RHI)|Percentage of COVID-19 patients with impaired endothelial vasodilator function.|Percentage of non-COVID-19 patients with impaired endothelial vasodilator function.""}"
"253","Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)","","NCT04452942","EC1153-2-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452942","Not yet recruiting","2020-07-01","2021-04-01","{""locations"":""Stony Brook University Hospital, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes on eicosanoid lipid mediators|Changes on plasma levels of a panel of 40 human cytokines and chemokines|Severe clinical outcome""}"
"254","Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)","COALITION-V","NCT04466540","30415320.8.1001.0070","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04466540","Recruiting","2020-05-12","2021-03-30","{""locations"":""Centro de Pesquisas Cl\u00ednicas Dr. Marco Mota HCOR, Macei\u00f3, Alagoas, Brazil|Hospital e Cl\u00ednica S\u00e3o Roque, Ipia\u00fa, Bahia, Brazil|Cl\u00ednica Otorhinus, Salvador, Bahia, Brazil|Hospital da Bahia, Salvador, Bahia, Brazil|Hospital Santa Izabel, Salvador, Bahia, Brazil|Instituto C\u00e1rdio Pulmonar da Bahia, Salvador, Bahia, Brazil|Hospital SAMUR, Vit\u00f3ria Da Conquista, Bahia, Brazil|Hospital Maternidade S\u00e3o Vicente de Paulo, Barbalha, Cear\u00e1, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, Cear\u00e1, Brazil|Unimed Sul Capixaba, Cachoeiro De Itapemirim, Esp\u00edrito Santo, Brazil|Hospital das Cl\u00ednicas Universidade Federal de Goi\u00e1s, Goi\u00e2nia, Goi\u00e1s, Brazil|Santa Casa de Miseric\u00f3rdia de Passos, Passos, Minas Agerais, Brazil|Hospital J\u00falia Kubitschek, Belo Horizonte, Minas Gerais, Brazil|Instituto da Pequenas Mission\u00e1rias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Casa de Caridade de Carangola, Carangola, Minas Gerais, Brazil|Hospital Maternidade e Pronto Socorro Santa Lucia, Po\u00e7os De Caldas, Minas Gerais, Brazil|Hospital da Unimed, S\u00e3o Jo\u00e3o Del Rei, Minas Gerais, Brazil|Santa Casa de Miseric\u00f3rdia de S\u00e3o Jo\u00e3o Del Rei, S\u00e3o Jo\u00e3o Del Rei, Minas Gerais, Brazil|Hospital de Cl\u00ednicas da Universidade Federal do Triangulo Mineiro, Uberaba, Minas Gerais, Brazil|Hospital de Cl\u00ednicas da Universidade Federal de Uberl\u00e2ndia, Uberl\u00e2ndia, Minas Gerais, Brazil|Hospital do Rocio, Campo Largo, Paran\u00e1, Brazil|Cl\u00ednica Clinilive, Maring\u00e1, Paran\u00e1, Brazil|Hospital Universit\u00e1rio Regional de Maring\u00e1, Maring\u00e1, Paran\u00e1, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Real Hospital Portugu\u00eas de Benefic\u00eancia em Pernambuco, Recife, Pernambuco, Brazil|SECRETARIA MUNICIPAL DE SA\u00daDE DE SAIR\u00c9 (Unidade Mista Ol\u00edlia Mendon\u00e7a Souto Maior), Sair\u00e9, Pernambuco, Brazil|Complexo Hospitalar de Niter\u00f3i, Niter\u00f3i, Rio De Janeiro, Brazil|Hospital Unimed Volta Redonda, Volta Redonda, Rio De Janeiro, Brazil|Associa\u00e7\u00e3o Dr. Bartholomeu Tacchini, Bento Gon\u00e7alves, Rio Grande Do Sul, Brazil|Hospital S\u00e3o Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Santa Casa de Miseric\u00f3rdia de Porto Alegre (ISCMPA), Porto Alegre, Rio Grande Do Sul, Brazil|Universidade Federal de Santa Maria, Santa Maria, Rio Grande Do Sul, Brazil|CEPEM Centro de Pesquisa de Medicina Tropical de Rond\u00f4nia, Porto Velho, Rond\u00f4nia, Brazil|Irmandade de Miseric\u00f3rdia Do Hospital Da Santa Casa de Monte Alto, Monte alto, Salto Alto, Brazil|Maestri e Kormann Consultoria Medico Cientifica, Blumenau, Santa Catarina, Brazil|Imigrantes Hospital e Maternidade, Brusque, Santa Catarina, Brazil|Hospital S\u00e3o Jos\u00e9, Crici\u00fama, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Santa Casa de Araras, Araras, S\u00e3o Paulo, Brazil|Hospital de Amor, Barretos, S\u00e3o Paulo, Brazil|Santa Casa de Miseric\u00f3rdia de Barretos, Barretos, S\u00e3o Paulo, Brazil|Alphacor Cardiologia Clinica E Diagn\u00f3stica LTDA, Barueri, S\u00e3o Paulo, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, S\u00e3o Paulo, Brazil|Hospital Regional do Litoral Norte, Caraguatatuba, S\u00e3o Paulo, Brazil|Hospital de Cordeir\u00f3polis, Cordeir\u00f3polis, S\u00e3o Paulo, Brazil|Centro de Combate ao Coronav\u00edrus de Itapevi, Itapevi, S\u00e3o Paulo, Brazil|Dux Medicina, Jundia\u00ed, S\u00e3o Paulo, Brazil|Hospital Carlos Fenando Malzoni, Mat\u00e3o, S\u00e3o Paulo, Brazil|Centro de Atendimento Para O Enfrentamento A Covid-19 Da Prefeitura Municipal de Monte Altoprefeitura de Monte Alto, Monte alto, S\u00e3o Paulo, Brazil|Faculdade de Medicina de Ribeir\u00e3o Preto, Ribeir\u00e3o Preto, S\u00e3o Paulo, Brazil|Unimed Ribeir\u00e3o Preto, Ribeir\u00e3o Preto, S\u00e3o Paulo, Brazil|Hospital Casa de Sa\u00fade de Santos, Santos, S\u00e3o Paulo, Brazil|Kaiser Cl\u00ednica e Hospital Dia, S\u00e3o Jos\u00e9 Do Rio Preto, S\u00e3o Paulo, Brazil|Hospital Policlin, S\u00e3o Jos\u00e9 Dos Campos, S\u00e3o Paulo, Brazil|Hospital Regional de S\u00e3o Jos\u00e9 dos Campos, S\u00e3o Jos\u00e9 Dos Campos, S\u00e3o Paulo, Brazil|Santa Casa de Miseric\u00f3rdia de Votuporanga, Votuporanga, S\u00e3o Paulo, Brazil|ESF Dr. Jo\u00e3o Paccola Primo, Len\u00e7ois Paulista, Brazil|Cardioclinica da Ilha do Governador, Rio De Janeiro, Brazil|International Research Center - Hospital Alem\u00e3o Oswaldo Cruz, S\u00e3o Paulo, Brazil|Hospital do Cora\u00e7\u00e3o, S\u00e3o Paulo, Brazil|Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil|Hospital Leforte, S\u00e3o Paulo, Brazil|Hospital Moriah, S\u00e3o Paulo, Brazil|Hospital Samaritano, S\u00e3o Paulo, Brazil|Hospital Santa Paula, S\u00e3o Paulo, Brazil|Hospital S\u00e3o Camilo Pomp\u00e9ia, S\u00e3o Paulo, Brazil|Hospital S\u00e3o Paulo - UNIFESP, S\u00e3o Paulo, Brazil|Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization|Uncontrolled asthma after \u2265 5 days of starting study medication|Pneumonia|Otitis media|Fever resolution time|Time to improve respiratory symptoms|Hospitalization in the Intensive Care Unit|Need for Orotracheal Intubation|Mechanical Ventilation Time|Mortality""}"
"255","Validation of COVID-19 Tests","","NCT04404062","C20010","Diagnostic Test: Covid-19 Rapid Test Kit (RAPG-COV-019)|Diagnostic Test: Quantitative IgG Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04404062","Active, not recruiting","2020-03-16","2020-08-01","{""locations"":""Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of asymptomatic carriers of SARS-CoV-2|Validation of the ability of the immunoassay kit to detect antibodies to SARS-CoV-2|Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2|Exploration of SARS-CoV-2 epidemiology""}"
"256","Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19","","NCT04501783","TL-FVP-t-01","Drug: Favipiravir|Drug: Standard of care (SOC)|Drug: standard concomitant therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04501783","Active, not recruiting","2020-05-20","2020-08-01","{""locations"":""Medical center LLC \""Neuroprofi\"", Korolev, Russian Federation|Federal budgetary institution of science \""Central Research Institute of Epidemiology\"" of Russian Federal Supervision Service for Consumer Rights Protection and People's Welfare, Moscow, Russian Federation|Medical centers JSC \""Medsi Group of Companies\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""City Clinical Hospital \u211657 of the Moscow City Healthcare Department\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""City Clinical Hospital \u211667 n.a. LA Vorokhobova of the Moscow City Healthcare Department\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""Infectious Diseases Clinical Hospital \u21161 of the Moscow City Healthcare Department\"", Moscow, Russian Federation|Medical center LLC \""Medical Center Eco-safety\"", Saint Petersburg, Russian Federation|St. Petersburg State Budgetary Healthcare Institution \""City Hospital No. 40 of the Kurortny District\"", Saint Petersburg, Russian Federation|Budgetary healthcare institution of the Voronezh region \""Voronezh Regional Clinical Hospital No. 1\"", Voronezh, Russian Federation|State Budgetary Healthcare Institution of the Moscow Region \""Zhukovskaya City Clinical Hospital\""., Zhukovskiy, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""168"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Time to clinical improvement|Time to viral clearance|Rate of clinical improvement at separate time points|Rate of viral clearance at separate time points|Time to body temperature normalization|Rate of resolution of lung changes on CT|Rate of adverse drug reactions (ADR) and serious ADR|Rate of severe ADR|Rate therapy termination due to ADR""}"
"257","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)","","NCT04350073","Pro00105221","Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04350073","Recruiting","2020-04-20","2021-12-01","{""locations"":""Duke University Medial Center, Durham, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device|Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device|Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients|Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3\/Th3|Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic\/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg\/Intercostal\/Head Muscles|Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy|Phase Angle in COVID-19 Patients: Measured via Multifrequency""}"
"258","Emotional Support and Stress Management in Patients Diagnosed With COVID-19","WWCOVID-19","NCT04482023","2020663","Behavioral: Training video on anxiety, fear and loneliness in the COVID-19 environment.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04482023","Not yet recruiting","2020-09-01","2020-12-31","{""locations"":""Montserrat Monta\u00f1a, Sabadell, Barcelona, Spain"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of care actions identified by nurses|Rate of care actions taken by nurses""}"
"259","Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19)","COVID-OLFA","NCT04407494","RECHMPL20_0176","Biological: Reporting of anosmia, ageusia and other clinical symptoms","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407494","Completed","2020-03-01","2020-04-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""809"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diagnostic values of anosmia and ageusia for COVID-19|Diagnostic values of CODA""}"
"260","Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)","COVID_MSV","NCT04361942","TerCel_007|2020-001682-36","Biological: Mesenchymal Stromal Cells|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04361942","Recruiting","2020-05-01","2021-12-31","{""locations"":""Hospital Universitario Rio Hortega, Valladolid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses""}"
"261","Crizanlizumab for Treating COVID-19 Vasculopathy","CRITICAL","NCT04435184","IRB00249874","Drug: Crizanlizumab|Other: 0.9% saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04435184","Completed","2020-07-09","2021-01-04","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Soluble P-selectin level|D-dimer level|VWF level|CRP level|Change in clinical status as assessed by the World Health Organization (WHO) Ordinal Scale for COVID-19 Trials|Time to hospital discharge|Safety of Crizanlizumab as assessed by adverse events""}"
"262","Data Collection on the Model Schools Pediatric Health Initiative at 5 SBHC Sites: COVID-19 Questionnaire","SBHC","NCT04534595","19-060","Other: COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04534595","Recruiting","2019-04-30","2021-03-01","{""locations"":""Unity Health Toronto, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""4 Years to 13 Years \u00a0 (Child)"",""outcome_measures"":""Direct Experience with COVID-19 virus|Family's overall experience with COVID-19 pandemic|Child's experience with cancellations and access to services|Caregiver's experience during COVID-19|stress or unpleasant experiences endured by the caregiver during COVID-19|Activities the caregiver engaged in during COVID-19|Describe the caregiver's parenting during COVID-19|The impact of school closure on the child|Describing the child's character|Childs daily routine|Childs interest about COVID-19|COVID-19 preventative measures.|How can the SBHC help?""}"
"263","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","COVIDAXIS","NCT04328285","20PH061|2020-001188-96","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04328285","Active, not recruiting","2020-04-14","2021-03-30","{""locations"":""CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|AP-HP - H\u00f4pital Bichat, Paris, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)""}"
"264","Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults","COVID-AGE","NCT04362943","PAS-BAR-2020-04","Drug: Baricitinib or Anakinra","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362943","Recruiting","2020-04-20","2020-07-31","{""locations"":""Complejo Hospitalario Universitario de Albacete, Albacete, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""576"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Mortality|X-ray changes|Disability changes|Ambulation changes|lymphocyte count changes|C-Reactive Protein changes|Ferritin changes|D-Dimer changes""}"
"265","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)","","NCT04347954","IRB-56134","Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04347954","Completed","2020-08-15","2020-12-13","{""locations"":""Stanford Health Care, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2|Compliance with study drug administration|Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT)""}"
"266","Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19","COVID-PREVENT","NCT04416048","COVID-PREVENT|2020-002282-33","Drug: Rivaroxaban|Other: Standard Of Care (SOC)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04416048","Recruiting","2020-11-30","2021-05-30","{""locations"":""Kardiologie und Angiologie I Universit\u00e4tsherzzentrum Freiburg, Freiburg, Baden-W\u00fcrttemberg, Germany|Friedrichshafen Hospital Clinic for cardiology, angiology, pneumology and internal intensive care medicine, Friedrichshafen, Baden-W\u00fcrttemberg, Germany|Clinic for Gastroenterology, Infectology and Poisoning Universit\u00e4sklinikum Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany|Cardiology and Pneumology Clinic Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Bayern, Germany|Medical Clinic and Polyclinic I. L. Ludwigs-Maximilians-University Clinic, Munich, Munich, Bayern, Germany|Cardiology, Pneumology and Intensive Care Clinic, M\u00fcnchen Klinik Neuperlach, M\u00fcnchen, Bayern, Germany|Immanuel Klinikum Bernau Herzzentrum Brandenburg ( Immanuel Clinic Bernau Heart Center Brandenburg), Bernau, Brandenburg, Germany|Internal Medicine and Cardiology Klinik Henningsdorf. Oberhavel Kliniken, Hennigsdorf, Brandenburg, Germany|Clinic for Cardiology, Angiology und Nephrology Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Frankfurt am Main, Hessen, Germany|Clinic and Polyclinic Internal Medicine Universit\u00e4tsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|Cardiology and Pneumology Clinic Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Niedersachsen, Germany|Clinic for Cardiology and Intensive Care - Klinikum Bielefeld, Bielefeld, Nordrhein-Westfalen, Germany|Westdeutsches Herz- und Gef\u00e4\u00dfzentrum Essen (West German Heart and Vascular Center Essen), Essen, Nordrhein-Westfalen, Germany|Medical Clinic I. Marien Hospital, Universit\u00e4tsklinikum der Ruhr Universit\u00e4t Bochum, Herne, Herne, Nordrhein-Westfalen, Germany|Pneumology, Allergology, Sleep-and Respiratory Medicine Clinic Helios Universit\u00e4tsklinikum Wupperthal, Wuppertal, Nordrhein-Westfalen, Germany|Katholisches Klinikum Koblenz-Montabaur (Catholic Hospital Koblenz-Montabaur), Koblenz, Rheinland-Pfalz, Germany|Center for Cardiology, University Medicine Mainz, Mainz, Rheinland-Pfalz, Germany|Universit\u00e4tsklinikum Halle (Saale) (University Hospital Halle (Saale)), Halle, Sachsen-Anhalt, Germany|Clinic for Vascular Medicine, St\u00e4dtisches Krankenhaus Dresden, Dresden, Sachsen, Germany|Medical Clinic I. Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Dresden, Sachsen, Germany|Cardiology, Pneumology and Intensive Care Clinic Helios Klinikum Pirna, Dresden, Pirna, Sachsen, Germany|Medical Clinic II, University Clinic Schleswig-Holstein - Campus L\u00fcbeck, L\u00fcbeck, Schleswig-Holstein, Germany|Department of Pneumology and Infectology Charit\u00e9 University Medicine Berlin, Campus Mitte, Berlin, Germany|Internal Medicine II, Cardiology, Sana Klinikum, Lichtenberg. Berlin, Berlin, Germany|Medical Clinic II. St. Joseph Hospital Berlin, Berlin, Germany|Department of Cardiology Charit\u00e9 University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany|Internal Medicine, Hospital Bethel Berlin in Lichterfelde, Berlin, Germany|Internal Medicine\/Cardiology department Unfallkrankenhaus Berlin, Berlin, Germany|Department of Cardiology Charit\u00e9 University Medicine Berlin, Campus Virchow, Berlin, Germany|Internal Medicine, Cardiology and Intensive Care Clinic Vivantes Humboldt Klinikum, Berlin, Berlin, Germany|Berlin Vivantes Hospital Spandau Clinic for internal medicine, cardiology and conservative intensive care medicine, Berlin, Germany|Intensive Care and Cardiology, Hospital Havelh\u00f6he, Berlin, Germany|Internal Medicine Deparment Hospital Waldfriede, Berlin, Berlin, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite endpoint of venous thromboembolism (DVT and\/or fatal or non-fatal PE), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause mortality or progression to intubation and invasive ventilation|Development of disseminated intravascular coagulation (DIC) according to the ISTH criteria|Number of days requiring invasive ventilation|Number of days requiring non-invasive ventilation|Improvement on a seven-category ordinal scale recommended by the WHO as clinical improvement scale for patients with respiratory infections""}"
"267","CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch","CoronaWatch","NCT04376853","CoronaWatch","Device: Apple Watch Series 5","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376853","Recruiting","2020-04-15","2020-07-01","{""locations"":""Department III of Internal Medicine, University Hospital Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Biomarker|Protective factors|SmartWatch compliance|Arrhythmias|QT time changes|Longitudinal risk models""}"
"268","PROphylaxis for paTiEnts at Risk of COVID-19 infecTion","PROTECT","NCT04389359","A095590","Drug: Hydroxychloroquine Sulfate 200 MG","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04389359","Withdrawn","2020-09-01","2025-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to confirmed diagnosis of COVID-19|All-cause mortality|Severity of COVID-19 disease|Incidence of COVID-19 complications""}"
"269","Hydroxychloroquine in COVID-19 Patients","","NCT04394442","SNH1352020","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04394442","Recruiting","2020-03-21","2020-08-01","{""locations"":""SNH, Mecca, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""time to viral clearance|% of mortality|Length of stay|time to be afebrile|need for mechanical ventilation""}"
"270","COVID-19 Pandemic and Worldwide Organ Procurement","COVID","NCT04416256","COVID/W.W.","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416256","Recruiting","2020-02-01","2022-02-01","{""locations"":""Paris Transplant Group, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""230000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Organ transplantation activity during COVID-19 pandemic|Further analysis on organ transplantation with stratification""}"
"271","The COVID-19 Mobile Health Study (CMHS)","CMHS","NCT04275947","CAALC-008-CMHS","Other: nCapp, a cell phone-based auto-diagnosis system","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04275947","Recruiting","2020-02-14","2020-05-31","{""locations"":""Renmin Hospital of Wuhan University, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""450"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Accuracy of nCapp COVID-19 risk diagnostic model""}"
"272","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","","NCT04315298","6R88-COV-2040","Drug: Sarilumab|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04315298","Completed","2020-03-18","2020-09-02","{""locations"":""Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1912"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent change in C-reactive protein (CRP) levels in patients with serum IL-6 level greater than the upper limit of normal|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of \u22642 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths\/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation \u226594% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale|Proportion of patients who recover|Proportion of deaths|Proportion of patients alive not receiving mechanical ventilation|Proportion of patients alive not requiring extracorporeal membrane oxygenation (ECMO)|Proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale|Time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale|Time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale|Proportion of patients receiving mechanical ventilation|Proportion of patients receiving ECMO|Proportion of patients discharged and alive|Time to recovery|Time to death due to any cause|Number of ventilator free days|Proportion of patients with serious adverse events|Proportion of patients with Grade 4 neutropenia (ANC <500\/mm3)|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia (ANC <500\/mm3)|Proportion of patients with hypersensitivity reactions|Proportion of patients with infusion reactions|Proportion of patients with gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level""}"
"273","Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19","","NCT04681079","0192","Drug: albuterol sulfate (MDI)|Drug: albuterol sulfate (nebulizer)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04681079","Recruiting","2021-02-01","2021-04-01","{""locations"":""Theravance Biopharma Investigational Site, Kansas City, Kansas, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral Load""}"
"274","Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)","CCOVID-19","NCT04535869","MS.20.08.1214","Drug: Sofosbuvir 400 MG plus Daclatasvir 200mg","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04535869","Recruiting","2020-12-28","2021-09-03","{""locations"":""Mansoura Faculty of Medicine, Mansoura, Dakahlyia, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""rate of virological cure by Rt -PCR for COVID -19using the triple therapy as compared to standard treatment|resolution of pneumonia BY high resolution Computed tomography""}"
"275","Non-contact ECG Sensor System for COVID19","","NCT04341506","20-0407","Device: Non-contact ECG","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341506","Recruiting","2020-09-08","2021-12-15","{""locations"":""Northwestern Medicine, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ECG changes associated with COVID-19""}"
"276","A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness","CONCOR-1","NCT04418518","20-04021981","Biological: Convalescent plasma","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04418518","Recruiting","2020-06-24","2021-12-01","{""locations"":""Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medicine, New York, New York, United States|Lower Manhattan Hospital, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1200"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE)""}"
"277","Vitamin D and COVID-19 Management","","NCT04385940","00100606","Dietary Supplement: Ddrops® products, 50,000 IU, Oral|Dietary Supplement: Vitamin D3","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04385940","Not yet recruiting","2020-06-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""64"",""age"":""17 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Symptoms recovery|Hospitalization|Blood white blood cell count (WBC)|Duration of mechanical ventilation|Duration of hospitalization|Intensive care unit (ICU) admission|Duration of ICU stay|Blood C-reactive protein (CRP)|Blood Lymphocyte count|Blood Ferritin|Blood platelet count|Blood interleukin-6 (IL-6)|Blood Tumor Necrosis Factor alpha (TNF)""}"
"278","COVID-19 Active Research Experience (CARE)","","NCT04368065","IQVIA_COVIDREGISTRY_2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368065","Recruiting","2020-04-02","2023-06-01","{""locations"":""IQVIA, Cambridge, Massachusetts, United States|IQVIA, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 symptom occurrence and severity|COVID-19 treatments|Hospitalization""}"
"279","A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19","","NCT04363372","MRx-4DP0004-II-001","Drug: MRx-4DP0004|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363372","Recruiting","2020-06-01","2020-09-01","{""locations"":""University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in mean clinical status score in each treatment arm|Number of adverse events in each treatment arm|Number of patients with an improvement in clinical status score in each treatment arm|Number of patients with a deterioration in clinical status score in each treatment arm|Number of patients with at least 95% oxygen saturation on room air in each treatment arm|Time to patients with at least 95% oxygen saturation on room air in each treatment arm|Number of patients with an improvement in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients with an deterioration in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients requiring Continuous Positive Airway Pressure in each treatment arm|Number of patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to patients requiring Continuous Positive Airway Pressure in each treatment arm|Time to patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to discharge in each treatment arm|Number of deaths in each treatment arm""}"
"280","Allocetra-OTS in COVID-19","","NCT04513470","DM003","Biological: Allocetra-OTS","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04513470","Active, not recruiting","2020-08-01","2021-02-01","{""locations"":""Hadassah Medical Center, Jerusalem, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""5"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE)|Preliminary Efficacy: Recovery from COVID-19 as determined by negative PCR or asymptomatic by the NIH classification for the severity of illness|Mortality|Preliminary Efficacy: To assess prevention of respiratory deterioration associated with COVID-19 by measuring the PaO2\/FiO2 ratio|Hospitalization|Life support|Clinical status by the new NIH Patient Classification for the severity of illness|Clinical status by NEWS2|Support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale|Support measurements: improvement of severity rating on a 7-point ordinal scale|Virus Clearance|Exploratory: Serum cytokines\/chemokines and immunomodulating factors|Exploratory: complete blood counts|Exploratory: Histone and cell-free DNA levels""}"
"281","Screening for COVID-19","","NCT04615208","B2020:070 (HS24165)","Diagnostic Test: suspected of COVID-19 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04615208","Recruiting","2020-12-19","2021-12-30","{""locations"":""University of Manitoba, Winnipeg, Manitoba, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""being positive or negative on COVID-19 swab fluid test""}"
"282","Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19","CovRep","NCT04379466","APHP200544|2020-A01245-34","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379466","Recruiting","2020-05-05","2021-04-01","{""locations"":""H\u00f4pital Pitie Salp\u00e9tr\u00e8re, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A list of COVID-19 specific TCR sequences|One or more measures from peripheral blood immunophenotyping that is\/are associated with COVID-19 outcome|Group of COVID-19 specific TCR sequences that is associated with COVID-19 outcome""}"
"283","COVID-19 Patient Positioning Pragmatic Trial","","NCT04359797","200727","Other: Prone|Other: Usual Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04359797","Active, not recruiting","2020-04-27","2021-06-01","{""locations"":""NorthShore University HealthSystem, Highland Park, Illinois, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""503"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Modified WHO Ordinal Scale|FIO2""}"
"284","Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults","COMVIVIR","NCT04475991","DI/20/407/04/38","Drug: Maraviroc + Currently used therapy|Procedure: Curently used therapy for COVID-19 non-critical patients|Drug: Favipiravir + Currently used therapy|Drug: Maraviroc+Favipiravir+CT","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04475991","Not yet recruiting","2021-02-01","2021-06-01","{""locations"":""Hospital General de M\u00e9xico \""Dr. Eduardo Liceaga\"", Mexico City, Cdmx, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients free of mechanical ventilation or death|Time of clinical improvement|Rate of change in phosphorylated CCR5|Rate of change in peripheral blood levels of proinflammatory cytokines and chemokines|Change in the trafficking and activation pattern of peripheral leukocytes""}"
"285","Treatment of COVID-19 Patients With Anti-interleukin Drugs","COV-AID","NCT04330638","COV-AID","Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04330638","Active, not recruiting","2020-04-03","2021-04-12","{""locations"":""AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jessa ZH, Hasselt, Belgium|University Hospital Brussels, Jette, Belgium|CHU Tivoli, La Louvi\u00e8re, Belgium|CHR de la Citadelle, Li\u00e8ge, Belgium|University Hospital Li\u00e8ge, Li\u00e8ge, Belgium|Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium|AZ Delta, Roeselare, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""342"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients, according to the adapted Berlin criteria|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate""}"
"286","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","TOCIVID-19","NCT04317092","TOCIVID-19|2020-001110-38","Drug: Tocilizumab Injection","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04317092","Active, not recruiting","2020-03-19","2022-12-19","{""locations"":""Azienda Ospedaliera \""SS. Antonio e Biagio e C. Arrigo\"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialit\u00e0 Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialit\u00e0 Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""402"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Lethality rate two weeks after registration|Lethality rate one month after registration|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) \/ FiO2 (fraction of inspired oxygen, FiO2) ratio (or P\/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms""}"
"287","Methodist Health System COVID-19 Patient Registry","","NCT04477889","024.CRI.2020.A","Other: Treatment for COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04477889","Recruiting","2020-06-20","2026-12-01","{""locations"":""Clinical Research Institute Methodist Health System, Dallas, Texas, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Characteristics|Treatment Measures and Intervention strategies|Clinical and survival outcomes""}"
"288","Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)","","NCT04377620","INCB 18424-369","Drug: Placebo|Drug: Ruxolitinib","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04377620","Recruiting","2020-05-24","2021-04-30","{""locations"":""Honor Health Research Institute, Scottsdale, Arizona, United States|Sharp Memorial Hospital, San Diego, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Teradan Clinical Trials, Brandon, Florida, United States|University of Florida, Gainesville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Northshore University Health System, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Healthpartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|Mercy Research, Springfield, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Njms Clinical Research Unit, Newark, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Kettering Cancer Care, Dayton, Ohio, United States|Jefferson University Hospitals, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Allegheny Health Network, Wexford, Pennsylvania, United States|St David'S Medical Center, Austin, Texas, United States|University of Texas Health Science Center At Houston - McGovern Medical School, Houston, Texas, United States|University of Texas Health Science Cente, San Antonio, Texas, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Aurora Research Institute, Milwaukee, Wisconsin, United States|Sbih City Hospital 15, Saint Petersburg, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who have died due to any cause|Number of Ventilator free days|Number of ICU free days|Oxygen free days|Vasopressor free days|Hospital free days|Improvement in the COVID-19 ordinal scale|Change in SOFA Score|Number of treatment-related adverse events""}"
"289","Beat COVID-19 - Observational Trial","JUPITER","NCT04337762","20200835","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337762","Recruiting","2020-04-06","2021-07-01","{""locations"":""Beat COIVD, LLC, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100000"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health Outcomes""}"
"290","Rapid Experimental Medicine for COVID-19","DEFINE","NCT04473053","AC20063","Drug: Nafamostat Mesilate|Drug: TD139|Other: Standard care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04473053","Recruiting","2020-07-03","2021-12-03","{""locations"":""NHS Lothian, Edinburgh, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""The safety of the candidate therapies in COVID-19 patients by measuring physiological changes in the circulatory and respiratory system.|The safety of the candidate therapies in COVID-19 patients by recording the number of treatment related adverse events.|Measuring the PK of the proposed trial treatments in COVID-19 patients.|Measure a change in the expression of key coagulation biomarkers in the blood of COVID-19 patients during and after treatment period.|Measure a change in the expression of key cytokines in the blood of COVID-19 patients during and after treatment period.|To evaluate the improvement or deteroriation of patients in each treatment arm.|To evaluate the number of oxygen-free days.|To evaluate incidence of any form of new ventilation use.|To evaluate ventilator-free days|Change in the ratio of the oxygen saturation to fraction of inspired oxygen concentration (SpO2\/FiO2)|To evaluate SARS-CoV-2 viral load.|To evaluate time to discharge|To evaluate the use of renal dialysis or haemofiltration for each treatment arm.""}"
"291","Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India","","NCT04641195","VR3- 172649","Dietary Supplement: Vitamin D3 (cholecalciferol)|Dietary Supplement: Zinc (zinc gluconate)|Dietary Supplement: Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04641195","Not yet recruiting","2021-03-01","2022-03-31","{""locations"":""Saifee Hospital, Mumbai, Maharashtra, India|King Edward Memorial (KEM) Hospital, Pune, Maharashtra, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery|All-cause mortality|Necessity for assisted ventilation|Individual symptoms duration|Vitamin D|Zinc|Interleukin 6 (IL-6)|Angiopoietin-2|sTREM-1|Immunoglobulin M (IgM)|Immunoglobulin (IgG)""}"
"292","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19","COVID-Aging","NCT04359953","7747","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04359953","Recruiting","2020-04-25","2021-06-01","{""locations"":""CHU de Strasbourg, Strasbourg, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1600"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants""}"
"293","Novel COVID-19, A National Analysis","","NCT04413045","Novel COVID-19 Prevalence","Other: Prevalence of COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04413045","Completed","2020-05-20","2020-07-28","{""locations"":""Assiut University Hospitals, Assiut, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""61"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Patient Prognosis Score|Oxygen Saturation|Laboratory Data|Radiological Features|Hospital Stay|Liver Function|Kidney Function""}"
"294","ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19","","NCT04604184","1434-0009|2020-003211-96","Drug: BI 764198|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04604184","Recruiting","2020-11-03","2021-05-26","{""locations"":""University of California Irvine, Orange, California, United States|Rapides Regional Medical Center, Alexandria, Louisiana, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Mercy Health St. Vincent Medical Center, Toledo, Ohio, United States|Providence Regional Medical Center, Everett, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Hospital Luxemburgo, Belo Horizonte, Brazil|IPECC - Instituto de Pesquisa Cl\u00ednica de Campinas, Campinas, Brazil|Hospital Sao Jose, Criciuma, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Brazil|Hospital Regional Hans Dieter Schmidt, Santa Catarina, Brazil|Hospital de Base - Fac Med de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil|Hospital Padre Alberto Hurtado, Santiago, Chile|Hospital Carlos Van Buren, Valparaiso, Chile|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Hospital General de Culiac\u00e1n \""Dr. Bernardo J. Gastellum\"", Culiac\u00e1n, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico|Hospital Auxilio Mutuo, Hato Rey, Puerto Rico|Hospital Municipal de San Juan, Rio Piedras, Puerto Rico|VA Caribbean Healthcare System, San Juan, Puerto Rico|Hospital A Coru\u00f1a, A Coru\u00f1a, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Son Espases, Palma de Mallorca, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""130"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients alive and free of mechanical ventilation|Patients alive and discharged free of oxygen|Patients with occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation|Time to response|Number of ventilator free days|Mortality""}"
"295","Dynamic Evaluation of COVID-19 Diagnostic Tests","TRODVID-19","NCT04337996","RIPH_2020_6","Diagnostic Test: COVID-19 diagnostic test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04337996","Completed","2020-07-13","2021-01-13","{""locations"":""CH Tourcoing, Tourcoing, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""8"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies|Positive or negative Covid-19 test|Positive or negative character of the antibodies test|Biological parameters|medical-economic comparison""}"
"296","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","KILLER","NCT04371965","KILLER","Drug: Povidone-Iodine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04371965","Completed","2020-09-01","2020-10-23","{""locations"":""University Hospital of Poitiers, Poitiers, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures|Thyroid tests at Day0 and Day7|Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)|Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea|Need for ward or intensive care hospitalization""}"
"297","Famotidine Outpatient COVID-19 Treatment Study","","NCT04389567","1605914-1","Drug: Famotidine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389567","Completed","2020-05-12","2020-05-25","{""locations"":""Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptomatic improvement|Peripheral blood oxygen saturation""}"
"298","Leflunomide in Mild COVID-19 Patients","","NCT04361214","IRB20-0622","Drug: Leflunomide","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04361214","Recruiting","2020-05-05","2021-02-01","{""locations"":""University of Chicago, Chicago, Illinois, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Tolerability of high dose leflunomide as measured by leflunomide dose modifications|Tolerability of high dose leflunomide as measured by discontinuation of leflunomide|Tolerability of high dose leflunomide as measured by Adverse Events|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol""}"
"299","Lanadelumab for Treatment of COVID-19 Disease","COVID_LAN","NCT04422509","UMCN-AKF20.04","Biological: lanadelumab|Other: regular care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04422509","Recruiting","2020-10-03","2021-08-03","{""locations"":""Jereoen Bosch hospital, 's-Hertogenbosch, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Tergooi ziekenhuizen, Blaricum, Netherlands|Amphia hospital, Breda, Netherlands|Haga hospital, Den Haag, Netherlands|Radboudumc, Nijmegen, Netherlands|Elisabeth-Tweesteden ziekenhuis, Tilburg, Netherlands|UMC Utrecht, Utrecht, Netherlands|Isala klinieken, Zwolle, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""oxygen|adverse events""}"
"300","Complementary Intervention for COVID-19","","NCT04487964","0925-0586","Dietary Supplement: Licorice extract","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04487964","Recruiting","2020-01-01","2021-01-01","{""locations"":""Faculty of Medicine, Assiut University, Assiut, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""70"",""age"":""12 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Increased number of people recovering from COVID-19|Decrease number of patients that require respiratory support ,|Decrease duration of hospital stay""}"
"301","Treating COVID-19 With Hydroxychloroquine (TEACH)","","NCT04369742","20-00463","Drug: Hydroxychloroquine (HCQ)|Other: Pacebo: Calcium citrate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04369742","Suspended","2020-04-15","2021-06-01","{""locations"":""State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, United States|NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""626"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of SAEs through day 30|Cumulative incidence of grade 3 or 4 AEs through day 30|Incidence of discontinuation of therapy (for any reason)|Severe disease progression composite outcome|Cumulative incidence of events|Hospital length of stay|Days of fever|Days of non-invasive ventilator use|Days of non-rebreather mask oxygen supplementation|Score on Cytokine Release Syndrome (CRS) Grading Scale|Percentage of subjects reporting each severity score on 8 point ordinal scale Day 1 and EOT (End of Treatment - Day 6)|Percentage of subjects with qTC prolongation at EOT|Cumulative Incidence of mortality|Cumulative Incidence of ICU admission|Cumulative Incidence of Invasive mechanical ventilation|Cumulative Incidence of ECMO|Cumulative Incidence of hypotension requiring vasopressor support|SARS-CoV-2 viral eradication from nasopharyngeal specimens at EOT|Change in Alanine Aminotransferase (ALT) levels|Change in Aspartate Aminotransferase (AST) levels|Change in Creatinine levels|Change in Glucose levels|Change in White Blood Cell (WBC) count|Change in Hemoglobin levels|Change in Platelet count|Change in total bilirubin levels|Change in Lactate Dehydrogenase (LDH) levels|Change in C-Reactive Protein (CRP) levels|Change in Interleukin 6 (IL-6) levels""}"
"302","Duke COVID-19 Shared Data and Specimen Repository","","NCT04368234","Pro00105316","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368234","Recruiting","2020-04-18","2025-04-30","{""locations"":""Duke University Medical Center, Durham, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Development of data repository to provide a secure, centralized storage location for COVID-19 related specimens""}"
"303","Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia","","NCT04485429","31180820600005249","Drug: Methylprednisolone|Drug: Heparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04485429","Recruiting","2020-07-20","2020-12-31","{""locations"":""D'Or Institute for Research and Education, Rio de Janeiro, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""268"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of invasive mechanical ventilation|Severity assessment by ordinal severity scale|Severity assessment by SOFA score|Length of hospital stay|Length of stay in intensive care|Death rate""}"
"304","COVID-19: A POC Test Under Research & Evaluation","CAPTURE","NCT04408066","S-CLIN-PROT-00028","Diagnostic Test: Sample Collection/Performance Evaluation (A)|Diagnostic Test: Sample Collection/Performance Evaluation (B)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04408066","Recruiting","2020-04-30","2022-04-30","{""locations"":""Barts Health NHS Trust, London, United Kingdom|Homerton University Hospital NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Performance of the LumiraDx Assay versus reference methods with regards to clinical sensitivity and specificity for the detection of the SARS-COV-2 IgG\/IgM and viral antigen in patient samples.""}"
"305","Mushroom-based Product for COVID-19","MACH19","NCT04667247","200633","Drug: FoTv","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04667247","Recruiting","2020-12-03","2021-08-01","{""locations"":""University of California, Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse Events|Creatinine|Aspartate transaminase|Alanine transaminase|Prothrombin time|Partial Thromboplastin Time|Duration of viral illness|Hospitalization rate|ICU admission|Ventilatory requirement|Lymphocyte count|Neutrophil count|Ferritin|D-Dimer|Lactate Dehydrogenase|C-Reactive Protein|Troponin|Mid-turbinate nasal swabs|Peripheral Blood Mononuclear Cell (PBMC) immune profiling""}"
"306","COPING With COVID-19( CWC-19)","","NCT04343690","Pro00105319","Behavioral: Crisis management coaching","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04343690","Withdrawn","2020-03-27","2020-05-01","{""locations"":""Duke University, Durham, North Carolina, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in stress level as measured by survey|Change wellness as measured by survey""}"
"307","I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","I-SPY_COVID","NCT04488081","I-SPY-COVID","Drug: Remdesivir|Drug: Cenicriviroc|Drug: Icatibant|Drug: Razuprotafib|Drug: Apremilast","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04488081","Recruiting","2020-07-31","2022-11-01","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality""}"
"308","Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19","","NCT04381884","IVM-AR-1","Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04381884","Completed","2020-05-18","2020-09-29","{""locations"":""Hospital de Cuenca Alta, Ca\u00f1uelas, Buenos Aires, Argentina|Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas \""Norberto Quirno\"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital de Infecciosas Francisco Javier Mu\u00f1iz, Ciudad Autonoma de Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""18 Years to 69 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2""}"
"309","A COVID-19 Symptom, Exposure and Immune Response Registry","","NCT04348942","OBVIO-OBV-001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04348942","Active, not recruiting","2020-05-29","2021-05-01","{""locations"":""ObvioHealth, Orlando, Florida, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Registry Data""}"
"310","Hypertonic Saline for COVID-19 Symptoms","","NCT04465604","RAC # 2201072|H-01-R-007","Other: Wearing surgical face mask sprayed with hypertonic saline","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04465604","Recruiting","2021-02-01","2022-05-01","{""locations"":""King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of respiratory symptoms|Improvement of respiratory signs|ICU admission|Mechanical ventilation""}"
"311","COVID-19 Pandemic and Academic Performance of Veterinary Students","","NCT04387214","1-2020","Other: survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387214","Completed","2020-04-13","2020-08-10","{""locations"":""South Valley University, Qin\u0101, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""1426"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Measure the effect of COVID-19 pandemic on the academic performance of veterinary medical students|Measure the average studying time|Evaluate on-line education during COVID-19 pandemic lockdown|Evaluate on-line education in practical lessons during COVID-19 pandemic lockdown""}"
"312","Telmisartan for Treatment of COVID-19 Patients","","NCT04355936","2020-001","Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04355936","Completed","2020-05-19","2020-11-30","{""locations"":""Hospital de Cl\u00ednicas 'Jos\u00e9 de San Mart\u00edn', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital Espa\u00f1ol de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""C reactive protein|Admission to intensive care unit (ICU)|Occurrence of mechanical ventilation|Death|Composite occurrence of admission to ICU, mechanical ventilation or death (what occur first)|Time from randomization to discharge|Proportion of patients not requiring supplemental oxygen at day 15|Significative differences in serum lactate dehydrogenase""}"
"313","COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80","","NCT04498273","ACTIV4-Outpatient","Drug: Apixaban 2.5 MG|Drug: Apixaban 5MG|Drug: Aspirin|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04498273","Recruiting","2020-09-07","2021-09-01","{""locations"":""University of Florida at Gainesville, Gainesville, Florida, United States|University of Floridia at Jacksonville, Jacksonville, Florida, United States|Lakeland Regional, Lakeland, Florida, United States|Bond Community Health Center, Tallahassee, Florida, United States|USF Tampa General Hospital, Tampa, Florida, United States|UIC - Mile Square, Chicago, Illinois, United States|Jesse Brown VA, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|UPMC Passavant Cranberry, Cranberry, Pennsylvania, United States|UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC East, Monroeville, Pennsylvania, United States|UPMC Magee, Pittsburgh, Pennsylvania, United States|UPMC Presby, Pittsburgh, Pennsylvania, United States|UPMC Mercy, Pittsburgh, Pennsylvania, United States|UPMC Shadyside, Pittsburgh, Pennsylvania, United States|UPMC Passavant McCandless, Pittsburgh, Pennsylvania, United States|McGoven Medical School - UT- Houston, Houston, Texas, United States|University of Texas at Tyler, Tyler, Texas, United States|Intermountain Healthcare, Murray, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""7000"",""age"":""40 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization for cardiovascular\/pulmonary events""}"
"314","Cardiovascular Effects of COVID-19","","NCT04365699","20-00416","Drug: AT-001","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04365699","Completed","2020-04-08","2021-01-31","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects with decreased left ventricular ejection fraction \u226510% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction \u226510% from baseline at time of hospitalization""}"
"315","Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19","","NCT04400890","McCreary2020","Drug: Resveratrol|Dietary Supplement: Vitamin D3","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04400890","Active, not recruiting","2020-09-12","2021-03-01","{""locations"":""Mt Carmel HealthSystems, Columbus, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""45 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization rates for COVID-19|ICU Admission Rates|Invasive Ventilation Rates|Pneumonia""}"
"316","Loneliness During Strict and Lifted Social Distancing Protocols Against the COVID-19 Pandemic","","NCT04444115","802810-1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444115","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""10084"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""UCLA Loneliness Scale-8 (ULS-8)|Patient Health Questionnaire-9 (PHQ-9)|Generalized Anxiety Disorder-7 (GAD-7)""}"
"317","Hyperbaric Oxygen for COVID-19 Patients","","NCT04332081","s20-00399","Device: hyperbaric oxygen therapy (HBOT)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04332081","Terminated","2020-04-06","2020-05-29","{""locations"":""NYU Winthrop Hospital, Mineola, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Need for mechanical ventilation|Days on invasive mechanical ventilation""}"
"318","COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)","COLOR-19","NCT04377477","NP 4097","Radiation: Single fraction whole lung radiotherapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04377477","Recruiting","2020-05-10","2022-08-30","{""locations"":""Radiation Oncology Department, ASST SpedaliCivili, Brescia, Brescia, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Lenght of hospital stay (days)|Number of Intensive Care Unit admissions|Variation of the Brescia COVID-19 Respiratory Severity Scale after treatment|Occurence of CTCAE 5.0 adverse events|Variation of the chest X-ray radiological findings according to Brixia scoring system""}"
"319","Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, Given in Combination With rAd26-S, Recombinant Adenovirus Type 26 Component of Gam-COVID-Vac Vaccine, for the Prevention of COVID-19.","","NCT04686773","AZD1222 - rAd26-S","Biological: AZD1222|Biological: rAd26-S","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04686773","Not yet recruiting","2021-02-10","2021-09-20","{""locations"":""Baki Saglamic Merkezi, Baku, Azerbaijan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Serious Adverse Events (SAEs) post first dose until the study end|Incidence of unsolicited Adverse Events (AEs) for 28 days post each dose|Incidence of local and systemic solicited AEs for 7 days post each dose|Incidence of Adverse events of special interest (AESIs) post first dose until study end|assessment of time course of antibody to Spike protein of one IM dose of AZD1222 followed by one IM dose of rAd26-S|Determination of anti-SARS-CoV-2 neutralising antibody levels in serum following one IM dose of AZD1222 followed by one IM dose of rAd26-S|Proportion of participants who have a post treatment seroresponse""}"
"320","MSCT Chest in Suspected COVID-19 Patients","","NCT04492865","CTCOV","Device: MSCT","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492865","Not yet recruiting","2020-07-30","2020-10-30","{""locations"":""Assiut university, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Accuracy of non contrast MSCT chest in COVID-19|MSCT chest can be used as an alternative diagnostic tool for COVID-19 cases.""}"
"321","SCB-2019 as COVID-19 Vaccine","","NCT04405908","CLO-SCB-2019-001","Biological: SCB-2019|Biological: SCB-2019 with AS03 adjuvant|Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04405908","Active, not recruiting","2020-06-19","2021-05-25","{""locations"":""Linear Clinical Research Ltd, Nedlands, Western Australia, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""150"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of solicited adverse events (AEs) after vaccination|Incidence of unsolicited AEs after vaccination|Immunogenicity(Anti-SCB-2019 Antibody Titers)|Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs)|Immunogenicity( serum anti SARS-CoV-2 neutralizing antibody titers (ACE2 receptor-based) )|Immunogenicity(serum anti SARS-CoV-2 neutralizing antibody titers (cell based) )|Immunogenicity(serum anti SARS-CoV-2 whole virus antibody titers)|Antibody kinetics of each SCB 2019 vaccine formulation after first and second doses""}"
"322","Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).","","NCT04452474","CL04041080","Drug: Olokizumab 64 mg|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04452474","Not yet recruiting","2020-06-30","2021-01-29","{""locations"":""George Washington University Medical Center, Washington, District of Columbia, United States|Center For Haptitis C\/ Atlanta Medical Center, Atlanta, Georgia, United States|PMG Research of DuPage Medical Group, Downers Grove, Illinois, United States|Northwest Indiana Center for Clinical Research, Portage, Indiana, United States|Baystate Infectious Diseases Clinical Research, Springfield, Massachusetts, United States|PMG Research, Inc., Winston-Salem, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""376"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the \""Not hospitalized\"" category|Subjects' clinical status distribution based on 5-point clinical status scale during the study|28-day case fatality rates""}"
"323","Anxiety And Depression During COVID-19 IN INDIA","","NCT04369300","Covid-19/MHC/PSYCH/20-10","Behavioral: Registery Data Collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04369300","Recruiting","2020-04-24","2021-02-24","{""locations"":""Max Super Speciality hospital, New Delhi, Delhi, India"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence (magnitude) of anxiety of general adult population during COVID-19|prevalence (magnitude) of depression and anxiety of general adult population during COVID 19""}"
"324","Arrhythmias in Patients With COVID-19","ACOVID","NCT04395664","H-20021500","Device: C3+ Holter Monitor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395664","Completed","2020-04-16","2020-09-01","{""locations"":""Department of Cardiology, Herlev & Gentofte Hospital, Copenhagen, Hellerup, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis""}"
"325","Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)","","NCT04380519","CL04041078","Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04380519","Completed","2020-04-23","2020-07-24","{""locations"":""Federal State Budget Institution \""National Medical Surgery Center named after N.I. Pirogov\"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution \""City Clinical Hospital \u2116 15 named after O.M. Filatov\"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution \""Federal Center for Cerebrovascular Pathology and Stroke\"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution \""National Medicine Research Center on Cardiology\"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare \""City Clinical Hospital #52\"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare \""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare\"", Moscow, Russian Federation|State Budget Healthcare Institution \""City Clinical Hospital #40\"", Moscow City Healthcare Department, \""Communarca\"" Division, Moscow, Russian Federation|\u0410\u041e \""State Company \""Medsi\"" based on Clinical Hospital \u21161\"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare \""Clinical infectious diseases hospital named after S.P. Botkin\"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare \""City Hospital \u211640\"", Saint Petersburg, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""372"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19""}"
"326","Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic","PAPESCO-19","NCT04421625","ICO-2020-16","Diagnostic Test: Diagnostic test for SARS-Cov2 for patients and health staff","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04421625","Recruiting","2020-06-15","2022-06-15","{""locations"":""Institut de Cancerologie de l'Ouest, Angers, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""12000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Establishment of a clinical basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.|Establishment of a biological basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.|Dosage of IgM and IgG anti SARS-CoV2|Evaluate the diagnostic performance of the minute test for IgM|Evaluate the quantification of IgG in long term (M12) in the Cancer Centres populations|Evaluate the frequency of reinfections among the persons who have developed IgG|Evaluate the threshold of protective IgG among the subjects who have developed IgG|Evaluate the influence of polymorphisms of receptor of IgG Fc-gamma low-affinity (Fc\u03b4IIA, Fc\u03b4IIIa) on the humoral immune response|Evaluate the severity of Covid-19 infection (invisible, visible, prolonged, severe and fatal) by age group|Evaluate the frequency of reinfection by Covid-19 (recurrence of evocative clinical symptoms and positive viral PCR or positive IgM serology) during follow-up|Evaluate the risk factors (clinical and therapeutic) to develop severe forms of Covid-19 infection in patients|Evaluate the changes in health care practice|Evaluate the resources associated with organizational changes|Evaluate the allocated resources|Evaluate the incidence of Covid-19 infections|Evaluate the distribution of risk factors for contamination in patients and in the general population|Evaluate the anxiety state over time|Evaluate the depression over time|Evaluate the post-traumatic developments|Evaluate the change in health care change frequency|Evaluate the number of patients concerned by health care changes|Evaluate the rate of morbidity|Evaluate the rate of mortality""}"
"327","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","SARPAC","NCT04326920","SARPAC","Drug: Sargramostim|Other: Control","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04326920","Completed","2020-03-24","2021-02-26","{""locations"":""AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium|UZ Brussel, Jette, Belgium|AZ Delta Roeselare, Roeselare, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function""}"
"328","Convalescent Plasma in COVID-19 Elderly Patients","RESCUE","NCT04569188","Asstmantova","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04569188","Completed","2020-05-15","2020-09-03","{""locations"":""Transfusion Service, Mantova, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""21"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Death|Viral load""}"
"329","Camostat Mesylate in COVID-19 Outpatients","","NCT04353284","2000027971","Drug: Camostat Mesilate|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04353284","Recruiting","2020-06-19","2021-05-31","{""locations"":""Yale University, New Haven, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""114"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature""}"
"330","A Pilot Study of Sildenafil in COVID-19","","NCT04304313","GST-G1","Drug: Sildenafil citrate tablets","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04304313","Recruiting","2020-02-09","2020-11-09","{""locations"":""Department and Institute of Infectious Disease, Wuhan, Hubei, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event""}"
"331","Current Pharmacological Practices in Severe COVID-19","","NCT04691921","NMCSH","Behavioral: Current clinical practices of participating physicians","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04691921","Completed","2021-01-04","2021-01-31","{""locations"":""Reliance Hospital, Mumbai, Mumbai, Mahrastra, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1055"",""age"":""20 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Choice and indication of pharmacological agents for management of Severe COVID-19""}"
"332","Tele-monitoring of COVID-19 Survivors for Long-Term Impacts","","NCT04644341","B2020:114 (HS24395)","Combination Product: cardiovascular and respiratory systems monitoring","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04644341","Recruiting","2021-01-15","2021-11-01","{""locations"":""University of Manitoba, Winnipeg, Manitoba, Canada"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""20"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Blood pressure|Breathing sounds average power|Risk of aspiration|SaO2 level|Montreal Cognitive Assessment (MoCA)""}"
"333","Abatacept for Patients With COVID-19 and Respiratory Distress","","NCT04477642","2020-P-00XXX","Drug: Abatacept","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04477642","Withdrawn","2020-08-01","2020-12-01","{""locations"":""Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation-free survival|Duration of days on a ventilator|Days until pulse oxygen is > 93% on room air|Days until supplemental oxygen is no longer required|Duration of fever >= 38\u00b0C|Overall survival|Infusion reactions|Secondary infections|Change in Clinical Status, based on 7-point ordinal scale|Viral load|Radiographic Improvement""}"
"334","Immune Biomarkers of Outcome From COVID-19","IBOC","NCT04436484","20/HEP/381","Diagnostic Test: Peripheral blood sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04436484","Recruiting","2020-04-29","2021-02-19","{""locations"":""University Hospitals Plymouth NHS Trust, Plymouth, Devon, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Disease severity""}"
"335","CAP-1002 in Severe COVID-19 Disease","","NCT04338347","CAP-1002-COVID-19","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04338347","No longer available","1970-01-01","1970-01-01","{""locations"":""Cedars-Sinai Medical Center, Los Angeles, California, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"336","COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study","","NCT04422379","COVID 19/LI/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422379","Not yet recruiting","2020-06-07","2020-08-30","{""locations"":""Max Super Speciality Hospital, Saket (A Unit Of Devki Devi Foundation), New Delhi, Dlelhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""314"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Positive Case""}"
"337","GRAd-COV2 Vaccine Against COVID-19","","NCT04528641","RT-CoV-2","Biological: GRAd-COV2","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04528641","Recruiting","2020-08-10","2021-07-31","{""locations"":""INMI Spallanzani, Rome, Italy|Centro Ricerche Cliniche, Verona, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""90"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of solicited local AE signs and symptoms|Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of solicited systemic AE signs and symptoms|Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of unsolicited AE|Assess the safety of GRAd-COV2 by laboratory measures: full blood count; blood Biochemistry (Sodium, Potassium, Albumin, Liver Function Tests; Renal function, lactate dehydrogenases (LDH), alkaline phosphatases (ALP)).|Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of serious AE|Immunogenicity""}"
"338","Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia","","NCT04709172","MPS-ME1207/401","Drug: Cefditoren pivoxil 400mg","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04709172","Recruiting","2021-01-05","2021-09-30","{""locations"":""HU Henares, Coslada, Madrid, Spain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evolution of patient status|Assessment of Clinical improvement|Additional visit to the Emergency room|Need for hospitalization|Occurrence of adverse events""}"
"339","Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program","","NCT04363034","260944","Biological: Convalescent Plasma","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04363034","Available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"340","Antiviral Agents Against COVID-19 Infection","REVOLUTIOn","NCT04468087","REVOLUTIOn","Drug: Atazanavir|Drug: Daclatasvir 60 mg|Drug: Sofusbuvir + Daclastavir 60 mg|Drug: Placebo Atazanavir|Drug: Placebo Daclatasvir 60 mg|Drug: Placebo Sofusbuvir + Daclatasvir 60 mg","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04468087","Not yet recruiting","2020-12-01","2021-04-30","{""locations"":""Hospital do Coracao, Sao Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1005"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase II first step: Change in the slope of SARS-COV 2 viral load|Phase II second step: Change in the slope of SARS-COV 2 viral load|Phase III: Number of free days from respiratory support""}"
"341","Home Usability Study of the SARS-CoV-2 (COVID-19) Test","","NCT04395391","2020-06","Diagnostic Test: SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395391","Completed","2020-05-18","2020-06-16","{""locations"":""Exact Sciences, Madison, Wisconsin, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Valid SARS-CoV-2 Test""}"
"342","Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection.","","NCT04362124","PEC03_2020","Biological: vaccine BCG|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04362124","Withdrawn","2020-08-01","2021-11-01","{""locations"":""Program for Research and Control in Tropical Diseases - PECET, Medell\u00edn, Antioquia, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""0"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary outcome|Secondary outcome""}"
"343","The Role of Ultrasound in COVID-19","","NCT04377035","H-20021500","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377035","Recruiting","2020-03-31","2021-03-01","{""locations"":""Cardiovascular Non-Invasive Imaging Research Laboratory, department of Cardiology, Herlev & Gentofte Hospital, Hellerup, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident ARDS (Adult Respiratory Distress Syndrome) and intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Death from any cause after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident stroke after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident heart failure after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident myocardial infarction after hospital admission with a confirmed COVID-19 diagnosis at follow-up""}"
"344","Attitude and Perception Towards COVID-19 Pandemic","","NCT04400812","ZU#IRB#6138-17-5-2020","Other: questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04400812","Enrolling by invitation","2020-05-19","2020-10-01","{""locations"":""Zagazig University, Zagazig, Sharkia, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""5000"",""age"":""16 Years to 70 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Knowledge about COVID-19 by questionnaire|Perception about COVID-19 by questionnaire|Attitude towards COVID-19 by questionnaire""}"
"345","To Observe Whether Isoflurane Can Treat COVID-19 Patients","","NCT04492943","2020P001048","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492943","Completed","2020-04-20","2020-06-30","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""35"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival Outcome|COVID-19 Testing Methods|COVID-19 Clearance""}"
"346","Awake Prone Position for Early Hypoxemia in COVID-19","APPEX-19","NCT04344587","H-40070","Other: Self-prone position recommendation|Other: Usual care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04344587","Enrolling by invitation","2020-04-23","2021-04-01","{""locations"":""Long Beach Medical Center - MemorialCare, Long Beach, California, United States|Alvarado Hospital, San Diego, California, United States|St. Joseph's Hospital National Jewish Health, Denver, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Piedmont Atlanta, Atlanta, Georgia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Creighton University, Omaha, Nebraska, United States|Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas, United States|VCU Medical Center, Richmond, Virginia, United States|Hospital Universitario La Paz, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""560"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in respiratory status|Length of time participant spends in the prone position|Length of time participant spends in the supine position|Length of time participant spends lying on side|Length of time participant spends sitting up|Length of time participant spends standing or walking|Dyspnea or difficult\/labored breathing|Discomfort with proning|Length of hospital stay|Invasive mechanical ventilation|Loss of IV access as a consequence of turning in bed|Acute respiratory distress syndrome (ARDS) diagnosis|Hospital mortality""}"
"347","Convalescent Plasma for the Treatment of COVID-19","","NCT04389710","20D.379","Drug: Convalescent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04389710","Recruiting","2020-04-15","2021-04-14","{""locations"":""Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma""}"
"348","CovidDB: The Covid-19 Inpatient Database","","NCT04344171","CovidDB","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344171","Recruiting","2020-03-30","2023-06-30","{""locations"":""RoMed - Klinikum Bad Aibling, Bad Aibling, Germany|DONAUISAR Klinikum Deggendorf, Deggendorf, Germany|DONAUISAR Klinikum Dingolfing, Dingolfing, Germany|RoMed - Klinikum Prien am Chiemsee, Prien, Germany|RoMed - Klinikum Rosenheim, Rosenheim, Germany|Universit\u00e4tsklinikum Ulm, Ulm, Germany|RoMed - Klinikum Wasserburg Am Inn, Wasserburg Am Inn, Germany|Klinikum Altm\u00fchlfranken, Wei\u00dfenburg, Germany|Timi\u015f County Emergency Clinical Hospital, Timisoara, Romania"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Outcome comparison between different antiviral therapies|Outcome comparisons between ventilation types|Identification of risk factors|Number of days in hospital vs. clinical classification""}"
"349","Geriatric Population COVID-19 Observational Study (GEROCOVIDobs)","GEROCOVIDobs","NCT04379440","GC01-Obs","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379440","Recruiting","2020-04-25","2020-11-30","{""locations"":""RSA La Quiete, Castiglione Cosentino, Calabria, Italy|ASP Catanzaro, Catanzaro Lido, Calabria, Italy|AOU Ferrara, Ferrara, Emilia Romagna, Italy|Policlinico Campus Bio-Medico, Rome, Roma, Italy|AOU Careggi, Firenze, Toscana, Italy|AOU Pisana Geriatria, Pisa, Toscana, Italy|Ospedale di Comunita' ULSS 6 Euganea- COVID Center, Camposampiero, Veneto, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1500"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health status (WHO classification)|Incidence of Serious Adverse Events|COVID-19 prevalent symptoms at onset|COVID-19 Prognostic Factors|Incidence of COVID-19 in the RSA cohort|Affective\/mood state change from baseline in the \"" At home \"" cohort|Cognitive function in the \""Dementia\"" and \""At home \"" cohorts|Daily Life Function in the \""Dementia\"" and \""At home \"" cohorts|Instrumental Daily Life function in the \""Dementia\"" and \""At home \"" cohorts|Residual signs and symptoms in the \"" Outcomes \"" cohort|Incidence of outcomes in the \"" Outcomes \"" cohort per Frailty Status|Incidence of outcomes in the \"" Outcomes \"" cohort per Comorbidity burden at baseline""}"
"350","Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity","","NCT04441996","STUDY00000949","Biological: Therapeutic plasma exchange (TPE)|Other: Standard of care","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04441996","Active, not recruiting","2020-07-17","2021-02-01","{""locations"":""Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Plasma Viscosity|All Cause Mortality|Bleeding and Thromboembolic Complications|Time to Treatment Failure|Duration of ICU Stay|Duration of Hospital Stay|Discharge Disposition|Change in Clinical Status|Change in Body Temperature|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Heart Rate|Change in Respiratory Rate|Change in Ventilator Days|Change in Ventilator Oxygen Percent (FiO2)|Change in Positive End-Expiratory Pressure (PEEP)|Change in Vasopressor Requirements|Change in Need for Treatment from a Registered Respiratory Therapist (RRT)|Change in Sequential Organ Failure Assessment (SOFA) Score|Change in Partial Pressure of Arterial Oxygen (PaO2)\/Percentage of Inspired Oxygen (FiO2) Ratio|Change in Ventilatory Ratio|Change in White Blood Count (WBC)|Change in Hemoglobin (Hb)|Change in Hematocrit (Hct)|Change in Platelet Count|Change in Mean Platelet Volume (MVP)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Bilirubin|Change in Total Protein|Change in Albumin|Change in C-reactive Protein (CRP)|Change in Interleukin 6 (IL-6)|Change in Prothrombin Time (PT)|Change in International Normalized Ratio (INR)|Change in Activated Partial Thromboplastin Time (aPTT)|Change in Anti-factor Xa (anti-Xa)|Change in Fibrinogen|Change in D-dimer""}"
"351","SCIL-1Ra in COVID-19 Feasibility & PK/PD","SCIL_COV19","NCT04462757","282110|2020-001636-95","Drug: Anakinra 100Mg/0.67Ml Inj Syringe","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04462757","Suspended","2020-05-28","2020-12-31","{""locations"":""Manchester Univesity NHS Foundation Trust, Manchester, United Kingdom|Salford Royal NHS Foundation Tust, Salford, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""5"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Plasma IL-1Ra levels|Plasma IL-6 levels|Plasma markers|Safety Endpoints related to the Serious adverse reactions of the IMP|Safety Endpoints related to the anaphylactic reactions of the IMP|Safety Endpoints related to neutropenia caused by the IMP|Safety Endpoints related to any severe laboratory abnormalities|Feasibility endpoints related to IMP and deviations|Exploratory Data on Clinical efficacy by time to recovery|Exploratory Data on Clinical efficacy|Exploratory Data on Clinical efficacy of the ordinal scale""}"
"352","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","","NCT04337541","2020-04-02","Other: Surgical facial mask","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04337541","Completed","2020-04-02","2020-06-02","{""locations"":""Rigshospitalet, Copenhagen, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""6000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary endpoint is the difference in SARS-CoV-2 infection between the two groups after 1 months and is a combined endpoint consisting of primary outcome components 1, 2 and\/or 3:|Positive oropharyngeal\/nasal swab (PCR);""}"
"353","Atorvastatin as Adjunctive Therapy in COVID-19","STATCO19","NCT04380402","MountAuburn","Drug: Atorvastatin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04380402","Not yet recruiting","2020-05-20","2022-05-08","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients that progress to severe or critical requiring ICU admission and\/or emergency salvage therapy, or death|Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement|Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement|Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7""}"
"354","Clinical Course and Treatment of COVID-19 Inpatients in Hospital","","NCT04527497","WI_20-1294","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04527497","Recruiting","2020-08-01","2021-08-31","{""locations"":""Institut f\u00fcr Pneumologie an der Universit\u00e4t zu K\u00f6ln \/ Wissenschaftliches Institut Bethanien f\u00fcr Pneumologie e.V., Solingen, Nordrhein-Westfalen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""convalescence\/death|length of stay in the intensive care unit|length of stay in hospital""}"
"355","Vocal Feature Analysis Algorithm for COVID-19 Detection","","NCT04418544","002 Soniphi","Device: Device used to record voice for screening","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04418544","Recruiting","2020-06-01","2020-12-01","{""locations"":""Soniphi, Sebastopol, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity and Specificity""}"
"356","Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure","ZILU-COV","NCT04382755","ZILU-COV","Drug: Zilucoplan®|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04382755","Active, not recruiting","2020-05-22","2021-04-30","{""locations"":""OLVZ Aalst, Aalst, Belgium|AZ Sint Jan Brugge, Brugge, Belgium|Erasmus University Hospital, Brussels, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jan Yperman Ziekenhuis Ieper, Ieper, Belgium|University Hospital Li\u00e8ge, Li\u00e8ge, Belgium|AZ Delta, Roeselare, Belgium|AZ Vesalius, Tongeren, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""81"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean change in oxygenation|Median change in oxygenation|number of AE's (Adverse Events)|number of SAE's (Serious Adverse Events)|mean change in 6-point ordinal scale change|Time since randomization until improvement in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence of fever (defined as 37.1\u00b0C or more) for more than 48h without antipyretic|Number of days with fever|Mean change in CRP levels between day 1 and day 6|Mean change in CRP levels between day 1 and day 15 (or discharge whichever comes first)|Mean change in ferritin levels between day 1 and day 6|Mean change in ferritin levels between day 1 and day 15 (or discharge, whichever comes first)|Incidence of AE's|Incidence of SAE's|Incidence of SUSAR's (Suspected Unexpected Serious Adverse Reaction)|Incidence of SAR's (Serious Adverse Reaction)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change of SOFA score between day 1 and day 6 (or on discharge, whichever is first)|Mean change of SOFA score between day 1 and day 15 or on discharge, whichever is first)|Percentage of patients reporting each severity rating on a 6-point ordinal scale at randomization, day 6 and 15 (or discharge, whichever comes first) and day 28 (phone call)|6-point Ordinal Scale at 6 and 15 days (or discharge whichever comes first) and day 28 (phone call), in relation to serum D-dimers and complement C5a levels at randomization|Incidence of nosocomial bacterial or invasive fungal infection for 28 days (phone call) after enrolment in trial|Time since randomization until first use of high-flow oxygen devices in non-ventilated patients|Time since randomization until first use of non-invasive mechanical ventilation in non-ventilated patients|Time since randomization until first use of invasive mechanical ventilation in non-ventilated patients|Number of ventilator-free days|Duration of invasive and non-invasive mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial on invasive or non-invasive mechanical ventilation for less than 24h prior to or after randomization|Time since randomization to progression to ARDS (Acute Respiratory Distress Syndrome)|Time to progression to ARDS in ventilated patients according to D-dimers at randomization|Time to progression to ARDS in ventilated patients according to complement C5a at randomization|All-cause mortality rate (excluding group that entered during ventilation)|All-cause mortality rate (including group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities at follow up|Incidence of lung fibrosis on chest CT scan at follow up|All cause mortality for the entire study population""}"
"357","A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients","PRANA","NCT04458298","OP-101-004","Drug: OP-101|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04458298","Recruiting","2020-07-01","2021-01-31","{""locations"":""Research Site, Loma Linda, California, United States|Research site, Fort Lauderdale, Florida, United States|Research Site, Atlanta, Georgia, United States|Research site, Baltimore, Maryland, United States|Research Site, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with Treatment Emergent Adverse Events Graded as Assessed by CTCAE Version 4.0|Time to Improvement (2 points) in Clinical Status Assessment Using the World Health Organization 7-Point Ordinal Scale (WHO 7OS)|Time to Resolution of Fever for at least 48 hours Without Antipyretics for Patients with Documented Fever (>=37.2 degree celsius [oral], or >=37.8 degree celsius [rectal], or >=38.0 degree celsius [tympanic])|Time to Improvement in Oxygenation for at least 48 hours|Change from Baseline in the World Health Organization (WHO)-7 Point Ordinal Scale|Time to Discharge from Clinic or Hospital or to National Early Warning Score 2 (NEWS2) of <=2 and maintained for 24 hours|Percentage of Patients Alive and not Using Supplemental Oxygen at Time of Discharge from Hospital\/Clinic or Day 30|Number of Days of Resting Respiratory Rate of more than 24 breath\/min|Number of Days with Hypoxemia|Number of Days of Supplemental Oxygen use|Number of Ventilator-free Days|Number of Days in Intensive Care Unit (ICU)|Number of Days of Hospitalization for Survivors|Number of Participants with all cause deaths|Percent change from baseline in Proinflammatory Cytokines|Incidence of Drug-related Serious Adverse Events (SAEs)""}"
"358","Evaluating the Immune Response for COVID-19","COVIDIMMUNE","NCT04348422","105-20-ASF","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: COVID-19 Serology|Other: Symptoms questionnare","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04348422","Recruiting","2020-05-01","2021-12-31","{""locations"":""Assaf-Harofeh Medical Center, Ramla, Israel"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of symptomatic patients with immune response (IgM\/IgG\/IgA)|Proportion of Asymptomatic patients with immune response (IgM\/IgG\/IgA)|Time to IgM|Time to IgG|Time to IgA|Serology kits inter-observer agreement|Proportion of symptomatic patients with immune response (IgM\/IgG\/IgA)- long term|Proportion of Asymptomatic patients with immune response (IgM\/IgG\/IgA) -long term""}"
"359","Detection of COVID-19 Subjects Using DiaNose Exhalation Test","","NCT04476927","CORON01","Device: DiaNose","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04476927","Not yet recruiting","2020-08-01","2021-06-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""collecting and analyzing of DiaNose sensors signals from potential VOC markers in the breath samples of all subjects to build and validate a predictive algorithmic model for diagnosing COVID 19.""}"
"360","Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)","RELIC","NCT04723589","300005853","Biological: Thawed plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04723589","Not yet recruiting","2021-02-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants completing plasma infusion for COVID-19|Number of participants intubated|Sequential Organ Failure Assessment (SOFA) score change|National Early Warning Score change|Ventilator-free Days|Intensive care unit-free Days|In hospital mortality|Angiopoietin 1&2 blood test|Soluble Tie2 blood test|Soluble Thrombomodulin blood test|Syndecan-1 blood test|Prothrombin time blood test|Partial thromboplastin time blood test|D-dimer blood test|Fibrinogen blood test|Thromboelastography blood test|Von Willebrand Factor Antigen blood test|Factor VIII blood test""}"
"361","Etoposide in Patients With COVID-19 Infection","","NCT04356690","H-40102","Drug: Etoposide","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04356690","Recruiting","2020-05-08","2022-06-01","{""locations"":""Boston Medical Center, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""64"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in pulmonary status|Change in ferritin levels|Change in C-reactive protein levels|Change in d-dimer levels|Change in white blood cell count|Incidence of serious adverse events|Overall survival|Length of hospitalization|Duration of ventilation|Ventilator free days|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)""}"
"362","Tofacitinib for Treatment of Moderate COVID-19","I-TOMIC","NCT04415151","2000027848","Drug: Tofacitinib 10 mg|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04415151","Recruiting","2020-07-29","2021-03-31","{""locations"":""Yale New Haven Health System, New Haven, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease Severity|Clinical improvement|Time to recovery|Time to clinical improvement|Clinical status|Mortality|Mechanical Ventilatory Support|Mechanical Ventilatory Support Duration|Freedom from mechanical ventilation|Adverse events|Additional intervention|Viral titer""}"
"363","Dietary Intake and Eating Habits During the COVID-19 Pandemic","COVIDiet","NCT04407533","20-04-064","Other: Diet tracking and survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407533","Recruiting","2020-05-25","2022-08-31","{""locations"":""McGill University - School of Human Nutrition, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""1920"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dietary intake|Diet quality|Eating habits""}"
"364","Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","INHIXACOV19","NCT04427098","2020-001308-40","Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution|Drug: Enoxaparin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04427098","Recruiting","2020-05-22","2020-10-30","{""locations"":""Policlinico S. Orsola Malpighi Dipartimento Malattie Infettive, Bologna, Emilia Romagna, Italy|Azienda Ospedaliero-Universitaria di Parma Anestesia e Rianimazione Dipartimento di Medicina e Chirurgia, Parma, Emilia Romagna, Italy|I.R.C.C.S. \""Casa Sollievo della Sofferenza\"", San Giovanni Rotondo (FG) UOVD Emostasi e trombosi- Poliambulatorio Giovanni Paolo II Viale Padre Pio n.7 San Giovanni Rotondo (FG), San Giovanni Rotondo, Foggia, Italy|Fondazione Poliambulanza Chirurgia Vascolare, Brescia, Italy|Piazzale Spedali Civili, 1, 25123 Brescia BS Medicina Interna UniBS 2\u00b0 Medicina ASST Spedali Civili, Brescia, Italy|Azienda Ospedaliero-Universitaria \""Policlinico - V. Emanuele\"", Catania Anestesia e Rianimazione UO Malattie Infettive, Catania, Italy|ASST Cremona Unit\u00e0 Operativa di Chirurgia Vascolare Dipartimento di Medicina di Laboratorio e di Radiologia- Centro Emostasi e Trombosi, Cremona, Italy|Ospedale Morgagni Pierantoni U.O.C. Malattie Infettive, Forl\u00ec, Italy|Ospedale Carlo Poma di Mantova MALATTIE INFETTIVE Padiglione 37 Str. Lago Paiolo, 10, 46100 Mantova, Mantova, Italy|AZIENDA OSPEDALIERA Regionale S CARLO POTENZA Struttura Complessa Interaziendale \""Malattie Infettive\"", Matera, Italy|Ospedale San Raffaele Unit\u00e0 Funzionale dell'Unit\u00e0 Operativa di Malattie Infettive Osp. San Raffaele, Milano, Italy|Ospedale Amedeo di Savoia Torino Universit\u00e0 di Torino Malattie Infettive, Torino, Italy|Azienda Ospedaliera Universitaria Integrata Verona UOC Malattie Infettive e Tropicali, Verona, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.|To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19.|To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19.""}"
"365","A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)","","NCT04351243","KIN-1901-2001","Drug: Gimsilumab|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04351243","Active, not recruiting","2020-04-12","2021-03-01","{""locations"":""Banner University Medical Center, Phoenix, Arizona, United States|HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States|HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States|HonorHealth, Scottsdale, Arizona, United States|HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States|Banner University Medical Center, Tucson, Arizona, United States|UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Miami Cancer institute, Miami, Florida, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai West, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Jack & Jane Hamilton Heart and Vascular Hospital, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor Scott & White All Saints Medical Center, Fort Worth, Texas, United States|Memorial Hermann Hospital Affiliated with University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|Baylor Scott & White Medical Center, Irving, Texas, United States|Baylor Scott & White Medical Center, Plano, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""227"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of mortality|Incidence of subjects who are alive and not on mechanical ventilation|Number of ventilator-free days|Time to hospital discharge""}"
"366","Cyclosporine in Patients With Moderate COVID-19","","NCT04412785","842998","Drug: Cyclosporine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04412785","Recruiting","2020-06-30","2021-12-01","{""locations"":""University of Pennsylvania, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety-oxygen, ICU transfer and ventilation|Safety-changes in absolute lymphocyte count|Safety-changes in creatinine clearance|Safety-secondary bacterial infections|Laboratory measurements of safety and antiviral efficacy related to COVID-19-SARS-CoV-2 by measuring the clearance of SARS-CoV-2 from respiratory secretions|Laboratory measurements-D-dimer levels|Laboratory measurements-ferritin|Laboratory measurements- IL-6""}"
"367","A Randomized Trial of Anticoagulation Strategies in COVID-19","","NCT04359277","s20-00479","Drug: Enoxaparin Higher Dose|Drug: Lower-dose prophylactic anticoagulation","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04359277","Terminated","2020-04-21","2020-09-20","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""77"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite incidence of: all-cause mortality, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, stroke, or shock|Score on WHO Ordinal Scale|Incidence of acute kidney injury (KDIGO criteria for Acute Kidney Injury (AKI))|Requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Cardiac injury|Hypercoagulability|Disseminated Intravascular Coagulation (DIC) Score|Length of Hospital Stay""}"
"368","Respiratory Physiotherapy in Severe COVID-19 Patients","FTR-COVID","NCT04459819","FTR-COVID","Other: Respiratory physiotherapy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459819","Completed","2020-03-01","2020-09-30","{""locations"":""Department of Pathophysiology and Transplantation, University of Milan Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""84"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of physiotherapy treatments|Type of physiotherapy treatments|Time of the first physiotherapy treatment|First time standing|First time walking|First time sitting out of bed|6 minutes walking test (6MWT)|1 minute sit-to-stand test (1m-STST)|Upper extremity muscles strength|Lower extremity muscles strength|Functional independence in ADL|ICU stay length|Length of hospitalization|Duration of invasive mechanical ventilation (IMV)|Patients returned home|Patients discharged to in-patient rehabilitation|Patients transferred to other hospitals|Exitus""}"
"369","Administration of Chlorpromazine as a Treatment for COVID-19","","NCT04354805","Medical","Drug: Chlorpromazine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04354805","Not yet recruiting","2020-08-01","2020-11-01","{""locations"":""Cairo University, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement""}"
"370","Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","ReCOVery-SIRIO","NCT04351763","NCU-COVID19","Drug: Amiodarone|Drug: Verapamil","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04351763","Recruiting","2020-04-27","2021-04-10","{""locations"":""Nicolaus Copernicus University, Bydgoszcz, Poland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""804"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement|Mean change in the 7-point ordinal scale|Mortality|Time to resolution of fever|Clinical improvement or fever resolution|Tachyarrhythmias|Mortality or tachyarrhythmias|Time to clinical improvement from admission using the 7-point ordinal scale|Change in NEWS2 score|Duration of hospitalization|PO2\/FIO2""}"
"371","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","","NCT04341168","KICC19","Other: this study is non- interventional","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341168","Not yet recruiting","2020-04-01","2020-10-01","{""locations"":""University Hospital Cologne, Cologne, NRW, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""160"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical course of COVID-19|Analysis of development of antibodies to SARS-CoV-2|Estimation of viral load|Detection of viral coinfections|Measurement of cytokine and chemokine response|Characterisation of virus-host-interaction|Identification of disease patterns in proteome|Analysis of change in lymphocyte subtypes|Analysis of histological changes in severe lung disease|Detection of bacterial coinfections""}"
"372","Hexoskin Feasibility Study With COVID-19 Patients","","NCT04453891","Hexoskin COVID-19 Study","Device: Monitoring physiological data with the Hexoskin smart shirt","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453891","Not yet recruiting","2021-07-15","2021-12-15","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""16"",""age"":""55 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Qualitative assessment of the feasibility of the Hexoskin Platform and Virtual Recruitment Process via three subjective feedback questionnaires provided to all patients enrolled in the study.|Ensure the collection of high-quality data during wake and sleep activities, registered as overall > 90% good quality cardiac data and overall > 90% good quality respiratory data per recording.|Ensure adequate patient compliance, qualified as > 75% of total recording hours completed, and > 75% of daily questionnaires completed.|Investigate the predictive power of Hexoskin physiological data, patient information and symptoms information to correctly classify patient disease progression quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.70).""}"
"373","Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction","MiRCOVID","NCT04381351","1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04381351","Recruiting","2020-04-16","2021-07-31","{""locations"":""Klinik f\u00fcr An\u00e4sthesiologie, D\u00fcsseldorf, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""predicitive value of noncoding RNAs in COVID-19 associated organ dysfunction""}"
"374","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","COMIHY","NCT04340544","COMIHY","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04340544","Terminated","2020-04-22","2020-10-12","{""locations"":""Institute for Tropical Medicine, T\u00fcbingen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""17"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 days""}"
"375","Treatment of Angiotensin Peptide (1-7) for COVID-19","","NCT04375124","KSSEAH--0059","Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04375124","Recruiting","2020-04-25","2020-09-30","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality""}"
"376","Accelerated Prone Position Ventilation of Patients With COVID-19","PROVENT-COVID","NCT04384900","H-20027361","Procedure: Prone position ventilation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04384900","Recruiting","2020-05-11","2020-12-01","{""locations"":""Nordsj\u00e6llands Hospital, Hiller\u00f8d, Region Hovedstanden, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days alive without respiratory life support (invasive mechanical ventilation) at day 28.|Days alive and out of hospital on day 28 after randomisation.|Days alive at day 28 without life support (vasopressor\/inotropic support, invasive mechanical ventilation or renal replacement therapy).|Number of participants with one or more SARs as described in section 6.1 plus incidence of new persistent nerve injury or grade 3 or 4 (full-thickness skin loss or worse) pressure wounds.|28-days all-cause mortality.""}"
"377","Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection","","NCT04509999","IRB202001669-A|OCR38162","Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04509999","Recruiting","2020-10-26","2022-09-01","{""locations"":""University of Florida Clinincal Research Vehicle, Gainesville, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion x 100 = percent of patients with improved COVID-19 symptoms""}"
"378","COVID-19 With Convalescent Plasma","","NCT04616976","COVID-19 convalescent plasma","Biological: convalescent plasma","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04616976","Completed","2020-01-01","2020-11-01","{""locations"":""Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""78"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28-day mortality|SARS-CoV-2 negative conversion rate""}"
"379","Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals","COVID","NCT04376398","COVID-ANESTHESIO","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376398","Completed","2020-04-06","2020-08-30","{""locations"":""Cliniques Universitaires Saint Luc, Brussels, Belgium"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""up to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Global evaluation of the implication of the Belgian anesthesiologists during COVID-19 pandemic|If any compare our results with other countries""}"
"380","Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection","COVERSCAN","NCT04369807","20/SC/0185","Diagnostic Test: Outpatient MRI","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04369807","Recruiting","2020-04-21","2023-05-31","{""locations"":""Mayo Clinic Healthcare, London, United Kingdom|Gemini, Oxford, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""507"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)|Characterise prevalence and severity of organ volume change and damage (lung, pancreas and spleen)|Change from Baseline in liver-specific biomarkers: volume, iron corrected T1(cT1), fat content and T2star|Change from Baseline in organ-specific biomarkers characterising organ volume change in the heart and spleen along with organ volume and damage in the kidney, liver and pancreas assessed by volume, iron corrected T1 (cT1) and fat infiltration|Change in patient reported outcome measured by the Dyspnea-12 questionnaire|Change in patient reported outcome measured by the St. George's Respiratory questionnaire (SGRQ)|Change in patient reported outcome measured by the EQ-5D-5L questionnaire|Degree of change in liver MR-derived biomarkers""}"
"381","Epidemiological Multicohort Study of Latent COVID-19 Infections","","NCT04695678","WI-2020179","Diagnostic Test: COVID-19 nasal/pharyngeal swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04695678","Active, not recruiting","2020-07-01","2021-06-30","{""locations"":""Institut f\u00fcr Pneumologie an der Universit\u00e4t zu K\u00f6ln \/ Wissenschaftliches Institut Bethanien f\u00fcr Pneumologie e.V., Solingen, Nordrhein-Westfalen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of latent COVID-19 infections at one point in time among residents and staff of all old people's and nursing homes in Solingen.|Prevalence of latent COVID-19 infections over a follow-up period of 6 months among staff of one single nursing home|Analysis of risk factors (previous illnesses, medication...)""}"
"382","Effect of Quercetin on Prophylaxis and Treatment of COVID-19","","NCT04377789","KSSEAH--0058","Dietary Supplement: Quercetin Prophylaxis|Dietary Supplement: Quercetin Treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04377789","Completed","2020-03-20","2020-08-31","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""447"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID-19 calculated using a questionnaire|Standardized Mortality rate|Morbidity rate""}"
"383","IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)","","NCT04575610","2000028042","Drug: PF-06650833|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04575610","Recruiting","2020-11-30","2021-03-31","{""locations"":""Yale New Haven Hospital, New Haven, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""68"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality at Day 29|Disease Severity (8 point scale)|Mortality|P\/F ratio|Change of the SOFA score.|Duration (days) of mechanical ventilation|Ventilator free days.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0""}"
"384","Ramipril for the Treatment of COVID-19","RAMIC","NCT04366050","RAMIC Trial","Drug: Ramipril 2.5 MG Oral Capsule|Drug: Placebo oral capsule","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04366050","Recruiting","2020-05-11","2021-05-01","{""locations"":""University of California, San Diego, La Jolla, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""560"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite of mortality or need for ICU admission or ventilator use""}"
"385","PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams","PROTECT","NCT04483635","MP-21-2021-3044","Dietary Supplement: Placebo|Dietary Supplement: Vitamin D","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04483635","Recruiting","2021-02-08","2021-12-31","{""locations"":""CHUM, Montreal, Quebec, Canada|CHU Sainte-Justine (CHUSJ), Montreal, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""2414"",""age"":""18 Years to 69 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in incidence of laboratory-confirmed COVID-19 infection|Distribution of disease severity|Duration of symptoms in COVID-19 positive participants|Number of participants with COVID-19 positive IgG serology|Number of workday absences due to COVID-19 suspected\/confirmed infection|Number of workday absences for any reason|Adverse health events""}"
"386","High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)","","NCT04383002","20-5449","Drug: Nitric Oxide","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04383002","Recruiting","2020-09-02","2020-12-01","{""locations"":""University Health Network, Toronto General Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 PCR status at completion of treatment (day 7) from tracheal aspirate""}"
"387","Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19","","NCT04443725","CUKA-003","Drug: Hydroxychloroquine , Sofosbuvir, daclatasvir|Drug: Standard of care treatment","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04443725","Not yet recruiting","2020-07-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virological cure""}"
"388","Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19","","NCT04667780","ATH/IRB/Colchicine/25.11.2020","Drug: Colchicine|Drug: Standard COVID-19 care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04667780","Recruiting","2020-12-10","2021-07-09","{""locations"":""Ayub Teaching Hospital, Abbottabad, Khyber Pakhtunkhwa, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""102"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality""}"
"389","Low Dose Whole Lung Radiotherapy for Older Patients With COVID-19 Pneumonitis","","NCT04493294","IGRG01","Radiation: Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04493294","Not yet recruiting","2020-11-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Mortality rate|Duration of hospitalization|Time to recovery|Oxygen saturation rate|Patient inflammatory status""}"
"390","Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients","SnPPIX","NCT04371822","Proposed by Mahmoud Elkazz","Drug: SnPP Protoporphyrin plus Sunlight exposure|Drug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Other: placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04371822","Not yet recruiting","2020-08-01","2020-11-01","{""locations"":""Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|Serum ferritin|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap""}"
"391","Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study","TVP-COVID-RIV","NCT04361981","RIV-R3","Other: Deep Venous Disease Diagnostic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361981","Not yet recruiting","2020-04-01","2020-12-31","{""locations"":""Red de Investigacion Vascular (SEACV), Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Deep Venous Disease Incidence|30-days mortality|ICU admission|Anticoagulant treatment""}"
"392","Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19","","NCT04472013","2020-01503; ch20Hutter","Other: Data collection from lumbar puncture|Other: Data collection from blood draw|Other: CNS magnetic resonance imaging (MRI) imaging|Other: Microscopy of defined brain regions on autopsy specimens","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04472013","Recruiting","2020-08-12","2022-12-01","{""locations"":""Neurosurgery, University Hospital Basel, Basel, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""MRI imaging data|Proteomic analysis|Peripheral blood leukocyte Cytof Mass Cytometry Analysis for cell population frequency|CODEX (high dimensional microscopy) workflow analysis of defined regions on brain autopsy specimens""}"
"393","Jinhua Qinggan Granules in the Treatment of COVID-19","RCT","NCT04723524","CRO-003-TCM- JHQG -2020","Combination Product: Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Other: Placebo Comparator","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04723524","Recruiting","2020-09-22","2021-08-01","{""locations"":""Center for Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, university of Karachi, Karachi, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Primary symptom (cough)|Change in Primary symptom (Fever)|Time for Negative COVID-19 Test|Body temperature|white blood cells count|C-reactive protein test|ferritin test|Radiology|Quality of life assessment:""}"
"394","Remote-by-Default Care in the COVID-19 Pandemic","","NCT04435041","283196","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04435041","Active, not recruiting","2020-06-01","2021-11-30","{""locations"":""University of Oxford, Oxford, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""1"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""RECAP Early warning score""}"
"395","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19","","NCT04327674","COVID-FLUS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04327674","Recruiting","2020-03-14","2020-05-15","{""locations"":""Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""375"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.""}"
"396","Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic","","NCT04521088","WI-1252","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04521088","Recruiting","2020-07-02","2020-12-31","{""locations"":""Institut f\u00fcr Pneumologie an der Universit\u00e4t zu K\u00f6ln \/ Wissenschaftliches Institut Bethanien f\u00fcr Pneumologie e.V., Solingen, Nordrhein-Westfalen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""possible risk factors|frequency of positive test results after prescribed protective measures|frequency of positive test results within the family or other social groups|number of COVID-19 tests in the outpatient clinic""}"
"397","Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19","KetoCOVID","NCT04573764","H-20021500","Dietary Supplement: D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|Dietary Supplement: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04573764","Not yet recruiting","2020-10-01","2022-01-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Left Ventricular ejection fraction|Global longitudinal strain|Cardiac output|Peripheral blood oxygen saturation|Venous blood oxygen saturation|Urine creatinine clearance""}"
"398","Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","","NCT04516746","D8110C00001","Biological: AZD1222|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04516746","Active, not recruiting","2020-08-28","2023-02-14","{""locations"":""Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Berkeley, California, United States|Research Site, El Centro, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, San Francisco, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, Atlantis, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Fairway, Kansas, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Bloomington, Minnesota, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Henderson, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Berlin, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Yukon, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Fort Belvoir, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, South Charleston, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Caba, Argentina|Research Site, Ciudad Aut\u00f3noma de Bs. As., Argentina|Research Site, Ciudad Aut\u00f3noma de Buenos Aire, Argentina|Research Site, Quillota, Chile|Research Site, Region Metropolitana, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Floridablanca, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Angers, France|Research Site, Bron, France|Research Site, Creteil, France|Research Site, Dijon Cedex, France|Research Site, Lille, France|Research Site, Limoges cedex, France|Research Site, Marseille, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, St Etienne, France|Research Site, Callao, Peru|Research Site, Cercado De Lima, Peru|Research Site, Cercardo De Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""32459"",""age"":""18 Years to 130 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19|The safety and tolerability of 2 IM doses of AZD1222 compared to saline placebo|The reactogenicity of 2 IM doses of AZD1222 compared to saline placebo (Substudy only)|The efficacy of 2 IM doses of AZD1222 compared tosaline placebo for the prevention of SARS-CoV-2 infection|The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of symptomatic COVID-19 using CDC criteria|The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of University of Oxford defined symptomatic COVID-19|The efficacy of 2 IM doses of AZD12222 compared to saline placebo for the prevention of severe or critical symptomatic COVID-19.|The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19-related Emergency Department visits|Antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or saline placebo (Substudy and Illness Visits only)|Anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or saline placebo (Substudy and Illness Visits only)|The efficacy of 2 IM doses of AZD1222 compared to saline placebo in the prevention of COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection|The efficacy of AZD1222 compared to saline placebo for the prevention of COVID-19 following the first dose""}"
"399","Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs","LAUREL","NCT04628039","F3666-R|1I01RX003666-01","Other: Rehabilitation-focused program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04628039","Not yet recruiting","2021-03-01","2024-10-31","{""locations"":""VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""506"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""EuroQol 5 Dimension 5 Level (EQ-5D-5L) visual analog score|WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)|EuroQol 5 Dimension 5 Level (EQ-5D-5L) overall utility index""}"
"400","Mesenchymal Stem Cell Infusion for COVID-19 Infection","","NCT04444271","NIBMT-MSc-COVID-2020","Drug: Mesenchymal stem cells|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04444271","Recruiting","2020-05-01","2020-09-30","{""locations"":""NIBMT, Rawalpindi, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""10 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Overall survival|Clinical improvement|Time of COVID19 PCR negativity|Radiological improvement (day 15 and day 30 assessment)|days required to discharge from hospital""}"
"401","Comparison of Two Different Doses of Bemiparin in COVID-19","BEMICOP","NCT04604327","BEMICOP","Drug: Bemiparin sodium","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04604327","Recruiting","2020-10-26","2021-07-31","{""locations"":""Hospital Rey Juan Carlos, M\u00f3stoles, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Clinic, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital Universitario Bellvitge, L'Hospitalet De Llobregat, Spain|Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain|Hospital Cl\u00ednico San carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario de Toledo, Toledo, Spain|Hospital Universitario R\u00edo Hortega, Valladolid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""164"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical deterioration""}"
"402","COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.","","NCT04397757","843003 (PennCCP-02)","Biological: COVID-19 Convalescent Plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04397757","Active, not recruiting","2020-05-13","2021-06-30","{""locations"":""Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participants with serious adverse events.|Comparison of clinical severity score between patients on the experimental versus control arms;|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms|Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Non-invasive ventilation\/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of non-invasive ventilation\/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of non-invasive ventilation\/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Ventilator\/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|Mortality of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of Grade 3 and Grade 4 clinical and\/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms""}"
"403","Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers","","NCT04445415","COVID-19 antibodies testing","Diagnostic Test: COVID-19 antibodies testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445415","Not yet recruiting","2020-07-01","2021-09-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""diagnostic value of COVID-19 antibodies testing|Role of COVID -19 Antibodies testing in treatment of Patients|Assement of COVID -19 prevalence among healthcare workers""}"
"404","Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol","","NCT04424797","20-6034","Other: Prone Positioning|Other: Supine Positioning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04424797","Recruiting","2020-07-13","2020-12-01","{""locations"":""UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|UCHealth Medical Center of the Rockies, Loveland, Colorado, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of intubation|Maximum oxygen requirement|Length of Stay|Ventilator-free days|Treatment failure of prone positioning due to worsening SpO2 status while prone|Mortality""}"
"405","Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients","","NCT04451889","COVID-pCLE","Device: miniprobe Alveoflex","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04451889","Recruiting","2020-08-01","2021-09-01","{""locations"":""Federal Research Clinical Center FMBA Russia, Moscow, Russian Federation"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""15"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of COVID-19 Participants With Notable Differences in the pCLE images in comparison with the pCLE images of non-COVID-19 Participants|Number of Participants With the Correspondence of pCLE Images to High Resolution Computer Tomography and Morphologic Data as a Measure of Specificity and Sensitivity of the Method""}"
"406","Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19)","","NCT04561193","033.PHA.2020.A","Other: Observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04561193","Recruiting","2020-05-30","2021-05-01","{""locations"":""Methodist Dallas Medical Center, Dallas, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of subsequent and co-infections|In-hospital mortality|Hospital length of stay (LOS)""}"
"407","Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)","","NCT04480424","GC2007","Biological: GAMUNEX-C|Drug: Standard Medical Treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04480424","Recruiting","2020-09-17","2021-05-01","{""locations"":""University of Louisville, Louisville, Kentucky, United States|McLaren Flint, Flint, Michigan, United States|McLaren Health Care-Macomb, Mount Clemens, Michigan, United States|McLaren Health Care Oakland, Pontiac, Michigan, United States|CHI Health, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Summa Health, Akron, Ohio, United States|Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States|CHRISTUS Health, Tyler, Texas, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-Cause Mortality Rate Through Day 29|Time to Actual ICU Discharge|Duration of Mechanical Ventilation|Time to Actual Hospital Discharge|Duration of Any Oxygen Use|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale|Overall Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Number of Participants who Develop ARDS Distributed by Severity|Change from Baseline in Sequential Organ Failure Assessment (SOFA) Score|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS \u2264 2 Maintained for 24 hours""}"
"408","Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors","","NCT04665752","10000078|000078-EI","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04665752","Recruiting","2021-02-02","2023-06-30","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of participants|Correlation of findings|Proportion of patients""}"
"409","Desidustat in the Management of COVID-19 Patients","","NCT04463602","DESI.20.004","Drug: Desidustat|Other: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04463602","Active, not recruiting","2020-07-25","2021-02-28","{""locations"":""Avant Sante Site 1, Monterrey, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Clinical status of subject on a 7-point ordinal scale|PCR test|Supplemental Oxygen|Mechanical Ventilation|Incidence of Treatment-Emergent Adverse Events|Laboratory Assessments|C-reactive protein (CRP)|Interleukin 6 (IL-6)|D-dimer""}"
"410","Trial of Imatinib for Hospitalized Adults With COVID-19","","NCT04394416","2038GCCC","Drug: Imatinib|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04394416","Recruiting","2020-06-02","2023-06-01","{""locations"":""University of Maryland Medical Center, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""204"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of patients with a two-point change using the 8-category ordinal scale|All-Cause mortality|Time to a 2-point clinical change|Hospitalization|Duration of ECMO or invasive mechanical ventilation|Duration of ICU stay|SARS-CoV-2 negative|Negative oropharyngeal or nasopharyngeal swab|Serious adverse events (SAEs)|Discontinuation due to adverse events""}"
"411","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia","SCOPE","NCT04341675","2020-0337","Drug: Sirolimus|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04341675","Recruiting","2020-04-24","2020-09-01","{""locations"":""Loyola University Medical Center, Chicago, Illinois, United States|University of Cincinnati, Cincinnati, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who are alive and free from advanced respiratory support measures at day 28.|Proportion of patients who require escalation in care|Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)|Proportion of patients surviving to hospital discharge|Drug safety profile|Duration of advanced respiratory support|Duration of hospital stay|Time from treatment initiation to death|Time to resolution of fever|Proportion of patients who require initiation of off-label therapies""}"
"412","Inflammatory Regulation Effect of NAC on COVID-19 Treatment","INFECT-19","NCT04455243","E-20-4934","Drug: N-Acetyl cysteine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04455243","Not yet recruiting","2020-08-01","2021-08-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Recovery""}"
"413","Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia","PREDCOVID","NCT04451174","2092","Drug: Prednisone","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04451174","Recruiting","2020-06-23","2020-12-30","{""locations"":""Hospital Santiago Oriente, Santiago, Pe\u00f1alolen, Chile"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""184"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation or All-cause Death by Day 28""}"
"414","Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial","GETAFE","NCT04361643","COVID19-EC01","Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04361643","Not yet recruiting","2020-10-27","2021-12-31","{""locations"":""Hospital Universitario de Getafe, Getafe, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement|Immune-inflammatory improvement|Mortality""}"
"415","Study to Assess the Effect of Meplazumab on COVID-19","","NCT04586153","MPZ-II-02","Drug: Meplazumab for Injection|Drug: Sterile normal saline (0.9%)","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04586153","Not yet recruiting","2020-12-30","2021-09-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""456"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to sustained clinical improvement|Response rate|Mortality|Proportion of subjects alive and discharged without supplemental oxygen|Proportion of subjects alive and discharge without supplemental oxygen|Weight in kilogram|Blood pressure in mmHg|saturation in percentage|Temperature in \u2103|12-lead electrocardiograms (ECGs)|Virologic load|Antidrug antibody (ADA) titers|Adverse events (AEs) of special interest|Time to sustained recovery""}"
"416","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","HCQ4COV19","NCT04304053","HCQ4COV19|2020-001031-27","Drug: Treatment and prophylaxis|Other: Standard Public Health measures","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04304053","Completed","2020-03-18","2020-06-15","{""locations"":""Departament de Salut, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Study 1- Clinical and virological outcome in exposed contacts|Study 1- Transmission of SARS-CoV-2 in exposed contacts|Study 2- Virological outcome in index cases|Study 2- Clinical outcome in index cases""}"
"417","The Evaluation of Hemostasis in Hospitalized COVID-19 Patients","TARGET-COVID","NCT04493307","1602903","Diagnostic Test: Phlebotomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04493307","Recruiting","2020-06-30","2021-06-01","{""locations"":""Sinai Center for Thrombosis Research, Baltimore, Maryland, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""3 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Frequency of Hypercoagulability as measured by thromboelastography measured by TEG and platelet aggregation.|Frequency of High Platelet Reactivity (HPR)|Frequency of thrombo-inflammatory syndrome|Correlation between TEG6s parameters and clinical outcomes|Correlation between HPR and clinical outcomes|Determine response to anticoagulation therapy|Determine level of platelet aggregation|Determine platelet thrombi and fibrin rich platelet thrombus Area Under the Curve|Determine short and long IgG, IgM and IgG antibody levels""}"
"418","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19","","NCT04333628","EMC 0045-20","Drug: chloroquine|Other: standard care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04333628","Terminated","2020-06-01","2020-09-01","{""locations"":""Haemek Medical Center, Afula, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""5"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease""}"
"419","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","PATCH","NCT04329923","842838","Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet","Interventional","Has Results","Phase 2","https://ClinicalTrials.gov/show/NCT04329923","Terminated","2020-04-09","2020-11-13","{""locations"":""University of Pennsylvania, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""173"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Release From Quarantine Time|Time to Hospital Discharge|Number of Health Care Workers Who Developed SARS-COV-2 Infection|Rate of Housemate Infection|Rate of Hospitalization""}"
"420","Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS","ARCHITECTS","NCT04412772","RA-2020-019","Drug: Tocilizumab|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04412772","Recruiting","2020-06-12","2021-12-31","{""locations"":""Queen's Medical Center, Honolulu, Hawaii, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation""}"
"421","Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter","COSA","NCT04361500","COSA-8998","Device: Seraph 100","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361500","Recruiting","2020-04-15","2021-10-01","{""locations"":""Academic Teaching Hospital Brunswick, Brunswick, Lower Saxony, Germany|Hannover Medical School, Hannover, Germany"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival|Length of ICU stay|Length of Hospital stay|Length of ventilator therapy|Adverse events""}"
"422","ACT-20 in Patients With Severe COVID-19 Pneumonia","","NCT04398303","AHS 20-03","Biological: ACT-20-MSC|Biological: ACT-20-CM|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04398303","Not yet recruiting","2020-05-01","2020-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality at day 30|Ventilated Subjects - Ventilator Free Days|Ventilated Subjects - Improvement in Ventilator Settings|High-Flow O2 Support Subjects - Step-Down O2 Therapy|High Flow O2 Support Subjects - Respiration Rate|Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days|Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement|Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score""}"
"423","Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19","","NCT04541979","NETSC-19","Drug: aerosolized DNase|Drug: NaCl","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04541979","Recruiting","2020-06-04","2021-06-01","{""locations"":""Lund ED, Lund, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to cessation of oxygen therapy DNase I to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy hospitalized patients with COVID-19 and respiratory dysfunction.|28-day mortality|Number of Days alive and without ventilator treatment|Number of Days alive and without high flow nasal oxygen treatment (Optiflow)|Number of Days alive and free of stay in the ICU|Number of Days alive and outside hospital|Number of Days alive and free of a new episode and with oxygen saturation \u226493% after primary endpoint has been met|Number of Days alive and without need of supplemental oxygen|Number of patients with adverse reactions""}"
"424","Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection","","NCT04365738","PR COVID-19","Other: Rehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04365738","Completed","2020-03-11","2020-04-26","{""locations"":""Istanbul Bilgi University, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""270"",""age"":""28 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Dyspnea|Chest expansion|Fatigue severity|Visual Analog Scale for pain|Hospital anxiety and depression scale""}"
"425","A Study of Baricitinib (LY3009104) in Participants With COVID-19","COV-BARRIER","NCT04421027","17830|I4V-MC-KHAA|2020-001517-21","Drug: Baricitinib|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04421027","Recruiting","2020-06-12","2021-06-20","{""locations"":""Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Valleywise Health, Phoenix, Arizona, United States|St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Westchester General Hospital, Miami, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|South Shore Hospital, Weymouth, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Renown Regional Med. Center, Reno, Nevada, United States|SUNY Downstate, Brooklyn, New York, United States|East Carolina University, Greenville, North Carolina, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States|Swedish Medical Center, Seattle, Washington, United States|Multicare Health System, Tacoma, Washington, United States|Sanatorio Sagrado Coraz\u00f3n, Ciudad de Buenos Aires, AR, Argentina|Cl\u00c3-nica Zabala, Ciudad de Buenos Aires, AR, Argentina|Hospital Z.G.A.D \""Evita Pueblo\"", Berazategui, Buenos Aires, Argentina|Sanatorio de la Trinidad Mitre, Caba, Buenos Aires, Argentina|Fundacion Sanatorio Guemes, Caba, Buenos Aires, Argentina|Casa Hospital San Juan de Dios, Ramos Mej\u00eda, Buenos Aires, Argentina|Hospital Interzonal General de Agudos \""Eva Peron\"", San Martin, Buenos Aires, Argentina|Clinica Adventista Belgrano, Caba, Ciudad Aut\u00f3noma De Buenos Aire, Argentina|Centros de Investigaciones Cli-nicas. Clinica Viedma, Viedma, Rio Negro, Argentina|Clinica Central S.A., Villa Regina, Rio Negro, Argentina|Hospital San Roque, Cordoba, Argentina|Hospital Fel\u00edcio Rocho, Belo Horizonte, Minas Gerais, Brazil|Centro Hospitalar de Reabilitacao Ana Carolina Moura Xavier, Curitiba, Parana, Brazil|CEPETI Centro de Ensino e Pesquisa em Terapia Intensiva, Curitiba, Paran\u00e1, Brazil|CPCLIN, Natal, Rio Grande Do Norte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Carlos Fernando Malzoni Matao, Matao, Sao Paulo, Brazil|Pesquisare, Santo Andre, Sao Paulo, Brazil|Praxis Pesquisa Medica, Santo Andr\u00e9, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Upeclin - Unidade de Pesquisa Cl\u00ednica da Faculdade de Medicina de Botucatu - UNESP, Botucatu, S\u00e3o Paulo, Brazil|IPECC - Instituto de Pesquisa Clinica de Campinas, Campinas, S\u00e3o Paulo, Brazil|Hospital PUC-CAMPINAS, Campinas, S\u00e3o Paulo, Brazil|CECIP - Centro de Estudos do Interior Paulista, Ja\u00fa, S\u00e3o Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clinicos EPP Ltda, S\u00e3o Bernardo do Campo, S\u00e3o Paulo, Brazil|Real e Benemerita Associa\u00e7\u00e3o Portuguesa de Beneficiencia, S\u00e3o Paulo, Brazil|Hospital Alem\u00e3o Oswaldo Cruz, S\u00e3o Paulo, Brazil|Universidade Federal de S\u00e3o Paulo - Escola Paulista de Medicina, S\u00e3o Paulo, Brazil|Hospital Santa Paula, S\u00e3o Paulo, Brazil|Casa de Saude Santa Marcelina - Centro de Pesquisa Clinica, S\u00e3o Paulo, Brazil|Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany|Klinikum Rechts der Isar der TU M\u00fcnchen, M\u00fcnchen, Bayern, Germany|Universit\u00e4tsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Unity Hospital, Surat, Gujarat, India|Medanta-The Medicity, Gurgaon, Haryana, India|Government Medical College (GMC) Aurangabad, Aurangabad, Maharashtra, India|Government Medical College, Nagpur, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Medica Superspecialty Hospital, Kolkata, West Bengal, India|Aakash Healthcare Super Speciality Hospital, New Delhi, India|Ospedale SS Annunziata, Chieti Scalo, Chieti, Italy|INMI Lazzaro Spallanzani, Roma, Rome, Italy|Ospedale Luigi Sacco, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|Nuovo Ospedale di Prato S. Stefano, Prato, Italy|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Edogawa Medicare Hospital, Edogawa-ku, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Seoul, Korea, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, DF, Mexico|Instituto Nacional de Cancerologia, Mexico City, FD, Mexico|Hospital General Agust\u00edn O'Hor\u00e1n, Yucatan, Merida, Mexico|ITESM Campus Monterrey, Monterrey, Nuevo Leon, Mexico|Hospital Universitario \""Dr. Jose Eleuterio Gonzalez\"", Monterrey, Nuevo Le\u00f3n, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran- Medicina Critica, Federal District, Mexico|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|City Clinical Hospital #15 named after O.M. Filatov, Moscow, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, Russian Federation|Saint-Petersburg City Pokrovskaya Hospital, Saint-Petersburg, Russian Federation|Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitario Infanta Leonor-INTERNAL MED, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain|The Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Barnet Hospital, Barnet, Herts, United Kingdom|St. George's University Hospitals NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants who Die or Require Non-Invasive Ventilation\/High-Flow Oxygen or Invasive Mechanical Ventilation (including extracorporeal membrane oxygenation [ECMO])|Percentage of Participants with at Least 1-Point Improvement on NIAID-OS or Live Discharge from Hospital|Number of Ventilator-Free Days|Time to Recovery|Overall Improvement on the NIAID-OS|Duration of Hospitalization|Percentage of Participants with a Change in Oxygen Saturation from <94% to \u226594% from Baseline|Mortality|Duration of Stay in the Intensive Care Unit (ICU) in Days|Time to Clinical Deterioration (one-category increase on the NIAID-OS)|Time to Resolution of Fever, in Participants with Fever at Baseline|Mean Change from Baseline on the National Early Warning Score (NEWS)|Time to Definitive Extubation|Time to Independence from Non-Invasive Mechanical Ventilation|Time to Independence from Oxygen Therapy in Days|Number of Days with Supplemental Oxygen Use|Number of Days of Resting Respiratory Rate <24 Breaths per Minute""}"
"426","Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)","COLHEART-19","NCT04355143","20-000685","Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04355143","Recruiting","2020-05-01","2021-04-25","{""locations"":""UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|UCLA Santa Monica Hospital, Santa Monica, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)|Delta (peak minus baseline) troponin level|Delta (baseline to peak) brain natriuretic peptide (BNP) level|Change in left ventricular ejection fraction (LVEF) on echocardiography|Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level|Delta (peak minus baseline) D-Dimer inflammatory biomarker level|Time (days) to primary endpoint|Number of participants requiring mechanical ventilation|Number of participants requiring mechanical circulatory support (MCS)|Re-hospitalization at 90 days|All-cause mortality""}"
"427","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","CODIV-ACE","NCT04318418","DEP_012020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04318418","Completed","2020-03-23","2020-06-30","{""locations"":""IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""3400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Severe COVID-19|Death""}"
"428","Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19","TREATNOW","NCT04372628","200827","Drug: Lopinavir/Ritonavir 400 mg/100 mg|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04372628","Recruiting","2020-06-01","2021-05-01","{""locations"":""University of Colorado School of Medicine, Aurora, Colorado, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Wisconsin, Madison, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Modified COVID Ordinal Outcomes Scale: Study Day 15|Modified COVID Ordinal Outcome Scale: Study Day 8|Modified COVID Ordinal Outcome Scale: Study Day 29|Proportion of patients hospitalized: Day 1 to 29|Time to hospitalization Day 1 to Day 29|Time to symptom resolution: Day 1 to Day 29|All-cause, all-location mortality: Day 1 to Day 29|Oxygen-free days: Day 1 to Day 29|Fever-free days: Day 1 to Day 29|Ventilator-free days: Day 1 to Day 29|ICU-free days: Day 1 to Day 29|Hospital-free days: Day 1 to Day 29""}"
"429","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","","NCT04285801","2020.059","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04285801","Completed","2020-02-14","2020-02-25","{""locations"":""Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""8"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement""}"
"430","Longitudinal Population-based Observational Study of COVID-19 in the UK Population","COVIDENCE UK","NCT04330599","COVIDENCE UK","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04330599","Recruiting","2020-05-01","2025-04-01","{""locations"":""Queen Mary University of London, London, County (optional), United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""12000"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Incidence of confirmed COVID-19|Incidence of probable or suspected COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of the COVID-19 pandemic and the societal response on participants' financial status|Incidence of COVID-19 on participant's physical health|Impact of COVID-19 on participants' mental health|Impact of COVID-19 on physical health of offspring born to participants during follow-up""}"
"431","Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19","","NCT04427865","CUKA-002","Drug: prophylactic lactoferrin daily","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04427865","Not yet recruiting","2020-07-01","2020-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of SARS-CoV-2|Severity of disease in confirmed infected participants""}"
"432","Effect of Vitamin D on Morbidity and Mortality of the COVID-19","COVID-VIT-D","NCT04552951","2020-019-PF-CAANJ","Drug: Cholecalciferol","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04552951","Recruiting","2020-04-04","2020-12-30","{""locations"":""Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality|Admission to Intensive Care Unit (ICU)|Time of hospitalization|Clinical changes|Radiological changes|Calcidiol changes|Inflammation markers changes (CRP)|Inflammation markers changes (IL-6)|Inflammation markers changes (Leucocytes)|Inflammation markers changes (D-dimer)|General biochemical parameters changes (Creatinine)|General biochemical parameters changes (Ferritin)|General biochemical parameters changes (Bilirubin)|General biochemical parameters changes (Albumin)|General biochemical parameters changes (Haemoglobin)|General biochemical parameters changes (HDL cholesterol)|General biochemical parameters changes (Procalcitonin)|General biochemical parameters changes (Protonin)|General biochemical parameters changes (Calcium)|General biochemical parameters changes (Phosphate)|General biochemical parameters changes (pO2)""}"
"433","Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia","CELMA","NCT04429763","202001","Biological: Umbilical cord derived mesenchymal stem cells|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04429763","Not yet recruiting","2020-07-01","2020-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical deterioration or death""}"
"434","Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19","PENFS COVID-19","NCT04514627","1600899","Device: Auricular percutaneous neurostimulation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04514627","Recruiting","2020-07-13","2021-07-31","{""locations"":""Olive View-UCLA Medical Center, Sylmar, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hypoxemia via oxygen level, or saturation (SpO2) in percent|Progression to mechanical ventilation, ECLS or death|Oxygen requirements|Days of hospitalization|Time to hospital discharge|Time to resolution of fever|Days of resting respiratory rate|Serious adverse events or patient or worsening condition|Erythrocyte Sedimentation Rate (ESR)|C-Reactive Protein (CRP)|Ferritin|D-Dimer|Creatine Phosphokinase, Total (CK)|Troponin|Lactate Dehydrogenase (LDH)|Procalcitonin (PCT)|B-Type Natriuretic Peptide (BNP)|N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP)|Interleukin-6 (IL-6), High Sensitive ELISA|Complete Blood Count (CBC) with Differential|Comprehensive Metabolic Panel (CMP)|7-Point Ordinal Scale of Clinical Status|Modified Borg Dyspnea Scale (MBS)""}"
"435","Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital","SCREENING","NCT04380792","SCREENING042020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380792","Completed","2020-04-13","2020-10-13","{""locations"":""Manuel Monreal, Badalona, Barcelona, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""2497"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""VTE events and complications""}"
"436","Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","","NCT04690387","CL-COV-P02-ID","Biological: AV-COVID-19|Other: GM-CSF","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04690387","Active, not recruiting","2020-12-07","2022-01-01","{""locations"":""Rumah Sakit Umum Pusat Dr. Kariadi, Semarang, Jawa Tengah, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""27"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence and severity of adverse events (safety)|Establish optimal dose formulation|Duration of detection of antibodies against SARS-CoV-2""}"
"437","Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)","","NCT04583592","NI03-CV19-001","Drug: Camostat Mesilate|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04583592","Active, not recruiting","2020-11-09","2021-03-30","{""locations"":""Palmtree Clinical Research, Inc. (Site 125), Palm Springs, California, United States|Synergy Healthcare, LLC (Site 124), Bradenton, Florida, United States|Clinical Research of Brandon, LLC (Site 123), Brandon, Florida, United States|Reliable Clinical Research, LLC (Site 100), Hialeah, Florida, United States|A+ Research (Site 112), Miami, Florida, United States|NextPhase Research Alliance at CANO HEALTH (Site 107), Miami, Florida, United States|Ezy Medical Research (Site 106), Miami, Florida, United States|Eminat LLC (Site 117), Plantation, Florida, United States|Invictus Clinical Research Group, LLC (Site 101), Pompano Beach, Florida, United States|Visionaries Clinical Research, LLC (Site 121), Atlanta, Georgia, United States|Family Care Research (Site 114), Boise, Idaho, United States|Cedar Crosse Research Center (Site 122), Chicago, Illinois, United States|Massachusetts General Hospital (Site 110), Boston, Massachusetts, United States|Oakland Medical Research Center (Site 108), Troy, Michigan, United States|Cary Research Group (Site 111), Cary, North Carolina, United States|Onsite Solutions (Site 118), Charlotte, North Carolina, United States|STAT Research (Site 109), Springboro, Ohio, United States|Toledo Institute of Clinical Research, Inc.(Site 105), Toledo, Ohio, United States|Advanced Medical Trials (Site 104), Georgetown, Texas, United States|Next Innovative Clinical Research (Site 115), Houston, Texas, United States|Rio Grand Valley Clinical Research Institute (Site 120), Pharr, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease Progression at Day 28|Survival Rate|Time to Fever Resolution|Time to Disease Progression|Resolution of Viral Shedding|Rate of Adverse Events and Serious Adverse Events|Cumulative Rate of Grade 3 and 4 Adverse Events|Rate of Discontinuation|Change in Laboratory Parameter - Platelet Count|Change in Laboratory Parameter - Potassium Level|Change in Laboratory Parameter - Aspartate Aminotransferase (AST)|Change in Laboratory Parameter - Alanine Aminotransferase (ALT)|Change in Laboratory Parameter - Alkaline Phosphatase (ALP)|Change in Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)|Change in Laboratory Parameter - Albumin|Change in Laboratory Parameter - Bilirubin|Change in Vital Signs - Heart Rate|Change in Vital Signs - Blood Pressure|Change in Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2)""}"
"438","Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","","NCT04362085","RAPID COVID-COAG","Drug: Therapeutic Anticoagulation","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04362085","Recruiting","2020-05-11","2022-04-01","{""locations"":""St. Michael's Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""462"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite outcome of ICU admission (yes\/no), non-invasive positive pressure ventilation (yes\/no), invasive mechanical ventilation (yes\/no), or all-cause death (yes\/no) up to 28 days.|All-cause death|Composite outcome of ICU admission or all-cause death|Composite outcome of mechanical ventilation or all-cause death|Major bleeding|Number of participants who received red blood cell transfusion|Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and\/or fibrinogen concentrate.|Renal replacement therapy|Number of hospital-free days alive up to day 28|Number of ICU-free days alive up to day 28|Number of ventilator-free days alive up to day 28|Number of organ support-free days alive up to day 28|Number of participants with venous thromboembolism|Number of participants with arterial thromboembolism|Number of participants with heparin induced thrombocytopenia|Changes in D-dimer up to day 3""}"
"439","BNP, Serum Troponin and D-dimer as Risk Factors in Patients With COVID-19","","NCT04433026","Cardiac markers in COVID-19","Diagnostic Test: N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433026","Not yet recruiting","2020-08-01","2021-09-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""90"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Measurement of N-terminal pro-B type natriuretic peptide, troponin-I and D-dimer in COVID-19 patients|Cardiac complications in COVID-19 patients associated with more adverse effects""}"
"440","Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19)","","NCT04376879","2020-A01076-33","Other: Data monitoring for 48h within the first 24 hours of admission for COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376879","Recruiting","2020-05-16","2022-05-01","{""locations"":""Louis Mourier hospital (AP-HP), Colombes, France|Brabois Hospital (CHRU de Nancy), Vand\u0153uvre-l\u00e8s-Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""384"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the number of intubations in COVID-19 patients initially hospitalised in wards|the number of intubations in COVID-19 patients initially hospitalised in wards.""}"
"441","Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection","","NCT04484545","IRAS 282807","Diagnostic Test: Prognostic score","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04484545","Active, not recruiting","2020-04-01","2021-06-01","{""locations"":""Glasgow Royal Infirmary, Glasgow, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality""}"
"442","Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia","","NCT04676971","hzVSF_v13-0006","Drug: hzVSF-v13|Drug: Placebo (Normal saline solution)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04676971","Recruiting","2020-12-11","2021-10-18","{""locations"":""UOC Pneumologia, Bergamo, Italy|Dipartimento di Medicina Interna, Milano, Italy|Federal Siberian Scientific and Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Russian Federation|Central City Hospital of Novoshakhtinsk, Novoshakhtinsk, Russian Federation|Regional Clinical Hospital, Saratov, Russian Federation|Federal State Budgetary Educational Institution of Higher Education, Ufa, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""105"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical failure at Day 28|Clinical Improvement, defined as a decrease of at least 2 points on the World Health Organization (WHO) ordinal scale|Rate of overall survival (OS) at Day 28 and Day 60|Incidence and severity of adverse events according to NCI CTCAE v5.0""}"
"443","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak","","NCT04319315","AssiutU-3-2020","Other: survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04319315","Recruiting","2020-03-11","2020-04-16","{""locations"":""Assiut University Hospitals, Assiut, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""25 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice""}"
"444","Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients","","NCT04424849","2020/5-4","Diagnostic Test: CT-Scan","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424849","Recruiting","2020-03-15","2020-07-15","{""locations"":""Tepecik Training and Research Hospital, Izmir, Izmir, Konak, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Invasive respiratory support in patients with COVID-19|Mortality in patients with COVID-19""}"
"445","Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)","CATCH COVID-19","NCT04372004","TCAI_CATCH COVID-19","Diagnostic Test: diagnostic tests for COVID-19 infection","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04372004","Recruiting","2020-05-08","2021-06-01","{""locations"":""Texas Cardiac Arrhythmia Institute, Austin, Texas, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""100"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""detection of viral infection using serology and viral-RNA detection kits|Temporal trend of antibodies in blood""}"
"446","Convalescent Plasma as a Possible Treatment for COVID-19","","NCT04442191","2020-0441","Biological: Convalescent plasma|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04442191","Recruiting","2020-05-05","2021-05-05","{""locations"":""University of Illinois at Chicago, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygen supplementation|28-day and in-hospital mortality rate|Number of participants transferred to the Intensive Care Unit (ICU)|Number of participants intubated|Length of hospital stay in days|Type of respiratory support|C-reactive Protein (CRP)|Lymphocyte count|Length or respiratory support required, in days|Lactate dehydrogenase (LDH)|Ferritin|D-Dimer|White Blood Cell (WBC) Count""}"
"447","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19","","NCT04351620","IRB20-0572","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04351620","Recruiting","2020-04-01","2020-06-01","{""locations"":""University of Chicago, Chicago, Illinois, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Tolerability of high dose HCQ as measured by HCQ dose modification|Tolerability of high dose HCQ as measured by discontinuation of HCQ|Tolerability of High Dose HCQ as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol""}"
"448","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","HyAzOUT","NCT04334382","1051360","Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04334382","Recruiting","2020-04-02","2021-12-31","{""locations"":""Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1550"",""age"":""45 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days""}"
"449","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","CATCO","NCT04330690","2114","Drug: Interferon beta-1a|Drug: Remdesivir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04330690","Recruiting","2020-03-18","2022-05-18","{""locations"":""Peter Lougheed Centre, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Misericordia Community Hospital, Edmonton, Alberta, Canada|University of Alberta Hopsital, Edmonton, Alberta, Canada|Grey Nuns Community Hospital, Edmonton, Alberta, Canada|Interior Health Royal Inland Hospital, Kamloops, British Columbia, Canada|Lions Gate Hospital, North Vancouver, British Columbia, Canada|Richmond Hospital, Richmond, British Columbia, Canada|Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada|Island Health - Victoria General Hospital, Victoria, British Columbia, Canada|Island Health - Nanaimo Regional General Hospital, Victoria, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|Eastern Regional Health Authority, Saint John's, Newfoundland and Labrador, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|William Osler Health System - Brampton Civic Hospital, Brampton, Ontario, Canada|William Osler Health System - Etobicoke General Hospital, Etobicoke, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's General Hospital, Kitchener, Ontario, Canada|St.Joseph's Health Care, London, Ontario, Canada|University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners -Mississauga Site, Mississauga, Ontario, Canada|Trillium Health Partners-Credit Valley Hospital, Mississauga, Ontario, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|H\u00f4pital Montfort, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Niagara Health, Saint Catharines, Ontario, Canada|Scarborough Health Network - Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network - General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network - Birchmount Hospital, Scarborough, Ontario, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Michael Garron Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health Toronto - St. Joseph's Health Centre, Toronto, Ontario, Canada|CISSS de la Mont\u00e9r\u00e9gie Centre, Greenfield Park, Quebec, Canada|Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Quebec, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montr\u00e9al, Quebec, Canada|CHU de Qu\u00e9bec - Universit\u00e9 Laval, Qu\u00e9bec, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec- Universit\u00e9 Laval, Qu\u00e9bec, Quebec, Canada|Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)""}"
"450","Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19","","NCT04360278","200092|20-CC-0092","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04360278","Recruiting","2020-04-21","2030-04-14","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Collection of convalescent plasma""}"
"451","An Outpatient Study Investigating Non-prescription Treatments for COVID-19","PROFACT-01","NCT04621149","Profact-01","Other: chlorine dioxide|Dietary Supplement: zinc acetate|Drug: Famotidine|Other: placebo|Dietary Supplement: lactoferrin, green tea extract","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04621149","Recruiting","2020-11-15","2021-03-31","{""locations"":""AZ Good Health Center, Tempe, Arizona, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""20 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in Participant Symptoms of COVID-19|Incidence of Treatment-Emergent Adverse Events|Rate of Hospitalization|Change in Oxygen Saturation|Change in Body Temperature""}"
"452","COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life","NAPKON-POP","NCT04679584","COVIDOM-Protokoll_V01F_2020-10|DRKS00023742","Other: Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04679584","Recruiting","2020-11-16","2030-12-31","{""locations"":""University Hospital Wuerzburg, W\u00fcrzburg, Bavaria, Germany|University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany|University Hospital Charit\u00e9 Berlin, Berlin, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Longterm morbidities and sequels of SARS-CoV-2 infections in the general population|Longterm quality of life of SARS-CoV-2 infected individuals recruited from the general population|Longterm health care utilization of SARS-CoV-2 infected individuals recruited from the general population""}"
"453","A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)","COVIDothèque","NCT04347850","RECHMPL20_0185","Other: blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347850","Recruiting","2020-02-01","2022-12-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of confirmed COVID-19|Number of severe COVID-19|Identification and validation of predictive biomarkers of a poorer respiratory evolution associated with positive testing for SARS-CoV-2 infection|Evaluate the morbidity and mortality and these risk factors linked to Covid-19 in the congenital heart disease population in France|Identify the characteristics of physiotherapy care for patients with COVID-19 in intensive care|To assess the accuracy and prognostic performance of clinical and biological parameters measured on admission to the emergency department to stratify patients suspected of COVID-19|Evaluate diagnostic tests for olfactory function in relation to the RT-PCR procedure|Assessment of Extra Vascular Lung Water and Pulmonary Permeability by transpulmonary thermodilution in critically ill patients with Coronavirus Disease 2019 pneumonia under invasive mechanical ventilation|Description of trans pulmonary motor pressure in COVID 19+ patients in severe stage in intensive care|Immuno-monitoring of COVID-19 positive patients|Characterization in clinical proteomics of the SARS-CoV-2 spike protein|Diagnosis of endocrine dysfunctions in Covid-19|describe the occurrence of Covid19 infection in patients with systemic lupus erythematosus treated with hydroxychloroquine over the long term|Acral cutaneous thrombotic vasculopathy and Covid-19 infection : search for acquired thrombophilia and interferon-alpha signature|Evaluation of a COVID-19 screening strategy combining chest low dose CT and RT-PCR test for patients admitted for surgical or interventional procedures during the COVID 19 outbreak""}"
"454","Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients","","NCT04393311","56639","Drug: Ulinastatin|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04393311","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29|Incidence of mortality at Day 29|Incidence of in-hospital mortality|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29|Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29|Duration of mechanical ventilation|Duration of ECMO|Duration of noninvasive ventilation|Duration of ICU stay|Duration of hospital stay|Change in oxygen saturation""}"
"455","Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment","","NCT04363216","JT#15681","Drug: Ascorbic Acid","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363216","Not yet recruiting","2020-05-01","2021-05-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Improvement|Patient status upgraded to ICU level [Clinical decline]|Oxygen supplementation|Days with fever|Days to discharge|SAEs""}"
"456","Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19","","NCT04403386","200108|20-E-0108","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403386","Recruiting","2020-06-01","2022-05-31","{""locations"":""NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""30 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Levels of senescent CD16+CD8+ T cells prior to COVID-19 disease and time to COVID-19 disease morbidity (antibody positvity).""}"
"457","Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients","BADS-PTSD","NCT04473118","MRC-05-017","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473118","Recruiting","2020-07-11","2021-06-01","{""locations"":""Hamad Medical Corporation, Doha, Qatar"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To reflect the effect of COVID-19 on the burnout, anxiety, depression and stress levels of healthcare professionals during the COVID-19 crisis|To reflect the effect of COVID-19 on the post-trauma stress disorder levels of healthcare professionals following the COVID-19 crisis""}"
"458","Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19","KONS-COVID19","NCT04357990","KS-0470","Device: Viruxal Oral and Nasal Spray|Other: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04357990","Recruiting","2020-09-04","2021-03-01","{""locations"":""National Hospital of Iceland (Landsp\u00edtali), Reykjav\u00edk, Iceland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""128"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days until complete resolution of symptoms per group|Number of hospital admissions per group|Number of days until a reduction in symptoms per group|Number of adverse events per group""}"
"459","Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19","","NCT04463420","IR.BMSU.REC.1399.176","Drug: PHR160 Spray|Drug: Placebo|Drug: Standard treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04463420","Recruiting","2020-08-15","2020-12-15","{""locations"":""Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""224"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dyspnea|long of hospitalization|Radiological Treatment Response|Mortality|Allergic drug|Laboratory Treatment Response|O2 saturation without supplemental oxygen|drug reactions Adverse""}"
"460","A Study of LAM-002A for the Prevention of Progression of COVID-19","","NCT04446377","LAM-002A-CVD-CLN01","Drug: Apilimod Dimesylate Capsule|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04446377","Recruiting","2020-07-15","2021-04-30","{""locations"":""Yale University, New Haven, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""142"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral Load Change|Safety and Tolerability|Clinical Efficacy|Change in COVID-19 Clinical Status|Oxygen Saturation""}"
"461","Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients","GARGLES","NCT04410159","USIMalaysia","Drug: Povidone-Iodine|Drug: Essential oils|Other: Tap water","Interventional","Has Results","Phase 2","https://ClinicalTrials.gov/show/NCT04410159","Completed","2020-06-22","2020-07-06","{""locations"":""Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants With Early Viral Clearance|Number of Participants With Negative RT-PCR Results|Number of Patients That Progress to More Severe Disease|Number of Patients With Abnormal Radiological Findings|Number of Patients With Abnormal Laboratory Findings""}"
"462","To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia","","NCT04500132","EC-18-C201","Drug: EC-18|Drug: Placebo EC-18","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04500132","Recruiting","2020-05-28","2022-05-01","{""locations"":""Chungbuk National University Hospital, Cheongju-si, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of transition to ARDS""}"
"463","Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19","","NCT04438057","MIDC-CCP","Biological: CCP","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04438057","Recruiting","2020-08-12","2021-08-12","{""locations"":""Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Resolution of Symptoms|SAEs within 24 hours of plasma infusion|Decrease in Inflammatory Markers|Hospitalization within 28 days""}"
"464","Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease","","NCT04392414","CovPlas-Covid19","Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04392414","Completed","2020-05-01","2020-09-23","{""locations"":""Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The number and proportion of patients with the normal body temperature (\u226437.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate""}"
"465","Tobacco and Nicotine Consumption and the Risk of Acquisition of Coronavirus Disease 2019 (COVID-19)","NICORISCOVID","NCT04583761","APHP200663","Behavioral: questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04583761","Active, not recruiting","2020-10-12","2021-03-01","{""locations"":""Hotel-Dieu Hospital, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""questionnaire to assess strength of correlation between current smoking and SARS-CoV-2 RT-PCR positivity|questionnaire to assess strength of correlation between current alternative nicotine delivery systems and SARS-CoV-2 RT-PCR positivity|questionnaire to assess strength of correlation between former smokers and SARS-CoV-2 RT-PCR positivity|questionnaire to assess strength of correlation between former alternative nicotine delivery systems and SARS-CoV-2 RT-PCR positivity""}"
"466","Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19","COVID'HEMOS","NCT04367662","2020/0104/OB","Procedure: blood sampling","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04367662","Completed","2020-04-09","2020-05-14","{""locations"":""Rouen University Hospital, Rouen, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""99"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical worsening (yes\/no) of the patient during hospitalization|D-DIMERS plasma levels in blood|Fibrin monomers plasma levels in blood|Antithrombin plasma levels in blood|Prothrombin Fragment 1 plasma levels in blood|Prothrombin Fragment 2 plasma levels in blood|Thrombin generation test plasma levels in blood|Microvesicles of platelet plasma levels in blood|Cross-linked platelets plasma levels in blood|Willebrand Factor plasma levels in blood|Factor VIII plasma levels in blood""}"
"467","Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia","","NCT04679350","IM_hzVSF_v13-0004","Drug: hzVSF-v13|Drug: Placebo (Normal saline solution)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04679350","Not yet recruiting","2021-03-01","2021-07-01","{""locations"":""Yeungnam University Medical Center, Daegu, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes from baseline in the clinical improvement score on an 8-point scale at Day 21|Changes from baseline in the clinical improvement score on an 8-point scale at Day 7, Day 14, and Day 28|Time to discontinuation of oxygen therapy after investigational product administration|Time to recovery* after investigational product administration (days)|Changes from baseline in PaO2\/FiO2 at Day 7, Day 14, Day 21, and Day 28|Changes from baseline in the NEWS 2 score at Day 7, Day 14, Day 21, and Day 28|Mortality at Day 28 and Day 60 after investigational product administration""}"
"468","Covid-19 Pediatric Observatory","PANDOR","NCT04336956","PANDOR","Other: hospitalized children with Covid19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04336956","Recruiting","2020-04-07","2021-06-30","{""locations"":""Chu Felix Guyon, Saint Denis, La R\u00e9union, France|Ch St Esprit, Agen, France|Ch General Aix En Provence -, Aix-en-Provence, France|CHU Angers, Angers, France|CH d'ANGOULEME, Angoul\u00e8me, France|Pringy - Ch D'Annecy, Annecy, France|CH Argenteuil, Argenteuil, France|Ch Armentieres, Armenti\u00e8res, France|CH Arpajon, Arpajon, France|Ch Auxerre, Auxerre, France|CH GENERAL Henri Duffaut, Avignon, France|CHU de BESANCON, Besan\u00e7on, France|Hopital Femme Enfant, Caen, France|Ch de Pontoise, Cergy-Pontoise, France|Ch W. Morey, Chalon-sur-Sa\u00f4ne, France|CH de CHAMBERY, Chamb\u00e9ry, France|Ch Hotel Dieu, Chartres, France|CHU Estaing, Clermont-Ferrand, France|Hopital Louis Pasteur, Colmar, France|Hopital Louis Mourrier, Colombes, France|CH Sud Francilien, Corbeil-Essonnes, France|Centre Hospitalier intercommunal de Creteil, Creteil, France|Ch de Dax, Dax, France|Hopital D'Enfants Chu Dijon, Dijon, France|CH Louviers Val de Reuil, Elbeuf, France|CH Gonesse, Gonesse, France|CH d'HYERES, Hy\u00e8res, France|Ch de Marne La Vallee, Jossigny, France|Chru de Grenoble, La Tronche, France|CHG\u00e9n\u00e9ral du HAVRE, Le Havre, France|Hopital Jeanne de Flandre, Lille, France|Hopital Roger Salengro - Lille, Lille, France|Hopital Saint Vincent de Paul, Lille, France|Ch de Longjumeau, Longjumeau, France|Lorient - Ch de Bretagne Sud, Lorient, France|Hopital Femme Mere Enfant-Bron, Lyon, France|Hopital de Mantes, Mantes-la-Jolie, France|Hopital Nord Enfants, Marseille, France|Hopital de Meaux, Meaux, France|Ch de Melun, Meulin, France|CH de Montargis, Montargis, France|CH de MONTBRISON, Montbrison, France|Hopital Arnaud de Villeneuve, Montpellier, France|CHRU de Nancy, Nancy, France|Nantes - Hopital Mere Enfant, Nantes, France|Ch de Neuilly Sur Seine, Neuilly-sur-Seine, France|Hopital Lenval, Nice, France|CHU Nimes Caremeau, N\u00eemes, France|Chr Orleans, Orl\u00e9ans, France|Assistance Publique H\u00f4pitaux de Paris, Paris, France|Hopital St Jean Roussillon, Perpignan, France|POISSY - CH de POISSY, Poissy, France|QUIMPER - CH de Cornouaille, Quimper, France|RANG du FLIERS - C.H.A.M., RANG du FLIERS, France|Hopital Am\u00e9ricain CHU REIMS, Reims, France|CH RODEZ, Rodez, France|CH de ROMANS, Romans-sur-Is\u00e8re, France|Chu Rouen, Rouen, France|Hopital Charles-Nicolle, Rouen, France|Chu St Etienne, Saint Etienne, France|Ch de Saint Denis, Saint-Denis, France|Ch de Saint Malo, Saint-Malo, France|Ch Du Pays Du Mont Blanc, Sallanches, France|Chg Salon de Provence, Salon de Provence, France|CH Hautepierre, Strasbourg, France|CH Tarbes, Tarbes, France|CH Bel Air, Thionville, France|Hopital Sainte Musse, Toulon, France|CHU Toulouse-h\u00f4pital des Enfants, Toulouse, France|H\u00f4pital Gatien De Clocheville, Tours, France|CH de TROYES, Troyes, France|H\u00f4pital Nord Franche-Comt\u00e9, Tr\u00e9venans, France|Ch Bretagne Atlantique, Vannes, France|Ch Le Chesnay, Versailles, France|Hopital de Villeneuve Saint Georges, Villeneuve-Saint-Georges, France|CH Jean Monnet, \u00c9pinal, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""250"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days""}"
"469","INB03 for the Treatment of Pulmonary Complications From COVID-19","","NCT04370236","INB03-COVID-19_01","Drug: INB03|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04370236","Recruiting","2020-10-21","2021-02-01","{""locations"":""NEA Baptist, Jonesboro, Arkansas, United States|St. Bernard's, Jonesboro, Arkansas, United States|Jewish Hospital, Louisville, Kentucky, United States|Mississippi Baptist, Kosciusko, Mississippi, United States|Baptist Memorial Hospital-DeSoto, Southard, Missouri, United States|Richmond University Medical Center, Staten Island, New York, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States|Memorial Hermann, Houston, Texas, United States|Memorial Hermann Southeast, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""366"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants with disease progression from randomization to 28 days post-randomization|Proportion of participants with all-cause mortality|Proportion of participants who transfer to ICU level care by Day 28 (ICU level care is defined as a hospital setting where patient to nurse ratio is < 4);|Proportion of participants with a new onset of neurologic disease (requiring medical intervention), including stroke by Day 28;|Proportion of participants with evidence of new CHF or new MI requiring medical intervention by Day 28;|Proportion of participants with a new onset embolus or thrombus by Day 28;|Proportion of participants who develop a need for renal replacement therapy (defined as need for any type of dialysis including intermittent or continuous peritoneal or hemodialysis) by Day 28;|Proportion of participants with an increase in the WHO Ordinal Scale of Clinical Improvement score at any time during the study;|Length of hospital stay defined as the number of days in hospital from time of randomization to time of discharge or death, whichever occurs first;|Change from baseline in inflammation markers over time.""}"
"470","Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19","","NCT04537117","pedodontists during Covid-19","Other: Questionaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04537117","Completed","2020-04-20","2020-05-05","{""locations"":""Fayoum University, Fayoum, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""202"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Responses""}"
"471","Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19","","NCT04362189","Allogeneic Treatment COVID-19","Drug: HB-adMSC|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04362189","Active, not recruiting","2020-06-30","2021-10-31","{""locations"":""River Oaks Hospital and Clinics, Houston, Texas, United States|United Memorial Medical Center, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Interleukin-6|C Reactive protein|Oxygenation|TNF alpha|IL-10|Return to room air (RTRA)|EKG qt interval|Leukocyte differential|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|NK cell surface antigen (CD3-CD54+)|CD4+\/CD8+ ratio|Myoglobin|Troponin|Creatinine kinase MB|Serum ferritin|Adverse events|7-point ordinal scale|D-dimer|Chest X-ray|CT scan|PCR test for SARS-CoV-2""}"
"472","Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection","","NCT04391127","2020-A-09","Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04391127","Completed","2020-05-04","2020-11-06","{""locations"":""Jose Manuel Arreola Guerra, Aguascalientes, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""108"",""age"":""16 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization""}"
"473","Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial","CoVUm","NCT04368013","CoVUm","Procedure: Extended sampling and procedures","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04368013","Not yet recruiting","2020-04-28","2026-04-14","{""locations"":""Incectious Diseases Clinic, Ume\u00e5, V\u00e4sterbotten, Sweden"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""400"",""age"":""15 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality""}"
"474","Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19","","NCT04358549","FAVI-COV-US201","Drug: Favipiravir + Standard of Care|Drug: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04358549","Active, not recruiting","2020-04-17","2021-05-01","{""locations"":""HonorHealth, Scottsdale, Arizona, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Boston Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Memorial Health Care, Worcester, Massachusetts, United States|Atlantic Health System \/ Morristown Medical Center, Morristown, New Jersey, United States|Houston Methodist Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to viral clearance|Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15|Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2)|Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax)|Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin|Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC""}"
"475","Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","ACOVACT","NCT04351724","ACOVACT","Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Remdesivir|Drug: Asunercept 400mg|Drug: Asunercept 100mg|Drug: Asunercept 25mg|Drug: Pentaglobin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04351724","Recruiting","2020-04-16","2022-03-31","{""locations"":""Medical University of Innsbruck, Innsbruck, Tirol, Austria|Medical University of Graz, Graz, Austria|Kepler University Hospital, Linz, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|SMZ S\u00fcd Kaiser Franz Josef Spital, Vienna, Austria|KH Hietzing, Vienna, Austria|SMZ Baumgartner H\u00f6he Otto Wagner Spital, Vienna, Austria|SMZ Ost Donauspital, Vienna, Austria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""sustained improvement (>48h) of one point on the WHO Scale|Time to improvement on WHO Scale|Mean change in the ranking on an ordinal scale from baseline|time to discharge or a National Early Warning Score (NEWS) \u22642 (maintained for 24h), whichever occurs first|change from baseline in National Early Warning Score (NEWS)|Oxygenation free days|Incidence of new oxygen use during the trial|duration of oxygen use during the trial|Ventilator free days until day 29|Incidence of new mechanical ventilation use during the trial|duration of mechanical ventilation use during the trial|Viral load\/viral clearance|Duration of Hospitalization|Mortality|Obesity - mortality|Obesity - duration of hospitalization|Obesity - ICU admission|Obesity - new oxygen use|Drug-drug interactions with lopinavir\/ritonavir|Renin Angiotensin System (RAS) fingerprint|SpO2\/FiO2 ratio|paO\/FiO2 ratio|modified Sequential Organ Failure Assessment|C-reactive protein|Interleukin-6|procalcitonin|IgM Concentrations|IgA Concentrations|differential blood counts""}"
"476","Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19","","NCT04358211","2020-595","Biological: Biological: COVID-19 convalescent plasma","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04358211","No longer available","1970-01-01","1970-01-01","{""locations"":""Tulane Medical Center, New Orleans, Louisiana, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"477","Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients","ETHIC","NCT04492254","TRI-08892|2020-003125-39","Drug: Enoxaparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04492254","Not yet recruiting","2020-07-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1370"",""age"":""55 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital Admission|Death|Bleeding (as defined by ISTH criteria)|Diagnosis of VTE""}"
"478","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","GO2 PEEP","NCT04331366","STUDY00000381","Device: GO2 PEEP MOUTHPIECE","Interventional","Has Results","Not Applicable","https://ClinicalTrials.gov/show/NCT04331366","Completed","2020-04-08","2020-08-31","{""locations"":""Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""2"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygen Saturation by Pulse Oximetry|Respiratory Rate|Heart Rate|Blood Pressure|Count of Participants With Subjective Work of Breathing""}"
"479","Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19","","NCT04549337","H-20033733|75068","Behavioral: Exercise training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04549337","Recruiting","2020-09-25","2021-05-01","{""locations"":""Rigshospitalet, Copenhagen, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""10"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""10-point Likert scale|Participant adherence to the training dose|Participant adherence to the training intensity|Adverse effects|Rate of perceived exertion|Post COVID-19 Functional scale""}"
"480","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","APN01-COVID-19","NCT04335136","APN01-01-COVID19","Drug: RhACE2 APN01|Drug: Physiological saline solution","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04335136","Completed","2020-04-30","2020-12-26","{""locations"":""Medizinische Universit\u00e4t Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universit\u00e4t Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsj\u00e6llands Hospital, Hiller\u00f8d, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany|Regional State Budgetary Educational Institution \""Clinical Hospital \u2116 5, Barnaul\"", Barnaul, Russian Federation|State Healthcare Institution \""State Clinical Hspital \u2116 15 named after O.M. Filatov\"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution \""City Clinical Hospital \u211652 of Health Department of Moscow\"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution \""N.V. Sklifosovsky Research Institute for Emergency Medicine of Health Department of Moscow\"", Moscow, Russian Federation|Saint Petersburg SBHI City Hospital 38 named after N A Semashko, Pushkin, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""Ryazan State Medical University named after I.P. Pavlov\"" HD RF, Ryazan, Russian Federation|Alexandrovskaya Hospital, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budget Healthcare Institution City Hospital 15, Saint-Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \"" Saratov State Medical University named after V.I. Razumovsky\"" HD RF, Saratov, Russian Federation|Regional State Budgetary Healthcare Institution \""Clinical Hospital \u21161\"", Smolensk, Russian Federation|State budgetary institution of Healthcare of Tver region \""Regional clinical hospital\"", Tver, Russian Federation|Yaroslavl Regional Clinical Hospital for Military Veterans - International Centre for Gerontological Problems \""Healthy Ageing\"", Yaroslavl, Russian Federation|Cambridge University Hospitals NHS Trust\/University of Cambridge, Cambridge, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All Cause-death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death""}"
"481","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers","","NCT04333225","020-132","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04333225","Completed","2020-04-03","2020-06-30","{""locations"":""Baylor University Medical Center, Dallas, Texas, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""228"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of COVID-19 positive conversion|Time-to-first clinical event""}"
"482","Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients","","NCT04389645","MM-5000-BV","Diagnostic Test: IP-10 in CDS protocol","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389645","Completed","2020-04-07","2020-05-12","{""locations"":""Rabin Medical Center, Petach Tikva, Israel"",""study_designs"":"""",""enrollment"":""52"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IP-10 levels""}"
"483","Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)","","NCT04396106","AT-03A-001","Drug: AT-527|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04396106","Recruiting","2020-05-26","2021-05-01","{""locations"":""Atea Study Site, Scottsdale, Arizona, United States|Atea Study Site, Davis, California, United States|Atea Study Site, Los Angeles, California, United States|Atea Study Site, Washington, District of Columbia, United States|Atea Study Site, Orlando, Florida, United States|Atea Study Site, Atlanta, Georgia, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Boston, Massachusetts, United States|Atea Study Site, Butte, Montana, United States|Atea Study Site, Charlotte, North Carolina, United States|Atea Study Site, Cincinnati, Ohio, United States|Atea Study Site, Columbus, Ohio, United States|Atea Study Site, Charleston, South Carolina, United States|Atea Study Site, Columbia, South Carolina, United States|Atea Study Site, Brussels, Belgium|Atea Study Site, Mechelen, Belgium|Atea Study Site, Belo Horizonte, Brazil|Atea Study Site, Bras\u00edlia, Brazil|Atea Study Site, Campo Largo, Brazil|Atea Study Site, Porto Alegre, Brazil|Atea Study Site, S\u00e3o Paulo, Brazil|Atea Study Site, Chisinau, Moldova, Republic of|Atea Study Site, Bucharest, Romania|Atea Study Site, Bloemfontein, South Africa|Atea Study Site, Cape Town, South Africa|Atea Study Site, Centurion, South Africa|Atea Study Site, George, South Africa|Atea Study Site, Worcester, South Africa|Atea Study Site, Brovary, Ukraine|Atea Study Site, Kyiv, Ukraine"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""190"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportions (active vs. placebo) of subjects with progressive respiratory insufficiency.|Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events|Time to clinical recovery|Proportions (active vs. placebo) of subjects with respiratory failure or death""}"
"484","Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation","","NCT04456452","AP-016","Biological: Ampion|Other: Standard of Care","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04456452","Completed","2020-07-27","2020-11-30","{""locations"":""Research Site, Colorado Springs, Colorado, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence and severity of adverse events""}"
"485","Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19","","NCT04457726","COVID-T 2.0","Biological: SARS-CoV-2 Specific T Cells","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04457726","Recruiting","2020-07-01","2022-12-01","{""locations"":""Changi General Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Sengkang General Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""1 Year to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Dose-Limiting Toxicities|National Early Warning Score (NEWS)|Time to improvement by one category on a WHO ordinal scale|Time-to-SARS-CoV-2 negativity after infusion of SARS-CoV-2 specific T cells|Duration of persistence of SARS-CoV-2 specific T cells in the recipient's blood circulation|Time-to-normalization of cytokine level, lymphocyte subsets, and gene transcriptome after T cell infusion|Overall survival (OS) at 3 months after infusion of SARS-CoV-2 specific T cells""}"
"486","Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia","CORTICOVIDHUGO","NCT04359511","CORTI-COVID-19-HUGO|DR200136","Drug: Prednisone|Drug: Hydrocortisone","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04359511","Not yet recruiting","2020-06-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""210"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement defined by the improvement of 2 points on a 7-category ordinal scale, at 14 days.|Proportion of patients free of oxygen at day 14 and 28|Proportion of patients discharged alive from hospital at day 14 and 28|Time to discharge for patients alive|Proportion of patients that were hospitalized to ICU or who died at day 14 and 28|14 and 28 day mortality rate|The time until weaning from oxygen therapy|The proportion of patients with clinical degradation of at least 1 point on the ordinal scale to 7 categories on D14 and D28""}"
"487","Registry of CytoSorb Therapy in COVID-19 ICU Patients","CTC REGISTRY","NCT04391920","2020-001|FDA EUA","Device: CytoSorb 300 mL device","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04391920","Recruiting","2020-08-28","2022-10-01","{""locations"":""Medical Center of Aurora, Aurora, Colorado, United States|University of Chicago Medicine, Chicago, Illinois, United States|Baptist Memorial Hospital, Southaven, Mississippi, United States|New York University Medical Center, New York, New York, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU mortality|Duration of ECMO after start of CytoSorb|Duration of mechanical ventilatory support after start of CytoSorb|Duration of pharmacologic hemodynamic support after start of CytoSorb|Change in serum concentrations of inflammatory biomarkers after start of CytoSorb|Change in Pa02\/Fi02 ratio after start of CytoSorb""}"
"488","A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）","","NCT04425772","FNC-Hope4","Drug: FNC+Standard of Care|Drug: FNC dummy tablet+Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04425772","Not yet recruiting","2020-06-12","2020-08-12","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""342"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change (reduction) in viral load from baseline|proportion of subjects change from mild or moderate type to severe type|proportion of subjects change from severe type to critical type|novel coronavirus nucleic acid conversion rate|Novel coronavirus nucleic acid negative conversion time|The time and proportion of improvement in pulmonary imaging|Time and proportion of temperature return to normal|time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.)|time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms|Changes of blood oxygen detection index|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of adverse events""}"
"489","Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients","","NCT04352465","LDE-MTX_COVID19","Drug: Methotrexate","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04352465","Not yet recruiting","2020-05-01","2020-11-30","{""locations"":""Prevent Senior Private Operadora de Sa\u00fade LTDA., S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in clinical conditions|Change of Clinical symptoms - respiratory rate|Hypoxia|Changes of blood oxygen|Inflammatory parameters|Evolution of Acute Respiratory Syndrome|Hospital discharge|ICU discharge|Rate of mortality""}"
"490","Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination","","NCT04417335","NL73430.091.20|2020-001591-15","Biological: BCG vaccine|Biological: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04417335","Active, not recruiting","2020-04-16","2021-05-01","{""locations"":""Radboud University, Nijmegen, Gelderland, Netherlands|UMC Utrecht, Utrecht, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""2014"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 related hospital admission|the duration of hospital admission due to documented COVID-19|the cumulative incidence of documented SARS-CoV-2 infection|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented SARS-CoV-2 infection|the cumulative incidence of hospital admission for any reason|the cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection""}"
"491","A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness","BLAZE-4","NCT04634409","18160|J2X-MC-PYAH","Drug: LY3819253|Drug: LY3832479|Drug: Placebo|Drug: VIR-7831","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04634409","Recruiting","2020-01-29","2021-06-29","{""locations"":""The Institute for Liver Health, Mesa, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Sun City West, Arizona, United States|Fiel Family Medicine, Tempe, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States|Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States|Smart Cures Clin Research, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|VCT-Covina, Covina, California, United States|AMCR Institute, Escondido, California, United States|Chemidox Clinical Trials, Lancaster, California, United States|Ark Clinical Research, Long Beach, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Inland Empire CT, LLC, Rialto, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Wolverine Clinical Trials, LLC, Santa Ana, California, United States|St. Joe Heritage HC-Santa Rosa, Santa Rosa, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|Infect Disease Doctors Med Grp, Walnut Creek, California, United States|Allianz Research Institute, Westminster, California, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Synergy Healthcare LLC, Bradenton, Florida, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Elixia CRC, Hollywood, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Testing Matters Lab, Sunrise, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|Triple O Research Inst, West Palm Beach, Florida, United States|Cleveland Clinic of Weston Florida, Weston, Florida, United States|Clinical Site Partners, LLC DBA CSP Orlando, Winter Park, Florida, United States|Gwinnett Research Inst, Buford, Georgia, United States|Paramount Rch Sol - College Pk, College Park, Georgia, United States|IACT Health - VHC, Columbus, Georgia, United States|Central Georgia Infectious Disease, Macon, Georgia, United States|Rophe Adult and Pediatric Medicine, Union City, Georgia, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Qualmedica Research Evansville, Evansville, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|St.Vincent - Indy, Indianapolis, Indiana, United States|Qualmedica Research, LLC, Owensboro, Kentucky, United States|Tandem Clinical Research,LLC, Marrero, Louisiana, United States|Imperial Health Urgent Care Center - Moss Bluff, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Revive Research Institute, Farmington Hills, Michigan, United States|Revival Research Institute, Sterling Heights, Michigan, United States|Sky Clinical Prime and Health Wellness Clinic, Fayette, Mississippi, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Sky Clin Resch - Quinn HC, Ridgeland, Mississippi, United States|Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Prime Global Research, LLC, Bronx, New York, United States|Monroe Biomed Research, Monroe, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Hometown UC and Rch- Cincy, Cincinnati, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Dayton, Ohio, United States|META Medical Research Institute, LLC, Dayton, Ohio, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VITALINK - Anderson, Anderson, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Univ Diab & Endo Consult, Chattanooga, Tennessee, United States|New Phase R and D, Knoxville, Tennessee, United States|Central Texas Clinical Rch, Austin, Texas, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|1960 Family Practice, PA, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|BioPharma Family Practice Center McAllen, McAllen, Texas, United States|BRCR Medical Center, Inc, McAllen, Texas, United States|North Hills Medical Research, North Richland Hills, Texas, United States|Bay Area Infectious Diseases Associates, Pasadena, Texas, United States|Baylor - Round Rock, Round Rock, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|APD Clinical Research, Splendora, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CLS Research Ctr, PLLC, Webster, Texas, United States|CARE ID, Annandale, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Dorado Medical Complex Inc, Dorado, Puerto Rico|GCM Medical Group, PSC - Hato Rey Site, San Juan, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""700"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Percentage of Participants with SARS-CoV-2 Viral Load Greater than 5.27|Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death|Change from Baseline to Day 7 in SARS-CoV-2 Viral Load|Percentage of Participants Demonstrating Symptom Resolution|Percentage of Participants Demonstrating Symptom Improvement|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3832479|Pharmacokinetics (PK): Mean Concentration of LY3819253 and VIR-7831""}"
"492","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease","RCT","NCT04344444","COVID 2020-001","Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04344444","Active, not recruiting","2020-04-13","2021-12-10","{""locations"":""University Medical Center New Orleans, New Orleans, Louisiana, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Most severe outcome""}"
"493","Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection","","NCT04377659","20-185","Drug: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04377659","Active, not recruiting","2020-05-01","2022-05-01","{""locations"":""Memorial Sloan Kettering Cancer Center, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""9"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Progression of respiratory failure or death""}"
"494","The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans","","NCT04601077","IND150758 Pilot","Drug: Nitric Oxide lozenges, 30 mg|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04601077","Recruiting","2020-11-01","2021-07-31","{""locations"":""American Institute of Therapeutics, Lake Bluff, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""50 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Low blood pressure|dizziness|Incidence of hospitalization, ICU admission, intubation, dialysis and death""}"
"495","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","COVIDOSE","NCT04331795","IRB20-0515","Drug: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04331795","Completed","2020-04-04","2020-06-05","{""locations"":""University of Chicago Medicine, Chicago, Illinois, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor\/inotrope utilization|Duration of vasopressor\/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline""}"
"496","Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age","","NCT04474457","COVID-19-PMS-FAV","Drug: Favipiravir","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04474457","Active, not recruiting","2020-06-11","2021-06-01","{""locations"":""Hacettepe University, School of Medicine, Ankara, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oximetry from baseline|Changes in fever from baseline""}"
"497","Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial","DISTANSE COVID","NCT04359264","20-081","Other: Cash transfer","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04359264","Active, not recruiting","2020-04-20","2020-12-30","{""locations"":""Municipality of Assiginack Family Health Team, Assiginack, Ontario, Canada|St Michael's Hospital Academic Family Health Team, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""392"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms consisent with COVID-19|Number of close contacts|Number of participants with positive test for COVID-19|Self-reported health based on the single question: \""In general, would you say your health is..\""|Ability to make ends meet based on the single question: \""At the end of the month, are you able to make ends meet?\""""}"
"498","Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19","","NCT04452617","REA-03-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452617","Completed","2020-03-19","2020-07-01","{""locations"":""Institut Mutualiste Montsouris, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""occurrence of severe cardiac arrhythmia: torsade de pointes and cardiac arrest or sudden death|assessment of QTc interval prolongation during the treatment period compared to baseline ECG""}"
"499","Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease","","NCT04429867","1604885","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04429867","Active, not recruiting","2020-05-07","2020-12-07","{""locations"":""Wellstar Kennestone Hospital, Marietta, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe\/critical disease.|Hospital length of stay|30-Day Mortality|Resolution of Symptoms|Incidence of QTc >500ms after initiation of therapy|Incidence of discontinuation of therapy""}"
"500","Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19","","NCT04486313","RM08-3008","Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04486313","Active, not recruiting","2020-08-13","2021-02-08","{""locations"":""Invesclinic US LLC, Fort Lauderdale, Florida, United States|RH Medical Urgent Care, Bronx, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1092"",""age"":""12 Years to 120 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Reducing the Time to Sustained Response|Reducing the Rate of Progression""}"
"501","Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia","","NCT04679415","hzVSF_v13-0007","Drug: hzVSF-v13|Drug: Placebo (Normal saline solution)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04679415","Recruiting","2020-12-17","2021-05-01","{""locations"":""Rumah Sakit Pusat Pertamina (include RSPP Extension Simprug), Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia|Rumah Sakit Pasar Minggu, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia|Rumah Sakit Umum Persahabatan, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""63"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical failure rate at Day 28|Changes from baseline in the clinical improvement score on an 8-point scale at Day 7, Day 14, and Day 28|Time to discontinuation of oxygen therapy after investigational product administration|Time to recovery* after investigational product administration (days)|Time to Clinical Improvement from randomization to clinical improvement (2 points decreased from the baseline score) (days)|Changes from baseline in PaO2\/FiO2 at Day 7, Day 14, Day 21, and Day 28|Changes from baseline in the NEWS 2 score at Day 7, Day 14, Day 21, and Day 28""}"
"502","A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection","CureCovid-2019","NCT04637828","GNS561-CL-I-Q-0291","Drug: GNS561","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04637828","Recruiting","2020-11-18","2021-10-30","{""locations"":""Genoscience Pharma, Marseille, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""178"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number and proportion of participants, per randomized group, with a loss of one or two grades of National Early Warning Score (NEWS2) score at day-7 compared to baseline|the 28-day survival rate|the rate of intensive care unit admission|the rate of nasopharyngeal swab negativation at D7, D14 and D28""}"
"503","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","CYTOCOV-19","NCT04344080","CYTOCOV-19|U1111-1250-2078|DRKS00021199","Device: CytoSorb-Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04344080","Recruiting","2020-04-01","2021-02-01","{""locations"":""University Medical Center Hamburg-Eppendorf, Hamburg, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours|Change in organ dysfunction|Lactate clearance|Renal replacement therapy|Extracorporeal Membrane Oxygenation|ICU length of stay|Time on mechanical ventilation|Cumulative catecholamine dose|Overall and ICU mortality|Change of plasma Interleukin-6 (IL6) level|Change of plasma Interleukin-10 (IL10) level|Change of plasma Procalcitonin (PCT) level|Change of HLA-DR level|Change of TNF alpha level after ex-vivo stimulation""}"
"504","Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses","BLEEDING","NCT04380779","BLEEDING042020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380779","Completed","2020-04-13","2020-10-13","{""locations"":""Manuel Monreal, Badalona, Barcelona, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""2430"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Bleeding events and complications""}"
"505","A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19)","BLAZE-5","NCT04701658","18216|J2X-MC-PYAJ","Drug: Bamlanivimab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04701658","Recruiting","2021-02-01","2021-08-07","{""locations"":""Presbyterian Medical Center, Albuquerque, New Mexico, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""3000"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants who Experience COVID-19 Related Hospitalization or Death|Proportion of Participants with a COVID-19-related Hospitalization, Defined as up to Days 60 and 90|Proportion of Participants with a COVID-related Emergency Department (ED) Visit Through Days 29, 60, and 90""}"
"506","Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia","","NCT04348448","CANASCOV","Drug: Canakinumab 150 MG/ML [Ilaris]","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04348448","Not yet recruiting","2020-04-01","2020-09-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event""}"
"507","Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers","","NCT04666012","AdCLD-CoV19-001","Biological: AdCLD-CoV19","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04666012","Recruiting","2020-12-29","2022-04-01","{""locations"":""Korea University Guro Hospital, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""150"",""age"":""19 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of solicited adverse events(AEs)|Incidence of unsolicited AEs|Incidence of serious adverse events(SAEs)|Incidence of adverse events of special interest(AESIs)|Seroconversion rate(SCR) of neutralization antibody using wild type SARS-CoV-2|Geometric mean titer(GMT) of neutralization antibody using wild type SARS-CoV-2|GMT of S protein specific antibody|Index of T cell response""}"
"508","Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial)","EPIC","NCT04405843","ScDi823|IVE-PA","Drug: Ivermectin Oral Product|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04405843","Completed","2020-07-14","2020-12-21","{""locations"":""Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica, Cali, Valle, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""476"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention|Duration of fever""}"
"509","Natural Language Processing (NLP) Analysis of Free Text Notes to Investigate Coronavirus (COVID-19)","","NCT04432961","A095625","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04432961","Not yet recruiting","2020-07-01","2021-07-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""research database of EHR records from COVID-19 patients processed using NLP tools for named entity recognition and linking adapted to CUH EMR data to identify variables of interest|A set of annotation guidelines to produce human-expert (gold) labelled data for a subset of the EHR|A comparison of the NLP output to terms in the structured problem list to identify missing terms in the structured problem list""}"
"510","Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19","","NCT04429711","SHEBA-20-7156-ES-CTIL","Drug: Ivermectin Oral Product","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04429711","Recruiting","2020-05-12","2020-10-31","{""locations"":""Sheba Medical Center, Ramat-Gan, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral clearance at day 6|Viral shedding duration|Symptoms clearance time""}"
"511","Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise","VENTED","NCT04427566","VENTED","Radiation: Radiation therapy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04427566","Recruiting","2020-07-23","2021-12-31","{""locations"":""Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate of subjects treated with whole lung low-dose radiation|Survival rate of subjects treated with whole lung low-dose radiation|Change in number of Intensive care unit days|Change in number of days using supplemental oxygen|Change in oxygenation index\/oxygen saturation index for 14 days post treatment or until extubated|Quantitation of Lung Involvement using Chest CT|Quantitation of Lung Opacities using Chest CT|SARS-CoV2 viral titers|Incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs|Change in performance status after low dose radiation to lungs""}"
"512","A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients","","NCT04432766","BAT-2020-001-CR","Drug: BAT2020","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04432766","Not yet recruiting","2020-10-20","2021-08-18","{""locations"":""Snake River Research, Idaho Falls, Idaho, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""174"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events (AEs)""}"
"513","COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses","SEROBL-COVID19","NCT04483908","BASEC Project-ID 2020-00816","Diagnostic Test: blood draw|Diagnostic Test: fingertip tests for POC assays|Diagnostic Test: saliva collection|Diagnostic Test: collection of swabs","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04483908","Recruiting","2020-04-10","2022-05-30","{""locations"":""Department of Health, Economics and Health Directorate Canton Basel-Land, Liestal, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""550"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Qualitative method validation (yes\/ no)|Quantitative method validation (antibody concentrations)|Immune cell repertoire sequencing""}"
"514","COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY","","NCT04367896","Covid-19_V1","Other: Survey Group","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367896","Completed","2020-03-24","2020-04-17","{""locations"":""Fondazione Policlinico Universitario \""Agostino Gemelli\"", Rome, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1819"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Management of Solid Organ Transplant during COVID-19 pandemic|Equity of resource distribution|Equity rank of resource distribution""}"
"515","A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19","","NCT04411628","17823|J2W-MC-PYAA","Drug: LY3819253|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04411628","Completed","2020-05-28","2020-08-26","{""locations"":""Cedars Sinai Medical Center, Los Angeles, California, United States|Veterans Affairs Medical Center San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Alexandria Center for Life - NYC\/ NYCEDC, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Unified Research Enterprise Brody School of Medicine at ECU, Greenville, North Carolina, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science"",""enrollment"":""24"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration-time Curve (AUC) of LY3819253|Pharmacodynamics (PD): Change from Baseline to Day 29 in Viral Load""}"
"516","Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19","","NCT04709835","WV43042","Drug: AT-527|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04709835","Not yet recruiting","2021-01-15","2021-02-15","{""locations"":""Multiprofile Hospital For Active Treatment Dr. Tota Venkova JSC, Gabrovo, Bulgaria|MHAT Dr. Atanas Dafovski AD, Kardzhali, Bulgaria|Multiprofile Hospital for Active Treatment - Prof. Dr. Paraskev Stoyanov AD, Lovech, Bulgaria|Multiprofile Hospital for Active Treatment Plovdiv, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment (MHAT) - Targovishte, Targovishte, Bulgaria|Connolly Hospital, Dublin, Ireland|Tower Family Healthcare - Moorgate Primary Care Ce, Bury, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Change from Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA|Time to Cessation of SARS-CoV-2 Viral Shedding|Time to Sustained Non-Detectable SARS-CoV-2 Virus RNA|Proportion of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints|Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA|Time to Alleviation of COVID-19 Symptoms|Duration of Fever|Frequency of COVID-19 Related Complications|Time to Alleviation of an Individual Symptom|Percentage of Participants with Adverse Events (AEs)|Plasma Concentration of AT-511, AT-551, AT-229 and AT-273|Relationship Between Plasma Concentration of AT- 273 and Anti-Viral Activity""}"
"517","Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection","","NCT04363814","MV130-SLG-35","Biological: Bactek-R","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04363814","Recruiting","2020-06-10","2021-07-31","{""locations"":""Hospital Metropolitano Santiago, Santiago De Los Caballeros, Dominican Republic"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical recovery|Clinical worsening|Clinical severity|Time to symptoms remission|Medication Use|Hospitalization time|Blood routine test|Heart rate|Blood pressure|Cardiac auscultation|Oxygen saturation|Adverse events""}"
"518","A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.","","NCT04365634","TJ20200202","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365634","Completed","2020-02-02","2020-04-01","{""locations"":""Tongji Hospital, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""306"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis|Demographics and clinical characteristics|Laboratory parameters and radiography image features|Treatment, complications and clinical outcomes""}"
"519","Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19","","NCT04344236","s20-00444","Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04344236","Recruiting","2020-04-09","2020-05-09","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load (and\/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient""}"
"520","Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19","","NCT04536090","IRCM-IQC-001","Drug: Isoquercetin (IQC-950AN)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04536090","Not yet recruiting","2020-11-01","2021-05-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease Progression|Changes in viral load from baseline to end of treatment - Mean viral load|Changes in viral load from baseline to end of treatment - Area under the viral load vs. time profiles|Changes in viral load from baseline to end of treatment - Time profile of viral load|Changes in viral load from baseline to end of treatment - Percentage of patients that are viral negative|Disease Recovery|Change in WHO Clinical Progression Scale score|Incidence of all-cause mortality|Progression to supplementary oxygen requirement|Incidence of mechanical ventilation|Incidence of ICU admission|Time to hospital discharge|Changes in serum C reactive protein levels (CRP)|Changes in D-dimer levels|Changes in soluble low-density lipoprotein receptor (sLDLR) expression and proprotein convertase subtilisin\/kexin type 9 (PCSK9) and soluble angiotensin converting enzyme 2 (sACE2) levels|Changes in LDL-cholesterol|Changes in creatinine|Changes in liver enzymes""}"
"521","Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults","","NCT04386252","CL-COV-P01-US","Biological: AV-COVID-19","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04386252","Not yet recruiting","2021-02-01","2022-02-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""175"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Confirm safety|Suggestion of efficacy|Optimal dose of SARS-CoV-2 antigen and GM-CSF|Duration of detecting IgG against SARS-CoV-2 in blood after vaccination""}"
"522","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia","","NCT04329650","SILCOR-COVID-19","Drug: Siltuximab|Drug: Methylprednisolone","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04329650","Recruiting","2020-04-15","2020-05-20","{""locations"":""Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Cl\u00ednic de Barcelona, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari M\u00fatua de Terrassa, Terrassa, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary \u2264 36.6 \u00b0 C, oral \u2264 37.2 \u00b0 C, or rectal or tympanic \u2264 37.8 \u00b0 C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 \/ mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT\u2265 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.""}"
"523","Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19","","NCT04385849","QUILT-COVID-19","Biological: N-803|Other: Saline","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04385849","Not yet recruiting","2020-06-01","2020-07-11","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence|Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.|Preliminary safety and efficacy evaluation of N-803 by changes in lymphocyte counts|Further evaluate efficacy of N-803 using changes to the National Early Warning Score (NEWS)|Further evaluate the safety of N-803 using change from baseline in hemoglobin|Further evaluate the safety of N-803 using change from baseline in platelets|Further evaluate the safety of N-803 using change from baseline in white blood cell count""}"
"524","A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19","CORONA","NCT04397562","BCD-089-4","Drug: Levilimab|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04397562","Completed","2020-04-29","2020-08-03","{""locations"":""State Budgetary Healthcare Institution Kaluga region \""Kaluga Regional Clinical Hospital\"", Kaluga, Russian Federation|State Budget Institution of the Republic of Dagestan \""Republican Clinical Hospital\"", Macha\u010dkala, Russian Federation|A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russian Federation|City Clinical Hospital No. 40 of the Department of Health of the city of Moscow, Moscow, Russian Federation|City Clinical Hospital No.52, Moscow, Russian Federation|City Clinical Hospital \u2116 15 named. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital \u21161 named after N.I. Pirogov, Moscow City Health Department, Moscow, Russian Federation|Federal State Budgetary Institution \""Central Clinical Hospital with Clinic\"", Office of the President of the Russian Federation, Moscow, Russian Federation|I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|Railway clinical hospital named after N.A. Semashko, Moscow, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg, Russian Federation|North-western State Medical University named after I.I.Mechnikov, Saint Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""Bashkir State Medical University\"" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""North Ossetian State Medical Academy\"" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia), Vladikavkaz, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""206"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with sustained clinical recovery|Proportion of patients reporting each category of 7-Category Ordinal Scale of Clinical Status|Proportion of patients transferred to the ICU|Duration of fever|Duration of hospitalization|Change in ESR|Change in serum CRP level|Change in serum IL-6 level""}"
"525","Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization","HITCH","NCT04397718","COVID19-8900-15","Drug: Degarelix|Other: Saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04397718","Recruiting","2020-07-06","2021-07-06","{""locations"":""Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Philadelphia MultiService Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""198"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation\/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.|Time to clinical improvement|Inpatient mortality|Duration of hospitalization|Duration of intubation for mechanical ventilation.|Time to normalization of temperature.|Maximum severity of COVID19 illness.|A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation\/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.""}"
"526","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","","NCT04307693","S2020-0472-0001","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04307693","Terminated","2020-03-11","2020-04-30","{""locations"":""Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""65"",""age"":""16 Years to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir\/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir\/ritonavir and hydroxychloroquine""}"
"527","Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation","","NCT04400461","165/20","Other: Data collection and clinical testing of subjects","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04400461","Active, not recruiting","2020-05-15","2021-03-31","{""locations"":""Medical ICU. Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Surgical ICU. Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Medical Research Council sum score (MRC- SS).|The Functional Status Score for the ICU (FSS-ICU)|Age|Sex|Body Mass Index|Baseline mobility|APACHE II score|Length of stay in ICU|Number of days on mechanical ventilation|Polyneuropathy diagnosis|Number of days on Neuromuscular Blockers|Episodes of prone positioning|Length of stay in hospital|Continuation of care""}"
"528","A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)","","NCT04364763","REN-005","Drug: RBT-9 (90 mg)|Drug: 0.9% sodium chloride (normal saline)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04364763","Recruiting","2020-08-05","2021-12-31","{""locations"":""New Smyrna Beach, FL, New Smyrna Beach, Florida, United States|Berkley, MI, Berkley, Michigan, United States|El Paso, TX, El Paso, Texas, United States|Fort Worth, TX, Fort Worth, Texas, United States|Houston, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""252"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the effect of RBT-9 versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale|Time to first occurrence of death from any cause or new\/worsened organ dysfunction|All-cause survival|Oxygen saturation (SpO2)\/fraction of inspired oxygen (FiO2) ratio|Fever incidence|Acute kidney injury (AKI) incidence|New or worsening congestive heart failure (HF)|Hospitalization status|Ventricular tachycardia or fibrillation lasting at least 30 seconds and\/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest|Oxygen-free days|Intensive care unit (ICU) status|Days on ventilator|Time to and duration of vasopressor or inotrope utilization|Dialysis status""}"
"529","A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","OAHU-COVID19","NCT04345692","RA-2020-018","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04345692","Terminated","2020-03-26","2020-08-31","{""locations"":""Queen's Medical Center, Honolulu, Hawaii, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""17"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality""}"
"530","Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients","COVID19-HOPE","NCT04374903","20 KHCC 74","Drug: HCQ & AZ vs HCQ+SIR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04374903","Not yet recruiting","2020-05-01","2020-09-01","{""locations"":""King Hussein Cancer Center, Amman, Jordan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""58"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical improvement (TTCI)|Clinical failure defined as death or need for Intubation and mechanical ventilation|Adverse effects|QT interval prolongation|Failure to continue assigned therapy|Time to viral clearance""}"
"531","A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19","CAPSID","NCT04433910","CAPSID2020-DRK-BSD|2020-001310-38","Drug: Convalesscent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04433910","Active, not recruiting","2020-08-30","2021-02-22","{""locations"":""University Hospital Ulm, Ulm, Baden-W\u00fcrttmberg, Germany|University Hopsital Frankfurt, Frankfurt, Hessia, Germany|Saarland University Hospital, Homburg, Saarland, Germany|University Hospital Berlin, Charite, Berlin, Germany|Universitiy Hospital Dresden, Dresden, Germany|University D\u00fcsseldorf, D\u00fcsseldorf, Germany|University Hospital Freiburg, Freiburg, Germany|University Hospital Gie\u00dfen, Gie\u00dfen, Germany|University Hopsital Greifswald, Greifswald, Germany|St\u00e4dtisches Klinikum Karslruhe, Karlsruhe, Germany|Universtity Hospital Schleswig-Holstein, Kiel, Germany|Universtity Hospital Schleswig-Holstein, L\u00fcbeck, Germany|University Hospital Mannheim, Mannheim, Germany|University Hospital Marburg, Marburg, Germany|Klinikum Stuttgart, Stuttgart, Germany|University Hospital T\u00fcbingen, T\u00fcbingen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""106"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19.|Time to clinical improvement|Frequency and severity of adverse events by CTCAE v5.0, (Key secondary endpoint)|Case fatality rate|Length of hospital stay Length of hospital stay (if applicable)|Length of stay in ICU|Duration of ventilation support \/ ECMO|Time until negative SARS-CoV-2 PCR (nasopharyngeal sample)|Predictive value of comorbidities|Predictive value of coagulation markers|Predictive value of inflamation|Percentage of former COVID-19 patients willing to donate qualifying for plasma donation.|Amount of Plasma Units that could be collected for the clinical trial|Titer of anti-SARS-CoV-2 in transfused plasma units|Impact of donor characteristics on anti-SARS-CoV-2 humoral response|Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes.|Effect of timing of plasma transfusions""}"
"532","Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","ARCHAIC","NCT04362332","NL73529.041.20 versie 3","Drug: Chloroquine Sulfate|Drug: Hydroxychloroquine|Other: Standard supportive care","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04362332","Terminated","2020-04-14","2020-06-08","{""locations"":""UMCU, Utrecht, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""25"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite endpoint with disease progression defined as a NEWS2score \u2265 7 within 14 days or resulting in admission to Intensive\/Medium Care unit or resulting in death within 14 days.|Side effects""}"
"533","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19","","NCT04331470","97548","Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04331470","Recruiting","2020-04-04","2020-05-20","{""locations"":""Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""15 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clear chest CT-scan|PCR test|Physical statues of patient""}"
"534","A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia","","NCT04623021","A108_02CVD2014","Drug: Nafamostat Mesilate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04623021","Completed","2020-09-25","2020-12-12","{""locations"":""A108_02CVD2014 Site# 9, Barnaul, Russian Federation|A108_02CVD2014 Site# 26, Krasnoyarsk, Russian Federation|A108_02CVD2014 Site# 5, Moscow, Russian Federation|A108_02CVD2014 Site# 8, Moscow, Russian Federation|A108_02CVD2014 Site# 31, Ryazan, Russian Federation|A108_02CVD2014 Site# 25, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 29, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 30, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 3, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 4, St. Petersburg, Russian Federation|A108_02CVD2014 site#1, Ufa, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""104"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Time to recovery|Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status|Proportion of patients with recovery as defined as the subject satisfies one of the following|Change of clinical status assessed by 7-category ordinal scale|Change in National Early Warning Score (NEWS)|Time to National Early Warning Score (NEWS) of \u2264 2 which is maintained for 24 hours|Changes on CT scan\/X-ray|Change from baseline of CRP|Time to normalize the CRP|Duration of hospitalization|Duration of non-invasive ventilation or high flow oxygen use|Incidence of non-invasive ventilation or high flow oxygen use|Duration of supplement oxygen use|Incidence of supplement oxygen use|Duration of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|28-Day mortality""}"
"535","Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians","","NCT04706143","AssiutU21","Biological: COVID-19 Vaccines","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04706143","Not yet recruiting","2021-01-15","2021-08-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""25 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""measure immune cell activation induced by the vaccine|measure antibody response to vaccines|measure the cytokine response to different vaccines""}"
"536","Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19","","NCT04434131","20-227","Drug: Convalescent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04434131","Recruiting","2020-04-28","2025-04-28","{""locations"":""University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples""}"
"537","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness","BLAZE-1","NCT04427501","17947|J2W-MC-PYAB","Drug: LY3819253|Drug: LY3832479|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04427501","Recruiting","2019-11-17","2021-05-31","{""locations"":""Arizona Clin Trials-Mesa, Mesa, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Sun City West, Arizona, United States|Fiel Family Medicine, Tempe, Arizona, United States|Orange Grove Banner Clinic, Tucson, Arizona, United States|Arizona Clin Trials-Tucson, Tucson, Arizona, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States|Smart Cures Clin Research, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|VCT-Covina, Covina, California, United States|AMCR Institute, Escondido, California, United States|Valley Research, Fresno, California, United States|Chemidox Clinical Trials, Lancaster, California, United States|Ark Clinical Research, Long Beach, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|University of CA, Irvine, Orange, California, United States|Inland Empire CT, LLC, Rialto, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Zion Medical Center, San Diego, California, United States|Kaiser Permanente - SD Med Ctr, San Diego, California, United States|Wolverine Clinical Trials, LLC, Santa Ana, California, United States|St. Joe Heritage HC-Santa Rosa, Santa Rosa, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|Infect Disease Doctors Med Grp, Walnut Creek, California, United States|Allianz Research Institute, Westminster, California, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Synergy Healthcare LLC, Bradenton, Florida, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Elixia CRC, Hollywood, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|GCPR, Saint Petersburg, Florida, United States|Testing Matters Lab, Sunrise, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|Triple O Research Inst, West Palm Beach, Florida, United States|Cleveland Clinic of Weston Florida, Weston, Florida, United States|Clinical Site Partners, LLC DBA CSP Orlando, Winter Park, Florida, United States|Gwinnett Research Inst, Buford, Georgia, United States|Paramount Rch Sol - College Pk, College Park, Georgia, United States|IACT Health - VHC, Columbus, Georgia, United States|Central Georgia Infectious Disease, Macon, Georgia, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|Northwestern University, Chicago, Illinois, United States|J H. Stroger Hosp of Cook Co, Chicago, Illinois, United States|University of Chi Med Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Qualmedica Research Evansville, Evansville, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|St.Vincent - Indy, Indianapolis, Indiana, United States|Qualmedica Research, LLC, Owensboro, Kentucky, United States|Tandem Clinical Research,LLC, Marrero, Louisiana, United States|Imperial Health Urgent Care Center - Moss Bluff, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|University of Michigan Health Systems, Ann Arbor, Michigan, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Revive Research Institute, Farmington Hills, Michigan, United States|Revival Research Institute, Sterling Heights, Michigan, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Sky Clin Resch - Quinn HC, Ridgeland, Mississippi, United States|Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Care Access Research - Bronx, Bronx, New York, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Monroe Biomed Research, Monroe, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Carolina Research Center, Inc., Shelby, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Hometown UC and Rch- Cincy, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|OH State Univ College of Med, Columbus, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Dayton, Ohio, United States|META Medical Research Institute, LLC, Dayton, Ohio, United States|Ascension St. John Tulsa OK, Tulsa, Oklahoma, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VITALINK - Anderson, Anderson, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Univ Diab & Endo Consult, Chattanooga, Tennessee, United States|New Phase R and D, Knoxville, Tennessee, United States|Central Texas Clinical Rch, Austin, Texas, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Centex-Houston, Houston, Texas, United States|BioPharma Clinc Site, Houston, Texas, United States|Centex-Wesfield, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|BioPharma Family Practice Center McAllen, McAllen, Texas, United States|BRCR Medical Center, Inc, McAllen, Texas, United States|North Hills Medical Research, North Richland Hills, Texas, United States|Bay Area Infectious Diseases Associates, Pasadena, Texas, United States|Baylor - Round Rock, Round Rock, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|APD Clinical Research, Splendora, Texas, United States|Baylor Scott and White Medical Center, Temple, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CLS Research Ctr, PLLC, Webster, Texas, United States|CARE ID, Annandale, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Dorado Medical Complex Inc, Dorado, Puerto Rico|GCM Medical Group, PSC - Hato Rey Site, San Juan, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""3300"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause|Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load|Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold|Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization|Percentage of Participants Demonstrating Symptom Resolution|Percentage of Participants Demonstrating Symptom Improvement|Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479|PK: Mean Concentration of LY3832479 in the Presence of LY3819253|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death from Any Cause|Change from Baseline to Day 7 in SARS-CoV-2 Viral Load|Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization or Death from Any Cause|Time to Sustained Symptom Resolution|Time to SARS-CoV-2 Viral Clearance""}"
"538","Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","COVID-Lambda","NCT04331899","55619","Drug: Peginterferon Lambda-1a|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04331899","Active, not recruiting","2020-04-24","2021-05-01","{""locations"":""Stanford University School of Medicine, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of Viral shedding of SARS-CoV-2 by qRT-PCR|Sars-CoV-2 viral load|Area under the curve of SARS-COV-2 viral load|Time to alleviation of all symptoms Time to alleviation of all symptoms|Number of participants requiring emergency department visits or hospitalizations within 28 days of initiation of treatment""}"
"539","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","PrEP_COVID","NCT04331834","PrEP_COVID","Drug: Hydroxychloroquine|Drug: Placebos","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04331834","Completed","2020-04-03","2020-12-31","{""locations"":""ISGlobal, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""275"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank""}"
"540","COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers","","NCT04591717","QUILT-COVID-19-hAd5-Vaccine","Biological: hAd5-S-Fusion+N-ETSD vaccine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04591717","Recruiting","2020-10-19","2021-11-19","{""locations"":""Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of MAAEs and SAEs|Incidence and severity of solicited local reactogenicity AEs|Incidence and severity of solicited systemic reactogenicity AEs|Incidence and severity of unsolicited AEs|Incidence of abnormal changes of laboratory safety examinations|Vital Signs - Fever|Vital Signs - Tachycardia|Vital Signs - Bradycardia|Vital Signs - Hypertension|Vital Signs - Hypotension|Vital Signs - Respiratory Rate|GMFR in IgG titer|GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus|Percentage of subjects who seroconverted|GMFR in neutralizing antibody|GMT|Seroconversion rate of neutralizing antibody|CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein|CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein""}"
"541","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","","NCT04323631","0154-20-RMB","Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04323631","Withdrawn","2020-04-30","2020-04-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number patients developing severe infection or death""}"
"542","Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection","PREPCOV","NCT04481633","RC31/20/0186|2020-A01906-33","Diagnostic Test: COVID 19 serology|Other: COVID 19 Self-Questionnaire","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04481633","Recruiting","2020-09-09","2021-09-01","{""locations"":""Limoges university Hospital, Limoges, France|Montpellier University Hospital, Montpellier, France|Piti\u00e9 Salp\u00eatri\u00e8re Hospital - H\u00e9patologie, Paris, France|Piti\u00e9 Salp\u00eatri\u00e8re Hospital - M\u00e9decine interne, Paris, France|Haut-L\u00e9v\u00eaque Hospital - Gastro-ent\u00e9rologie, Pessac, France|Haut-L\u00e9v\u00eaque Hospital - M\u00e9decine interne, Pessac, France|Joseph Ducuing Hospital - M\u00e9decine interne, Toulouse, France|Toulouse university Hospital - Larrey Dermatologie, Toulouse, France|Toulouse University Hospital - Rhumatologie, Toulouse, France|Toulouse University Hospital, Toulouse, France|University Hospital of Toulouse - Rangueil M\u00e9decine interne, Toulouse, France|University hospital Toulouse - Purpan M\u00e9decine interne, Toulouse, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of patients with positive anti-COVID19 serology|Rate of patients with symptomatic or severe (hospitalization) form of infection""}"
"543","The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","","NCT04313023","PUL-042-501","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04313023","Recruiting","2020-06-09","2021-06-01","{""locations"":""University of California Irvine, Orange, California, United States|Premier Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Willis-Knighton Physcian Network, Bossier City, Louisiana, United States|Englewood Health, Englewood, New Jersey, United States|Ascension St John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality""}"
"544","Clazakizumab vs. Placebo - COVID-19 Infection","","NCT04494724","Pro00025969","Drug: Clazakizumab|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04494724","Recruiting","2020-07-13","2021-07-31","{""locations"":""Houston Methodist Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Endpoint|Requirement for mechanical ventilation and\/or extracorporeal membrane oxygenation (ECMO)|Infusion-related reactions during 24 hours from the time of infusion|Patient survival at 28 days|Patient survival at 60 days|Requirement for open-label clazakizumab|Time in the intensive care unit (ICU)|Time in the hospital|Time to mechanical ventilation|Clinical status improvement assessed by the World Health Organization (WHO) Clinical Progression Scale at day 14|Clinical status improvement assessed by World Health Organization (WHO) Clinical Progression Scale at day 28|Change in Radiologic Assessment of Lung Edema (RALE) at day 14|Change in Radiologic Assessment of Lung Edema (RALE) at day 28""}"
"545","Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk","PREVENT","NCT04371926","TCAI_PREVENT","Drug: Hydroxychloroquine Sulfate","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04371926","Withdrawn","2020-06-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention"",""enrollment"":""0"",""age"":""18 Months to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Time to reach normal body temperature|Development of COVID-19 symptoms during HCQ preventive therapy in staff|COVID-19 test result at follow-up in patients|Worsening of symptoms in COVID-19 patients""}"
"546","Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program","","NCT04443803","202005391","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443803","Not yet recruiting","2020-07-01","2020-08-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""9"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Perioperative transmission of SARS-CoV-2""}"
"547","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients","","NCT04336254","2020K-G005|hDPSC-CoVID-2019-02-2020","Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04336254","Recruiting","2020-05-06","2021-12-31","{""locations"":""Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg\/L)""}"
"548","Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals","PROFISCOV","NCT04456595","COV-02-IB","Biological: Adsorbed COVID-19 (inactivated) Vaccine|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04456595","Active, not recruiting","2020-07-21","2022-02-01","{""locations"":""Universidade de Bras\u00edlia, Brasilia, DF, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Hospital Universit\u00e1rio J\u00falio M\u00fcller, Cuiab\u00e1, Mount, Brazil|Hospital Universit\u00e1rio Maria Aparecida Pedrossian, Campo Grande, MS, Brazil|Hospital das Cl\u00ednicas da Universidade Federal do Paran\u00e1, Curitiba, PR, Brazil|Hospital Escola da Universidade Federal de Pelotas, Pelotas, RS, Brazil|Hospital S\u00e3o Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, RS, Brazil|Hospital de Amor - Funda\u00e7\u00e3o Pio XII, Barretos, SP, Brazil|Hospital das Cl\u00ednicas da UNICAMP, Campinas, SP, Brazil|Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo, Ribeirao Preto, SP, Brazil|Instituto de Infectologia Em\u00edlio Ribas, Sao Paulo, SP, Brazil|Centro de Pesquisas Cl\u00ednicas do Instituto Central do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, Sao Paulo, SP, Brazil|Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, SP, Brazil|Universidade Municipal de S\u00e3o Caetano do Sul, S\u00e3o Caetano do Sul, SP, Brazil|Faculdade de Medicina de S\u00e3o Jos\u00e9 do Rio Preto - FAMERP, S\u00e3o Jos\u00e9 Do Rio Preto, S\u00e3o Paulo, Brazil|Instituto de Infectologia Evandro Chagas - Fiocruz, Rio De Janeiro, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""12688"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID-19 cases after two-doses immunization schedule|Frequency of adverse events up to seven days after immunization|Incidence of COVID-19 cases after two-doses immunization schedule according to previous exposure|Incidence of COVID-19 cases after 14-days of first immunization|Combined incidence of SARS-CoV-2 infection|Incidence of severe COVID-19 cases after two-doses immunization schedule|Frequency of adverse events up to 28 days after immunization|Frequency of severe COVID-19 cases|Frequency of adverse events of special interest after immunization|Seroconversion rate|Cell-mediated immune profile|Seropositivity rate""}"
"549","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","TOCOVID","NCT04332094","IIBSP-COV-2020-23","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04332094","Recruiting","2020-04-02","2020-10-01","{""locations"":""Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""276"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit""}"
"550","Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19","","NCT04466280","IR.BMSU.REC.1399.086","Drug: Hydroxychloroquine|Drug: Mucodentol|Device: Personal protective equipment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04466280","Recruiting","2020-07-15","2020-12-15","{""locations"":""Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PCR test|Laboratory Treatment Response|drug reactions Adverse|Allergic drug|Radiological Treatment Response""}"
"551","#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19","#StayHome","NCT04385264","Unisante","Drug: Hydroxychloroquine|Drug: Mannitol","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04385264","Not yet recruiting","2020-05-12","2020-10-01","{""locations"":""Unisant\u00e9, Lausanne, Vaud, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of poor outcomes (in index cases)|Secondary household attack rate (in household contacts)|Subjective disease severity (in index cases)|Rate of acute respiratory distress syndrome (in index cases)|Severity of radiological lung pathology (in index cases)|Objective disease severity (in index cases)|Safety: Unintended toxic HCQ accumulation (in index cases)|Safety: Adverse events (in index cases)|Social distancing knowledge, attitudes and practices amongst index cases and household contacts""}"
"552","Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)","","NCT04465474","COVID-MAP","Other: Non Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04465474","Recruiting","2020-05-01","2022-12-31","{""locations"":""Peking University First Hospital, Beijing, Beijing, China|Kwong Wah Hospital, Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|United Christian Hospital, Hong Kong, Hong Kong|Hospital Universitario de Torrej\u00f3n, Torrej\u00f3n De Ardoz, Madrid, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroconversion during pregnancy - DSS1|Seroconversion during pregnancy - At delivery|Pregnancy loss|Pregnancy course and perinatal outcome|Vertical transmission|Potential mechanisms for vertical transmission 1) placental barrier, 2) immune response and 3) fetal damage of vertical transmission and mechanism in SARS-CoV-2 infection.""}"
"553","Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting","","NCT04501952","GS-US-540-9012|2020-003510-12","Drug: RDV|Drug: Placebo to Match RDV","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04501952","Recruiting","2020-09-18","2021-04-01","{""locations"":""Arizona Liver Health, Chandler, Arizona, United States|Arizona Clinical Trials, Tucson, Arizona, United States|St Joseph Hospital Eureka, Eureka, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Ruane Clinical Research Group, Los Angeles, California, United States|LA Universal Center, INC., Los Angeles, California, United States|Mills Clinical Research, Los Angeles, California, United States|Kaiser Permanente Northern California, Oakland, California, United States|FOMAT Medical Research, Oxnard, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Northern California, 6600 Bruceville Road, Sacramento, California, United States|Kaiser Permanente Northern California, 2025 Morse Ave, Sacramento, California, United States|Kaiser Permanente Northern California, 1200 El Camino Real, San Francisco, California, United States|Kaiser Permanente Northern California, 2425 Geary Blvd, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Kaiser Permanente Northern California, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Northern California, 2500 Merced St, San Leandro, California, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Premiere Medical Center of Burbank, Inc, Toluca Lake, California, United States|Kaiser Permanente Northern California, 975 Sereno Drive, Vallejo, California, United States|New Hope Research Development DBA HCD, Whittier, California, United States|Centura Health Porter Place, Denver, Colorado, United States|Nuvance Health, Danbury, Connecticut, United States|RecioMed Clinical Research Network, Boynton Beach, Florida, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Evolution Clinical Trials, Hialeah Gardens, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|L&C Professional Medical Research Institute, Miami, Florida, United States|Laguna Clinical Research Associates, Miami, Florida, United States|CTMD Research, Inc, Palm Springs, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Luminous Clinical Research - South Florida Urgent Care, Pembroke Pines, Florida, United States|St. Josephs Comprehensive Research Institute, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast, Vero Beach, Florida, United States|Triple O Research Institute PA, West Palm Beach, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Mercer University School of Medicine, Macon, Georgia, United States|Infectious Disease Associates of Kansas City, P.C.Infectious Disease Associates of Kansas City, P.C., Burr Ridge, Illinois, United States|Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States|NorthStar Medical Center, Chicago, Illinois, United States|NorthShore University Healthsystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|University of Maryland Baltimore, Baltimore, Maryland, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|Be Well Medical Center, Berkley, Michigan, United States|Onyx Research Institute, Flint, Michigan, United States|Memorial Hospital of Gulfport, Gulfport, Mississippi, United States|Metro Infectious Disease Consultants, Kansas City, Missouri, United States|Quality Clinical Research Inc., Omaha, Nebraska, United States|AB Clinical Trials, Las Vegas, Nevada, United States|AXCES Research Group, Santa Fe, New Mexico, United States|New York Presbyterian Hospital, Flushing, New York, United States|Northwell Health, New Hyde Park, New York, United States|Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Rosedale Infectious Diseases, Huntersville, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|Cherokee Nation WW Hastings Hospital, Tahlequah, Oklahoma, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|University of Tennessee Health Science Center, Knoxville, Tennessee, United States|Central Texas Clinical Research, Austin, Texas, United States|UT Physicians, Bellaire, Texas, United States|Baylor University Medical Center, 700 Scott and White Dr., College Station, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Care United Research, LLC, Forney, Texas, United States|VIP Trials, Harlingen, Texas, United States|University of Texas, Houston, Texas, United States|The Crofoot Research Center, Inc, Houston, Texas, United States|Baylor University Medical Center, 1901 North McArthur Blvd, Irving, Texas, United States|Laguna Clinical Research Associates, Laredo, Texas, United States|Diagnostic Clinic of Longview - Center for Clinical Research, Longview, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|Baylor University Medical Center, 2201 MacArthur Dr., Suite 100, Waco, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Sound Medical Research, Port Orchard, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Wisconsin Corporation for Biomedical Research, Milwaukee, Wisconsin, United States|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus N, Denmark|Rigshospitalet, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|University College Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1264"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Composite Endpoint of Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-cause Death by Day 28.|Proportion of Participants Experiencing Treatment-Emergent Adverse Events|Composite Endpoint of COVID-19 Related MAVs (Medical Visits Attended in Person by the Participant and a Health Care Professional) or All-cause Death by Day 28|All-cause Mortality at Day 28|Rate of Hospitalization by Day 28|Composite Endpoint of COVID-19 Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-cause Death by Day 14|Composite Endpoint of COVID-19 Related MAVs (Medical Visits Attended in Person by the Participant and a Health Care Professional) or All-cause Death by Day 14|Time-weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load from Baseline to Day 7|Time to Alleviation (Mild or Absent) of Baseline Coronavirus Disease 2019 (COVID-19) Symptoms as Reported on the COVID-19-adapted InFLUenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)|Proportion of Participants Progressing to Requiring Oxygen Supplementation by Day 28""}"
"554","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","","NCT04334980","bacTRL-Spike-1","Biological: bacTRL-Spike","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04334980","Active, not recruiting","2020-11-02","2022-02-28","{""locations"":""Nucleus Network Pty Ltd (Trading as Centre for Clinical Studies), Melbourne, Victoria, Australia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of Adverse Events|Immune response against SARS-CoV-2 Spike protein|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination|Immunity against SARS-CoV-2""}"
"555","Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting","","NCT04370782","20-21","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04370782","Completed","2020-04-28","2020-09-30","{""locations"":""St Francis Hospital, Roslyn, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""30 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and\/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms""}"
"556","A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients","","NCT04377711","ALV-020-001","Drug: Ciclesonide|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04377711","Recruiting","2020-06-08","2020-12-01","{""locations"":""University of Buffalo, Buffalo, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""12 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Percentage of patients hospital admission or death by day 30|All-cause mortality by day 30|COVID-19-related mortality by day 30|Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID 19 by day 30|Time to hospital admission or death|Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, > 3 AM\/PM assessments)|Change from baseline in oxygen saturation levels|Change from baseline in COVID-19 viral load in nasopharyngel sample nasal secretions at day 30|Safety will be assessed based on adverse events.""}"
"557","Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19","","NCT04348409","NITFQM0320OR","Drug: Nitazoxanide Tablets|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04348409","Recruiting","2020-05-25","2020-07-31","{""locations"":""Hospital Vera Cruz, Campinas, S\u00e3o Paulo, Brazil|Centro de Genomas, S\u00e3o Paulo, Brazil|Hospital Em\u00edlio Ribas, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation""}"
"558","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","","NCT04312997","PUL-042-502","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04312997","Recruiting","2020-06-16","2021-05-01","{""locations"":""University of California Irvine, Orange, California, United States|Premeir Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|DBC Research Corp., Tamarac, Florida, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 14 days|Severity of COVID-19 symptoms|ICU admission|Mechanical Ventilation|Mortality""}"
"559","A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19","SCB-2019","NCT04672395","CLO-SCB-2019-003","Biological: CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Biological: Placebo; 0.9% saline","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04672395","Not yet recruiting","2021-03-01","2022-07-01","{""locations"":""Anima, Alken, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Private Practice RESPISOM Namur, Namur, Belgium|Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, Rio Do Janeiro, Brazil|Instituto Atena de Pesquisa Clinica, Natal, Rio Grande Do Norte, Brazil|CPCLIN - Centro de Pesquisas Cl\u00ednicas de Natal, Natal, Rio Grande Do Norte, Brazil|Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital da Universidade Federal de Santa Maria CEP\/UFSM, Santa Maria, Rio Grande Do Sul, Brazil|Centro de Atenci\u00f3n e investigaci\u00f3n M\u00e9dica S.A.S, CAIMED S.A.S - sede Bogot\u00e1 D.C., Bogot\u00e1, Cundinamarca, Colombia|Centro de Atenci\u00f3n e investigaci\u00f3n M\u00e9dica S.A.S, CAIMED S.A.S - sede Acac\u00edas, Acac\u00edas, Colombia|Cl\u00ednica de la Costa Ltda., Barranquilla, Colombia|Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S. - CEIP S.A.S., Cali, Colombia|Centro de Atenci\u00f3n e investigaci\u00f3n M\u00e9dica S.A.S, CAIMED S.A.S - sede Aguazul, Casanare, Colombia|Centro de Atenci\u00f3n e investigaci\u00f3n M\u00e9dica S.A.S, CAIMED S.A.S - sede Yopal, Yopal, Colombia|Centro Sanitario de Santo Domingo (Satellite Site), Santo Domingo, Dominican Republic|Hospital Universitario Maternidad Nuestra Senora de la Altagracia., Santo Domingo, Dominican Republic|Klinikum W\u00fcrzburg Mitte gGmbH - Standort Juliusspital, Wuerzburg, Bayern, Germany|IKF Pneumologie GmbH & Co. KG, Frankfurt am Main, Hessen, Germany|IKF Pneumologie Mainz, Mainz, Rheinland Pfalz, Germany|Berliner Centrum f. Reise- und Tropenmedizin (BCRT), Berlin, Germany|Institute of Medicine, Maharajgunj, Kathmandu, Nepal|Dhulikhel Hospital, Dhulikhel, Nepal|Cevaxin David, David, Doleguita, Panama|Cevaxin 24 de diciembre, Ciudad de Panam\u00e1, Panama|Cevaxin Panama Clinic, Ciudad de Panam\u00e1, Panama|CEVAXIN Chorrera, Panama, Panama|Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia INDICASAT, Panama, Panama|Cevaxin Av Mexico, Panam\u00e1, Panama|De La Salle Medical and Health Sciences Institute, Dasmari\u00f1as, Cavite, Philippines|Las Pinas Doctors Hospital, Las Pi\u00f1as, Philippines|Tropical Disease Foundation, Makati, Philippines|Manila Doctors Hospital, Manila, Philippines|University of the Philippines Manila - College of Public Health, Manila, Philippines|Asian Hospital and Medical Center, Muntinlupa, Philippines|UERM Memorial Medical Center, Quezon City, Philippines|University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines|FEU-NRMF Medical Center, Quezon City, Philippines|St. Luke's Medical Center, Taguig, Philippines|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|KO-MED Centra Kliniczne Pulawy, Pu\u0142awy, Poland|Centrum Medyczne Medyk, Rzesz\u00f3w, Poland|Centrum Medyczne Pratia Poznan, Sk\u00f3rzewo, Poland|KO-MED Centra Kliniczne Staszow, Stasz\u00f3w, Poland|ETG Warszawa, Warszawa, Poland|Wits Clinical Research, Johannesburg, Gauteng, South Africa|DJW Research, Krugersdorp, Gauteng, South Africa|Soweto Clinical Trials Centre, Soweto, Gauteng, South Africa|Dr JM Engelbrecht Trial Site, Somerset West, Western Cape, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""22000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with a First Occurrence of COVID-19 of Any Severity Starting 14 Days after Second Dose of SCB-2019|Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited AEs|Number of Participants with Serious Adverse Events (SAEs), or Medically Attended AEs (MAAEs), or AEs Leading to Early Termination, or Adverse Events of Special Interest (AESIs)|Number of Participants with a First Occurrence of Moderate-to-Severe COVID-19 Starting 14 Days after Second Dose of SCB-2019|Number of Participants with First Occurrence of Any Laboratory-Confirmed SARS-CoV-2 infection Starting 14 Days after Second Dose of SCB-2019 or Placebo|Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of SCB-2019 or Placebo|Number of Participants with First Occurrence of Any Laboratory-Confirmed Asymptomatic SARS-CoV-2 infection Starting 14 Days after Second Dose of SCB-2019 or Placebo|Burden of Disease Score of COVID-19 or SARS-CoV-2 Infection Cases Starting 14 Days after Second Dose of SCB-2019 or Placebo|Number of Participants with a First Occurrence of COVID-19 of Any Severity, Associated with Hospitalization, Starting 14 Days after Second Dose of SCB-2019 or Placebo|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of SCB-2019 or Placebo, regardless of evidence of prior SARS-CoV-2 Infection|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of SCB-2019 or Placebo, regardless of risk of severe COVID-19|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of SCB-2019 or Placebo|Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb|Number of Participants with Seroconversion for SARS-CoV-2 Specific nAb|Geometric Mean Titer (GMT) of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor|Number of Participants with Seroconversion for of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor|Geometric Mean Titer (GMT) of SCB-2019 binding antibody|Geometric Mean Fold Rise (GMFR) of SCB-2019 binding antibody|Number of Participants with Seroconversion for SCB-2019 binding antibody|Geometric Mean Titer (GMT) of Trimer-Tag binding antibody|Geometric Mean Fold Rise (GMFR) of Trimer-Tag binding antibody""}"
"560","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)","","NCT04292899","GS-US-540-5773|2020-000841-15|ISRCTN15874265","Drug: Remdesivir|Drug: Standard of Care","Interventional","Has Results","Phase 3","https://ClinicalTrials.gov/show/NCT04292899","Completed","2020-03-06","2020-06-30","{""locations"":""Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital\/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, D\u00fcsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universit\u00e4tsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik f\u00fcr H\u00e4matologie, Onkologie, Immunologie, M\u00fcnchen, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcal\u00e1 De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coru\u00f1a, A Coru\u00f1a, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Gen\u00e8ve, Gen\u00e8ve 14, Switzerland|Ospedale Regionale di Locarno La Carit\u00e0, Lugano, Switzerland|Universit\u00e4tsspital Z\u00fcrich, Z\u00fcrich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""4891"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)""}"
"561","Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP)","COVID-HOP","NCT04418375","APHP200609|2020-A01364-35","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04418375","Recruiting","2020-06-08","2022-03-01","{""locations"":""HEGP, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of markers associated with asymptomatic COVID + status (results of the serological test) versus symptomatic COVID + status through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Identification of markers associated with a positive or a negative serology through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Description of the serological status according to the professional risk of exposure to the virus|Description of the clinical manifestations of COVID-19 infection in hospital professionals|Identification of risk factors associated with the loss of anti SARS-CoV-2 immunity through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Identification of markers associated with symptomatic COVID-19 infection during follow-up despite the presence of anti SARS-CoV-2 antibodies through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Correlation between the serology result and the PCR result (swabs) for people who have been tested as part of routine care.|Identification of potential therapeutic targets to avoid developing a symptomatic form|Identification of potential therapeutic targets to promote the maintenance of an anti SARS-CoV2 protective immunity|Creation of COVIDneg and COVID + asymptomatic control groups for other COVID-19 biological collections.""}"
"562","Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19","","NCT04576312","UNI911-101","Drug: UNI911 INHALATION","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04576312","Active, not recruiting","2020-06-29","2021-04-30","{""locations"":""DanTrials, Copenhagen, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""64"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assess safety of UNI911 INHALATION in healthy volunteers: AE frequency""}"
"563","Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","","NCT04539262","GS-US-553-9020","Drug: Remdesivir (RDV)|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04539262","Active, not recruiting","2020-09-14","2021-04-01","{""locations"":""The Institute for Liver Health, Mesa, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|Franco Felizarta, MD, Bakersfield, California, United States|Aurora FDRC Inc., Costa Mesa, California, United States|Elevated Health, Huntington Beach, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Western Clinical Research, Placentia, California, United States|UC Davis Health\/Medical Center, Sacramento, California, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Evolution Clinical Trials, Inc., Hialeah Gardens, Florida, United States|Research in Miami, Inc., Hialeah, Florida, United States|Optimus U Corporation, Miami, Florida, United States|L & C Professional Medical Research Institute, Miami, Florida, United States|Westchester Research Center at Westchester General Hospital, Miami, Florida, United States|MedBio Trials, Miami, Florida, United States|Nuovida Research Center, Corp, Miami, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Triple O Research Institute, PA, West Palm Beach, Florida, United States|Family Care Research, Boise, Idaho, United States|CTU Covid Research Center, New Orleans, Louisiana, United States|STAT Research, Vandalia, Ohio, United States|Inquest Clinical Research, Baytown, Texas, United States|DFW Clinical Research, Dallas, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|PCP for Life-Tidwell, Houston, Texas, United States|Providence Regional Medical Center Everett, Everett, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""156"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time-weighted Average Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation|Composite of All-Cause Medically Attended Visits (MAVs) (Medical Visits Attended in Person by the Participant and a Health Care Professional) or Death by Day 28|Composite of COVID-19 related MAVs or Death by Day 28|Proportion of Participants Hospitalized by Day 28|Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: AUClast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: CLss\/F of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: t1\/2 of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Vz\/F of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Cmax of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Tmax of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Clast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Tlast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: AUCtau of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: \u03bbz of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Ctau of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|Change in SARS-CoV-2 Viral Load From Baseline to Day 5|Change in SARS-CoV-2 Viral Load From Baseline to Day 7|Change in SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B|Time to Negative SARS-CoV-2 Polymerase Chain Reaction (PCR)|Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO\u00a9) Questionnaire""}"
"564","The Offer of Neurosurgery Care in the Grand Est of France During the Health Crisis Linked to Covid-19","NeurochirCOVID","NCT04701905","7780","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04701905","Recruiting","2020-04-30","2021-04-30","{""locations"":""Department of Neurosurgery - Strasbourg University Hospitals, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective analysis of the management of neurosurgical pathologies in a health crisis situation of the Covid-19 pandemic""}"
"565","Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19","","NCT04353518","CRSC20005","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04353518","Recruiting","2020-06-30","2021-05-30","{""locations"":""All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India|All lndia Institute of Medical Science, Delhi, Delhi, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of subject acquiring COVID-19 infection|Incidence of Adverse Event and Serious Adverse Event (safety and tolerability)|Number of subject developing Upper Respiratory Tract Infection (URTI) symptoms|Number of subject developing severe COVID-19 infection based on ordinal scale""}"
"566","Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill","","NCT04358809","CRSC20006","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04358809","Recruiting","2020-06-30","2021-04-30","{""locations"":""All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India|All India Institute of Medical Sciences, Bhopal, Bhopal, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India|All India Institute of Medical Sciences, Delhi, Delhi, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""480"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with increased disease severity|Incidence of adverse events and serious adverse events (Safety)|Number of COVID-19 patients discharged from hospital|Number of COVID-19 patients transfer to ICU|Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale|Number of of symptom free patients""}"
"567","Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients","","NCT04360551","H051","Drug: Telmisartan 40mg|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04360551","Recruiting","2020-07-01","2021-06-30","{""locations"":""University of Hawaii - Manoa, John A Burns School of Medicine UH Clinics at Kakaako, Honolulu, Hawaii, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Maximum clinical severity of disease|Incidence of treatment emergent adverse events|Renin angiotensin system peptides|Plasma biomarkers""}"
"568","SARS-CoV-2/COVID-19 Prevalence Study","","NCT04658121","CoVPN 5002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04658121","Enrolling by invitation","2021-02-04","2021-05-30","{""locations"":""Children's Hospital Colorado CRS, Aurora, Colorado, United States|U of Miami, IDRU at Jackson Memorial Hospital CRS, Miami, Florida, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|UIC Project Wish CRS, Chicago, Illinois, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|John's Hopkins CRS, Baltimore, Maryland, United States|New Jersey Medical School CRS, Newark, New Jersey, United States|Harlem Prevention, New York, New York, United States|Bronx Prevention Center, New York, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Cincinnati CRS, Cincinnati, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|St. Louis University VTEU-CAIMED-PHSU, Ponce, Puerto Rico"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""3920"",""age"":""2 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""To estimate the prevalence of SARS-CoV-2 IgG seropositivity among individuals in communities surrounding selected NIAID clinical research sites|To estimate prevalence of SARS-CoV-2 infection based on results of SARS-CoV-2 RNA testing|To estimate prevalence of SARS-CoV-2 infection by presence versus absence of symptoms consistent with COVID-19|To estimate seroprevalence of SARS-CoV-2|To assess correlation between demographic, clinical and social factors with SARS-CoV-2 infection and seroprevalence|To estimate potential size of populations for referral to COVID-19 prevention and treatment studies|To assess knowledge, attitudes, and behavior about SARS-CoV-2 and COVID-19 through a study questionnaire|To compare performance characteristics of PCR-based and serologic SARS-CoV-2 tests using saliva and\/or oral fluid and DBS samples""}"
"569","Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients","MOPHYDA","NCT04354597","20 KHCC 67","Drug: HCQ & AZ","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04354597","Not yet recruiting","2020-05-01","2020-10-15","{""locations"":""King Hussein Cancer Center, Amman, Jordan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""25 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate""}"
"570","Immune Profiling of COVID19-patients Admitted to ICU","IMPROVISE","NCT04473131","MRC-05-007","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473131","Recruiting","2020-04-27","2022-06-01","{""locations"":""Hamad Medical Corporation, Doha, Qatar"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To create an immune profile for each COVID19-positive patient during their ICU stay|To correlate patients' immune profile to disease severity and patient's outcome""}"
"571","A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19","","NCT04460183","RESP301-002","Drug: RESP301, a Nitric Oxide generating solution|Other: Standard of Care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04460183","Recruiting","2020-07-29","2021-04-23","{""locations"":""Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom|Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, United Kingdom|Pennine Acute Hospitals Trust (Nroth Manchester General Hospital), Manchester, United Kingdom|Royal Preston Hospital, Preston, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who progress by at least one level higher on the modified WHO ordinal scale by Day 14|Change in room air oxygen saturation (SpO2) from baseline over time|Change in National Early Warning Score (NEWS) 2 symptom score from baseline over time|Change from baseline on the modified WHO ordinal scale at each visit up to Day 28|Time to improvement of at least one level lower on the modified WHO ordinal scale|Time to progression of at least one level higher on the modified WHO ordinal|Number of participants with adverse events and serious adverse events""}"
"572","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","","NCT04343989","s20-00392","Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04343989","Active, not recruiting","2020-03-31","2021-01-30","{""locations"":""New York University School of Medicine, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative incidence of intubation|Time to extubation|Length of ICU stay|Number of patients who present a decrease in C-reactive protein|Patient Survival""}"
"573","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19","","NCT04329572","HIAPRE0320OR","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04329572","Suspended","2020-04-23","2020-06-30","{""locations"":""Prevent Senior Private Operadora de Sa\u00fade LTDA., S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days""}"
"574","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","","NCT04348435","Allogeneic COVID-19 Protection","Drug: HB-adMSCs|Drug: Placebos","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04348435","Enrolling by invitation","2020-05-14","2021-04-30","{""locations"":""Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper\/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9""}"
"575","Convalescent Plasma for the Treatment of Patients With COVID-19","","NCT04372368","20-0990","Biological: COVID-19 Convalescent Plasma","Expanded Access:Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04372368","No longer available","1970-01-01","1970-01-01","{""locations"":""Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"576","Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure","PLACO-COVID","NCT04428021","CS3/33","Drug: Standard Therapy Protocol (STP)|Other: STP + Standard Plasma (SP)|Other: STP + COVID-19 Convalescent Plasma (CP)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04428021","Recruiting","2020-06-15","2021-12-15","{""locations"":""AO Citt\u00e0 della salute e della scienza di Torino, Torino, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30-days survival|Ventilator free survival|6-months survival|Incidence of complications|Days in intensive care units (ICU)|Positivity for Immunoglobulin G to SARS-Cov-2|Clearance of viral load|Sequential Organ Failure Assessment (SOFA) score|Any variation from Standard Therapy Protocol""}"
"577","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)","CARAVAN","NCT04431453","GS-US-540-5823|2020-001803-17","Drug: Remdesivir","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04431453","Recruiting","2020-07-21","2022-02-01","{""locations"":""Children's Hospital of Alabama, Birmingham, Alabama, United States|Ronald Reagan University of California, Los Angeles Medical Center, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Tampa General Hospital (Inpatient Visits), Tampa, Florida, United States|Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Spectrum Health\/Helen De Vos Children's Hospital, Grand Rapids, Michigan, United States|Children's Minnesota, Minneapolis, Minnesota, United States|Children's Hospital and Medical Center, Omaha, Nebraska, United States|NYC Health + Hospitals\/Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Northwell Health-Cohen Children's Medical Center, New Hyde Park, New York, United States|Carolinas Medical Center-Levine Children's Hospital, Charlotte, North Carolina, United States|Lehigh Valley Hospital\/Lehigh Valley Health Network (LVH\/LVHN), Allentown, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Medical Center, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Azienda Ospedaliero Universitaria Meyer, Florence, Italy|University Hospital of Padova, Clinic of Pediatric Hematology-Oncology, Padova, Italy|University Hospital of Parma, Parma, Italy|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Sant Joan de D\u00e9u, Esplugues de llobregat, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Cl\u00ednico Universitario de Santiago, Santiago de Compostela, Spain|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King's College NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""52"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Plasma Concentrations of Remdesivir (RDV) and Metabolites|Change From Baseline in Oxygenation Use|Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Clinical Improvement on a 7-point Ordinal Scale|Time (days) to Discharge From Hospital|Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result|Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load|Bilirubin Concentrations in < 14-day-old Participants|Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale|Plasma Concentrations of Sulfobutylether \u03b2-cyclodextrin Sodium (SBECD)|Proportion of Participants With Concomitant Use of Medications other than RDV for Treatment of Coronavirus Disease 2019 (COVID-19)""}"
"578","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment","","NCT04292730","GS-US-540-5774|2020-000842-32|ISRCTN85762140","Drug: Remdesivir|Drug: Standard of Care","Interventional","Has Results","Phase 3","https://ClinicalTrials.gov/show/NCT04292730","Completed","2020-03-15","2020-06-26","{""locations"":""Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College\/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, D\u00fcsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universit\u00e4tsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik f\u00fcr H\u00e4matologie, Onkologie, Immunologie, M\u00fcnchen, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcal\u00e1 De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coru\u00f1a, A Coru\u00f1a, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Gen\u00e8ve, Gen\u00e8ve 14, Switzerland|Ospedale Regionale di Locarno La Carit\u00e0, Lugano, Switzerland|Universit\u00e4tsspital Z\u00fcrich, Z\u00fcrich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1113"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)""}"
"579","Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)","","NCT04463264","NTZ-COVID ARG1","Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04463264","Recruiting","2020-06-26","2020-12-26","{""locations"":""Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""135"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Eradication of SARS COV-2 from patients' respiratory tract secretions by treatment day 7th.|Comparative decrease of the viral load|Clinical improvement|Pneumonia patients meeting severity criteria.|Number of days with fever""}"
"580","Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019)","","NCT04569851","BigCoviData","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04569851","Enrolling by invitation","2020-01-01","2021-10-30","{""locations"":""Hospital Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitario La Princesa, Madrid, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""100000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Factors that predict disease prognosis and outcomes in COVID-19 patients - Hospitalization|Factors that predict disease prognosis and outcomes in COVID-19 patients - ICU|The demographic and clinical characteristics of COVID-19 patients|The demographic and clinical characteristics of COVID-19 patients-Age at diagnosis|The demographic and clinical characteristics of COVID-19 patients -Percentage of patients in each age range|The demographic and clinical characteristics of COVID-19 patients with available PCR (Polymerase Chain Reaction) results|The demographic and clinical characteristics of COVID-19 patientsTime since first symptom until diagnosis|The demographic and clinical characteristics of COVID-19 patients - Physical examination|The demographic and clinical characteristics of COVID-19 patients - Physical examination of patients who are pregnant|The demographic and clinical characteristics of COVID-19 patients - Physical examination Temperature|The demographic and clinical characteristics of COVID-19 patients - Physical examination Heart rate (bmp)|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Hemoglobin|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Hemoglobin II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Red Blood Cells|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Red Blood Cells II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology: Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology: Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology- INR (International Normalized Ratio)|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology- INR II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Glucose, Cholesterol, Triglycerides|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Glucose, Cholesterol, Triglycerides II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Bilirubin|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Bilirubin II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Creatinine, Glucose|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Creatinine, Glucose II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Procalcitonin|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH (Potential Hydrogen), O2 Saturation, FIO2 (Fractional Inspired Oxigen), PAFI [Blood pressure of oxygen \/ inspired fraction of oxygen (PaO2\/FiO2)]|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: O2 saturation, FIO2, PAFI|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: O2 saturation, FIO2, PAFI II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: pCO2 (partial pressure of carbon dioxide), pO2 (partial pressure of oxygen)|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: pCO2, pO2 II|The demographic and clinical characteristics of COVID-19 patients- Comorbidities, Medication, Symptoms|The patient management (treatment and procedures) in the target population|The outcomes of COVID-19 (discharge, hospitalization, transfer to ICU\/ mechanical medical ventilation, in-hospital death) in correlation to patients' clinical and demographic characteristics, and treatment received""}"
"581","Influence of the COVId-19 Pandemic on STRESS, and Screening Procedures (COVISTRESS Screening)","","NCT04538586","2020 COVISTRESS Screening","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04538586","Recruiting","2020-05-01","2025-12-01","{""locations"":""Univeristy Hospital, Clermont-Ferrand, Clermont-Ferrand, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Stress measures|Screening|Sociodemographic characteristics""}"
"582","Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19","COVID19","NCT04467047","20200148","Biological: Mesenchymal Stromal Cells infusion","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04467047","Not yet recruiting","2020-07-25","2020-12-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Overall survival|Changes on inflammatory C-reactive protein|Hospital stay|Oxygenation index (PaO2\/FiO2)|Improvement in Liao's score (2020)|Radiological improvement|Time of COVID19 PCR negativity""}"
"583","Predictors of COVID-19 Infection and Disease Progression","Portsaiduni","NCT04484597","Prof. Refat Sadeq","Diagnostic Test: Rt PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04484597","Recruiting","2020-03-15","2020-09-15","{""locations"":""Prof. Refat Sadeq, Port Said, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""correlation of COVID-19 antibody to PCR|correlation of ancillaey tests to PCR""}"
"584","Testing for COVID-19 Infection in Asymptomatic Persons","","NCT04345510","COVID-19-1.0-DKFZ","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04345510","Recruiting","2020-04-20","2021-09-30","{""locations"":""German Cancer Research Center, Heidelberg, Baden-W\u00fcrttemberg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 infection""}"
"585","COVID-19 PrEP HCW HCQ Study","","NCT04354870","s20-00390","Drug: Hydroxychloroquine (HCQ)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04354870","Completed","2020-04-03","2020-10-01","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""130"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of seroconversion to SARS-CoV-2|Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion|Hospital admission rate|ICU admission rate|Mortality rate|Incidents of AEs or SAEs related to HCQ upon study termination time""}"
"586","Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease","PC-COVID-HCM","NCT04542967","047/2020","Biological: Biological","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04542967","Recruiting","2020-06-23","2020-09-30","{""locations"":""Hospital Central Militar, Mexico City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease progression|Side effects|Mortality|Respiratory improvement|Clinical improvement|Acute adverse events (AAE)""}"
"587","Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients","CAPRI","NCT04421404","20-30794","Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04421404","Active, not recruiting","2020-06-09","2021-04-30","{""locations"":""San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center at Mount Zion, San Francisco, California, United States|University of California, San Francisco Medical Center (Parnassus Campus), San Francisco, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical Ventilation or Death Endpoint|8-Point Ordinal Scale Endpoint""}"
"588","Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study","","NCT04426084","4","Other: Hypertension|Other: Diabetes type 2|Other: Obesity|Drug: Antihypertensive Agents|Drug: Statins (Cardiovascular Agents)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04426084","Active, not recruiting","2020-03-01","2022-12-31","{""locations"":""S\u00f6dersjukhuset, Stockholm, Sweden"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""22784"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severe Covid-19|Severe Covid-19 with pulmonary embolism|CRRT(Continuous Renal Replacement Therapy)|ECMO (Extracorporeal Membrane Oxygenation )|ICU Mortality""}"
"589","Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence","","NCT04582903","10000044|000044-I","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04582903","Recruiting","2021-03-16","2025-08-31","{""locations"":""Niaid\/Lcim, Rockville, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""up to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Characterization of the dynamic changes of innate and adaptive immune responses during SARS CoV 2 infection and convalescence.|Identification of genetic variants that are associated with either severe\/lethal COVID-19 or resistance to SARS CoV 2 infection.|Measurement of proinflammatory\/anti inflammatory cytokines produced during SARS CoV 2 infection and convalescence, including the IFN signature response.|Survey of other potential blood proteomic biomarkers of disease.|Characterization of serological responses against SARS CoV 2, other viruses or microbiota, and host antigens.|Characterization of intrapatient SARS-CoV-2 genetic variation andevolution during infection and convalescence.""}"
"590","Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants","","NCT04382586","BGB-3111-219","Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04382586","Active, not recruiting","2020-07-06","2021-04-30","{""locations"":""Honor Health, Scottsdale, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|MedStar Heath Research Institute\/ MedStar Washington Hospital Center, Washington, District of Columbia, United States|Augusta University, Augusta, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Atlantic Health System, Inc. \/ Chilton Medical Center, Pompton Plains, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|Therapeutic Concepts, Houston, Texas, United States|Covenant Health System, Lubbock, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""93"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Respiratory failure-free survival rate at day 28|Median reduction in days spent on supplemental oxygen|All-cause mortality|Proportion of participants experiencing respiratory failure or death|Mechanical ventilation-free survival|Days on mechanical ventilation|Duration of hospitalization|Time to discharge|PaO2:FiO2 and\/or oxygenation index|Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale""}"
"591","Dexamethasone for COVID-19","","NCT04707534","12927","Drug: Dexamethasone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04707534","Recruiting","2021-01-21","2021-06-21","{""locations"":""University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""World Health Organization ordinal scale at day 28|Ventilator-free days|28-day mortality""}"
"592","Ruxolitinib in the Treatment of Covid-19","","NCT04414098","CZabala","Drug: INC424 / Ruxolitinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04414098","Not yet recruiting","2020-06-01","2020-09-15","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome|Evaluate the median duration of hospitalization.|Evaluate the evolution of systemic inflammation parameters.|Evaluate COVID-19 mortality rate|Evaluate the proportion of the requirement of mechanical ventilation.|Evaluate ruxolitinib adverse reactions|Evaluate the proportion of secondary infections during the treatment with ruxolitinib""}"
"593","Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients","ConPlas-19","NCT04345523","ConPlas-19","Other: Blood and derivatives.|Drug: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04345523","Recruiting","2020-04-03","2021-04-01","{""locations"":""Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Arag\u00f3n, Spain|Hospital Universitario M\u00fatua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Severo Ochoa, Legan\u00e9s, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Pr\u00edncipe de Asturias, Meco, Madrid, Spain|Hospital General de Albacete, Albacete, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Donostia, Donostia, Spain|Hospital Doctor Josep Trueta, Girona, Spain|Hospital Doctor Negr\u00edn, Las Palmas, Spain|Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain|Hospital Universitario Arnau de Vilanova, Lleida, Spain|Hospital San Pedro, Logro\u00f1o, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Quironsalud Pozuelo, Madrid, Spain|Hospital Sant Joan de Deu de Manresa. Fundaci\u00f3n Althaia, Manresa, Spain|Hospital Universitario de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Cl\u00ednica Universidad de Navarra (CUN). Sedes Pamplona y Madrid, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Sant Joan de Reus, Reus, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain|Complejo Hospitalario de Toledo, Toledo, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""278"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Category Changes in the \""7-Ordinal Scale\""|Time to category 5, 6 or 7 of the \"" 7-Ordinal scale\""|Time to an improvement of one category from admission in the \""7-Ordinal scale\""|Status at day 30 in the \""11-Ordinal scale\""|Status at day 15 and 30 in the \""11-Ordinal scale\""|Time to first deterioration|Mean change in the ranking in the \""7-Ordinal scale\"" from baseline to days 3,5,8,11,15,29 and 60|Mean change in the ranking in the \""11-Ordinal scale from baseline to days 3,5,8,11,15,29 and 60.|Mortality of any cause at 15 days|Mortality of any cause at 28 days (day 29)|Mortality of any cause at 60 days|Oxygenation free days|Ventilator free days|Duration of hospitalization (days)|Infusion-related adverse events|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load|Incidence of thrombotic arterial events|Incidence of thrombotic venous events|rate of rehospitalizations""}"
"594","Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19","","NCT04542850","68 / 02-Aug-2020","Dietary Supplement: 5-ALA-Phosphate + SFC (5-ALA + SFC)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04542850","Recruiting","2020-11-15","2021-09-15","{""locations"":""Bahrain Defense Force Royal Medical Services, Military Hospital, Manama, Bahrain|Salmaniya Medical Complex, Manama, Bahrain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""21 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of treatment emergent Adverse Events (safety and tolerability) of 5-ALA-Phospate + SFC in patients with acute moderate or severe respiratory illness secondary to infection with SARS-CoV-2 virus (COVID-19).|Sum COVID-19 Modified Ordinal Scale for Clinical Improvement maximum daily score over 28 days of dosing for Moderate group and for Severe group|Rate of change in COVID-19 Modified Ordinal Scale for Clinical Improvement maximum daily score over 28 days of dosing for individual subjects in Moderate group and in Severe group|Patient and subgroup profile of COVID-19 Modified Ordinal Scale for Clinical Improvement score vs. days hospitalized|Overall survival|Results of investigator\u00b4s assessment of patient\u00b4s oxygen therapy|Results of mechanical ventilation settings|Results of duration of ventilation|The time to resolution of patient\u00b4s symptoms|Results of patient\u00b4s oxygen saturation (respiratory parameters)|Length of hospitalization|The total time in ICU|Results of investigator\u00b4s assessment of patient\u00b4s condition using (q)SOFA score|Results of patient\u00b4s PT parameter|Results of patient\u00b4s D-Dimer parameter|Results of patient\u00b4s PTT parameter|Results of patient\u00b4s SARS-CoV-2 viral load status (efficacy)|Results of patient\u00b4s Procalcitonin level.|Results of patient\u00b4s IL-6 level|Results of patient\u00b4s Serum Ferritin level|Results of patient\u00b4s C-Reactive protein (CRP) level|Results of patient\u00b4s T helper cells (CD4\/CD8) level.|Results of patient\u00b4s Bilirubin level.|Results on patient\u00b4s Leucocytes|Results on patient\u00b4s Neutrophils|Results on patient\u00b4s Lymphocyte|Results on patient\u00b4s Platelets|Results on patient\u00b4s Hemoglobin|Results on patient\u00b4s Albumin|Results on patient\u00b4s AST|Results on patient\u00b4s ALT|Results on patient\u00b4s Total bilirubin|Results on patient\u00b4s Blood urea nitrogen|Results on patient\u00b4s Serum creatinine|Results on patient\u00b4s Creatinine kinase|Results on patient\u00b4s LDH|Results on patient\u00b4s Myoglobin glucose|Results on patient\u00b4s aPTT|Results on patient\u00b4s urine|Results on hepatic function|Results on patient\u00b4s renal function|Results on patient\u00b4s iron parameters|Results on patient\u00b4s physical examination|Results on patient\u00b4s Co-infections|Results on patient\u00b4s Care Level|Results on patient\u00b4s Mean arterial pressure(MAP)|Results on patient\u00b4s heart rate (HR)|Results on patient\u00b4s respiratory rate (RR)|Results on patient\u00b4s 12-lead ECG|Organ damage""}"
"595","COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells","MEMO-COV2","NCT04402892","APHP200551","Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04402892","Not yet recruiting","2020-06-01","2021-03-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immunological memory: resolution of COVID-19 after SARS-CoV2 infection.""}"
"596","Study of Hemostasis in Case of Severe COVID-19","THROMBOVID","NCT04359992","7774","Other: Extra blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359992","Not yet recruiting","2020-04-17","2021-05-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Platelet activation intensity with the occurrence of clinical thrombotic complications""}"
"597","Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia","","NCT04428268","IF20-00003","Drug: Chloroquine Phosphate Tablets","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04428268","Withdrawn","2020-03-10","2021-02-16","{""locations"":""Hospital Universitario Jos\u00e9 E. Gonzalez, Monterrey, Nuevo Leon, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall mortality|Clinical outcome assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Time to negative SARS-CoV-2 test""}"
"598","Health After Covid-19 in Tyrol","","NCT04661462","20200928-2379","Other: online survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04661462","Recruiting","2020-09-30","2021-12-31","{""locations"":""Medizinische Universit\u00e4t Innsbruck, Innsbruck, Tyrol, Austria"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Population based data on spectrum and recovery from COVID-19 symptoms|Predictors of recovery.""}"
"599","Pegylated Interferon Lambda Treatment for COVID-19","","NCT04343976","2020P001083","Drug: Pegylated interferon lambda","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04343976","Enrolling by invitation","2020-06-22","2021-09-30","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Undetectable COVID PCR at day 7|Undetectable COVID PCR at day 3, 10 and 14|Percentage of subjects on Lambda vs placebo with symptomatic improvement|Percentage of subjects on Lambda vs placebo with improved clinical outcomes""}"
"600","Max COVID19- Study","","NCT04339608","Covid-19/MHC/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339608","Recruiting","2020-04-02","2020-06-30","{""locations"":""Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 positive case""}"
"601","COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation","","NCT04476953","20-003936","Drug: Placebo|Drug: Fisetin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04476953","Enrolling by invitation","2020-08-03","2021-07-01","{""locations"":""Mayo Clinic in Rochester, Rochester, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serious Adverse Events|Change in oxygenation status|CoV Severity Category""}"
"602","Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen","","NCT04346615","BHV3500-203","Drug: Zavegepant (BHV-3500)|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04346615","Recruiting","2020-04-25","2021-07-01","{""locations"":""Georgetown University Medical Center, Washington, District of Columbia, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Roper Hospital, Charleston, South Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To compare the efficacy of zavegepant (BHV-3500) to placebo in subjects hospitalized with COVID-19 infection requiring supplemental oxygen, using a six-point rating scale at Day 15. .|Proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at Day 29.|Proportion of subjects who have a 6-point severity rating of 2 or 3, or use any ventilation or high-flow nasal cannula as procedures, on any day through Day 29.|Proportion of subjects admitted into an ICU on any day through Day 29 from AE eCRFs.|Proportion of subjects who have a 6-point severity rating of 3, 4, 5, or 6, are alive, and do not use invasive mechanical ventilation as a procedure at Day 15. The analogous definition is applied to Day 29.|Proportion of subjects who have a 6-point severity rating of 4, 5 or 6, or use a low- or high-flow nasal, are alive, and do not use any ventilation at Day 15. The analogous definition is applied to Day 29.|Difference between treatment groups in the mean 6-point severity rating at Day 29|Number of days from baseline to the first day through Day 29 with any 6-point severity rating greater than baseline.|Number of days from baseline to the first of any 2 consecutive days through Day 29 with all SpO2\/FiO2 ratios > 400 on both days.|Number of days from baseline to the first day through Day 29 with \u2265 1-point decrease in any NEWS2 score from baseline.|Number of days from baseline to the first day through Day 29 with all NEWS2 scores < 2 on that day.|Mean change from baseline in NEWS2 score at Days 15 and 29 for subjects who are alive at these time points|Proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at Day 15.|Proportion of subjects who are discharged from the hospital, have a 6-point severity rating of 6 on any day after discharge, and use supplemental oxygen on any day after discharge.|Mean number of days with respiratory rate > 24 breaths\/minute through Day 29 for subjects who are alive at Day 29 and do not use invasive mechanical ventilation.|Mean number of days with supplemental oxygen use through Day 29 for subjects who are alive at Day 29. A day in which any 6-point severity rating is 2, 3, or 4, or supplemental oxygen is used as a procedure counts.|Number of days from baseline to the first day through Day 29 on which any SpO2 \u2265 90%, any 6-point severity rating is 5 or 6, and no supplemental oxygen is used as a procedure.|Mean number of ventilator-free days through Day 29 for subjects who are alive at Day 29.|Mean SOFA total scores at ICU admission and Day 29 (if still in ICU), from SOFA and AE eCRFs.|Mean number of days of hospitalization through Day 29 for subjects who are alive on Day 29. All days on study on or before hospitalization discharge are days of hospitalization, from 6-point severity rating scale eCRFs|Number of days from baseline to the first of any 2 consecutive days through Day 29 in which all temperatures show lack of fever on both days and no antipyretics are used on either day.|Number of subjects with deaths, SAEs, severe AEs, and Grade 3 or 4 laboratory test abnormalities at any time on study.|Number and percentage of subjects with severe or life-threatening bacterial, invasive fungal, or opportunistic infections at any time through Day 29 from AE\/SAE eCRFs.|Number and percentage of subjects with intranasal administration reactions at any time through Day 29 from AE\/SAE eCRFs.|Proportion of subjects with \u2265 50% reduction in eGFR from baseline at any time on study from laboratory test eCRFs.""}"
"603","Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","","NCT04560881","BIBP2020003AR","Biological: Inactivated SARS-CoV-2 vaccine (Vero cell)|Biological: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04560881","Active, not recruiting","2020-09-16","2021-12-01","{""locations"":""Fundaci\u00f3n Hu\u00e9sped, Ciudad Aut\u00f3noma de Buenos Aires, Buenos Aires, Argentina|Vacunar Liniers, Ciudad Aut\u00f3noma de Buenos Aires, Buenos Aires, Argentina|Vacunar Ca\u00f1itas, Ciudad Aut\u00f3noma de Buenos Aires, Buenos Aires, Argentina|Vacunar Coghlan, Ciudad Aut\u00f3noma de Buenos Aires, Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""3000"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID-19 cases after two-doses of vaccination|The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Increase (GMI) of anti-SARS-CoV-2 neutralizing antibody|Incidence of any adverse reactions\/events|Incidence of adverse reactions\/events|Incidence of serious adverse events (SAE)""}"
"604","COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department","","NCT04356560","DT P-2020-353","Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356560","Enrolling by invitation","2020-03-23","2020-12-31","{""locations"":""Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incidence of healthcare workers with SARS-CoV-2|Incidence of ENT patients with SARS-CoV-2|Development of SARS-CoV-2 antibodies among healthcare workers|Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers|SARS CoV-2 and bacterial super infections in upper respiratory airways""}"
"605","Cytokine Storm Among Bangladeshi Patients With COVID-19","","NCT04598334","PR-20084","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04598334","Not yet recruiting","2021-02-15","2021-06-01","{""locations"":""Icddr,B, Dhaka, Bangladesh"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""75"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 positive participants having high cytokines|High cytokine burden and severe COVID-19""}"
"606","Trial to Promote Recovery From COVID-19 With Endocrine Therapy","RECOVER","NCT04374279","COV2003|IRB00249425","Drug: Bicalutamide 150 Mg Oral Tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04374279","Withdrawn","2021-04-01","2022-01-01","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events""}"
"607","Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial","","NCT04445935","MRC-05-082","Drug: Bivalirudin Injection|Drug: Standard treatment","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04445935","Recruiting","2020-06-28","2021-03-28","{""locations"":""Hamad Medical Corporation, Doha, Qatar"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""100"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""P\/F ratio|Kidney function""}"
"608","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","","NCT04313322","COVID-19","Biological: WJ-MSCs","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04313322","Recruiting","2020-03-16","2020-09-30","{""locations"":""Stem Cells Arabia, Amman, Jordan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""5"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical outcome|CT Scan|RT-PCR results""}"
"609","Flow Controlled Ventilation in ARDS Associated With COVID-19","","NCT04399317","MRC-05-018","Device: Flow controlled ventilation (Evone-ventilator)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04399317","Recruiting","2020-05-28","2020-08-01","{""locations"":""Hamad Medical Corporation, Doha, Qatar"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""arterial oxygen partial pressure (PaO2)""}"
"610","NO-mediated Vascular Function in Covid-19 Patient","","NCT04625036","ICS Maugeri 2437 CE","Diagnostic Test: Single passive leg movement","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04625036","Recruiting","2020-05-30","2021-06-01","{""locations"":""ICS Maugeri IRCCS, U.O. Emergenza Coronavirus di Lumezzane, Lumezzane, Brescia, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""30"",""age"":""30 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Leg Blood Flow|Clinical evaluations|Clinical characteristics|Presence of device|Therapy|Biochemical evaluations - ProBNP|Biochemical evaluations - D-dimer|Biochemical evaluations - PCR|Functional evaluations - 1-Minute Sit To Stand|Functional evaluations - 6-Minute Walking Test|Functional evaluations - Biceps' muscle strength with dynamometer|Functional evaluations - Quadriceps' muscle strength with dynamometer""}"
"611","A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)","ATOMIC2","NCT04381962","ATOMIC2|2020-001740-26|282892|20/HRA/2105","Drug: Azithromycin Capsule","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04381962","Recruiting","2020-05-29","2020-10-13","{""locations"":""Horton General Hospital, Banbury, Oxfordshire, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Birmingham City Hospital, Birmingham, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""800"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)|Proportion progressing to respiratory failure or death (SARS-CoV-2 PCR positive)|All cause mortality|Proportion progressing to pneumonia.|Proportion progressing to severe pneumonia|Peak severity of illness|Safety and tolerability""}"
"612","PET/CT Imaging in COVID-19 Patients","","NCT04376593","1592298","Drug: 18F-αvβ6-BP","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04376593","Enrolling by invitation","2020-05-01","2022-05-01","{""locations"":""University of California Davis, Sacramento, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Administration of 18F-\u03b1v\u03b26-BP|Determine whether 18F-\u03b1v\u03b26-BP demonstrates accumulation in lung damage""}"
"613","Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19","PED-COVID","NCT04355533","APHP200467|2020-A00999-30","Biological: serology test|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04355533","Recruiting","2020-07-29","2022-12-01","{""locations"":""H\u00f4pital necker Enfants-Malades, \u00a8Paris, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Seroconversion against SARS-CoV2 in children|Measure of Ab antiN and Ab anti-S1\/2|Neutralization activity|Positive qPCR in children|correlation between different Ab and qPCR and neutralization activity|Protective immunity|duration of viral carriage in stool, saliva and or nasopharynx|correlation between antibody profile and viral clearance|Ab profile and memory of immunity|saliva biofluid characteristics of COVID-19 infected|Presence of the virus|Reinfection|Immune response|Mucosal immunity|seroconversion against SARS-CoV2 in parents|Measure of Ab antiN and Ab anti-S1 and neutralization activity|Positive qPCR in parents|correlation between different Ab and qPCR""}"
"614","Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)","FUTURE-T","NCT04379479","IC-20-001|SH-001-2020","Drug: Dialyzable Leukocyte Extract|Drug: Placebo oral","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04379479","Not yet recruiting","2020-05-01","2020-12-01","{""locations"":""Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Mexico City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""562"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the score of the \""Contingency scale to assess the severity of acute respiratory disease in cases suspected\/confirmed by COVID-19\""|Clinical deterioration|Duration of the clinical status""}"
"615","Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce","","NCT04491292","2020-0428|NCI-2020-04259","Other: Questionnaire Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04491292","Recruiting","2020-05-18","2021-04-30","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""20000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in psychosocial outcomes|Change in stress-related outcomes|Demographic and occupational factors associated psychological and stress-related outcomes""}"
"616","Tetrandrine Tablets Used in the Treatment of COVID-19","TT-NPC","NCT04308317","TT-NPC","Drug: Tetrandrine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04308317","Enrolling by invitation","2020-03-05","2021-05-01","{""locations"":""Tetrandrine Tablets, Jinhua, Zhejiang, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival rate|body temperature""}"
"617","Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19","","NCT04568018","Sur/ARDS-2020","Drug: Surfactant","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568018","Recruiting","2020-07-03","2021-12-01","{""locations"":""FSAEI of Higher Education I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean duration of oxygen therapy (days) in the treatment group and in the control group.|The proportion of patients who required ALV within 5 days after the start of treatment.|Change from baseline in PaO2\/FiO2 ratio dynamics within 5 days after the start of treatment.|Change from baseline in SpO2 dynamics within 5 days after the start of treatment.|Proportion of patients who achieved an oxygenation index (PaO2\/FiO2) of > 300 mm hg.|Proportion of patients dead of any reason within 30 days after the start of treatment.|Time to patient transfer to mechanically ventilated.|Change from the baseline in the severity assessment of the patient's condition according to the NEWS-II scale within 5 days after the start of treatment.|Change from baseline in leukocytes within 5 days after the start of treatment.|Change from baseline in lymphocytes within 5 days after the start of treatment.|Change from baseline in CRP within 5 days after the start of treatment.|Change from baseline in ferritin within 5 days after the start of treatment.|Change from baseline in D-dimer within 5 days after the start of treatment.""}"
"618","Angiotensin 1-7 as a Therapy in the Treatment of COVID-19","","NCT04605887","0328-20-RMB|MOH_2020-11-02_009463","Drug: Angiotensin 1-7","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04605887","Recruiting","2021-01-18","2024-04-01","{""locations"":""Rambam Medical Center, Haifa, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need for mechanical ventilation|Death""}"
"619","ImmuneSense™ COVID-19 Study","","NCT04583982","PRO-00781","Other: T-Detect™ SARS-CoV-2 Assay","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04583982","Completed","2020-10-09","2020-12-04","{""locations"":""Adaptive Biotechnologies Clinical Investigational Site, Secaucus, New Jersey, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""180"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Demonstrate clinical agreement of T-Detect\u2122 SARS-CoV-2 Assay""}"
"620","RAPA-501-Allo Off-the-Shelf Therapy of COVID-19","","NCT04482699","RAPA-501-ALLO-COVID-19","Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04482699","Recruiting","2020-12-30","2022-06-01","{""locations"":""Hackensack University Medical Center, Hackensack, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""88"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dose-Limiting Toxicity (DLT)|Mortality Rate|Ventilation Support|Days of Hospitalization|Number of Deaths|Incidence of Infection|GVHD Incidence""}"
"621","Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia","","NCT04444531","COVID Networking group","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444531","Completed","2020-03-20","2020-05-26","{""locations"":""Policlinic Ibiza Hospital, Ibiza, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""18"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Time to clinical improvement|Rate of patients with Clinical improvement at day 14|Rate of patients with Clinical improvement at day 28|Time to a 2-fold decrease of C-protein reactive from baseline|Time to a 2-fold decrease of ferritin from baseline|Time to a 2-fold decrease of Lactate Dehydrogenase from baseline|Time to a 2-fold decrease of D-dimer from baseline""}"
"622","Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic","","NCT04482647","2020-0483|NCI-2020-04931","Other: Media Intervention|Procedure: Meditation Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Procedure: Yoga","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04482647","Recruiting","2020-06-17","2021-07-01","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""up to 70 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Study recruitment|Acceptability of study|Adherence to the practice|Change in resilience|Perceive stress and psychological impact|Breath holding time""}"
"623","Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care","RECOVER-19","NCT04456036","NeuroRehabAN_Covid_2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04456036","Recruiting","2020-07-01","2021-06-30","{""locations"":""Neurorehabilitation Clinic, University Hospital Ospedali Riuniti di Ancona, Ancona, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from pre-COVID-19 condition in ADL independence on the mod. Rankin scale score at the enrolment (T0) assessment, at 3, 6 and 12 months|Change from pre-COVID-19 condition in walking performance on the Walking Handicap scale (WHS) at 3, 6 and 12 months|Patient-reported health-related well-being perception on the 36-Item Short Form Survey - SF-36 at 3, 6 12 months follow-up|Change in global ADL disability on modified Barthel Index (mBI), from the enrolment (T0), at 3, 6 12 months follow-up|Change in walking capacity on Functional Ambulation Category (FAC), from the enrolment (T0) assessment, at 3, 6 12 months follow-up|Change in cognitive abilities on the Montreal Cognitive Assessment (MoCA) from the enrollment (T0) assessment, at 3, 6 12 months follow-up|Change in patient-reported pain on Numerical Rating Scale from the enrollment (T0) assessment, at 3, 6 12 months follow-up|Change in swallow abilities on Dysphagia Outcome Severity Scale (DOSS) from the first functional assessment in acute care, at 3, 6 12 months follow-up|Change in endurance on 6-Minutes Walking Test (6MWT) from the enrolment (T0) assessment, at 3, 6 12 months follow-up|Change in mood status on Beck Depression Inventory (BDI) from the enrolment (T0) assessment, at 3, 6 and 12 month follow-up""}"
"624","Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia","","NCT04534790","PI-2020-2858","Radiation: Low Dose Radiotherapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04534790","Completed","2020-07-24","2021-01-08","{""locations"":""Social Secure Mexican Institute, Leon, Guanajuato, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement|improvement of laboratory and imaging parameters""}"
"625","COntinuous Signs Monitoring In Covid-19 Patients","COSMIC-19","NCT04581031","CFTSp187","Device: Continuous vital sign monitoring - Isansys Patient Status Engine|Other: Machine Learning/AI Algorithm","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04581031","Recruiting","2020-07-11","2021-02-01","{""locations"":""The Christie NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""60"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Development of an AI model to predict clinically relevant outcomes for ward-based patients with COVID-19 monitored for up to 20 days. Metrics to be employed depend on the algorithm used but include, Log-Loss, precision and\/or recall and confusion matrix.|Performance of the wearable vital signs sensor as measured by the percentage of possible data capture that is actually obtained|Look for evidence of circadian disruption in the vital signs of the enrolled patients.""}"
"626","Control of COVID-19 Outbreaks in Long Term Care","","NCT04448119","CONTROL-COVID-Favipiravir-1","Drug: Favipiravir|Drug: Favipiravir Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04448119","Recruiting","2020-10-16","2021-03-01","{""locations"":""Mount Sinai Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""760"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Control of Outbreak|Mortality (Residents)|COVID-19 Infection (Residents)|COVID-19 Infection (Staff)|Hospitalization (Residents)|Medication Discontinuation (Residents)|Medication Discontinuation (Staff)|COVID-19 in new LTCH Units (a)|COVID-19 in new LTCH Units (b)|COVID-19 in new LTCH Units (c)""}"
"627","Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children","AP-PEDCOVID","NCT04490811","HNeckerNM","Other: no intervention. observational cohort study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04490811","Recruiting","2020-04-09","2021-12-31","{""locations"":""Necker Hospital, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""800"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""serological test|neutralizing Ab|Immuno phenotyping""}"
"628","Immune Modulators for Treating COVID-19","ACTIV-1 IM","NCT04593940","Pro00106301","Drug: Infliximab|Drug: Abatacept|Drug: Remdesivir|Drug: cenicriviroc","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04593940","Recruiting","2020-10-15","2021-09-01","{""locations"":""University of Arkansas Medical Sciences, Little Rock, Arkansas, United States|Scripps Clinical Medical Group, La Jolla, California, United States|UCLA - Ronald Reagan Medical Center, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCLA Medical Center- Santa Monica, Santa Monica, California, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Tulane School of Medicine, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|The University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|MidMichigan Medical Center- Gratiot, Alma, Michigan, United States|MidMichigan Medical Center - Midland, Midland, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Trinitas Hospital, Elizabeth, New Jersey, United States|Rutgers New Jersey Medical School, New Brunswick, New Jersey, United States|New York University Langone Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|St Lawrence Health System, Potsdam, New York, United States|University of Rochester Medical Center-Strong Memorial Hospital, Rochester, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Avera McKennan Hospital, Sioux Falls, South Dakota, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Trinity Mother Frances Hospital, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Providence Medical Research Center, Spokane, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Gundersen Health System, La Crosse, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""2160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients that recovered from COVID-19|Change in number of patients hospitalized on invasive mechanical ventilation|number of patients that improved clinically|Number of patient deaths|Number of patients with decreased supplemental oxygenation needed|Change in number of patients needing non-invasive ventilation\/ high flow oxygen|Number of days patients are in the hospital|Number of SAEs and AEs of grade 3 and 4|Number of patients with changes in abnormal WBC counts""}"
"629","Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection","","NCT04408209","245-14-4-20","Procedure: Convalescent Plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04408209","Recruiting","2020-04-23","2021-09-15","{""locations"":""\""Evangelismos\"" General Hospital, Athens, Attiki, Greece|\""Agios Savas\"" Oncology Hospital, Athens, Attiki, Greece|\""Alexandra\"" General Hospital, Athens, Attiki, Greece|\""Sotiria\"" General Hospital, Athens, Attiki, Greece|Attikon\"" University General Hospital, Athens, Chaidari, Greece|University General Hospital of Patras, Patra, Rio, Greece"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival|Clinical improvement ie percentage of patients not fulfilling the criteria for severe disease""}"
"630","Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic","","NCT04521010","3/2020/Reh","Other: COVID-19 pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04521010","Completed","2020-01-01","2020-04-30","{""locations"":""Department of Rehabilitation and Physiotherapy Rehabilitation,, Pozna\u0144, Poland"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""700"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of days an individual person was absent""}"
"631","A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease","","NCT04347369","XQonc-015","Other: other","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347369","Recruiting","2020-01-17","2020-12-31","{""locations"":""Xinqiao Hospital of Chongqing, Chongqing, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""discrimination|Calibration|Net benefit""}"
"632","The COvid-19 Symptom MOntelukast Trial","COSMO","NCT04389411","443807","Drug: Montelukast 10mg","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04389411","Not yet recruiting","2020-10-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Emergency Room Visits and Hospitalizations|Emergency room visit count|Hospitalization admission count|Time to ER Visit|Time to hospitalization|All-cause mortality|Inpatient Length of stay|Time to ICU admission|Time to intubation|Time to other serious COVID-19 complications""}"
"633","Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia","","NCT04381858","2020-A-10","Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04381858","Completed","2020-05-06","2020-11-26","{""locations"":""Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""196"",""age"":""16 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mean hospitalization time|Mean Oxigenation index evolution|Rate of severe ARDS|Rate and time to dead|Mean time with invasive mechanical ventilation|Time to Viral PCR Negativization""}"
"634","Efficacy of Early Administration of Tocilizumab in COVID-19 Patients","","NCT04346355","RCT-TCZ-COVID-19|2020-001386-37","Drug: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04346355","Terminated","2020-03-31","2020-06-06","{""locations"":""Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unit\u00e0 Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria \""Maggiore della Carit\u00e0\"" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unit\u00e0 Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale \""Dell'Angelo\"", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""126"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 \/ FiO2 ratio|Evaluate the trend over time of the lymphocyte count""}"
"635","Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)","","NCT04363866","STUDY00021303","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363866","Withdrawn","2020-08-01","2021-09-01","{""locations"":""Oregon Health and Science University, Portland, Oregon, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale|Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5|Toxicity of Study Drug Assessed by Incidence of Adverse Events""}"
"636","Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs","","NCT04461925","#4/24.04.2020","Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|Drug: Antibiotics|Drug: Hormones|Drug: Anticoagulant Therapy|Device: Оxygen therapy","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04461925","Recruiting","2020-05-02","2021-12-01","{""locations"":""Institute of Cell Therapy, Kyiv, Ukraine"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes of oxygenation index PaO2\/FiO2, most conveniently the P\/F ratio.|Changes in length of hospital stay|Changes in mortality rate|Changes of \u0421-reactive protein (CRP, mg\/L)|Evaluation of Pneumonia Improvement|Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.)|Peripheral blood count recovery time""}"
"637","Role of Microparticles in Covid-19 Infection","MICO","NCT04448743","7829","Other: Blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04448743","Not yet recruiting","2020-06-01","2021-11-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""175"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Western blot measurement of ACE2 receptor expression in porcine cells""}"
"638","Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia","","NCT04460105","TAK-743-1002","Drug: Lanadelumab|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04460105","Withdrawn","2020-10-31","2021-01-27","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with Treatment emergent adverse events (TEAEs)|Pharmacokinetic (PK) Plasma Concentrations of Lanadelumab|Percentage Change from Baseline in Plasma Kallikrein Activity (pKal)|Percentage Change from Baseline in Cleaved High Molecular Weight Kininogen (cHMWK)|Percentage Change from Baseline in Functional C1-Inhibitor (C1-INH)""}"
"639","Health Professional Exposure Assessment to Covid-19","SERODRON","NCT04429724","RIPH_2020_8","Diagnostic Test: Diagnostic test Covid-19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04429724","Active, not recruiting","2020-07-06","2021-12-01","{""locations"":""CH Roubaix, Roubaix, France|CH Tourcoing, Tourcoing, France|CH Wasquehal, Wasquehal, France|CH Wattrelos, Wattrelos, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2129"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of contaminated personnel|Number of symptomatic staff by occupational category and service|Number of contaminated personnel with effective protection|comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodies""}"
"640","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","BEST-RCT","NCT04305106","QLEmer","Drug: Bevacizumab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04305106","Recruiting","2020-03-17","2020-07-31","{""locations"":""Qilu Hospital of Shandong University, Jinan, Shandong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""140"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The time from randomization to clinical improvement""}"
"641","Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study","CIPOLLINI","NCT04359459","CIPOLLINI","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359459","Not yet recruiting","2020-06-01","2022-06-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Nasal epithelial transcriptional response to SARS-CoV2|ACE2-AngII system""}"
"642","Implications of Covid-19 on the Lifestyle Changes","","NCT04423978","ICOLS_CovidStyle","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04423978","Completed","2020-05-04","2020-06-15","{""locations"":""Elisa Mazzini, Reggio Emilia, Italy"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""1826"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The ratio of individuals living in the province of Reggio Emilia who completed the survey|The ratio of individuals who changed the lifestyles during the lock-down|The number and the type of support services used the most by participants""}"
"643","NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","HOPE","NCT04315987","HOPE","Biological: NestaCell®|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04315987","Not yet recruiting","2020-06-01","2020-08-01","{""locations"":""Hospital Vera Cruz, Campinas, S\u00e3o Paulo, Brazil|Hospital de Barueri, S\u00e3o Paulo, Brazil|IncCOR, S\u00e3o Paulo, Brazil|UNIFESP, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Clinical Condition|Rate of mortality within 10-days|Change of Clinical symptoms - respiratory rate|Hypoxia|PaO2 \/ FiO2 ratio|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group|Complete blood count, cardiac, hepatic and renal profiles;""}"
"644","To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)","","NCT04541485","DW_DWJ1516101_Phillipphines","Drug: DWRX2003|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04541485","Not yet recruiting","2020-10-06","2021-01-29","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events|Time to SARS-CoV-2 eradication (days) by Nasopharyngeal specimen|Rate of SARS-CoV-2 eradication by Nasopharyngeal specimen""}"
"645","Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients","","NCT04713176","DW_DWJ1248302","Drug: DWJ1248 with Remdesivir|Drug: Placebo with Remdesivir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04713176","Recruiting","2021-02-02","2021-06-30","{""locations"":""National Medical Center, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1022"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of mortality or ECMO patients|Recovery days|Desirable of Outcome Ranking (DOOR)|Hospitalization period|Rate of Mortality""}"
"646","Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure","","NCT04244591","Glucocorticoid COVID-19","Drug: methylprednisolone therapy|Other: Standard care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04244591","Completed","2020-01-26","2020-04-13","{""locations"":""Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Lower Murray lung injury score|The difference of PaO2\/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality""}"
"647","A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19","","NCT04639466","20447","Drug: Placebo Administration|Biological: Vaccine Therapy","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04639466","Recruiting","2020-12-11","2022-11-10","{""locations"":""City of Hope Medical Center, Duarte, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""129"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of adverse events|Humoral immunity|Level of SARS-CoV-2-specfic neutralizing antibodies|Th1 vs Th2 polarization|SARS-CoV-2- antigen specific T cell responses to the COH04S1 vaccine|Evolution of activated\/cycling and memory phenotype markers on the surface of SARS-CoV-2- specific T cells elicited as a result of the COH04S1 vaccination|Comparison of one vaccine injection vs two vaccine injections for immunogenicity|Comparison of one vaccine injection vs two vaccine injections for adverse events""}"
"648","Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)","","NCT04498325","202009065","Drug: NT-I7|Drug: Placebo|Procedure: Blood for research purposes|Procedure: Blood for pharmacokinetic samples|Procedure: Nasopharyngeal, oropharyngeal, or saliva swab|Procedure: Blood for anti-drug antibody (ADA)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04498325","Not yet recruiting","2021-02-28","2021-11-30","{""locations"":""Saint Louis University Hospital, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safe and tolerable dose of NT-I7 (Phase I only)|Percent change in absolute lymphocyte count (ALC)|Change in SARS-CoV-2 viral load|COVID-19 Symptom severity as measured by WHO Ordinal Scale for clinical improvement|Time to resolution of COVID-19 symptoms|Incidence of treatment-emergent adverse events|Number of participants by PCR result status (positive or negative)""}"
"649","Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial","","NCT04382625","18244","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04382625","Withdrawn","2020-10-01","2022-06-01","{""locations"":""Kootenai Health, Coeur d'Alene, Idaho, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from Baseline Oxygenation on Day 1 to Day 5|Change from Baseline Oxygenation at Day 5|Intensive Care length of stay|Required Mechanical Ventilation|Required Oxygen supplementation|Hospitalization length of Stay|Mortality|Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia|Cardiac Arrhythmia - Ventricular Tachycardia|Cardiac Arrhythmia - Lengthening QTc""}"
"650","Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives","","NCT04357535","2210061","Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357535","Completed","2020-05-10","2020-08-01","{""locations"":""King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""314"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity of COVID-19 Infection|Degree of severity of respiratory disease|Septic shock as defined by sepsis-3 criteria""}"
"651","A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine","","NCT04522089","ADPCT20011X","Biological: AdimrSC-2f","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04522089","Recruiting","2020-08-24","2021-03-20","{""locations"":""National Taiwan University Hospital, Taipei, Taiwan"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""70"",""age"":""20 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""The solicited adverse events (SoAEs)|Incidence of abnormal laboratory tests results|Safety of AdimrSC-2f vaccine: AE|Immunogenicity""}"
"652","Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19","","NCT04551547","PRO-nCOV-1003","Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04551547","Recruiting","2020-10-31","2021-09-01","{""locations"":""Zanhuang county Center for Disease Control and Prevention, Shijiazhuang, Hebei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""552"",""age"":""3 Years to 17 Years \u00a0 (Child)"",""outcome_measures"":""Safety index-incidence of adverse reactions|Immunogenicity index-seroconversion rates of neutralizing antibody|Safety index-incidence of serious adverse events|Immunogenicity index-seropositive rates of neutralizing antibody|Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody|Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody""}"
"653","MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients","","NCT04646603","MRG2020","Drug: MRG-001|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04646603","Recruiting","2021-01-28","2021-06-05","{""locations"":""ICON Early Phase Services, San Antonio, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Phase I|Phase IIa|Change in percentages from baseline in circulating white blood cell subpopulations|Change in Plerixafor concentration (ng\/ml) from baseline in blood|Change in Tacrolimus concentration (ng\/ml) from baseline in blood|Change from baseline in ALT, AST|Change in percentages from baseline in circulating stem cells and immune cells|Change from baseline in platelets|Change from baseline in total Bilirubin|Change from baseline in LDH|Change from baseline in blood urea nitrogen (BUN)|Change from baseline in glomerular filtration rate (GFR)|Change from baseline in hemoglobin""}"
"654","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVACTA","NCT04320615","WA42380|2020-001154-22","Drug: Tocilizumab (TCZ)|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04320615","Completed","2020-04-03","2020-07-28","{""locations"":""University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital\/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sj\u00e6llands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|H\u00f4pital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Uniklinik K\u00f6ln, K\u00f6ln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St George's Clinical Research Facility, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of <\/= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Time to Recovery|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ""}"
"655","A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19","","NCT04487210","CT-COV-11","Biological: MVC-COV1901","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04487210","Active, not recruiting","2020-10-07","2021-06-30","{""locations"":""National Taiwan University Hospital, Taipei, Taiwan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""45"",""age"":""20 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Safety of MVC-COV1901|Immunogenicity (neutralizing antibody titers and antigen specific binding antibody titers)|Immunogenicity (antigen specific cellular immune responses)""}"
"656","Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.","","NCT04407130","PR-20039","Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04407130","Completed","2020-06-16","2020-11-20","{""locations"":""Icddr,B, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""72"",""age"":""40 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virological clearance|Remission of fever|Remission of cough|Patients requiring oxygen|Patients failing to maintain SpO2 >93% despite oxygenation|Number of days on oxygen support|Duration of hospitalization|All causes of mortality""}"
"657","A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia","EMPACTA","NCT04372186","ML42528","Drug: Placebo|Drug: Tocilizumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04372186","Recruiting","2020-05-14","2021-12-01","{""locations"":""Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|El Centro Regional Medical Center, El Centro, California, United States|Harper University Hospital, Fountain Valley, California, United States|eStudySite, La Mesa, California, United States|Highland Hospital Oakland, Oakland, California, United States|St. Joseph'S Hospital, Orange, California, United States|San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States|Howard University, Washington, District of Columbia, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|Miami Veterans Administration Healthcare System - NAVREF, Miami, Florida, United States|University of Miami Pulmonary, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St. Lukes Boise Medical Center, Boise, Idaho, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Ochsner Clinic, New Orleans, Louisiana, United States|LSU-Shreveport, Shreveport, Louisiana, United States|Holy Cross Germantown Hospital, Germantown, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai Grace Hospital, Detroit, Michigan, United States|Optum Health Care, Las Vegas, Nevada, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|St. Barnabas Hospital, Bronx, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Flushing Hospital, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|NYC Health and Hospitals Queens, Jamaica, New York, United States|Harlem Hospital, New York, New York, United States|Canton-Potsdam Hospital, Potsdam, New York, United States|Novant Health Presbyterian Medical Center (Presbyterian Hospital), Charlotte, North Carolina, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Novant Health Rowan Medical Center, Salisbury, North Carolina, United States|Novant Health Foryth Medical Center, Winston-Salem, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|JPS Health Network, Fort Worth, Texas, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|McAllen Medical Center, McAllen, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Sentara Medical Group, Virginia Beach, Virginia, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Hospital Unversitario Walter Cantidio, Fortaleza, CE, Brazil|Hospital Agamenon Magalh\u00e3es, Recife, PE, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Centro Multidisciplinar de Estudos Cl\u00ednicos CEMEC FMABC, Sao Bernardo Do Campo, SP, Brazil|BR Trials - Pesquisa Cl\u00ednica, Sao Paulo, SP, Brazil|Escola Paulista de Medicina Da Universidade Federal de S\u00e3o Paulo - EPMUNIFESP, Sao Paulo, SP, Brazil|Hospital Heli\u00f3polis, Sao Paulo, SP, Brazil|Aga Khan University Hospital, Nairobi, Kenya|Organismo Publico Descentralizado Hospital Juarez de Mexico, Ciudad De M\u00e9xico, Mexico|Hospital General de Culiacan, Culiacan, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Hospital Militar Central, Jesus Maria, Peru|Hospital Nacional Sergio E. Bernales, Lima, Peru|Hospital Nacional Arzobispo Loayza; Oncology, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Hospital Nacional Hipolito; Unanue, Lima, Peru|Hospital Maria Auxiliadora, Lima, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|University of the Free State, Bloemfontein, South Africa|George Provincial Hospital, George, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Milpark Hospital, Parktown West, South Africa|University of Stellenbosch; Respiratory Research, Parow, South Africa|Phoenix Pharma, Port Elizabeth, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""379"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or \""Ready for Discharge\"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >\/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and\/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)|Quality of Life (QoL) as Reported by the Short Form 36 Question Health Survey Version 2 (SF-36v2)|QoL as Reported by the Euro-QoL-5D-5-L (EQ-5D-5L) Instrument|QoL as Reported by Living with Idiopathic Pulmonary Fibrosis Symptoms Questionnaire-Modified (L-IPF-M)|QoL as Reported by the Montreal Cognitive Assessment (MoCA)|Lung Texture as Measured by High-Resolution Computed Tomography (HRCT) Scan of Chest|Prevalence and Incidence of COVID-19 Antibodies""}"
"658","The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","","NCT04659239","20200404","Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04659239","Enrolling by invitation","2021-01-28","2022-07-01","{""locations"":""CEMEC Pesquisa Clinica, S\u00e3o Bernardo do Campo, S\u00e3o Paulo, Brazil|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""34020"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of COVID-19 cases after two-doses of vaccination|The incidence of solicited AEs.|The incidence of COVID-19 cases after at least one dose of immunization.|The Geometric Mean Titer (GMT) of neutralizing antibody|The Geometric Mean Titer (GMT) of IgG antibody|The positive rates of neutralizing antibody|The positive rates of IgG antibody|The seroconversion rates of neutralizing antibody|The seroconversion rates of IgG antibody|Specific T cells with ELISPOT assay|The incidence of AEs|The incidence of SAEs|The occurrence of Antibody Dependent Enhancement (ADE)\/ Vaccine Enhanced Disease(VED)""}"
"659","Stopping ACE-inhibitors in COVID-19","ACEI-COVID","NCT04353596","EudraCT 2020-001206-35","Drug: ACE inhibitor, angiotensin receptor blocker","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04353596","Completed","2020-04-20","2021-02-24","{""locations"":""Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Medical University of Graz, Graz, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Klinikum Lienz, Lienz, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|University Hospital Aachen, Aachen, Germany|University Hospital Augsburg, Augsburg, Germany|Asklepios Stadtklinik Bad T\u00f6lz, Bad T\u00f6lz, Germany|Klinikum Dachau, Dachau, Germany|University Hospital Erlangen, Erlangen, Germany|University Hospital Essen, Essen, Germany|University of Freiburg, Freiburg, Germany|Klinikum Memmingen, Memmingen, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|M\u00fcnchen Klinik Bogenhausen und Schwabing, Munich, Germany|Rotkreuzklinikum Munich, Munich, Germany|Krankenhaus M\u00fchldorf, M\u00fchldorf, Germany|Klinikum Rosenheim, Rosenheim, Germany|Krankenhaus Weiden, Weiden, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""216"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death|Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death|Mean and area under the curve of Sequential Organ Failure Assessment (SOFA) Score|Rates of non-invasive ventilation|Rates of renal replacement therapies|Change of viral burden|Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)|Number of patients with systolic\/diastolic blood pressure > 180\/120 mmHg|Hospitalisation due to cardiac decompensation|Rates of mechanical ventilation|Rates of clonal hematopoiesis of indeterminate potential (CHIP)""}"
"660","Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked","CARDOVID","NCT04455347","HJ-20-CARDOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04455347","Recruiting","2020-06-15","2022-06-01","{""locations"":""H\u00f4pital Necker, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""up to 20 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Imaging data at Baseline|Imagine data at Follow-up""}"
"661","Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","","NCT04412538","20200401","Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Placebo on a 0- and 28-day schedule|Biological: Placebo on a 0- and 14-day schedule","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04412538","Recruiting","2020-05-15","2021-09-01","{""locations"":""West China Second University Hospital, Sichuan University \/ West China women's and children's Hospital, Chengdu, Sichuan, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""942"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Adverse reactions\/events rate|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Serious adverse events|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)""}"
"662","Study of LAU-7b for the Treatment of COVID-19 Disease in Adults","RESOLUTION","NCT04417257","LAU-20-01","Drug: LAU-7b|Drug: Placebo oral capsule","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04417257","Recruiting","2020-06-29","2021-05-30","{""locations"":""Chandler Regional Medical Center \/ Mercy Gilbert Medical Center, Chandler, Arizona, United States|Baptist Medical Center Beaches, Jacksonville Beach, Florida, United States|St Lukes Hospital, Boise, Idaho, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Anne Arundel Medical Center, 2001 Medical Parkway, Belcher Pavillion, Annapolis, Maryland, United States|Wayne State University, Harper University Hospital and Detroit Receiving Hospital, Detroit, Michigan, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Centre d'\u00e9tudes cliniques CIUSS SLJ, H\u00f4pital Chicoutimi, Chicoutimi, Quebec, Canada|CIUSSSS de l'Est-de-l'Ile-de-Montr\u00e9al, H\u00f4pital Maisonneuve-Rosemont, Montr\u00e9al, Quebec, Canada|Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Quebec, Canada|Jewish General Hospital, Montr\u00e9al, Quebec, Canada|McGill University Health Centre, Montr\u00e9al, Quebec, Canada|CISSS Ds Laurentides, Saint-J\u00e9r\u00f4me, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients alive and free of respiratory failure (Ordinal Scale scores 1-4)|The safety of LAU-7b therapy will be assessed through the monitoring of treatment emergent adverse events, compared to placebo|Health status of the patient on the 7-point Ordinal Scale compared to placebo|Rate of all-causes death, depicted by a change from baseline in the Ordinal Scale score to category 7|Rate of COVID-19 disease-related aggravation, depicted by a change from baseline in the ordinal scale score of at least one category, compared to placebo|Rate of COVID-19 disease-related transfer to intensive care unit, depicted by a change from baseline in the ordinal scale score to categories 5 or 6, compared to placebo|Rate of COVID-19 disease-related transfer to mechanical ventilation, depicted by a change from baseline in the ordinal scale score to category 6, compared to placebo|Mean change from baseline of the ordinal scale patient health status as a function of assessment time, compared to placebo|Time to an improvement of one category on the ordinal scale patient health status, compared to placebo|Time to recovery, defined here as the time to reach categories 2 or 1 on the ordinal scale patient health status (first occurrence if more than once), compared to placebo|Time to mechanical ventilation, defined here as time to reach category 6 on the ordinal scale patient health status, compared to placebo|Time to death, defined here as a time to reach category 7 on the ordinal scale patient health status, censored to Day 29 if it happens later than Day 29, compared to placebo|Duration of hospitalization (days) within the study period Days 1-29, compared to placebo|Time to attain an undetectable viral load through oropharyngeal swabs done at specified times, compared to placebo|The change from baseline in the score obtained on the EQ-5D-5L quality-of-life survey""}"
"663","Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19","SENTAD-COVID","NCT04473170","CT.001.1.0.SENTAD-COVID","Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|Drug: COVID-19 standard care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04473170","Completed","2020-04-04","2020-07-14","{""locations"":""Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""146"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse reactions incidence.|Rate of mortality within 28-days.|Time to clinical improvement on a seven-category ordinal scale.|Assessment of the immune response profile.|Assessment of acute-phase serum markers.""}"
"664","Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19","NORCOVID","NCT04534478","2020-003651-15","Drug: Prednisone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04534478","Not yet recruiting","2020-09-07","2021-12-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in pulmonary diffusion.""}"
"665","A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia","MARIPOSA","NCT04363736","CA42481","Drug: Tociliuzumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363736","Completed","2020-05-05","2020-08-12","{""locations"":""Mayo Clinic - Arizona, Phoenix, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|LAC + USC Medical Center, Los Angeles, California, United States|USC Keck Medical Center of USC, Los Angeles, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Renown Institute for Heart & Vascular Health, Reno, Nevada, United States|St Joseph's Regional Medical Center, Wayne, New Jersey, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg\/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg\/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg\/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg\/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg\/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg\/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg\/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg\/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection""}"
"666","A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia","COVASTIL","NCT04386616","GA42469|2020-002713-17","Drug: MSTT1041A|Drug: MSTT1041A-matched Placebo|Drug: UTTR1147A|Drug: UTTR1147A-matched Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04386616","Completed","2020-06-02","2021-02-12","{""locations"":""University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|eStudySite, La Mesa, California, United States|Alta Bates Summit Medical Center, Oakland, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Denver Health Medical Center, Denver, Colorado, United States|Bay Pines VA Medical Center - NAVREF, Bay Pines, Florida, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|Northside Hospital; Peachtree Dunwoody Medical Center, Atlanta, Georgia, United States|WellStar Research Institute, Marietta, Georgia, United States|University Of Iowa Hospitals And Clinics, Coralville, Iowa, United States|DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS, Alexandria, Louisiana, United States|MedPharmics, Metairie, Louisiana, United States|Southeast Louisiana Veterans Health Care System - NAVREF, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Lincoln Medical Mental Health Center, Bronx, New York, United States|Jacobi Medical Center; Lewis M. Fraad Department of Pediatrics, Bronx, New York, United States|Staten Island University Hospital; Department of Pharmacy, Staten Island, New York, United States|Cape Fear Valley Health System, Fayetteville, North Carolina, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Providence Portland Medical Center; Investigational Drug Services\/Regional Research, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple Uni Medical Center; Pulmonary & Critical Care Medicine, Philadelphia, Pennsylvania, United States|Parkland Health & Hospital System, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|MultiCare Institute for Research and Innovation; Clinic\/Outpatient Facility, Tacoma, Washington, United States|Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ, Rio de Janeiro, RJ, Brazil|Centro De Estudos Pesquisas em Molestias Infecciosas - CPCLIN, Natal, RN, Brazil|Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Instituto do Cora\u00e7\u00e3o - HCFMUSP, Sao Paulo, SP, Brazil|Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Instituto Nacional De Enfermedades Respiratorias INER National Institute of Respiratory Diseases, Mexico, Mexico|Hospital General de Tijuana, Tijuana, Mexico|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario A Coru\u00f1a, Coruna, LA Coru\u00f1a, Spain|Hospital San Pedro, Logro\u00f1o, LA Rioja, Spain|Hospital Costa del Sol; Servicio de Oncologia, Marbella, Malaga, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Spain|Hospital Clinico Universitario Valladolid, Valladolid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""410"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Recovery, Defined as the Time to a Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First)|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Hospital Discharge or \""Ready for Discharge\""|Duration of Supplemental Oxygen|Percentage of Participants Alive and Free of Respiratory Failure|Clinical Status, Assessed Using a 7-Category Ordinal Scale|Incidence of Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Ventilator-Free Days|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)|Mortality Rate at Days 14 and 28|Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of \u22642 Maintained for 24 hours|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)|Change from Baseline in Respiratory Rate|Change from Baseline in Pulse Rate|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Body Temperature|Change from Baseline in Oxygen Saturation|Change from Baseline in RR, QRS, PR, QT, and QTcF Intervals, as Measured by Electrocardiogram (ECG)|Change from Baseline in Heart Rate, as Measured by Electrocardiogram (ECG)|Number of Participants with Clinical Laboratory Test Abnormalities in Hematology Parameters|Number of Participants with Clinical Laboratory Test Abnormalities in Blood Chemistry Parameters|Serum Concentration of UTTR1147A at Specified Timepoints|Serum Concentration of MSTT1041A at Specified Timepoints|Prevalence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study""}"
"667","Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","CLARITY","NCT04394117","11052020","Drug: Angiotensin Receptor Blockers|Other: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04394117","Recruiting","2020-06-19","2021-08-30","{""locations"":""Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal prince Alfred Virtual Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|The Sutherland Hospital, Caringbah, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Northern Health, Epping, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Alfred Health, Melbourne, Victoria, Australia|Western Health, St Albans, Victoria, Australia|Lok Nayak Jai Prakash, Delhi, India|Christian Hospital, Nabarangpur, India|All India Institute of Medical Science, Raipur, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""7-Point National Institute of Health Clinical Health Score|Mortality|Intensive Care Unit Admission|Intensive Care Unit Number of Days|Respiratory Failure|Dialysis Requirement|Hospitalisation Days|Ventilator-Free Days|Dialysis Days|Acute Kidney Injury|Hypotension Requiring Vasopressors""}"
"668","Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19","","NCT04435808","20-206","Drug: Hydroxychloroquine","Interventional","Has Results","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04435808","Terminated","2020-04-14","2020-07-15","{""locations"":""University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 Infection|Symptomatic vs. Asymptomatic Infection With SARS-CoV-2|Occupational Health Exposure|Impact of Hydroxychloroquine Use on Need for Hospitalization With SARS-CoV-2 Infection|Impact of Hydroxychloroquine Use on Need for ICU Care With SARS-CoV-2 Infection|Adverse Effect Profile of Hydroxychloroquine|Seroconversion Following SARS-CoV-2 Infection|Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates""}"
"669","Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years","","NCT04470609","20200402","Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Placebo on a 0- and 28-day schedule","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04470609","Enrolling by invitation","2020-07-10","2021-11-01","{""locations"":""West China Second University Hospital, Sichuan University \/ West China women's and children's Hospital, Chengdu, Sichuan, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""471"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse reactions\/events rate|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIb|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIb|Serious adverse events|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ib|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ib|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ib|Level of IgG antibodies against SARS-CoV-2 Phase Ib|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIb|Level of IgG antibodies against SARS-CoV-2 Phase IIb""}"
"670","Convalescent Plasma for Early Treatment of COVID-19","","NCT04390503","AAAT0052","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04390503","Recruiting","2021-03-01","2022-04-01","{""locations"":""National Institute of Infectious Diseases Evandro Chagas (INI), Rio de Janeiro, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of Severe Disease|Rate of measurable anti-SARS-CoV-2 titers|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA""}"
"671","Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)","","NCT04383574","PRO-nCOV-1002","Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04383574","Active, not recruiting","2020-05-22","2021-05-30","{""locations"":""Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""422"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety index-incidence of adverse reactions|Immunogenicity index-seroconversion rates of neutralizing antibody|Safety index-incidence of serious adverse events|Immunogenicity index-seropositive rates of neutralizing antibody|Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody|Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody""}"
"672","Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)","","NCT04352608","PRO-nCOV-1001","Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of placebo at the emergency vaccination schedule|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of placebo at the routine vaccination schedule","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04352608","Active, not recruiting","2020-04-16","2020-12-13","{""locations"":""Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""744"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Safety indexes of adverse reactions|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule \uff08day 0,14\uff09|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)|Occurrence of abnormal changes of laboratory safety examinations (hemoglobin,WBCs, platelets, ALT, AST, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte)|Safety indexes of serious adverse events (SAEs\uff09|Immunogenicity indexes of neutralizing-antibody seroconversion rates|Immunogenicity indexes of IgG antibody seropositivity rates|Immunogenicity indexes IgM antibody seropositivity rates|Immunogenicity indexes of GMT of neutralizing-antibody|Immunogenicity indexes of GMR of neutralizing-antibody""}"
"673","TXA and Corona Virus 2019 (COVID19) in Outpatients","TCOutpatient","NCT04338074","TXACOVID1","Drug: Tranexamic acid tablets|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04338074","Recruiting","2020-06-01","2021-12-31","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization""}"
"674","Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)","IPCO","NCT04712344","UKER-COV2-01","Biological: COVID-19 convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04712344","Recruiting","2021-01-18","2021-09-01","{""locations"":""University Hospital Erlangen, Erlangen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""58"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SOFA score from Baseline Visit|Assessment of impact of immune therapy with COVID-19 convalescent plasma on markers for ARDS due to severe COVID-19 infection|Assessment of impact of immune therapy with COVID-19 convalescent plasma on short-term all-cause mortality|Assessment of impact of immune therapy with COVID-19 convalescent plasma on oxygen supply in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on oxygen demand in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on Duration of Oxygen supply in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on PEEP in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on FiO2 in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on driving pressure in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on Duration of invasive mechanical Ventilation in patients with ARDS due to severe COVID-19""}"
"675","Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19)","VOC-COVID","NCT04379154","2020_0060","Device: Volatile Organic Compounds analysis","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04379154","Recruiting","2020-04-14","2021-02-01","{""locations"":""H\u00f4pital Foch, Suresnes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Profiles of volatile organic compounds (VOCs) in exhaled air between 2 health conditions|Profiles of volatile organic compounds (VOCs) in exhaled air on 1 health condition|Profiles of volatile organic compounds (VOCs) in exhaled air between 2 periods""}"
"676","A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home","","NCT04455815","CRUKD/20/002","Drug: Camostat","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04455815","Recruiting","2020-09-25","2021-08-31","{""locations"":""The University of Edinburgh, Edinburgh, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|Preston Lantern Centre, Preston, United Kingdom|Clarence Medical Centre, Rhyl, United Kingdom|Velindre Cancer Centre, Wales, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""389"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants who require hospital admission and require supplemental oxygen.|Rate of COVID-19 related hospital admission in patients with SARS-CoV-2 infection.|Number of supplementary oxygen-free days at 28 days (from randomisation).|Number of ventilator-free days at 28 days (from randomisation).|To evaluate overall mortality.|Time to worst point on the scale or deterioration of two points or more (from randomisation) on a 9-point category ordinal scale.""}"
"677","COVID SAFE: COVID-19 Screening Assessment for Exposure","COVID SAFE","NCT04508777","843565-OBS","Behavioral: Saliva-based testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04508777","Enrolling by invitation","2020-09-09","2021-03-01","{""locations"":""Penn Medicine, Philadelphia, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Test compliance""}"
"678","PEP Flute-selfcare in COVID-19","PEP-CoV","NCT04530435","0211-00023B","Device: PEP flute","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04530435","Active, not recruiting","2020-10-06","2021-04-30","{""locations"":""Research Unit for Dietary Studies at the Parker Institute, Bispebjerg and Frederiksberg Hospitals, Frederiksberg, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Self-reported CAT-score (COPD Assessment Test)|Hospital admissions|Use of antibiotics""}"
"679","Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients","","NCT04649840","IBCE_COVID19_Immunity","Diagnostic Test: Humoral and cellular immunity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649840","Enrolling by invitation","2020-10-01","2021-12-31","{""locations"":""Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The dynamics of humoral and cellular immunity""}"
"680","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","","NCT04273581","20200214-COVID-19-S-T","Drug: placebo|Drug: Thalidomide","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04273581","Not yet recruiting","2020-02-18","2020-05-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of \u2264 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-\u03b1, IL-1\u03b2, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1\u03b1 and other cytokine expression levels before and after treatment""}"
"681","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","","NCT04273529","20200214-COVID-19-M-T","Drug: thalidomide|Drug: placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04273529","Not yet recruiting","2020-02-20","2020-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence""}"
"682","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","COVID-19","NCT04344457","HIZ-PRC-COVID-19","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04344457","Recruiting","2020-04-16","2020-09-30","{""locations"":""Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement""}"
"683","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome","","NCT04346017","CHUB-IL6-COVID-19","Diagnostic Test: Cytokines dosage|Diagnostic Test: Complement dosage","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346017","Recruiting","2020-03-20","2020-12-01","{""locations"":""CHU Brugmann, Brussels, Belgium"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""IL6 concentration|IL6 concentration change from baseline value|Complement parameters|Complement parameters change from baseline values|Inflammatory cytokines baseline concentrations|Inflammatory cytokines change from baseline values|Concentration of markers of macrophage activation|Markers of macrophage activation change from baseline values""}"
"684","Effect of COVID-19 Pandemic on Pediatric Cancer Care","","NCT04374838","COVID-19 and Pediatric Cancer","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374838","Recruiting","2020-05-15","2021-09-01","{""locations"":""South Egypt Cancer Institute, Assiut University, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""20"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""pediatric cancer care pattern during COVID 19 pandemic""}"
"685","A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia","REMDACTA","NCT04409262","WA42511|2020-002275-34","Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04409262","Completed","2020-06-16","2021-03-08","{""locations"":""Valleywise Health Medical Center, Phoenix, Arizona, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Hoag Hospital Irvine, Irvine, California, United States|Providence St. John's Health Center, Santa Monica, California, United States|Yale University School of Medicine; HIV Clinical Trials Program, New Haven, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St Luke's Health System; Rheumatology Research, Boise, Idaho, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center\/Ochsner, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Medical Center, Novi, Michigan, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Wyckoff Heights Medical Center, Staten Island, New York, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Providence Saint Vincent's Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health-Midlands, Columbia, South Carolina, United States|The Liver Institute at Methodist Dallas, Arlington, Texas, United States|Baylor Scott and White Medical Center - College Station, College Station, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor Scott & White Medical Center - Irving, Irving, Texas, United States|Baylor Scott & White Hospital - Plano, Plano, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|The Providence Regional Medical Center Everett, Everett, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital Nossa Senhora das Gra\u00e7as; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil|Instituto de Pesquisa Clinica Evandro Chagas - IPEC FIOCRUZ, Rio de Janeiro, RJ, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|CEMEC - Centro Multidisciplinar de Estudos Cl\u00ednicos, Sao Bernardo Do Campo, SP, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Instituto de Infectologia Emilio Ribas, Sao Paulo, SP, Brazil|Instituto do Cora\u00e7\u00e3o - HCFMUSP, Sao Paulo, SP, Brazil|Medsi Clinic, Moscow, Adygeja, Russian Federation|Clinical Infectious Diseases Hospital #1; Chair of Infectious Disease and Epidemiology, Moskva, Moskovskaja Oblast, Russian Federation|City Clinical Hospital #15, Moscow, Russian Federation|City Clinical Hospital # 52, Moscow, Russian Federation|Pokrovsky City Hosptial, St Petersburg, Russian Federation|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Principe de Asturias; Medicina Interna - Servicio de Enfermedades Infecciosas, Alcala de Henares, Madrid, Spain|Hospital Universitario HM Torrelodones, Torrelodones, Madrid, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""649"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Time from randomization to hospital discharge or \""ready for discharge\"" up to Day 28|Time to mechanical ventilation or death up to Day 28, defined as the time from randomization to the first occurrence of mechanical ventilation or death (whichever occurs first)|Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status up to Day 28|Clinical status as assessed by the investigator using a 7-category ordinal scale of clinical status on Days 7, 14, 21, 28, and 60|Proportion of participants requiring initiation of mechanical ventilation post-baseline up to Day 28 and Day 60 (participants who do not require mechanical ventilation at baseline)|Proportion of participants who are alive and free of respiratory failure at (participants requiring mechanical ventilation at baseline) at Day 28 and Day 60|Duration of mechanical ventilation (participants requiring mechanical ventilation at baseline) up to Day 28|Time to death up to Days 28 and 60|Mortality on Days 14, 28, and 60 (proportions at specified timepoints)|Time to recovery up to Day 28, defined as the time from randomization to the time when a category of 2 on the 7-category ordinal scale (non-ICU hospital ward or \""ready for hospital ward\"" not requiring supplemental oxygen) or better is observed|Proportion of participants who are discharged or \""ready for discharge\"" up to Day 28|Proportion of participants who require initiation of mechanical ventilation post-baseline or die up to Day 28""}"
"686","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19","","NCT04343742","Genesis AKCOVID- FG-1","Drug: chlorine dioxide 3000 ppm","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04343742","Recruiting","2020-04-01","2020-06-01","{""locations"":""Hospital Fhsj, Bogota, Cundinamarca, Colombia|San Carlos Hospital, Bogota, Cundinamarca, Colombia"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""negative testing of covid19""}"
"687","Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic","PedCan-COVID","NCT04404244","FMASU P25a/ 2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04404244","Recruiting","2020-01-01","2021-06-01","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Incidence of COVID-19 among children with cancer|Families training""}"
"688","Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection","","NCT04374032","EN-COVCS-01","Drug: metenkefalin + tridecactide|Drug: The standard of care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04374032","Completed","2020-05-01","2020-11-03","{""locations"":""Clinical Center University of Sarajevo, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Hospital Travnik, Travnik, Bosnia and Herzegovina|Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to onset of change in the patient's clinical condition|Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE|Length of in-hospital stay|Survival rate|Intubation rate|Proinflammatory markers levels""}"
"689","Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital","CovidRegOUH","NCT04345536","CovidRegOUH","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04345536","Recruiting","2020-03-15","2022-05-01","{""locations"":""Oslo University Hospital, Oslo, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality|Severe disease""}"
"690","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","ConCoVid-19","NCT04342182","NL73489.078.20","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04342182","Active, not recruiting","2020-04-08","2021-07-31","{""locations"":""Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|NoordWest Ziekenhuisgroep, Alkmaar, Netherlands|Onze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini Hospital, Groningen, Netherlands|Spaarna Gasthuis, Haarlem, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|ZorgSaam Hospital, Terneuzen, Netherlands|Bernhoven Hospital, Uden, Netherlands|VieCuri, Venlo, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""426"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 300ml convP therapy on hospital days|Impact of 300ml convP on weaning from oxygen therapy|Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways|Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer|Safety of convP therapy|Change of the 8-point WHO COVID19 disease severity scale on day 15|Change of the 8-point WHO COVID19 disease severity scale on day 30|Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80.|Impact of plasma therapy on risk of long-term structural lung damage and lung function""}"
"691","A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients","","NCT04347174","CRSC20004","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04347174","Completed","2020-04-30","2020-08-21","{""locations"":""All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India|All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|All lndia Institute of Medical Science, Delhi, Delhi, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)|Sequential Organ Failure Assessment (SOFA) scores|Incidence of AE \/ SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time (in days) from treatment initiation to death|All-cause mortality""}"
"692","Implementation of Physiotherapy on COVID-19 Patients in ICU","PHYSIO-COVID","NCT04347070","RECHMPL20_0175","Other: Phsyiotherapy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347070","Active, not recruiting","2017-04-01","2022-12-01","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time of physiotherapy|Type of physiotherapy implemented""}"
"693","Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients","","NCT04409522","IR.BMSU.REC.1399.039","Drug: Melatonin|Drug: The usual treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04409522","Recruiting","2020-05-12","2020-09-25","{""locations"":""Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""55"",""age"":""16 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Melatonin|Inflammatory cytokines|C-reactive protein (CRP)|Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route""}"
"694","COVID-19 Recovered Volunteer Research Participant Pool Registry","","NCT04359602","20-000625","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359602","Recruiting","2020-04-08","2042-04-20","{""locations"":""Ronald Reagan UCLA Medical Center, Los Angeles, California, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serological testing of COVID patients|Immune response""}"
"695","Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise","","NCT04472494","IM101-873|U1111-1250-4217","Biological: Abatacept|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04472494","Recruiting","2020-08-24","2021-01-14","{""locations"":""Norton Infectious Disease Institute, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Atlantic Health System, Morristown, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, Dallas, Texas, United States|Local Institution, Guaynabo, Puerto Rico|Local Institution, Monterrey Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""129"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants with composite end point of mechanical ventilation or death prior to or on Day 28|Change from baseline in the Ordinal 8-point Outcome Scale on Day 28|All-cause mortality on Day 28|Proportion of participants alive and free of respiratory failure on Day 28|Proportion of participants returned to room air by Day 28|Proportion of participants alive and discharged home by Day 28|Proportion of participants with Serious Adverse Events (SAEs)|Proportion of participants with serious infections""}"
"696","The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection","","NCT04360980","SBMU.IR.REC.165423","Drug: Colchicine Tablets","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04360980","Recruiting","2020-03-20","2021-11-30","{""locations"":""SBMU, Tehran, Iran, Islamic Republic of|Nooshin Dalili, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""CRPxN\/R ratio change|Clinical deterioration by the WHO definition|PCR Viral Load|CT severity involvement index|LDH change""}"
"697","Early Versus Delayed Intubation of Patients With COVID-19","EUDOCO","NCT04632043","32635, 13-10-2020","Other: Endotracheal intubation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04632043","Recruiting","2020-11-18","2021-06-01","{""locations"":""Evangelismos Hospital, Athens, Attiki, Greece"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time from onset of severe acute hypoxemic respiratory failure to intubation|Organ failure-free days|Need for continuous renal replacement therapy|Ventilator-free days|ICU-free days|Mortality|Number of severe post-intubation adverse events""}"
"698","Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors","","NCT04355884","COVID_LVD_SCREEN","Diagnostic Test: Standard 12-lead ECG, NT-proBNP, echocardiography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355884","Not yet recruiting","2020-04-20","2020-05-01","{""locations"":""The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""New-onset cardiac arrhythmia|Elevation of NT-proBNP|Left ventricular dysfunction""}"
"699","Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)","ANA-COVID-GEAS","NCT04443881","ANA-COVID-GEAS","Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret]","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04443881","Recruiting","2020-05-08","2021-03-01","{""locations"":""Hospital Clinic, Barcelona, Catalu\u00f1a, Spain|Hospital Universitario Vall d\u00b4Hebron, Barcelona, Catalu\u00f1a, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Galicia, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment success, defined as number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Time to mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Time to oxygen saturation normalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Stay in ICU and hospitalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Total mortality rate to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|Mortality 48 hours, 7 days, in ICU and hospital to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|Viral clearance \/ viral shedding to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|To assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.""}"
"700","Proctologic Practice and Covid-19","PROCTOLOCK","NCT04392245","1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04392245","Completed","2020-04-15","2020-04-26","{""locations"":""Gallo Gallo, Catanzaro, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1050"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Predictive power of respondents' and hospitals' demographics on the change of status of proctologic surgical and outpatient activities""}"
"701","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms","","NCT04393246","TACTIC-E","Drug: EDP1815|Drug: Dapagliflozin|Drug: Ambrisentan|Other: Standard of care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04393246","Recruiting","2020-07-03","2021-06-15","{""locations"":""Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1407"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: IL-6|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: ferritin|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: c-reactive protein (CRP)|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: D-dimer|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: neutrophil\/lymphocyte ratio|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: lactate dehydrogenase (LDH)|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Time to each of the individual endpoints of the composite primary outcome measure|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All-cause mortality at day 28|Time to clinical improvement""}"
"702","Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19","STRIKESARS","NCT04661527","STRIKESARS-COV|2020-001255-40","Drug: Sarilumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04661527","Recruiting","2020-04-22","2020-12-30","{""locations"":""Cl\u00ednica Universidad de Navarra, Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in a severity rating on a 7-point ordinal scale|Percentage of patients reporting each severity rating on a 7-point severity ordinal scale|Duration of mechanical ventilation|Evaluate the safety of sarilumab in patients with severe pneumonia caused by COVID 19|Number of ventilator free days in the first 28 days|Patients requiring mechanical ventilation|Change from baseline in PaO2\/FiO2 in patients on mechanical ventilation|Time to improvement in oxygenation for at least 48 hours|Time to saturation > 93.9% on room air|Time to resolution of fever without antipyretics for at least 48 hours (T\u00ba > 36.6\u00baC - axilla; > 37.2\u00baC -oral; > 37.8 -rectal or tympanic)|Changes from baseline in white blood cell count if available on V2, V3, V4, V5, and V6|Changes from baseline in hemoglobin levels if available on V2, V3, V4, V5, and V6|Changes from baseline in platelet cell count if available on V2, V3, V4, V5, and V|Changes from baseline in D-Dimer leves if available on V2, V3, V4, V5, and V6|Number of deaths due to any cause|Organ failure|Changes from baseline in C Reactive protein if available on V2, V3, V4, V5, and V6|Changes from baseline in Ferritin leves if available on V2, V3, V4, V5, and V6|Changes from baseline in Troponin leves if available on V2, V3, V4, V5, and V6|Changes from baseline in blood urea nitrogen leves if available on V2, V3, V4, V5, and V6|Changes from baseline in creatinine leves if available on V2, V3, V4, V5, and V6|Changes from baseline in blilirrubin leves if available on V2, V3, V4, V5, and V6|Changes from baseline in Aspartate transaminase (AST) leves if available on V2, V3, V4, V5, and V6|Changes from baseline in Alanine transaminase (ALT) leves if available on V2, V3, V4, V5, and V6""}"
"703","NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30","","NCT04365816","2020-A01120-39","Other: Interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365816","Completed","2020-04-30","2020-07-10","{""locations"":""Marie-France VAILLANT, Grenoble, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""403"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of food intake at 1 month after discharge from hospital for COVID|Weight variation during the infection|Clinical signs limiting food intake|Factors limiting food intake|Implemented nutritional strategy|Pre-existing chronic disorders|Covid-19 repercussions""}"
"704","Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19","","NCT04344925","137654","Device: Aerosol-reducing Mask|Device: Standard Mask","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344925","Terminated","2020-04-18","2020-11-27","{""locations"":""London Health Science Centre, London, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""21"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total Leak Volume of Non Invasive Ventilation Mask|Glasgow Coma Scale(GCS)|Respiratory Rate|Heart Rate|Metabolic Data: Blood Gas Measurements|Metabolic Data: Bicarbonate (HC03)|Metabolic Data: Partial Pressure of Carbon Dioxide (PaC02)|Metabolic Data: Partial Pressure of Oxygen (Pa02)""}"
"705","Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients","","NCT04573153","COVID-19-MCS","Drug: Hydroxychloroquine + Metabolic cofactor supplementation|Drug: Hydroxychloroquine + Sorbitol","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04573153","Recruiting","2020-09-21","2021-03-31","{""locations"":""University of Health Sciences Istanbul \u00dcmraniye Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The evaluation of clinical efficacy of the combination of metabolic cofactor supplementation and hydroxychloroquine|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Chest Tomography|ECG Measurement|Change of complete blood count from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in creatinine levels from baseline|Changes in D-dimer levels from baseline|Changes in ferritin levels from baseline|Changes in triglycerides levels from baseline|Changes in LDH levels from baseline""}"
"706","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","","NCT04436471","02-Gam-COVID-Vac-2020","Biological: Gam-COVID-Vac","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04436471","Completed","2020-06-17","2020-08-10","{""locations"":""Main military clinical hospital named after academician N. N. Burdenko, Moscow, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""38"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Changing ofantibody levels against the SARS-CoV-2 glycoprotein S in 42 days|Number of Participants With Adverse Events|Changing of of virus neutralizing antibody titer|Changing of antigen-specific cellular immunity level""}"
"707","Myocardial Damage in COVID-19","","NCT04312464","MD-COVID-19","Other: non","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04312464","Enrolling by invitation","2020-01-01","2020-03-18","{""locations"":""Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death""}"
"708","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","BCG-CORONA","NCT04328441","NL73249.041.20","Drug: BCG Vaccine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04328441","Active, not recruiting","2020-03-25","2021-04-30","{""locations"":""Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health Care Workers absenteeism|the cumulative incidence of documented COVID-19|the cumulative incidence of Hospital Admission due to documented COVID-19|the number of days of unplanned absenteeism, because of documented COVID-19|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented COVID-19|the cumulative incidence of Intensive Care Admission due to documented COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19|the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|the number of days of self-reported fever (\u226538 gr C)|the cumulative incidence of self-reported fever (\u226538 gr C)|the number of days of self-reported acute respiratory symptoms|the cumulative incidence of self-reported acute respiratory symptoms|the cumulative incidence of death for any reason|the cumulative incidence of Intensive Care Admission for any reason|the cumulative incidence of Hospital Admission for any reason|the cumulative incidence and magnitude of plasma\/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period""}"
"709","Assiut University Registry for ACS Patients During COVID-19 Pandemic","","NCT04691609","ACS in COVID-19 era","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04691609","Recruiting","2020-03-01","2023-09-01","{""locations"":""Samah ObiedAllah Fouad, Assiut, Resident, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""2500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Main Number, distribution and oucome of all ACS patients coming to Assiut heart hospital|To register pathological events occurring to all acute coronary syndrome patients coming to Assiut university heart hospital through one year during COVID- 19 pandemic""}"
"710","Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection","","NCT04458519","PROBCO|249512","Other: Probiorinse|Other: Saline solution","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04458519","Recruiting","2020-07-16","2021-04-30","{""locations"":""Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Change in severity of COVID-19 infection|Number of days with any symptom of anosmia|Maximal intensity attained in overall assessment of symptoms of COVID-19 infection as measured on Visual Analogue Scale (VAS).|Number of days where rescue medication is required""}"
"711","COVID-19 Among Healthcare Workers in Belgian Hospitals","COVHECBEHO","NCT04373889","Sciensano","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373889","Active, not recruiting","2020-04-22","2021-04-30","{""locations"":""Sciensano, Brussels, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""850"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of prevalence of COVID-19 infection among Belgian active hospital healthcare workers (HCW)|Change of seroprevalence of SARS-CoV-2 among Belgian active hospital HCW|Change in new cases (incidence) of COVID-19 among Belgian hospital HCW|Change in SARS-CoV-2 seroconversion among Belgian hospital HCW|Sensitivity and specificity of serological tests|Sensitivity and specificity of saliva sampling method (sampling with Oracol or equivalent)|Validate the nasal swab against the standard|Potential risk factors for the infection|The proportion of asymptomatic cases among new cases that develop during a period of 12 months""}"
"712","A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19","","NCT04425460","HS216C17(MRCT)","Drug: Favipiravir|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04425460","Not yet recruiting","2020-06-01","2020-09-01","{""locations"":""The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Shangcheng District, China|Peking University First Hospital, Beijing, Xicheng District, China|Department of Internal Medicine Pneumology and infectious diseases Neuk\u00f6lln Clinic, Berlin, Germany|Medical clinic and polyclinic IV Hospital of the University of Munich, M\u00fcnchen, Germany|Infectious Diseases Hospital Cluj-Napoca, Cluj-Napoca, Cluj, Romania|National Institute of Infectious Diseases \""Prof.Dr.Matei Bals\"", Bucharest, Ilfov, Romania|\""Dr.Victor Babes\"" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timisoara, Timis, Romania|\""Dr.Victor Babes\"" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timi\u015foara, Timis, Romania|Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timi\u015foara, Timis, Romania|Emergency County Hospital \""Pius Brinzeu\""Timisoara, Timi\u015foara, Timis, Romania"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""256"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time from randomization to clinical recovery|Negativity in RT-PCR nucleic acid test|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Incidence of deterioration\/aggravation of pneumonia|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy or non-invasive ventilation|ICU admission rate within 28 days of randomization|All-cause mortality within 28 days of randomization.""}"
"713","The Noninvasive Ventilation to COVID-19 Patients","","NCT04568655","FAHGuangzhouYLS03","Device: noninvasive ventilation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568655","Completed","2020-02-01","2020-07-01","{""locations"":""The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""23"",""age"":""20 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""success rate|the intubtion rate|blood lymphocyte|B-type natriuretic peptide|Procalcitonin|Oxygen Saturation""}"
"714","QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19","QT-Logs","NCT04371744","CIL 2020-52","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371744","Completed","2020-04-17","2020-06-05","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Corrected QT (QTc) interval measurement""}"
"715","Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19","","NCT04528667","BTK-COV-202BR","Drug: STI-5656|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04528667","Recruiting","2021-01-06","2021-05-01","{""locations"":""Hospital e Maternidade Christov\u00e3o da Gama, Santo Andr\u00e9, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects discharged from hospital|Incidence of adverse events (safety)|Time to hospital admission, treatment, and discharge|Number of days hospitalized|Change in clinical status as assessed using a 0-8 ordinal scale|Change in RT-PCR test results|Change in C-reactive protein levels|AUC of STI-5656 (PK)|Cmax of STI-5656 (PK)|t\u00bd of STI-5656 (PK)|Change in cytokine levels|Tmax of STI-5656 (PK)""}"
"716","Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients","Covid19Reh","NCT04572360","HKCOVID19Rehab","Other: Cardiorespiratory Exercise|Other: Modified Bai He Gu Jin Tang","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04572360","Not yet recruiting","2020-10-01","2023-06-30","{""locations"":""Linda Zhong, Kowloon Tong, Kowloon, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""172"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Six-Minute Walk Test (6MWT) in Cardiorespiratory Fitness Test|Blood Pressure|Heart Rate|Peripheral oxygen saturation (SpO2)|Borg Dyspnea Scale|Body composition - Segmental Muscle Mass|Body composition - Body Mass Index (BMI)|Body composition - Anatomical Circumferences|FVC (L) in Lung function Test using Spirometry|FEV1 (L) in Lung function Test using Spirometry|MVV (L\/min) in Lung function Test using Spirometry|Fractional exhaled Nitric Oxide (FeNO)|Diffusing capacity of the lungs for carbon monoxide (DLCO)|Cardiopulmonary Exercise Test (CPET) - Work Rate(WR)|Cardiopulmonary Exercise Test (CPET) - Breath by Breath Measurements of Minute ventilation (VE)|Cardiopulmonary Exercise Test (CPET) - CO2 output (VCO2)|Cardiopulmonary Exercise Test (CPET) - O2 uptake (VO2)|Change in Chinese Medicine (CM) Diagnostic Pattern & Clinical Characteristics using CM Syndrome Differentiation Assessment|Change in Body Constitution Scores using Body Constitution Questionnaires Assessment|Blood Biochemistry Tests - Serum Levels of Insulin (pmol\/l)|Blood Biochemistry Tests - Prothrombin Time (seconds)|Quality of Life - Personal Wellbeing Index - Chinese Version (Adult)|Other mental health-related measures - Depression Anxiety Stress Scale (DASS-21)|Other mental health-related measures - Revised UCLA Loneliness Scale (R-UCLA)|Other mental health-related measures - General Health Questionnaire (GHQ)|Gut microbiome Test|Metabolomics-related Measurement of Depression - Metabolomics Analysis""}"
"717","Expressive Writing for COVID-19 Resilience for Parents","","NCT04589117","Pro00105586","Behavioral: Expressive writing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04589117","Completed","2020-05-27","2020-08-02","{""locations"":""Duke Integrative Medicine, Durham, North Carolina, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""11"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Resilience|Perceived stress|Depression symptoms|Parental stress""}"
"718","Hydroxychloroquine for COVID-19","COV-HCQ","NCT04342221","COV-HCQ|2020-001224-33","Drug: Hydroxychloroquine Sulfate|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04342221","Recruiting","2020-03-29","2022-02-01","{""locations"":""Zollernalb Klinikum Balingen, Balingen, Germany|Klinikum Darmstadt, Darmstadt, Germany|Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Klinikum am Steinenberg, Reutlingen, Germany|RoMed Klinikum Rosenheim, Rosenheim, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Institute for Tropical Medicine, T\u00fcbingen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect of HCQ on in vivo viral clearance""}"
"719","Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients","HEMOCOVID19","NCT04689477","2020/579","Device: Vascular occlusion test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04689477","Recruiting","2020-05-25","2021-12-01","{""locations"":""Hospital de Clinicas da UNICAMP, Campinas, Sao Paulo, Brazil|Hospital General de M\u00e9xico, M\u00e9xico, Mexico|Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed, Sabadell, Barcelona, Spain|Hospital Cl\u00ednic i Provincial de Barcelona, Barcelona, Spain|Hospital Parc Salut Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""612"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28-day mortality""}"
"720","Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19","","NCT04584697","AMG-COV-102","Biological: COVI-AMG|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04584697","Withdrawn","2020-12-01","2021-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events by type, frequency, severity, and causality (safety)|Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety)|Incidence of serious adverse events by type, frequency, severity, and causality (safety)|Incidence of dose-limiting toxicities (safety)|Incidence of clinically meaningful laboratory abnormalities (safety)|Viral load as assessed using plasma and salivary samples at various timepoints|Time from onset of COVID-19 symptoms to treatment (Day 1)|Presence and levels of anti-drug antibodies directed to COVI-AMG|Cytokine levels post-treatment|AUC of COVI-AMG (PK)|Cmax of COVI-AMG (PK)|Tmax of COVI-AMG (PK)|t\u00bd of COVI-AMG (PK)""}"
"721","Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients","COVID-19","NCT04483622","IBR#S20-133","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04483622","Recruiting","2020-06-12","2021-02-15","{""locations"":""Sohag University Hospital, Sohag, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""16 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""rising titre of IGg antibodies""}"
"722","COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)","COST ACTION","NCT04367402","2020/ST/057","Other: BioMedomics COVID-19 IgM-IgG Rapid Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367402","Recruiting","2020-03-30","2020-09-01","{""locations"":""AO San Paolo, Milan, IT, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective study on individuals with or without symptoms to verify the reliability of a prognostic\/diagnostic test based on IgM\/IgG analysis.|ACE2 expression in patients with COVID-19 infection""}"
"723","Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients","INTERCOP","NCT04449380","INTERCOP","Drug: Interferon-ß-1a|Combination Product: Standard of Care (SOC)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04449380","Recruiting","2020-11-02","2021-06-01","{""locations"":""IRCCS Ospedale San Raffaele, Milano, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""126"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to negative conversion of SARS-CoV-2 nasopharyngeal swab|Improvement in clinical severity score (a)|Improvement in clinical severity score (b)|Incidence of new oxygen use, non-invasive ventilation, or high flow oxygen devices during the trial|Oxygenation free days in the first 28 days|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial|Number of patients transferred to Intensive Care Unit (ICU)|Mortality rate|Changes from baseline in pulmonary computed tomography (CT) imaging severity score|Duration of hospital stay expressed in days|Viral load measured on plasma with RT-PCR""}"
"724","Genetic Basis of COVID-19 Infection","","NCT04384250","RP:20.05.70","Diagnostic Test: Whole Exome Sequencing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384250","Recruiting","2020-05-10","2021-05-01","{""locations"":""Mansoura University, Mansoura, Dakahlyia, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""up to 50 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Mutations leading to increase susceptibility to SARS-COV-2 infection""}"
"725","Neonatal Complications of Coronavirus Disease (COVID-19)","","NCT04386109","14905","Other: No intervention - exposure is to COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386109","Recruiting","2020-04-01","2021-09-30","{""locations"":""Imperial College, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""up to 29 Days \u00a0 (Child)"",""outcome_measures"":""Incidence of neonatal COVID-19|Incidence of vertically transmitted COVID-19|Presentation and natural history of neonatal COVID-19|Presentation of neonates with COVID-19 positive mothers|Outcomes for neonates with COVID-19|Clinical treatment of neonatal COVID-19|Neonatal secondary impacts of maternal COVID-19""}"
"726","Study of Sargramostim in Patients With COVID-19","iLeukPulm","NCT04411680","PTX-001-002","Drug: Sargramostim|Drug: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04411680","Active, not recruiting","2020-08-18","2021-05-01","{""locations"":""St. Jude Medical Center, Fullerton, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|California Pacific Medical Center - Van Ness Campus, San Francisco, California, United States|TidalHealth Peninsula Regional, Inc, Salisbury, Maryland, United States|University of Missouri Health Care, Columbia, Missouri, United States|Great Plains Health, North Platte, Nebraska, United States|Richmond University Medical Center, Staten Island, New York, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""122"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in oxygenation parameter of P(A-a)O2 gradient by Day 6|Percent of patients who have been intubated by Day 14|Change in ordinal scale|All cause 28-day mortality|Number of patients with treatment-emergent serious adverse events or clinically significant adverse drug reactions (ADRs)""}"
"727","Effect of COVID-19 on Platelet Aggregation","","NCT04447131","SDC 5089/20/118","Other: venipuncture in peripheral vein","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04447131","Recruiting","2020-04-29","2021-07-30","{""locations"":""Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Platelet aggregation analyzed by Multiplate-ADP|Platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.|Platelet aggregation for COVID-19 versus patients hospitalized for respiratory symptoms but negative for Influenza and COVID-19 research.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for influenza or COVID-19 research.|Platelet aggregation in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Platelet aggregation versus time (days) of total hospitalization and in the ICU|Reticulated platelet fraction versus time (days) of total hospitalization and in the ICU|Platelet aggregation versus WHO ordinal scale of outcomes for COVID-19""}"
"728","Fatigue and Sleep in Patients With COVID-19","COFATSOM","NCT04657419","CHUBX 2020/52","Other: survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04657419","Not yet recruiting","2020-12-05","2021-06-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""720"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Fatigue Severity Scale|COVID Diagnosis|Fatigue evolution|Sleep hygiene""}"
"729","Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia","","NCT04713878","2020.05.20","Other: Mesenchymal stem cells","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04713878","Completed","2020-05-08","2020-07-15","{""locations"":""University of Health Sciences, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""21"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of clinical symptoms as respiratory distress or need for oxygen support|Change of cytokine storm parameters|Change of pulmonary functions|Change of clinical symptoms""}"
"730","Convalescent Plasma Treatment in COVID-19","COLLATE","NCT04476888","CON000000000880","Biological: Convalescent Plasma (CP)|Other: Drugs and supportive care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04476888","Completed","2020-04-26","2020-10-10","{""locations"":""Aga Khan University Hospital, Karachi, Sind, Pakistan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""110"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decrease length of stay|Overall mortality|Incidence of adverse events related to Convalescent Plasma transfusion|Ordinal scale|Improvement in Laboratory Parameters: Serum Ferritin|Improvement in Laboratory Parameters: Procalcitonin|Improvement in Laboratory Parameters: C-Reactive Protein|Improvement in Laboratory Parameters: D-Dimer|Improvement in Laboratory Parameters: Complete Blood count|Chest X-Ray findings""}"
"731","The Vietnam Chloroquine Treatment on COVID-19","VICO","NCT04328493","COVID","Drug: Chloroquine phosphate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04328493","Recruiting","2020-04-07","2022-04-01","{""locations"":""National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|fever clearance time|Ordinal outcome scale|Development of ARDS""}"
"732","SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding","SHIELD","NCT04478019","2020-0540|A534265|SMPH/MEDICINE/INFECT DIS|Protocol Version 6/1/2020","Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04478019","Recruiting","2020-07-07","2021-04-30","{""locations"":""University of Wisconsin-Madison, Madison, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""94"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with COVID-19 diagnosis|SARS-Cov-2 Viral Load|Fidelity of the treatment regimen|Feasibility of the treatment regimen""}"
"733","Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure","DAMPENCOVID","NCT04445285","USAH 1002 000","Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|Drug: 0.9%sodium chloride","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04445285","Recruiting","2020-04-28","2021-02-28","{""locations"":""University of South Alabama, Mobile, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""44"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality at 28 days|Systemic Therapeutic Response|Respiratory Response|Legnth of ICU Stay|Legnth of Hospital Stay|Pulmonary Function""}"
"734","Rapid, Onsite COVID-19 Detection","","NCT04460690","2020-0855|A536300|SMPH/PATHOL-LAB MED/ANAT PATH|Protocol Version 8/30/2020|5P51OD011106-59","Device: Rapid Onsite COVID-19 Detection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04460690","Enrolling by invitation","2020-07-13","2021-07-01","{""locations"":""University of Wisconsin, Madison, Wisconsin, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""10000"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of Samples Tested Consistently and Accurately per Protocol|Safety: COVID-19 rates of Investigators vs Communities tested""}"
"735","Assessment of SARS-CoV-2 Seroprevalence in Detention","COVIDET","NCT04516512","APHP200667","Biological: Blood draw","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04516512","Not yet recruiting","2020-09-01","2021-01-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""2500"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determination of the immunological parameters (Immunoglobins G) of the SARS-CoV-2 infection|Symptoms suggestive of COVID-19|Factors assumed to be related to infection with SARS-CoV-2 and the occurrence of moderate to severe forms of COVID-19""}"
"736","Treatment for COVID-19 in High-Risk Adult Outpatients","","NCT04354428","STUDY00009878|INV-017062","Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04354428","Active, not recruiting","2020-04-16","2021-01-01","{""locations"":""Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]""}"
"737","Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19","","NCT04663737","CX4945 AV01-IIT","Drug: Silmitasertib|Drug: SOC","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04663737","Recruiting","2020-12-03","2021-06-30","{""locations"":""Center for Advanced Research and Education, Gainesville, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) within the CX-4945 Treatment Group assessed by CTCAE v5.0|Clinical Recovery associated with COVID-19 within the CX-4945 Treatment Group|Anti-Viral Activity of CX-4945|Maximum Plasma Concentration [Cmax] of CX-4945|Clinical Benefit of CX-4945 i.e. All-Cause Mortality|Clinical Benefit of CX-4945 i.e. Number of Respiratory Failures|Clinical Benefit of CX-4945 i.e. Number of Hospitalized Days|Clinical Benefit of CX-4945 i.e. Changes in Pulse Oxygen Saturation|Clinical Benefit of CX-4945 i.e. Changes in Clinical Status|Clinical Benefit of CX-4945 i.e. Self-Reported Quality of Life|CX-4945 Inflammatory Marker Outcomes i.e. Plasma IL-6|CX-4945 Inflammatory Marker Outcomes i.e. Plasma CRP|CX-4945 Inflammatory Marker Outcomes i.e. Plasma LDH|CX-4945 Inflammatory Marker Outcomes i.e. Plasma CPK|CX-4945 Inflammatory Marker Outcomes i.e. Plasma Ferritin|CX-4945 Inflammatory Marker Outcomes i.e. Plasma D-Dimer""}"
"738","How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department","MONACOVID","NCT04401241","20-06","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401241","Completed","2020-02-01","2020-05-15","{""locations"":""Centre Hospitalier Princesse Grace, Monaco, MON, Monaco"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""257"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""routine biomarkers and blood cell count are discriminant to diagnose COVID-19|Probability of COVID-19 and CRP|Probability of COVID-19 and PCT|Probability of COVID-19 and Ddimers|Probability of COVID-19 and NTproBNP|Probability of COVID-19 and cTnT-HS|Probability of COVID-19 and blood cell counts|performance of combined routine biomarkers|Assess usual biomarkers and blood cell count""}"
"739","Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients","","NCT04718480","SD-COVID19-01|2020-002299-11","Drug: Placebo|Drug: Fluvoxamine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04718480","Recruiting","2020-11-27","2021-12-01","{""locations"":""D\u00e9l-pesti Centrumk\u00f3rh\u00e1z, Budapest, Hungary|Semmelweis Egyetem Pulmonol\u00f3giai Klinika, Budapest, Hungary|Orsz\u00e1gos Kor\u00e1nyi Pulmonol\u00f3giai Int\u00e9zet, Budapest, Hungary|Debreceni Egyetem Ken\u00e9zy Gyula K\u00f3rh\u00e1z Infektol\u00f3gia, Debrecen, Hungary"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical recovery after treatment""}"
"740","Slovenian National COVID-19 Prevalence Study","SLO-COVID-19","NCT04376996","ULMF2020-COVID-19","Diagnostic Test: NO intervention planned due to the observational study design - only a diagnostic testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376996","Recruiting","2020-04-20","2020-12-01","{""locations"":""University of Ljubljana, Ljubljana, Slovenia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples|Prevalence of anti-SARS-CoV-2 antibodies in blood samples""}"
"741","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)","","NCT04283461","20-0003|5UM1AI148684-02","Biological: mRNA-1273","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04283461","Active, not recruiting","2020-03-16","2022-11-22","{""locations"":""Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""120"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean fold rise (GMFR) in IgG titer from pre-first dose baseline|Geometric mean fold rise (GMFR) in IgG titer from pre-third dose baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted|Percentage of subjects who seroconverted from pre-first dose baseline|Percentage of subjects who seroconverted from pre-third dose baseline""}"
"742","Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients","X-Covid 19","NCT04366960","2020-001708-41","Drug: Enoxaparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04366960","Recruiting","2020-05-14","2021-11-01","{""locations"":""Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2712"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of venous thromboembolism detected by imaging|In hospital major complications|Number of deep venous thrombosis events|Sequential organ failure assessment|C-reactive protein|Interleukin-6|D-dimer|hs-troponin levels|Acute Respiratory Distress Syndrome|Hospital stay|Right ventricular function|Number of pulmonary embolism events""}"
"743","Hydroxychloroquine for the Treatment of SARS-CoV2 (COVID 19) : Pharmacokinetic Study","CHLORO-VID","NCT04625218","RC31/20/0155|2020-A01094-35","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04625218","Not yet recruiting","2021-01-01","2021-05-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""residual plasma concentration|The number of days without artificial ventilation|The length of hospital stay in intensive care|Survival|Viral replication in the control bronchoalveolar lavage fluid on Day 7|Viral replication in the control bronchoalveolar lavage fluid on Day 14""}"
"744","Anti COVID-19 Convalescent Plasma Therapy","","NCT04345679","AntiCOVID19ORT","Biological: anti-SARS-CoV-2 convalescent plasma","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04345679","Recruiting","2020-04-14","2021-09-01","{""locations"":""Semmelweis University's Department of Pulmonology, Budapest, Hungary"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality""}"
"745","Expressive Writing for COVID-19 Resilience","","NCT04589104","Pro00105575","Behavioral: Expressive writing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04589104","Completed","2020-05-26","2020-08-17","{""locations"":""Duke Integrative Medicine, Durham, North Carolina, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""63"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Resilience|Perceived stress|Depression symptoms|Post-traumatic growth""}"
"746","Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19","Explore","NCT04346056","FMASU P17a/ 2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346056","Recruiting","2020-04-14","2020-12-01","{""locations"":""Faculty of Medicine Ain Shams University, Cairo, Non-US, Egypt|Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""1 Year to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Exploring the presence of COVID-19""}"
"747","Colchicine in Moderate Symptomatic COVID-19 Patients","COLCOVIDBD","NCT04527562","U1111-1255-3541","Drug: Colchicine|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04527562","Completed","2020-07-14","2020-12-10","{""locations"":""Dhaka Medical College Hospital, Dhaka-1000, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""299"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to develop clinical deterioration, defined as the time from randomization to a deterioration of two points (from the status at randomization) on a Seven-category ordinal scale.|Length of hospital stay|Number of participant requiring increased amount of supplemental oxygen|Number of participants requiring mechanical ventilation|Number of participants who die""}"
"748","Selective Estrogen Modulation and Melatonin in Early COVID-19","SENTINEL","NCT04531748","20-842","Drug: Toremifene|Drug: Melatonin|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04531748","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""390"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Peak increase in COVID-19 Sign and Symptom score|Nadir Oxygen Saturation|Peak Heart Rate|Time to COVID-19 Sign and Symptom score resolution|Time to WHO 7-point ordinal scale score of 3 or higher""}"
"749","Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica","","NCT04644198","ECP/195,19/20","Biological: Convalescent Plasma Infusion","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04644198","Recruiting","2021-04-01","2021-12-01","{""locations"":""University of the West Indies, Kingston, Jamaica"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Viral load|Antibody titre for Immunoglobulin (IgG) anti-SARS-CoV-2 antibody|Antibody titre for Immunoglobulin A (IgA) anti-SARS-CoV-2 antibody|Procalcitonin titres|Interleukin 6 (IL-6)|D-dimer|C-reactive protein|Ferritin|Length of ICU admission|Days to recovery""}"
"750","A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 Against COVID-19 in Healthy Participants","","NCT04713553","C4591017","Biological: BNT162b2","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04713553","Recruiting","2021-02-15","2021-04-24","{""locations"":""Kaiser Permanente Oakland, Oakland, California, United States|Clinical Research Consulting, Milford, Connecticut, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Solaris Clinical Research, Meridian, Idaho, United States|Kentucky Pediatric\/Adult Research, Bardstown, Kentucky, United States|Amici Clinical Research LLC, Raritan, New Jersey, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|J. Lewis Research, Inc. \/ Foothill Family Clinic South, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1530"",""age"":""12 Years to 50 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Geometric Mean Ratio (GMR) of SARS-CoV-2 full-length S-binding or S1-binding antibody levels between US lots (Arms 1, 2 and 3) in participants without evidence of infection during the study|GMR of SARS-CoV-2 full-length S-binding or S1-binding antibody levels between the EU lot (Arm 4) and pooled US lots (Arms 1, 2, and 3) in participants without evidence of infection during the study|GMR of SARS-CoV-2 neutralizing antibody levels between the 20-microgram dose group (Arm 5) and the corresponding 30-microgram dose group (Arm 1, 2, or 3) in participants without evidence of SARS-C0V-2 infection during the study.|Percentage of participants reporting local reactions|Percentage of participants reporting systemic events|Percentage of participants reporting adverse events|Percentage of participants reporting serious adverse events|Geometric Mean Concentrations (GMCs) of SARS-CoV-2 full-length S-binding or S1-binding antibody levels in participants vaccinated with one of the 30-microgram lots (US or EU).|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 full-length S-binding or S1-binding antibody levels in participants vaccinated with one of the 30-microgram lots (US or EU)|GMCs of SARS CoV-2 neutralizing antibody levels in participants vaccinated with the 20-microgram or 30-microgram dose (from same US lot)|GMFRs of SARS-CoV-2 neutralizing antibody levels in participants vaccinated with the 20-microgram or 30-microgram dose (from same US lot).""}"
"751","Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia","","NCT04382729","ESC270320","Other: Neuromuscular Electrical Stimulation|Other: Physical Therapy Exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04382729","Recruiting","2020-04-17","2020-07-01","{""locations"":""San Luigi Gonzaga Hospital, Orbassano, TO, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Short Physical Performance Battery (SPPB) Score|Functional Independence Measure (FIM) Scale Score|Fatigue Severity Scale Score|Muscle Strength|Two Step Test Length|Six Minutes Walking Test Distance|Muscle Thickness""}"
"752","Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection","SARCODO","NCT04624997","APHP200521|2020-A01048-31","Other: biological sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04624997","Recruiting","2020-06-08","2020-12-01","{""locations"":""H\u00f4pital Cochin, Paris, France|H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure D-dimers (ng\/ml) to study coagulopathy to characterize COVID-19|Measure fibrin monomers (\u00b5g\/ml) to study coagulopathy to characterize COVID-19|Study troponin (ng\/ml) to characterize COVID-19 and identify patient populations who will develop or aggravate a micro or macro thrombotic process|Study von Willebrand factor antigen (%) to characterize COVID-19 and identify patient populations who will develop or aggravate a micro or macro thrombotic process|Study association of genetical and constitutive factors of thrombophilia :blood type ABO and COVID-19 severity according to OMS classification|Study association of genetical and constitutive factors of thrombophilia: deficit in S protein and COVID-19 severity according to OMS classification|Study association of genetical and constitutive factors of thrombophilia:deficit in C protein and COVID-19 severity according to OMS classification|Study association of genetical and constitutive factors of thrombophilia: mutation in V factor of coagulation and COVID-19 severity according to OMS classification|Study association of genetical and constitutive factors of thrombophilia:mutation in II factor of coagulation and COVID-19 severity according to OMS classification""}"
"753","COVID-19 - Quality of Life After Infection","","NCT04377464","NTEC-2020-0227","Other: SF12, EQ-5D-5L and work status standardized quantitative assessments","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377464","Not yet recruiting","2020-05-05","2022-04-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Six-month SF-12v2(HK) Scores|Six-month EQ-5D-5L Scores|One-month SF-12v2(HK)|One-month EQ-5D-5L Scores|Three-month SF-12v2(HK) Scores|Three-month EQ-5D-5L Scores|One, Three and Six-month Return to Work Status""}"
"754","Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)","DAMPEN-CI","NCT04487886","STUDY00000701","Drug: Duvelisib|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04487886","Recruiting","2020-11-18","2022-02-01","{""locations"":""Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants Requiring Mechanical Ventilation or Dying|Days to Recovery|Duration of Hospitalization|Incidence of Death|Proportion of Participants Transferred to ICU|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score|Incidence of Grade III-V Adverse Events|Incidence of Secondary Bacterial or Viral Infections|Change in Th1 T Cell Frequency|Change in Th17 T Cell Frequency|Change in Interleukin-2 (IL-2)|Change in Interleukin-2 receptor (IL-2R)|Change in Interleukin-6 (IL-6)|Change in Interleukin-7 (IL-7)|Change in Interleukin-8 (IL-8)|Change in Interleukin-10 (IL-10)|Change in Interferon gamma-induced Protein 10 (IP-10)|Change in Macrophage Inflammatory Protein 1alpha (MIP-1a)|Change in Monocyte Chemoattractant Protein-1 (MCP-1)|Change in Granulocyte Colony-stimulating Factor (G-CSF)|Change in Tumor Necrosis Factor (TNF)-alpha|Change in Vasoactive Intestinal Peptide (VIP)|Change in Gene Expression Profile of Regulatory T Cells (Tregs)|Change in Gene Expression Profile of cluster of differentiation 8 (CD8)+Interferon Gamma (IFNg)+ Granulocyte-macrophage colony-stimulating factor (GM-CSF)+|Change in Gene Expression Profile of CD8+ T cell immunoglobulin and mucin domain-containing protein 3 (Tim3)+ Programmed cell death protein 1 (PD-1)+|Change in Gene Expression Profile of cluster of differentiation 14 (CD14)+ cluster of differentiation (CD16)+ monocytes|Change in SARS-CoV-2 Viremia|Change in Immunoglobulin G (IgG) Antibodies|Change in Immunoglobulin M (IgM) Antibodies|Overall Survival""}"
"755","Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)","END CoV-2","NCT04513990","2020-0318|NCI-2020-03470","Procedure: Biospecimen Collection|Other: Questionnaire Administration","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04513990","Recruiting","2020-04-09","2021-04-30","{""locations"":""Lyndon Baines Johnson General Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""1500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Sensitivity of diagnostic test|Specificity of diagnostic test|Concordance of the novel point-of-care diagnostic test|Positive predictive value (PPV) of the novel point-of-care diagnostic test|Negative predictive value (NPV) of the novel point-of-care diagnostic test|Viral load metrics|Disease progression""}"
"756","COVID-19 Antibodies Among Healthcare Workers","","NCT04425889","IF20-00008","Diagnostic Test: COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04425889","Completed","2020-05-05","2020-06-01","{""locations"":""Hospital Universitario Jos\u00e9 E. Gonzalez, Monterrey, Nuevo Leon, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""156"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of antibody""}"
"757","WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey","WHF","NCT04475471","RA1413","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04475471","Recruiting","2020-06-11","2021-12-30","{""locations"":""Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Sanatorio G\u00fcemes Hospital, Buenos Aires, Argentina|University Clinical Center Republic of Srpska, Srpska, Bosnia and Herzegovina|Komfo Anokye Teaching Hospital, Kumasi, Ghana|Kumasi South Regional Hospital, Kumasi, Ghana|Dayanand medical college hospital, Ludhiyana, Punjab, India|Amin Hospital, Isfahan, Iran, Islamic Republic of|Amin Hospital, Isfahan, Iran, Islamic Republic of|Khorshid Hospital, Isfahan, Iran, Islamic Republic of|Fedail Hospital, Khartoum, Sudan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of the patients for major adverse cardiovascular events (MACE)|Assessment of the patients for Pulmonary outcomes including Pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in ICU or ICCU, need of ventilator]|Assessment of the patients for Neurological Outcomes including stroke and Transient Ischemic Attack (TIA)|All cause deaths""}"
"758","Saliva as Source of Detection for SARS-CoV-2","","NCT04424446","200128|20-CC-0128","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424446","Recruiting","2020-07-13","2021-06-01","{""locations"":""Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Saliva SARS-CoV-2 RT-PCR test results|Saliva and midturbinate swab SARS-CoV-2 RT-PCR test results""}"
"759","Efficacy and Safety of Sirolimus in COVID-19 Infection","","NCT04461340","sirolimus in COVID 19","Drug: Sirolimus","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04461340","Recruiting","2020-08-15","2020-11-30","{""locations"":""Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical recovery|Viral clearance|radiological lung extension|drug adverse events|28 day mortality|intensive care unit (ICU) admission rate|Duration of hospital stay""}"
"760","Impact of Adipose Tissue in COVID-19","COVIFAT","NCT04639440","APHP200983|2020-A02403-36","Other: Adipose tissue","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04639440","Not yet recruiting","2020-11-23","2021-11-23","{""locations"":""H\u00f4pital de la Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of the expression of ACE2 and TMPRSS2 in the subcutaneous and visceral adipose tissue of obese patients. Determination of cells expressing ACE2 and TMPRSS2 in whole human adipose tissue.|Demonstration of entry and replication of SARS-CoV-2 in human adipose tissue|Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.|Effect of SARS-CoV-2 infection of adipose tissue \/ adipocytes from thin and obese subjects on endoplasmic reticulum (ER) homeostasis.|Target endoplasmic reticulum stress to reduce spread of SARS-CoV-2 from adipose tissue""}"
"761","COVID-19: Salvage TOcilizumab as a Rescue Measure","COVIDSTORM","NCT04577534","EudraCT 2020-002039-31|2020-002039-31|T124/2020|KLnro 36/2020|dnro 68/06.00.01/2020","Drug: iv Tocillizumab (TCZ)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04577534","Recruiting","2020-08-14","2021-12-31","{""locations"":""Turku University Hospital, Turku, Finland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical status at day 28|Time to clinical improvement|Time to decline of at least 2 categories|Incidence of mechanical and\/or non-invasive ventilation|Number of ventilator-free days to day 28|Organ failure free days to day 28|Incidence of ICU stay|Duration of ICU stay|Time to clinical failure|SAPS II|CCI|APACHE II|SOFA 6|Mortality rate|Time to hospital discharge or \""ready for discharge\""|Duration of supplemental oxygen""}"
"762","Surveillance of Individuals Following SARS-CoV-2 Infection","","NCT04383444","200117|20-I-0117","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383444","Recruiting","2020-07-07","2023-08-01","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1050"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Results of SARS-CoV-2 RT- PCR testing, antibody assay, and culture|SARS-CoV-2 culture and RT-PCR results|Symptom checklist and RT-PCR cycle threshold""}"
"763","Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","","NCT04368728","C4591001|2020-002641-42","Biological: BNT162b1|Biological: BNT162b2|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04368728","Active, not recruiting","2020-04-29","2023-01-31","{""locations"":""North Alabama Research Center, LLC, Athens, Alabama, United States|Birmingham Clinical Research Unit, Birmingham, Alabama, United States|Medical Affiliated Research Center, Huntsville, Alabama, United States|Optimal Research, LLC, Huntsville, Alabama, United States|Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States|Chinle Comprehensive Health Care Facility, Chinle, Arizona, United States|Johns Hopkins Center for American Indian Health, Chinle, Arizona, United States|The Pain Center of Arizona, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States|Whiteriver Indian Hospital, Whiteriver, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Collaborative Neuroscience Research, LLC, Long Beach, California, United States|Long Beach Clinical Trials Services Inc., Long Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Providence Clinical Research, North Hollywood, California, United States|Paradigm Clinical Research Center, Redding, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|Kaiser Permanente Santa Clara, Santa Clara, California, United States|Bayview Research Group, Valley Village, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|Clinical Research Consulting, LLC, Milford, Connecticut, United States|Yale Center for Clinical Investigations (CSRU), New Haven, Connecticut, United States|Alliance for Multispecialty Research, Coral Gables, Florida, United States|DeLand Clinical Research Unit, DeLand, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Acevedo Clinical Research Associates, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|IACT Health, Columbus, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Solaris Clinical Research, Meridian, Idaho, United States|Optimal Research, LLC, Peoria, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Alliance for Multispecialty Research, LLC, Newton, Kansas, United States|Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States|Kentucky Pediatric\/ Adult Research, Bardstown, Kentucky, United States|Benchmark Research, Metairie, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|LSUHSC-Shreveport Clinical Trials Office, Shreveport, Louisiana, United States|LSUHSC-Shreveport, Shreveport, Louisiana, United States|Pharmaron CPC, Inc., Baltimore, Maryland, United States|University of Maryland, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States|Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Michigan Center for Medical Research, Farmington Hills, Michigan, United States|MedPharmics, LLC, Gulfport, Mississippi, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital dba Bozeman Health Clinical Research, Bozeman, Montana, United States|Methodist Physicians Clinic \/ CCT Research, Fremont, Nebraska, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Wake Research-Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Amici Clinical Research, Raritan, New Jersey, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Johns Hopkins Center for American Indian Health, Gallup, New Mexico, United States|Johns Hopkins Center for American Indian Health, Shiprock, New Mexico, United States|Meridian Clinical Research, LLC, Binghamton, New York, United States|Meridian Clinical Research LLC, Endwell, New York, United States|NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Rochester Regional Health\/Rochester General Hospital, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|PMG Research of Raleigh, LLC d\/b\/a PMG Research of Cary, Cary, North Carolina, United States|PMG Research of Charlotte LLC, Charlotte, North Carolina, United States|Duke University Medicine Circle- Duke Early Phase Clinical Research Unit, Durham, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|PriMED Clinical Research, Dayton, Ohio, United States|Senders Pediatrics, South Euclid, Ohio, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Kaiser Permanente Northwest-Center for Health Research, Portland, Oregon, United States|Lehigh Valley Health Network\/Network Office of Research and Innovation, Allentown, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Main Street Physician's Care, Little River, South Carolina, United States|Main Street Physician's Care, Loris, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|Trinity Clinical Research, Tullahoma, Tennessee, United States|Benchmark Research, Austin, Texas, United States|ARC Clinical Research at Wilson Parke, Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|North Texas Infectious Diseases Consultants, P.A., Dallas, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Ventavia Research Group, LLC, Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Ventavia Research Group, LLC, Keller, Texas, United States|SMS Clinical Research, LLC, Mesquite, Texas, United States|LinQ Research, LLC, Pearland, Texas, United States|Benchmark Research., San Angelo, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|J. Lewis Research, Inc. \/ Foothill Family Clinic, Salt Lake City, Utah, United States|J. Lewis Research, Inc. \/ Foothill Family Clinic South, Salt Lake City, Utah, United States|Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID), Annandale, Virginia, United States|Virginia Research Center LLC, Midlothian, Virginia, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|Wenatchee Valley Hospital, Wenatchee, Washington, United States|Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Caba, Argentina|Hospital Santo Antonio\/ Associacao Obras Sociais Irma Dulce, Salvador, BA, Brazil|CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda (Casa Branca), Sao Paulo, Brazil|CRS Clinical Research Services Berlin GmbH, Berlin, Germany|Medizentrum Essen Borbeck, Essen, Germany|IKF Pneumologie GmbH & Co KG, Frankfurt am Main, Germany|Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany|CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany|Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher, Stuhr, Germany|Newtown Clinical Research Centre, Johannesburg, Gauteng, South Africa|Jongaie Research, Pretoria, Gauteng, South Africa|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa|Tiervlei Trial Centre, Basement Level, Karl Bremer Hospital, Cape Town, Western CAPE, South Africa|Ankara Universitesi Tip Fakultesi, Ibni Sina Hastanesi, Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi-Cerrahpasa, Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Medipol Mega Universite Hastanesi, Istanbul, Turkey|Acibadem Atakent Hastanesi, Istanbul, Turkey|Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi, Sakarya, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""43998"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Percentage of participants in Phase 1 reporting local reactions|Percentage of participants in Phase 1 reporting systemic events|Percentage of participants in Phase 1 reporting adverse events|Percentage of participants in Phase 1 reporting serious adverse events|Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values|Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments|In the first 360 participants randomized into Phase 2\/3, percentage of participants reporting local reactions|In the first 360 participants randomized into Phase 2\/3, percentage of participants reporting systemic events|In the first 360 participants randomized into Phase 2\/3, percentage of participants reporting adverse events|In the first 360 participants randomized into Phase 2\/3, percentage of participants reporting serious adverse events|In a subset of at least 6000 participants randomized in Phase 2\/3, percentage of participants reporting local reactions|In a subset of at least 6000 participants randomized in Phase 2\/3, percentage of participants reporting systemic events|Percentage of participants in Phase 2\/3 reporting adverse events|Percentage of participants in Phase 2\/3 reporting serious adverse events|Confirmed COVID-19 in Phase 2\/3 participants without evidence of infection before vaccination|Confirmed COVID-19 in Phase 2\/3 participants with and without evidence of infection before vaccination|Percentage of participants 12-15 years of age in Phase 3 reporting adverse events|In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting local reactions|In participants 12-15 years of age randomized in Phase 3, percentage of participants reporting systemic events|In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs|In Phase 1 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point|Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels|In Phase 1 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs|Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels|In Phase 1 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point|In Phase 1 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels|Confirmed severe COVID-19 in Phase 2\/3 participants without evidence of infection before vaccination|Confirmed severe COVID-19 in Phase 2\/3 participants with and without evidence of infection before vaccination|Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2\/3 participants without evidence of infection before vaccination|Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2\/3 participants with and without evidence of infection before vaccination|GMR of SARS CoV 2 neutralizing titers in the 2 age groups (12-15 years of age to 16-25 years of age)|Incidence of asymptomatic SARS CoV-2 infection based on N binding antibody seroconversion in participants with no serological or virological evidence of past SARS CoV-2 infection or confirmed COVID-19 prior to 1 month after receipt of the second dose|Incidence of asymptomatic SARS CoV-2 infection based on central laboratory-confirmed NAAT in participants with no serological or virological evidence (up to the start of the asymptomatic surveillance period) of past SARS-CoV-2 infection""}"
"764","Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)","","NCT04586413","Med_Asst 33","Other: No intervention - quality of life measure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04586413","Recruiting","2020-10-07","2025-10-01","{""locations"":""Medialis, Oxford, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Design of PAC19QoL Measure (Phase One)|Completion of PAC19QoL Measure monthly for 12 months (Phase Two)""}"
"765","Catalysing the Containment of COVID-19","C3-RCT","NCT04523090","C3-RCT","Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04523090","Recruiting","2020-08-27","2021-08-01","{""locations"":""University of Cape Town, Cape Town, Western Cape, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""960"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time specific disease severity|Progression to severe disease|Need for respiratory support (high flow nasal oxygen, non-invasive ventilation, or intubation) in those admitted to hospital because of disease progression.|In-hospital and 30- and 60-day all-cause mortality. available).|Time-specific viral load as measured by RT-PCR using NP swabs and sputum (where available).|Cough aerosol sampling positivity""}"
"766","An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","","NCT04437875","03-Gam-COVID-Vac Lyo-2020","Biological: Gam-COVID-Vac Lyo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04437875","Completed","2020-06-17","2020-08-10","{""locations"":""Sechenov First Moscow State Medical University, Moscow, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""38"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days|Number of Participants With Adverse Events|The changing of virus neutralizing antibody titer|The changing of antigen-specific cellular immunity level""}"
"767","Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection","NIVISCO","NCT04413838","69HCL20_0478","Drug: NIVOLUMAB|Other: Routine standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04413838","Not yet recruiting","2020-06-15","2021-09-15","{""locations"":""H\u00f4pital Lyon Sud Service Endocrinologie, Diab\u00e8te et Nutrition, Pierre-B\u00e9nite, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient's clinical state|Readmission|Mortality|Oxygen flow needs|Requirement of oxygen|Discharge from hospital|Adverse events|Presence of nasopharyngeal SARS-CoV-2|nasopharyngeal SARS-CoV-2 viral charge|Number of total Lymphocytes T|Number of CD3+ Lymphocytes T(lymphocyte subpopulation of CD3+ T cells)|Number of CD4+ Lymphocytes T(lymphocyte subpopulation of CD4+ T cells)|Number of CD8+ Lymphocytes T(lymphocyte subpopulation of CD8+ T cells)|Interleukin 6 (IL-6)|Interleukin 10 (IL-10)|Tumor Necrosis Factor alpha (TNF\u03b1 )|Interferon gamma (IFN\u03b3)|Type I Interferon (type I IFN)|Tim3 expression|PD1 expression|PD-L1 expression|Human Leukocyte Antigen - DR isotype gene expression (HLA-DR expression)|Production of IFN\u03b3 by lymphocytes T|Production of granzyme B by lymphocytesT|Lipopolysaccharides (LPS)|LBP(LPS-Binding Protein)|sCD14|High Density Lipoproteins|Apolipoprotein""}"
"768","Host Response Mediators in Coronavirus (COVID-19) Infection","ARBS CORONA I","NCT04510623","H20-00600","Other: ARBs and/or ACE inhibitors|Other: Usual Care","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04510623","Recruiting","2020-03-17","2022-06-30","{""locations"":""University of Calgary - Foothills, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Pauls Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|William Osler Health System, Brampton, Ontario, Canada|Queens University, Kingston, Ontario, Canada|Humber River Hospital, North York, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montr\u00e9al, Quebec, Canada|McGill University Health Center, Montr\u00e9al, Quebec, Canada|Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 WHO ordinal scale|Organ Dysfunction|28-day mortality|Hospital\/ICU length of stay|ICU admission""}"
"769","COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients","PIIPPI","NCT04364802","58748","Drug: Povidone-Iodine Nasal Spray and Gargle","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04364802","Recruiting","2020-04-29","2021-05-01","{""locations"":""University of Kentucky, Lexington, Kentucky, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""300"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent of healthcare workers testing positive for COVID-19.|Percent of patients testing positive for COVID-9.|Percent of community participants testing positive for COVID-9.|PVP-I Ease of Use|PVP-I Comfort""}"
"770","Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19","","NCT04542421","20-0781","Diagnostic Test: Lung ultrasound use in patients hospitalized with COVID","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04542421","Recruiting","2020-07-01","2021-12-01","{""locations"":""University of Colorado, Denver, Colorado, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""90"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adoption of lung ultrasound by hospitalists caring for patients with COVID|Percentage of patients with COVID who receive a lung ultrasound|Chest x-ray utilization|Adequacy of Lung ultrasound images, interpretation and clinical decision-making as measured by a lung ultrasound expert|Inpatient mortality""}"
"771","Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respiratory Failure","CYTOAID","NCT04422626","20802-5/2020/EÜIG","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422626","Not yet recruiting","2020-07-01","2022-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""42"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the partial pressure of oxygen\/fraction of inspired oxygen (PaO2\/FiO2) ratio after CytoSorb therapy|Change in inflammatory biomarker levels during treatment|change in organ function|length of stay in ICU|length of hospital stay|Duration of mechanical ventilation|Duration of vasopressor therapy|Duration of renal replacement therapy|Occurrence of critical illness polyneuropathy and\/or myopathy|need for extracorporeal membrane oxygenation (ECMO)|cost calculation|device-related adverse and serious adverse events|In-hospital mortality""}"
"772","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","DEXA-COVID19","NCT04325061","2020-001278-31","Drug: Dexamethasone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04325061","Terminated","2020-04-03","2020-06-19","{""locations"":""ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Cl\u00ednic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Cl\u00ednico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario R\u00edo Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario R\u00edo Hortega, Valladolid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""19"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""60-day mortality|Ventilator-free days""}"
"773","Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia","","NCT04572412","285167","Radiation: Low dose Radiotherapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04572412","Recruiting","2020-11-25","2021-04-01","{""locations"":""Lancashire Teaching Hospitals NHS, Preston, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""13"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of Recruitment|Tolerability of Low dose Radiotherapy|Withdrawal|Adverse events|Feasibility of biochemical analysis""}"
"774","A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)","CTII-nCoV","NCT04341389","JSVCT089","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04341389","Active, not recruiting","2020-04-12","2021-01-31","{""locations"":""Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""508"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of adverse reactions|Anti SARS-CoV-2 S IgG antibody response(ELISA)|Neutralizing antibody response to SARS-CoV-2|Occurrence of adverse events|Occurrence of serious adverse reaction|Neutralizing antibody response to Ad5-vector|IFN-\u03b3 ELISpot responses to SARS-CoV-2 spike protein""}"
"775","The Protective Potential of Exercise Training on the Cardiopulmonary Morbidity After COVID-19","","NCT04647734","H-20033733 v.2","Behavioral: High intensity interval training|Behavioral: Standard care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04647734","Not yet recruiting","2021-01-01","2021-12-31","{""locations"":""Rigshospitalet, Copenhagen, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research"",""enrollment"":""40"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in left ventricular mass|Change in right ventricular volume|Stroke volume|end-diastolic volume|IVS thickness (intact ventricular septum)|LVID (left ventricular internal dimensions)|PWT (posterior wall thickness)|LAVI (left atrial volume index)|LVEF|Global longitudinal strain|E\/A ratio|E\u00b4|RV volumes|RVEF|TAPSE|Change in maximal tricuspid regurgitation velocity and pressure gradient|RV s\u00b4|Peak E velocity|Peak A velocity|Septal e\u00b4|Lateral e\u00b4|E\/e\u00b4 septal|E\/e\u00b4 lateral|Cardiac inflammation|Vascular dysfunction|Extracellular volume|Diffuse fibrotic changes|Blood and plasma volume|Body composition analysis measured with DXA|Cardiorespiratory fitness|Dynamic spirometri|Whole body plethymography|Diffusion capacity|Oral glucose tolerance test|Continuous glucose monitoring|Axial accelerometer-based physical activity monitors|Blood samples analysed for markers related to low grade inflammation|Blood samples analysed for markers related to cardiometabolic biomarkers.|SF-36, King\u00b4s Brief Interstitial Lung Disease Questionnaire, Post-COVID-19 Functional Status|King\u00b4s Brief Interstitial Lung Disease Questionnaire|Post-COVID-19 Functional Status""}"
"776","KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","","NCT04473690","KBP-201","Biological: Low Dose of KBP-COVID-19|Biological: High Dose of KBP-COVID-19|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04473690","Recruiting","2020-12-30","2022-03-23","{""locations"":""Velocity Clinical Research, Boise, Idaho, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|ICON CRU, San Antonio, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""180"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Solicited Administration site reactions|Solicited systemic events|Unsolicited Adverse Events and medically attended adverse events|Serious Adverse Events, Medically Attended Adverse Events and New Onset Chronic Diseae|Vaccine ELISA and neutralizing antibody titers for each treatment group|Seroconversion rates""}"
"777","Direct and Indirect Impact of COVID-19 In Older Populations","COVID-OLD","NCT04381312","38RC20.118|2020-A00846-33","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04381312","Recruiting","2020-04-09","2021-10-09","{""locations"":""Chu Grenoble Alpes, Grenoble Cedex 9, Grenoble, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""mortality|Risk factors for death|Describe clinical symptoms specific to old population|describe specific and non-specific treatments used for COVID 19|describe all acute complications|functional decline|Rehospitalisation|medical complications|Admission in nursing home|risk factors for 3-month functional decline, acute complication and admission to nursing home""}"
"778","Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19","","NCT04456049","COVID_ENZA","Drug: Enzalutamide","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04456049","Not yet recruiting","2020-07-01","2021-12-01","{""locations"":""Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of Enzalutamide|Disease progression|Tollerability of Enzalutamide""}"
"779","Fingolimod in COVID-19","","NCT04280588","MRCTA, ECFAH of FMU [2020]027","Drug: Fingolimod 0.5 mg","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04280588","Withdrawn","2020-02-22","2020-07-01","{""locations"":""Wan-Jin Chen, Fuzhou, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The change of pneumonia severity on X-ray images""}"
"780","MAVIPAN: My Life and the COVID-19 Pandemic","","NCT04575571","To be assigned","Other: No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04575571","Recruiting","2020-04-29","2025-04-29","{""locations"":""VITAM-Research Center in Sustainable Health, Qu\u00e9bec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Depression, Anxiety and Stress Scale-21 (DASS-21)|Insomnia Severity Index|Warwick-Edinburgh Mental Well-Being Scale|Hostility subscale- Symptoms Checklist-90-Revised|Substance use|Brief COPE|Dyadic Adjustment Scale|Parental Stress Index|Child Conflict Tactic Scale|Strengths and Difficulties Questionnaire|Healthcare workers adaptation""}"
"781","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","HYDRA","NCT04315896","HidroxycloroquinaCOVID19","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04315896","Active, not recruiting","2020-04-14","2020-08-15","{""locations"":""Instituto Nacional de Enfermedades Respiratorias, \""Ismael Cos\u00edo Villegas\"", Mexico, City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction""}"
"782","Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19","","NCT04646031","T89-ROUSA-01","Drug: T89 capsule","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04646031","Available","1970-01-01","1970-01-01","{""locations"":""MultiCare Health System, Tacoma, Washington, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""""}"
"783","Defibrotide in COVID-19 Pneumonia","DEFI-VID19","NCT04335201","DEFI-VID19","Drug: Defibrotide Injection","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04335201","Recruiting","2020-05-20","2021-08-31","{""locations"":""Ospedale San Raffaele, Milano, Lombardia, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival""}"
"784","COVID-19 and Its Effects on Chronic Pain Patients","","NCT04715815","REC.63-359-8-1","Other: No intervention (only interview)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04715815","Not yet recruiting","2021-02-01","2022-06-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To explain how the COVID-19 affects chronic pain patients in terms of pain and pain management.|To explain how the COVID-19 affects chronic pain patients' psychological status.""}"
"785","Role of Inflammasomes in COVID-19 Disease","CoVInnate","NCT04385017","20-PP-07","Other: COVID-19 patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04385017","Recruiting","2020-05-11","2021-06-12","{""locations"":""Ch Cannes, R\u00e9animation, Cannes, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils during COVID-19|Genes nucleoside polymorphism analysis""}"
"786","COVID-19 Remote Monitoring","","NCT04350476","GCO 20-0932","Diagnostic Test: VitalConnect Vital Sign Patch","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04350476","Withdrawn","2020-04-17","2020-05-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of different arrhythmias|Temperature|Oxygen Saturation""}"
"787","NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes","COVGUT20","NCT04540406","NBTNM10810012020","Drug: NBT-NM108|Other: Usual Care Only","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04540406","Recruiting","2021-02-08","2021-06-01","{""locations"":""University of South Florida Morsani College of Medicine, Tampa, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 69 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Gut Microbiota Composition|Outcome of COVID-19 related illnesses|Proportion of participants who are \""alive and not admitted to the hospital\""|Proportion of participants who visit the emergency room|Proportion of participants who have complete resolution of all objective symptoms|Proportion of participants who have complete resolution of subjective symptoms|Illness severity based on the categorization from FDA COVID-19 Guidance Document|Illness severity based the Ordinal Scale for Clinical Improvement from the World Health Organization|Body temperature (F)|Oxygen saturation SpO2 level|Pulse rate per minute|Respiratory rate per minute|Fasting blood glucose (mg\/dl)""}"
"788","Thymic Function in Patients With COVID-19","COVITHYM","NCT04716907","2020/06","Genetic: Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|Biological: Blood sample|Diagnostic Test: CT Scan","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04716907","Not yet recruiting","2021-02-01","2022-02-01","{""locations"":""CMC Ambroise Par\u00e9, Neuilly-sur-Seine, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Genetic Predisposition to severe forms of COVID-19|Genetic Predisposition to thymic enlargement observed during COVID-19 infection|Genetic Predisposition to enhanced thymic function during COVID-19 infection|Genetic Predisposition to severity of COVID-19 pathology|Basal thymic function in COVID patients|Thymic function in COVID patients|Immune response in COVID patients|Inflammatory response in COVID patients""}"
"789","Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations","","NCT04558307","20-004046","Diagnostic Test: Pilot a rapid SARS-CoV-2 testing strategy|Other: Community-driven messages to promote COVID-19 testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04558307","Enrolling by invitation","2020-06-03","2021-12-01","{""locations"":""Mayo Clinic, Rochester, Minnesota, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Intervention Feasibility Measures - FQHC Staff|2. Uptake of rapid SARS-CoV-2 testing strategy at the FQHC- Effectiveness of community-driven messaging to patients|Uptake of rapid SARS-CoV-2 testing strategy at the FQHC|Intervention Satisfaction Measures - Participant Satisfaction with COVID-19 testing|5. Intervention Satisfaction Measures - Participant Satisfaction with community-driven messaging""}"
"790","Study of Efficacy and Safety of MAS825 in Patients With COVID-19","MAS-COVID","NCT04382651","CMAS825F12201","Drug: MAS825|Drug: Matching placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04382651","Active, not recruiting","2020-06-07","2021-04-14","{""locations"":""Novartis Investigative Site, Chula Vista, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, La Mesa, California, United States|Novartis Investigative Site, Mission Hills, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Lafayette, Louisiana, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Bend, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Mesquite, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""APACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier)|Serum C-reactive protein (CRP levels)|Ferritin levels|Proportion of participants without the need for invasive mechanical ventilation|Proportion of participants with at least one level improvement in clinical status|Clinical status over time""}"
"791","Estrogen Therapy in Non-severe COVID-19 Patients","","NCT04539626","03","Drug: Estrogen Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04539626","Recruiting","2020-10-01","2022-12-01","{""locations"":""CMN \""20 de Noviembre\"", Mexico City, Benito Ju\u00e1rez, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improve to estrogen therapy in non-severe COVID-19 patients Clinical improve to estrogen therapy in non-severe COVID-19 patients|Clinical improve to estrogen therapy in non-severe COVID-19 patients|Symptomatic improve to estrogen therapy in non-severe COVID-19 patients|Biochemical improve to estrogen therapy in non-severe COVID-19 patients""}"
"792","Behaviour and Experience of Communities Healthcare Professionals Facing the SARS CoV-2 (COVID-19) Epidemic","COVecu","NCT04625296","AP-HP 200512","Behavioral: Semi-directive interview|Behavioral: Questionnaire : Preparedness for Caregiving Scale","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04625296","Recruiting","2020-09-17","2021-01-01","{""locations"":""URC\/CIC Paris Centre, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diversity of themes extracted about care situations management of the COVID-19 epidemic.|Preparedness for caregiving scale (PCS)""}"
"793","Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19","Co-CLARITY","NCT04567173","PHRR200824-002868","Drug: Anti-SARS-CoV-2 convalescent plasma","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04567173","Recruiting","2020-09-21","2021-06-30","{""locations"":""UP Philippine General Hospital, Manila, Philippines"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""136"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of serious adverse events|Quick SOFA (qSOFA) score|Cardiopulmonary arrest|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Dialysis-free days|Vasopressor-free days|ICU-free days|28-day mortality|Anti-SARS-CoV-2 antibody titers|SARS-CoV-2 RNA by RT-PCR""}"
"794","Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19","Covid19COVINIB","NCT04346147","24032020","Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet|Other: Supportive tratment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04346147","Recruiting","2020-05-07","2021-09-01","{""locations"":""Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""165"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""time to clinical improvement|Safety of treatments|Tolerability of treatments""}"
"795","Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients","","NCT04673162","RCT-MP-COVID-19","Drug: Methylprednisolone, Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04673162","Not yet recruiting","2020-12-01","2021-06-01","{""locations"":""SOC Pneumologia, SOC Malattie Infettive, SOC Reumatologia, Az USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""260"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Length of hospitalization""}"
"796","Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination","COVID19vac-1","NCT04706390","COVID-19vacc-1","Biological: covid-19 vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04706390","Recruiting","2021-01-12","2024-01-12","{""locations"":""University of Bergen, Bergen, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""20 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""immune responses|Duration and breadth of B- and T cell responses|Immune responses in healthy people and patient groups at risk""}"
"797","Outpatient Use of Ivermectin in COVID-19","","NCT04530474","1285242","Drug: Ivermectin Pill|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04530474","Not yet recruiting","2020-10-01","2021-12-31","{""locations"":""Temple University Hospital, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Improvement""}"
"798","SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem","","NCT04497610","Tera-CR-1","Diagnostic Test: Breath sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497610","Not yet recruiting","2020-08-04","2020-08-15","{""locations"":""Instituto Costarricense de Investigaciones Cl\u00ednicas, San Jos\u00e9, Costa Rica"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""7 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Presence of disease""}"
"799","Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia","RHEA-COVID19","NCT04627519","Pharm-202010.01","Dietary Supplement: Rhea Health Tone®","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04627519","Recruiting","2020-12-09","2021-03-15","{""locations"":""Rumah Sakit Darurat Penanganan Covid-19 Wisma Atlet Kemayoran (RSDCWA), Jakarta, DKI Jakarta, Indonesia|Dr. Hasan Sadikin Central General Hospital, Bandung, West Java, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""85"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Length of stay|Duration of oxygenation|Duration of ventilation|PCR conversion|Inflammatory biomarkers 1|Inflammatory biomarkers 2|Inflammatory biomarkers 3|Percentage of improvement of subjects' clinical status|X-Ray""}"
"800","Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS","COVIDANCE","NCT04643691","2020-24|2020-001766-11","Drug: Losartan 50 mg and Spironolactone 25 mg pillules oral use","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04643691","Recruiting","2020-09-11","2022-10-30","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SOFA score|Pa02\/Fi02|Duration of mechanical ventilation|Death""}"
"801","Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19","","NCT04410107","2020-0169","Diagnostic Test: Lung Function tests|Diagnostic Test: Exercise capacity|Diagnostic Test: Exercise physiology|Diagnostic Test: Health-related quality of life|Diagnostic Test: Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04410107","Recruiting","2020-05-15","2022-08-02","{""locations"":""Universidade de Passo Fundo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Cl\u00ednicas de Porto Alegre\/Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Univesidade de Ci\u00eancias da Sa\u00fade de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Concei\u00e7\u00e3o, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""134"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Forced expiratory volume in the first second\/forced vital capacity|Total lung capacity|Lung diffusion capacity for carbon monoxide|6-minute walk test distance|Short-form 36 questionnaire (SF-36)|Forced vital capacity|Residual volume\/total lung capacity|Inspiratory capacity\/total lung capacity|Airway resistance (Raw)|Resistance at 20Hz and 5Hz (R5-R20)|Reactance at 5Hz (X5)|Resonant frequency (Fres)|Reactance area (A\u0425)|Pulse oximetry (SpO2) at rest|Pulse oximetry (SpO2) during exercise|Respiratory symptoms adapted from American Thoracic Society Questionnaire|Oxygen uptake at peak exercise|Minute-ventilation\/carbon dioxide output during exercise|Dyspnea during exercise|Inspiratory capacity during exercise|Beck Anxiety Inventory (BAI)|Beck Depression Inventory (BDI)|Post-traumatic stress symptoms questionnaire""}"
"802","A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","COVID-19","NCT04510207","CNBG2020003SQ","Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04510207","Recruiting","2020-07-16","2021-09-16","{""locations"":""Bahrain International Exhibition & Convention Centre Affiliated to Salymynia Medical Complex S, Sanabis, Bahrain|Katameya Medical Center, Cairo, Egypt|Vacsera health Care facilities , MoH, Cairo, Egypt|Prince Hamza Hospital, Amman, Jordan|Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates|Al Qarain Primary Health Care Centre-MOHAP, Sharjah, United Arab Emirates"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""45000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of COVID-19 cases after two-doses of vaccination|The incidence of severe cases of SARS-CoV-2 pneumonia and deaths accompanied by COVID-19 after two-doses of vaccination|The incidence of any adverse reactions\/events|The incidence of serious adverse events (SAE)|The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody|The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody|The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody""}"
"803","Core Warming of COVID-19 Patients","","NCT04426344","202005150","Device: ensoETM device","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04426344","Withdrawn","2020-10-01","2020-12-01","{""locations"":""Barnes-Jewish Hospital, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load measured in tracheal aspirate 72 hours after initiation of core warming|PaO2\/FiO2 ratio 72 hours after initiation of core warming|Duration of mechanical ventilation""}"
"804","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","","NCT04273646","202001","Biological: UC-MSCs|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04273646","Not yet recruiting","2020-04-20","2022-02-15","{""locations"":""Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pneumonia severity index|Oxygenation index (PaO2\/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+\/CD8+ratio""}"
"805","Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization","PAPR","NCT04368000","IRB_00132123","Behavioral: Intermittent prone positioning instructions|Behavioral: Usual care positioning with no instructions","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04368000","Terminated","2020-04-29","2020-08-06","{""locations"":""University of Utah Health Sciences Center, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in imputed partial pressure of oxygen over fraction of inspired oxygen (PaO2\/FiO2) from peripheral capillary oxygen saturation over fraction of inspired oxygen (SpO2\/FiO2)|Change in imputed PaO2\/FiO2 from SpO2\/FiO2|Proportion of participants requiring endotracheal intubation|Proportion of participants requiring mechanical ventilation|Proportion of participants transferred to intensive care for worsening respiratory failure|Proportion of participants who had escalated oxygen delivery needs|Average number of days hospitalized|Average number of ventilator-free days|Proportion of participants discharged from hospital on hospice|Proportion of participants with all-cause inpatient mortality""}"
"806","A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function","","NCT04486482","K032-120","Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04486482","Recruiting","2021-01-12","2021-03-01","{""locations"":""Cullman Clinical Trials, Cullman, Alabama, United States|American Institute of Research, Los Angeles, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|Next Phase Research Alliance, Boca Raton, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Hope Clinical Trials, Miami, Florida, United States|Kendall South Medical Center, Inc., Miami, Florida, United States|Quad Clinical Research, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Inquest Research, Baytown, Texas, United States|Olympus Family Medicine, Salt Lake City, Utah, United States|South Ogden Family Medicine Center, South Ogden, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)|Relative abundance of microbial taxa in fecal samples as assessed by shotgun profiling based on shotgun sequencing.""}"
"807","Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection","","NCT04513158","20-N0124","Biological: Convalescent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04513158","Recruiting","2020-08-14","2021-12-31","{""locations"":""Norton Hospital, Louisville, Kentucky, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Audubon Hospital, Louisville, Kentucky, United States|Norton Brownsboro Hospital, Louisville, Kentucky, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19).|Determine the immunologic effects of convalescent plasma infusion|Absolute lymphocyte count (10*3\/uL)|reatinine kinase (mg\/dL)|C-reactive protein (mg\/dl)|D-Dimer (ng\/ml FEU)|Interleukin-6 (pg\/ml)|Ferritin (ng\/mL)""}"
"808","A Study of Risk Factors for the COVID-19 Virus Infection","","NCT04697927","20-418","Other: Questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04697927","Recruiting","2020-12-30","2022-12-01","{""locations"":""Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Rockville Centre, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""develop a comprehensive registry database""}"
"809","Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain","COVID19@Spain","NCT04355871","COVID-19/SEIMC-FSG","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355871","Completed","2020-03-18","2020-04-17","{""locations"":""Comp. Hosp. Univ. A Coru\u00f1a, A Coru\u00f1a, Spain|H. Quiron A Coru\u00f1a, A Coru\u00f1a, Spain|H. de Alcaniz, Alca\u00f1iz, Spain|H. Gral Univ. de Alicante, Alicante, Spain|H. Univ. San Juan de Alicante, Alicante, Spain|H. Univ. de la Ribera, Alzira, Spain|H. Santos Reyes, Aranda De Duero, Spain|H. Dr. Jose Molina Orosa, Arrecife, Spain|Consorcio Sanitari Integral (CAIDM), Barcelona, Spain|H. Clinic, Barcelona, Spain|H. del Mar, Barcelona, Spain|H. Parc Sanitari Sant Joan de Deu, Barcelona, Spain|H. Santa Creu y Sant Pau, Barcelona, Spain|H. Univ. de Bellvitge, Barcelona, Spain|H. Vall d'Hebron, Barcelona, Spain|Hospital CIMA-Sanitas, Barcelona, Spain|SCIAS H. de Barcelona, Barcelona, Spain|H. Clinica de Benidorm, Benidorm, Spain|H. de Cruces, Bilbao, Spain|H. San Eloy_Barakaldo, Bilbao, Spain|H. Univ. de Basurto, Bilbao, Spain|H. Urduliz-Alfredo Espinosa, Bilbao, Spain|H. Gral de La Palma, Bre\u00f1a Alta, Spain|H. de Puerto Real, Cadiz, Spain|H. de Calahorra, Calahorra, Spain|H. Sant Jaume de Calella, Calella, Spain|H. Univ Santa Lucia, Cartagena, Spain|H. Univ de Henares, Coslada, Spain|Hospital Marina Salud de D\u00e9nia, Denia, Spain|Hospital Don Benito-Villanueva de la Serena, Don Benito, Spain|H. Gral Univ. de Elche, Elche, Spain|H. Univ. del Vinalopo, Elche, Spain|Comp. Hospt. Univ. de Ferrol, Ferrol, Spain|H. Francesc de Borja, Gandia, Spain|H. de Figueres, Gerona, Spain|H. Comarcal de Blanes, Girona, Spain|H. Josep Trueta, Girona, Spain|H. Clinico San Cecilio, Granada, Spain|Hospital HLA Inmaculada, Granada, Spain|H. de Guadalajara, Guadalajara, Spain|H. de Guadarrama, Guadarrama, Spain|H. Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain|H. Riotinto, Huelva, Spain|H. Can Misses, Ibiza, Spain|H. Universitario de Ja\u00e9n, Ja\u00e9n, Spain|H. Univ. de Jerez de la Frontera, Jerez De La Frontera, Spain|H. Univ Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|H. Universitario de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|H. Univ. Severo Ochoa, Legan\u00e9s, Spain|H. San Pedro, Logro\u00f1o, Spain|H. Univ. Menez Rafael Mendez, Lorca, Spain|H. Lucus Augusti, Lugo, Spain|H. 12 de Octubre, Madrid, Spain|H. Clinica Univ. de Navarra_ Campus Madrid, Madrid, Spain|H. Clinico San Carlos, Madrid, Spain|H. Fundacion Jim\u00e9nez D\u00edaz, Madrid, Spain|H. Gral de la Defensa Gomez Ulla, Madrid, Spain|H. HLA Univ. Moncloa, Madrid, Spain|H. HM Sanchinarro, Madrid, Spain|H. Puerta de Hierro, Madrid, Spain|H. Univ HM Madrid, Madrid, Spain|H. Univ Principe de Asturias, Madrid, Spain|H. Univ. de Alcorc\u00f3n, Madrid, Spain|H. Univ. de Getafe, Madrid, Spain|H. Univ. de M\u00f3stoles, Madrid, Spain|H. Univ. Gregorio Mara\u00f1on, Madrid, Spain|H. Univ. HM Monteprincipe, Madrid, Spain|H. UNiv. HM Puerta del Sur, Madrid, Spain|H. Univ. Infanta Leonor, Madrid, Spain|H. Univ. La Paz, Madrid, Spain|H. Univ. La Princesa, Madrid, Spain|H. Univ. Ram\u00f3n y Cajal, Madrid, Spain|H. Univ. Rey Juan Carlos, Madrid, Spain|H. Costa del Sol, Marbella, Spain|H. de Mataro, Matar\u00f3, Spain|H. de Melilla, Melilla, Spain|H. de Mendaro, Mendaro, Spain|Hospital Alto Deba, Mondrag\u00f3n, Spain|H. Virgen de la Arrixaca, Murcia, Spain|H. Marbella Internacional, M\u00e1laga, Spain|H. Virgen de la Victoria, M\u00e1laga, Spain|H. Vega Baja, Orihuela, Spain|H. Univ. Central de Asturias, Oviedo, Spain|H. de Palamos, Palam\u00f3s, Spain|H. Son Espases, Palma De Mallorca, Spain|H. Son Llatzer, Palma De Mallorca, Spain|H. Clinica Univ. Navarra, Pamplona, Spain|H. Virgen del Puerto, Plasencia, Spain|H. El Bierzo, Ponferrada, Spain|H. Do Salnes, Pontevedra, Spain|H. UNiv. Los Arcos del Mar Menor, Pozo Aledo, Spain|H. Santa Barbara, Puertollano, Spain|H. Parc Tauli, Sabadell, Spain|Complejo Asist. Univ. de Salamanca, Salamanca, Spain|H. Infanta Sofia, San Sebasti\u00e1n De Los Reyes, Spain|H. de Donostia, San Sebasti\u00e1n, Spain|H. de l'Esperit Sant, Santa Coloma De Gramenet, Spain|H. Univ. Marques de Valdecilla, Santander, Spain|H. Clinico Univ. Santiago de Compostela, Santiago De Compostela, Spain|H. Univ de Valme, Sevilla, Spain|H. Univ. Virgen del Rocio, Sevilla, Spain|H. Univ. Virgen Macarena, Sevilla, Spain|H. Virgen Macarena, Sevilla, Spain|H. Univ Joan XXIII, Tarragona, Spain|H. U. de Canarias, Tenerife, Spain|H. Univ. Nuestra Sra. de la Candelaria, Tenerife, Spain|H. Mutua de Terrasa, Terrassa, Spain|Complejo Hospitalario Virgen de la Salud, Toledo, Spain|H. Univ. HM Torrelodones, Torrelodones, Spain|H. Quiron Salud Torrevieja, Torrevieja, Spain|H. Virgen de la Cinta, Tortosa, Spain|H. Reina Sofia de Tudela, Tudela, Spain|H. Arnau de Vilanova-Lliria, Valencia, Spain|H. Clinico Univ. de Valencia, Valencia, Spain|H. de Sagunto, Valencia, Spain|H. Univ. y Polit. La Fe, Valencia, Spain|H. Clin. Univ. de Valladolid, Valladolid, Spain|H. Rio Hortega, Valladolid, Spain|H. Alvaro Cunqueiro, Vigo, Spain|H. de Viladecans, Viladecans, Spain|H. de la Marina Baixa, Villajoyosa, Spain|Hospital de la Plana, Villareal, Spain|H. Univ de Alava, Vitoria, Spain|H. Virgen de la Concha, Zamora, Spain|H. Lozano Blesa, Zaragoza, Spain|H. Miguel Servet, Zaragoza, Spain|H. Ntra. Sra. de Gracia, Zaragoza, Spain|Complejo Asistencial de Avila, \u00c1vila, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""4035"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Overall mortality|Mechanical ventilation""}"
"810","Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","CORIPLASM","NCT04345991","APHP200375-10|2020-001246-18","Drug: Transfusion of COVID-19 convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04345991","Recruiting","2020-04-15","2020-06-01","{""locations"":""SMIT, Saint Antoine hospital, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival without needs of ventilator utilization or use of immunomodulatory drugs|WHO progression scale \u22656|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs""}"
"811","Neuroradiolological Analysis of COVID-19 Patients","NEURO-COVID-19","NCT04368390","7759","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368390","Recruiting","2020-04-03","2021-04-01","{""locations"":""Service d'Imagerie 2 - Neuroradiologie, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Neuroradiological analysis of patients brain MRI""}"
"812","Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome","","NCT04565665","2020-0365|NCI-2020-06741","Other: Best Practice|Biological: Mesenchymal Stem Cell","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04565665","Recruiting","2020-07-29","2021-04-30","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of composite serious adverse events (Pilot)|Patients alive without grade 3, 4 infusional toxicity (Phase II)|Patients alive with grade 3 or 4 infusional toxicity (Phase II)|Patients not alive (Phase II)|Proportion of successfully extubated patients who present intubated on ventilator support (Pilot)|Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot)|Overall survival rate (Pilot)|Survival rate in patients who present intubated on ventilator support (Pilot)|Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot)|Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters|Hospitalization stay (Pilot)|Intensive care unit stay (Pilot)|Incidence of infusion-related adverse events (Pilot)""}"
"813","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","ACTION","NCT04332107","20-30504","Drug: Azithromycin|Drug: Placebos","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04332107","Recruiting","2020-05-22","2021-12-30","{""locations"":""University of California San Francisco, San Francisco, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""2271"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Day 14 Binary Assessment of Symptoms|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)|Death|Hospitalization""}"
"814","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness","","NCT04337359","CINC424A2001M","Drug: Ruxolitinib","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04337359","No longer available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""6 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""""}"
"815","Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China","","NCT04463433","bnulxy","Behavioral: Cognitive and behavioral intervention.|Behavioral: Problem-solving and relationship improvement intervention.","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04463433","Recruiting","2020-02-01","2022-01-31","{""locations"":""Beijing Normal University, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""300"",""age"":""30 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Parent-child conflict|Parent-child communication|Parent-child Relationship|Couple Relationship Quality|Marital Stability""}"
"816","Physical Activity Program Implementation in Hospitalized Positive Covid-19 Older Adults","Cov-activity","NCT04647682","RC31/20/0145","Other: physical activity program","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04647682","Recruiting","2020-11-01","2021-12-31","{""locations"":""University Hospital Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""75 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Change of adherence of the intervention|Change of physical performances""}"
"817","BCG Vaccination to Prevent COVID-19","NUEVA","NCT04632537","USUHS.2020-062","Drug: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Drug: Preservative-free saline","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04632537","Recruiting","2020-12-07","2023-04-01","{""locations"":""Uniformed Services University, Bethesda, Maryland, United States|Carl R. Darnall Army Medical Center, Fort Hood, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""550"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of symptomatic rt-PCR-confirmed SARS-CoV-2 infection|incidence of Serology-confirmed infection with SARS-CoV-2|severity of COVID-19 disease|symptomatic respiratory infection|effect of prior adult immunization with other vaccines associated with trained immunity""}"
"818","Antioxidant Therapy for COVID-19 Study","GSHSOD-COVID","NCT04466657","GSHSOD-COVID2020","Dietary Supplement: Antioxidation Therapy|Other: Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04466657","Not yet recruiting","2020-11-01","2021-04-30","{""locations"":""Abia State Isolation Centre, Amachara, Umuahia, Abia State, Nigeria|Benue State University Teaching Hospital, Makurdi, Benue State, Nigeria|Brigadier Abba Kyari Memorial Hospital, Borno, Borno State, Nigeria|University of Maiduguri Teaching Hospital, Maiduguri, Borno State, Nigeria|University of Calabar Teaching Hospital, Calabar, Cross River, Nigeria|Federal Medical Centre Idi-Aba, Abeokuta, Ogun State, Nigeria|Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria|Infectious Disease Hospital, Amanawa, Sokoto State, Nigeria|Murtala Muhammad Speciaist Hospital, Sokoto, Sokoto State, Nigeria|Occupational Therapy Center, Sokoto, Sokoto State, Nigeria|Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""90"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Time to SARS-CoV-2 negativity|Clinical status on day 14|Proportion of participants with SARS-CoV-2 PCR negative result at Day 7|Proportion of participants with SARS-CoV-2 PCR negative result at Day 28|28 Day mortality|Duration of hospitalization in survivors|Time from treatment initiation to death""}"
"819","Hyperimmune Plasma for Patients With COVID-19","IMMUNO-COVID19","NCT04614012","IMMUNO-COVID19","Other: treated with hyperimmune plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04614012","Recruiting","2020-07-02","2022-07-02","{""locations"":""Anna Falanga, Bergamo, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death|time to extubation|length of intensive care unit stay|length of hospitalization|immune response|viral load""}"
"820","COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers","CHAMPS","NCT04370821","IRB FY2020-215","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370821","Recruiting","2020-05-09","2040-04-27","{""locations"":""Villanova University, Villanova, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sample Size of enrolled CHAMPS Study participants by demographic characteristics during the first two years of the study|Exposure to SARS-CoV-2 based on models computed from participant baseline data and community variables, if available.|Infectious disease and chronic disease incidence rates by demographic characteristics|Completeness of data by demographic characteristics.|Participation rates in ancillary and sub-studies within the CHAMPS registry.|Number of participants enrolled in randomized trials based on the CHAMPS registry""}"
"821","Convalescent Plasma for Treatment of COVID-19: An Open Randomised Controlled Trial","","NCT04649879","CP3","Biological: SARS-CoV-2 convalescent plasma|Other: Standard of care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04649879","Not yet recruiting","2020-12-03","2022-02-01","{""locations"":""Department of Infectious Disease, Falu Hospital, Falun, Dalarn, Sweden|Department of Geriatrics, Karolinska University Hospital, Stockholm, Sweden|Danderyd Hospital, Stockholm, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""920"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 related mortality within 28 days|COVID-19 related mortality within 60 days|Requirement of invasive ventilation or Pao2\/FiO2 \u2264 70 for \u2265 12 hours in the case of patients not eligible for intensive care|Adverse events|Dose of plasma needed to clear viremia|Time to clearance of viremia""}"
"822","A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19","","NCT04414124","K031-120","Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04414124","Active, not recruiting","2020-08-02","2021-02-01","{""locations"":""Healthstar Research, Hot Springs, Arkansas, United States|Axon Clinical Research, Riverside, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Vista Health Research, Miami, Florida, United States|Bio-Medical Research, Miami, Florida, United States|Mount Vernon Clinical Research, Atlanta, Georgia, United States|Centex Studies, Inc. - Lake Charles, Lake Charles, Louisiana, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Wake Research - Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Carolina Institute For Clinical Research, Fayetteville, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|TruCare Internal Medicine and Infectious Diseases, DuBois, Pennsylvania, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Global Medical Research, DeSoto, Texas, United States|Centex Studies, Houston, Texas, United States|Infectious Diseases Associates of Central Virginia, Lynchburg, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)|Change from baseline to end of intake in overall composite COVID-19 symptom score|Time to resolution of fever|Proportion of patients with decreased oxygen saturation|Effect of COVID-19 symptoms on physical activities|Proportion of patients requiring hospitalization|Time to resolution of overall 13 COVID-19 related symptoms.|Time to resolution of overall 8 cardinal COVID-19 related symptoms.""}"
"823","Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19","","NCT04444596","1104/2020","Diagnostic Test: Conjunctival swab and nasopharyngeal swab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04444596","Recruiting","2020-06-17","2021-03-31","{""locations"":""Medical University Innsbruck, Innsbruck, Tirol, Austria"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV2 positive conjunctival swabs|Conjunctival swab vs nasopharyngeal swab""}"
"824","Rehabilitation Needs After COVID-19 Hospital Treatment","REACT","NCT04438239","428/2020/OSS/AUSLRE","Other: none, this study is observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04438239","Completed","2020-06-22","2020-12-31","{""locations"":""Azienda USL-IRCCS S.Maria Nuova Hospital, Reggio Emilia, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of participants with considerable dyspnea: Medical Research Council (MRC, 0-4, lower score better outcome)|number of participants with fatigue|number of participants with anxiety|number of participants with depression|level of independence in B-ADL|level of participation in social|description of qualitative data about patients' experience""}"
"825","Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 Moves Through the Body of Adult Participants Hospitalized With Coronavirus Disease 2019 (COVID-19)","","NCT04644120","M20-404|2020-005203-39","Drug: ABBV-47D11|Drug: Placebo for ABBV-47D11","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04644120","Recruiting","2020-12-10","2021-08-03","{""locations"":""Glendale Adventist Medical Center \/ID# 225188, Glendale, California, United States|University of Miami \/ID# 225038, Miami, Florida, United States|University of Illinois Hospital and Health Sciences System \/ID# 224323, Chicago, Illinois, United States|Pikeville Medical Center \/ID# 224539, Pikeville, Kentucky, United States|Wayne State University \/ID# 224740, Detroit, Michigan, United States|Henry Ford Health System \/ID# 224320, Detroit, Michigan, United States|Michigan State University \/ID# 224907, East Lansing, Michigan, United States|Saint Peter's University Hospital \/ID# 225183, New Brunswick, New Jersey, United States|Saint Michaels Medical Center \/ID# 225258, Newark, New Jersey, United States|The Christ Hospital \/ID# 224541, Cincinnati, Ohio, United States|Prisma Health Upstate \/ID# 224556, Greenville, South Carolina, United States|St. David's Healthcare Partnership, L.P., LLP \/ID# 225053, Austin, Texas, United States|Hadassah Ein Kerem Hospital \/ID# 225827, Jerusalem, Yerushalayim, Israel|Sheba Medical Center \/ID# 225857, Ramat Gan, Israel|Universitair Medisch Centrum Utrecht \/ID# 225919, Utrecht, Netherlands|San Juan Bautista School of Medicine \/ID# 225963, Caguas, Puerto Rico|Manati Medical Center \/ID# 225936, Manati, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants With Study-Drug Related Grade 3 or Higher Adverse Events (AEs)|Number of Participants With Study-Drug Related Grade 3 or Higher Infusion-Related Reactions|Maximum Observed Serum Concentration (Cmax) of ABBV-47D11|Time to Cmax (Tmax) of ABBV-47D11|Area Under the Serum Concentration-Time Curve (AUC) From Day 1 (0 hour) to Day 29 (672 hour) (AUC0-672h) of ABBV-47D11|Terminal Phase Elimination Half-Life (t1\/2) of ABBV-47D11|AUC From Time 0 to Infinity (AUCinf) of ABBV-47D11|Detection of Anti-Drug Antibodies (ADA)|Detection of Neutralizing Anti-Drug Antibodies (nADA)|AUC for Change From Baseline (Day 1) in SARS-CoV-2 Ribose Nucleic Acid (RNA) Reverse Transcription-Polymerase Chain Reaction (RT-PCR)|Time to Negative SARS-CoV-2 by RT-PCR|Negative SARS-CoV-2 RNA by RT-PCR""}"
"826","Computed Tomography for COVID-19 Diagnosis","STOIC","NCT04355507","APHP200434","Diagnostic Test: Chest computed tomography (CT)|Diagnostic Test: Reverse-transcription polymerase chain reaction (RT-PCR)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355507","Completed","2020-03-01","2020-10-16","{""locations"":""Cochin Hospital, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""10735"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictive values of CT criteria|Accuracy of CT composite severity score|Accuracy of deep-learning based score|Predictive values of deep-learning based diagnostic algorithms|Dice similarity coefficient between manual and automated segmentation of lung disease abnormalities""}"
"827","BCG Vaccination for Healthcare Workers in COVID-19 Pandemic","","NCT04379336","TASK-008 BCG-CORONA","Biological: Bacille Calmette-Guérin (BCG)|Other: Placebo Comparator","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04379336","Recruiting","2020-05-04","2021-04-28","{""locations"":""TASK Foundation, Cape Town, Western Cape, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of HCWs hospitalized due to COVID-19 per arm|Incidence of SARS-CoV-2 infection per arm|Incidence of upper respiratory tract infections per arm|Days of unplanned absenteeism due to COVID-19 or any reason per arm|Incidence of hospitalization for any reason per arm|Incidence of intensive care unit admission per arm|Incidence of death per arm|Prevalence of latent TB infection|Incidence of active TB per arm|Compare the effect of latent TB on morbidity and mortality due to COVID-19 per arm|Incidence of treatment related adverse events""}"
"828","COVID-19 (VA CURES-1)","VA CURES-1","NCT04539275","COVID19-8900-22","Drug: Convalescent Plasma|Other: Masked Saline Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04539275","Recruiting","2020-11-16","2022-07-18","{""locations"":""Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida\/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Orlando VA Medical Center, Orlando, FL, Orlando, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States|VA Southern Nevada Healthcare System, North Las Vegas, NV, Las Vegas, Nevada, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""702"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants developing acute hypoxemic respiratory failure or all-cause death|Time (in days) to recovery|Time (in days) to death or respiratory failure|Proportion of patients who died from any cause, had respiratory failure, or required humidified heated high-flow nasal cannula (HHHFNC) at 15 Lpm|Time (in days) to death or respiratory failure or HHHFNC at 15 Lpm|Subject 28-day all-cause mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Participant's clinical status by ordinal scale|Mean change in the ordinal scale|Time to discharge or to a National Early Warning Score (NEWS)-2 of = 2 and maintained for 24 hours, whichever occurs first|Change in NEWS-2 Score from Day 1 (baseline) to Days 2, 4, 7, 11, 15, and 29|Duration of hospitalization|Number of hospitalizations related to COVID-19|Cumulative incidence of Serious Adverse Events (SAEs)|Cumulative incidence of Grade 3 and 4 clinical and\/or laboratory adverse events (AEs)|Incidence of discontinuation or temporary suspension of study product administrations (for any reason)|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in total bilirubin|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in prothrombin time (PT)""}"
"829","COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach","MD","NCT04424940","UKinshasa|Tshima Guyguy Kabundi","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424940","Not yet recruiting","2020-09-01","2021-09-01","{""locations"":""Cliniques Universitaires de Kinshasa, Kinshasa, Congo, The Democratic Republic of the"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""15 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-TOMEKA\u00ae usage as assessed by Education|Change From Baseline in nutraceuticals usage on the care of the Covid-19 at 9 months""}"
"830","Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures","","NCT04668625","PRIMACOV","Behavioral: Participate in a massive musical event","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04668625","Completed","2020-11-30","2021-01-08","{""locations"":""Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence rate of people infected with SARS-CoV-2 8 days after randomization|SARS-CoV-2 genome sequence|Incidence rate of appearance of symptoms compatible with COVID 19|Time spent in testing the total number of participants in the study.|Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 compared to PCR in asymptomatic subjects.|Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 using a nasopharyngeal swab sample compared to sample obtained trough saliva|Presence of viable SARS-CoV-2 from cell culture|Satisfaction in relation to the test procedure""}"
"831","CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients","","NCT04512118","2020PI153","Diagnostic Test: PET-CT of 18F-FDG","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04512118","Completed","2020-03-15","2020-07-30","{""locations"":""CHRU of Nancy, Vand\u0153uvre-l\u00e8s-Nancy, Grand Est, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""22"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Visual analysis of pulmonary lobes|Measurement of metabolic activity""}"
"832","Hematology and Clinical Picture in Pediatric COVID-19 Infection","","NCT04487119","RC 6-7-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04487119","Completed","2020-08-12","2020-08-23","{""locations"":""Benha Faculty of Medicine, Banh\u0101, Qalubia, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""29"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""hematological findings|clinical presentations""}"
"833","Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19","","NCT04545047","2030","Biological: COVID-19 convalescent plasma","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04545047","Active, not recruiting","2020-05-01","2022-06-30","{""locations"":""VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""21 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality""}"
"834","Treatment of SARS Caused by COVID-19 With Ruxolitinib","","NCT04334044","HAL 345/2020","Drug: Ruxolitinib Oral Tablet","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04334044","Recruiting","2020-09-01","2021-05-01","{""locations"":""Grupo Cooperativo de Hemopat\u00edas Malignas, Huixquilucan, Estado De M\u00e9xico, Mexico"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate""}"
"835","Investigation the Effect of Montelukast in COVID-19","","NCT04718285","MON786.168.1","Drug: Montelukast Oral Tablet|Drug: Montelukast plus Favicovir (Favipiravir)|Drug: Favicovir (Standard Treatment)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04718285","Not yet recruiting","2021-01-30","2021-05-30","{""locations"":""Bahcesehir University, School of Medicine, Department of Biophysics,, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""380"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalized patient rates|Emergency room visit rates of patients|Time to emergency room visit|Time to hospitalization|Inpatient length of stay|Time to ICU admission|Time to intubation|Mortality rate|Family members rates with PCR positive test results|Number\/characteristics of AEs and SAEs|Changes in blood pressure from baseline|Changes in pulse from baseline|Changes in respiratory rate from baseline|Changes in fever from baseline|Changes in oxygen saturation from baseline""}"
"836","COVID-19 Infection in Cancer Pantients","COICA","NCT04569292","COICA_PAG_01","Other: No intervention on patients","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04569292","Recruiting","2020-01-01","2021-08-01","{""locations"":""Oncology Unit, Hospital Andrea Tortora, Pagani, Salerno, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""describe cancer patients with COVID-19 and their clinical course""}"
"837","Sitagliptin Treatment in Diabetic COVID-19 Positive Patients","SIDIACO-RETRO'","NCT04382794","5/2020","Drug: Retrospective case-control analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382794","Completed","2020-05-14","2020-06-15","{""locations"":""ASST FBF-Sacco P.O. Sacco, Milan, MI, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|Ospedale dell'Angelo, Venezia-Mestre, Mestre, Italy|Humanitas Hospital, Milan, Italy|University of Pavia, Pavia, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""338"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical parameter of acute lung disease|Death|Biochemical parameter of acute lung disease""}"
"838","Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms","","NCT04393558","STU00212522","Device: ADAM Sensor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393558","Recruiting","2020-04-20","2022-12-31","{""locations"":""Shirley Ryan AbilityLab, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Body temperature|Cough Frequency|Respiratory frequency|Heart Rate Instantaneous heart rate every 15 minutes.""}"
"839","D-dimer Levels in Pregnant With COVID-19","","NCT04389554","MTalmac","Other: Blood D-dimer assay","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389554","Completed","2020-05-14","2020-05-29","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turgut Ozal, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Compare D-dimer values of COVID-19 patients and healthy pregnant women""}"
"840","The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)","","NCT04712279","CORPO-DRUG-SARSCoV2-001","Drug: Ivermectin 0.6mg/kg/day|Drug: Ivermectin 1.0mg/kg/day|Drug: Placebo|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04712279","Not yet recruiting","2021-01-25","2021-04-20","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""294"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""World Health Organization (WHO) Clinical Progression Scale [0 to 10; 0 = uninfected; 10 = death]|World Health Organization (WHO) COVID=19 Ordinal Scale for Clinical Improvement [1 to 8; 1 = not hospitalized, no limitation on activities; 8 = death] [Time Frame: Day 7]|Time-to-recovery|Viral load|Positivity rate of rtPCR-SARS-CoV-2 (qualitative analysis)|Duration of fatigue|Duration of anosmia|Overall duration of clinical manifestations|Proportion of subjects needing additional drugs or interventions|Proportion of subjects needing oxygen use|Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation|Proportion of hospitalizations|Proportion of mechanical ventilation use|Proportion of pressors use|Proportion of deaths|Proportion of post-COVID mental symptoms|Proportion of post-COVID physical symptoms|Proportion of post-COVID overall symptoms|Duration of new oxygen use|Duration of hospitalization|Duration of mechanical ventilation|Proportion of increased ultrasensitive C-reactive protein (usCRP) (defined as usRCP > 7 mg\/L)|Proportion of decrease in erythrocyte sedimentation rate (ESR) (defined as ESR decrease > 50% compared to Day 1)|Proportion of increase in eosinophils (defined as eosinophils increase > 50% compared to Day 1)|Proportion of increased d-dimer (defined as d-dimer > 500 mg\/dL)|Disease duration|Change in viral load from baseline to Day 5""}"
"841","Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling","Snowball","NCT04437706","Pro00105430","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04437706","Enrolling by invitation","2020-12-11","2022-06-30","{""locations"":""Duke University Medical Center, Durham, North Carolina, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with Active Infection|Number of Participants with Antibodies Indicating Past Exposure""}"
"842","Enzalutamide Treatment in COVID-19","COVIDENZA","NCT04475601","COVIDENZA","Drug: Enzalutamide Pill","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04475601","Recruiting","2020-07-15","2022-05-08","{""locations"":""Anders Bjartell, Malm\u00f6, Sk\u00e5ne, Sweden|Ryhovs Hospital, J\u00f6nk\u00f6ping, Sm\u00e5land, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to worsening of disease|Time to improvement of disease|Adverse events|Duration of supplemental oxygen (days)|Admission to ICU|Laboratory assessment of Hemoglobin concentration day 0, 2, 4 and 6|Virus load assessment day 0, 2, 4 and 6|Hospital stay (days)|Re-admission to hospital due to rebound COVID-19|Mortality at 6 months|Hormonal status at 6 months|Serological immunity for COVID-19|Laboratory assessment of CRP concentration day 0, 2, 4 and 6|Laboratory assessment of liver function day 0, 2, 4 and 6|Laboratory assessment of creatinine concentration day 0, 2, 4 and 6|Laboratory assessment of D-dimer concentration day 0, 2, 4 and 6|Laboratory assessment of platelets concentration day 0, 2, 4 and 6|Laboratory assessment of IL-6 concentration day 0, 2, 4 and 6|Laboratory assessment of B- and T-lyphocytes concentration day 0, 2, 4 and 6""}"
"843","COVID-19: Human Epidemiology and Response to SARS-CoV-2","HEROS","NCT04375761","DAIT-COVID-19-001","Procedure: Collection of Biological Samples|Procedure: Symptom and Exposure Surveys","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375761","Completed","2020-05-01","2021-01-24","{""locations"":""Children's Hospital Colorado: Inner City Asthma Consortium (ICAC) Site, Aurora, Colorado, United States|Children's Hospital Colorado: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Aurora, Colorado, United States|Children's National Medical Center: Inner City Asthma Consortium (ICAC) Site, Washington, District of Columbia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago: Food Allergy Outcomes Related to White and African American Racial Differences (FORWARD) and Improving Technology-Assisted Recording of Asthma Control in Children (iTRACC) Site, Chicago, Illinois, United States|Massachusetts General Hospital:Childhood Microbiome (CHIME) and Wheezing Index (WIND) Site, Boston, Massachusetts, United States|Boston Children's Hospital: School Inner-City Asthma Study (SICAS-2), Environmental Assessment of Sleep in Youth (EASY), Severe Asthma Research Program (SARP) and Preventing Asthma in High Risk Kids (PARK) Site, Boston, Massachusetts, United States|Boston Medical Center: Inner City Asthma Consortium (ICAC) Site, Boston, Massachusetts, United States|Henry Ford Health System: Childhood Allergy Study (CAS) Site, Detroit, Michigan, United States|Henry Ford Health System: Inner City Asthma Consortium (ICAC) Site, Detroit, Michigan, United States|Henry Ford Health System: Microbes, Asthma, Allergy and Pets (MAAP) and Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study (WHEALS) Site, Detroit, Michigan, United States|St. Louis Children's Hospital: Inner City Asthma Consortium (ICAC) Site, Saint Louis, Missouri, United States|Columbia University Medical Center: Inner City Asthma Consortium (ICAC) Site, New York, New York, United States|Cincinnati Children's Hospital Medical Center: Greater Cincinnati Pediatric Clinic Repository (GCPCR) and Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium (ICAC) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center:Cincinnati Childhood Allergy & Air Pollution Study (CCAAPS) Site, Cincinnati, Ohio, United States|Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) Site, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center: Inner City Asthma Consortium (ICAC) Site, Dallas, Texas, United States|University of Wisconsin Hospital and Clinics: Childhood Origins of Asthma (COAST) Site, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics: Wisconsin Infant Study Cohort (WISC) Site, Madison, Wisconsin, United States"",""study_designs"":""Observational Model: Family-Based|Time Perspective: Prospective"",""enrollment"":""5599"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Cumulative Incidence of SARS-CoV-2 RNA Detection in Nasal Samples Among Index Participants and Their Household Contacts Over the Study\/Surveillance Period|Percent of Index Participants and Their Household Contacts with Detectable SARS-CoV-2-Specific Antibodies in Serum Over the Study\/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study\/Surveillance Period|Percent of Index Participants with Asthma and Other Atopic Disease with Detectable SARS-CoV-2-Specific Antibodies in Serum Compared to Index Participants without Atopic Disease Over the Study\/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study\/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study\/Surveillance Period|Symptoms Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study\/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants using Topical Steroids Compared to Index Participants that are Not Using Topical Steroids Over the Study\/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants Using Topical, Oral, or Inhaled Steroids Compared to Index Participants that are Not Using Topical, Oral, or Inhaled Steroids During the Study\/Surveillance Period|Analysis of Factors, Baseline and Prior History, for Possible Association with the Cumulative Incidence of SARS-COV-2 Detection in Nasal Samples: Index Participants and Their Household Contacts Over the Study\/Surveillance Period""}"
"844","Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness","EPIC-19","NCT04642014","2020.ABM.COVID19.0005","Biological: COVID-19 convalescent plasma treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04642014","Not yet recruiting","2020-12-01","2022-05-01","{""locations"":""Wroclaw Medical University, Wroclaw, Dolno\u015bl\u0105skie, Poland"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death, for any reason|For patients with respiratory support, the time to take one's own breath (extubation)|Stay in the intensive care unit (ICU)|Time to disconnect CPAP respiratory support|Time to elimination of SARS-Cov-2 (RT-PCR)|Time to serological response (anti-SARS-COv-2 antibodies)""}"
"845","COVID-19 Infection in Patients With Hepatocellular Carcinoma","COVID19-CHIEF","NCT04367805","PI2020_843_0042","Diagnostic Test: nasopharyngeal Covid 19 RT-PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367805","Recruiting","2020-04-27","2020-10-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France""}"
"846","Corticosteroids in Severe COVID-19(ASAP-C Study)","ASAP-C","NCT04648410","ASAP-C study","Other: questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04648410","Recruiting","2021-02-16","2021-12-01","{""locations"":""University Hospital Brno, Brno, Czechia"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""up to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Systemic corticosteroids among patients with COVID-19 ARDS practice - questionnaire (electronic survey)""}"
"847","Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions","","NCT04348240","200094|20-D-0094","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04348240","Recruiting","2020-04-16","2021-07-01","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To determine SARS-CoV-2 viral load and infectivity insaliva that may contribute to asymptomatic transmission""}"
"848","Progesterone for the Treatment of COVID-19 in Hospitalized Men","","NCT04365127","STUDY00000611","Drug: Progesterone 100 MG","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04365127","Completed","2020-04-27","2020-08-20","{""locations"":""Cedars Sinai Medical Center, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in clinical status of subjects at Day 7 based on the following 7-point ordinal scale|Change in clinical status of subjects assessed daily while hospitalized and on Day 15|Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization""}"
"849","Ivermectin Nasal Spray for COVID19 Patients","","NCT04510233","IvrInh","Drug: Ivermectin nasal|Drug: Ivermectin oral|Other: standard care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04510233","Not yet recruiting","2020-09-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""PCR of SARS-Cov2 RNA""}"
"850","To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19","MAOP3","NCT04709328","SCTA01-A301","Drug: SCTA01|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04709328","Not yet recruiting","2021-03-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""690"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who experience COVID-19 related hospitalization (defined as at least 24 hours of acute care) or death (all cause) up to Day 29.|Time to sustained resolution of all COVID-19-related symptoms|- Change in symptom score (total of ratings)|Time to symptom improvement;|Proportion of participants admitted to hospital due to COVID-19|Proportion of participants with \u22651 COVID-19 related hospitalization|Proportion of participants with \u22652 COVID-19 related hospitalizations|Total number of COVID-19 related hospitalization|Proportion of participants who experience COVID-19 related emergency room (ER) visit|Proportion of participants with \u22651 ER visit due to COVID-19|Proportion of participants with \u22652 ER visits due to COVID-19 through Day 29|Proportion of participants admitted to an intensive care unit (ICU) due to COVID-19|Proportion of patients with all-cause mortality|Proportion of participants with O2 requirement|Proportion of participants with ventilation requirements|Proportion of participants that achieve SARS-CoV-2 clearance in nasopharyngeal (NP) or oropharyngeal (OP) samples|Change from baseline (Day 1) to Day 8 or Day 15 in SARS-CoV-2 viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in NP or OP samples for SARS-CoV-2 test.|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 1, 2, 3 and 4 adverse events (AEs)|Discontinuation or temporary suspension of infusions (for any reason)|Number and proportion of patients with ADE|Mean concentration-time profiles of SCTA01|Incidence and titers (if applicable) of anti-drug antibodies (ADA) to SCTA01""}"
"851","Predictive Factors COVID-19 Patients","MI-COVID","NCT04427345","MI-COVID","Other: Predictive factors for clinical response in patients with COVID-19.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04427345","Recruiting","2020-04-30","2021-04-30","{""locations"":""ASST Monza-Ospedale San Gerardo, Monza, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identify risk factors for intra-hospital mortality.|Identify risk factors to build a prognostic score.|Predictive factors for the hospitalization duration.|Predictive factors for clinical status patients based on \""Ordinal Scale for Clinical Improvement\""|Describe the anti-viral therapies used commonly in this emergency in terms of efficacy|Describe the anti-viral therapies used commonly used in this emergency in terms of safety|Monitor the clinical course of the disease in discharged patients.""}"
"852","Clinical Study of Pregnant Women With COVID-19","PregWom-Covid","NCT04701944","7794","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04701944","Recruiting","2020-04-21","2021-04-21","{""locations"":""Department of Gynecology-Obstetrics and Fertility - Strasbourg University Hospitals, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""54"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A retrospective review of the medical records of pregnant women with COVID-19 at the University Hospitals of Strasbourg""}"
"853","Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19","","NCT04705844","A21-070","Drug: Adalimumab|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04705844","Not yet recruiting","2021-02-01","2022-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1444"",""age"":""40 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Establish whether treatment with adalimumab is associated with a lower rate of progression to severe disease as defined by severe illness or critical illness, or death in outpatient subjects with COVID-19|Assess the safety of adalimumab in subjects with COVID-19|Assess the impact of treatment with adalimumab on clinical course of COVID-19 infection""}"
"854","Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans","","NCT04649515","SCT-301","Biological: TY027|Other: 0.9% saline","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04649515","Recruiting","2020-12-04","2021-12-30","{""locations"":""Singapore General Hospital, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1305"",""age"":""21 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate the efficacy of a single dose intravenous (IV) infusion of TY027 in reducing disease progression, defined as progression to score 4 and below on COVID scale|Rate of AEs (grade 3 and above) and SAEs in COVID-19 patients|All cause mortality rate|Proportion of subjects in categories 4, 3, 2 and 1 of the COVID scale|Number of days COVID-19 patients require supplemental oxygen, high flow oxygen, non-invasive and invasive mechanical ventilation (if applicable)|Proportion of COVID-19 patients tested negative for SARS-CoV-2 via reverse transcriptase-polymerase chain reaction (RT-PCR)|Proportion of COVID-19 patients with a minimum of 0.5 log time-weighted viral load reduction from saliva samples, via sub-genomic qRT-PCR""}"
"855","Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 Epidemic","","NCT04703777","7814","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04703777","Recruiting","2020-04-04","2021-04-04","{""locations"":""Adult Emergency Department - Strasbourg University Hospitals, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective study on the relationship between social status and use of healthcare services during the confinement period linked to the COVID-19 epidemic in Bas-Rhin, France""}"
"856","COVID-19 Virtual Care at Home","","NCT04420182","CTO 3210","Other: Virtual Care at Home","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04420182","Recruiting","2020-08-17","2021-12-31","{""locations"":""St. Mary's General Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Heart Research Institute, Ottawa, Ontario, Canada|Niagara Health, St. Catharines, Ontario, Canada|St. Joseph's Health Centre, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""14 Day Patient Satisfaction Questionnaire|Emergency Department Visits|14 Day EQ-5D-5L Scores""}"
"857","Iota-carrageenan Nasal Spray COVID-19 Prophylaxis for Healthcare Professionals","ICE-COVID","NCT04590365","283187","Device: Carrageenan nasal and throat spray|Device: Saline nasal and throat spray","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04590365","Not yet recruiting","2021-01-30","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""480"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of COVID-19 infection in healthcare professionals|Severity of COVID-19 infection|Severity of COVD-19 infection""}"
"858","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study","","NCT04329559","CHESS2002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04329559","Completed","2020-03-30","2021-02-10","{""locations"":""Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""21"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis""}"
"859","Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers","ProBCG","NCT04659941","31942220.8.1001.5257","Biological: BCG vaccine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04659941","Recruiting","2020-10-01","2022-10-01","{""locations"":""Universidade Federal do Rio de Janeiro, Rio De Janeiro, RJ, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Compare the cumulative incidence of SARS-CoV-2 infection|Compare the cumulative incidence of severe forms of COVID-19|Assess the BCG vaccine-mediated immune response in health care workers""}"
"860","Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit","AziA","NCT04363060","RC20_0168","Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04363060","Not yet recruiting","2020-04-30","2020-07-30","{""locations"":""Chu Angers, Angers, France|CHD Vend\u00e9e, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""104"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion""}"
"861","CAPTION AI to Minimize Risk of COVID Exposure","CAPTION AI","NCT04336774","pro00105212","Device: Caption AI","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04336774","Withdrawn","2020-07-01","2020-11-09","{""locations"":""Duke Health, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent of patient echos that are not interpretable|Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)|Time to acquire images as measured by time stamps|Percent of agreement between AI calculate LVEF and LVEF read by physician""}"
"862","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","","NCT04343248","RM08-3006","Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04343248","Recruiting","2020-05-12","2021-06-30","{""locations"":""The Chappel Group Research, Kissimmee, Florida, United States|Clinical Trial Specialists, Inc., Acworth, Georgia, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centex Studies, Inc., Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""800"",""age"":""55 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI""}"
"863","Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection","","NCT04372017","PEPCOH","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04372017","Active, not recruiting","2020-05-14","2021-06-04","{""locations"":""Sanford Health, Sioux Falls, South Dakota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.|Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.""}"
"864","Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA","","NCT04413955","001-Seraph®-100 for SARS-CoV-2","Device: Seraph®-100 Microbind® Affinity Blood Filter","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04413955","Recruiting","2020-06-01","2021-12-31","{""locations"":""AdventHealth Orlando, Orlando, Florida, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of known, expected, or unanticipated adverse device effects|Change in cardiovascular hemodynamic stability|Change in cardiovascular hemodynamic support|Change in pulmonary\/respiratory status|Change in laboratory measures of cytokine reactions and\/or viral sepsis: IL-6|Change in laboratory measures of cytokine reactions and\/or viral sepsis: CRP|Change in laboratory measures of cytokine reactions and\/or viral sepsis: Ferritin|Change in laboratory measures of cytokine reactions and\/or viral sepsis: D-Dimer|Change in laboratory measures of cytokine reactions and\/or viral sepsis: ALC""}"
"865","Povidone-Iodine Rinses in the Management of COVID-19","","NCT04449965","Betadine COVID-19","Drug: Povidone-iodine|Drug: Placebo","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04449965","Not yet recruiting","2020-07-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""81"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SARS-CoV-2 positivity in the saliva|Change in the SAR-CoV-2 viral load in the saliva|Change in Wisconsin Upper Respiratory Symptom Survey (WURSS-44)|Change Sino nasal Outcome Test (SNOT-22)|Change in clinical condition""}"
"866","Vitamin D on Prevention and Treatment of COVID-19","COVITD-19","NCT04334005","COVITD-19","Dietary Supplement: Vitamin D","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04334005","Not yet recruiting","2020-04-10","2020-06-30","{""locations"":""Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""40 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery""}"
"867","At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19","UNITED","NCT04656691","2020-0081_","Drug: bamlanivimab","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04656691","Enrolling by invitation","2021-01-04","2021-05-01","{""locations"":""QueryLab, Minnetonka, Minnesota, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""7500"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Efficacy - determining hospitalization rates|Safety - documenting adverse events after infusion""}"
"868","Hypertension in Patients Hospitalized With COVID-19","HT-COVID19","NCT04318301","HT-COVID19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04318301","Completed","2020-03-21","2020-03-30","{""locations"":""Hankou Hospital, Hankou, Hubei, China"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""275"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of Death|the severity of pneumonia""}"
"869","Intravenous Infusion of CAP-1002 in Patients With COVID-19","INSPIRE","NCT04623671","CAP-1002-COVID-19-02","Biological: CAP-1002|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04623671","Recruiting","2020-11-15","2021-06-30","{""locations"":""Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California Davis, Sacramento, California, United States|Henry Ford Health System, Detroit, Michigan, United States|PharmaTex Research, LLC, Amarillo, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety of CAP-1002|Efficacy of CAP-1002 on Cytokine|Efficacy of CAP-1002 on Laboratory Biomarker""}"
"870","COVID 19 Serology in Pulmonologists","Pneumoserocov","NCT04422574","RECHMPL20_0343","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422574","Completed","2020-05-01","2020-05-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""97"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""covid 19 serology|risk factors for positive serology testing""}"
"871","Role of Famotidine in the Clinical Improvement of COVID-19 Patients.","","NCT04504240","10000753/980","Drug: Famotidine 20 MG","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04504240","Active, not recruiting","2020-08-01","2021-04-10","{""locations"":""Chattogram General Hospital, Chittagong, Bangladesh|M. Abdur Rahim Medical College Hospital, Din\u0101jpur, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""16 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Time to Clinical Improvement (TTCI)|Time to symptomatic recovery.|Mortality Rate|Duration of ICU Stay.|Total hospital stay.|Time to clinical failure or death.|Time to Viral clearance \/ COVID-19 recovery.""}"
"872","Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","","NCT04469179","SAB-185-102","Biological: SAB-185|Other: Normal Saline","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04469179","Active, not recruiting","2020-08-20","2021-04-01","{""locations"":""Quantum Clinical Trials, Miami Beach, Florida, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Sanford Health, Sioux Falls, South Dakota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""21"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of Participants Having Adverse Events|Number of Participants Having Transfusion-Related Adverse Events|Assesment of the PD of SAB-185 administered intravenously|Immune response elicited by SAB-185|Concentration of subject anti-SAB-185 antibodies elicited by SAB-185|Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens|Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens""}"
"873","Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic","","NCT04668469","Re96.2020","Drug: Ivermectin|Drug: Hydroxychloroquine|Behavioral: personal protective Measures","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04668469","Completed","2020-06-08","2020-10-30","{""locations"":""Benha Faculty of Medicine, Benha University, Banh\u0101, Qaluopia, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of participants with improvement of clinical condition (symptoms and signs)|Reduction of recovery time, hospital stay days and mortality rate|improvement of laboratory investigations and 2 consecutive negative PCR tests taken at least 48 hours apart.""}"
"874","A Trial of Remdesivir in Adults With Mild and Moderate COVID-19","","NCT04252664","CAP-China remdesivir 1","Drug: Remdesivir|Drug: Remdesivir placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04252664","Suspended","2020-02-12","2020-04-27","{""locations"":""Jin Yin-tan hospital, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""308"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events""}"
"875","CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19","CRISIS2","NCT04575038","CCB-CRISIS-02","Drug: Brequinar|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04575038","Recruiting","2020-11-19","2021-02-28","{""locations"":""Central Alabama Research, Homewood, Alabama, United States|Ark Clinical Research, Long Beach, California, United States|Doral Medical Research, Doral, Florida, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Monroe Biomedical Research, Monroe, North Carolina, United States|Wilmington Health, Wilmington, North Carolina, United States|Remington-Davis, Inc., Columbus, Ohio, United States|Toledo Institute of Clinical Research, Toledo, Ohio, United States|VitaLink - Gaffney, Gaffney, South Carolina, United States|Self Regional Healthcare Research Center - Self Medical Group, Greenwood, South Carolina, United States|VitaLink Research, Spartanburg, South Carolina, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Centex Studies, Inc. - McAllen, McAllen, Texas, United States|Synexus Clinical Research US, Inc. - Olympus Family Medicine, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 viral load|Rates of AEs and SAEs including laboratory assessments|Viral shedding duration|Hospital Admission""}"
"876","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection","","NCT04359680","RM08-3007","Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04359680","Active, not recruiting","2020-05-13","2021-03-29","{""locations"":""HealthStar Research LLC, Hot Springs, Arkansas, United States|So Cal Clinical Research, Huntington Beach, California, United States|Long Beach Clinical Trials, LLC, Long Beach, California, United States|Meris Clinical Research, Brandon, Florida, United States|Invesclinica US LLC, Fort Lauderdale, Florida, United States|The Chappel Group Research, Kissimmee, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|DMI Research, Pinellas Park, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States|Chicago Medical Research Institute, Inc., Chicago, Illinois, United States|Quad Clinical Research, Chicago, Illinois, United States|Chicago Medical Research, LLC, Hazel Crest, Illinois, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Beacom Family Health Connection, Fremont, Nebraska, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|RH Medical Urgent Care Professional PLLC, Bronx, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|The New York Center for Travel and Tropical Medicine, New York, New York, United States|Centex Studies, Inc., Houston, Texas, United States|SMS Clinical Research LLC, Mesquite, Texas, United States|LinQ Research LLC, Pearland, Texas, United States|Rio Grande Valley Clinical Research Institute, Pharr, Texas, United States|BFHC Research, San Antonio, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1407"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.|The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.""}"
"877","Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","","NCT04596085","NS-VC-CT01-20","Dietary Supplement: Investigational Product - ViraCide|Other: Placebo - Starch Powder Soft gels","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04596085","Recruiting","2020-09-16","2021-01-30","{""locations"":""Department of General medicine\/ clinical research. Government medical college and Government general hospital, Srikakulam, Andhra Pradesh, India|Gunjkar Multispeciality Hospital, Pune, Maharashtra, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care"",""enrollment"":""124"",""age"":""50 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""NEWS Score|7-point ordinal scale|Rate of progression on NEWS score|Rate of progression on 7 point ordinal score|Time to COVID-19 nucleic acid testing|ICU admissions|survival rate|mechanical ventilation|Assessmentofcomorbidcondition|worsening comorbid condition""}"
"878","CSL324 in COVID-19","","NCT04519424","CSL324_COVID-19","Biological: CSL324|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04519424","Withdrawn","2020-09-01","2021-05-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects progressing to endotracheal intubation or death prior to endotracheal intubation|Proportion of deaths from all causes|Proportion of subjects intubated|Median length of stay in hospital|Number and proportion of subjects with at least a 2-point improvement in the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale|Number and proportion of subjects within each of the categories of the NIAID ordinal scale|Proportion of subjects using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP)|Proportion of subjects using high-flow nasal cannula (HFNC)|Proportion of subjects using extracorporeal membrane oxygenation (ECMO)|Maximum Change in Sequential Organ Failure Assessment (SOFA) score|Change in SOFA score and in individual components of the SOFA score|Number and proportion of subjects experiencing adverse events (AEs)|Number and proportion of subjects experiencing serious adverse events (SAEs)|Number and proportion of subjects experiencing adverse events of special interest (AESIs)|Presence of anti-CSL324 antibodies|Maximum concentration (Cmax) of CSL324|Time to reach maximum concentration (Tmax) of CSL324|Area under the concentration-time curve (AUC0-last) of CSL324|Trough concentration (Ctrough) of CSL324""}"
"879","The VOICE-COVID-19","","NCT04508972","2020-6583","Device: Alexa Amazon","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04508972","Recruiting","2020-07-01","2020-11-01","{""locations"":""Muhc-Rimuhc, Montreal, Quebec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between data captured using Amazon Alexa compared to manual (human) collected data.""}"
"880","Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste","FORECAST","NCT04377815","132311|20/HRA/1879","Other: General Public cohort","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377815","Completed","2020-04-23","2020-06-24","{""locations"":""University College London Hospital, London, United Kingdom|GP Practices, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""569"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of people reporting changes in smell\/taste|mortality rate|Percentage of people with change in smell\/taste before other symptoms|proportion of other COVID-19 linked symptoms in people with smell and\/or taste change|Percentage of people with persistent changes in smell and\/or taste|Percentage of hospitalisation|co-morbidities association|prevalence of changes in smell\/taste|clinical outcomes""}"
"881","Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19","","NCT04676867","DAL-401","Drug: Dalcetrapib|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04676867","Recruiting","2021-01-11","2021-03-01","{""locations"":""Institut de Cardiologie de Montr\u00e9al, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""208"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate the time to sustained clinical resolution of symptoms of COVID-19""}"
"882","Genetics of COVID-19 Susceptibility and Manifestations","","NCT04371432","200090|20-HG-0090","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371432","Recruiting","2020-05-05","2025-06-01","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""3 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Molecular etiology of host susceptibility to severe COVID-19|Mechanisms of disease""}"
"883","Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity","","NCT04670328","FMHCMD","Diagnostic Test: not required","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04670328","Completed","2020-05-01","2020-07-31","{""locations"":""FMH college of medicine and dentistry, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""101"",""age"":""17 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""complete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio|PT, APTT and D-dimer""}"
"884","VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)","VA-REACH","NCT04363203","20-30517","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04363203","Suspended","2020-04-30","2021-08-01","{""locations"":""San Francisco VA, San Francisco, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""216 Months and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days to resolution of cough, fever and shortness of breath|Days to resolution of all COVID-19 symptoms|All cause hospitalization|All cause mortality|COVID-19 specific mortality|COVID-19 specific hospitalization""}"
"885","Survey of the Anxiety Associated With the COVID-19 Pandemic","CORA","NCT04331106","EA1/071/20","Diagnostic Test: Online Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04331106","Recruiting","2020-03-27","2022-04-01","{""locations"":""Charit\u00e9-Universit\u00e4tsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""7500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characteristics of COVID-19-related anxiety|COVID-19-related anxiety symptoms|Self-efficacy and coping with COVID-19|Consequences of COVID-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of COVID-19-related anxiety|Change in COVID-19-related anxiety symptoms""}"
"886","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","COVID19PUGG2","NCT04343781","ar20-0031v1","Other: observation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04343781","Completed","2020-03-22","2020-04-05","{""locations"":""Angers University Hospital, Angers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""353"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""symptoms of COVID-19 in older patients""}"
"887","Moxibustion Plus Cupping in Convalescent Patients With COVID-19","","NCT04374084","2020YFC0845000","Other: Moxibustion plus Cupping","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04374084","Recruiting","2020-05-10","2021-12-01","{""locations"":""Hubei Province Hospital, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The change of the average VAS score from baseline to week 4|The change of the average VAS score from baseline to week 2, and week 8|The change of the severity VAS score from baseline to week 2, week 4 and week 8|The change of the average insomnia VAS score from baseline to week 2, week 4 and week 8|The change of the average VAS score of sweating, mental fatigue, anorexia and nervousness from baseline to week 2, week 4 and week 8|The change of the average times of diarrhea and complete spontaneous bowel movement to week 2, week 4 and week 8|The proportion of patients with 50%\/75% improvement of clinical symptoms to week 2, week 4 and week 8|The change of the walking distance of six-minute-walking test from baseline to week 2, week 4 and week 8|The change of the lowest oxygen saturation of six-minute-walking test from baseline to week 2, week 4 and week 8|The proportion of patients in recovery of pulmonary function on week 2 and week 4|The proportion of patients whose lung CT return to normal on week 4|The change of the WHO QOL-BREF score from baseline to week 4 and week 8|The change of the SAS score from baseline to week 4 and week 8|The change of the SDS score from baseline to week 4 and week 8|The change of the blood CRP value from baseline to week 4|The change of the blood LYMPH# value from baseline to week 4|The change of the blood NEUT% value from baseline to week 4|The change of the average VAS score from baseline to week 4 in different age groups.|The change of the average VAS score from baseline to week 4 in different gender groups.|The change of the average VAS score from baseline to week 4 in different clinical classification of COVID-19.""}"
"888","A Trial of GC4419 in Patients With Critical Illness Due to COVID-19","","NCT04555096","COV-4419-201","Drug: GC4419|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04555096","Recruiting","2020-09-09","2021-12-01","{""locations"":""University of Iowa, Iowa City, Iowa, United States|Saint Louis University, Saint Louis, Missouri, United States|Mercy Research, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28 day all-cause mortality""}"
"889","The Nitazoxanide Plus Atazanavir for COVID-19 Study","NACOVID","NCT04459286","NACOVID","Drug: Nitazoxanide and atazanavir/ritonavir|Other: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04459286","Recruiting","2020-10-09","2021-04-30","{""locations"":""Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria|Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria|State Specialist Hospital Asubiaro, Osogbo, Osun State, Nigeria|Infectious Disease Hospital, Olodo, Ibadan, Oyo State, Nigeria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""98"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Time to SARS-CoV-2 negativity|Difference in SARS-CoV-2 AUC|Time to symptoms resolution|Clinical status as assessed with the seven-category ordinal scale on days 7 and 14|Duration of hospitalization in survivors|Day 28 mortality|Time from treatment initiation to death|Proportion with viral RNA detection over time""}"
"890","Asunercept in Patients With Severe COVID-19","ASUNCTIS","NCT04535674","APG101_CD_017|2020-001887-27","Biological: Asunercept","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04535674","Recruiting","2020-10-09","2021-05-01","{""locations"":""Federal State Budgetary Educational Institution of Higher Education \""Kuban State Medical University\"" of the Ministry of Health of the Russian Federation, Krasnodar, Russian Federation|State Budgetary Healthcare Institution \""Scientific Research Institute - Regional clinical hospital No. 1 n.a. professor S.V. Ochapovsky\"" of the Ministry of Healthcare of Krasnodar Krai, Krasnodar, Russian Federation|State Budgetary Institution of Health of the Nizhny Novgorod Region \""Infectious Clinical Hospital No. 2 of Nizhny Novgorod\"", Nizhny Novgorod, Russian Federation|Saint Petersburg state budgetary healthcare institution \""Botkin clinical infectious diseases hospital\"", Saint Petersburg, Russian Federation|Saint Petersburg state budgetary healthcare institution \""City hospital of Saint George the great Martyr\"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Healthcare Institution \""Mariinskaya City hospital\"", Saint Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""Bashkir State Medical University\"" of the Ministry of Health of the Russian Federation, Ufa, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""Bashkir State Medical University\"" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Hospital Universitario Infanta Sofia, San Sebasti\u00e1n De Los Reyes, Spain|Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to sustained improvement of one category (i.e. two consecutive days) from randomisation|Efficacy according to the National Early Warning Score (NEWS)|Oxygenation|Ventilation|Hospitalisation - Length|Hospitalisation - Proportion on ICU|Mortality""}"
"891","Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19","ERap-COV","NCT04405492","APHP200556","Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|Device: Capillary and salivary sampling","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04405492","Not yet recruiting","2020-05-25","2021-03-25","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""1210"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical performance of several diagnostic tests : tests based either on detection of the virus SARS-CoV-2 or detection of human antibodies generated in response to infection|Sensitivity and specificity of immunological, antigenic, molecular and proteomic tests according to symptom duration, stage of the disease: asymptomatic, ambulatory, hospitalized, ventilated|Description of the incidence of infection among hospital caregivers, time to seroconversion according to clinical form, medium-term antibody persistence|Sensitivity and specificity of immunodiagnostic tests according to the sample used (serum and capillary blood) and according to the duration of the symptoms|Sensitivity and specificity of antigenic rapid tests, molecular tests, proteomic tests according to the sample used (salivary samples or nasopharyngeal swabs) and according to the duration of the symptoms|Suitability of rapid tests in view of its intended purpose for self-testing""}"
"892","Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo","","NCT04521296","DW_DWJ1248201","Drug: DWJ1248|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04521296","Not yet recruiting","2020-08-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to SARS-CoV-2 eradication|Rate of SARS-CoV-2 eradication|Time to clinical improvement of subjective symptoms""}"
"893","Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease","COLDSTER","NCT04657484","INT/IEC/2020/SPL-1528","Drug: Medium dose prednisolone|Drug: Low dose prednisolone","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04657484","Recruiting","2020-12-08","2021-12-07","{""locations"":""Postgraduate Institute of Medical Education and Research, Chandigarh, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects with a complete radiologic response|Proportion of subjects with a complete or good response radiologic response|Proportion of subjects with a good composite response|Forced vital capacity as a percentage of the predicted|Change in resting oxygen saturation|Proportion of subjects with oxygen desaturation on exercise testing|Change in dyspnea score|Severity of dyspnea|Respiratory health status|Health-related quality of life|Adverse effects of prednisolone""}"
"894","Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection","","NCT04622891","SVU-MED-CHT019-420860","Drug: Clarithromycin 500mg|Drug: Azithromycin|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04622891","Completed","2020-04-01","2020-07-30","{""locations"":""south-Vally University faculty of medicine, Qena, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""time to fever control|PCR conversion""}"
"895","Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19","","NCT04426253","COVID19_HUNGEN_001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04426253","Active, not recruiting","2020-06-05","2021-07-31","{""locations"":""University of P\u00e9cs 1st Department of Internal Medicine Intensive Care Unit, P\u00e9cs, Hungary|University of P\u00e9cs First Department of Internal Medicine, P\u00e9cs, Hungary|University of P\u00e9cs Infection Department of the Coronavirus Center, P\u00e9cs, Hungary|University of P\u00e9cs Institute of Laboratory Medicine, P\u00e9cs, Hungary|University of P\u00e9cs Szent\u00e1gotahi Research Centre, P\u00e9cs, Hungary|University of P\u00e9cs Szent\u00e1gothai Research Centre Genomics and Bioinformatics Core Facility, P\u00e9cs, Hungary|University of Szeged Szent\u00e1gothai Research Centre Virology Research Group, P\u00e9cs, Hungary|University of Szeged Department of Anaesthesiology And Inthensive Therapy, Szeged, Hungary|University of Szeged Department of Dermatology and Allergology, Szeged, Hungary|University of Szeged Department of Medical Biology, Szeged, Hungary|University of Szeged Department of Paediatrics, Szeged, Hungary|University of Szeged First Department of Medicine, Szeged, Hungary|University of Szeged Institute of Clinical Microbiology, Szeged, Hungary|University of Szeged Institute of Medical Microbiology and Immunobiology, Szeged, Hungary"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of genetic factors determining the course of the disease in case of COVID-19""}"
"896","The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia","","NCT04422678","Alex CCM 2020/5","Drug: Imatinib Mesylate|Drug: Standard of Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04422678","Not yet recruiting","2020-06-01","2020-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary endpoint: Disease Progression|Improvement in Hypoxic Index|Hospital Length of Stay|Days on invasive mechanical ventilation|Inflammatory Markers|Viral clearance|Radiological assessment|Safety of Imatinib""}"
"897","Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers","HERD","NCT04446065","MEL109042020","Drug: Previfenon®|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04446065","Not yet recruiting","2020-09-30","2021-10-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""524"",""age"":""25 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR|Rate of positive cases for IgM and IgG anti-SARS-CoV-2|Composite outcome considering symptomatic and asymptomatic cases with positive rtPCR test|Hospitalization due to any acute respiratory infection|Event of upper and lower airway respiratory infection""}"
"898","Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans","","NCT04565067","10000140|000140-AG","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04565067","Recruiting","2021-03-16","2022-09-01","{""locations"":""National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine CD8 T cells that are responsive to SARS-CoV-2.""}"
"899","COVID 19-Caregivers IGg Seroconversion","CoSigS","NCT04353323","87RI20_0016/CoSigS","Other: Blood sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04353323","Not yet recruiting","2020-05-25","2020-12-25","{""locations"":""CHU de Limoges, Limoges, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""130"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroconversion""}"
"900","Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients","PredictCovid-D","NCT04371510","20-PP-08","Other: blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04371510","Recruiting","2020-04-22","2021-02-22","{""locations"":""CHU de nice, Nice, Alpes-Maritimes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""115"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation""}"
"901","Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19","NOVATION-1","NCT04669015","JH-COR-003","Biological: Novaferon|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04669015","Not yet recruiting","2021-01-01","2021-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""914"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of clinical deterioration|Rate of recovery|Hospital discharge rate|Mortality rate|Duration of hospitalization|Adverse events""}"
"902","Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients","","NCT04500418","CVC for COVID-19|2020-001493-29","Drug: Cenicriviroc (CVC)|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04500418","Recruiting","2020-08-25","2021-09-30","{""locations"":""Medical Department of Hepatology and Gastroenterology, Charit\u00e9 University Medicine, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Berlin, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""183"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Subject\u00b4s Responder status (score on the 7-point ordinal scale on Day 15)|Evaluation of change in clinical condition based on the 7-point ordinal scale|Evaluation of change in clinical condition based on the 7-point ordinal scale and Responder Status|Hospital resource utilization comparison""}"
"903","Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic","","NCT04403581","Egyptian doctors in COVID-19","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403581","Not yet recruiting","2020-05-01","2020-06-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""384"",""age"":""23 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Cross-sectional descriptive study: Egyptian Doctors Stresses, Knowledge and Attitude during COVID-19 Pandemic""}"
"904","Determination of Serum Trace Element and Physical Activity Levels in COVID-19","","NCT04694716","2020-12-141","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694716","Recruiting","2021-01-06","2021-03-01","{""locations"":""Kadirhan Ozdemir, \u0130zmir, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""35 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Levels of serum trace elements parameters|Physical Activity Level|Levels of Routine Blood Samples""}"
"905","The Heart Hive COVID-19 Study","","NCT04468256","20IC6036","Other: COVID-19 experience surveys","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468256","Recruiting","2020-07-26","2022-07-01","{""locations"":""Imperial College London, London, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Qualitative measures of exposure, perception of risk, behaviour, and experience during the COVID-19 pandemic.|Health Outcomes""}"
"906","Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19","","NCT04346628","56032","Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04346628","Enrolling by invitation","2020-07-12","2021-07-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time until cessation of oral shedding of SARS-CoV-2 virus|Sars-CoV-2 viral load|Count of participants with clinical worsening of COVID-19 disease|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Count of participant with absence of development of any symptoms|Cmax of favipiravir|Cmin of favipiravir""}"
"907","Efficacy and Safety of Favipiravir in Management of COVID-19","FAV-001","NCT04349241","FMASU P14 / 2020","Drug: favipiravir|Drug: Standard of care therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04349241","Completed","2020-04-18","2020-06-20","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral clearance|Clinical improvement|Radiological Improvement""}"
"908","Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection","HEPMAB","NCT04600141","5057/20/086","Drug: Tocilizumab|Drug: Heparin - Therapeutic dosage|Drug: Heparin - Prophylactic dosage","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04600141","Recruiting","2020-11-10","2021-12-31","{""locations"":""Funda\u00e7\u00e3o S\u00e3o Francisco Xavier, Ipatinga, Minas Gerais, Brazil|UNIMED Varginha, Varginha, Minas Gerais, Brazil|Universidade Federal de Sergipe, Aracaju, Sergipe, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""308"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with clinical improvement|Hospital and ICU length of stay;|Duration of invasive mechanical ventilation|Duration of vasopressor use|Renal failure by AKIN criteria|Incidence of cardiovascular complications|Incidence of venous thromboembolism|Mortality""}"
"909","Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.","CORSA","NCT04345315","IRSTB113","Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing (NGS) analysis|Other: serum chemistry analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04345315","Recruiting","2020-03-27","2022-03-01","{""locations"":""UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""epidemiology|Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.|phylogenetic map|interactions between the virus and host cells""}"
"910","suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19","SAVE-MORE","NCT04680949","SAVE-MORE","Drug: Anakinra|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04680949","Recruiting","2020-12-23","2021-12-20","{""locations"":""2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|10th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece|1st Department of Internal Medicine, AMALIA FLEMING Prefecture General Hospital of Melissia, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece|1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION, Athens, Greece|1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO, Athens, Greece|1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece|1st University Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece|2nd Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S., Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA, Athens, Greece|4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece|4th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece|5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece|COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Athens, Greece|Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens, Greece|Department of COVID-19, Evangelismos General Hospital, Athens, Greece|Department of Internal Medicine, General Hospital of Athens Elpis, Athens, Greece|\u2022 1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|\u2022 Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA, Athens, Greece|Department of Pulmonary Medicine, General Hospital of Kerkyra, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Io\u00e1nnina, Greece|Department of Internal Medicine, University General Hospital of Larissa,, Larissa, Greece|Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Patra, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO, Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessalon\u00edki, Greece|1st Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki, Thessalon\u00edki, Greece|2nd Department of Propedeutic Medicine, Ippokrateion University General Hospital of Thessaloniki, Thessalon\u00edki, Greece|3rd University Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki, Thessalon\u00edki, Greece|Dipartimento di Medicina Dipartimento di Malattie Infettive, ASST Spedali civili, Brescia, Italy|Unit\u00e0 Operativa Clinica Malattie Infettive, Ospedale Policlinico San Martino, Genova, Italy|Dipartimento di Medicina Interna, Istituto Clinico Humanitas, Milano, Italy|Medicina Interna, Reumatologia, Immunologia, IRCCS San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive e Tropicali e Microbiologia, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy|Dipartimento di Malattie Infettive ad alta Intensit\u00e0 di cura ed altamente contagiose, IRCCS Lazzaro Spallanzani, Roma, Italy|Dipartimento Scienze di laboratorio e infettivologiche, Policlinico Universitario Agostino Gemelli, Roma, Italy|Dipartimento di Malattie infettive e tropicali-Universit\u00e0 dell'Insubria, ASST dei Sette Laghi, Varese, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of the distribution of frequencies of each score of a 5-scale patient state evaluated from the 11-point WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment|Absolute change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS)|Relative change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS)|Absolute change of the SOFA score|Relative change of the SOFA score|Time until hospital discharge|Time until discharge from the intensive care unit|Comparison of the rate of serious and non-serious adverse events between the two arms of treatment|Relative changes of circulating concentrations of suPAR (\u03bcg\/liter), D-dimers (\u03bcg\/liter), ferritin (\u03bcg\/liter), and Interleukin-6 (\u03bcg\/liter) by Day 7 from baseline Day 1|Relative changes of circulating concentrations of C-reactive protein (mg\/liter) by Day 7 from baseline Day 1|Relative changes of circulating concentrations of suPAR (\u03bcg\/liter),D-dimers (\u03bcg\/liter), ferritin (\u03bcg\/liter), and Interleukin-6 (\u03bcg\/liter) by Day 4 from baseline Day 1|Relative changes of circulating concentrations of C-reactive protein (mg\/liter) by Day 4 from baseline Day 1|Absolute change of the viral load by Day 7 from baseline Day 1|Relative change of the viral load by Day 7 from baseline Day 1|Absolute change of the viral load by Day 4 from baseline Day 1|relative change of the viral load by Day 4 from baseline Day 1|Transcriptomic analysis|Proteomic analysis""}"
"911","A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)","RESCUE","NCT04511650","AKB-9778-CI-6001","Drug: Razuprotafib Subcutaneous Solution|Drug: Placebo Subcutaneous Solution","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04511650","Recruiting","2020-10-21","2021-02-01","{""locations"":""University of Southern California, Los Angeles, California, United States|University of California- Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Snake River Research, Idaho Falls, Idaho, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Cincinnati, Cincinnati, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects alive and free of respiratory failure at Day 7|Proportion of subjects alive and free of respiratory failure at Day 28|Length hospitalized and free of respiratory failure from baseline to Day 7|Length hospitalized and free of respiratory failure from baseline to Day 28|Length of hospitalization from baseline to Day 7|Length of hospitalization from baseline to Day 28|Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7|Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28|Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7|Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28|All-cause mortality at Day 7|All-cause mortality at Day 28|Length of ICU stay from baseline to Day 28|Number of subjects in each category of the NIAID 8-point ordinal scale at Day 7|Number of subjects in each category of the NIAID 8-point ordinal scale at Day 28|Time to return to prehospitalization oxygen requirement|Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 7|Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 28|Change in PaO2:FiO2 ratio from baseline to Day 7|Change in PaO2:FiO2 ratio from baseline to Day 28|Number of participants with any serious adverse event from baseline to Day 7|Number of participants with any treatment emergent adverse event from baseline to Day 28|Number of participants with any treatment emergent adverse event from baseline to Day 7|Number of participants with any serious adverse event from baseline to Day 28""}"
"912","Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19","","NCT04358068","ACTG A5395|38720","Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04358068","Completed","2020-05-01","2020-07-07","{""locations"":""Alabama CRS, Birmingham, Alabama, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Harbor-UCLA CRS, Torrance, California, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset""}"
"913","Local Thermotherapy for Patients With Mild-to-moderate COVID-19","TherMoCoV","NCT04363541","U1111-1250-7416","Device: Electric pad for human external pain therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363541","Recruiting","2020-08-27","2022-06-01","{""locations"":""Hospital Dr. \u00c1ngel Lea\u00f1o, Guadalajara, Jalisco, Mexico|Hospital Regional de Alta Especialidad \""Dr. Juan Graham Casasus\"", Villahermosa, Tabasco, Mexico|Unidad Temporal Movil COVID-19 Aut\u00f3dromo Hermanos Rodr\u00edguez IMSS, Mexico City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""274"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Progression of disease (composite outcome)|Mortality at day 15|Mortality at day 28|Time to progression to severe COVID-19|Time to progression to critical COVID-19|Hospitalization time|Percentage of participants at each clinical status in the Ordinal Scale at Day 15|Percentage of participants at each clinical status in the Ordinal Scale at Day 28|Time (days) to last requiring supplementary oxygen according to modality|Change in National Early Warning Score 2 (NEWS-2) with respect to baseline|Proportion of patients requiring invasive mechanical ventilation|Proportion of patients requiring admission to intensive care unit (ICU)|Time to requiring invasive mechanical ventilation|Time to requiring admission to intensive care unit (ICU)|Proportion of patients with adverse events according to outcome|Proportion of patients with adverse events according to severity|Proportion of patients with adverse events according to causality|Proportion of patients tolerating the intervention (no comparison)""}"
"914","Endoscopic Interventions in Patients With COVID-19","","NCT04423003","242/2020BO2","Procedure: Endoscopic intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04423003","Completed","2020-03-01","2020-05-15","{""locations"":""University Hospital of Tuebingen, Tuebingen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""death in time of observation""}"
"915","Long-term Characterization of Patients With Severe/Critical Infection by COVID-19 Virus","","NCT04559100","1631 COVID-LFT","Radiation: chest radiography|Radiation: thoracic computed tomography scan|Diagnostic Test: spirometry|Diagnostic Test: Diffusing capacity of carbon monoxide|Diagnostic Test: 6 minute walk test|Diagnostic Test: saint george respiratory questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04559100","Enrolling by invitation","2020-11-15","2021-10-01","{""locations"":""Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""112"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Lung function|Radiological alterations|Quality of life alterations""}"
"916","FREEDOM COVID-19 Anticoagulation Strategy","FREEDOM COVID","NCT04512079","GCO 20-2115","Drug: Enoxaparin|Drug: Apixaban","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04512079","Recruiting","2020-09-08","2022-03-01","{""locations"":""Icahn School of Medicine at Mount Sinai, New York, New York, United States|Instituto do Cora\u00e7\u00e3o - INCOR, S\u00e3o Paulo, Brazil|Instituto Prevent Senior - IPS, S\u00e3o Paulo, Brazil|Cl\u00ednica de la Costa, Barranquilla, Colombia|Cl\u00ednica Shaio, Bogot\u00e1, Colombia|Fundaci\u00f3n Cardioinfantil, Bogot\u00e1, Colombia|Fundacion Oftalmol\u00f3gica de Santander - Foscal, Bucaramanga, Colombia|Centro M\u00e9dico Imbanaco, Cali, Colombia|CardioVid, Medell\u00edn, Colombia|Eternal Heart Care Centre and Research Ins Pvt Ltd., Jaipur, India|Jaipur National University, Jaipur, India|Sawai Mann Singh Hospital, Jaipur, India|Jaslok Hospital & Research Center, Mumbai, India|Saifee Hospital, Mumbai, India|Sengupta Hospital & Research Institute, Nagpur, India|D Y Patil University School of Medicine & D Y Patil Hospital, Navi Mumbai, India|Hospital Cardiol\u00f3gica Aguascalientes, Aguascalientes, Mexico|Centro M\u00e9dico Nacional 20 de Noviembre, Mexico City, Mexico|Christus Muguerza Hospital Alta Especialidad, Monterrey, Mexico|Centro de Estudios Clinicos de Quer\u00e9taro S.C., Santiago de Quer\u00e9taro, Mexico|Centro Medico Hospital del Prado, Tijuana, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""3600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to first event|Number of in-hospital rate of BARC 3 or 5|Number of participants with Myocardial infarction|Number of participants with Deep Vein Thrombosis|Number of participants requiring Ventilation|Number of All Death|Cause of Death|Number of participants with Stroke|Number of participants with Pulmonary Emboli|Number of participants with Systemic Thromboembolism""}"
"917","Forecast Number of Covid-19 Cases Worldwide","Covid19TmeSer","NCT04460274","TurkishMOHITH-TimeSeries","Other: Model Building|Other: Model validation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04460274","Completed","2019-12-31","2020-06-20","{""locations"":""Republic of Turkey, Health Sciences University, Izmir Bozyaka Education and Training Hospital, \u0130zmir, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""7882471"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of Confirmed cases of Covid-19""}"
"918","A Survey Study to Assess the Impact of the COVID-19 Pandemic on Participants With Pre-Existing Mental Health Diagnosis","","NCT04568135","SCR-SUR-001","Other: survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568135","Not yet recruiting","2020-10-31","2021-12-31","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survey: Epidemic-Pandemic Impacts Inventory (EPII)""}"
"919","Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution","BIOMARK-COVID","NCT04664023","BIOMARK-COVID","Procedure: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04664023","Recruiting","2020-12-09","2022-07-30","{""locations"":""C.H.U.de Poitiers, Poitiers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Neutralizing antibodies|T CD8 lymphocytes|Inflammatory markers|Metabolic markers""}"
"920","Community Pharmacists Behaviour During Covid-19","","NCT04374513","Pharmacists and covid-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374513","Completed","2020-04-02","2020-07-01","{""locations"":""Damanhour university, Beheira, Damanhour, Egypt|Damanhour universty, Alexandria, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""318"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""community pharmacists facing covid-19""}"
"921","National Covid-19 Surveillance Physicians","NAT-COV-SURV","NCT04459312","2020_2","Diagnostic Test: Antibody test (SARS-CoV2)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459312","Recruiting","2020-06-01","2020-09-30","{""locations"":""University Hospital Duesseldorf, Dept. of Anesthesiology, Duesseldorf, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of antibodies against SARS-COV2""}"
"922","Role of Co-trimoxazole in Severe COVID-19 Patients","","NCT04470531","BSMMU/2020/6969","Drug: oral co-trimoxazole","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04470531","Recruiting","2020-07-12","2021-01-30","{""locations"":""Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""94"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Length of stay in hospital (in days)|In-patient mortality|SpO2\/FiO2 ratio|respiratory rate|C-reactive Protein|Fever|Ventilator support|Proportion of drug adverse reaction""}"
"923","A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults","","NCT04537949","BNT162-04|2020-003267-26|U1111-1254-4840","Biological: BNT162b3","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04537949","Active, not recruiting","2020-09-09","2022-02-01","{""locations"":""Contract Research Organization, Berlin, Germany|Contract Research Organization, Mannheim, Germany"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""96"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Solicited local reactions at the injection site (pain\/tenderness, erythema\/redness, induration\/swelling) recorded up to 7 days after each immunization.|Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7 days after each immunization.|The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE) occurring up to 21 days after the prime immunization.|The proportion of subjects with at least 1 unsolicited TEAE occurring up to 28 days after the boost immunization.|Functional antibody responses.|Fold increase in functional antibody titers.|Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline.""}"
"924","Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants","","NCT04610138","CNMZnAg.202","Drug: CNM-ZnAg|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04610138","Not yet recruiting","2021-02-01","2021-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""276"",""age"":""40 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of participants who require COVID-19 related hospitalization, are hospitalized for COVID-19 related medical support, or are deceased within 28-days following randomization.|Time to substantial alleviation of COVID-19 symptoms.""}"
"925","Piclidenoson for Treatment of COVID-19","","NCT04333472","CF101-241COVID-19","Drug: Piclidenoson|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04333472","Recruiting","2021-01-06","2021-07-06","{""locations"":""Hadassah Medical Center, Jerusalem, Israel|Shaare Zedek Medical Center, Jerusalem, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects alive and free of respiratory failure|Proportion of subjects discharged home alive|Treatment-emergent adverse events (AEs)|Clinical status|Time to improvement|Incidence of mechanical ventilation|Ventilator-free days|Incidence of Intensive Care Unit (ICU) admission|Duration of ICU stay|Time to hospital discharge|Duration of need for supplemental oxygen|Time to virus negativity|SARS-CoV-2 viral load|AEs leading to withdrawal|Treatment-emergent serious AEs (SAEs)|Treatment-emergent abnormalities in clinical laboratory parameters or electrocardiograms (ECGs)|Incidence of meeting safety-related stopping rules|Pharmacokinetics of piclidenoson in this patient population|Serum cytokine levels""}"
"926","Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air","COVIDAIR","NCT04706039","69HCL20_1148","Diagnostic Test: Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04706039","Not yet recruiting","2021-01-01","2021-03-01","{""locations"":""Centre de pr\u00e9l\u00e8vement COVID-19 HCL et M\u00e9tropole de Lyon, Lyon, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""3000"",""age"":""6 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Sensitivity of the COVID-19 diagnostic using the Vocus PTR-TOF process.""}"
"927","COVID - AirPollution","","NCT04463862","7922","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04463862","Recruiting","2020-06-04","2020-09-04","{""locations"":""Unit\u00e9 de neurologie-g\u00e9riatrie, H\u00f4pital Erasme, Cliniques Universitaires de Bruxelles, Bruxelles, Belgium|Service de G\u00e9riatrie, H\u00f4pital Larrey, H\u00f4pitaux Universitaires d'Angers, Angers, France|Unit\u00e9 de soins palliatifs g\u00e9riatriques, Centre Hospitalier D\u00e9partemental de Bischwiller, Bischwiller, France|Unit\u00e9 post urgence g\u00e9riatriques, H\u00f4pital Pellegrin, H\u00f4pitaux Universitaires de Bordeaux, Bordeaux, France|Service de G\u00e9riatrie, Centre Hospitalier D\u00e9partemental de Vend\u00e9e, La Roche Sur Yon, France|Service de g\u00e9riatrie-g\u00e9rontologie, H\u00f4pitaux Universitaires de Lille, Lille, France|Service de m\u00e9decine aig\u00fce g\u00e9riatrique, H\u00f4pital Nord Laennec, H\u00f4pitaux Universitaires de Nantes, Nantes, France|Service de G\u00e9riatrie, H\u00f4pitaux Bichat et Bretonnaux, Assistance Publique des H\u00f4pitaux de Paris, Paris, France|Service de M\u00e9decine Interne et G\u00e9riatrie, H\u00f4pitaux Universitaires de Reims, Reims, France|Service de G\u00e9riatrie, H\u00f4pital de la Robertsau, H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France|Service de m\u00e9decine g\u00e9riatrique, H\u00f4pitaux Universitaires de Tours, Tours, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""250"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 related-mortality|COVID-19 confirmed cases""}"
"928","Hospital COVID-19 Surge and Associated Mortality Risk","","NCT04688372","BD022386","Other: Surge Index","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04688372","Active, not recruiting","2020-10-01","2021-02-15","{""locations"":""National Institutes of Health Clinical Center (primary center conducting large database study), Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality or discharge to hospice|In-hospital mortality""}"
"929","Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers","","NCT04366180","P054","Dietary Supplement: Probiotic|Dietary Supplement: Control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04366180","Recruiting","2020-04-24","2020-10-01","{""locations"":""Raquel Rodriguez Blanque, Granada, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""314"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of SARS CoV-2 infection in healthcare workers|Incidence of hospital admissions caused by SARS-CoV-2 infection|Incidence of ICU admissions caused by SARS-CoV-2 infection|Incidence of pneumonia caused by SARS-CoV-2 infection|Incidence of oxygen support requirement caused by SARS-CoV-2 infection|Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection|Days with body's temperature > 37.5 \u00baC|Days with cough|Days with fatigue|Medical treatment""}"
"930","Impact of COVID-19 on Personal Protection Among Dentist in Egypt","","NCT04403828","PPE in COVID-19","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403828","Completed","2020-05-20","2020-07-15","{""locations"":""Faculty of Dentistry, Fayoum, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""323"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Personal protection measures|impact of Covid-19 pandemic on type of face masks used in dental clinic""}"
"931","Covid-19: Possible Role of Neutrophil Extracellular Traps","NETSINCOVID","NCT04412382","NETS IN COVID-19","Diagnostic Test: NETosis markers","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412382","Recruiting","2020-06-01","2021-12-31","{""locations"":""Univeristy of Verona, Verona, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""NETOSIS AND MORTALITY|NETOSIS AND DCOVID-19 SEVERITY|NETOSIS AND INFLAMMATION|NETOSIS AND VENOUS THROMBOSIS""}"
"932","PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19)","RaDiCo","NCT04613310","2020-02269","Diagnostic Test: Rapid Diagnostic Test vs PCR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04613310","Recruiting","2020-09-25","2020-12-31","{""locations"":""Unisant\u00e9, Lausanne, Vaud, Switzerland"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""1250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of SARS-CoV-2 positive patients for the two different sampling types (saliva vs nasopharyngeal) and two methods (RDT vs PCR) .|Viral loads of SARS-CoV-2 by PCR on saliva and nasopharyngeal swabs""}"
"933","Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19","","NCT04389944","Req-2020-00508; me20khanna2","Other: convalescent plasma application to SARS-CoV-2 infected patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04389944","Completed","2020-03-31","2020-06-30","{""locations"":""Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serious adverse events in convalescent plasma treated patients|Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients|Transfer to ICU|in-hospital death|Virologic clearance in plasma of convalescent plasma treated patients|Time to discharge from hospital after enrolment|Humoral immune response""}"
"934","Immunological Characteristics of COVID-19 Patients","","NCT04679428","Golnik_Covid-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04679428","Recruiting","2020-05-07","2023-05-07","{""locations"":""University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immunological changes during and after COVID-19 infection""}"
"935","Acceptance of Telemedicine During the COVID-19 Pandemic","","NCT04400448","TELECOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04400448","Not yet recruiting","2020-06-01","2020-10-31","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acceptance of telemedicine|Patient satisfaction""}"
"936","Preventing COVID-19 in Healthcare Workers With HCQ: A RCT","","NCT04347889","IRB2020-00222","Drug: Hydroxychloroquine|Other: Vitamin C","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04347889","Withdrawn","2020-04-20","2020-12-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Seroconversion rate|Admission for Covid-19""}"
"937","Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure","COMBAT-COVID","NCT04420741","COMBAT-COVID-19|2020-001296-33","Drug: Iloprost|Drug: Isotonic saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04420741","Active, not recruiting","2020-06-15","2021-04-23","{""locations"":""Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark|Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hiller\u00f8d, Denmark|Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital, Hvidovre, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation free days|28 and 90-day mortality|Modified Sequential Organ Failure Assessment (SOFA)|Vasopressor free days|Renal replacement free days|Serious adverse reactions (SARs)|Serious adverse events (SAEs)""}"
"938","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","BLAZE-2","NCT04497987","18063|J2X-MC-PYAD|CoVPN #3501","Drug: LY3819253|Drug: Placebo|Drug: LY3832479","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04497987","Recruiting","2020-08-02","2021-06-29","{""locations"":""Unv of AL Sch of Med Div of Infectious Diseases, Birmingham, Alabama, United States|Care Access Research, Phoenix, Arizona, United States|Allergy and Asthma Clin of NW Ark, Bentonville, Arkansas, United States|Care Access Research LLC, Huntington Beach, California, United States|Alta Bates SMC, Oakland, California, United States|University of Colorado-Anschultz Medical Campus, Aurora, Colorado, United States|NIAID, Miami, Florida, United States|NIAID, Decatur, Georgia, United States|Belmont Village Lincoln Park, Lincoln Park, Illinois, United States|Family Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Care Access Rch Lake Charles, Lake Charles, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|NIAID - National Institute of Allergy & Infectious Diseases, Bethesda, Maryland, United States|Care Access, Boston, Massachusetts, United States|St. Paul IDA-CARe, Saint Paul, Minnesota, United States|Care Access, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Hospital & Medical Center, Omaha, Nebraska, United States|Care Access Research - Bronx, Bronx, New York, United States|NIAD, Chapel Hill, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Univ of Cin College of Med, Cincinnati, Ohio, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Donahoe Manor, Bedford, Pennsylvania, United States|Belmont Village, West Univ, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants with COVID-19 within 21 Days of Detection|Percentage of Participants with Moderate or Worse Severity COVID-19 within 21 Days of Detection|Percentage of Participants with SARS-CoV-2|Percentage of Participants Who are Hospitalized or Have Died due to COVID-19|Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Percentage of Participants Who Die Due to COVID-19|Pharmacokinetics (PK): Mean Concentration of LY3819253 Administered Alone|PK: Mean Concentration of LY3819253 in the Presence of LY3832479|PK: Mean Concentration of LY3832479 in the Presence of LY3819253""}"
"939","COVID-19 Immunologic Antiviral Therapy With Omalizumab","CIAO","NCT04720612","CIAO (2021-7500)","Biological: Omalizumab|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04720612","Not yet recruiting","2021-02-01","2022-01-01","{""locations"":""Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Death|Time to Clinical Improvement|Incidence of Mechanical Ventilation|Duration of Mechanical Ventilation|Duration of Hospitalization|Number of adverse events and serious adverse events""}"
"940","Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19","","NCT04411433","COVID-19-FAV","Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04411433","Active, not recruiting","2020-05-08","2021-06-01","{""locations"":""Hacettepe University, School of Medicine, Ankara, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1008"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oxymetry from baseline|Changes in fever from baseline""}"
"941","Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19","","NCT04420299","BEMICOVID-19|2020-001548-24","Drug: Bemiparin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04420299","Recruiting","2020-06-04","2021-03-31","{""locations"":""Hospital Universitario HM Montepr\u00edncipe, Boadilla Del Monte, Madrid, Spain|Hospital Universitario HM Puerta del Sur, M\u00f3stoles, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients that worsen|Mortality from any cause at day 28|Proportion of subjects that requires admission to the ICU|Proportion of subjects requiring non-invasive mechanical ventilation|Proportion of subjects requiring invasive mechanical ventilation.|Proportion of subjects with some organ failure|Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline|Proportion of subjects with pathological angioTAC|Proportion of subjects with improvement in chest radiography|Proportion and median hospital discharge between patients in both groups.|Titration score|Ferritin score|D-dimer modification score|Adverse events (total and serious).|Related adverse events (total and serious).|Clinically relevant major and non major hemorrhages.""}"
"942","Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention","RECOVE","NCT04718506","3036/2020","Behavioral: Exercise|Behavioral: Controls","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04718506","Recruiting","2021-01-12","2021-12-12","{""locations"":""Faculty of Sport Sciences, Murcia, San Javier, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in subject clinical status|Changes in cardiovascular fitness: Maximal oxygen consumption (VO2max)|Changes in neuromuscular performance during resistance exercise: Barbell Mean Propulsive Velocity (MPV)|Changes in balance: center of pressure (COP) sway|Changes in pulmonary function: Forced Vital Capacity (FVC)|Changes in pulmonary function: Forced expiratory volume (FEV)|Changes in high sensitivity C-reactive protein (hsCPR)|Changes in D-dimer|Changes in Troponin|Changes in glutamic-pyruvic transaminase (GPT)|Changes in serum creatine kinase (CK)|Changes in lactate dehydrogenase (LDH)|Changes in physical activity levels|Changes in tolerance to exercise: DePaul Symptom Questionnaire for Post-exertional malaise (DSQ-PEM) scores|Changes in fatigue: Chalder Fatigue Scale scale (CFQ-11)|Changes in anxiety: Generalized Anxiety Disorder scale (GAD7)|Changes in depression: Patient Health Questionnaire (PHQ9)|Changes in health related quality of life: 12-item Short Form Survey (SF12)""}"
"943","Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19","","NCT04412668","ATYR1923-C-003","Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04412668","Completed","2020-06-12","2020-12-21","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States|aTyr Investigative Site, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|aTyr Investigative Site, Vineland, New Jersey, United States|aTyr Investigative Site, Toledo, Ohio, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Alliance Medical Service, Cardio Pulmonary Research, Guaynabo, Puerto Rico|Manati Medical Center, Manat\u00ed, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of treatment-emergent adverse events (TEAEs)|Time to hospital discharge|Time to recovery (World Health Organization [WHO] Ordinal Scale score \u22643)|Proportion of patients achieving recovery by Day 14 and Day 28|Duration of supplemental oxygen (O2) requirement|Number of days with fever (temperature >100.4\u00baF [38.0\u00baC])|Change from baseline in World Health Organization (WHO) Ordinal Scale score on Days 5, 7, 14, 28, and 60|Time to improvement from inpatient hospital admission based on at least a 1 point reduction in WHO Ordinal Scale score|All-cause mortality at Days 14, 28, and 60""}"
"944","Prevalence Of COVID-19 Among Health-workers in a French General Hospital","POCAH-COVID","NCT04548908","POCAH-COVID19","Diagnostic Test: Serelogy testing, RT PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04548908","Recruiting","2020-08-03","2021-06-30","{""locations"":""Centre Hospitalier Sud Essonne, Etampes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""General prevalence of COVID-19|Number of asymptomatic healthcare workers|Number of symptomatic healthcare workers|Number of healthcare workers with a severe form of COVID-19 which led to an hospitalization|Number of healthcare workers infected with COVID-19 and hospitalized in a critical care unit|Influencing factors of the prevalence of the COVID-19 among healthcare workers""}"
"945","Convalescent Plasma Trial in COVID -19 Patients","","NCT04356534","BDF/R&REC/2020-423","Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04356534","Completed","2020-04-19","2020-07-09","{""locations"":""Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Requirement for invasive ventilation|Change in viral clearance|Radiological change|Change in white cell count|C reactive protein measurement|lactate dehydrogenase measurement|Procalcitonin measurement|D Dimer measurement|Ferritin measurement|Troponin T measurement|Brain naturetic peptide measurement|Mortality rate""}"
"946","Immunophenotyping Assessment in a COVID-19 Cohort","IMPACC","NCT04378777","DAIT-COVID-19-002","Procedure: Biological sample collection|Procedure: Data Collection: Clinical Care Assessments","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04378777","Enrolling by invitation","2020-05-01","2022-03-01","{""locations"":""University of Arizona (UA) College of Medicine - Tucson: UA Health Sciences Asthma and Airway Disease Research Center, Tucson, Arizona, United States|University of California, Los Angeles: Department of Medicine, Los Angeles, California, United States|University of California San Francisco School of Medicine, San Francisco, California, United States|Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|University of South Florida Health Tampa, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|University of Oklahoma ,Oklahoma Health Sciences Center: Pulmonary\/Critical Care, Department of Medicine, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Texas at Austin: UT Health Austin, Austin, Texas, United States|Baylor College of Medicine: Department of Medicine, Houston, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality Rate Among COVID-19 Patients|Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and\/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 28|Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28|Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28|Mechanistic: Antibody Isotype\/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12|Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28|Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28|Duration of Mechanical Ventilation in Patients with COVID-19 Over Time to Day 28|Proportion of Patients with COVID-19 with Requirement for New (Or Increased from Baseline if on Home Oxygen) Supplemental Oxygen Over Time to Day 28|Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients with COVID-19 Over Time to Day 28|Mechanistic: Immune Cell Frequencies and Activation Status (CyTOF) in Blood and Endotracheal Aspirate over time Through Day 28 and In blood at Select Study Visits Through Month 12|Mechanistic: Gene Expression (Transcriptomics) in Blood|Mechanistic: Gene Expression (Transcriptomics) in Respiratory Epithelium|Mechanistic: Gene Expression (Transcriptomics) in Plasma Protein|Mechanistic: Gene expression (Transcriptomics) in Metabolic Profiling|Mechanistic: Circulating Immune Mediators Assessed by OLINK Methodology""}"
"947","Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment","","NCT04530422","14","Drug: Sofosbuvir plus Ledipasvir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04530422","Completed","2020-04-15","2020-07-23","{""locations"":""Almaza Military Fever Hospital, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""250"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Therapeutic success (cured)|28 days in hospital mortality|Percentage of clinical failure of treatments|Length of hospital stay|Incidence of side effects""}"
"948","Tableted COVID-19 Therapeutic Vaccine","COVID-19","NCT04380532","Imm24","Biological: V-SARS","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04380532","Active, not recruiting","2020-05-15","2021-06-15","{""locations"":""Immunitor Inc, Vancouver, BC - British Columbia, Canada|Aldar Bourinbayar, Ulaanbaatar, BZD, 3-khoroo, Mongolia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect on CBC as per CTCAE v4.0|Effect on biochemistry parameters as per CTCAE v4.0|Lack of adverse events as per CTCAE v4.0""}"
"949","The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.","Bee-Covid","NCT04480593","31099320.6.0000.0048","Drug: Brazilian Green Propolis Extract (EPP-AF)|Other: Standard care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04480593","Completed","2020-06-02","2020-08-30","{""locations"":""Hospital Sao Rafael, Salvador, BA, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite clinical outcome with oxygen therapy dependency time or hospitalization time|Percentage of participants with adverse events during the use of propolis|Rate and severity of acute kidney injury during the study|Renal replacement therapy.|Rate of need for vasopressor use|Need for intensive care unit (ICU)|Intensive care unit (ICU) readmission|Invasive oxygenation time|Variation of plasma c-reactive protein""}"
"950","VIR-7831 for the Early Treatment of COVID-19 in Outpatients","COMET-ICE","NCT04545060","VIR-7831-5001|GSK Study 214367","Biological: VIR-7831|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04545060","Recruiting","2020-08-27","2021-07-01","{""locations"":""Investigative Site, Anniston, Alabama, United States|Investigative Site, Cullman, Alabama, United States|Investigative Site, Mesa, Arizona, United States|Investigative Site, Tucson, Arizona, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Northridge, California, United States|Investigative Site, Oxnard, California, United States|Investigative Site, Rolling Hills Estates, California, United States|Investigative Site, Sacramento, California, United States|Investigative Site, Doral, Florida, United States|Investigative Site, Gainesville, Florida, United States|Investigative Site, Hialeah, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miramar, Florida, United States|Investigative Site, North Miami, Florida, United States|Investigative Site, Palmetto Bay, Florida, United States|Investigative Site, Pembroke Pines, Florida, United States|Investigative Site, Pompano Beach, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Decatur, Georgia, United States|Investigative Site, Idaho Falls, Idaho, United States|Investigative Site, Mishawaka, Indiana, United States|Investigative Site, Lake Charles, Louisiana, United States|Investigative Site, Marrero, Louisiana, United States|Investigative Site, Baltimore, Maryland, United States|Investigative Site, Caro, Michigan, United States|Investigative Site, Hazelwood, Missouri, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Santa Fe, New Mexico, United States|Investigative Site, Bronx, New York, United States|Investigative Site, Asheboro, North Carolina, United States|Investigative Site, Charlotte, North Carolina, United States|Investigative Site, Columbus, Ohio, United States|Investigative Site, Smithfield, Pennsylvania, United States|Investigative Site, Chattanooga, Tennessee, United States|Investigative Site, Austin, Texas, United States|Investigative Site, Baytown, Texas, United States|Investigative Site, Beaumont, Texas, United States|Investigative Site, El Paso, Texas, United States|Investigative Site, Forney, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Humble, Texas, United States|Investigative Site, Laredo, Texas, United States|Investigative Site, McAllen, Texas, United States|Investigative Site, Mesquite, Texas, United States|Investigative Site, Sugar Land, Texas, United States|Investigative Site, Kirkland, Washington, United States|Investigative Site, Seattle, Washington, United States|Investigative Site, Vienna, Austria|Investigative Site, Vienna, Austria|Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Investigative Site, Maring\u00e1, Parana, Brazil|Investigative Site, Natal, Rio Grande Do Norte, Brazil|Investigative Site, Passo Fundo, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Chapec\u00f3, Santa Catarina, Brazil|Investigative Site, Santo Andr\u00e9, Sao Paulo, Brazil|Investigative Site, Vila Assuncao, Sao Paulo, Brazil|Investigative Site, Campinas, S\u00e3o Paulo, Brazil|Investigative Site, Sarnia, Ontario, Canada|Investigative Site, Toronto, Ontario, Canada|Investigative Site, Qu\u00e9bec, Quebec, Canada|Investigative Site, Santiago, Region Metropolitana, Chile|Investigative Site, Argenteuil, France|Investigative Site, Limoges, France|Investigative Site, Melun, France|Investigative Site, Valenciennes, France|Investigative Site, Bellavista, Callao, Peru|Investigative Site, El Agustino, Lima, Peru|Investigative Site, Huaral, Lima, Peru|Investigative Site, San Isidro, Lima, Peru|Investigative Site, Bella Vista, Peru|Investigative Site, Lima, Peru|Investigative Site, Terrassa, Barcelona, Spain|Investigative Site, Albacete, Spain|Investigative Site, Centelles, Spain|Investigative Site, Girona, Spain|Investigative Site, Granada, Spain|Investigative Site, Granada, Spain|Investigative Site, Vigo, Spain|Investigative Site, Belfast, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1360"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who have progression of COVID-19 through Day 29|Occurence of of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of adverse events of special interest (AESI)|Incidence and titers (if applicable) of serum ADA to VIR-7831|Cmax|Clast|Tmax|Tlast|AUCinf|AUClast|%AUCextrap|t1\/2|Vz|Vss|CL|Proportion of participants who have progression of COVID-19 as defined by hospitalization >24 hrs or death at Day 8, Day 15, or Day 22|Proportion of participants who progress to develop severe and\/or critical respiratory COVID-19 as manifest by requirement for and method of supplemental oxygen at Day 8, Day 15, Day 22, or Day 29|Severity and duration of participant-reported symptoms of COVID-19 related illness using the FLU-PRO patient-reported outcome instrument|Detection of SARS-CoV-2 in nasal secretions by PCR at baseline and during follow-up period through Day 29|29-day, 60-day, and 90-day all-cause mortality""}"
"951","COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)","","NCT04625257","2020-01112; ch20Savic2","Other: Saliva based assay: crude RNA extraction|Other: Validation of the NGS method|Other: Validation of the LAMP assays|Other: Validation of the POCT Antigen and Antibody tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04625257","Recruiting","2020-10-24","2021-03-01","{""locations"":""Cantonal Office of Public Health, Economics and Health Directorate, Canton Basel-Landschaft, Liestal, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""qualitative method validation of the crude extraction in combination with the LAMP or the NGS (count values for detection)""}"
"952","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","","NCT04336332","002011|Pro2020000712","Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04336332","Active, not recruiting","2020-04-01","2021-04-30","{""locations"":""Saint Barnabas Medical Center, Livingston, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood""}"
"953","Canakinumab MAP in COVID-19 Pneumonia With CRS","","NCT04476706","CACZ885D2001M","Drug: canakinumab","Expanded Access","No Results Available","","https://ClinicalTrials.gov/show/NCT04476706","No longer available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"954","Singapore COVID-19 Chemosensory Tracking (SCCT) Study","","NCT04492904","2020/00810","Other: Home-use Test and Follow-up Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492904","Recruiting","2020-07-23","2021-03-31","{""locations"":""Clinical Nutrition Research Centre, Singapore, Singapore, Singapore"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""5000"",""age"":""21 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Taste and smell acuity|Experienced symptoms, changes in appetite and food-related quality of life""}"
"955","Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test","ASPIRE","NCT04557046","S-CLIN-PROT-00032","Diagnostic Test: Nasal Swab|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Throat swab|Diagnostic Test: Fingerstick|Diagnostic Test: Saliva specimen","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04557046","Recruiting","2020-06-26","2021-12-31","{""locations"":""Children's Pediatric Associates of Altamonte Springs, Altamonte Springs, Florida, United States|Chappel Group, Kissimmee, Florida, United States|Good Samaritan Minute Clinic, Georgia Tech, Atlanta, Georgia, United States|Gvozden Pediatrics, Millersville, Maryland, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Physicians Quality Care of Jackson, Jackson, Tennessee, United States|Village Health Partners, Plano, Texas, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Performance Evaluation""}"
"956","COVID-19 And Geko Evaluation: The CAGE Study","CAGE","NCT04651374","ISS-COV-002","Device: geko T3","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04651374","Not yet recruiting","2020-12-01","2021-04-01","{""locations"":""London Health Sciences Centre, London, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of recruitment|Safety of device: AE|Protocol Adherence|Mortality|Morbidity""}"
"957","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)","","NCT04329507","282014","Diagnostic Test: Breath test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04329507","Recruiting","2020-03-25","2021-03-25","{""locations"":""NHS Lothian, Edinburgh, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To perform a study in patients with clinical features of pneumonia\/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .""}"
"958","Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients","","NCT04523181","GHCovid-2-001","Drug: Antroquinonol|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04523181","Recruiting","2020-10-08","2021-05-31","{""locations"":""Franciscan Health Michigan City, Michigan City, Indiana, United States|Ascension.Via Christi Research, Wichita, Kansas, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Centro Gallego, Buenos Aires, Capital Federal, Argentina|Clinica de los Virreyes, Buenos Aires, Capital Federal, Argentina|Hospital Rawson, Cordoba, Cuidad De Cordoba, Argentina|Cl\u00ednica Internacional S.A. - Sede Lima, Lima Cercado, Lima, Peru|Hospital de Chancay, Chancay, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""174"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""recover ratio|Time to 2-point improvement|Duration of hospitalization|Time to virological clearance""}"
"959","Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","","NCT04341116","TJ003234COV201","Drug: TJ003234|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04341116","Recruiting","2020-04-11","2021-12-01","{""locations"":""Olive View-UCLA Medical Center, Sylmar, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|The GW Medical Faculty Associates, Washington, District of Columbia, United States|OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|UNM Hospitals, Albuquerque, New Mexico, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univeristy Hospital, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""384"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion (%) of subjects recovered|Proportion (%) of subjects recovered on Day 30|All-cause mortality rate by Day 30|Time to recovery among subjects alive by Day 30|Length of hospitalization|Incidence of treatment-emergent Adverse events by Day 30""}"
"960","Fase I Clinical Trial on NK Cells for COVID-19","","NCT04634370","20200210","Biological: Natural Killer Cells infusion","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04634370","Not yet recruiting","2021-01-02","2021-03-30","{""locations"":""Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival|Changes on inflammatory C-reactive protein|Hospital stay|Oxygenation index (PaO2\/FiO2)|Improvement in Liao's score (2020)|Radiological improvement""}"
"961","Study of the Sars-Cov2 Neuroinvasiveness - COVID19","CORONEVRAXE","NCT04427254","PBN_2020_16","Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04427254","Recruiting","2020-06-26","2023-01-01","{""locations"":""Fondation A de Rothschild, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with COVID-19 positive samples\/biopsies""}"
"962","Smell and Taste Disorders in COVID-19 Patients","COVID-19 ORL","NCT04427332","COVID-19 ORL","Other: Investigation of smell and taste disorders","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04427332","Completed","2020-06-11","2020-10-16","{""locations"":""ASST Monza-Ospedale San Gerardo, Monza, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""376"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of demographic and clinical factors in covid19 patients.|Description of the disturbances of smell and taste|Description of factors that influence smell and taste""}"
"963","COVID-19 Detection Tests in Different Body Fluids","","NCT04473352","COVID Fluids","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473352","Not yet recruiting","2020-09-01","2021-11-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Accuracy of Covid19 Detection""}"
"964","Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID)","YCOVID","NCT04490837","2020/587","Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04490837","Active, not recruiting","2020-06-22","2020-09-30","{""locations"":""Parc Tauli University Hospital, Sabadell, Barcelona, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""3500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IgG anti-COVID-19|IgM anti-COVID-19|IgA anti-COVID-19|Time of onset symptoms|COVID-19 PCR results|Radiological studies""}"
"965","Silymarin in COVID-19 Pneumonia","SCOPE","NCT04394208","CairoU COVID-19 Study Group","Drug: Silymarin|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04394208","Recruiting","2020-08-16","2021-02-28","{""locations"":""Cairo University, Giza, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Clinical outcome|Duration of Mechanical Ventilation|Hospitalization|Virologic Response|Adverse events""}"
"966","Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients","","NCT04584606","FMASU P30/ 2020","Diagnostic Test: Lab workup (on admission and regularly during follow up).","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04584606","Recruiting","2020-06-27","2020-12-30","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recovery|Mortality|Conversion of nucleic acid testing for SARS-CoV-2 from positive to negative.|Radiological progression of the COVID 19 disease|Functional progression of the COVID 19 disease""}"
"967","WGS Analysis of COVID-19 Positive Patients","CALYPSO","NCT04353401","VP-01-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04353401","Enrolling by invitation","2020-08-03","2021-05-01","{""locations"":""Vanda Investigational Site, Cleveland, Ohio, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Associations with severity and outcomes""}"
"968","Rapid Diagnostic Profiling of SARS-CoV-2 (COVID-19)","Profile-Cov","NCT04473365","RIA2020EF-2905","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473365","Recruiting","2020-07-20","2021-06-30","{""locations"":""Mekelle University College of Health Sciences, Mekelle, Ethiopia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""186"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of patients identified as Covid-19 by and monitoring virus clearance with COVID-19 using algorithm of RDTs.|Proportion of non-Covid-19 cases identified as negative by antibody assay""}"
"969","Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo","VEP-COV","NCT04549376","PiRCC-1131-2020","Drug: Povidone-Iodine 0.4% NI|Drug: Povidone-Iodine 0.5% NI|Drug: Povidone-Iodine 0.6% NI|Drug: Povidone-Iodine 0.5% NS|Drug: Povidone-Iodine 0.6% NS|Other: Placebo comparator: DW-NI|Other: Placebo comparator: DW-NS","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04549376","Recruiting","2020-07-01","2020-10-30","{""locations"":""Dhaka Medical College, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""15 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Proportion of COVID-19 positive cases following intervention|Adverse events""}"
"970","Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19","","NCT04360122","FMASU P20a/ 2020","Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04360122","Not yet recruiting","2020-05-20","2020-12-01","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decrease the incidence of COVID-19 infection or its severity""}"
"971","Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease","","NCT04358081","CJWT629A12301","Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04358081","Completed","2020-05-01","2020-07-27","{""locations"":""Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo""}"
"972","Assess the Seroconversion Status of Health Care Workers Suspected or Confirmed Cases of COVID-19 Patients","","NCT04368884","Covid-19/MHC-2/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368884","Recruiting","2020-04-22","2021-07-30","{""locations"":""Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of antibodies""}"
"973","Sildenafil in COVID-19","","NCT04489446","UNAB-003","Drug: Sildenafil|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04489446","Recruiting","2020-08-19","2021-03-01","{""locations"":""Hospital Naval Almirante Nef, Vi\u00f1a Del Mar, Valparaiso, Chile"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Arterial Oxygenation|Alveolo-arterial gradient|Intensive care unit admission|Noninvasive Mechanical Ventilation or Requirement of High-Flow Nasal Cannula|Invasive mechanical ventilation|Survival""}"
"974","Effect of Prone Positioning in Patients With COVID-19","","NCT04710771","138","Other: Prone Lying Position|Other: alternate nostril breathing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04710771","Completed","2020-11-23","2021-01-29","{""locations"":""DHQ Hospital, Faisalabad, Punjab, Pakistan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""40 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PaO2|FiO2|General Anxiety Disorder-7 Score""}"
"975","Elmo Respiratory Support Project - COVID-19","","NCT04470258","4.104.233","Other: ELMO PROJECT AT COVID-19: STUDY IN HUMANS|Device: ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04470258","Recruiting","2020-08-02","2020-12-01","{""locations"":""Hospital Leonardo Da Vinci, Fortaleza, Brazil"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Usability tests of the Elmo system using Euristic usability principles|Evaluation of the effectiveness of the ELMO system using physiological parameters""}"
"976","Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection","","NCT04523831","ERC-DMC/ECC/2020/117","Drug: Ivermectin and Doxycycline|Drug: Standard of care","Interventional","Has Results","Phase 3","https://ClinicalTrials.gov/show/NCT04523831","Completed","2020-06-01","2020-09-10","{""locations"":""Dhaka Medical College, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Patients With Early Clinical Improvement|Number of Participants With Late Clinical Recovery|Number of Patients Having Clinical Deterioration.|Number of Patients Remain Persistently Positive for RT-PCR of Covid-19""}"
"977","Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt","","NCT04694651","AssiutU18","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694651","Recruiting","2020-12-15","2021-02-15","{""locations"":""AssiutU, Assiut, Egypt|Aliae AR Mohamed-Hussein, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure frequency of acceptance of vaccination|Describe causes of refusal of vaccination""}"
"978","Mesenchymal Stem Cells in Patients Diagnosed With COVID-19","","NCT04611256","060I.2020","Biological: MSC|Drug: Control","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04611256","Recruiting","2020-08-01","2020-12-30","{""locations"":""Hospital Regional Lic Adolfo Lopez Mateos, Mexico City, Ciudad De Mexico CDMX (Mexico City), Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change form baseline in Arterial oxygen saturation|Days to clinical improvement|Change Form Baseline in C reactive protein at 25 days|Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes|Change Form Baseline in pro-inflammatory cytokines: IL-1\u03b2, IL- 2, TNF-\u03b1, ITN-\u03b3, IL-4, IL-6, IL-10|Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE.""}"
"979","Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","","NCT04588480","C4591005","Biological: BNT162b2|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04588480","Active, not recruiting","2020-10-21","2021-11-30","{""locations"":""SOUSEIKAI Sumida Hospital, Sumida-ku, Tokyo, Japan|SOUSEIKAI PS Clinic, Fukuoka, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""160"",""age"":""20 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of participants reporting local reactions|Percentage of participants reporting systemic events|Percentage of participants reporting adverse events|Percentage of participants reporting serious adverse events|Percentage of subset participants with abnormal hematology and chemistry laboratory values|Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments|SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs|GMFR in SARS-CoV-2 serum neutralizing titers|SARS-CoV-2 S1-binding IgG levels, expressed as GMCs|GMFR in SARS-CoV-2 S1-binding IgG levels|GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point|GMFR in SARS-CoV-2 S1-binding IgG levels from before vaccination to each subsequent time point|GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 S1-binding IgG levels""}"
"980","The CEDiD Study (COVID-19 Early Diagnosis in Doctors and Healthcare Workers)","CEDiD","NCT04363489","CEDiD Study","Device: Wearable Medical Device (Empatica E4)|Diagnostic Test: COVID-19 PCR Swab|Diagnostic Test: Pulse Oximeter","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363489","Not yet recruiting","2020-08-01","2020-09-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Infection|Symptoms|Clinical Observations""}"
"981","Pronation in COVID-19 Patients Undergoing Non Invasive Respiratory Support","PRINCESS","NCT04649658","UModenaReggio10","Behavioral: Prone position","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649658","Completed","2020-03-01","2020-11-30","{""locations"":""Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""93"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Endotracheal intubation|Mortality|Tracheostomy|Length of Respiratory Intensive Care Unit stay|Length of Hospital stay""}"
"982","Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19","CoronaStem1","NCT04486001","PSC-CP-004","Biological: PSC-04","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04486001","Recruiting","2020-12-15","2022-01-15","{""locations"":""Fresno Community Hospital, Fresno, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of all adverse events|Frequency of infusion related serious adverse events|Frequency of serious adverse events|Mortality|Ventilator Free Days|ICU Free Days|Total Hospital Days|Total ICU Days|Improvement in Oxygenation""}"
"983","Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients","SECR-01","NCT04610502","R020-SABI-00259","Biological: Administration of Equine immunoglobulin anti SARS-CoV-2","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04610502","Active, not recruiting","2020-09-06","2020-12-06","{""locations"":""Centro Especializado de Atenci\u00f3n COVID19 (CEACO), San Jos\u00e9, Costa Rica|Hospital Dr. Rafael \u00c1ngel Calder\u00f3n Guardia, San Jos\u00e9, Costa Rica|Hospital M\u00e9xico, San Jos\u00e9, Costa Rica|Hospital San Juan de Dios, San Jos\u00e9, Costa Rica"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""26"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate the efficacy and safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins (\""S\"" and \""M\"").|To evaluate safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins (\""S\"" and \""M\"").|Viral load|Mortality|Hospital stay|ventilatory support|blood levels of immunoglobulins against SARS-CoV-2|inflammatory markers|thrombotic marker levels|negativization period of RT-PCR on nasopharyngeal swabbing (Reverse transcription polymerase chain reaction)|SpFI (Partial saturation Oxigen\/inspired fraction of Oxigen) gain|Lung Ultrasound|Adverse events""}"
"984","Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED","EUROCOV","NCT04682093","123456","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04682093","Enrolling by invitation","2020-03-09","2021-02-28","{""locations"":""EUSEM RN Country lead, Zagreb, Croatia|EUSEM RN Country lead, H\u00e4meenlinna, Finland|EUSEM RN Country lead, Tours, France|EUSEM RN Country lead, Athens, Greece|EUSEM RN Country lead, Forl\u00ec, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""8000"",""age"":""18 Years to 130 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""hospitalization|length of hospital stay|in-hospital mortality|ICU admission""}"
"985","Almitrine and COVID-19 Related Hypoxemia","","NCT04380727","2020PI080_2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380727","Completed","2020-03-20","2020-04-25","{""locations"":""Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""17"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes from baseline PaO2 (mmHg)|Changes from baseline ScvO2 (%)""}"
"986","IMUNOR® Preparation in the Prevention of COVID-19","","NCT04710381","FNO-IMUNOR-2020","Drug: IMUNOR","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04710381","Not yet recruiting","2021-02-01","2021-06-30","{""locations"":""University Hospital Ostrava, Ostrava, Moravian-Silesian Region, Czechia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Prevention of COVID-19 disease|Prevention of hospitalisations due to COVID-19|Incidence of sick-leave episodes""}"
"987","To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database","Strain","NCT04346043","FMASU P16a/ 2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346043","Not yet recruiting","2020-04-20","2020-12-01","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dominant viral genome strain""}"
"988","COVID-19 Follow up Intensive Care Studies","COFICS","NCT04460170","COFICS201800422","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04460170","Recruiting","2020-07-01","2022-02-01","{""locations"":""University Medical Center Groningen, Groningen, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""General Health|Anxiety and Depression|Long function|Frailty|Family functioning|Effect of an ICU admission on return to work|age|Gender|Social status|APACHE IV|Comorbidity|Body mass index|ICU stay|Mechanical ventilation|Delerium|Hospital stay|Discharge locationn|Mortality|Relationship with the patient|Educational level|Readmission|Health care consumption|Weight|Hypertensive|Thrombosis|Diabetes""}"
"989","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19","","NCT04401475","EB05-04-2020","Biological: SOC plus 15mg/kg EB05 IV|Other: SOC plus Placebo IV","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04401475","Recruiting","2020-11-25","2021-04-01","{""locations"":""St. Jude Medical Center\/ Providence, Fullerton, California, United States|St. Joseph Hospital, Orange - Providence, Orange, California, United States|University of Miami Hospital, Coral Gables, Florida, United States|Methodist Medical Center IL, Peoria, Illinois, United States|Providence Regional Medical Center - Everett, Everett, Washington, United States|UW Medicine Valley Medical Center, Renton, Washington, United States|West Virginia University Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States|North York General Hospital, Toronto, Ontario, Canada|H\u00f4pital Maisonneuve Rosemont, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""396"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the proportion of patients that are alive without any need for oxygen support defined as a score of 3 or less on the WHO COVID-19 nine-point scale|Time to therapeutic response (primary efficacy endpoint).|The proportion of patients with clinical improvement, defined as a decrease of two points or more on the WHO 9 - point ordinal scale at Day 28|The proportion of patients that are alive and discharged home without any need for oxygen support (WHO Scale of \u2264 2) at Day 28.|The proportion of patients that are alive and free of respiratory failure (WHO scale \u2264 4) at Day 28.|The proportion of patients with clinical improvement, defined as a decrease of two points or more on the WHO 9 - point ordinal scale at Day 60.|The proportion of patients with clinical improvement, defined as a decrease of one point or more on the WHO 9 - point ordinal scale at Day 28.|The proportion of patients with clinical improvement, defined as a decrease of one point or more on the WHO 9 - point ordinal scale at Day 60.|The proportion of patients that are alive and discharged home without any need for oxygen support (WHO Scale of \u2264 2) at Day 60.|The proportion of patients that are alive and free of respiratory failure (WHO scale \u2264 4) at Day 60.|Time to clinical improvement by 2 points on the WHO ordinal scale described above.|Time to clinical improvement by 1 point on the WHO ordinal scale described above.|Change in the NEWS-2 Scale at 28 days.|Time to News-2 = 0.|The proportion of patients that experience disease progression, defined as an increase of one point or more in the WHO 9-point ordinal scale, at Day 28.|Ventilator-free days.|Duration of ventilation.|Mortality rate at 28-days and 60-days post-treatment initiation.|Duration of hospitalization.|Time to independence from supplementary oxygen therapy.|Time to normalization of oxygen saturation, defined as SaO2\/SpO2 > 94% sustained a minimum of 24 hours.|Change in Sequential Organ Failure Assessment (SOFA) score, while hospitalized.|Radiological response to treatment based on Thoracic Computerized Tomography Scan (CT-Scan) or Chest X-Ray.|Change in cytokines, including IL-6, and C-reactive protein (CRP) levels.|Time to resolution of fever for at least 48 hours without antipyretics.|The decision by the attending physician to initiate treatment with another targeted immunomodulator (i.e. dexamethasone).|Change in the Berlin ARDS severity scale.|Change in Acute Kidney Injury Network (AKIN) classification.|Change in troponin levels.""}"
"990","Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","","NCT04350931","FMASU P19a/ 2020","Biological: intradermal injection of BCG Vaccine|Other: placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04350931","Not yet recruiting","2020-04-20","2020-12-01","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""incidence of confirmed COVID-19|Effectiveness of BCG vaccine""}"
"991","Tracheobronchitis in Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients","","NCT04629222","2020PI154","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04629222","Completed","2020-03-11","2020-07-23","{""locations"":""CHRU of Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""10"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Tracheobronchitis signs may be observed on ventilation lung scintigraphy during COVID-19 infection.""}"
"992","The Salivary Raman COVID-19 Fingerprint","DISCOVER","NCT04583306","FDG_SalivaCOVID01","Other: Raman analysis of saliva, characterization of the Raman database and building of the classification model","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04583306","Recruiting","2020-06-01","2021-06-01","{""locations"":"", IRCCS Fondazione Don Carlo Gnocchi, Centro Spalenza, Rovato, BS, Italy|IRCCS Fondazione Don Carlo Gnocchi, Santa Maria Nascente Hospital (Milano), Milano, MI, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification and characterization of a new COVID-19 salivary signature through Raman spectroscopy|Evaluation of the spectral differences between the experimental groups|Determination of the classification model through multivariate analysis|Correlation with the clinical data|Test of the methodology|Portable Raman as point of care""}"
"993","Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)","","NCT04575584","4482-001|2020-003367-26|MK-4482-001|PHRR201210-003189","Drug: Molnupiravir|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04575584","Recruiting","2020-10-19","2021-12-30","{""locations"":""Kaiser Foundation Hospital - South Bay ( Site 1832), Harbor City, California, United States|Cedars-Sinai Medical Center ( Site 1822), Los Angeles, California, United States|University of California Davis Health ( Site 1809), Sacramento, California, United States|University Of Florida ( Site 1810), Gainesville, Florida, United States|Wellstar Kennestone Hospital ( Site 1801), Marietta, Georgia, United States|Loretto Hospital ( Site 1838), Chicago, Illinois, United States|LSU-HSC Shreveport ( Site 1824), Shreveport, Louisiana, United States|Henry Ford Health System ( Site 1821), Detroit, Michigan, United States|University of Mississippi Medical Center ( Site 1846), Jackson, Mississippi, United States|University of Nebraska Medical Center ( Site 1835), Omaha, Nebraska, United States|University of New Mexico, Health Sciences Center ( Site 1806), Albuquerque, New Mexico, United States|Carolinas Medical Center ( Site 1850), Charlotte, North Carolina, United States|ECU Adult Specialty Care ( Site 1865), Greenville, North Carolina, United States|Sanford Health ( Site 1851), Fargo, North Dakota, United States|Temple University ( Site 1836), Philadelphia, Pennsylvania, United States|CHRISTUS Institute for Innovation & Advanced Clinical Care ( Site 1864), Corpus Christi, Texas, United States|Houston Methodist Hospital ( Site 1863), Houston, Texas, United States|Swedish Medical Center ( Site 1812), Edmonds, Washington, United States|Valley Medical Center ( Site 1815), Renton, Washington, United States|Swedish Medical Center ( Site 1861), Seattle, Washington, United States|Chronos Pesquisa Cl\u00ednica ( Site 0105), Brasilia, Distrito Federal, Brazil|Santa Casa de Misericordia de Belo Horizonte ( Site 0100), Belo Horizonte, Minas Gerais, Brazil|Hospital de Clinicas da Universidade Federal do Parana ( Site 0104), Curitiba, Parana, Brazil|Hospital Tacchini ( Site 0107), Bento Goncalves, Rio Grande Do Sul, Brazil|FUNFARME Hospital de Base Centro Integrado de Pesquisa ( Site 0101), Sao Jose do Rio Preto, Sao Paulo, Brazil|University Health Network - Toronto General Hospital ( Site 0201), Toronto, Ontario, Canada|Hospital Clinico Fusat ( Site 0300), Rancagua, Libertador General Bernardo O Higgins, Chile|Clinica Universidad de los Andes ( Site 0301), Santiago, Region M. De Santiago, Chile|Hospital Sotero del Rio [Santiago, Chile] ( Site 0304), Santiago, Region M. De Santiago, Chile|Complejo Hospitalario San Jose ( Site 0306), Santiago, Region M. De Santiago, Chile|Servicio de Salud Sur Hospital Lucio Cordova ( Site 0305), Santiago, Region M. De Santiago, Chile|Hospital Pablo Tobon Uribe ( Site 0404), Medellin, Antioquia, Colombia|Clinica de la Costa Ltda. ( Site 0402), Barranquilla, Atlantico, Colombia|Oncomedica S.A. ( Site 0406), Monteria, Cordoba, Colombia|Hospital Universitario San Ignacio ( Site 0401), Bogota, Distrito Capital De Bogota, Colombia|Fundacion Cardiovascular de Colombia ( Site 0403), Bucaramanca, Santander, Colombia|Fundacion Valle del Lili ( Site 0400), Cali, Valle Del Cauca, Colombia|Groupe Hospitalier Pellegrin ( Site 0511), Bordeaux, Gironde, France|Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 0504), Paris, Ile-de-France, France|C.H.U. de Toulouse, Hopital de Purpan ( Site 0501), Toulouse, Midi-Pyrenees, France|Centre Hospitalier de Tourcoing ( Site 0502), Tourcoing, Nord, France|CHU Hopital Saint Antoine ( Site 0505), Paris, France|Hopital Bichat - Claude Bernard ( Site 0503), Paris, France|Rambam Medical Center ( Site 2102), Haifa, Israel|Hadassah Medical Center. Ein Kerem ( Site 2103), Jerusalem, Israel|Chaim Sheba Medical Center ( Site 2100), Ramat Gan, Israel|Chungnam National University Hospital ( Site 2202), Daejeon, Taejon-Kwangyokshi, Korea, Republic of|Inha University Hospital ( Site 2204), Incheon, Korea, Republic of|The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 2205), Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0802), Ciudad de mexico, Distrito Federal, Mexico|Hospital Regional de Alta Especialidad del Bajio ( Site 0807), Leon, Guanajuato, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0800), Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez ( Site 0803), Monterrey, Nuevo Leon, Mexico|Lung Center of the Philippines ( Site 0902), Quezon City, National Capital Region, Philippines|Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 1001), Lodz-Baluty, Lodzkie, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1004), Lublin, Lubelskie, Poland|Centrum Medyczne Pratia, Mazowiecki Szpital Specjalistyczny, Oddzia\u0142 Obserwacyjno - Zaka\u017any ( Site 1, Ostroleka, Mazowieckie, Poland|Centrum Medyczne w Lancucie Sp.zo.o. ( Site 1000), Lancut, Podkarpackie, Poland|Krasnogorsk City Hospital Number 1 ( Site 1119), Krasnogorsk, Moskovskaya Oblast, Russian Federation|City Clinical Hospital #40 ( Site 1109), Moscow, Moskva, Russian Federation|FSBI Central Hospital with Policlinics ( Site 1105), Moscow, Moskva, Russian Federation|Moscow Clinical Hospital #52 ( Site 1103), Moscow, Moskva, Russian Federation|City Hospital #40 ( Site 1113), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Pokrovskaya hospital ( Site 1116), Saint-Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Hospital #1 ( Site 1112), Smolensk, Smolenskaya Oblast, Russian Federation|Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 1100), Kazan, Tatarstan, Respublika, Russian Federation|IATROS International ( Site 1202), Bloemfontein, Free State, South Africa|Wits Baragwanath Clinical Trial Site ( Site 1204), Soweto, Gauteng, South Africa|TREAD Research ( Site 1201), Cape Town, Western Cape, South Africa|Clinical Projects Research Centre ( Site 1205), Worcester, Western Cape, South Africa|Hospital Universitari Vall d Hebron ( Site 1305), Barcelona, Cataluna, Spain|Hospital Clinic ( Site 1304), Barcelona, Spain|Hospital Universitari Germans Trias i Pujol ( Site 1303), Barcelona, Spain|Hospital Universitario Gregorio Maranon ( Site 1302), Madrid, Spain|Hospital Universitario Ramon y Cajal ( Site 1301), Madrid, Spain|Hospital Universitario La Paz ( Site 1300), Madrid, Spain|Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 1605), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|CNPE of Kharkiv RC Regional Clinical Infectious Diseases Hospital ( Site 1606), Kharkiv, Kharkivska Oblast, Ukraine|\u0421ommunal non-com. Institution Oleksandrivska clinical hospital Kyiv ( Site 1600), Kyiv, Kyivska Oblast, Ukraine|Odesa City Clinical Infectious Hospital ( Site 1611), Odesa, Odeska Oblast, Ukraine|Communal Non-Commercial Enterprise Central City Hospital ( Site 1615), Rivne, Rivnenska Oblast, Ukraine|Volyn Regional Clinical Hospital ( Site 1613), Lutsk, Volynska Oblast, Ukraine|Royal Free London NHS Foundation Trust ( Site 1700), London, London, City Of, United Kingdom|King's College Hospital ( Site 1705), London, London, City Of, United Kingdom|North Manchester General Hospital ( Site 1701), Manchester, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time-to-sustained recovery|Percentage of participants with an adverse event (AE)|Percentage of participants who discontinued study intervention due to an AE|Percentage of participants with all-cause mortality|Pulmonary score on a scale|Pulmonary+ score on a scale|National Early Warning Score on a scale|WHO 11-point outcomes score on a scale""}"
"994","Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","EpiVacCorona","NCT04527575","COV/pept-01/20","Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|Other: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04527575","Active, not recruiting","2020-07-27","2021-05-01","{""locations"":""Federal State Budgetary Institution of Healthcare \""Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency\"" (FGBUZ MSCH-163, FMBA of Russia), Koltsovo, Novosibirsk Region, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""The proportion of vaccinated volunteers with no laboratory confirmed symptoms caused by SARS-CoV-2 within 9 months post vaccination|The proportion of volunteers with increased levels of the immune response in terms of geometric mean titers of specific antibodies in ELISA following the vaccination compared with a placebo.|The proportion of volunteers with increased levels of the immune response in terms of specific neutralizing antibody titers in ELISA following the vaccination, compared with a placebo|The proportion of volunteers with an ex vivo cellular immune response following the vaccination, compared with a placebo|Incidence and type of adverse events during the study|Incidence of serious adverse events during the study|Cases of early termination of the study due to the development of adverse events \/ sever adverse events""}"
"995","Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)","","NCT04530656","JSVCT098","Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Biological: Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Biological: Two doses of placebo at the schedule of day 0, 28（high-dose group）|Biological: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04530656","Active, not recruiting","2020-08-28","2021-08-28","{""locations"":""Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""168"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of adverse reactions (AR) within 7 days after each dose of the recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.|Occurrence of adverse events (AE) within 7 days after each dose of the recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.|Occurrence of AE up to Day 28 after prime and boost vaccination.|The proportion of SAEs up to Day 28 after prime and boost vaccination.|The proportion of SAEs up to Month 12 after prime and boost vaccination.|The proportion of abnormal markers of hematology, blood chemistry and urine analysis within 7 days before prime vaccination and at Day 3 after each dose of recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.|GMT of anti-RBD specific antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|Four-fold increase in anti-RBD specific antibody titers, at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|GMFI of anti-RBD specific antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|GMT of SARS-CoV-2 neutralizing antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|Four-fold increase in SARS-CoV-2 neutralizing antibody titers, at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|GMFI of SARS-CoV-2 neutralizing antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after prime and boost vaccination.|Seroconversion rates of IFN-\u03b3 stimulated by the overlapping peptide library of S-RBD protein at Day 14, Day 28 after boost vaccination.""}"
"996","Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19","PEP-CQ","NCT04408456","IEC-04/2020-1624","Drug: HCQ|Other: Standard therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04408456","Completed","2020-03-01","2020-07-31","{""locations"":""Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""325"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence confirmed case of COVID-19|Incidence of probable case of COVID-19|Incidence of adverse drug reaction (ADR)""}"
"997","Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)","","NCT04575597","4482-002|2020-003368-24|MK-4482-002|PHRR201209-003186","Drug: Molnupiravir|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04575597","Recruiting","2020-10-19","2021-12-26","{""locations"":""Phoenix Medical Group ( Site 1822), Peoria, Arizona, United States|Ruane Clinical Research Group, Inc. ( Site 2406), Los Angeles, California, United States|Men's Health Foundation ( Site 1820), Los Angeles, California, United States|UC Davis Medical Center ( Site 1833), Sacramento, California, United States|Emerson Clinical Research Institute ( Site 1828), Washington, District of Columbia, United States|Midway Immunology and Research Center ( Site 1837), Fort Pierce, Florida, United States|Indago Research & Health Center, Inc ( Site 1809), Hialeah, Florida, United States|Advanced Research For Health Improvement LLC ( Site 1816), Immokalee, Florida, United States|Advanced Research For Health Improvement LLC ( Site 1813), Naples, Florida, United States|Bliss Healthcare Services ( Site 1847), Orlando, Florida, United States|Javara Inc. ( Site 1869), Albany, Georgia, United States|IACT Health ( Site 1818), Columbus, Georgia, United States|Javara Inc. ( Site 1868), Fayetteville, Georgia, United States|Loretto Hospital ( Site 1886), Chicago, Illinois, United States|University of Nebraska Medical Center ( Site 2414), Omaha, Nebraska, United States|University of New Mexico, Health Sciences Center ( Site 1819), Albuquerque, New Mexico, United States|Saint Hope Foundation, Inc. ( Site 1830), Bellaire, Texas, United States|The Crofoot Research Center, Inc. ( Site 1812), Houston, Texas, United States|Javara Inc. ( Site 1866), Sugar Land, Texas, United States|Swedish Medical Center First Hill ( Site 1807), Seattle, Washington, United States|Multicare Health System ( Site 1811), Spokane, Washington, United States|Multicare Health System ( Site 1814), University Place, Washington, United States|Chronos Pesquisa Cl\u00ednica ( Site 0155), Brasilia, Distrito Federal, Brazil|Santa Casa de Misericordia de Belo Horizonte ( Site 0150), Belo Horizonte, Minas Gerais, Brazil|Hospital de Clinicas da Universidade Federal do Parana ( Site 0154), Curitiba, Parana, Brazil|Hospital Tacchini ( Site 0157), Bento Goncalves, Rio Grande Do Sul, Brazil|Instituto de Infectologia Emilio Ribas ( Site 0153), Sao Paulo, Brazil|University Health Network - Toronto General Hospital ( Site 0201), Toronto, Ontario, Canada|Clinica Universidad de los Andes ( Site 0302), Santiago, Region M. De Santiago, Chile|Fundacion Arturo Lopez Perez ( Site 0305), Santiago, Region M. De Santiago, Chile|Espacio EME ( Site 0304), Santiago, Region M. De Santiago, Chile|Clinica Bicentenario Spa ( Site 0306), Santiago, Region M. De Santiago, Chile|Hospital Pablo Tobon Uribe ( Site 0405), Medellin, Antioquia, Colombia|Clinica de la Costa Ltda. ( Site 0403), Barranquilla, Atlantico, Colombia|Oncomedica S.A. ( Site 0407), Monteria, Cordoba, Colombia|Caja de Compensaci\u00f3n Familiar CAFAM. Sede Centro de Atenci\u00f3n en Salud CAFAM Floresta ( Site 0406), Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia ( Site 0402), Bucaramanca, Santander, Colombia|Fundacion Valle del Lili ( Site 0401), Cali, Valle Del Cauca, Colombia|Groupe Hospitalier Pellegrin ( Site 0511), Bordeaux, Gironde, France|C.H.U. de Toulouse Hopital Purpan ( Site 0501), Toulouse, Midi-Pyrenees, France|Centre Hospitalier de Tourcoing ( Site 0502), Tourcoing, Nord, France|CHU Hopital Saint Antoine ( Site 0505), Paris, France|Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 0504), Paris, France|Hopital Bichat Claude Bernard ( Site 0503), Paris, France|Universitaetsklinikum Essen ( Site 2305), Essen, Baden-Wurttemberg, Germany|Universitaetsklinikum Frankfurt ( Site 2302), Frankfurt a main, Hessen, Germany|ZIBP-Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH ( Site 2301), Berlin, Germany|Hadassah Medical Center. Ein Kerem ( Site 2100), Jerusalem, Israel|Lung Center of the Philippines ( Site 0902), Quezon City, National Capital Region, Philippines|Central Scientific Research Institute of Epidemiology ( Site 1104), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 1105), Moscow, Moskva, Russian Federation|Medical Research Institute LLC ( Site 1116), Saint Petersburg, Sankt-Peterburg, Russian Federation|St.Petersburg Outpatient Clinic #109 ( Site 1119), Saint-Petersburg, Sankt-Peterburg, Russian Federation|Limited liability company \""Scientific research center Eco-safety\"" ( Site 1117), Saint-Petersburg, Sankt-Peterburg, Russian Federation|Smolensk State Medical University ( Site 1110), Smolensk, Smolenskaya Oblast, Russian Federation|Strategic Medical System LLC ( Site 1114), Saint-Petersburg, Russian Federation|IATROS International ( Site 1212), Bloemfontein, Free State, South Africa|Mzansi Ethical Research Centre ( Site 1225), Mpumalanga, Gauteng, South Africa|Jongaie Research ( Site 1223), Pretoria-West, Gauteng, South Africa|Wits Baragwanath Clinical Trial Site ( Site 1214), Soweto, Gauteng, South Africa|Wentworth Provincial Hospital ( Site 1216), Durban, Kwazulu-Natal, South Africa|Limpopo Clinical Research Initiative ( Site 1227), Thabazimbi, Limpopo, South Africa|TREAD Research ( Site 1211), Cape Town, Western Cape, South Africa|Be Part Yoluntu Centre ( Site 1218), Paarl, Western Cape, South Africa|Clinical Projects Research Centre ( Site 1215), Worcester, Western Cape, South Africa|Hospital General Universitario Gregorio Maranon ( Site 1302), Madrid, Madrid, Comunidad De, Spain|CAP Sardenya - Barcelona ( Site 1307), Barcelona, Spain|Hospital Clinic ( Site 1304), Barcelona, Spain|Hospital Universitari Germans Trias i Pujol ( Site 1303), Barcelona, Spain|Hospital Universitario Ramon y Cajal ( Site 1301), Madrid, Spain|Hospital Universitario La Paz ( Site 1300), Madrid, Spain|Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 1605), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Non profit municipal enterprise City hospital student of Kharkiv city council ( Site 1621), Kharkiv, Kharkivska Oblast, Ukraine|LLC \""Adonis plus\"" ( Site 1619), Kyiv, Kyivska Oblast, Ukraine|Kyiv railway clinical hospital 2 of Branch Health center ( Site 1602), Kyiv, Kyivska Oblast, Ukraine|ARTEM. State Holding Company ( Site 1618), Kyiv, Kyivska Oblast, Ukraine|Layton Medical Centre ( Site 1705), Blackpool, Lancashire (England), United Kingdom|Royal Free London NHS Foundation Trust ( Site 1700), London, London, City Of, United Kingdom|King's College Hospital ( Site 1707), London, London, City Of, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust ( Site 1704), Newcastle upon Tyne, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of participants who are hospitalized and\/or die|Percentage of participants with an adverse event (AE)|Percentage of participants who discontinued study intervention due to an AE|Time to sustained resolution or improvement of each targeted COVID-19 sign\/symptom|Time to progression of each targeted COVID-19 sign\/symptom|WHO 11-point outcomes score on a scale""}"
"998","Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma","","NCT04432103","ABC-20-14","Biological: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Biological: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04432103","Not yet recruiting","2020-06-19","2020-09-30","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""INCIDENCE OF CRITICAL PNEUMONIA|MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS|INCIDENCE OF MECHANICAL VENTILATION|DAYS OF MECHANICAL VENTILATION""}"
"999","Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19","","NCT04373044","0S-20-3|NCI-2020-02685|P30CA014089","Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04373044","Recruiting","2020-05-01","2022-05-01","{""locations"":""Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC \/ Norris Comprehensive Cancer Center, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""144"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients requiring invasive mechanical ventilation or dying|Identification of clinical features (vitals signs - body temperature)|Identification of clinical features (vital signs - respiratory rate)|Identification of clinical features (vital signs - heart rate)|Identification of clinical features (vital signs - blood pressure)|Identification of clinical features (Imaging)|Identification of clinical features (Lab - White Blood Count)|Identification of clinical features (Lab - Absolute Lymphocyte Count)|Identification of clinical features (Lab - Hemoglobin)|Identification of clinical features (Lab - Creatinine)|Identification of biomarkers (C-reactive protein)|Identification of biomarkers (Interleukin-6)|Identification of biomarkers (Tumor Necrosis Factor-alpha)|Identification of adverse events""}"
"1000","Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.","EC-COVID-PCS","NCT04323878","EC-COVID-PCS-Fenice","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04323878","Recruiting","2020-06-01","2021-12-01","{""locations"":""Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death or need of intubation|30-day mortality""}"
"1001","A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19","","NCT03891420","BCX4430-108|272201300017C-18-0-1|DMID18-0022","Drug: Galidesivir|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT03891420","Recruiting","2020-04-09","2021-05-31","{""locations"":""Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Parana, Brazil|Hospital Sao Vicente de Paulo-PPDS, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Foundation Regional Faculty of Medicine of S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 Do Rio Preto, SP, Brazil|Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Cl\u00ednicas, School of Medicine, USP, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""132"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of subjects with treatment emergent adverse events and serious adverse events|number of subjects with change in laboratory parameters|exposure of galidesivir as measured by plasma concentrations|yellow fever virus (YFV) titer (Group A)|antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B)|changes in clinical status using 8-point ordinal scale in COVID-19 (Group B)|changes from baseline and time to improvement using NEWS in COVID-19 (Group B)|mortality""}"
"1002","Chloroquine as Antiviral Treatment in Coronavirus Infection 2020","","NCT04331600","WROCLAW CORONA STUDY 2020","Drug: Chloroquine phosphate|Other: Telemedicine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04331600","Completed","2020-04-16","2020-12-17","{""locations"":""Uniwersytecki Szpital Kliniczny, Wroc\u0142aw, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, Pozna\u0144, Ul. Szwajcarska 3, Poland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""16"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications""}"
"1003","Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto","HETHICO","NCT04393805","HETHICO","Drug: Low Molecular Weight Heparin","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393805","Recruiting","2020-06-01","2020-12-01","{""locations"":""Giuseppe Camporese, Padova, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""877"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Bleeding|Thrombosis|Mortality|Worsening|LOS""}"
"1004","Evaluating the Impact of EnteraGam In People With COVID-19","PICNIC","NCT04682041","PICNIC Study","Dietary Supplement: Bovine Plasma-Derived Immunoglobulin Concentrate|Other: Standard of care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04682041","Recruiting","2020-12-22","2021-06-30","{""locations"":""Hospital del Mar, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""420"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in plasma IL-6 levels|COVID-19 disease progression by Week 2|Change in dyspnea|Change in diarrhea|Change in fever|Change in neutrophil count|Change in lymphocyte count|Change in neutrophil\/lymphocyte ratio|Change in platelet count|Change in C-reactive protein|Change in ferritin|Change in D-dimer|Change in AST|Change in ALT|Time to worsening clinical status""}"
"1005","An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients","","NCT04471051","20-0986","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04471051","Recruiting","2020-04-30","2021-04-01","{""locations"":""Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Inpatient Mortality|Requirement for mechanical ventilation|Transfer to ICU|ICU Mortality|ICU Length of Stay (LOS)|Hospital Mortality|Hospital Length of Stay (LOS)""}"
"1006","TD-0903 for ALI Associated With COVID-19","","NCT04402866","0188|2020-001807-18","Drug: TD-0903|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04402866","Recruiting","2020-06-24","2021-04-01","{""locations"":""Theravance Biopharma Investigational Site, Duarte, California, United States|Theravance Biopharma Investigational Site, Denver, Colorado, United States|Theravance Biopharma Investigational Site, Sebring, Florida, United States|Theravance Biopharma Investigational Site, Boston, Massachusetts, United States|Theravance Biopharma Investigational Site, Fall River, Massachusetts, United States|Theravance Biopharma Investigational Site, Kalispell, Montana, United States|Theravance Biopharma Investigational Site, Glens Falls, New York, United States|Theravance Biopharma, Hyde Park, New York, United States|Theravance Biopharma Investigational Site, Columbus, Ohio, United States|Theravance Biopharma Investigational Site, Allentown, Pennsylvania, United States|Theravance Biopharma Investigational Site, Bethlehem, Pennsylvania, United States|Theravance Biopharma Investigational Site, Wenatchee, Washington, United States|Theravance Biopharma Investigational Site, Bela Vista, Brazil|Theravance Biopharma Investigational Site, Botucatu, Brazil|Theravance Biopharma Investigational Site, Caxias Do Sul, Brazil|Theravance Biopharma Investigational Site, S\u00e3o Jos\u00e9 Do Rio Preto, Brazil|Theravance Biopharma Investigational Site, Helsinki, Finland|Theravance Biopharma Investigational Site, Turku, Finland|Theravance Biopharma Investigational Site, Chisinau, Moldova, Republic of|Theravance Biopharma Investigational Site, Bucharest, Romania|Theravance Biopharma Investigational Site, Brovary, Ukraine|Theravance Biopharma Investigational Site, Kyiv, Ukraine|Theravance Biopharma Investigational Site, Manchester, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""222"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Part 2: Respiratory Failure-Free Days (RFDs)|Part 2: Clinical Status Scale|Part 2: Subjects alive and respiratory failure-free|Part 2: SaO2\/FiO2 ratio""}"
"1007","COVID-19 in Home Healthcare","","NCT04642196","Home healthcare 2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04642196","Completed","2020-05-02","2020-10-10","{""locations"":""Dept of anesthesia, Link\u00f6ping, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""155"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Frailty|Comorbidity""}"
"1008","AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19","","NCT04507256","D8850C00001","Combination Product: AZD7442|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04507256","Active, not recruiting","2020-08-18","2021-10-25","{""locations"":""Research Site, Harrow, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Number of participants with adverse events (AEs) and serious AEs|Observed maximum concentration (Cmax) (IV infusion)|Time to reach maximum concentration (Tmax) (IV infusion)|Terminal elimination half life, estimated as (ln2)\/\u03bbz (t\u00bd\u03bbz) (IV infusion)|Area under the concentration curve from time zero to the time of last quantifiable concentration (AUClast) (IV infusion)|Area under the concentration time curve from time zero extrapolated to infinity (AUCinf) (IV infusion)|Volume of distribution at steady state (Vss) (IV infusion)|Volume of distribution at terminal phase (Vz) (IV infusion)|Systemic clearance (CL) (IV infusion)|Cmax (IM injection)|Tmax (IM injection)|t\u00bd\u03bbz (IM injection)|AUClast (IM injection)|AUCinf (IM injection)|Extravascular systemic clearance (CL\/F) (IM injection)|Bioavailability (F) (IM injection)|Extravascular terminal-phase volume of distribution (Vz\/F) (IM injection)|Number and percentage of participants who are ADA positive""}"
"1009","Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19","","NCT04505709","STOP-Coronavirus|COV20/00181","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04505709","Enrolling by invitation","2020-08-01","2021-08-01","{""locations"":""Fundacion Jimenez Diaz, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Identification of host genetic markers associated with the evolution of COVID-19|Analysis of bioethical aspects related to in-hospital management of the health crisis|Analysis of the spectrum of mutants of SARS-CoV-2 and its possible association with the clinical evolution of COVID-19""}"
"1010","European Pathology Laboratories and COVID-19","","NCT04476823","20labocovid01","Other: Activity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04476823","Completed","2020-03-15","2020-05-31","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""71"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Activity""}"
"1011","Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","ASCOT ADAPT","NCT04483960","ERM 62646-A","Drug: Nafamostat Mesilate|Biological: Convalescent plasma|Drug: Enoxaparin|Drug: Dalteparin|Drug: Tinzaparin|Drug: Aspirin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04483960","Recruiting","2020-07-28","2022-12-31","{""locations"":""Calvary Public Bruce Hospital, Bruce, Australian Capital Territory, Australia|The Canberra Hospital, Canberra, Australian Capital Territory, Australia|Armidale Hospital, Armidale, New South Wales, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|The Sutherland Hospital, Caringbah, New South Wales, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Griffith Base Hospital, Griffith, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Lismore Base Hospital, Lismore, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Caboolture Hospital, Caboolture, Queensland, Australia|Cairns Hospital, Cairns, Queensland, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mackay Base Hospital, Mackay, Queensland, Australia|Logan Hospital, Meadowbrook, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Mater, South Brisbane, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Townsville University Hospital, Townsville, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Ballarat Health Services, Ballarat Central, Victoria, Australia|St John of God Ballarat Hospital, Ballarat, Victoria, Australia|Bendigo Health, Bendigo, Victoria, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Northern Health, Epping, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Frankston Hospital - Penninsula Health, Frankston, Victoria, Australia|Peninsula Private Hospital, Frankston, Victoria, Australia|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Epworth Richmond, Richmond, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Western Health, St Albans, Victoria, Australia|Latrobe Regional Hospital, Traralgon, Victoria, Australia|West Gippsland Hospital, Warragul, Victoria, Australia|Albury Wodonga Health, Wodonga, Victoria, Australia|Rockingham General Hospital, Cooloongup, Western Australia, Australia|Joondalup Health Campus, Joondalup, Western Australia, Australia|Armadale Health Service, Mount Nasura, Western Australia, Australia|Fiona Stanley Hospita, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Knox Private Hospital, Wantirna, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death from any cause or requirement of new intensive respiratory support (invasive or non-invasive ventilation) or vasopressor\/inotropic support.|Time to clinical recovery|WHO 8-point ordinal outcome scale|All-cause mortality|Days alive and free of hospital|Days alive and free of invasive or non-invasive ventilation|Shortness of breath|Quality of life|Antiviral domain-specific outcome: Viral clearance|Antiviral domain-specific outcome: Viral load|Antiviral domain-specific outcome: Safety (Liver enzymes)|Antiviral domain-specific outcome: Safety (potassium)|Antiviral domain-specific outcome: Safety (sodium)|Antiviral domain-specific outcome: Safety (bleeding)|Antiviral domain-specific outcome: Safety (thrombophlebitis)|Antiviral domain-specific outcome: serious adverse reactions|Antibody domain-specific outcome: Serious treatment-related adverse events|Antibody domain-specific outcome: Haemolysis|Antibody domain-specific outcome: Confirmed arterial thrombosis|Antibody domain-specific outcome: Confirmed venous thrombosis|Anticoagulation domain-specific outcome: Confirmed deep venous thrombosis|Anticoagulation domain-specific outcome: Confirmed pulmonary embolus|Anticoagulation domain-specific outcome: Confirmed acute myocardial infarction|Anticoagulation domain-specific outcome: Confirmed ischemic cerebrovascular event|Anticoagulation domain-specific outcome: Major bleeding|Anticoagulation domain-specific outcome: Clinically relevant non-major bleeding|Anticoagulation domain-specific outcome: Heparin-induced thrombocytopenia (HIT)""}"
"1012","Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection","LIVECOVIDFREE","NCT04584671","ROB0050","Diagnostic Test: Hyperpolarized Xenon-129 MRI of the lungs|Diagnostic Test: Computed Tomography (CT)|Diagnostic Test: Pulmonary Function Tests (PFT)|Diagnostic Test: Six Minute Walk Test (6MWT)|Diagnostic Test: Sputum analysis|Diagnostic Test: Blood analysis|Other: Questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04584671","Not yet recruiting","2020-12-01","2024-12-01","{""locations"":""Department of Medicine (Respirology), McMaster University, Hamilton, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by VDP.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FEV1.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FVC.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by TLC.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FRC.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by RV.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FOT.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by LCI.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FeNO.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by exercise capacity.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by baseline dyspnea index questionnaire|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by (mMRC) dyspnea scale questionnaire.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by CAT.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by SGRQ.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by IPAQ.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by eosinophil count.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by VDP.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FEV1.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FVC.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by TLC.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FRC.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by RV.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FOT.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by LCI.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FeNO.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by exercise capacity.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by the baseline dyspnea index questionnaire.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by the mMRC dyspnea scale questionnaire.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by CAT.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by SGRQ.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by IPAQ.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by eosinophil count..|Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by sex.|Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by age.|Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by smoking history measured in pack-years.""}"
"1013","COVID Screening Strategies in Homeless Shelters","","NCT04438070","2020-10864-T","Diagnostic Test: COVID-19 Swab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04438070","Recruiting","2020-04-10","2020-06-01","{""locations"":""Various Homeless Shelters, Hamilton, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Detection Rate|Number of outbreaks|Enrollment over time""}"
"1014","A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","","NCT04498247","V591-001|2020-003493-46","Biological: V591|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04498247","Terminated","2020-08-27","2021-03-05","{""locations"":""Research Centers of America, LLC ( Site 0014), Hollywood, Florida, United States|Alliance for Multispecialty Research, LLC ( Site 0013), Wichita, Kansas, United States|Central Kentucky Research Associates, Inc. ( Site 0011), Lexington, Kentucky, United States|The Center for Pharmaceutical Research PC ( Site 0012), Kansas City, Missouri, United States|SCRI-CCCIT GesmbH ( Site 0006), Salzburg, Austria|Medizinische Universitaet Wien ( Site 0007), Wien, Austria|Universitair Ziekenhuis Gent ( Site 0003), Gent, Oost-Vlaanderen, Belgium|SGS Life Science Services ( Site 0001), Antwerpen, Belgium|ATC - Clinical Pharmacology Unit ( Site 0002), Liege, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""263"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants with at Least 1 Solicited Injection Site Adverse Event|Percentage of Participants with at Least 1 Solicited Systemic Adverse Event|Percentage of Participants with at Least 1 Unsolicited Adverse Event|Percentage of Participants with at Least 1 Serious Adverse Event|Percentage of Participants who Discontinued Study Treatment due to an Adverse Event|Percentage of Participants with at Least 1 Medically Attended Adverse Event|Geometric Mean Titers for Serum Neutralizing Antibodies (nAb) as Measured by Measured by Pseudo-virus Neutralization Assay (PNA): All Panels|Geometric Mean Concentration of Total Anti-Spike Immunoglobulin G (IgG) Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA): All Panels|Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by PNA: Panels A,B, I and J|Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA: Panels A,B, I and J|Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by PNA: Panels K and L|Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA: Panels K and L|Geometric Mean Titers for Serum nAb as Measured by PNA|Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA""}"
"1015","The COVID-RASi Trial (COVID-19)","","NCT04591210","CTO-3212","Drug: Angiotensin converting enzyme inhibitor|Drug: Angiotensin II Receptor Blockers","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04591210","Recruiting","2021-01-27","2022-08-01","{""locations"":""University of Ottawa Heart Institute, Ottawa, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1155"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Death|Mechanical ventilation|ICU admission|Major Adverse Cardiac Events (MACE)|Days alive and out of hospital|Cardiovascular mortality|All cause hospitalization|Percent of patients require intensive care|Percent of patients requiring ventilation|Percent of patients requiring dialysis""}"
"1016","Evaluating Clinical Parameters of COVID-19 in Pregnancy","COpregVID","NCT04470583","C&W20/034|283995","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04470583","Recruiting","2020-10-09","2021-12-02","{""locations"":""Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Chelsea and Westminster Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""116"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Proportions of leukocyte subsets and thrombocytes in pregnant\/postnatal and non-pregnant COVID-19 positive women.|Concentrations of other biochemical markers of severity in pregnant and non-pregnant COVID-19 positive women.|Profiling of clinical severity, determined by clinical symptoms and observations in pregnant and non-pregnant COVID-19 positive women.""}"
"1017","Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test","CAPTURE-2","NCT04597047","S-CLIN-PROT-0031","Diagnostic Test: Capillary Collection & Testing|Diagnostic Test: Venous Draw & Testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04597047","Recruiting","2020-08-20","2022-12-31","{""locations"":""Eclipse Clinical Research, Tucson, Arizona, United States|Centura Health Physician Group, Northglenn Office, Northglenn, Colorado, United States|Professional Research Network of Kansas, Wichita, Kansas, United States|Physicians Quality Care of Jackson, Jackson, Tennessee, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""2 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Performance Evaluation""}"
"1018","Fight COVID-19 Trial","FIGHT-COVID-19","NCT04303299","TH-DMS-COVID19 study","Drug: Oral","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04303299","Recruiting","2020-08-19","2021-12-31","{""locations"":""Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""320"",""age"":""16 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment""}"
"1019","The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection","","NCT04664049","NRICM101","Dietary Supplement: NRICM101","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04664049","Recruiting","2020-12-23","2022-12-31","{""locations"":""National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""51000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""negative of COVID-19 test|free of COVID 19 disease symptoms and signs""}"
"1020","Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure","PRO-CARF","NCT04477655","048/20","Procedure: Awake prone positioning|Procedure: Standard oxygen therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04477655","Recruiting","2020-05-03","2020-12-30","{""locations"":""Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital General de Occidente, Guadalajara, Jalisco, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intubation rate|Total hours of prone position at day|Total number of prone sessions at day|Hours of the longest prone session each day|Change in oxygenation 1-hour after first prone session|Change in the ROX-index 1-hour after first prone session|Total days of prone positioning therapy|Adverse effects of prone positioning therapy|Mechanical ventilation days|Intensive care unit length of stay|Hospital length of stay|Hospital mortality""}"
"1021","A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult","COVID-19","NCT04695652","CT-COV-21","Biological: MVC-COV1901(S protein with adjuvant)|Biological: MVC-COV1901(Saline)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04695652","Recruiting","2020-12-30","2022-06-01","{""locations"":""Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Municipal Wan Fang Hospital, Taipei, Taiwan|Taipei Veteran General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang-Guang Memorial Hospital Lin-Kou, Taoyuan, Taiwan|Tao-Yuan General Hospital, Taoyuan, Taiwan|National Institute of Hygiene and Epidemiology, Hanoi, Vietnam"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""3700"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Adverse Event within 28 days post the second study intervention (Safety of MVC-COV1901)|Immunogenicity of MVC-COV1901|Incidence of Adverse Event throughout study conduct (Safety of MVC-COV1901)|lot to lot consistency""}"
"1022","Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial","","NCT04678739","M.A.R.M.C.D./2020/1985","Drug: Remdesivir|Drug: Tocilizumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04678739","Recruiting","2020-08-15","2021-02-28","{""locations"":""Chattogram General Hospital, Chittagong, Bangladesh|Cox's Bazar 250 Bed District Sadar Hospital, Cox's Bazar, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""16 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Time to Clinical Improvement (TTCI)|Duration of ICU Stay|Mortality Rate|Time to Recovery|Hospital stay|Rate of daily Supplemental Oxygen Use|Time to Clinical Failure""}"
"1023","Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu","","NCT04279197","Fzhy-ncp-2","Drug: Fuzheng Huayu Tablet|Drug: Vitamin C tablets|Other: Placebo|Other: respiratory function rehabilitation training","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04279197","Recruiting","2020-04-23","2021-12-01","{""locations"":""Shuguang Hospital, Shanghai, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The improvement proportion of pulmonary fibrosis|Blood oxygen saturation|Clinical symptom score|Quality of Life-BREF (QOL-BREF)|Patient Health Questionnaire-9(PHQ-9)|Generalized anxiety disorder-7(GAD-7)|The 6-minute walk distance""}"
"1024","Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19","ARTAN-C19","NCT04712357","CAAE: 34182620.0.0000.5045","Drug: Vitamin C 500 MG Oral Tablet|Drug: Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Drug: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04712357","Recruiting","2020-11-09","2023-01-01","{""locations"":""N\u00facleo de Biomedicina - NUBIMED, Fortaleza, Cear\u00e1, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""219"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale.|SARS-CoV-2 RNA viral load measurements change.|Proportion of patients with qualitative serum IgM \/ IgG.|Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-\u03b1, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change.""}"
"1025","Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals","SARAH","NCT04348214","FMASU P18a/ 2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04348214","Recruiting","2020-04-22","2020-12-01","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Risk categorization of healthcare workers|COVID-19 infection rate among health care workers|Risk factors for COVID-19 among health care workers|Adherence of health care workers to infection prevention|Validity of the available rapid serological test for detecting COVID-19 virus infection|Clinical spectrum of COVID-19|Effectiveness of infection prevention in the health care facility|Emergency infection prevention and control needs|Isolation rate and emergency health care worker replacement needs|Rate of seroconversion""}"
"1026","Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19","","NCT04351152","HGEN003-06","Biological: Lenzilumab|Drug: Standard of Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04351152","Active, not recruiting","2020-05-05","2021-03-01","{""locations"":""Mayo Clinic, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of Southern California (USC) Medical Center, Los Angeles, California, United States|USC - Los Angeles County Medical Center, Los Angeles, California, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Mercy Medical Center, Rockville Centre, New York, United States|Atrium Health, Charlotte, North Carolina, United States|St. David's Healthcare, Austin, Texas, United States|St. David's North Austin Medical Center, Austin, Texas, United States|Texas Health, Dallas, Texas, United States|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|CPCLIN - Centro de Pesquisas Cl\u00ednicas de Natal, Natal, Rio Grande Do Norte, Brazil|Hospital S\u00e3o Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Crici\u00fama, Santa Catarina, Brazil|Hospital Dia do Pulm\u00e3o, Blumenau, S\u00e3o Paulo, Brazil|Hospital Guilherme Alvaro, Santos, S\u00e3o Paulo, Brazil|Clinica de Alergia Martti Antila S\/S LTDA, Sorocaba, S\u00e3o Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Cl\u00ednicos LTDA-EPP, S\u00e3o Bernardo do Campo, S\u00e3o Paulo, Brazil|Escola Paulista de Medicina (UNIFESP), S\u00e3o Paulo, Brazil|Hospital Heli\u00f3polis, S\u00e3o Paulo, Brazil|Hospital S\u00e3o Luiz do Jabaquara\/IDOR, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""520"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator-free Survival|Ventilator-free Days|Duration of Intensive Care Unit (ICU) Stay|Incidence of Invasive Mechanical Ventilation, ECMO and\/or Death|Time to Death|All-cause Mortality|Time to Recovery|Incidence of severe acute respiratory distress syndrome (ARDS)|Duration of Hospitalization|Time to Improvement in 1 or 2 Categories using 8-point Ordinal Scale|Number of Subjects Alive and Off Oxygen|Percentage of Participants Experiencing Adverse Events|Percentage of Participants Experiencing Serious Adverse Events|Proportion of Subjects Discharged from Hospital|Time to improvement in oxygenation for > 48 hours|Incidence of Non-invasive Ventilation (or Use of High-flow Oxygen Device)|Time to Clinical Improvement, Defined as NEWS2 < 2 Maintained for 24 Hours|Change from Baseline to Day 28 in Clinical status Based on the 8-point Ordinal Scale|Duration of Time on Low-flow or High-flow Supplemental Oxygen""}"
"1027","COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH","","NCT04469647","IRB20-09","Diagnostic Test: Serology Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04469647","Enrolling by invitation","2020-07-19","2021-06-15","{""locations"":""Johns Hopkins Aramco Healthcare, Dhahran, Eastern, Saudi Arabia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroconversion status|The proportion of asymptomatic infections among staff who have seroconverted|The durability of COVID 19 seroconversion in asymptomatic healthcare workers at JHAH|Identification of risk factors for COVID 19 seroconversion in asymptomatic healthcare workers""}"
"1028","Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19","","NCT04604678","ALRx003","Drug: Metformin|Drug: Naltrexone","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04604678","Not yet recruiting","2021-02-01","2021-10-01","{""locations"":""AgelessRx, Ann Arbor, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""30 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction of COVID-19 symptoms after 1 week of treatment with metformin and LDN|Reduction of COVID-19 symptoms after 2 weeks of treatment with metformin and LDN|Reduction in recovery time from COVID-19|Reduction in hospitalizations|Reduction in requirement of additional treatment due to COVID-19|Reduction in mortality""}"
"1029","Impact of the Coronavirus (COVID-19) on Patients With Cancer","","NCT04330521","55596","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04330521","Recruiting","2020-04-08","2022-05-01","{""locations"":""Stanford University School of Medicine, Stanford, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants who fill out the survey and participate in the semi-structured interviews.""}"
"1030","Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection)","COVIDGEN","NCT04644146","69HCL20_1072","Genetic: GENETIC","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04644146","Recruiting","2020-12-01","2021-12-01","{""locations"":""University Hospital LYON (Hospices Civils de LYON), Lyon, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary criteria of data evaluation""}"
"1031","CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION","CROWN CORONA","NCT04333732","202004099|INV-017499","Drug: MR or M-M-R II ® vaccine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04333732","Recruiting","2020-09-04","2021-08-01","{""locations"":""Washington University School of Medicine, Saint Louis, Missouri, United States|University of Ghana Medical Centre, Accra, Greater Accra Region, Ghana|Groote Schuur\/J52, Desmond Tutu Health Foundation, Mowbray, Cape Town, South Africa|Masiphumelele, Desmond Tutu Health Foundation, Sunnydale, Cape Town, South Africa|JOSHA Research, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Hillbrow, Johannesburg,Gauteng, South Africa|Clinical HIV Research Unit (CHRU), Auckland Park, Johannesburg, South Africa|Perinatal HIV Research Unit (PHRU), Diepkloof, Johannesburg, South Africa|Setshaba Research Centre, Soshanguve, Tshwane, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|FAMCRU (Family Clinical Research with Ubuntu), Cape Town, South Africa|Emavundleni, Desmond Tutu Health Foundation, Cape Town, South Africa|Chatsworth, HIV Prevention Research Unit, South African Medical Research Council, Chatsworth, South Africa|Isipingo, HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa|Aurum Institute Tembisa, Tembisa, South Africa|University College London, London, United Kingdom|Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia|University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""30000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptomatic COVID-19|Severity of COVID-19 over the study period|Effectiveness of preventing\/reducing SARS-CoV-2 infection""}"
"1032","Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention","","NCT04471766","BHP MASK01","Other: Certified cloth face mask plus preventive information|Behavioral: Preventive information","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04471766","Active, not recruiting","2020-07-20","2021-08-01","{""locations"":""Bandim Health Project, Bissau, Bissau Codex, Guinea-Bissau"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""40000"",""age"":""10 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Reported COVID-like illness|Consultation|Severe illness|Mortality""}"
"1033","Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients","","NCT04591600","IVM-DOX","Drug: Ivermectin and Doxycyline|Drug: Standard of care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04591600","Completed","2020-07-01","2020-10-14","{""locations"":""Akarkh Healt hdirectorate, Baghdad, Iraq"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""140"",""age"":""16 Years to 86 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality rate|Rate of progression disease|Time to recovery""}"
"1034","Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients","","NCT04386044","TGH1234","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386044","Not yet recruiting","2020-06-01","2021-06-01","{""locations"":""Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne, Greater Manchester, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 infection|Oxygen therapy for COVID-19|Discharge following COVID-19 hospitalisation|Death due to COVID-19""}"
"1035","Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19","LILIADE-COVID","NCT04357444","APHP200406|2020-001571-32","Drug: 1: ILT101|Drug: 2: Placebo Comparator","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04357444","Recruiting","2020-10-23","2021-02-23","{""locations"":""Service Anesth\u00e9sie R\u00e9animation - Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The PaO2\/FiO2 ratio at D11|Changes in Tregs between Baseline and Day 7 (expressed in %)|Number of days alive with oxygen therapy within 28 days|Maximal oxygen rate within 28 days|Number of days alive free of invasive or non-invasive ventilation within 28 days|Number of days alive outside ICU within 28 days|Number of days alive outside hospital within 28 days|Time (in days) from randomization to death|Mortality rate at D28|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Use of antibiotics for respiratory (proved or suspected) infection within 28 days|Number of prone positioning sessions|Changes in Tregs during the different visits between baseline and day 28|Cytokines analysis on plasma samples at Day 0, 7 and 14|Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14|T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline|T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline|Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.""}"
"1036","Spanish Survey on Third Wave of COVID-19","","NCT04659473","CovidSal01/2020","Other: Online survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659473","Not yet recruiting","2020-12-09","2020-12-20","{""locations"":""Universidad de Salamanca, Salamanca, Spain"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""What's your work or study system nowadays?|Habits before the Covid-19 pandemic|Habits in the Covid-19 pandemic|Personal Covid-19 exposure and disease|Positive Covid-19: tests, diagnosis, symptoms and quarantine|Negative Covid-19: tests and quarantine|Expectations|Date of birth|Sex|Height|Weight|Blood type|Pathologic history|Region of residence|City of residence|Rural or urban environment|Cohabitants in the family unit""}"
"1037","COVID-19 Tests With Saliva Specimens","","NCT04567953","PLRD202001","Other: Saliva collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04567953","Active, not recruiting","2020-07-28","2021-06-27","{""locations"":""Paradigm Laboratories, Tucson, Arizona, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The clinical evaluation of saliva as specimen for COVID-19 molecular test""}"
"1038","Frailty in Elderly Patients With COVID-19","FRA-COVID","NCT04412265","FRA-COVID","Other: Relation between frailty and clinical outcomes in elderly patients with COVID-19.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412265","Recruiting","2020-04-16","2021-03-01","{""locations"":""Dipartimento di Geriatria, Fondazione Poliambulanza, Brescia, Italy|Dipartimento di Medicina e Riabilitazione, Istituto Clinico Ospedale S. Anna, Brescia, Italy|UO Malattie Infettive, Spedali Civili, Brescia, Italy|UOC Medicina I a indirizzo Geriatrico, Spedali Civili, Montichiari, Italy|ASST Monza-Ospedale San Gerardo, Monza, Italy|SCDU Geriatria, AOU Citt\u00e0 della Salute e della Scienza - Presidio Molinette, Torino, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of a tool to measure frailty|A \""proxy\"" variable of the fragility index can be built on the basis of regional administrative databases only.|Give elements to focus the screening policies for COVID19.|Give the prevention of contagion at the elderly population level.""}"
"1039","Non-invasive Ventilatory Support of Patients Affected by COVID-19","WARd-COVID","NCT04382235","WARd-COVID","Device: Non-invasive ventilatory support","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382235","Active, not recruiting","2020-03-26","2020-12-30","{""locations"":""Policlinico San Marco - Ospedale Zingonia, Zingonia, BG, Italy|ASST Papa Giovanni XXIII - Bergamo, Bergamo, Italy|Azienda Ospedaliera - Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|ASST Spedali Civili - Brescia, Brescia, Italy|ASST Valle Olona - Ospedale di Busto Arsizio, Busto Arsizio, Italy|ASST Lariana - Ospedale Sant'Anna, Como, Italy|ASST Crema - Ospedale Maggiore di Crema, Crema, Italy|ASST Cremona - Ospedale di Cremona, Cremona, Italy|Istituto Clinico Humanitas Gavazzeni, Cremona, Italy|ASST Garda - Presidio di Desenzano del Garda, Desenzano Del Garda, Italy|ASST Monza - Desio, Desio, Italy|ASST Spedali Civili -Ospedale di Gardone Val Trompia, Gardone Val Trompia, Italy|ASST Lecco - Ospedale \""A. Manzoni\"", Lecco, Italy|ASST Ovest milanese - Ospedale di Legnano, Legnano, Italy|ASST Lodi - Ospedale Maggiore di Lodi, Lodi, Italy|ASST OVEST Milanese - Ospedale di Magenta, Magenta, Italy|ASST Garda - Ospedale di Manerbio, Manerbio, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|ASST Melegnano e della Martesana - Presidio di Melzo-Gorgonzola, Melzo, Italy|ASST Fatebenefratelli - Presidi Fatebenefratelli & M. Melloni, Milano, Italy|ASST Fatebenefratelli - Sacco, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Giuseppe, Milano, Italy|ASST Spedali Civili -Presidio Ospedaliero di Montichiari, Montichiari, Italy|ASST Monza - Ospedale San Gerardo, Monza, Italy|Fondazione IRCCS Policlinico San Matteo - Pavia, Pavia, Italy|Policlinico San Pietro, Ponte San Pietro, Italy|Istituto Clinico Humanitas Rozzano, Rozzano, Italy|ASST Valle Olona - Ospedale di Saronno, Saronno, Italy|ASST Bergamo OVEST - Ospedale \""Treviglio-Caravaggio\"" di Treviglio, Treviglio, Italy|Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|ASST Vimercate - Ospedale di Vimercate, Vimercate, Italy|ASST Melegnano e della Martesana - Ospedale di Vizzolo Predabissi, Vizzolo Predabissi, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The number of patients treated with non-invasive ventilation devices.|Incidence of patients requiring mechanical ventilation|Incidence of organ failure|Duration of hospitalization|Clinical outcome at hospital discharge""}"
"1040","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Covid","NCT04328272","Ath/ct101/22/3","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04328272","Not yet recruiting","2020-03-28","2020-06-28","{""locations"":""Ayub Teaching Institution, Abbott\u0101b\u0101d, K.p.k, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""75"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers""}"
"1041","Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma","","NCT04497779","20204|NCI-2020-04000|P30CA033572|TGen","Procedure: Biospecimen Collection|Other: Diagnostic Laboratory Biomarker Analysis|Other: Electronic Health Record Review|Other: Questionnaire Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497779","Recruiting","2020-07-13","2022-08-21","{""locations"":""City of Hope Medical Center, Duarte, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients|All-cause mortality|Donor antibody levels|Incidence of adverse events|CCP recipient outcomes""}"
"1042","A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection","","NCT04659122","AT-100/002","Biological: AT-100","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04659122","Not yet recruiting","2021-01-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""9"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determining the highest-tolerated & safety-tested AT-100 dose|Reduction in mechanical ventilation""}"
"1043","Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias","","NCT04649320","1264/2020","Other: questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649320","Recruiting","2020-11-23","2020-12-31","{""locations"":""Medical University of Innsbruck, Innsbruck, Tyrol, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Influence of the COVID-19 pandemic on cancer patient's daily life""}"
"1044","Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial","","NCT04360876","20-0811","Drug: Dexamethasone injection|Drug: Placebos","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04360876","Withdrawn","2020-09-01","2021-01-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator Free Days (VFD) at Day 28|Clinical Status at day 14 as measured by World Health Organization (WHO) 7-point ordinal scale.|Clinical Status at day 28 as measured by WHO 7-point ordinal scale|In-Hospital Mortality at day 28|In-Hospital Mortality at day 90|Time to Mortality to day 28|ICU-free days to day 28|Hospital Length of Stay among survivors to day 90|Severity of ARDS to day 10|Days to resolution of fever|Change in C-Reactive Protein (CRP) level from baseline to day 10|Vasopressor-free days to day 28|Renal replacement-free days to day 28|Duration of mechanical ventilation to day 28|Oxygenation-free days to day 28|Incidence of New Mechanical Ventilation to day 28|Change in sequential organ failure assessment (SOFA) score from baseline to day 10|In-hospital adverse events to day 28|Discontinuation of study drug infusion""}"
"1045","Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19","","NCT04568096","COVID-2019","Combination Product: Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|Other: Standard treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04568096","Not yet recruiting","2020-11-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Frequency of adverse events and severe adverse events|Angiotensin II (Ang II) changes over time|Sequential organ failure assessment score(SOFA score) over time|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Thrombin time (TT)""}"
"1046","Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above","","NCT04526990","CS-CTP-AD5NCOV-Ⅲ","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04526990","Recruiting","2020-09-15","2022-01-30","{""locations"":""Fundaci\u00f3n Socolinsky Centro de Vacunaci\u00f3n Proteger - Recoleta, Caba, Buenos Aires, Argentina|Hospital Pirovano, Caba, Buenos Aires, Argentina|Htal de Alta Complejidad Cuenca Alta N\u00e9stor Kirchner, Ca\u00f1uelas, Buenos Aires, Argentina|Hospital Interzonal de Agudos \""San Juan de Dios\"" de La Plata, La Plata, Buenos Aires, Argentina|Hospital Rossi, La Plata, Buenos Aires, Argentina|Inst. M\u00e9dico Platense, La Plata, Buenos Aires, Argentina|Instituto de Investigaciones Cl\u00ednicas, Mar Del Plata, Buenos Aires, Argentina|Htal Mariano y Luciano de la Vega, Moreno, Buenos Aires, Argentina|Hospital Houssay, Vicente L\u00f3pez, Buenos Aires, Argentina|Hospital Zonal General de Agudos \""Cetrangolo\"", Vicente L\u00f3pez, Buenos Aires, Argentina|Instituto Cer, Vicente L\u00f3pez, Quilmes, Argentina|Previvax Centro de Vacunaci\u00f3n, C\u00f3rdoba, Argentina|Hospital Dr. Hernan Henriquez Aravena Temuco, Temuco, IX Region, Chile|CIMER Centro de Investigaciones Medicas Respiratorias Santiago, Providencia, Region Metropolitana, Chile|Hospital San Borja Arriar\u00e1n Santiago, Santiago, Region Metropolitana, Chile|Cl\u00ednica Andes Salud Concepci\u00f3n, Concepci\u00f3n, VII Regi\u00f3n, Chile|Hospital de Puerto Montt Dr. Eduardo Sch\u00fctz Schoroeder Puerto Montt, Puerto Montt, X Regi\u00f3n De Los Lagos, Chile|Hospital Base de Osorno, Osorno, XIV Regi\u00f3n, Chile|Clinica Alemana de Valdivia Valdivia, Valdivia, XIV Regi\u00f3n, Chile|Centro de investigaci\u00f3n M\u00e9dica Aguascalientes (CIMA), Aguascalientes, Ags, Mexico|Instituto de Servicios de Salud del Estado de Baja California, Mexicali, Baja California Norte, Mexico|Instuto de Ciencias M\u00e9dicas y de la Nutrici\u00f3n Salvador Subir\u00e1n (INCMNSZ), Tlalpan, Cdmx, Mexico|Instituto Nacional de Medicina Gen\u00f3mica, Tlalpan, Cdmx, Mexico|Centro de Investigacion Integral MEDIVEST SC, Chihuahua, Chhihuahia, Mexico|Centro de Investigacion Clinica Chapultepec SA de CV (Hidra), Coyoac\u00e1n, Ciudad De Mexico, Mexico|Instituto Mexicano del Seguro Social (IMSS), Cuahtemoc, Ciudad De Mexico, Mexico|Clinical Research Institute Saltillo SA de CV, Saltillo, Cuahuila, Mexico|Centro de Investigaci\u00f3n Cl\u00ednica del Pacifico S.A. de C.V. (CICPA), Acapulco, Guerrero, Mexico|Asociaci\u00f3n Mexicana para la investigaci\u00f3n cl\u00ednica (AMIC), Pachuca de Soto, Hidalgo, Mexico|Instituto Jaliscience de Metabolismo, S. C., Guadalajara, Jalisco, Mexico|Asociaci\u00f3n de investigaci\u00f3n pedi\u00e1trica y adultos (AINPAD), Morelia, Mochoac\u00e1n De Ocampo, Mexico|JM Research, Cuernavaca, Morelos, Mexico|Hospital Metropolitano \""Dr. Bernardo Sep\u00falveda\"", San Nicol\u00e1s De Los Garza, Nuevo Le\u00f3n, Mexico|Oaxaca site management organization (OSMO), Oaxaca, Oax, Mexico|Centro de Investigaci\u00f3n y Avances M\u00e9dicos Especializados (CIAME), Canc\u00fan, Quintana Roo, Mexico|FAICIC, Veracruz, Veracrua, Mexico|Kohler & Milstein Research, M\u00e9rida, Yucatan, Mexico|PEMEX, Ciudad de mexico, Mexico|Instituto Nacional de Pediatr\u00eda (INP), Ciudad de M\u00e9xico, Mexico|Instituto de Investigaciones aplicada a las Neurociencias (IIAN), Durango, Mexico|Administraci\u00f3n de Especialistas de Puebla S.C. (UDEP), Puebla, Mexico|Shifa International Hospital, Islamabad, Islamabad Capital Territory, Pakistan|Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Punajb, Pakistan|University of Health Scinces, Lahore, Lahore, Punjab, Pakistan|Aga Khan University Hospital, Karachi, Sindh, Pakistan|The Indus Hospital, Karachi, Sindh, Pakistan|Research Center Eco-safety, Saint Petersburg, Saint-Petersburg, Russian Federation|OOO Meditsinskie Tekhnologii, Saint Petersburg, Saint-Petersburg, Russian Federation|OOO \""Baltijskaya Meditsina\"", Saint Petersburg, Saint-Petersburg, Russian Federation|Research Center Eco-safety, Saint Petersburg, Saint-Petersburg, Russian Federation|Federal State Budgetary Institution \""Scientific Research Institute of Influenza named after A. A. Smorodintsev\"" of the Ministry of Healthcare of the Russian Federation named after A. A. Smorodintsev\"" of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, Saint-Petersburg, Russian Federation|Saint Petersburg State Budgetary Healthcare Institution \""City Polyclinic #106\"", Saint Petersburg, Saint-Petersburg, Russian Federation|Saint-Petersburg State Healthcare Institution \""Nikolaev Hospital\"", Saint Petersburg, Saint-Petersburg, Russian Federation|OOO \""Piterclinica\"", Saint Petersburg, Saint-Petersburg, Russian Federation|State Budgetary Healthcare Institution of Sverdlovsk Region \""Aramil City Hospital\"", Aramil, Sverdlovsk, Russian Federation|Non-state Institution of Healthcare \""Road Clinical Hospital at Chelyabinsk station of open corporate society \""Russian Railways\"", Chelyabinsk, Russian Federation|State Budgetary Educational Institution of Higher Professional Education \""Chita State Medical Academy\"" of the Ministry of Healthcare of the Russian Federation, Chita, Russian Federation|Federal State Budgetary Institution \""Main Military Clinical Hospital n.a. N.N. Burdenko\"" Ministry of Defense of Russian Federation, Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution \""City Polyclinic #2 of the Moscow City Healthcare Department\"", Moscow, Russian Federation|Health Central Clinical Hospital of Russian Academy of Sciences, Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of Ministry of Healthcare of the Russian Federation (Sechenovsky University), Moscow, Russian Federation|Private Healthcare Institution \""Central Clinical Hospital \""RZhD-Medicine\"", Moscow, Russian Federation|State Regional Budgetary Healthcare Institution \""Murmansk Regional Clinical Hospital n.a.P.A. Bayandin\"", Murmansk, Russian Federation|State Regional Autonomous Healthcare Institution \""Monchegorsk Central District Hospital\"", Murmansk, Russian Federation|Private Healthcare Institution \""Clinical Hospital \""RZHD-Meditsina\"" of Nizhniy Novgorod\"", Nizhniy Novgorod, Russian Federation|\""Life Benefits Service, Ltd', Novosibirsk, Russian Federation|Budgetary Institution of Heathcare of Omsk region \""City Clinical Hospital #1 n.a. Kabanova A.N.\"", Omsk, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""Perm State Medical University named after E.A. Vagnera\"" Ministry of Healthcare of Russian Federation, Perm, Russian Federation|OOO Zvyezdnaya Klinika, Saint Petersburg, Russian Federation|Limited Liability Company \""Hospital \""OrKli\"", Saint-Petersburg, Russian Federation|OOO \""Tsentr DNK issledivaniy\"", Saratov, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""Saratov State Medical University named after V.I. Razumovsky\"" the Ministry of Health of the Russian Federation - Clinical hospital n.a. S.R.Mirotvortseva, Saratov, Russian Federation|OOO \""Zdorovye\"", Tomsk, Russian Federation|State Autonomous Healthcare Institution of Yaroslavl region \""Clinical Emergency Hospital named after N.V. Solovyev\"", Yaroslavl, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""40000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID-19 cases|Incidence of SAE|Incidence of severe COVID-19 cases|Incidence of solicited adverse reactions|Incidence of unsolicited adverse events|Immunogencity of S-RBD IgG antibody (ELISA method)|Immunogencity of neutralizing antibody|Cell-mediated immune profile""}"
"1047","FOLLOW-UP OF PATIENTS WITH COVID-19.","TeleRea'nCo","NCT04609839","TeleRea'nCo|7883","Other: Follow-up of patients with COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04609839","Recruiting","2020-10-27","2023-04-27","{""locations"":""Hopitaux Universitaires de Strasbourg, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The presence of respiratory, renal, cardiac, motor, neurological, and psychological sequelae will be assessed by specialist doctors during the 12 months following the patient's discharge from intensive care.|1) The sequelae by type of impairment will be assessed by specialist doctors at 3, 6 and 12 months|2) Number of re-hospitalizations at 3, 6 and 12 months|3) Date of death|4.1) Quality of life score (SF-36 questionnaire) at 3, 6 and 12 months|4.2) The Pittsburgh sleep quality index (PSQI questionnaire) at 3, 6 and 12 months|5) Cost of health expenditure""}"
"1048","A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)","","NCT04657497","FOY305-01","Drug: FOY-305|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04657497","Recruiting","2020-11-09","2021-05-31","{""locations"":""Aichi Clinical Site 1, Tokoname, Aichi, Japan|Chiba Clinical Site 1, Narita, Chiba, Japan|Fukuoka Clinical Site 1, Okawa, Fukuoka, Japan|Ibaraki Clinical Site 1, Tsuchiura, Ibaraki, Japan|Ishikawa Clinical Site 1, Kanazawa, Ishikawa, Japan|Kanagawa Clinical Site 3, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site 1, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site 2, Yokosuka, Kanagawa, Japan|Mie Clinical Site 1, Yokkaichi, Mie, Japan|Niigata Clinical Site 1, Nagaoka, Niigata, Japan|Osaka Clinical Site 2, Daito, Osaka, Japan|Saitama Clinical Site 3, Kawagoe, Saitama, Japan|Saitama Clinical Site 1, Kuki, Saitama, Japan|Saitama Clinical Site 2, Kumagaya, Saitama, Japan|Tokyo Clinical Site 5, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site 9, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site1, Hachioji, Tokyo, Japan|Tokyo Clinical Site 7, Itabashi-ku, Tokyo, Japan|Tokyo Clinical Site 3, Meguro-ku, Tokyo, Japan|Tokyo Clinical Site 4, Shinagawa-ku, Tokyo, Japan|Tokyo Clinical Site 8, Sibuya-ku, Tokyo, Japan|Tokyo Clinical Site2, Sibuya-ku, Tokyo, Japan|Tokyo Clinical Site 6, Tachikawa, Tokyo, Japan|Okayama Clinical Site 1, Okayama, Japan|Osaka Clinical Site 1, Osaka, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""110"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to SARS-CoV-2 negative test|Proportion of subjects who test negative for SARS-CoV-2|Ordinal scale for severity|Proportion of subjects on mechanical ventilator|Survival status (alive\/death)""}"
"1049","Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19","","NCT04513184","DI/20/407/04/36","Drug: IV Dexamethasone|Drug: Nasal Dexamethasone","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04513184","Recruiting","2020-07-14","2021-07-31","{""locations"":""Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Cdmx, Mexico|Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Mexico City, Cdmx, Mexico|El Instituto Nacional de Neurologia Y Neurocirugia Manuel Velasco Suarez, Mexico City, Cdmx, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time of clinical improvement|Time-to-death from all causes|Time free from mechanical ventilation|Viral load|Length of hospital stay""}"
"1050","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","","NCT04327531","turkishcovid19","Behavioral: turkish physicians","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04327531","Completed","2020-03-26","2020-05-28","{""locations"":""Pinar Yalcin Bahat, Istanbul, \u0130\u0307stanbul, Turkey"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""25 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future""}"
"1051","Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)","","NCT04409509","CSL312_COVID-19","Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04409509","Completed","2020-07-01","2021-01-12","{""locations"":""Nova Clinical Research, LLC, Bradenton, Florida, United States|Theia Clinical Research, LLC, Saint Petersburg, Florida, United States|MercyOne North Iowa Medical Center, Mason City, Iowa, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Inspira Health Center Vineland, Vineland, New Jersey, United States|Sisters of Charity Hospital\/ St. Joseph's Campus, Buffalo, New York, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Monument Health Clinical Research, Rapid City, South Dakota, United States|PharmaTex Research, Amarillo, Texas, United States|UT Health Science Center, McGovern Medical School, Houston, Texas, United States|Inova Alexandria Hospital, Alexandria, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""124"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of tracheal intubation or death prior to tracheal intubation|Proportion of subjects with death from all causes|Proportion of subjects intubated|Number and proportion of subjects with \u2265 2-point improvement on National Institute of Allergy and Infectious Diseases (NIAID) Ordinal scale|Number and proportion of subjects within each of the categories of the NIAID|Proportion of subjects requiring continuous positive airway pressure (CPAP)|Proportion of subjects requiring bilevel positive airway pressure (BiPAP)|Proportion of subjects requiring high-flow nasal cannula (HFNC)|Proportion of subjects requiring extracorporeal membrane oxygenation (ECMO)|Maximum change from baseline in Sequential Organ Failure Assessment (SOFA) score|Change from Baseline in SOFA score and in the individual components of SOFA score|Length of hospital stay|Number and proportion of subjects experiencing Adverse Events (AEs)|Number and proportion of subjects experiencing serious adverse events (SAEs)|Number and proportion of subjects with adverse events of special interest (AESIs)|Number and proportion of subjects with CSL312 induced anti-CSL312 antibodies|Maximum plasma concentration (Cmax) of CSL312|Time to maximum plasma concentration (Tmax) of CSL312|Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-last) of CSL312|Terminal half-life (T1\/2) of CSL312""}"
"1052","The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes","","NCT04389476","KSPH-2020-03","Other: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389476","Not yet recruiting","2020-06-15","2023-07-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Psychological impacts by CoronaVirus Disease 2019(COVID-19)""}"
"1053","Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS","NIRS-COV","NCT04392089","H-20027818","Device: Masimo, LidCO","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04392089","Recruiting","2020-05-01","2021-05-01","{""locations"":""Hvidovre Hospital, Copenhagen, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization|Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization|Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization|Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization|Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization|Changes in heart rate (HR) during cardiovascular and pulmonary optimization|Changes in stroke volume (SV) during cardiovascular and pulmonary optimization|Changes in cardiac output (CO) during cardiovascular and pulmonary optimization|Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization|Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization|Changes in pH during cardiovascular and pulmonary optimization|Changes in PaO2 during cardiovascular and pulmonary optimization|Changes in PaCO2 during cardiovascular and pulmonary optimization|Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization|Changes in PvO2 during cardiovascular and pulmonary optimization|Changes in PvCO2 during cardiovascular and pulmonary optimization|Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization|Changes in lacatate during cardiovascular and pulmonary optimization|Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization|Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization""}"
"1054","Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients","","NCT04529499","CVD-04-CD-001","Drug: AVIGAN|Drug: Placebo Comparator","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04529499","Active, not recruiting","2020-08-20","2021-03-31","{""locations"":""Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait|Mishref Field Hospital (Mishref), Kuwait City, Kuwait"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""780"",""age"":""21 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Efficacy Endpoint: Time to resolution of hypoxia (Stage I)|Time to alleviation of symptoms (Stage I)|Percentage of patients with score of 0 = absent or mild = 1 (Stage I)|Time to improvement in each of the symptoms (Stage I)|Percentage of patients reporting a 'clinical relapse' (Stage I)|Time to negative conversion of detectable SARS-CoV 2 (Stage I)|Percentage of patients showing negative conversion of detectable SARS-CoV 2 (Stage I)|Changes over time in patient's clinical status on the 10-point ordinal scale of clinical status (Stage I)|Changes over time in patient's clinical status on the 8-point ordinal scale of clinical status (Stage I)|Changes over time in findings on chest X-ray (Stage I)|Changes over time in the National Early Warning Score-2 (Stage I)|Percentage of patients requiring ICU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Time (no. of days) from randomization to ICU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Duration (no. of days) the patient requires CU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Percentage of Patients dying (all cause and due to COVID-19) (Stage I)|Percentage of 'clinical relapse' (Stage I + Stage II)|Incidence of treatment emergent adverse events (Stage I + Stage II)""}"
"1055","Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19","ESsCOVID","NCT04576728","998","Drug: Trimodulin|Other: Placebo (human albumin 1%)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04576728","Recruiting","2020-10-06","2021-05-01","{""locations"":""Investigational site # 5503, Porto Alegre, Brazil|Investigational site # 5502, Santo Andr\u00e9, Brazil|Investigational site # 5505, Santo Andr\u00e9, Brazil|Investigational site # 5501, S\u00e3o Paulo, Brazil|Investigational Site # 3301, Paris, France|Investigational site # 3305, Saint-\u00c9tienne, France|Investigational site # 0702, Moscow, Russian Federation|Investigational Site # 0704, Moscow, Russian Federation|Investigational site # 0701, Saint Petersburg, Russian Federation|Investigational Site # 3401, Barcelona, Spain|Investigational Site # 3402, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""164"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical detoriation rate|28-day all-cause mortality rate|Clinical deterioration rate|28-days all-cause mortality rate on day 29|Time to clinical deterioration|Time to Mortality|Proportion of subjects in each of the 9-categories of the ordinal scale|Time to clinical improvement|Proportion of subjects with score \u22642|Days on IMV|Days without oxygen supply|Time to discontinuation from any form of oxygen supply|Proportion of subjects without any form of oxygen supply|Hospital-free-days|SARS-CoV-2 status|Adverse events (AEs), treatment-emergent AEs (TEAEs), AEs of special interest, infusional TEAEs|TEAEs|SAEs|Dose modifications|Time to recovery|Change over time in ECG parameters|Change over time in vital signs""}"
"1056","A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","","NCT04566770","JSVCT093","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04566770","Recruiting","2020-09-24","2022-10-20","{""locations"":""Taixing City center for Disease Control and Prevention, Taizhou, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""481"",""age"":""6 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Safety indexes of adverse reactions|Immunogencity indexes of GMT|Immunogencity indexes of neutralizing antibody|Safety indexes of adverse events|Safety indexes of Hematological examination measures\uff08Hemoglobin, WBC\uff09|Safety indexes of Blood routine measures(ALT, AST)|Safety indexes of SAE|Immunogencity indexes of cellular immune""}"
"1057","Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.","LIFESAVER","NCT04374526","3205","Biological: COVID-19 Convalescent Plasma","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04374526","Recruiting","2020-05-27","2021-06-30","{""locations"":""Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, RM, Italy|Ospedale SS Annunziata, Chieti, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""182"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Rate of COVID-19 progression""}"
"1058","Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program","","NCT04681950","00047586","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04681950","Recruiting","2020-11-24","2020-12-31","{""locations"":""Biocerna LLC, Fulton, Maryland, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Matching results from different collection types""}"
"1059","Evaluation of the Effect of Anatolian Propolis on Covid-19 in Healthcare Professionals","","NCT04680819","AtaturkU2","Dietary Supplement: Anatolian Propolis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04680819","Not yet recruiting","2020-12-25","2021-01-25","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Covid-19 positive""}"
"1060","A Study of LY3127804 in Participants With COVID-19","","NCT04342897","17824|I7W-MC-UDAA","Drug: LY3127804|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04342897","Terminated","2020-04-20","2020-10-12","{""locations"":""Banner Univ Med Ctr Phoenix, Phoenix, Arizona, United States|Banner Univ Med Ctr Tucson, Tucson, Arizona, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Nuvance Danbury Hospital, Danbury, Connecticut, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Henry Ford Hospital Detroit, Detroit, Michigan, United States|Allina Hospital Network, Minneapolis, Minnesota, United States|State University of New York Hospital, Syracuse, New York, United States|East Carolina University, Greenville, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""95"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Ventilator Free Days|Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment|Percentage of Participants who are Alive and Respiratory Failure Free|Mortality|Length of Hospitalization|Number of Participants with any Serious Adverse Event (SAE)|Number of Participants with any Treatment Emergent Adverse Event (TEAE)""}"
"1061","PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer","","NCT04404361","PAC319","Drug: Pacritinib|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04404361","Recruiting","2020-05-22","2021-10-31","{""locations"":""St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare, Orange, California, United States|Ascension St. Vincent's Riverside Hospital, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|St. Vincent Medical Group, Inc, Indianapolis, Indiana, United States|St. Agnes Healthcare, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Ascension Providence Hospital - Novi Campus, Novi, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Overlook Medical Center, Morristown, New Jersey, United States|Chilton Medical Center, Pompton Plains, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States|Ascension All Saints, Racine, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""364"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who progress to IMV and\/or ECMO or death during the 28 days following randomization""}"
"1062","Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse","TRAPSAH","NCT04356417","APHP200412","Other: - Synthetic anti-malarial drugs","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356417","Not yet recruiting","2020-04-01","2020-06-01","{""locations"":""Assistance Publique H\u00f4pitaux de Paris - CHU Henri Mondor, Cr\u00e9teil, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""6000000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of serious COVID-19 infections|Pneumonia infections|ICU stay|Oro-tracheal intubation|Death""}"
"1063","AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19","ARCADIA","NCT04516759","SGS.1656.201|2020-002211-21","Drug: AZD1656|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04516759","Recruiting","2020-08-12","2021-03-01","{""locations"":""Masarykova Univerzita - Fakultni Nemocnice U SV Anny V Brne (308), Brno, Czechia|Nemocnice B\u0159eclav (301), B\u0159eclav, Czechia|Nemocnice Ho\u0159ovice (309), Ho\u0159ovice, Czechia|Oblastni Nemocnice Kol\u00edn (306), Kol\u00edn, Czechia|Klaudianova Nemonice (302), Mlad\u00e1 Boleslav, Czechia|Fakultni Nemocnice V Motole (303), Prague, Czechia|Thomayerova Nemonice (310), Prague, Czechia|Nemocnice T\u0159eb\u00ed\u010d (305), T\u0159eb\u00ed\u010d, Czechia|Masarykova Nemocnice (304), \u00dast\u00ed Nad Labem, Czechia|Colentina Clinical Hospital (204), Bucharest, Romania|Spitalul Clinic de Boli Infectioase Cluj-Napoca (203), Cluj-Napoca, Romania|Spitalul Clinic de Pneumoftiziologie \""Leon Daniello\"" Cluj-Napoca (202), Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase Constan\u0163a (207), Constan\u0163a, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr Victor Babes Craiova (206), Craiova, Romania|Spitalul Judetean de Urgenta Deva (208), Deva, Romania|Spitalul Clinic de Boli Infectioase \""Sfanta Parascheva\"" Ia\u015fi (205), Ia\u015fi, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr Victor Babes Timi\u015foara (201), Timi\u015foara, Romania|Barnsley Hospital NHS Foundation Trust (105), Barnsley, United Kingdom|Bolton NHS Foundation Trust (122), Bolton, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust (103), Bradford, United Kingdom|North Bristol NHS Trust (116), Bristol, United Kingdom|County Durham and Darlington NHS Foundation Trust (121), Darlington, United Kingdom|The Dudley Group NHS Foundation Trust (107), Dudley, United Kingdom|Medway NHS Foundation Trust (108), Gillingham, United Kingdom|Hull & East Yorkshire NHS Trust (102), Hull, United Kingdom|Barts Health NHS Trust (101 and 111), London, United Kingdom|Royal Free London NHS Foundation Trust (119), London, United Kingdom|St George's University Hospitals NHS Foundation Trust (114), London, United Kingdom|Penine Acute Hospitals NHS Trust (106), Salford, United Kingdom|Sheffield Hospitals NHS Foundation Trust (104), Sheffield, United Kingdom|Somerset NHS Foundation Trust (109), Taunton, United Kingdom|Walsall Healthcare NHS Trust (113), Walsall, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Improvement by Day 14|*Title: Clinical Improvement at Day 7, 14 and 21|Glycaemic Control|Occurrence of Adverse Events|Occurrence of Serious Adverse Events|Duration of Hospitalisation|Time to Intubation\/ Mechanical Intervention|Mortality Rate""}"
"1064","Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)","","NCT04570449","00015598","Drug: Fluoxetine|Drug: Placebo","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04570449","Withdrawn","2020-11-01","2021-12-01","{""locations"":""Milton S. Hershey Medical Center Clinical Research Center, Hershey, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of hospitalization|Physical symptoms assessed through daily checklist|Rate of intubation|Rate of death|Depressive symptoms assessed weekly|Post traumatic stress disorder symptoms assessed weekly|Anxiety symptoms assessed weekly|Suicidality assessed daily""}"
"1065","Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients","","NCT04434157","NR-09-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04434157","Completed","2020-03-28","2020-05-05","{""locations"":""Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, State Of Mexico, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""221"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical complications and Mortality|Neutrophil-Lymphocyte and Lymphocyte-Platelet ratio""}"
"1066","Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19","LUSCOVIDPREG","NCT04432805","2020-30|2020-A01303-36","Device: Performing of lung ultrasound","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04432805","Recruiting","2020-06-15","2021-06-15","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Description of the lesions""}"
"1067","Laparoscopy and COVID-19 Contamination","LAPCOV","NCT04608383","APHP200611","Other: Additional and minimal collection of products of the human body carried out during a sample for standard of care","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04608383","Recruiting","2020-11-19","2022-01-01","{""locations"":""AP-HP, Bic\u00eatre Hospital, Anesthesia Department, Le Kremlin Bic\u00eatre, France|AP-HP, Bic\u00eatre Hospital, Gynecology department, Le Kremlin Bic\u00eatre, France|AP-HP, Bic\u00eatre Hospital, Department of Digestive and Oncological Surgery, Le Kremlin-Bic\u00eatre, France|AP-HP, Bic\u00eatre Hospital, Urology Department, Le Kremlin-Bic\u00eatre, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The main objective of the study is to demonstrate the presence of SARS-COV-2 in the exsufflated gas at the end of laparoscopy.|The secondary objective of the study is to demonstrate the presence of SARS-COV-2 in the peritoneal fluid during laparoscopy""}"
"1068","Study of the Spread of COVID-19 in Saint Petersburg, Russia","","NCT04406038","CDRU-001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406038","Active, not recruiting","2020-05-27","2021-10-28","{""locations"":""Clinic \""Scandinavia\"", Saint Petersburg, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1038"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia|Prevalence odds ratios|Immune response dynamics""}"
"1069","Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test","COVID-VIRO","NCT04609969","CHRO-2020-18","Diagnostic Test: RT-qPCR test|Diagnostic Test: COVID-VIRO® test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04609969","Completed","2020-10-13","2020-10-17","{""locations"":""Centre Hospitalier R\u00e9gional d'Orl\u00e9ans, France, Orl\u00e9ans, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of COVID VIRO\u00ae diagnostic specificity|Evaluation of COVID VIRO\u00ae diagnostic sensitivity|Evaluation of COVID VIRO\u00ae diagnostic sensitivity for RT-qPCR Cycle threshold value < or > 28""}"
"1070","Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab","UHID-COVID19","NCT04359667","UHID-04","Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359667","Recruiting","2020-06-16","2021-05-15","{""locations"":""University Hospital for Infectious Diseases \""Dr Fran Mihaljevic\"", Zagreb, Croatia"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab""}"
"1071","The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients","PROVIDENCE","NCT04701606","SP-PA-COV-203","Drug: Artecom® (pyronaridine-artesunate)|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04701606","Not yet recruiting","2021-02-15","2021-09-30","{""locations"":""Philippine General Hospital, Manila, Taft Ave, Ermita, Manila, 1000 Metro, Philippines"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""402"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants with clinical improvement as defined by an improvement of categories on the WHO Ordinal Scale of clinical status until Days 28.|Time to clinical improvement was defined as time from randomization to an improvement of categories on the WHO Ordinal Scale of clinical status.|Changes in the WHO Ordinal Scale for Clinical Improvement until Days 28 compared to Baseline.|Changes in National Early Warning Score (NEWS) until Days 28 compared to Baseline.|Proportion of participants with negative for COVID-19 as determined by real-time RT-PCR test until Days 14.|Changes in viral load until Days 14 compared to Baseline.|The time to body temperature normalization after the administration of investigational Product (IP).|The time to respiratory rate normalization after the administration of IP.|The time to oxygen saturation (SpO2) normalization after the administration of IP.|Mortality rate at Day 28.|Duration of hospitalization (Day 1 to Day 28).|The incidence of adverse events (AEs).|The incidence of serious adverse events (SAEs).""}"
"1072","Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)","","NCT04402840","2004963113","Procedure: Stellate Ganglion Block","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04402840","Recruiting","2020-04-24","2021-12-01","{""locations"":""West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""5"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse events related to SGB|All Adverse events|Death|Assessment of respiratory\/ pulmonary function|Radiographic criteria|Cardiac function""}"
"1073","COVID-19 and Chilblains","ECCES","NCT04455308","35RC20_8888_ECCES","Diagnostic Test: Biological sample collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04455308","Completed","2020-07-21","2020-10-19","{""locations"":""CHU Angers, Angers, France|CHRU Brest, Brest, France|CHU Nantes, Nantes, France|CHU Rennes, Rennes, France|CHRU Tours, Tours, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""269"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Level of viral exposure in \""case family\"" compared to \""comparator family\""|Comparison of seropositivity rates in subjects with chilblains and their age-matched controls|Comparison of SARS-CoV-2 seropositivity rates among members of case (subject with chilblains) and control (subject without chilblains) outbreaks|Antibody avidity and differentiated IgG and IgM assay by subject in the homes""}"
"1074","COVID-19 Vaccine Induced Immunity","","NCT04713163","B2021:008","Drug: covid19 vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04713163","Not yet recruiting","2021-01-01","2021-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Nasal T cell responses|Systemic T cell responses|Systemic and nasal antibody responses""}"
"1075","Favipiravir vs Hydroxychloroquine vs Control in COVID -19","","NCT04387760","40 / 07-May-2020","Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04387760","Recruiting","2020-08-11","2021-05-14","{""locations"":""Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary outcome is the Medial clinical scale at end of study follow up|Requirement of Escalation of Respiratory Support|Adverse effects(cardiac, renal, hepatic, hypoglycaemia (defined as RBS <3.9 mmol\/L))|Requirement of ICU Admission|Mortality rate|Readmission rate|Daily National Early Warning (NEWS) 2 Score|Daily Sequential Organ Failure Assessment (SOFA) score|Change in Laboratory indices|Discharge and Length of Hospital Stay|QT prolongation|Cardiac arrythmia (fatal and non fatal)|Viral clearance""}"
"1076","GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia","GI-COVID","NCT04569877","KKS-279|2020-001654-21","Drug: Molgramostim nebuliser solution|Other: Placebo nebuliser solution","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04569877","Recruiting","2020-09-24","2022-12-25","{""locations"":""Prof. Dr. Susanne Herold, PhD, Gie\u00dfen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""238"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation|Clinical status of subject at day 15 and day 29 (on a 7-point ordinal scale):|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Oxygen supply|Clinical parameter: temperature|Clinical parameter: blood pressure|Clinical parameter: heart beat|Clinical parameter: respiratory rate|Severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR)|Laboratory: C-reactive protein test|Laboratory: ferritin|Laboratory: Interleukin-6|Laboratory: procalcitonin|Bacterial pneumonia|Vaso-active drugs|Mortality|GM-CSF""}"
"1077","Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults","CTCOVID-19","NCT04313127","JSVCT088","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04313127","Active, not recruiting","2020-03-16","2022-12-20","{""locations"":""Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""108"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Safety indexes of adverse reactions|Safety indexes of adverse events|Safety indexes of SAE|Safety indexes of lab measures|Immunogencity indexes of GMT(ELISA)|Immunogencity indexes of GMT(pseudoviral neutralization test method)|Immunogencity indexes of seropositivity rates(ELISA)|Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|Immunogencity indexes of GMI(ELISA)|Immunogencity indexes of GMI(pseudoviral neutralization test method)|Immunogencity indexes of GMC(Ad5 vector)|Immunogencity indexes of GMI(Ad5 vector)|Immunogencity indexes of cellular immune""}"
"1078","DISulfiram for COvid-19 (DISCO) Trial","DISCO","NCT04485130","DSF151837","Drug: Disulfiram|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04485130","Not yet recruiting","2021-02-01","2022-02-01","{""locations"":""University of California San Francisco, Fresno, Fresno, California, United States|San Francisco General Hospital, San Francisco, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immunologic impact of 5 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines (e.g, interleukin 6, interleukin 1-beta, etc.).|Virologic impact of 5 days of disulfiram, as measured by the fold-change in copies of SARS-CoV-2 virus per million cells between Baseline and Day 31.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Change in COVID-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score (SSS-8)""}"
"1079","Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?","","NCT04347876","AssiutU12","Diagnostic Test: Tuberculin test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347876","Recruiting","2020-04-11","2020-06-30","{""locations"":""AssiutU, Assiut, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""12 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Pneumonia severity index|Need for ICU admission|COVID -19 test conversion|Mortality""}"
"1080","Clinical Application of Methylene Blue for Treatment of Covid-19 Patients","Covid-19","NCT04370288","IR.MUMS.REC.1399.122","Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04370288","Recruiting","2020-04-19","2020-09-21","{""locations"":""Imam Reza Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients remaining free of need for mechanical ventilation in both groups|Mortality rate in both groups|Improvement in Pa02\/Fi02 ratio in both groups|Duration of hospital stay in both group.|Duration of Intensive Care Unit stay in both groups|Days free of dialysis in both groups|C-reactive proteins|WBC Count""}"
"1081","Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial","HASCOPT","NCT04365231","HASCOPT2020","Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04365231","Withdrawn","2020-04-01","2021-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit""}"
"1082","Austrian COVID-19 Registry","","NCT04351529","AGMT_COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351529","Recruiting","2020-04-01","2021-12-01","{""locations"":""LKH Feldkirch: Innere Medizin II\/ Interne E (H\u00e4matologie und Onkologie), Feldkirch, Austria|Kepler Universit\u00e4tsklinikum Linz, Med. Campus III., Klinik f\u00fcr Lungenheilkunde \/ Pneumologie, Linz, Austria|IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria|KH Zams: Innere Medizin Internistische Onkologie und H\u00e4matologie, Zams, Austria"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Documentation of natural course and the therapeutic landscape of patients with COVID-19.""}"
"1083","Convalescent Plasma for COVID-19 Research Donor Study","CONCOR-Donor","NCT04555109","1000070462","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04555109","Recruiting","2020-06-30","2022-03-31","{""locations"":""The Hospital for Sick Children, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""17 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Seroprevalence and duration of protective immunity""}"
"1084","Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients","MG-COVID","NCT04371406","APHP200447|2020-001702-35","Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04371406","Withdrawn","2020-04-01","2020-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy (after day 2) at day 14|The rate of use of secondary antibiotic therapy (after day 2) at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14""}"
"1085","The McGill RAAS-COVID-19 Trial","RAAS-COVID","NCT04508985","MP-37-2021-6614","Other: Temporarily holding the RAAS inhibitor [intervention]|Other: RAAS inhibitor [continued standard of care]","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04508985","Not yet recruiting","2020-09-01","2021-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Global rank score""}"
"1086","Glucocorticoids in COVID-19 (CORTIVID)","CORTIVID","NCT04438980","CORTIVID","Drug: Methylprednisolone|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04438980","Recruiting","2020-05-15","2021-02-01","{""locations"":""Hospital Sant Joan Desp\u00ed Mois\u00e8s Broggi, Sant Joan Desp\u00ed, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""72"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients developing treatment failure|Mortality at day 28|Proportion of patients requiring ICU admission|Proportion of patients requiring rescue-therapy with tocilizumab|Length of hospital stay|Proportion of severe adverse events|Proportion of bacterial, fungal or opportunistic infections|Evolution of inflammatory biomarkers related to COVID-19|Proportion of SARS-CoV-2 clearance.""}"
"1087","Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients","","NCT04427267","PPE-02","Other: Personal protective equipment from biological hazard","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04427267","Completed","2020-06-03","2020-06-27","{""locations"":""Federal State Budgetary Scientific Institution Izmerov Research Institute of Occupational Health, Moscow, Russian Federation"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""6"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Skin thermometry|Hygrometry under costume|Heart rate|Air thermometry|Air hygrometry""}"
"1088","Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Participants ≥ 60 Years of Age and Hospitalized With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure","","NCT04705597","BGE-175-201","Drug: BGE-175|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04705597","Not yet recruiting","2021-03-01","2022-04-01","{""locations"":""University of Maryland Medical System, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""132"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who have died or progressed to respiratory failure|Proportion of participants experiencing treatment-emergent adverse events|Survival|Viral load|Clinical worsening on a 9-point ordinal scale|Clinical improvement|Time to extubation|Time to discharge from hospital intensive care unit|Incidence of supplemental oxygen administration|Duration of supplemental oxygen administration|Duration of noninvasive ventilation by nonrebreather mask or high-flow nasal cannula|Incidence of noninvasive ventilation by nonrebreather mask or high-flow nasal cannula|Duration of mechanical ventilation plus additional organ support using vasopressors, and\/or renal replacement therapy and\/or ECMO|Incidence of mechanical ventilation plus additional organ support using vasopressors, and\/or renal replacement therapy and\/or ECMO|Daily ratio of oxygen saturation (SpO2) to fractional inspired O2 (SpO2\/FiO2)|Time to discharge from the hospital|Time to re-hospitalization|Proportion of participants requiring intensive care unit admission""}"
"1089","Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19","COVIMMUNITY","NCT04648709","20CH207|2020-A02943-36","Diagnostic Test: ELISPOT|Diagnostic Test: QUANTIFERON","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04648709","Not yet recruiting","2021-04-01","2022-12-01","{""locations"":""CHU Saint-Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""T cell immune response|B cell immune response|Platelet immune response|Immune response and chronic forms""}"
"1090","Prediction of Clinical Course in COVID19 Patients","COVID-CTPRED","NCT04377685","20CH109|IRBN652020/CHUSTE","Other: CT-Scan","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377685","Recruiting","2020-03-01","2021-06-30","{""locations"":""Chu Saint-Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""diagnostic of COVID disease composite""}"
"1091","Case Fatalities in Hospitalised COVID-19 Patients in the UK","","NCT04527458","ISARIC_COVID_CF","Other: Patient Characteristics|Other: COVID-19 treatments|Other: Differences in triage|Other: Surge capacity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04527458","Completed","2020-02-24","2020-08-02","{""locations"":""University of Edinburgh, Edinburgh, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""70000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Case fatality""}"
"1092","Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","CORONA","NCT04518735","IIBSP-COV-2020-24","Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04518735","Completed","2020-04-01","2020-06-30","{""locations"":""Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""1707"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality|Transfer to the Intensive Care Unit (ICU)|Thromboembolic complications|Major bleeding complications""}"
"1093","Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment","Antibodies","NCT04396067","COVID-19","Drug: Aerosolized 13 cis retinoic acid|Drug: Aerosolized All trans retinoic acid|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04396067","Not yet recruiting","2020-10-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""360"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|d-dimers|Absolute lymphocyte counts|The immune correlates of protection against future exposure to SARS-CoV-2|Immunological profile|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Occurrence of adverse event related to immunoglobulins|IgG, IgA and IgM against COVID-19|ACE2 expression in patients with COVID-19 infection|All cause mortality rate [|Ventilation free days|ICU free days""}"
"1094","Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19","PROMETEO","NCT04452812","HUS-001/2020","Biological: Convalescent plasma","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04452812","Not yet recruiting","2020-07-06","2021-04-01","{""locations"":""Hospital Universitario \""Dr. Gonzalo Vald\u00e9s Vald\u00e9s\"", Saltillo, Coahuila, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Side effects|Length of stay in Intensive Care Unit (ICU)|Length of stay in hospitalization|Days of mechanical ventilation|Inflammatory biomarkers (d-dimer)|Inflammatory biomarkers (c-reactive protein)|Inflammatory biomarkers (lactate dehydrogenase)|Inflammatory biomarkers (ferritin)""}"
"1095","COVID-19 and Deep Venous Thrombosis","","NCT04338932","JessaH_COVID19_DVT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04338932","Completed","2020-04-17","2020-05-15","{""locations"":""Jessa hospital, Hasselt, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""12"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the prevalence of a DVT in patients at the ICU.|Oxygen partial pressure and Carbon dioxide partial pressure levels in the blood|Potassium, Sodium, Calcium, Bicarbonate, Base excess, Lactate levels in the blood|glucose, haemoglobin, ureum, creatinine, total bilirubin levels in the blood|oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood|white blood cells, red blood cells and platelets in the blood|PT (%)aPTT (sec)Fibrinogen (g\/L)D-dimers (mg\/L) PT (INR) (ratio) AST (U\/L)ALT (U\/L)Lactate dehydrogenase (U\/L)Troponin T (ng\/L)CRP (mg\/L)Ferritin (mg\/L)in the blood|prevalence of co-morbidities|prevalence of vital signs at icu admission|prevalence of complications during icu stay|evaluation of treatment|evaluation of the oxygen therapy""}"
"1096","Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)","","NCT04346368","SC-2020-01","Biological: BM-MSCs|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04346368","Not yet recruiting","2020-04-01","2020-12-01","{""locations"":""Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes of oxygenation index (PaO2\/FiO2)|Side effects in the BM-MSCs treatment group|Clinical outcome|Hospital stay|CT Scan|Changes in viral load|Changes of CD4+, CD8+ cells count and concentration of cytokines|Rate of mortality within 28-days|Changes of C-reactive protein""}"
"1097","DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)","DISCONNECT-1","NCT04409925","DISCONNECT-1","Drug: rhDNase I","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04409925","Recruiting","2020-12-25","2021-08-01","{""locations"":""Hamilton General Hospital, Hamilton Health Sciences, Hamilton, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety of inhaled rhDNase1 in non-ventilated COVID-19 patients by reporting of adverse events|Time to first study participant enrolment|Enrolment rate|Eligible patient consent rate|Completeness of drug delivery|Completeness of study-specific tests or procedures|Completeness of data collection|Hypoxia rate|Supplemental oxygen requirement type|Progression to mechanical ventilation rate|Duration of mechanical ventilation|Radiological progression|Renal dysfunction rate|Renal dysfunction extent|Secondary bacterial infections rate|Duration of ICU admission|Time to hospital discharge or in-hospital mortality""}"
"1098","The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine","","NCT04568811","JSVCT100","Biological: Adenovirus Type-5 Vectored COVID-19 Vaccine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04568811","Active, not recruiting","2020-09-26","2021-09-27","{""locations"":""A rehabilitation centre in Wuhan, Wuhan, Hubei, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""89"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Occurrence of adverse reactions within 14 days after booster vaccination|Occurrence of adverse events within 14 days after booster vaccination|Occurrence of adverse events within 28 days after booster vaccination|Occurrence of serious adverse events within 28 days after booster vaccination|Occurrence of serious adverse events within 6 months after booster vaccination|Occurrence of serious adverse events within 12 months after booster vaccination|Changes in laboratory test indicators before and 1 day after vaccination|Antibody of S-RBD at day 14, day 28, month 6 and month 12 after booster vaccination|Cellular immunity at day 14 after booster vaccination""}"
"1099","SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES","","NCT04482361","SEROEPIDEMIOLOGY COVID IN CABA","Diagnostic Test: Presence of specific anti-SARS-CoV-2 antibodies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04482361","Completed","2020-08-06","2020-12-22","{""locations"":""Ministerio de Salud de la Ciudad Aut\u00f3noma de Buenos Aires, Ciudad Aut\u00f3noma de Buenos Aires, Argentina"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""5900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of IGG for COVID-19|Changes in prevalence of IGG for COVID-19""}"
"1100","COVID-19 and Mental Health","","NCT04407195","20-05-22","Other: Exposure to the SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407195","Active, not recruiting","2020-06-01","2021-06-01","{""locations"":""Northeastern University, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Emotional Impact|Depression|Anxiety|Insomnia|Resilience|Crisis Support Scale""}"
"1101","COVID-19 SAFE Enrollment","COVID SAFE","NCT04506268","843565","Behavioral: Opt-out Recruitment Email|Behavioral: Opt-in Recruitment Email","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04506268","Completed","2020-09-09","2020-10-30","{""locations"":""Penn Medicine, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Screening"",""enrollment"":""412"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion Enrolled|Participant Age|Participant Sex|Participant Race\/Ethnicity|Participant Income|Participant Education|Test Completion""}"
"1102","LYT-100 in Post-acute COVID-19 Respiratory Disease","","NCT04652518","LYT-100-2020-02","Drug: LYT-100|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04652518","Recruiting","2020-12-11","2021-12-01","{""locations"":""University of Southern California - Keck School of Medicine, Los Angeles, California, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Southeastern Research Center, Winston-Salem, North Carolina, United States|Site Coordinator, Austin, Texas, United States|Institutul de Pneumoftiziologie \""Marius Nasta\"" (\""Marius Nasta\"" Pneumoftiziology Institute), Bucharest, Romania|National Institute for Infectious Diseases \""Prof. Dr. Matei Bal\u015f\"" (Arensia Eploratory Medicine), Bucharest, Romania|Spitalul Clinic De Pneumoftiziologie \""Leon Daniello\"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova, Craiova, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes - Timisoara, Timi\u015foara, Romania"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""168"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in distance walked on the six-minute walk test (6MWT)|Change in Modified Borg Dyspnoea Scale (mBDS) score|Quality of Life assessment as collected using the SF-36""}"
"1103","Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis","","NCT04551781","SVU-MED-CHT019420861","Drug: 20 Mg Prednisone for 14 days|Drug: control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04551781","Completed","2020-04-01","2020-07-30","{""locations"":""south-Vally University faculty of medicine, Qena, Kena, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""improved""}"
"1104","Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?","","NCT04445610","FMASU P31a/ 2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445610","Not yet recruiting","2020-07-01","2020-11-01","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Viral clearance""}"
"1105","The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19","","NCT04558463","20-04-0455","Drug: Favipiravir|Drug: Oseltamivir 75mg","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04558463","Recruiting","2020-04-16","2020-10-30","{""locations"":""Cipto Mangunkusumo National Referral Hospital, Jakarta, DKI Jakarta, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical radiologic changes|Percentage of RT-PCR test convertion|Adverse event|Hospital length of stay (LOS)|Case Fatality Rate (CFR)""}"
"1106","COVID-19 and Cancer Consortium Registry","CCC19","NCT04354701","VICC MD 2032","Other: Web-based REDCap survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354701","Recruiting","2020-03-17","2022-12-01","{""locations"":""Vanderbilt University Medical Center, Nashville, Tennessee, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Web-based REDCap survey""}"
"1107","Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older","","NCT04537208","VAT00001|U1111-1250-4757","Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 1|Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 2|Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 1|Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 2|Biological: SARS-CoV-2 vaccine formulation 2 without adjuvant|Biological: Placebo (0.9% normal saline)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04537208","Active, not recruiting","2020-09-03","2021-11-01","{""locations"":""Investigational Site Number 8400004, Birmingham, Alabama, United States|Investigational Site Number 8400012, Rolling Hills Estates, California, United States|Investigational Site Number 8400011, Hollywood, Florida, United States|Investigational Site Number 8400019, Melbourne, Florida, United States|Investigational Site Number 8400016, Boston, Massachusetts, United States|Investigational Site Number 8400002, Omaha, Nebraska, United States|Investigational Site Number 8400001, Rochester, New York, United States|Investigational Site Number 8400007, Rochester, New York, United States|Investigational Site Number 8400008, Cleveland, Ohio, United States|Investigational Site Number 8400003, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400014, Mount Pleasant, South Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""440"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Neutralizing Antibody Titer at Day 1|Neutralizing Antibody Titer at Day 22|Neutralizing Antibody Titer at Day 36|Fold-rise of Neutralizing Antibody Titer at Day 22|Fold-rise of Neutralizing Antibody Titer at Day 36|2-fold and 4-fold Rise in Neutralization Antibody titer at Day 22|2-fold and 4-fold Rise in Neutralization Antibody titer at Day 36|Percentage of Participants with Neutralizing Antibody Seroconversion at Day 22|Percentage of Participants with Neutralizing Antibody Seroconversion at Day 36|Number of Participants with Immediate Adverse Events|Number of Participants With Solicited Injection Site or Systemic Reactions|Number of Participants with Unsolicited Adverse Events|Number of Participants with Medically Attended Adverse Events|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Adverse Events of Special Interest|Number of Participants with Out-of-range Biological Test Results|Binding Antibody Concentration|Binding Antibody Concentration Ratio|Fold Rise in Binding Antibody Concentration|Neutralizing Antibody Titer|Fold-rise in Neutralization Titer at Day 181 and Day 366 (Cohort 1) and Day 202 and Day 387 (Cohort 2)|2-fold and 4-fold Rise in Neutralization Titer [Post\/Pre] at Day 181 and 366 (Cohort 1) and Day 202 and Day 387 (Cohort 2)|Percentage of Participants with Neutralizing Antibody Seroconversion at Day 181 and 366 (Cohort 1) and Day 202 and Day 387 (Cohort 2)|Number of Participants with Virologically-confirmed COVID-19-like Illness|Number of Participants with Serologically-confirmed SARS-CoV-2 Infection|Correlates of Risk \/ Protection Based on Antibody Responses to SARS-CoV-2""}"
"1108","Virtual Assistant for COVID-19 PPE","","NCT04435275","20-5399","Other: Virtual Assistant first, then Human Coach|Other: Human Coach first, then Virtual Assistant","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04435275","Recruiting","2021-01-02","2021-05-01","{""locations"":""University Health Network, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""performance of healthcare workers""}"
"1109","Niclosamide in COVID-19","","NCT04542434","FW-COV-003","Drug: Niclosamide Oral Tablet|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04542434","Not yet recruiting","2021-06-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""148"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|TEAE|SAEs|Safety laboratory|Blood pressure|fecal RNA virus clearance|Body temperature|Heart rate|SaO2|ECG""}"
"1110","Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic","LIO-C","NCT04386668","15281/003","Other: Let It Out (LIO)-C|Other: Neutral writing control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04386668","Terminated","2020-05-26","2020-08-31","{""locations"":""University College London, London, Kent, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Kessler Psychological Distress Scale (K10)|Perceived Stress Scale (PSS-10)|Pittsburgh Sleep Quality Index (PSQI)|Self-compassion scale (SCS)|UCLA Loneliness Scale (UCLA LS)|Uptake of existing mental health services (MHS)|Mood and meaning|Acceptability""}"
"1111","A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing","","NCT04537572","R2020-1002","Diagnostic Test: comparison of sample collection methods","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04537572","Not yet recruiting","2020-09-01","2022-09-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""300"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Laboratory determination of presence of anti-SARS-COV2 antibodies (IgM, IgA, and IgG)""}"
"1112","Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients","","NCT04526054","2020_0057","Diagnostic Test: ENT exam|Diagnostic Test: Olfactometry|Diagnostic Test: Brain MRI","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04526054","Recruiting","2020-09-03","2021-09-03","{""locations"":""Hopital Foch, Suresnes, Ile-de-France, France|Hopital Raymond Poincare, Garches, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To compare the qualitative and quantitative morphological abnormalities of the olfactory bulb detected by MRI on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients.|To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients.|Longitudinal evaluation of qualitative and quantitative abnormalities of olfactory bulbs on MRI in in COVID-19 anosmic patient at initial examination, between 6 weeks and 2 months and between 6 and 9 months.""}"
"1113","Tele-rehabilitation Versus Home Exercise Program in COVID-19","","NCT04482634","2020.219.IRB1.069","Other: Remote controlled exercise|Other: Home exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04482634","Recruiting","2020-09-01","2022-08-01","{""locations"":""Koc University School of Medicine, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""122"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""6-minute walk test|Short form - 36|Chair- stand test|Timed up and go test|St. George's Respiratory Questionnaire|The COPD Assessment Test|Medical Research Council Dyspnea Scale|Hand grip strength""}"
"1114","COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box","","NCT04366141","H20-01270","Device: COVID-19 barrier box","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04366141","Completed","2020-05-01","2021-02-01","{""locations"":""Providence Health Care, Vancouver, British Columbia, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to tracheal intubation (TTI)|First pass success rate|Total time of airway manipulation|Number of intubation attempts|Number of Operators needed for intubation|Number of alternative techniques used for intubation|Cormack-Lehane Grade for the first attempt of intubation|Lifting force applied on laryngoscope blade|Laryngeal pressure application|Vocal cord position|Anesthesiologist perception of intubation difficulty|Anesthesiologist perception of contributors to difficulty in intubation, if any|Patient acceptability of the COVID Barrier Box|Patient comfort with the COVID Barrier Box|Patient comments on the COVID Barrier Box""}"
"1115","Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique","AfriCoVER","NCT04442165","AfriCoVER","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442165","Recruiting","2020-12-15","2021-07-14","{""locations"":""INS, Maputo, Mozambique"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""15393"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""COVID-19 disease incidence rate (symptomatic infections per month)|COVID-19 related hospitalization rate due to SARS-CoV-2|Case (disease) fatality risk (percent) due to SARS-CoV-2|Proportion asymptomatic infections, by age group|SARS-CoV-2 infection annual attack rate (percent)|SARS-CoV-2 infection fatality risk|Infection fatality of SARS-CoV-2 infection.|Serial interval number of SARS-CoV-2 infection|Reproduction number of SARS-CoV-2 infection|Correlation between anti-coronavirus (endemic coronavirus or SARS-CoV-2) antibody titers and reinfection|Antibody titers against SARS-CoV-2 over time""}"
"1116","COVID-19 Saliva Test Research Study","","NCT04531501","283560","Diagnostic Test: Saliva and NPS test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04531501","Recruiting","2020-06-29","2020-09-29","{""locations"":""Gloucestershire Royal Hospital, Gloucester, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""400"",""age"":""18 Years to 117 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Test Result""}"
"1117","Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.","","NCT04395170","LFCOLCOVID-19-001","Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04395170","Not yet recruiting","2020-09-01","2021-06-01","{""locations"":""LifeFactors Zona Franca SAS, Medell\u00edn, Antioquia, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Admission to ICU and\/or mechanical ventilation|Length of hospital stay|Neutralizing antibody (IgG) titers against COVID-19|Safety - Adverse events|Death""}"
"1118","Long Term Outcomes of Coronavirus Disease-19 (COVID-19)","","NCT04715919","195/ADF14","Diagnostic Test: Chest Computed Tomography|Diagnostic Test: Pulmonary Function Tests|Other: Six Minutes Walk Test|Other: Quality of Life","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04715919","Recruiting","2021-01-15","2021-06-01","{""locations"":""1University of Health Sciences Turkey, Dr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, Intensive Care Unit, \u0130zmir, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Structural Change in Lung|Carbon monoxide diffusion capacity (DLCO)|Exercise Capacity|Short Form Health Survey Score (SF-16)""}"
"1119","First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","","NCT04350736","0183|2020-000577-24","Drug: TD-0903|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04350736","Completed","2020-04-23","2020-06-24","{""locations"":""Theravance Biopharma Investigational Site, Manchester, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""54"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Safety and Tolerability of SAD of TD-0903: Adverse Events|Safety and Tolerability of MAD of TD-0903: Adverse Events|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax""}"
"1120","COVID-19 Vaccines International Pregnancy Exposure Registry","C-VIPER","NCT04705116","PR004","Biological: COVID-19 vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04705116","Not yet recruiting","2021-04-01","2025-12-31","{""locations"":""Pregistry, Los Angeles, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Obstetric outcomes|Neonatal outcomes|Infant weight|Infant developmental milestones|Infant COVID-19 diagnosis|Infant height""}"
"1121","COVID-19 in Patients With Chronic Liver Diseases","COLD","NCT04439084","55819","Other: Prospective Chart Review","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04439084","Enrolling by invitation","2020-03-06","2021-06-01","{""locations"":""University of Arizona,, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|UCSF Fresno, Fresno, California, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Georgetown University, Washington, District of Columbia, United States|VA Medical Center, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Oschner Medical Center, Baton Rouge, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Hennepin County Medical Center (HCMC), Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Liver-related mortality|Overall survival|Number of patients with hepatic decompensation|Number of patients requiring hospitalization|Duration of hospitalization|Length of intensive care unit (ICU) stay|Number of participants requiring mechanical ventilation""}"
"1122","Cardiac Assessment After Covid-19 Disease in Elite Altheltic Population","CADE","NCT04653857","RECHMPL20_0648","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04653857","Active, not recruiting","2020-04-01","2021-01-01","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""10 Years to 50 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Prevalence of cardiac abnormality|Demographic variables""}"
"1123","Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)","TS-COVID","NCT04627467","FVL-1567","Drug: Chloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04627467","Active, not recruiting","2020-03-28","2021-02-14","{""locations"":""Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""3217"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 infection|IgG antibodies seropositivity against SARS-CoV-2""}"
"1124","Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients","BUCOSARS","NCT04707742","Interventional","Drug: Betadine© bucal 100 mg/ml|Drug: Oximen® 3%|Drug: Clorhexidine Dental PHB©|Drug: Vitis Xtra Forte©|Drug: Distilled Water","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04707742","Completed","2020-06-15","2020-11-18","{""locations"":""Alejandro Mira, Valencia, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""84"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect of 5 different mouthwashes on the SARS-Cov2 viral load.""}"
"1125","Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19)","","NCT04358939","HIGH-PRONE-COVID-19|2020-A01121-38|DR200125","Other: Prone decubitus","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04358939","Recruiting","2020-04-27","2021-11-24","{""locations"":""Intensive Care Unit, University Hospital, Aix, Aix-en-Provence, France|Medical Intensive Care Unit, University Hospital, Amiens, Amiens, France|Intensive Care Unit, Hospital, Argenteuil, Argenteuil, France|Intensive Care Unit, Hospital,, Blois, France|Medical Intensive Care Unit, University Hospital, Bordeaux, Bordeaux, France|Medical Intensive Care Unit, University Hospital, Brest, Brest, France|Medical Intensive Care Unit, Hospital, B\u00e9thune, B\u00e9thune, France|Medical Intensive Care Unit, University Hospital, Caen, Caen, France|Intensive Care Unit, Louis Mourier-APHP, Colombes, France|Intensive Care Unit, Hospital, Dax, Dax, France|Medical Intensive Care Unit, University Hospital, Dijon, Dijon, France|Medical Intensive Care Unit, University Hospital, Grenoble, Grenoble, France|Intensive Care Unit, Hospital, La Roche-sur-Yon, La Roche-sur-Yon, France|Intensive Care Unit, Hospital, Le Mans, Le Mans, France|Intensive Care Unit, University Hospital, Lille, Lille, France|Intensive Care Unit, Hospital, Lorient, Lorient, France|Medical Intensive Care Unit, Hospital, Mont-de-Marsan, Mont-de-Marsan, France|Medical Intensive Care Unit, University Hospital, Montpellier, Montpellier, France|Medical Intensive Care Unit, University Hospital, Nantes, Nantes, France|Medical Intensive Care Unit, University Hospital, Nice, NIce, France|Medical Intensive Care Unit, Hospital, Orl\u00e9ans, Orl\u00e9ans, France|Medical Intensive Care Unit, Tenon-APHP, Paris, France|Medical Intensive Care Unit, University Hospital, Poitiers, Poitiers, France|Medical Intensive Care Unit, University Hospital, Tours, Tours, France|Surgical Intensive Care Unit, University Hospital, Tours, Tours, France|Intensive Care Unit, Hospital, Valence, Valence, France|Medical Intensive Care Unit, University Hospital, Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France|Intensive Care Unit, Hospital, Vannes, Vannes, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""404"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Therapeutic failure within 14 days of randomization|Therapeutic failure within 28 days of randomization|Timeframe of intubation or death|Timeframe of therapeutic escalation (in case of non-invasive ventilation at two pressure levels)|Evolution of oxygenation (PaO2\/FiO2 ratio or SpO2\/FiO2 surrogate) over the 14 days following randomization|Evolution of the SpO2\/FiO2 ratio during the first prone session|Evolution of the ROX index during the first prone session|Evolution of the World Health Organization disease severity score of COVID|Patient comfort before, during and after the first prone position session|Occurrence of skin lesions on the anterior surface of the body|Displacement of invasive devices during reversals|Days of nasal High-Flow therapy use in the general population, in non-intubated patients and in intubated patients|Days spent in the intensive care unit and in the hospital|Mortality in the intensive care unit and in the hospital|Ventilator-free-days within 28 days of randomization""}"
"1126","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia","COVIDICUS","NCT04344730","APHP200388|2020-001457-43","Drug: Dexamethasone injection|Drug: placebo|Procedure: conventional oxygen|Procedure: CPAP|Procedure: HFNO|Procedure: mechanical ventilation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04344730","Active, not recruiting","2020-04-10","2021-12-31","{""locations"":""Hopital Bichat - Aphp, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""550"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The time-to-death from all causes|The time to need for mechanical ventilation (MV)|The viral load in the respiratory tract|Number of patient with at least one episode of healthcare-associated infections|Number of days alive without mechanical ventilation|Measure of SOFA score|Number of days alive without renal replacement therapy|Lengths of ICU-stay|Lengths of hospital-stay|Number of patients with severe hypoxemia,|Proportion of patients with cardiac arrest within 1 hour after intubation|Overall survival""}"
"1127","Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia","","NCT04599998","2020.188.IRB1.056","Diagnostic Test: spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04599998","Enrolling by invitation","2020-10-15","2021-03-01","{""locations"":""Ko\u00e7 University Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""37"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Forced vital capacity (FVC)|Lung diffusion capacity for carbon monoxide (DLCO)|6-minute walk test distance|Short-form 36 questionnaire (SF-36)|Oxygen uptake at peak exercise|Minute-ventilation\/carbon dioxide output during exercise|Dyspnea during exercise|Thoracic CT findings|Forced expiratory volume in 1 second|FEV1\/FVC ratio|Forced vital capacity %predicted (FVC%)|Signs and symptoms|Time to hospital discharge|ICU discharge|Weaning from intubation|Weaning from supplemental oxygen|Weaning from noninvasive mechanical ventilation|Mortality""}"
"1128","Polk COVID-19 and Flu Response","PCFR","NCT04682132","00001784","Diagnostic Test: COVID-19 antigen and antibody tests, and influenza rapid test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04682132","Active, not recruiting","2020-05-26","2021-01-01","{""locations"":""Polk County Fire Rescue, Bartow, Florida, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""686"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID-19 amongst county emergency personnel|Correlation of common COVID-19 symptoms with result of COVID-19 test|Co-existence of influenza and COVID-19 positive test results""}"
"1129","Oral 25-hydroxyvitamin D3 and COVID-19","","NCT04386850","IRCT2020-0401046909N2|IRCT20200401046909N1","Drug: Oral 25-Hydroxyvitamin D3","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04386850","Recruiting","2020-04-14","2021-03-15","{""locations"":""Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1500"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 (SARA-Cov-2) infection|Severity of COVID-19 (SARA-Cov-2) infection|Hospitalization|Disease duration|Death|Oxygen support|Type of oxygen support|Symptoms of COVID-19|Serum Levels of 25-hydroxyvitamin D3|Serum levels of calcium|Serum levels of phosphorus|Serum levels of creatinine|Serum levels of albumin|Serum levels of the blood urea nitrogen (BUN)|Serum levels of the parathyroid hormone (PTH)""}"
"1130","Follow-up and Rehabilitation of Survivors of Severe Coronavirus Disease 2019 (COVID-19) Infection","SegCov","NCT04563156","4047553","Diagnostic Test: Lung Function Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04563156","Enrolling by invitation","2020-06-23","2021-12-31","{""locations"":""Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo-HCFMUSP, S\u00e3o Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Quality of life assessment of a survivor of severe COVID-19 infection 6 months after hospital discharge;|Quality of life questionnaire EQ-5D|Evaluation of dyspnea by the Modified Medical Research Council Scale (mMRC)|The Hospital Anxiety and Depression Scale|Baseline and Transition Dyspnea Indexes (BDI-TDI)|Clinical frailty scale measured after discharge from the ICU,|Lawton-Brody Instrumental Activities of Daily Living (iADL) scale|Muscle strength according to the Medical Research Council (MRC) scale|Maximum inspiratory pressure, diaphragmatic mobility and diaphragm thickness|Sit-to-stand test in 1 minute|Cognitive dysfunction measured using the Montreal Cognitive Assessment (MoCA) test|Pulmonary function test with Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurements|Hemoglobin, hematocrit, creatinine and Fasting plasma glucose (FPG)|Quantitative computerized tomography scan|Maximum VO2 during Cardiopulmonary exercise testing|Return to work|Occurrence of thromboembolic events after|Occurrence of falls|Need for readmission|Mortality""}"
"1131","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus","","NCT04293692","Pr20200225","Biological: UC-MSCs|Other: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04293692","Withdrawn","2020-02-24","2020-02-25","{""locations"":""Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1\u03b2, IL-6, IL-8,IL-10,TNF-\u03b1)|Concentration of the myocardial enzymes""}"
"1132","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","TOSCA","NCT04332913","0064468/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04332913","Recruiting","2020-04-01","2021-03-31","{""locations"":""Ospedale San Salvatore, L'Aquila, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases""}"
"1133","Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)","SARCOVID","NCT04357808","SARCOVID|2020-001634-36","Drug: Sarilumab|Other: Standar of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04357808","Completed","2020-04-13","2020-12-04","{""locations"":""Hospital Universitario de la Princesa, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|Duration of hospitalisation (days)|Death|Time to become afebrile (days)|Time to non-invasive mechanical ventilation (days)|Time to invasive mechanical ventilation (days)|Time to independence from supplementary oxygen therapy (days)|Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation""}"
"1134","COVID-19 and the Developement of Phobic Fears of Disease","","NCT04359121","32-354 ex 19/20","Other: Questionnaires for specific phobia","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359121","Recruiting","2020-04-15","2024-04-15","{""locations"":""Medical University of Graz, Graz, Styria, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of phobias""}"
"1135","RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population","COVID-19GAOM","NCT04427358","7838","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04427358","Completed","2020-05-07","2020-09-07","{""locations"":""Service SSR G\u00e9riatrique, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""100"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""1. Analysis of the rate of RT-PCR SARS-CoV-2 positive at 1 month of COVID infection|2. Assess quantitative evaluation of a nasopharyngeal swab SARS-CoV-2 RT-PCR test|Assessment of late stool SARS-CoV-2 RT-PCR, serological status and associated factors with death and RT-PCR results 1 month after the date of first symptom onset""}"
"1136","Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19","","NCT04403880","HVTN 405/HPTN 1901|5UM1AI068614-14","Other: Sample collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403880","Recruiting","2020-05-13","2021-08-01","{""locations"":""Alabama Vaccine CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|Bridge HIV CRS, San Francisco, California, United States|George Washington University CRS, Washington, District of Columbia, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States|Adolescent & Young Adult Research at The CORE Center (AYAR at CORE), Chicago, Illinois, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States|Fenway Health Clinical Research Site CRS, Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Bronx Prevention Research Center CRS, Bronx, New York, United States|Harlem Prevention Center CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|New York Blood Center CRS, New York, New York, United States|University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|Vanderbilt Vaccine CRS, Nashville, Tennessee, United States|Seattle Vaccine and Prevention CRS, Seattle, Washington, United States|Malawi CRS, Lilongwe, Malawi|Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS, Maputo, Mozambique|CITBM - UNIDEC, Centro de Investigaciones Tecnol\u00f3gicas, Biom\u00e9dicas y Medioambientales CRS, Bellavista, Callao, Peru|San Miguel CRS, San Miguel, Lima, Peru|Asociacion Civil Selva Amazonica (ACSA) CRS, Iquitos, Maynas, Peru|Via Libra CRS, Lima, Peru|Barranco CRS, Lima, Peru|Josha Research CRS, Bloemfontein, South Africa|Emavundleni CRS, Cape Town, South Africa|Groote Schuur HIV CRS, Cape Town, South Africa|Khayelitsha CRS \/ (CIDRI UCT), Cape Town, South Africa|Masiphumelele Clinical Research Site (MASI) CRS, Cape Town, South Africa|Chatsworth CRS, Chatsworth, South Africa|Botha's Hill CRS, Durban, South Africa|CAPRISA eThekwini CRS, Durban, South Africa|Vulindlela CRS, Durban, South Africa|Isipingo CRS, Isipingo, South Africa|Kliptown Soweto CRS, Johannesburg, South Africa|Soweto HVTN CRS, Johannesburg, South Africa|Aurum Institute Klerksdorp CRS, Klerksdorp, South Africa|Qhakaza Mbokodo Research Clinic CRS, Ladysmith, South Africa|Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa|Synexus Stanza Clinical Research Centre CRS, Pretoria, South Africa|Rustenburg CRS, Rustenburg, South Africa|Setshaba Research Centre CRS, Soshanguve, South Africa|Tembisa Clinic 4 CRS, Tembisa, South Africa|The Aurum Institute Tembisa Clinical Research Centre CRS, Tembisa, South Africa|Tongaat CRS, Tongaat, South Africa|Verulam CRS, Verulam, South Africa|National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS, Mbeya, Tanzania|Matero Reference Clinic CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Lusaka CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Ndola CRS, Ndola, Zambia|St Mary's CRS, Chitungwiza, Zimbabwe|Zengeza CRS, Chitungwiza, Zimbabwe|Seke South CRS, Harare, Zimbabwe"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""727"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Humoral responses to peptide antigens derived from SARS-CoV-2 structural proteins and regions of the spike protein not present in vaccines|SARS-CoV-2-specific antibody binding response rate|SARS-CoV-2-specific antibody binding response magnitude|SARS-CoV-2-specific antibody binding response epitope specificity|SARS-CoV-2-specific antibody neutralization response rate|SARS-CoV-2-specific antibody neutralization response magnitude|SARS-CoV-2-specific antibody neutralization response epitope specificity|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response rate|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response magnitude|SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response epitope specificity|SARS-CoV-2-specific CD4+ and CD8+ T cell responses|SARS-CoV-2-specific CD4+ and CD8+ T cell response rate|SARS-CoV-2-specific CD4+ and CD8+ T cell response magnitude|SARS-CoV-2-specific CD4+ and CD8+ T cell response functional profiling|SARS-CoV-2-specific memory B cell characterization|SARS-CoV-2-specific infection presentation, including clinical course, along with demographics and corresponding medical history of participants|Detection of viral RNA in nasopharyngeal or nasal swab samples|Response rate of SARS-CoV-2-specific binding antibodies in nasal samples|Response magnitude of SARS-CoV-2-specific binding antibodies in nasal samples""}"
"1137","Effect of Using Barrier Devices for Intubation in COVID-19 Patients","","NCT04412226","2020/56","Device: aerosol box|Device: transparent sheet","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412226","Completed","2020-06-10","2020-06-30","{""locations"":""Kocaeli Derince Training and Research Hospital, Kocaeli, Izmit, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""13"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""First pass success|Time to endotracheal intubation|Difficulty level of accessing the equipment|Difficulty level of inserting the endotracheal tube into the glottis|Clarity of the view of the patient's face""}"
"1138","The Clinical Study of Carrimycin on Treatment Patients With COVID-19","","NCT04286503","BeijingYouan Hospital","Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04286503","Not yet recruiting","2020-02-23","2021-02-28","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""520"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment""}"
"1139","COVID-19 Project ECHO in Nursing Homes","","NCT04499391","PCORI Nursing Homes","Other: Project ECHO","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04499391","Recruiting","2020-12-04","2022-07-01","{""locations"":""Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Infection rate|Hospitalization|Death""}"
"1140","Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia","","NCT04519125","2020 /143|77389","Drug: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Other: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04519125","Not yet recruiting","2020-08-30","2021-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""950"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection|Serious and non-serious adverse events|Discontinuation of using TDF\/FTC for any reason|Adherence to TDF\/FTC|Severity of SARS-CoV-2 infection""}"
"1141","RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers","RU","NCT04700163","RUCOV1|CGA-1015","Biological: C144-LS and C-135-LS","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04700163","Recruiting","2021-01-11","2022-04-15","{""locations"":""The Rockefeller University, New York, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Grade 2 and higher adverse events 4 weeks after administration.|Grade 3 and higher adverse events 4 weeks after administration.|Related Serious adverse events (SAEs) throughout the study period|Elimination half-life (t1\/2) of C135-LS and C144-LS|Clearance rate of C135-LS and C144-LS|Area under the curve of C135-LS and C144-LS|Investigational product (IP)-related adverse events during study follow up.|Anti-C144-LS and anti-C135-LS antibodies in all study groups.|Serum neutralizing activity against SARS-CoV-2""}"
"1142","Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)","","NCT04288102","2020-013-D","Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04288102","Completed","2020-03-05","2020-07-09","{""locations"":""General Hospital of Central Theater Command, Wuhan, Hubei, China|Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in lesion proportion (%) of full lung volume from baseline to day 28.|Change in lesion proportion (%) of full lung volume from baseline to day 10 and 90|Change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Pulmonary fibrosis - related morphological features in CT scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening|Lung densitometry: Change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in HU) \u00d7 voxel volume (in voxel)|Lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.|Time to clinical improvement in 28 days.|Oxygenation index( PaO2\/FiO2)|Duration of oxygen therapy(days)|Blood oxygen saturation|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)|mMRC (Modified Medical Research Council) dyspnea scale|Changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.|Changes of cytokine\/chemokine levels from baseline to day 6, 10, 28 and 90.|Adverse events|Serious adverse events|All-cause mortality""}"
"1143","COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7","Tomeka","NCT04537585","TOMEKA","Combination Product: Tomeka®|Drug: ""Vernonia amygdalina""","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04537585","Not yet recruiting","2020-11-01","2022-12-01","{""locations"":""Cliniques Universitaires de Kinshasa, Kinshasa, Congo, The Democratic Republic of the"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2000"",""age"":""15 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-TOMEKA\u00ae usage|Change From Baseline in herbs Vernonia amygdalina usage""}"
"1144","Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients","","NCT04361565","20odontocovid01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361565","Enrolling by invitation","2020-03-20","2020-05-31","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Anosmia|Ageusia|Duration of the loss of anosmia ageusia""}"
"1145","Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19","","NCT04349592","MRC-05-001","Drug: Hydroxychloroquine|Drug: Azithromycin|Other: Placebo Tablet|Other: Placebo capsules","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04349592","Completed","2020-04-14","2020-08-30","{""locations"":""Hamad Medical Corporation, Doha, Qatar"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""456"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of virologically cured (PCR-negative status) as assessed on day six|virologic cure on other study days|virologic semiquantitative analysis of changing viral load|proportion of initially symtomatic subjects with disappearance of clinical symptoms|proportion of initially asymtomatic subjects with appearance of new clinical symptoms|proportions of subjects with potentially medication- related adverse events""}"
"1146","CLBS119 for Repair of COVID-19 Induced Pulmonary Damage","","NCT04522817","CLBS119-P01","Biological: CLBS119","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04522817","Withdrawn","2020-10-05","2021-05-01","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse events|Change in oxygen saturation""}"
"1147","Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors","AEO","NCT04592354","TB-AEO-2020 Post Covid Fatigue","Dietary Supplement: Oxaloacetate Medical Food/Dietary Supplement","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04592354","Recruiting","2020-10-15","2021-06-15","{""locations"":""Energy Medicine research Institute, Boulder, Colorado, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fatigue|Depression""}"
"1148","COVID-19 IgG Antibodies in the Serum of Recovered Patients","","NCT04470414","Cov-PH2020","Diagnostic Test: IgG antibodies immunoassay","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04470414","Not yet recruiting","2020-08-01","2021-09-01","{""locations"":""Faculty of medicine- Assiut university, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Levels of IgG in the serum of recovered COVID-19 patients|Factors related to IgG level""}"
"1149","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial","AZIQUINE-ICU","NCT04339816","AZIQUINE-ICU-25032020|2020-001456-18","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04339816","Terminated","2020-05-13","2020-11-04","{""locations"":""Franti\u0161ek Du\u0161ka, Praha, \u010cesk\u00e1 Republika, Czechia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""3"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90""}"
"1150","Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","","NCT04345276","ASC-CTP-HS-01","Drug: Danoprevir+Ritonavir","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04345276","Completed","2020-03-18","2020-04-15","{""locations"":""Huoshenshan Hostipal, Wuhan, Hubei, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event""}"
"1151","Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","","NCT04291729","ASC-CTP-NC-01","Drug: Ganovo+ritonavir+/-Interferon nebulization","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04291729","Completed","2020-02-17","2020-03-19","{""locations"":""The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""11"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event""}"
"1152","A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","PREVENT-HD","NCT04508023","CR108849|39039039DVT3004","Drug: Rivaroxaban|Other: Placebo|Other: Standard of Care (SOC)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04508023","Recruiting","2020-08-13","2022-01-31","{""locations"":""University of Arizona, Tucson, Arizona, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Kaiser Permanente Northern California, Oakland, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Florida Hospital Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northshore Universite Healthsystem, Evanston, Illinois, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Lenox Hill Hospital -Northwell Health, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Health Physicians Group, Fort Worth, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, All-cause Hospitalization and All-cause Mortality|Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Mortality|Time to First Occurrence of All-cause Hospitalization|Time to First Occurrence of Symptomatic VTE|Time to First Occurrence of an Emergency Room (ER) Visit|Time to First Occurrence of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Hospitalization|Percentage of Participants who are Hospitalized or Dead From Any Cause|Time to All-cause Mortality up to Day 35|Time to First Occurrence of International Society on Thrombosis and Hemostasis (ISTH) Critical Site and Fatal Bleeding|Time to First Occurrence of ISTH Major Bleeding Events|Time to First Occurrence of Clinically Relevant Non-major Bleeding""}"
"1153","Eosinophil and Anticoagulation in COVID-19 Patients","","NCT04507282","Bursa Postgraduate Hospital","Drug: LMWH","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04507282","Completed","2020-05-15","2020-07-15","{""locations"":""Bursa Y\u00fcksek \u0130htisas Hastanesi, Y\u0131ld\u0131r\u0131m, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""subprophylactic anticogulation level""}"
"1154","COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy","COROMEC","NCT04678193","CORAVT 001","Drug: Coromec Registry with ECL-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04678193","Enrolling by invitation","2020-12-24","2022-06-30","{""locations"":""Multiple Locations, Phoenix, Arizona, United States|Multiple Locations, Bangalore, India|Multiple Locations, Stockholm, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""27000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictors of post COVID-19 complications and predictors of hospitalization|Health symptom score|Vital signs SpO2 score|Vital signs BMI score of 40 kg\/m2|Chronic Illness score|Mental health assessment high score >11 on PHQ9 Depression score|Mental health assessment high score >11 on GAD 7 Anxiety score|Evaluate a treatment strategy with ECL-19""}"
"1155","A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers","","NCT04405466","M-2020-360","Procedure: Blood sampling|Procedure: Throat swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04405466","Recruiting","2020-04-22","2021-01-31","{""locations"":""Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, NRW, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immune responses to components of SARS-Cov-2|Swabs for the presence of SARSCoV-2|Difference between the study groups in anti-SARS-CoV 2 seropositivity status""}"
"1156","Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure","","NCT04451291","U-DEPLOY: DSC-COVID-19|20-5527","Biological: Decidual Stromal Cells (DSC)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04451291","Not yet recruiting","2020-08-24","2021-02-24","{""locations"":""Toronto General Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of ventilator free days following infusion of decidual stromal cells|Mortality rate from COVID-19|All-cause morality rate|Average number of days in ICU|Average number of days of hospital admittance|Average days not requiring vasopressors|Overall survival rate|Average viral clearance|Average number of days of supplemental oxygenation|Average number of day without supplemental oxygen|Mean PaO2\/FiO2 as compared to patient baseline""}"
"1157","Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine","","NCT04654416","04-2020","Drug: Corticosteroid with or without colchicine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04654416","Completed","2020-03-20","2020-08-20","{""locations"":""Cl\u00ednica Medell\u00edn - Grupo Quir\u00f3nsalud, Medell\u00edn, Antioquia, Colombia"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""301"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Outcome""}"
"1158","Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection","","NCT04366830","MSB-MSC-ARDS001","Drug: Remestemcel-L","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04366830","No longer available","1970-01-01","1970-01-01","{""locations"":""Mount Sinai Hospital, New York, New York, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"1159","Tafenoquine in Patients With Mild to Moderate COVID-19","","NCT04533347","TQ 2020_06","Drug: Tafenoquine Oral Tablet|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04533347","Recruiting","2021-02-19","2021-06-22","{""locations"":""Clinical Trial Network, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""275"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with clinical recovery of COVID-19 symptoms on Day 14|Increases the proportion of patients with absence of clinical symptoms by individual symptom at Day 14|Decreases the hospitalization rate due to COVID-19 by Day 14|Decreases the number of medical follow-up visits by Day 14.""}"
"1160","Detection of COVID-19 Decompensation","DeCODe","NCT04575532","CTP-004","Device: Use of the pinpointIQ solution (physIQ, Inc.)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04575532","Enrolling by invitation","2020-10-05","2021-01-22","{""locations"":""University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of Covid Decompensation Index|Feasibility""}"
"1161","Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study","ATHLOS","NCT04368845","1","Device: Telerehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04368845","Recruiting","2020-05-11","2021-03-31","{""locations"":""Clinical exercise Physiology and rehabilitation research laboratory, Lamia, Greece"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""20 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical Performance|Cardiorespiratory fitness|Lower limb Strength|Health Related Quality of Life|Anxiety and Depression|Physical Activity|Fatigue|Dyspnea""}"
"1162","Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).","APEL-COVID","NCT04632732","2021-3862-APEL-COVID","Diagnostic Test: COVID-19 test|Diagnostic Test: Blood sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04632732","Recruiting","2020-10-26","2021-12-01","{""locations"":""Sherbrooke University, Sherbrooke, Quebec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Blood apelins-13\/12, -17\/16, -36|Blood angiotensin II|Blood Clara cell protein (CC16)|Blood interleukine-6 (IL-6)|Blood surfactant protein D (SP-D)|Plasma apelins degradation speed measurement by UPLC|Plasma ACE2 activity measurement by fluorometry|Plasma kallikrein activity measurement by fluorometry|Plasma neprilysin activity measurement by fluorometry|Plasma ras activity measurement by fluorometry|APACHEII|Oxygenation index|Mechanical ventilation|Pulmonary compliance (Dynamic, real-time, on ventilator device: Tidal volume \/ Plateau pressure - PEEP|Length of hospital stay|SOFA""}"
"1163","Seroconversion in COVID-19 Recovered Population","","NCT04558385","LGH006","Diagnostic Test: IgG SARS CoV2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04558385","Active, not recruiting","2020-07-01","2021-02-15","{""locations"":""Lahore General Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""275"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""IgG SARS CoV2""}"
"1164","COVID-19 Watch + COVID-19 Pulse","","NCT04581863","844043","Device: pulse oximeter|Other: COVID Watch","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04581863","Active, not recruiting","2020-11-30","2021-10-31","{""locations"":""Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""850"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Difference in Days Alive and Out of Hospital""}"
"1165","COVID Cohort Study","","NCT04393155","16-540","Other: COVID-19+ observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393155","Terminated","2020-04-16","2021-01-25","{""locations"":""University of Vermont College of Medicine, Burlington, Vermont, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""16"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Six minute walk distance (6MWD)|Hospital Anxiety and Depression Scale (HADS)|EuroQol Group standardized measure of health status (EQ-5D-5L)|MoCA-BLIND|Health Care Utilization Survey (HUS)|Death|Forced vital capacity (FVC)|Forced expiratory volume in 1 second (FEV1)|4-meter timed walk|Peripheral blood mononuclear cell type: CD4+ T cells (#cells\/ml)|Peripheral blood mononuclear cell type: CD8+ T cells (#cells\/ml)|Peripheral blood mononuclear cell type: B cells (#cells\/ml)|Peripheral blood mononuclear cell type: NK cells (#cells\/ml)|Peripheral blood mononuclear cell type: monocytes (#cells\/ml)|Circulating markers of inflammation: C-Reactive Protein (CRP) (mg\/l)|Circulating markers of inflammation: Interleukin 6 (IL-6) (pg\/ml)|Circulating markers of inflammation: Interleukin 8 (IL-8) (pg\/ml)|Circulating markers of inflammation: Interferon gamma (IFNg) (pg\/ml)|Circulating markers of inflammation: Interferon alpha (IFNa) (pg\/ml)|Circulating markers of inflammation: Tumor necrosis factor alpha (TNFa) (pg\/ml)|Circulating markers of inflammation: Interleukin 1 beta (IL-1b) (pg\/ml)""}"
"1166","Canadian COVID-19 Emergency Department Registry","CCEDRRN","NCT04702945","H20-01015","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04702945","Recruiting","2020-03-01","2023-12-31","{""locations"":""Foothills Medical Centre, Calgary, Alberta, Canada|Peter Lougheed Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Northeast Community Health Centre, Edmonton, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Abbotsford Regional Hospital, Abbotsford, British Columbia, Canada|Royal Inland Hospital, Kamloops, British Columbia, Canada|Kelowna General Hospital, Kelowna, British Columbia, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|Lions Gate Hospital, North Vancouver, British Columbia, Canada|Eagle Ridge Hospital, Port Moody, British Columbia, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|Mount Saint Joseph Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Dartmouth General Hospital, Dartmouth, Nova Scotia, Canada|Halifax Infirmary, Halifax, Nova Scotia, Canada|Cobequid Community Health Centre, Lower Sackville, Nova Scotia, Canada|Hants Community Hospital, Windsor, Nova Scotia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre (University Hospital), London, Ontario, Canada|London Health Sciences Centre (Victoria Hospital), London, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Health Science North, Sudbury, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|H\u00f4tel-Dieu de L\u00e9vis, L\u00e9vis, Quebec, Canada|H\u00f4pital du Sacr\u00e9-Coeur, Montr\u00e9al, Quebec, Canada|Jewish General Hospital, Montr\u00e9al, Quebec, Canada|Montr\u00e9al General Hospital (MUHC), Montr\u00e9al, Quebec, Canada|Royal Victoria Hospital (MUHC), Montr\u00e9al, Quebec, Canada|Centre Hospitalier de l'Universit\u00e9 Laval (CHU de Qu\u00e9bec), Qu\u00e9bec, Quebec, Canada|H\u00f4pital de l'Enfant-J\u00e9sus (CHU de Qu\u00e9bec), Qu\u00e9bec, Quebec, Canada|H\u00f4pital du Saint-Sacrement (CHU de Qu\u00e9bec), Qu\u00e9bec, Quebec, Canada|H\u00f4pital Saint-Fran\u00e7ois d'Assise (CHU de Qu\u00e9bec), Qu\u00e9bec, Quebec, Canada|H\u00f4tel-Dieu de Qu\u00e9bec (CHU de Qu\u00e9bec), Qu\u00e9bec, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Qu\u00e9bec, Quebec, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Royal University, Saskatoon, Saskatchewan, Canada|Saskatoon City Hospital, Saskatoon, Saskatchewan, Canada|St Paul's Hospital, Saskatoon, Saskatchewan, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""200000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Confirmed COVID-19 diagnosis|Hospital admission|Mechanical ventilation|Emergency department revisits|Hospital re-admissions|30 day mortality|Clinical recovery|Patient quality of life""}"
"1167","COVID-19 PCR Test Results in Asymptomatic Pregnants","","NCT04410939","Gpolat1","Diagnostic Test: Reverse transcription polymerase chain reaction","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04410939","Completed","2020-04-10","2020-05-21","{""locations"":""Istanbul Medipol University, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Retrospective"",""enrollment"":""179"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Rate of positive COVID-19 cases in asymptomatic pregnant women""}"
"1168","Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant","","NCT04368988","2019nCoV-101","Biological: SARS-CoV-2 rS - Phase 1|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Other: Normal saline solution (NSS), Placebo - Phase 1|Other: Normal saline solution (NSS), Placebo - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2|Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2|Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04368988","Active, not recruiting","2020-05-25","2021-11-18","{""locations"":""Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Phase 2, Savannah, Georgia, United States|Advanced Clinical Research - Meridian - ERN-PPDS - Phase 2, Meridian, Idaho, United States|Alliance for Multispecialty Research, LLC - Phase 2, Newton, Kansas, United States|Alliance for Multispecialty Research, LLC - Phase 2, Wichita, Kansas, United States|Central Kentucky Research Associates Inc - Phase 2, Lexington, Kentucky, United States|Meridian Clinical Research-(Rockville Maryland) - Platinum - PPDS - Phase 2, Rockville, Maryland, United States|Synexus Clinical Research US, Inc. - Cincinnati - Phase 2, Cincinnati, Ohio, United States|Rapid Medical Research Inc - ERN-PPDS - Phase 2, Cleveland, Ohio, United States|Paratus Clinical Research - Canberra - Phase 2, Bruce, Australian Capital Territory, Australia|Paratus Clinical Research - Western Sydney - Phase 2, Blacktown, New South Wales, Australia|Paratus Clinical Research - Central Coast - Phase 2, Kanwal, New South Wales, Australia|Australian Clinical Research Network - Phase 2, Maroubra, New South Wales, Australia|Scientia Clinical Research Limited - Phase 2, Randwick, New South Wales, Australia|Q Pharm Pty Limited - Phase 1, Herston, Queensland, Australia|University of the Sunshine Coast, Health Hub Morayfield - Phase 2, Morayfield, Queensland, Australia|University of the Sunshine Coast - Phase 2, Sippy Downs, Queensland, Australia|Barwon Health - Phase 2, Geelong, Victoria, Australia|Center for Clinical Studies - Phase 1 and Phase 2, Melbourne, Victoria, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1419"",""age"":""18 Years to 84 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participants with Solicited Adverse Events (AEs) - Phase 1|Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1|Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1|Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1|Serum IgG Antibody Levels Expressed as GMTs - Phase 2|Serum IgG Antibody Levels Expressed as GMFRs - Phase 2|Serum IgG Antibody Levels Expressed as SCRs - Phase 2|Participants with Solicited Adverse Events (AEs) - Phase 2|Participants with Unsolicited AEs - Phase 2|Participants with Unsolicited AEs - Phase 1|Participants with Abnormal Vital Signs - Phase 1|Changes from Baseline in Body Temperature - Phase 1|Changes from Baseline in Blood Pressure - Phase 1|Changes from Baseline in Pulse Rate - Phase 1|Participants with MAAEs - Phase 1|Participants with Related MAAEs; Serious Adverse Events (SAEs); and Adverse Events of Special Interest (AESI) - Phase 1|Assessment of Serum IgG Antibody Levels Expressed as GMTs at Multiple Time Points - Phase 1|Assessment of Serum IgG Antibody Levels Expressed as GMFRs at Multiple Time Points - Phase 1|Assessment of Serum IgG Antibody Levels Expressed as SCRs at Multiple Time Points - Phase 1|Assessment of Serum IgG Antibody Levels Expressed by Seroresponse Rates (SRRs) at Multiple Time Points - Phase 1|Angiotensin-Converting Enzyme 2 (ACE2) Receptor Binding Inhibition Assay Expressed as GMTs - Phase 1|ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs - Phase 1|ACE2 Receptor Binding Inhibition Assay Expressed as SCRs - Phase 1|ACE2 Receptor Binding Inhibition Assay Expressed as SRRs - Phase 1|Neutralizing Antibody Activity Expressed as GMTs - Phase 1|Neutralizing Antibody Activity Expressed as GMFRs - Phase 1|Neutralizing Antibody Activity Expressed as SCRs - Phase 1|Neutralizing Antibody Activity Expressed as SRRs - Phase 1|Assessment of Cell-Mediated (T helper 1 [Th1]\/T helper 2 [Th2]) Pathways - Phase 1|Assessment of Serum IgG Antibody Levels Expressed as GMTs - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as GMFRs - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as SCRs (\u2265 4-fold change) - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as GMTs at Multiple Time Points - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as GMFRs at Multiple Time Points - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as SCRs (\u2265 4-fold change) at Multiple Time Points - Phase 2|ACE2 Receptor Binding Inhibition Assay Expressed as GMTs - Phase 2|ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs - Phase 2|ACE2 Receptor Binding Inhibition Assay Expressed as SCRs - Phase 2|Neutralizing Antibody Activity Expressed as GMTs - Phase 2|Neutralizing Antibody Activity Expressed as GMFRs - Phase 2|Neutralizing Antibody Activity Expressed as SCRs (\u2265 4-fold change) - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as GMTs - Phase 2 Boost|Assessment of Serum IgG Antibody Levels Expressed as GMFRs - Phase 2 Boost|Participants with MAAEs - Phase 2|Participants with Related MAAEs; SAEs; and AESIs - Phase 2|Participants with Abnormal Vital Signs - Phase 2|Changes from Baseline in Body Temperature - Phase 2|Changes from Baseline in Blood Pressure - Phase 2|Changes from Baseline in Pulse Rate - Phase 2|Participants with SARS-CoV-2 Positivity - Phase 2|Assessment of SARS-CoV-2 by Qualitative PCR - Phase 2|Assessment of Cell-Mediated (Th1\/Th2) Pathways - Phase 2""}"
"1169","Prognostic Models for COVID-19 Care","","NCT04689711","PCORI-ME-1606-35555","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04689711","Enrolling by invitation","2020-12-07","2021-08-31","{""locations"":""Tufts Medical Center, Boston, Massachusetts, United States|Northwell Health (The Feinstein Institutes for Medical Research), Manhasset, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""16"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in model discrimination (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model discrimination (Model 2: mortality in patients receiving MV)|Changes in model discrimination (Model 3: length of stay in the ICU)|Changes in model calibration (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model calibration (Model 2: mortality in patients receiving MV)|Changes in model calibration (Model 3: length of stay in the ICU)|Changes in net benefit (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in net benefit (Model 2: mortality in patients receiving MV)|Changes in net benefit (Model 3: length of stay in the ICU)|Changes in model discrimination in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model discrimination in external database after updating (Model 2: mortality in patients receiving MV)|Changes in model discrimination in external database after updating (Model 3: length of stay in the ICU)|Changes in model calibration in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model calibration in external database after updating (Model 2: mortality in patients receiving MV)|Changes in model calibration in external database after updating (Model 3: length of stay in the ICU)|Changes in net benefit in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in net benefit in external database after updating (Model 2: mortality in patients receiving MV)|Changes in net benefit in external database after updating (Model 3: length of stay in the ICU)|Stakeholder perceptions, beliefs and opinions on COVID prediction models""}"
"1170","SuPAR in Adult Patients With Covid-19","SPARCOL","NCT04590794","UTHDA-AC03","Diagnostic Test: Soluble Urokinase Plasminogen Activator Receptor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04590794","Active, not recruiting","2020-10-11","2021-04-02","{""locations"":""University Hospital of Larisa, Department of Anesthesiology, Larissa, Thessaly, Greece"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""respiratory complications|Hypotension|need for vasoactive drugs|Number of participants with acute new cardiovascular disorder|Number of participants with organ failure|Number of participants with overall survival up to 8 weeks""}"
"1171","Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation","JAKINCOV","NCT04366232","2020-CHITS-003|2020-001963-10","Drug: Anakinra alone (stages 2b/3)|Drug: Anakinra and Ruxolitinib (overcome stage 3)|Other: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04366232","Terminated","2020-08-19","2020-10-02","{""locations"":""AP-HM, H\u00f4pital de la Conception, Marseille, Bouches-du-Rh\u00f4ne, France|H\u00f4pital Sainte-Musse, Toulon, VAR, France|Sainte Anne Teaching Military Hospital, Toulon, Var, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Biological criteria|Duration of oxygen therapy (days)|Number of intensive care units admissions|Number of days in intensive care units|Mortality rate|Total number of days in hospital|Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score)|Number of bacterial and\/or fungal sepsis""}"
"1172","Treat COVID-19 Patients With Regadenoson","","NCT04606069","HP-00091372","Drug: Regadenoson|Other: Placebo Control","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04606069","Not yet recruiting","2020-11-01","2022-01-31","{""locations"":""University of Maryland Medical Center, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients alive and free of respiratory failure through the 30-day trial.|Change of the levels of the inflammatory cytokines prior, during and post drug infusion.|Change of the levels of MMP-2 and MMP-9 prior, during and post drug infusion.""}"
"1173","Low Dose Radiation Therapy for Covid-19 Pneumonia","","NCT04394793","COVID-AIIMS","Radiation: Low dose radiation therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04394793","Active, not recruiting","2020-06-13","2020-09-01","{""locations"":""All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptomatic improvement by National Early warning score (NEWS)|Length of hospital stay|Number of ICU admissions or deaths""}"
"1174","Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients","NIV COVID19","NCT04715243","SQU-EC/206/2020","Device: High flow nasal cannula (HFNC)|Device: Helmet NIV|Device: Face-mask NIV","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04715243","Recruiting","2021-01-01","2021-07-30","{""locations"":""Sultan Qaboos University Hospital, Muscat, Oman"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""360"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of endotracheal intubation|Hospital mortality|Hospital length of stay|Ventilator free days""}"
"1175","Northern Colorado COVID-19 Biobank","NoCo-CoBio","NCT04603677","20-10063H","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04603677","Enrolling by invitation","2020-07-08","2022-07-30","{""locations"":""Colorado State University, Fort Collins, Colorado, United States|Poudre Valley Hospital, UCHealth, Fort Collins, Colorado, United States|Greeley Hospital, UCHealth, Greeley, Colorado, United States|Medical Center of the Rockies, UCHealth, Loveland, Colorado, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease""}"
"1176","Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19","RASCOVID-19","NCT04351581","H-20026484|2020-001544-26","Other: Discontinuation of ACEi/ARB|Other: Continuation of ACEi/ARB","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04351581","Recruiting","2020-05-18","2020-12-01","{""locations"":""Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Capital Region Of Denmark, Denmark|Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Capital Region Of Denmark, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""215"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days alive and out of hospital within 14 days after recruitment|Key-secondary composite endpoint: Occurrence of worsening of COVID-19|Occurrence and time to occurrence of each of the components of the key-secondary composite endpoint|Kidney function assessed by plasma creatinine|Duration of index hospitalisation|30-day mortality|Number of days alive during the intervention period|Number of participants not yet discharged at day 30|Number of readmissions after 30 days.|Kidney function as assessed by eGFR""}"
"1177","EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","TEACHCOVID","NCT04347512","7783","Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04347512","Withdrawn","2020-06-02","2020-06-02","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of patients reaching a significant hypoxemia, in each arms.""}"
"1178","COVID-19 Risk From Attending Outpatient Radiology Appointments","","NCT04544176","20NS031","Other: Observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04544176","Completed","2020-01-01","2021-01-01","{""locations"":""Nottingham University Hospitals, NHS Trust, Nottingham, Nottinghamshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""48000"",""age"":""16 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""A microbiological diagnosis of COVID infection.""}"
"1179","Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure","","NCT04353206","Acute Care CP Consortium Trial","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04353206","Recruiting","2020-06-27","2021-05-01","{""locations"":""8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.""}"
"1180","Extracorporeal Blood Purification as a Treatment Modality for COVID-19","","NCT04478539","EBPZ.357","Device: Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04478539","Recruiting","2020-06-01","2021-07-01","{""locations"":""Zan Mitrev Clinic, Skopje, North Macedonia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""35"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in cytokine levels of Interleukin (IL) 6, IL-8 and Tumor Necrosis Factor-\u03b1 (pg\/mL)|Changes in inflammatory markers; C-Reactive Protein (CRP) (mg\/L)|Changes in thrombocyte counts (10^3 counts\/microL)|Changes in the coagulation marker Fibrinogen (g\/L)|ICU length of stay after admission (days)|Changes in Neutrophil-to-Lymphocyte Ratio|Changes in the coagulation marker D-Dimers (ng\/mL)|Changes in the Activation Clotting Time (seconds).""}"
"1181","The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation","","NCT04377750","0224-20-HMO-CTIL","Drug: Tocilizumab","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04377750","Recruiting","2020-04-08","2021-05-08","{""locations"":""Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel|Barzilai Medical Center, Ashkelon, Israel|Wolfson Medical Center, H\u0331olon, Israel|Sheba Medical Center, Ramat Gan, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival""}"
"1182","Dysautonomia in Patients Post COVID-19 Infection","DYSCO","NCT04716465","DYSCO","Other: Dysautonomia","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04716465","Recruiting","2021-01-19","2023-01-01","{""locations"":""Universitair Ziekenhuis Brussel, Jette, Brussel, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Heart rate variability|Electrodermal activity|Respiration rate|Blood volume pulse|Functionality and disability""}"
"1183","CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome","CACOLAC","NCT04404426","35RC20_9815_CACOLAC|CPP 1288 HPS1|2020-A01189-30","Dietary Supplement: L-citrulline|Other: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04404426","Recruiting","2020-11-02","2021-09-15","{""locations"":""Rennes University Hospital, Rennes, Britanny, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SOFA|Number and phenotype of lymphocytes|HLA-DR|Number of Myeloid-derived suppressor cells|Plasma cytokines \/ chemokines|Repertoire T|Lymphocyte T exhaustion|Mitochondrial activity|Plasma amino acids|Duration of hospitalization in intensive care|Duration of hospital stay in hospital|Duration of mechanical ventilation|Mortality in intensive care on day 28|Hospital mortality on day 28|Measurement of the presence of SARS-CoV2|Nosocomial infections|Number of days of exposure to each antibiotic per 1000 days of hospitalization""}"
"1184","Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19","","NCT04459325","DRN-ALI-III|#216 eff date 27.05.2020","Biological: Tigerase® and best available care|Other: Best available care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04459325","Completed","2020-06-01","2020-07-20","{""locations"":""City Clinical Hospital #15, Moscow, Russian Federation|I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation|City Clinical Hospital #51, Moscow, Russian Federation|City Clinical Hospital #52, Moscow, Russian Federation|N.V. Sklifosovsky Scientific Research Institute of First Aid, Moscow, Russian Federation|Siberian State Medical University (SibMed), Moscow, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of patients with mechanical ventilation|Category change on WHO Ordinal Scale for Clinical Improvement|Proportion of patients surviving 28 days after inclusion in the study|Number of days of oxygen therapy during the treatment period|Change in C-reactive protein level|Change in oxygenation index|Change in SpO2\/FiO2 index|Change in ferritin level|Change in D-dimer level|Change in neutrophil-leucocyte ratio|Change in leucocyte-C-reactive protein ratio|Change in the level of relative (%) number of lymphocytes of the general blood test""}"
"1185","Nasal Irrigation to Reduce COVID-19 Morbidity","","NCT04559035","1603291","Other: Nasal lavage","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04559035","Enrolling by invitation","2020-09-24","2020-12-31","{""locations"":""Augusta University, Augusta, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""55 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency|Reduction""}"
"1186","Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales","","NCT04674644","355","Behavioral: The psychosocial effects of COVID-19 pandemic on dental professionals","Interventional","Has Results","Not Applicable","https://ClinicalTrials.gov/show/NCT04674644","Completed","2020-10-16","2020-10-23","{""locations"":""Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department, Isparta, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""850"",""age"":""23 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 Scale|The Psychosocial Effects of COVID-19 Pandemic Using the Turkish Version of the Coronavirus Anxiety Scale""}"
"1187","COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures","","NCT04649333","20200609","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649333","Completed","2020-06-15","2020-08-31","{""locations"":""Medical University Innsbruck, Innsbruck, Tyrol, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1336"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The type, extent and intensity of physical activity""}"
"1188","COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes","COVID-PRICE","NCT04659759","20F.1043","Other: COVID-19 exposure|Biological: COVID-19 vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659759","Recruiting","2020-11-17","2022-06-30","{""locations"":""Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Maternal COVID-19 serology (IgG and IgM)|Maternal\/neonatal IgG and IgM concordance|Maternal COVID serology time\/profile following vaccination|Breastmilk Serology|Cytokine|Neonatal cytokine|COVID disease vs vaccination immune response|COVID vaccine in pregnant vs nonpregnant""}"
"1189","Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.","Prolectin-M","NCT04512027","CIMED - 002- 2020","Other: Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|Other: Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04512027","Completed","2020-09-15","2020-10-16","{""locations"":""Mazumdar Shaw Medical Centre, Bangalore, Karnataka, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""SarsCoV2 viral copy number|b. Disease progression will be measured on a 7-point scale at 28 days. A 2-point change will be considered disease progression.""}"
"1190","Long-term Effects of COVID-19 in Adolescents","LoTECA","NCT04686734","LoTECA","Other: No active intervention (observational only)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04686734","Not yet recruiting","2021-01-06","2021-10-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""12 Years to 25 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Fatigue""}"
"1191","N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia","","NCT04487951","2020-7-1","Other: Pro BNP , Vitamin D","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04487951","Recruiting","2020-07-01","2021-01-01","{""locations"":""Kasr Alainy Cairo University, Cairo, Giza, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""NT-pro-BNP and Vitamin D|Assessment of any possible correlation between NT-pro-BNP and Vitamin D and the need for mechanical ventilation or mortality in COVID-19 infection""}"
"1192","Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19","","NCT04425837","PLASMA COVID-19","Biological: SARS-CoV-2 convalescent plasma treatment|Other: Standard care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04425837","Not yet recruiting","2020-07-01","2021-02-01","{""locations"":""Fundaci\u00f3n Santa Fe de Bogot\u00e1, Bogot\u00e1, Cundinamarca, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""236"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Adverse events|ICU admission|Mechanical ventilation|ICU length|Reduction of D Dimer|LDH reduction|Reduction of Troponin level|Decrease in ferritin level|Decrease in procalcitonin level|Decrease in CRP|Increase in lymphocyte count|Increase in PaO2 \/ Fio2|Decrease in Sequential Organ failure assessment (SOFA ) score|Extracorporeal membrane oxygenation (ECMO)|Lung infiltration""}"
"1193","Surgery in the Time of COVID-19 Pandemic","","NCT04684433","CHUB-Farid","Other: Data extraction from medical files","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04684433","Recruiting","2020-04-14","2020-12-31","{""locations"":""St Pierre, Brussels, Belgium|CHU Brugmann, Brussels, Belgium|Erasme, Brussels, Belgium|UZ Brussel, Brussel, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""707"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Surgery code|Urgency|Type of anesthesia|Delay between surgery and first symptoms|Surgery duration|Hospital stay (in days)|Intensive care unit stay (in days)|Post-op complications|Covid status before surgery|Covid status post-surgery|COVID19 Diagnosis by CT scan|COVID19 Diagnosis by swab test|COVID 19 Diagnosis by antibody test|COVID19 symptoms - dry cough|COVID19 symptoms - fever|COVID19 symptoms - myalgia|COVID19 symptoms - anosmia|COVID19 symptoms -respiratory distress|Treatment for COVID19 - Plaquenil|Treatment for COVID19 - Antivirals|Need for intubation|Death|Age|Gender|Ethnicity|BMI|Comorbidities""}"
"1194","Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia","","NCT04459676","ANG3777-ALI-201","Drug: Standard of Care (SOC) + ANG-3777|Drug: Standard Of Care (SOC) + Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04459676","Recruiting","2020-07-31","2020-10-01","{""locations"":""UPCLIN - Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, Brazil|Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo (HCFMRP), Ribeir\u00e3o Preto, Brazil|Hospital Guilherme Alvaro, Santos, Brazil|Escola Paulista de Medicina (Universidade Federal de S\u00e3o Paulo), S\u00e3o Paulo, Brazil|Hospital Alemao Oswaldo Cruz, S\u00e3o Paulo, Brazil|Hospital Heli\u00f3polis-SP, S\u00e3o Paulo, Brazil|Santa Casa de Misericordia de Sao Paulo, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients alive, without the need for mechanical ventilation and free of the need for RRT (on an ongoing basis) at Day 28""}"
"1195","COVID-19 Impact on the Lombardy Region's Emergency System","","NCT04669925","Tsunami","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04669925","Active, not recruiting","2020-09-01","2021-07-01","{""locations"":""Ospedale Papa Giovanni XXIII, Bergamo, Italy|Presidio Ospedaliero di Lodi, Lodi, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|Ospedale San Carlo Borromeo, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Daily calls to the Emergency System|Daily count of Emergency Department visits|Daily average boarding time|Outcome at ED discharge|Mortality""}"
"1196","Diagnosis of Endocrine Dysfunctions in Covid-19","Dyhor-19","NCT04587375","RECHMPL20_0205","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04587375","Completed","2020-03-01","2020-05-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Plasma aldosterone levels|Plasma renin levels|covid-19 infection severity|Maximum severity of Covid-19 infection|Plasma aldosterone level|Plasma ACTH level|Plasma cortisol level|Plasma T3l level|Plasma LH level|Plasma DHEA level|Plasma estradiol (female) or testosterone (male) level|Plasma FSH level|type of treatments|Clinical characteristics|radiological characteristics""}"
"1197","ACTIV-3: Therapeutics for Inpatients With COVID-19","TICO","NCT04501978","014 / ACTIV-3","Biological: LY3819253|Drug: Placebo|Biological: Remdesivir|Biological: VIR-7831|Biological: BRII-196/BRII-198|Biological: AZD7442","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04501978","Recruiting","2020-08-04","2022-07-01","{""locations"":""Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States|Southern Arizona VA Health Care System (Site 074-009), 3601 S. 6th Ave., Tucson, Arizona, United States|Community Regional Medical Center (Site 203-005), 2823 Fresno Street, Fresno, California, United States|VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street, Loma Linda, California, United States|Keck Hospital of USC (Site 301-020), 1500 San Pablo Street, Los Angeles, California, United States|Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd., Los Angeles, California, United States|Mount Zion Hospital, UCSF Medical Center (Site 203-007), 1600 Divisadero St., San Francisco, California, United States|San Francisco VA Healthcare System (Site 074-002), 4150 Clement St., San Francisco, California, United States|Moffitt-Long Hospital, UCSF Medical Center (Site 203-001), 505 Parnassus Ave., San Francisco, California, United States|Stanford University Hospital & Cinics (Site 203-003), 300 Pasteur Dr., Stanford, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson Street, Torrance, California, United States|University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue, Aurora, Colorado, United States|Denver Public Health (Site 017-004), 605 Bannock St., MC2600 (Infectious Disease Clinic), Denver, Colorado, United States|National Jewish Health (Site 204-003), 1400 Jackson Street, Denver, Colorado, United States|MedStar Georgetown University Hospital (Site 067-001), 3800 Reservoir Road NW, Washington, District of Columbia, United States|VA Medical Center (Site 009-004), 50 Irving Street NW, Washington, District of Columbia, United States|Bay Pines VA Healthcare System (Site 074-004), 10000 Bay Pines Blvd., Bldg. 100, Room 5B-104, Bay Pines, Florida, United States|Baycare Health System (Site 301-025), Morton Plant Hospital, 300 Pinellas Street, Clearwater, Florida, United States|Memorial Healthcare System (Site 648-002), Memorial Regional Hospital, 3501 Johnson Street, Hollywood, Florida, United States|Miami VA Healthcare System (Site 074-003), 1201 NW 16 Street, Miami, Florida, United States|The Emory Clinic (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE, Atlanta, Georgia, United States|Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard, Fort Wayne, Indiana, United States|University of Kentucky Hospital (Site 210-004), 1000 South Limestone St., Lexington, Kentucky, United States|Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway, New Orleans, Louisiana, United States|University of Maryland (Site 301-019), 22 South Greene Street, Baltimore, Maryland, United States|Massachusetts General Hospital (Site 202-002), 55 Fruit Street, Boston, Massachusetts, United States|Baystate Medical Center (Site 201-001), 759 Chestnut Street, Springfield, Massachusetts, United States|University of Michigan (Site 205-001), 1500 East Medical Center Drive, Ann Arbor, Michigan, United States|Henry Ford Health System, Henry Ford Hospital (Site 014-001), 2799 W. Grand Blvd., Detroit, Michigan, United States|Allina Health System, dba Abbott Northwestern Hospital (Site 301-026), 800 East 28th Street, Minneapolis, Minnesota, United States|Hennepin Healthcare (Site 027-001), 701 Park Avenue, Minneapolis, Minnesota, United States|Minneapolis VA Health Care System (Site 105-001), 1 Veterans Drive, Bldg 70, Minneapolis, Minnesota, United States|University of Mississippi Medical Center (Site 202-005), 2500 North State Street, Jackson, Mississippi, United States|Dartmouth-Hitchcock Medical Center\/Mary Hitchcock Memorial Hospital (Site 301-024), One Medical Center Drive, Lebanon, New Hampshire, United States|Lincoln Medical Center (New York Health and Hospitals\/Lincoln) (Site 003-016), 234 E. 149th Street, Bronx, New York, United States|Montefiore Medical Center Weiler Hospital (Site 206-003), 1825 Eastchester Road, Bronx, New York, United States|Montefiore Medical Center Moses Hospital (Site 206-001), 111 E. 210th Street, Bronx, New York, United States|Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States|Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center (Site 207-003), 234 Goodman Ave., Cincinnati, Ohio, United States|Cleveland Clinic Fairview Hospital (Site 207-005), 18101 Lorain Avenue, Cleveland, Ohio, United States|Cleveland Clinic Foundation (Site 207-001), 9500 Euclid Avenue, Cleveland, Ohio, United States|Cleveland Clinic Marymount Hospital (Site 207-006), 12300 McCraken Road, Garfield Heights, Ohio, United States|Oregon Health & Science University (Site 208-003), 3181 SW Sam Jackson Park Rd., Portland, Oregon, United States|UPMC Presbyterian Hospital (Site 209-001), 200 Lothrop Street, Pittsburgh, Pennsylvania, United States|VA Tennessee Valley Healthcare System (TVHS) Nashville Campus (Site 074-022), 1310 24th Avenue South, Nashville, Tennessee, United States|Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive, Nashville, Tennessee, United States|UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor, Dallas, Texas, United States|Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave., Dallas, Texas, United States|Memorial Hermann Hospital (Site 203-006), 6411 Fannin Street, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center (MEDV AMC) (Site 074-006), 2002 Holcombe Blvd., Houston, Texas, United States|Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street, Murray, Utah, United States|University of Utah Health (Site 211-002), 419 Wakara Way, Suite 207, Salt Lake City, Utah, United States|LDS Hospital (Site 211-004), 8th Ave. C Street, Salt Lake City, Utah, United States|University of Virginia (Site 301-021), 1215 Lee Street, Charlottesville, Virginia, United States|Virginia Commonwealth University Health System (Site 210-005), 1250 East Marshall Street, Richmond, Virginia, United States|Salem VA Medical Center (Site 074-014), 1970 Roanoke Blvd., Salem, Virginia, United States|Harborview Medical Center (Site 208-001), 325 9th Avenue, Seattle, Washington, United States|Swedish Medical Center (Site 208-005), 747 Broadway, Seattle, Washington, United States|University of Washington Medical Center - Montlake (Site 208-006), 1959 NE Pacific Street, Seattle, Washington, United States|WVU Medicine (Site 301-023), One Medical Center Drive, Morgantown, West Virginia, United States|Aalborg University Hospital (Site 625-005), Hobrovej 18, Aalborg, Denmark|Department of Infectious Diseases (Site 625-002), Aarhus University Hospital, Skejby, Palle Juul-Hensens Boulevard 99, Aarhus N, Denmark|Righospitalet (Site 625-006), Blegdamsvej 9,, Copenhagen \u00d8, Denmark|Bispebjerg Hospital (Site 625-013), Bispebjerg Bakke 23, Copenhagen, Denmark|Herlev Hospital (Site 625-012), Medicinsk Afdeling, Herlev Ringvej 75, Herlev, Denmark|Nordsj\u00e6llands Hospital (Site 625-009), Dyrehavevej 29, Hiller\u00f8d, Denmark|Hvidovre Hospital (Site 625-001), Department of Infectious Diseases, Ketteg\u00e5rd all\u00e9 30, Hvidovre, Denmark|Medicinsk Afdeling (Site 625-011), Kolding Sygehus, Sygehusvej 24, Kolding, Denmark|Odense Universitetshospital (Site 625-004), Infektionsmedicinsk Forskningsenhed,J.B. Winsl\u00f8wsgade 4, Odense, Denmark|Zealand University Hospital, Roskilde (Site 625-010), Sygehusvej 10, Roskilde, Denmark|Chennai Antiviral Research and Treatment Clinical Research Site (Site 612-402), VHS-IDMC, Voluntary Health Services, Rajiv Gandhi Salai, Taramani, Chennai, Tamil Nadu, India|Wojew\u00f3dzki Szpital Zakazny (Site 625-302), Wolska 37, Warsaw, Poland|Tan Tock Seng Hospital (Site 612-201), National Centre for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng, Singapore, Singapore|Germans Trias i Pujol Hospital (Site 626-003), Unidad de enfermedades infecciosas, Carretera de Canyet s\/n, Badalona, Barcelona, Spain|Hospital Del Mar (Site 626-025), Paseo Maritimo 25-29, Barcelona, Spain|Hospital Cl\u00ednic de Barcelona (Site 626-004), Carrer de Villaroel 170, Barcelona, Spain|Hospital General Universitario Gregorio Mara\u00f1\u00f3n (Site 626-001), Dr. Esquerdo, 46, Madrid, Spain|Hospital Clinico San Carlos (Site 626-017), Enfermedades infecciosas, C\/Martin Lagos CN, Madrid, Spain|UCICEC (Clinical Trial Unit) Hospital Universitario La Paz (Site 626-012), Paseo de la Castellana 261, 2\u00b0 planta Hospital Maternal, Madrid, Spain|University Hospital Zurich (Site 621-201), Department of Infectious Diseases and Hospital Epidemiology, Raemistrasse 100, Z\u00fcrich, Zurich, Switzerland|Royal Free Hospital (Site 634-006), Dept. of Infectious Diseases \/ HIV Medicine, Pond Street, Hampstead, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time from randomization to sustained recovery|All-cause mortality|Composite of time to sustained recovery and mortality|Days alive outside short-term acute care hospital|Pulmonary ordinal outcome|Pulmonary+ ordinal outcome|Incidence of clinical organ failure|Composite of death or serious clinical COVID-19 related events|Composite of cardiovascular events and thromboembolic events|Composite of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death|Incidence of infusion reactions|Composite of SAEs or death|Change in SARS-CoV-2 neutralizing antibody levels|Change in overall titers of antibodies|Change in neutralizing antibody levels|Incidence of home use of supplemental oxygen above pre-morbid oxygen use|Incidence of no home use of supplemental oxygen above pre-morbid oxygen use""}"
"1198","COVID-19 Vaccine Messaging, Part 1","","NCT04460703","2000027983","Other: Control message|Other: Baseline message|Other: Personal freedom message|Other: Economic freedom message|Other: Self-interest message|Other: Community interest message|Other: Economic benefit message|Other: Guilt message|Other: Embarrassment message|Other: Anger message|Other: Trust in science message|Other: Not bravery message","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04460703","Completed","2020-07-03","2020-07-08","{""locations"":""Yale University, New Haven, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intention to get COVID-19 vaccine|Vaccine confidence scale|Persuade others item|Fear of those who have not been vaccinated|Social judgment of those who do not vaccinate""}"
"1199","Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva","SALICOV","NCT04578509","APHP200960|2020-A02431-38","Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Saliva sample|Other: Data collection|Diagnostic Test: axillary sweat sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04578509","Recruiting","2020-10-19","2021-06-01","{""locations"":""SARS-CoV-2 screening device of Assistance Publique des H\u00f4pitaux de Paris (AP-HP), Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2750"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Positivity of RT-PCR on nasopharyngeal swab for the SARS-CoV-2 virus|Positivity of RT-PCR on saliva sample for the SARS-CoV-2 virus|Positivity of new detection approach on saliva sample for the SARS-CoV-2 virus|Positivity of antigenic test on nasopharyngeal swab for the SARS-CoV-2 virus|Practicability to samples|Practicability to premises|Practicability to interpretation|Practicability to render time|IgG Antibody detection in saliva|IgM Antibody detection in saliva|IgA Antibody detection in saliva|Positivity of canine olfactory detection of SARS-CoV-2|Patient tolerance of the salivary self-sampling|Operator tolerance of the salivary self-sampling|Cost of each approach""}"
"1200","Covid-19 Rapid Diagnostic Tests on Blood Drop","COVID-TEST","NCT04467008","2020/05","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04467008","Completed","2020-07-15","2020-08-15","{""locations"":""CMC Ambroise Par\u00e9, Neuilly-sur-Seine, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""113"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Positivity of the rapid diagnostic test""}"
"1201","Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19","DHYSCO","NCT04347980","2037815010","Drug: Dexamethasone and Hydroxychloroquine|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04347980","Recruiting","2020-04-01","2020-08-01","{""locations"":""Reanimation adulte. Hopital Marie Lannelongue, Le Plessis-Robinson, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""122"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Day-28 mortality|Ventilator-free days|Intensive Care Unit mortality|Day-60 mortality|Nosocomial pneumonia|Bacteremia""}"
"1202","Emergency Ventilator Splitting Between Two or More Patients (COVID-19)","","NCT04381013","57573","Device: Emergency Ventilator Splitter","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04381013","Not yet recruiting","2021-03-01","2021-04-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility"",""enrollment"":""4"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Completion of 1-minute test|Completion of 24-hour test""}"
"1203","Swallowing Impairment After COVID-19 Infection","","NCT04537650","CAPCR 20-5477|3R01DC011020-08S1","Diagnostic Test: Videofluoroscopic Swallowing Study (VFSS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04537650","Enrolling by invitation","2021-01-01","2021-12-31","{""locations"":""University of Florida, Gainesville, Florida, United States|McMaster University, Hamilton, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Swallowing safety|Swallowing efficiency|Time-to-Laryngeal-Vestibule-Closure|Laryngeal Vestibule Closure duration|Pharyngeal Constriction""}"
"1204","International ALLIANCE Study of Therapies to Prevent Progression of COVID-19","","NCT04395768","Alliance-COVID19","Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04395768","Recruiting","2020-09-09","2021-12-31","{""locations"":""National Institute of Integrative Medicine, Melbourne, Victoria, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support""}"
"1205","COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19","COVIDISC","NCT04703140","2020/09","Diagnostic Test: Rapid Diagnostic Test vs PCR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04703140","Recruiting","2021-02-11","2022-09-11","{""locations"":""CHI Robert Ballanger, Aulnay-sous-Bois, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparaison of the performance of the diagnostic performance (sensitivity, sensibility) of RT-LAMP test using the RT-PCR test as a reference.|Compare the diagnostic performances of RT-LAMP to clinical diagnosis.""}"
"1206","Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)","Isotretinoin","NCT04353180","Proposed by Mahmoud Elkazzaz","Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Drug: Isotretinoin (13 cis retinoic acid ) capsules|Drug: Aerosolized 13 cis retinoic acid|Drug: Standard treatment","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04353180","Not yet recruiting","2021-03-01","2021-07-01","{""locations"":""Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100000"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|Absolute lymphocyte counts (CD4,CD8 and CD25+FOXP3+ Regulatory T)|Serum levels of IL-6,TNF,TLR3,CRP, ESR and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme II (ACE2) changes over time|Frequency of adverse events and severe adverse events|Angiotensin II (Ang II) changes over time|Sequential organ failure assessment score(SOFA score) over time|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Thrombin time (TT)|IgA antibodies|Melanoma differentiation-associated protein-5, retinoic acid inducible gene-1 (RIG-1)""}"
"1207","Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia","MICOV","NCT04380376","PSRI05-20","Drug: Melphalan|Other: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04380376","Recruiting","2020-04-30","2020-10-30","{""locations"":""Kirill Zykov, Moscow, Russian Federation|Clinical hospital, Moscow, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The changes of COVID Ordinal Outcomes Scale|Percentage of the patients with Clinical Recovery|The changes of the Borg's scale|CRP level|Lymphocyte count|D-dimer|IL-6|Percentage of patients without artificial lung ventilation""}"
"1208","Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial","","NCT04548557","UniversityHSL-IVIG","Biological: intravenous immunoglobulin therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04548557","Not yet recruiting","2020-09-15","2020-11-15","{""locations"":""University of Health Sciences, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In hospital days|14 day mortality|D-dimers|C-reactive protein|Oxygen saturation|TNF alpha|IL-6|Ferritin|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0""}"
"1209","A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","","NCT04412291","2020-001748-24","Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04412291","Recruiting","2020-06-11","2021-06-01","{""locations"":""Karolinska University Hospital, Huddinge, Stockholm, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery|Mortality|Number of Days on mechanical ventilation|Number of days of supplemental oxygen use|Number of patients requiring initiation of mechanical ventilation|Time to improvement in oxygenation for at least 48 hours|Mean change in the 8-point ordinal scale|Proportion of patients on level e-h on the 8-point ordinal scale at day 15|Time to improvement in one category from baseline using the 8-point ordinal scale|Mean change in Sequential organ failure assessment score (SOFA)|Time to resolution of fever for at least 48 hours by clinical severity|Time to improvement of three points from baseline in National Early Warning Score 2 (NEWS2) scoring system|Time to score of <2 maintained for 24 hours in NEWS2 scoring system (National Early Warning Score)|Mean change in NEWS2 scoring system (National Early Warning Score)|Number of days with fever.|Number of days of resting respiratory rate >24 breaths\/min|Time to saturation \u226594% on room air|Cumulative dose of steroids; equivalent to betamethasone dosage (mg)|Cumulative dose of steroids during the study; equivalent to betamethasone dosage (mg)|Incidence of serious adverse events|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Number of ventilator free days in the first 28 days|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients requiring Extracorporeal membrane oxygenation (ECMO)|Number of patients that have been admitted into an intensive care unit (ICU)|Number of patients that have been admitted into a High Dependency Unit (\""Intermedi\u00e4rv\u00e5rdsavdelning\"")|Number of days admitted into a High Dependency Unit (\""Intermedi\u00e4rv\u00e5rdsavdelning\"") or intensive care unit (ICU) [|Number of days of hospitalization in survivors|Number of patients discharged to institution other than normal domicile.|Number of deaths due to any cause""}"
"1210","Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19","","NCT04603651","18165|J2X-MC-Y001","Drug: Bamlanivimab","Expanded Access:Individual Patients","No Results Available","","https://ClinicalTrials.gov/show/NCT04603651","No longer available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""""}"
"1211","Montelukast - a Treatment Choice for COVID-19","","NCT04714515","01032020-7","Drug: Montelukast|Drug: Hydroxychloroquine|Drug: Ivermectin","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04714515","Completed","2020-02-20","2020-04-20","{""locations"":""Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China, Shanghai, China|Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""150"",""age"":""20 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients admittance to ICU|Length of total stay at the hospital|Alleviating the symptoms of COVID-19|Interleukin levels""}"
"1212","COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis","","NCT04650087","Pro00107078","Drug: Apixaban 2.5 MG|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04650087","Recruiting","2021-02-15","2021-09-01","{""locations"":""University of Illinois at Chicago, Chicago, Illinois, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""5320"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality as measured by hospital records.|The composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality as measured by hospital records.|New, symptomatic VTE (inclusive of DVT, PE, or other venous thrombosis) for up to 30 days after randomization as measured by hospital records.|New, symptomatic ATE (inclusive of ischemic stroke, MI, or peripheral arterial thromboembolism) for up to 30 days after randomization as measured by hospital records.""}"
"1213","Impact of the COVID-19 Pandemic on Vaccination","COVIDVacImpac","NCT04657263","RECHMPL20_0655","Other: Vaccine coverage assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04657263","Recruiting","2020-11-01","2021-05-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of persons at risk of infection up to date with their mandatory and recommended vaccinations during COVID19 pandemic|Number of persons at risk of infection accepting COVID19 vaccination""}"
"1214","Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","","NCT04456439","MSB-MSC-MISC001","Biological: Remestemcel-L|Drug: Hydrocortisone|Drug: Diphenhydramine","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04456439","Available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""2 Months to 17 Years \u00a0 (Child)"",""outcome_measures"":""""}"
"1215","Musculoskeletal Pain in Patients With Covid-19 Who Have Hospital Care","Covid19-Pain","NCT04632355","Covid19-Pain","Other: Interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04632355","Not yet recruiting","2020-12-01","2021-07-31","{""locations"":""Jorge Hugo Villafa\u00f1e, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Self-reported Version of the Leeds Assessment of Neuropathic Symptoms and Signs|PainDETEC|EuroQol-5D|The Hospital Anxiety and Depression Scale""}"
"1216","Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients","COMETS","NCT04516486","APHP200418","Other: retrospective metagenomics on clinical samples collected during hospitalization","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04516486","Active, not recruiting","2020-03-09","2020-12-31","{""locations"":""CHU Henri Mondor, Cr\u00e9teil, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identify two endotypes (hyper-inflammatory and co-infections) and quantify their prognostic value in terms of short-term mortality (Day 28) in patients treated for ARDS infected with SARS-Cov2.|Nature of viral, bacterial and fungal co-infections in the different clusters identified|Comparison of SARS CoV-2 viral replication dynamics in the different clusters identified|4. Characterization of the viral genetic determinants selected over time in the different clusters identified""}"
"1217","Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT","","NCT04519255","ZDWY.FZYX.008","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04519255","Active, not recruiting","2020-07-01","2023-07-31","{""locations"":""Hongjun Jin, Zhuhai, Guangzhou, China"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of clinically cured patients with severe COVID-19|Number of clinically cured patients with mild COVID-19|Number of healthy people who are not infected with COVID-19|Ki comparison between the severe, the mild and the healthy|SUVmax comparison between the severe, the mild and the healthy""}"
"1218","The Corona and COVID-19 Study in Telemark and Agder","COVITA","NCT04514003","COVITA","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04514003","Recruiting","2020-07-01","2035-12-31","{""locations"":""Telemark Hospital, Skien, Vestfold And Telemark, Norway"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 IgG antibody level|Risk factors for COVID-19""}"
"1219","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","","NCT04545749","V-122","Biological: UB-612","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04545749","Recruiting","2020-09-25","2021-08-31","{""locations"":""China Medical University Hospital, Taichung, Taiwan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""20 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Safety of UB-612 vaccine|Safety|Immunogenicity""}"
"1220","Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID)","REHABCOVID","NCT04634318","2020-CHITS-06|2020-A02838-31","Other: Respiratory rehabilitation program (RR).|Other: Respiratory tele-rehabilitation program (TRR).","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04634318","Recruiting","2020-12-10","2022-12-01","{""locations"":""H\u00f4pital Ren\u00e9e Sabran, Hy\u00e8res, Var, France|HIA Sainte Anne, Toulon, Var, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""118"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Distance walked in the 6-min walk test (6 MWT).|Number of repetitions performed in a 1-min Sit-to-Stand (STS) test|Dyspnea evaluated by the modified Medical Research Council (mMRC)|Fatigue evaluated by the Multidimensional Fatigue Inventory (MFI-20)|Anxiety and Depression evaluated by the Hospital Anxiety and Depression Scale (HADS)""}"
"1221","Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece","COV-EAT","NCT04437121","COV-EAT","Other: Online Survey about Dietary and Lifestyle Habits","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04437121","Completed","2020-04-30","2020-05-24","{""locations"":""Department of Nutrition-Dietetics, Tr\u00edkala, Thessaly, Greece"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""397"",""age"":""24 Months to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Change in weight (child)|Behaviour (child)|Behaviour (parents)|Physical Activity Levels (child)|Screen Time (child)|Sleep Duration (child)""}"
"1222","Nebulized PL for Post-COVID-19 Syndrome","","NCT04487691","RGX2020-RCT01","Biological: Nebulized Platelet Lysate|Other: Nebulized Sterile Saline","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04487691","Recruiting","2020-12-08","2021-12-30","{""locations"":""Centeno-Schultz Clinic, Broomfield, Colorado, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Spirometry-FVC and FEV1\/FVC tests|6 Minute Walk Distance test (6MWD)|Distance-desaturation product from 6MWD|San Diego Shortness of Breath Questionnaire (SOBQ)|Short Form-36 (SF-36)|Modified Single Assessment Numeric Evaluation (SANE)|Medications|Incidence of adverse events|Incidence of surgical\/other treatment interventions""}"
"1223","Risks of COVID19 in the Pregnant Population","","NCT04379284","20-003251","Other: Biospecimen collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379284","Recruiting","2020-05-08","2021-07-31","{""locations"":""Mayo Clinic Rochester, Rochester, Minnesota, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Determine the prevalence of maternal fetal transmission of COVID19|Describe the outcomes of COVID19 positive pregnancies|Understand the placental impact of COVID19 in pregnancy at various gestational ages""}"
"1224","Spartan COVID-19 System: Evaluation of Clinical Sample Collection","","NCT04473248","VNV-00552","Device: Spartan COVID-19 System","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04473248","Completed","2020-06-28","2020-08-30","{""locations"":""Humber River Hospital, North York, Ontario, Canada|The Univeristy of Ottawa Heart Institute, Ottawa, Ontario, Canada"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic"",""enrollment"":""27"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Asses the % agreement between predicate results and Spartan COVID-19 results.""}"
"1225","Sex-Informed Data in the COVID-19 Pandemic.","G-COV","NCT04497402","SAPIENZAGENDERCOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497402","Recruiting","2020-09-01","2022-06-01","{""locations"":""Sapienza University of Rome - Policlinico Umberto I Roma, Rome, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""88"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sex differences in platelet and immune function and COVID19 severity|Gut microbiome and COVID19 severity""}"
"1226","Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment","EPILOGUE","NCT04343339","RECHMPL20_0195","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04343339","Completed","2020-04-08","2020-09-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evolution of consumption|health care access""}"
"1227","Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19","VTE-COVID","NCT04359212","VTE-COVID","Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359212","Completed","2020-05-01","2020-07-31","{""locations"":""Giuseppe Camporese, Padova, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism|the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism""}"
"1228","TREM-1 Pathway Activation in COVID-19","CoviTrem1","NCT04544891","2020PI120","Other: blood sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04544891","Not yet recruiting","2020-10-01","2023-04-01","{""locations"":""CHRU Limoges, Limoges, France|Central hospital, Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""prognostic value of the TREM-1 pathway activation on clinical worsening""}"
"1229","Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19","","NCT04386694","3.985.226","Device: Active PBMT/sMF|Device: Placebo PBMT/sMF","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04386694","Completed","2020-05-18","2020-09-17","{""locations"":""Hospital Tacchini, Bento Gon\u00e7alves, RS, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Time until discharge|Survival rate|Diaphragm muscle function|Platelet count|Leukogram|Erythrogram|C-reactive protein|D-dimer|Immunoglobulin G|Immunoglobulin M|Levels of positive end-expiratory pressure (PEEP)|Fraction of inspired oxygen (FiO2)|Arterial partial pressure of oxygen (PO2)|Arterial partial pressure of oxygen (PO2)\/Fraction of inspired oxygen (FiO2) ratio|Levels of tumor necrosis factor-\u03b1 (TNF-\u03b1)|Levels of vitamin D""}"
"1230","Healthy Volunteer COVID-19 Antibody Testing Study","","NCT04529460","134035","Diagnostic Test: COVID-19 antibody point of care test kit","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04529460","Not yet recruiting","2020-09-01","2021-04-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity and specificity of the COVID-19 antibody testing kit""}"
"1231","Predictors of Severe COVID-19 Outcomes","PRESCO","NCT04388813","102293","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388813","Recruiting","2020-05-28","2021-03-01","{""locations"":""The University of Arizona, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Inova Health Care Services, Falls Church, Virginia, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Performance (discrimination \/ calibration) of models""}"
"1232","Polyvalent Immunoglobulin in COVID-19 Related ARds","ICAR","NCT04350580","D20-P013|2020-001570-30","Drug: Human immunoglobulin|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04350580","Recruiting","2020-04-11","2021-06-01","{""locations"":""CHU Sud Amiens, Amiens, France|CHU Angers, Angers, France|Service de r\u00e9animation polyvalente, rond point de Girac, Angoul\u00eame, France|CH Aulnay, Aulnay-sous-Bois, France|Centre hospitalier de B\u00e9thune, Beuvry, France|Hopital Avicenne, Bobigny, France|CH Chalons en champagne, Chalons en champagne, France|CH-Nord-Ardennes, Charleville-M\u00e9zi\u00e8res, France|Hopital d'instruction des arm\u00e9es Percy, Clamart, France|Centre Hospitalier de Dieppe, Dieppe, France|H\u00f4pital Raymond Poincar\u00e9, Garches, France|CHU de Grenoble, Grenoble, France|Grand hopital de l'est Francilien - site de Jossigny, Jossigny, France|Hopital Robert Boulin, Libourne, France|P\u00f4le de M\u00e9decine intensive\/r\u00e9animation H\u00f4pital Salengro, CHRU de Lille, Lille, France|Groupement Hospitalier Edouar Herriot, Lyon, France|H\u00f4pital de la Croix Rousse Novembre 2019, Lyon, France|Hopital Jacques Cartier, Massy, France|Hopital Jacques Monod, Montivilliers, France|Service de M\u00e9decine Intensive-R\u00e9animation, CHU, Nantes, France|CHR Orl\u00e9ans, Orl\u00e9ans, France|Centre Hospitalier Sainte-Anne, Paris, France|CHU Lariboisiere, Paris, France|CHU Piti\u00e9 Salp\u00e9triere Service de r\u00e9animation chirurgicale, Paris, France|CHU Saint Antoine, Paris, France|Fondation ophtalmologique Rotschild, Paris, France|H\u00f4pital Paris Saint-Joseph, Paris, France|H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France|Institut Mutualiste Montsouris, Paris, France|CHU Robert D\u00e9br\u00e9, Reims, France|CH Poissy, Saint-Germain-en-Laye, France|Groupe hospitalier Saint Vincent, Strasbourg, France|H\u00f4pital de Hautepierre, Strasbourg, France|Hopital de Tarbes, Tarbes, France|H\u00f4pital Nord Franche-Comt\u00e9, Tr\u00e9venans, France|CH Valenciennes, Valenciennes, France|Chu Nancy - Brabois, Vand\u0153uvre-l\u00e8s-Nancy, France|Hopital de Vannes, Vannes, France|Institut Gustave Roussy, Villejuif, France|CH Etampes, \u00c9tampes, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""138"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator-free days|Mortality|Sequential Organ Failure Assessment Score|P\/F ratio|Lung compliance|Radiological score|Biological efficacy endpoints - C-reactive protein|Biological efficacy endpoints - Procalcitonin|Immunological profile|Number of patients using other treatments for COVID-19 related ARDS|Occurrence of deep vein thrombosis or pulmonary embolism|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Kidney Disease: Improving Global Outcomes (KDIGO) score and need for dialysis|Occurrence of adverse event related to immunoglobulins|Occurrence of critical illness neuromyopathy|Occurrence of ventilator-acquired pneumonia""}"
"1233","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","OHB10cov","NCT04344431","2020PPRC03","Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04344431","Recruiting","2020-04-14","2022-04-01","{""locations"":""H\u00f4pital d'Instruction des Arm\u00e9es Laveran, Marseille, France|Centre Hospitalier Intercommunal de Toulon - La Seyne-sur-Mer, Toulon, France|H\u00f4pital d'Instruction des Arm\u00e9es Sainte-Anne, Toulon, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to normalize the oxygen requirement (oxygeno-dependence)|Days of hospitalization between the HBO group and the control group.|Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.|Days on invasive mechanical ventilation|Mortality""}"
"1234","COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality","","NCT04390074","UTN: U1111-1251-8195","Other: COVID-19 and Intensive Care","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04390074","Completed","2020-05-27","2020-06-04","{""locations"":""Bj\u00f6rn Ahlstr\u00f6m, Falun, Sweden"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""9905"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Chronic medications as risk factor of intensive care for COVID-19|Comorbidities as risk factor of intensive care for COVID-19|Chronic medications as risk factor of death during intensive care for COVID-19|Comorbidities as risk factor of death during intensive care for COVID-19""}"
"1235","A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients","GARGLES","NCT04341688","2020-Sur-ERC-4926","Drug: Gargle/Mouthwash","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04341688","Not yet recruiting","2021-02-01","2021-07-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intraoral viral load|Salivary cytokine profile""}"
"1236","Antibiotic Misuse During COVID-19 Pandemic","","NCT04553055","AA86","Other: online questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04553055","Completed","2020-07-20","2020-09-15","{""locations"":""BeniSuefU, Cairo, BeniSuef, Egypt"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""413"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""antibiotic misuse""}"
"1237","Convalescent Plasma for COVID-19 Patients","CPCP","NCT04516954","ISC.20.11.1","Biological: Convalescent COVID 19 Plasma","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04516954","Enrolling by invitation","2020-08-01","2020-12-30","{""locations"":""Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the safety|Change in requirement for mechanical ventilatory support""}"
"1238","Serological Profile of Children and Young Adolescents With at Least One COVID-19 Diagnosed Family Member","","NCT04649944","GMT_CD_CT_LG_EB_10_2020","Diagnostic Test: Serological test and phone interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649944","Not yet recruiting","2021-02-05","2021-12-31","{""locations"":""UOC Maxillofacial Surgery and Odontology, University of Milan, Milan, Lombardy, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""4 Years to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Detection of IgG and IgM antibodies for Sars-Cov-2 in children aged between 4 and 16 y.o. cohabiting with at least a subject with a previous diagnosis of COVID-19.|Detection of IgG and IgM antibodies for Sars-Cov-2 in adults with a previous diagnosis of COVID-19 cohabiting with at least a child aged between 4 and 16 y.o.""}"
"1239","OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 ""","","NCT04584567","UR17DN05","Drug: Doxycyclin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04584567","Recruiting","2020-11-20","2021-03-01","{""locations"":""Military Hospital of Tunis, Tunis, Montfleury, Tunisia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""decreasing the number of cases infected with covid 19|Measurement of the emergence of clincal symptoms of COVID 19|the seroprevalence of SARS- CoV 2 IgM\/IgG positive samples at study entry and study conclusion in all participants receiving DOXY compared to those receiving placebo.""}"
"1240","Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia","POCUSars-CoV-2","NCT04370275","CEUR-2020-Os-086","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370275","Recruiting","2020-04-23","2020-05-31","{""locations"":""SC Pronto Soccorso e Medicina d'Urgenza, Latisana, Udine, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""235"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Negative Predictive Value of Lung Ultrasound in the diagnosis of COVID-19|Positive Predictive Value of Lung Ultrasound in the diagnosis of COVID-19|Sensitivity and Specificity of Lung Ultrasound in the diagnosis of COVID-19""}"
"1241","COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol","","NCT04662086","COPPS-Master Protocol","Drug: Acebilustat|Drug: Camostat","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04662086","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""For Viral Domain:Time until cessation of shedding of SARS-CoV-2 virus|For Clinical Domain: Time from randomization to sustained symptom resolution assessed over a 28-day period|Time to first resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2""}"
"1242","Convalescent Plasma in Outpatients With COVID-19","C3PO","NCT04355767","C3PO|1OT2HL156812-01","Biological: Convalescent Plasma|Biological: Saline","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04355767","Active, not recruiting","2020-08-11","2021-04-01","{""locations"":""Chandler Regional Medical Center, Chandler, Arizona, United States|Valleywise Health Medical Center, Phoenix, Arizona, United States|UCSD Health La Jolla, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Stanford University, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Spectrum Health Hospitals Butterworth Hospital, Grand Rapids, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|HealthPartners Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|William P. Clements Jr. University Hospital, Dallas, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University of Utah Healthcare, Salt Lake City, Utah, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""511"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with disease progression|Worst severity rating on the WHO COVID Ordinal Scale for Clinical Improvement during the 30 days following randomization|Time to disease progression|Number of Hospital-free days during the 30 days following randomization|All-cause mortality""}"
"1243","A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults","","NCT04533399","2019nCoV-501","Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04533399","Recruiting","2020-08-17","2021-11-01","{""locations"":""ZA018, Bloemfontein, Free State Of South Africa, South Africa|ZA003, Hillbrow, Gauteng, South Africa|Site ZA001, Johannesburg, Gauteng, South Africa|ZA012, Johannesburg, Gauteng, South Africa|Site ZA015, Pretoria, Gauteng, South Africa|ZA023, Pretoria, Gauteng, South Africa|ZA019, Durban, KwaZulu-Natal, South Africa|ZA020, Durban, KwaZulu-Natal, South Africa|ZA021, Durban, KwaZulu-Natal, South Africa|ZA024, Durban, KwaZulu-Natal, South Africa|ZA007, Thabazimbi, Limpopo, South Africa|ZA022, Madibeng, North-West, South Africa|ZA013, Cape Town, Western Cape, South Africa|ZA014, Worcester, Western Cape, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""4400"",""age"":""18 Years to 84 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19|Cohort 1: HIV- Participants with Symptomatic Moderate or Severe COVID-19|Cohort 1: HIV- Participants with Solicited Adverse Events (AEs)|Cohort 1: HIV- Participants with Unsolicited AEs|Cohort 2: HIV+ Participants with Solicited AEs|Cohort 2: HIV+ Participants with Unsolicited AEs|Cohort 2: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs)|Cohort 2: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs)|Cohort 2: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs)|Cohort 1: HIV- Participants with Individual Strata of Symptomatic Virologically Confirmed, Mild, Moderate, or Severe COVID-19|Cohort 1: HIV- Participants with COVID-19 Requiring Hospitalization|Cohort 1: Incidence, Maximum Severity Score, and Symptom Duration of SARS-CoV-2 Infection by Severity Classification|Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMTs|Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMFRs|Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as SCRs|Cohort 1: Angiotensin-Converting Enzyme 2 (ACE2) Receptor Binding Inhibition Assay Expressed as GMTs|Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs|Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as SCRs|Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as Seroresponse Rates (SRRs)|Cohort 1: Neutralizing Antibody Activity Expressed as GMTs|Cohort 1: Neutralizing Antibody Activity Expressed as GMFRs|Cohort 1: Neutralizing Antibody Activity Expressed as SCRs|Cohort 1: Neutralizing Antibody Activity Expressed as SRRs|Cohort 1: HIV- Participants with Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs)|Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMTs|Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMFRs|Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as SCRs|Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as GMTs|Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs|Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as SCRs|Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as SRRs|Cohort 2: Neutralizing Antibody Activity Expressed as GMTs|Cohort 2: Neutralizing Antibody Activity Expressed as GMFRs|Cohort 2: Neutralizing Antibody Activity Expressed as SCRs|Cohort 2: Neutralizing Antibody Activity Expressed as SRRs|Cohort 2: HIV+ Participants with MAAEs, AESIs, and SAEs|Cohort 2: HIV+ Participants with Symptomatic Virologically Confirmed, Mild, Moderate, or Severe COVID-19|Cohort 2: Incidence, Maximum Severity Score, and Symptom Duration of SARS-CoV-2 Infection by Severity Classification""}"
"1244","The Prevent Severe COVID-19 (PRESECO) Study","PRESECO","NCT04600895","ATI0220","Drug: Favipiravir|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04600895","Recruiting","2020-11-30","2021-10-01","{""locations"":""Elixia Clinical Research Collaborative, Hollywood, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""826"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to sustained clinical recovery|Time to Patient Reported Global Daily impression|Proportion of patients showing sustained resolution of Symptoms|Time to improvement in symptoms|Proportion of patients that progress to severe COVID-19|Reduction in Death Related to COVID-19|Reduction in Patient Hospitalization|Reduction in incidence of hospitalization for respiratory distress or O2 saturation|Time to sustained clinical recovery among SARS-CoV-2 IgG-negative subjects at enrollment from start of study treatment|Time to sustained clinical recovery among subjects with \u22643 days of COVID-19 symptoms at enrollment from start of study treatment|Time to negative conversion of detectable SARS-CoV-2 viral RNA in RT-PCR assays of saliva|Proportion of patients showing negative conversion of detectable SARS-CoV-2 viral RNA in saliva""}"
"1245","Early Use of Hyperimmune Plasma in COVID-19","COV-II-PLA","NCT04721236","100490/2020","Other: hyperimmune plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04721236","Recruiting","2020-11-19","2022-05-19","{""locations"":""Catherine Klersy, Pavia, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement (efficacy)|ventilation|WHO (World Health Organization) scale|SOFA (Sequential Organ Failure Assessment) score|naso-pharyngeal swab|SARS-CoV2|P\/F|thrombosis|curarization|complication kidney|complication lung|Leucocytes|Lymphocytes|C-reactive protein|D-dimer|Troponin I (TnI)|PCTI (Procalcitonin) (ng\/mL)|Ferritin|Albumin|LDH|Lung Ultrasound Score (LUS)|ecmo|death|hospitalization|Lung Function tests|High resolution computed tomography (HRCT)|Improvement mortality""}"
"1246","Chest Radiography in COVID-19 Patients","","NCT04485338","RALE-COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04485338","Recruiting","2020-08-01","2021-03-01","{""locations"":""Amsterdam UMC location AMC, Amsterdam, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The prognostic capacity of the Radiographic Assessment of Lung Edema (RALE) score of the first CXR under invasive ventilation in patients with severe COVID-19.|The prognostic capacity of changes in the RALE score of consecutive CXRs under invasive ventilation in patients with severe COVID-19|Number of ventilator-free day and alive at day 28 (VFD)""}"
"1247","Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali","BAMACOV","NCT04710316","C20-41","Diagnostic Test: SARS-CoV-2 screening by molecular biology|Diagnostic Test: Serological screening","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04710316","Not yet recruiting","2021-01-30","2022-09-30","{""locations"":""Hopital du Point-G, Bamako, Mali|Hopital Gabriel Toure, Bamako, Mali|H\u00f4pital dermatologique de Bamako, Bamako, Mali|H\u00f4pital du Mali, Bamako, Mali"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence rate of positive SARS-Cov-2 RT-PCR in Bamako hospital departments during the study|Number of Cepheid Xpert\u00ae Xpress SARS-Cov-2 cartridges available for 19.8 USD\/number required for the project|Percentage of positive serological tests among the caregivers of the hospital departments of Bamako.|Percentage of caregivers asymptomatic but immunized to SARS-CoV-2|Percentage of caregivers immunized and re-infected with SARS-CoV-2|Number of SARS-CoV-2 mutations\/variants detected during the study|Percentage of SARS-CoV-2 mutations\/variants detected during the study""}"
"1248","COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)","CON-VINCE","NCT04379297","CNER 202004/01|831x6ce0d|FNR/CON-VINCE","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379297","Active, not recruiting","2020-04-10","2021-12-31","{""locations"":""Luxembourg Institute of Health, Strassen, Luxembourg"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg|Collection of samples for research|Psycho-social evaluation""}"
"1249","Kidney Injury Severity and COVID-19","","NCT04386564","Sechenov-COVID19_AKI","Diagnostic Test: mRNA in urine test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386564","Completed","2020-05-15","2020-09-01","{""locations"":""Sechenov University., Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""340"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The effect of COVID-19 severity on the severity of renal failure|The expression of viral RNA in the urine with the severity of renal failure|The severity of microalbuminuria in patients with COVID-19 of different conditions and renal failure|Assessment of the severity of renal impairment in patients who died from COVID-19|Estimation of the duration of urinary viral RNA isolation in patients undergoing COVID-19|Expression of ACE-2 receptors in the kidneys of patients with renal failure who died from COVID-19""}"
"1250","COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol","COPPS","NCT04662073","COPPS-Camostat","Drug: Camostat|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04662073","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""For Viral Domain:Time until cessation of shedding of SARS-CoV-2 virus|For Clinical Domain: Time from randomization to sustained symptom resolution assessed over a 28-day period|Time to first resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2|Time to event from randomization to worsening of symptoms or disease progression""}"
"1251","Using Smart Watches to Detect and Monitor COVID-19","CovIdentify","NCT04623047","PRO00106404","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04623047","Not yet recruiting","2021-07-01","2023-02-01","{""locations"":""Duke University, Durham, North Carolina, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by self-reports of symptom questionnaire.|Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by COVID-19 and influenza test result.|Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by hospital admission questionnaire.|Accuracy comparison of symptom-only model to sensor-only model to symptom + sensor model to predict Covid-19 symptoms.""}"
"1252","Modulation of Hyperinflammation in COVID-19","","NCT04353674","115785","Device: Control group|Device: SLEDD with a L-MOD","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04353674","Recruiting","2020-04-28","2021-01-01","{""locations"":""University Hospital, London, Ontario, Canada|Victoria Hospital - Critical Care Trauma Centre, London, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of a L-MOD against controls receiving supportive care in ICU.|Mortality|Hospital Discharge|Leukocyte Monitoring|Sequential Organ Failure Assessment (SOFA) Score|Intubation length|Markers of Inflammation|Leukocytes and Macrophages|Myocardial damage|Renal recovery""}"
"1253","Convalescent Plasma for Severe COVID-19 Patients","PLACOVID","NCT04547660","2020-0158","Biological: Convalescent Plasma|Other: Best Supportive Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04547660","Completed","2020-07-16","2021-01-07","{""locations"":""Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement|6-point ordinal scale proportion at 14 days|6-point ordinal scale proportion at 28 days|Overall mortality|Days alive and free of respiratory support (DAFOR28)|Mechanical ventilation|PaO2\/FiO2 ratio|Hospital stay|Lactate Dehydrogenase|Troponin I|C Reactive Protein|D-Dimers|Fibrinogen|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (APTT)|Tumor Necrosis Factor Alfa (TNF-Alfa)|Interleukin-6 (IL-6)|RT-PCR|Sequential Organ Failure Assessment (SOFA) score|National Early Warning Score 2 (NEWS) 2|Safety and Adverse Events""}"
"1254","Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","","NCT04564716","04-Gam-COVID-Vac-2020-RB","Biological: Gam-COVID-Vac|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04564716","Active, not recruiting","2020-09-28","2021-04-10","{""locations"":""Health Institution \""14th Central Regional Polyclinic of the Partisan district of Minsk\"", Minsk, Belarus|Health Institution \""19th Central Regional Polyclinic of the Pervomaysk district of Minsk\"", Minsk, Belarus|Health Institution \""1st Central Regional Clinical Polyclinic of the Central district of Minsk\"", Minsk, Belarus|Health Institution \""28th Regional Polyclinic of Minsk\"", Minsk, Belarus|Health Institution \""4th City Polyclinic of Minsk\"", Minsk, Belarus|Health Institution \""5th City Clinical Polyclinic of Minsk\"", Minsk, Belarus|Health Institution \""Minsk Order of the Red Banner of Labor Regional Clinical Hospital, Minsk, Belarus|Health Institution \""Vitebsk Regional Clinical Hospital\"", Vitebsk, Belarus"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose|the severity of the clinical course of COVID-19|Changing of antibody levels against the SARS-CoV-2 glycoprotein S|Incidence of adverse events in trial subjects|Severity of adverse events in trial subjects""}"
"1255","A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","","NCT04583995","2019nCoV-302","Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant|Other: Placebo|Biological: Licensed seasonal influenza vaccine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04583995","Recruiting","2020-09-28","2022-01-14","{""locations"":""Belfast Health and Social Care Trust (BHSCT) (Site UK011), Belfast, Antrim, United Kingdom|Synexus Midlands Clinical Research Centre (Site UK024), Edgbaston, Birmingham, United Kingdom|The Royal Cornwall Hospitals NHS Trust (Site UK036), Truro, Cornwall, United Kingdom|Royal Devon and Exeter Hospital (Site UK013), Exeter, Devon, United Kingdom|\""Maidstone Hospital - Central Research and Development Office Above Breast Care Centre - 1st Floor\"" (Site UK028), Maidstone, Kent, United Kingdom|Queen Elizabeth University Hospital (Site UK008), Glasgow, Lanarkshire, United Kingdom|Blackpool Teaching Hospitals (Site UK010), Blackpool, Lancashire, United Kingdom|Salford Hospital (Site UK030), Oldham, Lancashire, United Kingdom|Synexus Merseyside Clinical Research Centre (Site UK026), Waterloo, Liverpool, United Kingdom|Royal Free (Site UK012), Hampstead, London, United Kingdom|St. George's University Hospitals NHS Foundation Trust Clinical Research Facility (Site UK001), Tooting, London, United Kingdom|North Wales Clinical Research Centre (NWCRC) (Site UK027), Wrexham, North Wales, United Kingdom|Lakeside Healthcare, Lakeside Surgery (Site UK005), Corby, Northants, United Kingdom|Warneford Hospital (Site UK016), Oxford, Oxfordshire, United Kingdom|Aberdeen Royal Infirmary (Site UK007), Foresterhill, Aberdeen, United Kingdom|Bradford Teaching Hospitals NHS Trust (Site UK018), Bradford, United Kingdom|Synexus Wales Clinical Research Centre (Site UK025), Cardiff, United Kingdom|Synexus Lancashire Clinical Research Centre (Site UK022), Chorley, United Kingdom|Colchester Hospital (Site UK034), Colchester, United Kingdom|AES - Glasgow (Site UK033), Glasgow, United Kingdom|University Hartlepool Hospital (Site UK021), Hartlepool, United Kingdom|Synexus Hexham Clinical Research Centre (Site UK023), Hexham, United Kingdom|Royal Lancaster Infirmary (Site UK029), Lancaster, United Kingdom|Research & Innovation Centre, St. James's University Hospital (Site UK019), Leeds, United Kingdom|St. Thomas' Hospital (Site UK020), London, United Kingdom|Chelsea & Westminster NHS Foundation Trust (Site UK006), London, United Kingdom|AES - Synexus Manchester (Site UK032), Manchester, United Kingdom|Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk and Norwich University Hospital (Site UK015), Norwich, United Kingdom|Wansford and Kingscliffe Practice (Site UK035), Peterborough, United Kingdom|AES - Synexus Thames Valley (Site UK031), Reading, United Kingdom|University Hospital Southampton NHS Foundation Trust (UHS) (Site UK014), Southampton, United Kingdom|Midlands Partnership NHS Foundation Trust Headquarters (Site UK017), Stafford, United Kingdom|Stockport NHS Foundation Trust (Site UK009), Stockport, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""15000"",""age"":""18 Years to 84 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)|Participants with Symptomatic Moderate or Severe COVID-19|Participants with Symptomatic Mild, Moderate, or Severe COVID-19 Regardless of Baseline Serostatus|Participants with Asymptomatic or Symptomatic COVID-19|Participants with COVID-19 requiring Hospitalization, Intensive Care Unit (ICU), or Mechanical Ventilation|Participants with Symptomatic Mild COVID-19|Serum IgG Antibody Levels at Multiple Time Points Expressed as Geometric Mean ELISA Units (GMEUs)|Participants with Serious Adverse Events (SAEs)|Participants with Medically Attended Adverse Events (MAAEs) Related to Study Vaccination|Participants with Adverse Events of Special Interest (AESIs)|Participants with Solicited Local and Systemic Adverse Events (AEs)|Participants with All MAAEs Through Day 35|Participants with Unsolicited AEs Through Day 49""}"
"1256","COVIDIG (COVID-19 Hyper-ImmunoGlobulin)","","NCT04555148","GC5131A-HIG_P0201","Biological: GC5131|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04555148","Recruiting","2020-09-20","2021-08-01","{""locations"":""Samsung Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ordinal scale outcome|Viral negative|Change in NEWS|mortality""}"
"1257","Western Kenya Integrated COVID-19 Response","","NCT04501458","001","Other: Training of youth, community health assistants and community health workers.|Other: Training clinicians in basic critical care and the management of severe COVID-19 cases","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04501458","Active, not recruiting","2020-08-10","2021-06-10","{""locations"":""Surgical Systems Research Group\/Tropical Institute of Community Health, Kisumu, Kenya"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""200000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Number of confirmed COVID-19 cases in Siaya""}"
"1258","COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol","COPPS","NCT04662060","COPPS-Acebilustat","Drug: Acebilustat|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04662060","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""For Viral Domain:Time until cessation of shedding of SARS-CoV-2 virus|For Clinical Domain: Time from randomization to sustained symptom resolution assessed over a 28-day period|Time to first resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2|Time to event from randomization to worsening of symptoms or disease progression""}"
"1259","Low Dose Radiotherapy for COVID-19 Pneumonitis","LOWRAD-Cov19","NCT04420390","LOWRAD-Cov19","Radiation: Radiotherapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04420390","Recruiting","2020-05-01","2020-09-08","{""locations"":""Servicio de Oncolog\u00eda Radioter\u00e1pica. Hospital Cl\u00ednico San Carlos, Madrid, Spain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""41"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Radiological response|Remission of respiratory symptoms|SPO2 and PaO2\/FiO2|Adverse events|Hospitalization|Overall survival|Ferritin value|blood cell count|C-reactive protein|D-dimer|LDH levels""}"
"1260","Urine Alkalinisation to Prevent AKI in COVID-19","","NCT04655716","283852","Drug: Sodium Bicarbonate 150Meq/L/D5W Inj","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04655716","Not yet recruiting","2021-02-01","2022-03-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""proportion of patients treated who achieve >50% of urine measurements above pH 7.0 over the duration of intervention""}"
"1261","CoVID-19 Plasma in Treatment of COVID-19 Patients","","NCT04355897","20-23","Biological: Convalescent COVID 19 Plasma","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04355897","Recruiting","2020-04-28","2020-08-01","{""locations"":""The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events.""}"
"1262","Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19","","NCT04534712","yet to be assigned","Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04534712","Not yet recruiting","2020-09-01","2021-02-01","{""locations"":""Sir Ganga Ram Hospital, New delhi, Delhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""progression|mortality""}"
"1263","Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients","","NCT04420988","Pro2020000746, Pro2020000911","Biological: COVID-19 Convalescent Plasma","Expanded Access:Individual Patients|Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04420988","Available","1970-01-01","1970-01-01","{""locations"":""Rutgers New Jersey Medical School, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"1264","Hamburg Edoxaban for Anticoagulation in COVID-19 Study","HERO-19","NCT04542408","HERO-19","Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH)|Drug: Low dose Low molecular weight heparin or Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04542408","Recruiting","2020-11-12","2021-09-30","{""locations"":""Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany|Universit\u00e4tsklinikum Freiburg, Freiburg, Germany|Marienkrankenhaus, Hamburg, Germany|Universit\u00e4rsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hanover, Germany|Krankenhaus K\u00f6ln-Merheim, K\u00f6ln, Germany|TU M\u00fcnchen Klinikum rechts der Isar, M\u00fcnchen, Germany|Universit\u00e4tsklinikum M\u00fcnster, M\u00fcnster, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""172"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Combined endpoint: all-cause mortality and\/ or venous thromboem-bolism and\/ or arterial thromboembolism|All-cause mortality|Mortality related to venous thromboembolism|Mortality related to arterial thromboembolism|Rate of venous and\/ or arterial thromboembolism|Rate and length of mechanical ventilation|Length of initial stay at ICU after application of IMP|Rehospitalisation|Rate and length of renal replacement therapy|Cardiac arrest\/ CPR""}"
"1265","Hydroxychloroquine, Azithromycin in the Treatment of Covid-19","PACTT","NCT04405921","PACTT","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04405921","Not yet recruiting","2020-07-01","2021-03-01","{""locations"":""University Hospital Farhat Hached, Sousse, Tunisia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical recovery at day-14, from the start of treatment.|Viral Clearance via RT-PCR at day 5- 7-10 and day 14""}"
"1266","Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis","","NCT04582331","SH2020.COV01","Other: Smartphone-based voice and self-reported symptom collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04582331","Recruiting","2020-09-10","2021-04-30","{""locations"":""UC San Diego Medical Center, San Diego, California, United States|Brigham & Woman's Hospital, Boston, Massachusetts, United States|Montefiore Medical Center, New York, New York, United States|Deenanath Mangeshkar Hospital & Research Centre, Pune, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Vocal biomarker performance in COVID-19 positive vs. healthy controls|Vocal biomarker vs. symptom burden correlation in COVID-19 positive|Vocal biomarker performance in COVID-19 positive vs. COVID-19 negative symptomatic""}"
"1267","Efficacy and Safety of COVID-19 Convalescent Plasma","","NCT04397523","ITM05/2020MKD","Biological: anti-SARS-CoV-2 convalescent plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04397523","Recruiting","2020-04-30","2021-04-29","{""locations"":""Institute for Transfusion Medicine of RNM, Skopje, North Macedonia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of oxygenation and ventilation support|Hospital length of stay (LOS)|ICU admission|Ventilator free days|Incidence of serious adverse events|Type of respiratory support|Number of participants with different clinical outcomes including death, critical illness and recovery""}"
"1268","ARB, ACEi, DRi in COVID-19","BIRCOV","NCT04364984","COVID20","Drug: Angiotensin converting enzyme inhibitor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04364984","Recruiting","2020-04-01","2021-08-01","{""locations"":""Medical Practice Prof D.Ivanov, Kiev, Please Select, Ukraine"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""BP (hypertensive efficacy)|COVID-19 course|Cough in COVID-19 course|Throat pain in COVID-19 course|Diarrhea inf COVID-19 course|Need to apply to hospital in COVID-19 course""}"
"1269","COVID-19 Study of Safety and Tolerability of Alvelestat","COSTA","NCT04539795","IRB-300005845","Drug: Alvelestat|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04539795","Recruiting","2020-11-01","2021-09-30","{""locations"":""UAB Lung Health Center, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Numbers and % of subjects who experience at least 1 treatment-emergent adverse event|Mortality rate|Adverse events of special interest|Effect of alvelestat on blood pharmacodynamic biomarkers of inflammation""}"
"1270","Evaluating the Impact of COVID-19 (Coronavirus) on Research in Care Homes","","NCT04716972","2021COV114","Other: survey|Other: Interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04716972","Not yet recruiting","2021-04-01","2021-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Acceptability of vaccine studies in the care home setting through feedback questionnaire with loose themes and no unique measurements.|Acceptability of vaccine studies in the care home setting through feedback interview with loose themes and no unique measurements|Acceptability of new ways of delivering research through explorative interview with loose themes and no unique measurements|Acceptability of new ways of delivering research through explorative questionnaire with loose themes and no unique measurements""}"
"1271","Inhaled Heparin for Hospitalised COVID-19 Patients","INHALE-HEP","NCT04635241","INHALE-HEP meta-trial","Drug: Unfractionated heparin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04635241","Recruiting","2020-06-01","2021-06-01","{""locations"":""San Camilo Clinic, Buenos Aires, Argentina|15th May hospital, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""712"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intubation rate|WHO ordinal scale COVID19|Oxygenation""}"
"1272","Clinical Study Spartan COVID-19 V2 System","","NCT04575168","VNV-00615","Diagnostic Test: Spartan COVID-19 Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04575168","Recruiting","2020-10-30","2020-11-01","{""locations"":""Wake Research Mt. Vernon, Sandy Springs, Georgia, United States|Clinical Chemistry Research Lab, University of Maryand-Baltimore, Baltimore, Maryland, United States|Wake Research ClinSearch, Chattanooga, Tennessee, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent Agreement between SOC test and Spartan COVID-19 test""}"
"1273","Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff","","NCT04723459","SVU MED CIT0 23 4 21 1 121","Other: ivermectin impregnated mask","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04723459","Recruiting","2021-01-23","2021-02-28","{""locations"":""Zaky Aref, Qina, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of persons in each group who Complain of any suspected Symptoms|Number of persons in each group who are diagnosed as COVID-19 patients""}"
"1274","Plasma Rich Antibodies From Recovered Patients From COVID19","PRA-001","NCT04348877","FMASU P15/ 2020","Other: Antibody-Rich Plasma from COVID-19 recovered patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04348877","Not yet recruiting","2020-04-20","2020-12-01","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""viral COVID-19 clearance|Decrease of radiological abnormalities|Clinical improvement""}"
"1275","Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study","PURIFY-OBS-1","NCT04606498","PURIFY-OBS-1","Other: Observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04606498","Recruiting","2020-12-18","2022-02-01","{""locations"":""VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Southeast Georgia Health System - Brunswick Campus, Brunswick, Georgia, United States|Eisenhower Army Medical Center (EAMC), Fort Gordon, Georgia, United States|Uniformed Services University, Bethesda, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Forrest General Hospital, Hattiesburg, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Baylor Scott & White, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Methodist Hospital, San Antonio, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time spent on medications used to increase blood pressure|Time spent on mechanical ventilation|Time spent in the intensive care unit (ICU)|Time spent in the hospital|Time spent on dialysis|Mortality""}"
"1276","PCR Cycle Threshold Values and COVID-19 Outcomes","","NCT04651413","286389","Diagnostic Test: PCR Value","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04651413","Recruiting","2020-11-24","2021-03-31","{""locations"":""University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""800"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Determine if there is an inverse correlation with risk of poor outcome including admission to intensive care; mechanical ventilation and 28-day mortality.|Differences in cycle threshold (Ct) levels amongst patients with community acquired SARS-CoV-2""}"
"1277","Study on the Recovery of Pulmonary Function, Chest CT, Hematologic, and Immune & Inflammatory Conditions in COVID-19 Rehabilitation Patients","","NCT04456101","NCIP03","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04456101","Recruiting","2020-06-19","2022-06-01","{""locations"":""Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""240"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pulmonary Function|Chest CT|Changes in hematology|Changes in immune and inflammatory states|St. George's Respiratory Questionnaire(SGRQ)""}"
"1278","Rapid Turnaround, Home-based Saliva Testing for COVID-19","","NCT04568122","58629","Device: Saliva test kit","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04568122","Recruiting","2020-11-20","2021-08-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""3015"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""An indicator for discrepancy in interpretation of findings by participant versus by technician via photo (interrater reliability)|An indicator for whether the home saliva test is positive as determined by the patient (to assess sensitivity and specificity by the patient)|An indicator for ambiguous findings as measured by percent confidence (if < 80% confident) in interpretation of results by participant and by technician (ease of interpretation)|An indicator that the participant appropriately followed instructions for using the kit (\u2265 80% confident) (ease of use)|An indicator for whether participant called technical support and by reason (e.g., processing was not possible due to broken part) (ease of use)|An indicator by participant that the sample was sufficient and reached the indicated line for sample integrity (sample integrity)|An indicator for whether the home saliva test is positive as determined by the technician (to assess sensitivity and specificity by the technician)""}"
"1279","ImmuneRACE - Immune Response Action to COVID-19 Events","","NCT04494893","ADAP-006","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04494893","Recruiting","2020-04-24","2021-01-31","{""locations"":""Adaptive Biotechnologies, Seattle, Washington, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of disease-specific TCR signatures in patients and controls|Identify the immunodominant antigens that elicit a T-cell response to COVID-19|Risk Stratification based on an individual's immune signature|Determine whether an immune signature can be detected in individuals exposed to SARS-CoV-2 earlier than currently available tests|Explore whether additional research assays could potential identify and\/or confirm antigenic binding""}"
"1280","Symptom-Based Markers for COVID-19 Transmission","","NCT04665245","202007450","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04665245","Enrolling by invitation","2020-12-15","2021-04-01","{""locations"":""University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Body Temperature|COVID-19 Symptoms""}"
"1281","Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic","","NCT04581083","PROY - UAJMS001/2020","Diagnostic Test: RT-PCR|Diagnostic Test: LAMP|Diagnostic Test: POOL RT-PCR|Diagnostic Test: POOL LAMP","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581083","Completed","2020-10-08","2020-10-30","{""locations"":""Universidad Aut\u00f3noma Juan Misael Saracho, Tarija, Bolivia"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""30"",""age"":""21 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Validation|RT- PCR (Saliva)|LAMP|POOL PCR|POOL LAMP""}"
"1282","Suloexide in the Treatment of Early Stages of COVID-19","SulES-COVID","NCT04483830","Clidm/Vas/2020-05-01","Drug: Sulodexide|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04483830","Completed","2020-06-05","2020-09-07","{""locations"":""Clinedem, San Luis Rio Colorado, Sonora, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""243"",""age"":""40 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""hospital care|days of hospital care|days of need suplemental oxigen|serum level of d-dimmer|serum level of creatinine|thromboembolic event|need for mechanical ventilation""}"
"1283","Lung Recruitment Device for COVID-19","","NCT04361435","MP-21-2020-2871","Procedure: Chest physiotherapy using a non-invasive oscillating device","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04361435","Not yet recruiting","2020-05-01","2020-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""SpO2\/FIO2 Ratio|Blood pressures|Heart rates|Respiratory rate|Body temperature|Modified Wood Clinical Asthma Score (m-WCAS)|Expiratory tidal lung volume.|End-tidal CO2|Clinical Respiratory severity scores.""}"
"1284","Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus","","NCT04403672","30005052020","Device: performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403672","Recruiting","2020-05-18","2020-07-24","{""locations"":""Institute of Epidemiology, Disease Control and Research (IEDCR), Mohakhali, Dhaka (For sample collection & sample storage), Institute for Developing Science & Health Initiatives (ideSHi); Mohakhali, Dhaka (For sample analysis, data collection, data analys, Dhaka, Bangladesh"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""5 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Performance evaluation of RealDetect\u2122 COVID-19 RT-PCR kit|Reduce the price of RT-PCR based COVID-19 diagnostic test kits.""}"
"1285","Helmet Non-Invasive Ventilation for COVID-19 Patients","Helmet-COVID","NCT04477668","RC20/306/R","Device: Helmet non-invasive ventilation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04477668","Recruiting","2021-02-08","2022-01-01","{""locations"":""Intensive Care Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""320"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""28-day all-cause mortality|Requirement for endotracheal intubation within 28 days|ICU mortality|Hospital mortality|ICU free days at day 28|Ventilator free days at day 28|Renal replacement therapy free days at day 28|Vasopressor free days at day 28|Skin pressure ulcers|Tolerance of helmet (>1-hour use)|180-day mortality|180-day 5-level EQ-5D version""}"
"1286","Risk Stratification of COVID-19 Patients Discharged From the Emergency Department","CODED","NCT04629183","COVID-ED-IntRisk","Other: integrated clinical evaluation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04629183","Recruiting","2020-11-01","2021-07-31","{""locations"":""Ospedale Maria Vittoria, D.E.A., Torino, Piemonte, Italy|A.O.U.C. Azienda Ospedaliero-Universitaria Careggi, D.E.A., Firenze, Toscana, Italy|Ospedale U. Parini, Medicina e Chirurgia d'accettazione e Urgenza (MeCAU), Aosta, Italy|A.O. S. Croce e Carle, Medicina e Chirurgia d'Urgenza, Cuneo, Italy|A.O.U. Careggi, Medicina e Chirurgia d'Urgenza e Accettazione, Firenze, Italy|A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Ospedale Molinette, S.C. Medicina d'Urgenza U (MECAU), Torino, Italy|Ospedale San Giovanni Bosco, Medicina e Chirurgia d'accettazione e urgenza (MeCAU), Torino, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""composite outcome|death (COVID-19)|death (other disease)|hospital admission (COVID-19)|hospital admission (other disease)""}"
"1287","LLLT Treatment of Lung Inflammation in COVID-19","","NCT04524715","CP19-02","Device: Non-invasive red LLLT treatment to chest of patient.|Device: Sham Device Treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04524715","Not yet recruiting","2021-03-31","2022-03-31","{""locations"":""Wellness Junction, Millsboro, Delaware, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""64"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Inflammation of the lungs - O2|Inflammation of the lungs - CRP|Inflammation of the lungs - IL6""}"
"1288","Late Clinical Events Associated With COVID-19 Infection","COCO-LATE","NCT04591613","RIPH_2020_09","Other: Questionnaire|Other: Biocollection|Other: Follow-up visit","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04591613","Recruiting","2020-12-31","2022-08-01","{""locations"":""Ch Auxerre, Auxerre, France|CHU Caen, Caen, France|CHRU Lille, Lille, France|CH Melun Marc Jacquet, Melun, France|AP-HP H\u00f4pital H\u00f4tel-Dieu, Paris, France|CHU de Saint-Etienne, Saint-Priest-en-Jarez, France|CH Tourcoing, Tourcoing, France|CHRU Tours, Tours, France|CHRU Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France|Centre Hospitalier Bretagne Atlantique, Vannes, France|CH Andr\u00e9 Rosemon de Cayenne, Cayenne, French Guiana"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical description of asthenia|Clinical description of dyspnea|Clinical description of thoracic disorders|Clinical description of neurological disorders|Clinical description of anosmia""}"
"1289","COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With Salivette® Cortisol for Viral RNA Sampling for RT-qPCR","","NCT04599959","0352-2150","Diagnostic Test: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04599959","Completed","2020-10-26","2021-01-20","{""locations"":""Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Mexico, Mexico"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""144"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2-RNA detectability in Swab and Salivette samples""}"
"1290","Ivermectin to Prevent Hospitalizations in COVID-19","IVERCORCOVID19","NCT04529525","IVERCORCOVID19MSPICC","Drug: Ivermectin|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04529525","Recruiting","2020-08-19","2021-03-15","{""locations"":""Ministry of Public Health of the Province of Corrientes, Corrientes, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Hospitalization of medical cause in patients with COVID-19 in each arm|Time to hospitalization|Percentage of Use of invasive mechanical ventilation support in each arm|Time to invasive mechanical ventilation support|Percentage of dialysis in each arm|All-cause mortality|Negative of the swab at 3\u00b11 days and 12\u00b12 days after entering the study|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])""}"
"1291","Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia","COVID-19EXO2","NCT04602442","COVID-19 EXO Extended","Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04602442","Enrolling by invitation","2020-10-01","2021-12-30","{""locations"":""Medical Centre Dinasty, Samara, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other"",""enrollment"":""90"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with non-serious and serious adverse events during trial|Number of participants with non-serious and serious adverse during inhalation procedure|Time to clinical recovery (TTCR)|SpO2 concentration changes|Chest Imaging Changes|Blood biochemistry (CRP)|Procalcitonin concentration|Ferritin concentration|Creatinine concentration|Urea concentration""}"
"1292","The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice","","NCT04558203","PR0014","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04558203","Recruiting","2020-09-22","2021-05-30","{""locations"":""Asalam, Maadi, Cairo, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""450"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""incidence of autoimmune conditions""}"
"1293","MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study","C3PI","NCT04424004","Pro00105703","Other: COVID-19 PCR and serology testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424004","Active, not recruiting","2020-06-09","2021-06-30","{""locations"":""Duke CTSI Translational Population Health Office, Kannapolis, North Carolina, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Estimate the prevalence of COVID-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.|Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies|Estimate of the prevalence of active infection in Cabarrus County.|Estimate of the prevalence of exposure and potential immunity to COVID-19.""}"
"1294","Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.","SabanaHerons","NCT04497623","202006-25502","Device: Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04497623","Completed","2020-07-28","2020-09-20","{""locations"":""Fundacion Neumologica Colombiana, Bogot\u00e1, Bogota, Colombia|Universidad de la Sabana, Chia, Cundinamarca, Colombia|Clinica Universidad de la Sabana, Ch\u00eda, Cundinamarca, Colombia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility"",""enrollment"":""5"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement or maintenance of the oxygenation level measured by PaO2|Improvement or maintenance of the oxygenation level measured by O2 Saturation|Improvement or maintenance of adequate levels of carbon dioxide measured by PaCO2|Improvement or maintenance of adequate levels of HCO3|Improvement or maintenance of adequate levels of excess base.|Improvement or maintenance of adequate levels of blood pH|Improvement or maintenance of PaO2\/FiO2|Improvement or maintenance of SatO2\/FiO2|Uninterrupted and faultless operation in the period of use of the ventilator|Inspiratory peak pressure> 35 cm H2O that does not have a clinical explanation other than the ventilator (such as a mucus plug)|Plateau airway pressure> 30 cm H2O that does not have a clinical explanation other than the ventilator|VT> 8 cc \/ kg of ideal weight that does not have a clinical explanation other than the ventilator|Decrease or increase in respiratory rate, tidal volume, PEEP, peak inspiratory pressure, FiO2, not due to a clinician order (changes not ordered by the clinical team but due to the ventilator variability)|Pneumothorax (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Pneumomediastinum (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Subcutaneous emphysema (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Hemodynamic deterioration in the hour following the start of the Unisabana-Herons ventilator that requires a 100% increase in the dose of vasopressors and that does not have a clinical explanation other than the ventilator|Cardiac arrest without a clinical explanation other than the ventilator|Death without a clinical explanation other than the ventilator|Elevation of creatinine that does not have a clinical explanation other than the ventilator|Elevation of BUN that does not have a clinical explanation other than the ventilator|Digestive bleeding without a clinical explanation other than ventilator|Stress ulcers (upper gastrointestinal tract) without a clinical explanation other than ventilator|Pneumonia associated with ventilator.|Tracheobronchitis associated with ventilator.|Critical care polyneuropathy that does not have a different explanation for the use of the ventilator and \/ or muscle relaxants necessary for mechanical ventilation|Critical care myopathy that does not have a different explanation for the use of the ventilator and \/ or muscle relaxants necessary for mechanical ventilation""}"
"1295","Surgical Face Mask Effects in Patients With COVID-19","","NCT04689542","COSIT","Other: Sit-To-Stand test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04689542","Recruiting","2021-01-01","2021-08-01","{""locations"":""Cliniques universitaires Saint-Luc, Brussels, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in dyspnea level|Changes in respiratory rate|Changes in heart rate|Changes in pulsed oxygen saturation (SpO2)|Number of sit-to-stand repetition""}"
"1296","The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak","","NCT04650035","The Impact of COVID-19 Jordan","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04650035","Completed","2020-11-01","2020-11-10","{""locations"":""Yarmouk University, Irbid, Jordan"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""60"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of surgical operations performed whether elective or emergency""}"
"1297","Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia","COVID-Scan","NCT04355715","RECHMPL20_0223","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355715","Completed","2019-04-01","2020-10-20","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Confirmed diagnosis of COVID-19 infection|Incidence of unexpected COVID-19 positive patients admitted to the hospital|Number of contaminating events avoided by the early detection of COVID-19 patients|Incidence of SARS-Cov-2 seroconversion""}"
"1298","Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen","Opaganib-RHB","NCT04502069","ABC-112","Drug: Opaganib","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04502069","Withdrawn","2020-08-01","2021-06-01","{""locations"":""Shaare Zedek Medical Center, Jerusalem, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to breathing room air|Adverse Event Grading and Coding""}"
"1299","Use of the Nasal Cannula During COVID-19","","NCT04376580","Nasal cannulas flow rate","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376580","Enrolling by invitation","2020-04-30","2020-11-30","{""locations"":""Carolina Frederico, Buenos Aires, Caba, Argentina"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of physician using los flow nasal cannula during COVID 19 pandemia|Number of physician getting sick during Covid 19 pandemic""}"
"1300","The Critical Care Response to the COVID-19 Pandemic in Madrid","Tetrix","NCT04393324","Madrid COVID Tetrix","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393324","Recruiting","2020-04-24","2020-06-30","{""locations"":""Hospital Clinico San Carlos, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""2500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality|Length of ICU stay""}"
"1301","Hyperpolarized 129Xe MRI of Survivors of COVID-19","","NCT04659707","00146646","Drug: Hyperpolarized Xe129","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04659707","Recruiting","2021-02-22","2021-12-31","{""locations"":""University of Kansas Medical Center, Kansas City, Kansas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilation Defect Percentage""}"
"1302","Clinical Evolution and Becoming of Adult Patients Infected With Covid-19 Hospitalized at Strasbourg University Hospitals","","NCT04706260","7839","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04706260","Recruiting","2020-04-14","2021-04-14","{""locations"":""Adult Emergency Department - Strasbourg University Hospitals, Strasbourg, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective evaluation of the clinical evolution and becoming of adult patients infected with Covid-19 hospitalized at the University Hospitals of Strasbourg from the Emergency Structure""}"
"1303","Allocetra-OTS in COVID-19, Phase II","","NCT04590053","DM004","Biological: Allocetra-OTS","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04590053","Recruiting","2020-10-20","2021-03-01","{""locations"":""Barzilai Medical Center, Ashkelon, Israel|Hadassah Medical Center, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""24"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE)|Preliminary Efficacy: Recovery from COVID-19 as determined by negative PCR or asymptomatic by the NIH classification for the severity of illness|Mortality|Preliminary Efficacy: To assess prevention of respiratory deterioration associated with COVID-19 by measuring the PaO2\/FiO2 ratio|Hospitalization|Life support|Clinical status by the new NIH Patient Classification for the severity of illness|Clinical status by NEWS2|Support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale|Support measurements: improvement of severity rating on a 7-point ordinal scale|Virus Clearance|Exploratory: Serum cytokines\/chemokines and immunomodulating factors|Exploratory: complete blood counts|Exploratory: Histone and cell-free DNA levels""}"
"1304","Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation","","NCT04494867","COVID-19 Core Warming","Device: Core Warming|Other: Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04494867","Recruiting","2020-08-19","2020-12-01","{""locations"":""Sharp Memorial Hospital, San Diego, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PaO2\/FiO2 ratio|Viral Load Measurement|Duration of mechanical ventilation|Mortality""}"
"1305","French Cohort of COVID-19 Patients With Post-intensive Care Syndrome","COREADOM","NCT04590170","APHP200812","Behavioral: Post-intensive Care unit syndrome","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04590170","Recruiting","2020-10-30","2023-04-30","{""locations"":""Department of Physical Medicine and Rehabilitation, Issy-les-Moulineaux, France|Department of Rehabilitation, Institute of Rheumatology Cochin, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change on cognitive Impairment: Vigilance (RASS)|Change on cognitive Impairment: Cooperation|Change on cognitive Impairment: Communication|Change on cognitive Impairment: Agitation|Change on cognitive Impairment: Delirium|Change on cognitive Impairment : Introduction of neuroleptic|Change on cognitive Impairment: temporo-spatial disorientation|Change on physical Impairment : dyspnea|Change on physical Impairment: Modified Borg scale dyspnea score.|Change on physical Impairment : cough|Change on physical Impairment : respiratory rate|Change on physical Impairment : ventilation mode|Change on physical Impairment : Peripheral capillary oxygen saturation (SpO2) at rest|Change on physical Impairment : respiratory rate on activity|Change on physical Impairment : Peripheral capillary oxygen saturation (SpO2) on activity|Change on physical Impairment : orthostatic hypotension|Change on physical Impairment : electrocardiogram at rest|Change on physical impairment : numeric verbal scales of fatigue|Change on physical Impairment: numeric verbal scales of pain|Change on physical Impairment : stiffness or pain involving joints|Change on physical Impairment : stability of the trunk in siting|Change on physical Impairment : autonomy for bed-chair transfers|Change on physical Impairment autonomy for walking|Change on physical Impairment : sores|Change on Imagery cerebral|Change on physical Impairment neurologic exam|Change on physical Impairment Medical Research Council (MRC-SS MRC Sum score)|Change on physical Impairment five times sit to stand test|Change on cognitive Impairment The Montreal Cognitive Assessment (MoCA)|Cognitive Impairment Frontal Assessment Battery (FAB)|Change on psychological Impairment : sadness|Change on psychological Impairment : anxiety|Change on psychological Impairment: Insomnia|Change on psychological Impairment : Apathy|Change on psychological Impairment : sideration|Change on psychological Impairment : Despair|Change on psychological Impairment : Culpability|Change on psychological Impairment : Conduit addictive|Change on psychological Impairment : psychiatric or psychologic care|assess type of psychiatric treatment|Change on psychological Impairment : Hospital Anxiety and Depression Scale (HADS)|Change on psychological Impairment : Posttraumatic Stress Disorder Checklist Scale (PCL-S)|assess psychological Impairment|asses demographics information|assess comorbidities|assess past and current medications|assess related symptoms nature of COVID-19|assess characteristics of ongoing hospitalization|assess medical complications in intensive care|Descriptive data of the rehabilitation care pathway after stay in intensive care until return home|Number of new medical qualifying events since last contact|Social status|Activities of Daily Living (ADL) scale|Quality of life Medical outcome study short form 12 items (MOS-SF-12 ) questionnaire|Gait analysis 6-minute walk test (6MWT)|Balance and Gait analysis""}"
"1306","Checkpoint Blockade in COVID-19 Pandemic","COPERNICO","NCT04335305","MedOPP376|2020-001160-28","Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04335305","Recruiting","2020-04-09","2021-06-30","{""locations"":""Hospital Quir\u00f3nsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Arnau de Vilanova-Lliria, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with normalization of SpO2 \u226596% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)""}"
"1307","Spread Analysis of COVID-19 Outbreak in France by Self-assessment Web-application","SourceCOVID","NCT04670003","WP-2020-05","Other: users","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04670003","Not yet recruiting","2021-01-01","2021-03-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Description of the methods of contamination of patients|Evaluation in time of the spread of the virus during the 2nd epidemic wave.|Evaluation in space of the spread of the virus during the 2nd epidemic wave.""}"
"1308","COVID-19 Convalescent Plasma for Mechanically Ventilated Population","","NCT04388527","842996 (PennCCP-01)","Biological: COVID-19 Convalescent Plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04388527","Active, not recruiting","2020-04-30","2021-06-30","{""locations"":""Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participants with serious adverse events.|Time to clinical improvement.|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Non-invasive ventilation\/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of non-invasive ventilation\/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of non-invasive ventilation\/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Ventilator\/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Cumulative incidence of Grade 3 and Grade 4 clinical and\/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006..|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.""}"
"1309","COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units","TOCCIP","NCT04433325","35RC20_3091_TOCCIP","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433325","Not yet recruiting","2020-06-01","2020-09-01","{""locations"":""CHU Poitiers, Poitiers, France|CHU Tours, Tours, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of death|number of infections|number of days of mechanical ventilation|number of days of sedation|number of days of use of neuromuscular blocking agents|number of days of vasopressor use|number of days in Intensive Care Units|number of days in hospital""}"
"1310","Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm","","NCT04355247","CCAM 20-01","Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04355247","Recruiting","2020-04-14","2021-04-30","{""locations"":""San Juan City Hospital \/ Puerto Rico Medical Center, San Juan, Puerto Rico|Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical complete response criteria|Clinical Partial Response criteria|Secondary response criteria""}"
"1311","Convalescent Plasma for COVID-19 Patients (CPCP)","CPCP","NCT04521036","ISC.20.11.2","Biological: Convalescent Plasma as Therapy for Covid-19 patients","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04521036","Not yet recruiting","2020-12-01","2021-10-30","{""locations"":""Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""44"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in mortality|Change in requirement for mechanical ventilation|Change in the duration of mechanical ventilation|Incidence of Treatment-Emergent Adverse Events""}"
"1312","USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19","IVERCAR","NCT04425850","IVERCAR","Combination Product: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)","Observational","Has Results","","https://ClinicalTrials.gov/show/NCT04425850","Completed","2020-06-01","2020-08-10","{""locations"":""Hospital Eurnekian, Buenos Aires, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""229"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Infected Subjects|Adverse Events Other Than Those Resulting From Contagion or Disease Progression""}"
"1313","Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo","DynaCovid","NCT04701996","B3002020000141","Biological: serological surveillance","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04701996","Recruiting","2020-09-23","2021-12-31","{""locations"":""Centre de Recherche en Sant\u00e9 de Kimpese, Kimpese, Congo, The Democratic Republic of the"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1600"",""age"":""1 Month to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""To predict and monitor the transmission of SARS-CoV-2 in a rural Sub Saharan setting.|To inform intervention strategies targeted at limiting the spread of COVID-19 in a rural Sub Saharan setting.|To create social contact matrices that can be used to parameterise dynamic transmission models.""}"
"1314","Physical Activity and the Risk of COVID-19 Infection and Mortality","","NCT04631861","2020AN0292","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04631861","Completed","2014-01-01","2020-07-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""132069"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 positivity rate (%)|COVID-19 related mortality rate (%)""}"
"1315","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","","NCT04349631","Protection Against COVID-19","Drug: HB-adMSCs","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04349631","Active, not recruiting","2020-04-22","2021-05-01","{""locations"":""Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""56"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper\/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9""}"
"1316","Home Pulse Oximeter Use in Patients With COVID-19","","NCT04373161","2020032301","Device: Home Pulse Oximetry Monitoring","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04373161","Completed","2020-03-20","2020-04-22","{""locations"":""Swedish Hospital, Chicago, Illinois, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""209"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization in COVID-19 patients with low home SpO2|Trend in resting home pulse oximetry readings|Timing of SpO2 <92%|Home pulse oximeter use effect on subsequent ED visits|Reason for return to the Emergency Department|Hospitalization outcome - morbidity|Hospitalization outcome - mortality|Median Length of Stay""}"
"1317","Efficacy and Safety of Ovotransferrin in COVID-19 Patients","","NCT04643054","20201116","Dietary Supplement: Ovotransferrin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04643054","Not yet recruiting","2020-12-01","2021-03-30","{""locations"":""Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality|C reactive protein (CRP) levels|IL-6 levels|D-dimer levels|Hospital stay|Duration of positive PCR swab""}"
"1318","Patients Reactions Towards Their Diagnosis as Having COVID-19","","NCT04581928","PR0020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581928","Recruiting","2020-10-10","2021-04-15","{""locations"":""Asalam, Maadi, Cairo, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery""}"
"1319","Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection","","NCT04636086","D-COVID","Drug: Cholecalciferol|Other: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04636086","Recruiting","2020-11-12","2021-02-28","{""locations"":""CHU Li\u00e8ge, Li\u00e8ge, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Vitamin D serum concentration|Clinical improvement|Hospital length of stay.|Intensive care unit length of stay.|Supplemental oxygen, non-invasive or invasive ventilation or organ support|Duration of supplemental oxygen, non-invasive or invasive ventilation or organ support|Absence of fever|Time until negative laboratory SARS-CoV-2 test.|Mortality all causes.|Mortality related to Covid-19.|Biological markers""}"
"1320","Oral Manifestations of Coronavirus Disease 2019(COVID-19) :a Multicentre Study","","NCT04487665","8791","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04487665","Not yet recruiting","2020-09-15","2020-12-15","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""50"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""oral ulcer|hyposalivation""}"
"1321","Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19","","NCT04615429","COVID-AT|2020-002193-27","Biological: Mesenchymal stromal cells|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04615429","Active, not recruiting","2020-09-15","2022-01-01","{""locations"":""Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the PaO2\/FiO2* ratio from baseline to day 7 of treatment administration|All-cause mortality|Time to PaO2\/FiO2 ratio greater than 200 mmHg|Clinical status on the World Health Organization ordinal scale|PaO2\/FiO2 ratio|SOFA score|Oxygen therapy-free days|Duration of hospitalization|Duration of ICU admission|Incidence of non-invasive ventilation|Incidence of invasive mechanical ventilation|Duration of non-invasive ventilation|Duration of invasive mechanical ventilation|Mechanical ventilation-free days|Survival rate|Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest.""}"
"1322","Maternal Morbidity and Mortality During the COVID-19 Pandemic","MFMU COVID-19","NCT04519502","HD36801 - MFMU COVID-19|U01HD036801","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04519502","Recruiting","2020-06-23","2021-12-31","{""locations"":""University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Columbia University-St. Luke's Hospital, New York, New York, United States|University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|Brown Univeristy, Providence, Rhode Island, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""26400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Maternal Mortality and Morbidity Composite|Cesarean Delivery|Severe maternal morbidity or mortality|Adverse maternal outcomes|Adverse neonatal outcomes|Neonatal infection|Maternal in-patient hospitalization days|Maternal ICU admission|Duration of labor and delivery|Neonatal length of stay|Neonatal ICU length of stay""}"
"1323","Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologics","COV19-APTP-B","NCT03305341","PDP-153210-215451-761218|FWA00015357|IRB00009424|IORG0007849|IND153210|NDA215451|BLA761218","Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT03305341","Active, not recruiting","2020-07-18","2021-06-28","{""locations"":""Medicine Invention Design Incorporation (MIDI) - IORG0007849, North Bethesda, Maryland, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""22 Years to 72 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with Moderate COVID-19:|Rate of Positive COVID-19 nucleic acid:|Concentration of Active Ingredient:|Rate of Negative COVID-19 nucleic acid""}"
"1324","Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization","RiskSEARCH","NCT04709068","Pro00047371","Device: Current Health","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04709068","Recruiting","2021-02-08","2021-07-01","{""locations"":""Current Health, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2050"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization|Recovery|ICU Admission|Death""}"
"1325","A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)","","NCT04379271","P2-IMU-838-COV","Drug: IMU-838|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04379271","Recruiting","2020-06-11","2020-10-01","{""locations"":""Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria|UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria|University Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany|Clinic of the Hannover Medical School, Pneumology Clinic, Hannover, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients without any need* for INV until end-of-study (EoS)|Duration of ICU treatment until EoS|28-day all-cause mortality|Time to clinical improvement|Duration of hospitalization|Proportion of patients both for all patients and surviving patients free of renal-replacement therapy (RRT)* until EoS|Proportion of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)* until EoS|Proportion of patients free of INV until Days 6 and 14*|Proportion of patients free of RRT until Days 6 and 14*|Proportion of patients free ECMO until Days 6 and 14*|Proportion of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Proportion of patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28|Proportion of patients with clinical recovery: Axillary temperature \u226436.6 \u2103, or oral temperature \u226437.2 \u2103, or rectal or tympanic temperature \u226437.8 \u2103;|Proportion of patients with clinical recovery: Respiratory frequency \u226424 times\/min without oxygen inhalation; and|Proportion of patients with clinical recovery: Oxygen saturation \u226598% without oxygen inhalation|Proportion of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first|Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Duration of INV|Duration of ECMO|Duration of RRT|Duration of auxiliary oxygen therapy (including all types of oxygen therapy)|Duration of hospitalization for survivors|The rate of ICU* admission on Days 6, 14, and 28|Hospital-free days|Time from IMP treatment initiation to death|Time to first prescription of INV|Time to first prescription of RRT|Time to first prescription of ECMO|Time to first prescription of INV, RRT, and ECMO|Time to ICU admission|Cumulative dose of vasoactive therapies and days with vasoactive therapies (daily until Day 14)|Time to clinical recovery|Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28|Correlation of trough levels (quartiles) to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Adverse events (AEs) and serious AEs|Vital signs: height|Vital signs: weight|Vital signs: body temperature (\u00baC)|Vital signs: pulse rates,|Vital signs: systolic and diastolic blood pressures|Clinical laboratory parameters: blood chemistry|Clinical laboratory parameters: hematology|Clinical laboratory parameters: urinalysis|12-lead electrocardiogram: heart rate|12-lead electrocardiogram: PQ-interval|12-lead electrocardiogram: QRS-interval|12-lead electrocardiogram: QT interval|12-lead electrocardiogram: the heart rate-corrected QTc interval (according to Bazett's formula)|Temperature|D-dimer|Lactate dehydrogenase (LDH)|C-reactive protein|Troponin I|Procalcitonin|Correlation of disease markers to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Decrease of SARS-CoV-2 viral load|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Time course of SARS-CoV-2 viral load|Qualitative virologic clearance in spontaneous sputum and nasopharyngeal swab samples (= 2 consecutive negative SARS-CoV-2 reverse transcriptase polymerase chain reaction tests at least 24 hours apart)|Rate of conversion to a negative SARS-CoV-2 (qualitative) test on Days 6, 14 and 28|Time to conversion to a negative SARS-CoV-2 (qualitative) test|Interleukin (IL)-17|Interleukin (IL)-1\u00df|Interleukin (IL)-6|interferon gamma (IFN\u03b3)|tumor necrosis factor alpha|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: \u2022 Time to appearance of IgA and\/or IgG antibodies|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: \u2022 Proportion of patients with IgA and\/or IgG antibodies on Days 6, 14, and 28""}"
"1326","A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults","ENSEMBLE 2","NCT04614948","CR108916|2020-003643-29|VAC31518COV3009","Biological: Ad26.COV2.S|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04614948","Recruiting","2020-11-16","2023-05-11","{""locations"":""Achieve Clinical Research, LLC, Vestavia Hills, Alabama, United States|Hope Research Institute, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc, Tucson, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Synexus Clinical Research US, Inc, Cerritos, California, United States|eStudySite, Chula Vista, California, United States|Ark Clinical Research, Long Beach, California, United States|Anthony Mills Medical, Inc, Los Angeles, California, United States|Catalina Research Institute, Montclair, California, United States|Benchmark Research, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Paradigm Clinical Research Centers, Inc., Wheat Ridge, Colorado, United States|JEM Research, LLC, Atlantis, Florida, United States|Prestige Clinical Research Center, Inc., Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Health Awareness inc., Jupiter, Florida, United States|Altus Research, Inc, Lake Worth, Florida, United States|Compass Research, Melbourne, Melbourne, Florida, United States|Suncoast Research Group, Miami, Florida, United States|Behavioral Clinical Research , Inc, North Miami, Florida, United States|Advent Health Orlando, Orlando, Florida, United States|Clinical NeuroScience Solutions, Inc, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Accel Research Sites, Eatonton, Georgia, United States|The University Of Chicago Medicine, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|The South Bend Clinic Center for Research, South Bend, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Centennial Medical Group, Elkridge, Maryland, United States|Optimal Research, Rockville, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Cherry Street Services, Inc., Grand Rapids, Michigan, United States|Abbott Northwestern Hospital Clinic, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hassman Research Institute, LLC., Berlin, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Medpharmics, LLC, Albuquerque, New Mexico, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Allergy Asthma Immunology of Rochester, PC (AAIR) - Research Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|American Health Network, LLC, Charlotte, North Carolina, United States|Wilmington Health Associates, Wilmington, North Carolina, United States|CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Clinical NeuroScience Solutions, Inc, Memphis, Tennessee, United States|Centennial Medical Center, Nashville, Tennessee, United States|Tekton Research Inc., Austin, Texas, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Centex Studies, Inc., McAllen, Texas, United States|Endeavor Clinical Trials, LLC, San Antonio, Texas, United States|JBR Clinical Research, Salt Lake City, Utah, United States|Alliance for Multispeciality Research, Norfolk, Virginia, United States|Anima, Alken, Belgium|Institute of Tropical Medicine Antwerp, Antwerpen, Belgium|Hopital Erasme, Brussel, Belgium|Center for Vaccinology (CEVAC), Gent, Belgium|UZ Leuven, Leuven, Belgium|Az Sint-Maarten, Mechelen, Belgium|Private Practice RESPISOM Namur, Namur, Belgium|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital federal dos servidores do estado, Rio de Janeiro, Brazil|Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ, Rio de Janeiro, Brazil|Centro de Refer\u00eancia E Treinamento Dst\/Aids, Sao Paulo, Brazil|Instituto de infectologia Emilio Ribas, S\u00e3o Paulo, Brazil|Fundacion Cardiomet CEQUIN, Armenia, Colombia|IPS Centro Cientifico Asisitencial Jose Luis Accini S.A.S., Barranquilla, Colombia|Caja de Compensacion Familiar Cafam, Bogota, Colombia|Asistencia Cientifica de Alta Complejidad S.A.S, Bogota, Colombia|CAIMED Aguazul, Casanare, Colombia|Centro Medico Imbanaco de Cali S.A., Casanare, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia|Hospital General de Medellin Luz Castro de Gutierrez E.S.E, Medellin, Colombia|T Y C Inversiones S A S Grupsalud, Santa Marta, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Yopal - Casanare, Colombia|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Grenoble - H\u00f4pital Albert Michallon, La Tronche, France|CHU de Montpellier, Hopital Saint-Eloi, Montpellier, France|Hopital Saint-Antoine, Paris Cedex 12, France|Hopital Cochin, Paris, France|Groupe Hospitalier Sud H\u00f4pital Haut-Leveque Service d'hematologie, Pessac, France|CHU Saint-Etienne - H\u00f4pital Nord, Saint-Etienne Cedex 2, France|Hopital Purpan, Toulouse Cedex 09, France|Hopital Rangueil, Toulouse, France|Centre Hospitalier Universitaire de Tours, Tours Cedex, France|H\u00f4pital de Brabois Adultes, Vandoeuvre les Nancy, France|Uniklinik K\u00f6ln, K\u00f6ln, Germany|Klinikum rechts der Isar der TU Munchen, M\u00fcnchen, Germany|Riverside Medical Center, Bacolod, Philippines|West Visayas State University Medical Center, Iloilo City, Philippines|Tropical Disease Foundation, Makati, Philippines|Makati Medical Center, Manila, Philippines|Medical Center Manila, Manila, Philippines|TREAD Research Tygerberg Hospital, Cape Town, South Africa|Centre of Tuberculosis Research Innovation, Cape Town, South Africa|Worthwhile Clinical trials, Johannesburg, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Dr AA Mahomed Medical Centre, Moloto, South Africa|VX Pharma, Pretoria, South Africa|Dr J.M. Engelbrecht Trial Site, Somerset West, South Africa|Be Part Yoluntu Centre, Western Cape, South Africa|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Hospital Quiron Barcelona, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Clinica Univ. de Navarra, Madrid, Spain|Hosp. Univ. de La Paz, Madrid, Spain|Hosp. Quiron Madrid Pozuelo, Madrid, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Powys Teaching Local Health Board - Bronllys Hospital, Brecon, United Kingdom|Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospitals Bristol NHS Trust, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Royal Free Hospital, Hampstead, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Guy's and St Thomas' Hospital, London,, United Kingdom|Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|University of Oxford, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Southampton General Hospital, Southampton, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""30000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe\/Critical COVID-19 and who were Seronegative at Baseline|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe\/Critical COVID-19 Regardless of their Serostatus|Number of Participants with First Occurrence of COVID-19 Requiring Medical Intervention|SARS-CoV-2 Viral Load as Assessed by Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) in Participants with Molecularly Confirmed, Moderate to Severe\/Critical COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed Mild COVID-19|Number of Participants with First Occurrence of Molecularly confirmed COVID-19 Defined by the US FDA Harmonized Case Definition|Burden of Disease (BOD) Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19|Serologic Conversion Between Baseline (Day 1) and 14 days, 6 months, and 1 year after the 2nd vaccination Using an Enzyme-linked Immunosorbent Assay (ELISA)|Number of Participants with First Occurrence of SARS-CoV-2 Infection (Serologically and\/or Molecularly Confirmed)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Medically-attended Adverse Events (MAAEs)|Number of Participants with Medically-attended Adverse Events (MAAEs) Leading to Study Discontinuation|Number of Participants with Solicited Local Adverse Events (AEs) During 7 Days Following Each Vaccination|Number of Participants with Solicited Systemic AEs During 7 Days Following Each Vaccination|Number of Participants with Unsolicited Local Adverse Events (AEs) During 28 Days Post-vaccination|SARS-CoV-2 Binding Antibodies Assessed by ELISA""}"
"1327","Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age","","NCT04499300","CHUB-COVID-19-90+","Other: Data collection from medical files","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04499300","Recruiting","2020-06-09","2020-12-01","{""locations"":""CHU Brugmann, Brussels, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""90 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Demographic data|Comorbidities|Cumulative Illness Rating Scale-Geriatric (CIRS-G)|Treatments|Signs and symptoms|Fever|Hypoxemia|Tachycardia|Hypotension|Gasometry|Infectious data|Blood count|Ionogram|Liver function|Coagulation|Renal function|Albumin|CRP|Fibrinogen|D-dimers at hospital admission or first recorded|NTproBNP|CK|Troponin|Ferritin|Procalcitonin|Biology - highest rate|Biology - lowest rate|Percentage of pulmonary involvement on chest CT scan|Number of pulmonary lobes affected|Type of lesions|Need for oxygenotherapy|Means of ventilation|Treatment received|Length of ICU Stay|Status at hospital exit|Mortality""}"
"1328","Clinical Study Spartan COVID-19 V2 System (Canada Alternate)","","NCT04628208","VNV-00635","Diagnostic Test: Spartan COVID-19 v2 System","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04628208","Recruiting","2020-11-17","2021-01-01","{""locations"":""The Ottawa hospital, Ottawa, Ontario, Canada"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent Agreement between SOC test and Spartan COVID-19 test""}"
"1329","Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19","","NCT04703036","H48057","Dietary Supplement: Glycine|Dietary Supplement: N-acetylcysteine|Dietary Supplement: Alanine","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04703036","Recruiting","2021-01-11","2021-12-31","{""locations"":""Baylor College of Medicine, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other"",""enrollment"":""64"",""age"":""55 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Glutathione concentrations|Change in Interleukein 6 concentrations|Change in Ordinal scale|Change in oxidative stress|Change in marker of damage due to oxidative stress|Change in inflammatory cytokines|Change in mitochondrial energetics|Change in immune function|Change in cognition|Change in function|Change in fatigue|Change in circulating marker of memory""}"
"1330","Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)","HBOTCOVID19","NCT04358926","120-20-ASF","Device: Hyperbaric oxygen therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04358926","Completed","2020-04-30","2020-11-01","{""locations"":""Amir Hadanny, Zerifin, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SpO2|NEWS Score|Inflammation level -CRP|white blood cells number|Cytokines - IL1|Cytokines - IL2|Cytokines - IL6|Cytokines - IL10|Cytokines - TNFalpha|Inflammation level - procalcitonin|Inflammation level - ferritin|Symptoms level|Number of patients with IgM seroconversion|Number of patients with IgG seroconversion|FEV1\/FVC|Time to symptoms recovery|Number of patients who required invasive ventilation|Time to negative virus PCR|Mortality rate|Number of barotrauma events (safety)""}"
"1331","Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19","ASPEN","NCT04655586","NAPc-201/301","Drug: rNAPc2|Drug: Heparin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04655586","Recruiting","2020-12-10","2021-05-31","{""locations"":""ARCA Investigational Site #104, Aurora, Colorado, United States|ARCA Investigational Site #101, Jacksonville, Florida, United States|ARCA Investigational Site #113, New Orleans, Louisiana, United States|ARCA Investigational Site #105, Falls Church, Virginia, United States|ARCA Investigational Site #114, Richmond, Virginia, United States|ARCA Investigational Site #103, Tacoma, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in D-dimer level from Baseline to Day 8 (Phase 2b)|Number of major or non-major clinically relevant bleeding events within thirty (30) days of randomization (Phase 2b)|Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)|Change in D-dimer level from baseline to Day 10 (Phase 2b)|Number of major or non-major clinically relevant bleeding events with rNAPc2 vs. heparin (Phase 2b and 3)|Number of bleeding events in subjects treated with higher vs. lower dose rNAPc2 at Day 10 (Phase 2b)|Time to first occurrence of a composite of thrombotic events and all-cause mortality within thirty (30) days of randomization (Phase 3 only)|Time to first occurrence of thrombotic events within thirty (30) days of randomization (Phase 3 only)|Time to all-cause mortality within thirty (30) days of randomization (Phase 3 only)|Change in Tissue Factor laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b)|Change in interleukin-6 laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b)|Change in high sensitivity C-reactive protein laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b)""}"
"1332","Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm","","NCT04561024","EN-092020","Diagnostic Test: AI model","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04561024","Active, not recruiting","2020-03-01","2020-12-31","{""locations"":""University of Hong Kong, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""4000"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diagnostic Performance of AI model""}"
"1333","Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19","","NCT04496141","RC-2020-12","Diagnostic Test: SARS-CoV-2 antibody immunoassays","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04496141","Active, not recruiting","2020-07-27","2020-11-30","{""locations"":""Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""70"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The accuracy of the different commercial SARS-CoV-2 antibody immunoassays""}"
"1334","Study on the Use of Sarilumab in Patients With COVID-19 Infection","","NCT04386239","COVID-SARI-001","Drug: Sarilumab Prefilled Syringe","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04386239","Recruiting","2021-01-01","2021-12-01","{""locations"":""Divisione Clinicizzata di Malattie Infettive, ASST FBF-Sacco, Milano, MI, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 84 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-\u03b1|Evaluation of the rate of progression of White Blood Cell (WBC) fraction""}"
"1335","Bucillamine in Treatment of Patients With COVID-19","","NCT04504734","RT-003","Drug: Bucillamine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04504734","Enrolling by invitation","2020-11-27","2021-06-01","{""locations"":""Samuel Ross MD Inc., Beverly Hills, California, United States|ASCADA Research, Huntington Beach, California, United States|C & R Research Services USA, Coral Gables, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Columbus Clinical Services, Miami, Florida, United States|Verus Clinical Research, Miami, Florida, United States|Amavita Clinical Research, North Miami Beach, Florida, United States|Encore Medical Research of Weston LLC, Weston, Florida, United States|Quad Clinical Research LLC, Chicago, Illinois, United States|Machuca Family Medicine, Las Vegas, Nevada, United States|OnSite Clinical Solutions, Charlotte, North Carolina, United States|OnSite Clinical Solutions, LLC, Charlotte, North Carolina, United States|Encore Imaging and Medical Research, Houston, Texas, United States|Family Practice Center, McAllen, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy: Frequency of hospitalization or death|Safety: Changes in adverse events from baseline to end of study""}"
"1336","Assesment of the Metabolomic Signature in COVID-19 Patients","SignCov","NCT04497272","20-PP-18","Other: COVID-19 patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04497272","Recruiting","2020-08-07","2021-10-07","{""locations"":""CHU de nice, Nice, Alpes-Maritimes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identifying the metabolomic signature|Identification of the metabolomic profile according to clinical severity.""}"
"1337","Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection","Ta1","NCT04487444","SCN-16130571-2","Drug: Thymalfasin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04487444","Recruiting","2020-09-10","2021-06-01","{""locations"":""The Miriam Hospital, Providence, Rhode Island, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery (free of respiratory failure)|Lymphopenia|Survival|Hospital length of stay|Requirement for high flow oxygen supplementation|Duration of high flow oxygen supplementation|ICU admission|ICU length of stay|Mechanical ventilation|Duration of mechanical ventilation|Change in any existing comorbidities (e.g., worsening congestive heart failure) or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections (other respiratory, urinary tract, cellulitis, etc.)|AEs\/SAEs|Changes to vital signs|Changes in laboratory parameters""}"
"1338","Anxiety and Depression Among Pregnant Women During COVID-19 Pandemic","","NCT04558749","ADCOVID","Other: State-trait anxiety inventory scale|Other: Edinburgh Postnatal Depression Scale (EDPS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04558749","Recruiting","2020-10-01","2021-06-01","{""locations"":""Assiut Faculty of Medicine, Assiut, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The mean scores anxiety and depression among pregnant women during COVID-19 pandemic""}"
"1339","DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)","DYNAMIC","NCT04371952","RC20_0191","Drug: Doxycycline|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04371952","Not yet recruiting","2020-06-01","2020-12-01","{""locations"":""CHU Avicenne - APHP, Bobigny, France|CHU Bordeaux, Bordeaux, France|CHU Caen, Caen, France|CHU Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Nantes, Nantes, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""330"",""age"":""46 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Patients with Clinical Respiratory Aggravation|Percentage of patients hospitalized|Percentage of patients requiring ventilatory assistance|Positive SARS-CoV-2 PCR Test|Duration of symptoms|Duration of hospitalization|Hospitalization intensive care or reanimation|Duration of mechanical ventilatory assistance|Percentage of deaths related to SARS-CoV-2|AE \/ SAE in both arms""}"
"1340","Response of Korean Medicine Hospital to COVID-19","","NCT04529447","JMA-CT-2020-01","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04529447","Completed","2020-06-10","2020-08-10","{""locations"":""Jaseng Hospital of Korean Medicine, Seoul, Korea, Republic of"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""485"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Satisfactory service regarding hospital response to COVID-19|Feelings of apprehension regarding hospital visits|Medical staff wearing of facial masks and hand hygiene|Cleanliness and sterilization of hospital facilities|Convenience and accessibility of hand sanitizers|Helpfulness and readability of posters and stand-up banners|Satisfaction with hospital safety measures for COVID-19|Recommendation of hospital to friends and family""}"
"1341","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","NO COV-ED","NCT04338828","2019P00XXXX","Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04338828","Active, not recruiting","2020-04-18","2022-04-01","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""47"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality""}"
"1342","PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19","PHRUCov01","NCT04581915","PHRU CoV01","Drug: Triazavirin (Riamilovir)|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04581915","Recruiting","2020-09-08","2021-12-31","{""locations"":""The Perinatal HIV Research Unit - Matlosana, Klerksdorp, North West Province, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""420"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To compare the slope of cycle threshold(Ct) values of nasopharyngeal swabs in people receiving Triazavirin versus placebo|To assess the proportion of patients who progress to severe COVID-19 and the proportion who need ICU or die.|To determine the proportion of patients who develop grade 3 or grade 4 adverse events on treatment|To determine the proportion of patients who stop taking either placebo\/Triazavirin""}"
"1343","Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic","","NCT04709744","RP.21.01.91","Drug: Vitamin D|Diagnostic Test: ELISA","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04709744","Completed","2020-04-01","2020-12-30","{""locations"":""Mansoura University Hospital, Mansoura, DK, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""38"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Level of serum vitamin D in SLE infected with COVID-19|Vitamin D level with COVID-19 severity""}"
"1344","Rehabilitation After Admission in Intensive Care Unit for COVID-19","RECOVER","NCT04523051","2020-05Obs-CHRMT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04523051","Recruiting","2020-04-01","2021-05-01","{""locations"":""Etablissement de sant\u00e9 Filieris, Freyming-Merlebach, Moselle, France|Hopital Legouest, Metz, Moselle, France|CHR Metz Thionville, Metz, Moselle, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Functional Independence measure (FIM) at the admission|Functional Independence measure (FIM) 1-month hospitalization|Functional Independence measure (FIM) at the discharge|weight at admission|weight at the discharge|age|Estimated functional independence measure score before Covid-19|Estimated dyspnea symptoms before Covid-19|Length of stay in ICU unit|Length of stay in acute care|Length of stay in rehabilitation centers|Length of Invasive mechanical ventilation|Presence of pressure ulcers|Risk of bedsore|Joint limitation|Dominant side|Presence of psychic disorders|Muscle strength at the admission|Muscle strength at the discharge|Dyspnea symptoms at the admission|Dyspnea symptoms at the discharge|Functional exercise capacity|Destination of patients at discharge|Oxygen saturation of the blood at the admission|Oxygen saturation of the blood at the discharge|Presence of Hoffman signs|Presence of Babinski signs|Sex|Neurological examination at the admission|Neurological examination at the discharge""}"
"1345","Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease","","NCT04623619","20201109","Dietary Supplement: Acetyl L-Carnitine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04623619","Not yet recruiting","2020-12-15","2021-07-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality|C reactive protein (CRP) levels|IL-6 levels|D-dimer levels|Hospital stay|Duration of positive PCR swab""}"
"1346","Using Travelan to Boost Immune Response in Vitro to COVID-19","","NCT04643561","healthytravelancov19- HMO-CTIL","Other: Travelan OTC","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04643561","Active, not recruiting","2020-11-01","2020-12-31","{""locations"":""Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""5"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""increase levels of IFN\u03b3|registering adverse events""}"
"1347","TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)","","NCT04405271","5616","Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04405271","Not yet recruiting","2020-07-31","2020-11-15","{""locations"":""Sociedad Argentina de Infectolog\u00eda, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1378"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 incident cases|Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology|Severity of symptomatic COVID-19|Respiratory symptom duration in days|Relation between treatments and symptoms duration|Time course of specific IgM\/IgG seroconversion""}"
"1348","World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments","SOLIDARITY","NCT04647669","SRD/ETH/20","Drug: Remdesivir|Drug: Acalabrutinib|Drug: Interferon beta-1a|Other: Standard of Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04647669","Not yet recruiting","2021-02-01","2021-12-31","{""locations"":""Univeristy of the West Indies, Kingston, Jamaica"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All cause Mortality|Duration of hospital stay|Time to first receiving ventilation|Time to admission to the intensive care unit""}"
"1349","Ayurveda as Prophylaxis for Suspected COVID-19 Patients","","NCT04395976","BAMC01","Other: Ayurveda","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04395976","Withdrawn","2020-05-10","2020-09-01","{""locations"":""British Ayurvedic Medical Council, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical confirmation of Covid-19""}"
"1350","Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19","","NCT04634799","STU00213262","Drug: TM5614|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04634799","Recruiting","2021-01-08","2022-06-30","{""locations"":""Northwestern University, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement|Sequential organ failure assessment (SOFA) score change|PAI-1 Levels|Ventilator free days""}"
"1351","Prevalence of Myocardial Scars on CMR After COVID-19 Infection","COVID-CMR","NCT04636320","CHUBX 2020/22","Device: Contrast-enhanced CMR|Diagnostic Test: Exercise test ECG|Biological: Blood sample|Diagnostic Test: Resting 12 lead ECG|Diagnostic Test: 24 hour Holter ECG","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04636320","Recruiting","2020-06-13","2021-04-13","{""locations"":""Bordeaux University Hospital, Pessac, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""240"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of myocardial scars|CMR feature : Location and size of myocardial scars|CMR feature : native T1 and T2 values|CMR feature : extracellular volume fraction|CMR feature : ventricular volumes|CMR feature : ejection fraction|CMR feature : myocardial strain|ECG features|Biological feature : positivity of COVID-19 serology|Biological feature : troponin level|Biological feature : inflammatory markers level|Genetic profile research""}"
"1352","TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19","","NCT04573855","PCL04/2020","Biological: Anti-SARS-CoV-2 immunoglobulin","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04573855","Not yet recruiting","2020-12-01","2021-03-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""41"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of adverse events related to the infusion of anti-SARS-CoV-2 immunoglobulin through CTCAE v4.0.|Clearence of viral RNA evaluated by RT-PCR|Reduction of viral load evaluated by area under the curve of RT-PCR values|Length of hospital stay|Orotracheal Intubation Rate|Infusional reaction rate|Mortality rate|Assessment of adverse events|Evaluation of clinical status|Modulation of serum and cellular inflammatory marker""}"
"1353","The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19","NeuroCovid","NCT04576351","152727","Other: Observation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04576351","Recruiting","2020-09-01","2023-12-31","{""locations"":""S\u00f8rlandet Hospital Trust, Arendal, Norway|Haukeland University Hospital, Bergen, Norway|Nordlandssykehuset, Bodo, Norway|Vestre Viken Hospital Trust Drammen, Drammen, Norway|\u00d8stfold Hospital Trust Kalnes, Gr\u00e5lum, Norway|S\u00f8rlandet Hospital Trust, Kristiansand, Kristiansand, Norway|Innlandet Hospital Trust, Lillehammer, Norway|Akershus University Hospital, L\u00f8renskog, Norway|M\u00f8re og Romsdal Hospital Trust, Molde, Norway|Oslo University Hospital, Oslo, Norway|Ostfold Hospital Trust, Sarpsborg, Norway|Skien Hospital, Skien, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital of North Norway, Troms\u00f8, Norway|St. Olav Hospital, Trondheim, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of peripheral and central nervous affection|Rate of psychiatric disorders at 6-months follow-up|Rate of psychiatric disorders at 12-months follow-up|Neuropsychological function at 6-months follow up|Neuropsychological function at 12-months follow up and change in function from 6 to 12 months.|Rate of stroke at 6-months follow up|Rate of stroke at 12-months follow up|Rate of death at 6-months follow-up|Rate of death at 12-months follow-up|Rate of peripheral nervous affection assessed by clinical neurological examination and\/or EMG\/neurography at 6-months follow-up|Rate of peripheral nervous affection assessed by clinical neurological examination and\/or EMG\/neurography at 12-months follow-up|Rate of myopathy at 6-months follow-up|Rate of myopathy at 12-months follow-up|Rate of brain MRI pathology at 6-months follow-up|Rate of brain MRI pathology at 12-months follow-up|Levels of serum neurofilaments at 6-months follow-up|Levels of serum neurofilaments at 12-months follow-up|Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 6-months follow-up|Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 12-months follow-up|Duration of hospital and rehabilitation stay""}"
"1354","COVID-SErology in Rheumatoid Arthritis (COVID-19)","COVID-SERA","NCT04407559","RECHMPL20_0330","Other: Serological analyses to be lead on a pre-existing biobank","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407559","Completed","2020-05-01","2020-09-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""216"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the false positive results rate|Characterize the RF isotype (IgG, IgM or IgA) associated|Determine the influence of RA on the false positivity rate in subjects|Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test|Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test""}"
"1355","How Brazilian Chiropractors Are Facing the COVID-19 Pandemic","","NCT04534621","TrateTE","Other: Electronic survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04534621","Not yet recruiting","2020-08-26","2020-09-18","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""948"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""What measures have been implemented to avoid SARS-COV2 transmission when taking care of patients, during the COVID-19 pandemic.|Professionals SARS-COV2 infection rates.|Professional financial impact.""}"
"1356","Changes in Cellular Immune Profile During COVID-19 Infection","","NCT04470999","SRPH-CVD-01","Other: Leukapheresis","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04470999","Recruiting","2020-04-15","2020-12-31","{""locations"":""Seraph Research Institute, Los Angeles, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""25"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Cellular immune system profiling|Innate immune system profiling|Expansion of virus-specific innate immune cells""}"
"1357","Efficacy and Safety of Corticosteroids in COVID-19","","NCT04273321","Methylprednisolone in COVID-19","Drug: Methylprednisolone","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04273321","Completed","2020-02-14","2020-04-15","{""locations"":""Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""86"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days""}"
"1358","Outcomes in Emergency Laparotomies During COVID-19 Pandemic","","NCT04419571","133196","Procedure: Emergency Laparotomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04419571","Completed","2020-03-23","2020-06-16","{""locations"":""Queen's Hospital, Romford, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""94"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30-day mortality|7-day mortality|Number of participants returning to theatre|Length of stay|Post-operative respiratory failure|Post-operative ARDS|Post-operative sepsis|ITU\/HDU admission""}"
"1359","Investigation of Validity and Reliability of Post-COVID-19 Functional Status Scale","","NCT04584450","GO 20/788","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04584450","Completed","2020-09-02","2020-12-31","{""locations"":""Hacettepe University, Ankara, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Post-COVID-19 Functional Status Scale (Turkish version)|Dyspnea assessment|Evaluation of daily living activities|Assessment of the structural validity of the Post-COVID-19 Functional Status Scale""}"
"1360","Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19","ASKCOV","NCT04549922","ASKCOV_Trial","Drug: ISIS 721744|Drug: Normal Saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04549922","Active, not recruiting","2020-10-22","2021-12-01","{""locations"":""Hospital Naval Marc\u00edlio Dias, Rio De Janeiro, Brazil|BP-A Benefici\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil|Hospital S\u00e3o Paulo - UNIFESP, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""111"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days alive without respiratory support (any supplemental oxygen) after 15 days (DAFOR15)|SOFA - Sequential Organ Failure Assessment Score up to 15 days after randomization|Need for mechanical ventilation|Duration of mechanical ventilation""}"
"1361","Retrospective Study of ImmunoFormulation for COVID-19","","NCT04666753","IMUNO TF STUDY","Dietary Supplement: ImmunoFormulation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666753","Completed","2020-07-02","2020-09-29","{""locations"":""Clinic Bascoy, Barcelona, Spain|Cl\u00ednica Arvila Magna, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical symptoms duration""}"
"1362","Decision Support System Algorithm for COVID-19 Diagnosis","","NCT04479319","09081","Diagnostic Test: Thorax CT","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479319","Recruiting","2020-12-31","2021-10-01","{""locations"":""Ankara University Faculty of Medicine, Ankara, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diagnosing COVID-19""}"
"1363","Study to Evaluate the Effect of a Probiotic in COVID-19","","NCT04390477","COVID.PROB","Dietary Supplement: Probiotic","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04390477","Recruiting","2020-05-04","2021-09-01","{""locations"":""Hospital Universitario del Vinalop\u00f3, Elche, Alicante, Spain|Hospital Universitario de Torrevieja, Torrevieja, Alicante, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cases with discharge to ICU.|Patients with home discharge.|Mortality.|Treatment safety assessed by number of adverse events.|New cases of SARS-Cov-2 infection among healthcare personnel caring for the patients.|Patients with negative PCR result for SARS-CoV-2 infection.""}"
"1364","Randomised Study of Plasma Exchange in Severe COVID-19","COVIPLEX","NCT04623255","132796","Drug: OCTAPLAS","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04623255","Recruiting","2020-10-16","2021-11-01","{""locations"":""University College London Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Inflammatory Marker-CRP|Change in Inflammatory Marker-D Dimer|Change in Inflammatory Marker-LDH|Rates of mechanical ventilation|Rates of clinical thrombotic events|Change in inflammatory-thrombotic response|To compare the incidence of acute kidney injury|Mortality at day 28""}"
"1365","Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients","","NCT04500626","OHRI-HBOT-001","Drug: Oxygen","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04500626","Not yet recruiting","2021-04-01","2022-08-01","{""locations"":""The Ottawa Hospital, Ottawa, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""234"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""7-level COVID Ordinal Outcome Scale|Length of hospital stay|Days with oxygen supplementation|Daily oxygen flow values required to obtain saturation values \u226590%,|ICU admission|ICU length of stay|Days on invasive mechanical ventilation or high flow oxygenation|Major arterial and venous thrombotic events|Sleep quality|Fatigue|Mortality|Incidence of any adverse events related to HBOT""}"
"1366","Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)","Covid-19","NCT04379310","20200504441","Drug: ACE Inhibitors and Calcium Channel Blockers","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379310","Completed","2020-05-01","2020-05-08","{""locations"":""Vital Hospital, Bahcelievler, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""54"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""extend of lung involvement|oxygen saturation on admission""}"
"1367","Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic","SOCOVID","NCT04387292","MMT_2020_12","Procedure: Ophthalmologic exam","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04387292","Recruiting","2020-09-07","2021-05-01","{""locations"":""Fondation A de Rothschild, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Description of the ophthalmological problems observed""}"
"1368","Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic","","NCT04480060","KSSEAH--EDCC","Diagnostic Test: COVID-19 diagnostic PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04480060","Completed","2020-03-10","2020-07-14","{""locations"":""Seda Yilmaz Semerci, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100000"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Mortality of the COVID-19 patients""}"
"1369","Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs","","NCT04563247","LGH002","Diagnostic Test: IgG SARS CoV 2 antibodies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04563247","Completed","2020-07-01","2021-02-08","{""locations"":""Lahore General Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""970"",""age"":""20 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""SARS CoV 2 IgG antibodies""}"
"1370","Mild Hypothermia for COVID-19 ARDS","","NCT04570462","Protocol 5.18.2020 Approved","Other: Hypothermia Via Cooling Machine- Arctic Sun 5000","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04570462","Recruiting","2020-05-18","2020-12-31","{""locations"":""North Shore University Hospital, Manhasset, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in metabolic requirement during and after hypothermia|Changes in oxygen requirements and levels during and after hypothermia|length of intubation|Changes in carbon dioxide levels during and after hypothermia|does application of hypothermia reduce pro inflammatory response""}"
"1371","Protecting Health Care Workers During the COVID-19 Outbreak","","NCT04387643","AU/SA/01","Dietary Supplement: Ayurvedic Kadha","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387643","Completed","2020-03-01","2020-04-02","{""locations"":""Samta Ayurveda Prakoshtha, Jaipur, Rajasthan, India"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""52"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Physical Health|Psychological Health|Coping with distress|Self-Help""}"
"1372","Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease","","NCT04723537","RHB-107-01","Drug: Part A: Upamostat 200 mg|Drug: Part A: Upamostat 400 mg|Drug: Part A and B: Placebo|Drug: Part B: Upamostat 200 or 400 mg","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04723537","Recruiting","2021-02-16","2021-09-01","{""locations"":""South Florida Research Phase I-IV, Inc., Miami Springs, Florida, United States|Henry Ford Hospital, emergency department, Detroit, Michigan, United States|VA Sierra Nevada Health Care System, main hospital, Reno, Nevada, United States|University Hospitals Cleveland, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""310"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Part A - Determination of the safety and tolerability of two dose levels and selection of an upamostat dose for part B|Part B - Comparison between upamostat and placebo in time to sustained recovery from symptomatic illness. Sustained recovery is recovery, per below definition, maintained for at least 28 days or through end of study, whichever comes first.|Part B - Proportion of patients who are PCR-negative at various time points during the study.|Part B - Time to resolution of individual disease-related symptoms present at baseline|Part B - Development of new disease-related symptoms on study|Part B - Incidence of pneumonia during study among patients without baseline pneumonia|Part B - Changes in laboratory markers of disease severity|Part B - Hospitalization|Part B - Mortality|Part B - Adverse events""}"
"1373","Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection","","NCT04526717","JO201901-02","Drug: MPT0B640","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04526717","Not yet recruiting","2021-12-01","2022-12-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""MTD|Viral load|Time to clinical improvement""}"
"1374","Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger","TRASCOV","NCT04409483","Trascov","Drug: Lopinavir-Ritonavir Drug Combination|Combination Product: Standard Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04409483","Withdrawn","2020-06-01","2020-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Hospitalization or death|All-cause mortality|Time to hospitalization|Length of hospitalization|Admission to intensive care|Adverse events|Serious adverse events""}"
"1375","Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2 Responsible for COVID-19","ComCor","NCT04607941","2020-047|2020-A02560-39","Other: Questionnaires|Other: Phone interviews","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04607941","Recruiting","2020-10-27","2021-06-30","{""locations"":""Caisse Nationale d'Assurance Maladie, Paris, France|IPSOS, Paris, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""57720"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places reported by the participants in the online questionnaire|Proportion of cases infected in family environment by SARS-CoV-2 reported by participants in the phone interview|Proportion of cases infected in family environment by SARS-CoV-2 reported by participants in the online questionnaire|Proportion of cases infected in professional environment by SARS-CoV-2 reported by participants in the phone interview|Proportion of cases infected in professional environment by SARS-CoV-2 reported by participants in the online questionnaire|Level of adherence to mask-wearing reported in the phone interview|Level of adherence to mask-wearing reported in the online questionnaire|Level of adherence to hand-washing in the phone interview|Level of adherence to hand-washing in the online questionnaire|Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places reported by the participants in the phone interview""}"
"1376","Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia","","NCT04619719","20-00897","Device: Hyperbaric Oxygen Therapy (HBOT)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04619719","Not yet recruiting","2021-03-10","2022-02-15","{""locations"":""Greenwich Hospital - Yale New Haven Health, Greenwich, Connecticut, United States|Bozeman Health, Bozeman, Montana, United States|NYU Winthrop Hospital, Mineola, New York, United States|Legacy Emanuel Medical Center, Portland, Oregon, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""360"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of 60-Day Patient Mortality|Time to Mechanical Ventilation|Number of Patients with Ongoing Clinical Symptoms|Number of Participants Displaying Presence of Any Pulmonary Function Abnormality""}"
"1377","Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia","","NCT04469114","34810620.0.1001.0071","Drug: Tofacitinib 10 mg|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04469114","Active, not recruiting","2020-09-16","2021-03-01","{""locations"":""Centro de Pesquisa Cl\u00ednica do Cora\u00e7\u00e3o, Aracaju, Brazil|Hospital Universit\u00e1rio S\u00e3o Francisco de Assis Na Provid\u00eancia de Deu, Bragan\u00e7a Paulista, Brazil|Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Miseric\u00f3rdia de Bragan\u00e7a Paulista, Bragan\u00e7a Paulista, Brazil|Hospital do Cora\u00e7\u00e3o do Brasil, Brasilia, Brazil|Instituto de Pesquisa Cl\u00ednica de Campinas, Campinas, Brazil|Hospital Regional do Litoral Norte, Caraguatatuba, Brazil|Unimed Fortaleza Sociedade Corporativa M\u00e9dica LTD, Fortaleza, Brazil|Hospital Regional Jorge Rossmann, Itanhaem, Brazil|Hospital Bruno Born, Lajeado, Brazil|Hospital S\u00e3o Vicente de Paulo, Passo Fundo, Brazil|Hospital Israelita Albert Einstein, Sao Paulo, Brazil|Funda\u00e7\u00e3o Faculdade Regional de Medicina de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 Do Rio Preto, Brazil|Hospital Regional de Registro, S\u00e3o Jos\u00e9 Dos Campos, Brazil|Hospital Regional de S\u00e3o Jos\u00e9 dos Campos, S\u00e3o Jos\u00e9 Dos Campos, Brazil|Benefic\u00eancia Portuguesa, S\u00e3o Paulo, Brazil|BP Mirante, S\u00e3o Paulo, Brazil|Instituto do Cora\u00e7\u00e3o, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""260"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death or respiratory failure until Day 28|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale of disease severity at Day 14|Status of alive and not on mechanical ventilation or ECMO at Day 14 and 28 NIAID ordinal scale of disease severity at Day 14|Status of requiring supplemental oxygen at Day 28|Status of being alive and not hospitalized at Day 14 and 28|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale of disease severity at Day 14 NIAID ordinal scale of disease severity at Day 28|Number of patients with cure|Number of patients at the ICU or on ventilatory support at Day 28|Number of days free from mechanical ventilation at 28 days|Number of days in hospital|Number of days in ICU|Death or respiratory failure at Day 28""}"
"1378","A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19","NOXCOVID","NCT04555213","NOX66-007","Drug: NOX66","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04555213","Recruiting","2020-09-30","2021-12-01","{""locations"":""Institute of Emergency Medicine, Chisinau, Moldova, Republic of"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events|Change of National Early Warning Score 2 units from baseline|Change in WHO-9 point ordinal scale""}"
"1379","Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands","HOMECOMIN'","NCT04488562","MEC-2020-0318","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04488562","Recruiting","2020-05-08","2021-12-31","{""locations"":""Amsterdam University Center - location VUmc, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus MC, Rotterdam, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""VAS|Temperature|Oxygen measurements|Forced Vital Capacity (FVC) home spirometry in %|Forced Vital Capacity (FVC) home spirometry in L|Forced Vital Capacity (FVC) hospital spirometry in %|Forced Vital Capacity (FVC) hospital spirometry in L|Adherence to weekly home spirometry|EQ5D|FAS|GRoC|ABC tool|Correlation between FVC, HRCT patterns, symptoms and quality of life|Predictors for the course of recovery of COVID-19 infection after hospital admission|Satisfaction of patients and caregivers with the use of a home monitoring system""}"
"1380","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment","","NCT04673214","R-2020-785-176","Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Drug: Azithromycin / Ribaroxaban / Paracetamol","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04673214","Recruiting","2020-12-16","2021-02-12","{""locations"":""Alma Italia Guerrero Martinez, Mexico, Distrito Federal, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""62"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Estimate clinical symptoms by days of follow-up in patients with COVID-19 under treatment with Azithromycin\/Ivermectin\/Ribaroxaban\/Paracetamol vs. Azithromycin\/Ribaroxaban\/Paracetamol followed by video call for 14 days from U.M.F 13 and U.M.F 20|To assess adverse drug reactions by days of follow-up in patients with COVID-19 under treatment with Azithromycin\/Ivermectin\/Ribaroxaban \/Paracetamol vs. Azithromycin \/Ribaroxaban\/Paracetamol followed by video call for 14 days from U.M.F 13 and U.M.F 20""}"
"1381","Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs","","NCT04568525","01-2/141 27","Diagnostic Test: Passive Microwave Radiometry","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04568525","Completed","2020-07-01","2020-08-01","{""locations"":""Educational - clinical - scientific medical center of KSMA, Bishkek, Chui, Kyrgyzstan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic"",""enrollment"":""195"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine sensitivity and specificity of MWR diagnostics of pneumonia in patients with COVID-19. (diagnosed by PCR and CT)""}"
"1382","Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (COVID-19)","MEMORY-COVID","NCT04625075","20/NW/0249","Diagnostic Test: Cardiac MRI|Diagnostic Test: Cardiac CT|Diagnostic Test: Electrocardiogram (ECG)|Diagnostic Test: Blood samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04625075","Recruiting","2020-06-10","2022-06-10","{""locations"":""University of Edinburgh, Edinburgh, Scotland, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""MRI with gadolinium|Extra-cellular volume (ECV)|Manganese MRI|CTCA|Cardiac biomarkers|Electrocardiogram""}"
"1383","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19","","NCT04347538","200693","Other: Saline Nasal Irrigation|Other: Saline with Baby Shampoo Nasal Irrigation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04347538","Active, not recruiting","2020-05-01","2022-06-01","{""locations"":""Vanderblt University Medical Center, Nashville, Tennessee, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SARS-CoV-2 mucosal immune response in the nasopharynx|Change in microbial load in the nasopharynx|Change in Viral Load in the nasopharynx over the course of COVID-19 infection|Symptom assessment|Temperature assessment""}"
"1384","A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19","DF in COVID19","NCT04652115","2020P003203","Drug: Defibrotide","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04652115","Not yet recruiting","2021-01-01","2023-11-01","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The rate of adverse event of special interest (bleeding and hypotension)""}"
"1385","IFN-beta 1b and Remdesivir for COVID19","","NCT04647695","UW 20-535","Drug: Interferon beta-1b|Drug: Remdesivir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04647695","Recruiting","2020-11-20","2021-09-30","{""locations"":""Queen Mary Hospital, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement|Hospitalisation|NPS viral load|TS viral load|Inflammatory markers|Adverse events|Mortality""}"
"1386","Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist","NET_COV","NCT04594356","NET_COV","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04594356","Recruiting","2020-11-19","2021-06-30","{""locations"":""CHU Bichat Claude Bernard, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""126"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the netosis process|Evaluation of the netosis process at day 3|Link between this marker (DNA-MPO) and the clinical course of patients""}"
"1387","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","","NCT04338360","20-003312","Biological: COVID-19 convalescent plasma","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04338360","Approved for marketing","1970-01-01","1970-01-01","{""locations"":""Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"1388","Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia","","NCT04355026","SBCebromhexinCovid-19","Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04355026","Recruiting","2020-04-10","2020-07-31","{""locations"":""SB Celje, Celje, Slovenia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of hospitalization|Duration of disease|Hospital-aquired pneumonia|ICU stay duration|Oxygene therapy duration|Mechanical ventilatory support duration""}"
"1389","A Preventive Treatment for Migrant Workers at High-risk of COVID-19","","NCT04446104","2020/00561","Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04446104","Completed","2020-05-13","2020-08-31","{""locations"":""Tuas South Dormitory, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""4257"",""age"":""21 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Acute respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Febrile respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of hospitalization for COVID-19 and non-COVID-19 related indications in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Length of hospital stay in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Adverse events and serious adverse events in control arm (Vitamin C)|Drug discontinuation due to adverse events in control arm (Vitamin C)""}"
"1390","Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression","","NCT04400058","GAM10-10","Biological: Octagam 10%|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04400058","Completed","2020-06-01","2021-01-31","{""locations"":""Octapharma Research Site, Sheffield, Alabama, United States|Octapharma Research Site, Loma Linda, California, United States|Octapharma Research Site, Loma Linda, California, United States|Octapharma Research Site, Newport Beach, California, United States|Octapharma Research Site, Orange, California, United States|Octapharma Research Site, San Diego, California, United States|Octapharma Research Site, Washington, District of Columbia, United States|Octapharma Research Site, Honolulu, Hawaii, United States|Octapharma Research Site, Iowa City, Iowa, United States|Octapharma Research Site, Covington, Louisiana, United States|Octapharma Research Site, Midland, Michigan, United States|Octapharma Research Site, Las Vegas, Nevada, United States|Octapharma Research Site, Minot, North Dakota, United States|Octapharma Research Site, Charleston, South Carolina, United States|Octapharma Research Site, Tyler, Texas, United States|Octapharma Research Site, Ivanovo, Russian Federation|Octapharma Research Site, Moscow, Russian Federation|Octapharma Research Site, Moscow, Russian Federation|Octapharma Research Site, Ryazan', Russian Federation|Octapharma Research Site, Ivano-Frankivs'k, Ukraine|Octapharma Research Site, Kharkiv, Ukraine|Octapharma Research Site, Kremenchuk, Ukraine"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""208"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stabilization or Improvement in Clinical Status|Descriptive Clinical Status Analysis|Clinical Status Assessment|Time to death|Mechanical Ventilation Initiation|Mechanical Ventilation Duration|SARS-CoV-2 Test Result|Incidence of all AEs|Incidence of AEs considered related to the IMP|Incidence of serious adverse events (SAEs)|Radiological findings (chest CT\/chest X-ray)|Blood glucose|Blood calcium|Sodium|Potassium|Carbon dioxide|Chloride|Albumin|Total protein|Alkaline phosphatase|Alanine transaminase|Aspartate aminotransferase|Bilirubin|Blood urea nitrogen|D-dimer|Fibrinogen|PT|PTT|INR|hsCRP|Ferritin|LDH|IgG|IgM|IgA|IFE|Troponin|Red blood cell count|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|White blood cell count|White blood cell differential|Platelet count|Mean platelet volume|Platelet distribution width|SpO2|A-a gradient|Blood Pressure|Pulse|Respiration Rate|Body Temperature""}"
"1391","IMU-838 and Oseltamivir in the Treatment of COVID-19","IONIC","NCT04516915","RA486120","Drug: IMU-838|Drug: Oseltamivir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04516915","Recruiting","2020-06-15","2021-07-01","{""locations"":""University Hospital Coventry and Warwickshire NHS Trust, Coventry, West Midlands, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) vs. Oseltamivir alone in adult subjects with COVID-19|To evaluate safety (number of adverse events) and tolerability (laboratory abnormalities) of IMU 838 + Oseltamivir vs. Oseltamivir alone in adult subjects with COVID-19.|To determine the effects of IONIC Intervention on improvement of at least two points in clinical status scale (from 0 to 8; with 8 being no evidence of clinical infection and 8 being death)|To assess the effects of IONIC Intervention vs. Oseltamivir on the need for invasive ventilation, renal replacement therapy or ECMO|To assess the effects of IONIC Intervention vs. Oseltamivir on the length of hospital and intensive care unit (ICU) stay|To assess the effects of IONIC Intervention vs. Oseltamivir on the time from treatment initiation to death""}"
"1392","A Study of N-acetylcysteine in Patients With COVID-19 Infection","","NCT04374461","20-168","Drug: N-acetylcysteine|Other: Peripheral Blood","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04374461","Recruiting","2020-05-01","2023-05-01","{""locations"":""Memorial Sloan Kettering Cancer Center, New York, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""84"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Arm A: number of patients who are successfully extubated and\/or transferred out of critical care due to clinical improvement|Arm B: number of patients who are discharged from the hospital due to clinical improvement""}"
"1393","COVID-19 and Hereditary Metabolic Diseases","COVID19-MHM","NCT04645498","2020_52|2020-A02886-33","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04645498","Not yet recruiting","2021-01-01","2023-01-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""77"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Frequency of MHM imbalance triggered by COVID-19|Number of COVID-19 patients in Gaucher's disease|Number of COVID-19 patients in Urea Cycle Disorder|Severity of COVID-19 infection""}"
"1394","Study to Investigate the Benefits of Colchicine in Patients With COVID-19","","NCT04603690","LUMHS/REC/893","Drug: Colchicine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04603690","Withdrawn","2020-12-15","2021-06-14","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement in the clinical status|Changes in IL-6 concentrations|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation or ECMO|Number of days with high flow oxygen therapy|Changes in other inflammatory markers (C-reactive protein, IL-6) from randomization|Changes in severity markers (D-dimer, lymphocytes, and ferritin) from randomization|Changes in myocardial damage and stress markers (hsTnT and NT-proBNP) from randomization.|Time until reaching a virus negative status by RT-PCR assay|Length of hospital stay|Number of days in the intensive care unit|Mortality by causes""}"
"1395","Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic","","NCT04450277","2020/00660","Procedure: Emergency surgery","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04450277","Completed","2020-04-01","2020-05-31","{""locations"":""Khoo Teck Puat Hospital, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Surgical morbidity in patients with COVID-19 infection and general surgical conditions""}"
"1396","Safe Return to Regular Clinical Operation After COVID-19 Pandemic","","NCT04377802","KFSH-ONC-02","Diagnostic Test: molecular testing for virus RNA using RT-PCR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04377802","Not yet recruiting","2020-05-17","2020-12-30","{""locations"":""king Fahad specialist hospital, Dammam, Eastern Province, Saudi Arabia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""400"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health care provider safe return to work""}"
"1397","Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC","MEDIC-LAUMC","NCT04631536","Lebanese American University","Drug: Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04631536","Not yet recruiting","2021-01-10","2021-05-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Improvement|Need for invasive mechanical ventilation|Length of ICU stay|Length of hospital Stay|Length of need of mechanical ventilation|All cause mortality|Occurrence of side effects""}"
"1398","Novel Face Mask Sampling for COVID-19: A Diagnostic and Public Health Tool","COVMASK","NCT04481646","0775","Diagnostic Test: Face mask sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04481646","Recruiting","2020-06-12","2025-06-01","{""locations"":""University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""630"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Comparison with Naso-pharyngeal swab|Mask out over time|mask as a screening tool in asymptomatic people""}"
"1399","Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland","","NCT04546191","LSH-20-002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04546191","Completed","2020-07-01","2020-09-01","{""locations"":""Landspitali National University Hospital, Reykjav\u00edk, \u00cdsland, Iceland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1580"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms|Wellbeing - HRQL""}"
"1400","Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4)","","NCT04505774","ACTIV-4 ACUTE","Drug: theraputic heparin|Drug: prophylactic heparin|Drug: P2Y12","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04505774","Recruiting","2020-09-04","2021-12-01","{""locations"":""University of Alabama, Birmingham, Alabama, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC San Diego Hillcrest, San Diego, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States|UCSF San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Denver Health and Hospital Authority, Denver, Colorado, United States|Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Cook County Health, Chicago, Illinois, United States|University of Illinois at Chicago Health (UIH), Chicago, Illinois, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Boston University, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, ACCS Research, Saint Louis, Missouri, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Albany Medical College, Albany, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|VA New York Harbor Healthcare System, New York, New York, United States|NYU Langone, New York, New York, United States|Duke University Hospital, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|The MetroHealth System, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ascension St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott and White Medical Center - Temple, Temple, Texas, United States|Swedish Hospital, Seattle, Washington, United States|University of Wisconsin Hospital; Meriter Hospital (UW affiliated), Madison, Wisconsin, United States|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Cl\u00ednico Universitario de Salamanca, Salamanca, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""21 Day Organ Support (respiratory or vasopressor) Free Days|Key Platform Secondary Thrombotic Endpoint|Other Platform Secondary Endpoints of Morbidity and Hospitalization|All cause mortality""}"
"1401","Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment","","NCT04353336","chloroquine covid","Drug: Chloroquine or Hydroxychloroquine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04353336","Recruiting","2020-03-23","2030-12-23","{""locations"":""Tanta University, Assiut University, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patients with cure or death""}"
"1402","Predictivity of Hemogasanalysis and Lung UltraSound in Determining COVID-19 Severity","COVID-PEGALUS","NCT04689672","COVID-PEGALUS","Diagnostic Test: Lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04689672","Recruiting","2020-12-16","2021-05-10","{""locations"":""IRCCS San Raffaele, Milan, MI, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients' short-term outcome|Patients' long-term outcome|Intensity of care""}"
"1403","Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19)","8796","NCT04708912","8796","Other: Observation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04708912","Recruiting","2020-12-15","2021-02-01","{""locations"":""Bakirkoy Dr.sadi Konuk Training and Research Hospital, Istanbul, Turkey|Bakirkoy Dr.sadi Konuk Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determination of peripheral blood RNA microarray assay|Determination of nasopharunx Microbiota analysis|Determination of in vitro cytokines production|Determination of peripheral blood cytometry|Relation between study parameters""}"
"1404","A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults","","NCT04584710","RTB101-211|3R01AG064802-02S1","Drug: RTB101|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04584710","Active, not recruiting","2020-10-13","2021-02-01","{""locations"":""University of Connecticut, UConn Center on Aging, Farmington, Connecticut, United States|Hebrew Senior Life, Marcus Institute for Aging Research, Roslindale, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age \u2265 65 years|To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population|To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population|To assess the incidence of treatment-emergent of AEs and SAEs in subjects assigned to RTB101 as compared to placebo|To determine the percentage of subjects treated with RTB101 as compared to placebo who develop symptomatic laboratory-confirmed COVID-19 from first dose through Day 14|To determine the percentage of subjects treated with RTB101 as compared to placebo who die from any cause from first dose of study drug through Day 14 and 21|To determine the percentage of subjects treated with RTB101 as compared to placebo who develop laboratory-confirmed COVID-19 from first dose through Day 14 and are subsequently hospitalized for any reason through Day 21|To determine the percent of subjects treated with RTB101 or placebo who have laboratory-confirmed SARS-CoV-2 infection regardless of symptoms from first dose of study drug through Days 7, 14, 21.""}"
"1405","Dornase Alfa Administered to Patients With COVID-19 (DACOVID)","DACOVID","NCT04387786","216","Drug: Dornase Alfa","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387786","Completed","2020-03-31","2020-09-04","{""locations"":""Feinstein Insitute for Medical Research at Northwell Health, Manhasset, New York, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""5"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants discharged from the intensive care unit (ICU)|Number of participants who survived COVID-19|Mean change in FiO2""}"
"1406","A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19","","NCT04627584","MW33-2020-CP201","Combination Product: MW33 injection|Combination Product: MW33 injection placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04627584","Recruiting","2020-12-29","2021-09-01","{""locations"":""Shanghai Public Health Clinical Center, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 viral load""}"
"1407","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","SAC-COVID","NCT04317040","CD24Fc-007|20200674","Drug: CD24Fc|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04317040","Completed","2020-04-08","2021-01-30","{""locations"":""Baptist Health Research Institute, Jacksonville, Florida, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|Shady Grove Medical Center, Rockville, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Cooper University Hospital, Camden, New Jersey, United States|Atlantic Health System, Morristown, New Jersey, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Texas at Houston, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""243"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of COVID-19 disease status|Proportion of patients who died or had respiratory failure.|Disease progression of COVID-19|All cause of death|Proportion of clinical relapse|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of high flow oxygen therapy|Absolute lymphocyte count|Change of D-dimers""}"
"1408","Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)","","NCT04480138","PEGI.20.003","Drug: Pegylated Interferon-α2b|Other: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04480138","Recruiting","2020-08-11","2021-05-30","{""locations"":""Avant Sante Site 1, Monterrey, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Clinical status of subject on a 7-point ordinal scale|PCR test|Supplemental Oxygen|Mechanical Ventilation|Incidence of Treatment-Emergent Adverse Events|C-reactive protein (CRP)|Interleukin 6 (IL-6)|D-dimer|Interferon gamma|Ferritin|TNF alpha|Interleukin 1-\u03b2""}"
"1409","Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management","","NCT04343092","PRO20040001","Drug: Ivermectin (IVM)","Interventional","Has Results","Phase 1","https://ClinicalTrials.gov/show/NCT04343092","Completed","2020-04-18","2020-06-01","{""locations"":""General Directorate of Medical City, Bagdad, Baghdad, Iraq"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""16"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Cured Patients|Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group""}"
"1410","Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients","","NCT04713852","2020-174","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04713852","Completed","2020-03-13","2020-12-31","{""locations"":""Jessa hospital, Hasselt, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""116"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Predictive value""}"
"1411","RespiraConNosotros:a Mobile Application for COVID-19 Respiratory Rehabilitation.","","NCT04703478","CovidSal02","Other: Breathing exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04703478","Not yet recruiting","2021-01-20","2021-04-20","{""locations"":""Ines Llamas-Ramos, Salamanca, Spain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rating of perceived exertion (Borg Scale)|Level of satisfaction and acceptability.|St. George's Respiratory Questionnaire, SGRQ|Age|Sex|Diagnosis of respiratory pathology""}"
"1412","Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal","","NCT04694612","683-2020","Drug: Favipiravir|Drug: Placebo|Drug: Remdesivir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04694612","Recruiting","2021-01-01","2021-05-31","{""locations"":""Armed Police Force Hospital, Kathmandu, Bagmati, Nepal|Charak Memorial Hospital, Pokhara, Gandaki, Nepal"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""676"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""clinical improvements in mild cases|clinical improvements in moderate cases|Clinical deterioration in mild & moderate cases|Radiological improvement in moderate cases|28 days mortality in mold & moderate cases|symptomatic improvement or worsening in mild & moderate cases|compare change in SARS-CoV-2 viral load in nasopharyngeal swab in mild & moderate cases|Length of stay in hospital beyond 10 days in mild & moderate cases""}"
"1413","Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19)","","NCT04610489","IRB-20-1088|Epling-533","Diagnostic Test: Quidel Sofia SARS Antigen FIA","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04610489","Not yet recruiting","2020-11-01","2021-01-31","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity|Specificity|Area under the ROC curve""}"
"1414","Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients","","NCT04570501","58189","Drug: Angiotensin-(1-7)|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04570501","Not yet recruiting","2021-03-01","2021-08-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery|Incidence of mortality at Day 29|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of participants requiring mechanical ventilation or ECMO, or dying, through Day 29|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29""}"
"1415","Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19","","NCT04594343","SPR-001-201","Drug: Disulfiram|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04594343","Recruiting","2020-11-20","2021-04-01","{""locations"":""ETICA, Salvador, Bahia, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline to day 7 for cytokine IL-18|Percentage of subjects that do not require invasive mechanical ventilation|Mean number of days of invasive mechanical ventilation for those subjects requiring invasive mechanical ventilation|Mean number of days of non-invasive ventilation for those subjects requiring non-invasive ventilation|Mean number of days of supplemental oxygen|Percentage of subjects that deteriorate 1 or more points in the 7-point WHO Ordinal Scale from baseline to Day 14|Percentage of subjects that are not admitted to the Intensive Care Unit (ICU)|28-day mortality""}"
"1416","Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19","EliSpot","NCT04418206","20-PP-10","Other: patients COVID 19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04418206","Recruiting","2020-06-01","2021-06-01","{""locations"":""CH Antibes, Antibes, Alpes Maritimes, France|Ch Cannes, Pneumologie, Cannes, Alpes Maritimes, France|Ch Grasse, Grasse, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IgA specific cells of SARS|OMS progression scale""}"
"1417","Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study","","NCT04669990","749-2020","Drug: Remdesivir","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04669990","Recruiting","2020-11-19","2021-11-19","{""locations"":""Narayani Hospital, Birgunj, Nepal|Seti Provincial Hospital, Dhangadi, Nepal|BP Koirala Institute of Health Sciences (BPKIHS), Dhar\u0101n B\u0101z\u0101r, Nepal|Bheri Provincial Hospital, Nepalgunj, Nepal"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Demographics of recipients|Co-morbidity of recipient|Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy|Hospital and ICU length of stay|Disposition of patients including survival""}"
"1418","Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function","GenCov","NCT04506229","TCAI_GenCov","Genetic: Whole exome sequencing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04506229","Recruiting","2020-08-20","2021-09-01","{""locations"":""Texas Cardiac Arrhythmia Institute, Austin, Texas, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Genetic variants with vs without COVID-19|Cognitive function at baseline|Change in cognitive function at 1 month|Genetic analysis""}"
"1419","Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia","","NCT04334252","JessaH_COVID19_prescreening","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04334252","Completed","2020-04-17","2020-12-20","{""locations"":""Jessa hospital, Hasselt, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""528"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms""}"
"1420","Nigella Sativa in COVID-19","","NCT04401202","266-20","Dietary Supplement: Nigella sativa","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04401202","Recruiting","2020-05-21","2020-12-31","{""locations"":""King Abdulaziz University Hospital, Jeddah, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who are clinically recovered|Time to full clinical recovery or progression to pneumonia or hypoxia|Normalization of chest radiograph|Rate of complications|Death""}"
"1421","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection","","NCT04339426","HRI-COVID-19-Anti-Malarial-001","Drug: Atovaquone/Azithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04339426","Recruiting","2020-04-20","2021-12-01","{""locations"":""HonorHealth, Scottsdale, Arizona, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""25"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity""}"
"1422","Phase 2 Trial to Evaluate Safety and Efficacy of CYTO-205 in Mild COVID-19","","NCT04708327","CYTO-001","Drug: Naltrexone Hydrochloride","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04708327","Not yet recruiting","2021-04-01","2022-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who demonstrate progression of COVID-19 disease""}"
"1423","Trial to Study the Benefit of Colchicine in Patients With COVID-19","COL-COVID","NCT04350320","IMIB-COLVID-2020-03","Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04350320","Completed","2020-04-30","2020-12-30","{""locations"":""Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""102"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality""}"
"1424","COVID-19 Seroprevalence Study in ITM Staff","CovAb","NCT04503447","SARSCOV2SEROPREVALENCEITMSTAFF","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04503447","Completed","2020-08-01","2020-09-09","{""locations"":""Institute of Tropical Medicine, Antwerp, Belgium"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""330"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""SARS-CoV-2 seroprevalence ITM staff|SARS-CoV-2 seroprevalence in ITM staff, stratified by variables""}"
"1425","Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection","","NCT04542876","AYU/DSSR/03","Drug: Guduchi Ghan Vati","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04542876","Completed","2020-05-01","2020-08-18","{""locations"":""Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""46"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virologic clearance|Hospital Stay|Clinically relevant adverse effects|Laboratory tests""}"
"1426","Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19","","NCT04716998","CP-MCS-01","Biological: MesenCure","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04716998","Recruiting","2021-01-01","2022-01-01","{""locations"":""Rambam Health campus, Haifa, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""35"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety of Mesencure|Improvement in RA-O2 saturation|Elevation of lymphocytes level|Reduction of CRP|Improvement of health questionnaire|Reduced hospitalization duration|improvement in pulmonary infiltrates\/ pulmonary congestion""}"
"1427","Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)","Pepcid4COV19","NCT04565392","Pykonsult 201","Drug: Famotidine 20 milligram tablet","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04565392","Not yet recruiting","2021-05-01","2022-01-31","{""locations"":""Pykonsult headquarters, New Fairfield, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Course Binary Outcome|Serious Adverse Events|Time to symptomatic recovery|SCL18 (self-check list of 18 symptoms of COVID-19)|Patient's Global Impression of Change|Adverse Events|Day-60 Follow-up""}"
"1428","Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients","HCQ-COVID19","NCT04437693","MRC-02-20-442","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04437693","Not yet recruiting","2020-08-31","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""500"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Prevention of SARS-CoV-2 infection|Presence of any adverse effects related to HCQ|Incidence of COVID-19 related symptoms""}"
"1429","Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)","CoV-Early","NCT04589949","NL74972.078.20","Biological: ConvP|Biological: FFP","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04589949","Recruiting","2020-10-12","2023-11-01","{""locations"":""Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|University Medical Center Groningen (UMCG), Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Bernhoven Hospital, Uden, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""690"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Highest disease status|Percentage of deaths|Percentage of hospital admissions|Percentage of ICU admissions|Disease duration in days of symptoms|Age and clinical frailty score""}"
"1430","Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive","","NCT04605952","152473","Diagnostic Test: Repeat SARS-CoV-2 IgG antibodies at 45-65 days","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04605952","Completed","2020-07-01","2020-08-30","{""locations"":""Dr.Deb Sanjay Nag, Jamshedpur, Jharkhand, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""201"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 days""}"
"1431","HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment","HLA-G-COVID","NCT04613297","2020_0082","Other: Baseline and during hospitalization blood samples|Other: Baseline blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04613297","Recruiting","2020-10-19","2021-10-01","{""locations"":""Foch hospital, Suresnes, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of the percentage of T cells expressing the HLA-G receptor ILT2 (CD3+CD4+ILT2+ T cells, and CD3+CD8+ILT2+ T cells) between the 3 groups of patients.|Comparison of the expression of circulating soluble HLA-G, between the groups of patients.|1 month survival|Assessment of the severity of the disease according to the isoform of HLA-G|Comparison of the expression of one of the cell receptors of the SARS-CoV-2 virus, called BSG (Basigin), whose expression is modified by the interaction between HLA-G.""}"
"1432","IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients","","NCT04544033","IL6 in egyptian COVID patients","Diagnostic Test: interleuken 6 level measurment|Diagnostic Test: Interleukin-6 Gene-174C detection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04544033","Recruiting","2020-09-15","2021-01-01","{""locations"":""Bsant Safwat Kasem, Tanta, El Gharbyia, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""interleuken- 6 gene (174G\/C) single nucleotide polymorphism|interleukin 6 level""}"
"1433","CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis","COVID 19-IA","NCT04418245","NIMAO/2020/COVID 19-IA/JF-01","Diagnostic Test: Imaging by thoracic scanner","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04418245","Active, not recruiting","2020-03-01","2020-07-01","{""locations"":""CHU la Timone, Marseille, France|CHU Montpellier, Montpellier, France|CHU de Nimes, N\u00eemes, France|CHU Poitiers, Poitiers, France|CHU Strasbourg, Strasbourg, France|CHU Martinique, Fort-de-France, Martinique"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Vital status|Patient requiring more than 3 liters of oxygen to maintain a saturation >95% (intensive care unit or resuscitation department)|Percentage of lung affected on CT|Percentage of lung affected by ground glass opacity on scan|Percentage of lung affected by condensation on scan|Length of hospitalization|rehospitalization|Duration of intubation|Software operating time|C-reactive protein levels|lactate dehydrogenase|lymphocytemia|D Dimers level|Time until onset of symptoms|Time between RT-PCR positive results and first scan|Age|BMI> 30|Medical history of cardiovascular disease|Diabetes|Medical history of respiratory disease|Medical history of immunosuppressed condition|Current or previous history of smoking|Calculate a prognostic score from clinical, biological and CT parameters|Calculate a prognostic score from clinical and biological parameters only|Compare receiver operating curves of prognostic scores with and without CT parameters""}"
"1434","Remote Video Consultation for Quality of Life Assessment in Patients Hospitalised After COVID-19 Infection","TELECOVID","NCT04714138","2020-A03110-39","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04714138","Recruiting","2021-01-05","2021-03-15","{""locations"":""Groupe Hospitalier Du Havre, Montivilliers, Normandie, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""190"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health-related quality of life|Functional capacity|Independency""}"
"1435","Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research","","NCT04716647","AU/2187","Other: Ayurveda","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04716647","Completed","2020-10-09","2020-12-18","{""locations"":""Aarogyam UK, Leicester, Leicestershire, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""28"",""age"":""20 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical recovery|Proportion of patient with negative conversion in nasopharyngeal swab|Clinical Outcome""}"
"1436","Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19","COV2ICU-DK","NCT04354584","COV2ICU-DK|H-20023159|R349-2020-540","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354584","Recruiting","2020-04-06","2021-04-06","{""locations"":""Dept. of Intensive Care 542, University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""White blood cell counts|Lymphocyte populations|Cytokines|Lectin complement pathway|Microorganisms|Respiratory pathogens|Ribosomal RNA in the airways|Levels of SARS-CoV-2 in the airways|Surfactant in the airways|Autoantibodies against type I IFNs in the airways""}"
"1437","Study Evaluating Safety, Tolerability and Efficacy of Allocetra-OTS in Patients With COVID-19","","NCT04659304","ENX-CL-03-001","Drug: Allocetra-OTS|Other: Ringer's lactate","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04659304","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety - Adverse Events|Efficacy - PaO2 or SO2\/FiO2 Ratio|Efficacy - SOFA score|Efficacy - mortality|Efficacy - organ function \/ support measurements""}"
"1438","Vitamin D Status and Immune-inflammatory Status in Different UK Populations With COVID-19 Infection","","NCT04519034","285176","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04519034","Not yet recruiting","2020-09-01","2020-12-31","{""locations"":""GSTT NHS Trust, London, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""27000"",""age"":""1 Year to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Collecting vitamin D results in patients from the South-East London area together with age, sex, ethnicity and BMI and other relevant laboratory results.|Collecting Covid-19 screening results together with age, sex, ethnicity and BMI and other relevant laboratory results.""}"
"1439","Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients","COPS-2002","NCT04524663","56029","Drug: Camostat Mesilate|Drug: Placebo|Other: Standard of Care Treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04524663","Recruiting","2020-12-19","2021-06-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time until cessation of shedding of SARS-CoV-2 virus|Clinical worsening of COVID-19 disease in symptomatic patients|Development of antibodies to SARS-CoV-2|Time until resolution of symptoms|Time until progression of symptoms|Drug level on day five, one hour after a dose taken on an empty stomach""}"
"1440","Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis","Predi-COVID","NCT04380987","Predi-Covid","Biological: Biological sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380987","Recruiting","2020-05-04","2021-12-31","{""locations"":""Luxembourg Institute of Health, Luxembourg, Luxembourg"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Description of clinical manifestations|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of biological manifestations|Patient-related prognostic factors|Virus-related prognostic factors|Vocal biomarker of Covid-19 related respiratory complications""}"
"1441","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia","","NCT04331665","U-DEPLOY: RUX-COVID|20-5315","Drug: Ruxolitinib","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04331665","Not yet recruiting","2020-04-20","2021-01-31","{""locations"":""Princess Margaret Cancer Centre, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""64"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and\/or FiO2 of 60% of more)|Number of adverse events|All cause mortality rate|Average duration of hospital stay""}"
"1442","Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress","","NCT04606784","AP-014","Biological: Ampion|Other: Standard of Care","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04606784","Recruiting","2020-10-28","2021-03-31","{""locations"":""Research Site, Colorado Springs, Colorado, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence and severity of adverse events|Clinical status using 8-point ordinal scale""}"
"1443","Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital","ALCOVID","NCT04525911","2020- A01647-32","Diagnostic Test: Diagnostic Test: serology test for COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04525911","Recruiting","2020-08-26","2022-10-01","{""locations"":""BENNANI, Marseille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""258"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of post-traumatic stress symptoms (Post traumatic Stress Disorder (PTSD) scale) at M3 for patients and caregivers|Evaluation of post-traumatic stress symptoms (PTSD scale) at M12 and M24 for patients and caregivers|Change from M3 in the score of the mental (MCS), physical (PCS) components and the scores of the individual domains of the questionnaire SF36 to M12 and M24 for the entire study population|% of patients presenting a positive result by ELISA serology (= without distinction of IgG, IgM and IgA)|Comparison of M0 chest CT results at each follow-up for the entire study population""}"
"1444","Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","","NCT04343794","COVID19_Biovitals_Protocol_1","Device: BIOVITALS","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04343794","Recruiting","2020-04-01","2022-01-31","{""locations"":""The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to diagnosis of COVID-19 by RT-PCR in subjects|Compliance to complete the study|Sensitivity and specificity of Biovitals\u00ae Sentinel|Cross infection rate within the family cluster|Length of hospital stay of positive subjects|Length of ICU stay of positive patients|National Early Warning Score 2 rating of positive patients|Viral load of positive patients|Worsening of comorbidities|Mortality""}"
"1445","A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19","","NCT04621903","AU/WU/ 06","Other: Shanshamani Vati Plus","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04621903","Completed","2020-10-08","2020-11-03","{""locations"":""Aarogyam (UK) CIC, Leicester, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""26"",""age"":""20 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to COVID-19 symptoms relief|Prevention of severe stage of Covid19|Side effect\/ adverse events|COVID-19 severity worsening|Time to negative saliva""}"
"1446","Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers","","NCT04373096","20-5448","Device: current IPAC-UHN PPE|Device: modified IPAC-UHN PPE","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04373096","Recruiting","2020-12-07","2021-10-31","{""locations"":""Toronto Western Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""42"",""age"":""20 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of contamination of any part of the base clothing or exposed skin of the upper body|1) Number of body areas contaminated|2) Number of discrete areas of contamination of <1 cm2 and >1 cm2|3) Visibility during the simulated procedure|4) Ease of intubation procedures when wearing PPE|5) Ease of breathing while wearing PPE|6) Thermal comfort while wearing the PPE|7) Incidence of breaching of doffing procedures""}"
"1447","Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU","MY-CO-VID","NCT04368221","35RC20_8885_MY_CO_VID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368221","Active, not recruiting","2020-05-04","2021-05-01","{""locations"":""CHU Angers, Angers, France|CHU de Brest, Brest, France|CHU de Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Lille, Lille, France|CHU Lyon, Lyon, France|CHU Marseille, Marseille, France|CHU Nantes, Nantes, France|CHU de Nice, Nice, France|CHU Paris - Avicenne, Paris, France|CHU Paris - Bichat, Paris, France|CHU Paris - HEGP, Paris, France|CHU Paris - Mondor, Paris, France|CHU Paris - Tenon, Paris, France|H\u00f4pital Lariboisi\u00e8re\/ St Louis, Paris, France|H\u00f4pital Necker-Enfants Malades, Paris, France|H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France|CHU Poitiers, Poitiers, France|CHU Rennes, Rennes, France|CHU Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France|CHU Tours, Tours, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""576"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Opportunistic fungal co-infections.|Median time|Time between diagnosis and targeted treatment|Preventive strategies""}"
"1448","The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19","","NCT04644185","SCTA01-B301","Drug: SCTA01|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04644185","Not yet recruiting","2021-02-10","2021-10-10","{""locations"":""SCT study site, Ciudad Autonoma de Buenos aires, Argentina|SCT study site, Uberl\u00e2ndia, Brazil|SCT study site, Talca, Chile|SCT study site, Rionegro, Colombia|SCT study site, Monterrey, Mexico|SCT study site, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""795"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The clinical efficacy of SCTA01 (Phase II and III)|Cumulative incidence of SAEs(Phase II, III)|Change from baseline in viral shedding as measured by RT-qPCR(Phase II and III)|area under the curve (AUC0-t)(Phase II)|AUC0-\u221e(Phase II)|Half-life time (t1\/2)(Phase II)|Maximum concentration (Cmax)(Phase II)|Peak time (Tmax)(Phase II)|Clearance (CL)(Phase II)|Apparent volume of distribution (Vd)(Phase II)|Elimination rate constant (\u03bbz)(Phase II)|Immunogenicity as measured by anti-drug antibodies (ADA) (Phase II, III)""}"
"1449","Cri Analog PG1 Effectiveness and Safety in Covid-19","PGE1-COVID19","NCT04536363","CEIS-2020-089","Drug: Analogs, Prostaglandin E1|Drug: Standard therapeutic protocol","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04536363","Not yet recruiting","2020-10-01","2021-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""284"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Hypoxemia Resolution|Days from admission to intensive care unit and administration of ANALOG PGE1|ICU stay|Days with high flow oxygen|Days of invasive mechanical ventilation prior to administration of PGE1 ANALOG|Evolution time of the disease""}"
"1450","The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.","COLCOVID","NCT04328480","COLCOVID version 2.0","Drug: Colchicine|Other: Local standard of care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04328480","Recruiting","2020-04-17","2021-03-30","{""locations"":""Sanatorio Parque, Rosario, Santa Fe, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite outcome: New requirement for mechanical ventilation or death|Mortality|New requirement for mechanical ventilation or death from respiratory failure|New requirement for mechanical ventilation or death from non-respiratory failure|Mortality due to respiratory failure|Mortality due to non-respiratory failure|In hospital - Composite outcome|In hospital - Mortality|Composite outcome (New requirement for mechanical ventilation or death) evaluated in Non-intubated population|Mortality evaluated in Non-intubated population|Mean WHO descriptive score of COVID-19 during hospitalization|Highest WHO descriptive score of COVID-19 during hospitalization""}"
"1451","Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","ATTACC","NCT04372589","ATTACC|OZM-113","Drug: Heparin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04372589","Active, not recruiting","2020-05-20","2021-01-01","{""locations"":""Emory University Hospital Midtown, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic, Jefferson, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Henry Ford University, Dearborn, Michigan, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Louis University School of Medicine\/Saint Louis Veterans Affairs Medical Center, Saint Louis, Missouri, United States|Cooper University Health Care, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Montefiore-Einstein Center for Heart and Vascular Care, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Santa Casa de Misericordia de Itabuna, Itabuna, BA, Brazil|Hospital Unimed do Cariri, Juazeiro do Norte, CE, Brazil|Instituto Goiano de Oncologia e Hematologia - INGOH, Goiania, Goias, Brazil|Centro de Pesquisas Cl\u00ednicas Humap - UFMS, Campo Grande, Mato Grosso Do Sul, Brazil|Hospital Fel\u00edcio Rocho, Belo Horizonte, MG, Brazil|Clinica de Campo Grande S\/A, Campo Grande, MS, Brazil|Unimed Campo Grande, Campo Grande, MS, Brazil|Hospital Agamenon Magalhaes, Recife, Pernanbuco, Brazil|Hospital das Clinicas da UFPR, Curitiba, PR, Brazil|Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil|Parana Medical Research Center, Maringa, PR, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS, Brazil|Instituto de Medicina Vascular, Porto Alegre, RS, Brazil|AngioCor Blumenau, Blumenau, Santa Catarina, Brazil|Instituto de Cardiologia de Santa Catarina, Sao Jose, Santa Catarina, Brazil|Instituto de Pesquisa Cl\u00ednica de Campinas, Campinas, Sao Paulo, Brazil|Praxis Pesquisa Medica, Santo Andre, Sao Paulo, Brazil|Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil|Casa de Sa\u00fade Santa Marcelina, Sao Paulo, SP, Brazil|Instituto de Molestias Cardio Vasculares de Tatui, Tatui, SP, Brazil|Hospital 9 de Julho, S\u00e3o Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil|Instituto de Infectologia Emilio Ribas, S\u00e3o Paulo, Brazil|Instituto do Cora\u00e7\u00e3o do Estado de S\u00e3o Paulo, S\u00e3o Paulo, Brazil|Sociedade Beneficente Israelita Hospital Albert Einstein, S\u00e3o Paulo, Brazil|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Center Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|H\u00f4pital Montfort, Ottawa, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, Montr\u00e9al, Quebec, Canada|Centre Hospitalier de l'universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Quebec, Canada|Jewish General Hospital, Montr\u00e9al, Quebec, Canada|CHU de Quebec-University Laval, Qu\u00e9bec, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec (CRIUCPQ), Qu\u00e9bec, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Hospital de Infectolog\u00b4\u00f1ia Centro M\u00e9dico Nacional La Raza, Azcapotzalco, Mexico City, Mexico|Hospital General Regional 1 Carlos MacGregor S\u00e1nchez Navarro, Benito Ju\u00e1rez, Mexico City, Mexico|Hospital General regional 2 El Marqu\u00e9s, Quer\u00e9taro, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1203"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality and days free of organ support|Arterial and venous thrombotic conditions|Intubation and mortality|All-cause mortality|Intubation|Hospital-free days|Ventilator-free days|Myocardial infarction|Ischaemic stroke|Venous thromboembolism|Vasopressor-free days|Renal replacement free days|Hospital re-admission|Acute kidney injury|Systemic arterial thrombosis or embolism|ECMO support|Mechanical circuit thrombosis|WHO ordinal scale|Major bleeding|Heparin-induced thrombocytopenia (HIT)""}"
"1452","The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden","","NCT04625114","EudraCT number: 2020-003475-18","Drug: Camostat|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04625114","Recruiting","2020-11-04","2023-01-01","{""locations"":""Ghent University Hospital, Algemene Inwendige Ziekten, Gent, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy in terms of viral load or surrogate""}"
"1453","AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","Al-COVE","NCT04341103","Al-COVE","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341103","Not yet recruiting","2020-04-01","2021-03-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19""}"
"1454","Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic","","NCT04368260","HSR200127","Device: Control swab|Device: Prototype swab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04368260","Recruiting","2020-04-24","2020-07-31","{""locations"":""University of Virginia, Charlottesville, Virginia, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""up to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of subjects for which the prototype swab and the control swab provide the same COVID-19 PCR result""}"
"1455","Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia","","NCT04527224","ASVP1N2A-US","Drug: AstroStem-V","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04527224","Not yet recruiting","2020-12-01","2022-04-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""19 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment related adverse events|Number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values|Oxygenation index (PaO2 \/ FiO2 ratio)|Mortality rate|Ventilator treatment status|Improvement of pneumonia|SOFA score (Sequential Organ Failure Assessment)|2019 nCOV nucleic acid test|Duration of total hospitalization and intensive care unit stay (days)""}"
"1456","The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19","","NCT04389671","02-CL-2001a","Drug: Lucinactant","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04389671","Not yet recruiting","2020-10-01","2021-04-01","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygenation index (OI) area under the curve (AUC)0-12|FiO2|PaO2|Oxygenation from pulse oximetry (SpO2)|P\/F ratio|Ventilation Index (VI)|Lung compliance""}"
"1457","Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19","GERIA-COVID","NCT04560608","2020/100|ar20-0087v0","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04560608","Recruiting","2020-03-15","2021-01-31","{""locations"":""Angers University Hospital, Angers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""255"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Medical history and co-morbidities|The physical examination data, and reports of relevant investigations data provided by the physician and the family during hospitalization|Electrocardiography QT Interval|Number of different therapeutic classes|Comprehensive Geriatric Assessment (CGA)|Biological parameters|Medical imaging results|Diagnosis of COVID-19|Length of hospitalization|Number of death from any cause|Reports of relevant investigations data provided by the physician and the family during the two-month telephone follow-up""}"
"1458","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","ECMO-VID","NCT04341285","ECMO-VID","Procedure: ECMO Implantation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04341285","Not yet recruiting","2020-08-01","2022-05-01","{""locations"":""University Hospital Tuebingen, Tuebingen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28 day all cause mortality|90 day all cause mortality|Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days|duration of mechanical ventilation support|Ventilator Associated Pneumonia|Bleeding complications|Acute Renal Failure|Discharge Location""}"
"1459","Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home","SECURADOM","NCT04560855","2020-A00981-38","Device: Connected devices measurements","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04560855","Recruiting","2020-09-14","2021-09-14","{""locations"":""CHU Grenoble-Alpes, Grenoble, Auvergne-Rh\u00f4ne-Alpes, France|CHU d'Amiens, Amiens, Hauts-de-France, France|H\u00f4pital d'Instruction des Arm\u00e9es B\u00e9gin, Saint-Mand\u00e9, Ile De France, France|H\u00f4pital d'Instruction des Arm\u00e9es Percy, Clamart, Ile-de-France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity and Specificity of the patient's aggravation with a logistic regression model|Sensitivity and Specificity of the patient's aggravation with a cluster model|Study the evolution of daily patient parameters without aggravation over time|Subjective assessment of the connected devices""}"
"1460","Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment","","NCT04542200","20-0668","Biological: Antibody testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04542200","Enrolling by invitation","2021-01-01","2022-12-31","{""locations"":""Feinstein Institutes for Medical Research, Northwell Health, Great Neck, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""70812"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 antibodies""}"
"1461","Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19","","NCT04537858","33244620.5.0000.5505","Device: Virtual reality therapy first|Device: Conventional therapy first","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04537858","Active, not recruiting","2020-06-18","2020-12-01","{""locations"":""Comit\u00ea de \u00c9tica da Universidade Federal, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""20 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Heart Rate Variability|Motor Skills|Strength|Perceived Exertion|Satisfaction using the technology|Mood""}"
"1462","COVID-19 and HIV Patients","COCOVIH","NCT04523012","CREPATS 013","Other: Seroprevalence of SARS-CoV-2 infection in patients with HIV infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04523012","Recruiting","2020-07-01","2022-06-30","{""locations"":""Val\u00e9rie POURCHER, Paris, Ile De France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure of seroprevalence of COVID-19 infection assessed by the level of anti-Covid-19 IgG antibodies in the population of people living with HIV monitored at the Piti\u00e9-Salp\u00eatri\u00e8re hospital""}"
"1463","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)","","NCT04318444","AAAS9676","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04318444","Recruiting","2020-03-29","2022-03-01","{""locations"":""Columbia University Irving Medical Center, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with symptomatic, lab-confirmed COVID-19.""}"
"1464","Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients","COVID-HO","NCT04371679","Covid-HO","Other: No interventions planned","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371679","Recruiting","2020-04-01","2020-12-01","{""locations"":""Jessa Hospital, Hasselt, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Death (all-cause mortality) or discharge from ICU (limit of 4 months)""}"
"1465","COVID-19 Survivorship Registry","","NCT04527315","20-00909","Other: Questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04527315","Recruiting","2020-07-17","2023-08-01","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Level of Inflammatory Markers|Score on St. George's Shortness of Breath Questionnaire (SGSQ)|Score on Short Form Zarit Burden Interview (ZBI-12)""}"
"1466","Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19","","NCT04454398","GRD-COV-101","Biological: COVI-GUARD|Other: Standard of Care|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04454398","Withdrawn","2020-09-01","2021-01-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of serious adverse events (safety)|All-cause mortality at 29 and 60 days|Incidence of dose-limiting toxicities (safety)|Incidence of laboratory abnormalities (safety)|SARS-CoV-2 viral load as assessed using various sample types|Time to hospitalization, treatment, ICU admission, and discharge from ICU and\/or hospital|Anti-drug antibodies|Cytokine levels|AUC of COVI-GUARD (PK)|Cmax of COVI-GUARD (PK)|t\u00bd of COVI-GUARD (PK)|Tmax of COVI-GUARD (PK)""}"
"1467","Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","","NCT04467840","ABC-201","Drug: Opaganib|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04467840","Recruiting","2020-08-21","2021-06-01","{""locations"":""ABC-201 Site 408, Belo Horizonte, Brazil|ABC-201 Site 411, Belo Horizonte, Brazil|ABC-201 Site 405, Joinville, Brazil|ABC-201 Site 404, Paran\u00e1, Brazil|ABC-201 Site 410, Passo Fundo, Brazil|ABC-201 Site 409, Porto Alegre, Brazil|ABC-201 Site 401, Sao Paulo, Brazil|ABC-201 Site 402, S\u00e3o Bernardo Do Campo, Brazil|ABC-201 Site 403, S\u00e3o Paulo, Brazil|ABC-201 Site 407, Tubar\u00e3o, Brazil|ABC-201 Site 604, Antioquia, Colombia|ABC-201 Site 603, Bogot\u00e1, Colombia|ABC-201 Site 605, Cundinamarca, Colombia|ABC-201 Site 602, Medell\u00edn, Colombia|ABC-201 Site 601, Santiago de Cali, Colombia|ABC-201 Site 702, Ashdod, Israel|ABC-201 Site 704, Holon, Israel|ABC-201 Site 701, Jerusalem, Israel|ABC-201 Site 705, Nahariya, Israel|ABC-201 Site 706, Nazareth, Israel|ABC-201 Site 703, Safed, Israel|ABC-201 Site 203, Alessandria, Italy|ABC-201 Site 201, Lecco, Italy|ABC-201 Site 202, Milano, Italy|ABC-201 Site 204, Torino, Italy|ABC-201 Site 501, Mexico City, Mexico|ABC-201 Site 503, Sinaloa, Mexico|ABC-201 Site 303, Boles\u0142awiec, Poland|ABC-201 Site 302, Ostr\u00f3da, Poland|ABC-201 Site 301, Racib\u00f3rz, Poland|ABC-201 Site 110, Barnaul, Russian Federation|ABC-201 Site 122, Kirovsk, Russian Federation|ABC-201 Site 101, Moscow, Russian Federation|ABC-201 Site 132, Moscow, Russian Federation|ABC-201 Site 120, Murmansk, Russian Federation|ABC-201 Site 103, Ryazan, Russian Federation|ABC-201 Site 114, Ryazan, Russian Federation|ABC-201 Site 129, Saint Petersburg, Russian Federation|ABC-201 Site 108, Saratov, Russian Federation|ABC-201 Site 102, Smolensk, Russian Federation|ABC-201 Site 109, St Petersburg, Russian Federation|ABC-201 Site 111, St Petersburg, Russian Federation|ABC-201 Site 104, Tver, Russian Federation|ABC-201 Site 118, Volgograd, Russian Federation|ABC-201 Site 112, Yaroslavl, Russian Federation|ABC-201 Site 251, Gillingham, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""464"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Supplemental oxygen requirement|WHO Ordinal Scale for Clinical Improvement with a scale ranging from 8 down to 0|Time to recovery as defined by improvement to a score of 3 or less on the WHO Ordinal Scale for Clinical Improvement with a scale ranging from 8 down to 0|Time to low oxygen flow via nasal cannula|Time to discharge from hospital|Requiring intubation and mechanical ventilation|Time to negative swabs for SARS-CoV-2|Negative swabs for SARS-CoV-2 at day 14|Fever|Mortality""}"
"1468","A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants","ENSEMBLE","NCT04505722","CR108876|VAC31518COV3001","Biological: Ad26.COV2.S|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04505722","Active, not recruiting","2020-09-07","2023-01-02","{""locations"":""Synexus Clinical Research US, Inc, Birmingham, Alabama, United States|University of Alabama Birmingham, Birmingham, Alabama, United States|Alabama Vaccine Research Clinic at UAB, Birmingham, Alabama, United States|Optimal Research, Huntsville, Alabama, United States|Synexus Clinical Research US, Inc, Glendale, Arizona, United States|VA Medical Center, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Ark Clinical Research, Long Beach, California, United States|Anthony Mills Medical, Inc, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCSD Antiviral Research Center AVRC, San Diego, California, United States|Wr-McCr, Llc, San Diego, California, United States|VA Medical Center, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Denver, Colorado, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|North Florida South Georgia Veteran Health System, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Research Centers of America, LLC, Hollywood, Florida, United States|Suncoast Research Group, Miami, Florida, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Advent Health Orlando, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Pinellas Park, Florida, United States|James A Haley VA Hospital GNS, Tampa, Florida, United States|Synexus Clinical Research US, Inc, The Villages, Florida, United States|Emory University of Medicine, Atlanta, Georgia, United States|The Hope Clinic at Emory University, Decatur, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Jesse Brown VAMC Department of Surgery, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of IL Chicago, Chicago, Illinois, United States|The University Of Chicago Medicine, Chicago, Illinois, United States|Optimal Research, Peoria, Illinois, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Benchmark Research, Metairie, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Southeast Louisiana Veterans Health Care Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Optimal Research, Rockville, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Brigham and Women's Hospital, Inc., Boston, Massachusetts, United States|University of Michigan Neuorsurgery A. Alfred Taubman Health Care Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Cherry Street Services, Inc., Grand Rapids, Michigan, United States|Abbott Northwestern Hospital Clinic, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|MediSync Clinical Research, Petal, Mississippi, United States|The Center For Pharmaceutical Research, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, United States|Bronx Veterans Affairs Medical Center, Bronx, New York, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|New York Blood Center, New York, New York, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|Tryon Medical Group, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Durham VAMC, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc, Akron, Ohio, United States|CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Rapid Medical Research, Cleveland, Ohio, United States|Synexus Clinical Research US, Inc, Columbus, Ohio, United States|Corvallis Clinic PC, Corvallis, Oregon, United States|Clinical Research Institute of Southern Oregon, P.C., Medford, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|VA Medical Center, Columbia, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|PMG Research of Charleston, LLC, Mount Pleasant, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|Optimal Research, LLC, Austin, Texas, United States|AIDS Arms Incorporated Trinity Health and Wellness Center, Dallas, Texas, United States|Synexus Clinical Research US, Inc, Dallas, Texas, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|North Texas Infectious Diseases Consultants, Dallas, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Gordon Crofoot, MD, Houston, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States|CIPREC, Buenos Aires, Argentina|Helios Salud Sa, Buenos Aires, Argentina|CEMEDIC, Buenos Aires, Argentina|Centro Medico Viamonte SRL, Ciudad Autonoma Buenos Aires, Argentina|Clinical Trials Division-Stamboulian Servicios de Salud, Ciudad Autonoma Buenos Aires, Argentina|Cl\u00ednica y Maternidad Suizo Argentina, Ciudad Autonoma de Buenos Aires, Argentina|Fundacion Huesped, Ciudad Autonoma De Buenos Aire, Argentina|CEMIC Saavedra, Ciudad de Buenos Aires, Argentina|Hospital J. M. Ramos Mej\u00eda, Ciudad de Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Argentina|DIM Clinica Privada, Ramos Mejia, Argentina|Faculdade de Medicina Barretos FACISB, Barretos, Brazil|Hospital Das Clinicas Da Universidade Federal De Minas Gerais, Belo Horizonte, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil|L2IP - Instituto de Pesquisas Cl\u00ednicas, Bras\u00edlia, Brazil|HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil|Hospital S\u00e3o Jos\u00e9, Crici\u00fama, Brazil|Oncovida - Centro de Onco-Hematologia de Mato Grosso, Cuiab\u00e1, Brazil|Hospital Nossa Senhora Das Gracas, Curitiba, Brazil|Centro de Estudos e Pesquisas em Mol\u00e9stias Infecciosas, Natal, Brazil|Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeir\u00e3o Preto, Brazil|Hospital federal dos servidores do estado, Rio de Janeiro, Brazil|Instituto Brasil de Pesquisa Clinica, Rio de Janeiro, Brazil|FIO CRUZ- Funda\u00e7\u00e3o Oswaldo Cruz - Inst de Pesquisa Cl\u00ednica Evandro Chagas, Rio de Janeiro, Brazil|Hospital Geral De Nova Igaucu Brazil, Rio de Janeiro, Brazil|Funda\u00e7\u00e3o Bahiana De Infectologia, Salvador, Brazil|Universidade Municipal de Sao Caetano do Sul, Sao Caetano do Sul, Brazil|Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Brazil|Centro de Refer\u00eancia E Treinamento Dst\/Aids, Sao Paulo, Brazil|CPQuali Pesquisa Clinica LTDA ME, S\u00e3o Paulo, Brazil|Instituto de infectologia Emilio Ribas, S\u00e3o Paulo, Brazil|Hospital Sirio Libanes, S\u00e3o Paulo, Brazil|Real e Benem\u00e9rita Associa\u00e7\u00e3o Portuguesa de Benefic\u00eancia, S\u00e3o Paulo, Brazil|Cepic - Centro Paulista De Investigacao Clinica, S\u00e3o Paulo, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da USP, S\u00e3o Paulo, Brazil|Bioclinica Santiago Bulnes, Santiago, Chile|Facultad de Medicina Universidad de Chile, Santiago, Chile|Clinica del Maule, Talca, Chile|Hospital Dr Hernan Henriquez Aravena, Temuco, Chile|Clinica de la Costa, Barranquilla, Colombia|Centro de Reumatologia y Ortopedia, Barranquilla, Colombia|Hospital Universidad del Norte, Barranquilla, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Bogota, Colombia|Solano y Terront Servicios M\u00e9dicos Ltda., Bogota, Colombia|Medplus Medicina Prepagada S.A., Bogota, Colombia|Centro de Investigaciones Clinicas S.A.S., Cali, Colombia|Fundaci\u00f3n Valle del Lili, Cali, Colombia|Fundaci\u00f3n Cardiovascular de Colombia - Instituto del Coraz\u00f3n Floridablanca, Floridablanca, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia|Programa de Estudio y Control de Enfermedades Tropicales, Medellin, Colombia|Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia|Hospital Pablo Tobon Uribe, Medell\u00edn, Colombia|Instituto Nacional de Salud Publica, Cuernavaca, Mexico|Unidad de Atenci\u00f3n Medica e Investigacion en Salud (UNAMIS), Merida, Mexico|CAIMED Investigacion en salud S.A de C.V., Mexico, Mexico|Hospital Universitario de Nuevo Leon 'Dr Jose Eleuterio Gonzalez', Monterrey, Mexico|Centro de Invetigaciones Medicas, Callao, Peru|Centro de Investigaciones Tecnologicas, Biomedica y medio ambientales (CITBM), Callao, Peru|Asociacion Civil Selva Amazonica (ACSA), Iquitos, Peru|Asociacion Civil Impacta Salud y Educacion - Barranco, Lima - Barranco, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Asociacion Civil Via Libre, Lima, Peru|Asociacion Civil Impacta Salud y Educacion- San Miguel CRS, Lima, Peru|Josha Research, Bloemfontein, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|Family Clinical Research Unit FAM-CRU, Cape Town, South Africa|TASK Central, Cape Town, South Africa|Desmond Tutu HIV Foundation, Cape Town, South Africa|University of Cape Town IDM\/CIDRI Research Site, Cape Town, South Africa|Desmond Tutu Hiv Foundation - University of Cape Town, Cape Town, South Africa|Masiphumelele Research Centre, Cape Town, South Africa|Ndlovu Elandsdoorn Site, Dennilton, South Africa|SA Medical Research Council, Durban, South Africa|SA Medical Research Council, Durban, South Africa|CRISMO Bertha Gxowa Research Centre, Johannesburg, South Africa|Shandukani Research Centre, Johannesburg, South Africa|The Aurum Institute Klerksdorp Clinical Research Centre, Klerksdorp, South Africa|Qhakaza Mbokodo Research Centre, KwaZulu-Natal, South Africa|South African Medical Research Council Chatsworth Clinical Research Site, KwaZulu-Natal, South Africa|Centre for the AIDS Programme of Research in South Africa, KwaZulu-Natal, South Africa|Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Nelson Mandela Academic Clinical Research Unit 'NeMACRU', Mthatha, South Africa|PHOENIX PHARMA (Pty) Ltd, Port Elizabeth, South Africa|MeCRU Clinical Research Unit, Pretoria, South Africa|Synexus Watermeyer, Pretoria, South Africa|The Aurum Institute Rustenburg Clinical Research Site, Rustenburg, South Africa|Setshaba Research Centre, Soshanguve, South Africa|Perinatal HIV Research Unit (PHRU), Kliptown, Soweto, South Africa|Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa|The Aurum Institute: Tembisa - Clinic 4, Tembisa, South Africa|CAPRISA Vulindlela Clinic, Vulindlela, South Africa|University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre, Westdene Johannesburg Gauteng, South Africa|SATVI, Brewelskloof Hospital, Worcester, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""44325"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe\/Critical Coronavirus Disease (COVID-19) with Seronegative Status|Number of Participants with First Occurrence of Molecularly Confirmed Severe\/Critical Coronavirus Disease (COVID-19) with Seronegative Status|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe\/Critical COVID-19 Regardless of their Serostatus|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe\/Critical COVID-19 Regardless of Their Serostatus|Number of Participants with First Occurrence of COVID-19 Requiring Medical Intervention|SARS-CoV-2 Viral Load as Assessed by Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) in Participants with Molecularly Confirmed, Moderate to Severe\/Critical COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed Mild COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed COVID-19 Defined by the US Food and Drug Administration (FDA) Harmonized case Definition|Burden of Disease (BOD) Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19|BOD Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19|Serologic Conversion Between Baseline and (Day 1; Pre-vaccination), Day 71, 6 Months and 1- Year Post-vaccination using an Enzyme-linked Immunosorbent Assay (ELISA)|Number of Participants with First Occurrence of SARS-CoV-2 Infection (Serologically and\/or Molecularly Confirmed)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Medically-Attended Adverse Events (MAAEs)|Number of Participants with Medically-Attended Adverse Events (MAAEs) Leading to Study Discontinuation|Number of Participants with Solicited Local Adverse Events (AEs) During 7 Days Following Vaccination|Number of Participants with Solicited Systemic AEs During 7 Days Following Vaccination|Number of Participants with Unsolicited Local Adverse Events (AEs) During 28 Days Post-vaccination|SARS-CoV-2 Neutralizing Antibody Titers as Assessed by Virus Neutralization Assay (VNA)|SARS-CoV-2 Binding Antibodies Assessed by ELISA""}"
"1469","Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV)","AMBUCOV","NCT04703114","AMBUCOV|2020-A03102-37","Diagnostic Test: Blood count|Diagnostic Test: Blood collection|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Saliva samples|Diagnostic Test: Faeces samples|Genetic: Genetic blood collection|Other: Data collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04703114","Not yet recruiting","2021-02-01","2021-12-01","{""locations"":""H\u00f4pital Cochin, Paris, \u00cele-de-France, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Interferon response|Immunology : cytokines|Immunology : cell population|Immunology : proteins|Immunology : pathways|Immunology : antibody response|Virology : Nasopharyngeal Viral clearance kinetics|Virology : Saliva Viral clearance kinetics|Virology : faeces viral clearance kinetics|Virology : peripheral blood viral clearance kinetics|Virology : sequencing""}"
"1470","An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease","","NCT04352491","ILBS-COVID-03","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04352491","Completed","2020-04-24","2020-05-31","{""locations"":""Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""347"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Association between presence of Liver disease and fear levels|Association between presence of Liver disease and anxiety levels|Association between presence of Liver disease and stress levels|Correlation between Fear and Child-Turcotte-Pugh Score|Correlation between anxiety and Child-Turcotte-Pugh Score|Correlation between stress and Child-Turcotte-Pugh Score|Correlation between fear and Model for End Stage Liver Disease Score|Correlation between anxiety and Model for End Stage Liver Disease Score|Correlation between stress and Model for End Stage Liver Disease Score""}"
"1471","Effect of Obesity Among COVID-19 Patients in Critical Care Settings","","NCT04674553","16021982","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04674553","Completed","2020-11-10","2020-12-10","{""locations"":""Mehwish Iftikhar, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality|Recovery from COVID-19|COVID-19 severity|Oxygen requirement""}"
"1472","COVID19-OR (SARS-CoV-2): Observation,Risk & Recovery","","NCT04524520","20/YH/0157","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04524520","Recruiting","2020-05-05","2022-05-08","{""locations"":""Dr Luke Hodgson, Worthing, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical|Health Related Quality of life|Psychological|risk stratification""}"
"1473","Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)","COVITOZ-01","NCT04435717","COVITOZ-01","Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04435717","Recruiting","2020-05-04","2020-08-04","{""locations"":""Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""78"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3.|Progression of pneumonia|PaO2\/FiO2|cause mortality to 28 days after started treatment|Length of hospital stay|patients requiring Intensive Care Unit admission|evolution of inflammatory parameters IL12|evolution of inflammatory parameters IL-10, IL-1, IL-6, IL-17 and IFN-gamma|evolution of inflammatory parameters Procalcitonin (PCT),|evolution of inflammatory parameters C-reactive protein (PCR),|evolution of inflammatory parameters D-dimer|evolution of inflammatory parameters and ferritin|pharmacokinetics of tocilizumab Cmin|pharmacokinetics of tocilizumab Cmax|pharmacokinetics of tocilizumab Cmedia|pharmacokinetics of tocilizumab Tmax|pharmacokinetics of tocilizumab AUC|Adverse event|Adverse event to cause the treatment interruption.|Adverse event Abnormalities in laboratory""}"
"1474","Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19","","NCT04462393","SweCOVID","Other: Admission to ICU for COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04462393","Completed","2020-03-06","2020-05-06","{""locations"":""Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region \u00d6sterg\u00f6tland, Link\u00f6ping, \u00d6sterg\u00f6tland, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1563"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30-day mortality|ICU mortality""}"
"1475","Nudges to Improve Health Behaviors That Limit COVID-19 Spread","","NCT04379375","PRO00037864","Behavioral: Nudge","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04379375","Terminated","2020-07-27","2020-09-30","{""locations"":""Medical College of Wisconsin, Milwaukee, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""45"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hand Washing Behavior|Clinical Outcomes - General\/Internal Medicine|Clinical Outcomes - Obstetrics & Gynecology|Clinical Outcomes - Surgery""}"
"1476","Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19","","NCT04435314","NITFQM0620OR","Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04435314","Not yet recruiting","2020-06-01","2020-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of subjects with laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study|Incidence of Treatment-Emergent Adverse Events|The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study|The proportion of subjects with asymptomatic laboratory-confirmed COVID identified after the start of treatment and before the end of the study|Treatment adherence|Disease complication|Incidence of subjects that underwent unscheduled visit""}"
"1477","Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19","","NCT04498377","GC-652-04","Biological: F-652|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04498377","Recruiting","2021-01-26","2021-12-31","{""locations"":""Tulane University School of Medicine, New Orleans, Louisiana, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""38"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""NIAID 8-point ordinal scale""}"
"1478","Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support","","NCT04503434","Medicalitzed Hotel COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04503434","Completed","2020-05-15","2020-06-06","{""locations"":""Carme Hern\u00e1ndez, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""517"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The Picker Patient Experience Questionnaire|Open questions""}"
"1479","Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)","","NCT04596839","BEX-06001","Drug: Remdesivir|Other: Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04596839","Recruiting","2020-09-04","2021-04-30","{""locations"":""Combined Military Hospital, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of hospital stay (Days)|Time to Clinical Improvement (TTCI)|All causes mortality|Duration (days) of mechanical ventilation|Duration (days) of supplemental oxygenation|Time to 2019-nCoV RT-PCR negativity in Nasopharyngeal Swab|Frequency of serious adverse drug events""}"
"1480","Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19","Caards-1","NCT04384731","P20/06","Drug: poractant alfa","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04384731","Recruiting","2020-05-29","2021-07-31","{""locations"":""CH Francois Quesnay, Mantes la Jolie, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evolution of the PaO2 \/ FiO2 ratio between the measurements taken before (t0) and one hour after the end of the invasive procedure (H1).|Oxygenation : PaO2 \/ FiO2 ratio.|Oxygenation : area under the PaO2 \/ FiO2 curve.|Oxygenation : area under the SpO2 curve.|Evolution of thoraco-pulmonary compliance (mL \/ mbar) between before and one hour after the procedure.|Overall survival rate|Mortality rate at discharge from the intensive care unit.|Mortality rate at discharge from the hospital.|Number of ventilator-free days|Number of prone position sessions.|Time between inclusion and the last prone position session.""}"
"1481","A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19","","NCT04537806","547-ARD-301","Drug: Brexanolone|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04537806","Recruiting","2020-12-18","2021-10-01","{""locations"":""Sage Investigational Site, Fresno, California, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Burlington, Massachusetts, United States|Sage Investigational Site, Lansing, Michigan, United States|Sage Investigational Site, Richmond, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants Who are Alive and Free of Respiratory Failure at Day 28|Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)|All-cause Mortality Through Day 28""}"
"1482","Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh","","NCT04402203","29318042020","Drug: Favipiravir|Drug: Only Standard Treatment","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04402203","Recruiting","2020-05-01","2020-07-01","{""locations"":""Mahanagar General Hospital, Dhaka (Site-1), Mugda Medical College Hospital, Dhaka (Site-2), Kurmitola General Hospital, Dhaka (Site-3), Dhaka Medical College Hospital, Dhaka (Site-4), Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants negative by RT-PCR for the virus at 4-10 days after initiation of therapy.|Number of participants with lung condition change assessed with X-ray.|Number of participants with clinical recovery|Number of participants with adverse effects of drug.|Number of participants requiring ICU admission|Number of death""}"
"1483","Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)","XACT","NCT04640181","2020-001708-41","Drug: Enoxaparin|Drug: Rivaroxaban","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04640181","Not yet recruiting","2020-12-01","2021-07-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death or 30-day all cause mortality|Mechanical ventilation, intubation|Transfer to an ICU setting|New requirement for hemodialysis (HD) or continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO)|New thrombotic events|Major bleeding event|Time to recovery (defined as no limitation or minor limitation in activity level or hospitalized but require no oxygen)""}"
"1484","Compassionate Use of Hyperbaric Oxygen Therapy","","NCT04386265","HBOT-COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386265","Enrolling by invitation","2020-04-15","2022-05-11","{""locations"":""White River Wound Healing Center, Batesville, Arkansas, United States|Community Hospital, Monterey, California, United States|Innovative Healing Systems, Tampa, Florida, United States|Decatur Memorial Hospital, Decatur, Indiana, United States|Providence Medical Wound Care Center, Kansas City, Kansas, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|The Wound Treatment Center, Opelousas, Louisiana, United States|Christus Shreveport Bossier Hyperbaric & Wound Care Center, Shreveport, Louisiana, United States|Ascension Providence Rochester Hospital Wound Care Center, Rochester, Michigan, United States|CHI, Chattanooga, Tennessee, United States|Klinika Baromedical, Poznan, Wielkopolskie, Poland"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Gather information on patients treated with hyperbaric oxygen therapy|Gather information on adverse events""}"
"1485","Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19","2019nCoV_ICU","NCT04388670","PoliclinicoH","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388670","Recruiting","2020-02-22","2020-08-31","{""locations"":""Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall number and characteristics of patients with COVID-19 in ICU""}"
"1486","Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19","CORONA-SHIELD","NCT04357574","Pro00105266","Other: Telehealth","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357574","Enrolling by invitation","2020-04-14","2021-04-01","{""locations"":""Duke Cancer Center, Durham, North Carolina, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19|Number of missed telehealth clinical evaluation visits during COVID-19|Number of unplanned emergency department visits or hospital admissions during COVID-19|Number of acute care visits with listed reason as anemia, nutrition (including dehydration), diarrhea, emesis, infectious (including fever, pneumonia, and sepsis), nausea, neutropenia, pain category during COVID-19""}"
"1487","Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","","NCT04363502","IRB00247932","Drug: Clazakizumab|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363502","Recruiting","2020-05-07","2021-06-01","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in C-reactive protein (CRP) level""}"
"1488","Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?","","NCT04623385","SARS -2","Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|Drug: The standard therapy","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04623385","Not yet recruiting","2020-11-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Frequency of adverse events and severe adverse events|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Thrombin time (TT)""}"
"1489","CardioVascular Disease Progression and Prognosis in COVID-19","CVP-Covid19","NCT04606732","CV_SPP_COVID19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04606732","Recruiting","2020-09-20","2021-12-31","{""locations"":""Policlinico Sant'Orsola, Bologna, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality""}"
"1490","Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients","","NCT04563689","COVID-POC1","Other: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|Other: placebo rinse","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04563689","Completed","2020-06-18","2020-10-23","{""locations"":""Escuela odontologia. Facultad de Salud Hospital del Valle, Cali, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other"",""enrollment"":""23"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""exploratory change in viral load|number of patients who have decrease in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCR|number of patients with adverse events during 5 days study duration""}"
"1491","Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020","","NCT04352751","PIPK- 0000 /NIBD-0000/2020","Other: convalescent plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04352751","Recruiting","2020-05-01","2021-04-01","{""locations"":""National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD), Karachi, Sindh, Pakistan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""2000"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Change in COVID-19 severity status""}"
"1492","Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma","Inova-CCP","NCT04502472","Inova COVID-19 CCP","Biological: Convalescent plasma transfusion","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04502472","Recruiting","2020-06-06","2021-12-31","{""locations"":""Inova Fairfax Medical Campus, Falls Church, Virginia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change is clinical status|Transfusion related events|SOFA score at days 0, 7, 14, 21, 28|Length of Hospital Stay|Supplemental oxygen|Mechanical Ventilation|Change in mechanical ventilation status|Mortality|Change in inflammatory markers""}"
"1493","Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications","","NCT04374487","MHC-COVID-19-CP","Drug: Convalescent Plasma|Other: Standard Care Therapy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04374487","Active, not recruiting","2020-05-09","2021-08-09","{""locations"":""Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P\/F ratio 100) and 2. All-cause Mortality at 28 days|Time to symptom resolution-Fever,Shortness of Breath,Fatigue|Hospital length of stay|Change in SOFA pre and post transfusion|Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive|Radiological improvement|Adverse events (AE) associated with transfusion|To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion]|Levels of bio-markers pre and post transfusion|Need of Vasopressor use""}"
"1494","The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care","","NCT04683328","SCTA01-C301","Biological: SCTA01|Biological: SCTA01 Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04683328","Not yet recruiting","2021-02-25","2021-11-25","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""560"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality rate at D29|All-cause mortality rate at Day 60|Time to discontinue mechanical ventilation (MV) at Day 29|Time to improvement of two categories on WHO 10-Point Ordinal Scale from baseline at Day 29|Time to discontinue supplemental oxygen at Day 29|Time to hospital free at Day 29|Change from baseline in viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR)|SAE|Anti-drug antibody (ADA)""}"
"1495","To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.","","NCT04542447","BIAG-CSP-037","Drug: Nuvastatic","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04542447","Recruiting","2020-09-01","2020-09-30","{""locations"":""Navin Hospital, Ghaziabad, Uttar Pradesh, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate safety and efficacy Nuvastatic\u2122 (C5OSEW5050ESA)|IL-6 reduction|Serum c-reactive protein (CRP)|IgG|Hb|Total leucocyte count|F2-Isoprostane|Improvement in ARDS associated clinical symptoms cause""}"
"1496","The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19","LAVA","NCT04629157","290989","Device: Innova Lateral Flow Device","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04629157","Recruiting","2020-11-05","2020-11-19","{""locations"":""Alder Hey in the Park, Liverpool, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""400"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""Acceptability of test|Test failure rate""}"
"1497","CICERO- A Care Home Study of COVID-19","","NCT04453553","285524","Diagnostic Test: Q16 testing|Diagnostic Test: Nasopharyngeal swab and main laboratory","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04453553","Not yet recruiting","2020-07-02","2020-09-28","{""locations"":""Queen Mary University London, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""50"",""age"":""18 Years to 130 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""CoV-2 Infection after 21 days|CoV-2 Infection after 14 days|Cases of suspected or confirmed CoV-2 infection|Hospitalisation and death""}"
"1498","A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19","NICLONEX","NCT04558021","NOV2020/01930","Drug: Niclosamide suspension|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04558021","Recruiting","2020-10-08","2021-02-14","{""locations"":""Akdeniz \u00dcniversitesi T\u0131p Fak\u00fcltesi Hastanesi, Antalya, Turkey|Antalya E\u011fitim ve Ara\u015ft\u0131rma Hastanesi, Antalya, Turkey|Gaziantep \u00dcniversitesi T\u0131p Fak\u00fcltesi Hastanesi, Gaziantep, Turkey|Gaziosmanpa\u015fa Taksim E\u011fitim ve Ara\u015ft\u0131rma Hastanesi, Istanbul, Turkey|Dokuz Eyl\u00fcl \u00dcniversitesi Hastanesi, \u0130zmir, Turkey|\u0130zmir SB\u00dc Tepecik E\u011fitim ve Ara\u015ft\u0131rma Hastanesi, \u0130zmir, Turkey|SB\u00dc Dr. Suat Seren G\u00f6\u011f\u00fcs Hastal\u0131klar\u0131 ve Cerrahisi E\u011fitim ve Ara\u015ft\u0131rma Hastanesi, \u0130zmir, Turkey|\u0130zmir Katip \u00c7elebi \u00dcniversitesi Atat\u00fcrk E\u011fitim ve Ara\u015ft\u0131rma Hastanesi, \u0130zmir, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physician's judgment on clinical recovery from the time of admission|Clinical improvement in NEWS2|Improvement in serum biomarkers|Requirement for indotracheal intubation|Occurrence of Macrophage Activation Syndrome(MAS)|Occurrence of Coagulopathy""}"
"1499","Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection","VOC-COVID-Diag","NCT04614883","2020_0143","Device: Volatile Organic Compounds analysis|Other: Canine odor detection of Volatile Organic Compounds","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04614883","Recruiting","2020-10-21","2021-10-01","{""locations"":""Foch hospital, Suresnes, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Validate the interest of VOCs analyzed by electronic noses and \/ or mass spectrometry for the diagnosis of a COVID-19 infection|Identify the nature of VOCs associated with infection by SARS-CoV-2 by mass spectrometry in exhaled air and in sweat|Assessment of the specificity and sensitivity of canine olfactory detection of COVs associated with infection by SARS-CoV-2 (COVID-19)""}"
"1500","COVID-19 Nasal Swab Trial","","NCT04649424","B2020:121","Device: CanSwab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04649424","Recruiting","2020-12-22","2021-05-30","{""locations"":""St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other"",""enrollment"":""72"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Amount of SARS-CoV2 virus (COVID-19) collected|Clinical concordance rate|Patient comfort""}"
"1501","Patterns of Arrhythmias and Conduction Block in COVID-19 Patients and Its Relation to Myocardial Injury Detected by Cardiac Magnetic Resonance","","NCT04584411","arrhythmias in COVID-19","Diagnostic Test: Cardiac Magnetic resonance imaging","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04584411","Not yet recruiting","2020-11-01","2024-01-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the incidence of arrhythmia and conduction block in COVID-19 patients using Holter|Detection of myocardial injury in COVID-19 patients using CMR.""}"
"1502","Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure","","NCT04389840","CMX-DS-004","Drug: Dociparstat sodium|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04389840","Recruiting","2020-06-03","2021-06-01","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States|Advanced Pulmonary Research Institute\/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States|Augusta University, Augusta, Georgia, United States|Our Lady of the Lake, Baton Rouge, Louisiana, United States|Tulane University, New Orleans, Louisiana, United States|University Medical Center, New Orleans, Louisiana, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Texas Health Harris Methodist Hospital Fort Worth, Dallas, Texas, United States|Sentara Clinical Trials, Norfolk, Virginia, United States|Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States|Ascension All Saints Hospital, Racine, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""525"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who are alive and free of invasive mechanical ventilation|All-cause mortality""}"
"1503","Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome","MSC-COVID19","NCT04625738","2020-002772-12","Biological: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04625738","Not yet recruiting","2020-11-06","2022-08-06","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PaO2 \/ FiO2 ratio|respiratory function evolution|respiratory assistance|organ failures 1|organ failures 2|organ failures 3|duration of intensive care|Cause of death|respiratory morbidity (TDM, functional respiratory measures)|viral load|Anti-HLA antibody rate|immediate hypersensitivity reactions|thromboembolic adverse events 1|thromboembolic adverse events 2|infectious adverse events""}"
"1504","Registry on NEN Patients and COVID-19","","NCT04444401","IEO-1291","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444401","Recruiting","2020-06-15","2021-12-15","{""locations"":""European Institute of Oncology, IEO, IRCCS, Milan, MI, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between clinical parameters and SARS-CoV-2 infection|Clinical outcome of SARS-CoV-2 Infection|major demographic features|type of NEN""}"
"1505","Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.","COVID AMBU 60","NCT04363099","2020-A01059-30","Other: observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363099","Recruiting","2020-03-01","2020-12-31","{""locations"":""Msp de Creil, Creil, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1000"",""age"":""up to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""clinical description of covid 19 ambulatory cases.|Biological and radiological description of ambulatory cases|Prevalence of positive cases (PCR and\/or serological positive)""}"
"1506","Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia","","NCT04418128","2020-04-012","Drug: Nafamostat Mesylate","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04418128","Not yet recruiting","2020-06-10","2021-04-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""84"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with clinical improvement|Time to clinical improvement (TTCI)|Clinical status assessed by 7-category ordinal scale|Change in National Early Warning Score (NEWS)|Time to National Early Warning Score (NEWS) of \u2264 2 and maintained for 24 hours|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Incidence of new non-invasive ventilation or high flow oxygen use|Duration of new supplement oxygen use|Incidence of new supplement oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mortality at day 28|Time (days) from treatment initiation to death|Proportions of patients with a negative nasopharyngeal swab and sputum sample for SARS-CoV-2 quantitative RT-PCR|Viral load change (log10 viral load) of nasopharyngeal swab and sputum sample for SARS-CoV-2 quantitative RT-PCR|Adverse events that occurred during treatment""}"
"1507","An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19","","NCT04412018","Pro00043601","Drug: Icosapent ethyl","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04412018","Recruiting","2020-06-04","2020-12-01","{""locations"":""North York Diagnostic and Cardiology Clinic, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in hs-CRP levels from the randomization visit (Day 1) to the Day 14 visit|Change in D-dimer levels from the randomization visit (Day 1) to the Day 14 visit|Change in erythrocyte sedimentation rate from the randomization visit (Day 1) to the Day 14 visit|Change in complete blood count from the randomization visit (Day 1) to the Day 14 visit|Change in differential count from the randomization visit (Day 1) to the Day 14 visit|Change in serum albumin levels from the randomization visit (Day 1) to the Day 14 visit|Change in neutrophil-to-lymphocyte ratio (NLR) from the randomization visit (Day 1) to the Day 14 visit|Change in systemic immune-inflammation index from the randomization visit (Day 1) to the Day 14 visit""}"
"1508","The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia","","NCT04374591","Sodium Bicarbonate COVID-19","Drug: Sodium Bicarbonate","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04374591","Active, not recruiting","2020-08-01","2020-11-01","{""locations"":""Gomhoria Street, Mansoura, Outside U.S.\/Canada, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical recovery|Pulmonary recovery status""}"
"1509","Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.","PERSO-COVID","NCT04488484","PERSO-COVID","Other: Serology test follow-up","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04488484","Active, not recruiting","2020-07-01","2021-12-31","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immune Response description|Evolution of the SARS-CoV2 overtime|Clinical and Immunological Analysis|Comparison of the occurrence of clinical events with other immunological data""}"
"1510","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","PHYDRA","NCT04318015","ProfilaxisCOVID","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04318015","Recruiting","2020-04-14","2021-03-31","{""locations"":""Instituto Nacional de Enfermedades Respiratorias, \""Ismael Cos\u00edo Villegas\"", Mexico, City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel""}"
"1511","Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury","TACROVID","NCT04341038","TACRO-BELL-COVID|2020-001445-39","Drug: Tacrolimus|Drug: Methylprednisolone","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04341038","Recruiting","2020-04-01","2020-07-01","{""locations"":""Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""84"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to reach clinical stability|Time to reach an afebrile state for 48 hours.|Time to reach PaO2 \/ FiO2> 400 and \/ or SatO2 \/ FiO2> 300|Time to reach FR \u2264 24 rpm for 48 hours|Time to normalization of D-dimer (<250 ug \/ L)|Time until PCR normalization (<5mg \/ L).|Time until normalization of ferritin (<400ug \/ L)|Study the impact of immunosuppressive treatment on viral load using quantitative PCR|Time until hospital discharge|Need for ventilatory support devices|Duration that it is necessary to maintain ventilatory support.|COVID-19 mortality|all-cause mortality|Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission|Describe the side effects and their severity attributed to tacrolimus and \/ or methylprednisolone.""}"
"1512","Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19","","NCT04518969","BrugmannUH 1066","Device: CytoSorb","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04518969","Recruiting","2020-05-03","2020-12-01","{""locations"":""CHU Brugmann, Brussels, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""comparing % of change in cytokine's clearances of pro et anti -inflammatory types|Evaluation of the impact upon the survival rate at 28 and 90 days.|Chemokine kinetics|Cytokine kinetics|Complement pathway kinetics|PaO2\/FiO2 ratio""}"
"1513","Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients","","NCT04441398","NITFQM0720OR","Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04441398","Not yet recruiting","2020-07-01","2020-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in signs and symptoms scale|Incidence of Treatment-Emergent Adverse Events|The proportion of subjects hospitalized after start of treatment and before the end of the study|The proportion of subjects that need mechanical ventilation after start of treatment and before the end of the study|Duration of symptoms|Rate of mortality within 21-days""}"
"1514","Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects","","NCT04667442","Nanomix CVAG-202","Diagnostic Test: Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04667442","Recruiting","2020-12-01","2021-03-01","{""locations"":""Nanomix, Emeryville, California, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Demonstrate clinical agreement between an EUA RT-PCR methodology and the Nanomix eLab\u00ae COVID-19 Rapid Antigen Panel""}"
"1515","The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial","","NCT04581291","Aerobic exercise, COVID-19","Other: Moderate Intensity Aerobic Exercises","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04581291","Completed","2020-01-01","2020-10-01","{""locations"":""Motaz Alawna, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""30"",""age"":""24 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Immune system markers|Upper respiratory tract infection symptoms severity and progression""}"
"1516","Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol","CROWN","NCT04476602","20-0618","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04476602","Recruiting","2020-04-27","2020-12-31","{""locations"":""410 Lakeville Road, Suite 107, New Hyde Park, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital Admission""}"
"1517","Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers","COVIPACT","NCT04366154","2020-A00879-30","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366154","Active, not recruiting","2020-04-15","2021-05-01","{""locations"":""Centre Fran\u00e7ois Baclesse, Caen, France|Centre Henri Becquerel, Rouen, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""809"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To assess the impact of the COVID-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy|To assess the impact of the COVID-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy|To assess the impact of the COVID-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy|To assess the impact of the COVID-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy|Evaluate the perceived stress on cancer patients treated in unit day of hospital|Evaluate the post-traumatic stress on cancer patients treated in unit day of hospital|Evaluate the sleep disorders on cancer patients treated in unit day of hospital|Evaluate the quality of life on cancer patients treated in unit day of hospital|Evaluate the cognitive complaints on cancer patients treated in unit day of hospital|Evaluate the perceived stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|Evaluate the post-traumatic stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|Evaluate the burnout on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|Evaluate the feeling of personal effectiveness on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)""}"
"1518","A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy","","NCT04381988","20-176","Drug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04381988","Recruiting","2020-05-07","2021-05-01","{""locations"":""Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""132"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""cumulative incidence of SARS-CoV-2 infection|cumulative incidence of severe COVID-19 or death""}"
"1519","The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19","","NCT04468139","20-95M","Drug: Quercetin|Dietary Supplement: bromelain|Drug: Zinc|Drug: Vitamin C","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04468139","Recruiting","2020-06-20","2020-07-30","{""locations"":""Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""days of stay at hospital after treatment and discharge|serum zinc before and after treatment|questionnaire including parameters like BMI,,smoking , underling diseases, immunological treatment ,|day of negative conversion for nasopharyngeal swab for rt-PCR FOR covid-19""}"
"1520","Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia","TARGET-VIP","NCT04522076","02-07/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04522076","Active, not recruiting","2020-04-06","2022-05-01","{""locations"":""National Research Center for Preventive Medicine of the Ministry of Health, Moscow, Russian Federation|National Medical and Surgical Center named after N.I.Pirogov of the Ministry of Health of Russian Federation, Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1124"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival|Time to all-cause mortality or Artificial Pulmonary Ventilation (APV)|Time to all-cause mortality, nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization|Proportion of patients with severe pneumonia|Proportion of patients with low oxygen saturation value|Proportion of patients with Hb <90 g\/l (9.0 g\/dl) at any point during hospitalization|Proportion of patients hospitalized or transferred to Intensive Care Unit (ICU)|Time to nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization|Time to pneumonia\/recurrent pneumonia|Time to primary or recurrent coronavirus infection disease (COVID-19)""}"
"1521","Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia","","NCT04477954","AAMHEI2020-1","Combination Product: Hyperbaric Oxygen","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04477954","Terminated","2020-07-06","2020-12-30","{""locations"":""Hospital Central de San Isidro Dr. Angel Melchor Posse, San Isidro, Buenos Aires, Argentina|Hospital de Infecciosas F. J. Mu\u00f1iz, Ciudad Autonoma de Buenos AIres, Caba, Argentina|Hospital General de Agudos D.F Santojanni, Ciudad Autonoma de Buenos AIres, Caba, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to normalize the oxygen requirement (oxygen dependence)|Need for Invasive Mechanical Ventilation (IMV) and \/ or Respiratory Distress Syndrome Acute (ARDS)|Development of Acute Respiratory Distress Syndrome (ARDS)|30-day mortality|Hypotension with vasopressor requirement|Mortality""}"
"1522","Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19","SOC","NCT04440007","STI-5656-2001","Drug: Abivertinib|Other: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04440007","Recruiting","2020-10-09","2021-05-01","{""locations"":""MedStar Washington Hospital Center, Washington, District of Columbia, United States|Teradan Clinical Trials, Brandon, Florida, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Clinical Trials of SWLA, Lake Charles, Louisiana, United States|Quality Clinical Research, Omaha, Nebraska, United States|Memorial Hermann Memorial City Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects alive and free of respiratory failure at Day 28|Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656)|Proportion of subjects alive and free of respiratory failure at Day 60|Change in clinical status|Discharge from ICU|Time to respiratory failure or death|Change in CRP|Change from baseline in oxygenation index|All-cause mortality at Day 60 and Day 90|Number of days alive and free of respiratory failure at Day 28|Number of days with respiratory failure up to Day 28|Number of days hospitalized up to Day 28|Number of days in ICU (length of stay) up to Day 90|Number of days alive outside of hospital up to Day 28|Number of days alive outside of hospital up to Day 90""}"
"1523","Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19","","NCT04551768","BHC-RIB-5401-GL","Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04551768","Recruiting","2021-02-10","2021-07-01","{""locations"":""Bausch Health Site 201, Athens, Attika, Greece|Bausch Health Site 203, Athens, Attika, Greece|Bausch Health Site 204, Alexandroupoli, Evros, Greece"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment|Time to recover gas exchange to a PaO2\/FiO2 \u2265300 for at least 24 hours.|Time to reach peripheral capillary oxygen saturation (Sp02) >94% for at least 24 hours.""}"
"1524","RCT,Double Blind, Placebo to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU","","NCT04558424","BSMMU 2020","Dietary Supplement: zinc gluconate and ascorbic acid","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04558424","Not yet recruiting","2020-10-01","2021-09-01","{""locations"":""Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""symptoms reduction time frame|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Fatigue|Symptom Resolution: Muscle\/body aches|Symptom Resolution: Headache|Symptom Resolution: New loss of taste|Symptom Resolution: New loss of smell|Symptom Resolution: Congestion\/ runny nose|Symptom Resolution: Nausea|Symptom Resolution: Vomiting|Symptom Resolution: Diarrhea|Day 5 Symptoms|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects""}"
"1525","Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients","","NCT04568876","NORM_MPS-COVID|NORM_MPS_11","Dietary Supplement: Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Combination Product: Standard Therapy","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04568876","Recruiting","2020-10-23","2021-11-01","{""locations"":""Anestesia e Rianimazione Azienda Ospedaliera Universitaria Sant'Andrea, Roma, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of responder participants after 7 days of treatment|Change of pro-inflammatory markers (IL-6, IL-1 alpha, IL-1 beta, TNF-alpha, PCR, PCT, neopterin)|Change of anti-inflammatory markers (IL-4, IL-10)|Change of brain damage markers (S100b, ENS)|Change of coagulation indices (INR, fibrinogen, D-dimer)|Change of hematological parameters|Change of oxygenation indices (P\/F ratio, lactates)|Number of participants who developed delirium|Number of participants who developed anxiety and\/or depression""}"
"1526","Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19","COVID-19","NCT04416139","SCI-3354-20-21-1","Biological: Infusion IV of Mesenchymal Stem cells","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04416139","Recruiting","2020-05-01","2021-05-01","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Functional Respiratory changes: PaO2 \/ FiO2 ratio|Clinical cardiac changes: Heart rate per minute|Clinical Respiratory Changes: Respiratory rate per minute|Changes in body temperature|General biochemical changes in Leukocytes|General biochemical changes on lymphocytes|General biochemical changes on platelets|General biochemical changes on fibrinogen|General biochemical changes on pocalcitonin|General biochemical changes on ferritin|General biochemical changes on D-dimer|Changes on inflammatory C-reactive protein|Cahnges on Inflammatory cytokine TNFa|Changes on Inflammatory cytokine IL10|Changes on Inflammatory cytokine IL1|Changes on Inflammatory cytokine IL6|Changes on Inflammatory cytokine IL 17|Changes on VEGF|Radiological Changes|Immunological changes on T cell|Immunological changes on Dendritic cells|Immunological changes on CD4+ T|Immunological changes on CD8+ T|Immunological changes on NK cell|Adverse events|RNA detection by SARS-Cov2 PCR""}"
"1527","Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19","INSPIRATION","NCT04486508","99060","Drug: intermediate dose Enoxaparin/ unfractionated heparin|Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin|Drug: Atorvastatin 20mg|Drug: Matched placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04486508","Recruiting","2020-07-30","2021-05-07","{""locations"":""Masih Daneshvari Hospital, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""a composite of acute VTE, arterial thrombosis, treatment with ECMO, or all-cause mortality|Rate of all-cause mortality|Rate of objectively-confirmed VTE|Ventilator free days|Rate of major bleeding|Rate of clinically-relevant non-major bleeding|Rate of severe thrombocytopenia|Rate of rise in liver enzymes""}"
"1528","Dysphagia Management During COVID-19 Pandemic","","NCT04509752","Dysphagia during COVID-19","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04509752","Recruiting","2020-10-08","2021-02-28","{""locations"":""Hacetttepe University, Ankara, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""25 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Online survey""}"
"1529","Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients","","NCT04475120","4220","Drug: liposomal lactoferrin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04475120","Completed","2020-04-15","2020-07-02","{""locations"":""University of Rome Tor Vergata, Rome, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of viral clearance Time to viral clearance|Time to clinical improvement""}"
"1530","Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection","","NCT04651400","ATN01","Drug: Antithrombin III","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04651400","Recruiting","2020-10-19","2021-06-01","{""locations"":""Octapharma Research Site, Innsbruck, Austria|Octapharma Research Site, Wien, Austria|Octapharma Research Site, Strasbourg, France|Octapharma Research Site, Aachen, Germany|Octapharma Research Site, Essen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Antithrombin Levels|aPPT Levels|PT Levels|Quick Levels|INR Levels|D-dimer Levels|Fibrinogen Levels|Haemoglobin Levels|Platelet Levels|Thromboembolic complications and bleeding events between groups|Comparison of the duration of requirement for oxygen therapy, and invasive ventilation support or ECMO between groups|Hospital length of stay|Number of days in ICU|Number of days requiring oxygenation|Discharge disposition|Mortality""}"
"1531","Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19)","FALCON-C19","NCT04408170","B00944","Diagnostic Test: Point-of-care test for SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408170","Recruiting","2020-06-19","2021-06-30","{""locations"":""Sandwell General Hospital Birmingham NHS Trust, Birmingham, United Kingdom|University Hospitals of Derby and Burton NHS FT, Derby, United Kingdom|Frimley Health NHS FT, Frimley, United Kingdom|Airedale NHS FT, Keighley, United Kingdom|Leeds Teaching Hospital NHS FT, Leeds, United Kingdom|St George's University Hospitals NHS FT, London, United Kingdom|Manchester University NHS FT, Manchester, United Kingdom|Newcastle upon Tyne Hospitals NHS FT, Newcastle Upon Tyne, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Oxford University Hospitals NHS FT, Oxford, United Kingdom|Royal Berkshire Hospital NHS FT, Reading, United Kingdom|Barking, Havering & Redbridge Hospitals NHS FT, Romford, United Kingdom|Salford Royal NHS FT, Salford, United Kingdom|University Hospital Southampton NHS FT, Southampton, United Kingdom|University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""If the participant has an active SARS-CoV-2 infection during admission|The participant has had a past SARS-CoV-2 infection""}"
"1532","Psychological Impact, Mental Health and Sleep Disorder Among Patients Hospitalized and Health Care Workers During the 2019 Coronavirus Outbreak (COVID-19)","","NCT04497246","CHU-COVIDIMPACT","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497246","Recruiting","2020-05-29","2020-12-01","{""locations"":""CHU Brugmann, Brussels, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact Event Scale-Revised (IES-R)|Generalised Anxiety Disorder-7 (GAD-7)|Patient Health Questionnaire-9 (PHQ-9)|Insomnia severity index (ISI)|Demographic data|Hospitalization duration|ICU stay|Medical history|Alcohol consumption|Tobacco consumption""}"
"1533","Ketogenic Diet as Protective Factor During COVID-19","","NCT04615975","KDSARS0120","Dietary Supplement: Ketogenic diet with phytoextracts","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04615975","Recruiting","2020-11-01","2021-08-30","{""locations"":""Ospedale San Bortolo, Vicenza, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""28"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""inflammation panel: interleukine 6 (IL-6)|inflammation panel: tumor necrosis factor alfa (TNF\u03b1)|inflammation panel: C-reactive Protein (CRP)|inflammation panel: Erythrocyte sedimentation rate (ESR)|coagulation panel: D-Dimer|coagulation panel: fibrinogen|coagulation panel: thrombin clotting time (TT)|coagulation panel: activated partial thromboplastin time (aPTT)|Dyspnoea Visual Analog Scale Score (VAS)|Oxygen saturation|Evaluation of Lungs conditions|The total hospital stay|Mean Corpuscular Hemoglobin (MCH)|Mean corpuscular volume (MCV)|mean corpuscular hemoglobin concentration (MCHC)|haemoglobin Hb|Red blood cells count|beta - hydroxybutyrate (BHB)|Alanine transaminase (ALT)|Aspartate transaminase (AST)|lactate dehydrogenase (LDH)""}"
"1534","Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes","","NCT04409327","RTB101-210","Drug: RTB101|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04409327","Terminated","2020-07-11","2021-01-24","{""locations"":""Nursing Home, Middletown, Rhode Island, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""36"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""The percentage of subjects who develop laboratory-confirmed COVID-19: - with protocol-defined progressive symptoms OR - are hospitalized OR - die|The percentage of subjects who develop symptomatic laboratory-confirmed COVID-19 infection|Mortality rate in subjects who develop laboratory-confirmed COVID19|Percent of subjects who are hospitalized due to having one or more predefined COVID-19 symptoms and laboratory-confirmed SARS-CoV-2|Percent of subjects who require mechanical ventilation, noninvasive ventilation, high flow nasal canula oxygen delivery or ICU admission during the hospitalization for COVID19|Safety and tolerability will be assessed by report of AE\/SAEs""}"
"1535","Testing the Accuracy of a Digital Test to Diagnose Covid-19","","NCT04407585","Covid-19 Validation Study","Diagnostic Test: Covid-19 swab PCR test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407585","Recruiting","2020-06-01","2021-05-10","{""locations"":""King's College London, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection""}"
"1536","InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort","ILIAD-7-FR","NCT04407689","CLI107 COVID FR (ILIAD-7-FR)","Drug: Interleukin-7|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04407689","Recruiting","2020-06-08","2021-12-30","{""locations"":""University Hospital of Limoges, Limoges, France|H\u00f4pital Edouard Herriot, Lyon, France|hopital Edouard Herriot, Lyon, France|Chr Orleans La Source, Orl\u00e9ans, France|hopital COCHIN, Paris, France|Chru Tours, Tours, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""25 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC\u22641000\/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first|\""clinical improvement\"" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|a significant decline of SARS-CoV-2 viral load through day 30 or HD|frequency of secondary infections through day 45 compared tp placebo arm|length of hospitalization compared to placebo arm|length of stay in ICU compared to placebo arm|number of readmissions to ICU compared to placebo arm|organ support free days compared to placebo arm|Frequency of re-hospitalization through day 45 compared to placebo arm|All-cause mortality through day 45 compared to placebo arm|CD4+ and CD8+ T cell counts compared to placebo arm|level of other known biomarkers of inflammation: Ferritin compared to placebo arm|Level of other known biomarkers of inflammation: CRP compared to placebo arm|Level of other known biomarkers of inflammation: D-dimer compared to placebo arm|Physiological status through NEWS2 evaluation compared to Placebo arm""}"
"1537","Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home","AR0-CORONA","NCT04685512","20-070","Drug: tenofovir disoproxil and emtricitabine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04685512","Recruiting","2020-11-18","2021-04-01","{""locations"":""Caen University Hospital, Caen, Calvados, France|Regional Hospital, Orl\u00e9ans, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 2B: Reduction of SARS-CoV2 viral load assessed by Ct PCR at day-4 adjusted on Ct PCR SARS-CoV2 viral load at baseline (ANCOVA)|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-4 with Ct > or = 28|Phase 2B\/3: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Phase 3: Symptoms score|Phase 3: Proportion of secondary hospitalization|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-7 with Ct > or = 28""}"
"1538","Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","CORTI-Covid","NCT04344288","69HCL20_0321|2020-001553-48","Drug: Prednisone|Other: Control group","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04344288","Terminated","2020-04-21","2020-08-18","{""locations"":""H\u00f4pital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|H\u00f4pital Edouard Herriot, Lyon, France|H\u00f4pital St Joseph Saint Luc, Lyon, France|H\u00f4pital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-B\u00e9nite, France|CHU St Etienne, Saint-\u00c9tienne, France|Clinique Charcot, Sainte-Foy-l\u00e8s-Lyon, France|CHG Vienne, Vienne, France|M\u00e9dip\u00f4le, Villeurbanne, France|Clinique des Portes du Sud, V\u00e9nissieux, France|CH Annecy-Genevois, \u00c9pagny, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""11"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 <90% stabilized at rest and under not more than 5 L \/ min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|Duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than SARS-CoV-2|number of deaths""}"
"1539","Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients","CANCOVID-19","NCT04502342","RDIMFPG","Combination Product: Hydroxycloroquine and Azythromycine|Combination Product: Cospherunate/Azythromycine|Combination Product: Cospherunate/Phytomedicine/Azythromycien","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04502342","Enrolling by invitation","2020-06-01","2020-09-30","{""locations"":""Donka; Kenien; Gbessia, Conakry, Guinea"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virological clearance of throat swabs or lower respiratory tract secretions|Adverse effects|Worsened conditions|COVID-19 symptoms""}"
"1540","Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19","","NCT04423861","NITFQM0920OR-III","Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04423861","Not yet recruiting","2020-12-01","2021-05-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""380"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need of mechanical ventilation|Change in the pulmonary condition|Change in Clinical Condition|Change in tomographic pulmonary condition|Rate of mortality within 14-days|Change in inflammatory markers""}"
"1541","Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome","","NCT04604704","ALRx004","Drug: Naltrexone|Dietary Supplement: NAD+|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04604704","Recruiting","2021-01-28","2021-10-01","{""locations"":""AgelessRx, Ann Arbor, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction of fatigue in post-COVID-19 syndrome by treatment with LDN and NAD+|Improvement of quality of life in post-COVID-19 syndrome by treatment with LDN and NAD+.""}"
"1542","COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults","","NCT04710303","AW_001_ProVIVA-SA-1","Biological: hAd5-S-Fusion+N-ETSD vaccine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04710303","Recruiting","2021-03-02","2022-04-01","{""locations"":""Khayelitsha Clinical Research Site, Khayelitsha, South Africa"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""35"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of MAAEs and SAEs|Incidence and severity of solicited local reactogenicity AEs|Incidence and severity of solicited systemic reactogenicity AEs|Incidence and severity of unsolicited AEs|Incidence of changes of laboratory safety examinations|Vital Sign - Temperature|Vital Sign - Heart rate|Vital Sign - Blood Pressure|Vital Sign - Respiratory Rate|GMFR in IgG titer|GMT of S-specific, RBD-specific, and N-specific antibodies|Percentage of participants who seroconverted|GMFR in neutralizing antibody|GMT of neutralizing antibody|Seroconversion rate of neutralizing antibody|New HIV infections in vaccine recipients""}"
"1543","InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort","ILIAD-7-UK","NCT04379076","CLI107 COVID UK (ILIAD-7-UK)","Drug: Interleukin-7|Drug: Placebos","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04379076","Recruiting","2020-05-14","2021-12-30","{""locations"":""Sandwell Birmingham Hospital, Birmingham, United Kingdom|Sandwell Birmingham Hospital, Birmingham, United Kingdom|Bradford Institute for Health Research, Bradford, United Kingdom|ST JAMES's UNIVERSITY HOSPITAL, Leeds, United Kingdom|Medway Maritime Hospital, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King'S College Hospital, London, United Kingdom|Wythenshawe Hospital\/ Manchester Royal Infirmary, Manchester, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Royal Victoria Infirmary and Freeman Hospital, Newcastle, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Sunderland Royal Hospital, Sunderland, United Kingdom|Watford General Hospital, Watford, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""25 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC\u22641000\/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whicheve|To obtain \""clinical improvement\"" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|determine if CYT107 will lead to a significant decline of SARS-CoV-2 viral load through day 30 or HD|To compare the effect of CYT107 versus placebo on the frequency of secondary infections through day 45|To compare the effect of CYT107 versus placebo on the length of hospitalization|To compare the effect of CYT107 versus placebo on the length of stay in ICU|To compare the effect of CYT107 versus placebo on readmissions to ICU|To compare the effect of CYT107 versus placebo on organ support free days|To compare the effect of CYT107 versus placebo on the frequency of re-hospitalization through day 45|To assess the impact of CYT107 on all-cause mortality through day 45|To determine the effect of CYT107 on CD4+ and CD8+ T cell counts|To track and evaluate other known biomarkers of inflammation: Ferritin|To track and evaluate other known biomarkers of inflammation: CRP|To track and evaluate other known biomarkers of inflammation: D-dimer|Evaluation of physiological status through NEWS2 score""}"
"1544","Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19","","NCT04356677","BHC-RIB-5401-HC","Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04356677","Not yet recruiting","2021-02-01","2021-04-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment|Time to recover gas exchange to a PaO2\/FiO2 \u2265300 for at least 24 hours.|Time to reach peripheral capillary oxygen saturation (Sp02) >94% for at least 24 hours.""}"
"1545","Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19","NEBUHEPA","NCT04530578","CSanCamilo","Drug: Heparin sodium|Drug: Enoxaparin","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04530578","Recruiting","2020-06-01","2021-06-01","{""locations"":""Clinica San Camilo, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients requirement mechanical ventilation|Percentage of patients with PaO2 to Fi02 ratio > 300|Lengths of hospital-stay|Mortality rate""}"
"1546","Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19","","NCT04662671","EB-P12-01","Device: RD-X19","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04662671","Completed","2020-11-18","2021-01-30","{""locations"":""Site 2, Miami, Florida, United States|Site 1, College Station, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""31"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Safety Measure|Primary Efficacy Measure|Geometric Mean Viral Load|Viral Load Reduction|Time to Clearance of Viral Infection|Proportion of Subjects Demonstrating Clearance of Viral Infection|Median Time to Alleviation of Symptoms""}"
"1547","Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial","INTENSE-COV","NCT04466241","ANRS COV01 INTENSE COV","Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|Drug: Telmisartan 40Mg Oral Tablet|Drug: Atorvastatin 20 Mg Oral Tablet","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04466241","Recruiting","2020-11-27","2021-03-26","{""locations"":""Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, C\u00f4te D'Ivoire|Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, C\u00f4te D'Ivoire"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""294"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg\/L at Day 11|Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28|Kinetics of SARS-CoV-2 viral load|Death rate at Day 11 and Day 28|All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28|Time to hospital discharge|Duration of oxygen supplementation|Prevalence of grade III or IV adverse events|Residual concentration of lopinavir, telmisartan and atorvastatin|Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; na\u00efve\/memory T lymphocytes)|Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM\/CD31, CD42 and angiopoietin-2)|Proportion of patients with good results according to HIV status|Number of contact cases infected by COVID-19 at Day 28""}"
"1548","Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection","","NCT04488575","EDP1815-205","Drug: EDP1815|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04488575","Recruiting","2020-08-26","2021-07-06","{""locations"":""Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline to the lowest S\/F oxygen ratio|Change in S\/F Ratio|Percentage change in S\/F Ratio|Percentage of participants at each level on the WHO OSCI score|Percentage of participants with shifts from each level of the WHO OSCI score at baseline|Percentage of participants remaining at their baseline score on the WHO OSCI (or lower)|Percentage of participants reporting each level of the WHO OSCI score at their worst post-baseline day|The time in days spent at each participant's worst reported WHO OSCI score (excluding death).|Intubation and mechanical-ventilation free survival|Overall survival|Number of days requiring oxygen therapy|Number of days with pyrexia|Maximum daily temperature|SpO2 level|Time to discharge|Time to oxygen saturation (SpO2) \u226594%|Time to recovery|Number of participants experiencing AEs by seriousness and relationship to treatment|Incidence of clinically significant abnormal lab parameters""}"
"1549","A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy","","NCT04445220","SBI-101-02","Biological: SBI-101","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04445220","Recruiting","2020-11-19","2021-07-01","{""locations"":""University of New Mexico School of Medicine, Albuquerque, New Mexico, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""22"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety and tolerability as measured by incidence of IP-related serious adverse events""}"
"1550","ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings","","NCT04352764","TCAI_COVID-19","Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04352764","Recruiting","2020-03-27","2021-01-31","{""locations"":""St. David's Medical Center, Austin, Texas, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""prevalence of COVID-19 exposure|correlation between the test results with the presence or lack of COVID-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms""}"
"1551","Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19","Isotretinoin","NCT04577378","Isotretinoin","Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04577378","Not yet recruiting","2020-10-20","2020-11-20","{""locations"":""Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""15 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferons|All cause mortality rate|Serum level of viral RNA|Ventilation free days|ICU free days""}"
"1552","Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.","","NCT04577235","AyşeV","Other: severity of lung involvement with COVID-19.","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04577235","Completed","2020-06-05","2020-09-05","{""locations"":""Gaziosmanpasa Taksim Research and Education Hospital, Istanbul, Gazi\u0307osmanpa\u015fa, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic"",""enrollment"":""29"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The evaluation of the correlation between the baseline LUS score and mortality rate of patients with severe COVID-19 pneumonia who were followed up in the intensive care unit|The evaluation of the correlation between the baseline CT score and mortality rate of patients with severe COVID-19 pneumonia who were followed up in the intensive care unit""}"
"1553","A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","","NCT04495933","UQ-1-SARS-CoV-2-Sclamp|ACTRN12620000674932p","Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04495933","Recruiting","2020-07-13","2021-09-01","{""locations"":""Nucleus Network Brisbane (Q-Pharm Pty Ltd), Herston, Queensland, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""216"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of Solicited local reactogenicity adverse events (AEs)|Frequency of Solicited systemic reactogenicity adverse events (AEs)|Grading of Solicited local reactogenicity adverse events (AEs)|Grading of Solicited systemic reactogenicity adverse events (AEs)|Unsolicited adverse events (AEs)|Serious adverse events (SAEs), Medically attended adverse events (MAAEs) and any Adverse events (AEs) leading to study withdrawal at any time during the study|Geometric Mean Titer (GMT) of the serum antibody response|Geometric Mean Titer (GMT) of the serum neutralizing antibody (NAb) response to SARS-CoV-2 virus|Total serum antibody immune responses|proportion of participants with \u2265 4 fold increase in titer above baseline|GMT of the serum neutralizing antibody (NAb) titres""}"
"1554","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)","","NCT04551898","BGB-DXP593-102","Drug: BGB-DXP593|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04551898","Completed","2020-12-02","2021-01-25","{""locations"":""Elixia, Hollywood, California, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Baptist Medical Center, Jacksonville, Florida, United States|Homestead Associates in Research Inc., Miami, Florida, United States|Medical Research Center of Miami II, Inc., Miami, Florida, United States|US Associates in Research, Miami, Florida, United States|Continental Research Network, Miami, Florida, United States|Omega Research Orlando, Orlando, Florida, United States|Revival Research Institute, LLC., Dearborn, Michigan, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Amarillo Center for Clinical Research, Amarillo, Texas, United States|PanAmerican Clinical Research, Brownsville, Texas, United States|The Royal Prince Alfred Hospital, Camperdown, Australia|Funda\u00e7\u00e3o Universidade de Caxias do Sul - Instituto de Pesquisas em Sa\u00fade, Petropolis, Caxias Do Sul, Brazil|Hospital das Cl\u00ednicas da Faculdade de Medicina de Botucatu, Botucatu, Brazil|Irmandade da Santa Casa de Miseric\u00f3rdia de Porto Alegre, Porto Alegre, Brazil|Hospital Universit\u00e1ro de Santa Maria \/ UFSM, Santa Maria, Brazil|CMPC Pesquisa Clinica, Sorocaba, Brazil|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|JM Research, Cuernavaca, Mexico|Hospital General Dr. Manuel Gea Gonzalez, Mexico, Mexico|Iecsi S.C., Monterrey, Mexico|Clinica de Enfermedades Cronicas y de Procedimientos Especiales, S.C., Morelia, Mexico|Kohler & Milstein Research, M\u00e9rida, Mexico|PanAmerican Clinical Research, Quer\u00e9taro, Mexico|East Rand Research T\/A Worthwhile Clinical Trials, Benoni, South Africa|TASK, Cape Town, South Africa|TREAD Research CC, Cape Town, South Africa|Langeberg Clinical Trials, Cape Town, South Africa|Wits Clinical Research, Soweto, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""181"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline to Day 8 in SARS-CoV-2 viral shedding as measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swab samples|Time-weighted average change in viral shedding as measured by RT-qPCR in nasopharyngeal swab samples|Change from baseline to Day 15 in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasopharyngeal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Number of participants requiring hospitalization due to worsened COVID-19|Time to resolution of all COVID-19-related symptoms|All-cause mortality rate at Day 29|Number of participants experiencing Adverse Events (AEs)|Number of participants experiencing Serious Adverse Events (SAEs)""}"
"1555","Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)","CovImmune","NCT04355351","20-PP-05","Other: blood sampling|Other: additional blood tubes","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04355351","Recruiting","2020-05-05","2020-10-22","{""locations"":""Antibes Hospital, Antibes, France|Cannes Hospital, Cannes, France|Nice Hospital, Nice, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Level of IFN-gamma after a non-specific stimulation of T lymphocytes""}"
"1556","Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation","","NCT04429334","MOT-C-204","Drug: nangibotide|Drug: placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04429334","Not yet recruiting","2020-08-01","2021-03-01","{""locations"":""R\u00e9animation M\u00e9dicale, H\u00f4pital Central, Nancy, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse Events|Mortality""}"
"1557","COVID 19 Biomarkers","","NCT04363008","H20-00971","Diagnostic Test: serum inflammatory biomarkers","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363008","Recruiting","2020-03-30","2021-09-30","{""locations"":""Vancouver General Hospital, Vancouver, British Columbia, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Inflammation|Oxygenation|Chronic Pulmonary outcomes|Pulmonary artery pressure using transthoracic echocardiography|Exertion|Quality of life assessment""}"
"1558","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19","","NCT04348474","HIAPRE0420OR","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04348474","Suspended","2020-04-20","2020-07-31","{""locations"":""Prevent Senior Private Operadora de Sa\u00fade LTDA., S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity""}"
"1559","A Novel Nomogram to Predict Severity of COVID-19","","NCT04366024","XQonc-016","Other: other","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366024","Recruiting","2020-01-17","2021-12-31","{""locations"":""Xinqiao Hospital of Chongqing, Chongqing, Chongqing, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the consistency of predicted severe rate and observed severe rate of COVID-19 patients|Duration of severe illness""}"
"1560","RescuE pLAsma eXchange in Severe COVID-19","RELAX","NCT04685655","S-911/2020","Other: Therapeutic plasma exchange","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04685655","Recruiting","2020-01-07","2022-12-31","{""locations"":""Christian Nusshag, Heidelberg, Baden-W\u00fcrttemberg, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""228"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival|Ventilator-free days|Length of hospital an ICU stay|Improvement defined as two points on seven point ordinal WHO scale|Reduction of vasopressors after TPE treatments|Incidence of acute kidney injury, renal replacement therapy and renal recovery|Frequency of typical complications associated to therapeutic plasma exchange|Reduction of inflammation mediators, (auto-)antibodies, and coagulation-associated molecules and their temporal correlation to TPE|D-dimer-dependent assessment of therapeutic efficacy.""}"
"1561","The COVID-19 PUI Reality Check (CPRC) Study","CPRC","NCT04474288","1613182","Diagnostic Test: SARS-CoV-2 antibody testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04474288","Recruiting","2020-07-16","2021-07-01","{""locations"":""Bassett Medical Center, Cooperstown, New York, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 IgG|host immune response|pathogen protein expression""}"
"1562","COVID19 Severity Prediction and Health Services Research Evaluation","","NCT04463706","COVID19_0459","Other: Predictors adverse evolution|Other: Predictors of health care provide","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04463706","Recruiting","2020-06-01","2021-12-31","{""locations"":""Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain|Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""20000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical deterioration|Relief of symptoms|Mortality|Complications at follow up|Cost""}"
"1563","Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs","ACICOVID","NCT04373759","2020-CHITS-004","Other: Cardiopulmonary resuscitation|Other: Modified Rankin score","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373759","Completed","2020-05-02","2020-09-30","{""locations"":""CHU Caen, Caen, Calvados, France|H\u00f4pital Priv\u00e9 St Martin, Caen, Calvados, France|CH Angoul\u00e8me, Angoul\u00eame, Charente, France|CH Brive, Brive-la-Gaillarde, Corr\u00e8ze, France|CHU Dijon, Dijon, C\u00f4te-d'Or, France|CH Etampes, \u00c9tampes, Essonne, France|CHU Antoine B\u00e9cl\u00e8re AP-HP, Clamart, Haut-de-Seine, France|CHU Ambroise Par\u00e9 AP-HP, Boulogne-Billancourt, Hauts-de-Seine, France|CH Louis Mourier AP-HP, Colombes, Hauts-de-Seine, France|CHU Montpellier, Montpellier, H\u00e9rault, France|CHU Lariboisi\u00e8re AP-HP, Paris, Ile-de-France, France|CHU Saint Louis AP-HP, Paris, Ile-de-France, France|CHU St Antoine, Paris, Ile-de-France, France|Groupe Hospitalier Saint Joseph, Paris, Ile-de-France, France|CHU Necker Enfants Malades, Paris, Ile-de-France, France|CHU Piti\u00e9 Salp\u00e9tri\u00e8re, Paris, Ile-de-France, France|CHU Felix Guyon, Saint-Denis, La Reunion, France|CHR Orl\u00e9ans, Orl\u00e9ans, Loiret, France|CH Cahors, Cahors, Lot, France|CHRU Roger Salengro, Lille, Nord, France|CH Bethune, Beuvry, Pas-de-Calais, France|CH Lens, Lens, Pas-de-Calais, France|Grand H\u00f4pital de l'Est Francilien, Jossigny, Seine-et-Marne, France|CHU Meaux, Meaux, Seine-et-Marne, France|Groupe Hospitalier Sud Ile de France, Melun, Seine-et-Marne, France|CHU Rouen, Rouen, Seine-Maritime, France|CHU Amiens Picardie, Amiens, Somme, France|H\u00f4pital Nord Franche Comt\u00e9, Tr\u00e9venans, Territoire De Belfort, France|CH Argenteuil, Argenteuil, Val-d'Oise, France|CHU Henri Mondor AP-HP, Cr\u00e9teil, Val-de-Marne, France|CHU Kremlin Bic\u00eatre, Le Kremlin-Bic\u00eatre, Val-de-Marne, France|CH de la Drac\u00e9nie, Draguignan, Var, France|CHI Frejus St Raphael, Fr\u00e9jus, Var, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, Var, France|CH Versailles, Le Chesnay, Yvelines, France|CHU Martinique - Fort de France, Fort-de-France, Martinique"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""186"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of unexpected cardiac arrest|Charlson score|Organ failure score at ICU admission and\/or before unexpected in-ICU cardiac arrest|Etiology retained to explain cardiac arrest occurrence|Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months""}"
"1564","Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection","","NCT04361786","RECHMPL20_0211","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361786","Completed","2020-04-01","2020-10-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""10"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Biological acquired thrombophilia|Overexpression of interferon type I""}"
"1565","Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19","","NCT04377997","2020P001136","Drug: Enoxaparin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04377997","Not yet recruiting","2020-05-15","2022-01-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.|Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.""}"
"1566","Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center","","NCT04492358","2020-002462-14","Drug: Colchicine|Drug: Prednisone tablet|Drug: standard of care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04492358","Recruiting","2020-10-22","2021-10-01","{""locations"":""Centre Blaucl\u00ednic Dolors Aleu, Barcelona, Spain|Hospital Clinic, Department of Internal Medicine, Barcelona, Spain|Clinica Sant Antoni, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""144"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Number of patients that a short cycle of steroids administered together with colchicine reduces mortality from COVID-19|Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment|Percentage of patients who stop medication due to adverse events.|Severity of symptoms by COVID-19 in the two treatment arms""}"
"1567","Nebulised Heparin in Patients With Severe COVID-19","CHARTER-MT","NCT04545541","CHARTER meta-trial","Drug: Nebulised unfractionated heparin (UFH)","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04545541","Recruiting","2020-11-01","2022-06-01","{""locations"":""Frederick Health Hospital, Frederick, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Alive and Ventilator Free Score""}"
"1568","Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19","","NCT04380714","RECHMPL20_0273","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380714","Completed","2020-05-01","2020-08-01","{""locations"":""UH Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""percentage changes in the consumption of psychoactive substances|Assessment of the level of stress|Assessment of depression|Craving modification evaluation""}"
"1569","Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study","SCOUT","NCT04338568","CTU2020032","Diagnostic Test: Lung ultrasound","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04338568","Recruiting","2020-04-16","2020-12-30","{""locations"":""Ziekenhuis Oost Limburg, Genk, Limburg, Belgium"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Accuracy of the diagnosis of interstitial syndrome by lung ultrasound|Inter-observer variability""}"
"1570","EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )","EPISODE-PH-COV","NCT04445493","EPISODE-PH-COVID","Device: MindRhythm Harmony","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445493","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID-19 infection in suspected stroke population|Quality head pulse recordings""}"
"1571","Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","RESIST","NCT04530396","04-Gam-COVID-Vac-2020","Biological: Gam-COVID-Vac|Other: placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04530396","Active, not recruiting","2020-09-07","2021-05-01","{""locations"":""ARCHIMED V Clinic of new medical technologies limited liability company, Moscow, Russian Federation|Hadassah LTD, Moscow, Russian Federation|Medsi Group of companies joint-stock company\"", Moscow, Russian Federation|Niarmedic Plus, Moscow, Russian Federation|State budgetary healthcare institution of the city of Moscow \""City clinical hospital No. 52 of the Moscow city health Department\"", Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Consultation and Diagnosis Polyclinic No. 121, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, M. Konchalovsky Municipal Clinical Hospital, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, M. Zhadkevich Municipal Clinical Hospital, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 115, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 2, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 210, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 212, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 219, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 220, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Municipal Polyclinic No. 62, Moscow Healthcare Department, Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \"" city polyclinic No. 109 Of the Department of health of the city of Moscow\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \"" city polyclinic No. 170 Of the Department of health of the city of Moscow\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \"" city polyclinic No. 36 Of the Department of health of the city of Moscow\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \"" city polyclinic No. 46 Of the Department of health of the city of Moscow\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \"" city polyclinic No. 6 Of the Department of health of the city of Moscow\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \"" city polyclinic No. 68 Of the Department of health of the city of Moscow\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""Diagnostic center No. 5 with polyclinic Department Of the Department of health of the city of Moscow\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""Diagnostic clinical center No. 1 Of the Department of health of the city of Moscow\"", Moscow, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""33758"",""age"":""18 Years to 111 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose|the severity of the clinical course of COVID-19|Changing of antibody levels against the SARS-CoV-2 glycoprotein S|Changing of antigen-specific cellular immunity level|Changing of of virus neutralizing antibody titer|Incidence of adverse events in trial subjects|Severity of adverse events in trial subjects|estimation of the proportion of study subjects with antibodies to the N-protein of the virus SARS-CoV-2""}"
"1572","Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia","USCovid","NCT04433000","USCovid","Diagnostic Test: Butterfly","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433000","Recruiting","2020-03-15","2020-06-10","{""locations"":""Azienda Ospedaliera Universitaria Senese, Siena, Si, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""34"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Bland-Altman estimate of bias and Limits of Agreement (LoA) of patient mean scores obtained with the two instruments""}"
"1573","Nebulized Heparin for the Treatment of COVID-19","INHALE-HEP","NCT04723563","FHHep2121","Drug: Heparin|Drug: 0.9%sodium chloride","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04723563","Enrolling by invitation","2021-02-22","2021-05-29","{""locations"":""Frederick Health Hospital, Frederick, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need for mechanical ventilation at day 28|Hospital length of stay|Average daily SaO2\/FiO2""}"
"1574","Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions","REMPAR-EHPAD","NCT04579289","35RC20_8898_REMPAR-EHPAD","Other: questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04579289","Completed","2020-06-15","2020-09-01","{""locations"":""Centre Hospitalier Universitaire de Rennes, Rennes, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Retrospective"",""enrollment"":""230"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""case of COVID 19""}"
"1575","Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2","COV2020","NCT04611841","COV2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04611841","Enrolling by invitation","2020-07-21","2022-12-01","{""locations"":""Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""250"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determination of antibody binding of patients diagnosed with COVID-19 to proteins of the SARS-CoV-2 virus|Determination of the presence of peptides of the SARS-CoV-2 virus in the plasma of patients diagnosed with COVID-19|Determination of the degree of oxidative damage to lipids (lipid peroxidation) in the blood plasma of patients infected with coronavirus|Revealing the degree of protein damage in the blood plasma of patients infected with coronavirus|Measurement of iron (Fe3+) content in blood plasma of patients infected with coronavirus|Metagenomic analysis of viral and bacterial respiratory flora of selected samples|Analysis of the genetic variability of the SARS-CoV-2 virus, including the heterogeneity of the viral population in one patient""}"
"1576","Physical Activity Following the Containment Period Imposed by the COVID-19 Pandemic in Patients","PhysiCOVID","NCT04451317","RC31/20/0203","Other: Questionnaire, phone call","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04451317","Recruiting","2020-06-12","2021-08-01","{""locations"":""CHU Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical activity measure|Depression|Sleep quality|food activity|activity level of chronic pathology""}"
"1577","IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study","","NCT04462120","AssiutU15","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04462120","Active, not recruiting","2020-06-16","2020-07-30","{""locations"":""AssiutU, Assiut, Egypt|Assiut University Hospitals, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure level of polymorphisms of interleukin (IL)-12 receptor B1 (IL-12RB1) and TNF- \u03b1 alpha on COVID-19 related severe acute respiratory syndrome (SARS-CoV-2).""}"
"1578","Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?","","NCT04336657","AssiutU11","Other: Questionnaire|Diagnostic Test: IgG","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04336657","Recruiting","2020-04-01","2020-05-01","{""locations"":""AssiutU, Assiut, Egypt"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""8 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Measure frequency of people suffered from unusual flu-like symptoms before December 2019|Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible""}"
"1579","Fluoxetine to Reduce Intubation and Death After COVID19 Infection","","NCT04377308","FRIDA COVID19","Drug: Fluoxetine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04377308","Recruiting","2020-05-01","2021-10-20","{""locations"":""University of Toledo, Toledo, Ohio, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalizations|Intubation|Death|Number of days of illness|PHQ-9 score for depressive symptoms,|generalized anxiety Disorder-7 scale""}"
"1580","Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)","PRESAGE","NCT04528901","7879","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04528901","Recruiting","2020-09-04","2022-12-01","{""locations"":""Les H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, Bas-Rhin, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1080"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine and compare the seroprevalence for SARS-CoV2 among patients with respiratory pathologies monitored in Pneumology at the Strasbourg University Hospital, in the cluster zone of the Grand Est.""}"
"1581","TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia","TOFACoV-2","NCT04390061","2020-002035-30","Drug: Tofacitinib|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04390061","Not yet recruiting","2020-06-01","2020-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""116"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevention of severe Respiratory Failure requiring mechanical ventilation|Prevention of need of ICU admission|Prevention of COVID-19 related Deaths|Identification of predictors of outcome|Incidence of Treatment-Emergent Adverse Events""}"
"1582","Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients","","NCT04693026","M.A.R.M.C.D./2020/2637","Drug: Remdesivir|Drug: Baricitinib|Drug: Tocilizumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04693026","Recruiting","2020-09-10","2021-03-05","{""locations"":""M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Time to Clinical Improvement (TTCI)|Mortality Rate|Duration of ICU stay|Duration total hospital stay|Rate of daily Supplemental Oxygen Use|Time to Clinical Failure""}"
"1583","Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)","","NCT04358029","GCO 20-0931","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04358029","Recruiting","2020-04-09","2021-12-01","{""locations"":""Icahn School of Medicine at Mount Sinai, New York, New York, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""10000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Frequency of cardiac arrhythmias|Mode of death""}"
"1584","InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )","ILIAD-7-US-I","NCT04442178","ILIAD-7 COVID US INFECTIOUS","Drug: CYT107|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04442178","Recruiting","2020-09-15","2021-12-31","{""locations"":""University of Florida College of Medicine, Gainesville, Florida, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Rutgers Health, New Brunswick, New Jersey, United States|Stony Brook Medicine, Stony Brook, New York, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""25 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC\u22641000\/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first|\""clinical improvement\"" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|a significant decline of SARS-CoV-2 viral load through day 30 or HD|frequency of secondary infections through day 45 compared to placebo arm|length of hospitalization compared to placebo arm|Length of stay in ICU compared to placebo arm|number of readmissions to ICU compared to placebo arm|organ support free days compared to placebo arm|Frequency of re-hospitalization through day 45 compared to placebo arm|All-cause mortality through day 45 compared to placebo arm|CD4+ and CD8+ T cell counts compared to placebo arm|level of other known biomarkers of inflammation: Ferritin compared to placebo a|Level of other known biomarkers of inflammation: CRP compared to placebo arm|Level of other known biomarkers of inflammation: D-dimer compared to placebo arm|Physiological status through NEWS2 evaluation compared to Placebo arm""}"
"1585","InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )","ILIAD-7-US-O","NCT04426201","ILIAD-7 COVID US ONCO","Drug: CYT107|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04426201","Recruiting","2020-12-20","2021-12-31","{""locations"":""Memorail sloan kettering, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""25 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC\u22641000\/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first|\""clinical improvement\"" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|a significant decline of SARS-CoV-2 viral load through day 30 or HD|frequency of secondary infections through day 45 compared to placebo arm|length of hospitalization compared to placebo arm|length of stay in ICU compared to placebo arm|number of readmissions to ICU compared to placebo arm|organ support free days compared to placebo arm|Frequency of re-hospitalization through day 45 compared to placebo arm|All-cause mortality through day 45 compared to placebo arm|CD4+ and CD8+ T cell counts compared to placebo arm|level of other known biomarkers of inflammation: Ferritin compared to placebo arm|Level of other known biomarkers of inflammation: CRP compared to placebo arm|Level of other known biomarkers of inflammation: D-dimer compared to placebo arm|Physiological status through NEWS2 evaluation compared to Placebo arm""}"
"1586","Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP)","AP-TP-Bio","NCT03348670","BLA761214|FWA00015357|IRB00009424|IORG0007849|IND153116|NDA215432","Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT03348670","Active, not recruiting","2020-07-20","2021-06-28","{""locations"":""Medicine Invention Design, Inc. (MIDI) - c\/o - MIDINC Clinical Investigator Working Site, North Bethesda, Maryland, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""22 Years to 72 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Test Macrophage Migration Inhibitory Factor (MMIF)""}"
"1587","Minnesota COVID-19 Testing Project","","NCT04568889","IRB20-1444","Behavioral: A $10 Survey Incentive|Behavioral: A $20 Survey Incentive|Behavioral: Emphasis of Government Involvement|Behavioral: Emphasis of Academic Researchers Involvement|Behavioral: Cost-Benefit Frame|Behavioral: Duty Frame|Behavioral: Racial/Ethnic Frame|Behavioral: No Messaging","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04568889","Active, not recruiting","2020-09-28","2021-06-30","{""locations"":""Volunteers Enlisted to Assist People, Bloomington, Minnesota, United States|Southern Anoka Community Assistance, Columbia Heights, Minnesota, United States|People Reaching Out to People Food Shelf, Eden Prairie, Minnesota, United States|Fridley Covenant Church, Fridley, Minnesota, United States|Calvary Lutheran Church Food Shelf, Minneapolis, Minnesota, United States|NorthPoint Health and Wellness, Minneapolis, Minnesota, United States|Community Emergency Assistance Programs, Minneapolis, Minnesota, United States|Intercongregation Communities Association, Minnetonka, Minnesota, United States|Valley Outreach, Stillwater, Minnesota, United States|White Bear Area Foodshelf, White Bear Lake, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect of monetary incentives in increasing unit response 1|Effect of monetary incentives in increasing unit response 2|Effect of a government frame in reducing unit response 1|Effect of a government frame in reducing unit response 2|Interactions between monetary incentives and a government frame 1|Interactions between monetary incentives and a government frame 2|Interactions between monetary incentives and a government frame 3|Interactions between monetary incentives and a government frame 4|Demographic characteristics of participants assigned into each treatment arm|Effect of various messaging frames in increasing item non-response""}"
"1588","Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)","RACONA","NCT04352400","RACONA Nafamostat","Drug: Nafamostat Mesilate|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04352400","Not yet recruiting","2020-04-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""256"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time-to-clinical improvement|Responders|Critical or dead patients|pO2\/FiO2 ratio|SOFA score over time|Hospitalization|Mechanical ventilation|Mechanical ventilation duration|Cardiovascular disease""}"
"1589","Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance","","NCT04678700","20/139","Other: Chest physiotherapy post-covid19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04678700","Recruiting","2021-03-01","2021-08-01","{""locations"":""Marta de la plaza, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Euroqol-5d european quality of life-5 dimensions|Dysnea scale Borg|Respiratory rate|Effort dysnea Scale|Anxiety|Level oxigen %""}"
"1590","SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival","SAVE-ICU","NCT04415060","2149","Drug: Isoflurane Inhalant Product|Drug: Sevoflurane inhalant product","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04415060","Recruiting","2020-06-15","2023-06-15","{""locations"":""University of Alberta Hospital, Edmonton, Alberta, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|University Health Network - Toronto Western Hopsital, Toronto, Ontario, Canada|Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Quebec, Canada|H\u00f4pital Sacr\u00e9-Coeur de Montr\u00e9al, Montr\u00e9al, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ), Qu\u00e9bec, Quebec, Canada|Universite de Sherbrooke, Sherbrooke, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""752"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital Mortality|Ventilator-Free Days|ICU-Free Days|Participant Quality of Life at 3 and 12 months after discharge|Median Daily Oxygenation|Delirium and Coma Free Days|Adjunctive ARDS therapies|Hospital-Free Days|Disability|Cost Utility Analysis""}"
"1591","plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients","","NCT04622826","ATNONordOvest","Biological: immune plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04622826","Recruiting","2020-05-15","2020-12-31","{""locations"":""Ospedale delle Apuane, Massa, Toscana, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ITU admission|administration of O2|hospital mortality|immune plasma infusion adverse reaction""}"
"1592","Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection","","NCT04640233","RDI-GCV-001|CTRI/2020/11/029234","Biological: Gam-COVID-Vac|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04640233","Recruiting","2020-11-30","2021-09-01","{""locations"":""S N Medical College, Agra, India|MGM Medical College and Hospital, Aurangabad, India|KLE Prabhakar Kore Hospital, Belgaum, India|Apollo Hospital, Delhi, India|Batra Hospital, Delhi, India|HIMSR with CHRD-SAS, Delhi, India|ESIC Medical College & Hospital, Faridabad, India|AIG hospital, Hyderabad, India|Maharaja Agrasen Superspecialty Hospital, Jaipur, India|GSVM Medical College, Kanpur, India|Peerless Hospital, Kolkata, India|Atharva Hospital, Lucknow, India|St. George's Hospital, Mumbai, India|JSS Hospital, Mysore, India|INCLEN trust and Gurunanak Hospital, Palwal, India|PIMS, Puducherry, India|BJ Sassoon Hospital, Pune, India|KEM Hospital, Pune, India|Noble Hospital Private Limited, Pune, India|BAPS hospital, S\u016brat, India|Rhythm Heart Institute, Vadodara, India|Sumandeep Vidyapeeth, Vadodara, India|Christian Medical College, Vellore, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse Events|Immunogenicity|Immunogenicity assessment|Percentage of subjects with mild, moderate, severe coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose of the vaccine\/placebo|Incidence of coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose in trial subjects""}"
"1593","Comorbidities and Risk Score in COVID-19 Patients","Comorbidities","NCT04670094","Comorbidities","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04670094","Active, not recruiting","2020-12-30","2021-12-01","{""locations"":""ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy|ASST Spedali Civili, Montichiari, Italy|ASST Monza-Ospedale San Gerardo, Monza, Italy|Humanitas Clinical and Research Hospital, Rozzano, Italy|Centre for Tropical and Infectious Diseases and Microbiology, IRCCS Sacro Cuore, Verona, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality|Mortality up to 3 months from admission|Admission to Intensive care unit (ICU)|Complications occurred during the hospital course|Correlation between admission to ICU and in-hospital mortality""}"
"1594","COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients","","NCT04474340","MOHKuwait","Drug: COVID-19 Convalscent Plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04474340","Recruiting","2020-05-21","2020-12-30","{""locations"":""Ministry Of Health, Kuwait, Kuwait"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""15 Years to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|All cause mortality""}"
"1595","International COVID19 Clinical Evaluation Registry,","HOPE COVID 19","NCT04334291","20/241-E|EUPAS34399","Combination Product: Observational (registry)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04334291","Completed","2020-03-23","2020-05-31","{""locations"":""Hospital Lclinico San Carlos, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""8168"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.""}"
"1596","Prevention of COVID-19 Infection to Severe Pneumonia or ARDS","","NCT04569227","EC-18-204","Drug: EC-18|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04569227","Not yet recruiting","2020-11-16","2021-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients alive and free of respiratory failure through at Day 28|Probability of progression of mild pneumonia patients to severe pneumonia or ARDS within 28 days|Assessment of all-cause mortality|Respiratory failure defined based on resource utilization requiring at least 1 of the following:|Proportion of patients alive and free of invasive mechanical ventilation at a pre-specified timepoint|Proportion of patients alive and discharged from the hospital at a pre-specified timepoint|Lengths of ICU stay|Lengths of alive and respiratory failure-free days|Proportion of patients with objective measures of improvement (returning to room air) at time points (days 7, 14, and 28)|Confirmation of changes in subject's subjective clinical symptoms (e.g., patient questionnaire)""}"
"1597","Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia","","NCT04535063","RValentini","Biological: COVID19 convalescent plasma infusion","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04535063","Recruiting","2020-04-18","2021-02-25","{""locations"":""Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas, Buenos Aires, Argentina"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28 days survival|efficacy of plasma infusion according to antibodies levels in the infuse bags|clinical efficacy of plasma infusion according to frame time from symptoms onset and hospitalization|change in clinical WHO ordinal scale from 1 to 10 points""}"
"1598","A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)","","NCT04481685","IIT-2020-ATI-450-COVID-19","Drug: ATI-450|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04481685","Recruiting","2020-07-20","2022-07-01","{""locations"":""The University of Kansas Medical Center, Kansas City, Kansas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450|Change in 7 point-ordinal scale|Change in oxygen saturation-normalization|Need for advanced respiratory care|All-cause mortality|Percentage of adverse events (AEs)|Percentage of serious adverse events (SAEs)|Proportion of participants with normalization of fever for 24 hours|Number of participants who develop new bacterial infection|Number of participants who develop new fungal infection|Incidence of Adult Respiratory distress Syndrome (ARDS2)|Change in serum cytokine Interleukin (IL)-6|Change in serum cytokine IL-8|Change in serum cytokines IL-1\u03b2|Change in serum cytokine Tumor Necrosis Factor (TNF-\u03b1)""}"
"1599","Endoscopic Procedures of Children in the Normalization Process of Covid-19 Pandemic","","NCT04598256","TepecikTRH1","Procedure: Endoscopic procedure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04598256","Completed","2020-06-01","2020-08-31","{""locations"":""Tepecik Trh, \u0130zmir, \u0130\u0307zmi\u0307r, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""77"",""age"":""1 Year to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""The number of participiants who was infected with Covid-19. normalization process of Covid-19 pandemic|The time of seen covid 19 infection after the endoscopic procedures in participiants.|The characteristics of patients with Covid-19 infection.""}"
"1600","Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease","CARR-COV-02","NCT04521322","CEMIC","Drug: Iota-Carrageenan","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04521322","Recruiting","2020-07-24","2020-11-30","{""locations"":""centro de educaci\u00f3n m\u00e9dica e investigaciones clinicas (CEMIC), Buenos Aires, Capital Federal, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""diagnose of COVID19 disease|Progression to a more severe disease state, defined as need for oxygen therapy.|lasting of disease|Incidence of COVID-19 disease onset in the first week after treatment""}"
"1601","COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias","COVIM","NCT04416438","COVIM","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416438","Recruiting","2020-05-18","2020-12-31","{""locations"":""Paris Saint Louis, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of serious coronavirus infection in different MNP patient subgroups|Proportion of MNP patients who had COVID-19 infection during the 2020 epidemic.|Rate of death of MNP patients who had COVID-19|Rate of passages in intensive care with need for mechanical ventilation""}"
"1602","Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors","","NCT04447222","2020-0425|NCI-2020-03900|P30CA016672","Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Survey Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04447222","Recruiting","2020-05-12","2021-07-21","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1242"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Coronavirus disease-2019 (COVID19)-specific psychological distress|The extent to which COVID-19 experiences are associated with COVID-19 specific psychological distress, health, financial and social disruptions, perceived benefits and social support, and health-related quality of life (HRQoL)|Resiliency factors|Group differences in the outcomes assessed in the protocol relative to prior group assignment in the behavioral clinical trials|Health-related quality of life (HRQOL)|General quality of life (QOL)|Sleep disturbances|Depression|Changes in anxiety|Perceived availability of social support|Elements of mindfulness|Non-judgmental physical and emotional sensations associated with eating|The degree to which participants exercise compassion towards themselves under difficult circumstances and how this impacts their emotions|Physical activity|Intrusive thoughts, or the tendency to ruminate on or avoid thoughts about stressors|Basic fruit\/vegetable intake|Usual intake of percentage energy from fat|Engagement in the core mind-body practices that the patients learned""}"
"1603","Results of Emotional Support Activities During Hospital Admission With a Diagnosis of COVID19","WW2COVID-19","NCT04481477","2020664","Other: Nursing care to reduce anxiety, fear and loneliness","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04481477","Not yet recruiting","2020-09-01","2020-12-31","{""locations"":""CorporacionPT, Sabadell, Barcelona, Spain"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The adequacy of nursing care to the needs of the patient|Intervention effectiveness""}"
"1604","Hydrogen Therapy in Patients With Moderate Covid-19","H2Covid","NCT04633980","38RC20.277","Drug: Mixture 3,6% H2 in N2 (96.4%)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04633980","Not yet recruiting","2020-12-01","2021-09-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""adverse events|biomarkers of inflammation and oxidative stress.""}"
"1605","Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela","VENEZUELA","NCT04642339","01V-Gam-COVID-Vac-2020","Biological: Gam-COVID-Vac|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04642339","Not yet recruiting","2020-11-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroconversion rate|Incidence and severity of adverse events|Virus-neutralizing antibody levels against the SARS-CoV-2|Antibody levels against the SARS-CoV-2 glycoprotein|Percentage of trial subjects with coronavirus disease 2019 (COVID-19)""}"
"1606","Correlation Between the Incidence of COVID-19 in Nursing-homes and the Profile of Nursing Homes in the French Alps","PROCOPAD","NCT04695457","20-13","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04695457","Completed","2020-07-15","2020-11-16","{""locations"":""Ch Annecy Genevois, Pringy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""74"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Identification of factors associated with the occurrence of COVID-19 outbreak in French Alps' nursing homes""}"
"1607","Prevalence of COVID-19 Antibodies Kingman AZ","","NCT04533360","KRMC 0205","Diagnostic Test: VITROS Anti-SARS-CoV-2 IgG test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04533360","Enrolling by invitation","2020-09-28","2021-05-01","{""locations"":""Kingman Regional Medical Center, Kingman, Arizona, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevelence of SARS-CoV-2 Antibodies among Adults in Kingman AZ|Retention of SARS-CoV-2 Antibodies among Adults in Kingman AZ""}"
"1608","Risk Factors Worsening COVID19 for Out-patient With Home Monitoring","COVIDADOMEVA","NCT04380662","38RC20.135|2020-A01040-39","Other: Risk factors","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380662","Not yet recruiting","2020-06-30","2020-12-30","{""locations"":""Grenoble University Hospital, Grenoble, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Identify the factors associated with the worsening of the COVID19|Describe the clinical care pathway of patients from Day 0 to Day 14|Describe the health status at Day 30|Describe the quality of life during the disease""}"
"1609","Dräger COVID-19 Antigen Test Clinical Performance Study","","NCT04698993","Dräger Antigen Test SARS-CoV-2","Diagnostic Test: Dräger Antigen Test SARS-CoV-2","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04698993","Recruiting","2021-02-12","2021-03-01","{""locations"":""Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""831"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity|Specificity|Sensitivity and specificity in relation to the cycle threshold value of the reference RT-PCR|Sensitivity and specificity in relation to the time since symptom onset|Specificity in asymptomatic participants|Frequency of nosebleed or unbearable pain during or immediately after specimen collection""}"
"1610","A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19","","NCT04652102","CV-NCOV-004|2020-003998-22","Biological: CVnCoV|Biological: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04652102","Recruiting","2020-12-14","2023-03-04","{""locations"":""Centre for Vaccinology - Ghent University Hospital, Ghent, Belgium|University Hospital, Cologne, Germany|Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany|University Hospital T\u00fcbingen Institut f\u00fcr Tropenmedizin, T\u00fcbingen, Germany|Panamerican Clinical research Mexico (Guadalajara), Guadalajara, Mexico|Panamerican Clinical Research Mexico S.A. DE C.V., Juriquilla, Mexico|Unidad de Medicina Especializada SMA, San Juan Del R\u00edo, Mexico|Centro Medico Zambrano Hellion, San Pedro Garza Garcia, Mexico|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Universitair Medische Centra - Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|University of Utrecht, Utrecht, Netherlands|Hospital de Chancay y Servicios b\u00e1sicos de Salud, Chancay, Peru|Centro de Investigaci\u00f3n para ensayos Cl\u00ednicos UPCH, Lima, Peru|OSI Eskerraldea-Enkarterri-Cruces\/Hospital Universitario Cruces, Barakaldo, Spain|Hospital Universitario Donostia, Donostia-San Sebasti\u00e1n, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""36500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity|Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of moderate to severe COVID-19|Number of participants who experience one or more medically-attended adverse events (AEs)|Intensity grading of medically-attended adverse events (AEs) per FDA toxicity grading scale|Number of participants who experience one or more treatment-related medically-attended adverse events (AEs)|Number of participants who experience one or more serious adverse events (SAEs)|Intensity grading of serious adverse events (SAEs) per FDA toxicity grading scale|Number of participants who experience one or more treatment-related serious adverse events (SAEs)|Number of participants who experience one or more adverse events of special interest (AESI)|Intensity grading of adverse events of special interest (AESI) per FDA toxicity grading scale|Number of participants who experience one or more treatment-related adverse events of special interest (AESI)|Number of participants who experience a fatal serious adverse event (SAE)|Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} severe case of COVID-19|Number of participants with seroconversion to the nucleocapsid (N) protein of SARS-CoV-2 \u2265 15 days after the second study vaccination|Number of participants aged \u2265 61 who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity|Number of participants who experience a virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} SARS-CoV-2 infection, with or without symptoms|Burden of disease (BoD) based on first episodes of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} cases of COVID-19|Number of participants who experience a virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity with symptom onset at any time after the first study vaccination|Number of participants with serum antibodies to SARS-CoV-2 spike (S) protein|Number of participants who experience seroconversion to SARS-CoV-2 spike (S) protein|Number of participants with serum vital neutralizing antibodies to SARS-CoV-2 virus|Number of participants who experience seroconversion to SARS-CoV-2 virus|Phase 2b participants only: Number of participants who experience one or more solicited local adverse events (AEs)|Phase 2b participants only: Intensity grading of solicited local adverse events (AEs) per FDA toxicity grading scale|Phase 2b participants only: Duration of solicited local adverse events (AEs)|Phase 2b participants only: Number of participants who experience one or more solicited systemic adverse events (AE)|Phase 2b participants only: Intensity grading of solicited systemic adverse events (AEs)|Phase 2b participants only: Duration of solicited systemic adverse events (AEs)|Phase 2b participants only: Number of participants who experience one or more unsolicited adverse events (AEs)|Phase 2b participants only: Intensity grading of unsolicited adverse events (AEs)|Phase 2b participants only: Number of participants who experience one or more treatment-related unsolicited adverse events (AEs)|Number of participants who experience one or more adverse events (AEs) leading to vaccine withdrawal or trial discontinuation""}"
"1611","COVID-19 and Anti-CD14 Treatment Trial","CaTT","NCT04391309","DAIT COVID-19-003|NIAID CRMS ID#: 38756|UM1AI109565","Biological: anti-CD14|Other: Placebo|Drug: remdesivir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04391309","Not yet recruiting","2021-03-01","2022-02-01","{""locations"":""Harbor - UCLA Medical Center, Torrance, California, United States|University of Miami Medical Center, Miami Beach, Florida, United States|Sarasota Memorial Health Care System, Sarasota, Florida, United States|Emory University Medical Center, Atlanta, Georgia, United States|Ochsner Health, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical Recovery|Days Alive and Free of Acute Respiratory Failure through Day 28|Mean Change in the Ordinal Scale (Range 1 [Best] to 8 [Worst])|Ordinal Scale Value on Day 14 (Range 1 [Best] to 8 [Worst])|All-Cause Mortality through Days 28 and 60|Days Alive and Free of Any Episode of Acute Respiratory Failure through Day 28|Proportion of Participants Alive and Free of Any Episode of Acute Respiratory Failure through Day 28|Days Alive and Free of Invasive Mechanical Ventilation through Day 28|Proportion of Participants Alive and Free of Invasive Mechanical Ventilation through Day 28|Proportion of Participants Alive and Discharged from the Hospital through Day 28|Proportion of Participants who Begin Corticosteroid Therapy for Worsening COVID-19 Illness after Randomization|Serious Adverse Events (SAEs)|Adverse Events (AEs)|Safety of IC14 as Measured by Change from Baseline in ALT and AST Liver Function Tests|Safety of IC14 as Measured by Change from Baseline in Liver Function Measured by Total Bilirubin|Safety of IC14 as Measured by Change from Baseline in Serum Creatinine|Safety of IC14 as Measured by Change from Baseline in Hemoglobin|Safety of IC14 as Measured by Change from Baseline in White Blood Cell Count|Safety of IC14 as Measured by Change from Baseline in Differential White Blood Count|Safety of IC14 as Measured by Change from Baseline in Platelet Count|Safety of IC14 as Measured by Change from Baseline in Prothrombin Time""}"
"1612","Efficacy of Nicotine in Preventing COVID-19 Infection","NICOVID-PREV","NCT04583410","APHP200538|2020-003722-23","Drug: Nicotine patch|Drug: Placebo patch","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04583410","Recruiting","2020-10-22","2022-06-01","{""locations"":""Centre Hospitalier Gonesse, Gonesse, France|Groupe Hospitalier de la R\u00e9gion de Mulhouse Sud Alsace, Mulhouse, France|H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re - Service de M\u00e9decine Interne, Paris, France|H\u00f4pital Sainte-Anne, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1633"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-COV2 seroconversion between W0 and W19 after randomization|Proportion of documented symptomatic COVID-19 infection|SARS-COV2 seroconversion|Asymptomatic COVID-19 infection proportion at week 14|Proportion of severe COVID-19 infection|Number of sick leaves for a COVID-19 infection|Number of days off during sick leaves for a COVID-19 infection|Proportion of AE, SAE|Intensity and frequency of nausea, dizziness, feeling of empty head, headache, vomiting|Proportion of active smoker or active vapers or taking nicotine substitutes documented by examination|Proportion of active smoker or active vapers or taking nicotine substitutes documented by urinary cotinine|Mean score of Desire to smoke defined by French Tobacco Craving scale|Mean score of Withdrawal symptoms scale|Dosage of cotinine in the urine|Mean score of Fatigue Numeric rating scale|Weight|Mean score of Hospital anxiety and depression scale|Mean score of Insomnia severity scale|Positive and negative syndrome scale""}"
"1613","Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic","","NCT04474301","2020-0470|NCI-2020-04587|P30CA016672","Other: Survey Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04474301","Recruiting","2020-06-11","2021-07-01","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""1152"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Experiences during the COVID-19 pandemic|COVID-19-specific psychological distress|COVID-19-specific health|COVID-19-specific financial and social disruptions|COVID-19-specific perceived benefits and social support|COVID-19-specific health related quality of life (HRQoL)|Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL|Prior lifestyle data""}"
"1614","Recovery of Patients From COVID-19 After Critical Illness","COVID-Recovery","NCT04401254","COVID-Recovery V1.0 01May2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401254","Recruiting","2020-07-01","2022-04-01","{""locations"":""Canberra Hospital, Garran, Australian Capital Territory, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Ipswich Hospital, Ipswich, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Gold Coast Hospital, Southport, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Launceston Hospital, Launceston, Tasmania, Australia|Casey Hospital, Berwick, Victoria, Australia|Box Hill Hospital (Eastern Health), Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Northern Health, Epping, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Australian New Zealand Intensive Care Research Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Alfred Hospital, Prahran, Victoria, Australia|Epworth Richmond, Richmond, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disability-free survival|Physiotherapy intervention|Health status|Global function|Cognitive function|Anxiety and depression|Screening for post-traumatic distress|Work Status|Proportion of patients with COVID-19 who received physiotherapy in ICU|The reported barriers to delivering physiotherapy interventions|Adverse events during physiotherapy interventions|Phenomenological data of the patient and family experience""}"
"1615","Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia","","NCT04362345","7773","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362345","Recruiting","2020-04-09","2021-01-09","{""locations"":""Service des Maladies Infectieuses et Tropicales, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection""}"
"1616","Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","","NCT04477083","inhalable HCQ","Drug: inhalable hydroxychloroquine (HCQ)|Drug: supportive and symptomatic treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04477083","Active, not recruiting","2020-07-15","2020-08-15","{""locations"":""Mansoura University Hospital, Mansoura, Outside U.S.\/Canada, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical recovery defined as 3 days afebrile with improved cough and other clinical signs|Time to achieve viral clearance state determined by two successive negative PCR results for two oropharyngeal swabs separated by 48 hours.|Incidence of Treatment-Emergent Adverse Events""}"
"1617","Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers","BBV152","NCT04471519","BBIL/BBV152-A/2020|Protocol No:BBIL/BBV152-A/2020","Biological: BBV152A - Phase I|Biological: BBV152B - Phase I|Biological: BBV152C - Phase I|Biological: Placebo - Phase I|Biological: BBV152A - Phase II|Biological: BBV152B - Phase II","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04471519","Active, not recruiting","2020-07-13","2021-06-30","{""locations"":""King George Hospital, Visakhapatnam, Andhra Pradesh, India|All India Institute of Medical Sciences, Patna, Bihar, India|Pt BD SHARMA,PGIMS\/UHS, Rohtak, Haryana, India|Jeevan Rekha Hospital, Belgaum, Karnataka, India|Gillukar Multispeciality Hospital, Nagpur, Maharastra, India|All India Institute of Medical Sciences, Delhi, New Delhi, India|Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Orissa, India|SRM Hospital & Research center, Chennai, Tamilnadu, India|Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India|Rana Hospital and Trauma Center, Gorakhpur, Uttar Pradesh, India|Prakhar Hospital, Kanpur, Uttar Pradesh, India|Redkar Hospital and Research Centre, Goa, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""755"",""age"":""12 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Phase 1: Occurrence of adverse events and Serious Adverse events|Phase 2: Evaluation of Neutralizing Antibody Titers|Phase 1: Evaluation of Neutralizing Antibody Titers|Phase 2: Occurrence of adverse events and Serious Adverse events""}"
"1618","Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","RegCOVID19","NCT04347278","IDI-REM-2020-1","Drug: Patients with the treatment agains COVID19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347278","Recruiting","2020-04-22","2021-01-01","{""locations"":""Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Cantabria, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""1000"",""age"":""1 Year to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice|Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|Information on the patterns of use of these drugs (dose, duration of treatment,|Adverse events|Time of hospital admission and\/or stay in ICU and maximum severity reached.|Treatments for SARS-CoV-2 positive patients not described in the protocol|healthy survey for patients after their recovery\/discharge from hospital.""}"
"1619","CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients","CAMOVID","NCT04608266","APHP200702","Drug: Camostat Mesylate|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04608266","Recruiting","2020-12-03","2022-03-01","{""locations"":""Centre Hospitalier Victor Dupouy, Argenteuil, France|AP-HP H\u00f4pital Henri Mondor, Cr\u00e9teil, France|AP-HP H\u00f4pital Bichat, Paris, France|APHP - Saint Louis, Paris, France|Centre de Sant\u00e9 Richerand, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""596"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization for COVID-19 deterioration or death without hospitalization|Adverse events|Serious adverse events|Investigational medication discontinuation|Hospitalization for COVID-19 deterioration or death without hospitalization, evaluated by independent adjudication comittee|Clinical improvement using the Word Health Organization (WHO) COVID-19 scale|Need for intensive care|Duration of hospitalization|Need for invasive mechanical ventilation for severe COVID-19|Need for oxygen therapy for COVID-19|Overall survival|Duration of symptoms|SARS-CoV-2 virological assessment|SARS-CoV-2 serological assessment|Peripheral blood lymphocyte phenotyping|Acute kidney failure|Renal function|Concentration of urea in blood|Concentration of potassium in blood|Liver function|Liver function (2)""}"
"1620","Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers","","NCT04387890","5566","Diagnostic Test: Serologic SARS-CoV-2 screening","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387890","Not yet recruiting","2020-06-01","2020-08-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of anti SARS-CoV-2 antibodies (IgM and IgG) in health personnel|COVID-19 incidence through serology-based screening and\/or compatible symptoms in health personnel previously known to be unexposed to the virus|Incidence of reactivation\/reinfection for COVID-19 in health personnel with a positive serology for SARS-CoV-2""}"
"1621","Anti-COVID19 AKS-452 - ACT Study","ACT","NCT04681092","NL2020-005997-82","Biological: AKS-452","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04681092","Not yet recruiting","2021-01-18","2021-06-30","{""locations"":""University Medical Center Groningen, Groningen, Netherlands"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""130"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Safety \/ Tolerability|Immunogenicity""}"
"1622","Changing of Trace Element, Homocysteine, Oxidative Stress Parameters and Physical Activity Levels in Covid-19","","NCT04694703","2020-12-142","Drug: Covid-19 group","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694703","Recruiting","2021-01-06","2021-03-01","{""locations"":""Kadirhan Ozdemir, \u0130zmir, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""35 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of the levels of Trace Element at baseline and discharge|Change of Physical Activity Level at baseline and discharge|Change of the levels of Homocystein at baseline and discharge|Change of the levels of Oxidative Stress Parameters at baseline and discharge|Change of the levels of Routine Blood Samples (Hemogram) at baseline and discharge|Change of the levels of Routine Blood Samples (vitamin D, Troponin T, D-Dimer, iron and ferritin) at baseline and discharge|Change of the levels of Routine Blood Samples (C-reactive protein (CRP) and procalcitonin) at baseline and discharge|Change of the levels of Routine Blood Samples (uric acid, chlorine, blood urea nitrogen (BUN) creatine, albumin and bilirubin) at baseline and discharge""}"
"1623","Burden of COVID-19 Infection in Populations With High or Low Risk of Infection","","NCT04636203","DEP_032020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04636203","Not yet recruiting","2020-12-15","2022-06-15","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""3500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection|Burnout and post-traumatic stress disorder in HCWs|SARS-CoV-2 infection positivity factors\/determinants|Population cohort of immunized subjects|Biobank biospecimen collection""}"
"1624","Pilot Study to Detect SARS-CoV-2 Virus in Sperm","COVSPERM","NCT04584593","RC31/20/0202|2020-A01610-39","Biological: Sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04584593","Recruiting","2020-10-02","2022-02-01","{""locations"":""University Hospital Toulouse, Toulouse, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""50"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""SARS-CoV-2 genomic RNA in patient sperm|SARS-CoV-2 location in patient sperm""}"
"1625","Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);","","NCT04375709","2020_00899 / COV19_2020","Other: Physical exercise|Behavioral: Education sessions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375709","Recruiting","2020-03-15","2021-08-31","{""locations"":""Kantonsspital Winterthur, Winterthur, Z\u00fcrich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health-related quality of life; EuroQoL (EQ-5D-5L)|6-minute walk test|Jamar dynamometer|Hospital Anxiety and Depression Scale (HADS)|revised Impact of Event Scale (IES-R)|Mini-Nutritional Assessment (MNA)|Spirometry (bed-side)|Post-Covid Functional Scale (PCFS)|modified Medical Research Council Dyspnoea Scale (mMRC Dyspnoea)""}"
"1626","Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia","","NCT04540926","135.202","Drug: Cyclosporin A","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04540926","Not yet recruiting","2020-09-01","2020-09-30","{""locations"":""Jose Luis Jl Galvez-Romero, Puebla, Mexico"",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days to clinical improvement until hospital discharge or death.""}"
"1627","Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19","TOLD","NCT04424901","20-192-2.F","Drug: Dipyridamole","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04424901","Recruiting","2020-05-03","2021-05-30","{""locations"":""UConn Health, Farmington, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Coagulation system|Viral Detection""}"
"1628","[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse","","NCT04719208","[1607808","Other: Water (E) Mouth rinse with the solution provided|Other: Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Other: Hydrogen peroxide (B) Mouth rinse with the solution provided|Other: Betadine (C) Mouth rinse with the solution provided|Other: Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04719208","Recruiting","2020-10-06","2021-06-01","{""locations"":""Augusta University, Augusta, Georgia, United States|Augusta University-Dental College of Georgia, Augusta, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in oral SARS-CoV-2 load in oral cavity of COVID-19 patient using prophylactic mouth rinse""}"
"1629","Sirolimus in COVID-19 Phase 1","SirCO-1","NCT04371640","15680","Drug: Sirolimus 1 MG/ML|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04371640","Withdrawn","2020-07-06","2021-08-01","{""locations"":""Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment|Change in SARS-CoV-2 viral burden at days 1-6|Rate of treatment emergent adverse events""}"
"1630","Safety and Immunity of Covid-19 aAPC Vaccine","","NCT04299724","GIMI-IRB-20002","Biological: Pathogen-specific aAPC","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04299724","Recruiting","2020-02-15","2024-12-31","{""locations"":""Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""6 Months to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable""}"
"1631","S-Nitrosylation Therapy of COVID-19","","NCT04528771","STUDY20200453","Drug: SNO|Drug: Nitrogen gas","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04528771","Not yet recruiting","2020-10-31","2021-04-30","{""locations"":""University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""21"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Length of Hospital Stay|Number of Ventilator Days|Length of Intensive Care|All-Cause Mortality|Treatment Emergent Adverse Events|Time to Respiratory Status Improvement|Clinical Status|Respiratory Clinical Status""}"
"1632","Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease","covid19","NCT04603729","FMH-06-2020-IRB-763-M","Drug: Dexamethasone 2 MG/ML|Drug: Methylprednisolone Injection","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04603729","Completed","2020-05-30","2020-07-01","{""locations"":""Fatima Memorial Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""temperature (F)|oxygen saturation(%)|CRP (mg\/dl)|mortality|ICU transfer""}"
"1633","Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)","RUXCOVID","NCT04362137","CINC424J12301|INCB 18424-368|2020-001662-11","Drug: Ruxolitinib|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04362137","Completed","2020-05-02","2020-10-17","{""locations"":""Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, C A B A, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Blumenau, Santa Catarina, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sorocaba, SP, Brazil|Novartis Investigative Site, Rionegro, Antioquia, Colombia|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Colombes Cedex, France|Novartis Investigative Site, Eaubonne, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, M\u00e9xico, Distrito Federal, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Estado de Mexico, Mexico|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Yenisehir\/Izmir, Turkey|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""432"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (ICU) care|Clinical status|Percentage of patients with at least two-point improvement from baseline in clinical status|Percentage of patients with at least one-point improvement from baseline in clinical status|Percentage of patients with at least one-point deterioration from baseline in clinical status|Time to improvement in clinical status|Mean change from baseline in the clinical status|Mortality rate|Proportion of patients requiring mechanical ventilation|Duration of hospitalization|Time to discharge or to a NEWS2 score of \u22642|Change from baseline in NEWS2 score|Change from baseline in SpO2\/FiO2 ratio.|Proportion of patients with no oxygen therapy""}"
"1634","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","STOP COVID","NCT04342663","202004023","Drug: Fluvoxamine|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04342663","Completed","2020-04-10","2020-12-12","{""locations"":""BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""152"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)""}"
"1635","Over-the-counter Medications & COVID-19","OTC℞&COVID19","NCT04500639","Pro00100243","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04500639","Recruiting","2020-07-23","2023-03-31","{""locations"":""University of Alberta, Edmonton, Alberta, Canada"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""14000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Ibuprofen exposure for symptom management|Exposure to other drugs implicated in COVID-19 severity""}"
"1636","Risk Profiling of the Occupational Exposure of COVID-19 to Healthcare Workers.","","NCT04477213","NMCHCW-COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04477213","Not yet recruiting","2021-01-15","2021-02-15","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of COVID-19 in healthcare workers (HCWs)|clinical severity of infection in HCWs""}"
"1637","Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19","BRACE-CORONA","NCT04364893","PRJ_2003","Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04364893","Recruiting","2020-04-09","2020-12-01","{""locations"":""Idor, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Median days alive and out of the hospital|Number of participants with adverse cardiovascular outcomes and new worsening heart failure|Cardiovascular biomarkers related to COVID-19""}"
"1638","The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry","","NCT04449042","IRB-P00035427","Procedure: airway management during sedation or general anesthesia","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04449042","Recruiting","2020-04-01","2025-12-01","{""locations"":""Boston Children's Hopsital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""15000"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""airway complications|airway device|PPE|First pass success|induction techniques|failed intubation|complication risk factors""}"
"1639","Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients","","NCT04565379","Shaperon001|2020-003107-34","Drug: NuSepin® 0.1 mg|Drug: NuSepin® 0.2 mg|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04565379","Recruiting","2020-09-25","2020-11-30","{""locations"":""\""Leon Daniello\"" Clinical Hospital of Pneumophtisiology Cluj-Napoca Pneumology Clinic, Cluj-Napoca, Romania|Clinical Hospital for Infectious Diseases and Pneumophtisiology \""Victor Babes\"", Craiova Infectious Diseases Clinic for Adults, Craiova, Romania|\""Sf. Parascheva\"" Infectious Diseases Clinical Hospital Iasi Infectious Diseases Department, Ia\u015fi, Romania|\""Sf. Ioan cel Nou\"" Suceava County Emergency Hospital Infectious Diseases Department, Suceava, Romania"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Difference in Time to Clinical Improvement (TTCI) between the 2 treatments and the placebo group (in days)|Percentage of patients with CRP < 10 mg\/L or < 30% decreases from baseline|Clinical Status assessed by the six-category ordinal scale at fixed time points|Time to complete clinical remission OR NEWS2 (National Early Warning Score 2) of \u2264 2 maintained for 24 hours|All-cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Length of ICU stay (days)|Number of incidence of treatment emergent adverse events (TEAEs) in 3 treatment groups""}"
"1640","Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers","","NCT04438837","0193-20-RMB CTIL","Drug: Hydroxychloroquine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04438837","Not yet recruiting","2020-07-01","2022-06-01","{""locations"":""Rambam Health Care Campus, Haifa, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""582"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical COVID-19|Confirmed COVID-19|Time to virological recovery|Time to symptoms onset|Development of pneumonia|Development of severe disease|Need for hospitalization or ICU|Adverse events|Mortality|Time to de-isolation""}"
"1641","Covid-19 Messaging to Underserved Communities - 2nd Experiment","","NCT04502056","2029880","Behavioral: Acknowledgement Racial Injustice AMA|Behavioral: African American Sender Acknowledgement|Behavioral: African American Sender in Informational Videos.|Behavioral: Racial Inequality Highlighted|Behavioral: AMA Acknowledgement Drug Pricing|Behavioral: White Sender in Acknowledgement|Behavioral: White Sender in Informational Videos|Behavioral: No Racial Inequality Highlighting|Behavioral: Placebo videos","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04502056","Active, not recruiting","2020-07-31","2021-09-01","{""locations"":""JPAL North America, Cambridge, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""20000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The number of participants with knowledge of COVID related symptoms and transmission as assessed by a questionnaire we've developed specifically relevant to the intervention videos we are using for the project.|Behavioral outcome 1: Number of participants who report behavior change related to messages provided in the intervention videos; measured via a specific questionnaire instrument we've developed to correspond to the intervention.|Behavioral outcome 2: Willingness to pay (WTP) for masks|Behavioral outcome 3: Number of people who click on links for additional information on the covid-19 behaviors|Behavioral outcome 4: The amount of money donated to a COVID-19 relief fund.""}"
"1642","Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic","COVER-PRO","NCT04383886","69HCL20_0330","Other: stress and anxiety questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383886","Recruiting","2020-04-18","2020-08-18","{""locations"":""SAMU Hospices Civils de Lyon, Lyon, France|Service d'accueil des urgences, H\u00f4pital Edouard Herriot, Hospices Civlis de Lyon, Lyon, France|Service d'accueil des urgences, H\u00f4pital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service d'accueil des urgences, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France|H\u00f4pital de Villefranche-sur-Sa\u00f4ne, Villefranche-sur-Sa\u00f4ne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of emergency department staff's level of stress during the covid19 pandemic, measured using the Chamoux et Simard visual analogic scale""}"
"1643","Changing Susceptible Body Constitution for COVID-19 Prevention by Chinese Medicine in Hong Kong Residents","","NCT04668222","UW20-480","Drug: Yu-Ping-Feng formula|Drug: Xiang-Sha-Liu-Jun formula|Drug: Liu-Wei-Di-Huang formula|Drug: Placebo for ""Deficiency of Qi and Yang""|Drug: Placebo for ""Deficiency of Qi and Yin""","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04668222","Not yet recruiting","2020-12-15","2022-11-30","{""locations"":""The University of Hong Kong, Hong Kong, Hong Kong, China, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""480"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Potential COVID-19 susceptible body constitutions will be measured by the scale of \""Self-test for classification and judgment of body constitution by traditional Chinese medicine (TCM) theory\""|Changes of TCM-based syndromes will be measured by the \""Questionnaire of TCM symptom\""|Potential changes of fatigue status will be measured by Fatigue Scale|Complete Blood Count will be measured by Automated Cell Counter|Liver function biomarkers in blood will be measured by Automatic Blood Biochemistry Analyzer|Heart function biomarkers in blood will be measured by Automatic Blood Biochemistry|Kidney function biomarkers in blood will be measured by Automatic Blood Biochemistry|Inflammatory biomarker in blood will be measured by Automatic Blood Biochemistry|The changes of quantification of blood CD4 and CD8 populations will be measured by flow cytometric analyzer""}"
"1644","Test and Treat COVID 65plus+","COVID65plus","NCT04351516","COVID65plus|2020-001482-37","Drug: Hydroxychloroquine|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04351516","Withdrawn","2020-04-21","2021-05-01","{""locations"":""Uniklinikum Tuebingen, Tuebingen, Germany|Uniklinikum Ulm, Ulm, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""\u25cf Rate of hospitalization or death at day 7 after study inclusion""}"
"1645","Detection of COVID-19 Using Breath Analysis - Validation Study","COVID-19","NCT04602949","Cov-2-SMC-2020","Diagnostic Test: Breath Biopsy Analysis","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04602949","Not yet recruiting","2020-11-12","2021-02-28","{""locations"":""Shamir Medical Center, Be'er Ya'aqov, Israel"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""4000"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of Volatile Organic Compounds indicating carriers of COVID-19.|Association of exhaled biomarkers with participants' characteristics (age, gender, symptoms-severity, etc.).|sensitivity level of biomarkers' algorithm.""}"
"1646","Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic","OBVIONCO","NCT04437719","OBVIONCO","Other: Obvio-19 app","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04437719","Recruiting","2020-06-29","2021-12-31","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 infection's symptoms|Incidence and course of symptoms of COVID-19 infection|Correlation of the COVID-19 infection with the biological and clinical data of patients""}"
"1647","NeuroCovid - a Study of Intensive Care-requiring Covid-19 Patients","","NCT04578197","Dnr 2020-02760","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04578197","Recruiting","2020-08-18","2022-11-01","{""locations"":""Karolinska Universitetssjukhuset Solna, Stockholm, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The association between changes in blood biomarkers for inflammation and the presence of neuroradiologically verified brain injury and neurocognitive disorder|The association between changes in blood biomarkers for nerve cell damage and the presence of neuroradiologically verified brain injury and neurocognitive disorder|The association between changes in blood biomarkers for neurodegeneration and the presence of neuroradiologically verified brain injury and neurocognitive disorder|The association between changes in coagulation factors and the presence of neuroradiologically verified brain injury and \/ or neurocognitive disorder|The association between changes in coagulation ability (ROTEM analysis - rotational thromboelastometry) and the presence of neuroradiologically verified brain injury and \/ or neurocognitive disorder|The association between changes in inflammatory biomarkers and the presence of neuroradiologically verified brain injury and \/ or neurocognitive disorder|Blood biomarker changes of inflammation impact|Blood biomarker changes of neurological impact|Neuroradiological changes|Clinical course - Pulmonary gas exchange|Clinical course - Lung function recording|Patient characteristics""}"
"1648","Cytokine Status of Covid-19 Patients","","NCT04531345","Covid Cytokine","Diagnostic Test: Flow cytometric analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04531345","Completed","2020-10-01","2020-11-15","{""locations"":""Istanbul Training and Reseach Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cytokine levels of patients""}"
"1649","Photodynamic Therapy for the Treatment of COVID-19","","NCT04416113","Cu-NILES/16/20","Procedure: photobiomodulation and photodynamic therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04416113","Not yet recruiting","2020-08-01","2021-02-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Participants Achieving Either a Major Clinical Response or Partial Clinical Response (PCR) Defined by WHO""}"
"1650","Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19","","NCT04591015","3R01DK112322-05S1","Behavioral: Hospital: DD-CA|Behavioral: Hospital: Usual Care (UC)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04591015","Recruiting","2021-02-01","2021-08-31","{""locations"":""Scripps Mercy Hospital Chula Vista, Chula Vista, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""172"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Readmission rate (30-days)|Glycosylated Hemoglobin (HbA1c)|Diabetes Distress Scale|COVID-19 Patient Survey|Summary of Diabetes Self-Care Activities Survey|PROMIS Quality of Life Scale|Knowledge, Attitudes and Practice Toward COVID-19 Survey|Demographics Questionnaire""}"
"1651","BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)","","NCT04494646","20-00591","Drug: Bardoxolone Methyl|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04494646","Completed","2020-09-08","2021-01-08","{""locations"":""HSHS St. John's Hospital (Prairie Education and Research Cooperative), Springfield, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Coney Island Hospital, Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|NYU Bellevue Hospital Center, New York, New York, United States|NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Serious Adverse Events|Average number of renal replacement therapy (RRT)-free days|Average number of mechanical ventilation-free days|Incidence of All-Cause Mortality|Proportion of participants who experienced deterioration from baseline""}"
"1652","Early Detection of COVID-19 Using Breath Analysis","COVID-19","NCT04602884","Cov-2-IDF","Diagnostic Test: Breath biopsy sampling using the ReCIVA Breath Sampler","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04602884","Suspended","2020-09-22","2020-12-30","{""locations"":""IDF COVID 19 Isolation Facility, Ashkelon, Israel"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""50"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Correlation between Volatile Organic Compounds pattern and COVID-19 detection status.|Correlation between Volatile Organic Compounds pattern and time from COVID-19 detection.|Correlation between the set of Volatile Organic Compounds found in breath biopsy and disease intensity.""}"
"1653","Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","CORIMMUNO-COAG","NCT04344756","APHP200389-6","Drug: Tinzaparin or unfractionated heparin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04344756","Not yet recruiting","2020-04-20","2020-09-30","{""locations"":""R\u00e9animation h\u00f4pital Louis Mourier, Colombes, Hauts De Seine, France|r\u00e9animation h\u00f4pital Cochin, Paris, France|M\u00e9decine vasculaire, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""808"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival without ventilation (VNI or mechanical ventilation)|ventilator free survival|World Health Organisation(WHO) progression scale \u22645|World Health Organisation(WHO) progression scale|overall survival|Length of hospital stay|Length of ICU stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to Renal Replacement Therapy (RRT) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|Rate of clinically overt arterial thrombosis|Rate of unscheduled central venous catheter replacement for catheter dysfunction|Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)|Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Incidence of adverse events""}"
"1654","SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting","","NCT04519372","2020-00808","Diagnostic Test: Testing for SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04519372","Active, not recruiting","2020-04-01","2021-03-31","{""locations"":""University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology, Basel, Switzerland"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""4099"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of SARS-CoV-2 -infected patients""}"
"1655","Beaumont Health Large-scale Automated Serologic Testing for COVID-19","BLAST COVID-19","NCT04349202","2020-134","Diagnostic Test: EUROIMMUN assay","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04349202","Recruiting","2020-04-10","2021-06-01","{""locations"":""Beaumont Health System, Royal Oak, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""56000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence COVID antibodies in employees of Beaumont Health|COVID-19 re-infection in participants positive for antibodies to SARS-CoV-2|Correlation of dried blood spot and standard blood sampling positive for COVID-19 IgG antibodies|Correlation of dried blood spot and standard blood sampling negative for COVID-19 IgG antibodies|Correlation of dried blood spot and standard blood sampling positive for COVID-19 IgA antibodies|Correlation of dried blood spot and standard blood sampling negative for COVID-19 IgA antibodies|Reproducibility of SARS-CoV-2 IgG antibody detection from dried blood spots|Stability of dried blood spots for SARS-CoV-2 IgG antibody detection|Effect of shipping on dried blood spot samples for SARS-CoV-2 IgG antibody detection|Accuracy of participant-performed blood spot collection for SARS-CoV-2 IgG antibody detection|Ease of participant-performed blood spot collection|Correlation of SARS-CoV-2 antibodies between immediate family members""}"
"1656","Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)","","NCT04357327","68/2020","Diagnostic Test: rapid salivary test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04357327","Completed","2020-04-16","2020-07-31","{""locations"":""ASST dei Sette Laghi, Varese, VA, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic"",""enrollment"":""122"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Sensibility|Specificity""}"
"1657","Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2","","NCT04610801","LCH-3-082020","Drug: Nasal Spray","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04610801","Recruiting","2020-08-08","2021-08-08","{""locations"":""Larkin Community Hospital Palm Springs Campus, Miami, Florida, United States|Larkin Community Hospital, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline reactive to non-reactive on COVID 19 RT PCR in 7 days|Change of time to clinical recovery from baseline within 7 days""}"
"1658","poSt Covid-19 Infection centraL sENsitisaTion","SILENT 1","NCT04703452","SILENT 1","Other: Indicators of central sensitisation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04703452","Recruiting","2021-01-19","2022-01-01","{""locations"":""Universitair Ziekenhuis Brussel, Jette, Brussel, Belgium"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms of Central Sensitisation|Pressure pain thresholds|Temporal summation|Descending nociceptive inhibition|Functionality and disability""}"
"1659","Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19","ECMO-SL-CoV-2","NCT04446286","7904","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04446286","Recruiting","2020-06-18","2020-08-18","{""locations"":""Service de Chirurgie Thoracique Nouvel H\u00f4pital Civil H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective description of effect of the ECMO-VV or ECMO-VA in the management of severe ARDS refractory in patients of the Strasbourg and Louvain centres with covid-19""}"
"1660","Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","CORIMMUNO-BEVA","NCT04344782","APHP200389-7","Drug: Bevacizumab Injection","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04344782","Not yet recruiting","2020-04-15","2020-11-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""130"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of surviving patients without need for intubation for respiratory support|Saturation of Oxygen in the blood (SaO2)|Arterial oxygen partial pressure (paO2)|Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2\/FiO2)|CT-scan score|dyspnea|overall survival|admissionn to the intensive care unit (ICU)|incidence of mechanical ventilation|hospital length of stay|incidence of adverse event|VEGF plasma concentration""}"
"1661","Corticosteroid Nasal Spray in COVID-19 Anosmia","","NCT04484493","RC 4-7-2020","Drug: mometasone furoate nasal spray","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04484493","Completed","2020-08-08","2020-11-03","{""locations"":""Benha University Hospital, Faculty of Medicine, Banh\u0101, Qalubia, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""improvement of olfaction""}"
"1662","Association of Comorbidities With COVID19","","NCT04459390","COVID19","Diagnostic Test: realtime PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459390","Recruiting","2020-07-20","2020-11-20","{""locations"":""Faculty of Medicine, Assiut, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Rate of recovery\/ ICU admission\/ need for mechanical ventilation|Time to improvement""}"
"1663","Home-Based Covid-19 Rehabilitation Program","","NCT04406532","2020-11535","Behavioral: PT-Pal|Behavioral: Self-guided exercises","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04406532","Not yet recruiting","2021-05-01","2022-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in pulmonary function (St George's Respiratory questionnaire: SGRQ)|Change in physical function (Activity Measure for Post-Acute Care: AM-PAC)|Change in pulmonary function (Sabrasez single breath count)|Change in pulmonary function (Peak flow tests)|Change in physical function (5 times site to stand test)|Health events (emergency room visits and hospitalizations)|Change in psychological measures (Beck Anxiety Inventory: BAI)|Change in psychological measures (Center for Epidemiologic Studies Depression Scale: CES-D)|Feasibility (Adherence)|Feasibility (Acceptability)""}"
"1664","Early Detection of COVID-19 Using Breath Analysis - Feasibility Study","COVID-19","NCT04602871","Cov-2-2020","Diagnostic Test: Breath Biopsy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04602871","Recruiting","2020-07-03","2021-01-30","{""locations"":""Soroka Medical Center, Be'er Sheva, Israel|Meir Medical Center, Kfar Saba, Israel"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""108"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between Volatile Organic Compounds pattern in-breath biopsy and COVID-19 detection.|Correlation between Volatile Organic Compounds pattern and the course of the disease""}"
"1665","Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia","PLASM-AR","NCT04383535","5565","Other: Convalescent SARS COVID-19 plasma|Other: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04383535","Completed","2020-05-15","2020-09-27","{""locations"":""Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""333"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical status during follow-up at 30th day|Clinical status during follow-up at 7th day|Clinical status during follow-up at 14th day|Time until hospital discharge (days).|Time until discharge from ICU (days)|Time to death|Time until complete functional recovery|Percentage of participants with adverse events \/ serious adverse events|Percentage of patients with negative SARS-CoV-3 PCR at Day 14th|D Dimer plasma concentration at Day 14th|Ferritin plasma concentration at Day 13th|Plasma concentration of neutralizing antibodies at Day 2nd|Plasma concentration of neutralizing antibodies at Day 7th|Post-transfusion adverse reactions""}"
"1666","Treatment With Pirfenidone for COVID-19 Related Severe ARDS","","NCT04653831","SCRC20007","Drug: Pirfenidone|Other: Standard of care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04653831","Recruiting","2020-11-08","2021-12-01","{""locations"":""Soroka Medical Center, Be'er Sheva, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilation free days to day 28 (VFD28)|Severe adverse events (SAEs) rate|Mortality|ICU length of stay|Lung compliance|Tidal Volume|Positive End Expiratory Pressure (PEEP)|Driving Pressure|Quality of life questionnaire|Vital Capacity (VC)|Forced Vital Capacity (FVC)|Forced Expiratory Volume at first second (FEV1)|Diffusing Capacity for Carbon Monoxide (DLCO)|6 minutes walking test""}"
"1667","poSt Covid-19 Infection centraL Sensitisation 2","SILENT 2","NCT04701892","SILENT 2","Other: Indicators of central sensitisation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04701892","Recruiting","2021-01-19","2023-01-01","{""locations"":""Universitair Ziekenhuis Brussel, Jette, Brussel, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms of Central Sensitisation|Pressure pain thresholds|Temporal summation|Descending nociceptive inhibition|Functionality and disability""}"
"1668","Covid-19 Long-term Revalidation Follow-up","Colonel","NCT04685629","Colonel","Diagnostic Test: 25 post ICU-patients|Other: 25 post non-ICU patients","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04685629","Recruiting","2020-05-07","2022-12-01","{""locations"":""Antwerp University Hospital, Edegem, Antwerpen, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health related Quality of life (general well-being) questionnaire|Revalidation & Reintegration|Depression and\/or anxiety|Post traumatic stress syndrome""}"
"1669","A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic","SWitCh","NCT04408157","v1.1 06.05.2020","Behavioral: Self-management booklet (SWitCh: Stay well during COVID-19)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04408157","Recruiting","2020-05-20","2021-12-22","{""locations"":""Online recruitment through Qualtrics, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""548"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS): Tennant et al., 2007|Self-rated health status: Bombak, 2013|Brief Resilience Scale (BRS): Smith et al., 2008|Intolerance of Uncertainty Scale (IUS-12): Carleton et al., 2007|Positive Affect subscale of the Positive and Negative Affect Scale-X (PANAS-X): Watson & Clark, 1999|UCLA 3 item loneliness scale: Russell, 1996|Multidimensional Scale of Perceived Social Support (MSPSS): Zimet et al., 1988|Subjective Health Complaint Scale (SHC): Eriksen, Ihleb\u00e6k, & Ursin, 1999|Leeds Sleep Evaluation Questionnaire (LSEQ): Parrott & Hindmarch, 1980|Self-reported napping: Stone et al., 2018|Work and Social Adjustment Scale (WSAS): Mundt et al., 2002|International Physical Activity Questionnaire -short form (IPAQ-SF): Craig et al., 2003""}"
"1670","Face Masks to Reduce COVID-19 in Bangladesh","","NCT04630054","2000028482","Device: Face mask|Behavioral: Face mask awareness","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04630054","Recruiting","2020-11-15","2021-02-15","{""locations"":""Innovations for Poverty Action, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention"",""enrollment"":""450000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptomatic SARS-CoV2 infection|SARS-CoV2 infection|Observed prevalence of proper mask wearing|Respiratory infection prevalence""}"
"1671","Brief Informational Intervention for COVID-19 Misinformation Prophylaxis","","NCT04557241","Indiana_CTSI_Agley_2020","Behavioral: Brief informational infographic|Behavioral: Placebo control (non-behavioral infographic)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04557241","Completed","2020-01-14","2021-01-31","{""locations"":""Digital Intervention (Prolific Study Panel), Bloomington, Indiana, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1017"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in trust in science|Believability profiles|Preventive behavioral intentions""}"
"1672","Immunological Profiling of Patients With COVID-19 in Respiratory Distress","ACTICOV-2","NCT04351711","NIMAO/2020-01/PC-01","Other: Immunological profiling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351711","Recruiting","2020-04-09","2022-04-01","{""locations"":""CHU de Nimes, N\u00eemes, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""130"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 27 (na\u00efve\/central memory\/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).|Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).|Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled)|Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 before any respiratory distress against that of 150 volunteers from the general population (data already existing).|Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 with respiratory failure against versus those without respiratory failure|Mortality rate|Comparison of E-selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Granulocyte Macrophage Colony-Stimulating Factor levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of InterCellular Adhesion Molecule levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interferon alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interferon gamma levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-4 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-6 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-8 (C-X-C motif ligand 8) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-10 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-12p70 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-13 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-17A levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Induced Protein -10 (C-X-C motif chemokine 10) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Monocyte Chemoattractant Protein-1 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Macrophage Inflammatory Protein-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Macrophage Inflammatory Protein -1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of P-Selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Tumor necrosis factor alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Identify inflammatory mediators over-produced by the PBMC of patients with COVID-19 before respiratory distress|Compare the inflammatory mediators over-produced by the peripheral blood mononuclear cells of patients with COVID-19 with versus without respiratory failure|Comparison of transcriptome from peripheral blood mononuclear cells from 12 patients with respiratory failure (from intensive care ward) and 10 without (normal hospitalization)""}"
"1673","Oral Health, Microbial Burden and COVID-19","ORACLE","NCT04668911","EDGE 132868|283766","Other: Swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04668911","Recruiting","2020-12-13","2021-12-12","{""locations"":""University College Hospital (UCH), UCL Eastman Dental Institute, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oral microbial signature|Nasal microbial signature""}"
"1674","Timing of Corticosteroids in COVID-19","","NCT04530409","PR0012","Drug: Early-Dexamethasone|Drug: Late-Dexamethasone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04530409","Recruiting","2020-08-26","2021-05-01","{""locations"":""Asalam, Maadi, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of cases that will need hospitalization|Percentage of cases that deteriorate to acute respiratory distress syndrome|Percentage of cases with increased d-dimer|Time to recovery of diarrhea|Percentage reduction in CRP|Percentage reduction in LDH|Percentage reduction in ALT|Percentage reduction in Ferritin|Time to recovery of lymphopenia|Time to recovery of cough|Time to recovery of fever|Time to recovery of myalgia|Time to recovery of anosmia|Time to recovery of dyspnea""}"
"1675","One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia","","NCT04501822","TCRC-COVID","Diagnostic Test: Evaluation of clinical, instrumental and laboratory diagnostics tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04501822","Recruiting","2020-07-19","2021-12-31","{""locations"":""Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""380"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Echocardiographic assessment of cardiac function|\u041c\u0410\u0421\u0421\u0415|Quantitative analysis of parenchymal lung damage|Functional exercises capacity assessment|Evaluation of renal function|Evaluation of inflammation|Evaluation of coagulation abnormality|Evaluation of quality of life in first year after discharge""}"
"1676","the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19","","NCT04521400","Interferon in COVID","Drug: High dose Interferon-beta 1a|Drug: Lopinavir/Ritonavir|Drug: Low dose Interferon-beta 1a","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04521400","Not yet recruiting","2020-08-20","2020-09-11","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events""}"
"1677","The Influence of Covid-19 on the Audio-vestibular System","","NCT04709146","0226-20-EMC","Diagnostic Test: Audio-Vestibular evaluation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04709146","Not yet recruiting","2021-03-01","2022-06-30","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""70"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""sensoneural hearing level - PTA|vestibular function""}"
"1678","Management of Covid-19 Patients During Home Isolation","","NCT04368923","REC/012-2020","Device: Oxygen Therapy|Procedure: Physical Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04368923","Active, not recruiting","2020-03-15","2020-06-23","{""locations"":""M. Sedky, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""21 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Arterial Blood Gases (ABG): Partial Pressure of Oxygen and Carbon Dioxide|Arterial Blood Gases (ABG): Acidity Potential Hydrogen (pH)|Vital Signs (Temprature)|Vital Signs (Respiratory Rate)|Vital Signs (Oxygen Saturation)|Vital Signs (Heart Rate)|Vital Signs (Blood Pressure)""}"
"1679","Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia","","NCT04382053","CDFV890D12201|2020-001870-32","Drug: DFV890|Drug: Standard of Care (SoC)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04382053","Completed","2020-05-27","2020-12-24","{""locations"":""Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Coimbatore, Tamil Nadu, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Harderwijk, Netherlands|Novartis Investigative Site, San Martin de Porres, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""143"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""APACHE II severity of disease score on Day 15 or on the day of discharge (whichever is earlier)|Serum C-reactive protein (CRP) levels|Clinical status over time|Proportion of participants not requiring mechanical ventilation for survival.|Proportion of participants with at least one-point improvement from baseline in clinical status""}"
"1680","Predicting Outcomes for Covid-19 Using Sonography","POCUS","NCT04384055","IRB-55621","Diagnostic Test: Lung Ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384055","Enrolling by invitation","2020-03-21","2021-12-31","{""locations"":""University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Patients Experiencing Death, ICU Admission, Mechanical Ventilation, or Use of High-Flow Nasal Cannula|Number of Patients Requiring Mechanical Ventilation|Number of Patients Requiring Supplemental Oxygen Usage|Duration of Supplemental Oxygen Usage|Length of Stay|Characterization of Ultrasound Findings""}"
"1681","Predict Adverse Events by Covid-19 Nephritis","","NCT04347824","UMG_Co19-Nephritis","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347824","Recruiting","2020-04-27","2021-12-31","{""locations"":""University Medical Center Goettingen, G\u00f6ttingen, Germany"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Time to Disease-Aggravation|Complications|Resources|Blood-test""}"
"1682","Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen","COVIDOLIP","NCT04435223","NGUYEN AOIc 2020","Biological: biological assays in particular on the lipid metabolism","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04435223","Completed","2020-04-07","2020-05-07","{""locations"":""Chu Dijon Bourgogne, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""62"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cholesterol concentration|LDL cholesterol \/ HDL cholesterol\/ Lipoprotein size and composition\/ Non esterified Fatty acid\/ Triglyceridemia\/ CETP and PLTP activity\/ apolipoprotein canceration\/ lipid peroxidation\/ Pro and anti inflammatory profile.""}"
"1683","Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19 Exposed Population","","NCT04568850","LGH007","Diagnostic Test: Plasma IgG levels","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568850","Recruiting","2020-07-01","2021-02-28","{""locations"":""Lahore General Hospital, Lahore, Punjab, Pakistan|Lahore General Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Serum IgG for SARS CoV 2 will be monitored""}"
"1684","Hemostatic Profile in Patients Affected by COVID-19","EMO-COVID","NCT04595110","EMO-COVID-ASSTPG23","Other: Observational study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04595110","Recruiting","2020-03-25","2021-05-10","{""locations"":""Papa Giovanni XXIII Hospital - S.I.M.T., Bergamo, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of mortality among enrolled COVID-19 patients|Incidence of thrombosis among enrolled COVID patients|Evaluation the role of enoxaparin in the management of Covid-19-associated coagulopathy""}"
"1685","Semen Analysis Changes in Covid-19 Positivepatients","","NCT04595240","Semen analysis post covid-19","Diagnostic Test: semen analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04595240","Completed","2020-05-01","2020-10-15","{""locations"":""Mostafa Kamel, Assiut, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""20 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""changes of semen volume in (ML)by covid-19 from normal values.|changes of sperm concentration in (million\/ml) by covid-19 from normal values.|changes of sperm morphology in (percentage of normal forms) by covid-19 from normal values.|changes of sperm motility in percentage of (A+B) by covid-19 from normal values.|changes of semen volume in (ML) by covid-19 from from the first sample|changes of sperm concentration in (million \/ML) by covid-19 from from the first sample|changes of sperm morphology in percentage of normal form by covid-19 from from the first sample|changes of sperm motility in percentage of (A+B) by covid-19 from from the first sample""}"
"1686","AiM COVID for Covid 19 Tracking and Prediction","","NCT04354753","AU12","Other: No Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354753","Completed","2020-03-28","2020-04-17","{""locations"":""Aarogyam (UK), Leicester, United Kingdom"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical symptoms|Contact History|Travel History|Fever|Headache|Soar Throat|Runny nose|Cough|Shortness of breath|Nausea|Vomiting|Muscle pain|Joint pain|Diarrhoea|Other|Hospitalisation history|Co-morbid conditions""}"
"1687","Prospective Study of Persistent Dyspnea in Recovered COVID-19 Patients","DISCOVID19","NCT04689490","CASVE PI-20-1894","Diagnostic Test: Cardiopulmonary exercise test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04689490","Recruiting","2020-08-01","2020-12-31","{""locations"":""Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Aerobic capacity|Total Lung Capacity (TLC)|Force Expiratory Volume in 1 second (FEV1)|Difussing Lung Capacity of CO (DLCO)|Forced Vital Capacity (FVC)|Left Ventricular (LV) Function|Right Ventricular (RV) Function|Short Form 36 Health Survey (SF-36)|Kansas City Cardiomyopathy Questionnaire (KCCQ)|6 Minute Walk Test|N-terminal pro hormone B-type natriuretic peptide (NT-proBNP)|Troponin-T|Ferritin|D-Dimer|interleukine-6|C reactive protein (CRP)""}"
"1688","Immune Cell Subgroups in Covid 19 Patients","","NCT04531319","Covid Cell","Diagnostic Test: Flow cytometric analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04531319","Completed","2020-08-15","2020-10-01","{""locations"":""Istanbul Training and Reseach Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""T cell subtype ratios|Monocyte ratio""}"
"1689","The Nanowear Wearable Covid-19 Observational and Analysis Trend","NanoCOAT","NCT04717024","NWCT20-SS-002","Device: Observational Study - no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04717024","Recruiting","2020-09-15","2021-12-31","{""locations"":""Hackensack University Medical Center, Hackensack, New Jersey, United States|Maimonides Medical Center, Brooklyn, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hosptialized patient data|Trends in COVID 19 exacerbation""}"
"1690","Vienna Versus SARS-CoV-2 Virus Study","VIVI","NCT04407429","EK 1387/2020","Diagnostic Test: Laboratory Analyses","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407429","Recruiting","2020-05-27","2021-06-27","{""locations"":""Medical University of Vienna, Vienna, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""12000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence of antibody status in healthcare workers and in patients admitted for non-COVID-19 related symptoms over time|Incidence rate of sero-conversion|Identification of risk markers\/factors for SARS-CoV-2 infection""}"
"1691","Reduction of COVID 19 Transmission to Health Care Professionals","","NCT04462627","CHUB-BDS-COVID19","Diagnostic Test: Blood group determination|Diagnostic Test: Antibody titration|Dietary Supplement: Probiotic","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04462627","Recruiting","2020-04-14","2021-12-01","{""locations"":""CHU Brugmann, Brussels, Belgium"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anti-A antibody concentration|Anti-B antibody concentration|Blood group""}"
"1692","Effect of Covid-19 on Outcomes of Pregnancy","","NCT04629001","12789","Diagnostic Test: Covid-19 PCR , IGM","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04629001","Active, not recruiting","2020-09-01","2021-12-01","{""locations"":""Medicine, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Fetal morbidity""}"
"1693","Detection of Covid-19 by Volatile Organic Compounds in Exhaled Breath","Covid-VOC","NCT04714333","H20-01234","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04714333","Enrolling by invitation","2020-05-06","2021-05-05","{""locations"":""BC Cancer Research Centre, Vancouver, British Columbia, Canada|British Columbia Research Centre, Vancouver, British Columbia, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Collect breath samples from Covid-19 positive patients at time of diagnosis and post recovery""}"
"1694","New Treatment for COVID-19 Using Ethanol Vapor Inhalation .","","NCT04554433","20.08.79","Drug: Ethanol with Asprin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04554433","Not yet recruiting","2020-12-01","2022-06-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""20 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Disinfection of COVID-19 in human respiratory tract .|Improvement of general condition of mechanically ventilated patients confirmed COVID-19 positive ..""}"
"1695","Implementation of Rehabilitation Program for Post COVID-19","","NCT04694768","AssiutU19","Behavioral: Rehabilitation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694768","Recruiting","2020-07-01","2021-01-31","{""locations"":""Aliae AR Mohamed-Hussein, Assiut, Egypt|Aliae AR Mohamed-Hussein, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Optimizing health and functioning outcomes|improve recovery and reduce disability""}"
"1696","Gastrointestinal Symptoms in COVID-19","","NCT04691895","GI-COVID19_01","Other: SARS-CoV2 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04691895","Active, not recruiting","2020-05-01","2021-12-31","{""locations"":""IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease as assessed by GSRS questionnaire|Prognosis of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease|Long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) irritable bowel syndrome (IBS).|long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) dyspepsia.|Identification of risk factors for post-infection gastrointestinal symptom development.""}"
"1697","Inhaled Ciclesonide for Outpatients With COVID19","CONTAIN","NCT04435795","2021-6696","Drug: Normal Saline intranasal","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04435795","Recruiting","2020-09-14","2021-03-25","{""locations"":""McGill University Health Center, Montreal, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""454"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants with no symptoms of cough, fever or dyspnea|Improvement in dyspnea|Hospitalization for SARS-CoV-2|Oxygen Use|Mortality|Clinical status|Anxiety|Sleep Disturbance|Visual Analog scale""}"
"1698","Impact of COVID-19 on Pediatric Dental Practice During First and Second Wave.","","NCT04592510","y66cyyg6","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04592510","Not yet recruiting","2021-04-01","2022-01-01","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""345"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Attitude of pediatric dentists toward treating patients in time of COVID-19.""}"
"1699","COVID-19 Prophylaxis South Africa (COVER HCW)","COVER","NCT04561063","EZ-SS-025","Drug: Nitazoxanide|Drug: Sofosbuvir/Daclatasvir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04561063","Recruiting","2020-12-08","2021-07-01","{""locations"":""Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa|Sunnyside Office Park, Johannesburg, Gauteng, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1950"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of SARS-CoV-2 infections|Duration of symptoms|Maximum score on WHO Ordinal Scale|Time to onset of SARS-CoV-2 infection|Number of symptomatic SARS-CoV-2 infections|Number of asymptomatic SARS-CoV-2 infections|Peak score on modified Flu PRO""}"
"1700","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","eChoVid","NCT04335019","APHP200390|2020-A00768-31","Other: Pulmonary ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04335019","Not yet recruiting","2020-04-01","2020-05-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity|Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.|Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient|Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival""}"
"1701","Ivermectin In Treatment of COVID 19 Patients","","NCT04425707","14-2020/3","Drug: Ivermectin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04425707","Recruiting","2020-06-09","2020-09-01","{""locations"":""isolation and referal hospitals for COVID 19 patients, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""to evaluate the role of Ivermectin as a line of treatment for COVID 19|To asses the rate of viral clearance in comparison to other treatment protocols.""}"
"1702","Treatment of Covid-19 Using Infrared and/or Vitamin C","","NCT04584437","GAADMRI","Other: Infrared Energy and Dietary Supplement","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04584437","Withdrawn","2021-01-31","2021-07-10","{""locations"":""GAAD Medical Research Institute Inc. O\/A The Centre for Incurable Diseases, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Treatment and Prevention of COVID-19 Pandemic.""}"
"1703","Rapid Screening for Olfactory Disorders in Covid-19 Infection","OLFASCAN","NCT04696601","20-PP-27","Diagnostic Test: Olfactory test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04696601","Not yet recruiting","2021-01-10","2022-02-10","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Olfactory test""}"
"1704","COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study","COV-HI","NCT04385069","132388","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385069","Recruiting","2020-04-16","2020-07-05","{""locations"":""The Leeds Teaching Hospitals NHS Trust, St James University Hospital, Leeds, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Sheffield, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To collect retrospective demographic information on 500 people admitted to selected hospital sites across the UK with a COVID-19 diagnosis confirmed through positive laboratory PCR swab.|To record the results of each patient's measured medical observations, clinical investigations and outcomes during the course of their admission.|To conduct retrospective analysis of data collected to map each patient's clinical journey during their admission""}"
"1705","Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients","","NCT04397614","COVID-19 Mobile Health","Other: mHealth Assessments","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04397614","Recruiting","2020-07-22","2021-12-01","{""locations"":""Stephenson Cancer Center, Oklahoma City, Oklahoma, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of completion of smartphone based surveys|Time to resolution of symptoms|Hospitalization Status|Manifestations of severe disease|SARS-CoV-2 Related Hospital Admission|SARS-CoV-2 related ICU Admission|SARS-CoV-2 need for invasive mechanical ventilation|SARS-CoV-2 related mortality|Percent satisfied with monitoring and use of mHealth application""}"
"1706","Growth Hormone in Obese Cases With Covid-19","","NCT04532554","PR0015","Drug: Growth Hormone|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04532554","Withdrawn","2020-10-26","2020-12-20","{""locations"":""Asalam, Maadi, Cairo, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need for hospitalization|Time to recovery|Percentage of reduction in CRP|Percentage of reduction in LDH|Percentage of reduction in Ferritin|Time to recovery from leucopenia""}"
"1707","Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19","","NCT04548895","HSA-001","Device: Observational measurement of biometric data. No change to health care provided.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04548895","Recruiting","2020-12-30","2021-10-26","{""locations"":""Avalon Health & Rehabilitation Center, Pasco, Washington, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of quality signals obtained out of all monitoring time for each device|Predictive characteristics of the algorithm for respiratory tract infection""}"
"1708","Covid-19 Risk Factors and Pattern Between Healthcare Workers","","NCT04646551","Covid-19 patterrn","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04646551","Not yet recruiting","2020-12-01","2022-01-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""165"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of the Pattern and Risk Factors of Covid-19 between infected Healthcare Workers""}"
"1709","Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection","MARNEVO-Covid","NCT04361344","CHPAU2020/02","Biological: blood samples","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04361344","Terminated","2020-05-19","2020-10-25","{""locations"":""CH de Pau, Pau, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""2"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of neurodegeneration markers level""}"
"1710","Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease,COVID-19, in Hospitalized Patients","MicrobioCOVID","NCT04669938","APHP201083","Other: oropharyngeal and intestinal microbiota|Other: host genotype|Other: host immune factors|Other: viral sequence","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04669938","Recruiting","2020-12-04","2022-03-31","{""locations"":""LESCURE, Paris, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""identify risk factors associated with severe forms of COVID-19|link between the composition of the gut microbiota and admission to intensive care|predictive performance of semi-quantitative culture and rapid metagenomic evaluation""}"
"1711","COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities","CRC-COVID","NCT04363749","APHP200476","Other: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363749","Recruiting","2020-04-27","2021-11-27","{""locations"":""D\u00e9partement R3S, h\u00f4pital de la piti\u00e9-salp\u00eatri\u00e8re, Paris, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intensity of the emotional response to hypoxic exposure (14.3 et 12.7% FIO2)|Perception of a hypoxic stimulus induced dyspnea (14.3 et 12.7% FIO2)|Perception of a hypercapnic stimulus induced dyspnea (7% CO2)|Perception of a inspiratory mechanical constraint induced dyspnea|brain MRI""}"
"1712","Viral Shedding, Symptoms and Exposure of SARS-CoV-2 in Non-hospitalized Children With COVID-19","","NCT04666207","H-20028631-1","Diagnostic Test: PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666207","Recruiting","2020-05-25","2021-06-30","{""locations"":""Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""Salvia samples have equal or higher sensibility than nasal swaps in children for detection of SARS-CoV-2|Parental home testing of saliva and feces is feasible in children""}"
"1713","Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19","","NCT04545008","Pro00100394","Drug: Famotidine|Drug: N-Acetyl cysteine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04545008","Recruiting","2020-10-20","2021-10-31","{""locations"":""Prisma Health Baptist Easley Hospital, Easley, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Prisma Health Greer Memorial Hospital, Greer, South Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Rate of Hospitalization|Time to Symptom Resolution""}"
"1714","Characteristics of Critically Ill COVID 19 Patients","","NCT04465058","yte","Other: COVID19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04465058","Recruiting","2020-07-08","2020-08-10","{""locations"":""Assiut university, Assiut, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""clinical characteristics""}"
"1715","Covid-19 Breath Test","","NCT04459962","2020ATL01","Diagnostic Test: Breath Test & Cheek Swab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04459962","Completed","2020-06-29","2021-01-07","{""locations"":""Ashford and St Peter's Hospitals NHS Foundation Trust, Chertsey, Surrey, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""330"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""To investigate\/ examine the effectiveness of Nanotechnology Biomarker Tagging (NBT) in detecting COVID-19 infection using breath samples of patients with COVID-19 symptoms|-To profile the unique pattern of Volatile Organic Compounds (VOCs) found in the expired breath of COVID-19 patients using the NBT system (VOC analysis and ML).|To differentiate this unique profile from the patients that are found to be negative for COVID-19""}"
"1716","Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19","MELCOVID","NCT04568863","PHM-2020-001","Drug: Melatonin intravenous|Drug: Placebo intravenous","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04568863","Recruiting","2020-06-20","2020-11-30","{""locations"":""Hospital Universitario La Paz, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality""}"
"1717","Study in COvid-19 Patients With iveRmectin (CORVETTE-01)","","NCT04703205","CORVETTE-01","Drug: Ivermectin 3 MG|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04703205","Recruiting","2020-09-16","2021-09-30","{""locations"":""Kitasato University, Sagamihara, Kanagawa, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) Period until the COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) becomes negative""}"
"1718","COVID-19 Breastfeeding Guideline for African-Americans","COVID-BF","NCT04476940","330875","Behavioral: COVID-19 Breastfeeding Support","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04476940","Not yet recruiting","2020-09-01","2022-06-01","{""locations"":""Meharry Medical College, Nashville, Tennessee, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""COVID-19 breastfeeding guidance adherence at birth.|COVID-19 breastfeeding guidance adherence at 1-month postpartum.|COVID-19 breastfeeding guidance adherence at 3-months postpartum.|Exclusive breastfeeding at birth.|Exclusive breastfeeding at 1-month.|Exclusive breastfeeding at 3-months.|COVID_Status|COVID-19 Immunoglobulin G|COVID-19 Immunoglobulin M""}"
"1719","Views on COVID-19 and Vaccination","","NCT04706403","H00022244","Behavioral: Healthcare Providers' Communication about the COVID-19 Vaccine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04706403","Active, not recruiting","2021-01-04","2021-12-26","{""locations"":""Meyers Primary Care Institute, Worcester, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intent to be vaccinated against COVID-19.|Predictors of intent to be vaccinated against COVID-19.""}"
"1720","Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World","RINCOVID","NCT04604249","RINCOVID","Diagnostic Test: SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04604249","Active, not recruiting","2020-10-26","2021-12-31","{""locations"":""La Rinconada, Puno, Peru"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""1. Prevalence of seroconversion for SARS-CoV-2.|2. Occupational and environmental exposures associated with SARS-CoV-2 seroconversion.""}"
"1721","Gastrointestinal Manifestations Among Patients With COVID19","","NCT04544150","COVID19 and GUT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04544150","Completed","2020-06-01","2020-09-01","{""locations"":""Ahmed, Al Miny\u0101, Alminya, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""220"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""frequency of GIT symptoms among patients with COVID-19 infection""}"
"1722","Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19","","NCT04470297","MELCOV2020","Drug: Ramelteon 8mg","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04470297","Not yet recruiting","2020-09-01","2021-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to resolution of symptoms [National Early Warning Score 2 (NEWS2) of 0]|Clinical worsening to critical COVID-19 illness|Duration of supplemental oxygen therapy|Duration of mechanical ventilation (if applicable)|Duration of hospitalisation|Proportion of participants with virologic clearance in nasopharyngeal swab RT-PCR|C-reactive protein (CRP) level's reduction|Incidence of New Onset Lymphopenia|Direct bilirubin level's reduction|Side Effects""}"
"1723","High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients","","NCT04710329","CVIT-3334","Drug: Ascorbic acid","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04710329","Completed","2021-01-16","2021-02-10","{""locations"":""Sisli etfal training and resource hospital, Sisli, \u0130stanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""78"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""short term mortality|Length of Intensive Care Unit Stay|vasopressor requirement|invasive mechanical ventilation requirement|PaO2\/FiO2 ratio|C-reactive protein|procalcitonin|Lymphocyte count|ferritin|SOFA""}"
"1724","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection","","NCT04251767","WMT-YJ-202001","Other: washed microbiota transplantation|Other: placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04251767","Withdrawn","2020-02-05","2020-04-30","{""locations"":""Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""14 Years to 70 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of participants with improvement from severe type to common type""}"
"1725","A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers","COVID-Milit","NCT04377646","UR17DN02-001|TN2020-NAT-INS-38","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine (placebo)|Drug: Zinc|Drug: Zinc (Placebo)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04377646","Not yet recruiting","2020-05-04","2020-07-31","{""locations"":""Military Hospital of Tunis, Tunis, Tunisia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""660"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS CoV2 infection|COVID-19 symptoms description|Adverse Events""}"
"1726","CoVid-19 - Infection and Antibody Formation in the Viennese Population","","NCT04346264","LEAD CoVid-19","Diagnostic Test: NO intervention planned due to the observational study design only a diagnostic testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346264","Enrolling by invitation","2020-04-27","2020-09-30","{""locations"":""The LEAD Study Center, Vienna, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5500"",""age"":""6 Years to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Prevalence of SARS-CoV-2 antibody titres|Prevalence of SARS-CoV-2 antibody titres after 3 Months""}"
"1727","Comorbidities And Complications Associated With Covid-19 Infection","","NCT04563442","covid 19","Other: complication","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04563442","Not yet recruiting","2020-10-15","2023-02-25","{""locations"":"""",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identifying different co-morbidities and complications of covid-19 infection.""}"
"1728","A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2","","NCT04721535","DW_DWJ1248303","Drug: DWJ1248|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04721535","Not yet recruiting","2021-01-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1012"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of subjects with COVID-19|Percentage of subjects with hospitalization|Percentage of subjects who experience intensive care unit (ICU)""}"
"1729","Exploratory Study: COVID-19 and Pregnancy","","NCT04647994","30270820.3.0000.0068","Diagnostic Test: SARS-CoV-2 serology","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04647994","Recruiting","2020-09-21","2022-06-13","{""locations"":""Rossana P Fracisco, S\u00e3o Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""17 Years to 50 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Diagnostic test: SARS-CoV-2 serology|Laboratorial analysis of maternal and umbilical cord blood|Laboratorial analysis of Amniotic Fluid|Placenta biopsy|Laboratorial analysis of colostrum|Ovarian remains biopsy|Blood count analysis|Laboratorial analysis of thyroid hormones|PCR analysis|Laboratorial analysis of Interleukins|Fetal morphology ultrasound|Placental insufficiency ultrasound|Type of delivery|Gestational age at delivery|Apgar score|Newborn weight|Fatigue Scale|Prone Position|Use of mechanical ventilation|Pulmonary Ultrasound|Chest Tomography|Anxious and depressive symptoms - HAD questionnaire|Heart rate variability electrocardiogram|Laboratorial analysis of glycated hemoglobin""}"
"1730","Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19","","NCT04403035","1599159","Diagnostic Test: ID NOW vs. Accula","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403035","Recruiting","2020-05-10","2021-05-09","{""locations"":""Ascension St. John Hospital, Detroit, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Test characteristics""}"
"1731","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","","NCT04330144","3-2020-0036","Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04330144","Not yet recruiting","2020-04-01","2022-03-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""2486"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The rate of COVID-19""}"
"1732","Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","CAN-COVID","NCT04362813","CACZ885D2310|2020-001370-30","Drug: Canakinumab|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04362813","Completed","2020-04-30","2020-12-22","{""locations"":""Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""451"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of patients with clinical response|COVID-19-related death rate during the 4-week period after study treatment|Ratio to baseline in the C-reactive protein (CRP)|Ratio to baseline in the serum ferritin|Ratio to baseline in the D-dimer|Number of participants with Adverse Event (AE), serious adverse events (SAE), clinically significant changes in laboratory measures, and vital signs""}"
"1733","Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects","","NCT04334460","B-2660-204","Drug: BLD-2660","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04334460","Active, not recruiting","2020-05-04","2021-11-01","{""locations"":""Blade Research Site, Irvine, California, United States|Blade Research Site, Los Angeles, California, United States|Blade Reseach Site, San Jose, California, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Brandon, Florida, United States|Blade Research Site, Fort Pierce, Florida, United States|Blade Research Site, Panama City, Florida, United States|Blade Research Site, Tampa, Florida, United States|Blade Research Site, Idaho Falls, Idaho, United States|Blade Research Site, Peoria, Illinois, United States|Blade Research Site, Ames, Iowa, United States|Blade Research Site, Lexington, Kentucky, United States|Blade Research Site, Louisville, Kentucky, United States|Blade Research Site, Baltimore, Maryland, United States|Blade Research Site, Detroit, Michigan, United States|Blade Research Site, Farmington Hills, Michigan, United States|Blade Research Site, Omaha, Nebraska, United States|Blade Research Site, Ridgewood, New Jersey, United States|Blade Research Site, Charleston, North Carolina, United States|Blade Research Site, Durham, North Carolina, United States|Blade Research Site, Fayetteville, North Carolina, United States|Blade Research Site, Philadelphia, Pennsylvania, United States|Blade Research Site, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Blade Research Site, Dallas, Texas, United States|Blade Research Site, Spokane, Washington, United States|Blade Research Site, Campinas, Sao Paulo, Brazil|Blade Research Site, Bahia, Brazil|Blade Research Site, Belo Horizonte, Brazil|Blade Research Site, Botucatu, Brazil|Blade Research Site, Porto Velho, Brazil|Blade Research Site, Ribeir\u00e3o Preto, Brazil|Blade Research Site, S\u00e3o Jos\u00e9 Do Rio Preto, Brazil|Blade Research Site, Vit\u00f3ria, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs)""}"
"1734","Impact of COVID-19 on Psoriasis Practice","","NCT04581044","KAPU2020 10","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581044","Completed","2020-09-17","2020-10-23","{""locations"":""Department of Dermatology, Cairo University, Cairo, Egypt"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""197"",""age"":""25 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Questionnaire to assess 1) Prescription pattern for Psoriasis patients during COVID-19 2) Management pattern for Psoriasis patients during COVID-19|Questionnaire to assess 1) Impact of COVID-19 on the course of psoriasis in patients 2) Impact of COVID-19 on the psoriasis patients behaviour""}"
"1735","BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)","","NCT04534803","IRB20-1243","Drug: BCG Vaccine|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04534803","Not yet recruiting","2021-09-01","2022-11-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""2100"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""To assess the efficacy of BCG vaccination compared to placebo in reducing severe Covid-19 disease among elderly residents of skilled nursing facilities.|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases)|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases), continued|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of episodes)|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of days)""}"
"1736","Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard","CIRCA-19","NCT04400032","20200243-01H","Biological: Mesenchymal Stromal Cells","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04400032","Recruiting","2020-05-15","2021-06-01","{""locations"":""The Ottawa Hospital, Ottawa, Ontario, Canada"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""9"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28""}"
"1737","Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients","COVA","NCT04472728","BIO101-CL05","Drug: BIO101|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04472728","Recruiting","2020-06-16","2021-09-01","{""locations"":""Abrazo Health, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|Barnum Medical Research, Inc. 1029 Keyser Ave Suite H, Natchitoches, Louisiana, United States|Beaumont Health, Royal Oak, Michigan, United States|United Health Services Hospitals, Johnson City, New York, United States|WellSpan Health, York, Pennsylvania, United States|CHU Saint-Pierre, Brussels, Belgium|CHU Saint-Pierre, Brussel, Belgium|AZ-Sint Maarten, Mechelen, Belgium|CHU CLU Namur (Saint-Elisabeth) Place Louise Godin, Namur, Belgium|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Santa Casa de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Municipal de Barueri Dr. Francisco Moran, Barueri, S\u00e3o Paulo, Brazil|Hospital e Maternidade Celso Pierro - PUCCAMP, Campinas, S\u00e3o Paulo, Brazil|Hospital de Base Da Faculdade de Medicina de S\u00e3o Jos\u00e9 Do Rio Preto, S\u00e3o Jos\u00e9 Do Rio Preto, S\u00e3o Paulo, Brazil|Avenida Dr. En\u00e9as de Carvalho Aguiar, 44 - Centro de Pesquisa Cl\u00ednica Prof. Dr. F\u00falvio Pileggi - Bloco 1 - 1\u00ba Andar, S\u00e3o Paulo, Brazil|Unit\u00e9 ambulatoire Service de Pneumologie, M\u00e9decine Intensive et R\u00e9animation (SPMIR) 47-83 Boulevard de l'H\u00f4pital, Paris, Paris Cedex 13, France|Centre Hospitalier Argenteuil, Argenteuil, France|Centre Hospitalier Universitaire Bordeaux, Bordeaux, France|Centre Hospitalier Rene Dubos, Cergy-Pontoise, France|Centre Hospitalier D\u00e9partemental de Vend\u00e9e, La Roche-sur-Yon, France|H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, 47 bd de l'H\u00f4pital, 75013 Paris, Paris, France|FDI Clinical Research - San Juan City Hospital, San Juan, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""310"",""age"":""45 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""End-of-Part 1 interim analysis: Proportion of subjects with all cause mortality or with respiratory failure.|For part-2 sample size interim analysis: Proportion of subjects with all cause mortality or with respiratory failure.|For the final analysis: Proportion of subjects with all cause mortality or respiratory failure.|Interim analysis; indication of activity of BIO101: Oxygen saturation by pulse oximetry (SpO2) SpO2 \/ Fraction of inspired oxygen (FiO2) ratio|Interim analysis; indication of activity of BIO101: Inflammatory markers|Interim analysis; indication of activity of BIO101: Renin Angiotensin System biomarkers|Key secondary endpoint for final analysis: Proportion of participants with positive events|Additional secondary endpoints for final analysis: Respiratory function|Additional secondary endpoints for final analysis:proportion of patients who experienced negative events|Additional secondary endpoint for final analysis: The National Early Warning Score 2 (NewS2):|Additional secondary endpoint for final analysis: Population Pharmacokinetics study (pop-PK)|Additional secondary endpoint : Population Pharmacokinetics study (pop-PK)|Additional secondary endpoint: Population Pharmacokinetics study (pop-PK)|Additional secondary endpoint: Proportion of participants with events of all-cause mortality|Additional secondary endpoint: time to event: negative events|Additional secondary endpoint: time to event: positive events""}"
"1738","Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms","","NCT04356586","Jessa300","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356586","Completed","2020-05-04","2020-08-21","{""locations"":""Sciensano, Brussels, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""287"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of serological positive healthcare workers|Percentage of HCW with positive Saliva-sabs""}"
"1739","Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19","REMED","NCT04663555","CZECRIN No. 2020/47|2020-005887-70","Drug: Dexamethasone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04663555","Recruiting","2021-02-02","2023-03-31","{""locations"":""University Hospital Brno, Brno, Czechia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of ventilator-free days (VFDs) at 28 days after randomization|Mortality from any cause at 60 days after randomization|WHO clinical progression scale at day 14|Dynamics of inflammatory marker|Adverse events related to corticosteroids|Functional independence""}"
"1740","Covid-19 Infection and New Onset Type 1 Diabetes","","NCT04623697","S-20200119","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04623697","Recruiting","2020-11-01","2023-10-30","{""locations"":""Hospital of South West Jutland, Esbjerg, Denmark"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stimulated insulin secretion|HbA1c|Fasting blood glucose""}"
"1741","Diagnostic Validation of Rapid Detection of the COVID-19 Causative Virus (SARS-CoV-2) in Saliva Samples by Mass Spectrometry","SALICOV","NCT04712175","LOCAL-COVID/2020/AS-01","Diagnostic Test: Nasopharyngeal sampling|Diagnostic Test: Saliva sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04712175","Not yet recruiting","2021-01-01","2021-07-01","{""locations"":""CHU de N\u00eemes, N\u00eemes, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Detection of SARS-CoV-2 on nasopharyngeal samples (gold standard)|Detection of SARS-CoV-2 on a saliva samples by mass spectrometry|Detection of SARS-CoV-2 on saliva samples via RT-PCR""}"
"1742","Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19","ILIAD","NCT04354259","JF-4-2020","Drug: Peginterferon Lambda-1A|Other: placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04354259","Recruiting","2020-05-13","2020-11-30","{""locations"":""Toronto General Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint)|Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint)|Cohort B (Hospitalized) - Time to viral negativity (Primary Efficacy Endpoint)|Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint)|Cohort A (Ambulatory) - Symptom Resolution (Clinical Outcome #1)|Cohort A (Ambulatory) - Symptom severity scores (Clinical Outcome #2)|Cohort A (Ambulatory) - Hospitalization (Clinical Outcome #3)|Cohort A (Ambulatory) - Adverse and serious adverse events (Clinical Outcome #4)|Cohort A (Ambulatory) - Swab negative at day 3 (Virologic\/Immunological Outcome #1)|Cohort A (Ambulatory) - Time RNA negativity (Virologic\/Immunological Outcome #2)|Cohort A (Ambulatory) - Proportion viremic (Virologic\/Immunological Outcome #3)|Cohort A (Ambulatory) - Proportion with antibodies (Virologic\/Immunological Outcome #4)|Cohort A (Ambulatory) - Correlation with interferon lambda 4 genotype (Virologic\/Immunological Outcome #5)|Cohort A (Ambulatory) - Symptoms in household contacts (Transmission Outcome #1)|Cohort A (Ambulatory) - COVID-19 in household contacts (Transmission Outcome #2)|Cohort B (Hospitalized) - ICU admission (Clinical Outcome #1)|Cohort B (Hospitalized) - Need for intubation (Clinical Outcome #2)|Cohort B (Hospitalized) - Length of hospital stay (Clinical Outcome #3)|Cohort B (Hospitalized) - Change in respiratory symptom score (Clinical Outcome #4)|Cohort B (Hospitalized) - Readmission to hospital (Clinical Outcome #5)|Cohort B (Hospitalized) - All-cause mortality (Clinical Outcome #6)|Cohort B (Hospitalized) - COVID-19-related mortality (Clinical Outcome #7)|Cohort B (Hospitalized) - Adverse (AEs) and Serious Adverse Events (SAEs) (Clinical Outcome #8)|Cohort B (Hospitalized) - Dose reduction or dose omission (Clinical Outcome #9)|Cohort B (Hospitalized) - Proportion negative swab. (Virologic\/Immunological Outcome #1)|Cohort B (Hospitalized) - Proportion negative by day 14 (Virologic\/Immunological Outcome) #2)|Cohort B (Hospitalized) - Time to negativity by rectal swab (Virologic\/Immunological Outcome #3)|Cohort B (Hospitalized) - Correlation with interferon lambda 4 (IFNL4) genotype (Virologic\/Immunological Outcome #4)|Cohort B (Hospitalized) - Proportion with Antibody (Virologic\/Immunological Outcome #6)|Cohort B (Hospitalized) - Proportion with viremia (Virologic\/Immunological Outcome #7)""}"
"1743","Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19","","NCT04542980","CVDTRS001","Diagnostic Test: SARS-CoV2 Autoantibody detection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04542980","Not yet recruiting","2020-09-15","2020-12-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Qualitative assessment of IgM and\/or IgG by indirect ELISA assay.""}"
"1744","IFN Beta-1b and Ribavirin for Covid-19","","NCT04494399","UW 20-513","Drug: Interferon beta-1b|Drug: Ribavirin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04494399","Recruiting","2020-07-29","2022-08-01","{""locations"":""The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""96"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical symptoms alleviation|Hospitalisation|Time to negative viral load|Inflammatory changes|Mortality|Adverse events and serious adverse events""}"
"1745","Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID)","ACROVID","NCT04387955","ACROVID","Diagnostic Test: Biological Sample Collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04387955","Recruiting","2020-04-30","2021-06-01","{""locations"":""CHU de Poitiers, Poitiers, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""30"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Study of the link between SARS-CoV-2 infection and chilblains observed during COVID-19 epidemics.|Study of the SARS-CoV-2 virological profile of patients presenting chilblains during a COVID-19 epidemic.|Comparison of the clinical and biological profiles of patients presenting chilblains according to their SARS-CoV-2 virological status (in case of over-representation of SARS-CoV-2 positive patients, the results will be given without comparison).|Comparison of the capillaroscopic profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).|Comparison of the TCPO2 profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).|Comparison of the toe or Finger Pressure Index profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).|Comparison of histo-pathological profiles of chilblains according to their SARS-CoV-2 virological status of patients with the disease (in case of overrepresentation of SARS-CoV-2 positive patients, results will be given without comparison).|Comparison of the gene expression profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.|Comparison of the immunostaining profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.|Comparison of the ELISA assays profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.""}"
"1746","Inspiratory Effort in COVID-19","PERSIA","NCT04666246","UModenaReggio17","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666246","Recruiting","2020-03-01","2022-02-01","{""locations"":""University Hospital of Modena, Modena, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Inspiratory effort quantification|Non invasive respiratory support failure""}"
"1747","Early CPAP in COVID-19 Confirmed or Suspected Patients","PAP-COVID","NCT04390191","GCO 20-0900","Device: Continuous Positive Airway Pressure","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04390191","Recruiting","2020-05-07","2022-04-01","{""locations"":""Icahn School of Medicine at Mount Sinai, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy Endpoint composite score|Time to ICU admission|Time to Intubation and mechanical ventilation|14 day and 28 day mortality|Conversion rate of COVID household members in CPAP vs control|Clinical COPD Questionnaire (CCQ)|Percentage of patients electing to continue CPAP for greater than 72 hours|Degree of improvement in oxygen saturation|Time to hospital admission or ED""}"
"1748","Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19)","","NCT04556318","HC-N-H-2004","Device: Ion Mobility Spectrometry (IMS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04556318","Recruiting","2020-09-23","2021-03-01","{""locations"":""Technical University of Munich, Klinikum rechts der Isar, Munich, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""392"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 related volatile organic compounds (VOC)|To compare the SARS-CoV-2 specific VOC with the clinical symptoms of COVID-19 and diagnostic findings""}"
"1749","CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19","CONVINCE","NCT04516941","CONVINCE Version 1.0 12052020","Drug: Edoxaban Tablets|Drug: Colchicine Tablets","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04516941","Not yet recruiting","2020-10-01","2021-12-31","{""locations"":""Bern University Hospital, Bern, Switzerland|Ospedale regionale Lugano, Lugano, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""420"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Edoxaban vs. no active treatment|Colchicine vs no active treatment|Number of patients with asymptomatic proximal deep-vein thrombosis|Number of patients with symptomatic proximal or distal deep-vein thrombosis|Number of patient with symptomatic pulmonary embolism or thrombosis|Number of patients with myocardial infarction|Number of patients with ischemic stroke|Number of patients with non-CNS systemic embolism|Number of deaths|Ventilation need""}"
"1750","Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV","REPERCOV","NCT04561154","CHM-2020/S10/04","Other: questionnaire","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04561154","Recruiting","2020-06-11","2022-06-11","{""locations"":""Centre Hospitalier du Mans, Le Mans, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""134"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identify functionnal and psychosocial complaints|description of functionnal and psychosocial complaints|Identify the factors favoring the persistence of complaints|Describe functional, neuropsychological and social complaints at a distance|Describe the needs for medical and surgical consultations after discharge from hospital|Describe the needs for neuropsychological support, dietetics, social assistance after discharge from hospital.|Describe the factors of inequalities in access to care""}"
"1751","ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis","PAMOCOS","NCT04522310","2020-05","Other: MR-Pro-ADM","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04522310","Recruiting","2020-05-20","2021-06-28","{""locations"":""Hospital of Arras, Arras, France|Hospital of Boulogne\/mer, Boulogne-sur-Mer, France|Hospital of DOUAI, Douai, France|Hospital of Dunkerque, Dunkerque, France|Hospital Dr Schaffner, Lens, France|Hospital of Roubaix, Roubaix, France|Hospital of Tourcoing, Tourcoing, France|Hospitalier of Valenciennes, Valenciennes, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""183"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.|mortality at day 28 and day 90.|Association between MR-ProADM and mortality at day 28.|Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.""}"
"1752","Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19","PANCOLIN","NCT04543006","EssaiClinique_PANCOLIN","Diagnostic Test: serology","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04543006","Not yet recruiting","2020-09-08","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""170"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""anti-SARS-CoV-2 neutralizing antibody titers""}"
"1753","Endovascular Thrombectomy in COVID-19 Infected Patients","ET-COVID-19","NCT04406090","RECHMPL20_0322","Other: Mechanical Trombectomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406090","Completed","2020-04-01","2020-06-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intrahospital mortality|short-term morbidity|Angiographic success""}"
"1754","Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)","","NCT04553705","TQ/Omega-3 on COVID-19|DOI: 10.31219/osf.io/u56fc","Drug: Omega 3/Nigella Sativa Oil|Drug: Omega 3/Nigella Sativa Oil/Indian Costus|Drug: Omega 3/Nigella Sativa Oil/Quinine pills|Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule|Drug: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|Drug: Active Comparator","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04553705","Recruiting","2020-09-20","2020-12-04","{""locations"":""Maternity and Children hospital, Mecca, Makkah, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""25 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Clinical improvement|Recovery rate from positive to negative swaps|Fever to normal temperature in days|Remission of lung inflammation in CT or X-ray|Length of hospitalization|(PCR levels) polymerase chain reaction assay levels|Respiratory indexes|C-reactive protein mg\/L|Serum Ferritin ng\/ml|Lactic acid dehydrogenase U\/L|leukocytes count \u03bcl|Lipid profile [LDL, HDL, Total cholesterol ]|total plasma antioxidant capacity""}"
"1755","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","RuxCoFlam","NCT04338958","RuxCoFlam","Drug: Ruxolitinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04338958","Recruiting","2020-04-22","2021-07-31","{""locations"":""Universit\u00e4tsmedizin G\u00f6ttingen - Klinik f\u00fcr H\u00e4matologie und Onkologie, G\u00f6ttingen, Germany|University Hospital Jena, Jena, Germany|Klinikum der Landeshauptstadt Stuttgart gK\u00f6R, Stuttgart, Germany|Universit\u00e4tsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""overall response rate in reversal of hyperinflammation""}"
"1756","An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY","","NCT04575064","WHO-SOLIDARITY-GERMANY|2020-001549-38","Other: Standard of Care (SoC)|Drug: Remdesivir","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04575064","Active, not recruiting","2020-06-29","2022-11-01","{""locations"":""Gesundheit Nord gGmbH, Bremen, Germany|Universit\u00e4tsklinikum Gie\u00dfen, Gie\u00dfen, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Germany|Technische Universit\u00e4t M\u00fcnchen (TUM), M\u00fcnchen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of clinical status on the ordinal 7-point severity-scale at day 15.|Time to an improvement of one category from admission using the 7-point ordinal scale|Mortality: 28 days mortality; in-house mortality|Hospital stay: Duration of hospital stay due to COVID-19|Oxygen: Need of, time to first receiving and duration of oxygen|Intensive care: Need of, time to first receiving and duration of intensive care|Mechanical ventilation: Need of, time to first receiving and duration of mechanical ventilation|ECMO: Need of, time to first receiving and duration for extracorporeal membrane oxygenation|Superinfections, assessed with pathogen testing|Kidney failure|Myocardial failure|Multiple organ failure""}"
"1757","A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","","NCT04494984","CT-INM005-01","Drug: INM005|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04494984","Completed","2020-07-27","2020-12-30","{""locations"":""Hospital de Cuenca Alta, Ca\u00f1uelas, Buenos Aires, Argentina|Hospital Alta Complejidad \""El Cruce\"" Dr. N\u00e9stor Carlos Kirchner, Florencio Varela, Buenos Aires, Argentina|Hospital Prof. Dr. Bernardo A. Houssay, Florida, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Hospital Italiano de La Plata, La Plata, Buenos Aires, Argentina|Hospital Municipal Emilio Zerboni, San Antonio de Areco, Buenos Aires, Argentina|Hospital Municipal Dr. Diego E. Thompson, San Mart\u00edn, Buenos Aires, Argentina|Hospital Pablo Soria, San Salvador De Jujuy, Jujuy, Argentina|Hospital Provincial Neuqu\u00e9n \""Dr. Eduardo Castro Rend\u00f3n\"", Neuqu\u00e9n, Neuquen, Argentina|Hospital Centro de Salud Zen\u00f3n J. Santill\u00e1n, San Miguel De Tucum\u00e1n, Tucuman, Argentina|Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Mu\u00f1iz, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Pirovano, Ciudad Autonoma de Buenos Aires, Argentina|Centro Gallego de Buenos Aires, Ciudad Autonoma de Buenos Aire, Argentina|Cl\u00ednica Adventista Belgrano, Ciudad Autonoma de Buenos Aire, Argentina|Cl\u00ednica Pasteleros, Ciudad Autonoma de Buenos Aire, Argentina|Cl\u00ednica Zabala, Ciudad Autonoma de Buenos Aire, Argentina|Fundaci\u00f3n Favaloro, Ciudad Autonoma de Buenos Aire, Argentina|Hospital Espa\u00f1ol de Buenos Aires, Ciudad Autonoma de Buenos Aire, Argentina|Hospital G. A. Carlos G. Durand, Ciudad Autonoma de Buenos Aire, Argentina|Sanatorio Agote, Ciudad Autonoma de Buenos Aire, Argentina|Sanatorio Sagrado Coraz\u00f3n, Ciudad Autonoma de Buenos Aire, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""242"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical changes in COVID-19 symptoms|Pharmacokinetics evaluation of INM005|Time to progression of disease|Disease progression|Discharge|Intensive care unit (ICU) hospitalization|Mechanical ventilation assistance (MVA)|Mortality|Changes in viral load""}"
"1758","Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel","Bacmune","NCT04452643","MV130-SLG-037","Biological: BACMUNE (MV130)|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04452643","Withdrawn","2020-10-01","2021-12-01","{""locations"":""Instituto Nacional de Enfermedades Respiratorias (INER), Ciudad de M\u00e9xico, Mexico|Hospital General de Pachuca, Pachuca de Soto, Mexico|Hospital de Ciudad Valles, San Luis Potos\u00ed, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""0"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of subjects with COVID-19|Severity of COVID-19|Seroconversion to SARS-CoV-2|Subjects with symptoms|Hospital admission due to COVID-19|Admission to an intensive care unit due to COVID-19|Elapsed time until hospitalization|Elapsed time until admission into an care unit for COVID-19|Elapsed time until death not related to COVID-19""}"
"1759","COVID-19 Anosmia Study","","NCT04495816","GCO 20-1132","Drug: Omega-3 Fatty Acid Supplement|Drug: Placebo/Control","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04495816","Recruiting","2020-07-15","2021-08-01","{""locations"":""Mount Sinai Hospital, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""126"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Brief Smell Identification Test (BSIT)|Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)|Sinonasal Outcomes Test (SNOT-22)""}"
"1760","Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels","COVID-APE","NCT04373486","7840","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373486","Completed","2020-03-03","2020-05-01","{""locations"":""Service de Radiologie B - NHC, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of positivity for Acute Pulmonary Embolism""}"
"1761","International Registry of Healthcare Workers Exposed to COVID-19 Patients","UNITY Global","NCT04626076","CER-HCW-001","Other: Comparative Observational Cohort Study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04626076","Recruiting","2020-08-13","2021-10-31","{""locations"":""Aga Khan University, Karachi, Pakistan"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of SARS-CoV-2 infection among HCWs caring for COVID-19 patients, in terms of time, geography, healthcare setting, type of HCW.|Occurrence of SARS-CoV-2 uninfected HCWs|Occurrence of SARS-CoV-2 infection with ambulatory status and no limitation of activities|Occurrence of SARS-CoV-2 infection with ambulatory status and limitation of activities|Occurrence of hospitalization due to COVID-19 illness with mild disease|Occurrence of hospitalization due to COVID-19 illness with severe disease|Occurrence of all-cause mortality|Type of prophylactic treatments by dose, frequency and duration, overall and by country\/region\/site""}"
"1762","Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients","","NCT04497649","Tanta sofosbuvir covid","Drug: Sofosbuvir|Drug: Daclatasvir","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04497649","Recruiting","2020-07-01","2021-04-10","{""locations"":""Cairo and Tanta Universitities, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patients with improvement or mortality""}"
"1763","Aggrenox To Treat Acute Covid-19","ATTAC-19","NCT04410328","Pro2020001469","Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Other: Standard of care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04410328","Recruiting","2020-10-21","2021-12-15","{""locations"":""Rutgers New Jersey Medical School University Hospital, Newark, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""132"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Covid (Coronavirus Disease-19) Ordinal Scale|Mortality|Supplemental Oxygen|Invasive-ventilator|ICU stay|Hospital stay|Inflammatory markers|Thromboembolic complications|COVID ordinal scale""}"
"1764","Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19","DeCOPO","NCT04543760","2020-04-03","Other: Prone position|Other: Supine position","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04543760","Recruiting","2020-10-01","2021-05-01","{""locations"":""Hopital Saint Joseph, Marseille, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""18"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""[PaO2 \/ FiO2] ratio|\u0394Peso measured using an esophageal balloon catheter|Concentration of CO2 at the end of expiration (EtCO2, mmHg)|Intensity of dyspnea|Tolerance of the technique|The occurrence of side effects due to PP""}"
"1765","Electrocardiographic QRS Axis Shift ,Rotation and COVİD-19","","NCT04698083","22/7/2020-2152","Diagnostic Test: Electrocardiography ,Tomographic imaging","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04698083","Completed","2020-07-22","2020-11-05","{""locations"":""\u015eahbender Ko\u00e7, Ankara, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""160"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Differences in the electrocardiographic QRS axis shift(\u00b0),|Differences in the electrocardiographic rotation|Differences in the CO-RADS5\/CO-RADS1-4 ratio""}"
"1766","Optimising Resource Allocation Via Prediction of Outcomes for Covid-19","","NCT04473105","20GA039","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473105","Recruiting","2020-05-01","2021-01-31","{""locations"":""Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilation|Death""}"
"1767","Clinical Trial to Evaluate the Efficacy of Food Supplement Manremyc® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers","","NCT04452773","MANRECOVID19","Dietary Supplement: Manremyc|Dietary Supplement: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04452773","Recruiting","2020-07-14","2021-12-01","{""locations"":""CAP Cornell\u00e0 (La Gavarra), Cornell\u00e0 De Llobregat, Barcelona, Spain|CAP Maresme, Matar\u00f3, Barcelona, Spain|Cap Sant F\u00e8lix, Sabadell, Barcelona, Spain|EAP Riu Nord, Santa Coloma De Gramenet, BArcelona, Spain|Hospital Universitari Germans Trias i Pujol UBP Riscos Laborals, Badalona,, Badalona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""315"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Documented cumulative incidence of SARS-CoV-2 infection|Documented sick leave for SARS-CoV-2|days off work due to the quarantine|Quarantine imposed by close contact outside the center with SARS-CoV-2 positive|Fever|Cumulative incidence of self-reported acute respiratory symptoms|Number of days of self-reported acute respiratory symptoms|Incidence of pneumonia|Cumulative incidence of death from documented SARS-CoV-2 infection|Incidence of admission to ICU|Days in IUC|Incidence of mechanical ventilation|Incidence of hospital admissions|Days of hospitalization|Levels of IgG|Levels of IgM|Levels of SARS-CoV-2 antibodies at the end of the study period""}"
"1768","Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults","","NCT04563702","VXA-COV2-101","Biological: VXA-CoV2-1","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04563702","Active, not recruiting","2020-09-21","2021-10-01","{""locations"":""WCCT, Cypress, California, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""35"",""age"":""18 Years to 54 Years \u00a0 (Adult)"",""outcome_measures"":""Frequency of solicited symptoms of reactogenicity|Grade of solicited symptoms of reactogenicity|Frequency of unsolicited adverse events|Grade of unsolicited adverse events|Frequency of serious adverse events (SAEs)|Frequency of medically-attended adverse events (MAAEs)|SARS-CoV-2 specific IgG\/IgA|Neutralizing antibody titers to SARS-CoV-2|Antigen-specific IgG\/IgA antibody secreting (ASCs)|Th1\/Th2 polarization""}"
"1769","Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19","MESCEL-COVID19","NCT04366271","MESCEL-COVID19|2020-001450-22","Biological: Mesenchymal cells|Drug: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04366271","Recruiting","2020-05-07","2021-05-31","{""locations"":""Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Infantil Universitario Ni\u00f1o Jesus, Madrid, Spain|Hospital Ram\u00f3n Y Cajal, Madrid, Spain|Complejo Universitario La Paz, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""106"",""age"":""40 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events""}"
"1770","The United Kingdom Multiple Sclerosis Register Covid-19 Substudy","UKMSRCV19","NCT04354519","16SW0194","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354519","Recruiting","2020-03-14","2022-07-14","{""locations"":""Swansea Univeristy, Swansea, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID-19 Infections within an MS Cohort in the UK|Hospitalisations in MS Patients with COVID-19|Mortality|Patient Reported Expanded Disability Status Score|Hospital Anxiety and Depression Scale|Multiple Sclerosis Impact Scale 29 V2|Multiple Sclerosis Walking Scale 12 V2|Fatigue Severity Scale|EuroQol 5D (3l)""}"
"1771","Collection of Anti-SARS-CoV-2 Immune Plasma","NIAID","NCT04344977","200081|20-I-0081","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344977","Completed","2020-06-01","2021-03-03","{""locations"":""Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center, Torrance, California, United States|University of Miami Infectious Diseases Research Unit, Miami, Florida, United States|Bloodworks Northwest, Seattle, Washington, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""151"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma""}"
"1772","Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients","","NCT04530370","ossamahamdyresearcher7","Biological: recovered covid 19 patients plasma","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04530370","Recruiting","2020-05-29","2020-09-01","{""locations"":""South Valley University, Qin\u0101, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Satisfactory outcome""}"
"1773","COVidIVERmectin: Ivermectin for Treatment of Covid-19","COVER","NCT04438850","cover_1","Drug: Ivermectin|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04438850","Recruiting","2020-07-31","2021-05-01","{""locations"":""IRCCS Sacro Cuore Don Calabria hospital, Negrar, Verona, Italy|Policlinico S. Orsola, Bologna, Italy|Ospedale Luigi Sacco, Milan, Italy|Ospedale di Rovereto, Rovereto, Italy|Ospedale Amedeo di Savoia, Turin, Italy|Hospital Clinic\/ISGlobal, Barcelona, Spain|Hospital La Paz-Carlos III, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""102"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SADR|Viral load|Trend viral load|Clinical resolution|Viral clearance|Virological clearance|hospitalization rate|Severity score""}"
"1774","Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation","CognitiVID","NCT04468035","CognitiVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468035","Recruiting","2020-06-01","2021-12-31","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Medium-term evolution between 3 and 6 months|Cognitive impairment at M3|Cognitive impairment at M6|Memory Scores at M3|Memory Scores at M6""}"
"1775","Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients","TCInpatient","NCT04338126","TXACOVID2","Drug: Tranexamic acid|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04338126","Not yet recruiting","2021-09-30","2021-12-31","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Admission to Intensive Care Unit""}"
"1776","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","CORIMUNO-VIRO","NCT04341870","APHP200375-3","Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04341870","Suspended","2020-04-11","2020-08-01","{""locations"":""AP-HP H\u00f4pital Avicenne, Bobigny, France|AP-HP H\u00f4pital Ambroise Par\u00e9, Boulogne-Billancourt, France|AP-HP H\u00f4pital Beaujon, Clichy, France|AP-HP H\u00f4pital Piti\u00e9 Salp\u00e9tri\u00e8re, Paris, France|AP-HP H\u00f4pital Saint Antoine, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""27"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines""}"
"1777","Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19","","NCT04457349","plasma exchange in COVID 19","Procedure: Therapeutic Plasma Exchange (TPE)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04457349","Recruiting","2020-07-25","2021-01-20","{""locations"":""Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypt"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality|the mean time with oxygen therapy|the mean time with Non-invasive mechanical ventilation|the mean time of intubation|respiratory function parameters|radiological lung extension|mean duration of hospitalization and ICU use|the requirement of additional organ support|the levels of IL-6|Incidence of adverse events|time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity|the levels of CRP|the levels of procalcitonin (PCT)|levels of D-dimer|levels of ferritin""}"
"1778","Fluvoxamine for Adults With Mild to Moderate COVID-19","","NCT04711863","S2020-3124-0001","Drug: Fluvoxamine|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04711863","Recruiting","2021-01-16","2021-07-31","{""locations"":""Asan Medical Center, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical deterioration|Time to clinical deterioration|Rate of each component of primary outcome including WHO Clinical Progression Scale|Rate of transfer to general hospital regardless of any reasons|Evaluation of adverse events""}"
"1779","Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak","","NCT04401098","covid 19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401098","Recruiting","2020-05-02","2021-04-01","{""locations"":""Damanhour University, Damanh\u016br, Beheira, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""700"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""awareness of Egyptian population""}"
"1780","Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study","PRONE","NCT04517123","IRB00249663","Other: Prone Positioning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04517123","Recruiting","2020-09-01","2021-12-31","{""locations"":""Johns Hopkins Univeristy, Baltimore, Maryland, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|UPMC, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of an escalation in respiratory related care (yes vs no)|Oxygen Saturation|Respiratory Effort as assessed by Respiratory Rate""}"
"1781","At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study","","NCT04393961","2458","Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04393961","Recruiting","2020-04-05","2020-08-29","{""locations"":""ProofPilot Online App (https:\/\/p.proofpilot.com), New York, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility"",""enrollment"":""600"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Does Participant Accurately Read Result|Acceptability and Usability of Tests|Social Distancing Behavior Change|COVID-19 Related Anxiety""}"
"1782","Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)","","NCT04567810","CVR001","Drug: anti-SARS-CoV-2 IgY|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04567810","Completed","2020-09-18","2020-12-14","{""locations"":""Linear Clinical Research - Harry Perkins Research Institute, Nedlands, Western Australia, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""48"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Number of participants with treatment-related adverse events|Number of Participants With Vital Sign Findings Reported as TEAEs|Number of Participants With Clinically Significant Findings in Physical Examinations|Number of Participants With Clinically Significant Changes From Baseline in ECG Data|Number of participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters|Number of Participants with Presence of Serum anti-SARS-CoV-2 IgY""}"
"1783","Neuropathology in Adults Intensive Care Unit Patients With COVID 19","","NCT04453670","Obs2020","Procedure: autopsy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453670","Completed","2020-03-10","2020-05-15","{""locations"":""H\u00f4pital Raymond Poincar\u00e9, Garches, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""7"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""detection of severe acute respiratory syndrome related to coronavirus-2 in brain tissues|quantification of inflammation, necrosis and hemorrhage in different brain areas""}"
"1784","A Phase II/III Study of Sargramostim","","NCT04642950","NPC-26-1","Drug: Sargramostim|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04642950","Recruiting","2020-12-17","2021-10-31","{""locations"":""IUHW Narita Hospital, Narita City, Chiba, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan|Japanese Red Cross Society Saitama Red Cross Hospital, Saitama City, Saitama, Japan|St. Luke's International Hospital, Chuo-ku, Tokyo, Japan|Mishuku Hospital, Meguro-ku, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Center Hospital of the National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""20 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""2-rank improvement on a 7-point ordinal scale|Changes in alveolar-arterial oxygen partial pressure gradient (A-aDO)|Number of days until discharge from baseline|Proportion of subjects whose category has shifted to Category 1 or 2""}"
"1785","Microbial Infection and AMR in Hospitalized Patients With Covid 19","","NCT04479982","Microbial infection with covid","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479982","Recruiting","2020-09-24","2020-12-31","{""locations"":""Assiut hopital, Assiut, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""70"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Microbial infections and antimicrobial resistance (AMR) patterns associated with hospitalized patients with 2019 novel coronavirus disease (COVID 19)""}"
"1786","Attitude of Egyptian Population Toward COVID 19 in Ramadan","","NCT04401072","covid 19 in ramadan","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401072","Recruiting","2020-04-24","2020-10-01","{""locations"":""Damanhour University, Damanh\u016br, Beheira, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Attitude of the Egyptian population during the COVID 19 pandemic in Ramadan""}"
"1787","Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context","RECOVERY","NCT04391686","2020-04","Diagnostic Test: indirect calorimetry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04391686","Recruiting","2020-07-03","2021-11-02","{""locations"":""Arras general hospital, Arras, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The resting energy expenditure (in Kcal \/ 24h) measured by indirect calorimetry during the stay in intensive care.""}"
"1788","Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure","","NCT04519411","20-003743","Diagnostic Test: Transpulmonary pressure measurements","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04519411","Recruiting","2020-05-21","2022-01-31","{""locations"":""Mayo Clinic in Rochester, Rochester, Minnesota, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""10"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""Transpulmonary pressure""}"
"1789","Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France","CORSER","NCT04325646","2020-007","Other: Human Biological samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04325646","Recruiting","2020-03-13","2023-02-28","{""locations"":""CHU Amiens-Picardie, Amiens, France|EHPAD Villa Concorde, Asnieres sur seine, France|CHU Fran\u00e7ois Mitterand, Dijon, France|Centre Hospitalier D\u00e9partemental de Vend\u00e9e, La Roche-sur-Yon, France|CHU Limoges, Limoges, France|H\u00f4pital de la Croix Rousse, Lyon, France|EHPAD Les Etangs, Mennecy, France|CHRU de Nancy, Nancy, France|H\u00f4pitaux de Brabois, Nancy, France|CHR Orl\u00e9ans, Orl\u00e9ans, France|Institut Mutualiste, Paris, France|Institut Pasteur, Paris, France|EHPAD Villa Lecourbe, Paris, France|H\u00f4pital la Piti\u00e9 Salpetri\u00e8re, Paris, France|CHU Poitiers, Poitiers, France|H\u00f4pital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-\u00c9tienne, France|CHRU de Strasbourg, Strasbourg, France|CH de Tourcoing, Tourcoing, France|H\u00f4pital Bretonneau, Tours, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.|Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies""}"
"1790","Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2)","","NCT04637906","Bioarginina","Dietary Supplement: Bioarginina®","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04637906","Recruiting","2020-11-18","2021-09-18","{""locations"":""Azienda Ospedaliera Specialistica Dei Colli, Napoli, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""290"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction of P \/ F normalization times""}"
"1791","Collection of Biological Samples With Clinical Characterization of Covid-19 Patients","","NCT04363385","COVIGENET","Biological: Biological test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363385","Recruiting","2020-05-31","2021-05-31","{""locations"":""Centre hospitalier intercommunal de Cr\u00e9teil, Cr\u00e9teil, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Phenotype\/genotype correlation research modulating the severity of Covid-19 disease|Phenotype\/transcriptomic correlation research modulating the severity of Covid-19 disease|Phenotype\/biomarker correlation research modulating the severity of Covid-19 disease|Development of clinical-biological scores in the severity of Covid-19 disease|Development of predictive imaging scores in the severity of Covid-19 disease|Identification of pathophysiological pathways to susceptibility to Covid-19 disease|Identification of genetic markers for treatment response|Identification of transcriptomic markers for treatment response|Identification of proteomic for treatment response""}"
"1792","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine","","NCT04276896","GIMI-IRB-20001","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04276896","Recruiting","2020-03-24","2024-12-31","{""locations"":""Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""6 Months to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine\/CTL Events|Frequency of Serious vaccine\/CTL Events""}"
"1793","Early Treatment of Cytokine Storm Syndrome in Covid-19","","NCT04362111","Chatham-Cytokine Covid-19","Drug: Anakinra|Drug: Normal saline","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04362111","Recruiting","2020-07-29","2021-03-01","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients discharged from the hospital alive and without the need for mechanical ventilation.|Percentage of subjects with 25% change (decrease) in cytokine storm markers at 48 hours|Percentage of subjects without increase in oxygen requirement and no increase in oxygen delivery\/respiratory support measures after 48 hours.|Average time in days to achieve sustained \u226593% oxygen saturation without oxygen\/respiratory support|Percentage of subjects with resolution of laboratory markers of Cytokine Storm syndrome|Percentage of subjects who develop bacterial or fungal or non-Covid-19 viral infection|Percentage of subjects who develop neutralizing antibody to Covid-19""}"
"1794","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","TACTIC-R","NCT04390464","TACTIC-R","Drug: Ravulizumab|Drug: Baricitinib|Other: Standard of care","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04390464","Recruiting","2020-05-08","2022-05-01","{""locations"":""Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1167"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All cause mortality at day 28|Time to clinical improvement""}"
"1795","London's Exogenous Surfactant Study for COVID19","LESSCOVID","NCT04375735","9890","Drug: Bovine Lipid Extract Surfactant","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04375735","Not yet recruiting","2020-07-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse events (patient) - Decrease in oxygenation|Adverse events (patient) - Decrease in hemodynamics|Adverse event (healthcare worker) - Circuit breach|Adverse event (healthcare worker) - COVID-19 symptoms|Change in oxygenation|Change in Lung compliance|Ventilated days|Length of ICU stay|Length of hospital stay|Mortality|G-CSF levels (serum inflammatory biomarker)|GM-CSF levels (serum inflammatory biomarker)|IFN gamma levels (serum inflammatory biomarker)|IL-1 beta levels (serum inflammatory biomarker)|IL-4 levels (serum inflammatory biomarker)|IL-6 levels (serum inflammatory biomarker)|IL-10 levels (serum inflammatory biomarker)|I levels (serum inflammatory biomarker)|MCP-1 levels (serum inflammatory biomarker)|TNF alpha levels (serum inflammatory biomarker)""}"
"1796","Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients","","NCT04497389","132922","Biological: Human Amniotic Fluid","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04497389","Recruiting","2020-10-28","2021-09-15","{""locations"":""University of Utah Health, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""C-reactive protein""}"
"1797","Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms","SAVIOR","NCT04368156","SAVIOR","Device: gammaCore® (Vagus nerve stimulation)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04368156","Active, not recruiting","2020-04-20","2021-02-23","{""locations"":""Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""110"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of changes in specific clinical events in patients with covid-19.""}"
"1798","Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19","","NCT04551755","31211062020","Drug: Ivermectin and Doxycycline|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04551755","Not yet recruiting","2020-09-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""188"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to outcome measure of fever (<100.40F)and cough|Negative RT-PCR test on day 5 of treatment""}"
"1799","Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt","","NCT04531111","FMASU P66/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04531111","Recruiting","2020-07-07","2020-08-01","{""locations"":""Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""2 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Impact of COVID-19 pandemic and lockdown on glycemic control among a sample of Egyptian children and adolescents with type 1 diabetes|Impact of COVID-19 pandemic and lockdown on insulin dosage among a sample of Egyptian children and adolescents with type 1 diabetes""}"
"1800","Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","CRASH-19","NCT04343001","2020-KEP-420","Drug: Aspirin|Drug: Losartan|Drug: Simvastatin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04343001","Withdrawn","2020-10-01","2021-08-01","{""locations"":""University College Hospital, Ibadan, Oyo, Nigeria|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death|Myocardial infarction|Congestive cardiac failure|Severe cardiac arrythmia|Myocarditis|Respiratory failure including ARDS|Viral pneumonitis|Acute renal failure|Sepsis|Stroke|Gastrointestinal bleeding|Receipt of non invasive or mechanical ventilation|Ability to self care at hospital discharge""}"
"1801","Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection","CP IN COVID19","NCT04438694","N39-2020","Biological: Convalescent Plasma|Drug: Standard of Care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04438694","Recruiting","2020-06-01","2021-12-31","{""locations"":""Cairo University Hospital, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""67"",""age"":""21 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of hospitalization\/Recovery status""}"
"1802","Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants","","NCT04532294","BGB-DXP593-101","Drug: BGB DXP593|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04532294","Recruiting","2020-09-08","2021-06-15","{""locations"":""Q Pharm Pty Limited, Herston, Queensland, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science"",""enrollment"":""30"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of participants experiencing Treatment Emergent Adverse Events (TEAEs)|Number of participants experiencing Serious Adverse Events (SAEs)|Maximum observed plasma concentration (Cmax) of BGB-DXP593|Area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUCt) of BGB-DXP593|AUC from time zero to infinity (AUCinf) of BGB-DXP593|AUC from time zero to Day 29 (AUC0-29) of BGB-DXP593|Time to maximum observed plasma concentration (tmax) of BGB-DXP593|Terminal half life (t1\/2) of BGB-DXP593|Clearance (CL) of BGB-DXP593|Volume of distribution (Vz) of BGB-DXP593|Immunogenic response to BGB-DXP593 as assessed by the Detection of antidrug antibodies (ADA)""}"
"1803","Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals","","NCT04490824","KELEA-1","Device: KELEA Excellerated Water|Device: Water Without an Elevated Level of KELEA","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04490824","Recruiting","2020-10-01","2021-04-30","{""locations"":""Institute of Progressive Medicine, South Pasadena, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals""}"
"1804","Repeat Testing for SARS-CoV-2","","NCT04579549","2020-1142|A536300|SMPH/PATHOL-LAB MED/ANAT PATH|Protocol Version 8/17/2020|5P51OD011106-59","Device: Saliva Assay","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04579549","Enrolling by invitation","2020-09-29","2021-09-01","{""locations"":""University of Wisconsin, Madison, Wisconsin, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""10000"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of Participant Phone Survey Responses|Number of minimally trained personnel who achieve assay proficiency""}"
"1805","Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease","","NCT04348500","00000644","Drug: Clazakizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04348500","Active, not recruiting","2020-04-24","2021-03-31","{""locations"":""Cedars-Sinai Medical Center, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""17"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the safety of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement|Patient survival at 28 days|Patient survival at 60 days|Number of patients requiring the dose of open-label clazakizumab|Reduced duration of intensive care unit stay|Reduced duration of hospital stay|Reduced need for ventilation""}"
"1806","Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.","","NCT04445376","313","Other: Physical Exercises","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04445376","Completed","2020-07-03","2020-10-03","{""locations"":""Bin Inam Rehabilitation Center., Faisal\u0101bad, Punjab, Pakistan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""6 minute walk test|Modified Borg Dyspnea Scale|SF-36 QUESTIONNAIRE""}"
"1807","Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)","HYACINTHE","NCT04392128","2020-005|2020-002002-45","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04392128","Withdrawn","2020-09-02","2020-09-02","{""locations"":""Institut de Canc\u00e9rologie Strasbourg Europe, Strasbourg, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|Clinical evolution|Proportion of patients progressing to a severe form|Mortality|Evaluation of viral load drop|Tolerance of study treatment|Evaluation of the seroconversion|NK immunological study|Hospitalisation duration|Impact of the study treatment on the treatment of the hematological disease|Monitoring of the QT space|Dosage of residual concentration of azithromycine and hydroxychloroquine.|T immunological study""}"
"1808","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","","NCT04298814","COVEI","Other: severe covid-19 pneumonia with ET","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04298814","Withdrawn","2020-08-07","2020-12-30","{""locations"":""Tongji Hospital, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""0"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Success rate of intubation|Infection rate of Anesthesiologist|Extubation time""}"
"1809","Senior-COVID-Rea Multicentric Survey","SeniorCOVIDRea","NCT04422340","69HCL20_0386","Other: Group1","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422340","Recruiting","2020-04-01","2020-08-15","{""locations"":""Resuscitation unit at Hospital Emile Roux, Le Puy-en-Velay, France|- Resuscitation unit of the Groupement Hospitalier Nord - Hospices Civils de Lyon, Lyon, France|- Resuscitation unit of the Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France|Resuscitation unit of the Groupement Hospitalier Centre - Hospices Civils de Lyon, Lyon, France|Resuscitation unit of the Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France|Service de R\u00e9animation de l'H\u00f4pital Nord Ouest, Villefranche-sur-Sa\u00f4ne, France|Medipole Resuscitation unit, Villeurbanne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""185"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the impact of age on mortality at 30 days after admission to intensive care""}"
"1810","A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19","","NCT04682873","FK/FAV00А-CoV/2020","Drug: Enisamium Iodide|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04682873","Recruiting","2020-05-15","2021-07-01","{""locations"":""Municipal Enterprise \""Volyn Regional Clinical Hospital\"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise \""Kyiv City Clinical Hospital #9\"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-\u0421ommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""700"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy - Time from Day 1 (randomization and treatment start) to clinical change|Efficacy - Time to recovery (TTR) from Day 1 (randomization and treatment start)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms\/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Treatment emergent adverse events (TEAE)|Overall assessment of tolerability of treatment (patient and investigator)""}"
"1811","Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19","CHEER","NCT04359537","F.1-1/2015/ERB/SZABMU/549","Drug: Hydroxychloroquine Sulfate 200 MG|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04359537","Recruiting","2020-05-01","2020-09-25","{""locations"":""Shaheed Zulfiaqar Ali Bhutto Medical University, Islamabad, Federal Capital, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""COVID-19-free survival in experimental arms compared to placebo|Incidence of confirmed SARS-COV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related adverse events""}"
"1812","Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study","CONNAITRE","NCT04384614","ECC2020-07","Diagnostic Test: Test PCR|Genetic: TDR|Other: Clinical Examination","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384614","Withdrawn","2020-05-15","2020-07-15","{""locations"":""Eshmoun Clinical Research Centre, Tunis, Tunisia"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Differences related to epidemiological demographic characteristics""}"
"1813","COVID-19 Preventive Behavior in African Americans","","NCT04700462","IRB00250644|3R01AG056587-03S1","Behavioral: Sm-EMA","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04700462","Recruiting","2021-02-05","2021-10-30","{""locations"":""Johns Hopkins School of Nursing, Baltimore, Maryland, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""250"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Knowledge Test score as assessed by a questionnaire|Change in Self-efficacy as assessed by self-efficacy questionnaire|Change in preventive Behavior Score|Change in System Usability Scale (SUS) score|Change in Global Impression of Change as assessed by a questionnaire""}"
"1814","Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19","","NCT04438863","SHEBA-20-7022-SMC-LL-CTIL","Diagnostic Test: home spirometry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04438863","Recruiting","2020-08-08","2021-09-01","{""locations"":""Sheba Medical Center, Ramat Gan, Israel"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization""}"
"1815","Exploring Brain Damages After COVID-19 Infection","BRAINCOV","NCT04405986","CHUBX 2020/20","Procedure: Auditory Evoked Potentials (AEP)|Procedure: Blink and Masseter Inhibitory Reflex","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04405986","Recruiting","2020-05-19","2021-11-19","{""locations"":""CHU de Bordeaux, Bordeaux, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""38"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Latency of electrophysiological response|Delay of Muscle contraction|Delay of silent period|Duration of silent period|Inhibition rate""}"
"1816","A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19","","NCT04646590","LKM-2020-NCV-GJ01","Biological: Recombinant new coronavirus vaccine (CHO cell) group|Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04646590","Recruiting","2020-12-16","2022-04-01","{""locations"":""Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China|Biodimed Guayaquil Clinical Research Center, Guayaquil, Guayas, Ecuador|Biodimed Alemania Clinical Research Center, Quito, Pichincha, Ecuador|Biodimed Eloy Alfaro Clinical Research Center, Quito, Pichincha, Ecuador|Fkui-Rscm, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia|FK Unpad\/RSHS, Bandung, Jawa Barat, Indonesia|Aziz Fatimah Hospital, Faisalabad, Punjab, Pakistan|Avicenna Hospital, Lahore, Punjab, Pakistan|Central Park Medical college, Lahore, Punjab, Pakistan|Chughtai Lab, Lahore, Punjab, Pakistan|National Hospital & Medical Center, Lahore, Punjab, Pakistan|Shaukat Khanum Hospital, Lahore, Punjab, Pakistan|University of Health Sciences, Lahore, Punjab, Pakistan|Agha Khan Hospital, Karachi, Sindh, Pakistan|Indus Hospital, Karachi, Sindh, Pakistan|Shifa International Hospital, Islamabad, Pakistan|Family Hospital No.15, Tashkent, Uzbekistan|GUVD Poliklinika, Tashkent, Uzbekistan|IIV Markaziy Poliklinika, Tashkent, Uzbekistan|Toshkent viloyat IIV Poliklinika, Tashkent, Uzbekistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""29000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The endpoint of efficacy study|The endpoint of safety study|Endpoint of immunogenicity and immune persistence study""}"
"1817","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","HSC19","NCT04335097","127157","Device: Biosensors","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04335097","Recruiting","2020-04-22","2025-12-20","{""locations"":""Lillestrom legevakt, Lillestrom, Norway"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""214"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative\/peers evaluation of the patient|Serious of symptoms at admittance hospital""}"
"1818","Donated Antibodies Working Against nCoV","DAWN-Plasma","NCT04429854","S63992","Biological: Convalescent Plasma|Drug: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04429854","Active, not recruiting","2020-05-02","2021-11-02","{""locations"":""ZNA, Antwerpen, Belgium|Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium|Institut Bordet, Brussel, Belgium|UMC Sint-Pieter, Brussel, Belgium|CHU Brugmann, Brussel, Belgium|Erasmus Ziekenhuis, Brussel, Belgium|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St Luc, Brussel, Belgium|AZ Sint-Vincentius, Deinze, Belgium|AZ Maria Middelares, Gent, Belgium|AZ Sint-Lucas, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC Li\u00e8ge Mont L\u00e9gia, Li\u00e8ge, Belgium|CHR Citadelle Li\u00e8ge, Li\u00e8ge, Belgium|CHU Li\u00e8ge Sart-Tilman, Li\u00e8ge, Belgium|CHU Ambroise Par\u00e9, Mons, Belgium|CHR Jolimont Mons-Hainaut, Mons, Belgium|AZ Delta, Roeselare, Belgium|Sint-Trudo Ziekenhuis, Sint-Truiden, Belgium|Centre Hospitalier de Wallonie Picarde (CHwapi), Tournai, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""483"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients requiring mechanical ventilation or death|Clinical status of subject at day 15 and day 30 (on a 10-point \""WHO progression\"" ordinal scale)""}"
"1819","Obstetric Anesthesia Experiences in COVID-19 Positive Patients","","NCT04691934","U1111-1263-2201","Procedure: Anesthesia management","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04691934","Completed","2020-03-11","2020-12-25","{""locations"":""University of Health Sciences Turkey, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Y\u0131ld\u0131r\u0131m, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""61"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""obstetric anesthesia practices|anesthesia complications""}"
"1820","Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department","","NCT04583189","SPEEDYCOVI","Diagnostic Test: Performance of the test antigenic and test RT-PCR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04583189","Completed","2020-10-01","2020-11-25","{""locations"":""Centre hospitalier intercommunal de Cr\u00e9teil, Cr\u00e9teil, France|Cabinet de ville, Nogent sur Marne, France|Cabinet Dr Cohen, Saint-Maur-des-Foss\u00e9s, France|Cabinet de ville 13 Villa Beaus\u00e9jour, Vincennes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""500"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Comparison of the performance of the Biosynex Covid-19 Ag BSS rapid antigenic test against the RT-PCR Covid-19 reference test with the AllplexTM 2019-nCoV kit (Seegene, South Korea) in children with symptoms consistent with Covid19 infection|Sensitivity of the Biosynex Covid-19 Ag BSS rapid antigenic test compared to the RT-PCR Covid-19 reference test performed with the AllplexTM 2019-nCoV kit in children.|Comparison of the time it takes to report results between the two methods""}"
"1821","Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in Egypt","","NCT04536285","FMASU P59/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04536285","Completed","2020-05-01","2020-08-31","{""locations"":""Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""36"",""age"":""1 Year to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Clinical characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Laboratory characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Prognosis of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Incidence of new onset type 1 diabetes among confirmed cases of Covid-19 infection among children and adolescents|Presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes during COVID-19 Pandemic in Egypt""}"
"1822","Clinical Protocol for Convalescent Plasma and Remdesivir Therapy in Nepal","CPT-R-Nepal","NCT04570982","NHRC2020-001","Biological: Convalescent Plasma","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04570982","Recruiting","2020-07-30","2020-12-30","{""locations"":""Narayani Hospital, Birgunj, Nepal|Seti Provincial Hospital, Dhangadi, Nepal|BP Koirala Institute of Health Sciences (BPKIHS), Dhar\u0101n B\u0101z\u0101r, Nepal|Sukraraj Tropical Disease Hospital, Kathmandu, Nepal|TU Teaching Hospital, Kathmandu, Nepal|Bheri Provincial Hospital, Nepalgunj, Nepal"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Availability of convalescent plasma|Amount of Plasma|Demographics of recipients|Co-morbidity of recipient|Donor status|Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy|Hospital and ICU length of stay|Disposition of patients including survival""}"
"1823","Evaluating Auscul-X, a Touch Free Digital Stethoscope","","NCT04570189","Auscul-X","Device: Auscul-X","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04570189","Recruiting","2020-10-01","2021-01-01","{""locations"":""The University of Ottawa Heart Institute, Ottawa, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility and use of Auscul-X for listening to heart and lung sounds will be assessed by ICU clinicians to determine Auscul-X is at least equivalent to a digital stethoscope using a Likert scale for comparison.|The measurement for acoustic quality in high risk settings determined as clarity and loudness by means of a Likert scale for comparison of Auscul-X and digital stethoscopes by clinicians.""}"
"1824","Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients","GA&COVID19","NCT04381871","GA& COVID19","Dietary Supplement: Acacia Senegal|Dietary Supplement: Pectin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04381871","Not yet recruiting","2020-06-01","2020-09-01","{""locations"":""Omdurman Teaching Hospital, Khartoum, Omdurman, Sudan|Jabra Hospital,, Khartoum, Sudan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""110"",""age"":""5 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )|Mortality rate|Determine viral load in each patient""}"
"1825","Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection","","NCT04389801","0012","Drug: Desferal 500 MG Injection","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04389801","Not yet recruiting","2020-06-01","2020-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality rate|Duration of severe symptoms""}"
"1826","Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 Infection","","NCT04513210","JagiellonianU67","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04513210","Enrolling by invitation","2020-10-10","2022-02-28","{""locations"":""Jagiellonian University Medical College, Department of Neurology, Krak\u00f3w, Poland"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Relation of changes in ultrasound and progression to respiratory failure|Impact of ultrasonographic pneumonia signs on the day of admission on severity of COVID-19 infection|Sensitivity of ultrasonographic pneumonia signs in detecting respiratory failure|Sensitivity of ultrasound in detecting interstitial changes in the lungs|Impact change in severity of ultrasonographic pneumonia signs on severity of COVID-19 infection""}"
"1827","Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)","COVIDORNASE","NCT04355364","CGE_2020_9","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]|Procedure: standard procedure","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04355364","Recruiting","2020-04-21","2021-04-21","{""locations"":""H\u00f4pital Fondation A. de Rotschhild, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of intratracheal administration: occurrence of at least one grade improvement""}"
"1828","FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals","FLARE","NCT04499677","132084","Drug: Favipiravir|Drug: Lopinavir/ Ritonavir|Other: Favipiravir Placebo|Other: Lopinavir/ Ritonavir Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04499677","Recruiting","2020-09-24","2021-03-01","{""locations"":""Royal Free Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Upper respiratory tract viral load at Day 5|Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy|Proportion of participants with undetectable stool viral load after 7 days of therapy and 14 days post-randomisation|Rate of decrease in upper respiratory tract viral load during 7 days of therapy|Duration of fever following commencement of medication|Proportion of participants with hepatotoxicity after 7 days of therapy and 14 days post-randomisation|Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation|Proportion of participants admitted to hospital with COVID-19 related illness|Proportion of participants admitted to ICU with COVID-19 related illness|Proportion of participants who have died with COVID-19 related illness|Pharmacokinetics of favipiravir as measured by Clearance (CL)|Pharmacokinetics of favipiravir as measured by Volume of distribution (V)|Pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka)|Pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax)|Pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax)|Pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke)|Pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf)|Pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta)|Pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax)|Pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50)|Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 by Day 7 of treatment""}"
"1829","Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients","PHYTCOVID-19","NCT04501965","IRDPMAG","Combination Product: Hydroxychloroquine/Azithromycine|Combination Product: Quinquina-Stevia/Azythromycin|Combination Product: 4Plants/Azythromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04501965","Enrolling by invitation","2020-06-01","2020-09-30","{""locations"":""Support Centers of Donka, Kenien and Gbessia, Conakry, Guinea"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""231"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virologic clearance of throat swabs or lower respiratory tract secretions|COVID-19 symptoms development|Adverse effects|Worsened condition""}"
"1830","Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19","SEMPATICO","NCT04615871","UHNSEMPATICO1","Drug: semaglutide","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04615871","Not yet recruiting","2020-11-30","2022-03-31","{""locations"":""Instituto Prevent Senior, S\u00e3o Paulo, Brazil|State University of Campinas, S\u00e3o Paulo, Brazil|Trillium Health Partners, Mississauga, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network - Peter Munk Cardiac Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montr\u00e9al, Quebec, Canada|Hospital de Infectologia, Mexico City, Mexico|Hospital General Regional, Mexico City, Mexico|Hospital Regional 2, Quer\u00e9taro, Mexico|Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite of death or mechanical ventilation|cardiac troponin level|ECG|28-day organ support-free days|A composite of death or intensification of medical therapy""}"
"1831","Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)","","NCT04377334","RESCOVID","Biological: MSC","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04377334","Not yet recruiting","2020-10-01","2021-07-01","{""locations"":""University Hospital Tuebingen, Tuebingen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|D-dimers|phenotype|pro-resolving lipid mediators|cytokines|chemokines|Survival|extubation|lymphocyte subpopulations|SARS-CoV-2-specific antibody titers|complement molecules (C5-C9)""}"
"1832","Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection","Nancy-CovH-AKI","NCT04354610","2020PI072","Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04354610","Active, not recruiting","2020-04-27","2021-03-19","{""locations"":""CHRU de Nancy, Nancy, France|CHRU de Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""57"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection|Troponin greater than 99th percentile during hospitalization for Covid-19 infection|AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori)|Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori)|AKI KDIGO grade 1 or higher|Association with troponin elevation >99th|Association with elevation of serum creatinine >30%|With the onset of chronic renal failure (eDFG <60 ml \/ min \/ 1.73m2)|The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital|The occurrence of death from any cause during hospitalisation and three months after discharge from hospital""}"
"1833","COVID-19 Impact on Rheumatic Patients","","NCT04407299","COVID-19Rheum","Behavioral: self-administered structured questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407299","Completed","2020-04-20","2020-05-20","{""locations"":""Kasr Alainy Hospital, Cairo, Non-US\/Non-Canadian, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""360"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Score of five-item Brief Symptom Rating Scale (BSRS-5)""}"
"1834","Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients","","NCT04458948","20-156","Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04458948","Active, not recruiting","2020-03-24","2025-03-24","{""locations"":""University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of viral shedding|Evaluation of Fatality Rate|Evaluation of Clinical Response|Evaluation of Length of Hospital Stay""}"
"1835","Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up","CARDICoVRISK","NCT04371289","CE_2020_03_26_02","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371289","Active, not recruiting","2020-04-08","2021-09-10","{""locations"":""Istituto Auxologico Italiano, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictive modeling of in-hospital outcome|Clinical, pathophysiological and molecular mechanisms|Short -Term Sequelae""}"
"1836","Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients","","NCT04494204","MGCTS/20/105","Combination Product: Immunofree tablets and Reginmune capsule","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04494204","Completed","2020-08-07","2020-12-20","{""locations"":""Govt Medical College and Govt General Hospital (Old RIMSGGH), Srikakulam, Andhra Pradesh, India|Parul Institute of Ayurveda and Research Parul University, Vadodara, Gujrat, India|Lokmanya Hospital, Pune, Maharashtra, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time (Days) to clinical improvement from study enrollment|Proportion of participants in each group with oxygen saturation more than 94% on room air for more than 24h|Value of coagulation indicators|Time to first negative SARS-CoV-2 PCR in NP swab|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization""}"
"1837","Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis","","NCT04642326","MD2020/001","Device: Test Group: experimental - UVC Therapy applied","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04642326","Active, not recruiting","2020-06-26","2021-05-04","{""locations"":""Diyarbak\u0131r SB\u00dc Gazi Ya\u015fargil E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi, Diyarbak\u0131r, Kayap\u0131nar, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""40 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PCR Sampling|Blood Tests|Radiological Imaging""}"
"1838","A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease","INFLAMMACOV","NCT04424056","2020-23","Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04424056","Not yet recruiting","2020-09-01","2022-11-01","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""216"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilation free days at D28""}"
"1839","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","","NCT04323345","MUST23032020","Dietary Supplement: Natural Honey|Other: Standard Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04323345","Recruiting","2020-04-15","2021-01-15","{""locations"":""Mahmoud Tantawy, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""5 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results""}"
"1840","Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in Île-de-France.","COVID - EHPAD","NCT04677283","2020-A01027-32","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04677283","Recruiting","2020-04-05","2021-03-01","{""locations"":""Autonomy Department; ARS \u00cele-de-France, Paris, ARS \u00cele-de-France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2020"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To define positive cases of coronavirus by \""Polymerase Chain Reaction\"" results and symptomatologies|Assessment of commorbidity risk according Charlson score|Assessment of patient's level of dependence through an appreciation of instrumental activities of daily living according Lawton scale|Assessment of teh degree of autonomy according AGGIR score|Measuring cognitive impairment according Mini-Mental State Examination (MMSE) scores|Screening for a nutritional disorder according Body Mass Index (BMI) score""}"
"1841","Retrospective Study on Anosmias and Ageusias Linked to Infection by Covid-19","STras-Cov-2","NCT04681157","7754","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04681157","Recruiting","2020-04-03","2021-04-03","{""locations"":""Strasbourg University Hospitals - Otorhino-Laryngology Department, Strasbourg, Starsbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective analysis of demographic and clinical characteristics of patients with suspected or already confirmed SARS-Cov2 infection with anosmia and \/ or ageusia""}"
"1842","Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia","COVIDSTEROID2","NCT04509973","RH-ITA-009|2020-003363-25|2020-07-16|H-20051056","Drug: Dexamethasone","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04509973","Recruiting","2020-08-27","2022-02-17","{""locations"":""Dept. of Anaesthesia and Intensive Care, Aalborg University Hospital, Denmark., Aalborg, Denmark|Dept. of Intensive care, Aarhus University Hospital, Aarhus, Denmark|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Neuroanaesthesiology, Copenhagen, Denmark|Dept. of Thoracic Anaesthesiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept of Infectious diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Gentofte Hospital, Hellerup, Denmark|Dept. of Anaesthesia and Intensive Care, Herlev Hospital, Herlev, Denmark|Dept. of Anaesthesia, Regional Hospital West Jutland, Herning, Herning, Denmark|Dept. of Intensive Care, Nordsj\u00e6llands Hospital - Hiller\u00f8d, Denmark., Hiller\u00f8d, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Dept. of Anaesthesia and Intensive Care, Lillebaelt Hospital, Kolding, Denmark|Dept. of Intensive Care, K\u00f8ge University Hospital, K\u00f8ge, Denmark|Dept of Intensive Care, Odense University Hospital, Odense, Denmark|Dept. of Anaesthesia and Intensive Care, Zealand University Hospital Roskilde, Roskilde, Denmark|Dept. of Anaesthesia, Slagelse Hospital, Slagelse, Denmark|Dept. of Anaesthesia and Intensive Care, Viborg Hospital, Viborg, Denmark|Jawahar Lal Nehru Medical Collega, AMU, Aligarh, India|Apollo Hospital, Chennai, India|Amrita Institute of Medical Sciences, Kochi, India|Bombay Hospital & Medical Research Centre, Mumbai, India|K. J. Somaiya Super Specialty Hospital, Mumbai, India|P. D. Hinduja National Hospital & Medical Research Centre, Mumbai, India|S L Raheja Fortis Hospital, Mumbai, India|Tata Memorial Hospital, Mumbai, India|Wockhardt hospitals, Mumbai, India|Indraprastha Apollo Hospital, New Delhi, India|Max Super Specialty Hospital, Saket, New Delhi, India|Symbiosis University Hospital and Research Centre, Pune, India|Vishwaraj Hospital, Pune, India|Rajendra Institute of Medical Sciences, Ranchi, India|Gotri General Hospital, Vadodara, India|Christian Medical College Vellore, Vellore, India|Dept. of Anaesthesia and Intensive Care, Sahlgranska Universitetssjukhuset, G\u00f6teborg, Sweden|Dept. of Infectious Diseases, Sahlgranska Universitetssjukhuset, G\u00f6teborg, Sweden|Dept. of Anaesthesia and Intensive Care, Universitetssjukhuset i Link\u00f6ping, Link\u00f6ping, Sweden|Dept. of Anaesthesia and Intensive Care, Sk\u00e5nes Universitetssjukhus (SUS) Malm\u00f6, Malm\u00f6, Sweden|Dept. of Infectious Diseases, Sk\u00e5nes Universitetssjukhus (SUS) Malm\u00f6, Malm\u00f6, Sweden|Dept. of Anaesthesia and Intensive Care, Vrinnevisjukhuset, Norrk\u00f6ping, Norrk\u00f6ping, Sweden|Dept. of Anaesthesia and Intensive Care, Capio St G\u00f6rans Sjukhus, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Dept. of Cardiology, S\u00f6dersjukhuset, Stockholm, Sweden|Dept. of Infectious Diseases, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Infectious Diseases, Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Dept. of Infectious Diseases, S\u00f6dersjukhuset, Stockholm, Sweden|Dept. of Internal Medicine, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Internal Medicine, S\u00f6dersjukhuset, Stockholm, Sweden|S\u00f6dersjukhuset, Stockholm, Sweden|Dept. of Intensive Care Medicine, Bern University Hospital (Inselspital), Bern, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days alive without life support at day 28|Number of participants with one or more serious adverse reactions|All-cause mortality at day 28|All-cause mortality at day 90|Days alive without life support at day 90|Days alive and out of hospital at day 90|All-cause mortality at day 180|Health-related quality of life at day 180""}"
"1843","Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study","COV-NI","NCT04469491","PI2020_843_0041","Drug: inhaled type I interferon|Drug: WFI water nebulization","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04469491","Recruiting","2020-09-20","2021-09-01","{""locations"":""CH d'Abbeville, Abbeville, France|CHU Amiens, Amiens, France|CH Compi\u00e8gne-Noyon, Compiegne, France|CH de l'Arrondissement de Montreuil-sur-mer, Rang-du-Fliers, France|CH de Saint-Quentin, Saint-Quentin, France|CH de Tourcoing, Tourcoing, France|CH de valenciennes, Valenciennes, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""146"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""oxygen requirement score at day 0|oxygen requirement score at day 15|Variation oxygen requirement score between day 0 and day15""}"
"1844","Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19","COVID-19","NCT04668404","IEC-04/2020-1641","Diagnostic Test: Sonoclot","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04668404","Recruiting","2020-08-24","2021-02-01","{""locations"":""PGIMER, Chandigarh, India"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation of of conventional coagulation tests with point of care coagulation test using sonoclot in COVID-19 patients.|Clinical Evidence of thrombosis|Coagulation-related Bleeding Event|Presence of Endogenous Heparinoids as demonstrated on POC test [ Time Frame 0, 3 days]|Intensive care admission duration|28 day mortality""}"
"1845","Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.","DEFACOVID","NCT04348383","IMIB-DFC-2020-02","Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Drug: Placebo 250 cc 24 hours continuous infusion for 15 days","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04348383","Recruiting","2020-04-08","2021-05-15","{""locations"":""Hospital General Universitario Santa Luc\u00eda, Cartagena, Murcia, Spain|Hospital Clinico y Provincial de Barcelona, Barcelona, Spain|Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital General Universitario Reina Sof\u00eda, Murcia, Spain|Hospital Universitario Salamanca, Salamanca, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement.|1. Mortality rate|Rate os serious adverse events .|Clinical improvement by WHO|Clinical improvement by NEWS2 scales|Biologic response|Radiological response|Collection and storage of biological samples""}"
"1846","A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests","","NCT04568356","E25001_NEU2012","Diagnostic Test: Direct Antigen Tests for COVID-19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04568356","Completed","2020-04-24","2020-09-24","{""locations"":""JFK Medical Center, Miami, Florida, United States|Kendall Regional, Miami, Florida, United States|Aventura Hospital and Medical Center, Miami, Florida, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent Positive Agreement and Negative Percent Agreement""}"
"1847","Benefits of Using a Transparent Visor to Replace the Face Mask in Speech Therapy Rehabilitation of Oral-Linguo-Facial Praxies in the Context of COVID-19: a Series of Cases","Co-VIS","NCT04639427","APHP200876|IDRCB","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04639427","Not yet recruiting","2020-11-01","2021-02-01","{""locations"":""Unit\u00e9 de Soins de R\u00e9\u00e9ducation Post R\u00e9animation, Service de M\u00e9decine Physique et de R\u00e9adaptation, H\u00f4pital Raymond Poincar\u00e9, APHP, Garches, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""4"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oral-Linguo-Facial Motricity Test""}"
"1848","iNOPulse for COVID-19","NO-COVER","NCT04398290","20200449","Drug: Inhaled nitric oxide (iNO)|Drug: Nitrogen gas|Drug: Oxygen gas","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04398290","Withdrawn","2020-12-01","2021-07-15","{""locations"":""University of Miami Hospitals & Clinics, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of treatment emergent adverse events|Incidence of adverse events|Incidence of methemoglobinemia|Number of participants with progression of respiratory failure|Time until resolution of hypoxemia|Incidence of mortality|Duration of hospitalization""}"
"1849","Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)","","NCT04578236","SARS","Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Drug: Drug: Standard treatment Standard treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04578236","Not yet recruiting","2020-11-01","2021-01-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""360"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Time to first negative SARS-CoV-2 PCR in NP swap|All cause mortality rate|Ventilation free days|ICU free days""}"
"1850","Feasibility of Remote Evaluation and Monitoring of Acoustic Pathophysiological Signals With External Sensor Technology in Covid-19","REMAP-WEST-COV","NCT04695821","Senti-REMAP-WEST-COV-1","Device: Senti V1.0 Device","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04695821","Not yet recruiting","2021-01-01","2021-03-01","{""locations"":""Senti Tech, Liverpool, Merseyside, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient-rated device acceptability|Patient-rated device comfort|Patient-rated device ease of use|Expert-rated device data quality|Adverse events and adverse device events|Length of time spent with the device on the patient.|Length of time taken for the patient to apply the device|Time spent to train patients to use the device.|Pressure sore EPUAP grade""}"
"1851","Covid-19 Pandemic Triage Score","STC-19","NCT04371471","2020/P04/288","Diagnostic Test: STC-19 score","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371471","Completed","2020-03-01","2020-04-30","{""locations"":""Groupe Hospitalier de la Rochelle R\u00e9 Aunis, La Rochelle, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""STC-19 score""}"
"1852","COVID-19 Survival - The COVIVA Study","COVIVA","NCT04366765","UHospital Switz","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366765","Recruiting","2020-03-19","2021-06-30","{""locations"":""University Hospital Basel, Basel, Switzerland"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""short-term prognosis|Admission to the intensive care unit (ICU)|Invasive ventilation (Intubation)|Need for extracorporal membrane oxygenation (ECMO)|Hemodynamic support|Length of ICU stay|Acute respiratory distress Syndrome (ARDS)|Myocardial injury|ST-segment elevation myocardial infarction|In-hospital resource use|EQ-5D questionnaire""}"
"1853","Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS","COVISLEEP","NCT04371029","CHUBX 2020/14","Other: PSG","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04371029","Recruiting","2020-04-28","2020-12-28","{""locations"":""Hopital Pellegrin, Bordeaux, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with altered spleep|Sleep architecture at hospital discharge|Sleep monitoring during hospital stay after ICU discharge|Sleep quality|Sleep architecture at month-3|Cost of ICU hospitalization""}"
"1854","Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19","(COVID19_BMT)","NCT04349540","20BO08","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04349540","Active, not recruiting","2020-04-15","2021-01-15","{""locations"":""Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""3 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Comparison of inflammatory\/immunological biomarkers <72 hours after development of oxygen requirement|Overall survival at 30 and 100 days after development of oxygen requirement|Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression|Proportion of patients requiring mechanical ventilation|Incidence of secondary HLH (as defined by HS score)""}"
"1855","Pulmonary Optical Coherence Tomography in COVID-19 Patients","","NCT04410549","OCT COVID","Diagnostic Test: Optical Coherence Tomography (OCT)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04410549","Recruiting","2020-06-01","2021-12-31","{""locations"":""Incor - Heart Institute - University of Sao Paulo, S\u00e3o Paulo, Brazil|IRCCS San Raffaele, Milano, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""optical coherence tomography pulmonary microthrombosis assessment in COVID-19 pneumonia patients|Pulmonary artery vessel anatomy characterization|Correlation between TTE pulmonary hypertension and right ventricular disfunction|Correlations with standard inflammatory, coagulation and tissue damage""}"
"1856","Echocardiographic Manifestation in Patient With COVID-19 （EARLY-MYO COVID-19）","","NCT04352842","COVID19-Echocardiography","Other: Echocardiography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04352842","Completed","2020-01-21","2020-04-08","{""locations"":""Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""51"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death""}"
"1857","Rehabilitation Required Due to Clinical Disorders After Severe Covid-19 Infection","REHABCOV","NCT04681755","7725","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04681755","Recruiting","2020-05-19","2021-05-19","{""locations"":""Strasbourg University Hospitals - Anesthesia and surgical resuscitation service, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""55"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective analysis of the neurological disorder after severe SARS-CoV-2 infection""}"
"1858","Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth","","NCT04630015","20805|NCI-2020-08530","Other: Survey Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04630015","Recruiting","2020-08-31","2023-12-31","{""locations"":""University of California, San Francisco, San Francisco, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in the Patient Reported Outcome Measurement Information System (PROMIS) Anxiety Short Form over time|Changes in the Patient Reported Outcome Measurement Information System (PROMIS) Depression Short Form over time|Changes in the Functional Assessment of Cancer Therapy (FACT-G) scores""}"
"1859","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients","","NCT04346446","ILBS-COVID-02","Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04346446","Completed","2020-04-20","2020-05-30","{""locations"":""Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""29"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02\/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.""}"
"1860","The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19","BOIFIM","NCT04479202","Berberine treats COVID-19|XJ2020005101","Drug: Berberine|Drug: Montmorrillonite","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04479202","Completed","2020-02-08","2020-04-23","{""locations"":""Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""76"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in diarrhea frequency and Bristol Stool Scale|IL-6 (ng\/ml)|IL-10\uff08ng\/ml\uff09|IL-1\u03b2 (ng\/ml)|TNF-\u03b1 (pg\/ml)|leukocyte count (10^9\/l)|c reactive protein (mg\/l)|procalcitonin (ng\/ml)""}"
"1861","Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation","EMBELLIE","NCT04376944","RECHMPL20_0261","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376944","Recruiting","2020-04-01","2020-12-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of caregivers and agents with a positive serodiagnosis|Proportion of caregivers and agents with a positive RT-PCR""}"
"1862","Novaferon for COVID-19 Treatment Trial (NCTT-005)","","NCT04708158","JH-COR-005","Biological: Novaferon|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04708158","Not yet recruiting","2021-01-01","2021-06-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""385"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Rate of clinical improvement|Rate of clinical deterioration|Time to viral clearance|Rate of viral clearance|Change in viral load|Mortality rate|Duration of hospital stay|Time to resolution of symptoms|Requirement of supplemental oxygen|Requirement of mechanical ventilation|Rate of alive patients|Adverse events""}"
"1863","Convalescent Plasma in the Treatment of Covid-19","COP20","NCT04600440","Covid convalescent plasma","Biological: Convalescent plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04600440","Recruiting","2020-04-25","2022-02-28","{""locations"":""Sk\u00e5ne University Hospital, Lund, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days in need of oxygen|Number of days before discharge from hospital|Mortality within 3 months|Number of days before need of assisted ventilation""}"
"1864","Post COVID-19 Functional Status in Egypt","","NCT04479293","AssiutU16","Other: Post COVID-19 Functional Satus Scale","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479293","Recruiting","2020-07-01","2020-11-30","{""locations"":""Aliaa Hussein, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""number of functional limitations post COVID-19|number of psychologic changes|Sleep Disturbance and quality|Radiologic changes|Laboratory changes""}"
"1865","Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes","","NCT04550403","27557","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04550403","Recruiting","2020-07-30","2021-12-31","{""locations"":""Endocrinology and metabolic diseases Unit, Parma, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""700"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""prevalence of intensive care unit admission and\/or in-hospital mortality among COVID-19 inpatients|prevalence of death among COVID-19 inpatients with and without diabetes|prevalence of intensive care unit admission among COVID-19 inpatients with and without diabetes|demographic and clinical characteristics (age,gender, comorbidity status) and death and\/or intensive care unit admission during hospitalization|laboratory parameters (glycated hemoglobin, glucose at admission, renal and liver function markers, blood count, inflammatory markers, hemostasis) and death and\/or intensive care unit admission during hospitalization|pharmacological therapies and death and\/or intensive care unit admission during hospitalization|number of days of hospitalization in patients with and without diabetes""}"
"1866","SQuISH-COVID: A Pilot Study","","NCT04372472","CV-CLN-003","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04372472","Active, not recruiting","2020-04-07","2020-05-29","{""locations"":""Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection.""}"
"1867","Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19","","NCT04499313","10000753","Drug: Dexamethasone|Drug: Methylprednisolone","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04499313","Recruiting","2020-08-02","2020-11-30","{""locations"":""Chattogram General Hospital, Chittagong, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""20 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate (In hospital)|Clinical improvement|Ventilator free days|Changes in Oxygen level""}"
"1868","Pyridostigmine in Severe SARS-CoV-2 Infection","PISCO","NCT04343963","Inf-3323","Drug: Pyridostigmine Bromide|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04343963","Recruiting","2020-04-04","2021-04-30","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Ciudad de M\u00e9xico, Tlalpan, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""436"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Critical condition or death|IL-6""}"
"1869","A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19","","NCT04487574","XC221-03-02-2020","Drug: XC221|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04487574","Completed","2020-07-25","2020-10-29","{""locations"":""Regional State Budgetary Institution of Healthcare \""City Hospital No. 5, Barnaul\"", Barnaul, Altai Region, Russian Federation|State Budgetary Institution of Healthcare of Moscow Region \""Zhukovskaya City Clinical Hospital\"", Zhukovskiy, Moscow Region, Russian Federation|Municipal Budgetary Institution of Healthcare \""Central City Hospital of Novoshakhtinsk\"", Novoshakhtinsk, Rostov Region, Russian Federation|State Budgetary Institution of Healthcare of Moscow \""City Clinical Hospital No. 15 of the Moscow Department of Healthcare\"", Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University), Department of Faculty Therapy No. 2, Moscow, Russian Federation|State Budgetary Institution of Healthcare of Moscow \""City Clinical Hospital No. 52 of the Moscow Department of Healthcare\"", Moscow, Russian Federation|State Budgetary Institution of Healthcare of Moscow \""City Clinical Hospital No. 40 of the Moscow Department of Healthcare\"", Moscow, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare \""City Multidisciplinary Hospital\"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare \""City Hospital No. 40 of Kurortny District\"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare \""City Hospital No. 15\"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare \""City Pokrovskaya Hospital\"" (4th Cardiology Department), Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare \""City Pokrovskaya Hospital\"", Saint Petersburg, Russian Federation|Regional State Budgetary Institution of Healthcare \""Medical-Sanitary Unit No. 2\"", Tomsk, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""118"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient rate with a transition to category 3 or lower according to the WHO scale by Day 14 after the beginning of drug administration.|Time till clinical improvement, which is described by presence of all of the following factors during 48 hours in a row.|Patient rate with clinical improvement by day 2-28. Presence of all of the following factors during 48 hours in a row.|Patient rate with a negative test result for SARS-CoV-2 by Day 7\u00b11, 15\u00b11, 21 \u00b11 and 28 \u00b1 1.|Duration of hospitalization.|Patient rate transferred to the intensive care unit (ICU) during hospitalization.|Duration of ICU stay.|Patient rate with ARDS during hospitalization.|Presence of a fatal outcome.|Patient rate requiring oxygen therapy by Day 2-28.|Patient rate requiring high-flow oxygen therapy by Day 2-28.|Patient rate requiring non-invasive ventilation by Day 2-28.|Patient rate requiring invasive ventilation by Day 2-28.|Patient rate requiring extracorporeal membrane oxygenation (EMO) by Day 2-28.|The total duration of oxygen therapy by the last day of hospitalization.|The total duration of high-flow oxygen therapy by the last day of hospitalization.|The total duration of non-invasive ventilation by the last day of hospitalization.|The total duration of invasive ventilation of lungs by the last day of hospitalization.|The total duration of EMO by the last day of hospitalization.|Patient rate with Sp02 > 95% by Day 2-28.|Average alteration of Sp02 by Day 2-28 from baseline.|Average time to reach SpO2 \u2265 95%.|Patient rate with RR < 22 \/ min by Day 2-28.|Average alteration in RR by Day 2-28 from baseline.|Average time to reach RR \u2264 22 \/ min.|Patient rate with body temperature < 37.5\u00b0C by Day 2-28.|Average alteration in body temperature by Day 2-28 from baseline.|Average time until the patient reaches a body temperature of \u226437.5\u00b0C.|Patient rate with CT-1 according to CT data by Day 2-28.|Average alteration in CT data by 1 point in terms of severity (CT-1, CT-2, CT-3, CT-4) by Day 7, 10, 15, 18, 21 and 28 compared to the baseline value.|Average time to reach CT-1 according to CT data.|Patient rate with a score < 2 according to the Daytime and Nighttime Cough Scale by Day 2-28.|Mean change in Daytime and Nighttime Cough scores by Day 2-28 from baseline.|Average time to reach < 2 points when assessed according to the Daytime and Nighttime Cough Scale.|Patient rate with a score < 1 for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28.|Average change in score for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28 from baseline.|Average time to reach a score of < 1 for each symptom (general fatigue, feeling of congestion in the chest, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale.|Patient rate with a transition decrease to category 3 or lower according to the WHO scale by Day 2-13 and Day 15-28.|Mean WHO grade change by Day 2-28 from baseline.|Average time to reach the 3rd category or below according to the WHO scale.|Patient rate with a NEWS score < 2 by Day 2-28.|Average change in NEWS score by Day 2-28 from baseline.|Average time to reach a NEWS score \u2264 2.""}"
"1870","Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?","ImmCoV","NCT04469634","1412/20","Diagnostic Test: Assessing antibody responses, neutralizing capacity and memory B-cell function","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04469634","Active, not recruiting","2020-07-31","2021-07-01","{""locations"":""University Hospital Antwerp, Antwerpen, Belgium|Jessa Hospital, Hasselt, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""150"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody levels over time|Antibody neutralizing capacity|Memory B-cell function|Antibody-dependent enhancement|Re-infection with SARS-CoV2""}"
"1871","Awake Pronation for Covid-19 Treatment","","NCT04667286","1117/2020/Sper/AOUBo","Procedure: Prone Position (PP)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04667286","Not yet recruiting","2020-12-30","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of day free of ventilatory support|changes in respiratory pattern|daily changes in the ratio SaO2\/FiO2|dyspnea|comfort during PP""}"
"1872","Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy","Reszinate","NCT04542993","SHS KAPH NSWE 20090","Dietary Supplement: Zinc Picolinate|Dietary Supplement: Resveratrol|Dietary Supplement: Zinc Picolinate Placebo|Dietary Supplement: Resveratrol Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04542993","Active, not recruiting","2020-09-08","2022-06-01","{""locations"":""Swedish Medical Center, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in SARS-CoV-2 Viral load|Reduction in Severity of COVID-19 Disease""}"
"1873","CORE Study COVID-19","","NCT04531202","29496920.8.0000.5262","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04531202","Recruiting","2020-03-02","2021-09-30","{""locations"":""D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical characterization of coronavirus disease-2019 (COVID-19)""}"
"1874","GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)","","NCT04673149","CoV2-001","Biological: GLS-5310|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04673149","Recruiting","2020-12-23","2022-12-31","{""locations"":""Korea University Guro Hospital, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""345"",""age"":""19 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events|Geometric mean titer (GMT) of antigen-specific binding antibody titers|Evaluation of positive response rate of T cell responses induced by GLS-5310 DNA vaccine|Geometric mean titer (GMT) of neutralizing antibody titers""}"
"1875","Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19","","NCT04469153","2020_FerriGly COVID","Other: No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04469153","Recruiting","2020-06-29","2020-12-31","{""locations"":""hopital de la Croix Rousse, Lyon 4, Rhone Alpes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""57"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""assessment of the prognostic value of ferritin in sars-cov2 positiv patients""}"
"1876","Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients","PRONECOVID19","NCT04692129","2020/591","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04692129","Recruiting","2020-05-29","2021-12-31","{""locations"":""Hospital de Cl\u00f1inicas da UNICAMP, Campinas, Sao Paulo, Brazil|Hospital General de M\u00e9xico, M\u00e9xico, Mexico|Parc Taul\u00ed Hospital Universitari, Sabadell, Barcelona, Spain|Hospital Cl\u00ednic i Provincial de Barcelona, Barcelona, Spain|Hospital Parc Salut Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in tissue oxygenation (StO2)|Change in local hemoglobin content (THC)|Compare changes in tissue oxygenation (StO2) and arterial oxygenation (SaO2)""}"
"1877","Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial","MICHELLE","NCT04662684","21589 Michelle Trial","Drug: Rivaroxaban 10 MG","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04662684","Recruiting","2020-10-16","2021-06-30","{""locations"":""Science Valley Research Institute, Santo Andr\u00e9, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""320"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Venous thromboembolism and VTE related-death|Major bleeding""}"
"1878","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","CovidSurg","NCT04323644","CS-20200324","Procedure: Surgery","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04323644","Recruiting","2020-01-01","2020-09-30","{""locations"":""Hospital del Henares, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""30-day mortality|7-day mortality|30-day reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis""}"
"1879","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","HOPE","NCT04344951","UNIKINON-01/HOPE","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04344951","Recruiting","2020-04-06","2021-04-30","{""locations"":""Divine Providence Hospital \""Pammakaristos\"", Athens, Greece|Athens General Hospital \""Hippokrateio\"", Athens, Greece|Athens General Hospital of Thoracic Diseases \""SOTIRIA\"", 1st University Pulmonary Clinic, Athens, Greece|Athens General Hospital of Thoracic Diseases \""SOTIRIA\"", 3rd University Pathology Clinic, Athens, Greece|Corfu General Hospital Agia Irini, Corfu, Greece|University General Hospital of Ioannina, Io\u00e1nnina, Greece|General Hospital of Athens \""Sismanoglio\"", Maro\u00fasi, Greece|University General Hospital of Thessaloniki AHEPA, Thessalon\u00edki, Greece"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""50% reduction in symptom score for patients with lower respiratory tract infection|Lack of progression for patients with upper respiratory tract infection|Comparison of the primary endpoint with respective patients not receiving the treatment|Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment.|Frequency of AEs and SAEs""}"
"1880","Communication in ICU During COVID-19","","NCT04602351","ComICU","Behavioral: Communication","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04602351","Not yet recruiting","2021-01-15","2021-02-15","{""locations"":""NMC Specialty Hospital, Dubai, United Arab Emirates"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in the pattern of family members visiting process|Changes in process of communication between health care workers(HCWs) and family members|Changes in process of informed consent in ICU""}"
"1881","Covid-19 Associated Coagulopathy","","NCT04360824","202004235","Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04360824","Recruiting","2020-05-06","2021-04-16","{""locations"":""University of Iowa, Iowa City, Iowa, United States|Gundersen Health System, La Crosse, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""170"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Major Bleeding|Arterial Thrombosis|Venous Thromboembolism|ICU admission, intubation\/ventilation|Packed Red Blood Cell Transfusions|Platelet Transfusions|Fresh Frozen Plasma Transfusions|Cryoprecipitate Transfusions|Prothrombin Complex Concentrate Transfusions""}"
"1882","Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care","PRONE-COVID","NCT04589936","284061","Procedure: Prone positioning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04589936","Recruiting","2020-09-03","2021-06-30","{""locations"":""Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Peripheral Oxygen saturation|PaO2 :FiO2 ratio calculated from formulae|Respiratory rate measured with Masimo device|Heart rate measured with Masimo device|Blood pressure measured with Masimo device|Patient reported severity of breathlessness on a continuous linear scale of 0 to 10cm (10cm being the most severe)|Patient tolerability of prone position on a continuous linear scale of 0 to 10cm (10cm being the most unacceptable)|Investigator experience of delivering prone positioning|To assess patient's peripheral oxygen saturation""}"
"1883","Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients","","NCT04383548","Mini-pooled IVIG in COVID19","Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04383548","Not yet recruiting","2020-06-01","2021-01-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""21 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Efficacy of COVID19 hyper immunoglobulins for patients|Efficacy of COVID19 hyper immunoglobulins for high risk groups|Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events""}"
"1884","Complications and Mortality Following Emergency Digestive Surgery During the COVID-19 Pandemic","COVIDCIR","NCT04479150","COVIDCIR","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479150","Completed","2020-03-01","2020-08-31","{""locations"":""Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""5307"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30-day mortality|90-day mortality|Postoperative complications|Severe complications|Lenght of stay""}"
"1885","COVID-19 Community Research Partnership","","NCT04342884","IRB00064912","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04342884","Recruiting","2020-04-08","2021-12-01","{""locations"":""Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae""}"
"1886","Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection","","NCT04385095","SG016","Drug: SNG001|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04385095","Recruiting","2020-03-16","2021-05-31","{""locations"":""Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital,, Birmingham, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull, United Kingdom|Glenfield Hospital,, Leicester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|City Campus of Nottingham University, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton Nhs Foundation Trust, Southampton, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""820"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ordinal Scale for Clinical Improvement|Progression to pneumonia (hospital setting only)|Time to clinical improvement (hospital setting only)|National Early Warning Score 2 (NEWS2) assessment of acute-illness severity (hospital setting only)|Changes in daily breathlessness, cough and sputum scale (BCSS)|Safety and tolerability - blood pressure II. Viral load|Safety and tolerability - heart rate II. Viral load|Safety and tolerability - temperature II. Viral load|Safety and tolerability - respiratory rate II. Viral load|Safety and tolerability - oxygen saturation II. Viral load|Safety and tolerability - adverse events II. Viral load|Safety and tolerability - concomitant medications II. Viral load|Time to clinical improvement (home setting only)|Time to improvement of COVID-19 symptoms (home setting only).|Time to self-reported recovery (home setting only)|Self-reported daily rating of overall feeling of wellness (home setting only).|Quality of life measured using EQ-5D-5L (home setting only).|Virus clearance\/load (if samples are available)|Blood and sputum biomarkers (if samples are available).|Contact with health services (home setting only|Consumption of antibiotics (home setting only""}"
"1887","Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)","SARSCoV2CZImun","NCT04453280","UZIS 2020/2","Diagnostic Test: Quantitative analysis of anti-SARS-CoV-2-antibodies|Diagnostic Test: SARS-CoV-2 diagnostic rapid test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453280","Completed","2020-05-18","2020-06-03","{""locations"":""Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""695"",""age"":""8 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the categories of cured patients.|Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the age and to the severity of the disease.|The quantification of the dependence of the change in the concentration of anti-SARS-CoV-2 antibodies.""}"
"1888","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","FMTVDM","NCT04349410","FMTVDM2020","Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04349410","Completed","2020-04-11","2020-09-14","{""locations"":""FHHI-OI-Camelot; QME, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""1800"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status""}"
"1889","Can RIC Prevent Deterioration to Critical Care in Covid19","","NCT04699227","20/SC/0192","Procedure: Cuff application with inflation|Other: Sham inflation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04699227","Recruiting","2020-04-23","2021-04-30","{""locations"":""Royal Free London NHS Foundation Trust,, London, United Kingdom|East and North Hertfordshire NHS TrusEast and North Hertfordshire NHS Trus, Stevenage, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""20"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Endpoint|Secondary Endpoint""}"
"1890","Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19","VIRUS","NCT04370249","RC20_0164","Other: pulmonary ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370249","Completed","2020-04-09","2020-08-31","{""locations"":""Chu de Nantes, Nantes, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""313"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Construction of a composite clinical-echo score (VIRUScore) predictive of risk of worsening respiratory impairment in COVID-19 adult patients admitted to the Emergency Department|Evaluate the prognostic performance of the VIRUScore on the risk of pulmonary aggravation|Evaluate the prognostic performance of the VIRUScore on the risk of severe pulmonary aggravation defined by resuscitation admission and\/or death at D14 (sensitivity, specificity, positive predictive value, negative predictive value).|Construction of a decisional algorithm for triage and management of COVID-19 patients.|Search for \""ultrasound signature\"" (lung fields and\/or severity of involvement) associated with mild (return home) vs. moderate (oxygen therapy) vs. severe (resuscitation\/death) clinical forms.|Evaluate the analytical concordance between the pulmonary ultrasound (LUScore) and the Gold-standard CT-scan (CT score)|Construction of a score predictive of aggravation in the sub-population of patients returned home""}"
"1891","Postpartum Sexual Function in Pregnant Women With COVID-19","","NCT04389489","MTalmacCarol","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389489","Recruiting","2020-05-14","2020-09-30","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""140"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Evaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia Scale""}"
"1892","Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19","","NCT04516811","PROTECT-Patient trial","Biological: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|Biological: Standard of care (SOC) plus placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04516811","Recruiting","2020-09-21","2022-07-31","{""locations"":""Universitas Hospital, Bloemfontein, Free State, South Africa|Mitchells Plain Hospital, Cape Town, Western Cape, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Improvement|Adverse Events of special interest|Serious Adverse Events|Survival|Invasive mechanical ventilation|Disease severity|Time to outcomes of interest|Length of stay meausures|SARS-CoV PCR|Inflammatory markers|Radiography|Fever & Hypoxia|patients with HIV infection and other comorbidities|Timing of IP & Efficacy Outcome|Neutralising Ab|SARS CoV Antibody titre""}"
"1893","EMPOWER - BAME vs COVID","","NCT04399733","EMPOWER-BAME vs COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04399733","Not yet recruiting","2021-02-01","2024-02-01","{""locations"":""Future Genetics Limited, Birmingham, West Midlands, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""12800"",""age"":""6 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Identify COVID-19 specific host-defence (\""protective\"") or predisposing (\""susceptibility\"") genetic biomarkers|Epidemiological profiles of COVID-19 infections in different UK ethnic populations""}"
"1894","Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY","CAPACITY-COVID","NCT04325412","20-161/C","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04325412","Recruiting","2020-03-23","2021-06-23","{""locations"":""University Medical Center Utrecht, Utrecht, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of cardiovascular complications in patients with COVID-19""}"
"1895","NOWDx Test for the Detection of Antibodies to COVID-19","","NCT04690413","NOWDx COVID-19 Antibody POC","Device: NOWDx COVID-19 Test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04690413","Completed","2020-09-01","2020-12-31","{""locations"":""Del Sol Research Management, LLC, Tucson, Arizona, United States|Comprehensive Clinical Research, LLC, West Palm Beach, Florida, United States|Clinical Research Solutions, LLC, Jackson, Tennessee, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""129"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of clinical agreement between NOWDx COVID-19 Test and emergency use authorized or FDA cleared comparator.""}"
"1896","COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience","","NCT04554979","1004","Drug: Hydroxychloroquine Pill","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04554979","Completed","2020-06-01","2020-07-15","{""locations"":""Faculty of Medicine Cairo University, Cairo, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""199"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 disease spectrum and duration|GIT manifestations among COVID-19 patients|Non-communicable disease and COVID-19|Seasonal change and COVID-19|Possible region specific classification for COVID-19 disease""}"
"1897","COVID-19 Child Health Investigation of Latent Disease in Hamburg","C19CHILD","NCT04534608","PV7336","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04534608","Active, not recruiting","2020-05-11","2021-03-31","{""locations"":""Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany"",""study_designs"":""Observational Model: Family-Based|Time Perspective: Prospective"",""enrollment"":""6000"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Acute infection by SARS-CoV-2|Seroconversion for SARS-CoV-2|Immune phenotyping|HLA Typing|Matabolomics""}"
"1898","Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients","NICOVID-REA","NCT04598594","APHP200537|2020-003723-42","Drug: Patch, Nicotine|Drug: Patch, Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04598594","Recruiting","2020-11-06","2021-11-01","{""locations"":""Centre Hospitalier Victor Dupouy - Service de R\u00e9animation polyvalente et USC, Argenteuil, France|CHRU de Besan\u00e7on - Service de M\u00e9decine Intensive R\u00e9animation, Besan\u00e7on, France|Centre Hospitalier Sud Francilien - Service de r\u00e9animation, Corbeil-Essonnes, France|CHU Dijon - H\u00f4pital Fran\u00e7ois Miterrand Service de M\u00e9decine Intensive R\u00e9animation, Dijon, France|H\u00f4pital Simone VEIL - Service d'Anesth\u00e9sie-R\u00e9animation, Eaubonne, France|Grand H\u00f4pital de l'Est Francilien - Site Jossigny - R\u00e9animation, Jossigny, France|H\u00f4pital Bic\u00eatre - Service de M\u00e9decine Intensive R\u00e9animation, Le Kremlin-Bic\u00eatre, France|Grand H\u00f4pital de l'Est Francilien Site Meaux - Service de R\u00e9animation M\u00e9dico-Chirurgicale, Meaux, France|Groupement Hospitalier de la R\u00e9gion de Mulhouse Sud Alsace - Hop Emile MULLER, Mulhouse, France|CHU Nice - H\u00f4pital L'Archet 1 - Service de M\u00e9decine Intensive R\u00e9animation, Nice, France|CHR Orl\u00e9ans Service de M\u00e9decine Intensive R\u00e9animation, Orl\u00e9ans, France|H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re - ICU, Paris, France|H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re - ICU, Paris, France|H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re - Intensive care unit, Paris, France|Institut Mutualiste Montsouris Service de R\u00e9animation Polyvalente, Paris, France|H\u00f4pital Tenon - Service de M\u00e9decine Intensive R\u00e9animation, Paris, France|Centre Hospitalier Ren\u00e9 Dubos - Service de R\u00e9animation M\u00e9dico-Chirurgicale, Pontoise, France|H\u00f4pital DELAFONTAINE Service de M\u00e9decine Intensive R\u00e9animation, Saint-Denis, France|M\u00e9dip\u00f4le H\u00f4pital Priv\u00e9 - MHP Service de M\u00e9decine Intensive R\u00e9animation, Villeurbanne, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Time before successful extubation|Number of days living without invasive mechanical ventilation|Composite score incorporating death and the number of days living without mechanical ventilation|Mean evolution of blood gases|Mean evolution of Tidal Volume (ventilator parameters)|Mean evolution of respiratory rate (ventilator parameters)|Mean evolution of Positive Expiratory Pressure (ventilator parameters)|Mean evolution of plateau pressure (ventilator parameters)|Mean evolution of fraction of inspired oxygen (ventilator parameters)|Evolution of the Sequential Organ Failure Assessment (SOFA) score and its components by organ|Number of days alive without organ failure|Duration of hospitalization in intensive care unit|Duration of hospitalization in hospital|Number of days alive and out of the ICU and hospital|Evolution of viral load|Proportion of active smoker or active vapers or taking nicotine substitutes documented by examination|Proportion of active smoker or active vapers or taking nicotine substitutes documented by urinary cotinine|Mean score of Desire to smoke defined by French Tobacco Craving scale|Mean score of Withdrawal symptoms scale|Mean score of Hospital anxiety and depression scale|Post traumatic stress disorder scale|Mean score of Insomnia severity scale|Cotinin rate in blood""}"
"1899","HFNT vs. COT in COVID-19","COVID-HIGH","NCT04655638","1th Dec 2020","Device: High Flow Nasal Therapy|Device: Conventional Oxygen Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04655638","Recruiting","2021-02-10","2022-03-01","{""locations"":""Pulmonology and Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy, Arezzo, Italy|Respiratory Medicine Unit, \""Policlinico-Vittorio Emanuele San Marco\"" University Hospital, Catania, Italy, Catania, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy G. Giglio Foundation, Cefal\u00f9, Italy, Cefal\u00f9, Italy|Department of Human Pathology of the Adult and Evolutive Age \""Gaetano Barresi\"", Division of Anesthesia and Intensive Care, University of Messina, Policlinico \""G. Martino\"", Messina, Italy, Messina, Italy|IRCCS MultiMedica, Value-Based Healthcare Unit, Sesto San Giovanni, Milan, Italy, Milan, Italy|University Hospital of Modena Policlinico, Respiratory Diseases Unit, Department of Medical and Surgical Sciences SMECHIMAI, University of Modena Reggio Emilia, Italy, Modena, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy, Palermo, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy, Palermo, Italy|Dipartimento Universitario di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza \""G. D'Alessandro\"" (PROMISE), Division of Respiratory Medicine, \""Paolo Giaccone\"" University Hospital, University of Palermo, Italy, Palermo, Italy|Department of Medicina e Chirurgia Universit\u00e0 Insubria Varese-Como, Italy, Pavia, Italy|Emergency Department, \""S. Maria della Misericordia\"" Hospital, Perugia, Italy., Perugia, Italy|Department of Pneumology, A.O.U. Citt\u00e0 della Salute e della Scienza of Turin, Italy., Turin, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""364"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients needing escalation of treatment during hospital stay|Proportion of patients needing intubation during hospital stay|Proportion of patients who receive CPAP during hospital stay|Proportion of patients who receive NIV during hospital stay|Proportion of patients admitted to intensive care unit during hospital stay|Time to escalation of treatment to CPAP\/NIV during hospital stay|Time to escalation of treatment to intubation\/invasive ventilation during hospital stay|National Early Warning Score 2 (NEWS2) during hospital stay|Dyspnea score (BORG scale) during hospital stay|ROX index during hospital stay|Length of stay in hospital|Length of stay in ICU|Days free from CPAP\/NIV during hospital stay|Ventilator-free days during hospital stay|Oxygen-free days during hospital stay|28-day mortality|60-day mortality|Hospital mortality|Treatment interruption due to intolerance during study treatment""}"
"1900","Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers","","NCT04383587","20-004054","Other: Serologic testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04383587","Completed","2020-05-06","2020-07-31","{""locations"":""Mayo Clinic in Florida, Jacksonville, Florida, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID19 Antibody Positivity|Ability to predict immune status\/antibody positivity""}"
"1901","Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection","VitD-COVID19","NCT04482673","00099939","Drug: Daily Vitamin D3|Drug: Daily placebo|Drug: Bolus vitamin D3|Drug: Bolus placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04482673","Recruiting","2020-07-31","2021-12-31","{""locations"":""Medical University of South Carolina, Charleston, South Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""140"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in total circulating 25(OH)D concentration|Change in total circulating 25(OH)D concentration in COVID-19 positives|Change in SARS-CoV-2 antibody titers|Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha|Respiratory symptoms|Signs and symptoms of rhino\/sinusitis|NCI Dietary Intake|Charlson Comorbidity survey|Paffenberger Physical Activity Assessment|Perceived stress|Pandemic stress|NEO-Personality Inventory|GrassrootsHealth Monthly Health assessment""}"
"1902","Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness","ECHO-vid","NCT04498299","Cardiology-004","Diagnostic Test: echocardiogram 2D","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04498299","Recruiting","2020-09-01","2020-11-30","{""locations"":""Hospital Beneficencia Espa\u00f1ola de Puebla, Puebla, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""\u2022 LA volume index|\u2022 LV telediastolic diameter|\u2022 LV telesystolic diameter|\u2022 LV posterior wall|\u2022 RA area|\u2022 RV basal dimensi\u00f3n|\u2022 RV mid cavity dimension;|\u2022 RV longitudinal dimension|\u2022 Distal, RV outflow tract dimension at the distal or pulmonic valve level|\u2022 Proximal RV outflow tract dimension at the proximal subvalvular level|\u2022 TAPSE|\u2022 RV free Wall strain|\u2022 Inferior cava vein PW Doppler|\u2022 E wave mitral|\u2022 A wave mitral|\u2022 E wave \/A wave mitral|\u2022 E-wave at mitral annulus|\u2022 E-wave at mitral annulus \/ A-wave at the mitral annulus|\u2022 E wave\/ E-wave at the mitral annulus|\u2022 E tricuspid (E)|\u2022 A tricuspid (A)|\u2022 E\/A|\u2022 Systolic pulmonary artery pressure|\u2022 E-wave at the tricuspid annulus|\u2022 Mean pulmonary artery pressure|\u2022 Stroke volume|\u2022 Cardiac output""}"
"1903","Post Covid-19 Cardiopulmonary and Immunological Changes","covid-19","NCT04388436","20.05.67","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388436","Active, not recruiting","2020-05-11","2021-10-10","{""locations"":""Mansoura faculty of medicine, Mansoura, Dakahlia, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""measurement of pulmonary function changes either obstructive or restrictive also lung diffusion and if there is remaining interstitial fibrosis|measurement for cardiac function and ejection fraction changes and if there is changes in pulmonary artery pressure|assessment of IGM and IGG level and if there is immunological changes""}"
"1904","Myeloid Cells in Patients With Covid-19 Pneumonia","MyeloidCovid","NCT04590261","APHP201138|2020-A02700-39","Other: Blood sampling|Other: Nasal Brushing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04590261","Not yet recruiting","2020-11-01","2023-11-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""120"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Myeloid cell sub-population phenotype|Myeloid cell functions|Myeloid cell transcriptomic and proteomic study|Transcriptomic study of nasal epithelial cells|Plasma analyte concentration measurement""}"
"1905","Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia","LPSARS2","NCT04505605","LPSARS2","Other: Blood samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04505605","Active, not recruiting","2020-05-14","2020-11-30","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, Ile De France, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the dosage of biomarkers|Link between the biomarkers""}"
"1906","Convalescent Plasma in Pediatric COVID-19","","NCT04458363","STUDY00000789","Biological: Convalescent Plasma (CP)|Drug: Standard COVID-19 therapies","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04458363","Completed","2020-07-04","2020-09-01","{""locations"":""Children's Healthcare of Atlanta, Atlanta, Georgia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""3"",""age"":""up to 22 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion|Change in percent of supplemental oxygen|Number of patients that required change in level of respiratory support|Mortality|Mean length of ICU stay (days)|Mean length of hospital stay (days)|Mean length of ventilation (days)|Number of patients with progression to renal dysfunction and\/or multisystem organ failure|IL-6 level|Number of anti-SARS CoV 2 specific T cells|Diversity of circulating T cells|ARS-CoV-2 Antibody Titer|SARS-CoV-2 Neutralizing Titer""}"
"1907","Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients","COVID-19CAST","NCT04717011","IGX1-COV-NA-20-05","Diagnostic Test: PCR test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04717011","Recruiting","2021-02-01","2021-07-01","{""locations"":""Hospital Ruber Internacional, Madrid, Spain"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 semen result""}"
"1908","Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study","","NCT04605757","714/2020/Oss/AOUBo","Other: Clinical, functional and radiological lung involvement evolution","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04605757","Recruiting","2020-07-30","2021-07-30","{""locations"":""Respiratory and Critical Care Unit - S.Orsola-Malpighi University Hospital, Bologna, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Long term evolution of clinical involvement due to SARS-COV-2 pneumonia \/ symptoms|Long term evolution of clinical involvement due to SARS-COV-2 pneumonia \/ respiratory rate|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - blood gas exchange parameters\/partial pressure of oxygen and partial pressure of carbon monoxide|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - blood gas exchange parameters\/ ph|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - blood gas exchange parameters\/ oxygen saturation|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - blood gas exchange parameters: P\/F ratio|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - pulmonary function tests\/ forced expiratory volume in the first second; forced vital capacity; total lung capacity; residual volume|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - pulmonary function tests\/ FEV1\/FVC ratio and RV\/TLC ratio|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - diffusing capacity of carbon monoxide|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - six minute walking test distance|Long term evolution of functional involvement due to SARS-COV-2 pneumonia - presence of desaturation during six minute walking test|long term evolution of radiological involvement due to SARS-COV-2 pneumonia|identifying possible factors associated to the persistency of clinical, functional and radiological long term lung involvement due to COVID-19""}"
"1909","Halodine Nasal Antiseptic in Patients With COVID-19","","NCT04517188","HDN-N02-COV24A","Drug: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04517188","Not yet recruiting","2021-04-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Nasopharyngeal SARS-CoV-2 Viral Load""}"
"1910","Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome","","NCT04540120","OLT1177-10","Drug: dapansutrile capsules|Drug: placebo capsules","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04540120","Recruiting","2020-09-25","2021-07-01","{""locations"":""National Jewish Health, Denver, Colorado, United States|Atrium Health\/Charlotte-Mecklenburg Hospital Authority, Charlotte, North Carolina, United States|PanAmerican Clinical Research LLC, Brownsville, Texas, United States|J & S Studies, Inc., College Station, Texas, United States|VieCuri Medisch Centrum, Venlo, Netherlands|University Hospital Basel, Basel, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects with clinical deterioration|Proportion of subjects with complete resolution of fever symptoms and shortness of breath|Cumulative incidence of SAEs|Cumulative incidence of Grade 3 and Grade 4 Adverse Events|Discontinuation or temporary suspension of participation|Changes in white cell count|Changes in hemoglobin|Changes in platelets|Changes in creatinine|Changes in glucose|Changes in total bilirubin|Changes in ALT|Changes in AST|Incidence of new infection that occurs during the study|Incidence of opportunistic infections|Time to clinical improvement|Time to sustained absence of fever|Clinical improvement in symptoms relevant to COVID 19|Incidence of hospitalization, supplemental oxygen, mechanical ventilation, or death before Day 15|Duration of hospitalization, supplemental oxygen or mechanical ventilation before Day 15|Clinical improvement in symptoms|Improvement in oxygenation|Change in ALT|Change in AST|Change in blood glucose|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Hemoglobin A1c (HbA1C)|Change in Lactate dehydrogenase (LDH)|Change in Lymphocyte, Absolute count|Change in Monocyte, Absolute count|Change in Neutrophils, Absolute count|Change in Eosinophil, Absolute count|Change in CRP|Change in D-Dimer|Change in Ferritin|Change in Fibrinogen|Change in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR)|Change in IL-1\u03b2|Change in IL-6|Change in IL-18|Change in granulocyte colony-stimulating factor (G-CSF)|Change in interferon-\u03b3-induced protein 10 (IP-10)|Change in C3a""}"
"1911","PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial","PREPARE-IT","NCT04460651","PREPARE-IT. Version 1.2","Drug: Icosapent ethyl (IPE)|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04460651","Recruiting","2020-08-14","2021-01-01","{""locations"":""Instituto de Investigaciones Cl\u00ednicas - Rosario, Rosario, Santa Fe, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of SARS-CoV-2 positive subjects|Highest mean WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group.|Highest mean WHO score up to day 60 for the active treatment group as compared to placebo among subjects with a positive test received at any moment during the study after the first visit|Total cholesterol, LDL, HDL, triglycerides (mg\/dL) at baseline and at day 60|Ultrasensitive C-reactive Protein (mg\/dL) at baseline and at day 60|Difference in hospital length of stay between groups|Difference in duration of mechanical ventilation in both groups|Rate of hospital admissions due to SARS (Severe Acute Respiratory Syndrome) in patients who were negative for SARS CoV-2 upon admission|Mean highest WHO descriptive score in active treatment versus placebo groups up to day 60 among hospitalized patients (WHO grades 3 or more) without serum evidence \/ PCR detecting SARS-CoV-2 infection|Rate of total events, non-fatal myocardial infarction or non-fatal stroke or death (initial and subsequent), up to day 60""}"
"1912","Covid-19 Airway Management","","NCT04689724","20-5620","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04689724","Recruiting","2020-08-10","2022-05-01","{""locations"":""University Health Network, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serious adverse events at intubation|Signs, symptoms or confirmed COVID19 infection in healthcare providers""}"
"1913","A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections","","NCT04623138","COVID Signals","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04623138","Not yet recruiting","2020-11-01","2021-05-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""950"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of database containing physiological, behavioral data in combination with SARS-CoV-2 infection|Correlation between SARS-CoV-2 infection and collected wearable data and self-reported data|Development of analytical models for real-time COVID-19 surveillance at the individual and population levels|Performance of the analytical models for real-time COVID-19 surveillance at the individual and population levels.""}"
"1914","Cardiovascular Consequences After COVID-19","","NCT04452630","2020-36","Other: Infectious Disease and Cardiology Clinical Consultations","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452630","Recruiting","2020-06-23","2021-11-30","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of at least one clinical, biological and\/or imaging cardiovascular anomaly within 1 month of recovering""}"
"1915","COVID-19 and Venous Thromboembolism Risk","","NCT04569344","NOACs-1510-32651_enhancement","Other: Laboratory test positive for SARS-CoV-2 virus","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04569344","Enrolling by invitation","2020-01-01","2022-06-21","{""locations"":""Kaiser Permanente Northern California, Oakland, California, United States|Kaiser Permanente Southern California, Pasadena, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""40000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acute venous thromboembolism (VTE)|Death""}"
"1916","Saved From COVID-19","","NCT04349371","AAAS9992","Drug: Chloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04349371","Terminated","2020-04-21","2021-01-07","{""locations"":""Columbia University Irving Medical Center\/NYP, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""8"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of symptomatic illness in at risk healthcare workers|Number of healthcare workers with symptomatic COVID infections|Number of severe illness in at risk healthcare workers|Number of sero-conversions in at risk healthcare workers|Percentage of patients with adverse events Grade 3 or higher|Percentage of patients with GI intolerance""}"
"1917","Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection","Thy-Support","NCT04348513","T3inj-02/ThySupport","Drug: T3 solution for injection|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04348513","Recruiting","2020-05-29","2021-05-31","{""locations"":""Attikon University General Hospital, Haidari\/Athens, Greece"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of weaning from cardiorespiratory support|Assessment of hemodynamic status|Assessment of pulmonary function|Assessment of hepatic function|Assessment of renal function|Assessment of cardiac function|Assessment of cardiac injury|Assessment of the course of COVID-19 infection|Assessment of clinical outcome and safety""}"
"1918","Emotional Burden of Healthcare Professionals and Covid Infection 19","Emocovid","NCT04350099","87RI20_0015/Emocovid","Other: quetionnary","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04350099","Recruiting","2020-04-15","2021-06-15","{""locations"":""CH Esquirol, Limoges, France|CHU de Limoges, Limoges, France|HCL LYON, Lyon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""anxiety""}"
"1919","Fear Among Dentists During COVID-19 Pandemic","","NCT04383626","COVID-19 pandemic","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383626","Completed","2020-03-02","2020-05-05","{""locations"":""Cairo University, Cairo, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""216"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""fear among dentist during COVID 19 epidemic|practice modification among dentist during COVID 19 epidemic""}"
"1920","Tenecteplase in Patients With COVID-19","","NCT04505592","GCO 20-1764","Drug: Tenecteplase|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04505592","Recruiting","2020-09-25","2021-12-01","{""locations"":""Mount Sinai Hospital, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants free of respiratory failure|Number of occurrences of bleeding|Number of participants with in-hospital deaths at 14 days|Number of participants with death at 28 days|Number of ventilator-free days|Number of respiratory failure-free days|Number of vasopressor-free days|Vasopressor doses at 24 hours|Vasopressor doses at 72 hours|P\/F ratio at 24 hours|P\/F ratio at 72 hours|Number of ICU-free days|Hospital length of stay|Number of participants with new-onset renal failure|Number of participants with need for renal replacement therapy""}"
"1921","COVID-19 in Patients With HIV","","NCT04333953","262095","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04333953","Recruiting","2020-04-01","2020-10-01","{""locations"":""University of Missouri-Columbia, Columbia, Missouri, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality|Frequency of patients requiring hospital admissions|Frequency of patients requiring ICU admissions|Frequency of respiratory support use|Frequency of kidney injury|Frequency of liver injury""}"
"1922","Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est","","NCT04366206","GHTRB-2020-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366206","Recruiting","2020-03-14","2020-07-31","{""locations"":""Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Groupe Hospitalier Pitie Salpetriere, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""143"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Composite of death and mechanical ventilation|Need for mechanical ventilation|Death|Acute kidney injury|Acute respiratory distress syndrome|Cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation""}"
"1923","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","CORIMUNO19-ECU","NCT04346797","APHP200375-4","Drug: Eculizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04346797","Recruiting","2020-04-16","2020-12-31","{""locations"":""Saint Louis, Paris, Ile De France, France|R\u00e9animation m\u00e9dicale, Paris, France|saint Louis, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival without needs of intubation at day 14|Change in organ failure at day 3|Intubation free survival at day 14|WHO progression scale at days 4, 7 and 14|Survival at 14, 28 and 90 days|Time to discharge|Time to oxygen supply independency|Time to negative viral excretion|Incidence of secondary infections|Vasopressor-free survival|Ventilator-free survival|28-day ventilator-free days|Incidence of dialysis|PaO2\/FiO2 ratio|Rate of respiratory acidosis at day 4|Time to ICU discharge""}"
"1924","Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19","","NCT04411667","COVID-IVIG|2004902","Drug: Octagam","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04411667","Active, not recruiting","2020-04-28","2020-11-30","{""locations"":""Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hospital, San Diego, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""34"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical Ventilation|Oxygen Therapy|Length of Stay""}"
"1925","Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure","","NCT04642638","COVID19-311|INNOVATE","Drug: INO-4800|Device: CELLECTRA® 2000|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04642638","Active, not recruiting","2020-11-30","2022-09-01","{""locations"":""Synexus Clinical Research US, Inc - Phoenix Southeast, Chandler, Arizona, United States|Central Phoenix Synexus Clinical Research, Phoenix, Arizona, United States|AMR Tempe, Tempe, Arizona, United States|Optimal Research, LLC, San Diego, California, United States|AMR South Florida, Coral Gables, Florida, United States|Clinical Research Trials of Florida, Inc, Tampa, Florida, United States|AMR Lexington, Lexington, Kentucky, United States|Walter Reed Army Institute of Research, Silver Spring, Maryland, United States|Ascension St. John Hospital, Detroit, Michigan, United States|AMR Kansas City, Kansas City, Missouri, United States|AMR, Clinical Research Consortium- Las Vegas, Las Vegas, Nevada, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Tekton Research, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""401"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 2: Change From Baseline in Antigen-specific Cellular Immune Response Measured by Interferon-gamma (IFN-\u03b3) Enzyme-linked Immunospot (ELISpot) Assay|Phase 2: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay|Phase 3: Percentage of Participants With Virologically-confirmed COVID-19 Disease|Phase 2 and 3: Percentage of Participants With Solicited and Unsolicited Injection Site Reactions|Phase 2 and 3: Percentage of Participants With Solicited and Unsolicited Systemic Adverse Events (AEs)|Phase 2 and 3: Percentage of Participants With Serious Adverse Events (SAEs)|Phase 2 and 3: Percentage of Participants With Adverse Events of Special Interest (AESIs)|Phase 3: Percentage of Participants With Death From All Causes|Phase 3: Percentage of Participants With Non-Severe COVID-19 Disease|Phase 3: Percentage of Participants With Severe COVID-19 Disease|Phase 3: Percentage of Participants With Death From COVID-19 Disease|Phase 3: Percentage of Participants With Virologically-Confirmed SARS-CoV-2 Infections|Phase 3: Days to Symptom Resolution in Participants With COVID-19 Disease|Phase 3: Change From Baseline in Antigen-specific Cellular Immune Response Measured by IFN-gamma ELISpot Assay|Phase 3: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay""}"
"1926","Use of Ascorbic Acid in Patients With COVID 19","","NCT04323514","3143","Dietary Supplement: Vitamin C","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04323514","Recruiting","2020-03-13","2021-03-13","{""locations"":""A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging""}"
"1927","NOSOcomial COVID-19 in ICU (NOSOCOVID)","NOSOCOVID","NCT04659356","MR_NOSOCOVID","Other: Patients admitted in Intensive Care Units","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659356","Recruiting","2020-09-01","2021-03-01","{""locations"":""Nantes University Hospital, Nantes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of nosocomial COVID-19|Occurrence of a nosocomial COVID-19 that is certain and Occurrence of a nosocomial COVID-19 that is probable.|evaluate the occurence""}"
"1928","Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children","CONCOR-KIDS","NCT04377568","1000070143","Biological: Convalescent plasma (CP)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04377568","Recruiting","2020-10-07","2022-05-01","{""locations"":""Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montr\u00e9al, Quebec, Canada|McGill Univ Health Ctr - Montreal Children's Hospital, Montr\u00e9al, Quebec, Canada|Jim Pattison Children's Hospital, Saskatoon, Saskatchewan, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Clinical recovery|Combined mortality\/intubation|Respiratory status-1|Respiratory status-2|Respiratory status-3|respiratory status -4|respiratory status -5|respiratory status-6|Mortality 1a|Mortality 1b|Mortality 2a|Mortality 2b|Care and Critical Care|organ systems: renal|organ systems: cardiac|Transfusion-associated adverse events (AE)|Safety of the intervention|organ systems: multi-system inflammatory disease""}"
"1929","Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments","","NCT04527601","SafeBoosC COVID-19 ELGAN study","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04527601","Completed","2020-08-21","2020-09-13","{""locations"":""Neonatalklinikken, Rigshospitalet, Copenhagen, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""885"",""age"":""22 Weeks to 28 Weeks \u00a0 (Child)"",""outcome_measures"":""Number of ELGAN admissions during peak three months of COVID-19 compared to corresponding months in 2019|Regional difference in ELGAN admissions during peak three months of COVID-19 compared to corresponding months in 2019|Correlation between the level of lockdown restrictions and number of ELGAN admissions during peak three months of COVID-19 compared to corresponding months in 2019""}"
"1930","The Açaí Berry COVID-19 Anti-Inflammation Trial","ACAI","NCT04404218","CTO3176","Dietary Supplement: Açaí palm berry extract - natural product|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04404218","Recruiting","2020-08-04","2021-05-01","{""locations"":""Heart Health Institute Research Inc, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""480"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""7-point ordinal symptom scale|The composite of all-cause mortality and need for mechanical ventilation|The composite of all-cause mortality and hospitalization|All-cause mortality|Need for mechanical ventilation|Need for hospitalization""}"
"1931","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","","NCT04261517","HC-COVID-19","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04261517","Completed","2020-02-06","2020-02-25","{""locations"":""Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2""}"
"1932","Effects of Early Use of Nitazoxanide in Patients With COVID-19","","NCT04552483","SARITA-2|RBR-4nr86m|32258920.0.1001.5257","Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04552483","Completed","2020-06-08","2020-09-05","{""locations"":""Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""392"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days with fever|Days with cough|Days with asthenia|SARS-COV-2 viral load - absolute number|SARS-COV-2 viral load - percentage|Hospital admission rate - absolute number|Hospital admission rate - percentage|Serum Interleukin-6|Serum Interleukin-1-beta|Serum Interleukin-8|Serum tumor necrosis factor (TNF)-alfa|Serum interferon-gamma|Serum monocyte chemoattractant protein (MCP)-1|Complete blood count|C-reactive protein - absolute number|C-reactive protein - percentage""}"
"1933","Description of the Population With Genitourinary Tumors and COVID-19","SOGUGCOVID","NCT04578132","SOG-INM-2020-04","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04578132","Recruiting","2020-11-24","2021-10-01","{""locations"":""Institut Catal\u00e0 d'Oncologia L'Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Althaia, Manresa, Barcelona, Spain|Hospital Universitari Parc Taul\u00ed, Sabadell, Barcelona, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall d Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain|Instituto Catal\u00e1n de Oncolog\u00eda- Girona, Girona, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Cl\u00ednico San Carlos de Madrid, Madrid, Spain|Hospital Infanta Leonor,, Madrid, Spain|Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Quironsalud, Madrid, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Complejo Hospitalario Universitario Ourense, Orense, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Nuestra Se\u00f1ora del Prado, Talavera De La Reina, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Instituto Valenciano de Oncolog\u00eda, Valencia, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Miguel Servet, Zaragoza, Spain"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Other"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Baseline characteristics|Frequency of complications of COVID-19 intercurrent infection|Frequency of complications of COVID-19 infection in patients stratified by oncological treatment|Frequency of adverse events related to immunotherapy targeted to cancer (classified by type and severity)|Frequency of complications of COVID-19 infection in patients with prostate cancer stratified by anti-androgenic oncological treatment|COVID-19 mortality rate in patients with genitourinary cancer|COVID-19 complication rate in patients with genitourinary cancer|Asymptomatic rate|Frequency of delays\/modifications on cancer treatment schedule|Progression free survival in patients with genitourinary tumors that suffered COVID-19|Overall survival in patients with genitourinary tumors that suffered COVID-19""}"
"1934","Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil)","SARS-Brazil","NCT04479488","30047620.3.0000.0071","Other: Hospital admission|Other: Non-hospitalization procedures","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479488","Recruiting","2020-07-27","2021-02-01","{""locations"":""Hospital de Emergencia Dr. Daniel Houly, Arapiraca, Alagoas, Brazil|Universidade Federal da Bahia, Vit\u00f3ria Da Conquista, Bahia, Brazil|Alencar Servi\u00e7os M\u00e9dicos Ltda, Barbalha, Cear\u00e1, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, Espirito Santo, Brazil|Hospital Santa Rita de C\u00e1ssia, Vit\u00f3ria, Espirito Santo, Brazil|Funda\u00e7\u00e3o Educacional Lucas Machado, Belo Horizonte, Minas Gerais, Brazil|Funda\u00e7\u00e3o Hopitalar S\u00e3o Francisco de Assis, Belo Horizonte, Minas Gerais, Brazil|Hospital Santa Lucia, Po\u00e7os De Caldas, Minas Gerais, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital S\u00e3o Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Santa Casa de Votuporanga, Votuporanga, S\u00e3o Paulo, Brazil|Hospital Municipal Vila Santa Catarina, S\u00e3o Paulo, Brazil|Hospital S\u00e3o Camilo - Ipiranga, S\u00e3o Paulo, Brazil|Hospital S\u00e3o Camilo - Pomp\u00e9ia, S\u00e3o Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Incidence and course of symptoms of COVID-19 infection|Hospitalizations|Oxygen supplementation|Use of invasive mechanical ventilation|Intensive care unit length of stay""}"
"1935","Tannin Specific Natural Extract for COVID-19 Infection","TanCOVID","NCT04403646","HCJSM-20-005","Dietary Supplement: ARBOX|Other: PLACEBO","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04403646","Terminated","2020-06-12","2020-11-01","{""locations"":""Hospital de Clinicas, Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""124"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to hospital discharge|28-day all-cause mortality|invasive ventilation on day 28|Difference in Pro and antiinflammatory citoquine levels|Difference in fecal intestinal microbiota composition|Negativization of COVID-PCR at day 14""}"
"1936","Sargramostim Use in COVID-19 to Recover Patient Health","SCOPE","NCT04707664","PTX-001-003","Drug: Sargramostim|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04707664","Not yet recruiting","2021-03-01","2021-06-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19-related emergency room visit or COVID-19- related hospitalization, or death (any cause)|Disease Progression based on NIAID Score|Time to Disease Progression based on NIAID Score|Change from Baseline in Symptom Scores|Adverse Events""}"
"1937","Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","","NCT04347681","HAEM0321","Other: convalescent plasma from recovered COVID 19 donor","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04347681","Recruiting","2020-04-18","2021-04-11","{""locations"":""John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia|Dammam Medical Complex, Dammam, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia|king Fahad specialist hospital, Dammam, Saudi Arabia|DHahran Military Medical Complex, Dhahran, Saudi Arabia|International Medical Center, Jeddah, Saudi Arabia|Madinah General Hospital, Medina, Saudi Arabia|Ohud Hospital, Medina, Saudi Arabia|Taibah University, Medina, Saudi Arabia|Qatif Central Hospital, Qatif, Saudi Arabia|King Abdulaziz Medical City, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""575"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU length of stay|Safety of convalescent plasma & Serious adverse reactions.|Number of days on mechanical ventilation|30 days of mortality|Days to clinical recovery .""}"
"1938","Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","IMPROVE","NCT04367831","AAAS8980","Drug: Enoxaparin Prophylactic Dose|Drug: Heparin Infusion|Drug: Heparin SC|Drug: Enoxaparin/Lovenox Intermediate Dose","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04367831","Recruiting","2020-05-02","2021-04-01","{""locations"":""Columbia University Medical Center, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU|Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events|ICU Length of Stay|Total Number of Patients with the Need for Renal Replacement Therapy in the ICU|Total Number of Patients with Major bleeding in the ICU|Hospital Length of Stay""}"
"1939","Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early","ACHIEVE","NCT04398004","ACHIEVE|2020-001882-36","Drug: Clarithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04398004","Completed","2020-05-06","2020-11-30","{""locations"":""COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Io\u00e1nnina, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus \""Tzaneio\"", Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessalon\u00edki, Greece"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical outcome negative for two parameters(hospital admission\/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission\/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10\/TNF\u03b1 ratio between days 1 and 8""}"
"1940","Different PEEP Settings of COVID-19 Induced ARDS","","NCT04359251","COVID-19 PEEP titration","Other: Gas exchanges at different PEEP|Other: lung mechanics at different PEEP|Other: Hemodynamics changes at different PEEP","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04359251","Completed","2020-03-05","2020-03-25","{""locations"":""Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Respiratory system compliance improvement|Gas echanges improvement""}"
"1941","Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children","CiaoCorona","NCT04448717","2020-01336","Diagnostic Test: COVID-19 Antibody testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04448717","Recruiting","2020-06-16","2021-03-01","{""locations"":""Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""8000"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Seroprevalence of SARS-CoV-2 IgG, IgM and\/or IgA antibodies|Presence of self-reported symptoms|Proportion of seropositive children reporting COVID-19 related symptoms from January 2020|Incidence of symptoms in initially seropositive participants|Proportion of participants, seronegative at inclusion, with symptoms in the follow-up|Presence of risk factors for infection at inclusion (assessment via custom questionnaire)|Presence of risk factors for infection during follow-up (assessment via custom questionnaire)|Self-reported lifestyle changes of participants at inclusion|Self-reported lifestyle changes of participants during follow-up|Self-reported mental well-being (KINDL questionnaire)|Self-reported mental well-being (HBSC questionnaire)|Self-reported quality of life (KINDL questionnaire)|Prevalence of seropositive SARS-Cov-2 clusters in schools at inclusion|Incidence of seropositive SARS-Cov-2 clusters in schools during the follow-up|Change in seropositive participants within school or class, depending on the initial proportion of seropositive participants|Effect of risk factors and preventive measures on SARS-CoV-2 infection incidence within schools""}"
"1942","Nebulised Dornase Alfa for Treatment of COVID-19","COVASE","NCT04359654","132333","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04359654","Recruiting","2020-06-16","2021-11-01","{""locations"":""University College London Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measuring the change in inflammation|Number of patients that are alive at 28 days|Amount of days that patient requires oxygen|Average oxygenation index|Days patient admitted to hospital|Percentage of patients that need mechanical ventilation""}"
"1943","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Covid-19","NCT04333862","2020-00563","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04333862","Recruiting","2020-03-19","2022-01-31","{""locations"":""Guido Beldi, Bern, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire""}"
"1944","Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19","","NCT04389515","MTalmac3","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389515","Recruiting","2020-05-14","2020-09-30","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""75"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Evaluation of pregnant women diagnosed with COVID-19 with \""Post-operative Recovery Index\"" and \""Prenatal Care Satisfaction and Patient Expectations Scale\""""}"
"1945","Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation","","NCT04447469","KPL-301-C203","Drug: mavrilimumab|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04447469","Recruiting","2020-07-27","2022-02-01","{""locations"":""UCLA Medical Center, Los Angeles, California, United States|Sharp Health Care, San Diego, California, United States|Affinity Health, Oak Brook, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Allina Health System, Minneapolis, Minnesota, United States|Mercy Hospital, Springfield, Missouri, United States|University of Cincinnati, Cincinnati, Ohio, United States|Bryn Mawr, Bryn Mawr, Pennsylvania, United States|University of Texas Health Sciences, Houston, Texas, United States|Instituto M\u00e1rio Penna, Belo Horizonte, Brazil|Hospital Adventista de Belem, Bel\u00e9m, Brazil|UPECLIN - Unidade de Pesquisa Cl\u00ednica, Botucatu, Brazil|IPECC - Instituto de Pesquisa Cl\u00ednica de Campinas, Campinas, Brazil|IEP HGF - Instituto de Estudos e Pesquisas Clinicas do Cear\u00e1, Fortaleza, Brazil|Hospital Bruno Born, Lajeado, Brazil|Centro de Pesquisas Cl\u00ednicas, Natal, Brazil|Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo, Ribeir\u00e3o Preto, Brazil|Hospital Cardio Pulmonar, Salvador, Brazil|Funda\u00e7\u00e3o Faculdade Regional de Medicina de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9, Brazil|Hospital Alem\u00e3o Oswaldo Cruz, S\u00e3o Paulo, Brazil|Clinica Providencia, Santiago, Chile|Clinica Las Condes, Santiago, Chile|Hospital Essalud Alberto Sabogal Sologuren, Bellavista, Peru|Essalud - Hospital de Emergencias Grau, Lima Cercado, Peru|Hospital Nacional Cayetano Heredia, San Mart\u00edn De Porres, Peru|Clinica Providencia, San Miguel, Peru|IATROS International, Bloemfontein, South Africa|Tiervlei Trial Center, Cape Town, South Africa|TASK Eden, George, South Africa|Into Research - Little Company of Mary Medical Center, Pretoria, South Africa|Limpopo Clinical Research Initiative, Rustenburg, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""588"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cohort 1: Proportion of Participants Alive and Free of Mechanical Ventilation at Day 29|Cohort 2: Mortality Rate at Day 29|Cohort 1: Time to 2-point clinical Improvement by Day 29|Cohort 1: Time to return to room air or discharge by Day 29|Cohort 1: Mortality rate at Day 29|Cohort 2: Time to 1-point clinical improvement by Day 29""}"
"1946","Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients","","NCT04613050","MAHA2020","Other: Respiratory Training|Other: Aerobic training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04613050","Recruiting","2020-07-02","2022-02-20","{""locations"":""Police hospital-Nasr city, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""35 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Complete blood picture|Arterial blood gases|6-minute walk Distance|Breath-hold test|Oxygen saturation|Borg Dyspnea Scale score|Maximum oxygen consumption""}"
"1947","Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","","NCT04608305","IIBR 20-001","Biological: IIBR-100, low dose (prime)|Biological: IIBR-100 medium dose (prime)|Biological: IIBR-100 high-dose (prime)|Biological: IIBR-100 low-dose (prime-boost)|Other: Saline Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04608305","Recruiting","2020-10-28","2022-06-01","{""locations"":""Assuta - University Hospital, Ashdod, Israel|Barzilai MC, Ashkelon, Israel|Rambam MC, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir MC, Kfar Saba, Israel|Rabin MC, Petach Tikva, Israel|Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel|Sourasky MC, Tel Aviv, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1040"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase I and II - The number, grade and percentage of study participants who experience any study injection-associated AEs or SAEs.|Phase II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 per group at 28 days following last vaccination (in relation to Day 0-baseline).|Phase I and II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 at baseline (day 0) and throughout the study|Phase I and II - IIBR-100 immunogenicity as determined by GMT, GMFR, Seroconversion rates of the binding antibody titers to SARS-CoV-2 at baseline (day 0) and throughout the study|Phase I and II - Cellular immunity as assessed by ELISPOT and ELISA.""}"
"1948","Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH","COVIDHLH","NCT04347460","161/20 S","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347460","Recruiting","2020-03-27","2020-08-31","{""locations"":""Department of nephrology, Klinikum rechts der Isar, M\u00fcnchen, Bavaria, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of sHLH as determined by expert chart review by two independent reviewers|Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection|Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin > 10000 \u03bcg\/L) in Covid 19 viral infection|Characterization and incidence of the hyper-inflammatory state in COVID-19|all cause mortality assesed on day 15|all cause mortality assesed on day 29|immunophenotpye""}"
"1949","Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.","CORIMUNO-NIVO","NCT04343144","APHP200389-5","Drug: Nivolumab Injection","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04343144","Not yet recruiting","2020-04-15","2020-09-30","{""locations"":""Pneumologie h\u00f4pital Tenon, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""92"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Overall survival|Cumulative incidence of ICU admission|Length of hospital stay|Positive nasal PCR|Incidence of adverse events|Incidence of grade 3-4 adverse events|World Health Organisation (WHO) progression scale""}"
"1950","Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies","","NCT04515108","E1-20-672","Other: Clinical assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04515108","Completed","2020-03-10","2020-08-10","{""locations"":""Ankara City Hospital, Ankara, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""108"",""age"":""18 Years to 42 Years \u00a0 (Adult)"",""outcome_measures"":""complete blood count parameters (including the number of lymphocytes, Leukocytes, monocytes, platelets and red blood cells).|APGAR score|maternal and newborn length|maternal and newborn weight|body temperature""}"
"1951","Clinical Features of Severe Patients With COVID-19","","NCT04450017","COVID-ICU","Diagnostic Test: The demographic, clinical, laboratory, and instrumental data","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04450017","Recruiting","2020-04-06","2020-08-01","{""locations"":""Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""150"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation duration|Non-invasive Mechanical ventilation duration|Mortality|\u0421omplete blood count|Biochemistry analysis|\u0421omplete blood count dynamics|Biochemistry analysis dynamics|Computer tomography|High-sensitive troponin \u0422|High-sensitive troponin \u0422 dynamics|Vitamin D level|Vitamin D level dynamics|Immunogram|Immunogram dynamics""}"
"1952","Ivermectin in Adults With Severe COVID-19.","","NCT04602507","ECA-COVID-CES","Drug: Ivermectin|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04602507","Recruiting","2020-12-07","2021-03-01","{""locations"":""Clinica CES, Medell\u00edn, Antioquia, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Admission to the intensive care unit.|Hospital length of stay.|Mortality rate.|ICU length of stay.|Length of stay in ventilator time.|Adverse effects of ivermectin.""}"
"1953","REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia","RESOLVE","NCT04468971","CK0802.501.1","Biological: CK0802|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04468971","Recruiting","2020-09-29","2021-09-30","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States|Columbia University, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Baylor College of Medicine, St Luke's Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Regimen related \u2265 grade 3 toxicity within 48 hours of first infusion|28-day treatment success, defined as S28|Time to extubation|Oxygenation improvement|Ventilator free days|Organ failure free days|ICU free days|All-cause mortality""}"
"1954","NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure","","NCT04342104","08-04-2020","Other: Monitoring for aggravation|Other: Evaluate HACOR score effectivity in this patients","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04342104","Recruiting","2020-04-01","2021-11-15","{""locations"":""Hospital General Universitario Morales Meseguer, Murcia, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""HACOR score efficacy|HACOR score addaptation""}"
"1955","Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients","COVIDEYE","NCT04654325","APHP201268|2020-A02996-33","Diagnostic Test: conjunctival swab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04654325","Not yet recruiting","2020-12-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""1280"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""presence of SARS-CoV-2 genome in tears|presence of systemic symptoms evaluated at the time of making an appointment by a systematic standardized interrogation|assessement of viral load levels""}"
"1956","Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD)","","NCT04565080","10000159|000159-N","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04565080","Recruiting","2021-03-16","2021-12-31","{""locations"":""National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in neurological symptoms domain of the survey between pre and post COVID 19 in FMD and PD patients.""}"
"1957","Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients","NICOVID","NCT04608201","APHP200529|2020-003743-28","Drug: Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|Drug: Placebo of NICOTINE Transdermal patch","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04608201","Recruiting","2020-12-09","2021-12-01","{""locations"":""Hospital Piti\u00e9-Salp\u00eatri\u00e8re - AP-HP, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The unfavorable outcome on Day 14|Survival rate|Proportion of transfer to intensive care unit (ICU)|Proportion of indication of transfer to intensive care unit (carried out or not in case of LATA)|Number of days living without mechanical ventilation|Number of days living without non-invasive ventilation and mechanical ventilation|Proportion of patient with a score higher than 6 on the World Health Organization 10-point Clinical Progression Scale|Duration of hospitalization|Proportion of patient in each category of the World Health Organization 10-point Clinical Progression Scale|Proportion of patient in each category of the National Early Warning Scale (NEWS) 2|Proportion of patient with a SARS-CoV-2 viral load detection|Mean evolution of blood count|Mean evolution of platelets|Mean evolution of blood ionogram|Mean evolution of glycemia|Mean evolution of serum creatinine|Mean evolution of C reactive protein|Mean evolution of Interleukin 6 (IL-6)|Mean evolution of oxygen requirements (number of liters \/ min)|Mean evolution of SaO2|Proportion of active smoker or active vapers or taking nicotine substitutes documented by examination|Proportion of active smoker or active vapers or taking nicotine substitutes documented by urinary cotinine|Mean score of Desire to smoke defined by French Tobacco Craving questionnaire (FTCQ12 )|Mean score of Cigarette Withdrawal Scale (CWS)|Mean score of Hospital anxiety and depression scale (HAD)|Mean score of Positive and Negative Affect Schedule (PANAS)|Mean score of Insomnia severity scale (ISI)|weight evolution""}"
"1958","COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry","","NCT04559009","AH-NSI-COVID19-ALS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04559009","Recruiting","2020-10-15","2024-04-30","{""locations"":""Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 incidence and prevalence in the ALS population""}"
"1959","Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection","","NCT04375098","200415015","Biological: COVID-19 convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04375098","Completed","2020-05-04","2020-08-17","{""locations"":""Hospital Cl\u00ednico Universidad Cat\u00f3lica, Santiago, Chile"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""58"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization|Median duration of fever|Median duration of mechanical ventilation|Median length of ICU stay|Median length of admission|Hospital mortality rate (percentage)|30-day mortality (percentage)|Readmission rate (percentage)|Median length of viral clearance""}"
"1960","Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient","COVID-19","NCT04595136","COVID19-0001-USR","Drug: Drug COVID19-0001-USR|Drug: normal saline","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04595136","Not yet recruiting","2020-11-02","2021-01-29","{""locations"":""Cimedical, Barranquilla, Atlantico, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change on viral load results from baseline after using COVID19-0001-USR via nebulization""}"
"1961","Safety of TY027, a Treatment for COVID-19, in Humans","","NCT04429529","SCT-001","Biological: TY027|Other: 0.9% Saline","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04429529","Active, not recruiting","2020-06-09","2021-02-01","{""locations"":""SingHealth Investigational Medicine Unit, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""21 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-\u221e) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Half-Life (t1\/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment""}"
"1962","COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey","","NCT04470648","C20-50","Diagnostic Test: blood test for SARS-COV2 serology","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04470648","Recruiting","2020-07-22","2021-08-01","{""locations"":""Haltes pour femmes, Paris, France|LHSS Saint-Michel, Paris, France|LHSS Ridder-Plaisance, Paris, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""183"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-COV-2 seroprevalence in 3 centers for homeless and people in social distress|Morbidity rate|Covid-19 related death rate in the 3 centers from March to May 2020|Ratio of negative serology rate and positive serology rate in the 3 centers|Ratio of SARS-COV2 seroprevalence obtained in these centers to the estimated seroprevalence in the Ile de France region|kinetics of SARS-COV2 antibodies in people with initial positive serology""}"
"1963","Efficacy of Iodine Complex Against COVID-19 Patients","I-COVID-PK","NCT04473261","SZMC/IRB/Internal/216/2020","Drug: Iodine Complex|Drug: Placebo|Drug: Idoine Complex","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04473261","Recruiting","2020-07-14","2021-08-15","{""locations"":""Shaikh Zayed Hospital, Lahore, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""qRT-PCR|HRCT chest|Severity of Symptoms""}"
"1964","Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia","","NCT04424771","PTSD-COVID-19","Behavioral: Maslach Burnout Inventory (MBI)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424771","Completed","2020-03-01","2020-07-01","{""locations"":""Ospedale Perrino Asl Brindisi, Brindisi, Italy|Piazza della Vittoria 14 Studio medico - Ginecologia e Ostetricia, Genoa, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with diagnosis of PTSD.""}"
"1965","Sustained Immunity to SARS-CoV-2","","NCT04562285","13978","Diagnostic Test: Serologic immunoassays to SARS-CoV-2 antibodies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04562285","Recruiting","2020-06-23","2021-06-01","{""locations"":""Henry Ford Health System, Detroit, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Detection of antibodies to SARS-CoV-2 in human serum and plasma""}"
"1966","Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study","COVIDANS","NCT04374045","20CH095|2020-A01082-37","Other: ECG-Holter","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374045","Completed","2020-04-30","2020-06-18","{""locations"":""CHU Hopital nord, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of dysautonomia patients found within the first 24 hours of hospitalization (%)|Analyse the other mathematical indices measuring autonomic balance, obtained by Holter-ECG recording over the first 24 hours and throughout their hospitalisation, in search of possible dysautonomia|To investigate whether the autonomic balance of patients with CoV-2 SARS correlates with the severity of their clinical condition during their hospital stay.|To investigate whether the various autonomic parameters recorded are predictive of clinical worsening or improvement, by calculating a prediction threshold for each of the parameters.""}"
"1967","A Trial of Remdesivir in Adults With Severe COVID-19","","NCT04257656","CAP-China remdesivir 2","Drug: Remdesivir|Drug: Remdesivir placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04257656","Terminated","2020-02-06","2020-04-10","{""locations"":""Bin Cao, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""237"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of \u2264 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events""}"
"1968","EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19","MERMAIDS 2","NCT04364711","ReCoVer - MERMAIDS 2.0","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04364711","Not yet recruiting","2020-05-01","2022-04-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Pneumonia Severity indexes|Need for supplemental oxygen; non-invasive or invasive mechanical ventilation; extra-corporeal life support|Hospital - and ICU\/HCU length of stay|In-hospital mortality|Activities of daily life, quality of life, variations in home living status and employment status|Proportion of SARS-CoV2 positive patients""}"
"1969","Home-based Kidney Care in Native Americans of New Mexico (HBKC) - Enhancement","","NCT04520191","16-344-Enhancement","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04520191","Not yet recruiting","2020-09-01","2021-09-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""529"",""age"":""21 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disruption in Health care""}"
"1970","AiM Covid Self Monitoring","","NCT04425044","Au015","Other: Other","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04425044","Completed","2020-04-12","2020-05-28","{""locations"":""Mothers Touch Foundation, Mumbai, Maharashtra, India|NMP Medical Research Institite, Jaipur, Rajasthan, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fever|Shortness of Breath|Cough|Sore Throat|Headache|Muscle\/ Joint Pain|Diarrhoea|Vomiting\/ Nausea|Runny Nose|Loss of Smell\/Taste|Other symptoms""}"
"1971","COVID-19 and Lung Ultrasound Utility","","NCT04591158","0001","Device: Butterfly iQ","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04591158","Recruiting","2020-09-15","2021-09-01","{""locations"":""Markham Stouffville Hospital, Markham, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""100"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""If patients can perform lung ultrasound.|Correlate LUS radiographic findings with patient outcomes""}"
"1972","RT-PCR Database Analysis for COVID-19 Infections and Re-infection","ReCOV","NCT04653844","RECHMPL20_0640","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04653844","Active, not recruiting","2020-02-01","2021-03-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""7000000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""SARS-CoV-2 reinfection rate""}"
"1973","Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19","PHYSIO-COVID","NCT04347928","2020_32|2020-A00957-32","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347928","Completed","2020-04-20","2020-11-06","{""locations"":""Hopital Roger Salengro, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""intrapulmonary shunt ratio|Evolution of respiratory variables|Evolution of hemodynamic stability variables""}"
"1974","COVID-19 Mortality Prediction Model","","NCT04358510","04202001","Device: COViage","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04358510","Completed","2020-04-01","2020-04-17","{""locations"":""Dascena, Oakland, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""114"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality outcome in COVID-19 ICU patients|Mortality outcome in mechanically ventilated ICU patients|Mortality outcome in pneumonia ICU patients""}"
"1975","Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19","","NCT04392531","FJD-COVID19-20-01","Drug: Cyclosporine|Drug: Standard treatment","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04392531","Recruiting","2020-04-16","2021-03-01","{""locations"":""Complejo Hospitalario Universitario La Coru\u00f1a, La Coru\u00f1a, Galicia, Spain|Hospital Quiron La Coru\u00f1a, La Coru\u00f1a, Galicia, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital General de Villalba, Villalba, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Clinica Universitaria de Navarra, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity Category|Mortality Rate|Number of Days in hospital|Number of days in ICU beds|Fio2 Needs|Adverse events rate|Change in CRP|Change in ferritin|Change in LDH|Change in CPK|Change in D Dimer|Change in IL-6|Change in KL-6|Change in Viral Load|Change specific antibodies""}"
"1976","Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence","","NCT04448145","AAAS9722","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04448145","Recruiting","2020-03-26","2021-03-01","{""locations"":""Columbia University Medical Center, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""7 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Duration of SARS-CoV-2 viral persistence in naso\/oropharyngeal samples|Duration of SARS-CoV-2 viral persistence in stool or rectal swab samples|Duration of SARS-CoV-2 viral persistence in semen samples|Duration of SARS-CoV-2 viral persistence in breast milk samples|Prevalence of cell immune responses|Duration of COVID-19 Symptoms|Prevalence of post-viral sequelae|Prevalence of SARS-CoV-2 persistence and bacterial\/viral community structures""}"
"1977","The Prone Position in Covid-19 Affected Patients","PRON-COVID","NCT04365959","PRON-COVID","Procedure: Prone position","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365959","Active, not recruiting","2020-03-20","2020-12-31","{""locations"":""ASST Monza, Monza, MB, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""56"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients in whom the prone position caused an increase in oxygenation|The feasibility of prone position""}"
"1978","Borderline COVID-19 PCR Test Result","","NCT04636294","f/2020/166","Diagnostic Test: SARS-CoV-2 PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04636294","Completed","2020-08-01","2021-02-15","{""locations"":""Clinical Laboratory Jessa Hospital, Hasselt, Limburg, Belgium"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""30000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Ratio of positivity conversion after receiving a COVID-19 borderline PCR result.|Symptoms predicting COVID-19 positivity conversion after receiving a borderline PCR result.""}"
"1979","Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France","FRENCH ICU","NCT04420286","30RC20_0117","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04420286","Recruiting","2020-05-06","2021-06-05","{""locations"":""CHU de N\u00eemes, H\u00f4pital Universitaire Car\u00e9meau, Nimes, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""9000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""origin of the ICU beds created during the COVID-19 outbreak in France.|Human Resources""}"
"1980","Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers","","NCT04453488","RUTICOVID19","Biological: RUTI® vaccine|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04453488","Not yet recruiting","2020-07-30","2020-12-01","{""locations"":""Hospital Universitari Germans Trias i Pujol UBP Riscos Laborals, Badalona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""315"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Documented cumulative incidence of SARS-CoV-2 infection|Sick leave for SARS-CoV-2|Days off work due to the quarantine|Quarantine imposed by close contact outside the center with SARS-CoV-2 positive|Professional category|Fever|Incidence of self-reported acute respiratory symptoms|Days of self-reported acute respiratory symptoms|Incidence of pneumonia|Incidence of death from SARS-CoV-2 infection|Incidence of admissions to Intensive Care Unit (ICU)|Days in ICU|Incidence of mechanical ventilation|Incidence of hospital admissions|Days of hospitalization|Incidence of SARS-CoV-2 antibodies|Types of antibodies detected|Levels of SARS-CoV-2 antibodies""}"
"1981","Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression","COVID-19","NCT04491994","Sultan Mehmood Kamran 2","Drug: HCQ","Interventional","Has Results","Phase 3","https://ClinicalTrials.gov/show/NCT04491994","Completed","2020-04-10","2020-05-31","{""locations"":""Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""540"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants With Progression|Viral Clearance""}"
"1982","ANalyzing Olfactory Dysfunction Mechanisms In COVID-19","ANOSMIC-19","NCT04445597","S64042","Other: Sampling of tissue","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04445597","Recruiting","2020-05-07","2022-12-31","{""locations"":""UZ Leuven, Leuven, Vlaams-Brabant, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""90"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence of SARS-CoV-2 in the sampled tissue""}"
"1983","Compensatory Reserve Index (CRI) for Management of COVID-19","","NCT04457817","20-1406","Device: CRI management","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04457817","Enrolling by invitation","2020-12-01","2021-07-01","{""locations"":""University of Colorado, Aurora, Colorado, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Volume of IV fluid infused|Quantity of Blood pressure medication administered|Resuscitation status|FiO2 needs|Days on Oxygen|Number of participants with hospital acquired pneumonia|Number of Patients with Acute Kidney Injury (AKI)|Number of patients with hemodynamic collapse|mortality""}"
"1984","Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children (COVILLE2 )","COVILLE2","NCT04416893","COVILLE2","Diagnostic Test: RT-PCR SARS-Cov2|Diagnostic Test: Sars-Cov2 serology","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416893","Not yet recruiting","2020-06-07","2020-11-15","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""630"",""age"":""up to 15 Years \u00a0 (Child)"",""outcome_measures"":""Proportion of asymptomatic children or children with mild respiratory symptoms|Cov2-SARS cases by age|Cov2-SARS cases by symptoms|Viral load|Presence of anti-SARS-CoV-2 antibodies (IgM and IgG) by the rapid serological test""}"
"1985","Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19","oXAKI-COV","NCT04597034","NMM-3401-20-20-1","Procedure: AN69-Oxiris|Procedure: AN69-Standard","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04597034","Recruiting","2020-10-02","2022-03-30","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""35"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary outcome:|Secondary outcomes measures:""}"
"1986","COVID-19 and Tissue Damage in Vital Organs","","NCT04678687","COVID-19.PMB","Procedure: Liver, lung, heart and kidney biopsy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04678687","Active, not recruiting","2021-01-01","2022-01-01","{""locations"":""Dokuz Eylul University, \u0130zmir, Bal\u00e7ova, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The level of histopathological changes""}"
"1987","Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19","SISCOVID","NCT04505631","GHR 1052|IDRCB 2020-A01089-30","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04505631","Recruiting","2020-06-10","2021-06-01","{""locations"":""Groupe Hospitalier de Mulhouse et de la R\u00e9gion Sud-Alsace, Mulhouse, Alsace, France|Centre Hospitalier de la C\u00f4te Basque - Bayonne, Bayonne, France|Centre Hospitalier M\u00e9tropole Savoie, Chamb\u00e9ry, France|Centre Hospitalier Colmar, Colmar, France|Centre Hospitalier Douai, Douai, France|Centre Hospitalier de Dunkerque, Dunkerque, France|Centre Hospitalier D\u00e9partemental Vend\u00e9e - La Roche sur Yon, La Roche-sur-Yon, France|Centre Hospitalier du Mans, Le Mans, France|Centre Hospitalier Robert Boulin - Libourne, Libourne, France|Centre Hospitalier Annecy Genevois, Metz-Tessy, France|Centre Hospitalier R\u00e9gional Metz-Thioville, Metz, France|Centre Hospitalier Le Raincy Montfermeil, Montfermeil, France|Centre Hospitalier R\u00e9gional Orl\u00e9ans, Orl\u00e9ans, France|Centre Hospitalier de Soissons, Soissons, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of respiratory sequelae|Presence of respiratory sequelae on low dose thoracic tomodensitometry|Forced vital capacity (FVC, %)|Forced expiratory volume in 1 second (FEV1, %)|Tiffeneau-Pinelli index (FEV1\/FVC, %)|Total lung capacity (TLC, %)|Residual volume (RV, %)|RV\/TLC ratio (%)|Maximal inspiratory pressure (MIP, %)|Maximal expiratory pressure (MEP, %)|Diffusion capacity of the lungs for carbon monoxide (DLCO, %)|pH|Arterial oxygen partial pressure (PaO2, mmHg)|Arterial carbon dioxide partial pressure (PaCO2, mmHg)|Bicarbonate concentration (mmol\/L)|Arterial oxygen saturation (SaO2, %)|Six-minute walk test""}"
"1988","Does COVID-19 Pandemic Reduce In-hospital Mortality?","","NCT04480515","KSSEAH--IHM","Other: in-hospital mortality rate","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04480515","Completed","2020-03-11","2020-06-30","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality""}"
"1989","Pulmonary Embolism and COVID-19","COVID-19-PE","NCT04590378","UU-PE001","Other: intensive care unit admission ratio","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04590378","Recruiting","2020-03-01","2020-12-01","{""locations"":""U\u015fak University, Usak, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""pulmonary embolism|Intensive care unit|mortality""}"
"1990","Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","SILVERBULLET","NCT04407507","SARS-COV-IverMX-01","Drug: Ivermectin|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04407507","Not yet recruiting","2020-06-01","2020-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participants with a disease control status defined as no disease progression to severe.""}"
"1991","Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury","iNSPIRE","NCT04375397","M20-310","Drug: Ibrutinib|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04375397","Recruiting","2020-06-06","2021-08-25","{""locations"":""Desert Regional Medical Center \/ID# 224276, Palm Springs, California, United States|Stanford Univ School Medicine \/ID# 221954, Stanford, California, United States|Medstar Washington Hospital Center \/ID# 221886, Washington, District of Columbia, United States|GW Medical Faculty Associates \/ID# 222023, Washington, District of Columbia, United States|Midway Immunology and Research \/ID# 222004, Fort Pierce, Florida, United States|University of Miami \/ID# 223227, Miami, Florida, United States|Triple O Research Institute \/ID# 222944, West Palm Beach, Florida, United States|Brigham & Women's Hospital \/ID# 221847, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center \/ID# 222994, Boston, Massachusetts, United States|Intermountain Healthcare \/ID# 221955, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""46"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants Alive and Without Respiratory Failure|Change in the World Health Organization (WHO)-8 Point Ordinal Scale From Baseline|Median Reduction in Days Spent on Supplemental Oxygen|All-Cause Mortality|Percentage of Participants Experiencing Respiratory Failure or Death|Mechanical Ventilation-Free Survival|Days on Mechanical Ventilation|Duration of hospitalization|Time to Discharge|Partial Pressure of Oxygen in Arterial Blood (PaO2) to Fraction of Inspired Oxygen (FiO2) Ratio|Oxygenation Index|Number of Participants With Adverse Events|Number of Participants With Abnormal Laboratory Findings""}"
"1992","A Study of Immune Responses to the Virus That Causes COVID-19","CoVPN 5001","NCT04431414","CoVPN 5001|5UM1AI068614-14","Other: Sample collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04431414","Recruiting","2020-07-20","2021-09-01","{""locations"":""Alabama CRS, Birmingham, Alabama, United States|Bridge HIV CRS, San Francisco, California, United States|University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS, Miami, Florida, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States|Fenway Health (FH) CRS, Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Columbia P&S CRS, New York, New York, United States|New York Blood Center CRS, New York, New York, United States|University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|Seattle Vaccine and Prevention CRS, Seattle, Washington, United States|Fundacion Huesped CRS, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mej\u00eda CRS, Buenos Aires, Argentina|Gaborone CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil|Kisumu Crs, Kisumu, Kenya|Malawi CRS, Lilongwe, Malawi|Merida CRS, M\u00e9rida, Mexico|Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS, Maputo, Mozambique|CITBM - UNIDEC, Centro de Investigaciones Tecnol\u00f3gicas, Biom\u00e9dicas y Medioambientales CRS, Bellavista, Peru|Asociacion Civil Selva Amazonica (ASCA) CRS, Iquitos, Peru|Barranco CRS, Lima, Peru|San Miguel CRS, Lima, Peru|Via Libre CRS, Lima, Peru|Groote Schuur HIV CRS, Cape Town, South Africa|Khayelitsha CRS \/ (CIDRI UCT), Cape Town, South Africa|Masiphumelele Clinical Research Site (MASI) CRS, Cape Town, South Africa|Chatsworth CRS, Chatsworth, South Africa|Botha's Hill CRS, Durban, South Africa|CAPRISA eThekwini CRS, Durban, South Africa|Vulindlela CRS, Durban, South Africa|Ndlovu Research Centre CoVPN CRS, Elandsdoorn, South Africa|Isipingo CRS, Isipingo, South Africa|Kliptown Soweto CRS, Johannesburg, South Africa|Soweto HVTN CRS, Johannesburg, South Africa|Aurum Institute Klerksdorp CRS, Klerksdorp, South Africa|Qhakaza Mbokodo Research Clinic CRS, Ladysmith, South Africa|MeCRU CRS, Medunsa, South Africa|Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa|Rustenburg CRS, Rustenburg, South Africa|Setshaba Research Centre CRS, Soshanguve, South Africa|Tembisa Clinic 4 CoVPN CRS, Tembisa, South Africa|Tongaat CRS, Tongaat, South Africa|Verulam CRS, Verulam, South Africa|National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS, Mbeya, Tanzania|Matero Reference Clinic CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Lusaka CoVPN CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Ndola CoVPN CRS, Ndola, Zambia|St Mary's CRS, Chitungwiza, Zimbabwe|Milton Park CRS, Harare, Zimbabwe|Seke South CRS, Harare, Zimbabwe"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Response rate of SARS-CoV-2-specific B cells in peripheral blood samples|Magnitude of SARS-CoV-2-specific B cells in peripheral blood samples|Phenotypic characterization of SARS-CoV-2-specific B cells in peripheral blood samples|Response rate of SARS-CoV-2-specific antibody binding in serum samples|Response rate of SARS-CoV-2-specific neutralizing antibodies in serum samples|Magnitude of SARS-CoV-2-specific antibody binding antibodies in serum samples|Magnitude of SARS-CoV-2-specific neutralizing antibodies in serum samples|Response rate of SARS-CoV-2-specific binding antibodies in nasal wash samples|Magnitude of SARS-CoV-2-specific binding antibodies in nasal wash samples|Frequency of leukocyte populations in peripheral blood|Transcriptional profiles of peripheral blood leukocytes|Concentration of serum cytokines and other soluble factors|Response rate of SARS-CoV-2-specific CD4+ and CD8+ T cells|Magnitude of SARS-CoV-2-specific CD4+ and CD8+ T cells|Functional profiling, including intracellular cytokine staining, of SARS-CoV-2-specific CD4+ and CD8+ T cells|Quantitation of viral RNA in nasal swabs""}"
"1993","Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms","COVID-EP","NCT04420312","COVID-EP|MR 4516150520","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04420312","Completed","2020-03-01","2020-04-20","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""1024"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of PE on COVID-19 patients|Clinical and radiological characteristics""}"
"1994","Lung Irradiation for COVID-19 Pneumonia","","NCT04393948","2020P001494","Radiation: Phase 1|Radiation: Phase 2","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04393948","Recruiting","2020-06-01","2020-11-01","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 1: Feasibility and safety of treating hospitalized patients with SARS-CoV-2 pneumonia with single or bilateral whole lung irradiation|Phase 2: Proportion with clinical improvement on a 7-point ordinal scale on day 4 after randomization|Improvement or worsening on the 7-point ordinal scale over additional intervals|Rate and duration of use of supplemental oxygen|Rate and duration of fever > 38\u00baC|Rate and duration of invasive mechanical ventilation|Duration of hospitalization|Proportion of participants with overall survival up to 30 days after randomization|Improvement in radiographic findings related to infection\/inflammation; comparisons include on study versus baseline scans and irradiated vs. unirradiated lung in subjects randomized to receive single lung irradiation|Treatment-emergent adverse events""}"
"1995","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation","","NCT04463004","HM20019145","Drug: Mavrilimumab|Drug: Placebos","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04463004","Active, not recruiting","2020-09-02","2021-08-01","{""locations"":""Virginia Commonwealth University, Richmond, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""2"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects alive and off of oxygen at day 14|Proportion of subjects alive and without respiratory failure at 28 days""}"
"1996","Echocardiography in Critically-ill Patients With COVID-19 Pneumonia","ECHO-COVID","NCT04414410","RedCap19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04414410","Enrolling by invitation","2020-05-12","2020-09-30","{""locations"":""University Hospital Ambroise Pare, Boulogne-Billancourt, Hauts De Seine, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incidence of Left ventricular systolic dysfunction|Incidence of RV failure|Incidence of Vasoplegia|Incidence of Hypovolemia|Relation between plateau pressure and RV failure|Relation between tidal volume and RV failure|Relation between PaO2 and RV failure|Relation between PaCO2 and RV failure|Relation between PEEP and RV failure""}"
"1997","Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers","","NCT04345653","Pro2020-0356","Drug: Hydroxychloroquine Sulfate (HCQ)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04345653","Active, not recruiting","2020-04-14","2021-04-08","{""locations"":""Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""44"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recruitment Feasibility|Recourse utilization|Safety as reflected on the number and severity of adverse events and serious adverse events|Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.|Effect of basic inflammatory regulation""}"
"1998","Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19","FIBRO-COVID","NCT04607928","2020-002518-42","Drug: Pirfenidone|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04607928","Recruiting","2020-08-01","2021-08-01","{""locations"":""University Hospital of Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Cl\u00ednic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital La Princes, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Ram\u00f3n y Cajal, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""148"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To investigate the effect of pirfenidone on fibrotic signs induced by COVID19 infection|Maintenance of stability or functional improvement FVC|Decreased oxygen requirement for physical activity|Improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m|Hospitalizations (general and due to respiratory problems)|Visits to the Emergency or Day Hospital for respiratory causes|Lung transplantation|Death""}"
"1999","Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients","","NCT04379037","NCM-001","Device: Transcutaneous Auricular Vagus Nerve Stimulation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04379037","Recruiting","2020-06-27","2020-11-01","{""locations"":""Hospital Zonal Virgen del Carmen de Z\u00e1rate, Z\u00e1rate, Buenos Aires, Argentina"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival without need of mechanical ventilation|WHO progression scale \u2264 5 at day 4 since admission.|Cumulative incidence of successful tracheal extubation at day 14 since symptom onset.|WHO progression scale \u2264 7 at day 4 since admission.|Survival at day 14 of hospitalization|Duration of hospitalization|Time to hospital discharge""}"
"2000","COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits","CRASH","NCT04412473","7837","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412473","Recruiting","2020-04-30","2021-06-01","{""locations"":""Service M\u00e9decine Intensive et R\u00e9animation, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19""}"
"2001","Plasma Therapy of COVID-19 in Severely Ill Patients","","NCT04359810","AAAS9924","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04359810","Recruiting","2020-04-21","2021-04-01","{""locations"":""Columbia University Irving Medical Center\/NYP, New York, New York, United States|Hospital Federal dos Servidores do Estado, Rio De Janeiro, Brazil|Hospital Geral de Nova Igua\u00e7u, Rio De Janeiro, Brazil|Instituto Nacional de Infectologia Evandro Chagas, Rio De Janeiro, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""219"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Day 28 severity outcome|Proportion of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA|Duration of Need for Supplemental Oxygen|Duration of Hospitalization|In-hospital and 28-day mortality|Time-to-clinical improvement in-hospital|Host genetic differences at day 0|Host transcriptomic differences at days 0,7,14""}"
"2002","COVID-19 Related Health and Infection Control Practices Among Dentists","","NCT04423770","20-08","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04423770","Active, not recruiting","2020-06-08","2021-06-08","{""locations"":""American Dental Association, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 probable or confirmed case|Anxiety|Depression|Dental practice infection control efforts|Dentists' use of personal protective equipment""}"
"2003","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","CORON-ACT","NCT04335071","2020-00691|2020DR2044","Drug: Tocilizumab (TCZ)|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04335071","Terminated","2020-04-26","2020-09-27","{""locations"":""University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Lugano (EOC), Viganello, Switzerland|University Hospital Zurich, Zurich, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""5"",""age"":""30 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)""}"
"2004","Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19","DOCOV","NCT04385810","JDS_2020_13","Procedure: Ophthalmologic exam","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04385810","Completed","2020-04-27","2020-07-29","{""locations"":""Fondation Adolphe de Rothschild, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""23"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Describe ophthalmologic damage to the cornea with direct exam at day 0|Describe ophthalmologic damage to the cornea with direct exam at day 7|Describe ophthalmologic damage to the cornea with direct exam at day 14|Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital|Describe ophthalmologic damage to the cornea with slit lamp exam at day 0|Describe ophthalmologic damage to the cornea with slit lamp exam at day 7|Describe ophthalmologic damage to the cornea with slit lamp exam at day 14|Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital|Describe tear film anomalies at day 0|Describe tear film anomalies at day 7|Describe tear film anomalies at day 14|Describe tear film anomalies at discharge of hospital|Describe ophthalmologic damage to the retina at day 0|Describe ophthalmologic damage to the retina at day 7|Describe ophthalmologic damage to the retina at day 14|Describe ophthalmologic damage to the retina at discharge of hospital|Describe ophthalmologic damage to the optic nerve at day 0|Describe ophthalmologic damage to the optic nerve at day 7|Describe ophthalmologic damage to the optic nerve at day 14|Describe ophthalmologic damage to the optic nerve at discharge of hospital""}"
"2005","COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic","","NCT04487873","GO 20/602","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04487873","Recruiting","2020-07-23","2020-12-31","{""locations"":""Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Ankara, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""28"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""COVID-19 Phobia|Qol|Health anxiety|Physical activity|Quality of sleep""}"
"2006","Covid-19 Pandemic: Patients' Experience in T1D","","NCT04384471","2021-1079","Other: Online survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384471","Completed","2020-04-29","2020-07-01","{""locations"":""Institut de Recherches Cliniques de Montr\u00e9al, Montreal, Quebec, Canada"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""384"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Self-reported acute diabetes complication|Self-reported hypoglycemia|Ability to get diabetes supplies and to access diabetes care|Concern about not having access to diabetes supplies and to access diabetes care|Impact of the pandemic situation on daily life activities|Impact on stress, anxiety and depression for adults participants|Impact on stress, anxiety and depression for children and adolescents""}"
"2007","Trial of Hydroxychloroquine In Covid-19 Kinetics","THICK","NCT04353271","[1582736-1]","Drug: Hydroxychloroquine|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04353271","Terminated","2020-04-17","2020-07-08","{""locations"":""University of South Alabama, Mobile, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""58"",""age"":""19 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of virus free subjects|Disease severity|Incidence of hospitalization|Incidence of Death|Incidence of confirmed SARS-CoV-2 Detection|Incidence of all-cause study medication discontinuation or withdrawal|Immunity to Covid-19""}"
"2008","Differential Leucocyte Count and Covid-19 Diagnosis","","NCT04643860","DEP_042020","Diagnostic Test: Differential Leucocyte Count (CLDC) device and algorithm","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04643860","Not yet recruiting","2020-12-01","2021-05-01","{""locations"":""IRCCS INM Neuromed, Department of Epidemiology and Prevention, Pozzilli, IS, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""validation|test sensitivity""}"
"2009","Lactoferrin for Prevention of COVID-19 in Health Care Workers","LF-COVID","NCT04526821","SIDISI 202110","Dietary Supplement: Bovine Lactoferrin|Dietary Supplement: Maltodextrin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04526821","Not yet recruiting","2020-09-01","2021-11-01","{""locations"":""Hospital Nacional Arzobispo Loayza, Lima, Lim, Peru|Hospital Cayetano Heredia, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""336"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Number of COVID-19 infections during the 12 weeks of intervention|Severity of the COVID-19 infection|Duration of symptoms of the COVID-19 infection|Frecuency of symptoms of the COVID-19 infection""}"
"2010","Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)","COVID-AKI","NCT04393428","RECHMPL20_0294","Other: [TIMP-2]*[IGFBP-7]","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393428","Completed","2020-03-01","2020-06-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensibility and specificity of urinary""}"
"2011","Sensitivity Evaluation of Serological Tests for Covid-19","COVIDIAGNOSTIX","NCT04678024","COVIDIAGNOSTIX","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04678024","Enrolling by invitation","2020-11-18","2021-11-01","{""locations"":""Istituto Ortopedico Galeazzi, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""410"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Sensitivity|Specificity""}"
"2012","COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL","","NCT04542031","2020COV113","Other: Questionnaire","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04542031","Not yet recruiting","2020-10-01","2021-10-01","{""locations"":""The Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""7911"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID 19|Mortality rates from COVID 19|Health related quality of life - Short Form 12""}"
"2013","COVID-19 Search in Conjunctival Cells","COVID-T","NCT04364594","0013008/20","Diagnostic Test: conjunctival swab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04364594","Completed","2020-03-26","2020-05-30","{""locations"":""Maria Cristina Savastano, Roma, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Conjunctival swab results based on RT-PCR|Conjunctival swab positivity in relation to Pulmonary and blood abnormalities""}"
"2014","A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19","","NCT04646044","20-214-34","Drug: Bempegaldesleukin|Drug: Standard of Care|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04646044","Recruiting","2020-11-13","2021-03-27","{""locations"":""Investigator Site, Hialeah, Florida, United States|Investigator site, Mesquite, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""AUC of BEMPEG\/standard of care (SOC) (PK).|Cmax of BEMPEG \/SOC (PK).|Tmax of BEMPEG \/SOC (PK).|Incidence of adverse events.|Incidence of treatment emergent adverse events (TEAEs).|Incidence of serious adverse events (SAEs).|Incidence of dose limiting toxicities (DLT) for BEMPEG.|Presence and levels of anti-drug antibodies directed to BEMPEG.|Fold change from baseline in absolute lymphocyte count by Central Laboratory.|Percentage of patients who require supplemental oxygen.|Change from baseline on the daily collection World Health Organization (WHO) Clinical Progression Scale, an 11-point clinical status ordinal scale.""}"
"2015","Feasibility and Analytic Performance of TestNPass (IVDMD) for CoViD-19 Diagnosis on Saliva Sample","GraphealNpas","NCT04654442","38RC20.378|2020-A03087-32","Diagnostic Test: TestNPass","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04654442","Recruiting","2021-03-04","2021-05-15","{""locations"":""Grenoble University Hospital, Grenoble cedex 9, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of TestNPass IVDMD for CoViD19 diagnosis on saliva samples.|TestNPass IVDMD swiftness|TestNPass IVDMD ease of use|Analytics performance (sensibility) of TestNPass IVDMD|Analytics performance (specificity) of TestNPass IVDMD|Correlation of TestNPass electric signal intensity with RT-PCR Cycle threshold""}"
"2016","Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS","APRV-COVID19","NCT04386369","2020PI076","Other: Airway pressure release ventilation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386369","Completed","2020-04-15","2020-06-01","{""locations"":""Centre Hospitalier R\u00e9gional Universitaire de Nancy, Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""17"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients improving PaO2\/FiO2 ratio at 6 hours of APRV|Number of interventions on ventilator settings|Change in mean blood pressure|Change in heart rate|Changes in catecholamine doses|Changes in static compliance at the end of 6 hours of APRV|Variations of minute ventilation|Changes in static compliance 4 hours after stopping APRV|Proportion of patients with a decrease of the PaO2\/FiO2 ratio""}"
"2017","Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","OsCOVID19","NCT04386447","OsCOVID19","Drug: Oxytocin|Drug: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04386447","Withdrawn","2020-09-01","2020-12-31","{""locations"":""CNRS, Lyon, France|Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy|Ospedale San Francesco, Nuoro, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of cases who during 14 exhibit one of the following conditions|Mortality 28 days after randomization""}"
"2018","Psychiatric Consultation for COVID-19 Patients","","NCT04395872","CR-20-062","Behavioral: Psychiatric counseling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395872","Not yet recruiting","2020-05-28","2020-12-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""54"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change of PHQ-9 (Patient Health Questionnaire-9)|Change of GAD-7 (Patient Health Questionnaire-9)|Change of PC-PTSD-5 (Primary Care PTSD Screen for DSM-5)|Change of AIS (Athens Insomnia Scale)|Change of P4 (P4 Suicidality Screener)|Change of SF-36 (Short Form Health Survey Questionnaire)|Change of SCL-90-R""}"
"2019","A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19","BTL-TML-COVID","NCT04522830","2020-04-0311","Drug: BTL-TML-COVID|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04522830","Recruiting","2020-07-30","2021-07-01","{""locations"":""Intermountain Clinical Reserach, Draper, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean duration and severity of disease|Incidence\/Safety of Adverse Events""}"
"2020","EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY","","NCT04657445","931/17-11-2020","Diagnostic Test: visual analogue scale","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04657445","Recruiting","2020-11-17","2021-06-01","{""locations"":""University General Hospital of Ioannina, Ioannina, Epirus, Greece"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""oflactory and taste dysfunction in SARS-CoV2 infection""}"
"2021","Study to Evaluate the Efficacy and Safety of EG-HPCP-03a Compared to DEX in Patients With COVID-19 Pneumonia","","NCT04561180","HPC-EG-009A-2.1","Drug: EG-HPCP-03a|Drug: EG-HPCP-03a Placebo|Drug: Standard of Care|Drug: Dexamethasone","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04561180","Not yet recruiting","2021-06-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""96"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of patients alive and without respiratory failure""}"
"2022","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","CLOCC","NCT04338906","CLOCC-2020","Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04338906","Withdrawn","2020-05-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation > 94% on room air for >24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality""}"
"2023","Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to COVID 19","","NCT04659876","September 11, 2020: 550","Diagnostic Test: clinical features and laboratory values","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659876","Completed","2020-03-22","2020-12-08","{""locations"":""Diyarbak\u0131r Gazi Ya\u015fargil Training and Research Hospital, Diyarbak\u0131r, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""445"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality""}"
"2024","Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment","","NCT04500067","2020-BV-BP","Drug: IVIG","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04500067","Completed","2020-05-07","2020-09-15","{""locations"":""Site 08 - \""Central City Clinical Hospital of Ivano-Frankivsk City Council\"", Ivano-Frankivs'k, Ivano-Frankivs'k Region, Ukraine|Site 02 - \""Bila Tserkva City Hospital \u21163\"", Bila Tserkva, Kyiv Region, Ukraine|Site 03 - \""Lviv Regional Infectious Diseases Clinical Hospital\"", Lviv, Lviv Region, Ukraine|Site 04 - \""City Clinical Infectious Diseases Hospital\"", Odesa, Odesa, Odesa Region, Ukraine|Site 07 - \""Ternopil City Municipal Ambulance Hospital\"", Ternopil', Ternopil' Region, Ukraine|Site 06 - \""Vinnytsia City Clinical Hospital \u21161\"", Vinnitsia, Vinnitsia Region, Ukraine|Site 09 - \""Volyn Regional Clinical Hospital\"", Luts'k, Volyn Region, Ukraine|Site 01 - \""Kyiv City Clinical Hospital \u211617\"", Kyiv, Ukraine|Site 05 - \""Kyiv City Clinical Hospital \u21164\"", Kyiv, Ukraine"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""76"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Period duration (in days) to clinical improvement|O2 saturation (SPO2 percentage), with self-breathing|Respiratory movements rate (amount per minute), with self-breathing|Body temperature without antipyretics use|Lymphocyte count|Time from the onset of the disease to discharge, in days|Duration of the need for ventilatory support, in days|Duration of the need for intensive care, in days|Duration of need for oxygenation in days (SPO2 \u2264 93% with self-breathing)|The C-reactive protein (CRP) level|The tumor necrozis factor alpha (TNF-\u03b1) level|The interleukin-1\u03b2 (IL-1\u03b2) level|The interleukin-6 (IL-6) level|The D-dimer level|The Complement (C3 component) level|The Circulating immune complexes level|The ferritin level|The procalcitonin level|IgG subtypes|Survival assessment for a 28-day follow-up period since the onset of severe pneumonia""}"
"2025","ACTIV-2: A Study for Outpatients With COVID-19","","NCT04518410","A5401/ACTIV-2|38742","Drug: LY3819253|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04518410","Recruiting","2020-08-19","2021-12-01","{""locations"":""Pinnacle Research Group (Site 1082), 321 E 10th Street, Anniston, Alabama, United States|University of Alabama at Birmingham (Site 1005), 908 20th Street South, Birmingham, Alabama, United States|Jasper Summit Research, LLC. (Site 1056), 1280 Summit, Jasper, Alabama, United States|St. Jude Heritage Medical Group (Site 1093), 2151 N. Harbor Blvd., Fullerton, California, United States|Atella Clinical Research (Site 1111), 5451 La Palma Avenue, La Palma, California, United States|Loma Linda University Health (Site 1110), 11374 Mountain View, Dover Bldg, Ste. C, Loma Linda, California, United States|University of Southern California (Site 1057), 1300 N Mission Rd., Rm 349, Los Angeles, California, United States|UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100, Los Angeles, California, United States|Central Valley Research, LLC (Site 1085), 400 E Orangeburg Ave., Ste. 5, Modesto, California, United States|Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210, Northridge, California, United States|University of California Irvine (Site 1083), 843 Health Sciences Road, Orange, California, United States|FOMAT Medical Research (Site 1136), 300 South A Street, Oxnard, California, United States|Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive, Rancho Mirage, California, United States|University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd., Sacramento, California, United States|University of California San Diego (Site 1002), 220 Dickinson Street, San Diego, California, United States|Zion Medical Center (Site 1063), 4647 Zion Avenue, San Diego, California, United States|University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84, San Francisco, California, United States|Harbor UCLA (Site 1022), 1124 West Carson Street, Torrance, California, United States|University of Colorado (Site 1007), 12401 East 17th Avenue, Aurora, Colorado, United States|Bradenton Research Center Inc. (Site 1109), 3924 9th Ave. W, Bradenton, Florida, United States|Synergy Healthcare (Site 1099), 300 Riverside Drive E., Ste. 1350, Bradenton, Florida, United States|Midland Florida Clinical Research Center LLC (Site 1130), 665 Peachwood Drive, DeLand, Florida, United States|Universal Axon Clinical Research (Site 1077), 3650 NW 82nd Ave., Doral, Florida, United States|Holy Cross Health (Site 1072), 4725 North Federal Highway, Fort Lauderdale, Florida, United States|NW FL Clinical Research Group, LLC. (Site 1046), 400 Gulf Breeze Parkway, Gulf Breeze, Florida, United States|AGA Clinical Trials (Site 1026), 900 West 49th Street, Hialeah, Florida, United States|University of Florida Jacksonville (Site 1039), 655 West 8th Street, Jacksonville, Florida, United States|QC Trials (Site 1117), 300 W. 41st Street, Ste. 203, Miami Beach, Florida, United States|Lakes Research (Site 1037), 5801 NW 151 Street, Miami Lakes, Florida, United States|Miami Clinical Research (Site 1089), 2400 SW 69th Ave., Miami, Florida, United States|IMIC, Inc. (Site 1141), 18320 Franjo Rd, Palmetto Bay, Florida, United States|Tampa General Hospital Family Care Center Healthpark (Site 1088), 5802 N. 30th Street, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast (Site 1095), 981 37th Place, Vero Beach, Florida, United States|Triple O Research Institute PA (Site 1121), 2580 Metrocentre Blvd., Ste. 4, West Palm Beach, Florida, United States|The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast, Atlanta, Georgia, United States|Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive, Atlanta, Georgia, United States|IACT Health (Site 1035), 800 Talbotton Road, Columbus, Georgia, United States|Snake River Research, PLLC (Site 1120), 2900 Cortez Ave., Idaho Falls, Idaho, United States|Metro Infectious Disease Consultants (Site 1106), 901 McClintock Dr., Ste. 201, Burr Ridge, Illinois, United States|Chicago Clinical Research Institute (Site 1132), 611 W. Roosevelt Rd., Chicago, Illinois, United States|Northwestern University (Site 1025), 645 North Michigan Ave, Chicago, Illinois, United States|Rush University Medical Center (Site 1017), 600 Paulina St., Chicago, Illinois, United States|University of Chicago (Site 1064), 5841 S. Maryland Ave., Chicago, Illinois, United States|Great Lakes Clinical Trials (Site 1049), 5149 N. Ashland Ave., Chicago, Illinois, United States|University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard, Kansas City, Kansas, United States|MedPharmics (Site 1065), 3800 Houma Blvd., Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904, New Orleans, Louisiana, United States|Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States|Massachusetts General Hospital (Site 1016), 55 Fruit Street, Boston, Massachusetts, United States|Memorial Hospital at Gulfport (Site 1104), 4500 13th Street, Gulfport, Mississippi, United States|MedPharmics, LLC. (Site 1032), 15190 Community Rd., Gulfport, Mississippi, United States|Hannibal Clinic (Site 1129), 100 Medical Drive, Hannibal, Missouri, United States|Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital (Site 1115), 931 Highland Blvd, Ste. 3103, Bozeman, Montana, United States|Mercury Street Medical Group (Site 1074), 300 W. Mercury St., Butte, Montana, United States|Quality Clinical Research (Site 1112), 10040 Regency Circle, Omaha, Nebraska, United States|Las Vegas Medical Research (Site 1048), 8530 W. Sunset Rd., Las Vegas, Nevada, United States|Lincoln Hospital (Site 1092), 249 East 149th Street, Bronx, New York, United States|Jacobi Medical Center (Site 1105), 1400 Pelham Parkway South, Bronx, New York, United States|Flushing Hospital Medical Center (Site 1067), 4500 Parsons Blvd, Flushing, New York, United States|Jamaica Hospital Medical Center (Site 1066), 8900 Van Wyck Expressway, Jamaica, New York, United States|Columbia Partnership for Prevention and Control of HIV\/AIDS CTU (Site 1019), Columbia University Irving Medical Center, Department of Medicine - Division of Infectious Diseases, 180 Fort Washington Avenue, HP6 - Rm 604, New York, New York, United States|Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street, New York, New York, United States|Canton-Potsdam Hospital (Site 1076), 50 Leroy Street, Potsdam, New York, United States|University of Rochester (Site 1010), 601 Elmwood Ave, Rochester, New York, United States|SUNY Stony Brook NICHD (Site 1094), HSC L-02, Rm. 142 C, Stony Brook, New York, United States|University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor, Chapel Hill, North Carolina, United States|Duke University Medical Center (Site 1041), 40 Duke Medicine Circle, Durham, North Carolina, United States|Wake Forest University Health Sciences (Site 1038), 1 Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Health (Site 1084), 801 Broadway N, Fargo, North Dakota, United States|The Christ Hospital (Site 1119), 2123 Auburn Avenue, Cincinnati, Ohio, United States|Case Western Reserve University (Site 1033), 2061 Cornell Road, Cleveland, Ohio, United States|Ohio State University Medical Center (Site 1020), 480 Medical Center Drive, Columbus, Ohio, United States|Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way, Ohio City, Ohio, United States|STAT Research (Site 1107), 66 Remick Blvd., Springboro, Ohio, United States|Ascension St. John Clinical Research Institute (Site 1090), 1725 East 19th Street, Tulsa, Oklahoma, United States|Kaiser Permanente Center for Health Research (Site 1079), 3800 N. Interstate Ave., Portland, Oregon, United States|Doylestown Hospital (Site 1122), 595 W State Street, Doylestown, Pennsylvania, United States|University of Pennsylvania (Site 1031), 3400 Spruce Street, Philadelphia, Pennsylvania, United States|The University of Pittsburgh (Site 1018), 3471 5th Ave., Pittsburgh, Pennsylvania, United States|Medtrial, LLC (Site 1134), 1718 Saint Julian Pl., Ste. 2, Columbia, South Carolina, United States|Sanford USD Medical Center (Site 1078), 1305 W. 18th St., Sioux Falls, South Dakota, United States|Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183, Nashville, Tennessee, United States|Saint Hope Foundation Inc. (Site 1100), 6800 West Loop Street, Ste. 560, Bellaire, Texas, United States|PanAmerican Clinical Research, LLC. (Site 1069), 1416 Palm Blvd., Brownsville, Texas, United States|Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive, Galveston, Texas, United States|Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street, Houston, Texas, United States|University of Texas Health Science Center at Houston (Site 1055), 6431 Fannin Street, Ste. 2.112, Houston, Texas, United States|Dynamic Medical Research Group (Site 1081), 8314 Southwest Fwy, Houston, Texas, United States|SMS Clincial Research, LLC. (Site 1060), 1210 N. Galloway Ave., Mesquite, Texas, United States|Inova Fairfax Medical Campus (Site 1029), 3300 Gallows Road, Falls Church, Virginia, United States|EvergreenHealth (Site 1080), 12040 NE 128th Street, Ste MS-77, Kirkland, Washington, United States|University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave., Seattle, Washington, United States|Medical College of Wisconsin, Inc. (Site 1036), 8701 Watertown Plank Road, Milwaukee, Wisconsin, United States|Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II, San Juan, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of COVID-19 symptoms (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 3 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 7 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 14 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 21 (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA at Day 28 (Phase 2)|Incidence of new adverse event (AE) \u2265 Grade 3 (Phase 2)|Cumulative incidence of death from any cause or hospitalization (Phase 3)|Proportion of participants with new adverse event (AE) \u2265 Grade 3 (Phase 3)|Cumulative incidence of death from any cause or hospitalization (Phase 2)|Duration of COVID-19 symptoms (Phase 3)|Presence of SARS-CoV-2 RNA (Phases 2 and 3)|Level of SARS-Cov-2 RNA (Phases 2 and 3)|COVID-19 severity ranking (Phases 2 and 3)|Incidence of \u22651 worsening symptom of COVID-19 (Phases 2 and 3)|Duration of fever (Phases 2 and 3)|Time to self-report return to usual (pre-COVID-19) health (Phases 2 and 3)|Cumulative incidence of death from any cause or hospitalization (Phases 2 and 3)|Oxygen saturation level (Phase 2)|Level of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)|Level of SARS-CoV-2 RNA from saliva (Phase 2)|Level of SARS-CoV-2 RNA from self-collected nasal swabs (Phase 2)|Level of SARS-CoV-2 RNA (Phase 2)|Post-treatment presence of SARS-CoV-2 RNA in saliva (Phase 2)|Post-treatment level of SARS-CoV-2 RNA (Phase 2)|Incidence of new adverse event (AE) \u2265 Grade 3 (Phase 3)|Concentration of investigational agent (Phase 2 - LY3819253)|Level of anti-drug antibodies (Phase 2 - LY3819253)|AUC (Phase 2 - LY3819253)|Total body clearance (CL) (Phase 2 - LY3819253)|Elimination half-life (Phase 2 - LY3819253)|Cmax (Phase 2 - LY3819253)|Cmin (Phase 2 - LY3819253)""}"
"2026","Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19","","NCT04622865","AB20001|2020-001635-27","Drug: Masitinib|Drug: Isoquercetin|Drug: Best Supportive Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04622865","Recruiting","2020-06-01","2021-06-01","{""locations"":""Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France|Le Tripode, Groupe hospitalier Pellegrin CHU de Bordeaux, Bordeaux, France|CHU Clermont-Ferrand: Site Gabriel-Montpied, Clermont-Ferrand, France|Hopital Nord, AP-HM, Marseille, France|CHR Orleans, Hopital de la Source, Orl\u00e9ans, France|Hopital Larrey, CHU du Toulouse, Toulouse, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical status of patients at day-15 using a 7-point ordinal scale""}"
"2027","Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19","COVIDMES","NCT04390139","BST-COVID-01","Drug: XCEL-UMC-BETA|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04390139","Recruiting","2020-05-13","2020-12-01","{""locations"":""Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|M\u00fatua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 \/ FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin""}"
"2028","Incidence of COVID-19 Test Conversion in Post-surgical Patients","","NCT04392323","IRB #20-0404","Diagnostic Test: COVID-19 PCR and Serology","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04392323","Recruiting","2020-05-13","2020-07-31","{""locations"":""North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Test Conversion|Duration of Hospitalization|Rate of self-reported COVID-19 exposure|Rate of complications from COVID-19""}"
"2029","Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","CoronaVac3CL","NCT04651790","200708006","Biological: SARS-CoV-2 inactivated vaccine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04651790","Recruiting","2020-11-27","2022-03-01","{""locations"":""Centro de Especialidades M\u00e9dicas, Red de Salud UC Christus, Santiago, RM, Chile"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of solicited and unsolicited adverse events that occur during the period of one week after each dose of the vaccine in two vaccination schedules: 0,14 and 0,28 days stratified by age group (18-59 years, and 60 or more years).|Incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second dose of each vaccination schedule.|Incidence of hospitalized cases of COVID-19 two weeks after the second vaccination of two vaccination schedules|Incidence of severe cases or deaths of COVID-19 virologically confirmed two weeks after the second vaccination of two vaccination schedules|Incidence of adverse reactions to the vaccine, local and systemic, solicited and unsolicited, within the period of four weeks after each vaccination of two vaccination schedules, according to the age, adults (18-59 years old) and elder (>60 years)|Frequency of severe COVID-19 cases in participants who received at least one dose of vaccine in two vaccination schedules|Incidence of serious adverse events (SAE) and adverse events in participants who have received at least one dose of the vaccine, in two vaccination schedules|Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, in two vaccination schedules, determined by flow Cytometry and ELISPOT|Percentage of participants with a significant increase of anti-SARS-CoV-2 antibodies, determined by ELISA|Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, determined by flow Cytometry and ELISPOT""}"
"2030","Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19","EMOS-COVID","NCT04646655","HLS-02COVID19/2020","Drug: Enoxaparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04646655","Recruiting","2020-07-27","2021-07-31","{""locations"":""ASST Fatebenefratelli Sacco, Milan, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate|Progression of respiratory failure|Number of major bleeding episodes|Respiratory function improvement|Number of major cardiovascular events|Deep Vein Thrombosis""}"
"2031","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","ONCOVID","NCT04341207","2020-001250-21|2020/3078","Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04341207","Recruiting","2020-04-03","2022-04-01","{""locations"":""Gustave Roussy, Villejuif, Val De Marne, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin""}"
"2032","COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression","","NCT04530500","2020-5907","Genetic: COVID-19 Androgen Sensitivity Test (CoVAST)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04530500","Enrolling by invitation","2020-08-13","2023-06-24","{""locations"":""Applied Biology, Inc, Irvine, California, United States|University of California, Irvine - Dermatology Clinical Research, Irvine, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients deceased|Number of patients discharged""}"
"2033","An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","","NCT04713488","06 - Sputnik Light - 2020","Biological: Sputnik Light","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04713488","Active, not recruiting","2021-01-15","2021-07-31","{""locations"":""ECO-Safety, Sankt Peterburg, Russian Federation"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""110"",""age"":""18 Years to 111 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changing of antibody levels against the SARS-CoV-2 glycoprotein S|Number of Participants With Adverse Events|Changing of of virus neutralizing antibody titer|Changing of antigen-specific cellular immunity level""}"
"2034","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)","","NCT04345601","H-47561 MSC for COVID-19","Biological: Mesenchymal Stromal Cells|Other: Supportive Care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04345601","Recruiting","2021-02-12","2022-10-01","{""locations"":""Houston Methodist Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14""}"
"2035","Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients","COVELEC","NCT04414059","COVELEC|2020-A01376-33","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04414059","Not yet recruiting","2021-03-01","2021-08-01","{""locations"":""Clinique de l'Estr\u00e9e, Stains, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""155"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Complications onset|Risk value associated with each risk factor as identified at the end of the main study analysis|Predictive performance and risk associated with each individual protein fraction|Intra-patient kinetics evolution of the electrophoresis curves|Intra-patient kinetics evolution of biological risk factors|Inter-expert reproducibility analysis of electrophoretic inflammatory profiles centrally reviewed|Contribution of urinary electrophoresis inflammation profiles in the interpretation of serum electrophoresis curves|Exploratory biological objective: Definition of a more detailed electrophoretic inflammatory profile""}"
"2036","LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)","GRAVID","NCT04344002","GECP 20/02_GRAVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344002","Recruiting","2020-04-21","2021-06-30","{""locations"":""Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coru\u00f1a, Spain|H. Cl\u00ednica Benidorm, Benidorm, Alicante, Spain|Hospital de Elche, Elche, Alicante, Spain|Hospital General Universitario de Elda, Elda, Alicante, Spain|Hospital de Torrevieja, Torrevieja, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Cetir Centre M\u00e8dic, Esplugues De Llobregat, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Complejo Hospitalario de la Coru\u00f1a, La Coru\u00f1a, Coru\u00f1a, Spain|H. Insular de Gran Canarias, Las Palmas De Gran Canaria, Gran Canarias, Spain|Hospital San Pedro, Logro\u00f1o, La Rioja, Spain|Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Alcorc\u00f3n, Madrid, Spain|Hospital Severo Ochoa, Legan\u00e9s, Madrid, Spain|Hospital Universitario de M\u00f3stoles, M\u00f3stoles, Madrid, Spain|Hospital de Manacor, Manacor, Mallorca, Spain|Hospital Costa del Sol, Marbella, M\u00e1laga, Spain|Cl\u00ednica Universidad de Navarra, Pamplona, Navarra, Spain|Cl\u00ednica Universitaria de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Instituto Onkologikoa, San Sebasti\u00e1n, Pa\u00eds Vasco, Spain|Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|H. Universitario de Canarias, La Laguna, Tenerife, Spain|Hospital Universitario de La Ribera, Alzira, Valencia, Spain|Hospital de Manises, Manises, Valencia, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|H. Gen. Universitario Alicante, Alicante, Spain|H. Universitario Quir\u00f3n Dexeus, Barcelona, Spain|Hospital Cl\u00ednic de Barcelona, Barcelona, Spain|H. Duran i Reynals-ICO, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital La Mancha Centro, Ciudad Real, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Universitario de Puerto Real, C\u00e1diz, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Guadalajara, Guadalajara, Spain|Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain|Hospital San Millan Y San Pedro, Logro\u00f1o, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|MD Anderson, Madrid, Spain|H.U. Puerta de Hierro, Madrid, Spain|Fundaci\u00f3n Jimenez Diaz, Madrid, Spain|Hospital Universitario Infanta Sof\u00eda, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Carlos Haya, M\u00e1laga, Spain|Hospital Santa Mar\u00eda Na\u00ed, Ourense, Spain|Hospital Son Espases, Palma de Mallorca, Spain|H. Son Ll\u00e0tzer, Palma de Mallorca, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Roc\u00edo, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital universitario Nuestra Se\u00f1ora Candelaria, Tenerife, Spain|H. General U. de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital Polit\u00e8cnic i Universitari La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Instituto Valenciano de Oncolog\u00eda, Valencia, Spain|Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain|H. Miguel Servet, Zaragoza, Spain|Hospital Ntra. Sra. S\u00f3nsoles, \u00c1vila, Spain|Hospital Universitario de \u00c1raba, Vitoria, \u00c1raba, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical data of lung cancer patients with COVID-19 diagnoses|Diagnosis data|Treatments received|Prognostic factors""}"
"2037","Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury","TAC-COVID19","NCT04395482","TAC-COVID19","Other: Lung CT scan analysis in COVID-19 patients","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395482","Recruiting","2020-05-07","2021-06-15","{""locations"":""Ospedale Papa Giovanni XXIII, Bergamo, Italy|Policlinico San Marco-San Donato group, Bergamo, Italy|Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy|ASST di Lecco Ospedale Alessandro Manzoni, Lecco, Italy|ASST Melegnano-Martesana, Ospedale Santa Maria delle Stelle, Melzo, Italy|ASST Monza, Monza, Italy|AUSL Romagna-Ospedale Infermi di Rimini, Rimini, Italy|Istituto per la Sicurezza Sociale-Ospedale della Repubblica di San Marino, San Marino, San Marino"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A qualitative analysis of parenchymal lung damage induced by COVID-19|A quantitative analysis of parenchymal lung damage induced by COVID-19|The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure.|Automated segmentation of lung scans of patients with COVID-19 and ARDS.|Knowledge of chest CT features in COVID-19 patients and their detail through the use of machine learning and other quantitative techniques.|The ability within which the analysis of artificial intelligence that uses deep learning models can be used to predict clinical outcomes""}"
"2038","Blood Sample Measurements and Physical Activity Levels in Type II Diabetes and/or COVID-19","","NCT04695158","2020-12-143","Drug: COVID-19 group (Group I)|Drug: Type II Diabetes Mellitus and COVID-19 group (Group II)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04695158","Recruiting","2021-01-06","2021-03-01","{""locations"":""Kadirhan Ozdemir, \u0130zmir, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""35 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of the levels of Hemoglobin A1c and Lipid Profiles at baseline and discharge for Group I and Group II|The levels of Hemoglobin A1c and Lipid Profiles for Group III|Change of the levels of Homocystein and Oxidative Stress Parameters at baseline and discharge for Group I and Group II|The levels of Homocystein and Oxidative Stress Parameters for Group III|Change of Physical Activity Level at baseline and discharge for Group I and Group II|Physical Activity Level for Group III|Change of the levels of Routine Blood Samples at baseline and discharge for Group I and Group II|The levels of Routine Blood Samples for Group III""}"
"2039","CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients","","NCT04364737","20-00541","Biological: Convalescent Plasma|Other: Saline solution","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04364737","Recruiting","2020-04-17","2023-04-30","{""locations"":""Yale University School of Medicine, New Haven, Connecticut, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Health, New York, New York, United States|University of Texas Rio Grande Valley, Edinburg, Texas, United States|The University of Texas Health Science Center, Houston, Texas, United States|The University of Texas Health Science Center, Tyler, Texas, United States|Medical College of Wisconsin \/ Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Score on the WHO 11-point ordinal scale for clinical improvement at 14 days|Score on the WHO 11-point ordinal scale for clinical improvement at 28 days""}"
"2040","mHealth Intervention for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Uganda","","NCT04631367","idrc_covid","Behavioral: Kukaa Salama: mHealth intervention|Device: Face Mask + Soap","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04631367","Not yet recruiting","2021-02-01","2021-09-20","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""404"",""age"":""16 Years to 24 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Changes in COVID-19 Prevention Practices|Changes in COVID-19 Risk Awareness|Changes in Attitude towards COVID-19|Changes in COVID-19 Norms|Changes in COVID-19 Self-Regulation|Changes in Depression|Sexual and Reproductive Health|Food and Water insecurity""}"
"2041","Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","COVILLE","NCT04318431","COVILLE|2020-A00724-35","Diagnostic Test: Data collection and rhinopharyngeal swab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04318431","Completed","2020-04-14","2020-06-01","{""locations"":""Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevi\u00e8res-sur-Marne, France|14 Av ren\u00e9 Samuel, Clamart, France|Cabinet du Dr Corrard, Combs-la-Ville, France|10 rue Delambre, Lagny-sur-Marne, France|157 Avenue du G\u00e9n\u00e9ral Leclerc, Maisons-Alfort, France|21 Grande Rue Charles de Gaulle, Nogent-sur-Marne, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|4 all\u00e9e des Norottes, Noisy-le-Grand, France|Cabinet du Dr D'acremont, Paris, France|146 Avenue Ledru Rollin, Paris, France|132 Boulevard du Montparnasse, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|15 Quai Louis Bl\u00e9riot, Paris, France|Cabinet du Dr Michot, Paris, France|24 rue Volta, Puteaux, France|Cabinet du Dr Cohen, Saint-Maur-des-Foss\u00e9s, France|Cabinet de P\u00e9diatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beaus\u00e9jour, Vincennes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""605"",""age"":""up to 15 Years \u00a0 (Child)"",""outcome_measures"":""Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses|Sars-Cov2 IgM|Sars-Cov2 IgG""}"
"2042","Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects","","NCT04441918","JS016-001-I","Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04441918","Recruiting","2020-06-05","2020-12-11","{""locations"":""Huashan Hospital affiliated to Fudan University, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""15 Years to 45 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Correlation of adverse events with the investigational product|Primary pharmacokinetic variables""}"
"2043","Cardiovascular Risk Stratification in Covid-19","CaVaR-Co19","NCT04555187","STUDY00021368","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04555187","Active, not recruiting","2020-06-08","2021-12-01","{""locations"":""Oregon Health and Science University, Portland, Oregon, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""60000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number and rate of persons with cardiovascular composite outcome|Rate of all-cause death outcome|Rate of cardiac arrhythmia""}"
"2044","Oral Isotretinoin and Covid-19 Infection","","NCT04663906","1/095/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04663906","Not yet recruiting","2021-01-15","2021-05-31","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""16 Years to 40 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Primary Outcome|Secondary Outcome""}"
"2045","Evaluation of Humoral Immunity Following COVID-19 in Pregnancy","ImmunoCOVID","NCT04568044","20SM6089","Procedure: Blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568044","Recruiting","2020-09-16","2023-07-03","{""locations"":""Chelsea and Westminster NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""96"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Phenotyping antibody secreting cells (ASCs) and memory B cells during COVID-19 infection, and post recovery.|Quantification of SARS-CoV-2 specific IgG production by memory B cells to measure long-lasting immune protection against re-infection.|Quantification of SARS-COV-2 viral load using PCR.|Immuno-phenotype circulatory T follicular helper cells (cTFH) cells post SARS-CoV-2 infection.|Investigating T cell mediated immune function post COVID-19|In pregnancy, comparing antibody production, and immune phenotype and function (as outlined above) between COVID-19 infection, and influenza infected or vaccinated.""}"
"2046","Physical Rehabilitation of COVID-19 Survivors by Heat Therapy","","NCT04673318","2151","Behavioral: heat therapy|Behavioral: exercise training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04673318","Not yet recruiting","2021-01-01","2023-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""87"",""age"":""55 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Gait speed|Motor function|Glucose control|Skeletal muscle mitochondrial function|Vascular function""}"
"2047","Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19","SWITCH-COVID","NCT04493359","33575220.9.0000.0068","Drug: Renin-angiotensin system inhibitors","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04493359","Recruiting","2020-07-25","2022-02-14","{""locations"":""Instituto do Cora\u00e7\u00e3o - Incor HCFMUSP, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need for ICU or mortality|High sensitivity troponin levels and covid-19 severity|ACE-2 activity and disease severity|ACE-2 activity with different Renin-angiotensin system inhibitors|Blood control and acute renal failure""}"
"2048","COVID-19 in Pediatric Oncology and Hematology Centers in France","PEDONCOVID","NCT04433871","20-065","Other: No intervention, observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433871","Recruiting","2020-04-27","2023-04-27","{""locations"":""J\u00e9r\u00e9mie Rouger-Gaudichon, Caen, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""1 Month to 30 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Oncologic data|COVID-19 diagnosis|Clinical signs|Biological signs|Radiological signs|COVID-19 management|Potent COVID-19 sequelae""}"
"2049","Sleep Quality in Healthcare Personnel During COVID-19","","NCT04395300","AssiutU14","Other: Web Based Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395300","Completed","2020-03-30","2020-05-16","{""locations"":""AssiutU, Assiut, Egypt"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""143"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""measure sleep quality in healthcare worker|impact of covid-19 pandemic on general health|correlate between sleep quality and general health""}"
"2050","Contrast Enhanced Ultrasound in COVID-19","","NCT04640038","20-017501","Drug: Sulfur hexafluoride lipid-type A microspheres","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04640038","Recruiting","2020-12-18","2022-12-01","{""locations"":""The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""30"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""Estimate the proportion of patients with normal perfusion versus area(s) of hypoperfusion in heart, kidneys and\/or brain""}"
"2051","ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)","ABACCuS","NCT04432272","2020-198","Biological: COVID-19 convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04432272","Active, not recruiting","2020-07-16","2021-08-01","{""locations"":""William Beaumont Hospital, Royal Oak, Michigan, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Avoidance of intubation at 28 days (group A)|Mortality (group B)|Cardio-circulatory arrest|Patient Outcome at 28 days|Renal failure|Liver failure|Cytokine Storm|Respiratory support|Vasopressor medication support|Length of ICU length of stay|Intensive Care Unit (ICU) mortality|Hospital length of stay|Ventilator free days|Intubation duration|Readmission|Serum anti-SARS-CoV-2 IgG|SARS-CoV-2 RNA|Mortality (group A)|Time from Transfusion to end of ventilator support (group B)""}"
"2052","Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease","","NCT04352803","COVID-MSCIV","Biological: Autologous Adipose MSC's","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04352803","Not yet recruiting","2020-04-01","2026-04-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety - Incidence of unexpected adverse events|Efficacy - Frequency of progression to mechanical ventilation|Efficacy - Changes in length of mechanical ventilation|Efficacy - Changes in length of weaning of mechanical ventilation|Efficacy - Changes in length of hospital stay|Efficacy - Changes in mortality rate""}"
"2053","Inspiratory Muscle Training in COVID-19 Patients","ADDIMTCOVID","NCT04595097","CNPQ092020","Device: inspiratory muscle traiing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04595097","Not yet recruiting","2021-02-01","2021-09-30","{""locations"":""Secretaria de Sa\u00fade do Distrito Federal, Brasilia, DF, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health- related quality of life|Peak VO2|Minute Ventilation and Carbon Dioxide Production (VE\/VCO2 Slope)|Dyspnea|Respiratory muscle strength|Exercise Capacity|severity of fatigue|Anxiety and Depression|incremental cost-utility ratio""}"
"2054","Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?","ARBs CORONA II","NCT04606563","H20-01984","Drug: Losartan","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04606563","Recruiting","2020-10-09","2021-06-30","{""locations"":""University of Nebraska, Omaha, Nebraska, United States|Brown University, Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States|St. Luc University Hospital, Brussels, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|University of Calgary - Foothills, Calgary, Alberta, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queens University, Kingston, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|McGill University Health Center, Montr\u00e9al, Quebec, Canada|Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire d'Angers, Angers, France|Chiba University, Chiba, Japan|Hospital Cl\u00ednico San Carlos, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1372"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Hospital Mortality|ICU Admission|days alive and free of vasopressors, ventilation, and renal replacement therapy|SOFA score|Acute cardiac injury|Severe adverse events""}"
"2055","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","MultiCov","NCT04334850","APHP200392|2020-001324-33","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04334850","Recruiting","2020-04-20","2020-08-01","{""locations"":""Intensive care department-Hospital Tenon, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""194"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of antibiotic free days|Mortality rates|Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.|Antibiotics duration at D28|Number of organ-failure free days (based on SOFA)|Incidence rates of bacterial super-infections|Incidence rates of colonization\/infection with multidrug resistant bacteria and Clostridium difficile infections|ICU and hospital lengths of stay|Quality of life Quality of life""}"
"2056","A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition","START","NCT04573634","PHARM-20-COVID19-START","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04573634","Recruiting","2020-05-15","2023-12-31","{""locations"":""University of Kentucky, Lexington, Kentucky, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""960"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID-19|PCR Conversion in Exposed Individuals""}"
"2057","Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","","NCT04428073","GC004","Biological: Covax-19™","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04428073","Not yet recruiting","2020-07-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""To evaluate the safety of a therapeutic Covid-19 vaccine in participants by measuring the severity of local and systemic adverse events and laboratory abnormalities.|To evaluate the immunogenicity of a therapeutic Covid-19 vaccine in participants by measuring CD8+ T cells immune response|Virologic response after vaccination|Clinical outcome and progression after vaccinations""}"
"2058","Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19)","RECOVER-19","NCT04466800","35RC20_9875_RECOVER-19","Other: Intervention group_rehabilitation program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04466800","Recruiting","2020-07-30","2021-11-30","{""locations"":""CHU Rennes, Rennes, France|Centre Hospitalier de Saint-Brieuc, Saint-Brieuc, France|Centre Hospitalier Bretagne Atlantique, Vannes, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of a multidisciplinary and personalized rehabilitation program on COVID patients's quality of life|Impact of a multidisciplinary and personalized rehabilitation program in terms of Physical capacities|Impact of a multidisciplinary and personalized rehabilitation program in terms of Respiratory capacities|Impact of a multidisciplinary and personalized rehabilitation program in terms of Functional capacities|Impact of a multidisciplinary and personalized rehabilitation program in terms of Malnutrition prevalence rate using GLIM malnutrition diagnostic criteria|Impact of a multidisciplinary and personalized rehabilitation program in terms of mortality|Impact of a multidisciplinary and personalized rehabilitation program in terms of Quality of life|Impact of a multidisciplinary and personalized rehabilitation program in terms of Anxiety and depression|Impact of a multidisciplinary and personalized rehabilitation program in terms of Healthcare consumption|Impact of a multidisciplinary and personalized rehabilitation program in terms of Medico-economic evaluation|Patient's opinion concerning the rehabilitation program""}"
"2059","Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population","","NCT04391881","54678","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04391881","Recruiting","2020-05-30","2020-08-30","{""locations"":""Cairo university, Cairo, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""500"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Oral manifestation""}"
"2060","OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome","OUTCOV","NCT04365582","OUTCOV","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04365582","Suspended","2020-05-07","2021-02-07","{""locations"":""H\u00f4pital Priv\u00e9 d'Antony, Antony, France|H\u00f4pital Avicenne, Bobigny, France|Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Institut Mutualiste Montsouris, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""640"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events""}"
"2061","Impact of COVID-19 on the Benefit of Cardiac Rehabilitation","REACARDIOCOVID","NCT04513964","READCARDIOCOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04513964","Recruiting","2020-11-01","2021-06-30","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, Groupe Hospitalier Paris Saint-Joseph, France|H\u00f4pital Corentin Celton, Issy-les-Moulineaux, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of COVID-19 on exercise capacity gain after cardiovascular rehabilitation""}"
"2062","DIgital Online SuPport for COVID-19 StrEss","DISPOSE","NCT04324190","IPUB_2020_01","Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04324190","Recruiting","2020-04-08","2021-12-01","{""locations"":""Selfapy GmbH, Berlin, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Chronic stress items (9 items)|Generalized Anxiety Disorder Scale (GAD-7)|Patient Health Questionnaire (PHQ8)|Somatic Symptom Disorder (SSD-12)|Somatic Symptom Scale (SSS-8)|Allgemeine Selbstwirksamkeit Kurzskala (ASKU)|Screening Tool for Psychological Distress (STOP-D) - selected items""}"
"2063","COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes","COVID-FIS","NCT04537299","20-008867|1R01AG072301-01","Drug: Fisetin|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04537299","Not yet recruiting","2021-03-01","2023-12-01","{""locations"":""Mayo Clinic, Rochester, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Change in COVID-19 Severity""}"
"2064","Hydrocortisone for COVID-19 and Severe Hypoxia","COVID STEROID","NCT04348305","RH-ITA-008|2020-001395-15","Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04348305","Active, not recruiting","2020-04-17","2021-06-08","{""locations"":""Aarhus University Hospital - Dept of Intensive care, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Dept of Infectious diseases, Rigshospitalet, Copenhagen, Denmark|Herlev Hospital - Dept. of Intensive Care, Herlev, Denmark|North Zealand Hospital, Hiller\u00f8d, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|K\u00f8ge Hospital, K\u00f8ge, Denmark|Dept of Intensive Care, Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Slagelse Hospital, Slagelse, Denmark|Viborg Hospital, Viborg, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days alive without life support at day 28|All-cause mortality at day 28|Days alive without life support at day 90|All-cause mortality at day 90|Number of participants with one or more serious adverse reactions|Days alive and out of hospital at day 90|All-cause mortality at 1 year after randomisation|Health-related quality of life at 1 year""}"
"2065","Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection","RESPIRE","NCT04361903","2020.COVID-19.RUXO106","Drug: Ruxolitinib Oral Tablet","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361903","Not yet recruiting","2020-04-25","2020-05-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""13"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19|Improvement of respiratory performance - Arterial Blood Gas Analisys - pH|Improvement of respiratory performance - Arterial Blood Gas Analisys - pO2|Improvement of respiratory performance - Arterial Blood Gas Analisys - pCO2|Improvement of respiratory performance - ratio values|Evaluation of known adverse events related to the use of the drug - D-Dimer|Evaluation of known adverse events related to the use of the drug - fibrinogen|Evaluation of known adverse events related to the use of the drug - transaminases|Evaluation of known adverse events related to the use of the drug - aPTT|Evaluation of known adverse events related to the use of the drug - INR|Evaluation of known adverse events related to the use of the drug - glycemia|Evaluation of known adverse events related to the use of the drug - creatinine|Evaluation of known adverse events related to the use of the drug - Leucocytes count|Evaluation of known adverse events related to the use of the drug - Leucocytes formula|Evaluation of the epidemiological parameters: Chest CT|Evaluation of the epidemiological parameters: Eco Chest|Evaluation of the epidemiological parameters: CHEST X-ray|Monitoring of Serum levels of cytokines before and every 48 h from start to to end of treatment|Monitoring incidence of treatment Emergent Adverse Events of ruxolitinib therapy""}"
"2066","Screening of Health-care Workers in an University Hospital for SARS-CoV-2","STORM-HCW","NCT04567836","STORM-HCW","Other: Investigation of the prevalence of test positivity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04567836","Recruiting","2020-06-01","2020-12-01","{""locations"":""ASST Monza-Ospedale San Gerardo, Monza, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of test positivity|Correlation of the positive result of the test with the manifestations of the signs|Development of COVID|Analysis of genomic sequences of the virus|Evaluation of the test relevance|Evaluation of predictive biomolecular markers|The trend over time of the antibody response in subjects positive|The frequency of re-infection|Evaluation of the mode of transmission relatively anamnestic data|The relation between mode of transmission and the available clinical documentation|Evaluation of the mode of transmission for the use of barriers""}"
"2067","CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19","","NCT04487990","U1111-1252-0194|33351120.0.0000.0068","Drug: unfractionated Heparin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04487990","Recruiting","2020-06-29","2021-07-01","{""locations"":""University of S\u00e3o Paulo General Hospital, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clotted dialyzers|Time-free of clotting|Number of dialyzers used|Pressure variation|Urea sieving|Downtime of dialysis""}"
"2068","The Role of CT Chest Scan in the Pre-anesthetic Assessment of Suspected or Confirmed COVID -19 Patients","","NCT04560530","chest CT scan in COVID-19","Radiation: Non-enhanced CT scan of the chest","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04560530","Completed","2020-03-01","2020-09-01","{""locations"":""Security Forces Hospital, Riyadh, Saudi Arabia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""76"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""pneumonia severity.|Aorta diameter|Pulmonary artery diameter|Pulmonary artery diameter TO Aorta diameter ratio|Description of the lesions found in the CT scan""}"
"2069","Back to School COVID-19 Simulation Study","","NCT04531254","1000071861","Behavioral: Personal behaviours","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04531254","Completed","2020-08-10","2020-08-31","{""locations"":""The Hospital for Sick Children, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""190"",""age"":""4 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Total number of hand-to-face contacts per participant per hour|Total number of hand-to-mucus membrane contacts per participant per hour|Total number of hand-to-non-mucus membrane contacts per participant per hour|Total number of instances where participants are within 1 and 2 meters of each other|Total number of glo germ transfers to another person|Total number of glo germ transfers to teacher|Total number of glo germ transfers to a surface|Total number of instances of hand holding per participant per hour|Total number of touches to another person per participant per hour|Total number of hand hygiene actions per participant per hour|Total number of mask removals per participant per hour|Teacher concerns measured using study-specific post-simulation questionnaire|Teacher concerns measured using semi-structured group interviews|Student concerns measured using study-specific post-simulation questionnaire|Student concerns measured using semi-structured group interviews|Identify activity types that influence touching behaviour""}"
"2070","Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients","ProCOVRA","NCT04679272","RECHMPL20_0682","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04679272","Completed","2020-12-01","2021-02-01","{""locations"":""UH Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization rates for COVID-19|Critical care transfer rate for COVID-19 and death due to COVID-19|Pulmonary comorbidities, corticosteroids or DMARDs use|Age|Number of Participants with co-morbidities|Type of clinical presentation|Type of associated treatments""}"
"2071","Does COVID-19 Infection Increase the Risk of Pulmonary Embolism?","","NCT04696913","1-073-20","Diagnostic Test: Exposure: Positive COVID-19 infection|Diagnostic Test: Exposure: Negative COVID-19 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04696913","Not yet recruiting","2021-01-01","2021-11-22","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""347"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of pulmonary embolism cases related to COVID-19.|Severity, distribution of pulmonary embolism as determined by calculated Qanadli score.|Presence of right heart strain associated with pulmonary embolism.""}"
"2072","The Effect of Melatonin and Vitamin C on COVID-19","","NCT04530539","2020-68","Dietary Supplement: Vitamin C|Dietary Supplement: melatonin|Dietary Supplement: Placebo|Other: Symptom Survey","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04530539","Recruiting","2020-10-05","2021-12-01","{""locations"":""Lancaster General Health, Lancaster, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care"",""enrollment"":""150"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptom Severity|Symptom progression""}"
"2073","Spread and Course of COVID-19 Infections","CoV-ETH","NCT04377724","20-05","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377724","Active, not recruiting","2020-04-27","2021-06-30","{""locations"":""ETH, Z\u00fcrich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""seroprevalence as well as the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens|the property of peripheral blood mononuclear cells before and after an infection with SARS-CoV-2 as opposed to other pathogens|the property of IgM and IgA antibody titers against the nucleocapsid protein of SARS-CoV-2 in symptomatic as well as asymptomatic COVID-19 infections over the course of time following an infection|the immune response to common-cold (corona)virus and influenza virus infections in patients with COVID-19 infections""}"
"2074","Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients","PREAVIS","NCT04522466","20CH065|2020-001281-11","Drug: Hydroxychloroquine (HCQ)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04522466","Terminated","2020-04-03","2020-05-28","{""locations"":""Groupement Hospitalier des Portes de Province, Mont\u00e9limar, France|Centre Hospitalier de Roanne, Roanne, France|CHU Saint-Etienne, Saint-\u00c9tienne, France|Clinique Mutualiste, Saint-\u00c9tienne, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""7"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pharmacokinetics of hydroxychloroquine (HCQ)|Correlation between hydroxychloroquine (HCQ) concentration and cardiac toxicity (QT interval)|Correlation between Pharmacokinetic (concentration) and pharmacodynamic (viral load) of hydroxychloroquine (HCQ)|Pharmacokinetic model""}"
"2075","Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19","","NCT04397939","GCO 20-0965","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397939","Recruiting","2020-05-08","2022-03-01","{""locations"":""Mount Sinai Hospital, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of In-Hospital Death|Length of Stay|Number of Successful Treatment""}"
"2076","IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.","","NCT04402814","IgG/IgM COVID19|2005801","Diagnostic Test: Clungene rapid test cassette","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04402814","Recruiting","2020-05-05","2020-12-01","{""locations"":""Fadi A. Haddad MD Inc., La Mesa, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hosptial, San Diego, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IgG\/IgM antibodies""}"
"2077","NCI COVID-19 in Cancer Patients, NCCAPS Study","","NCT04387656","NCI-2020-02986|NCICOVID","Procedure: Biospecimen Collection|Other: Data Collection|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387656","Recruiting","2020-05-21","2023-05-31","{""locations"":""University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Veterans Administration Medical Center - Birmingham, Birmingham, Alabama, United States|USA Health Strada Patient Care Center, Mobile, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Banner Children's at Desert, Mesa, Arizona, United States|Cancer Center at Saint Joseph's, Phoenix, Arizona, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States|NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States|PCR Oncology, Arroyo Grande, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Providence Saint Joseph Medical Center\/Disney Family Cancer Center, Burbank, California, United States|Enloe Medical Center, Chico, California, United States|UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fresno Cancer Center, Fresno, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Veterans Affairs Loma Linda Healthcare System, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|UCLA \/ Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|UC Irvine Health\/Chao Family Comprehensive Cancer Center, Orange, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Salinas Valley Memorial, Salinas, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Cancer Center of Colorado at Sloan's Lake, Denver, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, United States|Beebe South Coastal Health Campus, Frankford, Delaware, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|TidalHealth Nanticoke \/ Allen Cancer Center, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|Florida Cancer Specialists - Bradenton, Bradenton, Florida, United States|Broward Health North, Deerfield Beach, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States|Florida Cancer Specialists - Sarasota Downtown, Sarasota, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Moffitt Cancer Center-International Plaza, Tampa, Florida, United States|Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Florida Cancer Specialists - Venice Island, Venice, Florida, United States|Florida Cancer Specialists - Venice Healthpark, Venice, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|University Cancer and Blood Center LLC, Athens, Georgia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Augusta Oncology Associates PC-D'Antignac, Augusta, Georgia, United States|Augusta Oncology Associates PC-Wheeler, Augusta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Northeast Georgia Medical Center Braselton, Braselton, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's\/Candler, Savannah, Georgia, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon\/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|IU Health North Hospital, Carmel, Indiana, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Indiana University\/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Physicians' Clinic of Iowa PC, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Blank Children's Hospital, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Olathe Health Cancer Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Ochsner High Grove, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center - Covington, Covington, Louisiana, United States|Northshore Oncology Associates-Covington, Covington, Louisiana, United States|Ochsner Hematology Oncology North Shore - Covington (West Region), Covington, Louisiana, United States|Women's Cancer Care-Covington, Covington, Louisiana, United States|Mary Bird Perkins Cancer Center - Houma, Houma, Louisiana, United States|Terrebonne General Medical Center, Houma, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|LSU Healthcare Network \/ Metairie Multi-Specialty Clinic, Metairie, Louisiana, United States|Ochsner LSU Health Monroe Medical Center, Monroe, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Ochsner LSU Health Saint Mary's Medical Center, Shreveport, Louisiana, United States|LSU Health Sciences Center at Shreveport, Shreveport, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Waldo County General Hospital, Belfast, Maine, United States|MaineHealth\/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine, United States|Southern Maine Health Center\/Biddeford Medical Center, Biddeford, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|MaineHealth\/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Maine Medical Partners - South Portland, South Portland, Maine, United States|University of Maryland\/Greenebaum Cancer Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Kaiser Permanente-Woodlawn Medical Center, Baltimore, Maryland, United States|Johns Hopkins University\/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|FMH James M Stockman Cancer Institute, Frederick, Maryland, United States|Kaiser Permanente-Gaithersburg Medical Center, Gaithersburg, Maryland, United States|Kaiser Permanente - Kensington Medical Center, Kensington, Maryland, United States|Kaiser Permanente - Largo Medical Center, Largo, Maryland, United States|Beverly Hospital, Beverly, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|Lahey Medical Center-Peabody, Peabody, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|McLaren Cancer Institute-Bay City, Bay City, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute-Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|McLaren Cancer Institute-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Wayne State University\/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Michigan State University Clinical Center, East Lansing, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Singh and Arora Hematology Oncology PC, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|McLaren-Greater Lansing, Lansing, Michigan, United States|Mid-Michigan Physicians-Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology\/Hematology Associates of Marlette, Marlette, Michigan, United States|Mid-Michigan Medical Center - Midland, Midland, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, United States|Ascension Providence Hospitals - Novi, Novi, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|McLaren-Port Huron, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Beaumont Children's Hospital-Royal Oak, Royal Oak, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Henry Ford Macomb Health Center - Shelby Township, Shelby, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology\/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Minnesota Oncology - Burnsville, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|University of Minnesota\/Masonic Cancer Center, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, United States|Gulfport Memorial Hospital, Gulfport, Mississippi, United States|Mississippi Baptist Medical Center, Jackson, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, M"
"2078","Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects","","NCT04483375","SCTA01-X101","Biological: SCTA01|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04483375","Completed","2020-07-24","2020-12-25","{""locations"":""Beijing SHIJITAN Hospital, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""33"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dose-limiting toxicity(DLT)|Maximal Tolerable Dose(MTD)|AUC0-t|AUC0-\u221e|t1\/2|Tmax|Anti-drug antibody(ADA)|Adverse events""}"
"2079","The Effect of COVID-19 on Diabetes Mellitus","COVID-19-DM","NCT04592055","UU-DM002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04592055","Recruiting","2020-03-20","2020-11-01","{""locations"":""Usak University Training and Research Hospital, Usak, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A1c""}"
"2080","Stellate Ganglion Blockade in COVID-19 Positive Patients","","NCT04445337","603.20.FB","Procedure: Stellate Ganglion Block","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04445337","Not yet recruiting","2020-07-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""19 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the safety of a new modified stellate ganglia block (SGB) in ARDS|Evaluate the efficacy of a new modified stellate ganglia block (SGB) in ARDS""}"
"2081","Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt","","NCT04488588","AssiutU17","Other: Kaplan Meier analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04488588","Completed","2020-03-15","2020-07-01","{""locations"":""AssiutU, Assiut, Egypt|Aliae Mohamed-Hussein, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1064"",""age"":""36 Years to 63 Years \u00a0 (Adult)"",""outcome_measures"":""number of co-morbidities in hospitalized patients with COVID-19|causes of ICU admission""}"
"2082","Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)","","NCT04569786","V590-001","Biological: V590|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04569786","Terminated","2020-10-29","2021-02-18","{""locations"":""Celerion ( Site 0002), Tempe, Arizona, United States|Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States|QPS Miami Research Associates ( Site 0005), South Miami, Florida, United States|Bio-Kinetic Clinical Applications (QPS) ( Site 0006), Springfield, Missouri, United States|Celerion ( Site 0001), Lincoln, Nebraska, United States|Alliance for Multispecialty Reseach, LLC ( Site 0004), Knoxville, Tennessee, United States|Worldwide Clinical Trials ( Site 0007), San Antonio, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""232"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants with at Least 1 Solicited Injection Site Adverse Event|Percentage of Participants with at Least 1 Solicited Systemic Adverse Event|Percentage of Participants with at Least 1 Unsolicited Adverse Event|Percentage of Participants with at Least 1 Medically Attended Adverse Event|Percentage of Participants with at Least 1 Serious Adverse Event|Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by Plaque Reduction Neutralization Test (Panels A - H)|Geometric Mean Titers for SNAs as Measured by PRNT (Panels A-H)|Geometric Mean Concentration of Total Anti-SARS-CoV-2 Spike SNAs as Measured by Enzyme-Linked Immunosorbent Assay (Panels A-H)|Percentage of Participants with Vaccine Viremia as Measured by Reverse Transcription-Polymerase Chain Reaction|Percentage of Participants with Vaccine Shedding in Saliva or Urine as Measured by RT-PCR|Percentage of Participants with Vaccine Shedding in Stool (If Assayed) as Measured by RT-PCR""}"
"2083","Recovery Profiles in Patients With SARS-CoV-2 Outcomes Undergoing Rehabilitation","","NCT04615390","Covid19_rehabilitation","Behavioral: Early rehabilitation|Behavioral: Subacute rehabilitation|Behavioral: Mindfulness training|Behavioral: Personalized ambulatory training","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04615390","Recruiting","2020-03-30","2021-06-03","{""locations"":""Department of Neuroscience and Rehabilitation, University Hospital of Ferrara, Ferrara, Emilia Romagna, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Borg scale|Heart rate|Oxygen saturation|30 seconds sit-to-stand test|Change in 1 minute sit-to-stand test between two time points|Change in Short form health survey between three time points|2-minute walking test|Change in 6-minute walking test between two time points|Change in Functional Independence Measure Scale between two time points|Change in Montreal Cognitive Assessment between two time points|Cognitive Reserve Index questionnaire|Change in Patient Health Questionnaire-9 between two time points|Change in Beck anxiety inventory between two time points|Change in Connor-Davidson Resilience Scale between two time points|Change in Impact of Event Scale - Revised between two time points|Change in General Self Efficacy Scale between two time points|Change in Pittsburgh Sleep Quality Index between two time points""}"
"2084","Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection","PROTECT","NCT04344600","IRB00248163","Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04344600","Recruiting","2020-05-29","2021-12-01","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""164"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants with no evidence of SARS-CoV-2 infection|Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples""}"
"2085","Prospective Two-arm Study of Fertility in Men With COVID-19","","NCT04716179","COVID-MFert-20","Diagnostic Test: Sperm test|Diagnostic Test: hormone levels (testosterone, FSH, LH, prolactin)|Diagnostic Test: SARS-CoV-2 Ig G levels|Other: Testis pathology samples","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04716179","Recruiting","2021-01-18","2021-05-18","{""locations"":""Sechenov University., Moscow, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""88"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Semen quality analysis - motility|Semen quantity analysis|Semen quality analysis - shape|Testosterone|FSH|LH|Prolactin|Damage of the testes on pathology""}"
"2086","COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;","C-SMART","NCT04534725","Peter Mac ID 20/135","Drug: Interferon alfa|Drug: Selinexor|Drug: Lenzilumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04534725","Recruiting","2020-12-17","2021-12-01","{""locations"":""Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""2282"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)|incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing|incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .|incidence of death and\/or need for invasive or non-invasive ventilation. assessed using medical records|time to clinical improvement or discharge from hospital assessed using medical records|ARM 1: Duration of acute respiratory\/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool|ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records|ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records|ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale|ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records|ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR|ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records|ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records|ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records.|ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records|ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale.|ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.|ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.|ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records|ARM 3: Time to clinical improvement assessed using medical records.|ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale|ARM 3: change to clinical condition assessed with Karnofsky Performance score|ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale|ARM 3: Time to all-cause mortality|ARM 3:Duration of hospitalisation assessed using medical records|ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary.|ARM 3: Duration of oxygen supplementation (days). assessed using medical records.|ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)|ARM 3: Safety and tolerability of selinexor using relevant medical records|ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records|ARM 4: Incidence of all cause death by day 28 and 60|ARM 4: Time to all-cause mortality|ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale|ARM 4: Incidence of ARDS assessed using medical records|ARM 4: incidence of HLH. assessed using medical records|ARM 4: Duration of hospitalisation. assessed using hospital medical records.|ARM 4: Proportion discharged from hospital. assessed using medical records|ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records|ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records|ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.|ARM 4: Incidence and duration of ICU admission. assessed using medical records|ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records|ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours.|ARM 4: incidence of non-invasive ventilation. assessed using medical records|ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records.|ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records|ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records|ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records|ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.""}"
"2087","REMdesivir-HU Clinical Study and Severe Covid-19 Patients","","NCT04610541","REM-ENY-01","Drug: Remdesivir-HU","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04610541","Active, not recruiting","2020-10-12","2021-11-30","{""locations"":""Department of Pulmonology Semmelweis University, Budapest, Hungary|National Kor\u00e1nyi Institute for Pulmonology, Budapest, Hungary|North - Central Buda Center New St. J\u00e1nos Hospital, Budapest, Hungary|Institute of Infectology, University of Debrecen, Debrecen, Hungary|1st Department of Medicine, University of P\u00e9cs, P\u00e9cs, Hungary|Department of Internal Medicine University of Szeged, Szeged, Hungary|First Department of Internal Medicine, University of Szeged, Szeged, Hungary"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""12 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""To assess the safety and tolerability of REM use in Hungary in the conditionally approved indication (EMA)|The proportion of patients with at least 1 treatment-emergent adverse event|Proportion of patients with treatment-emergent clinical""}"
"2088","Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge","COVINVAC","NCT04537130","PANIN3BIO/IN01_COVID19_01|2020-002874-28","Biological: IN01 vaccine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04537130","Not yet recruiting","2020-12-01","2022-06-01","{""locations"":""Hospital El Pilar, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety (Frequency\/severity of AEs)|Oxygen saturation|Quality of life (QoL)|Fibrotic pulmonary extension (measured as the size of the lesions)""}"
"2089","Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients","OzonoCOVID19","NCT04359303","P.Inv. Ozono-COVID19 Ver.1.2","Other: Systemic indirect endovenous ozone therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04359303","Not yet recruiting","2020-07-01","2020-12-01","{""locations"":""SEOT, Valencia, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID19 clinical scale|Number of died patients|Oro\/nasopharynx virus|Thorax imaging (0=none; 1=unilateral; 2=bilateral; 3=ground-glass opacification; 4=consolidation)|Days in hospital|Venous gas blood analysis""}"
"2090","Characteristics of COVID-19 Patients in Kazakhstan in Early 2020","","NCT04627194","76.29.31_48.04.06-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04627194","Active, not recruiting","2020-02-20","2020-12-01","{""locations"":""Semey Medical University, Semey, East Kazakhstan, Kazakhstan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical and demographic predictors of disease severity among hospitalized COVID-19 patients.|Clinical and demographic predictors of mortality among hospitalized COVID-19 patients.""}"
"2091","Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)","COVID+PA","NCT04351919","ECC2020-04","Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04351919","Withdrawn","2020-05-05","2020-07-15","{""locations"":""Eshmoun Clinical Research Centre\/ H\u00f4pital Abderrahmen Mami-Ariana, Tunis, Tunisia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""improvment or healing of clinical signs|Evolution of clinical signs""}"
"2092","Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins","SARS-CoV-2","NCT04465981","INANO-CV1","Diagnostic Test: Sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04465981","Recruiting","2020-07-01","2021-06-01","{""locations"":""TMC HealthCare, Tucson, Arizona, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Detection Test of COVID-19""}"
"2093","Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome","HBOTpCOVID","NCT04647656","332-20-ASF","Device: Hyperbaric oxygen|Device: Sham","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04647656","Not yet recruiting","2021-01-01","2023-01-01","{""locations"":""Assaf-Harofeh medical center, Zerifin, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cognitive health assessment (NeuroTrax)|Brain perfusion|Brain microstructure Brain microstructure|Brain function imaging|Post-COVID-19 symptom|Quality of Life SF-36|The Pittsburgh Sleep Quality Index PSQI|The Brief Symptom Inventory - 18 (BSI-18)|BPI - Brief pain inventory (short form)|Neuro-physical evaluation|Neurological evaluation|Smell and taste evaluations.|Cardiopulmonary exercise test|Echocardiography|Lung functions test|Immune system""}"
"2094","Silent Hypoxia and Awake Proning in COVID-19 Patients","SHYCOV","NCT04647747","SHYCOV2020","Other: Self measurement with pulse oximeter","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04647747","Recruiting","2020-11-30","2021-12-31","{""locations"":""Ostfold Hospital, Sarpsborg, Gr\u00e5lum, Norway"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""40"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients who manage to perform daily measurements of SpO2|Incidence rate of silent hypoxia in non-hospitalized COVID-19|Association between silent hypoxia and other subjective and objective measurements of disease severity|Effect of a self-managed physiotherapy program on alleviating hypoxia|Rate of persistent silent hypoxia episode per patients|Rate of silent hypoxia episode per patients|Rate of hospital admission and ICU admission|Incidence of thromboembolic event in outpatients diagnosed with COVID-19""}"
"2095","Predictive Factors for COVID-19 in Rheumatology","","NCT04567576","FPColCOVIDReuma2020","Drug: Disease-modifying antirheumatic drugs (DMARDs)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04567576","Not yet recruiting","2020-10-01","2021-10-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical behavior of the disease \/\/ COVID-19|Mortality""}"
"2096","SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)","SARS-CoV2_KIDS","NCT04581148","405_20 Bc","Diagnostic Test: Blood test for IgG antibodies against SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581148","Not yet recruiting","2020-10-05","2022-05-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Prevalence of IgG antibodies against SARS-CoV-2 at timepoint \""Month 6\""|Prevalence of IgG antibodies against SARS-CoV-2 at timepoint \""Month 12\""|Prevalence of IgG antibodies against SARS-CoV-2 at timepoint \""Month 18\""|Prevalence of IgG antibodies against SARS-CoV-2 at timepoint \""Month 24\""|Quantitative IgG antibodies against SARS-CoV-2 at timepoint \""Month 6\""|Quantitative IgG antibodies against SARS-CoV-2 at timepoint \""Month 12\""|Quantitative IgG antibodies against SARS-CoV-2 at timepoint \""Month 18\""|Quantitative IgG antibodies against SARS-CoV-2 at timepoint \""Month 24\""|Rate of SARS-CoV-2 antibodies in comparison betwen \""Month 6\"", \""Month 12\"", \""Month 18\"", and \""Month 24\""|Stratification of the antibodies against SARS-Cov-2 with patient characteristics (age, gender, clinical history) at timepoint \""Month 6\""|Stratification of the antibodies against SARS-Cov-2 with patient characteristics (age, gender, clinical history) at timepoint \""Month 12\""|Stratification of the antibodies against SARS-Cov-2 with patient characteristics (age, gender, clinical history) at timepoint \""Month 18\""|Stratification of the antibodies against SARS-Cov-2 with patient characteristics (age, gender, clinical history) at timepoint \""Month 24\""""}"
"2097","Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP","","NCT04575545","2020-A02018-31","Diagnostic Test: Serology test for COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04575545","Not yet recruiting","2020-10-01","2022-04-01","{""locations"":""BENNANI, Marseille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""% of patients with positive serological tests for covid-19|Presence and quantification of CD4 \/ CD8 reactivity to COVID-19 epitopes in patient with positive and negative serological tests for covid-19""}"
"2098","Effect of Pioglitazone on T2DM Patients With COVID-19","PIOQ8","NCT04604223","RA HM-2020- 011","Drug: Pioglitazone 45 mg","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04604223","Not yet recruiting","2020-11-15","2021-06-29","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1506"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""HsCRP level|Difference in the incidence at 4 weeks of a composite outcome comprised of:|Number of days free of mechanical ventilation|Number of days in the ICU|Duration of hospitalization|Change from baseline in qSOFA score|Change from baseline in SO2\/FiO2|Difference in respiratory rate|Incidence at 4 weeks of a composite of extrapulmonary disease comprised of :""}"
"2099","Outpatient Treatment of COVID-19 With Metformin","","NCT04510194","GIM-2020-29324","Drug: Metformin|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04510194","Recruiting","2021-01-01","2021-08-01","{""locations"":""University of Minnesota, Minneapolis, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""750"",""age"":""30 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decreased oxygenation|Emergency Department Utilization|Maximum symptom severity|Clinical Progression Scale|Time to meaningful recovery|Laboratory Outcome Subsidy""}"
"2100","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Covid-VAS","NCT04333693","RIV-2020-1","Procedure: Vascular surgery","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04333693","Not yet recruiting","2020-04-01","2020-11-01","{""locations"":""Spanish Society for Angiology and Vascular Surgery, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30-days mortality|7-days mortality|30-days reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis""}"
"2101","Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19","","NCT04377503","covid-19 hsd","Drug: Tocilizumab 180 MG/ML|Drug: Methylprednisolone Sodium Succinate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04377503","Not yet recruiting","2020-05-01","2020-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient clinical status 15 days after randomization|Improving oxygenation|Thorax CT improvement|ICU length of stay|Duration of mechanical ventilation|Incidence of acute kidney (AKI) with necessity of renal replacement therapy""}"
"2102","Liver Transplantation and Coronavirus Disease 2019 (COVID-19)","","NCT04695756","1405","Other: COVID-19 pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04695756","Recruiting","2020-12-15","2021-07-15","{""locations"":""Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To compare the number of patients registered on the liver transplant waiting list during the epidemiological weeks of COVID-19 pandemic in Argentina and the same weeks of 2019 according to national data registry of procurement and transplantation|To compare the number of deaths on the liver transplant waiting list during the epidemiological weeks of COVID-19 pandemic in Argentina and the same weeks of 2019 according to national data registry of procurement and transplantation|To compare the number of liver transplants during the epidemiological weeks of COVID-19 pandemic in Argentina and the same weeks of 2019 according to national data registry of procurement and transplantation""}"
"2103","Impact of Covid-19 in Congenital Heart Disease","COVID-CHD","NCT04336384","RECHMPL20_0155","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04336384","Completed","2020-03-01","2020-12-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence of Covid-19 infection in the overall CHD population|Prevalence of Covid-19 infection per CHD sub-group|Cardiovascular complications|Other complications|Number of deaths""}"
"2104","Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects","","NCT04638634","CSL760_1001","Biological: CSL760","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04638634","Recruiting","2021-02-02","2021-05-01","{""locations"":""CMAX Clinical Research, Adelaide, Australia"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""24"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total immunoglobulin (IgG) concentration of CSL760|Maximum concentration (Cmax) of CSL760|Time of Cmax (tmax) of CSL760|Area under the concentration-time curve (AUC) from time 0 to the last measurable concentration (AUC0-last) of CSL760|Number of subjects with Treatment-emergent adverse events (TEAEs)|Percent of subjects with TEAEs|Number of subjects with Serious adverse events (SAEs)|Percent of subjects with SAEs|Number of subjects with Clinically significant laboratory abnormalities that are reported as adverse events (AEs)|Percent of subjects with Clinically significant laboratory abnormalities that are reported as AEs""}"
"2105","Cholecalciferol to Improve the Outcomes of COVID-19 Patients","CARED","NCT04411446","001","Drug: Vitamin D|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04411446","Recruiting","2020-08-11","2020-12-28","{""locations"":""Hospital de Alta Complejidad en Red El Cruce, Florencio Varela, Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1264"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Respiratory SOFA.|Need of a high dose of oxygen or mechanical ventilation.|Change in oxygen saturation.|Oxygen desaturation.|Change in Quick SOFA score.|Myocardial infarction.|Stroke.|Acute kidney injury.|Pulmonary thromboembolism.|Combined endpoint (stroke, myocardial infarction, acute kidney injury and pulmonary thromboembolism.|Admission to ICU.|Invasive Mechanical Ventilation.|Hospital Length of Stay.|ICU length of stay.|Death""}"
"2106","Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","MALCOV","NCT04695197","20-063|202009642148520","Drug: Artemether-lumefantrine (AL)|Drug: Pyronaridine-artesunate (PA)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04695197","Recruiting","2021-01-08","2023-07-31","{""locations"":""Ouagadougou Hospitals, Ouagadougou, Burkina Faso|Kisumu County Referral Hospital, Kisumu, Kenya"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""142"",""age"":""6 Months to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Incidence of SARS-CoV-2 clearance|Median viral load of SARS-CoV-2|Cumulative incidence of SARS-CoV-2 clearance|Time to clearance of nasal SARS-CoV-2|Cumulative seroconversion rates (IgG, IgM, IgA)|IgG, IgM, IgA antibody titres against SARS-CoV-2|IL-6, IL-7, IL-10, TNF-alpha and Interferon-Gamma|CRP and angiotensin-2, angiopoietin-1 and angiopoietin-2|Genomic responses to SARS-CoV-2 infection|Cellular immune responses to SARS-CoV-2 infection|The clinical and parasitological antimalarial treatment response|COVID-19 disease severity|COVID-19 disease duration|COVID-19 fever duration|COVID-19 respiratory symptoms duration|COVID-19 disease duration in days|Treatment-related adverse events, serious adverse events, and adverse events resulting in treatment discontinuation""}"
"2107","A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)","SAVE","NCT04395456","AMY-101_SAVE","Drug: AMY-101|Other: WFI 5% glucose","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04395456","Not yet recruiting","2021-09-01","2022-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""144"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of patients who are alive, without evidence of ARDS (i.e. PaO2\/FIO2 >300 mm Hg), who do not require any oxygen support (in room air).|The proportion of patients assigned to each category, of a six-category ordinal scale.|Proportion of patients surviving|Proportion of respiratory failure-free survival|Cumulative incidence of resolution of ARDS (defined as PaO2\/FiO2 \u2265200 in room air)|Cumulative incidence of freedom from oxygen requirement|Proportion of patients requiring invasive mechanical ventilation due to worsening of ARDS|Proportion of patients requiring non-invasive mechanical ventilation (NIV) due to worsening of ARDS|Proportion of patients developing thrombotic microangiopathies|Changes in PaO2 and PaO2\/FIO2|Changes in quick Sequential Organ Failure Assessment Score (qSOFA: respiratory rate, systolic blood pressure, Glasgow Coma Scale (GCS)|Changes in maximal and minimal cardiovascular parameters: Respiratory rate|Changes in maximal and minimal cardiovascular parameters: Heart Rate|Changes in levels of biomarkers of inflammation (CBC, CRP, Ferritin, Procalcitonin, D-dimers, LDH)|Length of stay in ICU|Cumulative incidence of discharge from hospital|Number of adverse events|Changes in levels of anti-drug antibodies|Changes in levels of biomarkers of complement activity: C3, C3a, C5a, sC5b-9|Changes in levels of biomarkers of cytokine release syndrome: IL-1, IL-6, IL-12|Changes in levels of Club Cell protein CC16 (biomarker of lung damage )|Changes in levels of AMY-101 plasma level""}"
"2108","Furosemide as Supportive Therapy for COVID-19 Respiratory Failure","FaST-1","NCT04588792","FaST-1","Drug: Nebulized Furosemide|Drug: Nebulized Saline","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04588792","Recruiting","2021-02-01","2021-10-01","{""locations"":""University of Alberta, Edmonton, Alberta, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|Kingston Health Sciences Center, Kingston, Ontario, Canada|H\u00f4pital Maisonneuve-Rosemont, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""640"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement in pulmonary gas exchange|Requirement for mechanical ventilation|Mortality|Requirement for supplemental oxygen|Duration of ICU Stay|Length of hospitalization|Adverse events|Inhalation adverse events""}"
"2109","Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)","COVIDPROIMPACT","NCT04375644","69HCL20_0413","Other: Questionnaires on psychological quality of life","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375644","Completed","2020-05-07","2020-07-15","{""locations"":""Gyn\u00e9cologie-Obst\u00e9trique CHU de Angers, Angers, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital Pellegrin, Bordeaux, France|Gyn\u00e9cologie-Obst\u00e9trique CHRU de Brest, Brest, France|Gynaecology Department, H\u00f4pital Femme M\u00e8re Enfant, Hospices Civils de Lyon, Bron, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital Antoine B\u00e9cl\u00e8re (APHP), Clamart, France|Gyn\u00e9cologie-Obst\u00e9trique CHU Grenoble-Alpes, H\u00f4pital Couple Enfant, La Tronche, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital BICETRE (APHP), Le Kremlin-Bic\u00eatre, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital Jeanne de Flandre - CHRU Lille, Lille, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital de la M\u00e8re et de l'Enfant, Limoges, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital de la Croix Rousse, Lyon, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital La Conception, Marseille, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital de la Piti\u00e9 Salp\u00eatri\u00e8re (APHP), Paris, France|Gyn\u00e9cologie-Obst\u00e9trique Maternit\u00e9 Port-Royal, Groupe Hospitalier Cochin-Broca- Hotel Dieu (APHP), Paris, France|Gyn\u00e9cologie-Obst\u00e9trique CHU de Poitiers, Poitiers, France|Gyn\u00e9cologie-Obst\u00e9trique CHU Reims - Institut M\u00e8re Enfant Alix de Champagne, Reims, France|Gyn\u00e9cologie-Obst\u00e9trique CHU de Rennes, Rennes, France|Gyn\u00e9cologie-Obst\u00e9trique CHU de Saint Etienne, Saint-\u00c9tienne, France|Gyn\u00e9cologie-Obst\u00e9trique H\u00f4pital de Hautepierre, Strasbourg, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1565"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stress state score, during the confinement period""}"
"2110","The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications","","NCT04453748","COVID-19 Complications Study","Other: Complex diagnostic panel","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453748","Enrolling by invitation","2020-06-08","2021-11-30","{""locations"":""Silesian Centre for Heart Disease, Zabrze, Silesia, Poland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID-19 complications|Assessment of risk factors of COVID-19 complications""}"
"2111","Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients","OxyJet-CPAP","NCT04681859","BME-BUET-003","Device: High Flow Nasal Oxygen (HFNO) treatment|Device: Continuous Positive Airway Pressure (CPAP) therapy using OxyJet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04681859","Not yet recruiting","2020-12-30","2021-05-01","{""locations"":""Dhaka Medical College, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of ventilator-free days|Recovery of the patient|Death or need of intubation|Oxygen toxicity or other adverse events""}"
"2112","Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19","PROLUN","NCT04535154","PROLUN","Other: No interventions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04535154","Active, not recruiting","2020-03-31","2022-06-01","{""locations"":""Dept Pulmonary Medicine, L\u00f8renskog, Viken, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""264"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Forced vital capacity|Gas diffusion capacity of carbon monoxide|modified Medical Respiratory Council Dyspnea Scale|Parenchymal opacities of the lungs|Forced expiratory capacity during 1st second of expiration|FEV1\/FVC|Gas diffusion capacity adjusted for alveolar ventilation (KCO)""}"
"2113","Convalescent Plasma Therapy in Severe COVID-19 Infection","","NCT04403477","BSMMU/2020/6104","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04403477","Recruiting","2020-05-20","2020-10-30","{""locations"":""Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Proportion of In-hospital mortality|Time to death|Fever|Respiratory distress|Saturation of oxygen|Blood pressure|Oxygen requirement|C-reactive Protein|Ferritin|SGPT|SGOT|ICU stay|Ventilator support|Hospital stay|Proportion of Transfusion reaction""}"
"2114","Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia","BIOCOVID","NCT04485364","BIOCOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04485364","Active, not recruiting","2020-04-14","2020-10-31","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Inflammatory response in the evolution of respiratory diseases|Impact of the respiratory disease during mechanical ventilation""}"
"2115","Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19","MAOi-COV19","NCT04590222","APHP200989|2020-A02398-31","Other: blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04590222","Not yet recruiting","2020-11-01","2021-11-01","{""locations"":""CHU Bic\u00eatre, Le Kremlin-Bic\u00eatre, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""levels of lymphocytes T DR + CD38 + and of monocytes CD14 dim + CD16 +.|level of immune checkpoints|cytokine production and proliferation|levels of neutrophils|level of immune responses in obese patients|level of immune responses for men and women""}"
"2116","Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19","","NCT04547283","06-20-03E","Other: Usual Care|Other: APPS","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04547283","Recruiting","2020-06-14","2020-09-30","{""locations"":""Carolinas Medical Center, Charlotte, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Average S\/F ratio|Time spent with S\/F ratio < 315|Highest oxygen support|Number of patients requiring ICU admission during study period|Number of patients requiring ICU admission during hospitalization|Number of patients experiencing who die prior to discharge|Number of patients requiring intubation|Hospital length of stay""}"
"2117","The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19","COVID-19-DM2","NCT04591704","UU-DM003","Other: hospitalisation, necessity of ICU, mortality rate, lung involvement","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04591704","Recruiting","2020-03-20","2020-11-01","{""locations"":""Usak University Training and Research Hospital, Usak, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of Hospitalisation|The need for ICU|Mortality|Lung involvement""}"
"2118","Predictive Models for Intensive Care Admission and Death of COVID-19","","NCT04401228","0410508057","Other: predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401228","Active, not recruiting","2020-03-01","2021-01-01","{""locations"":""Clinique Saint-Pierre, Ottignies, Brabant Wallon, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""admission to ICU|death""}"
"2119","Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19","","NCT04569383","UKE-DZIF-SARS-CoV-2","Biological: MVA-SARS-2-S vaccinations (days 0 & 28)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04569383","Recruiting","2020-10-05","2021-05-01","{""locations"":""CTC North GmbH & Co KG at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""30"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol|Immunogenicity. Number of participants who seroconverted""}"
"2120","Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19","ZnD3-CoVici","NCT04351490","2020_30|2020-A00873-36","Dietary Supplement: Zinc gluconate|Dietary Supplement: 25-OH cholecalciferol","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04351490","Withdrawn","2020-04-01","2020-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival rate in asymptomatic subjects at inclusion|Survival rate in symptomatic subjects at inclusion|Survival rate in overall subjects|Cumulative incidence of Covid-19 infection in asymptomatic subjects at inclusion""}"
"2121","Parental Attitude Toward Children Dental Treatment During COVID-19 Pandemic","","NCT04512300","Covid -19 and dental visit","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04512300","Completed","2020-06-15","2020-06-25","{""locations"":""faculty of dentistry, Cairo university , Egypt, Cairo, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""267"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Assessment of parental attitude toward children dental visit during Coronavirus crisis""}"
"2122","Neurocognitive Functions of Recovered COVID-19 Patients","","NCT04622748","NIDD-2020-Neurocognition","Behavioral: Trier Social Stress Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04622748","Recruiting","2020-07-10","2020-12-10","{""locations"":""Wuhan Wuchang Hospital, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""160"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""working memory|Cognitive flexibility|Inhibitory control|Attention Bias|Serum TNFalpha|Serum IL-6|CRP|Depression|Anxiety|PTSD|Sleep|General cognition|Cardiopulmonary function 1|Cardiopulmonary function 2""}"
"2123","Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury","MIIC-MI","NCT04412369","A09565","Diagnostic Test: Non-invasive cardiac imaging","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412369","Not yet recruiting","2020-06-01","2021-06-01","{""locations"":""Cambridge Univeristy Hospitals NHS Foundation Trust, Cambridge, United Kingdom"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with a diagnosis of COVID-19 related myocarditis, Type 1 or 2 myocardial infarction and\/or other mechanism of cardiac injury confirmed by multi-modality imaging.|Comparison of a panel of inflammatory cytokines and immune cell profiles in patients categorized by cardiac diagnosis after imaging|Comparison of a panel of blood coagulation markers in patients categorized by cardiac diagnosis after imaging""}"
"2124","Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate","VTE-COVID-19","NCT04598620","ILG-VTE-COVID-19-2020|N-20200069","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04598620","Recruiting","2020-09-19","2021-10-01","{""locations"":""Aalborg Hospital, Aalborg, Denmark"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prediction of admission to ICU in hospitalized COVID-19 patients|Pathophysiology in COVID-19 patients""}"
"2125","Comparison Between Positive and Negative COVID-19 Pneumonia","","NCT04507893","ACPM26","Other: Clinical, laboratory and imaging characteristics of pneumonia","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04507893","Recruiting","2020-03-15","2022-12-01","{""locations"":""Infectious diseases Unit of the \""Cervello-Villa Sofia\"" Hospital, Palermo, PA, Italy|Internal Medicine Division of the \""Cervello-Villa Sofia\"" Hospital, Palermo, PA, Italy|Pulmonology Unit Dedicated to COVID-19 Patients, Palermo, PA, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""80"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the clinical characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as \""COVID-19 patients\"" and \""COVID-19 negative controls\"".|Evaluation of the laboratory characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as \""COVID-19 patients\"" and \""COVID-19 negative controls\"".|Evaluation of the imaging characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as \""COVID-19 patients\"" and \""COVID-19 negative controls\"".|Evaluation of mortality of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as \""COVID-19 patients\"" and \""COVID-19 negative controls\"".|Evaluation of clinical severity of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as \""COVID-19 patients\"" and \""COVID-19 negative controls\"".|Evaluation of hospital stay length of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as \""COVID-19 patients\"" and \""COVID-19 negative controls\"".""}"
"2126","Baseline Vitamin D Deficiency and COVID-19 Disease Severity","","NCT04628000","PIRB78","Other: Vitamin D","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04628000","Recruiting","2020-10-27","2022-04-14","{""locations"":""Parkview Medical Center, Pueblo, Colorado, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""LOS duration in days|Supp O2 flow volume in L\/min""}"
"2127","Rational Use of Personal Protective Equipment During COVID-19 Pandemic","RUPERT","NCT04712045","IRAS287865","Other: New PPE|Other: Old PPE","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04712045","Completed","2020-08-01","2020-12-12","{""locations"":""Professor Peter McCulloch, Oxford, Oxfordshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""67"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of participants and simulated patients with contamination as assessed by ultraviolet light|Participants' perception of personal comfort and safety and safety of the patients as assessed through structured questionnaire|changes in participants perception of personal comfort and safety and safety of patients as assessed through a semi-structured questionnaire|The difference in the area of contamination between New and Standard PPE as analyzed through python script""}"
"2128","MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome","","NCT04525378","PCL02/2020","Other: Mesenchymal stromal cell-based therapy","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04525378","Recruiting","2020-07-01","2020-10-31","{""locations"":""Hospital S\u00e3o Rafael, Salvador, Bahia, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intrahospital mortality|Length of stay in the ICU and Hospital|Days without mechanical ventilation in 28 days|PaO2 \/ FiO2 ratio|Incidence of secondary infections|Incidence of adverse events|Quantification of inflammatory response markers""}"
"2129","An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection","","NCT04581018","Synbiotic COV study","Other: Health supplements","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04581018","Recruiting","2020-08-13","2022-04-30","{""locations"":""The Chinese University of Hong Kong, Sha Tin, Hong Kong"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Combined symptom score|Clinical improvement|Time to develop antibody against SARS-CoV-2|Quality of life measured by EQ-5D-5L|Quality of life measured by SF-12|Duration of hospital stay|Time to negative PCR|Trend of symptom score|Gastrointestinal symptoms|Changes in fecal bacteria metabolites|Change in plasma cytokines level|Changes in the gut microbiome|Number of admission to Intensive Care Unit|Number of subjects with home discharge|Number of mortality|Number of days absent from work|Change of quality of life questionnaire|Number of adverse event""}"
"2130","Prediction Models for Diagnosis and Prognosis of Severe COVID-19","","NCT04525287","2020-12020001231","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04525287","Recruiting","2020-02-20","2020-08-20","{""locations"":""2nd Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Chest CT and clinical features""}"
"2131","The Effect of Diabetes Mellitus on Mortality of Patients With COVID-19","","NCT04663659","1559","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04663659","Completed","2020-03-15","2020-05-15","{""locations"":""SisliHamidiye Etfal Education and Training Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|length of stay in intensive care""}"
"2132","Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19","DuACT","NCT04563208","DUACT-101","Drug: Placebo|Drug: DuACT","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04563208","Recruiting","2020-12-09","2021-03-01","{""locations"":""Sunnyside Office Park, Johannesburg, Gauteng, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of decline in viral load|Time to resolution of viral load|Comparison of proportion of subjects who are asymptomatic and symptomatic|Change in modified NEWS-2|Proportion of subjects with treatment emergent adverse events""}"
"2133","Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit","ENVIROREA","NCT04355481","APHP200411|2020-A00897-32","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355481","Recruiting","2020-04-17","2020-12-17","{""locations"":""Service de r\u00e9animation H\u00f4pital Avicenne, Bobigny, France|Service de r\u00e9animation H\u00f4pital Bichat, Paris, France|Service de r\u00e9animation H\u00f4pital Tenon, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Estimate the proportion of patients hospitalized in intensive care for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter.""}"
"2134","Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System","KOVID","NCT04616950","KOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04616950","Recruiting","2020-12-01","2021-12-31","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, Groupe Hospitalier Paris Saint-Joseph, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital course of patients with cancer of the digestive system|Modeling of the hospital journey based on observations made during the period preceding the COVID-19 epidemic""}"
"2135","Mesenchymal Stem Cells for the Treatment of COVID-19","","NCT04573270","Pro00043080","Biological: PrimePro|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04573270","Completed","2020-04-24","2020-09-01","{""locations"":""Southern California Hospital at Culver City \/ Southern California Hospital at Hollywood, Culver City, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival Rates|Contraction Rates""}"
"2136","Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19","","NCT04716569","SVU MED CIT0 23 4 21 1 120","Drug: intranasal ivermectin spray","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04716569","Recruiting","2021-01-20","2021-03-02","{""locations"":""Zaky Aref, Qin\u0101, Qina, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""progression of covid 19 clinical picture""}"
"2137","Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome","ketocovidiet","NCT04492228","KETOCOV-1","Other: Ketogenic diet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04492228","Recruiting","2020-09-01","2021-05-30","{""locations"":""Samir Giuseppe Sukkar, Genova, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate in the ketogenic group diet vs standard one|Access in Intensive Care Unit in the ketogenic group diet vs standard one|Need of Non Invasive Ventilation in the ketogenic group diet vs standard one|Combined endpoint \""mortality, ICU transfer or need for CPAP or intubation\"" in the ketogenic group diet vs standard one""}"
"2138","Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients","","NCT04593654","Thromboprophylaxis COVID-19","Drug: Dose of tinzaparin or dalteparin","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04593654","Completed","2020-03-01","2020-10-15","{""locations"":""S\u00f6dersjukhuset, Stockholm, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""257"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""28-day mortality|Incidence of thromboembolic events|Incidence of bleeding events|ICU-free days alive from ICU-admission|90-day mortality""}"
"2139","Can the Electronic Nose Smell COVID-19?","","NCT04475562","eNoseCOVID","Device: Aeonose","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04475562","Completed","2020-04-06","2020-07-01","{""locations"":""Maastricht University Medical Center, Maastricht, Netherlands"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""219"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID 19 positive vs negative""}"
"2140","Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","","NCT04550325","Kamada Anti-SARS-CoV-2-001","Biological: Kamada Anti-SARS-CoV-2","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04550325","Completed","2020-08-05","2020-11-26","{""locations"":""Wolfson Medical Center, Holon, Israel|Hadassah Medical Center, Jerusalem, Israel|Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel|Kaplan Medical Center, Re\u1e96ovot, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse events, serious adverse events, and deaths|AUC0-7 of Anti SARS CoV-2 antibodies|Neutralization activity""}"
"2141","Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19","","NCT04341766","COVID-ECHO","Other: No special intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341766","Completed","2020-03-31","2020-06-30","{""locations"":""CHU Amiens, Amiens, France|CH de la C\u00f4te Basque, Bayonne, France|CHU Ambroise Par\u00e9, Boulogne-Billancourt, France|CHU Caen, Caen, France|CHG de Chambery, Chamb\u00e9ry, France|Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France|CHU de Limoges, Limoges, France|APHM - Hopital Nord, Marseille, France|CHU de Nancy, Nancy, France|CHU N\u00eemes, N\u00eemes, France|CHR Orl\u00e9ans, Orl\u00e9ans, France|CHU Cochin, Paris, France|CHU Poitiers, Poitiers, France|CHU Rouen, Rouen, France|CH Saint-Quentin, Saint-Quentin, France|CHU Larrey - Toulouse, Toulouse, France|CHU de Tours, Tours, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""106"",""age"":""18 Years to 105 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characteristics of pulmonary ultrasound for Covid-19 patients|Charateristics of pulmonary CT-scan for Covid-19 patients""}"
"2142","IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation","","NCT04616001","COVID-IVIG VENT|2010902","Drug: IVIG","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04616001","Not yet recruiting","2020-11-01","2021-06-30","{""locations"":""Sharp Memorial Hospital, San Diego, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital length of stay|Human metabolome and proteome""}"
"2143","Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation","","NCT04397796","QUILT-COVID-19-MSC","Biological: BM-Allo.MSC|Biological: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04397796","Recruiting","2020-08-03","2021-06-01","{""locations"":""St. Francis Medical Center, Lynwood, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of \u2264 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs""}"
"2144","Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19","COVCKD","NCT04367714","FHM-1-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367714","Recruiting","2020-03-15","2021-12-01","{""locations"":""Godstrup Hospital, Herning, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""AAntibody response""}"
"2145","Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases","ThalaCoV","NCT04526405","ThalaCoV","Diagnostic Test: SARS-CoV-2 S1/S2 IgG","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04526405","Completed","2020-07-14","2020-11-03","{""locations"":""ASST Monza - Ospedale San Gerardo, Monza, MB, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""63"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positive subjects""}"
"2146","Impact of an Intensified Thromboprofylaxis Protocol in COVID-19","","NCT04394000","Jessa_20.48","Other: thromboprofylaxis protocol|Other: standard protocol","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04394000","Completed","2020-05-04","2020-05-15","{""locations"":""Jessa hospital, Hasselt, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""72"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""2 week mortality|incidence of venous thromboembolism|1 week mortality|3 week mortality|1 month mortality|incidence of kidney failure|incidence of continuous renal replacement therapy (CRRT)|lowest PaO2\/FiO2 (P\/F) ratio|highest Sequential Organ Failure Assessment (SOFA) score|length of stay|highest bilirubin|highest ( AST|highest Aspartaat-Amino-Transferase (ALT)""}"
"2147","Inspiratory Muscle Training in Patients With COVID-19","","NCT04603963","34931220.1.0000.0071","Device: power breathe","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04603963","Terminated","2020-06-01","2020-10-23","{""locations"":""Municipal Hospital Vila Santa Catarina, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""55"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""impact on functionality""}"
"2148","Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac Injury","COLHEART-19","NCT04510038","152247","Drug: Colchicine|Other: Covid-19 Standard of Care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04510038","Recruiting","2020-01-01","2022-01-01","{""locations"":""Baptist Health South Florida, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""75"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All Cause Mortality|Mechanical Ventilation|Mechanical Circulatory Support|Time to Deterioration|Adverse Events|Troponin|Delta|BNP|Changes in C Reactive Protein|LOS|Re-Hospitalization|Changes in D Dimer""}"
"2149","Assessment of Lung Mechanics in COVID-19 Acute Respiratory Distress Syndrome","LungMechCoV-19","NCT04597853","2020-01999","Diagnostic Test: Assessment of lung mechanics and heart-lung interactions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04597853","Not yet recruiting","2020-10-20","2021-12-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time dependent compliance change|PEEP and time dependent change in dead space|PEEP and time dependent change in shunt fraction""}"
"2150","Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19","ONCOVID-21","NCT04510454","ONCOVID-21 - ET20-118","Diagnostic Test: Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04510454","Recruiting","2020-11-02","2021-05-01","{""locations"":""Centre Leon Berard, Lyon, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To determine the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the RT-qPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the ddPCR and RT-qPCR abilities to detect the SARS-CoV-2 in oropharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the ability of a clinical diagnosis based both on patients' symptoms and chest CT-scan to detect the SARS-CoV-2 in symptomatic patients with suspected COVID-19 infection|To determine the agreements between nasopharyngeal samples and oropharyngeal samples|To determine the agreements between a clinical diagnosis and ddPCR and RT-qPCR assays|To assess the 28-day mortality rate|To determine potential predictive factors of death among patients' characteristics|To evaluate the over risk of death of patients COVID+ versus COVID-""}"
"2151","SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19","","NCT04355494","ECU-COV-401","Biological: eculizumab","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04355494","No longer available","1970-01-01","1970-01-01","{""locations"":""Cedars-Sinai Medical Center, Los Angeles, California, United States|Boston Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|H\u00f4pital Henri Mondor, Creteil, France|H\u00f4pital Garches Raymond Poincar\u00e9, Garches, France|H\u00f4pital de Bic\u00eatre, Le Kremlin Bic\u00eatre, France|H\u00f4pital Saint Louis, Paris, France|H\u00f4pital Paul Brousse, Villejuif, France"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"2152","Baricitinib Therapy in COVID-19","","NCT04358614","HPrato-4","Drug: Baricitinib 4 MG Oral Tablet","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04358614","Completed","2020-03-16","2020-04-07","{""locations"":""Fabrizio Cantini, Prato, Tuscany, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.|To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.|ICU admission rate|Discharge rate.""}"
"2153","Mental Health Among Patients, Providers, and Staff During the COVID-19 Era","MHAPPS","NCT04700137","20-0052|PCORI HIS-2018C3-14695","Other: Caring Contacts Plus Introductory Phone Call (CC+)|Other: Caring Contacts without an introductory phone call (CC)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04700137","Enrolling by invitation","2021-01-18","2022-01-17","{""locations"":""St. Luke's Health System, Boise, Idaho, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""660"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Loneliness as measured by the National Institutes of Health (NIH) Toolbox Social Relationship Scale for Loneliness|Suicidal Ideation & Behavior as measured by the Columbia Suicide Severity Rating Scale|Suicide Attempts & Self-Harm as measured by the Columbia Suicide Severity Rating Scale|Perceived Burdensomeness & Thwarted Belongingness as measured by the Interpersonal Needs Questionnaire (INQ15)|Psychological Stress as measured by the National Institutes of Health (NIH) Toolbox Stress and Self-Efficacy Scales Perceived Stress measure|Alcohol and Illicit Drug Use as measured by questions adapted from Youth Risk Behavior Survey and related to COVID-19|Depression as measured by the Patient Health Questionnaire (PHQ-9)|Anxiety as measured by the Generalized Anxiety Disorder 7 Item Scale (GAD-7)|Attendance at Mental Healthcare Appointments: Self-Report""}"
"2154","COVID-19 Registry Rhineland-Palatinate (Germany)","","NCT04335188","COVID-19 Registry","Other: Prospective oberservational registry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04335188","Recruiting","2020-04-06","2021-09-30","{""locations"":""Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik f\u00fcr Herzchirurgie, Ludwigshafen, RLP, Germany"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge""}"
"2155","Operation of the GHPSJ Clinical Ethical Reflection Assistance Group During the COVID-19 Period","ETHICOVID","NCT04586140","ETHICOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04586140","Recruiting","2020-11-09","2022-04-30","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Interest of GAREC""}"
"2156","Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020","Covaé","NCT04514874","2020-COVID19-26|2020-A01459-30","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04514874","Completed","2020-09-01","2020-10-05","{""locations"":""Centre d'Expertise Medicale du Personnel Navigant (CEMPN) de l'H\u00f4pital d'Instruction des Arm\u00e9es Percy, Clamart, France|Centre d'Expertise Medicale du Personnel Navigant (CEMPN) de l'H\u00f4pital d'Instruction des Arm\u00e9es Sainte-Anne, Toulon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""479"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID-19 infection among French military professional aircrew|Predictive factors of COVID-19 infection|Techniques used for COVID-19 screening|Reasons for COVID-19 screening|Experienced symptoms of COVID-19|Medical care of COVID-19|Social consequences of the COVID-19 pandemic|Factors associated with pejorative consequences of the COVID-19 pandemic""}"
"2157","Pulmozyme to Improve COVID-19 ARDS Outcomes","","NCT04402944","P00035140","Drug: Pulmozyme|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04402944","Recruiting","2020-07-05","2021-12-31","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""3 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Ventilator-free days at 28 days|change in airway resistance|change in lung compliance|oxygenation (PaO2\/FiO2 ratio)|length of stay (ICU and hospital)|rate of barotrauma|mortality.""}"
"2158","A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects","","NCT04516564","AK119-101","Drug: AK119|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04516564","Recruiting","2020-09-01","2021-04-01","{""locations"":""Christchurch Clinical Studies Trust, Christchurch, New Zealand"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other"",""enrollment"":""32"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of treatment-emergent AEs|Maximum serum concentration (Cmax) of AK119|Area under the concentration-time curve (AUC) of serum concentration of AK119|Percentage of subjects who develop detectable anti-drug antibodies (ADAs)""}"
"2159","Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?","","NCT04470739","KSSEAH--CT","Diagnostic Test: chest x-ray","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04470739","Recruiting","2020-05-30","2020-10-30","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""20"",""age"":""up to 7 Hours \u00a0 (Child)"",""outcome_measures"":""Cardiothymic index|Immune profile""}"
"2160","A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE","SPUTNIK-UAE","NCT04656613","06-Gam-COVID-Vac-2020","Biological: Gam-COVID-Vac|Other: placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04656613","Not yet recruiting","2020-12-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 glycoprotein-specific antibodies titer|Seroconversion rate|IFN-gamma antigen-specific release|CD4+\/CD8+ proliferating cells|Virus-neutralizing antibodies titer|Incidence and severity of adverse events""}"
"2161","A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection","","NCT04659772","20-008170","Drug: Clazakizumab|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04659772","Completed","2020-12-03","2021-02-01","{""locations"":""Mayo Clinic in Arizona, Phoenix, Arizona, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse Events""}"
"2162","Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial","","NCT04395105","1264","Drug: Dexamethasone (high dose)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04395105","Recruiting","2020-05-21","2021-01-31","{""locations"":""CEMIC (Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas), Ciudad Autonoma de Buenos Aires, Argentina|Sanatorio Sagrado Corazon, Ciudad Autonoma de Buenos Aires, Argentina|Cl\u00ednica Bazterrica, Ciudad Aut\u00f3noma de Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""284"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator-free days at 28 days|28-days mortality|Frequency of nosocomila infections|Viral shedding|Serum C-reactive Protein variation|SOFA variation|Use of prone position|Delirium|Muscle weakness|90-day mortality""}"
"2163","N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)","","NCT04706416","IRB #2020-106","Dietary Supplement: N-acetyl glucosamine (NAG)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04706416","Active, not recruiting","2020-11-14","2021-01-15","{""locations"":""Valley Baptist Medical Center, Harlingen, Texas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of intubation|Rate of mortality|Length of stay (LOS)|Symptom duration|Intensive care unit (ICU) admission|Supplemental oxygen use|Supplemental oxygen duration""}"
"2164","Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19","","NCT04629989","DTM-003","Other: Standard Oxygen Delivery System|Other: Double-Trunk Mask|Other: Surgical Mask","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04629989","Completed","2020-11-13","2021-03-05","{""locations"":""Cliniques universitaires Saint-Luc, Brussels, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""27"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in PaO2|Change in PaCO2|Change in pH|Change in respiratory rate|Change in dyspnea|Change in O2 output""}"
"2165","Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality","","NCT04344938","2020A10","Other: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344938","Not yet recruiting","2020-04-01","2020-07-01","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""874"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic""}"
"2166","Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study","","NCT04337320","covid19pregnancynewborn","Other: newborns from covid 19 positive mothers","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337320","Completed","2020-03-15","2020-05-30","{""locations"":""Pinar Yalcin Bahat, Istanbul, \u0130\u0307stanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""up to 15 Minutes \u00a0 (Child)"",""outcome_measures"":""Evaluation of apgar status of newborns from covid 19 positive mothers""}"
"2167","Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia","PneumoCoV-Ambu","NCT04542044","CCER2020-01518","Other: management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04542044","Completed","2020-04-02","2020-06-30","{""locations"":""Geneva University Hospital, Geneva, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Secondary hospitalization(s) or death COVID-19 related|severity of COVID-19 disease|patient satisfaction with management strategies|Saved costs""}"
"2168","Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood","","NCT04699903","20-1106","Diagnostic Test: POC SARS-Cov-2 IgG Antibody test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04699903","Not yet recruiting","2020-12-28","2021-02-05","{""locations"":""Benchmark - SoCal, Colton, California, United States|Comprehensive Clinical Research, West Palm Beach, Florida, United States|Great Lakes Clinical Trials (GLCT), Chicago, Illinois, United States|UCCT- AFC Urgent Care Throgs Neck, Bronx, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""215"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""PPA (positive percent agreement) and NPA (negative percent agreement) of POC compared to SARS-CoV-2 reference PCR|PPA (positive percent agreement) of POC compared to SARS-CoV-2 reference PCR""}"
"2169","Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia","ANOSIRM","NCT04408391","NIMAO/2020-01/BL-001","Other: Brain MRI scan","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408391","Withdrawn","2020-05-20","2020-07-06","{""locations"":""CHU de Nimes, N\u00eemes, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Brain regional homogeneity between COVID-19 patients with and without anosmia|Topography of supra- or sub-tentorial lesions between COVID-19 patients with and without anosmia|Fractional anisotropy between COVID-19 patients with and without anosmia|Mean diffusivity between COVID-19 patients with and without anosmia|Radial diffusivity between COVID-19 patients with and without anosmia|Self-assessed olfactory and gustatory test|Ability to detect odor|Ability to taste a pinch of sugar|Presence of thrombotic and hemorrhagic lesions|Presence of lesions with hyperintensity|Projection network analysis of all patients|Blinded independent component analysis of all patients|default mode network analysis of all patients|executive control network analysis of all patients""}"
"2170","Covid-19 and ONline GAmbling","CONGA","NCT04714008","RC21_0010","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04714008","Recruiting","2020-12-01","2022-12-31","{""locations"":""Nantes University Hospital, Nantes, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Retrospective"",""enrollment"":""180000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Trajectories of gambling behaviors across time before and during the pandemics|Typologies of gamblers based on their gambling activity and their use of RG tools outside the pandemics|Gambling activity of early registered gamblers, during and outside the pandemics|Typologies of gamblers based on their gambling activity and their use of RG tools according to the type of gambling activity, gender, age groups and country""}"
"2171","The Effects of Multi-modality Physiotherapy in Delaying or Preventing COVID-19 Patient From Admitting to ICU","","NCT04617119","JALGHAITH","Device: Threshold IMT device|Other: Conventional physical therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04617119","Not yet recruiting","2020-11-01","2021-04-06","{""locations"":""Jaber Al-Ahmed Hospital, Kuwait city, Kuwait"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""38"",""age"":""21 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Changes in Respiratory muscle performance|Blood pressure|Heart rate|Oxygen saturation|Oxygen supplementation|Oxygen flow rate|Dyspnoea level|Pain level|Respiratory rate|Threshold IMT device""}"
"2172","Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?","TA/SARS-Cov2","NCT04427878","20-PP-15","Procedure: biopsies of subcutaneous adipose tissue","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04427878","Not yet recruiting","2020-07-01","2021-07-09","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""5"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The presence of SARS-CoV2 in adipose tissue of Covid19 patients|The expression of inflammatory cytokines in adipose tissue of Covid19 patients""}"
"2173","Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19)","","NCT04495803","CBT-COVID","Other: Cognitive Behavioural Group Therapy for Perinatal Anxiety","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04495803","Not yet recruiting","2020-08-10","2022-08-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""State-Trait Inventory of Cognitive and Somatic Anxiety (STICSA)|Intolerance of Uncertainty Scale (IUS)|Penn State Worry Questionnaire (PSWQ)|Edinburgh Postnatal Depression Scale (EPDS)|COVID-19 Stress Scales (CSS)|Pregnancy-Related Anxiety Questionnaire-Revised (PRAQ-R2)|Postpartum Specific Anxiety Scale (PSAS)|Overall Anxiety Severity and Impairment Scale (OASIS)|Parenting Sense of Competence Scale (PSOC)|Abbreviated Dyadic Adjustment Scale (ADAS)|Social Provisions Scale (SPS)|Maternal Antenatal Attachment Scale (MAAS)|Postpartum Bonding Questionnaire (PBQ)|Client Satisfaction Questionnaire (CSQ)|Perceived Stress Scale (PSS)""}"
"2174","The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul","","NCT04479124","KSSTHR-TPED","Diagnostic Test: COVID-19 PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479124","Completed","2020-03-10","2020-07-14","{""locations"":""Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Kucukcekmece, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""up to 50 Years \u00a0 (Child, Adult)"",""outcome_measures"":""trauma admissions""}"
"2175","COVID-19 Among Egyptian Health Care Providers","","NCT04357431","COVIDQ","Other: self-administered questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357431","Completed","2020-04-22","2020-05-30","{""locations"":""Ahmed Abbas, Assiut, Cairo, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""565"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The percentage of knowledge regarding COVID-19 information""}"
"2176","Can the Electronic Nose Smell COVID-19 Antibodies?","","NCT04475575","eNoseCOVIDantibodies","Device: Aeonose","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04475575","Completed","2020-04-06","2020-07-01","{""locations"":""Maastricht University Medical Center, Maastricht, Netherlands"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""222"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 antibodies vs COVID-19 negative""}"
"2177","Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects","","NCT04510402","2020p002323","Drug: Povidine iodine nasal swabs","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04510402","Not yet recruiting","2020-08-01","2021-04-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""50"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-related adverse events as assessed by self reporting, metabolic and endocrine metrics|Number of participants with dose dependent side effects determined by self reporting diaries, thyroid and metabolic testing""}"
"2178","Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan","Ivercar-Tuc","NCT04701710","5076-410-CH2020","Drug: Ivermectin / Iota-Carrageenan","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04701710","Completed","2020-10-15","2020-12-31","{""locations"":""SI.PRO.SA, Ministerio de Salud P\u00fablica, Tucum\u00e1n, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""300"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Pearson's Chi-square and proportion test.|Odd Ratio, probabilistic test|Logistic regression test""}"
"2179","Efficacy of Ivermectin in COVID-19","","NCT04392713","IVE-COV","Drug: Ivermectin 6 MG Oral Tablet (2 tablets)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04392713","Recruiting","2020-04-15","2020-07-01","{""locations"":""Combined Military Hospital Lahore, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""15 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Negative PCR|Need for mechanical ventilation""}"
"2180","Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children","ELIKYA COVID","NCT04432779","Elikya Covid","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04432779","Recruiting","2020-05-25","2024-06-01","{""locations"":""CHU SAINT Pierre, Brussels, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Outcome of pregnancy|Prevalence of positive serology to SARS-CoV-2 at delivery|Transplacental transfer of antibodies to SARS-CoV-2|To characterize placental alterations related to SARS-CoV-2 infection|Presence of maternal antibodies to SARS-CoV-2 in breast milk in breastfeeding mothers|To characterize the immunity transmitted to the newborn to cord blood and its persistence at the age of 1 month of life|Clinical evolution of the children""}"
"2181","Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome","COVID-NIV","NCT04667923","002-NIV-COVID","Diagnostic Test: Respiratory monitoring|Diagnostic Test: Respiratory muscles ultrasound|Diagnostic Test: Electro impedance tomography|Diagnostic Test: Capnography|Diagnostic Test: Arterial blood gas|Diagnostic Test: Quasistatic pressure-volume curve","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04667923","Recruiting","2020-10-01","2021-06-01","{""locations"":""Sechenov University clinic #4, Moscow, Russian Federation"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intubation rate|Mortality|Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2\/FiO2) ratio|Change in ventilatory ratio|Change in alveolar dead space|Change in tidal volume|Change in accessory respiratory muscles workload""}"
"2182","Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients","","NCT04682548","20-01799","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04682548","Recruiting","2021-01-05","2021-12-01","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Seropositivie Rate Against SARS-CoV-2|T Cell Response""}"
"2183","Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)","coVIHd-19","NCT04581746","RIPH_2020_7","Other: questionnaire","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04581746","Recruiting","2020-11-25","2021-12-01","{""locations"":""CHU Amiens Picardie, Amiens, France|CH Lens, Lens, France|CH Tourcoing, Tourcoing, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of SARS CoV2 infection in PVVIH in Hauts de France|Determine the incidence rate of COVID 19 among PVVIH antiretroviral treatment|Determine the incidence rate of COVID 19 among PVVIH discontinuing antiretroviral treatment|Determine the incidence rate of COVID 19 among PVVIH who stopped all follow-up|Psychological consequences of this epidemic among PVVIH : HAD|Psychological consequences of this epidemic among PVVIH : PROQOL-HIV""}"
"2184","Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.","","NCT04567979","HEM-3412-20-20-1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04567979","Active, not recruiting","2020-06-11","2020-10-30","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""149"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""SARS-CoV-2 infection rate in patients with solid tumors.""}"
"2185","Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome","SOS-COVID19","NCT04341415","CRN_2020_8","Procedure: Auricular neuromodulation|Procedure: Control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04341415","Recruiting","2020-04-09","2021-03-01","{""locations"":""Fondation Adolphe de Rothschild, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of the percentage of clinically improved inpatients between D0 and D14""}"
"2186","Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections","CORONAVIT","NCT04579640","289515","Dietary Supplement: Vitamin D","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04579640","Active, not recruiting","2020-10-27","2021-06-30","{""locations"":""Queen Mary University of London, London, County (optional), United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""6200"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Proportion of participants experiencing at least one doctor-diagnosed or laboratory-confirmed acute respiratory infection of any cause.|Proportion of participants seroconverting to SARS-CoV-2 (i.e. with test results for antibodies to SARS-CoV-2 transitioning from negative at baseline to positive at follow-up)|Proportion of participants developing antigen test-positive COVID-19|Proportion of participants developing 'probable COVID-19', as adjudged using a validated symptom score|Proportion of participants developing antigen test-positive influenza|Proportion of participants reporting symptoms of acute respiratory infection|Proportion of participants who are prescribed one or more courses of antibiotic treatment for acute respiratory infection|Proportion of participants with asthma who experience one or more exacerbations of asthma requiring treatment with oral corticosteroids and\/or requiring hospital treatment|Proportion of participants with COPD who experience one or more exacerbations of COPD requiring treatment with oral corticosteroids and\/or antibiotics, and\/or requiring hospital treatment|Proportion of participants who have had antigen test- or antibody test-confirmed SARS-CoV-2 infection who report symptoms of COVID-19 lasting more than 4 weeks after onset|Mean MRC dyspnoea score at the end of the study in people who have had antigen test- or antibody test-confirmed SARS-CoV-2 infection|Mean FACIT Fatigue Scale score at the end of the study in people who have had antigen test- or antibody test-confirmed SARS-CoV-2 infection|Mean COVID-19 Recovery Questionnaire score at the end of the study in people who have had antigen test- or antibody test-confirmed SARS-CoV-2 infection|Proportion of participants who experience one or more acute respiratory infections requiring hospitalisation|Proportion of participants who experience COVID-19 requiring hospitalisation|Proportion of participants hospitalised for COVID-19 requiring ventilatory support|Proportion of participants who experience influenza requiring hospitalisation|Proportion of participants dying of any cause during participation in the trial|Proportion of participants dying of acute respiratory infection during participation in the trial|Proportion of participants dying of COVID-19 during participation in the trial|Proportion of participants dying of influenza during participation in the trial \u2022 mean end-study 25(OH)D concentrations (sub-set of participants having end-study tests of vitamin D status)|mean end-study 25(OH)D concentration (sub-set of participants having end-study tests of vitamin D status) Mean end-study 25(OH)D concentration (sub-set of participants having end-study tests of vitamin D status)|Proportion of participants experiencing known hypercalcaemia|Proportion of participants experiencing a probable or definite adverse reaction to vitamin D supplementation|Proportion of participants experiencing a serious adverse event of any cause""}"
"2187","COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit","","NCT04374123","IECED-04-15-covid","Diagnostic Test: Serological screening for IgG and IgM antibodies against COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374123","Completed","2020-04-20","2020-06-15","{""locations"":""Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""111"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.|Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.|Technical success rate of endoscopic procedures during the 30-days study period.|IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.|Adverse events rate of endoscopic procedures during the 30-days""}"
"2188","Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare","","NCT04411576","COVID-19 Studien","Diagnostic Test: Throat swab sample for measuring current infection with SARS-CoV-2|Diagnostic Test: Blood sample for serology to measure past infection with SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04411576","Recruiting","2020-04-23","2020-12-31","{""locations"":""Karolinska University Hospital, Stockholm, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40000"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection""}"
"2189","Niclosamide In Moderate COVID-19","","NCT04436458","FW-COV-002","Drug: Niclosamide Oral Tablet|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04436458","Not yet recruiting","2021-06-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary endpoint is the rate of faecal SARS-CoV-2 virus clearance (rectal swab or stool sample) assessed by RT-PCR in the niclosamide group, compared to the placebo group""}"
"2190","The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19","MEND","NCT04537351","CYP-COVID-19-01","Biological: CYP-001","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04537351","Recruiting","2020-08-24","2021-03-31","{""locations"":""Nepean Hospital, Kingswood, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Footscray Hospital, Footscray, Victoria, Australia|Sunshine Hospital, Saint Albans, Victoria, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Trend in trajectory of PaO2\/FiO2 ratio (P\/F ratio) between groups|Incidence and severity of treatment-emergent adverse events|Change in C-reactive protein (CRP) levels|Proportional differences between groups on the Clinical Improvement Scale|Changes in P\/F ratio|Changes in respiratory rate|Changes in oxygenation index|Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)|Changes in positive end-expiratory pressure|Ventilator-free days|Proportional differences between groups on the SF-36|Proportional differences between groups on the mini mental state examination""}"
"2191","Ivermectin in Treatment of COVID-19","","NCT04445311","ZU-IRB#6151/31-5-2020","Drug: Ivermectin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04445311","Recruiting","2020-05-31","2020-08-15","{""locations"":""Waheed Shouman, Zagazig, Sharkia, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""time to be symptoms free|hospitalization|Mechanical ventilation|length of stay|mortality""}"
"2192","Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.","COV-HD","NCT04633915","COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04633915","Recruiting","2020-11-26","2021-08-01","{""locations"":""Saint-Petersburg State University Hospital, Saint Petersburg, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anti-SARS-COV-2 IgG level|Proportion of people with detectable Anti-SARS-COV-2 IgG in study groups""}"
"2193","Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia","AIRVM-COVID","NCT04357457","APHP200461|2020-001909-22","Drug: Almitrine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04357457","Recruiting","2020-09-03","2020-12-01","{""locations"":""Hospital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""212"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of endotracheal intubation|28-day mortality|In-hospital mortality|Number of ventilator-free days|Number of days in the ICU|Number of days in the hospital|Discontinuation rate of the treatment""}"
"2194","Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19","","NCT04358588","PULSE-EAP-001","Drug: iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04358588","No longer available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"2195","Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic","COVID_OMICS","NCT04441502","COVID19_OMICS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04441502","Recruiting","2020-03-30","2021-12-31","{""locations"":""IRCCS Policlinico San Donato, San Donato Milanese, MI, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""240"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Circulating markers for COVID-19 signature|COVID-19 signature and adverse cardiovascular events|COVID-19 related coagulation pattern""}"
"2196","Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum","COVID-Preg","NCT04410562","2020-001587-29","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04410562","Recruiting","2020-05-13","2021-08-01","{""locations"":""Hospital General de Segovia, Segovia, Cartilla Y Le\u00f3n, Spain|Hospital del Mar, Barcelona, Catalunya, Spain|Hospital Cl\u00ednic de Barcelona, Barcelona, Catalunya, Spain|Hospital de la Sant Creu i Sant Pau, Barcelona, Catalunya, Spain|Hospital Sant Joan de D\u00e9u, Esplugues De Llobregat, Catalunya, Spain|Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Alcorc\u00f3n, Madrid, Spain|HM Puerta del Sur, M\u00f3stoles, Madrid, Spain|Hospital Universitario de Torrej\u00f3n, Torrej\u00f3n De Ardoz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""714"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of PCR confirmed cases among pregnant women|Incidence of COVID-19 disease during pregnancy|Incidence of COVID-19-related admissions|Incidence of all-cause admissions|Incidence of all-cause outpatient attendances|Mean duration of symptoms-signs of COVID-19|Frequency and severity of adverse events|Incidence of preeclampsia|Incidence of gestational diabetes|Incidence of SARS-CoV-2 infections during pregnancy|Prevalence of intrauterine growth restriction|Maternal mortality rate|Proportion of neonates with SARS-CoV-2- intrauterine infection by PCR-confirmed SARS-CoV-2-infection in nasopharyngeal aspirate.|Proportion of neonates with clinical signs\/symptoms of COVID-19|Prevalence of low birth weight (<10th centile according to local standards)|Prevalence of preterm birth (<37 weeks of gestational age)|Prevalence of embryo and foetal losses (miscarriages and stillbirths)|Frequency of congenital malformations|Proportion of adverse perinatal outcome|Neonatal morbidity|Neonatal mortality rate""}"
"2197","Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","COVID-HEP","NCT04345848","2020-00794","Drug: Enoxaparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04345848","Recruiting","2020-04-28","2021-03-31","{""locations"":""Geneva University Hospitals, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Locarno, Locarno, Switzerland|H\u00f4pital du Valais, Sion, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality|Arterial thrombosis|Venous thromboembolism|Disseminated intravascular coagulation|All-cause mortality|Sepsis-induced coagulopathy|Acute respiratory distress syndrome|Durations of hospital stay, ICU stay, ventilation|Sequential organ failure assessment score|Clinical deterioration""}"
"2198","Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic","","NCT04583449","ETH2021-0006","Behavioral: Mental imagery","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04583449","Recruiting","2020-08-19","2020-12-01","{""locations"":""University of East London, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Face covering wearing consistency|Face covering wearing intention|Attitude toward wearing a face covering|Injunctive norm beliefs about wearing a face covering|Descriptive norm beliefs about wearing a face covering|Perceived behavioural control over wearing a face covering|Barrier self-efficacy to wearing a face covering""}"
"2199","A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit","","NCT04720235","07A-CLI-007","Device: Lucira COVID-19 All-In-One test kit","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04720235","Recruiting","2020-12-09","2021-03-30","{""locations"":""Neeraj Kochhar Family Medicine, Los Gatos, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""500"",""age"":""14 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""COVID-19 Prevalence Rate \/ Expected Values counts|COVID-19 Prevalence Rate \/ Expected Values percentages|Collection Performance\/ Incidence Rate counts|Collection Performance\/ Incidence Rate percentages|Sensitivity and specificity""}"
"2200","Prognosis in Pregnant With COVID-19","","NCT04409249","Mtalmacprognosis","Diagnostic Test: imaging, blood tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409249","Completed","2020-03-15","2020-05-28","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""155"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""the factors affecting prognosis in pregnant women diagnosed with COVID-19""}"
"2201","Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul","","NCT04479137","KSSEAH--PPC","Diagnostic Test: PCR for COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479137","Completed","2020-03-10","2020-07-14","{""locations"":""Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""5000"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""mortality based on COVID-19""}"
"2202","One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting","COVENTRY","NCT04373811","COVENTRY","Diagnostic Test: Lung ultrasound|Diagnostic Test: Muscle ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373811","Active, not recruiting","2020-04-16","2021-07-13","{""locations"":""Centre Hospitalier de B\u00e9thune, Beuvry, Hauts-de-France, France|APHP - H\u00f4pital Universitaire Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, Ile De France, France|H\u00f4pital Forcilles, F\u00e9rolles-Attilly, Ile-de-France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean in quality of life score at one year on the Short Form Health Survey (SF-36)|Mean in autonomy score on the Activities Daily Living (ADL) scale|Survival rate|Change from baseline in lung ultrasound aeration score|Change from baseline in diaphragm ultrasound thickness and excursion|Mean change from baseline in ultrasound muscle thickness|Mean change from baseline in ultrasound muscle cross-sectionnal area|Mean change from baseline in ultrasound muscle echogeneicity|Mean change from baseline in ultrasound muscle pennation|Mean change from baseline in Medical Research Council (MRC) sum score|Prevalence of adverse outcomes during early mobilization""}"
"2203","Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak","DolPsyCOVID","NCT04353011","2020_45|2020-A00912-37","Other: questionnaire assesment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04353011","Completed","2020-04-20","2020-04-27","{""locations"":""Hopital Roger Salengro, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Family-Based|Time Perspective: Cross-Sectional"",""enrollment"":""312"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital Anxiety and Depression Scale questionnaire|Quality of life (SF36)|self-reported questionnaire for painful|qualitive questionnaire""}"
"2204","Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak","OsPsyCOVID","NCT04351633","2020_31|2020-A00911-38","Other: questionnaire assesment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351633","Completed","2020-04-23","2020-04-30","{""locations"":""Hopital Roger Salengro, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Family-Based|Time Perspective: Cross-Sectional"",""enrollment"":""52"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""percentage of patient with feeling of disabilities""}"
"2205","Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite","","NCT04401527","SN02-01","Drug: Sodium Nitrite|Drug: Normal Saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04401527","Withdrawn","2020-07-22","2020-08-15","{""locations"":""Participating Research Facility, Tampa, Florida, United States|Participating Research Facility, Fort Worth, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival with Unassisted Breathing|Survival without Mechanical Ventilation|Survival without Intensive Care|Survival without Hospitalization|Survival without ECMO|Survival""}"
"2206","Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel","SeroCovEms","NCT04516928","2020-COVID19-29|2020-A02125-34","Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04516928","Completed","2020-09-21","2020-09-25","{""locations"":""Antenne M\u00e9dicale des Ecoles Militaires de Sant\u00e9 de Lyon-Bron (EMSLB), Bron, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""392"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of anti-SARS-CoV2 seropositive participants|Proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants)|Correlation coefficient between medical risk factors and a positive serology|Correlation coefficient between epidemiological risk factors and a positive serology|Correlation coefficient between social risk factors and a positive serology""}"
"2207","Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis","COVRTE-19","NCT04414293","FHPCS-20-001","Radiation: Lung Low Dose Radiation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04414293","Recruiting","2020-10-01","2021-12-31","{""locations"":""Hospital Provincial de Castellon, Castell\u00f3n De La Plana, Castellon, Spain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""41"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""blood oxygen saturation level|Torax X-ray|Hospitalization|days free of assisted mechanical respiration|Mortality""}"
"2208","A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure","","NCT04574869","RLS-0071-102","Drug: RLS-0071|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04574869","Not yet recruiting","2020-10-01","2021-07-01","{""locations"":""Prestige Clinical Research Center, Coral Gables, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 69 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency and severity of Adverse Events, including Serious Adverse Events, by treatment group and dose level, including the frequency of premature discontinuation of study intervention due to Adverse Events.|Incidence of clinically significant changes from baseline in clinical laboratory values, ADA, autoantibody panel, vital signs, physical examination, ECG, radiography, and concomitant medications.|Number of patients with positive ADA titers after receiving a single dose (Part A) or multiple doses (Part B) of RLS-0071.|Estimates of single-dose maximum plasma concentration (Cmax) for RLS-0071.|Estimates of single-dose time to maximum plasma concentration (Tmax) for RLS-0071.|Estimates of single-dose minimum plasma concentration (Cmin) for RLS-0071.|Estimates of single-dose area under the plasma concentration-time curve (AUC) for RLS-0071.|Estimates of single-dose apparent total volume of distribution for RLS-0071.|Estimates of single-dose apparent total body clearance for RLS-0071.|Estimates of single-dose apparent first-order terminal elimination half-life for RLS-0071.|Estimates of multiple-dose maximum plasma concentration (Cmax) for RLS-0071.|Estimates of multiple-dose peak time to maximum plasma concentration (Tmax) for RLS-0071.|Estimates of multiple-dose area under the plasma concentration-time curve (AUC) for RLS-0071.|Estimates of multiple-dose average plasma drug concentration observed (Cavg) for RLS-0071.|Estimates of multiple-dose trough concentration prior to dose administration (Ctrough).|Estimates of multiple-dose apparent total volume of distribution for RLS-0071.|Estimates of multiple-dose apparent total body clearance for RLS-0071.|Estimates of multiple-dose apparent first-order terminal elimination half-life for RLS-0071.|Assessment of dose response relationship of single and multiple doses of RLS-0071 on C1q levels and the complement activity assay.|Overall survival.|Incidence of progression to respiratory failure requiring mechanical ventilation.|Incidence of transfer to the ICU.|Duration of hospitalization after treatment (days).|Incidence, severity, and duration after treatment (days) of fever (\u2265 39.0\u00b0C).|Incidence, severity, and duration after treatment (days) of cough per investigator assessment of CTCAE's latest version.|Duration of requirement for supplemental oxygen after treatment (days).|PaO2\/FiO2|Incidence, severity, and duration after treatment (days) of new cardiovascular events as assessed by the investigator (e.g. myocardial infarction, stroke, TIA, ischemic limb) with CTCAE's latest version.|Incidence, severity, and duration after treatment (days) of respiratory acidosis as assessed by the investigator with CTCAE's latest version.|Incidence and duration after treatment (days) of dialysis.|Levels of complement activity (eg, CH50).|Levels of C1q (free and bound to RLS-0071).""}"
"2209","Impact of the Respiratory Isolation on the Quality of Life in Patients Hospitalized for Tuberculosis or COVID-19","ISO-BK","NCT04677478","APHP200227","Other: Impact of respiratory isolation on quality of life","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04677478","Not yet recruiting","2020-12-01","2022-01-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Quality of life using semi-structured interview.|Quality of life using 36-Item Short Form Health Survey (SF-36)|Quality of life using State-Trait Anxiety Inventory (STAY) A+B scale|Quality of life using Beck Depressive Inventory (BDI) -13""}"
"2210","Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers","","NCT04525417","GERES20200409|ID RCB 2020-A01031-38","Diagnostic Test: AAZ Covid-19 rapid test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04525417","Completed","2020-04-25","2020-10-25","{""locations"":""Bichat University Hospital, Paris, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To assess the predictive value of Covid-19 rapid test|Compare the results of rapid tests on serum and capillary samples|A posteriori diagnosis of a covid-19 recent infection with suggestive symptomatology|Analysis of factors associated with negativity of PCR test on oropharyngeal swabs and positive serology""}"
"2211","How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample)","","NCT04602312","2019000347-S4C","Other: Meditation (1 x 20-minute guided audio training)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04602312","Recruiting","2020-10-28","2021-03-01","{""locations"":""Health and Behavioural Sciences, Brisbane, Queensland, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""624"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Coronavirus-related catastrophizing""}"
"2212","Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19","","NCT04456361","MSC-ARDS-001","Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04456361","Active, not recruiting","2020-04-16","2020-12-15","{""locations"":""Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""9"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygen saturation|Oxygen pressure in inspiration|ground-glass opacity|Pneumonia infiltration|Lactate dehydrogenase|C-reactive protein|D-dimer|Ferritine""}"
"2213","Understanding Immunity to the COVID-19 Vaccines","","NCT04664309","IRB-60171","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04664309","Not yet recruiting","2021-03-01","2023-01-01","{""locations"":""Stanford University, Hospital, and Clinics, Stanford, California, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Percentage of participants with immunity to COVID-19 vaccines over time""}"
"2214","Telemedicine in Outpatient Covid-19 Patients","MR SPOC","NCT04471636","20-448","Device: Withings ScanWatch","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04471636","Recruiting","2020-09-18","2021-03-01","{""locations"":""LMU Klinikum, Munich, BY, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""40 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Rate of participants with a combination of hospitalization and unplanned use of hospital emergency department or emergency medical service|Rate of participants hospitalized|Rate of participants with unplanned use of hospital emergency department or emergency medical service|Rate of participants experiencing death of any cause|Rate of participants experiencing death of Covid-19""}"
"2215","A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19","COViNOX","NCT04421508","PULSE-CVD19-001","Combination Product: INOpulse|Combination Product: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04421508","Active, not recruiting","2020-07-12","2021-06-01","{""locations"":""Banner University Medical Center, Phoenix, Arizona, United States|Kaiser Permanente - Zion Medical Center, San Diego, California, United States|Kaiser Permanente - San Diego Medical Center, San Diego, California, United States|University of Miami Health System, Miami, Florida, United States|The Lung Research Center (St. Luke's), Chesterfield, Missouri, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Mercy Health St. Vincent Medical Center, Toledo, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Houston Methodist, Houston, Texas, United States|INOVA, Falls Church, Virginia, United States|St. Francis Medical Center, Richmond, Virginia, United States|Memorial Regional Medical Center, Richmond, Virginia, United States|Chippenham Medical Center, Richmond, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|St. Mary's Hospital, Richmond, Virginia, United States|Johnston-Willis Hospital, Richmond, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of subjects who died or had respiratory failure|Clinical status using National Institute of Allergy and Infectious Diseases (NIAID) 8-point ordinal scale|Proportion of subject to recover, defined as return to room air or baseline O2, or discharged alive|Proportion of subjects discharged alive from hospital|Duration of Hospitalization|Mortality - all cause and cardiopulmonary|Proportion of subjects with a negative conversion of reverse transcription polymerase chain reaction (RT-PCR) from a nasopharyngeal swab""}"
"2216","Estrogen Patch for COVID-19 Symptoms","","NCT04359329","SBU-EstrogenPatch-COVID19","Drug: Estradiol patch","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04359329","Recruiting","2020-04-20","2020-11-15","{""locations"":""Stony Brook University Hospital, Stony Brook, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""110"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of Hospitalization|Rate of Transfer to Intensive Care Unit|Rate of Intubation|Rate of Death""}"
"2217","USZ BioResource COVID","","NCT04414657","CTC HFV2","Other: blood sampling for biobank","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04414657","Recruiting","2020-04-09","2022-04-30","{""locations"":""University Hospital Zurich, Clinical Trials Center, Zurich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""blood sampling for biobank""}"
"2218","Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults","","NCT04672291","ONV2020-003","Drug: Poly-ICLC (Hiltonol®)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04672291","Not yet recruiting","2021-04-01","2024-01-16","{""locations"":""Health Research Innovation Centre, Calgary, Alberta, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""43"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Safety and tolerability, Dose Limiting Toxicity|Assess the response of the body to the study drug (pharmacodynamics)""}"
"2219","Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER)","RECOVER","NCT04629105","00-006","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04629105","Recruiting","2020-07-24","2025-07-01","{""locations"":""Miami VA Healthcare System, Miami, Florida, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Serious Adverse Events|Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.|Number of Participants with Changes in Echocardiography Overall Assessment|Number of Participants with Changes to overall assessment of Electrocardiogram|Time to recovery of Sp02|Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.|Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.|Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis|Immunity|Change in Imaging via X-ray|Change in Imaging via Computerized Tomography""}"
"2220","Canine COVID-19 Detection","","NCT04509713","LSH1285","Behavioral: Collection of odour samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04509713","Recruiting","2020-07-02","2020-10-31","{""locations"":""ARCTEC, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""16250"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Sensitivity and specificity precision of dogs to detect people with COVID-19 by their odour.|Identification of the volatile profile that is specific to asymptomatic or mild symptomatic participants with SARS-CoV-2 compared with uninfected individuals.""}"
"2221","Prophylactic Ivermectin in COVID-19 Contacts","","NCT04422561","ZU-IRB#6150/31-5-2020","Drug: Ivermectin Tablets","Interventional","Has Results","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04422561","Completed","2020-05-31","2020-07-27","{""locations"":""Zagazig University, Zagazig, Sharkia, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""340"",""age"":""16 Years to 70 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)|Development of COVID""}"
"2222","Evaluation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19","","NCT04598347","IIBSP-COV-2020-59","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04598347","Recruiting","2020-08-08","2022-01-23","{""locations"":""Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""225"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Perinatal SARS-CoV-2 infection""}"
"2223","Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients","","NCT04581161","CR-RR-2020-004","Device: Life2000® Ventilator","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04581161","Recruiting","2020-08-28","2020-10-01","{""locations"":""Park Nicolette, Bloomington, Minnesota, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Life2000\u00ae Compared to HFNC (AIRVO)|PEEP level""}"
"2224","Asymptomatic COVID-19 Trial","ACT","NCT04374552","Pro2020000872","Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04374552","Withdrawn","2020-05-05","2021-04-01","{""locations"":""Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary outcome is the rate of decline in viral load over the 10 days after randomization""}"
"2225","Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19","Covid19DPP4i","NCT04542213","CEI-22-2020","Drug: Linagliptin tablet|Drug: Insulin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04542213","Recruiting","2020-08-01","2020-09-30","{""locations"":""Hospital Regional de Alta Especialidad del Baj\u00eco, Le\u00f2n, Guanajuato, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""28"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Glucose levels|Number of patients who achieve metabolic control|Number of patients who die or need mechanical ventilation|C reactive protein levels""}"
"2226","Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.","AcNT-COVID19","NCT04596098","38RC20.132|2020-A00904-35","Other: Blood sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04596098","Recruiting","2020-04-30","2021-09-30","{""locations"":""UniversityGrenobleHospital, Grenoble, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Isolation of recombinant monoclonal neutralizing antibodies directed against SARS-CoV-2, isolated from COVID19 hospitalized patients blood probes.|Description of biological biomarkers (cytokine, IL6) predictive of worsening|Description of biological biomarkers (cytokine, IL10) predictive of worsening|Description of biological biomarkers (Cellular immune responses, lymphocytes) predictive of worsening|Description of biological biomarkers (Cellular immune responses, monocytes) predictive of worsening|Description of biological biomarkers (complement system, CH50) predictive of worsening|Description of biological biomarkers (complement system, CH50a) predictive of worsening|Description of biological biomarkers (complement system, C3) predictive of worsening|Description of biological biomarkers (complement system, C4) predictive of worsening""}"
"2227","Efficacy of Faviprevir in COVID-19 Treatment","","NCT04351295","faviprevir covid","Drug: Favipiravir|Drug: Placebos","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04351295","Recruiting","2020-04-20","2020-12-01","{""locations"":""Tanta University, Ainshams University, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patients with mortality or need for mechanical ventilation""}"
"2228","Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects","","NCT04573322","100-303","Drug: Trans Sodium Crocetinate|Drug: Normal saline","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04573322","Recruiting","2020-09-10","2021-12-14","{""locations"":""National Institute of Infectious Diseases- Prof. Dr. Matei Bal\u015f, Bucharest, Romania"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""224"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Time to recovery through Day 28|WHO Ordinal Severity Scale|WHO Ordinal Severity Scale - Time to Improvement|WHO Ordinal Severity Scale - Change from Baseline|National Early Warning Score (NEWS)|National Early Warning Score (NEWS) - Change from Baseline|Mechanical Ventilation|Mechanical Ventilation - Duration|Hospitalization|Oxygenation|Oxygenation - New Oxygen Use|Oxygenation - Advanced Therapies|Oxygenation - Time to Return to Baseline|Oxygenation - Pulse Oximetry|Oxygenation - ABG Measurements|Mortality""}"
"2229","Interferon Lambda Therapy for COVID-19","","NCT04388709","GCO 20-0820","Drug: Peginterferon Lambda-1A","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04388709","Withdrawn","2020-09-01","2021-02-05","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with resolution of hypoxia|Number of adverse events.|Days with fever|Time to resolution of fever|Rate of progression to requiring critical care|Overall survival|Time to discharge""}"
"2230","Physiopathology and Sequelae of COVID-19 Infection","SEQ-COV-PHYSIO","NCT04563676","PI2020_843_0096","Biological: blood test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04563676","Recruiting","2020-09-22","2021-03-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""8-hour cortisol level in patients with Covid19 pneumonia|TSH level in patients with Covid19 pneumonia""}"
"2231","Ivermectin as a Novel Therapy in COVID-19 Treatment","","NCT04403555","tanta covid treatment","Drug: Ivermectin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04403555","Recruiting","2020-06-01","2030-12-03","{""locations"":""Sherief Abd-Elsalam, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The number of patients with mortality|Length of hospital stay|The need for mechanical ventilation""}"
"2232","Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","","NCT04590274","CTP-HCQ-COVID19","Drug: Hydroxychloroquine|Dietary Supplement: Vitamins and Minerals|Drug: Azithromycin","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04590274","Not yet recruiting","2020-11-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percentage of individuals who develop COVID-19 symptoms""}"
"2233","Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS","","NCT04374149","PHU COVID-19-001","Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04374149","Active, not recruiting","2020-04-30","2020-12-01","{""locations"":""Prisma Health, Greenville, South Carolina, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""12 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Overall Response Rate""}"
"2234","Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia","THINC","NCT04528927","ECC2020-05","Drug: HCQ|Drug: Azithromycin|Drug: Doxycycline|Dietary Supplement: Zinc","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04528927","Withdrawn","2020-05-15","2020-07-15","{""locations"":""Eshmoun Clinical Research Centre, Tunis, Tunisia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the rate of patients cured at the end of the study.|Evaluate the rate of patients are pauci-symptomatic at the end of the study.|Evaluate the rate of patients with worsening clinical signs""}"
"2235","PSYCHIATRIC Disorders and Covid-19","PSYCHIC","NCT04358042","RC20_0165","Other: Brief Psychiatric Rating Scale|Other: Depression, Anxiety and Stress Scale|Other: Impact of Event Scale-Revised|Other: Connor-Davidson Resilience Scale 10 items (CD-RISC 10)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04358042","Recruiting","2020-04-24","2023-01-01","{""locations"":""Nantes University Hospital - IFAC, Nantes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""impact of the COVID-19 pandemic on psychiatric symptomatology""}"
"2236","COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial","","NCT04354155","COVAC-TP","Drug: Enoxaparin Prefilled Syringe [Lovenox]","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04354155","Recruiting","2020-06-02","2022-10-15","{""locations"":""Children's of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Hemostasis and Thrombosis Center UC Davis, Sacramento, California, United States|Rady Children's Hospital, San Diego, California, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Children's Hospital of Atlanta, Atlanta, Georgia, United States|Lurie Children's Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Johns Hopkins Hospital and Children's Center, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Cohen Children's Medical Center, New Hyde Park, New York, United States|Akron Children's Hospital, Akron, Ohio, United States|Children's Hospital Pittsburgh, Pittsburgh, Pennsylvania, United States|Children's Medical Center of Dallas, Dallas, Texas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""38"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Safety of in-hospital thromboprophylaxis|Median twice-daily enoxaparin dose""}"
"2237","COVID-19: Herd Immunity Study in the Czech Republic","SARSCoV2CZPrev","NCT04401085","UZIS 2020/1","Diagnostic Test: SARS-CoV-2 diagnostic rapid test|Diagnostic Test: Quantitative analysis of SARS-CoV-2 antibodies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401085","Completed","2020-04-23","2020-05-01","{""locations"":""Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""27000"",""age"":""8 Years to 89 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic.|Estimation of the proportion of people with a subclinical course of the disease|Estimation of the cumulative prevalence of the disease and the proportion of people with a subclinical course differences between subcohorts according to demographic, social and clinically relevant stratifications.|Estimation of the proportion of persons suitable for the donation of convalescent plasma""}"
"2238","Use of Remote Monitoring for COVID-19 Patient","RPM","NCT04425720","2020-11824","Device: LifeSignals Biosensor 1AX*|Other: Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04425720","Recruiting","2020-09-01","2021-06-01","{""locations"":""Montefiore Medical Center, Bronx, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""300"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Monitored versus Non-Monitored in-patient admission|Emergency Department Visits|Length of stay|patient satisfaction|the incidence of mechanical ventilation and ECMO|serious adverse events""}"
"2239","Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales","COSiN","NCT04383652","VISP2005","Other: Biological sample and clinical data collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383652","Recruiting","2020-05-06","2021-06-30","{""locations"":""NSW Health Pathology, Randwick, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Sydney Children's Hospital, Randwick, New South Wales, Australia|Blacktown Hospital, Blacktown, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|St Vincent's Hospital, Darlinghurst, Australia|Northern Beaches Hospital, Frenchs Forest, Australia|Royal North Shore Hospital, Saint Leonards, Australia|Westmead Hospital, Westmead, Australia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Coronavirus sequencing|Coronavirus culturing""}"
"2240","A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","","NCT04691180","BRII-196-198-001","Drug: BRII-196 and BRII-198|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04691180","Recruiting","2021-01-05","2021-08-01","{""locations"":""Investigative Site, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 49 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Mean of change from pre-dose baseline in ECG readings|Mean of change from pre-dose baseline in WBC count.|Mean of change from pre-dose baseline in RBC count|Mean of change from pre-dose baseline in Platelets count|Mean of change from pre-dose baseline in Hemoglobin result|Serum Concentration of BRII-196 and BRII-198""}"
"2241","Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers","COVID-19","NCT04535791","R-2020-785-090","Drug: Cholecalciferol","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04535791","Recruiting","2020-07-15","2021-07-01","{""locations"":""Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with COVID-19|Number of Participants with hospitalization for COVID-19|Serum concentration of 25 (OH) vitamin D""}"
"2242","Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection","","NCT04675086","CCR-2020-103188","Drug: alpha1-proteinase inhibitor|Drug: Antiviral Agents","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04675086","Withdrawn","2021-01-01","2021-12-01","{""locations"":""Blessing Corporate Services, Inc, Hannibal, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of new non-invasive ventilation or high flow oxygen use (measured by days)|Clinical status on a 7-point ordinal scale (from 1=death to 7=not hospitalized|The percentage change in cytokine levels from screening through day 10, Day 17 and Day 24|The percentage change in oxygen requirements including PEEP and FiO2 from screening through day 10.|The percentage of subjects that required mechanical ventilation during the treatment period.|The percent of patients with a SOFA score between 0-6 during treatment period.|The percent of mortality during the treatment period.|Evaluate the need, dosage and duration of vasopressors (number of days and average daily dose).|Number of Days fever free (defined by temperature of <100\u00b0F (oral) for 24 hours)|To evaluate the average number of days in the ICU|To evaluate the average number of days in the hospital|To evaluate the number of days with a PO2\/FiO2 <300 or other parameters decided on with oxygen|The risk of coagulopathy by measuring Prothrombin time & Partial Thromboplastin time|The risk of coagulopathy by measuring D-Dimer|The risk of coagulopathy by measuring Platelet Counts""}"
"2243","Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19","","NCT04387240","20-0192","Drug: Artemisinin / Artesunate|Other: placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04387240","Not yet recruiting","2020-12-01","2021-04-01","{""locations"":""Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""22"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""length of stay in hospital|number of ICU admission|resolution of symptoms""}"
"2244","Lung Ultrasound to Diagnose COVID-19","COVILUS","NCT04368338","PI2020_843_0030","Diagnostic Test: COVID-19 RT-PCR|Procedure: lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368338","Recruiting","2020-04-28","2021-09-28","{""locations"":""BAR, Amiens, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Lung ultrasound\/biological correlation research modulating the severity of Covid-19 disease""}"
"2245","Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre","CovidImmunEye","NCT04446338","292/2020BO2","Diagnostic Test: Antibody Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04446338","Recruiting","2020-05-13","2020-08-01","{""locations"":""University Tuebingen, Tuebingen, BW, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Seroprevalence|Agreement of the test results and questionnaire|Positive predictive \/ negative values of the tests applied""}"
"2246","Outcomes of Covid-19 Protective Measures in Endoscopy","","NCT04371354","2020-COCHE","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371354","Active, not recruiting","2020-04-27","2021-07-27","{""locations"":""Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of new Covid infection of patients and staff members|Covid disease prevalence in the patients referred to endoscopy|Categorization by clinical triage and Covid Test|Influence of the fype of endoscopy procedure and staff protective equipment""}"
"2247","Oral Side Effects of COVID-19 Vaccine","","NCT04706156","OSECV","Biological: COVID-19 Vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04706156","Recruiting","2021-01-27","2021-03-31","{""locations"":""Department of Public Health, Faculty of Medicine, Masaryk University, Brno, South-Moravia, Czechia|Department of Cranio-Maxillofacial Surgery, Justus-Liebig University Giessen, Giessen, Hesse, Germany|Clinic for Conservative Dentistry and Periodontology, School of Dental Medicine, Christian-Albrecht's University, Kiel, Schleswig-Holstein, Germany|Department of Maxillofacial Surgery, F. D. Roosevelt University Hospital, Bansk\u00e1 Bystrica, Banska Bystrica, Slovakia"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""1540"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oral Side Effects|Dermatologic Side Effects|General (common) Side Effects""}"
"2248","Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198","","NCT04479644","BRII-198-001","Drug: BRII-198|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04479644","Active, not recruiting","2020-07-13","2021-03-01","{""locations"":""Investigative Site, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""17"",""age"":""18 Years to 49 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Serum Concentration of BRII-198""}"
"2249","Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196","","NCT04479631","BRII-196-001","Drug: BRII-196|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04479631","Active, not recruiting","2020-07-12","2021-03-01","{""locations"":""Investigative Site, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""16"",""age"":""18 Years to 49 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Serum Concentration of BRII-196""}"
"2250","Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS","CHILL-pilot","NCT03376854","HP-00078506","Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT03376854","Recruiting","2018-05-01","2020-12-31","{""locations"":""University of Maryland Medical Center, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Targeted temperature compliance|Adverse event|28-day ICU-free days|Survival|non neurologic Sequential Organ Failure (SOFA) scores|Oxygen saturation (SpO2)|Plateau airway pressure|Mean airway pressure|Airway driving pressure|Oxygen saturation index|Core temperature|Urine output|comprehensive metabolic panel|Complete blood count with differential count and platelet count|Biomarkers|Serum electrolytes|Blood glucose|28-day ventilator-free days""}"
"2251","Fenofibrate for Patients With COVID-19 Requiring Hospitalization","FENOC","NCT04661930","0105-20-BRZ","Drug: TriCor® 145mg tablets|Other: Usual Care|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04661930","Recruiting","2020-12-13","2021-12-01","{""locations"":""Barzilai Medical Center, Ashkelon, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Difference in Plasma markers at 14 days|14-Day Mortality|Difference in Estimated P\/F Ratio at 14 days|Viral Clearance by Nasopharyngeal Swab|Number of Abnormal Biomarker Days|Difference in Estimated PEEP adjusted P\/F Ratio at 14 days|Difference in Oxygenation at 14 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation \/ Fractional Inhaled Oxygen (F\/S)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Disease Severity Rating|Viral Load by Nasopharyngeal Swab|Viral Load by Blood|Viral Clearance by Blood""}"
"2252","Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission","COVPROSHIELD","NCT04647305","1010166518","Other: Closed face shield with Surgical face mask use|Other: Surgical face mask use only","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04647305","Active, not recruiting","2021-01-16","2021-03-01","{""locations"":""Universidad de los Andes, Bogot\u00e1, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""233"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 incidence|Adherence to closed face shields use|Percentage of participants with a positive serological test at baseline|Percentage of seroconversion in the experimental group and active control group""}"
"2253","Novel Agents for Treatment of High-risk COVID-19 Positive Patients","","NCT04374019","MCC-20-COVID-01-PMC","Drug: Ivermectin|Drug: Camostat Mesilate|Dietary Supplement: Artemesia annua|Drug: Artesunate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04374019","Recruiting","2020-05-01","2021-05-01","{""locations"":""University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function""}"
"2254","COVID-19 Staff Testing of Antibody Responses Study (Co-Stars)","Co-Stars","NCT04380896","20CB17","Other: Blood test|Other: Standardised questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380896","Recruiting","2020-04-27","2026-07-27","{""locations"":""Great Ormond Street Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in serial monthly log-transformed antibody titre levels as measured|Proportion of completely asymptomatic healthcare workers with evidence of SARS-CoV-2 antibodies|The attack rate of SARS-CoV-2 in healthcare workers who have antibodies compared to those who do not|The immune correlates of protection against future exposure to SARS-CoV-2""}"
"2255","Convalescent Plasma to Limit SARS-CoV-2 Associated Complications","CSSC-004","NCT04373460","IRB00247590","Biological: SARS-CoV-2 convalescent plasma|Biological: Plasma from a volunteer donor","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04373460","Recruiting","2020-06-03","2023-01-31","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for American Indian Health - Chinle Office, Chinle, Arizona, United States|Mayo Clinic, Phoenix, Phoenix, Arizona, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Netowrk, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Network, Norwalk Hospital, Norwalk, Connecticut, United States|University of Miami, Coral Gables, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|MedStar Washington Hospital Center, Hyattsville, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan\/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1344"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of hospitalization or death prior to hospitalization|Cumulative incidence of treatment-related serious adverse events|Cumulative incidence of treatment-related grade 3 or higher adverse events|Change in serum SARS-CoV-2 antibody titers|Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity""}"
"2256","Cardiac Imaging in SARS-CoV-2 (COVID-19)","CISCO-19","NCT04403607","GN20ID164","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403607","Recruiting","2020-05-22","2021-08-01","{""locations"":""Royal Alexandra Hospital, Paisley, Renfrewshire, United Kingdom|Royal Infirmary, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary cardiac outcome is the proportion of patients with a diagnosis of myocardial inflammation (myocarditis).|The primary cardio-pulmonary outcome is the proportion of patients with thrombosis|Myocardial injury|Myocardial stress|Systemic inflammation|Vascular injury|Endothelial activation and haemostasis|Fibrin lysis|Coagulation|Platelet count|Renal function|Quantify myocardial perfusion as a measure of coronary microvascular function|Association of the primary outcome according to a prior history of cardiovascular disease or no history of prior cardiovascular disease.|Patient reported outcome measures (PROMS) - health status|PROMS - functional capacity""}"
"2257","Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","","NCT04401293","20-0340","Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04401293","Recruiting","2020-04-26","2021-04-26","{""locations"":""Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""308"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Day 30 \u00b1 2 days.|Major bleeding|Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Hospital Day 10 + 4|Sepsis-induced coagulopathy (SIC) score|Progression to Acute Respiratory Distress Syndrome (ARDS)|Need for Intubation|Re-hospitalization""}"
"2258","Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic","TeleCoviDiab","NCT04370171","7775","Other: care modalities|Other: Teleconsultation either by phone or by computer consultation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370171","Completed","2020-05-04","2020-05-29","{""locations"":""H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""610"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.|HbA1C measured at 6 months post-telemedicine consultation for the TC group \/ post-cancellation of the face-to-face consultation for the P group.|Total number of patients inaccessible to teleconsultation and number of patients inaccessible by type of associated reason.|Number of complications: severe hypoglycemia, ketoacidosis, myocardial infarction, stroke, foot ulcer.|Results of patient satisfaction questionnaire.|Results of doctor satisfaction questionnaire.|Number of patients infected with Covid-19 (positive smear by RT-PCR for SARS-CoV-2 virus).|Number of conventional hospitalizations, in intensive care and deaths.""}"
"2259","Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)","HALT","NCT04381364","2020-02183","Drug: Ciclesonide Inhalation Aerosol","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04381364","Recruiting","2020-05-29","2020-12-31","{""locations"":""Danderyd Hospital, Danderyd, Sweden|Capio S:t G\u00f6rans Hospital, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Visby Hospital, Visby, Sweden|V\u00e4stmanland County Hospital V\u00e4ster\u00e5s, V\u00e4ster\u00e5s, Sweden|\u00d6rebro University Hospital, \u00d6rebro, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""446"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of received supplemental oxygen therapy|Invasive mechanical ventilation or all-cause death (key secondary outcome)|All cause death|Invasive mechanical ventilation|Remaining dyspnea symptoms""}"
"2260","Relationship Between Biological Profiles and Clinical Evolutions Within the Same Cluster COVID-19 (COVIDCOLLECT)","COVIDCOLLECT","NCT04597736","RBPH 2020 HENQUELL|2020-A02381-38","Biological: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04597736","Not yet recruiting","2020-11-01","2022-02-01","{""locations"":""CHU de Clermont-Ferrand, Clermont-Ferrand, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Virological profile|Virological profile (serology)|Immunological profile with blood level for markers of inflammation (cytokine)|Immunological profile with blood level for markers of inflammation|Biochemical profile by blood dosage of CRP|Biochemical profile by blood dosage of ASAT\/ALAT|Biochemical profile by blood dosage of LDH|Biochemical profile by blood dosage of Lactate|Biochemical profile by blood dosage of D-Dimer|Biochemical profile by blood dosage of Troponin|Biochemical profile by blood dosage of Ferritin|Biochemical profile by blood dosage of RAGE|Biochemical profile by blood dosage of SUPAR|Haematological profile by blood dosage of leukocytes|Haematological profile by blood dosage of Red blood cells|Haematological profile by blood dosage of Hemoglobin|Haematological profile by blood dosage of Hematocrit|Haematological profile by blood dosage of Mean corpuscular volume|Haematological profile by blood dosage of Mean corpuscular hemoglobin|Haematological profile by blood dosage of average corpuscular concentration of haemoglobin|Haematological profile by blood dosage of polynuclear neutrophil|Haematological profile by blood dosage of polynuclear eosinophils|Haematological profile by blood dosage of polynuclear basophils|Haematological profile by blood dosage of lymphocytes|Haematological profile by blood dosage of monocytes|Haematological profile by blood dosage of platelets|Haematological profile by blood dosage of activated partial thromboplastin time|Haematological profile by blood dosage of fibrinogen|Haematological profile by blood dosage of factor V|SARS-CoV-2 salivary viral load|Comparison of viral sequences|microbiota analysis|environmental and societal factors (EPICE)|environmental and societal factors|environmental and societal factors (SF-36)|environmental and societal factors (Physical activity)|body weight|oxygen saturation|Respiratory rate|cardiac frequency|lung damage|lung evolution|blood pressure|body temperature|clinical exam (skin)|clinical exam (polypnea)|denutrition|Antibiotic treatment|Steroidal anti-inflammatory treatment|Anti-diabetic treatment|Gastric protector treatment|chills|Myalgia|Anorexia|Rhinitis|Confusion|Asthenia|Falls at home|Insomnia|Angina|Ageusia|Respiratory complaints|transmission rate|prolonged viral shedding""}"
"2261","Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine (AdoPro-Cov19)","AdoPro-Cov19","NCT04363671","P20-670","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363671","Not yet recruiting","2020-05-01","2020-12-01","{""locations"":""Maison de Solenn, Cochin Hospital, Paris, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""11 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Exploration of themes emerging from analysis of the content of the interview with the adolescents and therapists""}"
"2262","Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel","IveprofCovid19","NCT04527211","Epi1JaveCali","Drug: Ivermectin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04527211","Not yet recruiting","2020-09-07","2020-12-16","{""locations"":""Pontificia Universidad Javeriana, Cali, Valle Del Cauca, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""550"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical development of covid-19 disease during the intervention period|Seroconversion|Hospitalization requirement|Intensive Care Unit Requirement|Safety of the intervention""}"
"2263","Tocilizumab Treatment in Patients With COVID-19","","NCT04363853","INF-3343-20-22-1","Drug: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363853","Active, not recruiting","2020-06-01","2021-08-01","{""locations"":""National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hematic biometry|Blood chemistry|Blood gas|blood gas|thorax radiography""}"
"2264","Emergency Department (ED) Self-Monitoring Pilot COVID-19","","NCT04462783","HUM00181946","Other: Symptoms entered into the CovidX application","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04462783","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the percent of participants using the CovidX web application (app) on 50% or greater of days|Average compliance rate with daily symptom tracking by day 30|Recruitment rate|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety short form 4a|Change in Coronavirus Anxiety Scale|CovidX web application usability and utility measured adapted by mHealth App Usability Questionnaire|Differences in CovidX web application engagement between patients who do and do not receive a pulse oximeter""}"
"2265","Use of Convalescent Plasma for COVID-19","","NCT04408040","NSH 1281","Biological: Convalescent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04408040","Recruiting","2020-07-14","2024-07-31","{""locations"":""Northside Hospital, Atlanta, Georgia, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Arms 1 & 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate|Arms 1 & 2: number of critical and severe COVID-19 infected patients who survive the infection|Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate|Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate""}"
"2266","Diabetes Outcomes in COVID-19 Pandemic","","NCT04573335","16102019","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04573335","Completed","2020-06-01","2020-07-30","{""locations"":""Services Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1282"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|COVID-19 illness""}"
"2267","Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19","PExCoV","NCT04613986","SD01","Device: therapeutic plasmaexchnage","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04613986","Not yet recruiting","2020-12-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""relative ADAMTS13 deficiency""}"
"2268","Mouth Rinses for Inactivation of COVID-19","MOR","NCT04584684","20-2040","Drug: 1.5-2% w/v Hydrogen Peroxide|Drug: 0.12% Chlorhexidine Gluconate|Drug: 21% Ethanol plus essential oils|Drug: 1% w/v Povidone-iodide|Drug: 0.075% Cetylpyridinium Chloride|Other: Saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04584684","Recruiting","2020-12-18","2023-09-01","{""locations"":""General and Oral Health Center, Chapel Hill, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""480"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 15 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 30 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 45 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 60 Minutes""}"
"2269","Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO","","NCT04405973","EK-FR 329/20","Device: vv-ECMO","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04405973","Completed","2020-05-19","2020-09-30","{""locations"":""University Clinic Freiburg, Freiburg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""133"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""overall survival|duration of ECMO treatment|duration of ventilation treatment|duration of initiation of ECMO treatment to ICU discharge""}"
"2270","COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1","","NCT04356508","UW20213","Drug: Nivolumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04356508","Not yet recruiting","2020-04-14","2021-08-31","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral clearance kinetics|Treatment-related adverse events of nivolumab (Intervention arm only)|Lymphocyte kinetics|Cytokine kinetics|Length of inpatient stay due to COVID-19""}"
"2271","The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic""","","NCT04581070","CTRIAL-IE 20-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581070","Terminated","2020-04-29","2020-10-09","{""locations"":""Mater Misericordiae University Hospital, Dublin, Ireland|University Hospital Limerick, Limerick, Ireland|University Hospital Waterford, Waterford, Ireland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A qualitative description""}"
"2272","Rapid Detection of COVID-19 by Portable and Connected Biosensor","COR-DIAL-1","NCT04367142","2020_36|2020-A01147-32","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: Biosensor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367142","Not yet recruiting","2020-09-01","2020-12-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team|Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission""}"
"2273","Canakinumab in Covid-19 Cardiac Injury (The Three C Study)","","NCT04365153","IND 149328","Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04365153","Active, not recruiting","2020-04-24","2021-04-30","{""locations"":""Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement up to day 14, defined as the time in days from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever occurs first.|Mortality at day 28""}"
"2274","Renin-Angiotensin System Inhibitors and COVID-19","SARS-RAS","NCT04331574","SARS-RAS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04331574","Recruiting","2020-03-10","2020-04-30","{""locations"":""Spedali Civili di Brescia, Brescia, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""2000"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Numbers of COVID-19 patients enrolled that use ACE inhibitors and\/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and\/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity""}"
"2275","Assessment of Lung Inflammation With FDG PET/CT in COVID-19","","NCT04441489","PET-COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04441489","Completed","2020-03-27","2020-05-27","{""locations"":""Centre Hospitalier Princesse Grace, Monaco, Monaco"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""13"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary endpoint""}"
"2276","Sarilumab for Patients With Moderate COVID-19 Disease","","NCT04359901","IRB 3305","Biological: SARILUMAB","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04359901","Active, not recruiting","2020-04-10","2023-04-01","{""locations"":""VA Connecticut Healthcare System, West Haven, Connecticut, United States|VA Maine Healthcare System, Augusta, Maine, United States|VA Boston Healthcare System, Boston, Massachusetts, United States|Providence VA Medical Center, Providence, Rhode Island, United States|VA Medical Center - White River Junction, White River Junction, Vermont, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intubation or death""}"
"2277","Inhaled Iloprost for Suspected COVID-19 Respiratory Failure","ILOCOVID","NCT04445246","MRC-05-026","Drug: Inhaled ILOPROST","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04445246","Recruiting","2020-05-23","2021-05-31","{""locations"":""Hamad Medical Corporation, Doha, Qatar"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""change in oxygenation parameters|Rates of endotracheal intubation|Invasive ventilation duration|ICU length of stay|Hospital Length of stay|Rates of proning therapy|Rates of ECMO cannulation|Mortality""}"
"2278","SARS-CoV-2 IgG and IgM Serologic Assays","","NCT04562246","13839","Diagnostic Test: Serologic assays for antibodies to SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04562246","Recruiting","2020-08-14","2021-08-01","{""locations"":""Henry Ford Health System, Detroit, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of antibodies to SARS-CoV-2""}"
"2279","Post Covid Syndrome: Clinical Pattern and Functional Assessment","","NCT04561141","postcovid syndrome","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04561141","Not yet recruiting","2020-12-01","2022-01-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""85"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identify post covid symptoms|prevalance of post covid syndrome among survivours""}"
"2280","The Natural History of Hospitalized COVID-19 Patients","STORM","NCT04424992","STORM","Other: Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424992","Recruiting","2020-02-28","2021-12-01","{""locations"":""ASST Monza-Ospedale San Gerardo, Monza, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1433"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Covid19 infection clinical evolution|Risk factors for intra-hospital mortality|The impact of a fragility index (IF)|Prognostic score|The lung sequelae of SARS-COV-2 pneumonia|The accuracy of IF in elderly patients|Coagulation system anomalies|The impact of the prone position on the oxygenation""}"
"2281","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy","","NCT04338945","COVID-ItaliansurgRES-SPIGC","Behavioral: COVID-surgRES questionaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04338945","Completed","2020-03-15","2020-05-01","{""locations"":""U.O.C. Chirurgia Generale Universitaria \""V. Bonomo\"", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, Universit\u00e0 di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents""}"
"2282","Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation","","NCT04695301","34170820.0.1001.0071","Other: Rehabilitation protocol through a digital platform","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04695301","Recruiting","2020-07-01","2021-08-01","{""locations"":""Instituto Israelita de Ensino e Pesquisa Albert Einstein 's (IIEP), S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characterize the clinical function profile of patients affected by COVID-19|Characterize the exercise capacity of patients affected by COVID-19|Assess clinical and demographic data|Assess functional level at hospital discharge|Assess patient compliance of the rehabilitation program using the digital platform""}"
"2283","Low Dose Radiotherapy in COVID-19 Pneumonia","","NCT04390412","23568|IRCT20200509047366N1","Radiation: Low Dose Radiotherapy","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04390412","Active, not recruiting","2020-05-04","2020-12-01","{""locations"":""Imam Hossein Hospital, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""5"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline blood oxygenation|Number of Hospital stay days|Number of ICU stay days|Number of intubation events|WBC|Platelets|CRP|IL-6""}"
"2284","The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People","","NCT04658433","2020-PHA-22","Dietary Supplement: 300 mg of omega3-FA","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04658433","Recruiting","2020-12-05","2021-03-30","{""locations"":""Mahmoud S Abu-Samak, Amman, Jordan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""35 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""serum ACE levels|serum ACE2 levels|Lipid profile mg\/dL""}"
"2285","COVID 19 Preventive Measures Among Mansoura Nursing Students","","NCT04473547","p.0203","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473547","Completed","2020-07-10","2021-02-15","{""locations"":""Faculty of Nursing Mansoura University, Mansoura, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""144"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""adherence level to coronavirus disease 19 preventive measures among nursing students during written exams.|number of students who develop possible covid-19 symptoms during written exams|Eye,nose,mouth,Face and mask touch frequency during written exams|nursing students knowledge level of COVID 19|COVID 19 risk perception level among nursing students undergoing written exams""}"
"2286","Short Term, High Dose Vitamin D Supplementation for COVID-19","SHADE","NCT04459247","121/20","Drug: Vit D","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04459247","Active, not recruiting","2020-06-15","2020-09-10","{""locations"":""Deptt of Endocrinology, Chandigarh, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virus negativity|Inflammatory Marker|Inflammatory Marker 2""}"
"2287","An Adaptive Clinical Trial of Antivirals for COVID-19 Infection","VIRCO","NCT04445467","66223","Drug: Favipiravir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04445467","Recruiting","2020-08-01","2020-11-01","{""locations"":""Alfred Health, Melbourne, Victoria, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""190"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to virological cure|Safety|Clinical improvement|Clinical symptoms|Biomarkers""}"
"2288","COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","SEROCOV","NCT04304690","APHP200310","Other: blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04304690","Active, not recruiting","2020-03-16","2021-10-16","{""locations"":""Hopital Piti\u00e9 Salpetri\u00e8re, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|\"" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome \""""}"
"2289","Acquiring Convalescent Specimens for COVID-19 Antibodies","","NCT04342195","AAAS9517","Procedure: Blood draw","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04342195","Recruiting","2020-03-25","2021-03-01","{""locations"":""Columbia University Irving Medical Center\/NYP, New York, New York, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""50"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of antibodies against coronaviruses isolated and identified from patient samples""}"
"2290","Efficacy of Convalescent Plasma Therapy in Patients With COVID-19","","NCT04425915","ILBS-COVID-04","Biological: Convalescent Plasma|Other: Standard of Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04425915","Recruiting","2020-06-14","2021-05-30","{""locations"":""Maulana Azad Medical College, New Delhi, Delhi, India|Institute of Liver & Biliary Sciences, New Delhi, Delhi, India|Rajiv Gandhi Super Speciality Hospital, New Delhi, Delhi, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement (Clinical improvement: Reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier)|Proportion of patients in each category according to the ordinal scale|Duration of oxygen therapy in both groups|Duration of hospital stay in both groups|Proportion of patients on mechanical ventilation at day 7 in both groups|Mortality in both groups|Duration of Intensive Care Unit stay|Incidence of adverse effects in both groups|Presence of antibodies against SARS-CoV-2 in serum after plasma administration|Change in Cytokines in both groups|Change in acute phase reactants in both groups|Correlation of the titers in COVID-19 convalescent plasma donors with duration of illness, the severity of symptoms, duration of hospital stay, drugs used in therapy, duration between recovery, and donation.""}"
"2291","High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.","HiFlo-COVID","NCT04609462","001635","Procedure: Conventional oxygen therapy|Procedure: High flow nasal cannula","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04609462","Completed","2020-08-11","2021-02-10","{""locations"":""Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""199"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intubation rate|Modified 7-point ordinal scale improvement|Proportion of patients with requirement of early mechanical ventilation.|Intubation time|Mechanical ventilation (days off)|SOFA score over time|Extra-pulmonary SOFA score over time|Time free of mechanical ventilation in patients with initial PaO2\/FiO2 > and <150 mmHg.|Frequency of mechanical ventilation in patients with PaO2\/FiO2 > and <150 mmHg.|Time free of mechanical ventilation in patients with initial IL6 > and < 100 pg\/mL.|Time free of mechanical ventilation in patients with age > and < 60 years.|Frequency of mechanical ventilation in patients with age > and < 60 years.|High flow nasal canula and time free of mechanical ventilation.|High flow nasal canula and severity of multiorgan dysfunction according to SOFA score.|HACOR relationship to days off from mechanical ventilation.|HACOR relationship to multiorganic dysfunction.|ROX relationship to days off from mechanical ventilation.|ROX relationship to multiorganic dysfunction.|IL-6 and IL-8 levels over time|Variations in serum ferritin levels.|Variations in serum LDH levels.|Variations in serum leukocyte levels.|Variations in serum neutrophil\/lymphocyte count levels.|Variations in serum platelet count levels.|Variations in serum D-dimer measurements.|Days off from renal replacement therapy|ICU length of stay|Length of stay in hospital|All-cause day-28 mortality""}"
"2292","Human Ab Response & immunoMONItoring of COVID-19 Patients","HARMONICOV","NCT04373200","35RC20_9795_HARMONICOV|2020-A01100-39","Biological: Blood samples collection|Other: Saliva collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04373200","Recruiting","2020-05-25","2021-09-25","{""locations"":""CHU Rennes, Rennes, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of increased immune population|Number of decreased immune population|Number of statically different phenotypes compared to control patients|Gain or loss of functional phenotypic markers between D1 and D14|Gain or loss of functional phenotypic markers between between acute and mild infections|Gain or loss of functional phenotypic markers between D1 and month 4|Evaluation of V, D, J gene usage alterations in the immunoglobulin and T cell receptor (TCR) repertoires during ARDS linked to COVID-19|Identification of the Ig classes and of V, D, J sequences of anti-CoV-2 antibodies|Characterization of a new set of human antibodies from patients who have recovered of COVID-19""}"
"2293","The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment","","NCT04351347","ivermecin covid","Drug: Ivermectin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04351347","Recruiting","2020-06-16","2030-12-01","{""locations"":""Tanta University, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patients with improvement or died""}"
"2294","An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications","SISCO","NCT04322188","v 2 22nd April 2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04322188","Completed","2020-03-19","2020-05-08","{""locations"":""ASST - Papa Giovanni XXIII, Bergamo, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""220"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality in siltuximab treated patients|the need of invasive ventilation in siltuximab patients Reduction of the need of time of ventilatory support|clinical course of patients treated with siltuximab Percentage of patients that undergo to tracheostomy|Safety Improvement of the lung function assessed by radiologic findings|the effect on inflammatory parameters|Correlation of outcomes with IL-6 levels""}"
"2295","WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories","WAVE","NCT04357834","WAVE","Other: Equipment with smartwatch throughout hospital stay on the general ward","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357834","Recruiting","2020-05-01","2021-12-31","{""locations"":""Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerland"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).|Diagnostic accuracy of routine physiological data in predicting ICU requirement in COVID-19 contracted in-patients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).|Diagnostic accuracy of predicting hospital discharge without ICU admission in COVID-19 contracted in-patients quantified as area under the receiver operator characteristics curve|Change of heart rate from baseline (hospitalization) to ICU admission|Change of heart rate variability from baseline (hospitalization) to ICU admission|Change of skin temperature from baseline (hospitalization) to ICU admission|Change of blood oxygen saturation from baseline (hospitalization) to ICU admission|Change of respiration rate from baseline (hospitalization) to ICU admission|Change of physical activity from baseline (hospitalization) to ICU admission|Change of stress level from baseline (hospitalization) to ICU admission|Change of sleep pattern from baseline (hospitalization) to ICU admission|Change of steps per day from baseline (hospitalization) to ICU admission|Change of systolic blood pressure from baseline (hospitalization) to ICU admission|Change of diastolic blood pressure from baseline (hospitalization) to ICU admission|Change of body temperature from baseline (hospitalization) to ICU admission|Change of oxygen partial pressure (pO2) from baseline (hospitalization) to ICU admission|Change of CO2 partial pressure (pCO2) from baseline (hospitalization) to ICU admission|Change of blood pH from baseline (hospitalization) to ICU admission|Change of bicarbonate from baseline (hospitalization) to ICU admission|Change of base excess from baseline (hospitalization) to ICU admission|Change of oxygen flow rate from baseline (hospitalization) to ICU admission""}"
"2296","COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff","","NCT04346186","RegHCOVIDScreening","Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346186","Enrolling by invitation","2020-04-15","2021-08-01","{""locations"":""Herlev Hospital, Herlev, Region Hovedstaden, Denmark|Bispebjerg Hospital, K\u00f8benhavn NV, Region Hovedstaden, Denmark|Psykiatrisk Center Ballerup, Ballerup, Denmark|Psykiatrisk Center K\u00f8benhavn, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Psykiatrisk Center Amager, Copenhagen, Denmark|Psykiatrisk Center Stolpegaard, Gentofte, Denmark|B\u00f8rne- og Ungdomspsykiatrisk Center, Glostrup, Denmark|Psykiatrisk Center Glostrup, Glostrup, Denmark|Nordsjaellands Hospital, Hiller\u00f8d, Denmark|Psykiatrisk Center Nordsj\u00e6lland, Hiller\u00f8d, Denmark|Psykiatrisk Center Sankt Hans, Roskilde, Denmark|Bornholms Hospital, R\u00f8nne, Denmark|Psykiatrisk Center Bornholm, R\u00f8nne, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Positive IgM\/IgG tests|Comparison of the point of care test and Elisa|Re-infection rate|IgM\/IgG positive participants on follow-up test""}"
"2297","SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling","CoviDiagMS","NCT04460638","2020-COVID19-15|2020-A01249-30","Biological: Saliva collection|Other: Clinical assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04460638","Recruiting","2020-07-23","2022-07-01","{""locations"":""H\u00f4pital d'Instruction des Arm\u00e9es Laveran, Marseille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of a test based on the MALDI-TOF profiling method to detect individuals infected with SARS-CoV2 from saliva sample.|Rate of correct classification by the test (MALDI-TOF MS profiling) from saliva sample|Rate of correct classification by RT-PCR from saliva sample|Identification of proteins specific to the SARS-CoV2 infection|Presence of a positive anti-SARS-CoV2 antibody response by RT-PCR|Correlation between the identified protein markers and the clinical course of the participants.""}"
"2298","Coronavirus (COVID-19) ACEi/ARB Investigation","CORONACION","NCT04330300","C.A. 2348","Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04330300","Suspended","2020-04-30","2021-12-01","{""locations"":""University Hospital Galway, Galway, Ireland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2414"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)|Number of Covid-19 positive participants who die|Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)|Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)|Number of SARS-CoV-2 positive participants|Maximum troponin T value (ng\/L) among Covid-19 positive participants who require acute hospitalization|24 hour mean systolic BP (mmHg) on ambulatory BP monitoring|All-cause mortality""}"
"2299","Baricitinib Compared to Standard Therapy in Patients With COVID-19","BARICIVID-19","NCT04393051","BARICIVID-19","Drug: Baricitinib Oral Tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04393051","Not yet recruiting","2020-05-20","2020-07-30","{""locations"":""Azienda Ospedaliero Universitaria Pisana, Pisa, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""126"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need of invasive mechanical ventilation|Mortality|Time to invasive mechanical ventilation|Time to independence from non-invasive mechanical ventilation|Time to independence from oxygen therapy|Time to improvement in oxygenation for at least 48 hours|Length of hospital stay|Length of ICU stay|Instrumental response|Proportion of adverse events""}"
"2300","Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19","","NCT04447534","tanta zinc chloroquine","Drug: Chloroquine|Drug: zinc","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04447534","Recruiting","2020-06-23","2030-10-01","{""locations"":""Tanta university hospital, Assuit University, Ainshams University, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with improvement or mortality""}"
"2301","Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?","COVIDVIT","NCT04394390","1","Dietary Supplement: vitamin d","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04394390","Enrolling by invitation","2020-05-01","2020-06-30","{""locations"":""Bursa City Hospital, Bursa, Dogankoy, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""laboratory measured vitamin D levels""}"
"2302","Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia","TRONCHER","NCT04361032","ECC2020-06","Drug: Tocilizumab Injection|Drug: Deferoxamine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04361032","Not yet recruiting","2020-09-04","2020-10-04","{""locations"":""Eshmoun Clinical Research Centre\/ H\u00f4pital Abderrahmane Mami-Ariana, Ariana, Tunisia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""260"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the mortality rate""}"
"2303","Femoral frACturEs and COVID-19.","FACE COVID-19","NCT04657510","FACE COVID-19","Other: COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04657510","Recruiting","2020-11-14","2020-12-31","{""locations"":""IRCCS Istituto Ortopedico Galeazzi, Milano, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""140"",""age"":""45 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival at discharge day (comparison between the two groups)|Length of stay (comparison between the two groups)|Readmission rate (comparison between the two groups)|Complications rate (comparison between the two groups)|Survival at 30 days after discharge (comparison between the two groups)|Routine lab exams values (comparison between the two groups)""}"
"2304","Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19","DEXDO-COVID","NCT04413864","APHP200413|2020-A00799-30","Other: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04413864","Recruiting","2020-04-24","2021-02-28","{""locations"":""Intensive Care Unit and Respiratory division ; Groupe hospitalier Pitie-Salpetriere and Universite Pierre et Marie Curie Paris 6, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of inflammatory cytokines concentration (mmol \/ L) in Covid19 + patients from Baseline at 6 months|Change of interrelationship between inflammation (cytokines levels) and ICU delirium in Covid19 + patient from Baseline at 6 months|Modification in inflammatory genes expressed (expressed \/ non expressed) in PBMC between Baseline and M6|Change in quantity of chromatine's openings (chromatin accessibility profiles) in ICU patient recovering from covid19 infection|Change in genes expression in Covid-19 patient with delirium in ICU between Day2 and Month6""}"
"2305","Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)","","NCT04391101","002","Drug: Convalescent plasma","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04391101","Not yet recruiting","2020-06-01","2021-12-01","{""locations"":""Hospital San Vicente Fundacion, Medell\u00edn, Antioquia, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""231"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intrahospital mortality from any cause|Length of hospital stay|Free time for ventilatory support on day 60|Overall survival at day 60 since hospitalization|Cumulative incidence of adverse events: transfusion reactions (fever, flare), TRALI (transfusion-associated lung injury), TACO (transfusion-related circulatory overload), transfusion- related infections""}"
"2306","Primary Prevention of Infection by COVID-19 in Health Providers","PI-Covid-19","NCT04420260","UNIGEM PT-IC-02","Dietary Supplement: Group A: oropharygeal spray and immunostimulant|Dietary Supplement: Group B: Placebo oropharyngeal spray + Active principle immunostimulant|Dietary Supplement: Group C:Active principle oropharyngeal spray + Placebo taken PO|Dietary Supplement: Group D:Placebo oropharyngeal spray + Placebo taken PO","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04420260","Not yet recruiting","2020-07-01","2020-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""300"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Seroconversion of IgM for COVID-19.|Seroconversion of IgG for COVID-19.""}"
"2307","The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic","COVID-19","NCT04416061","RC-2020-08","Diagnostic Test: COVID 19 Diagnostic Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416061","Active, not recruiting","2020-05-25","2020-08-31","{""locations"":""Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of asymptomatic subjects|Proportion of subjects with recent contact history|Proportion of subjects with recent travel history""}"
"2308","Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19","","NCT04498936","COVID-19 treatment","Drug: Sofosbuvir and Ledipasvir|Drug: Nitazoxanide","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04498936","Completed","2020-07-15","2020-10-30","{""locations"":""15th May Hospital, Helwan, Cairo, Egypt|Assiut University Hospital, Assiut, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""12 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Change of PCR from positive to negative|Clinical improvement|Adverse events""}"
"2309","Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19","IvAzCol","NCT04399746","IvAzCol","Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04399746","Recruiting","2020-03-15","2020-06-10","{""locations"":""Outpatient treatment, Mexico City, Mexico"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral clearance|Symptoms duration|SpO2|SpO2\/FiO2""}"
"2310","Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome","","NCT04383678","COVID-19 ECMO","Device: Extracorporeal membrane oxygenation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383678","Recruiting","2020-03-01","2020-12-31","{""locations"":""Helsinki University Hospital, Helsinki, Finland|University Hospital Jean Minjoz, Besan\u00e7on, France|Nancy University Hospital, Nancy, France|Henri Mondon Unoversity Hospital, Paris, France|Robert Debr\u00e9 University Hospital, Reims, France|Hamburg University Heart Center, Hamburg, Germany|M\u00fcnster University Hospital, M\u00fcnster, Germany|S. Orsola Hospital, Bologna, Italy|Lecco Hospital, Lecco, Italy|Karolinska University Hospital, Stockholm, Sweden|University Hospitals of Leicester, Leicester, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""In-hospital mortality|Death on ECMO|Stroke|Blood stream infection|Lung complications requiring surgical treatment|Blood transfusion|Acute kidney injury|Duration of mechanical ventilation|Deep vein thrombosis|Pulmonary embolism|Length of ICU stay|Length of hospital stay|Death after hospital discharge""}"
"2311","Oscillation and Lung Expansion Therapy in Patients With COVID-19","","NCT04582214","CR-RR-2020-002","Device: MetaNeb® System","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04582214","Recruiting","2020-09-28","2021-01-01","{""locations"":""Emory University, Atlanta, Georgia, United States|Northwestern University, Evanston, Illinois, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time on mechanical ventilation""}"
"2312","Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19","","NCT04445207","H000020420","Biological: Convalescent Plasma","Expanded Access:Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04445207","Available","1970-01-01","1970-01-01","{""locations"":""UMass Medical School, Worcester, Massachusetts, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""""}"
"2313","Mother-infant Bonding During COVID-19","","NCT04531618","AAAT0140","Behavioral: Family Nurture Intervention (FNI)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04531618","Recruiting","2020-08-13","2021-12-01","{""locations"":""Morgan Stanley Children's Hopspital, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""280"",""age"":""up to 72 Hours \u00a0 (Child)"",""outcome_measures"":""Change in Welch Emotional Connection Score|Change in Maternal Caregiving Behavior Score (Acceptance versus Rejection)|Change in Maternal Caregiving Behavior Score (Sensitivity versus Insensitivity)|Change in Maternal Caregiving Behavior Score (Consideration versus Intrusiveness)|Change in Maternal Caregiving Behavior Score (Quality of Physical Contact)|Change in Maternal Caregiving Behavior Score (Quality of Vocal Contact)|Change in Maternal Caregiving Behavior Score (Effectiveness of Response to Baby's Crying)|Right and Left Frontal Mother & Infant EEG Synchrony|Heart Rate Variability (HRV)""}"
"2314","Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19)","","NCT04443712","FMASU P29 /2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443712","Recruiting","2020-05-29","2021-12-01","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1900"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The incidence of the new COVID19 among hospitalized patients|Cost of screening hospitalized patients""}"
"2315","EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up","EARSATS-19","NCT04529408","285603","Device: EarSats Pulse Oximeter Probe","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04529408","Recruiting","2020-08-26","2020-08-26","{""locations"":""Imperial College Healthcare NHS Trust, London, Non-US\/Non-Canadian, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-Ear vs finger SpO2""}"
"2316","COVID-19 Progression in End-Stage Kidney Disease","COPE","NCT04495907","20-M-0047-00","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04495907","Recruiting","2020-08-06","2021-06-01","{""locations"":""DCR Victorville, Victorville, California, United States|DCR Connecticut, Bridgeport, Connecticut, United States|DCR Twin Cities, Minneapolis, Minnesota, United States|DCR Las Vegas, Las Vegas, Nevada, United States|DCR Bronx, Bronx, New York, United States|DCR Canton, Canton, Ohio, United States|DCR El Paso, El Paso, Texas, United States|DCR Lewisville, Lewisville, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR Norfolk, Norfolk, Virginia, United States|DCR Milwaukee, Milwaukee, Wisconsin, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1000"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 IgG|Anti-SARS-CoV-2 IgG""}"
"2317","Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery","","NCT04480580","COVID-SURG","Diagnostic Test: SARS-CoV-2 Ab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04480580","Completed","2020-03-30","2020-06-30","{""locations"":""AOU Cagliari, Cagliari, CA, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Seroprevalence of SARS-CoV-2""}"
"2318","Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.","COVID-19EXO","NCT04491240","COVID-19 EXO","Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation","Interventional","Has Results","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04491240","Completed","2020-07-20","2020-10-20","{""locations"":""Medical Centre Dinasty, Samara, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants With Non-serious and Serious Adverse Events During Trial|Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure|Time to Clinical Recovery (TTCR)|SpO2 Concentration|C-reactive Protein|Lactic Acid Dehydrogenase (LDH)""}"
"2319","HYPONATREMIA IN COVID-19 PATIENTS","","NCT04493268","HYPONATREMIA IN COVID PATIENTS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04493268","Completed","2020-03-07","2020-07-21","{""locations"":""Hospital Posadas, Buenos Aires, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""1 Month to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""MORTALITY|ICU HOSPITALIZATION""}"
"2320","Prevalence of Thrombosis in COVID-Patients","","NCT04615026","COVID Thrombose","Diagnostic Test: duplex sonography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04615026","Recruiting","2020-11-04","2021-06-30","{""locations"":""University Hospital Augsburg, Augsburg, Germany"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""prevalence of thrombosis|correlation to immunity|Assessment of late complications""}"
"2321","Efficacy of Tocilizumab on Patients With COVID-19","","NCT04356937","2020P001159","Drug: Tocilizumab|Drug: Placebos","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04356937","Completed","2020-04-20","2020-08-27","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""243"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary endpoint is the time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation|Time from investigational medication (or placebo) to at least one point worsening on clinical improvement scale for subjects requiring supplemental oxygen (score >= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline|Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline""}"
"2322","Acute Kidney Injury in Patients Hospitalized With COVID-19","","NCT04316299","hkyy2020-005 AKI","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04316299","Completed","2020-02-26","2020-03-08","{""locations"":""Hankou Hospital, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""287"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay""}"
"2323","COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador","","NCT04362969","001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362969","Not yet recruiting","2020-05-01","2020-05-01","{""locations"":""GastroMu\u00f1oz, Guayaquil, Guayas, Ecuador"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical characteristics of patients with COVID-19|Prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death|Clinical characteristics of the patients with the worst prognosis|Relationship between the different treatments and the prognosis""}"
"2324","Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19","HYdILIC","NCT04372082","2020_40|2020-002188-72","Other: Standard of care (SOC)|Drug: Hydroxychloroquine|Drug: Association of diltiazem and niclosamide","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04372082","Withdrawn","2020-05-01","2023-05-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""death|clinical worsening (composite criteria)|Assisted-ventilation and\/or hospitalization (composite criteria)|National Early Warning Score (NEWS)|cumulative incidence of hospitalizations|cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)|Mortality|cumulative incidence of viral shedding on SARS-CoV-2 rt-PCR on nasopharyngeal swab;|adverse drug reactions""}"
"2325","Convalescent Plasma vs. Standard Plasma for COVID-19","","NCT04344535","SBU-COVID19-ConvalescentPlasma","Biological: Convalescent Plasma|Biological: Standard Donor Plasma","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04344535","Enrolling by invitation","2020-04-08","2021-08-31","{""locations"":""Stony Brook University Hospital, Stony Brook, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28 day ventilator free days|90 day all-cause mortality""}"
"2326","COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)","FALP-COVID","NCT04384588","FALP 001-2020","Biological: Convalescent Plasma from COVID-19 donors","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04384588","Recruiting","2020-04-07","2021-04-06","{""locations"":""Fundacion Arturo Lopez Perez, Providencia, Santiago, Chile"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma|safety of the use of convalescent plasma drom COVID 19 donors|Mortality at 30 days, 90 days, 6 months and 1 year|in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports|Number of days of hospitalization in high complexity facilities after convalescent plasma use|Number of days of hospitalization in intensive care unit after convalescent plasma use|Number of days of mechanical ventilatory support in patients after convalescent plasma use|Total number of days of mechanical ventilatory support|Total number of hospitalization days in patients treated with convalescent plasma|Number of hospitalization days in patients after treatment with convalescent plasma|Viral load measuring|Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies)|Negativization of COVID 19 load since convalescent plasma use|Negativization of COVID 19 load since hospitalization|Negativization of COVID 19 load since first reported symptoms COVID-19 related|Donor Interferon Gamma profile characterization|Donor Granulocyte Macrophage Colony Stimulating Factor characterization|Donor Tumor Necrosis Factor Alfa characterization|Donor Interleukin -1 beta characterization|Donor Interleukin-2 characterization|Donor Interleukin-4 characterization|Donor Interleukin-6 characterization|Donor Interleukin-8 characterization|Donor Interleukin-10 characterization|Receptor Interferon Gamma profile characterization|Receptor Granulocyte Macrophage Colony Stimulating Factor characterization|receptor Tumor Necrosis Factor Alfa characterization|receptor Interleukin -1 beta characterization|Receptor Interleukin-2 characterization|Receptor Interleukin-4 characterization|Receptor Interleukin-6 characterization|Receptor Interleukin-8 characterization|Receptor Interleukin-10 characterization""}"
"2327","New Antiviral Drugs for Treatment of COVID-19","","NCT04392427","20.05.69","Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04392427","Not yet recruiting","2020-10-01","2022-05-01","{""locations"":""Mansoura University, Mansoura, Select A State Or Province, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""negative test result for COVID-19""}"
"2328","Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)","SeroCoV-HUS","NCT04441684","7782","Diagnostic Test: Blood sample for serological test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04441684","Recruiting","2020-04-17","2021-08-01","{""locations"":""H\u00f4pitaux Universitaires de Strasbourg - Centre d'Investigation Clinique - Nouvel H\u00f4pital Civil et Hautepierre, Strasbourg, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""1800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of specific SARS-CoV2 antibodies in the serum in the 3 groups of subjects studied, at the inclusion visit (D0).|Detection and titration of neutralizing antibodies anti-SARS-CoV-2|Kinetics of antibodies and their persistence over a period of 1 year|Number of asymptomatic subjects in the PCR - and -PCR groups|Number of people with positive Sars-CoV-2 serology|Questionnaire (Type of health care personnel, Contact history, medical operation and respect of hygiene standards)""}"
"2329","The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease","","NCT04387279","2020-04-070","Other: Interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387279","Recruiting","2020-04-24","2021-03-30","{""locations"":""KeimyungUniversity, Daegu, Jung-gu, Korea, Republic of"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient's perception of COVID-19 and medical use patterns|Exacerbation of symptoms""}"
"2330","Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial","COLSTAT","NCT04472611","2000027950","Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04472611","Recruiting","2020-10-30","2022-08-01","{""locations"":""Bridgeport Hospital, Bridgeport, Connecticut, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Yale New Haven Hosptial System, New Haven, Connecticut, United States|Lawrence & Memorial Hospital, New London, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""466"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID 19 Severity""}"
"2331","Thromboembolic Risk Screening in Patients With Cancer and COVID-19","NEOTHROCOVID","NCT04616846","2020/20","Diagnostic Test: Peripheral venous ultrasound","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04616846","Recruiting","2020-08-04","2021-09-15","{""locations"":""Clinique Saint-Jean, Cagnes-sur-Mer, Alpes-Maritimes, France|Centre Azur\u00e9en de Canc\u00e9rologie, Mougins, Alpes-Maritimes, France|CHU Nice, Nice, Alpes-Maritimes, France|Clinique Saint-Georges, Nice, Alpes-Maritimes, France|Centre Antoine Lacassagne, Nice, Alpes-Maritimes, France|CHPG, Monaco, Monaco"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of venous thromboembolism|Hospitalization due to venous thromboembolism|Overall Survival|Specific survival|Safety profile using the common toxicity criteria from the NCI CTCAE V5.0|Predictive factors for venous thromboembolism|rate of symptomatic venous thromboembolism between the COVID-19 negative and COVID-19 positive patients""}"
"2332","Prasugrel in Severe COVID-19 Pneumonia","PARTISAN","NCT04445623","MGI-COVID-19-prasugrel","Drug: Prasugrel Hydrochloride 10 MG Oral Tablet|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04445623","Not yet recruiting","2020-07-01","2021-01-01","{""locations"":""Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""128"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""P\/F ratio at day 7|Daily P\/F ratio|Daily need for oxygen supply|Need for ICU|Death|MOF|Discharge|Clinical progression of the disease SOFA score|Clinical progression of the disease APACHE II|Venous thrombosis\/ pulmonary embolism\/thrombosis|Need for CT imaging|Daily Temperature|Daily blood pressure|Daily total blood count Hemoglobin|Daily total blood count Red Blood Cells|Daily total blood count Leukocytes|Daily total blood count Platelets|Daily indices of organ damage Liver|Indices of inflammation C-reactive protein|Indices of haemostasis PT|Daily progression at imaging (chest-X-ray)|Major bleeding|Total bleeding|Unexpected clinical or laboratory findings|Indices of inflammation D-dimer|Indices of inflammation Fibrinogen|Indices of inflammation IL-6|Indices of inflammation IL-1|Daily indices of organ damage kidney|Daily indices of organ damage heart|Haemostasis aPTT|Haemostasis VASP PRI|Haemostasis platelet-leukocytes aggregates""}"
"2333","BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots","","NCT04475302","2020010","Biological: BCG vaccine (Freeze-dried)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04475302","Recruiting","2020-07-01","2021-05-01","{""locations"":""Tuberculosis Research Centre, Chennai, Tamilnadu, India"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2175"",""age"":""60 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality due to COVID-19 disease|Hospital admission and ICU admission due to Covid-19, Severity of Covid-19 (mild, moderate or severe), Hospital admission due to other respiratory febrile illness, immunological outcomes in the sub study""}"
"2334","COVID-19 Biorepository","","NCT04568148","STUDY#00145602","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568148","Recruiting","2020-04-15","2021-12-31","{""locations"":""University of Kansas Medical Center, Kansas City, Kansas, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Biospecimen Collection|Establishing Connections|Continuing COVID Research""}"
"2335","Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","FORCE","NCT04371367","2020-21","Biological: avdoralimab|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04371367","Active, not recruiting","2020-04-27","2021-03-01","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""208"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement using WHO ordinal scale|Number of ventilator-free days at Day 28 (VFD28)|Number of participants with treatment-related adverse events""}"
"2336","Outcomes of Patients With COVID-19 in the Intensive Care Unit","MexCOVID-19","NCT04336345","3336","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04336345","Completed","2020-04-01","2020-06-04","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital mortality|Length of stay in the intensive care unit""}"
"2337","Complicated Grief in ICU in the Aftermath of COVID-19","DEPARTS","NCT04554264","PI2020_843_0071","Other: questionnaire","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04554264","Recruiting","2020-09-01","2022-09-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of complicated grief 4 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score.|Proportion of complicated grief 6 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score.|Proportion of complicated grief 12 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score.""}"
"2338","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","GRECCO-19","NCT04326790","906295542","Drug: Colchicine|Drug: Standard treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04326790","Recruiting","2020-04-03","2020-09-30","{""locations"":""AHEPA Hospital, Thessaloniki, Gibraltar"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee|Maximal concentration of cardiac troponin""}"
"2339","Transpulmonary Driving Pressure in ARDS COVID19 Patients","TRANSPULMONARY","NCT04381286","RECHMPL20_0194","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04381286","Recruiting","2019-04-01","2021-12-31","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of mechanical Ventilation|Number of Participants with during of Acute respiratory distress syndrom (SDRA)|Length of stay in intensive care unit|Mortality|number of patients with pulmonary complications|Number of Participants with pulmonary stress and strain""}"
"2340","Anakinra for COVID-19 Respiratory Symptoms","ANACONDA","NCT04364009","ANACONDA-COVID-19|2020-001734-36|DR200111","Drug: Anakinra plus oSOC|Drug: oSOC","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04364009","Terminated","2020-04-27","2020-11-03","{""locations"":""CHRU de TOURS, Tours, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""71"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment success|OMS progression scale (on a 7 point ordinal scale)|Overall survival|Time to ICU admission|Time to ventilatory support|Change in National Early Warning Score (NEW)from baseline to Day 3, Day 10, Day 14 and Day 28|Change in inflammatory parameter|Hospital length of stay|ICU parameter|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Predictors of efficacy of Anakinra""}"
"2341","Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors","","NCT04615949","CARDIOL 100-03","Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04615949","Not yet recruiting","2020-12-01","2021-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""422"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Requirement for ICU admission and\/or ventilatory support|CV complications""}"
"2342","Monocytes and NK Cells Activity in Covid-19 Patients","","NCT04375176","67/2020","Diagnostic Test: Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375176","Recruiting","2020-04-27","2020-10-31","{""locations"":""ATS Insubria, Varese, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immune cells activity|Protective factors and new therapeutic strategies""}"
"2343","Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study","","NCT04368871","Covid-19/RFTC/MHC/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368871","Recruiting","2020-04-28","2021-05-30","{""locations"":""Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Radiographic findings and their temporal changes in COVID-19 positive patient: A Prospective study""}"
"2344","SUNLIGHT Study: Online Support Groups for MS to Address COVID-19","","NCT04379661","AAAS9939","Behavioral: Online support Group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04379661","Completed","2020-05-07","2020-08-31","{""locations"":""Columbia University Medical Center, New York, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""32"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of completion|Rate of adherence|Score on the State Trait Anxiety Inventory (STAI)""}"
"2345","A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","","NCT04351503","2020-00769; qu20Egli2","Other: Study A|Other: Study B|Other: Study C|Other: Study D","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351503","Recruiting","2020-04-09","2022-04-01","{""locations"":""Viollier AG, Allschwil, Switzerland|University Hospital Basel, Basel, Switzerland|Biozentrum University of Basel, Basel, Switzerland|sciCore University of Basel, Basel, Switzerland|Department of Biosystems Science and Engineering ETH Zurich, Basel, Switzerland|Swiss Institute of Bioinformatics, Geneva, Switzerland"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""10000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Identification of factors associated with (i) infection (binary, yes\/no), (ii) hospitalization (binary, yes\/no), (iii) requirement for ICU treatment (binary, yes\/no)|duration of hospitalization (in days)|duration of Intensive Care Unit (ICU) stay (in days)|in-hospital mortality (binary, yes\/no)|Number of infected cases within the city of Basel|whole genome sequencing to study pathogen evolution (number, type, and complexity of viral genome)|Identification which treatment modality is associated with adverse events (binary, yes\/no)|Identification which treatment modality is associated with pulmonary recovery (binary, yes\/no)""}"
"2346","Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff","SEROSARSCOV","NCT04387838","2020-COVID19-10|2020-A01028-31","Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387838","Completed","2020-05-14","2020-08-15","{""locations"":""H\u00f4pital d'Instuction des Arm\u00e9es Sainte-Anne, Toulon, France|H\u00f4pital d'Instruction des Arm\u00e9es Robert Picqu\u00e9, Villenave-d'Ornon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""845"",""age"":""18 Years to 62 Years \u00a0 (Adult)"",""outcome_measures"":""Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.|Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.|Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.|Anti-SARS-Cov2 seroprevalence at Day 0.|Correlation between seroconversion and socio-demographic factors - sex|Correlation between seroconversion and socio-demographic factors - age|Correlation between seroconversion and professional factors - job type|Correlation between seroconversion and professional factors - personal protective equipment type|Correlation between seroconversion and non-professional factors - contact with infected individuals|Correlation between seroconversion and non-professional factors - wearing of professional equipment|Correlation between seroconversion and non-professional factors - respect of barrier gestures""}"
"2347","Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan","","NCT04697030","129","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04697030","Completed","2020-09-15","2020-12-22","{""locations"":""Sialkot College of Physical Therapy, Amin Welfare & Teaching Hospital, Sialkot, Punjab, Pakistan"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""443"",""age"":""13 Years to 19 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Burnout Rating Scale""}"
"2348","Epidemiological Investigation of COVID-19 in Laos Using a One-Health Approach in Human and Animals","LACOVISS","NCT04716543","ANRS COV20 LACOVISS","Diagnostic Test: ILI and COVID-19 detection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04716543","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5400"",""age"":""6 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Prevalence of SARS-CoV-2 RNA in respiratory samples collected from influenza-like illness patients from cohort study 2020-2021|Prevalence of SARS-CoV-2 RNA in respiratory samples from influenza-like illness patients from cohort study between 2015 and 2019""}"
"2349","Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study","COVID","NCT04508556","SARS-CoV-2 study","Device: Breath Biopsy face masks with removable filters and fitted PVA strip|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: oropharyngeal swabs","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04508556","Not yet recruiting","2020-09-01","2021-04-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positive control for technical validation|Evaluation of test performance""}"
"2350","Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff","IMMUNO-COVID","NCT04408001","2020-COVID19-04|2020-A01019-30","Other: Clinical interview|Biological: Blood collection|Biological: Saliva collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408001","Active, not recruiting","2020-06-04","2021-06-04","{""locations"":""H\u00f4pital d'Instuction des Arm\u00e9es Percy, Clamart, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""499"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Induced SARS-CoV2 immunity|Long-term protection of induced SARS-CoV2 immunity at 6 months|Long-term protection of induced SARS-CoV2 immunity at 1 year|Anti-SARS-CoV2 antibodies kinetics in blood throughout the study|Anti-SARS-CoV2 antibodies kinetics in saliva throughout the study|Kinetics of serum neutralization in blood throughout the study|Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 0|Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 21""}"
"2351","Prediction of Acute Kidney Injury in Patients With COVID-19","","NCT04406688","04-AnIt-20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406688","Recruiting","2020-06-22","2021-03-01","{""locations"":""University Hospital M\u00fcnster, M\u00fcnster, Germany|Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal|Centro Hospitalar e Universit\u00e1rio do Porto, Porto, Portugal|Hospital de la Vall d'Hebron, Barcelona, Spain|Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Mutua Terrassa, Terrassa, Spain|Hospital la Fe, Valencia, Spain|Guy's & St. Thomas Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurence of acute kidney injury (AKI)|Occurence of transient and persistent AKI|Occurence of Renal replacement therapy during hospital stay|Duration of renal replacement therapy|Mortality|Duration of mechanical ventilation|Duration of vasopressor administration|ICU length of stay|Hospital length of stay""}"
"2352","Use of PCR-Sars-CoV-2 in Children","VIGIL","NCT04412317","VIGIL","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412317","Recruiting","2020-06-03","2021-05-31","{""locations"":""ACTIV network, Cr\u00e9teil, France|PARI network, Cr\u00e9teil, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""up to 14 Years \u00a0 (Child)"",""outcome_measures"":""Percentage of children screened with a positive PCR result or a positive Rapid Antigenic Diagnostic (RAD) test|Percentage of PCR-Sars-CoV-2 positive in the sick child in the presence of a Covid contagion in the family environment or not|Percentage of RAD-Sars-CoV-2 positive in the sick child in the presence of a Covid contagion in the family environment or not""}"
"2353","Predicting Death and ICU Admission in COVID-19 Patients in ED","","NCT04371562","0017055/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371562","Completed","2020-03-01","2020-04-15","{""locations"":""Marcello Covino, Roma, RM, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""7-day death|7-day ICU""}"
"2354","Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS","","NCT04452097","BXU001-COVID19","Biological: Human umbilical cord mesenchymal stem cells + best supportive care|Other: Placebo control + best supportive care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04452097","Not yet recruiting","2021-03-01","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""39"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of infusion-related adverse events|Incidence of any treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)|Selection of an appropriate dose of BX-U001 for the following Phase 2 study|All-cause mortality|Proportion of patients achieving clinical response by the improvement of at least 2 points on the 7-point ordinal scale.|Duration of ICU stay|Duration of hospital stay|Changes in blood cytokine levels""}"
"2355","Registry of Sustained Immunity to COVID-19 Among ESKD Patients","RePAiR","NCT04495764","20-M-0044-00","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04495764","Completed","2020-07-20","2021-02-12","{""locations"":""DCR Victorville, Victorville, California, United States|DCR Connecticut, Bridgeport, Connecticut, United States|DCR Twin Cities, Minneapolis, Minnesota, United States|DCR Las Vegas, Las Vegas, Nevada, United States|DCR Bronx, Bronx, New York, United States|DCR Canton, Canton, Ohio, United States|DCR El Paso, El Paso, Texas, United States|DCR Lewisville, Lewisville, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR Norfolk, Norfolk, Virginia, United States|DCR Milwaukee, Milwaukee, Wisconsin, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2504"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anti-SARS-CoV-2 antibodies|Incidence and severity of COVID-19""}"
"2356","To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients","","NCT04468646","UniversityHSL-NK1R","Drug: NK-1R antagonist","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04468646","Recruiting","2020-06-15","2020-08-30","{""locations"":""Bahria International Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to improvement on a 7-point ordinal scale as compared to baseline|total in-hospital days and the total duration|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|Reduction from baseline of NRS for cough|Reduction from baseline of NRS for nausea|Time to normalization of fever for at least 48 hours|Time to improvement in oxygenation for at least 48 hours""}"
"2357","Protective Role of Inhaled Steroids for Covid-19 Infection","INHASCO","NCT04331054","P 200394|2020-001306-35","Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04331054","Recruiting","2020-04-13","2022-01-13","{""locations"":""H\u00f4pital Bichat - Service de Pneumologie, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""436"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time (in days) to clinical improvement within 30 days after randomization|Mortality rate at D30|Time (in days) from randomization to death|Number of days alive outside ICU within 30 days|Number of days alive free of invasive or non-invasive ventilation within 30 days|Number of days alive with oxygen therapy within 30 days|Maximal oxygen rate within 30 days|Difference between PaO2\/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)|Number of days alive outside hospital within 30 days|Use of antibiotics for respiratory (proved or suspected) infection within 30 days|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.""}"
"2358","Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure","COV-IMMUNO","NCT04442048","IC8","Biological: IMM-101|Other: Observation","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04442048","Recruiting","2020-06-25","2022-03-31","{""locations"":""Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Research Institute of the McGill University, Montreal, Quebec, Canada|CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The rate of \""flu-like illness\"" which includes:|The incidence of documented COVID-19 infection (confirmed by any Health Canada approved COVID-19 test. Both symptomatic and asymptomatic infections will be documented|The rate of severe respiratory and COVID-19 infection defined as a confirmed COVID-19 infection leading to hospitalization, ICU admission or death|The number of events that meet the definition of the primary endpoint, as measured within the one-year follow-up (patients may meet the primary endpoint more than once and be counted multiple times).|The incidence of COVID-19 seroconverted patients between baseline, 3 months, 6 months and 12 months|The incremental cost-effectiveness ratio (in the unit of CAD$ per life-years gained) measured with EQ-5D-5L|Failure-free survival, as time from enrollment to recurrence or progression declared by the investigator on the basis of objective standard evaluation consistent with the disease site or death|Overall survival (OS), as time from enrollment to death from any cause|Incidence, frequency, and severity of AEs considered possibly, probably or definitely related to receipt of IMM-101|Incidence and frequency of local injection site reactions subsequent to IMM-101 administration|Incidence and duration of ICU admission related to documented COVID-19 infection""}"
"2359","Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)","EpiCovCreil","NCT04404270","2020-COVID19-22|2020-A01368-31","Diagnostic Test: Anti-SARS-CoV2 Serology|Behavioral: Questionnaire|Diagnostic Test: Anti-SARS-CoV2 serological controls and serum neutralization","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04404270","Active, not recruiting","2020-05-26","2021-03-01","{""locations"":""24e antenne m\u00e9dicale de Creil, Creil, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1146"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion anti-SARS-CoV2 seropositive|Proportion of asymptomatic anti-SARS-CoV2 seropositive participants|Agreement between the anti-SARS-CoV2 serological results obtained using two different techniques (detecting the presence of different antibodies)|Proportion of serum neutralization positive|Change of antibody level over time""}"
"2360","GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel","","NCT04408183","T2R-002","Drug: GLS-1200|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04408183","Recruiting","2020-06-01","2021-03-01","{""locations"":""Sinus and Nasal Specialists of Louisiana, Baton Rouge, Louisiana, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""225"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0|Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group|Symptom score of documented SARS-CoV-2 infection relative to treatment group with a higher score being a worse outcome.""}"
"2361","LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia","","NCT04390217","LBS-COVID19-201","Drug: LB1148|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04390217","Not yet recruiting","2021-10-31","2022-03-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect of LB1148 on disease progression via measurement of the proportion of patients who are alive and free of respiratory failure.|Clinical status at fixed time points|Duration of hospital stay|Measurement of the number and proportion of patients requiring admission to the intensive care unit (ICU) during hospitalization|Duration of ICU stay|Invasive mechanical ventilation requirements|Duration of invasive mechanical ventilation|All-cause 28-day mortality|Safety and tolerability of LB1148""}"
"2362","Rhu-pGSN for Severe Covid-19 Pneumonia","","NCT04358406","BTI-202","Drug: Recombinant human plasma gelsolin (Rhu-pGSN)|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04358406","Recruiting","2020-07-30","2021-05-01","{""locations"":""Spitalul Clinic de Boli Infec\u0163ioase \u015fi Pneumoftiziologie, Timi\u015foara, Romania|Sant Joan de Reus SAM University Hospital, Reus, Spain|Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy: Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis|Safety and Tolerability: Proportion of subjects with serious adverse events (SAEs)|Efficacy: Daily change in the WHO 9-point severity score|Efficacy: All cause mortality rate at Days 28 and 90|Efficacy: Proportion of subjects alive without the ongoing use of vasopressors, ongoing intubation\/mechanical ventilation, ongoing residence in an intensive care unit (ICU), new ongoing need for dialysis\/renal replacement therapy|Efficacy: Proportion of subjects discharged to home or immediate prior residence|Efficacy: Length of stay (LOS) of surviving subjects in the hospital and in ICU|Efficacy: Proportion of subjects readmitted to the hospital|Safety and Tolerability: Proportion of subjects with adverse events (AEs)|Safety and Tolerability: Proportion of subjects with new or worsening clinically significant laboratory abnormalities|Immunogenicity: Proportion of subjects with rhu-pGSN antibodies|Pharmacokinetics: Maximum concentration (C max) of added rhu-pGSN|Pharmacokinetics: Time to maximum concentration (T max) of added rhu-pGSN|Pharmacokinetics: Half-life (T 1\/2) of added rhu-pGSN|Pharmacokinetics: Area under the curve from time 0 to 8 hours (AUC 0-8) of added rhu-pGSN|Pharmacokinetics: Area under the curve from time 0 to infinity (AUC 0-inf) of added rhu-pGSN""}"
"2363","Understanding COVID-19","","NCT04329546","2020-00516","Other: NA (no intervention)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04329546","Recruiting","2020-03-27","2022-03-31","{""locations"":""University Hospitals of Geneva, Geneva, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days|Virologic primary outcome: Peak viral load in the 56 days following diagnosis\/suspected diagnosis""}"
"2364","Maternal-foetal Transmission of SARS-Cov-2","TMF-COVID-19","NCT04395924","CHRO-2020-10","Diagnostic Test: Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395924","Recruiting","2020-05-05","2021-05-01","{""locations"":""CHR Orl\u00e9ans, Orl\u00e9ans, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 48 Years \u00a0 (Adult)"",""outcome_measures"":""COVID-19 by positive PCR in cord blood and \/ or positive serologies|COVID-19 by positive PCR in amniotic fluid and placenta|New born infected by COVID-19""}"
"2365","Evaluation of Antibody Tests for COVID-19","","NCT04360954","202004088","Diagnostic Test: Diagnostic test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04360954","Completed","2020-04-23","2020-07-08","{""locations"":""Washington University School of Medicine, Saint Louis, Missouri, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""461"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Test Sensitivity|Test Specificity""}"
"2366","Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy","THROMBCOVID2","NCT04377490","PI2020_843_0040","Other: venous ultrasound|Biological: blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377490","Recruiting","2020-05-04","2020-11-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation of thrombin time (in secondes) in Hospitalized Covid-19 patients|Variation of factor V concentration (U\/dL) in Hospitalized Covid-19 patients.|Variation of factor II concentration (U\/dL) in Hospitalized Covid-19 patients|Variation of concentration of fibrin and fibrinogen degradation products (\u2265 10 \u00b5gm\/mL) in Hospitalized Covid-19 patients.""}"
"2367","OCTA Study: Retinal Vascular Changes in Patients With SARS-CoV-2 Infection","","NCT04601012","2020/03","Diagnostic Test: Optical coherence tomography angiography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04601012","Completed","2020-09-20","2020-10-22","{""locations"":""University of Naples \""Federico II\"", Naples, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""40"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""The measurements of retinal features in patients with previous diagnosis of COVID19, using optical coherence tomography angiography.""}"
"2368","QuadraMune(TM) for Prevention of COVID-19","","NCT04421391","QuadraMune002","Dietary Supplement: QuadraMune(TM)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04421391","Recruiting","2020-06-08","2020-11-08","{""locations"":""Therapeutic Solutions International, Oceanside, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevention of COVID-19|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events""}"
"2369","Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease","","NCT04382924","AGN120-3","Drug: NP-120 (Ifenprodil)","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04382924","Active, not recruiting","2020-08-05","2022-02-01","{""locations"":""Westchester Research Center, Miami, Florida, United States|Affinity Health - Loretto Hospital, Chicago, Illinois, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Promedica Health: Toledo Hospital and BayPark Hospital, Toledo, Ohio, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Makati Medical Center, Manila, Philippines|Philippine General Hospital, Manila, Philippines|Lung Center of the Philippines, Quezon City, Philippines|National Institute of Infectious Diseases, Bucharest, Romania"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""682"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients:|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in IP versus control group patients|NEWS assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in IP versus control group patients|Rate of mechanical ventilation in IP versus control group patients|Duration of mechanical ventilation (if applicable) in IP versus control group patients|Duration of supplemental oxygen in IP versus control group patients|Time to return to room pressure (SpO2 > 94%) on room air|Duration in ICU (if applicable) in IP versus control group patients|Rate of Mortality in IP versus control group patients|Duration of hospitalization in IP versus control group patients|Time to discharge in IP versus control group patients|Effect on the rate of change of partial pressure of oxygen (PaO2) and PaO2\/FiO2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in IP versus control group patients""}"
"2370","Prayer in Commbate to Corona Virus - Covid -19","","NCT04631380","PRAYER-COVID19","Other: PRAYER","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04631380","Recruiting","2020-08-01","2021-01-01","{""locations"":""Hospital do Coracao, Sao Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""DEATH OR RECOVERY|NEED FOR MECHANICAL VENTILATION|TIME OF REMAINED INTUBATED|LENGTH OF STAY IN ICU|TIME OF STAY HOSPITALIZED|Occurrence of clinical complications.""}"
"2371","To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study)","SCOPe","NCT04367064","SCOPe/MHC/Covid-19/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367064","Recruiting","2020-04-25","2020-12-25","{""locations"":""Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""we will compare the clinical outcome of the COVID 19 patients with their age and gender|we will compare the effect of different treatments given to the COVID 19 patients at Max Hospital""}"
"2372","Lessening Organ Dysfunction With VITamin C - COVID-19","LOVIT-COVID","NCT04401150","MP-31-2021-3741","Drug: Vitamin C|Drug: Control","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04401150","Recruiting","2020-08-14","2022-01-01","{""locations"":""Research Center of the CHUS, Sherbrooke, Quebec, Canada|Research Centre of the CHUS, Sherbrooke, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death or persistent organ dysfunction|Number of intensive care unit-free days|Persistent organ dysfunction-free days in ICU|Number of patients deceased at 6 months|Health related quality of life in 6-month survivors|Organ function|Global tissue dysoxia|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia""}"
"2373","Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients","DW-MSC","NCT04535856","DW_DWP710101|U1111-1263-1723","Drug: allogeneic mesenchymal stem cell|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04535856","Completed","2020-11-14","2021-01-14","{""locations"":""Site 550: University of Hassanudin\/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""9"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of TEAE* in Treatment group|Survival rate|Duration of hospitalization|Clinical improvement Ordinal scale|Clinical improvement National EWS|Clinical improvement Oxygenation index|Clinical improvement Lung involvement change|Clinical improvement Inflammation markers change""}"
"2374","Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning","IDENTIFY","NCT04423991","060820","Device: COViage","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04423991","Completed","2020-03-10","2020-06-04","{""locations"":""Dascena, Oakland, California, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""290"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality outcome""}"
"2375","Covid-19 in Lupus Patients","","NCT04355702","RECHMPL20_0219","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355702","Completed","2020-03-01","2020-12-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""130"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""prevalence and severity of Covid-19 infection in patients with SLE|prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine""}"
"2376","Anakinra, COVID-19, Cytokine Storm","SOBI","NCT04603742","20-07022396","Drug: Anakinra|Drug: 0.9% Saline","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04603742","Not yet recruiting","2020-11-01","2022-02-01","{""locations"":""Weill Cornell Medcine, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of subjects alive without having required mechanical ventilation|60-day mortality|Patient Hospitalization|Patient Mechanical Ventilation""}"
"2377","Surgical Telemedicine in the COVID-19 Pandemic Era","","NCT04376710","20-1177","Other: Completion of pre-pandemic survey|Other: Completion of survey after peak of pandemic|Other: Completion of post telemedicine encounter survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376710","Completed","2020-07-01","2020-10-01","{""locations"":""Children's Hospital Colorado, Aurora, Colorado, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""180"",""age"":""31 Days to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Evaluate surgeon perceptions to telemedicine and perceived barriers to implementation|Evaluate patient perceptions to telemedicine and perceived barriers to implementation""}"
"2378","COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses","BBCovid","NCT04352959","BBCovid","Device: mouthrinse with bêta-cyclodextrin and citrox|Device: mouthrinse without bêta-cyclodextrin and citrox","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04352959","Completed","2020-04-27","2020-12-11","{""locations"":""Clinic of the Protestant Infirmary in Lyon, Caluire-et-Cuire, France|Hospital Center Emile Roux, Le Puy en Velay, France|Hospital Center Saint Luc Saint Joseph, Lyon, France|Intercommunal Hospital Center of Mont de Marsan, Mont de Marsan, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""176"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days|Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 7 days""}"
"2379","Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19","","NCT04406233","31303720.7.0000.0068","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406233","Recruiting","2020-05-23","2022-05-23","{""locations"":""Univsersity of Sao Paulo, Sao Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""176"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to medical discharge|All-cause mortality|Hospital readmission""}"
"2380","Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia","LidoCovid","NCT04609865","7820","Drug: Lidocaine 2%|Drug: Control","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04609865","Recruiting","2020-11-04","2024-02-04","{""locations"":""University Hospital of Hautepierre, Strasbourg, Bas-Rhin, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""alveolar-capillary gas exchange after two days of treatment|alveolar-capillary gas exchange From day 0 to day 21 or until coming out of intensive care|Ventilator-free days|Measure the effects of Intravenous Lidocaine on Biomarkers : Ferritin|Measure the effects of Intravenous Lidocaine on Biomarkers : bicarbonates|Measure the effects of Intravenous Lidocaine on Biomarkers : CRP|Measure the effects of Intravenous Lidocaine on Biomarkers : LDH|Measure the effects of Intravenous Lidocaine on Biomarkers : IL-6|Measure the effects of Intravenous Lidocaine on Biomarkers : Tropo HS|Measure the effects of Intravenous Lidocaine on Biomarkers : Triglycerides|Measure the effects of Intravenous Lidocaine on Biomarkers : CBC with lymphocytes count|Antithrombotic activity of Intravenous Lidocaine on platelets|Antithrombotic activity of Intravenous Lidocaine on ACT ratio|Antithrombotic activity of Intravenous Lidocaine on fibrinogen|Antithrombotic activity of Intravenous Lidocaine on D-Dimers|Antithrombotic activity of Intravenous Lidocaine on TEG|Antithrombotic activity of Intravenous Lidocaine on thromboembolic events|Plasma concentration of albumin and Lidocaine|Search for hemodynamic dysfynction: Blood pressure measurement in mmHg|Search for hemodynamic dysfynction: Cardiac frequency in beats per minute will be assessed|Search for hemodynamic dysfynction: Sinus rythm will be assessed|Search for hemodynamic dysfynction: Vasopressors and inotropes drugs use will be reported|Search for hemodynamic dysfynction: EKG : PR, QRS, QTc intervals in ms will be measured|ICU ileus: laxation response|Opioids, sedative and curare sparing effect (drugs dosage)|Evaluate the impact of Lidocaine IV on ICU outcomes : re-intubation|Evaluate the impact of Lidocaine IV on ICU outcomes : ICU length of stay|Evaluate the impact of Lidocaine IV on ICU outcomes : ICU complications|Cough at extubation time or in the 24 hours after extubation or weaning from respiratory support (in case of tracheostomy)""}"
"2381","Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER)","ReCOVER","NCT04399109","PID00770","Device: TCC-COVID mHealth solution","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04399109","Recruiting","2020-05-20","2021-05-19","{""locations"":""The Sutherland Hospital, Caringbah, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of avoidable Emergency Department presentations per diagnosed COVID-19 case|All cause mortality per diagnosed COVID-19 case All-cause mortality rate at 30 days per diagnosed COVID-19 case|Rate of hospital admission per diagnosed COVID case|Rate of MBS claims for un-referred visits to general practitioners and analogous COVID-19 MBS telehealth items per diagnosed COVID case|Average length of stay (LOS) for admitted patients per diagnosed COVID case|Rate of admission to Intensive Care Unit (ICU) for admitted patients per diagnosed COVID case|Time from presentation to admission to ICU for patients admitted to ICU per diagnosed COVID case|Rate of intubation in admitted patients per diagnosed COVID case|Rate of readmission within 30 days of discharge in admitted patients per diagnosed COVID case|All-cause mortality at 90 days per diagnosed COVID case|Rate of avoidable Emergency Department presentations with COVID-19 diagnosis per 100,000 population, during trial period|Rate of hospital admission with COVID-19 diagnosis per 100,000 population, during trial period|Rate of admission to ICU with COVID-19 diagnosis per 100,000 population during trial period|Rate of mortality with COVID-19 cause of death per 100,000 population, during trial period|Qualitative assessment of TCC-COVID app usability via a subjective feedback questionnaire provided to all patients enrolled in the study.|Cost-effectiveness of TCC-COVID by measuring the incremental cost per death averted, per ICU admission averted and per length of stay in ICU|Rate of hospital bed days with COVID-19 diagnosis per 100,000 population, during trial period|Rate of ICU bed days with COVID-19 diagnosis per 100,000 population, during trial period|Qualitative assessment of KIOLA physician portal usability via a subjective feedback questionnaire""}"
"2382","Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients","COBETOX","NCT04463849","6/2020","Diagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04463849","Recruiting","2020-06-30","2021-06-30","{""locations"":""Sacco University Hospital, Milan, MI, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""90"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serum \u03b2 - cellular function index insulin levels|Serum \u03b2 - cellular function index C-peptide levels|Serum \u03b2 - cellular function HOMA-\u03b2 index|Serum \u03b2 - cellular function pro-insulin\/insulin ratio|Evaluation of the secretory response of insulin to the arginine stimulation test|Percentage of patients with preserved \u03b2 cells function|Glucose values|Values of continuous glucose monitoring|Changes in the inflammatory marker interleukin 1-\u03b2|Changes in the inflammatory marker interleukin IL-2|Changes in the inflammatory marker interleukin IL-6|Changes in the inflammatory marker interleukin IL-7|Changes in the inflammatory marker interleukin IL-10|Changes in the inflammatory marker tumor necrosis factor-\u03b1|Changes in the inflammatory marker interferon gamma|Changes in the inflammatory marker macrophage inflammatory protein-1\u03b2|Changes in the inflammatory marker monocyte chemoattractant protein-1|Changes in the inflammatory marker granulocyte-macrophage colony-stimulating factor|Changes in the inflammatory marker granulocyte colony-stimulating factor""}"
"2383","Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","COVID-PACT","NCT04409834","CCCTN/TIMI COVID-PACT","Drug: Unfractionated Heparin IV|Drug: Enoxaparin 1 mg/kg|Drug: Clopidogrel|Drug: Unfractionated heparin SC|Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04409834","Recruiting","2020-08-05","2021-05-01","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""750"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary endpoint: Venous or arterial thrombotic events|Key secondary endpoint: Clinically evident venous or arterial thrombotic events""}"
"2384","Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19)","","NCT04378712","JT202005LZ","Device: Hydrogen Oxygen Generator with Nebulizer|Other: Standard-of-care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04378712","Completed","2020-01-21","2020-03-23","{""locations"":""First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of patients with improved disease severity at day 2|The proportion of patients with improved disease severity at day 3|The proportion of patients with improved disease severity at the day before hospital discharge|The change from baseline in oxygen saturation at day 2.|The change from baseline in oxygen saturation at day 3.|The change from baseline in oxygen saturation at the day before hospital discharge|The change from baseline in dyspnea scale at day 2.|The change from baseline in dyspnea scale at day 3.|The change from baseline in dyspnea scale at the day before hospital discharge.|The change from baseline in cough scale at day 2|The change from baseline in cough scale at day 3|The change from baseline in cough scale at the day before hospital discharge|The change from baseline in chest pain scale at day 2.|The change from baseline in chest pain scale at day 3.|The change from baseline in chest pain scale at the day before hospital discharge.|The change from baseline in chest distress scale at day 2.|The change from baseline in chest distress scale at day 3.|The change from baseline in chest distress scale at the day before hospital discharge.""}"
"2385","Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients","","NCT04685447","CER Liguria: 135/20","Procedure: Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|Procedure: Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04685447","Recruiting","2020-03-16","2021-03-01","{""locations"":""Ospedale IRCCS San Martino, Genova, Italy|Policlinico IRCCS Ospedale San Matteo, Pavia, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Longitudinal changes of interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and interferon-gamma (IFN-\u03b3) plasma levels during Covid19 in hemodialysis patients|Longitudinal changes of soluble TLR4 (sTLR4) plasma levels during Covid19 in hemodialysis patients|Longitudinal changes of cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), cluster of differentiation 19 (CD19), natural killer (NK) lymphocyte count and function during Covid19 in hemodialysis patients""}"
"2386","PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients","","NCT04360837","COVID-19EIT","Procedure: alveolar recruitment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04360837","Recruiting","2020-05-06","2021-06-01","{""locations"":""University of Szeged, Szeged, Hungary"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""10"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in lung compliance|Change in global impedance|Change in recruitability|Gas exchange|Plateau pressure|End expiratory lung impedance (EELI)|Antero-to-posterior ventilation ratio|Center of ventilation|Global inhomogeneity index""}"
"2387","Sero-prevalence COVID-19 Among Belgian Children","SeCoBelChild","NCT04613817","SC_044A","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04613817","Recruiting","2020-12-03","2021-08-31","{""locations"":""Sciensano, Brussels, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1640"",""age"":""8 Years to 14 Years \u00a0 (Child)"",""outcome_measures"":""Change of prevalence of antibodies against SARS-CoV-2 among Belgian children aged 8-9 years|Change of prevalence of antibodies against SARS-CoV-2 among Belgian children aged 13-14 years|Change in SARS-CoV-2 seroconversion among among Belgian children aged 8-9 years|Change in SARS-CoV-2 seroconversion among among Belgian children aged 13-14 years|Potential risk factors for the infection|The proportion of asymptomatic cases among new cases that develop during a period of 7 months""}"
"2388","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia","","NCT04344548","UNAL FSA COVID","Biological: Allogeneic NK transfer","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04344548","Not yet recruiting","2020-04-13","2020-11-10","{""locations"":""Fundacion Salud De Los Andes, Bogot\u00e1, Bogot\u00e1 Distrito Capital, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse effects and Safety|NK transfer Immunogenicity""}"
"2389","MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain","","NCT04556565","2020/9203/I","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04556565","Recruiting","2020-05-08","2021-05-01","{""locations"":""Hospital Universitario Pr\u00edncipe Asturias, Alcal\u00e1 De Henares, Spain|Hospital Universitario Torrec\u00e1rdenas, Almer\u00eda, Spain|Ag\u00e8ncia de Salut P\u00fablica Barcelona, Barcelona, Spain|Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut d'Investigaci\u00f3n en Atenci\u00f3 Prim\u00e0ria, IDIAP Jordi Gol, Barcelona, Spain|Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Parc Sanitari Sant Joan de D\u00e9u, Barcelona, Spain|Psmar-Imim, Barcelona, Spain|Sistema de Emergencias M\u00e9dicas de Catalu\u00f1a, Barcelona, Spain|Hospital Universitario Cruces, Bilbao, Spain|Hospital El Bierzo, Le\u00f3n, Spain|Gerencia de Atenci\u00f3n Primaria de Madrid-FIIBAP, Madrid, Spain|Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Universitario Donostia, San Sebasti\u00e1n, Spain|Hospital Cl\u00ednic Universitari, Valencia, Spain|Hospital Universitario Araba-Santiago, Vitoria, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""16000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Post-traumatic stress disorder|Depression|Generalized Anxiety Disorder|Suicidal thoughts and behaviors|Alcohol and drug use problems|Panic attacks|Health-related Quality of Life|Overall Perceived Health|Role limitation""}"
"2390","Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults","","NCT04715997","GX-19N-HV-002","Drug: GX-19N","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04715997","Recruiting","2020-12-30","2022-03-30","{""locations"":""KyungHee University Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Hanyang University Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""170"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of Solicited Adverse Events|Incidence of Unsolicited Adverse Events|Incidence of Serious Adverse Events|GMT and GMFR of Antigen-specific Binding Antibody Titers|Percentage of Subjects Who Seroconverted After Vaccination|GMT and GMFR of Neutralizing Antibody Level|GMSN and GMFR of Spot Forming Unit (SFU) detected by IFN-gamma ELISPOT assay""}"
"2391","A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19)","FITE19","NCT04439071","PTC299-VIR-015-COV19|2020-001872-13","Drug: PTC299|Other: SOC|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04439071","Recruiting","2020-07-09","2021-07-31","{""locations"":""University of California, Irvine, Orange, California, United States|Augusta University, Augusta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Salisbury VA Medical Center, Salisbury, North Carolina, United States|University Hospitals Cleveland, Cleveland, Ohio, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Columbia VA Health Care System, Columbia, South Carolina, United States|Westmead Hospital, Westmead, New South Wales, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Sunshine Hospital, St. Albans, Victoria, Australia|Hospital Vera Cruz, Belo Horizonte, MG, Brazil|Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, SP, Brazil|Hospital Guilherme Alvaro, Santos, SP, Brazil|Hospital Santa Casa de Misec\u00f3rdia de Sorocoba, Sorocaba, SP, Brazil|Instituto de Infectologia Em\u00edlio Ribas, S\u00e3o Paulo, SP, Brazil|Real e Benem\u00e9rita Associa\u00e7\u00e3o Portuguesa de Benefic\u00eancia, S\u00e3o Paulo, SP, Brazil|Hospital Alemao Oswaldo Cruz, S\u00e3o Paulo, SP, Brazil|Escola Paulista de Medicina (UNIFESP), S\u00e3o Paulo, SP, Brazil|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""380"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time from Randomization to Respiratory Improvement|Percentage of Participants Requiring Invasive Ventilation|Percentage of Participants Requiring Supplemental Oxygen or Non-Invasive Ventilation in Participants who did not Require Supplemental Oxygen at Baseline|Time from Randomization to Defervescence in Participants Presenting With Fever at Enrollment (Temperature of \u226537.6\u2103 Axilla, \u226538.0\u2103 Oral, or \u226538.6\u00b0C Tympanic or Rectal)|Time from Randomization to Respiratory Rate \u2264 24 Breaths per Minute on Room Air|Time from Randomization to Cough Reported as Mild or Absent|Time from Randomization to Dyspnea Reported as Mild or Absent|Reduction of Immune Responses|Reduction in Viral Load|Duration of Hospitalization|Number of Mortalities|Number of Participants with Treatment-Emergent Adverse Events (TEAEs)""}"
"2392","FAvipiravir and HydroxyChloroquine Combination Therapy","FACCT","NCT04392973","RC20/174","Combination Product: Favipiravir and Hydroxychloroquine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04392973","Recruiting","2020-05-21","2021-11-01","{""locations"":""King Abdulaziz Hospital - Al Ahsa, Hasa, Eastern Region, Saudi Arabia|AlMadina General Hospital, Al Mad\u012bnah, Saudi Arabia|Al-Qatif Central Hospital, Al-Qatif, Saudi Arabia|Imam Abdulrahman Al Faisal Hospital - Dammam, Dammam, Saudi Arabia|King Abdulaziz Medical City, Jeddah, Saudi Arabia|King Abdulaziz Hospital - Makkah, Mecca, Saudi Arabia|King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia|Imam Abdulrahman Alfaisal Hospital, Riyadh, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""520"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Improvement|Viral shedding""}"
"2393","Parental Compliance After Telephone Triage Advice During and After Confinement During the COVID-19 Epidemic in France","COVIDTEL","NCT04656444","20-HPNCL-03","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04656444","Not yet recruiting","2021-04-01","2021-06-01","{""locations"":""H\u00f4pitaux P\u00e9diatrique de Nice CHU Lenval, Nice, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""parental compliance|parental anxiety""}"
"2394","Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.","DMMETCOV19-2","NCT04625985","SIL-30000-II-20(2)","Drug: Metformin Glycinate|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04625985","Recruiting","2020-07-14","2021-03-31","{""locations"":""The American British Cowdray Medical Center, I.A.P, Mexico City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load|consciousness level|temperature|systolic blood pressure|Oxigen saturation|Heart rate|respiratory rate|Days of hospitalization|Days of supplementary oxygen if applies|Days of supplementary mechanical ventilation|Toxicity of study drug assessed by incidence of adverse events (grade 3 or 4)|Changes in laboratory test results""}"
"2395","Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients","","NCT04592705","LCH-1-092020","Device: Therapeutic plasma exchange","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04592705","Recruiting","2020-09-11","2021-08-30","{""locations"":""Larkin Community Hospital, South Miami, Florida, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility"",""enrollment"":""10"",""age"":""18 Years to 69 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical status downgrade or discharge.""}"
"2396","Prospective Evaluation of the Predictive Criteria of Severity for Respiratory Infection Due to COVID-19 Virus","COPREG","NCT04615676","RC31/20/0141","Other: Follow-up phone call","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04615676","Completed","2020-04-27","2020-07-17","{""locations"":""University Hospital of Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4734"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Hospitalization""}"
"2397","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore","","NCT04350450","2020-11445","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04350450","Withdrawn","2020-04-01","2020-08-01","{""locations"":""Montefiore Medical Center, Bronx, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to resolution of symptoms|Number of days from onset of illness to symptom resolution|Number of days to return to work|Rate of hospital admission in treated and untreated healthcare workers|Adverse effect of HCQ during treatment""}"
"2398","Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic","COVID-PRONE","NCT04438941","7911","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04438941","Recruiting","2020-03-25","2020-06-20","{""locations"":""Service d'Anesth\u00e9sie-R\u00e9animation - Nouvel H\u00f4pital Civil, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Analysis of the effect of prone position in patients with covid-19 in intensive care""}"
"2399","Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","","NCT04445389","GX-19-HV-001","Drug: GX-19|Drug: Saline","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04445389","Recruiting","2020-06-17","2022-06-17","{""locations"":""Severance hospital, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""210"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of solicited adverse events|Incidence of unsolicited adverse events|Incidence of serious adverse events|Geometric mean titer (GMT) of antigen-specific binding antibody titers|Percentage of subjects who seroconverted after vaccination|Geometric mean titer (GMT) of neutralizing antibody level|Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers""}"
"2400","HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients","","NCT04516850","COVID19-GeneExp","Genetic: Expression of receptors and activating proteases|Genetic: Polymorphism of the HSD3B1","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04516850","Not yet recruiting","2020-09-01","2021-08-31","{""locations"":""Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland|Clinica Luganese Moncucco, Lugano, Switzerland"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Expression of receptors and activating proteases|Prevalencen of olymorphisms of the HSD3B1|Association of polymorphisms of the HSD3B1""}"
"2401","SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak","COVEMUZ","NCT04426292","COVEMUZ","Diagnostic Test: Serological testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04426292","Recruiting","2020-05-12","2021-05-12","{""locations"":""UZ Brussel, Jette, Brussel, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""3500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevalence|seroconversions|Incidence of definite cases|Incidence of probable cases|Antibody kinetics|Potential work-related risk factors|Proportion of asymptomatic seroconversions|Concerns for safety for infection with COVID-19""}"
"2402","NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE","GERONIMO 19","NCT04403269","P20/07 GERONIMO 19","Drug: IgIV","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04403269","Recruiting","2020-05-05","2021-05-05","{""locations"":""Centre Hospitalier de Versailles, Le Chesnay, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""35"",""age"":""75 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Mortality|Total number of days of full hospitalization|Duration of oxygen therapy|Ferritin level in the blood|CRP level in the blood|LDH level in the blood|Lymphocyte level in the blood|PNN level in the blood|platelet level in the blood|WHO performance index|WHOQOL-OLD questionnaire|Lung function by pulmonary computed tomography|Lung function by EFR|Readmission Rates""}"
"2403","Hydrogen-oxygen Gas Mixture Inhalation in Patients With Convalescent Coronavirus Disease 2019 (COVID-19)","","NCT04594460","AMS-H-03-101","Device: Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Device: OLO-1 Medical Molecular Sieve Oxygen Generator","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04594460","Not yet recruiting","2020-10-31","2021-12-31","{""locations"":""Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China|First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""198"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""(VO2max)|(VE \/VCO2)|(VE \/VO2)|(VO2 \/HR)|(P (A-a) O2)|(P (a-et) CO2)|maximum exercise power|RER|The change from baseline in total exercise duration at maximum exercise load at Week 4 of treatment.|The change from baseline in total exercise duration at maximum exercise load at Week 8 of treatment.|The change from baseline in total exercise duration at maximum exercise load at Week 12 of treatment.|(SpO2)|(mMRC)""}"
"2404","Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19","","NCT04423640","R-2020, 3601-043","Other: Active COVID-19 disease","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04423640","Recruiting","2020-04-15","2020-08-15","{""locations"":""UMAE Hospital de Especialidades del Centro M\u00e9dico Nacional Siglo XXI, IMSS., M\u00e9xico, Ciudad De M\u00e9xico, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Serum levels of cytokines and chemokines|Viral load|Immunophenotype of myeloid cells|RBD-SARS-CoV Protein S- antibodies|Analysis of cellular immune response|Hematopoietic stem cells and progenitor cells populations in peripheral blood|Questionnaire of Sociodemographic, labor, pathological and personal characteristics|SOFA (Secuential Organ Failure Assessment Score)|Fibrinogen|C-Reactive protein""}"
"2405","Blood Volume Assessment in COVID-19 ICU Patients - BVAC19","","NCT04517695","20-00896","Device: BVA-100","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04517695","Recruiting","2020-08-01","2021-02-01","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total blood volume (absolute and relative to ideal body weight)|Red blood cell volume (absolute and relative to ideal body weight)|Plasma volume (absolute and relative to ideal body weight)|Transudation rate of the 131I albumin tracer|Incidence of new onset renal injury (failure) and requirement for renal replacement therapy""}"
"2406","Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation","AVoCaDO","NCT04357782","Davis 001","Drug: L-ascorbic acid","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04357782","Completed","2020-04-16","2020-10-13","{""locations"":""Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events|Incidence of serious adverse reactions|Incidence of adverse reactions|Ventilator-free days|ICU-free days|Hospital-free days|All-cause mortality|Change in S\/F ratio during HDIVC infusion|C-reactive protein (CRP)|Lactate dehydrogenase (LDH)|D-dimer|Lymphocyte count|Neutrophil to Lymphocyte ratio (NLR)|Serum Ferritin""}"
"2407","Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel","","NCT04466462","COVID-Hosp","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04466462","Completed","2020-05-26","2020-06-30","{""locations"":""Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital Municipal de Badalona, Badalona, Barcelona, Spain"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Other"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with past SARS-CoV-2 infection|Number of infections in health personnel who have taken voluntary hydroxychloroquine as a prevention strategy for COVID-19 infection|Number of infections in health personnel based on the degree of exposure to patients infected with COVID-19.|Number of infected participants who are active smokers and\/or have chronic lung disease and\/ or have history of hypertension.Relationship of degree of exposure to participants infected with SARS-CoV-2 admitted to the hospital.Professional category.|Number of participants infected with SARS-CoV-2 that presented symptoms and their grade. Number of participants infected with SARS-CoV-2 who required hospitalization. Number of participants infected with SARS-CoV-2 who received treatment.|Number of family members infected from each participant with SARS-CoV-2 infection""}"
"2408","Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19","","NCT04555005","Mind-COVID-19","Other: Mindfulness based intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04555005","Completed","2020-03-10","2020-04-26","{""locations"":""La Paz University Hospital, Madrid, Spain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Perceived helpfulness to reduce current stress""}"
"2409","Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial","SAINT","NCT04390022","SAINT","Drug: Ivermectin|Drug: Placebo","Interventional","Has Results","Phase 2","https://ClinicalTrials.gov/show/NCT04390022","Completed","2020-07-31","2020-10-09","{""locations"":""Clinica Universidad de Navarra, Pamplona, Navarra, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Proportion of Patients With a Positive SARS-CoV-2 PCR|Median Viral Load|Fever and Cough Progression|Seroconversion at Day 21|Proportion of Drug-related Adverse Events|Levels of IgG, IgM and IgA|Frequency of Innate Immune Cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells|Results From Cytokine Human Magnetic 30-Plex Panel""}"
"2410","Outpatient Treatment With CoVid-19 With Prexablu","","NCT04619290","064.I.2020","Drug: Sublingual Methylene blue|Other: Control patients","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04619290","Recruiting","2020-10-12","2020-12-30","{""locations"":""Hospital Regional Lic Adolfo Lopez Mateos, Mexico City, Ciudad De Mexico CDMX (Mexico City), Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""46"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change form baseline in Arterial oxygen saturation|Days to clinical improvement|Change Form Baseline in C reactive protein at 7 days|Change Form Baseline in IL-1\u03b2|Change Form Baseline in Erythrocyte sedimentation rate like procalcitonin|Change Form Baseline in Ferritin levels|Change Form Baseline in D dimer""}"
"2411","Evaluation of Covid 19 Anxiety in Endometriosis Patients","","NCT04337346","endocovid19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337346","Completed","2020-04-05","2020-04-25","{""locations"":""Pinar Yalcin Bahat, Istanbul, \u0130\u0307stanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Covid 19 Anxiety levels in Endometriosis Patients""}"
"2412","Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia","PaTS-COVID","NCT04703608","LEO 22628","Drug: Ivermectin|Drug: ASP|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04703608","Recruiting","2021-01-22","2022-07-01","{""locations"":""Mrcg@Lshtm, Fajara, Gambia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""1200"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Cohort 1 Index Case: Percentage of patients with COVID-19 associated mild disease\/moderate pneumonia progressing to severe pneumonia [Time frame 14 days]|Cohort 1 Household contacts: Percentage of HH members that get infected with SARS-CoV-2 [Time frame 14 days]|Cohort 2: Percentage of COVID-19 associated severe pneumonia patients worsening their condition [Time frame at discharge or day 28 (whichever is first)]|Cohort1 Index cases: Days from recruitment to virological clearance [Time frame 28 days]|Days from recruitment until clinical recovery|- IgG geometric mean titre (GMT) at day 14 and 28 after recruitment [Time frame 14 days and 28 days]|Household contacts IgG geometric mean titre (GMT) at day 14 after recruitment [Time frame 14 days]|Percentage of HH members infected that develop COVID19 symptoms [Time frame 14 days]|Cohort 2 - Hours from recruitment to hospital discharge [Time frame at discharge]|- Hours of duration on oxygen supplementation [Time frame at discharge or day 28 (whichever is first)]|- Death ratio during hospitalization [Time frame at time of death]|- Death ratio at 28 days after enrolment [Time frame 28 days]|- Death ratio at 90 days after enrolment [Time frame 90 days]|- Occurrence of clinical thrombotic and embolic events (myocardial infarction, pulmonary embolus, deep venous thrombosis, cerebrovascular accidents). [Time frame 90 days]|- Occurrence of clinical episodes of gastrointestinal bleeding [Time frame 90 days]|- Change in CRP and D-Dimer levels between baseline (enrolment) and day 3-5 [Time frame 5 days]|- Persisting breathlessness at 28 days and 90 days after enrolment [Time frame 28 days\/90 days ]|- Self-reported health at 28 days and 90 days [Time frame 28 days\/ 90 days]""}"
"2413","COVID19-FOIE National Observatory","","NCT04375670","IRB00006477","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375670","Recruiting","2020-05-11","2020-12-31","{""locations"":""Ganne, Bondy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1000"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate related to Covid-19 in patients with a chronic liver disease|mortality rate according the stage of fibrosis and the cirrhotic status|mortality related to Covid-19 according an history of hepatocellular carcinoma, an immunosuppressive treatment and this type the etiology-ies of liver disease at the infection and comorbidities.|Incidence of liver complications""}"
"2414","Study Project Comparing the Sequelae of SARS-CoV-2 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical Care","COMEBAC","NCT04704388","COMEBAC","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04704388","Recruiting","2020-06-01","2021-01-01","{""locations"":""Bic\u00eatre Hospital, Le Kremlin-Bic\u00eatre, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""830"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""post-intensive care syndrome (PICS)|Evaluate the 3-month mortality of patients released alive from intensive care|Describe the overall state of health and the main organ sequelae of these patients|functional respiratory sequelae""}"
"2415","Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.","","NCT04415879","20-538","Device: N-95 Respirator|Device: Cloth Face Mask|Diagnostic Test: Graded exercise test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04415879","Completed","2020-06-01","2020-08-01","{""locations"":""Cleveland Clinic, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Exercise Capacity""}"
"2416","Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency","COVIT-D","NCT04403932","20/428-E_COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403932","Completed","2020-04-17","2020-08-01","{""locations"":""Hospital Cl\u00ednico San Carlos, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""severe COVID-19""}"
"2417","C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19","","NCT04537975","CP-01-004","Device: C2Rx|Other: Standard of Care (SOC)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04537975","Withdrawn","2020-09-15","2021-01-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pulmonary Oxygenation Function|Pulmonary Compliance of Respiratory System (CRS)|Survival|Hospital Costs 1|Cardiovascular Vasoactive-Inotropic Score (VIS)|Hospital Costs 2|Hospital Costs 3|Hospital Costs 4|Hospital Costs 5""}"
"2418","Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.","","NCT04552340","2485","Other: Patient with SAR-CoV-2 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04552340","Recruiting","2020-03-16","2023-07-01","{""locations"":""Humanitas Research Hospital, Rozzano, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality predictors in patients with Respiratory Failure who require oxygen therapy in the Intensive Care Unit or ventilatory support.|Molecular profile of cell populations present in the BAL at early timepoint during SARS-CoV2 infection to predict severity of disease progression.|Type of possible complications such as AKI (Acute Kidney Injury) , infection, shock|SARS-CoV2 mechanisms of infection in alveolar macrophages|SARS-CoV2 genotypes in a cohort of patients representative of the Lombardy population|Number of successful respiratory weaning""}"
"2419","Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic: A Prospective Randomized Trial","","NCT04652674","STUDY00000944","Behavioral: Telemedicine visit|Behavioral: In-person postoperative visit","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04652674","Recruiting","2020-09-28","2021-06-30","{""locations"":""Cedars Sinai Medical Center, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""70"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient satisfaction|Safety score|Length of visit|Patient willingness to recommend provider to peers rated from 1 to 5|Combined patient satisfaction score from 1st and 2nd postoperative visits|Distance (in kilometers) of patient's primary residence to the clinic location""}"
"2420","Convalescent Plasma for Patients With COVID-19","","NCT04385199","13807","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04385199","Recruiting","2020-05-04","2020-08-01","{""locations"":""Henry Ford Hospital, Detroit, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement in respiratory disease|ICU Length of Stay|Length of Stay|Ventilator days|Tolerability of convalescent plasma|Radiographic improvement""}"
"2421","Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","","NCT04450004","CP-PRO-COVLP-019","Biological: Intramuscular Vaccine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04450004","Active, not recruiting","2020-07-10","2021-12-31","{""locations"":""Syneos Health, Montr\u00e9al, Quebec, Canada|Syneos Health, Qu\u00e9bec, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""180"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Immediate adverse event (AEs)|Solicited local and systemic adverse events (AEs)|Unsolicited adverse events (AEs)|Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths|Safety labs|Neutralizing antibody (Nab assay) response|Specific Th1 cell-mediated immunity (CMI) response|Specific Th2 cell-mediated immunity (CMI) response|Specific antibody response induced by the vaccine against the SARS-CoV-2 virus measured by total IgG and\/or IgM levels|Neutralizing antibody (Nab assay) response induced by the treatment groups against the SARS-CoV-2 virus|Specific Th1 cell-mediated immunity (CMI) response induced by the vaccine against the SARS-CoV-2 virus|Specific Th2 cell-mediated immunity (CMI) response induced by the vaccine against the SARS-CoV-2 virus""}"
"2422","Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19","CoCovSDRA","NCT04586114","2020PI109","Drug: Corticosteroids and Derivatives","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04586114","Active, not recruiting","2020-03-01","2020-12-31","{""locations"":""Hopital Central, Service de Reanimation Medicale, Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality in ICU|Mortality d28|acquired infections incidence|antibiotics duration|mechanical ventilation duration""}"
"2423","Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Adult Population In Peru","Cov-Peru","NCT04612972","UPeruanaCH","Biological: Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04612972","Recruiting","2020-09-10","2021-09-01","{""locations"":""Av. Honorio Delgado 430, Urb. Ingenier\u00eda, San Martin De Porres, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""6000"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Primary endpoint|Secondary endpoint|Safety endpoints""}"
"2424","A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","","NCT04405570","EIDD-2801-2003","Drug: EIDD-2801|Drug: Placebo (PBO)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04405570","Completed","2020-06-16","2021-02-21","{""locations"":""Benchmark Research, Colton, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|FOMAT Medical Research, Oxnard, California, United States|Indago Research and Health Center, Inc., Hialeah, Florida, United States|NOLA Research, New Orleans, Louisiana, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Duke, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Care United Research, LLC, Forney, Texas, United States|Laguna Clinical Research, Laredo, Texas, United States|Fred Hutch, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""204"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virologic Efficacy|Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach|Number of Participants With any Adverse Events (AEs), Grade 2 or higher as Assessed by Kaplan Meier Approach""}"
"2425","Acceptability of a COVID-19 Vaccine Among US Adults Over Two Time Periods","","NCT04703790","AAAT5154","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04703790","Not yet recruiting","2021-02-01","2022-08-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intention to get vaccinated for COVID-19|COVID-19 vaccination received""}"
"2426","RGD PET/CT Imaging in COVID-19 Patients","","NCT04596943","NL73551.091.20|2020-001325-31","Diagnostic Test: [68Ga]Ga-DOTA-(RGD)2 PET/CT","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04596943","Recruiting","2020-10-15","2021-01-30","{""locations"":""Radboudumc, Nijmegen, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""uptake of [68Ga]Ga-DOTA-(RGD)2 in the lung parenchyma|spatial correlation with chest-CT|spatial correlation with CT-subtraction|quantitative correlation with laboratory results|explore correlation with clinical parameters""}"
"2427","Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2","","NCT04382950","COV-2019 Treatment This is","Combination Product: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04382950","Not yet recruiting","2020-07-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Time course of body temperature (fever)|Viral load over time|P\/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Interleukin 6 (IL-6) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-\u03b1 (TNF-\u03b1) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Frequency of adverse events and severe adverse events""}"
"2428","Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).","CoVIHDis","NCT04526977","EC 273/20","Diagnostic Test: Immune response study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04526977","Recruiting","2021-01-10","2021-09-30","{""locations"":""Hospital Ramon y Cajal, Madrid, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""90"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in immune cellular response""}"
"2429","Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","","NCT04366245","PC/COVID-19","Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04366245","Recruiting","2020-04-23","2021-12-01","{""locations"":""Hospital U. Jerez de la Frontera, Jerez de la Frontera, C\u00e1diz, Spain|Hospital U. Puerto Real, Puerto Real, C\u00e1diz, Spain|Hospital Costa del Sol, Marbella, M\u00e1laga, Spain|Hospital U. Torrec\u00e1rdenas, Almer\u00eda, Spain|Hospital U. Puerta del Mar, C\u00e1diz, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. San Cecilio, Granada, Spain|Hospital Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain|Hospital Regional U. de M\u00e1laga, M\u00e1laga, Spain|Hospital U. Virgen de la Victoria, M\u00e1laga, Spain|Hospital Unversitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain|Hospital U. Nuestra Se\u00f1ora de Valme, Sevilla, Spain|Hospital San Juan de Dios, Sevilla, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""72"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale \u2265 3 after 72 hours of randomization or an increase of 2 points or more from the basal level|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure \/ clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients requiring treatment.|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.""}"
"2430","The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors","","NCT04551378","2020-0504|NCI-2020-06609","Other: Quality-of-Life Assessment|Other: Survey Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04551378","Recruiting","2020-07-13","2021-12-31","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years to 39 Years \u00a0 (Adult)"",""outcome_measures"":""Coronavirus disease 2019 (COVID-19) specific psychological stress|Survey responses|Patient reported outcomes|Changes of survey responses|Changes in discrete responses|Incidence of survey question non-response""}"
"2431","Extracellular Vesicle Infusion Therapy for Severe COVID-19","EXIT COVID-19","NCT04493242","DB-001","Biological: DB-001","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04493242","Not yet recruiting","2020-09-01","2020-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""all-cause mortality|median days to recovery""}"
"2432","Synthetic CBD as a Therapy for COVID-19","","NCT04686539","SHEBA-20-7526-HA-CTIL","Drug: CBD|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04686539","Not yet recruiting","2020-12-20","2022-01-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical deterioration|Changes in NEWS scale|Supportive care therapies|SARS-COV2 presence|Hospitalization Days|Cytokine Levels|Hamilton Anxiety Score""}"
"2433","Lift Mobile Mindfulness for COVID-19 Distress Symptoms","LIFTCOVID","NCT04581200","Pro00106306|3U01AT009974-03S1","Behavioral: Lift","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04581200","Recruiting","2021-01-25","2021-09-30","{""locations"":""University of Colorado - Denver, Aurora, Colorado, United States|University of Michigan, Ann Arbor, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health & Sciences University, Portland, Oregon, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Patient Health Questionnaire-9 Item scale (PHQ-9)|Change in Generalized Anxiety Disorder 7-item scale (GAD-7)|Change in EuroQOL-5DL scale|Cardiopulmonary symptoms""}"
"2434","FEnofibRate as a Metabolic INtervention for COVID-19","FERMIN","NCT04517396","843729","Other: Fenofibrate/fenofibric acid|Other: Placebo|Other: Usual care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04517396","Enrolling by invitation","2020-08-18","2021-10-31","{""locations"":""University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hierarchical composite endpoint|Number of days alive, out of the intensive care unit, free of mechanical ventilation\/extracorporeal membrane oxygenation, or maximal available respiratory support in the 30 days following randomization|Seven-category ordinal scale""}"
"2435","Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19","COVID-19","NCT04490486","20200575","Biological: UCMSCs|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04490486","Not yet recruiting","2021-09-01","2024-06-01","{""locations"":""University of Miami, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""21"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent of participants with treatment related Serious Adverse Events (SAE)|Change in inflammatory marker levels|Change in systemic inflammatory marker levels|COVID-19 Viral Load|Change in SOFA score|Change in electrolytes levels|Change in LDH levels|Number of subjects discharged from the ICU|Percentage of participants with less requirement for vasoactive agents|Rate of Mortality|Percentage of participants with changes in immune marker expression|Percentage of participants with changes in radiologic findings|Percentage of participants with less pneumonia symptoms""}"
"2436","COVID-19 Outbreak Consequences for Outpatients Followed in PRM","Handicall","NCT04384406","RECHMPL20_0262","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384406","Completed","2020-04-01","2020-05-09","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""467"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients necessitating the scheduling of a medical consultation|the reason for this urgent need of a medical consultation|the access to other medical services during the quarantine period|the interruption of home-based rehabilitation services""}"
"2437","COVID-19 IgG Formation in Physicians at ALGH and Their Household Members","","NCT04540484","1606472-1|M5500436","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04540484","Recruiting","2020-08-26","2021-09-24","{""locations"":""Advocate Lutheran General Hospital, Park Ridge, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identifying positive COVID-19 IgG formation|Physician Prevalence of COVID-19 serum IgG|Household Member Prevalence of COVID-19 serum IgG|Physician Risk of Exposure|Physician and Household Member Transmission|Asymptomatic Infection|PPE Use and Positivity|Antibody Persistence""}"
"2438","Compassionate Use of REGN-COV2 for the Treatment of COVID-19","","NCT04617535","R10933-10987-COV","Drug: REGN10933+REGN10987 combination therapy","Expanded Access:Individual Patients","No Results Available","","https://ClinicalTrials.gov/show/NCT04617535","Available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""""}"
"2439","Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults","","NCT04617483","PRO-nCOV-3001","Biological: Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04617483","Recruiting","2020-10-31","2021-05-31","{""locations"":""Dafeng District Center for Disease Prevention and Control, Yancheng, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1040"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immunogenicity index-geometric mean titer(GMT) of neutralizing antibody|Immunogenicity index-Seroconversion rate of the neutralizing antibody|Immunogenicity index-Seropositive rate of the neutralizing antibody|Safety index-Incidence of adverse reactions|Safety index-Incidence of serious adverse events""}"
"2440","Clinical Trial of Favipiravir Treatment of Patients With COVID-19","","NCT04600999","HUN-AVI-01","Drug: Favipiravir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04600999","Recruiting","2020-10-07","2021-06-01","{""locations"":""Department of Pulmonology Semmelweis University, Budapest, Hungary|National Kor\u00e1nyi Institute for Pulmonology, Budapest, Hungary|Institute of Infectology, University of Debrecen, Debrecen, Hungary|1st Department of Medicine, University of P\u00e9cs, P\u00e9cs, Hungary|First Department of Internal Medicine, University of Szeged, Szeged, Hungary"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 74 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to improvement in body temperature|Time to improvement in SpO2|Time to improvement in chest imaging findings|Time to improvement in negative SARS-CoV-2|(1) Changes in patient status on a 5-point scale|(2) Changes in the level of SARS-CoV-2 viral genome|(3) SARS-CoV-2 virus genome clearance rate|(4) Duration of pyrexia|(5) Changes in clinical symptoms|(6) Changes in NEWS (National Early Warning Score)|(7) Changes in chest imaging findings on Days 4,7,10,13,16,19,22,25,28.|(8) Percentage of patients requiring adjuvant oxygen therapy|(8) Adjuvant oxygen therapy average duration|(9) Percentage of patients requiring mechanical ventilation therapy|(9)Adjuvant oxygen therapy average durationduration""}"
"2441","Will Hydroxychloroquine Impede or Prevent COVID-19","WHIP COVID-19","NCT04341441","1410401","Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04341441","Terminated","2020-04-07","2020-12-15","{""locations"":""Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""624"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.|Determine the effect of hydroxychloroquine dose in the prevention of COVID-19 viremia and disease.|Assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention.|Comparison of the rate of SARS-CoV 2 infections as measured by IgM\/IgG seroconversion in study participants receiving randomized HCQ versus placebo.|Compare the seroprevalence of SARS-CoV 2 IgM\/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo.|Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.|To examine the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.|Determine the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events.|To examine other clinical determinants contributing to the risk of SARS-CoV 2 infection in healthcare workers and first responders.|Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results.|identify immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease.""}"
"2442","The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications","","NCT04435015","2000028279","Drug: Camostat Mesylate|Drug: Microcrystalline Cellulose, NF","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04435015","Not yet recruiting","2021-02-01","2021-07-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent change in plasma D-Dimer|Overall Safety and adverse event|Change in plasma Fibrinogen levels|Change in plasma troponin|New onset cardiomyopathy|Duration of intubation|Length of stay in the intensive care unit|Time to discharge from hospital|Occurrence of major adverse cardiovascular events""}"
"2443","Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection","","NCT04603664","FMASU P82b/2020","Diagnostic Test: serum NGAL and cystatin c","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04603664","Recruiting","2020-10-30","2021-03-01","{""locations"":""Ainshams hospitals, Cairo, Egypt|Sanaa Wasfy, New Cairo, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""88"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""measure both cystatin c and Neutrophil gelatinase-associated lipocalin every other day for 3 times (NGAL) as recent biomarkers in prediction of AKI in patients with COVID-19.|development of acute kidney injury lipocalin (NGAL) to AKI severity and prognosis of AKI in patients with COVID-19 infection""}"
"2444","Stress and Recovery in Frontline COVID-19 Workers","","NCT04713111","4UCOVID1901","Behavioral: Lifestyle (Meditation)|Behavioral: Lifestyle (Exercise)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04713111","Completed","2020-05-04","2020-11-30","{""locations"":""4YouandMe, Seattle, Washington, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""383"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Study Retention|Daily survey\/task adherence|Oura adherence|Garmin adherence""}"
"2445","Correlation Fear of COVID-19 & Dental Treatment Anxiety","","NCT04497818","QassimU2","Other: Cross Sectional study using scientifically validated psychometric Scales","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497818","Completed","2020-06-16","2020-07-25","{""locations"":""Dr Bugude Shiva Shankar, Ar Rass, Al Qassim, Saudi Arabia"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""385"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fear of COVID-19 infection|Dental Anxiety|Correlation of Fear of COVID-19 infection & Dental Anxiety|Correlation of the nearest Dental treatment seeking time and Fear of COVID-19 infection.|Correlation of the nearest Dental treatment seeking time and Dental Anxiety|Correlation of the Age and Fear of COVID-19 infection|Correlation of the Age and Dental Anxiety.""}"
"2446","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","","NCT04369365","OnCoVID-19 Trial","Drug: Azithromycin 500 milligram (mg) oral Tablet|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04369365","Recruiting","2020-04-27","2020-12-27","{""locations"":""AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections|Number of severe COVID-19 cases|Severity of COVID-19 cases|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of viral and bacterial infections|Number of participants with azithromycin-resistant bacterial strains in nasal swabs test""}"
"2447","Prognostic Value of Flow-mediated Dilation in Hospitalized COVID-19 Patients","","NCT04714125","FMDCOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04714125","Recruiting","2020-06-19","2022-06-01","{""locations"":""Hospital das Cl\u00ednicas da Faculdade de Medicina da USP - HCFMUSP, Sao Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite outcome|All-cause mortality|ICU admission|Intubation|Cardiovascular complications""}"
"2448","COVID-19 Pandemic and Parents of Disabled Children","","NCT04525742","105","Other: Difficulties lived by disabled children's parents in the period of COVID-19 pandemic","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04525742","Completed","2020-07-05","2020-09-15","{""locations"":""Health Science University Gaziosmanpasa Training and Research Hospital, \u0130stanbul, Gaziosmanpasa, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""309"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A questionnaire that we created will be used to determine the difficulties experienced by disabled children's parents during Covid 19 pandemic related to their medical follow-up|The Fear of COVID-19 Scale""}"
"2449","Anti-SARS Cov-2 T Cell Infusions for COVID 19","BATIT","NCT04401410","H-47739 BAT IT","Biological: Dose Finding Phase (MTD)|Biological: Partially HLA-matched SARS-CoVSTs|Other: Routine care (no SARS-CoVSTs)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04401410","Recruiting","2020-11-04","2021-08-15","{""locations"":""Houston Methodist Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""58"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dose Escalation Phase: Rate of Dose Limiting Toxicities by CTCAE 5.0 [14 days post infusion]|Randomized Trial: Rate of Clinical Response as assessed by the World Health Organization (WHO) Ordinal Scale [7 days post-randomization or hospital discharge]|Randomized Trial: Rate of Treatment-related adverse events (tAE) by CTCAE 5.0 [14 days post-randomization]""}"
"2450","Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic","","NCT04500600","2020-0473|NCI-2020-04604","Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04500600","Recruiting","2020-06-11","2021-07-01","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""50000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Experiences during the coronavirus disease 2019 (COVID-19) pandemic|COVID-19-specific psychological distress|COVID-19-specific health|COVID-19-specific financial and social disruptions|COVID-19-specific perceived benefits and social support|COVID-19-specific health related quality of life (HRQoL)|Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL""}"
"2451","Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19","RUXO-COVID","NCT04477993","32894720.3.0000.0068","Drug: Janus Kinase Inhibitor (ruxolitinib)|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04477993","Recruiting","2020-07-17","2021-12-31","{""locations"":""Hospital das Cl\u00ednicas, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A composite outcome of death or ICU admission or mechanical ventilation at day 14.|A composite outcome of death or ICU admission or mechanical ventilation at day 28|Time to treatment failure|Overall survival at days 14 and 28|Cumulative incidence of ICU admission rate at days 14 and 28|Cumulative incidence of mechanical ventilation at days 14 and 28|Duration of hospital stay|Duration of ICU stay|Duration of mechanical ventilation|Duration of non-invasive ventilation|Secondary hemophagocytic syndrome rate|Cumulative incidence nosocomial infection rate at days 14 and 28|Incidence of discontinuation of oxygen supplementation at days 14 and 28|Rate of grade 1-2 and 3-5 emerging adverse events at day 28|Cumulative dose of methylprednisolone at days 14 and 28|Change in PaO2\/FiO2 ratio from baseline to days 14 and 28|Change in interleukin 6 levels [pg\/mL] from baseline to days 14 and 28|Change in d-dimer levels [ng\/mL] from baseline to days 14 and 28|Change in fibrinogen levels [mg\/dL] from baseline to days 14 and 28|Change in ferritin levels [ng\/mL] from baseline to days 14 and 28|Change in C reactive protein levels [mg\/L] from baseline to days 14 and 28|Change in alanine aminotransferase [U\/L] from baseline to days 14 and 28|Change in aspartate aminotransferase [U\/L] from baseline to days 14 and 28|Change in creatinine levels [mg\/dL] from baseline to days 14 and 28|Change in glucose levels [mg\/dL] from baseline to days 14 and 28|Change in hemoglobin levels [g\/dL] from baseline to days 14 and 28|Change in platelet count [x10\u02c63\/mm\u02c63] from baseline to days 14 and 28|Change in absolute neutrophil count [x10\u02c63\/mm\u02c63] from baseline to days 14 and 28|Change in absolute neutrophil count [\/mm\u02c63] from baseline to days 14 and 28|Change in absolute lymphocyte count [\/mm\u02c63] from baseline to days 14 and 28|Change in prothrombin time ratio from baseline to days 14 and 28|Change in partial thromboplastin time ratio from baseline to days 14 and 28|Change in bilirubin [mg\/dl] from baseline to days 14 and 28|Change in lactate dehydrogenase [U\/L] from baseline to days 14 and 28|Change in CPK-MB [ng\/mL] from baseline to days 14 and 28|Change in troponin [ng\/mL] from baseline to days 14 and 28|Change in von Willebrand factor antigen level (VWF:Ag) [%] from baseline to days 14 and 28|Change in von Willebrand factor activity (ristocetin cofactor) [%] from baseline to days 14 and 28|Change in ADAMTS-13 [%] from baseline to days 14 and 28|Change in von Willebrand multimeters from baseline to days 14 and 28|Change in plasminogen activator inhibitor-1 levels [ng\/mL] from baseline to days 14 and 28|Change in E-selectin levels [ng\/mL] from baseline to days 14 and 28|Change in P-selectin levels [ng\/mL] from baseline to days 14 and 28|Change in endothelin [fmol\/mL] from baseline to days 14 and 28|Change in circulating microparticles from baseline to days 14 and 28|Change in thromboelastography from baseline to days 14 and 28""}"
"2452","Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient","BIOCOVU","NCT04341792","2020_33|2020-A00906-33","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341792","Recruiting","2020-04-11","2021-04-01","{""locations"":""H\u00f4pital Roger Salengro, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of secondary aggravation|Change of standart biological parameters|Change of Von willebrand factor (vWF) changes over time|Change of the Factor VIII (FVIII)|Prevalence of positivity of COVID-19 virus measured by PCR or serology""}"
"2453","Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)","CYCLOVID","NCT04608214","APHP200552|2020-002295-13","Drug: Alisporivir|Other: Standard of care (SOC)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04608214","Not yet recruiting","2020-11-01","2021-08-04","{""locations"":""Assistance Publique H\u00f4pitaux de Paris - CHU Henri Mondor, Cr\u00e9teil, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SARS-CoV-2 viral load in nasopharyngeal swabs|Viral Load Response Rate (VLRR)|Percentage of patients reporting each severity rating on an 8-point ordinal scale.|Change in National Early Warning Score scale|Changes in thoracic CT scan|Percentage of patients admitted to Intensive Care Unit (ICU)|Time to admission to Intensive Care Unit (ICU)|Percentage of patients requiring mechanical ventilation|Percentages of patients negative for SARS CoV 2 RNA in nasopharyngeal swabs|Time to negative viral load|Time to resolution of symptoms|Duration of need for supplemental oxygen|Duration of hospitalisation|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or ECMO use|Number of non-invasive ventilation\/high flow oxygen free days|Number of oxygenation free days|Patient all-cause mortality|Cumulative incidence of any AE|Cumulative incidence of Grade 3 and 4 AEs|Cumulative incidence of SAEs""}"
"2454","Semen Parameters and COVID-19 in Infertile Men","","NCT04643522","E1-20-1237","Other: Clinical assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04643522","Completed","2020-01-07","2020-10-10","{""locations"":""Ankara City Hospital, Ankara, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""21"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Semen analyses parameters including sperm motility (total, progressive, non-progressive and immotile|Semen analyses parameters including sperm concentration|Semen analyses parameters including sperm morphology|Semen analyses parameters including semen volume|Sex-related hormone levels including testosterone|Sex-related hormone levels including follicle stimulating hormone and luteinizing hormone""}"
"2455","Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","VOCOVID","NCT04701528","NL73762.058.20","Drug: Voclosporin|Drug: Tacrolimus","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04701528","Recruiting","2020-11-15","2022-10-25","{""locations"":""Leiden University Medical Center, Leiden, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to viral clearance of SARS-CoV-2|Time to 2 consecutive negative RT-qPCR tests with CT-value >37|Time to reduction in viral load|Time to 2 consecutive negative RT-qPCR tests with CT-value >24|Time to clinical recovery|Time to clinical symptom relief|Time to hospital discharge|Occurrence of treatment failures""}"
"2456","Camostat With Bicalutamide for COVID-19","COMBO","NCT04652765","COV2005|IRB00254142","Drug: Camostat Mesilate|Drug: Bicalutamide 150 mg","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04652765","Recruiting","2021-02-03","2023-01-01","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants requiring hospitalization|Number of participants experiencing symptoms|Number of drug-related adverse events|Number of drug-related serious adverse events|All-cause mortality""}"
"2457","Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)","","NCT04554992","00025121","Biological: COVID 19 Convalescent Plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04554992","Active, not recruiting","2020-03-20","2022-06-01","{""locations"":""Houston Methodist Hopsital, Houston, Texas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of serious adverse events related to the treatment intervention.|Mortality at Day 28 post-hospital admission.|Length of hospital stay|Length of supplemental oxygen requirement.|Length of mechanical ventilation requirement.|Length of ICU stay""}"
"2458","COVID-19 in Patients With Anosmia in Egypt","","NCT04473157","FMASU P45a/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473157","Completed","2020-07-01","2020-12-30","{""locations"":""Ain Shams University, Cairo, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""58"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recovery from Anosmia|Seroconversion|COVID 19""}"
"2459","Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults","PassItOn","NCT04362176","200738|3UL1TR002243-04S3","Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04362176","Recruiting","2020-04-24","2021-04-01","{""locations"":""University of Arizona, Phoenix, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Scripps Health, La Jolla, California, United States|University of Colorado Denver, Aurora, Colorado, United States|MedStar Health Research Institute\/MedStar Washington Hospital Center, Washington, District of Columbia, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States|University of Maryland, Baltimore (University of Maryland Medical Center), Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellelsey Hospital, Newton, Massachusetts, United States|Mercy Health Muskegon, Muskegon, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|University at Buffalo\/Buffalo General Medical Center, Buffalo, New York, United States|Rochester General Hospital, Rochester, New York, United States|The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Utah Valley Hospital, Provo, Utah, United States|University of Utah Health, Salt Lake City, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 7-point Ordinal Clinical Progression Outcomes Scale|All-location, all-cause 14-day mortality|All-location, all-cause 28-day mortality|Survival through 28 days|Time to hospital discharge through 28 days|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 3|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 8|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 29|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days through Day 28|Hospital-free days through Day 28""}"
"2460","Prediction of Unfavourable Outcome in Newly Covid-19 Hospitalized Patient","PredictCovid19","NCT04412031","20_185","Other: non applicable","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412031","Completed","2019-11-11","2020-05-15","{""locations"":""H\u00f4pital E Herriot - Hospices Civils de LYON, Lyon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""802"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need of mechanical ventilation, transfer to an intensive care unit or death within 21 days of admission.""}"
"2461","HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19","HOPE_BRAZIL","NCT04575558","LACOG 0220","Drug: Hydroxychloroquine and Azithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04575558","Withdrawn","2020-06-30","2020-10-30","{""locations"":""N\u00facleo de Oncologia da Bahia - NOB, Salvador, BA, Brazil|Oncocl\u00ednicas BH, Belo Horizonte, MG, Brazil|Centro Oncol\u00f3gico do Tri\u00e2ngulo - COT, Uberl\u00e2ndia, MG, Brazil|Multihemo, Recife, PE, Brazil|Oncoclinicas RJ, Rio De Janeiro, RJ, Brazil|Centro de Pesquisa em Oncologia PUCRS, Porto Alegre, RS, Brazil|Centro Paulista de Oncologia, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical deterioration rate|Mortality and cause of death|Incidence and type of Adverse Events (EAs)|Incidence and type of Serious Adverse Events (SAE)|Discontinuation rate or temporary suspension of treatment|Descriptive radiologic changes on chest CT scans""}"
"2462","COVID-19 and Obstetric Transmission","COVIDOB","NCT04418557","20200479","Diagnostic Test: RT-PCR and antibody testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04418557","Recruiting","2020-04-28","2021-07-31","{""locations"":""University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Presence of COVID-19 virus|Presence of antibodies to COVID-19 virus""}"
"2463","Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19","JOCOVID","NCT04320017","CIC1421-20-05","Diagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04320017","Recruiting","2020-03-20","2020-05-20","{""locations"":""Clinical Investigation Center Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes|Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival""}"
"2464","The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines","","NCT04391400","IVS-000-002","Diagnostic Test: nasal pharyngeal (NP) swab samples|Diagnostic Test: peripheral blood draw","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04391400","Not yet recruiting","2020-06-01","2021-06-30","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Identification of nucleic acid sequencing, antibodies and antigens to be used in detection methods or treatments and\/or vaccines""}"
"2465","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation","","NCT04492514","IND 149353","Drug: Mavrilimumab|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04492514","Recruiting","2020-05-20","2021-05-31","{""locations"":""University of Cincinnati, Cincinnati, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Outcome Measure:|Secondary Outcome Measures:""}"
"2466","Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19","","NCT04366323","AdiQure/COVID-19","Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04366323","Active, not recruiting","2020-04-27","2021-10-01","{""locations"":""Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, C\u00e1diz, Spain|Hospital Reina Sof\u00eda, C\u00f3rdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Unversitario Virgen del Roc\u00edo, Sevilla, Spain|Hospital Nuestra Se\u00f1ora de Valme, Sevilla, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""26"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate""}"
"2467","Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19","","NCT04632706","mdc-TTG-CT-001","Drug: Ivermectin|Drug: Placebo","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04632706","Recruiting","2020-09-22","2021-05-01","{""locations"":""MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence, Manchester, Greater Mancherster, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other"",""enrollment"":""24"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Pharmacokinetic concentrations - (Maximum Plasma Concentration [Cmax])|Pharmacokinetic concentrations - (Time to Reach Cmax [Tmax])|Pharmacokinetic concentrations - (Trough Plasma Concentration [Ctrough])|Pharmacokinetic concentrations - (Area under the plasma concentration-time curve from zero to 24 hours [AUC0-24h])|Pharmacokinetic concentrations - (Area under the plasma concentration-time curve from zero to 48 hours [AUC0-48h])|Pharmacokinetic concentrations - (Average Plasma Concentration at steady state [Cavg ss])|Pharmacokinetic concentrations - (Apparent Terminal Half-Life [T1\/2])|Safety and Tolerability - Number of participants with treatment emergent adverse events (TEAEs)|Safety and Tolerability - Number of participants with abnormal electrocardiograms (ECG)|Safety and Tolerability - Number of participants with abnormal clinical neurological exam, as assessed by the investigator|Safety and Tolerability - Number of participants with abnormal urine and\/or blood test, as compared to reference laboratory values|Safety and Tolerability - Number of participants with abnormal physical exams, as assessed by the investigator""}"
"2468","International Registry of Coronavirus (COVID-19) Exposure in Pregnancy","IRCEP","NCT04366986","0001","Other: Tested for SARS-CoV-2 (regardless of the result)|Other: Clinical diagnosis of COVID-19 by a health care professional","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366986","Recruiting","2020-06-23","2024-04-30","{""locations"":""Pregistry, Los Angeles, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pregnancy outcomes|Birth outcomes""}"
"2469","Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study","","NCT04652505","2020-0451|NCI-2020-06556","Other: Questionnaire Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04652505","Recruiting","2020-07-13","2021-03-31","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient-reported severity of depression|Patient-reported severity of anxiety|Patient-reported severity of distress|Patient-reported physical symptoms|Substance use|Patient-reported coping strategy|Patient-reported levels of apathy|Patient-reported engagement in the 5 health behaviors endorsed by World Health Organization intended to curb the spread of the coronavirus""}"
"2470","Vitamin D Testing and Treatment for COVID 19","","NCT04407286","STUDY00011960","Dietary Supplement: Vitamin D3","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04407286","Completed","2020-05-19","2020-11-30","{""locations"":""Arizona State University, Tempe, Arizona, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""41"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Vitamin D levels|severity of COVID 19 symptoms""}"
"2471","Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury","","NCT04397510","FHHep518","Drug: Heparin|Drug: 0.9% Sodium-chloride","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04397510","Enrolling by invitation","2020-06-01","2021-12-31","{""locations"":""Frederick Health Hospital, Frederick, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean daily PaO2 to FiO2 ratio|Duration of mechanical ventilation|ICU length of stay|Mortality Rate|Incidence of adverse drug events""}"
"2472","Early CPAP in COVID-19 Patients With Respiratory Failure.","EC-COVID-RCT","NCT04326075","EC-COVID-RCT-Fenice","Device: CPAP treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04326075","Recruiting","2020-12-01","2021-05-31","{""locations"":""Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""900"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death or need of intubation|30-day mortality""}"
"2473","High GRP78 Levels in Covid-19 Infection: A Case-Control Study","","NCT04628637","Clinical-2","Other: Serum protein level analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04628637","Completed","2020-04-16","2020-10-10","{""locations"":""Aylin Koseler, Denizli, Outside Of The US, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""144"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determination of the change of the serum GRP-78 protein levels in patients who have Covid-19 infection compared to control group|Determination of the change of the serum GRP-78 protein levels in patients who have Covid-19 infection compared to Covid-19 negative pneumonia group.|Determination of the correlations between laboratory parameters, clinical parameters and radiological parameters""}"
"2474","Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults","","NCT04636697","CP-PRO-CoVLP-021","Drug: Intramuscular injection|Biological: Intramuscular vaccine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04636697","Recruiting","2020-11-19","2022-04-30","{""locations"":""Alliance for Multispecialty Research, Coral Gables, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Meridian Clinical Research LLC, Norfolk, Nebraska, United States|Meridian Clinical Research LLC, Omaha, Nebraska, United States|DM Clinical Research\/Martin Diagnostic Clinic, Tomball, Texas, United States|IWK Health Centre- Dalhousie University-Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada|Dawson Clinical Research Inc., Guelph, Ontario, Canada|Manna Research (Mirabel), Mirabel, Quebec, Canada|McGill University Health Centre Vaccine Study Centre, Pierrefonds, Quebec, Canada|CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Quebec, Canada|Diex Research Quebec Inc., Qu\u00e9bec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-Borrom\u00e9e, Quebec, Canada|Q&T Research Sherbrooke Inc., Sherbrooke, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""30918"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 2 portion: Immediate adverse event (AEs)|Phase 2 portion: Solicited local and systemic adverse events (AEs)|Phase 2 portion: Unsolicited adverse events (AEs)|Phase 2 portion: Number of subjects with normal and abnormal clinically significant urine values|Phase 2 portion: Number of subjects with normal and abnormal clinically significant haematological values|Phase 2 portion: Number of subjects with normal and abnormal clinically significant biochemical values|Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant urine values|Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant haematological values|Phase 2 portion: Percentage of subjects with normal and abnormal clinically biochemical values|Phase 2 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths|Phase 2 portion: Neutralizing antibody (Nab assay) response|Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response|Phase 3 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection|Phase 2 portion: Solicited local and systemic AEs|Phase 3 portion: Immediate adverse event (AEs)|Phase 3 portion: Solicited local and systemic AEs|Phase 3 portion: Unsolicited adverse events (AEs)|Phase 3 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths|Phase 2 portion: Neutralizing antibody Geometric mean tiers (GMT) response|Phase 2 portion: Specific antibody (IgG) response|Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers|Phase 2 portion: Specific Th1 cell-mediated immunity (CMI) response|Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response|Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response|Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response|Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response|Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT)|Phase 3 portion: Specific antibody (IgG) response|Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers|Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response|Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response|Phase 3 portion: Specific cell-mediated immunity (CMI) response|Phase 2 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection|Phase 2 portion: Severe COVID-19 disease|Phase 3 portion: Severe COVID-19 disease|Phase 3 portion: COVID-19-related symptoms|Phase 3 portion: Laboratory-confirmed asymptomatic SARS-CoV-2 infection|Phase 3 portion: Laboratory-confirmed symptomatic SARS-CoV-2 infection|Phase 3 portion: Viral shedding after SARS-CoV-2 infection""}"
"2475","Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients","HBOT","NCT04409886","120-20-ASF","Device: Hyperbaric Chamber","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04409886","Not yet recruiting","2020-06-01","2021-03-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygenation index|SpO2|Symptoms level|Chest Xray""}"
"2476","Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients","MuCo","NCT04590352","2020-6342|NL73418.091.20","Procedure: nasopharyngeal and throat swab|Procedure: collection of mucosal lining fluid|Procedure: blood collection via fingerprick","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04590352","Completed","2020-03-26","2020-05-13","{""locations"":""Radboudumc, Nijmegen, Gelderland, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""187"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mucosal antibodies|Mucosal antibodies in all participants|SARS-CoV-2 infection|Serum antibodies|Functional antibody assays""}"
"2477","Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?","","NCT04443140","70/2020","Diagnostic Test: PCR, lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443140","Completed","2020-03-15","2020-07-10","{""locations"":""Zeynep Kamil Maternity and Childrens Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""131"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""PCR positivity""}"
"2478","Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients","","NCT04457609","ISMMSCCOVID19","Drug: Oseltamivir|Drug: Azithromycin|Biological: Umbilical Cord Mesenchymal Stem Cells","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04457609","Recruiting","2020-07-01","2020-09-01","{""locations"":""Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia|Persahabatan General Hospital, Jakarta, DKI Jakarta, Indonesia|Sulianti Saroso Center for Infectious Disease, Jakarta, DKI Jakarta, Indonesia|Universitas Indonesia Hospital, Depok, West Java, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement: Presence of dyspnea|Clinical improvement: presence of sputum|Clinical improvement: fever|Clinical improvement: ventilation status|Clinical improvement: blood pressure|Clinical improvement: heart rate|Clinical improvement: respiratory rate|Clinical improvement: oxygen saturation|General laboratory outcome from leukocyte level|General laboratory outcome from lymphocytes level|General laboratory outcome from blood pH|General laboratory outcome from blood level of CO2|General laboratory outcome from blood base excess level|General laboratory outcome from blood oxygen partial pressure|General laboratory outcome from blood level of HCO3|General laboratory outcome from blood level of O2 saturation|General laboratory outcome from level of CRP|General laboratory outcome from level of SGOT\/SGPT (AST\/ALT)|General laboratory outcome from the level of ureum\/creatinine level|General laboratory outcome from the level of eGFR|General laboratory outcome from the level of sodium|General laboratory outcome from the level of potassium|General laboratory outcome from the level of chloride|Changes in procalcitonin level|General laboratory outcome from albumin level|General laboratory outcome from total bilirubin level|Changes in D-Dimer level|Changes in fibrinogen level|Cardiac changes from troponin level|Cardiac changes from NT proBNP level|Changes in Leukemia Inhibiting Factor|Changes in level of IL-6|Changes in level of IL-10|Changes in level of vascular endothelial growth factor (VEGF)|Changes in level of ferritin|Changes in level of CXCR3|Changes in level of CD4|Changes in level of CD8|Changes in level of CD56|Radiologic Improvement from Chest X-Ray\/CT Scan""}"
"2479","Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT)","MEDEAS","NCT04636671","MEDEAS1","Drug: Methylprednisolone|Drug: Dexamethasone","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04636671","Not yet recruiting","2020-11-25","2021-04-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""680"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival|Reduction in the need for mechanical ventilation|Length of hospitalization|Need for tracheostomy|Reduction in systemic inflammation markers|Amelioration of oxygenation|Disease progression""}"
"2480","Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors","AFTER","NCT04663945","20-2415","Behavioral: Biobehavioral Tele-rehabilitation Sessions","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04663945","Recruiting","2020-12-11","2021-08-01","{""locations"":""University of Colorado Hospital, Aurora, Colorado, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""35 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30 Second Chair Stand Test|Adherence|System Usability Scale (SUS)|Safety Event Count|Timed Up-and-Go Test (TUG)|4-Stage Balance Test|MRC Dyspnea|Activities-Specific Balance Confidence (ABC) Scale|Three-Item Loneliness Scale|PROMIS Short Form (SF) v1.0 General Self-Efficacy 4a|PROMIS Short Form (SF) Self-Efficacy for Managing Chronic Conditions|PROMIS Scale v1.2 Global Health:|Montreal Cognitive Assessment (MoCA)-BLIND|Clinical Frailty Scale|Average Daily Step Count|Patient Health Questionnaire 8 (PHQ8)""}"
"2481","Characterizing the Immune Response and Neuronal Damage in COVID-19","","NCT04510012","nCOV19","Other: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04510012","Recruiting","2020-03-05","2021-03-05","{""locations"":""Bern University Hospital, Bern, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cytokine response to SARS-Cov-2|Innate immune response to SARS-Cov-2|Humoral immune response|Cell mediated immune response|Neurological damage|Complement activation""}"
"2482","Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity","COBRA","NCT04439045","20-5413","Biological: VPM1002|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04439045","Recruiting","2020-06-24","2021-07-01","{""locations"":""University Health Network, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention"",""enrollment"":""3626"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 infection|Incidence of hospitalization for COVID-19|Incidence of ICU admission for COVID-19|Incidence of ARDS|Mechanical ventilation for COVID-19|Secondary infection in COVID-19|COVID-19-related Mortality|Incidence of DVT""}"
"2483","Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19","","NCT04400799","OVID Trial","Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04400799","Recruiting","2020-06-15","2021-04-14","{""locations"":""University Hospital Basel, Basel, Switzerland|Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|University Hospital Bern, Bern, Switzerland|H\u00f4pitaux Universitaires Gen\u00e8ve, Geneva, Switzerland|Centre hospitalier universitaire vaudois, Lausanne, Switzerland|Clinica Luganese Moncucco, Lugano, Switzerland|University hospital zurich, Z\u00fcrich, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""hospitalizations|all-cause death|Number of cardiovascular events|any hospitalizations|Net clinical benefit|Disseminated intravascular coagulation""}"
"2484","Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)","CovILD","NCT04416100","20200429-2255","Diagnostic Test: Pulmonary function tests|Diagnostic Test: Imaging|Biological: Blood sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416100","Recruiting","2020-04-29","2022-04-28","{""locations"":""Medical University of Innsbruck, Innsbruck, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""130"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 1 month|Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 3 months|Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 6 months""}"
"2485","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation","","NCT04399980","IND 149324|IRB 20-523","Drug: Mavrilimumab|Drug: Placebos","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04399980","Active, not recruiting","2020-05-20","2021-05-31","{""locations"":""Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic Health System, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects alive and off of oxygen at day 14|Proportion of subjects alive at 28 days|Proportion of subjects alive and without respiratory failure at 28 days""}"
"2486","A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults","","NCT04591184","ENTVAX01-101","Biological: Covigenix VAX-001 placebo|Biological: Covigenix VAX-001","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04591184","Not yet recruiting","2021-03-01","2022-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""72"",""age"":""18 Years to 84 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety of a 2-dose regimen of VAX-001 when doses are given 14 days apart|Mean change from baseline in safety laboratory measures|Frequency of treatment-emergent Serious Adverse Events (SAE) throughout the study and up to 6 months post-second dose immunization (Day 196).|Percent seroconversion defined as a 4-fold or greater increase in IgG titers after one or two doses as measured by IgG ELISA|Geometric mean neutralizing antibody titers against pseudo-virion after one and two doses|Percent seroconversion defined as a 4-fold or greater increase in IgG titers after one or two doses as measured by pseudo-viral neutralization assay.|Persistence of IgG antibody titers as measured by ELISA and neutralizing antibody titers measured by pseudo-virion neutralization assay, six months after the second vaccine dose""}"
"2487","Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19","","NCT04540419","Prometheus_Rus","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04540419","Active, not recruiting","2020-09-11","2021-07-31","{""locations"":""Municipal budgetary institution \""Central City Hospital No. 7\"", Ekaterinburg, Russian Federation|Federal budgetary institution of science \""Central Research Institute of Epidemiology\"" of the Federal Service for Surveillance on Consumer Rights Protectionand Human Welfare, Moscow, Russian Federation|State Budgetary Institution of Healthcare of the City of Moscow \""City Polyclinic No. 2of the Department of Healthcare of the City of Moscow\"", Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education \""First MoscowState Medical University named after I.M. Sechenov \""of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Limited Liability Company \""Research Center Eco-safety\"", Saint Petersburg, Russian Federation|Federal State Budgetary Institution \""Research Institute of Influenza named after A.A.Smorodintsev \""of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation|Private health care institution \""Clinical hospital 'Russian Railways - Medicine' of the city of Yaroslavl\"", Yaroslavl, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""500"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Superiority of the vaccine Ad5-nCoV to placebo by the level of seroconversion|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (titer of SARS-CoV-2 antibodies)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (level of seroconversion)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (rise of SARS-CoV-2 antibodies)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (T-cell response)|Frequency of confirmed COVID-19|Frequency of confirmed cases of COVID-19, requiring hospitalization|Frequency of cases with severe course of COVID-19|Frequency of death due to COVID-19.|Reactogenicity of the vaccine Ad5-nCoV compared with placebo|Frequency and character of adverse events and serious adverse events.|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (blood pressure)|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (heart rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (respiratory rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of physical examination|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of electrocardiography (Heart rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of electrocardiography|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry (enzymes)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (hemoglobin)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (hematocrit)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (erythrocytes)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (erythrocyte sedimentation rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of coagulogram|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of coagulogram (fibrinogen)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (relative density)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (pH)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (protein)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (glucose)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of determination of immunoglobulin E serum concentrations.""}"
"2488","Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19","","NCT04674566","COR-101/001","Drug: COR-101|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04674566","Not yet recruiting","2021-01-31","2021-04-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with Treatment-Emergent Adverse Events (TEAEs)|Proportion of patients with Serious Adverse Events (SAEs)|Proportion of patients with Adverse Events of Special Interest (AESI)|Secondary efficacy endpoint: Proportion of patients with disease progression|Secondary efficacy endpoint: Time to negative RT-PCR for SARS-CoV-2|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of COR-101|Assessment of PK parameter: Time to Cmax (tmax) for COR-101|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for COR-101|Assessment of PK parameter: Clearance (CL) for COR-101|Assessment of PK parameter: Mean residence time (MRT) of COR-101|Secondary PD endpoint: Change of the viral load of SARS-CoV-2 from baseline, as measured from nasopharyngeal swab samples by qRT-PCR|Secondary immunogenicity endpoint: Percentage of patients with detectable neutralizing antibodies to COR-101""}"
"2489","Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury","","NCT04412057","CERC-002-CVID-201","Drug: CERC-002|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04412057","Completed","2020-06-09","2021-01-19","{""locations"":""Hoag Memorial Hospital, Newport Beach, California, United States|Midway Immunology and Research Center, Fort Pierce, Florida, United States|Triple O Research Institute, P.A., West Palm Beach, Florida, United States|Parkview Research Center, Fort Wayne, Indiana, United States|MedPharmics, LLC, Metairie, Louisiana, United States|LSUHSC - Shreveport, Shreveport, Louisiana, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|AnMed Health Medical Center, Anderson, South Carolina, United States|Lowcountry Infectious Diseases, P.A., Charleston, South Carolina, United States|BRCR Global Texas, McAllen, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""83"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patient alive and free of respiratory failure|Proportion of subjects who are alive""}"
"2490","Validation of COVILUS Score in Patients Suspected of COVID-19 Infection in the Emergency Room","COVILUS2","NCT04666064","PI2020_843_0129","Diagnostic Test: Covid19 RT-PCR|Other: lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666064","Recruiting","2020-12-10","2021-07-01","{""locations"":""BAR, Amiens, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""concordance between Covid19 RT-PCR results and lung ultrasound results""}"
"2491","Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection","","NCT04627233","IR.SBMU.REC.1399.023","Drug: Human Ezrin Peptide 1 (HEP1)|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04627233","Not yet recruiting","2020-12-20","2021-04-01","{""locations"":""Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement of disease symptoms|Duration of Hospitalization|Duration of artificial ventilation|CT Severity score|CBC|IL-1|IL-6|TNF|CRP""}"
"2492","Post Intensive Care Syndrome in COVID19 Patients","PICS-COVID19","NCT04422444","2020/577","Diagnostic Test: Questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422444","Recruiting","2020-06-01","2022-06-01","{""locations"":""Corporaci\u00f3 Parc Taul\u00ed, Sabadell, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline Short Form 12 Health Survey (SF12) at 12 month|Change from baseline Lawton & Brody Instrumental activities of daily living scale at 12 months|Change from baseline Perceived Deficits Questionnaire (PDQ) at 12 months|Change from baseline Hospital Anxiety and Depression Scale (HADS) at 12 months|Change from baseline Davidson Trauma Scale (DTS) at 12 months""}"
"2493","COVID19 Clinical Predictors and Outcome","","NCT04416347","2020.0115","Other: SARS-CoV2 Infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416347","Recruiting","2020-06-15","2022-04-30","{""locations"":""St. George's University Hospitals Foundation Trust., London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 hospital mortality|SARS-CoV-2 mortality in critical care unit""}"
"2494","Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia","","NCT04527354","COVID-TRE-03","Drug: Treamid|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04527354","Active, not recruiting","2020-09-08","2020-11-01","{""locations"":""State Federal-Funded Educational Institution of Higher Professional Training \""Kazan State Medical University\"" of the Ministry of Health Care and Social Development of the Russian Federation, Kazan, Russian Federation|Federal State-Funded Research Institution \""Research Institute of Complex Cardiovascular Diseases\"", Kemerovo, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training \""Kemerovo State Medical University\"" of the Ministry of Healthcare of the Russian Federation, Kemerovo, Russian Federation|SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow, Russian Federation|State Federal-Funded Institution of Health Care of the city of Moscow \""City Clinical Hospital named after M.E. Zhadkevich of the Moscow City Health Department\"", Moscow, Russian Federation|Moscow State Medical-Dentist University n.a. A.I. Evdokimov on basis of SMHI \""City Hospital \u2116 62\"", branch 5, Moscow, Russian Federation|State Budgetary Institution of Healthcare \""Leningrad region Clinical Hospital\"", Saint Petersburg, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training \""Saratov State Medical University named after V.I. Razumovsky\"" of the Ministry of Healthcare of the Russian Federation, Saratov, Russian Federation|State Federal-Funded Institution of Health Care \""Republican Clinical Hospital named after G.G. Kuvatov\"", Ufa, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training \""Bashkir State Medical University\"" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training \""Volgograd State Medical University\"" of the Ministry of Healthcare of the Russian Federation, Volgograd, Russian Federation|State autonomous healthcare institution of Yaroslavl Region \""\u0421linical hospital for emergency medical care n. a. N.V. Solovyov\"", Yaroslavl, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of clinically significant change in FVC and\/or DLCO at Week 4 relative to the baseline value|Change in distance covered for 6 minutes (6MWD) at Weeks 2 and 4 from the baseline value (based on 6-minute walk test)|Change in the score of the Borg scale at Weeks 2 and 4 from the baseline value (based on the 6-minute walk test)|Change in forced expiratory volume for the first second (FEV1) according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in FVC according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in FEV1\/FVC according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values|Change in DLCO according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|Change in Total Lung Capacity (TLC) according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|Change in Functional Residual Capacity (FRC) according to bodyplethysmography at Week 2 and Week 4 relative to baseline values|The rate of reduction in the lung damage degree based on the computed tomography (CT) at Week 4 relative to the baseline value|Change in mMRC Dyspnea Score in Week 1, Week 2, Week 3, and Week 4 from the baseline value|Change in the overall score of the KBILD Questionnaire at Week 2 and Week 4 relative to the baseline value""}"
"2495","Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)","","NCT04668950","202011101","Drug: Fluvoxamine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04668950","Recruiting","2020-12-22","2021-09-01","{""locations"":""Northwestern University, Evanston, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson, Seattle, Washington, United States|McGill University Health Center, Montreal, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1100"",""age"":""30 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical deterioration|Post Covid Functioning""}"
"2496","The Severity of COVID 19 in Diabetes and Non-diabetes Patients","COVID19","NCT04634214","IDRFARH015","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04634214","Not yet recruiting","2020-11-16","2021-05-16","{""locations"":""Orthomed Hospital, Chennai, Tamil Nadu, India|Medway Hospital, Chennai, Tamil Nadu, India|Venkateswara Hospital, Chennai, Tamil Nadu, India|Dr. Rela Institute & Medical Center, Chennai, Tamil Nadu, India"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""1050"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity of COVID 19 among people with and without diabetes|Number of patients who were in ICU|Number of patients who had tracheal intubation|Number of patients who had respiratory complication|Number of death|Correlation of BMI with complications, tracheal intubation and mortality|Length of hospital stay""}"
"2497","Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection","","NCT04432922","ISOCOV","Other: Hospitalized Patients for COVID-19 Infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04432922","Completed","2020-11-01","2020-11-15","{""locations"":""Centre hospitalier intercommunal de Villeneuve St Georges, Villeneuve St Georges, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To highlight the perceptions, representations and experiences of septic isolation of patients hospitalized for COVID-19 infection|to identify key elements to improve the medical discourse on septic isolation among patients""}"
"2498","Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19","","NCT04527471","RPL554-COV-201","Drug: Ensifentrine Dose 1|Drug: Placebo pMDI","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04527471","Active, not recruiting","2020-09-04","2021-03-01","{""locations"":""The University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with recovery|Time to recovery|Proportion of patients with improvement (from Day 1) of one category using the 7-point ordinal scale|Proportion of patients with improvement (from Day 1) of two categories using the 7-point ordinal scale|Mortality rate|Proportion of patients alive and not in respiratory failure|Proportion of patients needing re-hospitalization|Duration of hospitalization from Day 1|Mean change from baseline in 7-point ordinal scale|Total time on supplemental oxygen|Incidence of new non-invasive ventilation or high flow oxygen use|Duration of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Duration of new oxygen use|Incidence of new mechanical ventilator use|Duration of new mechanical ventilator use|Proportion of patients receiving invasive mechanical ventilation or ECMO""}"
"2499","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","PROTECT","NCT04338698","12(06)/2016-Coord","Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04338698","Recruiting","2020-04-22","2020-11-30","{""locations"":""Faislabad Medical University, Faisal\u0101bad, Pakistan|Gujranwala Medical College, Gujr\u0101nw\u0101la, Pakistan|Nawaz Sharif Medical College, Gujr\u0101t, Pakistan|Szabmu-Pims, Islamabad, Pakistan|Akram Medical Complex, Lahore, Pakistan|Fatima Jinnah Medical University, Lahore, Pakistan|King Edward Medical University-Mayo Hospital, Lahore, Pakistan|Lahore General Hospital, Lahore, Pakistan|Khyber Teaching Hospital, Peshawar, Pakistan|Rawalpindi Medical University, Rawalpindi, Pakistan|Sargodha Medical College, Sargodha, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Laboratory Result|Clinical Outcome""}"
"2500","A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","TeenCove","NCT04649151","mRNA-1273-P203","Biological: mRNA-1273|Biological: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04649151","Active, not recruiting","2020-12-09","2022-06-30","{""locations"":""Velocity Clinical Research - Banning, Banning, California, United States|Paradigm Clinical Research, La Mesa, California, United States|Accel Research Sites - Nona Pediatric Center, DeLand, Florida, United States|Tekton Research, Chamblee, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Velocity Clinical Research - Boise, Meridian, Idaho, United States|Velocity Clinical Research - Valparaiso, Valparaiso, Indiana, United States|Johnson County Clinical Trials, Lenexa, Kansas, United States|Medpharmics - Metairie, Metairie, Louisiana, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Medpharmics - Gulfport, Gulfport, Mississippi, United States|Medpharmics - Albuquerque, Albuquerque, New Mexico, United States|Child Healthcare Associates, Liverpool, New York, United States|Velocity Clinical Research - Cincinnati, Cincinnati, Ohio, United States|Lynn Health Sciences Institute, Oklahoma City, Oklahoma, United States|Velocity Clinical Research - Providence, Warwick, Rhode Island, United States|Coastal Pediatric Associates, Charleston, South Carolina, United States|Benchmark Research, Austin, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|Kool Kids Pediatrics, Houston, Texas, United States|ACRC Trials, Plano, Texas, United States|Tekton Research, San Antonio, Texas, United States|Tekton Research, San Antonio, Texas, United States|Velocity Clinical Research - Salt Lake City - Jordan Valley, West Jordan, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""3000"",""age"":""12 Years to 17 Years \u00a0 (Child)"",""outcome_measures"":""Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), or Adverse Events of Special Interest (AESI)|Number of Participants Who have Reached the Acceptable Threshold for the Serum Ab Level at Day 57|Comparison of the Geometric Mean of the Serum Neutralizing Antibody (nAb) level against the Geometric Mean of the Serum nAb level in Study mRNA-1273-P301 (NCT04470427)|Geometric Mean Value of SARS-CoV-2 Spike Protein (S2P)-specific binding antibody (bAb)|Geometric Mean Value of SARS-CoV-2-specific nAb|Number of Participants with a SARS-CoV-2 Infection Starting on Day 57|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo""}"
"2501","Oral Health and Psychosocial Factors During the Covid-19 Pandemic","","NCT04381273","S-303/2020","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04381273","Recruiting","2020-05-08","2020-07-31","{""locations"":""University Hospital Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""How do people assess their oral health-related quality of life in times of the Covid-19 pandemic?|Does the periodontitis risk have an influence on the severety of the Covid-19 disease and its' treatment?|Do psychosocial stress factors in times of the Covid-19 pandemic have an impact on their oral health related quality of life?|Have people changed their oral hygiene practices in times of the Covid-19 pandemic?""}"
"2502","A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","","NCT04470427","mRNA-1273-P301|75A50120C00034","Biological: mRNA-1273|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04470427","Active, not recruiting","2020-07-27","2022-10-27","{""locations"":""Ascension St. Vincent Birmingham, Birmingham, Alabama, United States|Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States|Hope Research Institute, Chandler, Arizona, United States|Synexus Clinical Research US, Inc. - Phoenix West, Glendale, Arizona, United States|Hope Research Institute, Peoria, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Quality of Life Medical and Research Center, Tucson, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Advanced Clinical Research - Rancho Paseo, Banning, California, United States|University of California San Diego, La Jolla, California, United States|eStudySite - La Mesa, La Mesa, California, United States|UCLA Vine Street Clinic CRS, Los Angeles, California, United States|VA Greater Los Angeles Healthcare (veterans only), Los Angeles, California, United States|Paradigm Clinical Research Institute Inc, Redding, California, United States|Benchmark Research - Sacramento, Sacramento, California, United States|Medical Center For Clinical Research - M3 Wake Research, San Diego, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Lynn Institute of The Rockies, Colorado Springs, Colorado, United States|George Washington University, Washington, District of Columbia, United States|Accel Research Site, DeLand, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Synexus - Optimal Research - Melbourne, Melbourne, Florida, United States|Suncoast Research Group, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Synexus Clinical Research US, Inc. - Orlando, Orlando, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Hope Clinic of The Emory Vaccine Center, Decatur, Georgia, United States|Meridian Clinical Research, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Synexus Clinical Research US, Inc. - Chicago, Chicago, Illinois, United States|UIC Project WISH CRS, Chicago, Illinois, United States|University of Chicago-Hospital, Chicago, Illinois, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Alliance for Multispecialty Research, Newton, Kansas, United States|Alliance for Multispecialty Research- East Wichita, Wichita, Kansas, United States|Meridian Clinical Research, Baton Rouge, Louisiana, United States|Benchmark Research - Metairie, Metairie, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Synexus - Optimal Research - Rockville, Rockville, Maryland, United States|Meridian Clinical Research, Rockville, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|MediSync Clinical Research Hattiesburg Clinic, Petal, Mississippi, United States|Saint Louis University, Saint Louis, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Meridian Clinical Research, Grand Island, Nebraska, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|AB Clinical Trials, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New Jersey Medical School, Newark, New Jersey, United States|Meridian Clinical Research, Binghamton, New York, United States|Weill Cornell Chelsea - (CRS), New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Tryon Medical Partners, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research - M3 Wake Research, Fayetteville, North Carolina, United States|M3 Wake Research, Inc - M3 Wake, Raleigh, North Carolina, United States|Trial Management Associates, Wilmington, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc. - Cincinnati, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Cincinnati CRS, Cincinnati, Ohio, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Crisor, Medford, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC University Center, Pittsburgh, Pennsylvania, United States|Keystone VitaLink Research, Anderson, South Carolina, United States|Keystone VitaLink Research - Greenville, Greenville, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Keystone VitaLink Research - Spartanburg, Spartanburg, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|WR-ClinSearch, Chattanooga, Tennessee, United States|Alliance for Multispecialty Research, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Medical Arts Building, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Medical Center North, Nashville, Tennessee, United States|Benchmark Research - Austin, Austin, Texas, United States|Synexus - Optimal Research - Austin, Austin, Texas, United States|Tekton Research, Austin, Texas, United States|Advanced Clinical Research - Be Well MD, Cedar Park, Texas, United States|Global Medical Research - M3 Wake Research, Dallas, Texas, United States|Synexus Clinical Research US, Inc. - Dallas, Dallas, Texas, United States|Benchmark Research - Fort Worth, Fort Worth, Texas, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|DM Clinical Research - Texas Center For Drug Development, Houston, Texas, United States|Laguna Clinical Research, Laredo, Texas, United States|Centex Studies, McAllen, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Synexus Clinical Research US, Inc. - Salt Lake City, Murray, Utah, United States|Foothill Family Clinic - North, Salt Lake City, Utah, United States|Foothill Family Clinic-South Clinic, Salt Lake City, Utah, United States|Kaiser Permanente - Seattle, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""30420"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy: Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of mRNA-1273|Safety: Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal|Safety: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Safety: Number of Participants with Unsolicited AEs|Safety: Number of Participants with Serious AEs (SAEs)|Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of mRNA-1273 or Placebo|Number of Participants with a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection regardless of symptomatology or Severity Starting 14 Days after Second Dose of mRNA-1273 or Placebo|Number of Participants with a Secondary Case Definition of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of mRNA-1273 or Placebo|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Regardless of Evidence of Prior SARS-CoV-2 Infection|Number of Participants with a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo|Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb|Quantified Levels or GMT of S Protein-Specific Binding Antibody (bAb)|GMFR of S Protein Specific bAb""}"
"2503","COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2","ANTI-COV-2","NCT04354766","69HCL20_0340|2020-A01038-31","Other: Blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354766","Recruiting","2020-04-29","2020-07-01","{""locations"":""H\u00f4pital de la Croix-Rousse, Lyon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.""}"
"2504","Assessment of COVID-19 in Tearfilm","","NCT04579458","201127","Procedure: Collection of tears and saliva.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04579458","Withdrawn","2020-12-28","2021-01-22","{""locations"":""Vanderbilt University Medical Center, Nashville, Tennessee, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Co-relation of COVID-19 activity""}"
"2505","An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers","","NCT04641481","BBIL/BBV152-C/2020","Biological: BBV152|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04641481","Active, not recruiting","2020-11-25","2022-12-01","{""locations"":""Pt BD SHARMA,PGIMS\/UHS, Rohtak, Haryana, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""25800"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""First occurrence of Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19.|First occurence of Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19 based on the case definition for the secondary efficacy symptomatic endpoint.|Virologically confirmed (RT-PCR positive) severe cases of COVID-19|Virologically confirmed COVID-19 cases of any severity occurring among participants 18 through 59 years of age and \u226560 years of age.|Virologically confirmed COVID-19 asymptomatic and symptomatic cases occurring from two weeks after the second vaccination.|Reactogenicity and Safety|The occurrence of enhanced respiratory disease episodes.|Immunogenicity: Lot-to-Lot consistency of three consecutive GMP Lots|Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)""}"
"2506","Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)","","NCT04360486","S-20-02|IND 19930","Biological: Anti-Sars-CoV-2 Convalescent Plasma","Expanded Access:Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04360486","Available","1970-01-01","1970-01-01","{""locations"":""Naval Hospital Camp Pendleton, Oceanside, California, United States|Navy Medical Center San Diego, San Diego, California, United States|USS Abraham Lincoln, San Diego, California, United States|USS Carl Vinson, San Diego, California, United States|USS Essex, San Diego, California, United States|USS Makin Island, San Diego, California, United States|USS Nimitz, San Diego, California, United States|USS Theodore Roosevelt, San Diego, California, United States|Evans Army Community Hospital, Fort Carson, Colorado, United States|Eglin Air Force Base, Eglin Air Force Base, Florida, United States|Naval Hospital Jacksonville, Jacksonville, Florida, United States|Martin Army Community Hospital, Fort Benning, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Keesler Medical Center, Biloxi, Mississippi, United States|Nellis Air Force Base, Las Vegas, Nevada, United States|Naval Medical Center Camp Lejeune, Camp Lejeune, North Carolina, United States|Wright Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|William Beaumont Army Medical Center, El Paso, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States|Naval Surface Force Atlantic, Norfolk, Virginia, United States|USS Dwight D. Eisenhower, Norfolk, Virginia, United States|USS Gerald R. Ford, Norfolk, Virginia, United States|Naval Medical Center Portsmouth, Portsmouth, Virginia, United States|Madigan Army Medical Center, Lakewood, Washington, United States|Craig Joint Theatre Hospital Bagram AFGH, Bagram, Afghanistan|Djibouti Expeditionary Medical Facility, Djibouti, Djibouti|Landstuhl Regional Medical Center, Landstuhl, Germany|Naval Hospital Guam, Aga\u00f1a, Guam|Baghdad Diplomat Support Center Iraq, Baghdad, Iraq|Misawa Air Force Base, Aomori, Japan|Yokota Air Base, Fussa, Japan|US Naval Hospital Okinawa, Okinawa, Japan|Naval Hospital Yokosuka, Yokosuka, Japan|USS America, Yokosuka, Japan|USS Ronald Reagan, Yokosuka, Japan|US Military Hospital Kuwait, Kuwait, Kuwait"",""study_designs"":"""",""enrollment"":"""",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""""}"
"2507","CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19","CORONA","NCT04378244","AF20-203","Drug: DeltaRex-G","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04378244","Not yet recruiting","2021-01-12","2022-03-12","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Maximum Tolerated Dose|Survival|Hospital Stay|Ventilator Therapy|Intensive Care Unit Stay|Cytokine Pattern""}"
"2508","hCT-MSCs for COVID19 ARDS","","NCT04399889","Pro00105410","Biological: human cord tissue mesenchymal stromal cells","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04399889","Recruiting","2020-06-18","2021-07-31","{""locations"":""Duke Hospital, Durham, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety of the Investigational Product|Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs""}"
"2509","Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency","COVIPOC","NCT04594668","2020-001420-34","Drug: Senicapoc","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04594668","Recruiting","2020-04-24","2021-12-31","{""locations"":""Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""46"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PaO2\/FiO2 ratio|Ventilator-free days|Mortality""}"
"2510","Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins","","NCT04690920","UOL/IMBB/2020/118","Drug: Tocilizumab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04690920","Completed","2020-07-23","2020-12-10","{""locations"":""The University of Lahore, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen|Hospital stay|Oxygen demand|Viral load""}"
"2511","Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","","NCT04405076","mRNA-1273-P201|75A50120C00034","Biological: Biological: mRNA-1273|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04405076","Active, not recruiting","2020-05-29","2021-10-06","{""locations"":""Meridian Clinical Research, Savannah, Georgia, United States|Alliance for Multispecialty Research, Newton, Kansas, United States|Alliance for Multispecialty Research, Kansas City, Missouri, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Trial Management Associates, Wilmington, North Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Benchmark Research, Austin, Texas, United States|Benchmark Research, San Angelo, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Medically-Attended Adverse Events (MAAEs)|Number of Participants with Serious Adverse Events (SAEs)|Change from Baseline in the Measure of Clinical Safety Laboratory Values in Cohort 2|Number of Participants with Abnormalities in Blood Pressure, Temperature, HR, or Respiratory Rate|Number of Participants with Abnormalities in Physical Examinations|Level of SARS-CoV-2-Specific Binding Antibody (bAb) as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)|Titer of SARS-CoV-2-Specific Neutralizing Antibody (nAb)|Seroconversion as Measured by an Increase of SARS-CoV-2-Specific Neutralizing Antibody (nAb) Titer""}"
"2512","PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","PRECISE","NCT04351191","NBC-COVID1902","Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04351191","Terminated","2020-04-15","2020-08-30","{""locations"":""Expo Covid Isolation Center \/ Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan|Mayo Hospital \/ King Edward Medical University, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan|Services Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""137"",""age"":""20 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""RT-PCR result|Progression of symptoms|Mortality""}"
"2513","LILLE COVID RESEARCH NETWORK (Covid-19)","LICORNE","NCT04475211","2020_54|2020-A01514-35","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04475211","Recruiting","2020-08-10","2022-08-01","{""locations"":""Hop Claude Huriez Chr Lille, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients \""confirmed cases\"" of SARS-CoV-2 infection who died at D28 of inclusion|Correlation between Infection characteristics of patients at inclusion and all predictors for Covid-19|Correlation between evolution infection characteristics of patients during stay of hospitalisation and all predictors for Covid-19|Positivity for Covid-19 patients performed and all predictors for Covid-19|Correlation between hospitalisation and all predictors for Covid-19|Correlation between risk factors measured at D0 for severe CoV-2 SARS infection and all predictors for Covid-19|Correlation between overall survival at Day 28 and all predictors for Covid-19|Cumulative incidence of at least one complication related to COVID 19|Cumulative incidence of the thrombosis complication related to COVID 19|All type of co-infections|Alteration of microbiota|Biobanking for further analyses such as SARS-CoV2 studies""}"
"2514","Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","POCUSCO","NCT04338100","2020-A00782-37","Procedure: Follow-up at 14 days","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04338100","Not yet recruiting","2020-04-06","2021-01-29","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Risk of unfavourable outcome at D14|Risk of unfavourable outcome over time|Risk-stratification threshold values|Adding value of POCUS score to previous risk-stratification clinical rules|POCUS score and patient clinical status at D14|POCUS and CT scan correlation|POCUS versus CT scan risk-stratification performances|POCUS score evolution performances""}"
"2515","WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound","INVICTUS","NCT04372680","RC31/20/0138|2020-A00916-33","Diagnostic Test: CTUS examination","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04372680","Recruiting","2020-04-22","2021-10-22","{""locations"":""CHU de LIMOGES, Limoges, France|CHU de TOULOUSE, Toulouse, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Delay from the start of Mechanical Ventilation weaning process to extubation|delay from intubation to extubation|Successful of extubation|mortality rate""}"
"2516","The Effect of Covid-19 on Patient Outcomes Among Operated Patients","","NCT04525716","CovidKirurgi","Other: COVID-19 infection status","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04525716","Recruiting","2020-03-01","2020-12-31","{""locations"":""Samtliga akutsjukhus i Region Stockholm, Stockholm, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Death|Length of stay|Complications""}"
"2517","Cod Liver Oil for Covid-19 Prevention Study","","NCT04609423","REK-172796","Dietary Supplement: Cod liver oil|Dietary Supplement: Corn oil (placebo)","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04609423","Recruiting","2020-11-10","2023-05-01","{""locations"":""Oslo University Hospital, Oslo, Norway"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""80000"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants diagnosed with serious Covid-19|Number of participants diagnosed with New Covid-19|Number of participants with laboratory confirmed respiratory tract infection|Number of participants with self-reported airway infection|Number of participants hospitalized due to Covid-19|Number of participants in Intensiv Care Unit (ICU) caused by Covid-19|Number of participants with any admissions to hospital|Infection with each of the mentioned pathogens|Number of visits at GP for infections|Number of visits at GP""}"
"2518","Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients","","NCT04480398","AYU/DSSR/02","Drug: Guduchi Ghan Vati","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04480398","Completed","2020-05-12","2020-07-03","{""locations"":""Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""91"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virologic clearance|Change in the number of patients going from asymptomatic to moderately disease|Hospital Stay|Clinically relevant adverse effects""}"
"2519","Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","PRODEX","NCT04350086","87RI20_0011 (PRODEX)","Drug: Treatment with Dexmedetomidine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04350086","Withdrawn","2020-04-20","2020-11-20","{""locations"":""University Hospital, Limoges, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.|Overall survival of patients on Dexmedetomidine|Daily analgesic effect of Dexmedetomidine|Other sedative pharmacological agents|Average dosage required for Dexmedetomidine to achieve mild to moderate sedation""}"
"2520","Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers","","NCT04412278","500600127","Other: Online Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412278","Completed","2020-06-01","2020-06-08","{""locations"":""Istanbul Okan University, Istanbul, Turkey"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""392"",""age"":""15 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Exercise Benefits and Barriers Scale|Sociodemographic information|International Physical Activity Questionairre""}"
"2521","Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]","COVID-OISE","NCT04644159","2020-060","Other: Human biological samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04644159","Recruiting","2020-11-13","2023-11-01","{""locations"":""H\u00f4pital de Cr\u00e9py en Valois, Cr\u00e9py-en-Valois, France|Institut Pasteur, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.|Presence of specific T cell response to the SARS-CoV-2""}"
"2522","Hydroxy Chloroquine and Covid in RA Patients","Covid-19","NCT04471649","002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04471649","Recruiting","2020-06-15","2020-11-01","{""locations"":""Tanta University Hospital, Tanta, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients in need for hospitalization|Length of hospitalization and ICU admission|The need for mechanical ventilation|Severity of COVID-19 disease""}"
"2523","Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer","ONCOVID-AURA","NCT04457570","69HCL20_0509","Other: mortality","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04457570","Recruiting","2020-06-15","2021-02-15","{""locations"":""Centre de lutte contre le Cancer JEAN PERRIN, Clermont-Ferrand, France|Centre Hospitalier Uniersitaire de Clermont-Ferrand, Clermont-Ferrand, France|Centre Leon Berard, Lyon, France|Institut de Canc\u00e9rologie de la Loire Lucien Neurwirth, Saint-Priest-en-Jarez, France|Centre Hospitalier Universitaire de St Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality for SARS-CoV-2 infection""}"
"2524","Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group","","NCT04477473","2020-01509","Other: Questionnaire-based observational study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04477473","Recruiting","2020-06-30","2020-08-31","{""locations"":""Centre antituberculeux; Geneva University Hospital, Geneva, Geneva 14, Switzerland"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Questionnaire""}"
"2525","Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome","","NCT04447144","1003","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04447144","Recruiting","2020-06-01","2020-09-01","{""locations"":""Faculty of Medicine Cairo University, Cairo, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Western versus Mediterranean diet in COVID-19 outcome|Gut- Lung axis in COVID-19|Protective role of minerals and vitamins in COVID-19 patients|non-communicable diseases and COVID-19""}"
"2526","SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort","","NCT04615000","BC-08104","Diagnostic Test: SARS-CoV-2 serological assessment (IgG)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04615000","Recruiting","2020-10-29","2021-11-01","{""locations"":""Ghent University Hospital, Ghent, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Seroconversion rate of children with chronic conditions followed in a tertiary centre|Epidemiological and social determinants of SARS-CoV-2 infection risk in children with chronic conditions|Clinical manifestations of COVID-19 in children with chronic conditions""}"
"2527","Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation","TubeObs-Covid","NCT04394429","7803","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04394429","Recruiting","2020-04-24","2021-06-24","{""locations"":""Service d'Anesth\u00e9sie-R\u00e9animation - Nouvel H\u00f4pital Civil, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""184"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Analysis of risk factors for intubation tube obstruction""}"
"2528","Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19","RESCUE1-19","NCT04433949","STUDY00000781|NCI-2020-04061|RAD5049-20|P30CA138292","Other: Best Practice|Radiation: Low Dose Radiation Therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04433949","Recruiting","2020-06-12","2022-05-30","{""locations"":""Emory University Hospital\/Winship Cancer Institute, Atlanta, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""52"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical recovery|Freedom from ICU admission|Temperature|Heart rate|Systolic Blood pressure|Oxygen saturation|Supplemental oxygenation need|Respiratory rate|Glasgow Comma Scale from minimum of 3 to maximum of 15.|Performance status|Survival|Serial chest x-rays severe acute respiratory syndrome (SARS) scoring|Changes on computed tomography (CT) scans pre and post RT|CRP|Serum chemistry + complete blood cell (CBC) with differential|Blood gases pH(when available)|Albumin|Procalcitonin|Aspartate aminotransferase (AST)|Creatine kinase|Prothrombin time (PT)\/partial thromboplastin time (PTT)|Troponin|Lactate|NT-pBNP (cardiac injury)|Gamma-glutamyl transferase (GGT)|Triglycerides|Fibrinogen|Changes in CD8 T cells|Changes in CD4 T cells|Changes in serum antibodies against COVID-19 epitope|LDH|D-Dimer|IL-6|Myoglobin|Potassium|Ferritin|ALT""}"
"2529","Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults","","NCT04671017","VLA2001-201","Biological: VLA2001","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04671017","Active, not recruiting","2020-12-16","2021-08-28","{""locations"":""Queen Elizabeth Hospital, Birmingham, United Kingdom|University Hospital Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|Newcastle University Medical School, Newcastle, United Kingdom|Southampton NIHR Clinical Research Facility, Southampton, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""153"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Frequency and severity of solicited AEs (local and systemic reactions) within 7 days after any vaccination|Geometric mean titre (GMT) for neutralizing antibodies against SARS-CoV-2|Frequency and severity of any unsolicited AE|Frequency and severity of any vaccine-related AE|Frequency and severity of any AE|Frequency and severity of any SAE|Frequency and severity of any AESI|Frequency and severity of an AESI|Immune response as measured by neutralizing antibody titres against SARS-CoV-2|Proportion of subjects with seroconversion in terms of neutralizing antibodies|Fold increase of SARS-CoV-2 neutralizing antibody titres compared with baseline|GMTs for IgG antibodies against SARS-CoV-2|Proportion of subjects with seroconversion in terms of IgG antibodies against SARS-CoV-2 in subjects negative for SARS-CoV-2 at screening""}"
"2530","A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes","","NCT04378920","2020-003|2020-001393-30|2020-A00900-39","Drug: LEAF-4L6715","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04378920","Recruiting","2020-04-14","2021-06-30","{""locations"":""H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France|Institut de canc\u00e9rologie Strasbourg Europe, Strasbourg, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""proportion of patients showing an increase of at least 25% of PaO2\/FiO2 ratio|proportion of patients with a PaO2\/FiO2 ratio above 200 mm Hg|all cause mortality""}"
"2531","Prone Positioning for Patients on General Medical Wards With COVID19","COVID-PRONE","NCT04383613","2020-1","Other: Prone positioning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04383613","Recruiting","2020-05-15","2021-06-01","{""locations"":""William Osler Health System, Brampton, Ontario, Canada|William Osler Health System, Etobicoke, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|St. Joseph's Health Centre, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more|Length of hospitalization|Adverse events of prone positioning (i.e., venous thromboembolism, pneumonia)|In-hospital all-cause mortality|Invasive or non-invasive mechanical ventilation|Need for FiO2 of 60% or more|Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more assessed at 30 days, 90 days and 1 year|Time spent in prone positioning among patients achieving the composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more""}"
"2532","Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19","","NCT04369599","STUDY00000402","Device: V/Q Vest","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04369599","Suspended","2020-08-11","2021-04-01","{""locations"":""Emory University Hospital, Atlanta, Georgia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Arterial Oxygenation Levels|Number of participants requiring advanced therapy|Number of participants avoiding proning ventilation|Number of participants delaying proning ventilation""}"
"2533","Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19","","NCT04342806","Pro00105284","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04342806","Recruiting","2020-04-10","2099-12-31","{""locations"":""Duke Clinical Research Institute, Durham, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100000"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis|Distribution of COVID-19 risk factors by participant characteristics|Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization)|Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study|Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment""}"
"2534","Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS","RAPA-CARDS","NCT04482712","HSC20200489H","Drug: Rapamycin|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04482712","Not yet recruiting","2021-04-01","2023-01-01","{""locations"":""University Hospital System, San Antonio, Texas, United States|Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival rate|Change in Clinical Status assessed by the World Health Organization (WHO) scale|Change in Clinical Status assessed by the National Institute of Allergy and Infectious Disease (NIAID) scale""}"
"2535","Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care","CO-CarES","NCT04409821","P-2020-544|0216-00030B","Behavioral: Tele-delivered psychological intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04409821","Recruiting","2020-05-29","2022-02-01","{""locations"":""Skejby Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Hospitalsenheden Vest, Horsens, Horsens, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Sygehus Lilleb\u00e6lt, Kolding, Kolding, Denmark|Odense University Hospital, Odense, Denmark"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recruitment rate|Completion rate|Peri-traumatic distress inventory (negative emotions)|Impact of Events Scale (6 item)|Prolonged Grief-13-scale|PROMIS Depression (8 item scale)|PROMIS Anxiety (8 item scale)|Perceived Stress Scale (4 item)""}"
"2536","Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19","CQOTE","NCT04360759","HIV-COVID-19 CQOTE","Drug: Chloroquine or hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04360759","Withdrawn","2020-05-01","2021-06-30","{""locations"":""Khayelitsha Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Event-free survival at 28 days post-randomization between experimental group and standard of care group|Incidence of serious adverse events|Incidence of adverse events of special interest related to investigational product at time of hospitalisation|Premature discontinuation of treatment|Time from treatment initiation to death, ARDS (PF\/SF ratio < 300), or mechanical ventilation|Proportion with moderate and severe ARDS|Duration of hospitalisation and ICU stay in survivors|Incidence of Covid-19 in household contacts""}"
"2537","Investigation of Safety and Efficacy of CARDIO Softgels in Former Smokers and Asthma Patients With COVID-19 Infection","","NCT04465513","20CCHH","Dietary Supplement: Best Standard of Care + CARDIO|Dietary Supplement: Best Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04465513","Not yet recruiting","2020-08-31","2021-08-31","{""locations"":""KGK Science Inc., London, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygenation requirements during hospital stay (oxygen saturation rates)|Oxygenation requirements during hospital stay (supplemental Oxygen)|Oxygenation requirements during hospital stay (ventilator support)|Clinical improvement|Clinical status|Serial chest CT or X-ray findings|Time to clinical recovery|Time to improvement in oxygenation for at least 48 hours|Hospitalization period|Amount of time on Ventilator|Intensive Care stay|Quality of life (QoL)|All-cause mortality|Temperature measurements|Oxygen saturation measurements|COVID-19 QoL measurements""}"
"2538","Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship","","NCT04609501","0082-20-HYMC","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04609501","Active, not recruiting","2020-06-01","2024-06-30","{""locations"":""Department of Obstetrics and Gynecology, Hillel-Yaffe Medical Center, Hadera, Israel"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""440"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""The relations between fear of COVID-19 and postnatal depression symptoms.""}"
"2539","Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease)","","NCT04649931","HC-N-H-2006","Device: Ion Mobility Spectrometry (IMS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649931","Recruiting","2020-12-14","2021-05-01","{""locations"":""University Hospital Gie\u00dfen and Marburg (UKGM), site Marburg, Marburg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 related volatile organic compounds (VOC)|To compare the SARS-CoV-2 specific VOC with the clinical symptoms of COVID-19 (Corona Virus Disease 2019)""}"
"2540","Inflammatory Signal Inhibitors for COVID-19 (MATIS)","MATIS","NCT04581954","20HH5926|2020-001750-22","Drug: Ruxolitinib|Drug: Fostamatinib|Other: Standard of care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04581954","Recruiting","2020-10-02","2021-07-31","{""locations"":""Imperial College Healthcare NHS Trust, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""456"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Number and proportion of patients requiring invasive ventilation|Number and proportion of patients requiring non-invasive ventilation (CPAP and high flow nasal oxygen)|Number and proportion of patients requiring invasive ventilation or extracorporeal membrane oxygenation (ECMO)|Number and proportion of patients requiring non-invasive ventilation including continuous positive airway pressure (CPAP) or high flow nasal oxygen|Number and proportion of patients requiring renal replacement therapy|Number and proportion of patients experiencing venous thromboembolism events|Length of stay|Number and proportion of serious adverse events and discontinuations|Absolute change in pneumonia severity on the modified WHO COVID-19 Ordinal Scale""}"
"2541","A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2","","NCT04611802","2019nCoV-301","Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Other: Placebo (Initial Vaccination Period)|Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|Other: Placebo (Crossover Vaccination period)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04611802","Active, not recruiting","2020-12-27","2022-12-30","{""locations"":""Accel Research Sites, Birmingham, Alabama, United States|HOPE Research Institute, Phoenix, Arizona, United States|AMR Tempe Clinical Research Consortium, Tempe, Arizona, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Anaheim Clinical Trials, Anaheim, California, United States|Advanced Clinical Research - Rancho Paseo, Banning, California, United States|eStudy Site, Chula Vista, California, United States|eStudySite - Corporate Offices, La Mesa, California, United States|Wr-Pri, Llc, Los Alamitos, California, United States|National Research Institute, Los Angeles, California, United States|Transitional Research Group, Inc., North Hollywood, California, United States|Empire Clinical Research, Pomona, California, United States|University of California Davis Health, Sacramento, California, United States|Benchmark Research, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|Dignity Health Medical Foundation - Woodland, Woodland, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Howard University Hospital Howard\/ University College of Medicine, Washington, District of Columbia, United States|University Clinical Research-Deland, LLC dba Accel Research Sites, DeLand, Florida, United States|SIMED Health, LLC \/ SIMED Research, Gainesville, Florida, United States|M D Clinical, Hallandale Beach, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Meridien Research\/Accel Research, Lakeland, Florida, United States|Miami Veterans Affairs Medical Center, Miami, Florida, United States|Suncoast Research Associates, LLC, Miami, Florida, United States|Clinical Neuroscience Solutions Inc, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Pinellas Park, Florida, United States|University of South Florida, Tampa, Florida, United States|Jedidiah Clinical Research, Tampa, Florida, United States|Synexus Clinical Research US, Inc., The Villages, Florida, United States|Comprehensive Clinical Trials, Llc, West Palm Beach, Florida, United States|Atlanta - Morehouse School of Medicine, Atlanta, Georgia, United States|Ponce CRS Emory University, Atlanta, Georgia, United States|Synexus Clinical Research US, Inc., Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|IACT Health (DBA John B. Amos Cancer Center), Columbus, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Synexus, Chicago, Illinois, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Providea Health Partners LLC, Mokena, Illinois, United States|Synexus USA, Evansville, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|University of Iowa Medical Center, Iowa City, Iowa, United States|Meridian Clinical Research, Sioux City, Iowa, United States|Johnson County Clin-Trials, Inc., Lenexa, Kansas, United States|Meridian Clinical Research, LLC, Baton Rouge, Louisiana, United States|Med Pharmics, LLC, Metairie, Louisiana, United States|Willis-Knighton Physician Network, Shreveport, Louisiana, United States|University Of Maryland School Of Medicine CVD, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|Wayne State University\/ Children's Hospital of Michigan, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|MedPharmics, LLC-Biloxi, Gulfport, Mississippi, United States|The Curators of University of Missouri, Columbia, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Meridian Clinical Research Associates, LLC, Omaha, Nebraska, United States|University Of Nebraska Medical Center, Omaha, Nebraska, United States|Synexus Clinical Research US, Inc., Henderson, Nevada, United States|Clinical Research Consortium, Las Vegas, Nevada, United States|Stony Brook Responder Vaccine Program, Commack, New York, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Rochester Clinical Research, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|The Charlotte-Mecklenburg Hospital Authority d\/b\/a Atrium Health, Charlotte, North Carolina, United States|M3-Emerging Medical Research, LLC, Durham, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Womack Army Medical Center, Fort Bragg, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Synexus Clinical Research, US, Inc., Akron, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc., Cincinnati, Ohio, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Medical Research International, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|CRISOR, LLC - Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States|The Miriam Hospital (TMH), Providence, Rhode Island, United States|Velocity Clinical Research, Providence, Warwick, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Medical University of South Carolina, SCTR Research Nexus, Charleston, South Carolina, United States|Missouri Breaks Industries Research Inc., Eagle Butte, South Dakota, United States|PMG Research of Bristol, Bristol, Tennessee, United States|WR Clinsearch, LLC, Chattanooga, Tennessee, United States|PMG Research, Inc. d\/b\/a PMG Research of Knoxville, Knoxville, Tennessee, United States|Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare, Memphis, Tennessee, United States|Clinical and Translational Research Center at Meharry Medical College, Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Centex Studies, Inc, McAllen, Texas, United States|Research Your Health, Plano, Texas, United States|Synexus, US - San Antonio, San Antonio, Texas, United States|University of Texas Health Science Center San Antonio, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Health Research of Hampton Roads, Inc, Newport News, Virginia, United States|MultiCare Institute for Research & Innovation, Cheney, Washington, United States|University of Washington VTEU, Seattle, Washington, United States|PanAmerican Clinical Research Mexico, Juriquilla, Queretaro, Mexico|Unidad de Atencion Medica e Investigacion en Salud (UNAMIS), Merida, Yucatan, Mexico|Instituto Nacional de Salud Publica (INSP) - Cuernavaca - Centro de Investigacion en Salud Poblacional (CISP), Cuernavaca, Mexico|CAIMED Investigacion en Salud S.A de C.V, Mexico City, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico|Faicic S. de R.L. de C.V., Veracruz, Mexico|Ponce Medical School Foundation Inc. \/ CAIMED Cneter, Ponce, Puerto Rico|University of Puerto Rico Medical Sciences Campus Maternal Infant Studies Center, San Juan, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""30000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)|Participants with Symptomatic Moderate or Severe COVID-19|Participants with Any Symptomatic COVID-19|Neutralizing Antibody Activity Expressed as Geometric Mean Titers (GMTs)|Neutralizing Antibody Activity Expressed as Geometric Mean Fold Rises (GMFRs)|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs|Serum IgG Antibody Levels Expressed as GMFRs|Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as GMTs|hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs at Later Time Points|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMFRs at Later Time Points|hACE2 Receptor Binding Inhibition Assay Expressed as GMTs at Later Time Points|hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs at Later Time Points|Neutralizing Antibody Activity Expressed as GMTs at Later Time Points|Neutralizing Antibody Activity Expressed as GMFRs at Later Time Points|Description of Course, Treatment and Severity of COVID-19|Reactogenicity Incidence and Severity|Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49|Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49|Incidence and Severity of MAAEs Attributed to Study Vaccine Through Month 12|Incidence and Severity of Serious Adverse Events (SAEs) Through Month 12|Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Month 12|Incidence and Severity of SAEs from Month 12 to Month 24|Incidence and Severity of MAAEs Attributed to Study Vaccine from Month 12 to Month 24|Incidence and Severity of AESIs from Month 12 to Month 24|Deaths Due to Any Cause|Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specific Time Points|Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Any Time Point|IgG antibodies to SARS-CoV-2 rS at Day 35 After First Crossover Vaccination""}"
"2542","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19","","NCT04278963","YHQW-V3.0","Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04278963","Suspended","2020-02-27","2021-01-01","{""locations"":""Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital\/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events""}"
"2543","Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients","","NCT04480411","56472","Behavioral: Doctorgram Patient Kit","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04480411","Not yet recruiting","2021-03-01","2022-02-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient provider experience survey score|Provider experience survey score|Use of personal protective improvement|Number of in-patient encounters with COVID patients as a measure of provider exposure to high risk illness""}"
"2544","Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects","","NCT04583228","HLX71-001US-253460","Drug: HLX71|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04583228","Not yet recruiting","2020-11-30","2021-05-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0|The proportion of subjects undergoing DLT events in each dose cohorts during the DLT observation period|PK parameters-Peak concentration|PK parameters-Time to peak|PK parameters-Areas under the concentration-time curves|PK parameters-Terminal elimination rate constant|PK parameters-Elimination half-life|PK parameters-Clearance (CL)|PK parameters-Volume of distribution|The concentration-time curves of plasma Ang1-10|The concentration-time curves of plasma Ang1-9|The concentration-time curves of plasma Ang1-8|The concentration-time curves of plasma Ang1-7|The concentration-time curves of plasma aldosterone|ADA positive rate|NAb positive rate""}"
"2545","Anti Infective Agents Impact in COVID-19 Pneumonia","AZITHROVID","NCT04453501","AZITHROVID|INDS","Drug: favorable outcome","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453501","Completed","2020-03-02","2020-04-25","{""locations"":""Benjamin Davido, Garches, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""132"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Favorable outcome|Risk factors 1|Risk factors 2|Interest of anti-infective agents""}"
"2546","A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19","","NCT04379492","20-187","Drug: Hydroxychloroquine|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04379492","Withdrawn","2020-05-05","2020-09-25","{""locations"":""Memorial Sloan - Kettering Cancer Center, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI)|Number of participants requiring mechanical ventilation for respiratory failure""}"
"2547","Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy","","NCT04715360","20-12-1526","Combination Product: autologous activated platelet-rich plasma|Drug: Avigan","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04715360","Recruiting","2020-12-29","2021-12-27","{""locations"":""Koja Regional Public Hospital, Jakarta, DKI Jakarta, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect of aaPRP on pro-inflammatory cytokines plasma level (IL-6, IL-1B, TNFa, IFN gamma, MCP-1) before and after intervention compared to control.|to evaluate the change of Effect of aaPRP on anti-inflammatory cytokines plasma level (IL-1RA, IL-4, IL-10) before and after intervention compared to control.|Effect of aaPRP on overall adverse event related to the treatment.|Effect of aaPRP on CRP level before and after intervention compared to control.|Effect of aaPRP on Thorax X-ray image pre and post intervention between control and aaPRP-treated group|Effect of aaPRP on duration of hospitality of patient compared to control""}"
"2548","COVID-19 in PID Survey","COPID19","NCT04459689","COPID19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459689","Recruiting","2020-03-15","2022-03-31","{""locations"":""Imagine Institute, Paris, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Survival of patients with PID affected by COVID-19|Rate of admission to ICU of patients with PID affected by COVID-19|Rate of oxygen therapy of patients with PID affected by COVID-19|Sequelae of patients with PID affected by COVID-19""}"
"2549","Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin Lymphoma","LYMPHO-Cov-2","NCT04641806","P20/21_LYMPHO-Cov-2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04641806","Not yet recruiting","2020-12-15","2021-09-16","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immunological response to SARS Cov2|Clinical evolution after Covid-19 diagnosis""}"
"2550","Frequency of Perforated Appendicitis in Times of COVID-19","","NCT04472052","AZ: 324/2020BO2","Other: appendectomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04472052","Completed","2020-03-16","2020-05-31","{""locations"":""University Hospital of Tuebingen, Tuebingen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""143"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""rate of perforated appendicitis""}"
"2551","Methylene Blue Treatment of COVID-19","","NCT04635605","MB treatment of COVID19","Drug: Methylene Blue|Drug: Control Test","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04635605","Recruiting","2020-11-05","2022-12-31","{""locations"":""Fondazione Epatocentro Ticino, Lugano, Ticino, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""64"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""to compare the viral load kinetics in the enrolled patients with a SARS-CoV-2 positive nasopharyngeal swab demonstrating a reduction of the area under the curve day 0- day 21 of at least 25%|To calculate the percentage of patients clearing SARS-CoV-2 by 3, 6, 9, 12, 15 and 21 days after diagnosis|To calculate the percentage of patients having a reduction of viral load of > 2 log by day 3|To calculate the percentage of patients having a poor outcome as measured by the need of hospitalization for COVID-19|To calculate the percentage of patients alive|Safety and tolerability of the administered drug are registered as \""adverse events\"", which are all symptoms related or supposed to be related to the drug that appeared after the drug intake and were NOT present at baseline or before|To measure the compliance by calculating the number of capsules taken by the patient and the overall number of patients who complete the treatment""}"
"2552","Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden","","NCT04382417","RegionVastmanland","Other: Observational study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382417","Completed","2020-03-26","2020-11-12","{""locations"":""Intensive Care Unit, V\u00e4ster\u00e5s Hospital, V\u00e4ster\u00e5s, V\u00e4stmanland, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""57"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Demographic characteristics of patients with Covid-19 receiving intensive care|Survival rate in patients with Covid-19 receiving intensive care|Clinical course characteristics of patients with Covid-19 receiving intensive care|Number of days on mechanical ventilation""}"
"2553","Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care","HYDRO COVID","NCT04716985","2020-A03137-32","Dietary Supplement: MOLECULAR HYDROGEN|Dietary Supplement: PLACEBO MAGNESIUM","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04716985","Recruiting","2021-01-22","2022-12-22","{""locations"":""Timc-Imag (Umr5525 Uga-Cnrs), Grenoble, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""450"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the incidence rate of the onset of clinical worsening|Assessment of tolerance|Assessment of compliance|Assessment of medium-long term dyspnea symptoms|Assessment of medium-long term fatigue symptoms|Assessment of oximetry symptoms|Assessment of quality of life|Assesment of sleep quality|Assessment of care consumption|Assessment of blind treatment|Assessment of COVID-19 contact cases|Assessment of risk factors|Analysis of older patients|Assessment of pain""}"
"2554","SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir)","","NCT04365595","2020-00745","Other: Questionnaires, spirometry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365595","Completed","2020-06-03","2021-02-17","{""locations"":""University Hospital Zurich, Zurich, Switzerland"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""58"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health-related quality-of-life|Anxiety and depression|Symptom burden|Spirometry""}"
"2555","Mechanisms of Multi-organ Failure in COVID-19","","NCT04399603","283783","Other: no intervention-mechanistic study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04399603","Not yet recruiting","2020-05-18","2021-11-17","{""locations"":""Imperial College NHS Trust, London, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19|Correlation of inflammatory mediators in the bronchoalveolar lavage fluid with extent of lung injury (e.g. based upon oxygen requirement)|Correlation of circulating inflammatory mediators with renal and cardiovascular markers|Assess the role of inflammatory mediators obtained from patients in the development of renal injury using in vitro models (i.e. applying these inflammatory mediators isolated from these clinical samples on kidneys cells in a petri dish)""}"
"2556","Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19","MoxiCov","NCT04587921","5058/20/087","Device: Digital oximeter monitoring","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04587921","Recruiting","2020-06-22","2021-06-22","{""locations"":""Funda\u00e7\u00e3o Zerbini - Instituto do Cora\u00e7\u00e3o (InCor), S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of the system: Determination of the number of valid versus not valid or missed measurements|Hypoxic burden|Hypoxic alarm|Satisfaction of the nursing, medical team and patients with the implemented system|Time of SpO2<90%, SpO2<85% and SpO2<80%|Number of false alarms caused by malfunctions or bad oximeter positioning|Total hospital stay|Time of supplementary oxygen use|Mortality of participants""}"
"2557","Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women","HyPreC","NCT04354441","1, March 30, 2020","Drug: hydroxychloroquine sulfate 200 MG|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04354441","Withdrawn","2020-05-01","2020-05-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""COVID-19-related hospital admissions|Symptoms related to COVID-19 infection|Adverse Events|Maternal outcomes|Newborn outcomes""}"
"2558","Association Between BMI and COVID-19","BMI-SARS-CoV-2","NCT04391738","DEC20-095","Other: Patients admitted to Intensive Care Unit with SARS-CoV2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04391738","Active, not recruiting","2020-02-01","2020-09-30","{""locations"":""Centre Hospitalier R\u00e9gional & Universitaire de Lille (CHRU), Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Relationship between body mass index (BMI) and SARS-CoV-2|Associations between BMI and outcomes is independent of the known cardiometabolic risk factors|Investigate the modifying effects of age and sex on the associations between BMI and outcome: Invasive mechanical ventilation|Investigate the modifying effects of age and sex on the associations between BMI and outcome: mortality""}"
"2559","Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly","NR-COVID19","NCT04407390","H-20026601","Dietary Supplement: Nicotinamide riboside|Dietary Supplement: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04407390","Recruiting","2020-06-01","2022-05-01","{""locations"":""Bispebjerg Hospital, Copenhagen NV, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Hypoxic respiratory failure|Mortality|Sepsis|Circulatory failure|Days in hospital|NAD levels""}"
"2560","Prevalence of COVID-19 Infection Among HCW in a French University Hospital","EXPOCOVIA","NCT04371692","2020_35|2020-A00951-38","Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371692","Not yet recruiting","2020-04-01","2020-09-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection|immunologic status of health Care Worker|inflammatory biomarkers status of Health Care Worker""}"
"2561","Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85","COVIDRASP","NCT04496245","BV-2020/19","Drug: Broncho-Vaxom®","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04496245","Recruiting","2020-08-24","2021-06-30","{""locations"":""The Prince Charles Hospital, Brisbane, Queensland, Australia|The Princess Alexandra Hospital, Brisbane, Queensland, Australia|Queensland Children's Hospital, South Brisbane, Queensland, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acute Respiratory Infection necessitating workforce removal|Time to ARI necessitating workforce removal.|The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal|The proportion of HCW with documented Cov infection.|Time to Lower respiratory infection (LRI) necessitating workforce removal.|The proportion of Health Care Workers contracting a LRI necessitating workforce removal|The proportion of HCW with documented Cov LRI.""}"
"2562","Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.","CONEC","NCT04347694","1357/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347694","Recruiting","2020-04-11","2021-04-11","{""locations"":""Medical University of Vienna, Division for Nephrology and Dialysis, Vienna, Austria"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Status of Immunization""}"
"2563","Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis","SAPRIS-SERO","NCT04392388","C20-26|2020-A01195-34","Biological: Non applicable","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04392388","Recruiting","2020-05-01","2020-12-31","{""locations"":""Inserm, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""110000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Cumulative incidence of SARS-Cov2 infection in the general population.|Maintenance over time of the acquisition of anti-SARS-Cov2 antibodies|Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection|Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social determinants|Proportion of tests proposed, accepted, performed, based on social and demographic characteristics|Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings \/ reasons, duration, frequency) and association with the level of seroprevalence|Strengths of associations between socio-behavioral factors and level of seroprevalence""}"
"2564","Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19","","NCT04716088","RADT for COVID-19 Golnik","Diagnostic Test: Rapid antigen test for SARS CoV2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04716088","Completed","2020-11-18","2020-12-22","{""locations"":""Universitiy Clinic for respiratory and allergic diseases, Golnik, Slovenia"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""36"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS CoV2 infection""}"
"2565","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","","NCT04335552","PRO00105339","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04335552","Terminated","2020-04-17","2020-06-26","{""locations"":""Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""11"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events""}"
"2566","Nitazoxanide Therapy for Patients With COVID-19 Pneumonia","","NCT04561219","SARITA-1|RBR-88bs9x|30662420.0.1001.0008","Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04561219","Completed","2020-04-19","2020-10-02","{""locations"":""Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Orotracheal intubation rate|Mechanical ventilation free days|Hospitalisation days|ICU days|Intranasal oxygen support days|Mortality rate|Days with fever|Days with cough|Days with dyspnea|Radiologic findings|Cardiologic findings|C-reactive protein - absolute number|C-reactive protein serum levels|Lactate dehydrogenase (LDH) serum levels|Troponin serum levels|Electrolytes serum levels|Glucose serum levels|Renal function|Coagulogram|Liver function panel|Ferritin|D-dimer|Blood cell count|Inflammatory mediators""}"
"2567","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","IMMUNONCOVID","NCT04333914","ET20-076 - IMMUNONCOVID-20|2020-001373-70","Drug: Autophagy inhibitor (GNS651)|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04333914","Recruiting","2020-04-15","2021-08-01","{""locations"":""Centre L\u00e9on B\u00e9rard, Lyon, Rh\u00f4ne, France|CHU Clermont Ferrand, Clermont Ferrand, France|Centre Oscar Lambret, Lille, France|AP-HP H\u00f4pital Saint Antoine, Paris, France|AP-HP La Piti\u00e9 Salp\u00e9tri\u00e8re, Paris, France|H\u00f4pital Saint-Joseph, Paris, France|AP-HP Tenon, Paris, France|AP-HP H\u00f4pital Bichat Claude Bernard, Paris, France|GH Diaconesses Croix Saint Simon, Paris, France|Institut Gustave Roussy, Villejuif, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""219"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28-day survival rate|Time to clinical improvement|Clinical status|Mean change in the ranking on the ordinal scale from baseline to D7, D14 and D28|Mean change in the ranking of the NEWS2 score from baseline to D7, D14 and D28|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|The rate of secondary infection by other documented pathogens (bacteria, fungi)|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)|The rate of patients with SARS-CoV-2 IgG antibodies at D7, D14 and D28""}"
"2568","Maraviroc in Patients With Moderate and Severe COVID-19","","NCT04435522","1611471-1","Drug: Maraviroc","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04435522","Completed","2020-10-01","2020-12-31","{""locations"":""Rhode Island Hospital, Providence, Rhode Island, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""9"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of Completion|Clinical improvement at Day 7|Change in Chitinase 3-like 1(Chi3l1) (ng\/mL)|Change in Interleukin-6 (IL-6) (pg\/mL)|Change in CCL5 (RANTES) (ng\/mL)|Mortality|Time to Discharge|Days on mechanical ventilation""}"
"2569","Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab)","COVISPERM","NCT04460534","2020-A01206-33","Diagnostic Test: diagnostic","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04460534","Recruiting","2020-05-07","2021-08-31","{""locations"":""H\u00f4pital Priv\u00e9 de Parly II, Le Chesnay, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Testing for the presence of COVID-19 (SARS-CoV-2 virus) in the semen|Kinetics of SARS-CoV-2 virus presence in the semen""}"
"2570","Evaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic","","NCT04558645","91610558-604.01.02","Other: Online Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04558645","Completed","2020-09-18","2020-12-26","{""locations"":""Zeliha \u00c7EL\u0130K, Ankara, \u00c7ankaya, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""118"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical activity level|General Quality of life|Depression|Anxiety|Self-reported hypoglycemia|Loneliness|Hypoglisemia fear|Dyspnea""}"
"2571","Sofosbuvir in Treatment of COVID 19","","NCT04460443","sofosbuvir","Drug: sofosbuvir|Drug: Sofosbuvir ledipsavir|Drug: Daclatasvir","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04460443","Recruiting","2020-08-01","2021-08-31","{""locations"":""Sherief Abd-Elsalam, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patients with response to treatment""}"
"2572","COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising","","NCT04433039","IRB (00012098), SN (0304669)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433039","Completed","2020-05-22","2020-06-14","{""locations"":""Faculty of Medicine, University of Alexandria, Alexandria, Egypt"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Retrospective"",""enrollment"":""130"",""age"":""4 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""COVID19 versus H1N1; radiological comparative study""}"
"2573","Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection","CovExc","NCT04649086","PHRCI 2020 COSTE (CovExc)|2020-A01201-38","Other: Rehabilitation by Eccentric exercises|Other: Rehabilitation by Concentric exercises","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04649086","Recruiting","2020-06-05","2021-12-05","{""locations"":""CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Dijon, Dijon, France|Centre M\u00e9dico-Chirurgical de R\u00e9adaptation (CMCR) des Massues, Lyon, France|CHU de Saint-Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Functional walking capacity|Evaluating of lower extremity functioning by Short Physical Performance Battery (SPPB) score|Evaluating the maximum muscle strength of the quadriceps by Quadriceps Isometric Maximum Strength (QIMS) test|Evaluating the fatigability of the quadriceps by Quadriceps Intermittent Fatigue (QIF) test|Evaluating the global fatigability by Modified Fatigue Impact Scale (MFIS)|Evaluating functional capacities with EuroQol - 5 Dimensions (EQ-5D) questionnaire|Evaluating the handgrip strength by standard handgrip strength test|Metabolomic Profile|Cross sectional area measurement|Capillary to fibre ratio.|Satellite cell number""}"
"2574","Head and Neck cancERs International cOviD-19 collabOraTion","","NCT04632173","HERODOTUS","Other: non interventional study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04632173","Not yet recruiting","2020-12-01","2021-06-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""750"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Demographic features|prevalence of comorbidities in head and neck cancer patients with COVID-19|proportion of head and neck cancer patients experiencing severe adverse events|proportion of head and neck cancer patients by COVID-19 clinical course severity|proportion of head and neck cancer patients with COVID-19 who received chemotherapy, surgery, radiotherapy, immune check point inhibitors in the last 3 months before, as well as during, COVID-19 infection|predictive factors of severe adverse events in head and neck cancer patients with COVID-19 including cancer-related treatment|prognostic factors of head and neck cancer patients with COVID-19 including cancer related treatment including Human papilloma virus(HPV).""}"
"2575","Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections","COVAPID","NCT04359693","2020_27|2020-A00995-34","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359693","Completed","2020-04-22","2020-07-01","{""locations"":""H\u00f4pital Roger Salengro, ICU, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1576"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of ventilator-associated lower respiratory tract infection|Cumulative incidence of ventilator-associated tracheobronchitis|Cumulative incidence of ventilator-associated pneumonia|the cumulative incidence of ICU acquired bacteremia diagnosed|ICU mortality|Mortality|the duration of mechanical ventilation|Length of stay in Intensive Care Unit""}"
"2576","Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland","","NCT04648800","BCG/COVID-19/UR/04/2020|2020-002111-22","Drug: BCG-10 vaccine|Drug: 0.9% saline","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04648800","Recruiting","2020-07-07","2021-04-01","{""locations"":""Department of Anesthesiology and Intensive Care, University Clinical Center, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland|Stefan \u017beromski Specialist Hospital, Krak\u00f3w, Poland|Voivodeship Hospital nr 2 in the Name of The Saint Queen Jadwiga, University of Rzesz\u00f3w, Poland, Rzesz\u00f3w, Poland|Saint Jadwiga \u015al\u0105ska Hospital, Trzebnica, Poland|Department of Pediatrics, Bielanski Hospital,, Warsaw, Poland|Praski Hospital, Warsaw, Poland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""25 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""death and life- or health-threatening condition (cardiac arrest with effective resuscitation, shock, severe respiratory failure, severe renal failure, stroke\/transient cerebral ischaemia)|Onset of clinical symptoms of COVID-19|asymptomatic SARS-CovV-2 infection|Hospitalisation|ICU Hospitalisation|Dyspnoea""}"
"2577","BCG Vaccination to Protect Healthcare Workers Against COVID-19","BRACE","NCT04327206","62586|U1111-1256-4104","Drug: BCG Vaccine|Drug: 0.9%NaCl","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04327206","Recruiting","2020-03-30","2022-03-30","{""locations"":""St Vincent's Hospital, Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Funda\u00e7\u00e3o de Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas, Brazil|Santa Casa Hospital, Campo Grande, Mato Grosso Do Sul, Brazil|CASSEMS Hospital, Campo Grande, Mato Grosso Do Sul, Brazil|Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso Do Sul, Brazil|Hospital Regional de Mato Grosso do Sul, Campo Grande, Mato Grosso Do Sul, Brazil|Centro de Estudos da Sa\u00fade do Trabalhador e Ecologia Humana, Rio de Janeiro, RJ, Brazil|Centro de Refer\u00eancia Prof H\u00e9lio Fraga, Rio de Janeiro, RJ, Brazil|Noord West Ziekenhuis, Alkmaar, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Hospital, Breda, Netherlands|St Antonius Hospital, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|University hospital in Utrecht (UMCU), Utrecht, Netherlands|University Hospital German Trias I Pujol, Badalona, Barcelona, Spain|Mutua Terrassa Univeristy Hospital, Terrassa, Barcelona, Spain|University Hospital Cruces, Barakaldo, Bizkaia, Spain|Marqu\u00e9s de Valdecilla University Hospital, Santander, Spain|University Hospital Virgen Macarena, Sevilla, Spain|Ide Lane Surgery, Alphington, Exeter, United Kingdom|St Leonard's Practice, St Leonards, Exeter, United Kingdom|Travel Clinic, Exeter, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""10078"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Fever or respiratory illness|Episodes of fever or respiratory illness|Work absenteeism due to fever or respiratory illness|Bed confinement due to fever or respiratory illness|Symptom duration of fever or respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with fever or respiratory illness|Unplanned work absenteeism|Local and systemic adverse events to BCG vaccination in healthcare workers""}"
"2578","Perceptions of Undergraduate Students and Teaching Staff on Online Teaching","","NCT04466371","PUB 1114005","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04466371","Not yet recruiting","2020-10-15","2021-11-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""9209"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Satisfaction with online learning|Knowledge about COVID-19 crisis|Perception of COVID-19 crisis""}"
"2579","Use of UC-MSCs for COVID-19 Patients","","NCT04355728","20200671|20200370","Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04355728","Completed","2020-04-25","2020-10-31","{""locations"":""Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of pre-specified infusion associated adverse events|Incidence of Severe Adverse Events|Survival rate after 90 days post first infusion|Ventilator-Free Days|Change in Oxygenation Index (OI)|Plat-PEEP|Sequential Organ Failure Assessment (SOFA) Scores|Small Identification Test (SIT) scores|Troponin I levels|C-Reactive Protein levels|Arachidonic Acid (AA)\/Eicosapentaenoic Acid (EPA) Ratio|D-dimer levels|25-Hydroxy Vitamin D levels|Alloantibodies levels|Blood white cell count|Platelets count""}"
"2580","Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients","SIZI-COVID-PK","NCT04472585","SZMC/IRB/Internal/215/2020","Drug: Ivermectin Injectable Solution|Other: Injectable Placebo|Drug: Zinc|Drug: Placebo empty capsule|Drug: Oral Ivermectin","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04472585","Recruiting","2020-11-14","2021-10-30","{""locations"":""Ali Clinic, Lahore, MA, Pakistan|Shaikh Zayed Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""qRT-PCR|Time taken for alleviation of symptoms|Severity of symptoms|Morality""}"
"2581","COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C","PRISM","NCT04588363","DAIT PRISM-01|NIAID CRMS ID#: 38772","Other: SARS-CoV-2 and/or MIS-C Exposure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04588363","Recruiting","2020-11-19","2022-11-01","{""locations"":""Loma Linda University Health, Loma Linda, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital at Montefiore, Bronx, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|NewYork-Presbyterian Queens Hospital, Flushing, New York, United States|Cohen Children's Medical Center - Northwell Health, New Hyde Park, New York, United States|Hassenfeld Children's Hospital at NYU Langone, New York, New York, United States|NewYork-Presbyterian Komansky Children's Hospital, New York, New York, United States|Mount Sinai Kravis Children's Hospital, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Duke University Children's Health Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Pediatric Rheumatology, Charleston, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Eccles Primary Children's: University of Utah Health, Salt Lake City, Utah, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""up to 20 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Proportion of Participants With Either COVID-19-Related Death, Rehospitalization, Major Complications after SARS-CoV-2 Illness and\/or MIS-C at 6 Months Post Illness Presentation|Proportion of Participants with Coronavirus Disease 2019 (COVID-19)-Related Death after Multisystem Inflammatory Syndrome in Children (MIS-C) at 1 Year Post Illness Presentation|All-Cause Mortality|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mortality|Hospitalization for Participants Enrolled as an Outpatient or Rehospitalization after First Admission in Hospitalized Participants|Coagulation Abnormality by D-Dimer Biomarker|Coagulation Abnormality by Fibrinogen Biomarker|Coagulation Abnormality by Prothrombin Time (PT) and Activated Partial Thromboplastin Time (PTT) Biomarkers|Coagulation Abnormality by International Normalised Ratio (INR) Biomarker|Coronary Artery Abnormalities|Pulmonary Hypertension|Cardiovascular System Dysregulation by B-type natriuretic peptide (BNP) Biomarker|Cardiovascular System Dysregulation by Troponin I Biomarker|Cardiovascular System Dysregulation by Echocardiogram|Cardiovascular System Dysregulation by Electrocardiogram (ECG)|Pulmonary Abnormalities|Pulmonary Function Characteristics|Renal\/Metabolic Biomarkers: Serum Creatinine and Blood Urea Nitrogen (BUN)|Renal\/Metabolic Biomarker: Estimated glomerular filtration rate (eGFR)|Hepatic\/Metabolic Biomarkers: Serum Alkaline Phosphatase (Alk Phos), Alanine Aminotransferase ( ALT\/SGPT)and Aspartate Aminotransferase (AST\/SGOT)|Hepatic\/Metabolic Biomarker: Total Bilirubin|Neurologic Abnormalities|Other End Organ and\/or functional abnormalities Occurring After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection\/ Coronavirus Disease 2019 (COVID-19) and\/or Multisystem Inflammatory Syndrome in Children (MIS-C)|Health Related Quality of Life""}"
"2582","Telmisartan in Respiratory Failure Due to COVID-19","STAR-COVID","NCT04510662","CI/HRAEZ2020/05","Drug: Telmisartan","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04510662","Recruiting","2020-08-01","2021-04-01","{""locations"":""Hospital Regional de Alta Especialidad de Zumpango, Zumpango, Estado De Mexico, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death|Mechanical ventilation|Occurrence of acute kidney injury|Incidence of hypotension|Incidence of hypotension requiring vasopressors|Incidence of Sepsis|Hospital length of stay""}"
"2583","Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19","","NCT04376840","PO20066","Other: Blood sample and data record","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04376840","Recruiting","2020-05-28","2022-10-28","{""locations"":""Damien JOLLY, Reims, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""270"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""medium-term respiratory complications|long-term respiratory complications""}"
"2584","Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo","","NCT04408014","COVID-19-Epi-01","Diagnostic Test: Serological test|Diagnostic Test: Nasopharyngeal Swab|Diagnostic Test: Oropharyngeal Swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408014","Not yet recruiting","2020-06-01","2020-07-30","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""18901"",""age"":""6 Months to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Prevalence of antibodies against SARS-CoV-2 through serological testing|Frequency of participants with a positive RT-PCR test result for SARS-CoV-2""}"
"2585","Ravulizumab and COVID-19","","NCT04570397","092420","Drug: Ravulizumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04570397","Recruiting","2020-12-18","2021-11-01","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assess the efficacy of ravulizumab to ameliorate SARS-CoV-2 (COVID-19)-induced acute kidney injury manifesting as thrombotic microangiopathy.|Evaluation of pharmacokinetics of ravulizumab in participants with COVID-19""}"
"2586","SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients","","NCT04402853","72/2020","Diagnostic Test: Tears swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04402853","Completed","2020-02-01","2020-05-20","{""locations"":""ASST Sette Laghi, Varese, Italy"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virus presence in COVID 19 patients tears|Concordance to Naso-Pharingeal Swab""}"
"2587","Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults","BCG-PRIME","NCT04537663","BCG-PRIME","Drug: Bacille Calmette-Guérin (BCG)|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04537663","Recruiting","2020-08-25","2021-04-01","{""locations"":""Meander Medical Center, Amersfoort, Netherlands|Amsterdam University Medical Center, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Amphia hospital, Breda, Netherlands|Hagahospital, Den Haag, Netherlands|Catharina hospital, Eindhoven, Netherlands|Zuyderland Hospital, Geleen, Netherlands|Martini hospital, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|St. Antonius hospital, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Ikazia Hospital, Rotterdam, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Bernhoven hospital, Uden, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""5200"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The trial has an adaptive primary endpoint. Based on predefined objective and quantitative criteria the primary endpoint will be either a clinically relevant respiratory tract infection, or COVID-19.|Cumulative incidence of SARS-CoV-2 infection (irrespective the presence of symptoms)|Cumulative incidence of asymptomatic, mild\/moderate, and severe (requiring hospitalization) SARS-CoV-2 infection.|Influenza infection|An acute respiratory tract infection|Medically attended acute respiratory tract infection|Acute respiratory tract infection related hospital admission|Pneumonia diagnosed by a GP or medical specialist|Functioning in daily activities|Serious adverse events and adverse events.|Major cardiovascular events|All cause 6-month mortality|History of falls|Quality of life using the EQ5D quality of life instrument|Activities in daily living""}"
"2588","Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers","COKITS","NCT04619407","BB 179/20","Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Serum testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04619407","Recruiting","2020-11-04","2021-03-01","{""locations"":""Greifswald University Medicine, Greifswald, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""3 Years to 67 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Share of participants with SARS-CoV-2 detectable in PCR|Seroprevalence of SARS-CoV-2 antibodies|SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life""}"
"2589","""NORPLASMA"" Covid-19 Convalescent Plasma Treatment Monitoring Study","MONITOR","NCT04463823","148622","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04463823","Recruiting","2020-07-06","2025-05-31","{""locations"":""Helse Fonna, Haugesund, Norway|Sorlandet hospital, Kristiansand, Norway|Akershus University Hospital, L\u00f8renskog, Norway|Oslo University Hospital, Oslo, Norway|Sykehuset Ostfold, Sarpsborg, Norway|Sykehuset Telemark, Skien, Norway|St.Olavs Hospital, Trondheim, Norway"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""observation""}"
"2590","Precision Immunology to Determine the Immune Response in Patients With COVID-19","","NCT04360733","BOST-03","Other: Blood draw","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04360733","Recruiting","2020-04-20","2022-09-01","{""locations"":""University Hospital Bonn, Bonn, Germany"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immune response""}"
"2591","Thromboprophylaxis for Patients in ICU With COVID-19","","NCT04623177","RegCoVid-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04623177","Active, not recruiting","2020-03-01","2020-11-01","{""locations"":""Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Arag\u00f3n, Spain|Hospital General de Ciudad Real, Ciudad Real, Castilla La Mancha, Spain|Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Castilla Y Le\u00f3n, Spain|Hospital Universitario Rio Ortega, Valladolid, Castilla Y Le\u00f3n, Spain|Hospital Clinic Barcelona, Barcelona, Catalu\u00f1a, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalu\u00f1a, Spain|Hospital de Terrasa, Barcelona, Catalu\u00f1a, Spain|Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain|Hospital Universitario San Juan de Alicante, Alicante, Comunidad Valenciana, Spain|Complejo Hospitalario de C\u00e1ceres, C\u00e1ceres, Extramedura, Spain|Hospital Unversitario A Coru\u00f1a, A Coru\u00f1a, Galicia, Spain|Complexo Hospitalario Universitario de Ferrol, A Coru\u00f1a, Galicia, Spain|Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain|Hospital Povisa, Pontevedra, Galicia, Spain|Hospital Universitario de Gran Canaria Dr. Negr\u00edn, Las Palmas, Gran Canaria, Spain|Hospital Universitario Severo Ochoa, Legan\u00e9s, Madrid, Spain|Cl\u00ednica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Araba, \u00c1lava, Pa\u00eds Vasco, Spain|Hospital del Mar, Barcelona, Spain|Hospital Sanitas Cima, Barcelona, Spain|Hospital Sant Joan Desp\u00ed, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Infanta Sofia, Madrid, Spain|Hospital Rafael M\u00e9ndez, Murcia, Spain|Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitari La Fe, Valencia, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""950"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU mortality|ICU incidence of thrombotic events|ICU incidence of bleeding events|Length of ICU stay|Length of invasive mechanical ventilation|Effect of LMWH in other parameters""}"
"2592","Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)","","NCT04466098","2020LS075|MT2020-12","Biological: Mesenchymal stromal cells|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04466098","Recruiting","2020-07-30","2021-12-01","{""locations"":""University of Minnesota, Minneapolis, Minnesota, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen""}"
"2593","Acute Encephalopathy in Critically Ill Patients With COVID-19","NeuroCOVID19","NCT04320472","Neuro-COVID-19","Other: Follow up","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04320472","Active, not recruiting","2020-03-23","2020-12-31","{""locations"":""Jackson Memorial Health System; University of Miami, Miller School of Medicine, Miami, Florida, United States|Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil|Fundaci\u00f3n Valle del Lili, University Hospital, Cali, Colombia|Cairo University Hospitals, Cairo, Egypt|Centre Hospitalier d'Argenteuil, Argenteuil, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre Hospitalier Universitaire Ambroise Par\u00e9, Boulogne, France|Centre Hospitalier de Bourg en Bresse, Bourg-en-Bresse, France|Centre Hospitalier R\u00e9gional Universitaire de Brest, Brest, France|Centre Hospitalier de Brives, Brive-la-Gaillarde, France|Centre Hospitalier Universitaire Beaujon, Clichy, France|Centre Hospitalier Universitaire Louis Mourier, Colombes, France|Centre Hospitalier Universitaire Henri Mondor, Cr\u00e9teil, France|Centre hospitalier de Dieppe, Dieppe, France|Centre Hospitalier Universitaire de Dijon, Dijon, France|Centre Hospitalier d'Etampes, Etampes, France|Grand H\u00f4pital de l'Est Francilien - Site de Marne-la-Vall\u00e9e, Jossigny, France|Centre Hospitalier de la Roche-sur-Yon, La Roche-sur-Yon, France|Centre Hospitalier de La Rochelle, La Rochelle, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire H\u00f4pital Edouard Herriot, Lyon, France|H\u00f4pital priv\u00e9 Jacques Cartier, Massy, France|Groupe Hospitalier Sud Ile-de-France, Melun, France|Centre Hospitalier R\u00e9gional d'Orl\u00e9ans, Orl\u00e9ans, France|Centre Hospitalier Universitaire Cochin, Paris, France|Groupe hospitalier Paris Saint-Joseph, Paris, France|H\u00f4pital Fondation Adolphe de Rothschild, Paris, France|Hopital Priv\u00e9 Claude Galien, Quincy-sous-S\u00e9nart, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Centre Hospitalier de Roanne, Roanne, France|Hopital Foch, Suresnes, France|Centre Hospitalier de Toulon, Toulon, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Tours, Tours, France|Gustave-Roussy, Villejuif, France|Hospital Regional De Alta Especialidad Del Baj\u00edo, Guanajuato, Mexico|Hospital Clinic Universitari, Valencia, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""prevalence|Favorable outcome""}"
"2594","RAS and Coagulopathy in COVID19","","NCT04419610","283093","Biological: TRV027|Other: sodium chloride 0.9%","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04419610","Recruiting","2020-10-09","2021-06-01","{""locations"":""Imperial College NHS Trust, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Coagulopathy associated with COVID-19|Markers of dysregulation of coagulation system|Markers of dysregulation of RAS|Markers of Haemolysis\/inflammation|Markers of Haemolysis\/Inflammation|Markers of Inflammation (bacterial sepsis)|Markers of organ dysregulation - kidney|Markers of dysregulation of cardiovascular system|marker of dysregulation of endocrine system""}"
"2595","COVID-19 Infection and Multiple Myeloma","EMN-COVID","NCT04492371","EMN-COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492371","Recruiting","2020-07-01","2021-07-01","{""locations"":""General Hopspital Vienna\/Medical University, Vienna, Austria|UCL Saint-Luc, Brussels, Belgium|University Hospital Ostrava, Ostrava, Czechia|University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany|Alexandra Clinical Terapeutics, Athens, Greece|AOU Consorziale Policlinico di Bari, Bari, Italy|Amsterdam UMC, Amsterdam, Netherlands|St James's University Hospital, Leeds, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Nature of COVID19|Costs related to COVID-19|Systemic anti-cancer therapy subgroup|Laboratory values collected at hospitalization|COVID-19 infection in myeloma patient subgroups|Incidence of COVID-19 infection in frail patients|Infection outcome in different countries""}"
"2596","Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia","CortiCORONA","NCT04619693","RECHMPL20_0292|2020-A0206-33|PHRCI-20-013","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04619693","Recruiting","2020-11-18","2021-09-18","{""locations"":""Clinique du Parc, Montpellier, France|University Hospitals of Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment failure (yes\/no)|Human Plasma BAK-125 proteomics profile|Circulating blood interferon level|A vector of repeated measures of SpO2|A vector of repeated measures of FiO2|A vector of repeated measures of temperature (\u00b0C)|A vector of repeated measures of respiratory rate (cycles per minute)|A vector of repeated measures of pulse (bpm)|A vector of repeated measures of systolic blood pressure (mmHg)|A vector of repeated measures of diastolic blood pressure (mmHg)|A vector of repeated measures of capillary glycemia (g\/L)|A vector of repeated measures of the qSOFA score|Hemoglobin|Platelet count|White blood cell count|Neutrophil percentage|Eosinophil percentage|Basophil percentage|Lymphocyte percentage|Monocyte percentage|Prothrombin rate (%)|Activated partial thromboplastin time ratio|Fibrinogen (g\/L)|D-Dimers (\u03bcg\/mL)|Aspartate aminotransferase (ASAT; UI\/L)|Alanine aminotransferase (ALAT; UI\/L)|Glucose (mmol\/L)|Glycated haemoglobin (HbA1c; %)|Urea (mmol\/L)|Creatinine (\u00b5mol\/L)|Estimated glomerular filtration rate (eGFR, ml\/min\/1.73m^2)|Albumin (g\/L)|C reactive protein (CRP, mg\/L)|Lactate dehydrogenase (LDH, UI\/L)|Hypersensitive troponin T (\u00b5g\/L)|Ferritin (\u00b5g\/L)|CD4 cell count|CD8 cell count|Natural killer cell count|Activated T cell percentage|Change in SARS-CoV-2 real-time polymerase chain reaction cycle threshold|Change in SARS-CoV-2 IgG serology (% of control signal = PCS)|Change in SARS-CoV-2 IgM serology (% of control signal = PCS)|Change from positivity at baseline to negativity at Day 7: yes\/no for SARS-CoV-2 real time polymerase chain reaction|Change from positivity at baseline to negativity at Day 7: yes\/no for SARS-CoV-2 IgG serology|Change from positivity at baseline to negativity at Day 7: yes\/no for SARS-CoV-2 IgM serology|Reduction in the extent of lesions visualized on computed tomography chest scan: yes\/no for grand glass opacities|Reduction in the extent of lesions visualized on computed tomography chest scan: yes\/no for consolidation|Reduction in the extent of lesions visualized on computed tomography chest scan: yes\/no for total lesions|Requirement for low flow oxygen therapy during the initial hospitalisation: yes\/no|Requirement for high flow oxygen therapy during the initial hospitalisation: yes\/no|Requirement for non-invasive ventilation during the initial hospitalisation: yes\/no|Requirement for invasive ventilation during the initial hospitalisation: yes\/no|Requirement for dialysis during the initial hospitalisation: yes\/no|Requirement for extracorporeal membrane oxygenation during the initial hospitalisation: yes\/no|Classification of acute respiratory distress syndrome (ARDS) according to the Berlin criteria during initial hospitalization: absent, mild, moderate or severe|Length of stay (hours) in intensive care|Length of stay (hours) in hospital|Days alive and without low flow oxygen therapy|Days alive and without high flow oxygen therapy|Days alive and without any oxygen therapy|Days alive and without non-invasive ventilation|Days alive and without invasive ventilation|Days alive and without extracorporeal membrane oxygenation|Days alive and without intensive care|Days alive and without hospitalisation|Mortality|Club cell secrectory protein polymorphism A38G""}"
"2597","Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers","SeCo","NCT04370119","BB 068/20","Diagnostic Test: Nasal swab|Diagnostic Test: Serum testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370119","Recruiting","2020-04-27","2025-05-01","{""locations"":""Greifswald University Medicine, Greifswald, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of people with detectable antibodies to SARS-CoV-2|Number of people with detectable SARS-CoV-2 nucleic acid""}"
"2598","COVID-19 in Liver Transplant Recipients","COVID19-SETH","NCT04361591","HCB/2020/0384","Other: Observational only","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361591","Recruiting","2020-03-01","2021-03-01","{""locations"":""SETH-affiliated Liver Transplant Programs in Spain, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incidence of COVID19 in LT recipients|Clinical characteristics of COVID19 in LT recipients|Survival and Mechanical ventilation \/ respiratory support|Observed treatments and immunosuppression management""}"
"2599","Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study","COMETE-19","NCT04430322","2020-02Obs-CHRMT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04430322","Recruiting","2020-03-01","2021-06-30","{""locations"":""CHR Metz Thionville, Metz, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""330"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""ICU admission|Hospitalization|Length of stay at the ICU|Death|CT scan result|C reactive protein|Blood Count|Sodium|Urea|Troponine|Liver function|Coagulation test|Creatinine|Clearance|Potassium|Calcium|Gamma-glutamyl transpeptidase|Bilirubine|Alcaline phosphatase|Prothrombine""}"
"2600","Using GM-CSF as a Host Directed Therapeutic Against COVID-19","","NCT04400929","SH-Leuk-01","Drug: Sargramostim|Other: Normal Saline 0.9%","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04400929","Recruiting","2020-06-02","2022-06-01","{""locations"":""Singapore General Hospital, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""21 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measuring oxygenation""}"
"2601","Police COVID-19 Serosurvey","PoliCOV","NCT04643444","2020-02650","Diagnostic Test: Blood sampling|Other: Online Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04643444","Enrolling by invitation","2021-02-09","2022-06-01","{""locations"":""University of Bern, Institute for Infectious Diseases, Bern, BE, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevalence|Risk profile assessment""}"
"2602","COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX)","OBELIX","NCT04409847","GN20CA245","Diagnostic Test: ABPM|Diagnostic Test: ECG|Diagnostic Test: FMD|Diagnostic Test: PWV|Diagnostic Test: Rarefaction","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409847","Recruiting","2020-06-01","2021-05-31","{""locations"":""NHS Greater Glasgow and Clyde, Glasgow, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""70"",""age"":""30 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""ABPM systolic blood pressure|24-hr ABPM DBP|day ABPM SBP|day ABPM DBP|night ABPM SBP|night ABPM DBP|dipping status|morning surge|24 hour ABPM HR|day ABPM HR|night ABPM HR|Immune phenotyping|Microparticle assessments""}"
"2603","Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test","","NCT04437940","Acibadem Maslak Ob&Gyn","Diagnostic Test: Vaginal fluid Covid-19 PCR test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04437940","Completed","2020-06-15","2020-11-30","{""locations"":""Acibadem Maslak Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""38"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Vaginal fluid Covid-19 PCR test result|becoming negative from positive""}"
"2604","Prognostic Factors of COVID19","Covid-HUS","NCT04405726","7760","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04405726","Recruiting","2020-03-27","2022-03-01","{""locations"":""Service de Virologie - H\u00f4pital Civil, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""500"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical Presentation and Incidence of Covid-19 Infection in patients hospitalised in Strasbourg Hospital""}"
"2605","HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists","","NCT04389294","2020-0850","Diagnostic Test: SARS-CoV2 serum antibody testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04389294","Completed","2020-05-05","2020-09-04","{""locations"":""Hospital for Special Surgery, New York, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""143"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between serology testing and clinical suspicion of COVID-19|Prevalence of SARS-CoV2 exposure|Correlation of pre-existing risk factors with results of serology testing|Number of asymptomatic participants with positive antibody serology|Proportion of antibody- positive participants who subsequently develop COVID-19|Proportion of participants who are eligible for in plasma donation""}"
"2606","Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients","WAYRA","NCT04649736","202852","Other: Respiratory and psychological rehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04649736","Recruiting","2020-10-26","2021-03-30","{""locations"":""Hospital Nacional Cayetano Heredia, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""108"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Six minute walk distance|Impact on overall health by respiratory diseases assessed by the score of the St. George's respiratory questionnaire (SGRQ)|Depressive symptomatology assessed by the Patient Health Questionnaire (PHQ-9)|Anxious symptoms assessed by the Generalized Anxiety Disorder (GAD-7) questionnaire|Quality of life assessed by the Short Form Health Survey (SF-36) questionnaire|Quality of life assessed by the Health-Related Quality of Life (EQ-5D) questionnaire|Forced expiratory volume in the first second|Forced Vital Capacity|Post-traumatic stress disorder symptomatology assessed by the Impact of Event Scale Revised (IES-R) questionnaire.""}"
"2607","suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)","SAVE","NCT04357366","SAVE|2020-001466-11","Drug: Anakinra","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04357366","Recruiting","2020-04-15","2022-04-15","{""locations"":""COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|1st Department of InternalMedicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece|1st University Departmentof Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseasesof Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens, Greece|1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece|1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION, Athens, Greece|1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO, Athens, Greece|2nd Department of Internal Medicine, 251 Air Force General Hospital, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece|3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S., Athens, Greece|5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece|Department of Internal Medicine, General Hospital of Athens ELPIS, Athens, Greece|Department of Infectious Diseases, General Hospital of Kerkira, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Io\u00e1nnina, Greece|Department of Internal Medicine, General Hospital of Katerini, Kater\u00edni, Greece|Department of Internal Medicine, University General Hospital of Larissa, Larissa, Greece|Department of Internal Medicine, General Hospital of Larisa KOUTLIMBANEIO & \u03a4\u03a1\u0399\u0391\u039d\u03a4\u0391F\u03a5LL\u0395\u0399\u039f, Larissa, Greece|Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Patra, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO, Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessalon\u00edki, Greece"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The ratio of patients who will develop serious respiratory failure (SRF)|Comparison of the rate of patients who will develop serious respiratory failure (SRF) until day 14 with comparators from Hellenic Sepsis Study Group Database receiving standard-of-care treatment|Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 7|Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 14|Change of SOFA score in enrolled subjects between days 1 and 7|Change of Sequential organ failure assessment (SOFA) score in enrolled subjects between days 1 and 14|Change of peripheral mononuclear blood cells' (PBMCs) functionality between days 1 and 7|Change of plasma inflammatory mediators levels between days 1 and 7|Rate of Mortality|Change of gene expression between days 1 nad 7""}"
"2608","Novel Regimens in COVID-19 Treatment","","NCT04382846","tanta covid treatment","Drug: Nitazoxanide","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04382846","Recruiting","2020-05-08","2030-12-01","{""locations"":""Tanta University, Assiut University, Tanta, Egypt|Sherief Abd-Elsalam, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with virological cure""}"
"2609","Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases","RetroCov","NCT04420637","RetroCov","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04420637","Enrolling by invitation","2020-06-15","2021-12-01","{""locations"":""Department of Internal Medicine, Medical University of Graz, Graz, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""liver disease|COVID infection in patients with chronic liver disease|decompensation of cirrhosis|Effect of Antiviral drugs on Covid-19 infection""}"
"2610","COVID-19 and Cancer Patients","OnCovid","NCT04393974","282140","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393974","Recruiting","2020-03-24","2022-03-24","{""locations"":""Imperial College Healthcare NHS Trust, London, United Kingdom"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Describe presenting characteristics and severity or SARS-CoV-2 infection in patients with cancer|Assessing what factors are involved in prognosis of cancer patients with COVID-19""}"
"2611","Prognositc Factors in COVID-19 Patients Complicated With Hypertension","","NCT04272710","2020-02","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04272710","Withdrawn","2020-01-25","2020-04-30","{""locations"":""The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""0"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery""}"
"2612","COVID-19 Advanced Respiratory Physiology (CARP) Study","CARP","NCT04668313","INGN20RM136","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04668313","Recruiting","2020-09-29","2021-09-29","{""locations"":""NHS Greater Glasgow and Clyde, Glasgow, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Machine-learning model development""}"
"2613","Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome","","NCT04366063","991919|IRCT20200217046526N2","Biological: Cell therapy protocol 1|Biological: Cell therapy protocol 2","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04366063","Recruiting","2020-04-05","2020-12-10","{""locations"":""Royan Institute, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse events assessment|Blood oxygen saturation|Intensive care unit-free days|Clinical symptoms|Respiratory efficacy|Biomarkers concentrations in plasma""}"
"2614","Long-term Pulmonary Outcomes After Infection With Sars-CoV-2","","NCT04401163","33510","Diagnostic Test: Imaging of the lungs","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401163","Not yet recruiting","2020-05-01","2022-12-01","{""locations"":""Aarhus University Hospital, Aarhus, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""180"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Imaging of the lungs|Pulmonary function tests|Six-minute walk test|Short Form-36 (SF-36) questionnaire|Fatigue Assessment Score|Cognitive sore (MOCA)|Hospital anxiety and Depression score (HADS)|Comorbidities|Blood sample at routine follow up.|Biobanking of blood""}"
"2615","Honey & Nigella Sativa Trial Against COVID-19","HNS-COVID-PK","NCT04347382","SZMC/IRB/Internal/0026/2020|IRB/2020/658/SIMS","Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04347382","Completed","2020-04-30","2020-08-30","{""locations"":""Federal Post-Graduate Medical Institute, Shaikh Zayed Hospital, Lahore, Punjab, Pakistan|Services Institute of Medical Sciences, Services Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""313"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days required to get a positive COVID-19 PCR to negative|Severity of symptoms progression|Duration of Hospital Saty|30 day mortality|Clinical Grade Status|Fever|Oxygen Saturation at room air""}"
"2616","PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)","","NCT04346342","PRoVENT-COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346342","Completed","2020-03-06","2020-09-01","{""locations"":""Flevoziekenhuis, Almere, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre ziekenhuizen, Apeldoorn, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medical Center, Eindhoven, Netherlands|St Anna Ziekenhuis, Geldrop, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Dijklander Ziekenhuis, Hoorn, Netherlands|Leeuwarden Medisch Centrum, Leeuwarden, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|St Antonius Ziekenhuis, Nieuwegein, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Zuyderland Medisch Centrum, Sittard, Netherlands|Isala Ziekenhuis, Zwolle, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1122"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilation Mode|Tidal volume set|Expiratory tidal volume|Positive end-expiratory pressure|Maximum airway pressure or plateau pressure (P plateau) or peak pressure (P peak) (cm H2O);|Level of pressure support above positive end-expiratory pressure (PEEP)|Inspired fraction of oxygen|Set and measured respiratory rate|Inspiration to expiration ratio|Number of ventilation-free days and alive at day 28|Duration of ventilation in survivors;|Use of prone positioning|Use of recruitment maneuvers|Incidence of acute kidney injury|Duration of ICU stay|Duration of hospital stay|ICU mortality|Hospital mortality|28-day mortality|90-day mortality""}"
"2617","Emergence of the COVID 19 Epidemic in the City of Nice","","NCT04449094","20dspcovid01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04449094","Completed","2020-02-28","2020-04-04","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Attack rate""}"
"2618","Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19","","NCT04345406","ACEIS COVID 19","Drug: ACEIs|Drug: Conventional treatment","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04345406","Not yet recruiting","2020-04-15","2029-12-01","{""locations"":""Tanta University, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""number of patients with virological cure""}"
"2619","Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males","COVIDSPERM","NCT04391829","COVIDSPERM","Diagnostic Test: Ejaculated semen sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04391829","Recruiting","2020-08-31","2021-08-31","{""locations"":""UZ Brussel, Brussels, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""20"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""detection of SARS-CoV-2 in the semen|duration of SARS-CoV-2 presence in semen|semen viscosity|semen volume|semen pH|Sperm motility|Sperm morphology|Sperm density""}"
"2620","COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients","","NCT04689464","1120","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04689464","Recruiting","2020-12-01","2021-05-01","{""locations"":""AlFayhaa Teaching hospital, Basra, Iraq"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""500"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""depression|anxiety""}"
"2621","Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)","CoCo-Neuro","NCT04362930","APHP200525","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362930","Recruiting","2020-04-27","2022-04-24","{""locations"":""H\u00f4pital Piti\u00e9 Salp\u00e9tri\u00e8re, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19|Progression of pre-existing neurological or psychiatric pathologies""}"
"2622","Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19","MICROVID","NCT04359706","2020_28|2020-A01042-37","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359706","Recruiting","2020-05-08","2020-09-01","{""locations"":""H\u00f4pital Roger Salengro, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composition of the fecal bacterial and fungal microbiota|Analysis of the faecal microbiota from rectal swab|Analysis of the respiratory microbiota from the bronchoalveolar lavage liquid|Serum inflammatory markers changes|Inflammatory markers changes|Mortality|mechanical ventilation free days""}"
"2623","Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients","","NCT04433988","RC-6-2020","Drug: Pentoxifylline|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04433988","Not yet recruiting","2021-06-13","2021-12-30","{""locations"":""Faculty of Medicine, Shib\u012bn Al Kawm, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Primary Outcome|Respiratory infection|Serious Adverse Events""}"
"2624","Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19)","LUS-COVID19","NCT04393402","20reamedcovid03","Procedure: lung ultrasound (LUS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393402","Recruiting","2020-03-20","2020-12-31","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""14"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""LUS applicability with COVID 19|Radiographic correlation (chest Xray and tomodensitometry)|LUS Mortality prediction|Prediction of Prone position response""}"
"2625","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19","Chloroquine UN","NCT04346329","UNAL-COVID-CP","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04346329","Not yet recruiting","2020-04-20","2020-10-01","{""locations"":""Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention"",""enrollment"":""86"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse effects|Immune-score|COVID-19 prevention|Clinical response""}"
"2626","Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic","PRO-SERO-COV","NCT04426006","IB 2020-01|2020-A01355-34","Other: PRO-SERO-COV","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04426006","Active, not recruiting","2020-06-01","2021-12-01","{""locations"":""Institut Bergoni\u00e9, Bordeaux, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""550"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serological immune status to an infection by the SARS-CoV-2 virus|The serological immune status to infection with the SARS-CoV-2 virus will also be determined from the different antibody isotypes (IgG and IgM), from a rapid diagnostic unit test (RDT).|kinetics of antibody production (IgG) against the SARS-CoV-2 virus|kinetics of antibody production (IgM) against the SARS-CoV-2 virus|kinetics of antibody production (IgA) against the SARS-CoV-2 virus|active COVID-19 infection|symptoms of anxiety""}"
"2627","Clinical and Haematological Phenotypes in Long COVID","","NCT04659889","LCV","Diagnostic Test: Blood sampling (venesection)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659889","Recruiting","2020-12-01","2021-06-01","{""locations"":""The Physicians' Clinic, London, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Observation of frequency of abnormal haematological parameters and association with long-Covid clinical phenotypes versus controls.""}"
"2628","COVID-19 Pandemic and Female Sexual Behavior","","NCT04374422","AcibademU cov","Behavioral: fsfi survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374422","Completed","2020-04-10","2020-04-12","{""locations"":""Haseki Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""58"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""FSFI (Female Sexual Function Index)SCORE difference""}"
"2629","Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19","CROWNLESS","NCT04456075","CROWNLESS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04456075","Recruiting","2020-04-01","2022-04-01","{""locations"":""Thoraxklinik at Heidelberg University, Heidelberg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""TLCO|D5-20|FEV1\/FVC|comorbidities|clinical symptoms|St. George's Respiratory Questionnaire total score""}"
"2630","Proactive Care of Ambulatory COVID19 Patients","AMBU-COVID","NCT04371107","PI2020_843_0039","Other: consultation|Drug: Azithromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04371107","Not yet recruiting","2020-04-29","2020-07-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""64"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Length of symptom duration (in days) with azithromycin treatment""}"
"2631","EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)","","NCT04335032","EPA-COV-001","Drug: Eicosapentaenoic acid gastro-resistant capsules|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04335032","Not yet recruiting","2020-11-09","2021-07-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""284"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of EPA-FFA efficacy compared to placebo|Time to and amount of clinical improvement|Change in recovery and survival rate|Reduction of CRP and IL-6|Increase in IFN-\u03b3|Reduction in proinflammatory chemokines and cytokines.""}"
"2632","Characteristics of Neonatal Covid-19 in Turkey","","NCT04401540","NICU-COVID-TR","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401540","Recruiting","2020-05-01","2020-12-30","{""locations"":""Recep Tayyip Erdogan University Medical School, Rize, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""up to 28 Days \u00a0 (Child)"",""outcome_measures"":""Vertical Transmission|Hospital stay|Early neonatal sepsis rate""}"
"2633","Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method","IIF","NCT04429620","SARS-CoV-2-IIF-002","Diagnostic Test: Immunfluorescence","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04429620","Recruiting","2020-05-30","2020-12-31","{""locations"":""University of Szeged, Albert Szent-Gy\u00f6rgyi Health Center, Szeged, Hungary"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity of the method by SARS-CoV2 ELISA compared|Detectability of the antibodies IgA type against SARS-CoV2 virus""}"
"2634","Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)","","NCT04639375","EMO-001","Biological: Vaccinated with polio vaccine (IPV)","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04639375","Recruiting","2020-11-15","2021-04-18","{""locations"":""Rac Ii Md, National City, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""300"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination|Determination of neutralizing titer of antibodies raised to SARS-CoV-2 following vaccination with polio vaccine""}"
"2635","Thrombosis and Covid-19","COVBIO","NCT04366778","69HCL20_0401 - COVBIO|ID-RCB","Diagnostic Test: TEM-tPA","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366778","Completed","2020-05-01","2021-01-01","{""locations"":""H\u00f4pital Louis Pradel, Bron, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""341"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Coagulability|Venous thrombotic event (VTE) or arterial thrombosis""}"
"2636","Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia","FVR","NCT04613271","FVR|U1111-1263-1797","Drug: Favipiravir|Drug: Azithromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04613271","Suspended","2020-10-15","2021-06-30","{""locations"":""RSJ Soerodjo, Magelang, Central Java, Indonesia|RSUP Dr. Kariadi, Semarang, Central Of Java, Indonesia|RSPI Sulianti Saroso, Jakarta, DKI Jakarta, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""210"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Clinical improvement measured by no sign & symptom for 3 days and RTPCR negative|Duration of hospitalization""}"
"2637","Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study","COVITRA","NCT04579471","s64036","Diagnostic Test: SARS-CoV-2 IgG","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04579471","Recruiting","2020-07-01","2021-12-31","{""locations"":""UZ Leuven, Leuven, Vlaams Brabant, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence and risk-factors for SARS-CoV-2 infection|Prevalence and risk-factors for COVID-19|Durability of IgG positivity""}"
"2638","Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada","","NCT04398147","Ad5-nCoV-2020003","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04398147","Not yet recruiting","2020-08-01","2021-12-30","{""locations"":""Canadian Center for Vaccinology, Halifax, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""696"",""age"":""18 Years to 84 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of the Solicited AE in all groups|Incidence of Unsolicited AE in all groups|Incidence of Serious adverse events (SAE) in all groups|Geometric mean titer (GMT) of the IgG antibody against SARS-CoV-2 (ELISA method);|Seroconversion rate of the IgG antibody against SARS-CoV-2(ELISA method )|Geometric Mean Increase Ratio (GMI) of the specific antibody against SARS-CoV-2(ELISA method);|Geometric mean titer (GMT) of the neutralizing antibody against SARS-CoV-2(Pseudo-viral neutralization assay)|Seroconversion rate of the neutralizing antibody against SARS-CoV-2(Pseudo-viral neutralization assay)|Geometric mean increase ratio (GMI) of neutralizing antibody against SARS-CoV-2 (Pseudo-viral neutralization assay)|Geometric Mean Titer (GMT) of the neutralizing antibody against adenovirus type 5 vector|Geometric mean increase ratio (GMI) of the neutralizing antibody against adenovirus type 5 vector|cellular immune response by ELISpot|cellular immune response by ICS""}"
"2639","Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation","COVERAGEFrance","NCT04356495","CHUBX 2020/12","Dietary Supplement: Vitamins|Drug: Telmisartan|Drug: Ciclesonide|Drug: interferon β-1b","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04356495","Recruiting","2020-07-29","2021-08-31","{""locations"":""CH de Bastia, Bastia, France|Bordeaux university Hospital, Bordeaux, France|CHU de Dijon-Bourgogne, Dijon, France|CHU de Montpellier, Montpellier, France|CHRU de Nancy, Nancy, France|Groupe hospitalier Paris Saint Joseph, Paris, France|IMEA, Paris, France|CHU de Toulouse, Toulouse, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""820"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pilot Phase: Proportion of participants who had a Grade 3 or 4 adverse event|Efficacy phase: Death|Efficacy phase: oxygen therapy|Efficacy phase: hospitalization|Proportion of hospitalizations, overall and by cause, in each group|Death and causes of death|Proportion of intensive care hospitalizations, overall and by cause, in each group|Proportion of participants with negative SARS-CoV-2 RT-PCR|Haematological markers evolution|Inflammatory markers evolution|Adverse events|Adverse reactions|Acceptability of the treatment|Antibiotic consumption|Oxygen saturation worsening|protocol follow-up""}"
"2640","PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort","PROSAIC-19","NCT04444609","20IC5943","Other: Blood tests sputum, nasal lavage and brushing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444609","Recruiting","2020-06-18","2022-06-01","{""locations"":""Royal Brompton & Harefileld NHS Trusts, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""230"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Anti-viral cytokine levels in blood samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection|Anti-viral cytokines profiles within sputum samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection|Anti-viral cytokine profiles within nasal lavage samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection associated with susceptibility to severe COVID-19 infection|Expression of inflammatory gene expression in upper respiratory epithelial airway cells using nasal brush specimens in chronic respiratory disease associated with susceptibility to severe COVID-19 infection|Identify the T cell antigens and B cell epitopes in chronic respiratory disease associated with susceptibility to severe COVID-19 infection|Peripheral blood mononuclear cell (PBMC) interferon mediated immune responses to pathogen recognition receptor agonists in chronic respiratory disease associated with susceptibility to severe COVID-19 infection|Identify endothelial function in chronic respiratory disease associated with susceptibility to severe COVID-19 infection using EndoPAT testing|Endothelial cell inflammation biomarkers in chronic respiratory disease associated with susceptibility to severe COVID-19 infection|Identify sputum 16S rRNA and ITS sequences in chronic respiratory disease associated with susceptibility to severe COVID-19 infection|Identify nasal lavage 16S rRNA and ITS sequences in chronic respiratory disease associated with susceptibility to severe COVID-19 infection|Identify quality of life markers in chronic respiratory disease associated with susceptibility to severe COVID-19 infection""}"
"2641","Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry","CV-COVID-19","NCT04359927","HCB/2020/0457","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359927","Recruiting","2020-04-20","2025-08-31","{""locations"":""Hospital Cl\u00ednic of Barcelona, Barcelona, Catalonia, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cardiovascular mortality|Acute myocardial infarction|Stroke""}"
"2642","Epidemiological Characteristics of COVID-19 in Patients With MS or NMO","COVISEP","NCT04355611","APHP200482","Other: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355611","Recruiting","2020-04-20","2022-04-20","{""locations"":""H\u00f4pital Piti\u00e9 Salp\u00e9tri\u00e8re, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical severity|EDSS (Expanded Disability Status Scale)""}"
"2643","A Study of Quintuple Therapy to Treat COVID-19 Infection","HAZDpaC","NCT04334512","PRG-044","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04334512","Recruiting","2020-06-22","2021-09-01","{""locations"":""ProgenaBiome, Ventura, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy""}"
"2644","Influence of COVID-19 on Vascular Endothelial Function","COVAS","NCT04468412","NL2020-6555","Diagnostic Test: Carotid Artery Reactivity Testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468412","Active, not recruiting","2020-07-14","2021-09-30","{""locations"":""Bernhoven, Uden, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""203"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Endothelial dysfunction|Major adverse cardiovascular events (MACE)""}"
"2645","Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19","","NCT04397172","2020-00730","Procedure: Study Arm","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397172","Recruiting","2020-04-09","2021-12-01","{""locations"":""Inselspital Bern, Bern, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Short Form (36) Health Survey (SF-36)|Mortality|Modified Rankin Scale (mRS)|Duration of mechanical ventilation in days|Barthel Index|Beck's Depression Inventory II (BDI-II)|Essener Questionnaire for Coping with a Disease (EFK)|Number of patients with Critical Illness Myopathy""}"
"2646","Nasal Photodisinfection COVID Proof of Concept Study","","NCT04615936","NasalPDF001","Other: Methylene-Blue Photodisinfection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04615936","Recruiting","2020-07-10","2021-05-31","{""locations"":""Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""RT-qPCR""}"
"2647","CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)","CORVax12","NCT04627675","2020000320 CORVax12","Drug: CORVax|Drug: IL-12 plasmid|Device: Cliniporator","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04627675","Recruiting","2020-12-30","2022-05-01","{""locations"":""Providence Portland Medical Center, Portland, Oregon, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Toxicity|Medically Attended Adverse Events (MAAEs)""}"
"2648","Convalescent Plasma for COVID-19","","NCT04365439","2020-00895","Biological: Blood plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04365439","Not yet recruiting","2020-04-27","2020-06-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors|Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma|Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1)|Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs|Number of patients with improvement in the 7-points Ordinal Scale|Proportion of patients with adverse events, severity of adverse events""}"
"2649","COVID-19 Seroprevalence Study in French Guiana","EPI-COVID-POP","NCT04490850","2020-048","Procedure: Blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04490850","Recruiting","2020-07-15","2021-07-15","{""locations"":""Centre Hospitalier Andr\u00e9e Rosemon, Cayenne, French Guiana|Laboratoire de biologie m\u00e9icale, Institut Pasteur de la Guyane, Cayenne, French Guiana|Laboratoires Eurofins Guyane, Cayenne, French Guiana|Laboratoire de biologie m\u00e9dicale de Kourou, Kourou, French Guiana|Laboratoire de biologie m\u00e9dicale du Centre hospitalier de Saint-Laurent du Maroni, Saint-Laurent du Maroni, French Guiana"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Measure of the COVID-19 immunity of the population|Evaluation of the level of asymptomatic and pauci-symptomatic infections""}"
"2650","Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae","COV-RECUP","NCT04519320","2020/499","Diagnostic Test: Pulmonary function testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04519320","Recruiting","2020-05-18","2025-08-18","{""locations"":""CHU Besan\u00e7on, Besan\u00e7on, Franche-Comt\u00e9, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""140"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""proportion of patients with an alteration of the capillary alveolus barrier at 12 months of follow-up, characterized by a decreased of the diffusing capacity for carbon monoxide (DLCO) below the lower limit of normal""}"
"2651","Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19)","PiCCOVID","NCT04376905","RECHMPL20_0193","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376905","Completed","2020-04-01","2020-09-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes of Extra Vascular Lung Water|Changes of Pulmonary Vascular Permeability Index|Changes of pulmonary compliance""}"
"2652","Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)","","NCT04328961","STUDY00009750|INV-016204","Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04328961","Completed","2020-03-31","2020-10-08","{""locations"":""University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""829"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion""}"
"2653","D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia","","NCT04584580","FMASU P35/ 2020","Drug: low-molecular-weight heparin","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04584580","Recruiting","2020-08-01","2020-12-31","{""locations"":""Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality|occurrence of venous and\/or arterial thrombosis|occurrence of Sepsis-induced coagulopathy|Occurrence of adult respiratory distress syndrome (ARDS)|Occurrence of sepsis|ICU admission and need for mechanical ventilation""}"
"2654","Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina","","NCT04472078","1831","Diagnostic Test: Serological Assay or IgG for SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04472078","Completed","2020-06-10","2020-12-11","{""locations"":""Hospital de Ni\u00f1os Ricardo Gutierrez, Buenos Aires, Caba, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""873"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""to establish the seroprevalence of SARS-CoV-2""}"
"2655","COVID-19 Thales Thermography Triage : Thermal Camera Feasibility Study","COVID3T","NCT04397380","INGC20AE209","Device: Thermography|Device: Tympanic Temperature","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397380","Not yet recruiting","2020-05-20","2020-07-01","{""locations"":""Queen Elizabeth University Hospital, Glasgow, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Temperature""}"
"2656","St. Jude Tracking of Viral and Host Factors Associated With COVID-19","","NCT04362995","SJTRC","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362995","Recruiting","2020-04-23","2025-03-01","{""locations"":""St. Jude Children's Research Hospital, Memphis, Tennessee, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1517"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of asymptomatic subjects|Positive CD4 and CD8 cell epitope positive response|Proportion of seroprevalence|T-cell response""}"
"2657","Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients","","NCT04621123","COnV-ert","Biological: Convalescent anti-SARS-CoV-2 MBT plasma|Other: Control Group","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04621123","Recruiting","2020-10-30","2021-10-01","{""locations"":""Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""474"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization rate (safety and efficacy)|SARS-CoV-2 viral load (safety and efficacy)|COVID-19 WHO Clinical progression scale score (safety and efficacy)|COVID-19 symptoms severity score (safety and efficacy)|Resolution of symptoms (safety and efficacy)|Death rate (safety and efficacy)|Adverse events (AE) (safety and efficacy) Adverse events (AE) Adverse events (AE)|Ferritin (safety and efficacy)|Prealbumin (safety and efficacy)|Interleukin 6 (IL-6) (safety and efficacy)|D-dimer (safety and efficacy)|C reactive protein (CRP) (safety and efficacy)|Leukocyte count (safety and efficacy)|Lymphocyte count (safety and efficacy)|Absolute neutralization titers against SARS-CoV-2 in plasma (safety and efficacy)|Titers of neutralizing antibodies against SARS-CoV-2 in plasma (safety and efficacy)|SARS-CoV-2 viral load of self-collected middle turbinate (MT) swab and saliva samples compared to nasopharyngeal swabs collected by a healthcare worker (safety and efficacy)|Reduction of SARS-CoV-2 viral load (safety and efficacy)""}"
"2658","Tolerability and Efficacy of RJX in Patients With COVID-19","RJX","NCT04708340","RPI015","Drug: Rejuveinix (RJX) Active Comparator|Drug: Placebo Comparator","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04708340","Not yet recruiting","2021-03-05","2023-02-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""237"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety as measured by DLTs and drug related SAE's|Tolerability and Efficacy measured by progression of disease through an ordinal scale.|Efficacy measured by time to resolution of respiratory failure|Efficacy as measured by day of ICU care.|Safety, Tolerability, Efficacy measured by mortality over 28 Days.|Efficacy measured by mean change in baseline clinical status on Days 7 and 14.|Efficacy measured by mean change in hospitalization days on Days 7 and 14.|Efficacy measured by time to coming off supplemental oxygen on Days 7 and 14.|Safety and Efficacy measured by time from first dose to renal therapy.""}"
"2659","Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy","TRANSCOVID","NCT04402918","2020/500","Diagnostic Test: biological samples day of delivery","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04402918","Recruiting","2020-05-17","2021-02-28","{""locations"":""Chu Besancon, Besancon, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Vrological profile of newborns.|Immunological profile of newborns.""}"
"2660","Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease","CRITICoVid","NCT04407169","2020PI081","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407169","Completed","2020-06-01","2020-11-17","{""locations"":""Valentin Simon, Vandoeuvre Les Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""617"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale|Determined potential predictive factors of critic form in patients with chronic lung diseases|Determined percentage of death|Determined duration of oxygen therapy|Determined duration of hospitalization|Determine mean values of the WHO CoVid-19 infection progression scale measured""}"
"2661","Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection","SynCov","NCT04420676","SynCov","Dietary Supplement: Omnibiotic AAD|Dietary Supplement: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04420676","Recruiting","2020-09-24","2022-12-01","{""locations"":""Department of Internal Medicine, Medical University of Graz, Graz, Austria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stool calprotectin|Stool frequency|Stool consistency|Gastrointestinal symptoms|Duration of Covid-19 disease|Severity of Covid-19 disease|Diarrhea|Stool Zonulin|Microbiome composition""}"
"2662","Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2","","NCT04479163","FundacionINFANT-Plasma","Biological: Convalescent Plasma|Other: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04479163","Completed","2020-06-04","2020-10-25","{""locations"":""Hospital Militar Central, Caba, Buenos Aires, Argentina|CEMIC, Caba, Buenos Aires, Argentina|Centro de Investigacion Clinica OSECAC, Caba, Buenos Aires, Argentina|Centro Gallego de Buenos Aires, Caba, Buenos Aires, Argentina|Sanatorio Anchorena, Caba, Buenos Aires, Argentina|Sanatorio de Los Arcos, Caba, Buenos Aires, Argentina|Hospital \""Simplemente Evita\"", Gonz\u00e1lez Cat\u00e1n, Buenos Aires, Argentina|Hospital Especializado de Agudos y Cr\u00f3nicos \""San Juan de Dios\"", La Plata, Buenos Aires, Argentina|Clinica Olivos, Buenos Aires, Argentina|Hospital Central de San Isidro, Buenos Aires, Argentina|Hospital General de Agudos \""Dr. Carlos Bocalandro\"", Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""165"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Development of severe respiratory disease defined as a respiratory rate (RR)>30 and\/or an O2 sat<93%|Life threatening respiratory disease|Critical systemic illness, defined as respiratory failure|Death|Combination of secondary outcomes #2 (Life threatening respiratory disease) and\/or #3 (Critical systemic illness, defined as respiratory failure) and\/\/or #4 (death)|Duration of oxygen support requirement in patients with covid-19 due to saturation in ambient air <93%.""}"
"2663","Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)","Nano-COVID19","NCT04610567","36746020.5.1001.0068","Drug: Methotrexate-LDE phase 1|Drug: Methotrexate-LDE phase 2|Drug: Placebo-LDE phase 2","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04610567","Recruiting","2020-10-27","2021-07-15","{""locations"":""Heart Institute (InCor) - University of S\u00e3o Paulo Medical School, S\u00e3o Paulo, Brazil, S\u00e3o Paulo, SP, Brazil|Hospital Santa Marcelina, S\u00e3o Paulo, SP, Brazil|Institute Prevent Senior, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of hospital stay|Number of participants requiring mechanical ventilation|Number of participants requiring vasoactive drugs|Number of participants requiring renal replacement therapy|Incidence of secondary infection|Sequential Organ Failure Assessment (SOFA) score|World Health Organization (WHO) COVID-19 score|Interleukin 6 (IL-6)|Dimer-D|Chest CT scan|Incidence and severity of laboratory alterations|Clinical side effects|Other adverse events""}"
"2664","Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection","COVIDUS-NOR","NCT04422691","REK129805","Diagnostic Test: Lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422691","Recruiting","2020-07-01","2025-12-01","{""locations"":""Haukeland universitetssykehus, Bergen, Norway|Nordland Hospital, Bod\u00f8, Norway|Drammen sykehus, Drammen, Norway|S\u00f8rlandet sykehus, Kristiansand, Kristiansand, Norway|Akershus University Hospital, Oslo, Norway|Ullev\u00e5l University Hospital, Oslo, Norway|Sykehuset Telemark HF, Skien, Norway|Stavanger Universitetssjukehus, Stavanger, Norway|St Olavs Hospital, Trondheim, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""17 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality|Level-of-care|In-hospital length of stay|Oxygen usage in the emergency department|Emergency department length of stay|Antibiotics usage""}"
"2665","Oropharyngeal Dysphagia in Patients With COVID-19","","NCT04346212","COVID_OD","Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346212","Recruiting","2020-04-14","2021-01-01","{""locations"":""Consorci Sanitari del Maresme (Hospital de Matar\u00f3), Matar\u00f3, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Changes in the prevalence of oropharyngeal dysphagia|Changes in the swallowing screening|Changes in the swallowing status|Changes in the nutritonal status of study patient's.|Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).|Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).|Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (incidence of readmissions).|Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (prevalence of readmissions).|Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (number of visits to emergency department).|Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (percentage of visits to emergency department).|Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (respiratory complications).|Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (mortality).""}"
"2666","P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19","","NCT04410510","CS002-COVID19","Drug: P2Et (Caesalpinia spinosa extract)|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04410510","Recruiting","2020-09-30","2021-06-01","{""locations"":""Hospital Universitario San Ignacio, Bogot\u00e1, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the efficacy of P2Et in reducing the length of hospital stay of patients with clinical suspicion or confirmed case of COVID-19|Efficacy of P2Et in reducing the time to clinically significant improvement in patients with clinical suspicion or confirmed case of COVID-19|Proportion of patients with clinical suspicion or confirmed case of COVID-19, who achieve clinical improvement after 14 days of treatment|Proportion of patients with clinical suspicion or confirmed case of COVID-19, who achieve clinical improvement after 28 days of treatment|Efficacy of P2Et in reducing the proportion of hospitalized patients with clinical suspicion or confirmed case of COVID-19 who require admission to the ICU due to worsening clinical symptoms.|Efficacy of P2Et in reducing the proportion of patients with clinical suspicion or confirmed case of COVID-19 who die from the disease.|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of the P2Et in patients with COVID-19""}"
"2667","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","","NCT04310865","YHQW-Severe-V2.0","Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04310865","Suspended","2020-11-01","2021-06-30","{""locations"":""Wuhan No.7 Hospital\/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital\/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University\/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital\/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""116"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts\/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events""}"
"2668","Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","","NCT04461379","EN20-00011","Biological: BCG vaccine|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04461379","Active, not recruiting","2020-07-21","2021-01-01","{""locations"":""Hospital Universitario \""Jos\u00e9 E. Gonz\u00e1lez\"", Monterrey, Nuevo Le\u00f3n, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""908"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Demonstrate COVID- 19 disease incidence among Health care workers:|Demonstrate cumulative incidence of hospitalization for COVID-19 among Health care workers:|Demonstrate the Incidence of specific Antibodies against SARS-CoV-2 at 3 and 6 months in health care workers|Hospitalization of severe disease COVID-19|Oxygen supplementation in severe disease COVID-19|Need for intubation or non-invasive ventilation for the patient.|Critical care admission with SARS-CoV2|Mortality associated to progressive pulmonary disease|Evaluate the safety of the vaccine by measuring the incidence rates of local and systemic adverse effects that occur after one month its application.|Calculate the incidence of COVID-19 complications|Determine the mean days of hospitalization and days in intensive care unit by COIVD-19|Calculate the cost associated with in-hospital medical care|Determine the scores of the Clinical Prediction Rules associated with mortality using Sequential Organ Failure Assessment (SOFA score) at the patient's hospital admission:|Determine the scores of the Clinical Prediction Rules associated with mortality using Acute Physiology and Chronic Health disease Classification System (APACHE) at the patient's hospital admission:|Evaluate and determine the alteration profile in laboratory studies at the patient's hospital admission|Registration of chronic medications|Need for vasopressors""}"
"2669","COVID-19 in ART: Perception and Experience","COVAPEX","NCT04456010","RECHMPL20_0351","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04456010","Completed","2020-06-01","2020-07-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation|Risk assessment|Patients'expectations regarding the management of an abrupt closure of the fertility center""}"
"2670","Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection","SEVO-COVID19","NCT04359862","SEVO-COVID19","Drug: Sevoflurane|Drug: Propofol","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04359862","Recruiting","2020-04-16","2021-04-30","{""locations"":""Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain|Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PaO2\/FiO2|TNF\u03b1|IL-1b|IL-6|IL-8|Mortality""}"
"2671","PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS","COLCHI-COVID","NCT04416334","COLCHICOVID","Drug: Colchicine plus symptomatic treatment (paracetamol)|Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04416334","Recruiting","2020-08-19","2021-12-31","{""locations"":""Atenci\u00f3n primaria (\u00c1rea 2), Laredo, Cantabria, Spain|Gerencia de atenci\u00f3n primaria (\u00c1rea 3), Reinosa, Cantabria, Spain|Atencion primaria (AREA 1), Santander, Cantabria, Spain|Gerencia de atenci\u00f3n primaria (\u00e1rea 4), Torrelavega, Cantabria, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""954"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants who die due to COVID-19 infection|Number of participants who require hospitalization due to COVID-19 infection""}"
"2672","MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)","","NCT04425733","5475-009|2020-002062-14|MK-5475-009","Drug: MK-5475|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04425733","Withdrawn","2020-07-07","2020-11-10","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants Who Experience an Adverse Event (AE)|Number of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)|Change From Baseline to Day 1 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2\/FiO2)|Change From Baseline to Day 2 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2\/FiO2)|Change From Baseline to Day 3 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2\/FiO2)|Change From Baseline to Day 4 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2\/FiO2)|Change From Baseline to Day 5 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2\/FiO2)|Change From Baseline to Day 6 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2\/FiO2)|Change From Baseline to Day 7 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2\/FiO2)""}"
"2673","SEVERITY SCORE FOR COVID-19 PNEUMONIA","","NCT04372199","3112","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04372199","Recruiting","2020-04-29","2020-05-27","{""locations"":""Massimo Montalto, Roma, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""248"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To identify the best predictors of critical coronavirus pneumonia and to realize a simple severity score able to early classify high-risk individuals admitted to Internal Medicine Department for COVID-19 disease, needing an intensive approach""}"
"2674","Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction","ESCAPE","NCT04339712","ESCAPE|2020-001039-29","Drug: Anakinra|Drug: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04339712","Completed","2020-04-02","2021-01-08","{""locations"":""2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Io\u00e1nnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, \""Latsio\"", Thriasio Elefsis General Hospital, Elefs\u00edna, Greece|Intensive Care Unit, \""Koutlimbaneio & Triantafylleio\"" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""102"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2\/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2\/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum\/plasma proteins|Classification of the immune function""}"
"2675","Outcomes and Prognostic Factors in COVID-19","COVIP","NCT04321265","20-004","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04321265","Recruiting","2020-03-19","2021-12-01","{""locations"":""Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark|H\u00f4pitaux de Paris, H\u00f4pital Saint-Antoine, service de r\u00e9animation m\u00e9dicale, Paris, France|INSERM, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France|Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France|Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany|Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway|Department of Clinical Medecine,University of Bergen, Bergen, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Survival|Fragilty""}"
"2676","Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy","","NCT04532372","20291|NCI-2020-05746|P30CA033572","Other: Best Practice|Drug: Leflunomide|Drug: Placebo Administration","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04532372","Recruiting","2021-01-07","2022-09-18","{""locations"":""City of Hope Medical Center, Duarte, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of toxicity, graded according to the NCI CTCAE version 5|Maximum tolerated dose (MTD) (Phase 1)|Clinical activity (Response)(Phase 2)|Time to Clinical activity (Response)|Overall Survival|Oxygen Saturation improvement|SARS-CoV-2 resolution|Hospitalization|Mechanical Ventilation required|Mechanical Ventilation duration|Vital status (alive\/dead)|Vital status (cause of death)""}"
"2677","Lung Ultrasound in COVID-19 Patients","LUS-COVID","NCT04487769","LUS-COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04487769","Recruiting","2020-06-01","2021-10-01","{""locations"":""Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Liberation from invasive ventilation|Mortality""}"
"2678","Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic","IBD-COVID-19","NCT04344249","RC20_0150","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344249","Recruiting","2020-04-10","2021-09-01","{""locations"":""Chu Nantes, Nantes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""850"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IgG and IgM anti SARS-CoV-2|Clinical factors and severity of COVID-19 infection|demographic factors and severity of COVID-19 infection|pharmacologic factors and severity of COVID-19 infection""}"
"2679","A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection","","NCT04392232","20-045","Drug: Convalescent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04392232","Recruiting","2020-05-05","2020-12-31","{""locations"":""Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Survival Rate""}"
"2680","Adolescents With COVID-19/MIS-C at HCFMUSP","","NCT04659486","37460620.8.0000.0068","Behavioral: Home-based exercise training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04659486","Enrolling by invitation","2020-09-24","2021-04-30","{""locations"":""Hospital das Clinicas Faculdade de Medicina USP, Sao Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""7 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Quality of Life assessed by the Pediatric Quality of Life Inventory (Peds-QoL)|Flow-volume loop assessed by spirometry|Health-related quality of life assessed by the Pediatric Outcomes Data Collection Instrument|Complete blood count (hemoglobin, leukocyte, lymphocyte and platelet count)|Inflammatory markers (C-reactive protein, fibrinogen, D-dimer and ferritin);|Lactate dehydrogenase|Aspartate and alanine aminotransferase|Serum urea and creatinine|Triglycerides|Creatinine phosphokinase (CK)|Amilase|Lipase|Troponin T|Pro-BNP|Lung abnormalities will be assessed by pulmonary computed tomography|Systolic and diastolic function will be assessed by echocardiogram|Valve dysfunction will be assessed by echocardiogram|Pericardial effusion will be assessed by echocardiogram|Coronary arteries will be assessed by echocardiogram|Ischemia will be assessed by echocardiogram|Immunocompetence, including thymic function|Leukogram will be assessed by leukocyte and lymphocyte counts|Immunophenotyping of lymphocytes T cell lineages will be evaluated by flow cytometry|Immunophenotyping of lymphocytes B cell lineages will be evaluated by flow cytometry|Immunophenotyping of lymphocytes NK cells will be evaluated by flow cytometry|Serum levels of anti-Streptococcus pneumoniae IgG antibodies|Anti-pneumococcal vaccine response will be assessed by ELISA|Evaluation of the thymus by the determination of TRECs (Thymic recent emigrant cells or T-cell receptor excision circles)|Changes in frequency of the autoantibodies of the thyroid gland|Changes in frequency of the anti-GAD antibody will be assessed using immunoprecipitation|Changes in frequency of the anti-islet antibody of Langerhans will be assessed using indirect fluorescence|Changes in frequency of the anti-insulin antibody will be assessed by radioimmunoassay|Diagnosis of thyroid dysfunction will be assessed by thyroid profile (TSH, free T4 and T3)|Diagnosis of type 1 diabetes mellitus will be assessed by the metabolic profile (fasting glucose, glycated hemoglobin and C peptide)|Linear growth will be assessed by using a standardized stadiometer, calculating standard deviation, growth curves, and growth speed|Development of puberty will be assessed according to the criteria of Tanner and Marshall in adolescents in the prepubertal age group|Bone age will be assessed using non-dominant hand and wrist radiography|Bone mineral density will be assessed by Bone densitometry (DXA) in the region of the lumbar spine|Bone mineral content will be assessed by Bone densitometry (DXA) in the region of the lumbar spine|Bone mineral density will be assessed by Bone densitometry (DXA) in the proximal femur|Bone mineral content will be assessed by Bone densitometry (DXA) in the proximal femur|Bone mineral density will be assessed by Bone densitometry (DXA) in the whole body|Bone mineral content will be assessed by Bone densitometry (DXA) in the whole body|Body composition (visceral adipose tissue) will be assessed by Bone densitometry|Body composition (lean mass) will be assessed by Bone densitometry|Body composition (fat mass) will be assessed by Bone densitometry|Bone biochemical and bone remodeling markers (calcium, phosphorus, 25OH alkaline phosphatase vitamin D, PTH, CTX, P1NP)|Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk used during the \""timed up and go\"" test|Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk during the 6-minute walk test|Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk during the 10 meter gait test|Pediatric gait assessment will be assessed by musculoskeletal ultrasound|Genetic Polymorphism Analysis will be assessed by salting out methodology followed by q-PCR (Real-time PCR) using the TaqMan assay using Step One Plus equipment|Mental health will be assessed by the \""Strengths and Weaknesses of Attention-deficit\/hyperactivity disorder (ADHD) symptoms and Normal behaviors\""|Mental health will be assessed by the \""Strengths and Difficulties Questionnaire\""|Mental health will be assessed by the \""Depression, Anxiety and Stress Scale\""|Physical activity levels assessed by ActivPAL|Food consumption levels assessed by food records|Blood flow will be assessed using a Doppler Ultrasound|Endothelial function will be assessed using a Doppler Ultrasound""}"
"2681","Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection","UNICODE","NCT04451577","UNICODE","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04451577","Recruiting","2020-06-01","2023-06-01","{""locations"":""Humanitas reseach hospital (ICH), Rozzano, Milan, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical response to COVID-19|Immunological response to COVID-19|Genetic predisposition to COVID-19|Microbiome-related response to COVID-19""}"
"2682","Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease","","NCT04405999","05-20-02-С","Drug: Bromhexine Hydrochloride","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04405999","Completed","2020-05-14","2020-08-31","{""locations"":""Almazov National Medical Research Centre, Saint Petersburg, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Polymerase chain reaction (PCR)|Time to symptoms|Time to positive PCR|Number of cases|Case severity|Drug tolerance""}"
"2683","Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia","PREVENT","NCT04466683","PREVENT","Radiation: Low dose radiation 35 cGy|Radiation: High dose radiation 100 cGy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04466683","Recruiting","2020-08-28","2022-12-31","{""locations"":""Boca Raton Regional Hospital Lynn Cancer Institute, Boca Raton, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Loyola University Chicago, Maywood, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Lowell General Hospital Cancer Center, Lowell, Massachusetts, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Ohio State University James Cancer Hospital, Columbus, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Step 1 Dose selection|Clinical benefit of Step 2 Radiation dose|Changes of the cost of care for the control arm versus the radiation arms""}"
"2684","COVID-19 and ICU-acquired MDR Bacteria","COVID-BMR","NCT04378842","2020_37|2020-A01157-32","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04378842","Recruiting","2020-05-18","2021-05-01","{""locations"":""H\u00f4pital Roger Salengro, ICU, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""690"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of ICU-acquired colonization related multidrug resistant bacteria|Cumulative incidence of ICU-acquired infection related to multidrug resistant bacteria|Mechanical ventilation duration|mortality|length of stay in intensive care unit""}"
"2685","Home-based Exercise in COVID-19 Survivors","","NCT04615052","4.342.082","Other: Exercise training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04615052","Recruiting","2020-09-26","2021-12-21","{""locations"":""University of Sao Paulo, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""40 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline on quality of life assessed by the SF-36 health survey questionnaire at 12 weeks.|Change from baseline on fatigue evaluated by the fatigue severity scale at 12 weeks.|Change from baseline on lipid profile at 12 weeks.|Change from baseline on insulin sensitivity at 12 weeks.|Change from baseline on inflammatory cytokine IL-1 at 12 weeks.|Change from baseline on inflammatory cytokine IL-1ra at 12 weeks.|Change from baseline on inflammatory cytokine IL-6 at 12 weeks.|Change from baseline on inflammatory cytokine IL-10 at 12 weeks.|Change from baseline on inflammatory cytokine TNF-alpha at 12 weeks.|Change from baseline on C-reactive Protein at 12 weeks.|Change from baseline on Creatine Kinase at 12 weeks.|Change from baseline on cardiopulmonary fitness assessed by a maximal exercise test at 12 weeks.|Change from baseline on lean body mass assessed by Dual-energy absorptiometry at 12 weeks.|Change from baseline body fat assessed by Dual-energy absorptiometry at 12 weeks.|Change from baseline on waist circumference at 12 weeks.|Change from baseline on hip circumference at 12 weeks.|Change from baseline on body weight at 12 weeks.|Change from baseline on muscular strength assessed by handgrip test at 12 weeks.|Change from baseline on muscular function assessed by Timed-Stand Test at 12 weesks.|Change from baseline on muscular function assessed by Timed-Up and Go Test at 12 weeks.|Change from baseline on anxiety symptoms assessed by Back Scale at 12 weeks.|Change from baseline on depression symptoms assessed by Back Scale at 12 weeks.|Change from baseline on functional status assessed by Post-COVID-19 Functional Status (PCFS) Scale at 12 weeks.|Change from baseline on physical activity levels evaluated by the International Physical Activity Questionnaire at 12 weeks.|Change from baseline on resting blood pressure assessed by an automated device at 12 weeks.""}"
"2686","The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department","UroCovid","NCT04409899","FundacióPuigvert","Diagnostic Test: Blood tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409899","Active, not recruiting","2020-03-20","2020-12-31","{""locations"":""Fundacio Puigvert, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Rate of SARS-CoV-2\/COVID-19 in a selected cohort of urological patients undergoing surgery|Post-operative COVID-19 related complication rates|Association between post-surgery inflammatory indexes and COVID-19 diagnosis during hospitalization""}"
"2687","Burden for STaff Working in the NHS","COST-NHS","NCT04506632","STH21373","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04506632","Recruiting","2020-06-02","2022-04-26","{""locations"":""Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Changes in Depression|Changes in Anxiety|Changes in feelings of paranoia|Traumatic Stress|conspiracy mentality and social interactions""}"
"2688","A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls","","NCT04498442","2020P000433","Behavioral: Simha Kriya|Behavioral: Reading a Book","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04498442","Completed","2020-05-22","2020-10-22","{""locations"":""Beth Israel Deaconess Medical Centre, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""8519"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Perceived Stress Levels|Changes in Resilience Levels|Changes in Covid-19 Prevalence|Changes in self-reported duration of fever and respiratory symptoms in COVID-19 positive participants|Changes in self-reported readiness to return to work in COVID-19 positive participants""}"
"2689","COVID-19 Serology and Immunosenescence","SERO-CoV-OLD","NCT04563650","PI2020_843_0079","Biological: blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04563650","Recruiting","2020-09-18","2021-11-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""330"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""titers of COVID-19 neutralising antibodies""}"
"2690","Prognostic Factors of Patients With COVID-19","","NCT04292964","2020-02-2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04292964","Completed","2020-03-01","2020-03-13","{""locations"":""The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""201"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""all-cause mortality|Severe state""}"
"2691","Bacteriotherapy in the Treatment of COVID-19","BACT-ovid","NCT04368351","DPHID-UniRoma05","Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368351","Active, not recruiting","2020-03-01","2020-07-31","{""locations"":""Department of Public Heath and Infectious Diseases. University of Rome \""Sapienza\"" (Italy), Rome, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""delta of time of disappearance of acute diarrhea|Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital""}"
"2692","UNITE Study (UMN-GE) for COVID-19","","NCT04701489","STUDY00011290","Device: Splenic ultrasound","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04701489","Enrolling by invitation","2021-01-14","2021-06-01","{""locations"":""M Health Fairview St. Joseph's Hospital, Saint Paul, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Between-arm change of IL-6 levels from baseline to end of treatment between groups|Between-arm change of IL-1\u03b2 levels from baseline to end of treatment between groups|Between-arm change of CRP levels from baseline to end of treatment between groups|Change in time to recovery""}"
"2693","Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa","ENDOCOVID","NCT04709302","ENDOCOVID","Biological: COVID-19|Biological: HIV|Drug: ART","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04709302","Recruiting","2021-02-01","2022-12-01","{""locations"":""University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria|Lagos Stae University Teaching Hospital Ikeja, Lagos, Nigeria|Walter Sisulu University, Mthatha, South Africa"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""342"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients developing Acute Respiratory Distress Syndrome|Number of ICU admissions|Number of Deaths|Cardiometabolic Status: ADMA|Cardiometabolic Status: Cholesterol|Cardiometabolic Status: Triglycerides|Cardiometabolic Status: HDL cholesterol|Cardiometabolic Status: LDL cholesterol|Cardiometabolic Status: Glucose|Cardiometabolic Status: Glycated Hemoglobin|Cardiometabolic Status: hs-CRP|Endothelial function and vascular changes: FMD|Endothelial function and vascular changes: PWV|Endothelial function and vascular changes: Retinal microvasculature analysis|Endothelial function and vascular changes: IMT|Coagulatory Parameters: D-dimer|Coagulatory Parameters: CAT|Coagulatory Parameters: TF""}"
"2694","Convalescent Plasma in the Treatment of COVID 19","","NCT04343261","SFH-20-23","Biological: Convalescent Plasma","Interventional","Has Results","Phase 2","https://ClinicalTrials.gov/show/NCT04343261","Completed","2020-04-10","2020-08-13","{""locations"":""Trinity Health Of New England, Hartford, Connecticut, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Viral Load|Serum Antibody Titers""}"
"2695","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19","COVIDMED","NCT04328012","1581969","Drug: Losartan|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04328012","Recruiting","2020-04-06","2021-08-01","{""locations"":""Bassett Medical Center, Cooperstown, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival""}"
"2696","COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens","","NCT04715607","2021-01","Diagnostic Test: Sequence of testing.","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04715607","Recruiting","2021-01-22","2021-05-30","{""locations"":""Valby COVID-19 teststed, Copenhagen, Valby, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic"",""enrollment"":""22000"",""age"":""16 Years to 120 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 detection rates for oropharyngeal swabs (OPS) compared with nasopharyngeal swabs and saliva collection.|SARS-CoV-2 RT-PCR cycle threshold (Ct) values|OPS, NPS and saliva test discomfort and likelihood to get retested|Ratio of mutations in SARS-CoV-2""}"
"2697","Early Short Course Corticosteroids in COVID-19","","NCT04374071","HFH IRB # 13739","Drug: Methylprednisolone","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374071","Completed","2020-03-12","2020-04-30","{""locations"":""Henry Ford Hospital, Detroit, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Transfer to Intensive care unit (ICU)|Need for Mechanical Ventilation|Mortality|Development and Severity of ARDS|Length of hospital stay (LOS).""}"
"2698","Atrium COVID-19 Syndromic and Serologic Surveillance","","NCT04361123","04-20-11A","Other: daily syndromic surveillance|Diagnostic Test: monthly serologic IgM/G test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361123","Enrolling by invitation","2020-05-06","2021-12-01","{""locations"":""Atrium Health, Charlotte, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""450000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|\u2022Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae""}"
"2699","Neurologic Manifestations of COVID 19 in Children","","NCT04379089","STUDY20060012|STUDY20040154|STUDY20040278","Other: Observational study only","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379089","Recruiting","2020-04-29","2022-12-31","{""locations"":""UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""Prevalence|Child and family health functions""}"
"2700","Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES)","","NCT04568707","APHP200845","Other: blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04568707","Recruiting","2020-10-23","2022-10-15","{""locations"":""H\u00f4pital Piti\u00e9 Salp\u00e9tri\u00e8re, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients|Serum neurofilaments""}"
"2701","BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic","EDCTP","NCT04641858","BCG-COVID-RCT","Biological: BCG-Denmark|Biological: Saline","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04641858","Recruiting","2020-12-03","2022-03-01","{""locations"":""Cape Verde, Praia, Santiago, Cape Verde|Bandim Health Project, Bissau, SAB, Guinea-Bissau|Manhi\u00e7a Health Research Centre, Manhi\u00e7a, Maputo, Mozambique"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1050"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days of unplanned absenteeism due to illness|Days of unplanned absenteeism due to documented COVID-19|Cumulative incidence of hospital admissions due to illness (minus accidents).|Death""}"
"2702","The COVID-19 Disease and CARdiac Events Study","COVICARE","NCT04438993","COVI-RW-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04438993","Recruiting","2020-05-29","2020-11-01","{""locations"":""University Hospital Hairmyres, Glasgow, Scotland, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cardiac abnormalities in COVID-19 disease in-patients|Biomarkers""}"
"2703","Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes","","NCT04397900","1586788","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397900","Recruiting","2020-04-09","2020-07-01","{""locations"":""Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Atlantic Health System, Morristown, New Jersey, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""80"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Identify the viral epitopes of memory CD8+ T cells from individuals that have recovered from SARS-CoV-2 infection.|Determine which SARS-CoV-2 proteins are frequently recognized by T cells in patients with varying HLA types.""}"
"2704","Helmet CPAP Versus HFNC in COVID-19","COVID HELMET","NCT04395807","COVID HELMET","Device: Helmet CPAP|Device: HFNC","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04395807","Recruiting","2020-06-03","2021-05-01","{""locations"":""Helsingborg's Hospital, Helsingborg, Region Skane, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator-Free Days (VFD)|SpO2\/FiO2-ratio|Patient comfort|Frequency of endotracheal intubation|Frequency of carbon dioxide rebreathing|Days alive within""}"
"2705","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","","NCT04324021","Sobi.IMMUNO-101|2020-001167-93","Biological: Emapalumab|Biological: Anakinra","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04324021","Terminated","2020-04-02","2020-11-13","{""locations"":""Regions hospital, Saint Paul, Minnesota, United States|The Valley hospital, Ridgewood, New Jersey, United States|NewYork-Presbyterian Queens, Flushing, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Utah Health, Salt Lake City, Utah, United States|ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|S.C. Malattie Infettive, Ospedale Galliera, Genova, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Dipartimento di Medicina - DIMED, Azienda Ospedale - Universit\u00e0 Padova, Padova, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensit\u00e0 di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy|ASL Citt\u00e0 di Torino, Unit of Infectious Diseases, Medicine, Rheumatology, Torino, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""16"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment success|Time to mechanical ventilation|Change from baseline in Modified Early Warning system score|Change from baseline in resting peripheral capillary oxygen saturation (SpO2)|Change from baseline in partial pressure of oxygen\/fraction of inspired oxygen (PaO2\/FiO2)|Change of pH in hemogasanalysis from baseline|Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline|Change of oxygen tension (pO2) in hemogasanalysis from baseline|Change of potassium in hemogasanalysis from baseline|Change of sodium in hemogasanalysis from baseline|Change of chloride in hemogasanalysis from baseline|Change of lactic acid in hemogasanalysis from baseline|Change of hemoglobin in hemogasanalysis from baseline|Change from baseline in oxygen supplementation|Change of findings of high-resolution computed tomography (CT) scan of the chest|Change from baseline in Ferritin|Change from baseline in lactate dehydrogenase (LDH)|Change from baseline in D-dimers|Change from baseline in White Blood Cells with differential counts|Change from baseline in Red Blood Counts|Change from baseline in Hemoglobin|Change from baseline in Platelet count|Change from baseline in Fibrinogen|Change from baseline in Complement factors C3\/C4|Change from baseline in Prothrombin time|Change from baseline in Cardiac troponin|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in total bilirubin levels|Change from baseline in C-Reactive Protein|Change from baseline in Creatinine|Overall survival|Time to hospital discharge""}"
"2706","Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City","COVIDGHPSJCite","NCT04365530","Cohorte COVID GHPSJ CiteH","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365530","Recruiting","2020-04-01","2022-12-31","{""locations"":""H\u00f4pital Marie Lannelongue, Le Plessis-Robinson, France|AURA Paris Plaisance, Paris, France|Fondation Sainte-Marie, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|H\u00f4pital Bellan, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""2000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical consequences of a Covid-19 infection in the care population|Risk factors at M6|Risk factors at year 1|Risk factors at year 2|Impact of hospital reorganization on medical care at M6|Impact of hospital reorganization on medical care at Year 1|Impact of hospital reorganization on medical care at Year 2""}"
"2707","African Covid-19 Critical Care Outcomes Study","","NCT04367207","ACCCOS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367207","Recruiting","2020-05-01","2020-12-31","{""locations"":""Groote Schuur Hospital, Cape Town, Western Cape, South Africa"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality|Risk factors (resources, comorbidities and interventions) associated with mortality""}"
"2708","Kidney Involvement in COVID-19 Disease (COVKID)","COVKID","NCT04355624","20reamedcovid02","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355624","Recruiting","2020-04-15","2020-07-30","{""locations"":""Centre hospitalier d'Antibes Juan les pins, Antibes, France|Centre hospitalier de Cannes, Cannes, France|Centre hospitalier de Grasse, Grasse, France|CHU de Nice, Nice, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Kidney involvement in COVID-19 disease|Physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection|To identify risk factors for kidney involvement in in SARS-CoV-2 infection|To evaluate the impact of kidney involvement in SARS-CoV-2 infection|To assess the long-term health effect of kidney injury on survivors of SARS-CoV-2 infection in case of AKI KDIGO 2 or 3""}"
"2709","Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19)","SERO-MARES","NCT04425759","SERO-MARES (56/20)","Diagnostic Test: Blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04425759","Recruiting","2020-06-08","2021-06-30","{""locations"":""Hospital de Matar\u00f3, Matar\u00f3, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibodies to SARS-CoV2: IgA, IgM, IgG|PCR of nasopharyngeal smears on all IgM +""}"
"2710","Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma","","NCT04468009","1725","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04468009","Recruiting","2020-06-25","2021-02-01","{""locations"":""Hospital Francisco Javier Mu\u00f1iz, Ciudad Autonoma de Buenos Aire, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""36"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality at ICU at 30 days|Mortality at ICU at 90 days|SOFA score of study days 1, 3, 5, 7, 14 and 28|Need for supportive therapy after enrollment|Lenght of stay in ICU|Lenght of mechanical ventilation|Lenght of hospitalization""}"
"2711","Mechanisms for Covid-19 Disease Complications","COVID MECH","NCT04314232","117589","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04314232","Recruiting","2020-03-18","2021-12-31","{""locations"":""Akershus University Hospital, L\u00f8renskog, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with ICU admission or death|Number of participants with ICU admission|Number of participants with death from all causes|Total duration of ICU stay|Total duration of hospital stay""}"
"2712","Global Impact of COVID-19 on Pulmonology Special Units","","NCT04554251","Assiut20","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04554251","Enrolling by invitation","2020-09-01","2020-12-30","{""locations"":""Aliae Mohamed-Hussein, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""global impact of COVID-19 on baseline patients number|measure the changes in practice in each unit|frequency of SARS-CoV-2 infection in healthcare workers""}"
"2713","Coagulation Changes Associated With COVID-19 Infection","","NCT04460664","HEMCS-035","Diagnostic Test: Quantra System","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04460664","Enrolling by invitation","2020-08-14","2021-02-15","{""locations"":""Texas Tech University Health Sciences Center El Paso, El Paso, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Quantra Clot Time results|Quantra Clot Stiffness results""}"
"2714","Pediatric Acute and Critical Care COVID-19 Registry of Asia","PACCOVRA","NCT04395781","2020/2094","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395781","Recruiting","2020-05-18","2023-12-31","{""locations"":""Chongqing Hospital Children's Medical Center, Chongqing, China|Zhengzhou Children's hospital, Zhengzhou, China|Post Graduate Institute of Medical Education and Research, Chandigarh, India|General Hospital H. Adam Malik, Medan, Indonesia|Murni Teguh Memorial Hospital, Medan, Indonesia|St. Marianna University School of Medicine, Kanagawa, Japan|Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Kuala Lumpur, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Penang General Hospital, Pulau Pinang, Malaysia|Hospital Tuanku Ja'afar, Seremban, Malaysia, Seremban, Malaysia|Aga Khan University Hospital, Karachi, Pakistan|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""2000"",""age"":""up to 21 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Overall severity of illness|Respiratory complications|Respiratory support|Other systems complications|Mortality|Length of hospital stay""}"
"2715","Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique","","NCT04406493","0059-20-HYMC","Diagnostic Test: Lung impedance technique","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04406493","Recruiting","2020-04-28","2021-04-28","{""locations"":""Hillel Yaffe MC,, Hadera, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""50"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between impudence deterioration to clinical conditions and hospitalization period""}"
"2716","COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking","COVIDHELP","NCT04408339","PV7313","Other: No Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408339","Recruiting","2020-04-15","2022-04-14","{""locations"":""University Hospital Hamburg Eppendorf, Hamburg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of hospitalization|Duration of hospitalization|Rate of admission to intensive care unit|Length of stay in intensive care unit|Need of mechanical ventilation|Duration of mechanical ventilation|Disease-specific mortality rate|Rate of patients, whose oncologic treatment had to be modified due to COVID-19|Cellular and humoral immune response to COVID-19 infection""}"
"2717","Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers","DIAL-COVID-19","NCT04565522","DIAL-COVID-19","Other: Prospective observation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04565522","Not yet recruiting","2020-09-21","2021-10-31","{""locations"":""AOU Mater Domini, Catanzaro, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""incident risk of COVID-19 infection|Evaluate the morbidity of COVID-19|Evaluate the mortality of COVID-19|Estimate the predictive role of comorbidities, inflammation indexes and therapy on the hospitalisation rate|Estimate the predictive role of comorbidities, inflammation indexes and therapy on the mortality rate|Evaluate the infective role of dialysis staff towards patients|Evaluate the infective role of patients towards dialysis staff""}"
"2718","Myeloproliferative Neoplasms (MPN) and COVID-19","MPN-COVID","NCT04385160","FROM - O-MPN-COVID-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385160","Recruiting","2020-05-13","2022-08-31","{""locations"":""New York-Presbyterian\/Weill Cornell Medical Center, New York, New York, United States|Hopital Saint-Louis, Paris, France|University Medical Center RWTH, Aachen, Germany|University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center, Minden, Germany|Ospedale San Gerardo di Monza, Monza, Monza Brianza, Italy|A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria, Alessandria, Italy|ASST-Papa Giovanni XXIII, Bergamo, Italy|Policlinico S.Orsola-Malpighi, Bologna, Italy|ASST-Spedali Civili, Brescia, Italy|AOU Ospedale Careggi, Firenze, Italy|Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero Universitaria Maggiore della Carit\u00e0, Novara, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy|A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy|Ospedale Policlinico \""G.B. Rossi\"" Borgo Roma, Verona, Italy|Ospedale San Bortolo, Vicenza, Italy|Sobas Wroclaw Medical University \u00b7, Wroc\u0142aw, Poland|Hospital Cl\u00ednic De Barcelona, Barcelona, Barcellona, Spain|Hospital del Mar, Barcelona, Barcellona, Spain|Institut Catal\u00e0 d' Oncologia - Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO L'Hospitalet - Hospital Mois\u00e8s Broggi, Sant Joan Desp\u00ed, Barcelona, Spain|Hospital Universitario Pr\u00edncipe de Asturias, Alcal\u00e1 De Henares, Madrid, Spain|Hospital General de La Palma, Bre\u00f1a Alta, Santa Cruz De Tenerife, Spain|Servicio de Hematolog\u00eda Hospital General Universitario de Albacete, Albacete, Spain|Hospital General de Elche, Alicante, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|ICO Girona Hospital Josep Trueta Servei d'hematologia, Girona, Spain|FEA Hematolog\u00eda Hospital Universitario de M\u00f3stoles, Madrid, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Moncloa, Madrid, Spain|Hospital Ram\u00f3n y Cajal, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Cl\u00ednico Universitario, Valencia, Spain|Guy's and St. Thomas' NHS Foundation Trust., London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""552"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""pulmonary embolism (PE)|fatal or non fatal thrombotic event|Continuous Positive Airway Pressure (CPAP)|invasive ventilation|admission in Intensive Care Unit (ICU)|death|treatments and interventions applied for MPN|treatments and interventions applied for COVID-19|thrombotic events association to patients characteristic and treatments|Mortality rate occurring in the single MPN phenotypes in relation to cytoreductive treatment|MPN progression rate""}"
"2719","Clinical Characterisation Protocol for COVID-19 in People Living With HIV","COVIDHIV","NCT04361604","2020-A00984-35","Biological: Biological collection (patients co infected HIV Sras-CoV-2)|Other: Auto-questionnaires (patients co infected HIV Sras-CoV-2)|Other: Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361604","Not yet recruiting","2020-04-01","2020-10-01","{""locations"":""Department of Internal Medicine and Clinical Immunology of Professor C\u00e9cile Goujard, Le Kremlin-Bic\u00eatre, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""270"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Describe the course of COVID-19 disease in patients infected with HIV,""}"
"2720","Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva","COVID-19","NCT04723446","TBC","Drug: Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|Drug: Colgate Peroxyl® -1.5% Hydrogen peroxide|Other: Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|Other: No rinsing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04723446","Not yet recruiting","2021-02-01","2022-01-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load changes in the saliva within groups|Difference in the viral load changes in the saliva between groups""}"
"2721","Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19","","NCT04551911","CTAP101-CL-2014","Drug: Rayaldee 30Mcg Extended-Release (ER) Capsule|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04551911","Recruiting","2020-10-26","2021-05-01","{""locations"":""OPKO Investigative Site, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity and duration of disease as evidenced by COVID-19 symptoms using the FLU-PRO\u00a9 questionnaire.|Concentration of serum total 25-hydroxyvitamin D maintained at or above 50 ng\/mL.""}"
"2722","Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients","ERCO-Park","NCT04466839","RC31/20/0193","Other: Questionnaire and interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04466839","Completed","2020-07-02","2020-12-18","{""locations"":""Centre Hospitalier R\u00e9gionale Universitaire de Besan\u00e7on, Besan\u00e7on, France|Centre Hospitalier Universitaire Lille, Lille, France|Centre Hospitalier Universitaire de Marseille, Marseille, France|Centre Hospitalier Universitaire de N\u00eemes - Caremeau, Nimes, France|Centre Hospitalier Universitaire de la Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France|Centre Hospitalier Universitaire de Reims, Reims, France|Centre Hospitalier Universitaire de Rouen, Rouen, France|CHU Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""411"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Impact of containment related to the Covid-19 pandemic.|Conditions of containment during the Covid-19 pandemic.|The number of patients infected or possibly infected with Covid-19|Symptoms modifications""}"
"2723","Detecting SARS-CoV-2 in Tears","","NCT04526769","STUDY00009512","Diagnostic Test: Tear Collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04526769","Not yet recruiting","2020-09-01","2021-04-01","{""locations"":""University of Minnesota, Minneapolis, Minnesota, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Virus Detection in Tears|COVID-19 Virus Detection in Nasopharyngeal Swabs|Expression of ACE2 in Lacrimal Gland Samples|Expression of ACE2 in Ocular Surface Samples""}"
"2724","Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)","COV-CREM","NCT04365322","2020/502","Other: Additional biological samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365322","Recruiting","2020-04-20","2025-04-20","{""locations"":""CHU Jean Minjoz, Besan\u00e7on, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Specific immune responses""}"
"2725","A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19","","NCT04674189","CV-NCOV-005","Biological: CVnCoV Vaccine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04674189","Recruiting","2020-12-23","2022-04-30","{""locations"":""Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz Langenbeckstr. 1, Mainz, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""2520"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with Medically-attended Adverse Events|Intensity of Medically-attended Adverse Events per Investigator's Assessment|Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine|Number of Participants with One or More Serious Adverse Events (SAEs)|Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment|Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine|Number of Participants with One or More Adverse Events of Special Interest (AESIs)|Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment|Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine|Number of Participants with Death due to a Serious Adverse Event (SAE)|Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Disctontinuation|Number of Participants with Solicited Local Adverse Events|Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale|Duration of Solicited Local Adverse Events|Number of Participants with Solicited Systemic Adverse Events|Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale|Duration of Solicited Systemic Adverse Events|Number of Participants with Unsolicited Adverse Events|Intensity of Unsolicited Adverse Events per the Investigator's Assessment|Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine|Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum|Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies|Number of Participants that Contract COVID-19 of Any Severity|Number of Participants that Contract Mild, Moderate, Severe and Moderate to Severe COVID-19|Number of Participants Seroconverting to the Nucleocapsid (N) Protein of SARS-SoV-2|Burden of Disease (BoD) Score Based on First Episodes of Virologically-confirmed Cases of COVID-19|Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum|Number of Participants Seroconverting to SARS-CoV-2|Individual Serum Antibodies to Spike (S) Protein of SARS-CoV-2""}"
"2726","Lung Ultrasonography in COVID-19 Pneumonia","","NCT04719234","2011-KAEK-25 2020/5-21","Device: lung ultrasonography","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04719234","Completed","2020-06-15","2020-12-01","{""locations"":""University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""60"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Relationship between Thoracic CT imaging results and LUS results|Characteristics of lesions""}"
"2727","Hospital Interns Psychological State During the COVID-19","RESICOV","NCT04669054","RECHMPL20_0665","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04669054","Active, not recruiting","2020-12-01","2021-07-30","{""locations"":""University hospital, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""102"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depressive Symptomatology (PHQ-9)|Sleep evaluation with the Insomnia Severity Index (ISI)|Anxiety with the Generalised Anxiety Disorder Assessment (GAD-7)|Psychological pain assessed with visual analogue scale (VAS)|Physical pain assessed with visual analogue scale (VAS)|Suicidal ideation assessed with visual analogue scale (VAS)|Anger assessed with the State Anger Expression Inventory (STAXI - state)|Stressful Event Impact (Horowitz scale)|Psychotropic drugs use|Tobacco consumption|Alcohol consumption|Illicit substances use""}"
"2728","Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19","RESCUE 1-19","NCT04366791","STUDY00000476|NCI-2020-02676|RAD5002-20|P30CA138292","Radiation: Low Dose Radiation Therapy","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04366791","Suspended","2020-04-23","2021-04-15","{""locations"":""Emory University Hospital Midtown\/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hosptial, Atlanta, Georgia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of extubation (for intubated patients)|Clinical outcome - Temperature|Clinical outcome - Heart Rate|Clinical outcome - Systolic blood pressure|Clinical outcome - Oxygenation|Clinical outcome - Respirations|Clinical outcome - FiO2|Clinical outcome - PEEP|Clinical outcome - Tidal volume|Clinical outcome - Intubation\/Extubation events|Clinical outcome - Overall survival|Radiographic outcome - Chest xray|Radiographic outcome - CT can|Serologic outcome - WBC|Serologic outcome - Hgb|Serologic outcome - Procalcitonin|Serologic outcome - ANC|Serologic outcome - Creatine kinase|Serologic outcome - Myoglobin|Serologic outcome - Albumin|Serologic outcome - PT\/PTT|Serologic outcome - D-Dimer|Serologic outcome - GGT|Serologic outcome -Triglycerides|Serologic outcome -Ferritin|Serologic outcome -Fibrinogen|Serologic Immune markers flow cytometry|Serologic outcome -Bilirubin|Serologic outcome - LDH|Serologic outcome - Creatinine|Serologic outcome - EGFR|Serologic outcome - CRP|Serologic outcome - ALT|Serologic outcome - AST|Serologic outcome - Troponin-I|Serologic outcome - BNP|Serologic outcome - Blood Gases pH|Serologic outcome - Blood Gases pO2|Serologic outcome - Blood Gases pCO2|Serologic outcome - Lactic Acid|Serologic outcome - IL-6|Serologic outcome - Potassium""}"
"2729","Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year","","NCT04455958","STUDY00021444|NCI-2020-02877","Drug: Lopinavir/Ritonavir|Drug: Placebo Administration|Other: Questionnaire Administration","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04455958","Not yet recruiting","2020-11-01","2021-11-01","{""locations"":""OHSU Knight Cancer Institute, Portland, Oregon, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity of symptoms|Clinical benefit rate of lopinavir\/ritonavir|Time to symptom progression|Time to improvement of participants|Time to hospital admission for those who develop severe of critical symptoms|Intensive care unit (ICU) admission: yes or no|Receiving ventilator support: yes or no|Overall survival""}"
"2730","Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19","","NCT04556864","FAB-HEM-2020-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04556864","Not yet recruiting","2020-10-01","2021-04-01","{""locations"":""1. A.H. Juan Ram\u00f3n Jim\u00e9nez., Huelva, Andalucia, Spain|5. Hospital Virgen de la Victoria, M\u00e1laga, Andaluc\u00eda, Spain|3. Hospital Universitario. Jerez de la Frontera., Jerez De La Frontera, C\u00e1diz, Spain|4. Hospital Universitario de \u00c1lava., Alava, Pa\u00eds Vasco, Spain|2. Hospital Universitario Infanta Leonor, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""67"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total amount of hypotension|Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Stroke volume)|Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Stroke volume variation)|Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Cardiac index)|Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor ( HPI)|Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Eadyn)|Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (dp\/dt max,)|Presence of treatment with noradrenaline; presence of treatment with dobutamine, presence of treatment with other vasoactive\/ionotropic\/hypotensive drugs|Furosemide treatment|Daily diuresis, daily water balance, accumulated water balance since ICU admission, daily parenteral nutrition volume, and daily enteral nutrition volume.|Atrial fibrillation|Acute kidney injury|Continuous renal replacement therapies|Need for Hemadsorption|Specific treatment for SARS-CoV2 (presence of tocilizumab, antimalarial drugs, antivirals)|Corticoid treatment.""}"
"2731","The Effect of Aromatherapy on COVID-19-induced Anxiety","","NCT04495842","20-7-5600","Other: Essential Oil Blend|Other: Control Blend","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04495842","Recruiting","2020-10-01","2021-06-30","{""locations"":""Franklin School of Integrative Health Sciences, Franklin, Tennessee, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""65"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline in state anxiety on the State portion of the State Trait Anxiety Scale (STAI-S) at 15 minutes""}"
"2732","Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island","","NCT04587258","1613494-3","Behavioral: Informational videos and social media campaigns encouraging cancer screening.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04587258","Recruiting","2020-08-28","2022-09-01","{""locations"":""Blackstone Valley Community Health Center, Pawtucket, Rhode Island, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Increase screening rates for breast and colorectal cancer|Impact of screening on cancer care|Community Engagement|Barriers to cancer screening during COVID19.""}"
"2733","Consequences of the QUARANTINE Relating to the COvid-19 Epidemic on the Mental Health of the Patients Followed in PSYchiatry","QUARCOPSY","NCT04405362","2020_39|2020-A01186-33","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04405362","Not yet recruiting","2020-05-01","2021-05-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""753"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with post-traumatic stress disorder (PTSD) defined by a total score on PCL-5 \u2265 31 at the time of quarantine|IES-R (Impact of Events Scale Revised)|Presence of suicidal ideation during the past month at the different times of the study|Total score at GHQ-28 (General Health Questionnaire)|Total score at BDI (Beck Depression Inventory)|Total score at ISI (Insomnia Severity Index)|Changes in alcohol and\/or cannabis consumption during and at the end of the quarantine period|Total score Warwick-Edinburgh Mental Well-Being Scale (WEMWBS)|Socio-demographic factors significantly associated with all scores""}"
"2734","Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection","","NCT04705831","IIS202001-Neuroimmune","Drug: Ruconest","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04705831","Recruiting","2020-12-30","2022-01-01","{""locations"":""IMMUNOe Research Centers, Centennial, Colorado, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Neuropsychological Measures (BRIEF-A)|Neuropsychological Measures (RBANS)|Neuropsychological Measures (BDI II)|Neuropsychological Measures (MoCA)|Patient-Rate Questionnaires (FSS)|Patient-Rate Questionnaires (MIDAS)|Patient-Rate Questionnaires (HIT)|Patient-Rate Questionnaires (Activities)|Patient-Rate Questionnaires (SF)|Patient-Rate Questionnaires (GSRS)|Patient-Rate Questionnaires (SF-36)|Neurological Exam (0)|Neurological Exam (9)|Neurological Exam (17)|Immunological Biomarkers (Toll)|Immunological Biomarkers (GAD)|Immunological Biomarkers (Com)|Immunological Biomarkers (Ig)|Immunological Biomarkers (IgG)|Immunological Biomarkers (TH\/TH)""}"
"2735","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","","NCT04382040","MGC-006","Drug: ArtemiC|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04382040","Completed","2020-05-08","2020-12-21","{""locations"":""Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, Maharashtra, India|Hillel Yaffe Medical Center, Hadera, Haifa, Israel|Nazareth Hospital EMMS, Nazareth, North, Israel|Rambam Health Care Campus, Haifa, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of <\/= 2 Maintained for 24 Hours in comparison to routine treatment|Percentage of participants with definite or probable drug related adverse events|Time to negative COVID-19 PCR|Proportion of participants with normalization of fever and oxygen saturation through day 14 since onset of symptoms|COVID-19 related survival|Incidence and duration of mechanical ventilation|Incidence of Intensive Care Init (ICU) stay|Duration of ICU stay|Duration of time on supplemental oxygen""}"
"2736","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)","","NCT04323761","GS-US-540-5821|2020-001453-49","Drug: Remdesivir","Expanded Access:Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04323761","Approved for marketing","1970-01-01","1970-01-01","{""locations"":""University of Alabama- Birmingham, Birmingham, Alabama, United States|Banner- University Medical Center Phoenix, Phoenix, Arizona, United States|Community Regional Medical Centers (CRMC), Fresno, California, United States|St. Jude Medical Center, Fullerton, California, United States|Scripps Memorial Hospital La Jolla, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Huntington Hospital, Pasadena, California, United States|Scripps Mercy Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California, Medical Center (Parnassus Campus), San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|San Mateo Medical Center, San Mateo, California, United States|Santa Rosa Memorial Hospital, Santa Rosa, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|PIH Health Whittier Hospital, Whittier, California, United States|The Medical Center Of Aurora, Aurora, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Middlesex Health, Middletown, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|The Stamford Health Medical Group- Pulmonary Associates, Stamford, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Aventura Hospital and Medical Center, Aventura, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States|Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Swedish Hospital, Chicago, Illinois, United States|Mercy Hospital & Medical Center, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States|St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States|Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States|Riverview Health, Noblesville, Indiana, United States|Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|CalvertHealth Medical Center, Prince Frederick, Maryland, United States|University of Maryland St. Joseph Medical Center, Towson, Maryland, United States|Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Charlton Memorial Hospital, Fall River, Massachusetts, United States|Lawrence General Hospital, Lawrence, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Huron Valley-Sinai Hospital, Commerce, Michigan, United States|Wayne Statue University\/ Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Health Care Corporation, Flint, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States|Clara Maass Medical Center, Belleville, New Jersey, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Trinitas Regional Medical Center, Elizabeth, New Jersey, United States|Englewood Health, Englewood, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|CentraState Medical Center, Freehold, New Jersey, United States|Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States|Jersey City Medical Center, Jersey City, New Jersey, United States|Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Atlantic Health System\/ Morristown Medical Center, Morristown, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Ocean Medical Center, Oakhurst, New Jersey, United States|Bayshore Medical Center, Red Bank, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Atlantic Health System\/Overlook Medical Center, Summit, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Capital Health, Trenton, New Jersey, United States|Virtua Health Voorhees Campus, Voorhees, New Jersey, United States|St. Peter's Hospital, Albany, New York, United States|Mount Sinai Queens, Astoria, New York, United States|Good Samaritan Hospital Medical Center, Bay Shore, New York, United States|Southside Hospital, Bay Shore, New York, United States|Lincoln Medical Center, Bronx, New York, United States|St Barnabus Hospital, Bronx, New York, United States|Montefiore Medical Center, Weiler Campus, Bronx, New York, United States|Montefiore Health System Moses Medical Center, Bronx, New York, United States|The Brooklyn Hospital Center, Brooklyn, New York, United States|Kingsbrook Jewish Medical Center, Brooklyn, New York, United States|University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States|Woodhull Medical Center, Brooklyn, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|New York Harbor VA Medical Center, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Interfaith Medical Center, Brooklyn, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Mount Sinai Brooklyn, Brooklyn, New York, United States|New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States|Kaleida Health System, Buffalo, New York, United States|Nassau University Medical Center, East Meadow, New York, United States|New York Presbyterian- Queens, Flushing, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Queens Hospital Center, Jamaica, New York, United States|NYU Langone Health, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States|NewYork-Presyterian\/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States|New York City Health + Hospitals \/ Harlem, New York, New York, United States|New York Presbyterian Lower Manhattan Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Rochester General Hospital, Rochester, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Ellis Hospital, Schenectady, New York, United States|Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States|Stony Brook University Hospital\/ Stony Brook Children's, Stony Brook, New York, United States|Samaritan Hospital, Troy, New York, United States|UNC Hospitals, Chapel Hill, North Carolina, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|The Ohio State University College of Medicine, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Saint Francis Hospital, Tulsa, Oklahoma, United States|St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States|Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|Kent Hospital, Warwick, Rhode Island, United States|St. Francis Hospital, Greenville, South Carolina, United States|Lexington Medical Center, West Columbia, South Carolina, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|St. David's South Austin Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|Texas Department of Criminal Justice Hospital (Hospital Galveston)\/University of Texas Medical Branch, Galveston, Texas, United States|HCA Houston Healthcare West, Houston, Texas, United States|Covenant Medical Center, Lubbock, Texas, United States|Methodist Mansfield Medical Center, Mansfield, Texas, United States|Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States|Saint Mark's Hospital, Salt Lake City, Utah, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Henrico Doctors Hospital, Richmond, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Gold Coast Hospital, Southport, Australia|Landeskrankenhaus Graz West, Graz, Austria|Universit\u00e4tsklinik f\u00fcr Innere Medizin II, Innsbruck, Austria|Kepler Universit\u00e4tsklinikum, Linz, Austria|Medical University and General Hospital Vienna, Vienna, Austria|Sozialmedizinisches Zentrum S\u00fcd - Kaiser-Franz-Josef-Spital, Wien, Austria|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Ghent University Hospital, Ghent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Li\u00e8ge, Li\u00e8ge, Belgium|H\u00f4pital Civil Marie Curie, Lodelinsart, Belgium|William Osler Health System, Brampton, Ontario, Canada|The Ottowa Hospital, Ottawa, Ontario, Canada|Nicosia General Hospital, Nicosia, Cyprus|V\u0161eobecn\u00e1 fakultn\u00ed nemocnice v Praze, Prague, Czechia|Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia|Nemocnice Na Bulovce, Praha 8 - Liben, Czechia|Rigshospitalet, Copenhagen, Denmark|P\u00f5hja-Eesti Regionaalhaigla, Tallinn, Estonia|Vilnius University, Tartu, Estonia|Hopital Avicenne, Bobigny, France|Centre Hospitalier Regional Universitaire Brest H\u00f4pital de la Cavale Blanche \u00e0 Brest, Brest Cedex, France|Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France|H\u00f4pitaux Civils de Colmar, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|H\u00f4pital Raymond Poincar\u00e9, Garches, France|Centre Hospitalier R\u00e9gional d'Orl\u00e9ans, Orl\u00e9ans, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|H\u00f4pital Charles-Nicolle, Rouen, France|H\u00f4pital Purpan, Toulouse, France|Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany|Universit\u00e4tsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitatsklinikum, Essen, Germany|Universit\u00e4tsklinikum Freiburg, Freiburg, Germany|Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany|Universit\u00e4tsklinikum des Saarlandes, Homburg, Germany|Caritas-Krankenhaus St. Josef, Regensburg, Germany|Klinikum W\u00fcrzburg Mitte, W\u00fcrzburg, Germany|University General Hospital of Patras Panagia I Voithia, Patra, Greece|General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece|Ken\u00e9zy Gyula K\u00f3rh\u00e1z \u00c9s Rendel\u0151int\u00e9zet, Debrecen, Hungary|Landsp\u00edtali, Reykjavik, Iceland|Kerry University Hospital, Tralee, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|Hasharon Hospital, Petah Tikva, Israel|Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria, Bologna, Italy|ASST Spedali Civili di Brescia, Brescia, Italy|Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy|Azienda Ospedaliero - Universitaria Careggi, Florence, Italy|Ospedale Policlinico San Martino, Genova, Italy|Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Gerardo di Monza, Monza, Italy|Azienda Ospedaliera dei Colli, Napoli, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|IRCCS Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma, Italy|Azienda Ospedaliero Universitaria, Turin, Italy|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Lithuania|Vilnius University, Vilnius, Lithuania|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|HagaZiekenhuis, The Hague, Netherlands|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojew\u00f3dzki Specjalistyczny Szpital im. dr. W\u0142. Biega\u0144skiego, Lodz, Poland|Wielospecjalistyczny Szpital Miejski Im J\u00f3zefa Strusia Zak\u0142ad Opieku\u0144czo Leczniczy, Poznan, Poland|Wojew\u00f3dzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland|Centro Hospitalar Universit\u00e1rio de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal|Centro Hospitalar Universit\u00e1rio do Porto E.P.E., Porto, Portugal|Centro Hospitalar Universit\u00e1rio De S\u00e3o Jo\u00e3o, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia\/Espinho, Vila Nova de Gaia, Portugal|Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania|Spitalul Clinic de Boli Infec\u0163ioase Sf\u00e2nta Parascheva Ia\u015fi, Iasi, Romania|Clinical hospital for infectious disease, Timisoara, Romania|Univerzitn\u00e1 Nemocnica L. Pasteura Ko\u0161ice - Pracovisko Rastislavova 43, Ko\u0161ice, Slovakia|Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia|Univerzitetni Klinicni Center Maribor, Maribor, Slovenia|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Spitalzentrum Biel, Biel, Switzerland|Kantonsspital Graub\u00fcnden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|H\u00f4pital du Valais -H\u00f4pital de Sion, Sion, Switzerland|University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|St. George's Hospital, London, United Kingdom|Southampton University Hospital, Southampton, United Kingdom"",""study_designs"":"""",""enrollment"":"""",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""""}"
"2737","COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur","Curie-O-SA","NCT04369066","IC 2020-07","Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)|Diagnostic Test: Nasopharyngeal swabs","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04369066","Recruiting","2020-04-28","2022-04-28","{""locations"":""Institut Curie, Paris, France|Institut Pasteur, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""2800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibodies against the SARS-CoV-2 virus in serum at inclusion|Antibodies against the SARS-CoV-2 virus in serum at 1 month|Antibodies against the SARS-CoV-2 virus in serum at 3 months|Antibodies against the SARS-CoV-2 virus in serum at 6 months|Antibodies against the SARS-CoV-2 virus in serum at 12 months|Comparative performance of anti-SARS-CoV-2 antibody detection techniques|Prevalence of immune subjects for SARS-CoV-2|Nature and quantity of anti-SARS-CoV-2 antibodies|Evolution of the different antibodies against the SARS-CoV-2 virus over time.|Prevalence of Anti-covid IgA response in the nasal mucosa""}"
"2738","Noninvasive Respiratory Support in COVID-19 (CATCOVID-AIR)","CATCOVID-AIR","NCT04668196","PR(AG)265/2020","Device: High-flow nasal cannula treatment|Device: Continuous positive airway pressure (CPAP) treatment|Device: Noninvasive ventilation treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04668196","Recruiting","2020-05-22","2021-01-01","{""locations"":""Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Fundaci\u00f3 Althaia, Manresa, Barcelona, Spain|Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed, Sabadell, Barcelona, Spain|Hospital Universitari M\u00fatua Terrassa, Terrassa, Bardelona, Spain|Hospital del Mar, Parc de Salut Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Dr.Josep Trueta, Girona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment failure|28-day mortality|Hospital mortality|Endotracheal intubation|Duration of hospital stay""}"
"2739","BAttLe Against COVID-19 Using MesenchYmal Stromal Cells","","NCT04348461","BALMYS-19","Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04348461","Not yet recruiting","2020-04-06","2020-09-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)|Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate""}"
"2740","The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice","","NCT04452682","R.20.06.898 - 2020/06/16","Other: COVID 19 impact","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452682","Completed","2020-05-25","2020-06-21","{""locations"":""Mansoura university, Mansoura, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""998"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The ICU admission with associated Pneumonia|Impact of COVID-19 on the different presentation of vascular surgery at the emergency|Mortality rates""}"
"2741","Facial Hair, PPE and COVID-19","FACIAL HAIR","NCT04579627","283609","Behavioral: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04579627","Completed","2020-05-14","2020-06-08","{""locations"":""Royal Cornwall Hospital, Truro, Cornwall, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""358"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in facial hair between January 2020 and during April 2020.|Does facial hair change adhere to the PPE guidance from PHE""}"
"2742","Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation","UPSAT","NCT04344561","IRB00246834","Other: Postural Positioning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04344561","Recruiting","2020-05-25","2021-05-01","{""locations"":""Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Mechanical Ventilation|Number of participants with supplemental oxygen requirements|Mean oxyhemoglobin saturation|Mean Nocturnal Oxyhemoglobin Saturation|Heart Rate|Respiratory Rate|Percentage of time in the assigned position""}"
"2743","Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19","","NCT04346420","DTM-001","Other: Standard interface|Device: Double-Trunk Mask","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346420","Completed","2020-04-09","2020-05-01","{""locations"":""Cliniques universitaires Saint-Luc, Brussels, Brussels Capital, Belgium"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""12"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in O2 output|Comfort with the interfaces|Changes in PaO2|Changes in PaCO2|Changes in pH|Changes in respiratory rate""}"
"2744","Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study","","NCT04373824","MHC-COVID-19- INV- ACT-BHR","Drug: Ivermectin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04373824","Recruiting","2020-04-25","2020-07-25","{""locations"":""Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""effect of Ivermectin on eradication of virus.""}"
"2745","Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers","","NCT04424017","COVID-19\004","Biological: Specific anti-SARS-CoV-2 antibodies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424017","Completed","2020-06-07","2020-10-30","{""locations"":""ECRRM, Cairo, Egypt|Faculty of Medicine, Cairo University, Cairo, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""1546"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies""}"
"2746","Immune Changes in Severe COVID-19 Pulmonary Infections","COVIDIMM","NCT04386395","CHRU NANCY : 2020PI080_1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386395","Active, not recruiting","2020-03-30","2020-05-30","{""locations"":""Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in monocytes HLA-DR expression|Changes in lymphocytes subpopulations numbers|Changes in monocytes number|TNFalpha level|INFgamma level|IL1beta level|SOFA score|number of recorded deaths|presence of pneumonia|presence of bacteremia|presence of urinary tract infection|C reactive protein|D Dimers""}"
"2747","Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study","","NCT04384042","MCO-002|NMRR-20-934-54803","Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384042","Recruiting","2020-06-06","2021-03-31","{""locations"":""Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence or absence of olfactory and taste disturbances in study participants|Adjusted odds ratio of olfactory & taste disturbances in COVID-19 infection|Clinical manifestations of study participants|Other pre-existing health conditions|Positive predictive value (PPV) of olfactory and taste disturbances in predicting diagnosis of COVID-19 infection|Negative predictive value (NPV) of olfactory and taste disturbances in predicting absence of COVID-19 infection|Sensitivity of olfactory and taste disturbances in predicting COVID-19 infection|Specificity of olfactory and taste disturbances in predicting COVID-19 infection""}"
"2748","The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19","","NCT04399681","KSSEAH--","Device: Bedside lung ultrasound","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04399681","Recruiting","2020-05-10","2020-09-10","{""locations"":""Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of viral pneumonia caused by COVID 19""}"
"2749","Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study","","NCT04390165","MCO-001|NMRR-20-934-54803","Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04390165","Completed","2020-06-06","2020-11-30","{""locations"":""Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""498"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence or absence of olfactory and taste disturbances in COVID-19 patients|Prevalence of olfactory disturbances in COVID-19 patients|Prevalence of taste disturbances in COVID-19 patients|Clinical manifestations of study participants|Other pre-existing health conditions|Rating of baseline sense of smell & taste in COVID-19 patients prior to diagnosis of their infection|Rating of sense of smell & taste in COVID-19 patients at time of diagnosis of their infection|Rating of sense of smell & taste in COVID-19 patients at time of answering questionnaire survey""}"
"2750","Endothelial Function, Inflammation and Organ Dysfunction in COVID-19","","NCT04408365","282930","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408365","Recruiting","2020-08-05","2021-05-31","{""locations"":""Guy's & St Thomas' Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""82"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of plasma bio-adrenomedullin|Change of plasma proenkephalin|Change of plasma dipeptidyl peptidase-3|Change of plasma renin|Change of plasma angiotensin II|Duration of vasodilatory shock|Acute kidney injury|Need for renal replacement therapy|Duration of ventilation|Duration of extracorporeal membrane oxygenation|Mortality""}"
"2751","Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients","CODYS","NCT04522037","CODYS_2020","Other: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04522037","Recruiting","2020-06-01","2021-02-01","{""locations"":""H\u00f4pital de la Croix Rousse \/ GHN, Lyon, France|H\u00f4pital Edouard Herriot, Lyon, France|H\u00f4pital Lyon Sud, Pierre-B\u00e9nite, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Title : Reduction of respiratory rate between Hour 0 and Hour 12 at initiation of morphine treatment""}"
"2752","A Study of TAK-019 in Healthy Japanese Adults (COVID-19)","","NCT04712110","TAK-019-1501|U1111-1262-6244|jRCT2071200084","Biological: TAK-019|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04712110","Recruiting","2021-02-24","2022-04-04","{""locations"":""Sumida Hospital, Sumida-ku, Tokyo, Japan|Nishi Kumamoto Hospital, Kumamoto, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination|Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination|Percentage of Participants with Unsolicited AEs for 49 Days Following First Vaccination (Day 1)|Percentage of Participants with Serious Adverse Events (SAE) until Day 50|Percentage of Participants with Adverse Event of Special Interest (AESI) until Day 50|Percentage of Participants with Medically-Attended Adverse Events (MAAEs) until Day 50|Percentage of Participants with Any AE Leading to Discontinuation of Vaccination|Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial until Day 50|Percentage of Participants with SARS-CoV-2 Infection until Day 50|Geometric Mean Titers (GMT) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36|Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36|Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36|Seroresponce Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36|Percentage of Participants with SAE throughout the Trial|Percentage of Participants with AESI throughout the Trial|Percentage of Participants with MAAEs throughout the Trial|Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial from the Day of Vaccination throughout the Trial|Percentage of Participants with SARS-CoV-2 Infection throughout the Trial|GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 22, 50, 202, and 387|GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 22, 50, 202, and 387|SCR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 22, 50, 202, and 387|SRR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 22, 50, 202, and 387|GMT of Serum Neutralizing Antibody Titters to Wild-type Virus on Day 22, 36, 50, 202, and 387|GMFR of Serum Neutralizing Antibody Titters to Wild-type Virus on Day 22, 36, 50, 202, and 387|SCR of Serum Neutralizing Antibody Titters to Wild-type Virus on Day 22, 36, 50, 202, and 387|SRR of Serum Neutralizing Antibody Titters to Wild-type Virus on Day 22, 36, 50, 202, and 387""}"
"2753","The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients","SIDIACO","NCT04365517","Sacco FBF","Drug: Sitagliptin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04365517","Not yet recruiting","2020-12-29","2021-12-30","{""locations"":""ASST FBF Sacco, Milan, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""170"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time for clinical improvement|Clinical parameter of acute lung disease|Biochemical parameter of acute lung disease|Clinical parameters of acute lung disease|Dipeptilpeptidase 4 expression in biological samples|Cytokine-inflammatory profile|Glycemic variability""}"
"2754","Clinical Trial of Sarilumab in Adults With COVID-19","SARICOR","NCT04357860","SARICOR","Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04357860","Not yet recruiting","2020-04-27","2020-07-27","{""locations"":""Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilation requirements|Crude mortality|Time to clinical improvement|Time until improvement in oxygenation|Proportion of patients requiring invasive mechanical ventilation|Proportion of patients having negative COVID-19 CRP at each visit|Mean of serum cytokine levels|Adverse events related to medication and its administration|Incidence in the appearance of serious bacterial, fungal or opportunistic infections|Incidence of perforation of the gastrointestinal tract|Leukocyte and neutrophil count|Hemoglobin levels|Platelet count|Levels of creatinemia|Bilirubin levels|ALT and AST levels""}"
"2755","Prognostication of Recovery in Early Disorders of Consciousness After COVID-19","PREDICT-COVID","NCT04476589","2020P001616","Diagnostic Test: Functional MRI","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04476589","Recruiting","2020-07-01","2023-03-30","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disability Rating Scale score""}"
"2756","COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?","LapCoVIDSurg","NCT04444687","052020","Diagnostic Test: Test for SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444687","Not yet recruiting","2020-08-01","2021-02-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-COV-2 RNA detection|Viral contamination of peritoneal cavity and fluid|Viral contamination of peritoneal cavity and fluid in open cases|Viral infection of members of the surgical team""}"
"2757","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure","","NCT04319731","131618","Biological: Human Amniotic Fluid","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04319731","Recruiting","2020-03-20","2021-03-20","{""locations"":""University of Utah Health, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation""}"
"2758","MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients","MOIST","NCT04525404","Pro00102389","Diagnostic Test: MRI (heart, brain, lungs, liver)|Diagnostic Test: Bloodwork|Other: Cognitive testing|Other: Olfaction testing|Diagnostic Test: Spirometry|Other: Walk Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04525404","Recruiting","2020-11-12","2021-09-01","{""locations"":""University of Alberta, Edmonton, Alberta, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""228"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Native myocardial T1 relaxation time|FLAIR imaging|Compare 12-week cognitive testing to the corresponding findings on MRI of brain, heart and lung at baseline|Compare 12-week spirometry to the corresponding findings on MRI of brain, heart and lung at baseline|Compare 12-week walk test results to the corresponding findings on MRI of brain, heart and lung at baseline|Compare 12-week cognitive testing in patients with normal smell and\/or normal appearing brainstem on MRI to patients with no or impaired smell and\/or injury to brainstem on MRI|Compare MRI measures of organ dysfunction at 12-24 weeks in survivors according to severity of prior COVID-19 illness: (i) hospitalized, (ii) symptomatic, not hospitalized and (iii) asymptomatic""}"
"2759","Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS","","NCT04657458","DB-EAP-001","Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04657458","Available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"2760","Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens","VIGIE-COVID","NCT04699851","vigie-covid","Behavioral: Tailored recommendations|Behavioral: General recommendation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04699851","Recruiting","2020-11-18","2021-05-18","{""locations"":""Laval University, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""improvement in mask wearing behavior|improvement in social distancing behavior|improvement in hand washing behavior|improvement in daily fruit consumption|improvement in the amount of daily sleep hours|improvement in the amount of weekly minutes of exercise|Platform participation|Platform sustainability short term|Platform sustainability long term""}"
"2761","Psychological Impact of COVID-19 Outbreak on Caregivers","PSY-CO-ICU","NCT04511780","Local/2020/JYL-03","Other: questionnaire filling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04511780","Not yet recruiting","2021-01-01","2022-09-01","{""locations"":""Intensive Care Unit, CHU d'Amiens, Amiens, France|Intensive Care Unit, CHU d'Angers, Angers, France|CHU de Besan\u00e7on, Besan\u00e7on, France|CHU de Bordeaux, H\u00f4pital Pellegrin, Bordeaux, France|Intensive care Unit CHU de Brest H\u00f4pital Cavale Blanche, Brest, France|CHU de Caen, Caen, France|CHU de Clermont Ferrand, Clermont-Ferrand, France|AP-HP, H\u00f4pital Henri Mondor, Cr\u00e9teil, France|CHU de dijon, Dijon, France|CHU de Grenoble, H\u00f4pital Michalon, La Tronche, France|AP_HP, H\u00f4pital du Kremlin Bic\u00eatre, Le Kremlin-Bic\u00eatre, France|Intensive Care Unit, CHRU de Lille, Lille, France|Intensive Care Unit, CHU de Limoges, Limoges, France|H\u00f4pitaux civils de Lyon, H\u00f4pital de la Croix Rousse, Lyon, France|H\u00f4pitaux civils de Lyon, H\u00f4pital Louis Pradel, Lyon, France|H\u00f4pitaux civils de Lyon, H\u00f4pital Edouard Herriot, Lyon, France|AP-HM, H\u00f4pital Nord, Marseille, France|AP-HM, H\u00f4pital Timone adultes, Intensive Care Unit, Marseille, France|AP-HM, H\u00f4pital Timone adultes, Neurotraumatology, Marseille, France|AP-HM, H\u00f4pital e la Conception, Marseille, France|CHU de Montpellier, H\u00f4pital Guy de chauliac, Montpellier, France|CHU de Montpellier, H\u00f4pital Lapeyronie, Montpellier, France|CHU de Montpellier, H\u00f4pital St Eloi SAR B, Montpellier, France|CHU De Montpellier, H\u00f4pital St Eloi-DAR B, Montpellier, France|CHU De Montpellier, H\u00f4pital St Eloi, Montpellier, France|Intensive Care Unit, CHU de Mulhouse, Mulhouse, France|Intensive CAre Unit CHRU de Nancy, H\u00f4pital Central, Nancy, France|Intensive Care Unit, CHU de Nantes, H\u00f4tel Dieu, Nantes, France|Intensive Care Unit, CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|Intensive care Unit CHU N\u00eemes, N\u00eemes, France|AP-HP, H\u00f4pital de la Piti\u00e9, Paris, France|AP-HP, H\u00f4pital Bich\u00e2t, Paris, France|AP-HP, H\u00f4pital Lariboisi\u00e8re, Paris, France|AP6HP, H\u00f4pital St Loui, Paris, France|AP_HP, H\u00f4pital G Pompidou, Paris, France|AP-HP, H\u00f4pital St Antoine, Paris, France|CH de Perpignan, Perpignan, France|CHU de Bordeaux, H\u00f4pital Haut Leveque, Pessac, France|Intensive care Unit, H\u00f4pitaux civils de Lyon, Lyon Sud, Pierre-B\u00e9nite, France|CHU de Poitiers, Poitiers, France|Intensive care Unit CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|Intensive Care Unit, CHU de Nantes, H\u00f4pital Laennec, Saint-Herblain, France|CHU de St Etienne, H\u00f4pital Nord, Saint-\u00c9tienne, France|Intesive Care Unit CHRU de Strasbourg, H\u00f4pital civil, Strasbourg, France|Intesive Care Unit CHRU de Strasbourg, H\u00f4pital Hautepierre, Strasbourg, France|CHU de Toulouse, Toulouse, France|Intensive care unit CHU de Tours, Tours, France|Intensive CAre Unit CHRU de Nancy, H\u00f4pital de Brabois, Vand\u0153uvre-l\u00e8s-Nancy, France|CH de Vesoul, Vesoul, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Post-Traumatic Stress Disorder|anxiety and depression|Burn out""}"
"2762","Determination of Acute Encephalopathy Predictors in Patients With COVID-19","","NCT04405544","NMSC-01-20","Diagnostic Test: CT-scan|Diagnostic Test: EEG|Diagnostic Test: EP|Diagnostic Test: Pulse oximetry|Diagnostic Test: Blood tests","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04405544","Completed","2020-05-22","2020-10-29","{""locations"":""N.I. Pirogov National Medical and Surgical Center, Moscow, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""51"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""The percentage of patients who have developed encephalopathy""}"
"2763","Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection","IDRA-COVID19","NCT04435587","323/2563 (IRB3)","Drug: Ivermectin Pill|Drug: Combined ART/hydroxychloroquine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04435587","Recruiting","2020-07-13","2021-11-01","{""locations"":""Siriraj Hospital, Bangkok Noi, Bangkok, Thailand|Siriaj Hospital, Bangkok, N\/A = Not Applicable, Thailand|Sireethorn Nimitvilai, Amphoe Maueng, Nakhonpathom, Thailand|Golden Jubilee Medical Center, Phutthamonthon District, Nakhonpathom, Thailand"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse event rates|Efficacy for shortening duration of SAR-CoV2 detection by PCR|Antibody detection rates""}"
"2764","To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19","","NCT04602000","CT-P59 3.2","Biological: CT-P59/Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04602000","Recruiting","2020-09-25","2021-09-01","{""locations"":""Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1020"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II)|To evaluate the therapeutic efficacy CT-P59 for Part 2 (Phase III)|To evaluate the overall efficacy of CT-P59 for Part 1 and 2|To evaluate the overall safety of CT-P59 for Part 1 and 2|To evaluate virology for part 1 and part 2""}"
"2765","The Impact of COVID-19 on Dialysis Users","","NCT04422873","004","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422873","Recruiting","2020-06-03","2021-01-01","{""locations"":""School of Sport, Health and Exercise Science, Portsmouth, Outside The United States Or Canada, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours|Thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the COVID-19 restrictions in the UK""}"
"2766","Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","PEACE","NCT04346667","NBC-COVID19-02","Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04346667","Terminated","2020-04-14","2020-08-30","{""locations"":""Expo Covid Center, Lahore, Punjab, Pakistan|Mayo Hospital, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""125"",""age"":""20 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""RT-PCR negative status|Progression of symptoms|Development of Symptoms|Adverse events""}"
"2767","ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","","NCT04467931","00132408","Drug: ACEI/ARB|Drug: Non-ACEI/ARB|Drug: ACEI|Drug: ARB","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04467931","Active, not recruiting","2020-01-19","2020-12-31","{""locations"":""University of Utah, Salt Lake City, Utah, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-Cause-Hospitalization or All-Cause Mortality|All-Cause Mortality|ICU admission|Duration of hospitalization|Mechanical ventilation|Dialysis""}"
"2768","Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19","COVID-19","NCT04502667","R-2020-3603-020","Drug: Cholecalciferol","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04502667","Recruiting","2020-07-15","2021-04-01","{""locations"":""Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""1 Month to 17 Years \u00a0 (Child)"",""outcome_measures"":""INTERLEUKINS (IL-2,6,7,10) (pg\/ml)|FERRITIN (ng\/ml)|DIMER-D|Vitamin D (ng\/ml)""}"
"2769","The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children","","NCT04699097","139","Drug: Azithromycin","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04699097","Completed","2020-07-01","2020-11-01","{""locations"":""S\u00fcleyman Sunkak, Kayseri, In The USA Or Canada, Please Select..., Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""105"",""age"":""1 Year to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Effect of azitromycin on ventricle repolarization""}"
"2770","ICU Trial in Critical Ill COVID-19 Patients","POINT-C","NCT04349982","250320","Diagnostic Test: Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04349982","Recruiting","2020-04-08","2022-07-31","{""locations"":""Medical University of Graz, Graz, Styria, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU CV risk and Biomarker (e.g. Troponin)|CV risk and Outcome during ICU stay""}"
"2771","This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","","NCT04593641","CT-P59 1.2|2020-003165-19","Biological: CT-P59","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04593641","Active, not recruiting","2020-09-04","2020-12-23","{""locations"":""Incheon Medical Center, Incheon, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""To evaluate the preliminary safety and tolerability of CT-P59 up to Day 14 of the last enrolled subject|To evaluate the viral efficacy and characterization of SARS-CoV-2 viral isolates of CT-P59|To evaluate the efficacy of CT-P59|To evaluate the Pharmacokinetics of CT-P59""}"
"2772","Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study","","NCT04618861","Clinical-1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04618861","Completed","2020-10-13","2020-11-02","{""locations"":""Aylin Koseler, Denizli, Outside Of The US, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""127"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Meassuring the serum surfactant protein D levels in patient who have Covid-19 infection or pneumonia.|Analyzing the correlations between serum surfactant protein D levels and demographic,laboratory, clinical and radiological datas.""}"
"2773","Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women","","NCT04629638","maternalattachmentcovid","Other: Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04629638","Completed","2020-08-01","2020-11-20","{""locations"":""Pinar Yalcin Bahat, Istanbul, \u0130\u0307stanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Maternal attachment in SARS- cov2 positive and negative pregnant women|Edinburgh depression scores in in SARS- cov2 positive and negative pregnant women|Postpartum anxiety scale scores in in SARS- cov2 positive and negative pregnant women""}"
"2774","A Study of TAK-919 in Healthy Japanese Adults (COVID-19)","","NCT04677660","TAK-919-1501|U1111-1261-9040|jRCT2071200069","Biological: TAK-919|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04677660","Active, not recruiting","2021-01-21","2022-03-03","{""locations"":""Sumida Hospital, Sumida-ku, Tokyo, Japan|PS Clinic, Fukuoka, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination|Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination|Percentage of Participants with Unsolicited AEs for 28 Days After Each Vaccination|Percentage of Participants with Serious AE (SAE) until Day 57|Percentage of Participants with Medically-Attended Adverse Events (MAAEs) until Day 57|Percentage of Participants with Any AE Leading to Discontinuation of Vaccination|Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial until Day 57|Percentage of Participants with SARS-CoV-2 Infection until Day 57|Geometric Mean Titers (GMT) of Serum binding antibody (bAb) Against SARS-CoV-2 on Day 57|Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57|Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57|Percentage of Participants with SAE throughout the Trial|Percentage of Participants with MAAEs throughout the Trial|Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial from the Day of Vaccination throughout the Trial|Percentage of Participants with SARS-CoV-2 Infection throughout the Trial|GMT of Serum bAb Against SARS-CoV-2 on Day 29, Day 43, Day 209 and Day 394|GMFR of Serum bAb Against SARS-CoV-2 on Day 29, Day 43, Day 209 and Day 394|SCR of Serum bAb Against SARS-CoV-2 on Day 29, Day 43, Day 209 and Day 394|GMT of serum neutralizing antibody (nAb) against SARS-CoV-2 on Day 29, Day 43, Day 57, Day 209, and Day 394|GMFR of serum nAb against SARS-CoV-2 on Day 29, Day 43, Day 57, Day 209, and Day 394|SCR of serum nAb against SARS-CoV-2 on Day 29, Day 43, Day 57, Day 209, and Day 394""}"
"2775","Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure","","NCT04641182","0001","Other: Prone position","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04641182","Completed","2020-07-06","2020-09-16","{""locations"":""Hospital Clinico Red de Salud UC - Christus, Santiago, Region Metropolitana, Chile"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Therapeutic failure|Mortality|Length of hospital stay|Days requiring high flow nasal oxygen|Days requiring supplemental oxygen|Displacement of invasive devices during position changes|Occurrence of pressure ulcers on the anterior surface of the body|Respiratory superinfection|Delirium|Caloric intake|Proteic intake""}"
"2776","Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients","","NCT04530617","3421","Drug: Camostat Mesilate|Drug: Artemisia Annua Leaf","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04530617","Recruiting","2020-10-05","2021-04-30","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, None - Non-US\/Canada, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""360"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of hospitalizations and oxygen use""}"
"2777","Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)","","NCT04581811","IRB-300005979","Other: Prolonged Proned Positioning|Other: Traditional Proning Arm","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04581811","Recruiting","2020-11-10","2021-06-01","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""52"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration in prone position|Change in P:F ratio|Change in Drive Pressure|Unplanned extubations|Pressure ulcers|Line displacement|Duration of mechanical ventilation|Mortality|Rescue Interventions""}"
"2778","Long-term Impact of Infection With Novel Coronavirus (COVID-19)","LIINC","NCT04362150","20-30479","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362150","Active, not recruiting","2020-04-21","2024-12-21","{""locations"":""Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participant age|Participant sex|Participant race\/ethnicity|Proportion of participants previously hospitalized.""}"
"2779","Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19","AtemNHK","NCT04653727","AtemNHK","Other: Cross-sectional survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04653727","Recruiting","2021-01-06","2021-12-01","{""locations"":""Charite University, Berlin, Germany"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""3000"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection|Influenza virus infection|Other respiratory infections|Dietary habits|Sports activity|Time spent in nature|Use of hydrotherapy\/Kneipp applications|Use of anthroposophic medicine|Use of digital health services|Use of phytotherapy|Use of dietary supplements|WHO-5 Well-Being Index|Numeric analog scale (NAS) stress|Numeric analog scale (NAS) anxiety|Numeric analog scale (NAS) depression|Use of relaxation \/ mind body approaches|Alcohol consumption|Cigarette consumption|Self-efficacy|Sick leave""}"
"2780","Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy","(ESCAPE)","NCT04361253","2020P001215","Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04361253","Recruiting","2020-04-30","2021-12-01","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""12 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Modified WHO Ordinal Scale (MOS) score""}"
"2781","Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine","","NCT04691908","QAZCOV-III-01/2020","Biological: QazCovid-in®-vaccine against COVID-19|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04691908","Active, not recruiting","2020-12-25","2021-07-30","{""locations"":""Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy, Jambul, Kazakhstan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Terms of seroconversion (the proportion of persons with a fourfold or higher change in antibody titers to SARS-CoV-2)|To evaluate the immunogenicity of the QazCovid-in\u00ae vaccine inactivated against COVID-19 versus placebo|Frequency of confirmed cases of COVID-19|Changing of antigen-specific cellular immunity level|Frequency of adverse events up to seven days after immunization|Frequency of adverse events up to 21 days after immunization|Incidence of serious adverse events during the study""}"
"2782","Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic","","NCT04431310","Journal-nr.: H-20022312","Other: Serial seroconversion measurements in hospital employees during the COVID-19 pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04431310","Recruiting","2020-03-27","2025-08-01","{""locations"":""Nordsj\u00e6llands Hospital, Hiller\u00f8d, Capital Region, Denmark|Nyk\u00f8bing Falster County Hospital, Nyk\u00f8bing Falster, Southern Region, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serology testing for specific COVID-19|SARS-CoV-2 infection""}"
"2783","Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19","","NCT04378829","COVID-19","Diagnostic Test: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04378829","Recruiting","2020-09-12","2020-10-21","{""locations"":""Yasin Tire, Konya, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in PDW and MPV parameters""}"
"2784","Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)","CAPTOCOVID","NCT04355429","APHP200410","Drug: captopril 25mg","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04355429","Not yet recruiting","2020-05-05","2020-08-01","{""locations"":""CH Victor Dupuy- Argenteuil, Argenteuil, France|H\u00f4pital Avicenne,, Bobigny, France|H\u00f4pital Avicenne, Bobigny, France|H\u00f4pital Avicenne, Bobigny, France|H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart, France|CH de Compi\u00e8gne-Noyon, Compi\u00e8gne, France|Groupe hospitalier Sud Ile de France, Melun, France|H\u00f4pital de la Piti\u00e9- Salp\u00eatri\u00e8re, Paris, France|H\u00f4pital Tenon, Paris, France|CHRU de Tours, H\u00f4pital Bretonneau, Tours, France|H\u00f4pital de Tours, Tours, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of captopril nebulization addition to standard of care compared to standard of care.""}"
"2785","A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","","NCT04515147","CV-NCOV-002","Biological: CVnCoV 6 μg|Biological: CVnCoV 12 μg|Biological: Hepatitis A vaccine|Biological: Pneumococcal vaccine|Biological: CVnCoV 12μg","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04515147","Active, not recruiting","2020-09-28","2021-11-09","{""locations"":""Centro de vacunaci\u00f3n internacional - CEVAXIN Panama Clinic, Panama city, Panama|Instituto de Investigaci\u00f3n Nutricional, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""674"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with Solicited Local Adverse Events|Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale|Duration of Solicited Local Adverse Events|Number of Participants with Solicited Systemic Adverse Events|Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale|Duration of Solicited Systemic Adverse Events|Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine|Number of Participants with Unsolicited Adverse Events|Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale|Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine|Number of Participants with One or More Serious Adverse Events (SAEs)|Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine|Number of Participants with One or More Adverse Events of Special Interest (AESIs)|Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine|Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies|Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum|Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies|Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies|Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum|Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies|Number of Participants with Solicited Local Adverse Events Following the Booster Vaccine|Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine|Duration of Solicited Local Adverse Events Following the Booster Vaccine|Number of Participants with Solicited Systemic Adverse Events Following the Booster Vaccine|Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine|Duration of Solicited Systemic Adverse Events Following the Booster Vaccine|Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine Following the Booster Vaccine|Number of Participants with Unsolicited Adverse Events Following the Booster Vaccine|Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine|Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine Following the Booster Vaccine""}"
"2786","Knowledge, Attitudes, and Practices Towards COVID-19 Among Health Care Professionals Among Healthcare Professionals","","NCT04492202","00010","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492202","Not yet recruiting","2020-08-01","2020-12-10","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""200"",""age"":""22 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Questionnaire for the Evaluation of Knowledge, Attitude and Practise Levels of Healthcare Professionals for COVID-19|Support Approach Survey for Patients in Recovery Stage after COVID-19 Diagnosis""}"
"2787","A Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy","COVIDTrach","NCT04572438","Z6364106/0000/00/00","Procedure: Tracheostomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04572438","Recruiting","2020-08-01","2021-08-01","{""locations"":""University College London NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to wean|Airway related outcomes|Complications|Length of stay|Mortality|Adherence of tracheostomy procedure to national guidance|Operator wellness""}"
"2788","Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth","","NCT04385901","COVID19Recovery","Behavioral: Therapy Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04385901","Completed","2020-05-19","2020-09-19","{""locations"":""Missouri Orthopedic Institute, Columbia, Missouri, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""26"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in 6 Minute Walk Test|Change in Short Form 35 (SF-36) Questionnaire|Change in Strength testing|Change in Peak Flow Meter Test""}"
"2789","Automatic Oxygen Titration With O2matic® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure","O2matic-COVI","NCT04565106","O2matic-COVID","Device: Closed-loop control of oxygen supplementation by O2matic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04565106","Completed","2020-04-15","2020-05-31","{""locations"":""Hvidovre University Hospital, Copenhagen, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""16"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time in SpO2 target|Time with SpO2 not more than 2 % outside target|Time with SpO2 more than 2 % outside target|Time with SpO2 < 85 %""}"
"2790","Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19","","NCT04614025","PLX-COV-03","Biological: PLX-PAD","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04614025","Recruiting","2020-11-01","2022-03-01","{""locations"":""University of hospital Bonn, Bonn, Germany|Hospital Cologne-Merheim, K\u00f6ln, Germany|Emek Medical Center, Afula, Israel|University Hospital Samson Assuta Ashdod, Ashdod, Israel|Bnai Zion Medical Center, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Galilee Medical Center, Nahariya, Israel|Baruch Padeh Medical Center, Poriya, Tiberias, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of ventilator-free days|All-cause mortality|Duration of mechanical ventilation""}"
"2791","Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine","","NCT04530357","QAZCOV-I/II-01/2020","Biological: QazCovid-in® - COVID-19 inactivated vaccine|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04530357","Completed","2020-09-19","2020-11-30","{""locations"":""Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy, Jambul, Kazakhstan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""244"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of adverse events up to seven days after immunization|Frequency of adverse events up to 21 days after immunization|The proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in ELISA following the vaccination, compared with a placebo|Changing of virus-neutralizing antibodies to SARS-CoV-2 virus in blood serum samples|Incidence of serious adverse events during the study|Cell-mediated immune profile""}"
"2792","Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic","MolCOVID","NCT04367545","2020/0094/OB","Diagnostic Test: Saliva collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04367545","Completed","2020-04-16","2020-05-17","{""locations"":""Rouen University Hospital, Rouen, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""130"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of positive patient using saliva method compared to number of positive patient using standard method|Number of negative patient using saliva method compared to number of negative patient using standard method""}"
"2793","Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study","","NCT04365764","CIC1421-20-06","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365764","Recruiting","2020-03-14","2020-12-31","{""locations"":""Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score""}"
"2794","Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19","","NCT04420247","CLOROTRIAL","Drug: Chloroquine|Drug: Hydroxychloroquine|Other: standard care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04420247","Completed","2020-04-16","2020-09-03","{""locations"":""Centro de Estudos e Pesquisa em Emergencias Clinicas e Terapia Intensiva, Curitiba, Parana, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""142"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""World Health Organization (WHO) 9-levels ordinal scale (from 0-8)|Mortality|Ventilation free days|ICU Lenght of Stay|Hospital Lenght of Stay|Acute Kidney Disease incidence|Percentage of patients needing dialysis|Coagulopathy incidence|Mean of C Reactive Protein Levels|Sequential Organ Failure Assessment (SOFA) scores|Neutrophils\/lymphocytes ratio""}"
"2795","The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers","","NCT04697654","TLC19A1001","Drug: TLC19|Drug: TLC19 Vehicle","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04697654","Active, not recruiting","2020-10-14","2021-04-30","{""locations"":""Scientia Clinical Reserach, Ltd, Randwick, Australia|Mackay Memorial Hospital Tamsui Branch, Taipei, Taiwan"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of AEs|Maximum blood concentration|Time to reach maximum blood concentration|Area under the blood concentration-time curve""}"
"2796","A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers","","NCT04683484","NNG26","Biological: Nanocovax|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04683484","Recruiting","2020-12-10","2021-08-10","{""locations"":""Military Medical Academy, Hanoi, Ha Dong, Vietnam"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""620"",""age"":""12 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Solicited adverse events|Anti-S IgG|SARS-CoV-2 neutralizing titers|Participants achieving \u22654-fold rise of Anti-S IgG|Cellular immune response (IFN\u03b3)|Cellular immune response (T CD4)|Cellular immune response (T CD8)|Serious adverse events|Unsolicited adverse events""}"
"2797","Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients","","NCT04434118","IRB: RC-5-2020","Drug: Traditional antirheumatic drugs","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04434118","Enrolling by invitation","2020-03-20","2021-12-30","{""locations"":""Faculty of Medicine, Shib\u012bn Al Kawm, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""The risk of COVID-19 infection among RA patients|The incidence of hospitalization for Covid-19 patients.""}"
"2798","SARS-COV2 Pandemic Serosurvey in a Rare Disease Population","","NCT04609085","10000210|000210-I","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04609085","Enrolling by invitation","2021-03-16","2023-04-30","{""locations"":""National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""up to 89 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""To estimate the proportion of people with rare diseases who have detectable antibodies to SARS-COV2 in the NCATS RDCRN Rare Diseases Survey over time.|To estimate the proportion of detectable antibodies across specific categories of rare diseases (e.g., people who live with rare diseases characterized by immune compromise vs. people with hyper-reactivity of the immune system).""}"
"2799","COVID-19 Related Lung Ventilation and Perfusion Injury","","NCT04549636","FIRH002","Other: V/Q SPECT-CT|Other: St. George's Respiratory Questionnaire (SGRQ)|Other: mMRC (Modified Medical Research Council) Dyspnea Scale|Other: Six-minute walk test (6MWT)|Other: Spirometry|Other: Plethysmography & DLCO|Other: Airwave Oscillometry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04549636","Recruiting","2020-09-18","2021-12-01","{""locations"":""St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""92"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy|Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy|Short-term difference in lung ventilation\/perfusion mismatch assessed by ventilation\/perfusion SPECT-CT - healthy|Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy|Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy|Long-term difference in ventilation\/perfusion mismatch assessed by ventilation\/perfusion SPECT-CT - healthy|Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic|Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic|Short-term difference in ventilation\/perfusion mismatch assessed by ventilation\/perfusion SPECT-CT - asthmatic|Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic|Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic|Long-term difference in ventilation\/perfusion mismatch assessed by ventilation\/perfusion SPECT-CT - asthmatic|Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - healthy|Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - healthy|Longitudinal change in ventilation\/perfusion mismatch assessed by ventilation\/perfusion SPECT-CT - healthy|Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic|Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic|Longitudinal change in ventilation\/perfusion mismatch assessed by ventilation\/perfusion SPECT-CT - asthmatic|Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score \u22644-weeks post COVID-19 recovery|Correlation of lung ventilation with six-minute walk distance (6MWD) \u22644-weeks post COVID-19 recovery|Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) \u22644-weeks post COVID-19 recovery|Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) \u22644-weeks post COVID-19 recovery|Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score 6-months post COVID-19 recovery|Correlation of lung ventilation with six-minute walk distance (6MWD) 6-months post COVID-19 recovery|Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) 6-months post COVID-19 recovery|Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) 6-months post COVID-19 recovery""}"
"2800","Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status","RECOVIDS","NCT04556513","QUENOT 2020","Other: Paraclinical examination|Other: Clinical Examination|Other: Semi-directive interview|Other: quality of life questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04556513","Recruiting","2020-09-18","2022-11-01","{""locations"":""Chu Dijon Bourgogne, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Respiratory sequelae 6 months after resuscitation.""}"
"2801","Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.","","NCT04432948","Maternal Covid 19","Other: PHQ-9 Depression Scale|Other: GAD-7 General anxiety disorder scale|Other: 38-questions questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04432948","Recruiting","2020-05-15","2020-12-01","{""locations"":""\""Elena Venizelou\"" General and Maternity Hospital of Athens, Athens, Attica, Greece"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Association between Covid-19 pandemic and maternal psychological distress|Association between Covid-19 pandemic, maternal psychological distress and anaesthetic practice""}"
"2802","Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)","","NCT04534569","C19ARFstudy","Other: Experts consensus","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04534569","Completed","2020-09-04","2020-10-06","{""locations"":""NMC Specialty Hospital, Dubai, United Arab Emirates"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Consensus using participating experts opinions.""}"
"2803","A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion","","NCT04720794","07A-CLI-006","Device: Lucira COVID-19 All-In-One test kit","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04720794","Completed","2020-09-25","2020-10-20","{""locations"":""Neeraj Kochhar Family Medicine, Los Gatos, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""101"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Prevalence Rate \/ Expected Values counts|COVID-19 Prevalence Rate \/ Expected Values percentages|Collection Performance\/ Incidence Rate counts|Collection Performance\/ Incidence Rate percentages|Sensitivity and specificity""}"
"2804","Repeated Employee Testing for Understanding Our Recovery to Normal","RETURN","NCT04472793","RETURN","Diagnostic Test: SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04472793","Recruiting","2020-05-11","2023-12-01","{""locations"":""Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The 6-month cumulative incidence of acquired COVID infection in the study cohort.""}"
"2805","A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19","","NCT04582318","621-CP-102","Biological: NGM621|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04582318","Recruiting","2020-11-08","2021-09-01","{""locations"":""NGM Clinical Study Site, Brisbane, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment emergent adverse events - Part 1|Treatment emergent adverse events - Part 2|Clinical status at Day 15 and Day 29 - Part 2|Maxiumum Serum Concentration [Cmax]|Mortality at Day 29|Duration of Supplemental Oxygen Requirement|Change in Hemolytic Assays (CH50 and AH50) from Baseline""}"
"2806","Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium","","NCT04513314","20200851","Drug: Valproate|Drug: Quetiapine|Other: Standard of Care","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04513314","Not yet recruiting","2021-11-01","2022-11-01","{""locations"":""Jackson Memorial Hospital, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline RASS score of +3 or greater|Total dose of dexmedetomidine administered|Incidence of Treatment Emergent Adverse Events""}"
"2807","Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19","BONSAI","NCT04504877","BONSAI Study","Drug: Cannabidiol","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04504877","Active, not recruiting","2020-06-16","2020-12-16","{""locations"":""Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto - USP, Ribeir\u00e3o Preto, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""120"",""age"":""24 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""aMBI-HSS: Abbreviated Maslach Burnout Inventory - Human Services Survey|Brief measure for assessing generalized anxiety disorder: The GAD-7|PHQ-9: Patient\u00b4s Health Questionnaire-9|Change in proinflammatory cytokine concentration|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)""}"
"2808","Efficacy and Safety of Itolizumab in COVID-19 Complications","","NCT04475588","ITOLI-C19-02-I-00","Drug: Itolizumab IV infusion|Drug: Best supportive care"" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04475588","Completed","2020-05-01","2020-07-08","{""locations"":""Topiwala National Medical College & B. Y. L. Nair Charitable Hospital,, Mumbai, India|Seth GS Medical College and KEM Hospital, Mumbai, India|MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital hospital, New Delhi, India|All India Institute Of Medical Sciences, New Delhi, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""One-month mortality rate between the two arms|Biomarkers (IL-6, TNF-a, IL1, IL17, etc\u2026)|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) \/ FiO2 (fraction of inspired oxygen, FiO2) ratio (or P\/F ratio)|Radiological response|Duration of hospitalization|Remission of respiratory symptoms""}"
"2809","Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus","Combination","NCT04389580","COV-19 Treatment This is","Drug: Drug: Isotretinoin plus Tamoxifen|Drug: Aerosolized Isotretinoin plus Tamoxifen","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04389580","Not yet recruiting","2020-06-01","2020-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap""}"
"2810","Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19","","NCT04347226","AAAS9881","Drug: BMS-986253","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04347226","Recruiting","2020-04-16","2022-09-01","{""locations"":""Columbia University Irving Medical Center, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""138"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Improvement in the 7-point ordinal scale|Time to Death|Time to Intubation|Proportion of patients requiring ICU admission|Percentage Rate of Mortality at 1 month""}"
"2811","Patient Recovery From Heart Surgery During the Covid-19 Pandemic","CardiacCovid","NCT04366167","132127","Other: Cardiac surgery","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366167","Recruiting","2020-04-18","2021-12-31","{""locations"":""St Bartholomew's Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Impact of Events scores|Survival|Morbidity|Change in Health-related quality of life scores|Change in Depression scores""}"
"2812","COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma","COPLA","NCT04357106","CHMI-030420-01","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04357106","Recruiting","2020-04-13","2020-08-01","{""locations"":""Centro de Hematolog\u00eda y Medicina Interna, Puebla, Mexico"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Lung injury|Overall survival|Adverse reactions to plasma""}"
"2813","Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","REPLACECOVID","NCT04338009","842810","Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04338009","Enrolling by invitation","2020-03-31","2020-12-31","{""locations"":""University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""152"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hierarchical composite endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, invasive mechanical ventilation or extracorporeal membrane oxygenation|AUC SOFA""}"
"2814","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019","","NCT04334265","2020 research 110","Drug: Anluohuaxian","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04334265","Recruiting","2020-04-01","2020-12-01","{""locations"":""The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""750"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung""}"
"2815","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","HERO-HCQ","NCT04334148","Pro00105274","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04334148","Completed","2020-04-22","2021-01-09","{""locations"":""Children's Hospital Colorado\/University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|University of Florida Health Central Florida, Leesburg, Florida, United States|University of Miami Florida, Miami, Florida, United States|Advent Health, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Northwestern Medicine, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States|University of Missouri-Columbia, Columbia, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hospital for Special Surgery, New York, New York, United States|Columbia University, Irving Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White Medical Center-Temple, Temple, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic Health System, Marshfield, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1363"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with clinical infection with COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events""}"
"2816","Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","","NCT04333589","2020 research 112","Drug: Favipiravir","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04333589","Recruiting","2020-04-01","2020-09-15","{""locations"":""The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""210"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral nucleic acid test negative conversion rate|Clinical cure rate""}"
"2817","Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome","","NCT04380935","convalescent plasma RSCM-FKUI","Biological: Convalescent plasma|Drug: Standard of care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04380935","Recruiting","2020-05-18","2020-10-31","{""locations"":""Dr. Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia|St. Carolus Hospital, Jakarta, DKI Jakarta, Indonesia|Ciputra Hospital CitraRaya, Jakarta, DKI Jakarta, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Length of stay in intensive care unit|Duration of mechanical ventilation|Body temperature (degree in Celsius)|The Sequential Organ Failure Assessment (SOFA) Score|PAO2\/FIO2 ratio|C-Reactive Protein (CRP) in mg\/L|D-Dimer in ng\/mL|Procalcitonin in ng\/mL|Interleukin 6 (IL-6) in pg\/mL|Allergic\/ anaphylaxis transfusion reaction|Hemolytic transfusion reaction|Transfusion Related Acute Lung Injury|Transfusion associated Circulatory Overload""}"
"2818","Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients","","NCT04412304","Anticoagulant therapy Covid-19","Drug: Dose of Tinzaparin or Dalteparin","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412304","Completed","2020-03-06","2020-05-28","{""locations"":""South General Hospital, Stockholm, Stockholms L\u00e4n, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""166"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""28-days ICU mortality|Incidence of thromboembolic events|Incidence of bleeding events|ICU-free days alive from ICU-admission.""}"
"2819","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","","NCT04311398","KY2020-COVID-19","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04311398","Not yet recruiting","2020-05-13","2020-12-01","{""locations"":""Huashan Hospital of Fudan University, Shanghai, Shanghai, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""16 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Sensitivity\uff0c spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform""}"
"2820","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","","NCT04310228","2020YFC0844100","Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04310228","Recruiting","2020-03-08","2020-05-01","{""locations"":""Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time""}"
"2821","Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19","","NCT04389450","PLX-COV-01","Biological: PLX-PAD|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04389450","Recruiting","2020-10-01","2022-03-01","{""locations"":""University of California Irvine, Irvine, California, United States|University of Southern California (USC) - Keck School of Medicine (KSOM), Los Angeles, California, United States|University Of California Davis,4860 Y Street, Sacramento, California, United States|Baptist Health Medical Center, Jacksonville, Florida, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|Sarah Cannon Research Institute, LLC (Mercer University School of Medicine), Macon, Georgia, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cooper Research Institute, Camden, New Jersey, United States|Holy Medical Center, Teaneck, New Jersey, United States|Montefiore Medical Center, New York, New York, United States|Maimonides Medical Center, New York, New York, United States|Mercy Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""140"",""age"":""40 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of ventilator free days|All-cause mortality|Duration of mechanical ventilation""}"
"2822","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","","NCT04302519","KT005HB001","Biological: Dental pulp mesenchymal stem cells","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04302519","Not yet recruiting","2020-03-05","2021-07-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen""}"
"2823","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","","NCT04295551","QF-XYP1990-1","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04295551","Not yet recruiting","2020-03-14","2021-04-14","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical recovery time""}"
"2824","CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19","COPLASCOV19","NCT04356482","TERAPLASCOV2","Biological: convalescent plasma","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04356482","Recruiting","2020-05-20","2020-12-01","{""locations"":""Hospital Del Issste Regional En Guadalajara Jalisco, Guadalajara, Jalisco, Mexico|Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado, Hermosillo, Sonora, Mexico|Hospital Central Norte Pemex, Mexico City, Mexico"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical improvement|improvement in tomographic image|test positivity for COVID-19|early and late complications associated to convalescent plasma|days at ICU""}"
"2825","Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection","PRIORITISE","NCT04441372","MSF0001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04441372","Recruiting","2020-10-01","2021-05-01","{""locations"":""All India Institute of Medical Sciences Patna (AIIMS), Patna, Bihar, India|Christian Medical College, Vellore, Vellore, Tamil Nadu, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical and biochemical prognostic markers|Evaluate field-based performance of POC""}"
"2826","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","COPCOV","NCT04303507","VIR20001","Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04303507","Recruiting","2020-04-29","2021-04-01","{""locations"":""RSUPN Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta, Indonesia|Istituto Sacro Cuore Don Calabria, Negrar, Negrar Di Valpolicella VR, Italy|Mahosot hospital, Vientiane, Lao People's Democratic Republic|The Aga Khan University Hospital, Karachi, Pakistan|Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand|University Hospitals Of Morecambe Bay NHS Foundation Trust, Kendal, Cumbria, United Kingdom|Torbay and South Devon NHS Foundation Trust, Torquay, Devon, United Kingdom|The Princess Alexandra Hospital NHS Trust, Harlow, Essex, United Kingdom|West Hertfordshire Hospitals NHS Trust, Watford, Hertfordshire, United Kingdom|Lewisham and Greenwich NHS Trust, Woolwich, London, United Kingdom|Sherwood Forest Hospitals NHS Foundation Trust, Sutton In Ashfield, Nottinghamshire, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""40000"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses""}"
"2827","Hydroxychloroquine to Prevent SARS-CoV-2 Infection","","NCT04414241","202087|20923","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04414241","Not yet recruiting","2020-06-01","2020-10-01","{""locations"":""Centro M\u00e9dico Naval \""Cirujano Mayor Santiago T\u00e1vara\"", Callao, Peru|Hospital Nacional Hip\u00f3lito Unanue, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Hospital Cayetano Heredia, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""320"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2|Safety: Proportion of participants with grade 3 or more adverse events|Tolerability: Proportion of participants that discontinue prophylactic treatment due to grade 1 or 2 adverse events""}"
"2828","Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room","ReCovER","NCT04351854","ReCovER","Other: Retrospective data collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351854","Recruiting","2020-04-20","2026-08-31","{""locations"":""University Hospital of Cologne, Cologne, Germany"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission.|Determination of the course of the disease (days since onset of symptoms, nature of symptoms, e.g. fever, chills, headache) and the state at which patients present to the ED|Identification of the ratio of patients with mild or moderate to severe disease""}"
"2829","Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection","","NCT04475068","HNEdgardoRebagliatiMartins","Procedure: Lateral Position (left and right lateral decubitus)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04475068","Recruiting","2020-07-17","2020-10-01","{""locations"":""Hospital Rebagliati, Jes\u00fas Mar\u00eda, Lima, Peru"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""12"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effects of a postural recruitment maneuver in lung aeration|Effects of a postural recruitment maneuver in distribution of ventilation|Effects of a postural recruitment maneuver in gas exchange|Effects of a postural recruitment maneuver in respiratory mechanics|Effects of a postural recruitment maneuver in hemodynamic|Feasibility of a postural recruitment maneuver""}"
"2830","The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection","","NCT04636034","GSPB-COVID-2020","Procedure: Sphenopalatine Ganglion Block with Local Anesthetic|Procedure: Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Procedure: ""Sham""-block with Placebo (Isotone NaCl)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04636034","Recruiting","2021-01-12","2021-11-01","{""locations"":""Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hyperactivity in the sphenopalatine ganglion assessed by pain intensity (0-100mm on a visual analogue scale, VAS) of the postdural headache in standing position in the group Ropivacine-Lidocaine and \""sham\"".|Number of patients with pain rating below 30mm in standing position (0-100mm on a visual analogue scale, VAS)|Worst experienced pain in standing position (0-10 on a numercial rating scale, NRS)|Average pain intensity (0-10 on a numercial rating scale, NRS)|Number of patients needing \""rescue GSP-block\""|Hyperactivity in the sphenopalatine ganglion assessed by pain intensity (0-100mm on a visual analogue scale, VAS) of the postdural headache in standing position in all 3 groups.""}"
"2831","Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study)","DECORE","NCT04401033","003","Behavioral: Telephonic medical visit|Procedure: Gastrointestinal endoscopy|Procedure: Abdominal ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401033","Completed","2020-05-11","2020-06-30","{""locations"":""Hospital Rio Hortega, Valladolid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection in patients|SARS-CoV-2 infection in HCW""}"
"2832","Cardiac Performance in Mechanically Ventilated COVID-19 Patients","","NCT04628195","200422002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04628195","Completed","2020-04-01","2020-08-01","{""locations"":""Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Regi\u00f3n Metropolitana, Chile"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with left ventricle dysfunction (hypokinetic)|Percentage of patients with acute cor pulmonale|Differences in respiratory system compliance between patients with and without acute cor pulmonale|Differences in partial arterial pressure of carbon dioxide (PCO2) between patients with and without acute cor pulmonale|Differences in PaO2\/FiO2 ratio between patients with and without acute cor pulmonale""}"
"2833","Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1)","LymphoCov1","NCT04386512","P20/12_LymphoCov","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386512","Completed","2020-05-15","2020-07-15","{""locations"":""CH de Versailles, Le Chesnay, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""89"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality|transfer to ICU""}"
"2834","Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina","SATICOVID19","NCT04611269","SATI","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04611269","Completed","2020-03-20","2020-10-31","{""locations"":""Hospital Interzonal General de Agudos Gral. San Mart\u00edn, La Plata, BA, Argentina|Sanatorio Las Lomas, san Isidro, BA, Argentina|Hospital General de Agudos Juan A. Fern\u00e1ndez, Buenos Aires, Caba, Argentina|Sanatorio Anchorena Recoleta, Buenos Aires, Caba, Argentina|Sanatorio Otamendi, Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""950"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU Mortality|Hospital mortality""}"
"2835","Psychological Health, Coping Strategies and Preferences of Military COVID-19 Deployers","","NCT04646642","FWH20200203E","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04646642","Not yet recruiting","2020-12-01","2021-05-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""160"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Patient Health Questionnaire-2 (PHQ-2)|Generalized Anxiety Disorder-2 (GAD-2)|Pittsburgh Sleep Quality Index-Addendum for PTSD (PSQI-A)|Deployer Identified COVID-19 Stressors|The Brief Coping Orientation to Problems Experienced (Brief COPE)|COVID-19 Coping Strategy and Resource Inventory|Demographic questionnaire""}"
"2836","Rehabilitation for People With COVID-19 in ICU","COVID_REHAB","NCT04381338","UPadova_1","Other: Pulmonary and Motor Rehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04381338","Not yet recruiting","2020-05-10","2020-09-30","{""locations"":""Teaching Hospital, University of Padova, Padova, Italy|Teaching Hospital, University of Verona, Verona, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""92"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Length of ICU stay|Length of hospital stay""}"
"2837","Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19","APRONOX","NCT04407468","1178/SESEQ-HSGJR/08-05-20/UTI","Procedure: Prone position","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407468","Completed","2020-05-01","2020-07-13","{""locations"":""Hospital Materno Celaya, Celaya, Guanajuato, Mexico|Hospital Santo Tomas, Quer\u00e9taro City, Queretaro, Mexico|Hospital General San Juan del Rio, Quer\u00e9taro City, Queretaro, Mexico|ISSSTE Hospital Regional Merida, M\u00e9rida, Yucatan, Mexico|Hospital General de Zona 48 San PEDRO Xalpa IMSS, Estado De M\u00e9xico, Mexico|Hospital Fernando Quiroz Gutierrez, Mexico City, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""827"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To analyze the relationship between the prone position and the need for orotracheal intubation.|The impact of the prone position on the partial oxygen saturation \/ inspired oxygen fraction index (SaO2 \/ FiO2).""}"
"2838","Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19","SAINT-PERU","NCT04635943","EC-CNTEI-014-2020","Drug: Ivermectin|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04635943","Recruiting","2020-08-28","2021-01-28","{""locations"":""Hospital Nacional Cayetano Heredia, Lima, Peru"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""68"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with a positive SARS-CoV-2 PCR.|Mean viral load|Fever and cough progression|Seroconversion at day 21|Proportion of drug-related adverse events|Levels of IgG, IgM and IgA|Frequency of innate immune cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells|Results from cytokine Human Magnetic 30-Plex Panel|Presence of intestinal helminths""}"
"2839","Intermediate IND Severe Illness COVID-19 CP","","NCT04411602","1589349","Drug: SARS-CoV-2 plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04411602","Recruiting","2020-04-07","2021-11-01","{""locations"":""Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Ascension Macomb-Oakland Hospital, Warren Campus, Warren, Michigan, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure.|Ventilatory free days|Patient mortality (including death from any cause)""}"
"2840","Pilot Study on Cytokine Filtration in COVID-19 ARDS","CytokCOVID19","NCT04361526","HCB/2020/0464","Device: Cytokine Adsorption","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04361526","Recruiting","2020-04-17","2020-07-01","{""locations"":""Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation-free days|30-day mortality|length of ICU stay (days)|length of hospital stay|Duration of renal replacement and cathecolamines therapies|Need for extracorporeal membrane oxygenation (ECMO) support|multi-organ failure measured by the Sequential Organ Failure Assessment (SOFA) score""}"
"2841","Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in Greece","","NCT04700254","Diabetes and COVID-19","Other: DASS questionnaire|Other: EAT-26 questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04700254","Completed","2020-12-28","2021-01-11","{""locations"":""General Hospital of Chania, Chania, Crete, Greece"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""DASS (Depression)|DASS (Anxiety)|Eating Attitudes Test (EAT-26)""}"
"2842","Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b","","NCT04453982","39373-b","Other: Human milk donors","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453982","Recruiting","2020-06-21","2021-02-01","{""locations"":""Sinai Health System, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence of SARS-CoV-2 in breastmilk|Prevalence of SARS-CoV-2 antibody in breastmilk""}"
"2843","Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a","","NCT04453969","39373-a","Other: COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453969","Recruiting","2020-05-24","2021-01-01","{""locations"":""Sinai Health System, Toronto, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Presence of SARS-CoV-2 in breastmilk|SARS-CoV-2 antibody in breastmilk""}"
"2844","COVID-19 Stroke Apical Lung Examination Study","","NCT04640428","COVID SALES 2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04640428","Recruiting","2020-07-10","2021-10-31","{""locations"":""King's College Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Accuracy of the computed tomography angiography biomarker relative to the COVID-19 RT-PCR test|Prognostic value of the computed tomography biomarker""}"
"2845","Impact of Covid-19 Pandemic on Management of Head and Neck Cancers","VADS-Covid","NCT04704466","PI2021_843_0003","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04704466","Recruiting","2021-01-07","2021-07-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation of delay (in days) between the first cancer consultation and the beginning of the first line of treatment""}"
"2846","Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE","APPROVE-CARE","NCT04347941","APPROVE-CARE-2020","Procedure: Prone Positioning|Procedure: Standard of care.","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04347941","Recruiting","2020-07-11","2021-09-11","{""locations"":""Galway University Hospital, Galway, Ireland|Galway University Hospital, Galway, Ireland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.|Length of time tolerating prone positioning|PaO2\/FiO2 measured before prone positioning|PaO2\/FiO2 ratio after 1 hours of prone positioning|SpO2\/FiO2 ratio measured before prone positioning|SpO2\/FiO2 ratio after 1 hours of prone positioning|Number requiring increase in ventilatory assistance (CPAP+BIPAP+IMV etc)|Work of breathing assessment (Respiratory distress scale)|Changes in bioimpedance measures of lung edema in patients in PP|Use of awake prone positioning as a rescue intervention in control patients""}"
"2847","Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic","","NCT04654481","GCO 20-2667|ISMMS-AFF-20","Device: HCFWO|Other: Standard Care Plus Monitoring","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04654481","Recruiting","2020-12-01","2021-11-01","{""locations"":""Mount Sinai Beth Israel, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in forced expiratory volume in one second (FEV1)|Change in Oxygen Saturation level|Change in Presence of Fever|Change in Presence of pneumonia symptoms via Community Acquired Pneumonia (CAP) Symptom Questionnaire|Change in Quality of life via Quality of Life Questionnaire-Respiratory (QOL-B)|Change in Mental health screening via Personal Health Questionnaire Depression Scale (PHQ-8)|Change in Mental health screening via General Anxiety Disorder-7 (GAD-7)|Change in COVID Symptom Checklist|AffloVest Usage""}"
"2848","Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.","","NCT04370015","16082019","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04370015","Not yet recruiting","2020-05-15","2020-10-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""374"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period|Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment|Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR|Clinical disease severity in confirmed SARS-CoV-2 participants|Incidence of any acute respiratory infection""}"
"2849","Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic","","NCT04609722","2020/751","Other: Solution-Focused Support Program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04609722","Recruiting","2020-07-01","2021-02-15","{""locations"":""Online- Data will be collected through the form created with the Google-Forms, Ad\u0131yaman, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""60"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""State-Trait Anxiety Inventory (STAI)""}"
"2850","Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns","Coropreg","NCT04463758","APHP200513","Other: An auto-questionnaire comprising three psychometric scales","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04463758","Recruiting","2020-05-11","2022-10-01","{""locations"":""AP-HP Cochin, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3060"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Joint evaluation of morbi-mortality for mother and child up to 12 weeks postpartum|Number of women infection COVID-19|Severe forms of COVID-19 infection in the mother|Severe neonatal morbidity""}"
"2851","Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)","","NCT04530604","HUM00182089","Drug: Defibrotide","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04530604","Recruiting","2020-10-01","2021-10-01","{""locations"":""University of Michigan, Ann Arbor, Michigan, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of major hemorrhagic complications within 14 days of initiation of treatment|Overall survival|Ventilator free survival|Number of ventilator free days within 14 days of study entry|The time to improvement in oxygenation|Mean change in the WHO COVID-19 Ordinal Scale during therapy""}"
"2852","COVID-19 in Pain Perspective","","NCT04454333","2811","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04454333","Completed","2020-06-03","2020-06-20","{""locations"":""\u015ei\u015fli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""466"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Numeric Rating Scale for Pain|Hospital Anxiety and Depression Scale (HADS)|SF-12 Health assesment Questionaire""}"
"2853","A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease","","NCT04346160","UChieti03","Diagnostic Test: Schirmer Test I","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346160","Not yet recruiting","2020-04-14","2020-04-30","{""locations"":""Ophtalmology Clinic, G.d'Annunzio University, Chieti, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""virus molecular analysis|host molecular analysis|Epidemiologic data""}"
"2854","Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure","COVID-AIV","NCT04311697","COVID-AIV","Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04311697","Completed","2020-05-15","2021-02-22","{""locations"":""St. Jude Medical Center, Fullerton, California, United States|University of California - Irvine, Irvine, California, United States|Miller School of Medicine \/ University of Miami Medical Center, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Heartland\/Mosaic Health, Saint Joseph, Missouri, United States|Hendrick Health, Abilene, Texas, United States|Texas Health Harris Methodist Hospital, Fort Worth, Texas, United States|Texas Health Hospital Frisco, Frisco, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""196"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Resolution of Respiratory Failure (Composite Endpoint)|Improvement on NIAID Scale (key secondary measure)|Survival through day 28 and day 60|Time to ICU discharge|Time on ventilation|Time to extubation|Time to discharge alive|Multi-organ failure free days""}"
"2855","PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs","PHENOTYPE","NCT04459351","C&W20/035","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459351","Recruiting","2020-06-19","2023-06-01","{""locations"":""Chelsea and Westminster Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of baseline characteristics which correlate with disease severity|Identification of blood biomarkers which correlate with disease severity|Genomic analysis of blood samples to look for genetic susceptibility to severe disease presentations|Incidence|Change in respiratory symptom scores|Change in frailty and quality of life scores|Relationship between serum markers and clinical outcomes""}"
"2856","Tomographic Findings in COVID-19 and Influenza","TOMOCOVIDMX","NCT04497311","HGL-ENSE-00743-20","Diagnostic Test: Thoraxic computed tomography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497311","Recruiting","2020-06-15","2022-04-30","{""locations"":""Hospital General Le\u00f3n-Milenio, Le\u00f3n, Guanajuato, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Radiological findings|Survival""}"
"2857","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation","","NCT04340479","20-0751","Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04340479","Recruiting","2020-07-30","2022-05-01","{""locations"":""Children's Hospital Colorado, Aurora, Colorado, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients""}"
"2858","Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients","CGM-ISO","NCT04430608","H-20025305","Device: Dexcom G6","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04430608","Recruiting","2020-05-25","2021-05-25","{""locations"":""Nordsj\u00e6llands Hospital, Hiller\u00f8d, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""72"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time In Range (TIR) for blood glucose|Saved patient-personnel contacts related to blood glucose measurements.|Glucose variations during hospitalization|Blood glucose lowering interventions|CGM sensor performance|Course of hospital stay.""}"
"2859","EEG-based Sedation Protocol for Patients on Mechanical Ventilation Due to SARS-CoV-2 Pneumonia","","NCT04699916","80320","Other: EEG based protocol for deep sedation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04699916","Not yet recruiting","2021-01-04","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""44"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator Free Days|Plasma propofol concentration|Total administered dose of propofol|Total administered dose of Fentanyl|Total administered dose of Norepinephrine|Propofol-Related Infusion Syndrome (PRIS) Incidence|Accidental extubation|Delirium Incidence|ICU length of stay|Hospital length of stay|Mortality|Success of the first weaning trial""}"
"2860","Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus","CoVid3S","NCT04441710","69HCL20_0395","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04441710","Recruiting","2020-10-27","2024-04-01","{""locations"":""CHU de Grenoble - H\u00f4pital Nord, La Tronche, France|H\u00f4pital de la Croix Rousse, Lyon, France|H\u00f4pital Henry Gabrielle, Saint-Genis-Laval, France|CHU de Saint Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Establishment of a reliable prediction model for the effectiveness of virus control""}"
"2861","Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19)","","NCT04491214","7890","Other: quality of live assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04491214","Completed","2020-07-24","2021-01-21","{""locations"":""H\u00f4pitaux Universitaires de Strasbourg (Nouvel H\u00f4pital Civil), Strasbourg, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""112"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""assess quality of life after severe COVID infection|Quality of life and Clinical status""}"
"2862","COVID19 Neurological Manifestation","","NCT04496128","STUDY20040037","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04496128","Enrolling by invitation","2020-04-13","2021-03-31","{""locations"":""University of Pittsburgh, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of neurological manifestations|Hospital Mortality|Global functional outcomes using modified Rankin score|Length of ICU stay|Length of hospital stay (in days)|30-day mortality|90-day mortality""}"
"2863","Stroke Rehabilitation Outcome During COVID-19 Lockdown","SROCL","NCT04373109","BASEC-Nr. 2020-00761","Behavioral: Observation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373109","Completed","2020-04-16","2020-10-12","{""locations"":""University Hospital Zurich, Zurich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rehabilitation data|Motor Activity Log - 14 Item Version|International Physical Activity Questionnaire|Patient-Reported Outcomes Measurement Information System - 29 Version|Global Rating of Perceived Changes (physical activity engagement and upper limb use)|Fatigue Severity Scale|Hospital Anxiety and Depression Scale|Montreal Cognitive Assessment|Functional Ambulation Categories|Ten-Meter Walk Test|Rivermead Mobility Index|Activities-specific Balance Confidence Scale|Fugl-Meyer Motor Assessment|Action Research Arm Test|modified Rankin Scale|National Institutes of Health Stroke Scale""}"
"2864","Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection","SOLID","NCT04407143","GECP 20/04_SOLID","Diagnostic Test: IgG test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407143","Recruiting","2020-04-15","2021-09-30","{""locations"":""Hospital General Universitario de Elche, Elche, Alicante, Spain|ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Torrej\u00f3n, Torrej\u00f3n, Madrid, Spain|Hospital Universitario Son Ll\u00e0tzer, Palma De Mallorca, Mallorca, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Complejo Hospitalario de A Coru\u00f1a, A Coru\u00f1a, Spain|Hospital La Esperanza, A Coru\u00f1a, Spain|Hospital Universitario de Ferrol, A Coru\u00f1a, Spain|Hospital Virgen de los Lirios, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Cl\u00ednic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Dexeus, Barcelona, Spain|Hospital Universitario Cruces, Bilbao, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Puerto Real, Cadiz, Spain|Hospital General La Mancha Centro, Ciudad Real, Spain|Hospital Universitario San Pedro de Alc\u00e1ntara, C\u00e1ceres, Spain|Hospital Universitario Puerta del Mar, C\u00e1diz, Spain|Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain|Hospital Universitario de Vinalop\u00f3, Elche, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Complejo Hospitalario de Ja\u00e9n, Ja\u00e9n, Spain|Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain|Hospital universitari Arnau de Vilanova, Lleida, Spain|Hospital San Pedro, Logro\u00f1o, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Cl\u00ednica Universidad de Navarra, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario de M\u00f3stoles, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Madrid, Spain|Hospital Universitario Infanta Cristina, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Infanta Sof\u00eda, Madrid, Spain|Hospital Universitario Pr\u00edncipe de Asturias, Madrid, Spain|Hospital General Universitario de M\u00e1laga, M\u00e1laga, Spain|Hospital Costa del Sol, M\u00e1laga, Spain|Complejo Hospitalario Universitario de Ourense Santa Mar\u00eda Nai, Ourense, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Cl\u00ednica Universidad de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Sant Joan de Reus, Reus, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Roc\u00edo, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital Universitario Nuestra Se\u00f1ora de Candelaria, Tenerife, Spain|Hospital Universitari i Polit\u00e9cnic La Fe, Valencia, Spain|Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital de Manises, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Llu\u00eds Alcany\u00eds, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario R\u00edo Ortega, Valladolid, Spain|Complejo Hospitalario Zamora, Zamora, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""128"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Description of the characteristics of patients""}"
"2865","Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19","DICER","NCT04391179","HUM00179783","Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04391179","Active, not recruiting","2020-05-31","2021-02-01","{""locations"":""North Shore UniversityHealth, Evanston, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in D-dimer|Global composite rank score""}"
"2866","The C3I COVID-19 Project","","NCT04506528","2020-069|OISE-20-66590-1|A534253|SMPH/MEDICINE|CTRI","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04506528","Recruiting","2020-08-10","2023-12-01","{""locations"":""University of Wisconsin School of Medicine and Public Health Center for Tobacco Research and Intervention, Madison, Wisconsin, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""170000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality due to COVID-19|COVID-19 Severity""}"
"2867","Risk Factors and Computed Tomography Findings in COVID-19.","","NCT04577105","20-1177","Diagnostic Test: Simple chest tomography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04577105","Completed","2020-04-01","2020-10-01","{""locations"":""Instituto Nacional Ignacio Chavez, Ciudad de mexico, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""233"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Assessment of the level of suspicion of SARS-CoV2 infection|Evaluate the severity degree of pulmonary affection by chest computed tomography|Percentage of patients requiring endotracheal intubation|Death from any cause|Modified Sequential Organ Failure Assessment (mSOFA)|Sepsis-induced coagulopathy (SIC)|National Early Warning Scale (NEWS 2)|COVID-GRAM severe illness risk score|Rapid Severity Index for COVID-19 (qCSI)|Neutrophil-Lymphocyte Ratio (NLR)|Alveolar-arterial gradient of oxygen|Berlin Criteria for Acute Respiratory Distress Syndrome""}"
"2868","Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2","ASTANA","NCT04434261","33467320.0.0000.0072","Diagnostic Test: PT-PCR test for SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04434261","Recruiting","2020-05-11","2021-09-30","{""locations"":""Instituto Brasileiro de Controle do Cancer - IBCC, Sao Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program|Incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test;|Postoperative complications|Mortality|Delay in the cancer treatment""}"
"2869","NoRCoRP Assessment Clinic","NoRCoRP","NCT04710836","20RM056","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04710836","Recruiting","2020-12-03","2032-08-31","{""locations"":""Nottingham City Hospital, Nottingham, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with symptoms at presentation to the research clinic|Short Physical Performance Battery|Quadricep muscle strength|Chalder's Fatigue Score|Number of participants with rehabilitation needs at presentation to clinic|EQ-5D-5L|Montreal Cognitive Assessment|Anxiety and Depression|Pittsburgh Sleep Quality Index|Healthcare service needs following COVID-19 diagnosis|Biological markers of recovery from COVID-19|Fried Frailty Index|Body composition""}"
"2870","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","","NCT04270383","BCH Lung 012","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04270383","Not yet recruiting","2020-02-15","2020-12-31","{""locations"":""Beijing Children's Hospital,, Beijing, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial""}"
"2871","Psychological Impact of the Covid-19 Pandemic on Student Nurses","StudentCov","NCT04402229","P17/04_StudentCov","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04402229","Completed","2020-05-12","2020-07-31","{""locations"":""Versailles hospital, Le Chesnay, France|Toulouse University Hospital, Toulouse, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of PTSD-related symptoms assessed by the IES-R|PTSD-related symptoms assessed by the IES-R in the total population of students nurses|PTSD-related symptoms assessed by the IES-R according to student's years of school""}"
"2872","Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","SINK COVID-19","NCT04365985","2020-097","Drug: Naltrexone|Drug: Ketamine|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04365985","Recruiting","2020-04-29","2021-08-01","{""locations"":""William Beaumont Hospital, Royal Oak, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Progression of oxygenation needs|Renal failure|Liver failure|Cytokine Storm|Mortality|Length of hospital stay|Intensive Care Unit (ICU) admission|Intensive Care Unit (ICU) duration|Intubation|Intubation duration|Time until recovery""}"
"2873","A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh","","NCT04434144","10000918","Drug: Ivermectin + Doxycycline|Drug: Hydroxychloroquine + Azithromycin","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04434144","Completed","2020-05-02","2020-06-05","{""locations"":""Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""116"",""age"":""16 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of participants with \""treatment success\"" determine by a negative RT PCR for COVID19.|Number of participants with \""adverse effects\"" determined by the existence of the pharmacological side effects of the particular drug during treatment.""}"
"2874","Rutgers COVID-19 Cohort Study","","NCT04336215","2020000679","Other: Non-Interventional","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04336215","Recruiting","2020-04-07","2021-10-21","{""locations"":""Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""750"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence|Incidence""}"
"2875","Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW)","CONSERVE-HCW","NCT04595175","20-510-157-66-21","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04595175","Recruiting","2020-06-10","2021-12-30","{""locations"":""Chandler Regional Medical Center, Chandler, Arizona, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Baseline IgG Assay Information|Change in IgG Assay Information|Compare seroprevalence of anti-SARS-CoV-2 IgG antibodies between groups|Impact of COVID-19 Pandemic on Perceived Wellness and Job Satisfaction""}"
"2876","Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)","","NCT04339998","GIM-2020-28740","Diagnostic Test: Point-of-Care Ultrasonography (POCUS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339998","Recruiting","2020-04-15","2020-10-01","{""locations"":""University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""POCUS Score - Lungs|POCUS Score - Heart""}"
"2877","WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19","WEAICOR","NCT04605965","2020-678","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04605965","Recruiting","2020-06-09","2022-06-01","{""locations"":""Tulane University, TRIAD Center, New Orleans, Louisiana, United States|Tulane University, New Orleans, Louisiana, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of major cardiovascular events|Incidence of atrial arrhythmia|Mental health effect of COVID-19 measured by incidence of Generalized Anxiety Disorder (GAD) using Generalized Anxiety Disorder 7-item (GAD-7) Scale|Mental health effect of COVID-19 measured by incidence of depression using Beck Depression Fast Screen Scale|Mental health effect of COVID-19 measured by incidence of Post Traumatic Stress Syndrome (PTSD) using the Post Traumatic Stress Disorder Checklist- Standard Form (PCL-S) scale|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of alcohol survey|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of drugs survey|Mental health effect of COVID-19 measured by incidence of substance abuse using a baseline use of nicotine products survey""}"
"2878","Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care","","NCT04396197","PhysioCOVID-19","Other: Physiotherapy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04396197","Completed","2020-03-01","2020-05-08","{""locations"":""UHB NHS Foundation Trust, Birmingham, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""92"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mobility level|Time taken to first mobilise|Discharge location""}"
"2879","Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19","TSUNAMI","NCT04393727","TSUNAMI","Biological: CONVALESCENT PLASMA","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04393727","Terminated","2020-05-01","2020-09-30","{""locations"":""Azienda Ospedaliero Universitaria Pisana, Pisa, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need of invasive mechanical ventilation|Mortality rates|Time to invasive mechanical ventilation|Time to virologic cure|Length of hospital stay|Adverse events""}"
"2880","Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia","","NCT04369469","ALXN1210-COV-305","Biological: Ravulizumab|Other: Best Supportive Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04369469","Active, not recruiting","2020-05-11","2021-07-01","{""locations"":""Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|LAC\/USC Health Center, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Alternative Research Associates, LLC, Hialeah, Florida, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Jupiter Medical Center, Jupiter, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Norton Healthcare, Louisville, Kentucky, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Health Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Mayo Clinic Health System in Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System, La Crosse, Wisconsin, United States|H\u00f4pital Raymond Poincar\u00e9, Garches, Hauts De Seine, France|H\u00f4pital Henri Mondor, Cr\u00e9teil, Val De Marne, France|H\u00f4pital Bic\u00eatre, Le Kremlin-Bic\u00eatre cedex, Val De Marne, France|H\u00f4pital Saint-Louis, Paris cedex, France|Medical Hospital, Tokyo Medical and Dental University, Bunky\u014d-Ku, Tokyo-To, Japan|Jikei University Hospital, Minato-Ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku-Ku, Tokyo, Japan|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|King's College Hospital, London, Greater London, United Kingdom|Hammersmith Hospital, London, Greater London, United Kingdom|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""270"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival (based on all-cause mortality) at Day 29|Number of days free of mechanical ventilation at Day 29|Duration of intensive care unit stay at Day 29|Change from baseline in Sequential Organ Failure Assessment at Day 29|Change from baseline in SpO2\/FiO2 at Day 29|Duration of hospitalization at Day 29|Survival (based on all-cause mortality) at Day 60 and Day 90""}"
"2881","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","","NCT04273763","2019NCP1.0","Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04273763","Active, not recruiting","2020-02-16","2020-06-01","{""locations"":""The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality""}"
"2882","Pediatrics HOT COVID-19 Database in NY Tristate","","NCT04445402","AAAT0268","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445402","Recruiting","2020-04-30","2022-05-01","{""locations"":""Connecticut Children's Hospital, Hartford, Connecticut, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Steven Halpern, Morristown, New Jersey, United States|Archana Sharma, New Brunswick, New Jersey, United States|Mount Sinai Beth Israel, Newark, New Jersey, United States|St. Joseph's Regional Medical Center, New Jersey, Paterson, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Maimondes Medical Center, Brooklyn, New York, United States|Mount Sinai, New York, New York, United States|NYU Langone Health, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Stephen Roberts, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Cohen Children's Northwell Health, Queens, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Westchester Medical Center, Valhalla, New York, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""up to 21 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Number of tristate area pediatric HOT patients tested for COVID-19 that completed 1 year follow-up|Change in PROMIS T-score|Number of collected and analyzed stool samples""}"
"2883","Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19","","NCT04565249","PLN-74809-ARDS-204","Drug: PLN-74809|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04565249","Recruiting","2020-10-22","2021-10-31","{""locations"":""Valleywise Health Medical Center, Phoenix, Arizona, United States|National Jewish Health, Denver, Colorado, United States|Advent Health, Orlando, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-related adverse events and laboratory abnormalities, assessed by CTCAE V5.0|Assessment of PLN-74809 plasma concentrations""}"
"2884","Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease","","NCT04335786","NL73547.091.20|2020-001320-34","Drug: Valsartan (Diovan)|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04335786","Recruiting","2020-04-17","2021-12-01","{""locations"":""Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Rijnstate, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Erasmus MC, Rotterdam, Netherlands|Franciscus Gasthuis, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""651"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""first occurrence of intensive care unit admission, mechanical ventilation or death|Death|Mechanical ventilation|Intensive care unit admission|Occurrence of acute kidney injury""}"
"2885","Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital","PRECOVIA","NCT04362267","2020_34|2020-A00950-39","Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362267","Recruiting","2020-06-15","2020-09-01","{""locations"":""H\u00f4pital Claude Huriez, CHU, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the incidence of SARS- Cov2 infection Heath Care Worker diagnosed by the positivity of SARS-Cov2 RT-PCT and serological testing|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection""}"
"2886","Respiratory Decompensation and Model for the Triage of COVID-19 Patients","READY","NCT04390516","051420","Device: COViage","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04390516","Completed","2020-03-24","2020-05-30","{""locations"":""Dascena, Oakland, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""197"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanically ventilated patient outcome|Mortality or mechanically ventilated patient outcome""}"
"2887","Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia","","NCT04388618","H-01-R-059","Other: NHANES smell and taste tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388618","Recruiting","2020-06-15","2020-12-31","{""locations"":""Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia|prince Mohammed bin Abdulaziz Hospital, Riyadh, Central, Saudi Arabia"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""12 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""correlation of anosmia and ageusia to covid19 positive patients|objective assessment of severity of smell and taste senses alterations in covid19 patients""}"
"2888","Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives","ICOS","NCT04357418","10477M-ICOS","Other: it is a survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357418","Completed","2020-04-01","2020-06-30","{""locations"":""URC Ville Evrard, Neuilly-sur-Marne, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""187"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""State Anxiety assessed by the State-Trait Anxiety Inventory (STAI)|Visual numeric scales assessing anger and stress the ongoing week.|Beck Depression Inventory""}"
"2889","Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients","COVID-19-IAMA","NCT04705753","78/26.03.2020","Dietary Supplement: Cretan IAMA","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04705753","Completed","2020-04-01","2020-10-15","{""locations"":""Cretan Medicare, Heraklion, Crete, Greece"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with symptom resolution|Number of people cohabiting with a patient not developing VRI symptoms|Median time to full symptom resolution|Intensity of symptoms|Duration of symptoms|Number of patients whose symptoms never exceeded a score of 3-4 (mild)|Quality of life (QoL) of patients""}"
"2890","National Survey on the Lockdown of Children With Disabilities","ECHO","NCT04395833","CHRU de BREST ECHO","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395833","Completed","2020-04-07","2020-05-11","{""locations"":""CHRU de Brest, Brest, France"",""study_designs"":""Observational Model: Family-Based|Time Perspective: Cross-Sectional"",""enrollment"":""2500"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Experience during lockdown|Health risk during lockdown|Impact on medical and rehabilitation follow up|Impact on daily living""}"
"2891","Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19","COVID-RT-01","NCT04598581","2020-02047qu20Papachristofilou","Radiation: Low Dose Radiation Therapy (LD-RT)|Other: Sham irradiation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04598581","Active, not recruiting","2020-11-02","2021-11-01","{""locations"":""Department of Radiooncology, University Hospital Basel, Basel, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""22"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator free days (VFD)|Change in pulmonary function, measured as relative change (%) from baseline in oxygenation index (PaO2 \/ FiO2)|Overall mortality|Change in levels of ferritin (ng\/ml)|Change in levels of c-reactive protein (mg\/l)|Change in levels of white blood cell counts (number of white blood cells per volume of blood)""}"
"2892","Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection","TITAN","NCT04447235","NP 1677/20","Drug: Placebo|Drug: Ivermectin|Drug: Losartan","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04447235","Recruiting","2020-07-23","2021-02-01","{""locations"":""Instituto do Cancer do Estado de Sao Paulo, SAo Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""176"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of severe complications due COVID-19 infection|Incidence of Severe Acute Respiratory Syndrome|Adverse events|Overall survival""}"
"2893","The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load","","NCT04721457","1384","Drug: Distilled Water|Drug: 1% Povidone Iodine (PVP-I)|Drug: 1.5% Hydrogen Peroxide (H2O2)|Drug: 0.075% Cetylpyridinium Chloride (CPC)|Drug: 0.1% Sodium Hypochlorite","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04721457","Recruiting","2021-01-03","2021-06-30","{""locations"":""Alhamra TETAMMAN clinic (PHC), Jeddah, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SARS-Cov-2 viral load (Quantitative Real-Time Reverse-Transcriptase Polymerase Chain Reaction (qRT-PCR))|ct values""}"
"2894","Cardiovascular Implications of COVID-19","","NCT04435457","STU-2020-0359","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04435457","Recruiting","2020-09-01","2021-06-30","{""locations"":""University of Texas Southwestern Medical Center, Dallas, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""70"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of Myocarditis|Prevalence of cardiac abnormalities by cardiac magnetic resonance imaging|Prevalence of molecular and genetic immune system abnormalities""}"
"2895","Measles Vaccine in HCW","MV-COVID19","NCT04357028","N-30-2020","Drug: Measles-Mumps-Rubella Vaccine|Drug: Placebos","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04357028","Suspended","2020-07-13","2021-01-01","{""locations"":""Cairo University Hospital, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""COVID-19 disease incidence|SARS-CoV-2 pneumonia|Critical care admission duration with SARS-CoV-2|Oxygen therapy with SARS-CoV-2""}"
"2896","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","","NCT04320511","2020-087","Device: CT-V","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04320511","Recruiting","2020-06-24","2022-06-01","{""locations"":""Beaumont Health, Royal Oak, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictive association between CT-V, PBM score and disease progression""}"
"2897","Assessment of Safety and Efficacy of CCP","COVIDIT","NCT04542941","CCP","Biological: COVID Convalescent Plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04542941","Completed","2020-06-16","2020-12-31","{""locations"":""Mulago Specialised Hospital, Kampala, Uganda"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""136"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to viral clearance (RT-PCR negativity)|Time to symptom resolution|Time to severe\/critical disease|Number of participants reporting an adverse event as evidenced by clinical manifestations""}"
"2898","INvestigating TELmisartin Study","INTEL","NCT04715763","H053","Drug: Telmisartan Oral Product|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04715763","Not yet recruiting","2021-02-01","2022-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of hospitalization|Duration of supplemental oxygen|Duration of mechanical ventilation|Number of deaths|Number of grade 3 and greater adverse events|Clinical severity of disease""}"
"2899","Using Whatsapp for the Consultation","","NCT04645563","Clinical-3","Other: Sending thorax ct video images via smartphone applications","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04645563","Completed","2020-03-11","2020-05-31","{""locations"":""Ramazan Sabirli, Kars, Outside Of The US, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""144"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Analyzing the effect of consultation via whatsapp to lenght of stay the patients in emergency medicine department.|Comparing the effect of bedside consultation and consultation via whatsapp on patient discharge or hospitalisation and readmission.""}"
"2900","Anxiety Level and Oral Hygiene Practice in Dental Students During Covid-19 Pandemic","","NCT04460469","Mai Zakaria 4","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04460469","Recruiting","2020-07-01","2020-09-01","{""locations"":""Faculty of Dentistry, Cairo University, Cairo, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""1500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""correlate between the level of anxiety and the practice of oral hygiene during covid-19 pandemic in dental students of Cairo university""}"
"2901","PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study)","PROVID","NCT04366856","APHP200504","Behavioral: 1: Prone positioning|Behavioral: 2: No instruction regarding positioning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04366856","Recruiting","2020-06-26","2021-01-01","{""locations"":""D\u00e9partement d'Anesth\u00e9sie R\u00e9animation - Kremlin Bic\u00eatre, Le Kremlin-Bic\u00eatre, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who meet one or both following criteria: need for intubation (for mechanical ventilation), occurrence of death during hospital stay.|Proportion of patients admitted to ICU (for patients included out of ICU)|Days alive and free from non invasive ventilation (NIV) or high flow nasal canula oxygen delivery (HFNC) (for those neither under NIV or HFNC at the time of study inclusion)|Days alive and out of ICU|Days alive and out of hospital|Maximum oxygenotherapy rate during hospital stay [Time Frame: At day28]""}"
"2902","Analysis of Mortality of Critically Ill Patients With COVID-19","","NCT04379258","COVID-UCI_Spain","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379258","Completed","2021-02-08","2021-02-08","{""locations"":""Hospital Universitario de Getafe, Getafe, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""868"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU mortality|hospital mortality|28-day mortality|effectiveness of treatment|length of ICU stay|length of hospital stay|ventilator-associated pneumonia|bacteriemia|barotrauma|duration of mechanical ventilation""}"
"2903","Bacillus Calmette-guérin Vaccination to Prevent COVID-19","ACTIVATEII","NCT04414267","Activate II|2020-002448-21","Biological: BCG vaccine|Biological: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04414267","Recruiting","2020-05-26","2021-05-25","{""locations"":""General Hospital of Argolida - Nafplion Unit, N\u00e1fplio, Argos, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Therapeutics, Alexandra General Hospital, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|4th Department of Internal Medicine, \""Attikon\"" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece|Department of Pulmonary Medicine- General Hospital of Kerkyra, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Io\u00e1nnina, Greece|Department of Internal Medicine, General Hospital of Karditsa, Kard\u00edtsa, Greece|General Hospital of Korinthos, K\u00f3rinthos, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Greece|General Hospital of Ptolemaida MPODOSAKEIO, Ptolema\u1e2fda, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessalon\u00edki, Greece|General Hospital of Imathia - Veria Unit, V\u00e9ria, Greece"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""900"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and\/or definitively related to COVID-19 on visit 3.|Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and\/or definitively related to COVID-19 on visit 4|Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and\/or definitively related to COVID-19 on visit 5|Prevalence of IgG\/IgM against SARS-CoV-2|Analysis of each of the components of the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and\/or definitively related to COVID-19.|The impact of new cardiovascular events between the two study groups|Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 5|Differences in cardiac ultrasound at visit 5 between the two sub-study groups|Changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groups""}"
"2904","HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial","HERO","NCT04352946","GFICOVID-19-1","Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04352946","Not yet recruiting","2020-04-24","2020-08-24","{""locations"":""The New York Center for Travel and Tropical Medicine, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""374"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative Incidence of COVID-19 Infection|Adverse events incidence|Duration of symptomatic COVID-19 disease|Days hospitalized attributed to COVID-19|Number or respiratory failure attributable to COVID-19 disease|Mortality Incidence|Days of work lost""}"
"2905","Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis","CovidSurg-Can","NCT04384926","CSC-20200324","Procedure: Elective Cancer Surgery","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384926","Recruiting","2020-03-30","2020-12-31","{""locations"":""Hospital del Henares, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30-day postoperative COVID-19 infection rate|30-day postoperative mortality rate|Postoperative critical care utilisation rate in high-risk cancer surgery patients.|Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery|Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery""}"
"2906","Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed","","NCT04395755","COVID-19-NOIVF","Behavioral: Generalized Anxiety Disorder-7 (GAD-7)|Behavioral: Patient Health Questionnaire-9 (PHQ-9)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395755","Completed","2020-04-01","2020-05-15","{""locations"":""IRCCS Ospedale Policlinico San Martino, Genoa, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""503"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severity of anxiety|Severity of depression""}"
"2907","Vital Sensor Monitors for CV19 Detection","","NCT04635787","STU00213040","Device: ANNE One","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04635787","Enrolling by invitation","2020-11-05","2022-10-30","{""locations"":""Northwestern Memorial Hospital, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""1.Efficacy of wearable device to detect respiratory infection parameters: cough count|2.Monitoring of respiratory infection symptoms, WURSS-11 Survey""}"
"2908","Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals","RES-Q-HR","NCT04681430","RES-Q-HR|2020-004695-18","Biological: Convalescent plasma|Drug: Camostat Mesilate|Drug: Placebo for Camostat Mesilate|Other: Standard of Care (SoC)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04681430","Recruiting","2021-01-08","2021-11-01","{""locations"":""Abteilung Infektiologie Klinik f\u00fcr Innere Medizin II Department Innere Medizin Universit\u00e4tsklinikum Freiburg, Freiburg im Breisgau, Baden-W\u00fcrttemberg, Germany|Klinik und Poliklinik f\u00fcr Innere Medizin II Klinikum rechts der Isar Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Bavaria, Germany|Universit\u00e4tsklinikum Frankfurt Medizinische Klinik 2: H\u00e4matologie, Onkologie, H\u00e4mostaseologie, Rheumatologie, Infektiologie\/HIV, Frankfurt am Main, Hessen, Germany|Universit\u00e4tsklinikum D\u00fcsseldorf Klinik f\u00fcr Hepatologie und Infektiologie, Duesseldorf, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1094"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""WHO ordinal Covid-19 scale up to day 28|Cumulative number WHO categories 4b-8|Cumulative number WHO categories 3-4a|Not hospitalized|All-cause mortality|Reinfection|Secondary sclerosing cholangitis (SSC)|chronic pulmonary disease as sequelae from COVID-19|patients with remdesivir treatment|COVID-19 WHO status of patients at start of remdesivir treatment|patients with dexamethasone treatment|COVID-19 WHO status of patients at start of dexamethasone treatment|resolution of COVID-19 symptoms|negative SARS-CoV-2-PCR test|Oxygen therapy|COVID-19 pneumonia|Percentage of participants requiring mechanical ventilation|Number of ventilation days per participant up to day 90|hospital stay and intensive care|Mortality|SAEs|Grade 3\/4 AEs|SARS-CoV-2 antibody IgA concentrations|SARS-CoV-2 antibody IgG concentrations|SARS-CoV-2 neutralizing antibody titers|Plasma treatment screening failures""}"
"2909","Risk of Air Contamination During Visceral Surgery in COVID19 Patients","COELIOCOVID","NCT04395599","2020_44|2020-A01461-38","Other: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04395599","Not yet recruiting","2020-05-01","2020-10-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Air contamination|Environment contamination|Surgical approach|Opening of the digestive tract|Biological fluids|Pneumoperitoneum""}"
"2910","COG-UK Project Hospital-Onset COVID-19 Infections Study","COG-UK HOCI","NCT04405934","CTU/2020/353|283014|20/EE/0118","Other: Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04405934","Not yet recruiting","2020-07-01","2021-04-01","{""locations"":"""",""study_designs"":""Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""2000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incidence rates of IPC-defined hospital-onset COVID-19 infection (HOCIs)|Change in incidence rates of IPC-defined HOCIs with rapid vs standard sequencing|Incidence rates of IPC-defined hospital outbreaks|Incidence rates of IPC+sequencing-defined hospital outbreaks|Changes to IPC actions following viral sequence reports|Recommended changes to IPC actions following viral sequence report - not implemented|Health economic benefit to IPC of standard vs rapid sequencing reports|Impact of both standard and rapid sequencing reports on number of HCW days off work""}"
"2911","The RAPID COVID TRIAGE Algorithm","","NCT04353154","20200228-01H","Diagnostic Test: Spartan Cube Point-of Care Covid-19 test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04353154","Active, not recruiting","2020-04-15","2021-02-28","{""locations"":""University of Ottawa Heart Institute, Ottawa, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity""}"
"2912","Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS","RuXoCoil","NCT04359290","KKS-278","Drug: Ruxolitinib administration","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04359290","Active, not recruiting","2020-07-01","2021-07-01","{""locations"":""Andreas Neubauer, Marburg, Germany"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival|Assessment of the duration of ventilation support|cytokine storm|time on ICU|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)|Rates of flow|Gas exchange|Forced expiratory volume in 1 second (FEV1)|Forced vital capacity (FVC)|Tiffeneau-Pinelli index""}"
"2913","Zofin (Organicell Flow) for Patients With COVID-19","","NCT04384445","19881","Biological: Zofin|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04384445","Recruiting","2020-09-08","2021-07-31","{""locations"":""Larkin Community Hospital, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of any infusion associated adverse events|Incidence of Severe Adverse Events|All Cause Mortality|Survival Rate|Cytokine Levels|D-dimer Levels|C-reactive protein Levels|Quantification of the COVID-19|Improved Organ Failure|Chest Imaging Changes""}"
"2914","Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population","PSYCOV-CV","NCT04397835","RC31/20/0135","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397835","Recruiting","2020-04-17","2021-04-20","{""locations"":""CHU de Toulouse, Toulouse, Occitanie, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""50 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""worsening of cardiovascular risk (treatments)|worsening of cardiovascular risk (smoking consumption)|worsening of cardiovascular risk (food balance)|worsening of cardiovascular risk (weight gain)|worsening of cardiovascular risk (physical activity)|psychological impact of the quarantine on anxiety|psychological impact of the quarantine on health|psychological impact of the quarantine on stress""}"
"2915","Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19","PASSPORT","NCT04716023","18IC4688","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04716023","Recruiting","2019-08-23","2022-02-02","{""locations"":""The Royal Brompton, London, United Kingdom"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""42"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Respiratory resistance at 5Hz - 20Hz (R5-R20) (kPa\/l\/s) related to airtrapping as determined by quantitative CT (Expiratory phase low attenuation area <856 HU (%LAA <856 HU)|Respiratory reactance at 5Hz: X5 (kPa\/l\/s)|Reactance area: Ax (kPa\/l\/s)|Functional residual capacity by MBNW: FRCgas (L)|Lung clearance index: LCI|Ventilation heterogeneity conducting airways: Scond (L\/s)|Ventilation heterogeneity acinar airways: Sacin (L\/s)|Forced expiratory volume in 1 second: FEV1 (L)|Forced vital capacity: FVC (L)|Total lung capacity: TLC (L)|Residual volume: RV (L)|Functional residual capacity by plethysmography: FRCpleth (L)|Airway mean luminal diameter (Dmean)|Airway inner lumen area (Ai)|Airway wall area (Aw), airway wall percentage (Aw%) as determined by [Aw\/(Ai + Aw) \u00d7 100%]|Air trapping - expiratory phase low attenuation area <856 HU (%LAA <856 HU)|Modified MRC dyspnoea score|St George's Respiratory Questionnaire Score|Asthma-related Quality of Life Questionnaire (AQLQ) (if asthmatic)|Asthma Control Questionnaire (ACQ) (if asthmatic)|6-minute walk distance (m)""}"
"2916","Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons","","NCT04401449","200113|20-CC-0113","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401449","Recruiting","2020-01-08","2024-05-01","{""locations"":""MedStar Health Research Institute \/MedStar Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""180"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Inflammatory responses of cells in lung and circulation""}"
"2917","Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS","","NCT04331613","ChineseASZQ-006","Biological: CAStem","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04331613","Recruiting","2020-01-27","2020-12-01","{""locations"":""Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""9"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse reaction (AE) and severe adverse reaction (SAE)|Changes of lung imaging examinations|Time to SARS-CoV-2 RT-PCR negative|Duration of fever (Celsius)|Changes of blood oxygen (%)|Rate of all-cause mortality within 28 days|Lymphocyte count (*10^9\/L)|Alanine aminotransferase (U\/L)|Creatinine (umol\/L)|Creatine kinase (U\/L)|C-reactive protein (mg\/L)|Procalcitonin (ng\/L)|Lactate (mmol\/L)|IL-1beta (pg\/mL)|IL-2 (pg\/mL)|IL-6 (pg\/mL)|IL-8 (pg\/mL)""}"
"2918","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19","PROTECT-Surg","NCT04386070","RG_20-029 COVID-19|2020-001448-24","Drug: Lopinavir-Ritonavir|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04386070","Not yet recruiting","2020-11-15","2026-05-14","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""6400"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death|Rate of Pneumonia|Rate of ARDs|Death rate|Rate of unexpected ventilation|COVID-19 pulmonary complications|Overall SARS-CoV-2 infected rate|Duration of hospital stay|Pulmonary function""}"
"2919","COVID-10 in the Pediatric Population: SARS-CoV-2 Seropositivity","","NCT04690114","0387-20-SZMC","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04690114","Recruiting","2020-10-01","2021-07-31","{""locations"":""Shaare Zedek Medical Center, Jerusalem, Israel"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Sars-CoV-2 Seropositivity""}"
"2920","Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection","","NCT04409184","PRO00037957","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409184","Withdrawn","2020-08-14","2020-08-14","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characterization of specific T cell responses in peripheral blood isolated from patients that have been exposed to SARS-CoV-2.""}"
"2921","Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:","COVAP","NCT04488510","COVAP","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04488510","Active, not recruiting","2020-05-06","2020-11-30","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Research of the bacteria responsible for nosocomial pneumonia|Additional evaluations to the study""}"
"2922","Impact of COVID-19 Pandemic on Depression and Quality of Life","","NCT04394078","56665618-204.01.07","Other: Online survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04394078","Completed","2020-05-06","2020-05-18","{""locations"":""Okan University, Istanbul, Turkey"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""543"",""age"":""15 Years to 65 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Sociodemographic information form|Zung Depression Scale|World Health Organization Quality of Life - Bref""}"
"2923","Pediatric Acute Kidney Injury in COVID-19","SPARC-1","NCT04466306","ChildrensHA","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04466306","Enrolling by invitation","2020-04-15","2021-07-01","{""locations"":""Children's Hospital of Alabama, Birmingham, Alabama, United States|Arkansas Children's Research Institute, Little Rock, Arkansas, United States|Cedars-Sinai Maxine Dunitz Children's Health Center, Los Angeles, California, United States|UCLA Mattel Children's Hospital, Los Angeles, California, United States|Lucile Packard Children's Hospital Standford, Palo Alto, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|UF Health Shands Children's Hospital, Gainesville, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Comer Children's Hospital - UChicago Medicine, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|Children's Mercy, Kansas City, Kansas, United States|John Hopkins Children's Center, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|Beaumont Children's Hospital, Royal Oak, Michigan, United States|St. Louis Children's Hospital of Washington University, Saint Louis, Missouri, United States|Oishei Children's Hospital of Buffalo, Buffalo, New York, United States|Golisano Children's Hospital - University of Rochester Medicine, Rochester, New York, United States|Stony Brook Children's Hospital, Stony Brook, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Duke Children's Hospital and Health Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Lifespan Hasbro Children's Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Shawn Jenkins Children's Hospital, Charleston, South Carolina, United States|Seattle Children's Hospital, Seattle, Washington, United States|Stollery Children's Hospital, Edmonton, Alberta, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada|Soroka University Medical Center, Be'er Sheva, Israel|Dana-Dwek Children's Hospital, Tel Aviv, Israel|Shizuoka Children's Hospital, Shizuoka, Japan|Institute for Mother and Child Healthcare, Belgrade, Serbia|University Children's Hospital, Belgrade, Serbia|Hospital 12 de Octubre, Madrid, Spain|Birmingham Children's Hospital NHS, Birmingham, United Kingdom|Alder Hey Children's Hospital NHS, Liverpool, United Kingdom|King's College Hospital NHS, London, United Kingdom|St. George's University Hospital NHS, London, United Kingdom|Great Ormond Street Hospital NHS, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""up to 25 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Acute Kidney Injury (AKI)|Survival|Rate of Extracorporeal Therapy Requirement|Fluid overload|Rate of nephrotoxic medication exposure""}"
"2924","Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19","CARDIO-COVID","NCT04624503","CARDIOCOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04624503","Recruiting","2020-10-01","2021-10-01","{""locations"":""Humanitas Research Hospital, Rozzano, Milan, Italy|Centro Cardiologico Monzino, Milan, Italy|IRCCS Auxologico San Luca, Milan, Italy|IRCCS San Donato, Milan, Italy|IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cardiovascular mortality|All-cause mortality|Major adverse cardiovascular events (myocardial infarction, cerebrovascular accident, hospitalizations due to heart failure, revascularizations, cardiovascular mortality)|NYHA class|Left ventricular systolic function (cardiac magnetic resonance, echocardiography)""}"
"2925","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","BATTLE","NCT04369794","COVID-19 BATTLE trial","Biological: BCG|Biological: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04369794","Recruiting","2020-08-10","2023-08-01","{""locations"":""Hospital das Cl\u00ednicas Unicamp, Campinas, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical evolution of COVID-19|SARS-CoV-2 elimination|Seroconversion rate and titration|Local and systemic adverse events to BCG vaccination""}"
"2926","Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit","","NCT04346810","CSC19APR","Other: Patient management suffering of coronavirus infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346810","Not yet recruiting","2020-04-15","2020-09-01","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit""}"
"2927","Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2","DIRECTOR","NCT04655521","109/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04655521","Recruiting","2020-12-02","2021-11-01","{""locations"":""Saarland University, Homburg, Germany"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""3 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Differential expression of biomarkers between COVID-19 and controls|Differential expression of biomarkers between severe and non-severe COVID-19|Correlation of biomarkers with disease severity|Biomarkers depending on therapy|Biomarkers depending on bacterial co-infection|Correlation of biomarkers with viral load""}"
"2928","EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19","WHO","NCT04396353","COVID-19","Other: Electronic questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04396353","Completed","2020-06-04","2020-10-01","{""locations"":""Marcelo Rodrigues dos Santos, S\u00e3o Paulo, Sao Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1574"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of hospitalizations|Percentage of symptoms of the disease|Length of hospital stay|Percentage of mechanical ventilation""}"
"2929","Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark","PISCA","NCT04351789","PISCA Study","Other: Psychoeducational intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04351789","Recruiting","2020-05-01","2023-04-01","{""locations"":""Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety 1 month|Anxiety 3 months|Depression 3 months|Post Traumatic Stress Disorder (PTSD) symptoms 3 months|Anxiety 12 months|Post Traumatic Stress Disorder (PTSD) symptoms 12 months|Depression 12 months""}"
"2930","Long-Term Experience and Health Effects of COVID-19","","NCT04477902","altcovid-192020","Other: none - observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04477902","Recruiting","2020-07-01","2022-07-01","{""locations"":""Altura, Mission Viejo, California, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""50000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Longitudinal survey""}"
"2931","Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients","NSpectroCovid","NCT04546737","PI2020_843_0087","Other: Magnetic Resonance Spectroscopy (MRS).","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04546737","Recruiting","2020-09-08","2022-05-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation from baseline of MRI radiological semiology in COVID-19 patients""}"
"2932","Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS","","NCT04536350","Aviptadil Trial","Drug: Aviptadil 67μg|Drug: Placebo 0.9% NaCl solution","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04536350","Not yet recruiting","2021-01-01","2022-03-01","{""locations"":""Cantonal Hospital Baselland Liestal, Liestal, BL, Switzerland|Cantonal Hospital St.Gallen, St.Gallen, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""time to clinical improvement|Frequency of mechanical ventilation|Time requiring oxygen supplementation|Slope in SaO2|Slope in FiO2|Slope in C-reactive Protein|Neutrophile ratio|lymphocyte ratio|Interleukine 6 level|Procalcitonin level|Frequency of Multi organ dysfunction Syndrome (MODS)""}"
"2933","Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic","COVIE-19/20","NCT04487171","PI2020_843_0049","Other: Questionnaire","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04487171","Recruiting","2020-07-21","2021-08-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""248"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation of prevalence of clinically-significant post-partum depressive symptoms""}"
"2934","ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers","","NCT04367857","AAAS9998","Other: COVID-19 Serology|Behavioral: Health Care Worker Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367857","Recruiting","2020-04-18","2021-10-01","{""locations"":""NewYork-Presbyterian Hosptial\/Columbia University Irving Medical Center, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion seropositive""}"
"2935","DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","STOP-Flu","NCT04298060","DAS181-2-07","Drug: DAS181|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04298060","Not yet recruiting","2020-07-01","2022-09-01","{""locations"":""Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""280"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent of subjects who have returned to room air|Percent change of subjects return to baseline oxygen requirement""}"
"2936","Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:","E-SPERANZA","NCT04695704","4R21/006","Drug: Montelukast|Other: placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04695704","Not yet recruiting","2021-04-01","2022-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""284"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COP Assessment Test Scale (CAT)|1min sit-to-stand test|O2 desaturation|Visual Analogical Scale (VAS)|All-cause mortality|Number of visits to primary care|Number of visits to the emergency room|Number of hospital admissions.|Medication side effects|Days of sick leave|Factors of inflamatory and prothrombotic processes: D-Dimer, N-terminal prohormone of brain natriuretic peptide (NT Pro-BNP), C-reactive protenin and Antinuclear antibodies (ANA)""}"
"2937","Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE)","CONSCIENCE","NCT04551690","COVID 19 Pregnancy HSJD Chile","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04551690","Completed","2020-04-15","2020-07-15","{""locations"":""Hospital San Juan de Dios, Santiago, Chile"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""720"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Prevalence of SARS-CoV-2 in pregnant patients on labor|Characterization of clinical features of patients who tested positive for COVID 19.|Characterization of living conditions of pregnant women with COVID 19|Neonatal hospitalization|Neonatal weight|Perinatal outcomes""}"
"2938","Physical Rehabilitation in ICU in ARDS Patients With COVID-19","","NCT04435080","2020.169.IRB1.037","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04435080","Completed","2020-03-15","2020-06-11","{""locations"":""Koc University School of Medicine, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""35"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hand grip strength|Short form - 36|Length of stay in intensive care unit|Length of stay in hospital|Duration of invasive mechanical ventilation|Manual muscle strength|Range of joint motion""}"
"2939","Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients","HAD-Covid","NCT04430049","2020 HAD-Covid","Procedure: Covid ICU containment measures","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04430049","Recruiting","2020-06-22","2023-01-22","{""locations"":""University hospital, Clermont-Ferrand, Clermont-Ferrand, Auvergne, France|CH Aurillac, Aurillac, France|CH Cannes, Cannes, France|Centre Jean Perrin, Clermont-Ferrand, France|CH Grenoble, Grenoble, France|CH Le Puy-en-Velay, Le Puy-en-Velay, France|University hopistal, Lyon, Lyon, France|CH Moulins, Moulins, France|CH P\u00e9rigueux, P\u00e9rigueux, France|CH Rodez, Rodez, France|CH Vichy, Vichy, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""480"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety|Depression|post-traumatic stress disorder""}"
"2940","Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials","","NCT04650178","2020-0508|NCI-2020-06014","Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04650178","Recruiting","2020-05-26","2021-07-01","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""274"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Health-related quality of life and coronavirus disease 2019 (COVID-19)-specific domains of interest|COVID-19 experiences and COVID-19 specific distress|Differences in outcomes between neuropathic pain patients|Coping and resilience factors""}"
"2941","Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR","","NCT04361448","20.43","Other: samling of oropharynx and nasopharynx","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04361448","Terminated","2020-04-20","2020-06-30","{""locations"":""Jessa Hospital, Hasselt, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""30"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""sensitivity""}"
"2942","Northeast COVID-19 and Pregnancy Study Group","NCOVIP","NCT04462367","NCOVIP","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04462367","Recruiting","2020-07-01","2022-12-20","{""locations"":""Instituto Materno Infantil Prof. Fernando Figueira, Recife, Pernambuco, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""180"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Near miss maternal:|Maternal death|Near miss neonate|Neonatal death|Early neonatal death|Fetal death|Perinatal death|Maternal age|Maternal pre-pregnancy weight|Maternal height|Pre-gestational nutritional classification|Pre-gestational body mass index (BMI)|Maternal color|Number of people living in the household|Family income per capita|Maternal education|Maternal occupation|Maternal occupation with financial income|Maternal marital status|Maternal origin|Maternal religion|Maternal smoking|Maternal alcoholism|Maternal use of illicit drugs|Number of pregnancies|Parity|Number of previous cesarean sections|Number of previous vaginal births|Number of previous abortions|Number of children alive|Number of prenatal consultations|Gestational age of the onset of flu-like signs and symptoms|Number of puerperium days of onset of flu-like signs and symptoms|Duration of maternal symptoms|Social isolation during the signs and symptoms of flu-like syndrome|Social distance before the signs and symptoms of flu-like syndrome|Quarantine|Need for hospitalization due to flu-like syndrome and\/or complications|Day of hospitalization due to flu syndrome and\/or complications|Length of hospital stay due to flu-like syndrome and\/or complications|Maternal signs and symptoms of flu-like syndrome at diagnosis, at 6 months, 12 months and 24 months|Result of polymerase chain reaction - real time (RT-PCR) for maternal COVID19 in diagnosis, at 6 months, 12 months and 24 months|Result of polymerase chain reaction - real time (RT-PCR) for the differential diagnosis of maternal respiratory syndrome (viral panel)|Maternal viral panel in the diagnosis, at 6 months, 12 months and 24 months|Rapid test for maternal COVID-19 at diagnosis, at 6 months, 12 months and 24 months|Serial maternal IgM COVID-19|Serial maternal IgA COVID-19|Serial maternal IgG COVID-19|Serial maternal serology day|Maternal reinfection|Cytokines in maternal diagnosis|Day of the first cytokine dosage from the beginning of the flu syndrome or COVID-19|Day of the first blood count from the beginning of the flu syndrome or COVID-19|Hemoglobin of maternal diagnosis|Leukocytes from maternal diagnosis|Deviation to the left of the maternal diagnosis|Platelets of maternal diagnosis|Typical lymphocytes of maternal diagnosis|Atypical lymphocytes of maternal diagnosis|Day of the first coagulogram from the beginning of the flu syndrome or COVID-19|Maternal diagnosis bleeding time (TB)|Maternal diagnosis clotting time (CT)|Maternal prothrombin time of diagnosis (TD)|Maternal active partial thromboplastin time of diagnosis (APTT)|International normalized ratio (INR)|Day of the first urea from the beginning of the flu syndrome or COVID-19|Urea from maternal diagnosis|Day of the first creatinine from the beginning of the flu syndrome or COVID-19|Creatinine of maternal diagnosis|Transaminases in maternal diagnosis|Day of the first erythrocyte sedimentation rate (VSH) of maternal diagnosis from the beginning of the flu syndrome or COVID-19:|VSH of maternal diagnosis|Day of the first C-reactive protein (CRP) from the beginning of the flu syndrome or COVID-19|CRP of maternal diagnosis|Day of the first D-dimer from the beginning of the flu syndrome or COVID-19|D-dimer of maternal diagnosis|Day of the first lactic dehydrogenase (DHL) from the beginning of the flu syndrome or COVID-19|DHL of maternal diagnosis|Day of the first alkaline phosphatase from the beginning of the flu syndrome or COVID-19|Alkaline phosphatase in maternal diagnosis|Day of the first troponin from the beginning of the flu syndrome or COVID-19|Troponin in maternal diagnosis|Day of the first ferritin from the beginning of the flu syndrome or COVID-19|Ferritin in maternal diagnosis|Bilirubins in maternal diagnosis|Day of the first blood culture from the beginning of the flu syndrome or COVID-19|Blood culture of maternal diagnosis|Blood culture microorganism in maternal diagnosis|Day of the first uroculture from the beginning of the flu syndrome or COVID-19|Uroculture of maternal diagnosis|Uroculture microorganism in maternal diagnosis|IgM COVID-19 worst maternal result|IgA COVID-19 worst maternal result|Maternal IgG COVID-19 - worst serial result|Cytokines worst maternal outcome|Day of the worst urea result from the beginning of the flu syndrome or COVID-19|Urea worst maternal result|Day of the worst creatinine result from the beginning of the flu syndrome or COVID-19|Creatinine worst maternal result|Transaminases worst maternal outcome|Day of the worst result of the erythrocyte sedimentation rate of maternal diagnosis (VSH) from the beginning of the flu syndrome or COVID-19|VSH worst maternal result|Day of the worst C-reactive protein (CRP) result from the onset of the flu syndrome or COVID-19|CRP worst maternal result|Day of the worst D-dimer result from the onset of the flu syndrome or COVID-19|D-dimer worst maternal result|Day of the worst result of lactic dehydrogenase (DHL) from the beginning of the flu syndrome or COVID-19|DHL worst maternal result|Alkaline phosphatase worst maternal result|Troponin worst maternal result|Ferritin worst maternal result|Bilirubins worst maternal result|Blood culture worst maternal result|Blood culture microorganism worst maternal result|Uroculture worse maternal result|Uroculture microorganism worst maternal result|Presence of changes in maternal chest radiography|Result of maternal chest radiography|Presence of changes in the mother's chest tomography|Day of normalization of the alteration of the tomography of the maternal chest|Result of maternal chest tomography|Use of maternal nasal catheter|Use of maternal Venturi Mask|Prone maternal position on spontaneous ventilation|Use of therapeutic antibiotics|Use of azithromycin|Use of maternal hydroxychloroquine\/chloroquine|Use of antiparasitic drugs|Use of anticoagulant|Use of antiretroviral|Use of pulse therapy|Use of convalescent plasma|Assisted Mechanical Ventilation (AMV)|Use of neuromuscular blocker|Use of Extracorporeal Circulation (ECMO)|Renal replacement therapy (dialysis)|Blood products|Other therapeutic modalities|Amniotic fluid in the last ultrasound examination|Fetal growth restriction|Small fetus for gestational age (SGA)|Presence of fetal morphological changes|Fetal morphological changes|Frequency of fetal tachycardia (FFT)|Doppler velocimetry parameters in the last ultrasound examination|Gestational age of amniocentesis|Amniocentesis indications|Result of amniocentesis for COVID19|Amniocentesis cytokines|Need for hospitalization due to obstetric causes|Maternal hospital stay|Obesity|Chronic arterial hypertension (CAH)|Superimposed preeclampsia|Gestational hypertension|Pre-eclampsia|Eclampsia|HELLP syndrome|Clinical diabetes|Gestational diabetes|Premature rupture of membranes|Premature labor|Placenta previa|Abortion|Normally inserted placental abruption|Maternal urinary tract infection|Maternal heart disease|Bronchial asthma|Chronic obstructive pulmonary disease (COPD)|Cerebrovascular disease|Chronic kidney injury|Immunosuppression|Maternal pneumonia|Maternal sepsis|Septic shock|Severe acute respiratory syndrome (SARS)|Postpartum hemorrhage|Infection of the operative site|Endometritis|Peritonitis|Need for postpartum hysterectomy|Type of delivery|Indication of cesarean section|Gestational age at birth|Use of labor analgesia|Type of anesthesia for cesarean section|Antenatal corticosteroid therapy (pulmonary maturity)|Use of maternal magnesium sulphate (prophylaxis of the newborn and \/ or prevention of eclampsia)|Maternal prophylactic antibiotic therapy (prophylaxis of neonatal sepsis)|Hospital discharge when pregnant|Hospital discharge when puerperal|Maternal death when pregnant|Maternal death when puerperal|Birth weight|Adequacy of birth weight|Apgar scores in the first minute|Apgar scores in the fifth minute|Neonatal ICU admission|Need for neonatal resuscitation|Need for neonatal mechanical ventilation|Neonatal nasal catheter|Neonatal Continuous Positive Airway Pressure (CPAP) mask|Neonatal hypothermia|Neonatal hypoglycemia|Neonatal infection|Chorioamnionitis|Neonatal respiratory distress modality|Neonatal congenital infection (TORCHS)|Congenital malformation|Breastfeeding|Cord ligation|Skin-to-skin contact|Breastfeeding in the delivery room|Days of life of the newborn's diagnostic suspicion|Result of the Polymerase Chain Reaction - Real Time (RT-PCR) for neonatal COVID-19 in diagnosis, at 6 months, 12 months and 24 months|Result of Polymerase Chain Reaction - Real Time (RT-PCR) for the differential diagnosis of neonatal respiratory syndrome (viral panel)|Neonatal viral panel in the diagnosis, at 6 months, 12 months and 24 months|Neonatal cytokines|Neonatal IgM COVID-19|IgA COVID-19 neonatal serial|Serial neonatal IgG COVID-19|Neonatal reinfection|Hemoglobin from neonatal diagnosis|Diagnostic neonatal bleeding time (BT)|Diagnostic neonatal clotting time (CT)|Urea from neonatal diagnosis|Creatinine from neonatal diagnosis|Transaminases of the neonatal diagnosis|Blood culture of the neonatal diagnosis|Uroculture of neonatal diagnosis|IgM COVID-19 - worst neonatal result|Neonatal IgG COVID-19 - worst serial result|Cytokines - worst neonatal result|Day of the worst blood count result from the beginning of the suspected diagnosis by COVID-19|Day of the worst value of the neonatal coagulogram from the suspicion of the diagnosis by COVID-19|Bleeding time - worst neonatal result (BT)|Urea - worst neonatal result|Creatinine - worst neonatal result|Transaminases - worst neonatal result|Blood culture - worst neonatal result|Uroculture - worst neonatal result|Gasometry - worst neonatal result|Result of RT-PCR of the placenta|Placental viral panel|Histopathological of the placenta|Result of RT-PCR in breast milk at diagnosis, at birth and with and at hospital discharge|Viral panel in breast milk|Presence of alteration of the neonatal chest radiography|Result of neonatal chest radiography|Presence of alteration of the neonatal chest tomography|Result of neonatal chest tomography|Parameters for monitoring the growth of the newborn at 6, 12 and 24 months - Head circumference|Parameters for monitoring the growth of the newborn at 6, 12 and 24 months - Weight|Parameters for monitoring the growth of the newborn at 6, 12 and 24 months - Height|Development of the newborn up to 6 months|Development of the newborn up to 12 months|Development of the newborn up to 24 months""}"
"2943","Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus","","NCT04344210","2020241093","Behavioral: Tele-interventions related to diabetes management and mental well-being","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04344210","Completed","2020-04-17","2020-09-20","{""locations"":""Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""149"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation in HbA1c levels|COVID-19 infection|Variation in lipid profile|Variation in blood pressure levels|Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups|Comparison of eating disorders between groups|Comparison of adherence to the proposed clinical treatment between groups|Comparison of minor psychiatric disorders between groups|Comparison of sleep pattern changes between groups""}"
"2944","The McMaster Multi-Regional COVID-19 Hospital Case Registry","COREG","NCT04508959","172754","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04508959","Recruiting","2020-04-15","2021-07-01","{""locations"":""Hamilton General Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's General Hospital, Kitchener, Ontario, Canada|Niagara Health System, St. Catharines, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serious COVID-19 infection|Severe infection (requiring admission)|COVID-19 related death|Length of stay|Complications|Intensive interventions""}"
"2945","SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)","","NCT04374370","1596191","Biological: SARSCoV2 Convalescent Plasma","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04374370","Available","1970-01-01","1970-01-01","{""locations"":""AdventHealth Orlando, Orlando, Florida, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""6 Years to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""""}"
"2946","SARS-COV2 Pandemic Serosurvey and Blood Sampling","","NCT04334954","200083|20-I-0083","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04334954","Active, not recruiting","2020-08-26","2022-03-31","{""locations"":""University of Alabama, Birmingham, Alabama, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""11363"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of people with detectable antibodies to SARS-COV2""}"
"2947","Netizens' Perception of COVID-19 Information & Information Sources.","","NCT04497441","QassimU3","Other: Electronic Survey questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497441","Recruiting","2020-06-10","2020-08-15","{""locations"":""Dr Bugude Shiva Shankar, Ar Rass, Al Qassim, Saudi Arabia"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""385"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Netizens' perception of the Sources of COVID-19 information|Netizens' perception on COVID-19 information|Correlation of Age and the Frequency of checking COVID-19 information updates|Correlation of Gender and the Frequency of checking COVID-19 information updates|Correlation of Age and the perception of newly infected COVID-19 cases information update|Correlation of Age and the perception of COVID-19 deaths information update|Correlation of Age and the perception of COVID-19 Vaccine information update|Correlation of Age and the perception of COVID-19 treatment medicines\/drugs information update""}"
"2948","SPI-1005 Treatment in Severe COVID-19 Patients","","NCT04483973","SPI-1005-292","Drug: Ebselen|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04483973","Not yet recruiting","2020-12-01","2021-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-related adverse events|WHO Ordinal Scale|Degree of supplemental oxygen|Peripheral Oxygen Saturation (SpO2)""}"
"2949","Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","","NCT04336787","FADP-2","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04336787","Not yet recruiting","2020-04-12","2020-06-10","{""locations"":""Istanbul University - Cerrahpa\u015fa, Istanbul, Turkey"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""International Physical Activity Questionnaire|Pittsburgh Sleep Quality Index|Perceived Stress Scale|Numerical Pain Rating Scale""}"
"2950","High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy","COVID-19 HD","NCT04408235","EudraCT N°: 2020-001972-13","Drug: Enoxaparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04408235","Not yet recruiting","2020-06-01","2021-06-01","{""locations"":""Azienda Ospedaliero-Universitaria, Modena, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:|Any of the following events occurring within the hospital stay|Mortality at 30 days""}"
"2951","COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2","COVID-pO2-RAAS","NCT04524156","P2020/238","Other: Physiology","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04524156","Not yet recruiting","2020-10-04","2023-05-04","{""locations"":""Erasme Hospital, Bruxelles, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Transcutaneous pO2 and pCO2 as predictive factors for respiratory deterioration|Pneumoproteins CC16 and SDP as predictive factors for respiratory deterioration|Diagnostic and prognostic utility of plasma concentration of ACE2, Ang II, Ang 1-7, Ang 1-9 in COVID-19""}"
"2952","Imaging Feature of SARS-CoV2 Infection","COVID19IF","NCT04394026","COVID-19 IF","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04394026","Recruiting","2020-04-16","2021-07-31","{""locations"":""Deaprtment of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Describe qualitative and quantitative variables|Ability of imaging to predict disease progression|Ability of imaging to predict disease evolution|Imaging findings and demographic data|Imaging findings and laboratory exams""}"
"2953","SPI-1005 Treatment in Moderate COVID-19 Patients","","NCT04484025","SPI-1005-291","Drug: Ebselen|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04484025","Not yet recruiting","2020-12-01","2021-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-related adverse events|WHO Ordinal Scale|Degree of supplemental oxygen|Peripheral Oxygen Saturation (SpO2)""}"
"2954","Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT","","NCT04382469","IRB (00012098), FWA (00018699)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382469","Completed","2020-02-01","2020-05-01","{""locations"":""Faculty of Medicine, University of Alexandria, Alexandria, Egypt"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Retrospective"",""enrollment"":""48"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Radiological pattern of initial presentation, disease progress, healing and recovery|Survey of co-morbid lung diseases""}"
"2955","Monovalent Recombinant COVID19 Vaccine","COVAX19","NCT04453852","13110","Biological: COVID19 vaccine|Biological: Saline","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04453852","Recruiting","2020-06-30","2021-07-01","{""locations"":""PARC,, Adelaide, South Australia, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""40"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Adverse Events|COVID19 neutralizing antibody titers|COVID19 T cell immunogenicity|Durability of antibody response""}"
"2956","Effects of Surgical Mask Use on Peak Torque, Total Work and Interset Fatigability During Isokinetic Strength Testing","","NCT04706299","20-1303","Other: Resistance Exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04706299","Recruiting","2021-01-12","2021-04-01","{""locations"":""Cleveland Clinic Sports Health, Garfield Heights, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the effects of wearing a surgical face mask while performing resistance exercise on average peak force and total work performed.|Identify changes in the level of discomfort experienced while wearing a surgical mask during resistance exercise.""}"
"2957","Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and ""Typical""ARDS Patients","","NCT04508933","0308202247","Device: Extravascular Lung Water Index|Device: Pulmonary Vascular Permeability Index","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04508933","Not yet recruiting","2020-09-01","2020-12-31","{""locations"":""Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Extravascular Lung Water Index|Pulmonary vascular permeability index""}"
"2958","Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection","PICOV","NCT04527614","PICOV2021","Diagnostic Test: qRT-PCR and serology","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04527614","Enrolling by invitation","2020-09-24","2021-05-30","{""locations"":""Sciensano, Brussels, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to occurrence of ILI and ARI both in participants previously exposed to SARS-COV-2 and controls|Number of patients with ILI or ARI, diagnosed with COVID-19, influenza, RSV|Validation of (SimplySpiro) to replace nasopharyngeal swabs|Identify the antibody characteristics in participants with reinfection with SARS-CoV-2|Correlation of the pre-existing antibody characteristics for COVID-19 with disease severity.|Correlation of the level of neutralization antibodies against influenza subtypes with protection against influenza reinfection""}"
"2959","Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection","","NCT04508439","NR-CEI-HRAEI-19-2020","Drug: Enoxaparin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04508439","Recruiting","2020-06-20","2020-12-30","{""locations"":""Hospital Regional de Alta Especialidad de Ixtapaluca, Mexico City, Ixtapaluca, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""130"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""low molecular weight heparin (enoxaparin) and ventilatory support time|thrombotic complications and Rivaroxaban|low molecular weight heparin (enoxaparin) and length of hospital stay|low molecular weight heparin (enoxaparin) and mortality rate""}"
"2960","Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19","ANTIOX-COVID","NCT04570254","09-CEI-011-20160627","Drug: Vitamin C|Drug: Vitamin E|Drug: Melatonin|Drug: N-acetyl cysteine|Drug: Pentoxifylline","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04570254","Active, not recruiting","2020-08-19","2020-11-15","{""locations"":""Unidad Temporal COVID-19 en Centro Citibanamex, Mexico City, Mexico"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""11"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Death from any cause|Percentage of patients who required orotracheal intubation|Assisted mechanical ventilation|Stay in an intensive care unit|Measure lipoperoxidation in basal and post-therapy samples|Evaluation of the total antioxidant capacity|Oxidative and antioxidant stress|Effect of antioxidant therapy at the level on organ failure secondary to SARS-COV2""}"
"2961","MSCs in COVID-19 ARDS","","NCT04371393","GCO 08-1078-0014","Biological: Remestemcel-L|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04371393","Active, not recruiting","2020-04-30","2022-02-01","{""locations"":""Dignity Health, Gilbert, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Emory University, Atlanta, Georgia, United States|Lutheran Hospital, Fort Wayne, Indiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|New York University Langone Health, New York, New York, United States|Mount Sinai Health, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|WakeMed, Raleigh, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor, Smith & White, Plano, Texas, United States|University of Virginia, Charlottesville, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""223"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of all-cause mortality|Number of days alive off mechanical ventilatory support|Number of adverse events|Number of participants alive at day 7|Number of participants alive at day 14|Number of participants alive at day 60|Number of participants alive at day 90|Number of participants alive at 12 Months|Number of participants with resolution and\/or improvement of ARDS|Severity of ARDS|Length of stay|Readmissions|Length of Stay in Intensive Care Unit|Clinical Improvement Scale|Change in plasma hs-CRP concentration|Change in serum hs-CRP concentration|Change in IL-6 inflammatory marker level|Change in IL-8 inflammatory marker level|Change in TNF-alpha inflammatory marker level|Pulmonary symptoms""}"
"2962","Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia","VT4COVID","NCT04349618","69HCL20_0322","Other: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATION","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04349618","Recruiting","2020-04-15","2023-04-15","{""locations"":""Service de M\u00e9decine Intensive R\u00e9animation CHU Gabriel Montpied, Clermont-Ferrand, France|Service de M\u00e9decine Intensive R\u00e9animation H\u00f4pital Michallon - CHU Grenoble Alpes, La Tronche, France|Service de M\u00e9decine Intensive R\u00e9animation H\u00f4pital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de R\u00e9animation Chirurgicale H\u00f4pital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de M\u00e9decine Intensive R\u00e9animation H\u00f4pital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de R\u00e9animation Chirurgicale H\u00f4pital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de r\u00e9animation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France|Service de R\u00e9animation Clinique de la Sauvegarde, Lyon, France|Service de R\u00e9animation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-B\u00e9nite, France|Service de R\u00e9animation Centre hospitalier Annecy Genevois, Pringy, France|Service de M\u00e9decine Intensive R\u00e9animation H\u00f4pital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""A composite score based on all-cause mortality and the number of ventilator free-days (VFD)|All-cause mortality (intention to treat)|Ventilator-free days (VFD)|All-cause mortality with per protocol analysis|Time to successful extubation|Length of hospital stay|Respiratory parameters assessed daily from inclusion to weaning of deep sedation or 14 days whichever comes first|Daily sedation dose during the first 14 days of the study|Rate of use of rescue therapies|Incidence density rate of severe mixed acidosis|Incidence density rate of ventilator associated pneumonia|Incidence density rate of acute cor pulmonale|Incidence density rate of barotrauma|Incidence density rate of any serious adverse events|Cognitive impairment assessed by phone call using the Telephone Montreal Cognitive Assessment (T-MoCA) test|Quality of life assessed by the RAND 36-Item Health Survey (SF-36) score|Post-traumatic stress disorder assessed by the Impact of Event Scale - revised (IES-R) score by phone call|Cost-efficacy ratio of the innovative strategy compared to the reference strategy""}"
"2963","Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic","","NCT04374656","IRB00249598","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374656","Recruiting","2020-05-18","2021-05-01","{""locations"":""Wilmer Eye Institute, Baltimore, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of conjunctival samples tested positive for SARS-CoV-2|Proportion of nasal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples|Proportion of nasopharyngeal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples|Rate of development of COVID-19 in the study patient population|Positive conjunctival sample rate in patient developed COVID-19""}"
"2964","Echocardiography in Patients With Covid-19","","NCT04412460","CovidEcho","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412460","Recruiting","2020-03-20","2021-12-31","{""locations"":""University Hospital Tubingen, Tubingen, BW, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU Mortality|ICU length-of stay|ICU ventilator free days|Hospital length-of-stay""}"
"2965","Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP","FamilyPEDCOVID","NCT04442087","APHP200627|2020-A01480-39","Biological: Serology SARS-CoV2|Behavioral: Data collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04442087","Recruiting","2020-06-19","2021-09-01","{""locations"":""Centre d'investigation clinique (CIC) Necker Cochin in Necker Children's Hospital, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Seroprevalence of antibodies anti- SARS Cov2 in children of Hospital workers|Number of Asymptomatic Children with a positive seroloy|Number of severely symptomatic Children with a positive serology|Prevalence of different clinical symptoms in children with a positive serology|Serological result of each member of the family|Number of spouses of hospital workers with a positive serology|Number of Asymptomatic spouses of hospital workers with a positive serology|Number of severely symptomatic spouses of hospital workers with a positive serology""}"
"2966","Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI)","CoVEHPI","NCT04709003","1051-20-RMC-C","Diagnostic Test: Serologic test|Diagnostic Test: Respiratory swabs","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04709003","Recruiting","2020-12-23","2022-06-01","{""locations"":""Haemek Medical Center, Afula, Israel|Soroka Medical Center, Be'er Sheva, Israel|Meir Medical Center, Kefar Saba, Israel|Beilinson hospital, Petach Tikva, Israel|Schneider Children's Medical Center of Israel, Petah tikva, Israel|Kaplan Medical Center, Re\u1e96ovot, Israel"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4504"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 vaccine effectiveness (VE)|Symptomatic SARS-CoV-2 infection in vaccinated vs. unvaccinated healthcare workers|asymptomatic SARS-CoV-2 infection in vaccinated vs. unvaccinated healthcare workers|Duration of effectiveness of the vaccine|Vaccine Effectiveness by age|Vaccine Effectiveness by comorbidity|Vaccine effectiveness in persons previously infected with SARS-CoV-2 virus|VE by degree of exposure to COVID-19 patients|VE by different SARS-CoV-2 variants|Vaccine effectiveness of one dose compared to two doses|Compartive vaccine Effectiveness of different vaccine brands""}"
"2967","Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19","","NCT04476667","PSIY-683-20","Behavioral: e-Psychotherapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04476667","Recruiting","2020-06-15","2021-05-01","{""locations"":""Hotel Dieu Hospital, Kingston, Ontario, Canada"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Stress|Change in Resilience|Change in Quality of Life Assessment|Change in Symptom Severity - 1|Change in Symptom Severity - 2|Change in Symptom Severity - 3|Qualitative Information: Healthcare Providers|Qualitative Information: Personal, social, and cultural factors""}"
"2968","Statin Therapy and COVID-19 Infection","STACOV","NCT04407273","106/2020","Drug: observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407273","Completed","2020-05-14","2020-12-30","{""locations"":""Facultat de Medicina i Ci\u00e8ncies de la Salut de Reus, Reus, Tarragona, Spain"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""2159"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy""}"
"2969","Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation","CONFIDENT","NCT04558476","2020-003102-31","Biological: Convalescent Plasma|Other: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04558476","Recruiting","2020-09-01","2022-09-01","{""locations"":""OLVZ Aalst, Aalst, Belgium|UZ Antwerpen, Antwerp, Belgium|Imelda ZH Bonheiden, Bonheiden, Belgium|AZ Sint-Jan Brugge, Bruges, Belgium|CHU Saint Pierre, Brussels, Belgium|Erasme, Brussels, Belgium|UZ Brussel, Brussel, Belgium|CHU Charleroi Marie Curie, Charleroi, Belgium|AZ Sint Blasius, Dendermonde, Belgium|UZ Gent, Gent, Belgium|AZ Groeningen Kortrijck, Kortrijk, Belgium|CHR Citadelle, Li\u00e8ge, Belgium|CHU Li\u00e8ge, Li\u00e8ge, Belgium|UC Louvain, Louvain, Belgium|AZ Delta, Roeselare, Belgium|CHU UCL Namur-Godinne, Yvoir, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Vital status|day 90 mortality|number of ventilator-free days at day 28|number of renal replacement therapy free days at day 28|number of vasopressors free-days at day 28|use of ECMO before day 28|value of the SOFA score at days 7, 14 and 28|changes in SOFA scores (delta SOFA) over 7, 14 and 28 days|assessment of the SARS-CoV-2 viral load|blood C reactive protein (CRP) concentration|ferritin concentration|lymphocyte count|length of stay in the acute care hospital|location of the patient|Katz Index of independence in Activity Day Living functional score|Hospital Anxiety and Depression Scale (HADS)|Quality of life scale EQ-5D-5L|Transfusion related adverse events""}"
"2970","Serological Testing for COVID-19 (SARS-CoV-2) in ESKD","","NCT04378686","S64000","Other: dialysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04378686","Recruiting","2020-04-23","2022-05-01","{""locations"":""Jessa Ziekenhuis, Hasselt, Limburg, Belgium|University Hospitals Leuven, Leuven, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibodies against SARS-CoV-2""}"
"2971","Impact of COVID19 Outbreak in Cardiac Acute Care","CCU-COVID19","NCT04344912","APHP200524|0522070420","Other: Data collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344912","Recruiting","2020-03-20","2020-08-01","{""locations"":""Unit\u00e9 de Soins Intensifs de Cardiologie, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, AP-HP, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of recurrent Major Cardiovascular Events (MACE) and urgent rehospitalization""}"
"2972","Antibodies Responses to COVID-19 Infection in Hospitalized Patients","No-SARS","NCT04520880","ICU-06072020","Diagnostic Test: Testing procedure for Binding antibodies|Diagnostic Test: Neutralizing antibodies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04520880","Not yet recruiting","2020-08-01","2021-02-01","{""locations"":""Imam Abdulrahman Bin Faisal University, Dammam, Eastern, Saudi Arabia"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""158"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in the levels of S specific antibodies in severely ill patients compared to mild cases.|Changes in the levels of N specific antibodies in severely ill patients compared to mild cases.|S specific binding antibodies of SARS-CoV-2|N specific binding antibodies of SARS-CoV-2|Neutralizing antibodies directed against S protein of SARS-CoV-2|The severity category of critically ill|Length of ICU|Length of hospital stays|Alive status at 28-days|Alive status at 90-day|Correlation between the levels of S neutralizing antibodies and disease severity|Correlation between the levels of N neutralizing antibodies and disease severity""}"
"2973","COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications","CORONA-VTE NET","NCT04535128","2020P000848","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04535128","Recruiting","2020-03-24","2021-03-30","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of arterial or venous thromboembolism over 30 days|Frequency of arterial or venous thromboembolism over 90 days|Frequency of all-cause death, bleeding, and thromboembolic outcomes at 30 days|Frequency of all-cause death, bleeding, and thromboembolic outcomes at 90 days""}"
"2974","Lung Ultrasound for COVID-19 Initial Triage and Monitoring","QUICK","NCT04474236","RC31/20/0182|2020-A01445-34","Other: thoracic lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04474236","Recruiting","2020-05-27","2021-03-27","{""locations"":""University Hospital Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""148"",""age"":""17 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Area Under the Curve (AUC) of a predictive model built on LUS and clinical (Q-SOFA, SpiO2\/FiO2) data|Area Under the Curve (AUC) of a predictive model built on CT scan and clinical (Q-SOFA, SpiO2\/FiO2) data|mortality""}"
"2975","To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003","","NCT04592835","DW_DWJ1516101_Australia","Drug: DWRX2003","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04592835","Not yet recruiting","2020-10-19","2021-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events|To assess PK parameters of niclosamide injectable (DWRX2003) through Cmax|To assess PK parameters of niclosamide injectable (DWRX2003) through tmax|To assess PK parameters of niclosamide injectable (DWRX2003) through AUC0-last|To assess PK parameters of niclosamide injectable (DWRX2003) through AUC0-\u221e|To assess PK parameters of niclosamide injectable (DWRX2003) through t1\/2""}"
"2976","Evolution of Facial Trauma During COVID Containment Measures","Traumax","NCT04355442","RECHMPL20_0228","Procedure: Facial fractures reduction or osteosynthesis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04355442","Completed","2020-04-01","2020-05-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""evolution of number of maxillofacial trauma|variability in terms of type of trauma|Comparative assessment of types of trauma by the inter-regional variability""}"
"2977","Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection","","NCT04362956","Perinatal COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362956","Completed","2020-07-10","2020-10-01","{""locations"":""Hospital Italiano, Buenos Aires, Argentina"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""114"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Vertical transmission|Neonatal protection due to maternal antibodies|Increase risk of neonatal morbidity|Increase risk of obstetric complications""}"
"2978","Community Health Workers Against COVID19","","NCT04426305","BC-07744.","Other: community health worker support|Other: care as usual","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04426305","Enrolling by invitation","2020-05-21","2020-10-30","{""locations"":""Department of Public Health and Primary Care, Ghent, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in patient-reported Emotional Support (based on the PROMIS\u00ae Emotional Support instrument)|Change in patient-reported Social Isolation (based on the PROMIS\u00ae Emotional Support instrument)|Change in patient-reported Ability to participate in social roles and activities (based on the PROMIS\u00ae ability to participate in social roles and activities instrument)|Change in patient-reported anxiety (based on the PROMIS\u00ae anxiety instrument)""}"
"2979","REassessement After Hospitalization for Sars-COV-2 disordER","REHCOVER","NCT04443257","RECHMPL20_0340","Other: assessment of the sequelae after hospitalization for Sars-COV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443257","Enrolling by invitation","2020-07-08","2021-07-25","{""locations"":""University hospital of Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development or worsening of a ventilatory disorder and\/or chronic respiratory failure assessed by spirometry|Assessment of dyspnea|Description of pulmonary lesions as assessed by lung CT scan|Development of pulmonary fibrosis as assessed by lung CT scan|Incidence or worsening of cardiovascular diseases|Incidence or worsening of renal disease|Incidence or worsening of liver disease|Incidence or worsening of psychological pathology : anxiety|Incidence or worsening of psychological pathology: depression|Incidence or worsening of psychological pathology: post-traumatic stress|Incidence or worsening of psychological pathology: insomnia|Assessment of the health-related quality of life|Assessment of the fatigue|Assessment of the socioeconomic deprivation|development or worsening of metabolic disorders: diabetes, thyroid diseases, dyslipidemia, adrenal disorders, malnutrition|Development of auto-immune disorders|Assessment of the evolution of the humoral anti-SARS-CoV-2 immunization profile|Patients' self-reported level of physical activity|Determination of risk factors associated with sequelae or comorbidities""}"
"2980","Study of the Pathogenesis of Olfactory Disorders in COVID-19","COVIDSMELL","NCT04366934","2020-021","Other: Nasal swab|Other: Taste and olfactory function evaluation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366934","Completed","2020-05-04","2020-10-29","{""locations"":""H\u00f4pital Lariboisi\u00e8re, Policlinique, Paris, France|H\u00f4pital Lariboisi\u00e8re, Service ORL, Paris, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""26"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Molecular and cellular defects in olfactory epithelium|Biological mechanisms involved in the pathogenesis of the disease|Epidemiological characteristics|Olfactory and taste dysfunction""}"
"2981","Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease","","NCT04419025","CHA-IRB-1139/05/20","Drug: N-acetylcysteine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04419025","Recruiting","2020-09-23","2021-06-30","{""locations"":""CHA Cambridge Hospital, Cambridge, Massachusetts, United States|CHA Everett Hospital, Everett, Massachusetts, United States|CHA Respiratory Clinic, Somerville, Massachusetts, United States|CHA Somerville campus, Somerville, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decrease in Respiratory Rate|Hospital length of stay (LOS)|Need for mechanical ventilation|Length of time intubated|Need for hospitalization|Recovery disposition""}"
"2982","Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan","","NCT04492501","Sultan Mehmood Kamran 3","Procedure: Therapeutic Plasma exchange|Biological: Convalescent Plasma|Drug: Tocilizumab|Drug: Remdesivir|Biological: Mesenchymal stem cell therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04492501","Completed","2020-04-01","2020-07-20","{""locations"":""Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""survival|duration of hospitalization|Time to resolution of cytokine release storm|Time of viral clearance|Complications""}"
"2983","The Geneva Covid-19 CVD Study","","NCT04384029","CCER-2020-00610","Other: Covid-19 + patients","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384029","Active, not recruiting","2020-03-24","2022-03-31","{""locations"":""Geneva University Hospital (HUG), Geneva, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""7000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mobidity discharge|mobidity at 30 days|mobidity 1 year after hospitalization|mortality discharge|mortality 30 days after hospitalization|mortality 1 year after hospitalization|Clinical outcomes according to medication at admission|Clinical outcomes related to preexisting cardiovascular risk factors at admission|New onset of CVD induced by COVID-19 disease|Cost of hospital stay|Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).|Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).""}"
"2984","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care","","NCT04334967","2020000186","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04334967","Suspended","2020-03-30","2022-05-27","{""locations"":""Portland Providence Medical Center, Portland, Oregon, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""13"",""age"":""45 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality""}"
"2985","Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019","","NCT04371601","MSC-CoViD-2020","Drug: Oseltamivir|Drug: hormones|Device: oxygen therapy|Procedure: mesenchymal stem cells","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04371601","Active, not recruiting","2020-03-01","2022-12-31","{""locations"":""Fuzhou General Hospital, Fuzhou, Fujian, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes of oxygenation index (PaO2\/FiO2) ,blood gas test|Detection of TNF-\u03b1 levels, IL-10 levels|Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).|Changes of c-reactive protein and calcitonin""}"
"2986","Intensive Care Therapy of Covid-19 Disease in Germany","","NCT04455451","DCIR","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04455451","Recruiting","2020-08-06","2023-06-01","{""locations"":""RWTH Aachen - Department for operative Intensive Care Medicine and intermediate Care, Aachen, Germany|Zollernalbklinikum, Balingen, Germany|Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany|UH Bochum - Department for Anesthesiology and Intensive Care Medicine, Bochum, Germany|Universit\u00e4tsklinikum Bonn, Bonn, Germany|Universit\u00e4tsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Ev. Krankenhaus Bethesda Duisburg Klinik f\u00fcr An\u00e4sthesiologie und Intensivmedizin, Duisburg, Germany|Univerrsit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany|Universit\u00e4tsklinikum Essen, Essen, Germany|Universit\u00e4tsklinikum Frankfurt, Frankfurt, Germany|University Hospital Freiburg - Department for Anesthesiology and Intensive Care Medicine, Freiburg, Germany|Universit\u00e4tsklinikum Giessen Klinik f\u00fcr Anaesthesiologie und operative Intensivmedizin, Gie\u00dfen, Germany|Universit\u00e4tsklinikum Greifswald, Greifswald, Germany|Universit\u00e4tsmedizin G\u00f6ttingen Klinik f\u00fcr An\u00e4sthesiologie, G\u00f6ttingen, Germany|Universit\u00e4tsklinikum Halle, Halle\/Saale, Germany|University Hospital Heidelberg - Department for Anesthesiologie and Intensive Care Medicine, Heidelberg, Germany|Universit\u00e4tsklinikum des Saarlandes, Homburg\/Saar, Germany|Klinikum der Universit\u00e4t Witten\/Herdecke - K\u00f6ln \/ Klinik f\u00fcr An\u00e4sthesiologie und operative Intensivmedizin, K\u00f6ln, Germany|Universit\u00e4tsklinikum Leipzig, Leipzig, Germany|UKSH Campus L\u00fcbeck - Department for Anesthesiology and Intensive Care Medicine, L\u00fcbeck, Germany|University Hospital Magdeburg - Department for Anesthesiology and Intensive Care Medicine, Magdeburg, Germany|Universit\u00e4tsklinikum Marburg, Marburg, Germany|Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany|Oberschwabenklinik Ravensburg Klinik f\u00fcr An\u00e4sthesie-, Intensiv-, Notfall- und Schmerzmedizin, Ravensburg, Germany|University Hospital T\u00fcbingen - Department for Anesthesiology and Intensive Care Medicine, T\u00fcbingen, Germany|Universit\u00e4tsklinikum Ulm, Ulm, Germany|Universit\u00e4tsklinikum W\u00fcrzburg Klinik und Poliklinik f\u00fcr An\u00e4sthesiologie, Intensivmedizin und Schmerztherapie, W\u00fcrzburg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|ICU length of stay""}"
"2987","Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","COVID-19","NCT04508075","CoV2-0320","Biological: SARS-CoV-2 vaccine (inactivated)|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04508075","Active, not recruiting","2020-08-10","2021-09-01","{""locations"":""Hasan Sadikin Hospital\/School of Medicine, Padjadjaran University, Bandung, West Java, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1620"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of laboratory-confirmed COVID-19 after the second dose|Incidence of suspected COVID-19 cases|Incidence of laboratory-confirmed cases (severe, critical and death)|Seroconversion rate anti-S antibody IgG titer (ELISA)|Seropositive rate of neutralizing antibodies""}"
"2988","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","","NCT04335773","20/03794","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04335773","Recruiting","2020-04-03","2030-12-31","{""locations"":""Akershus universistetssykehus, L\u00f8renskog, Norway"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""350"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Risk Factors for severe infection|Immunulogical mechanisms|Long term outcome""}"
"2989","Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","","NCT04649021","BNT162-06","Biological: BNT162b2|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04649021","Active, not recruiting","2020-12-04","2021-12-01","{""locations"":""Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""950"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 serum neutralizing titers - Seroconversion rates (SCR)|The geometric mean titer (GMT) of SARS-CoV-2 serum neutralizing titers at 1 month after dose 2|SARS-CoV-2 serum neutralizing titers - SCR|SARS-CoV-2 serum neutralizing titers - GMT|SARS-CoV-2 anti-S1 immunoglobulin G (IgG) antibody level - SCR|SARS-CoV-2 anti-S1 IgG antibody level - GMT|SARS-CoV-2 serum neutralizing antibody level - Geometric mean fold rise (GMFR)|SARS-CoV-2 anti-S1 IgG antibody level - GMFR|Percentage of participants reporting local reactions|Percentage of participants reporting systemic events|Hematology laboratory assessments|Chemistry laboratory assessments|Adverse events (AEs)|Serious AEs (SAEs)""}"
"2990","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","PROACTIVE-19","NCT04321928","IV/2428- 2 /2020/EKU","Behavioral: Personalized health education|Behavioral: General health education","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04321928","Recruiting","2020-04-01","2021-08-21","{""locations"":""Institute for Translational Medicine, University of P\u00e9cs, P\u00e9cs, Hungary"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""7576"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases|The number of general practitioner visits|The number of emergency, hospital admission and intensive care admission|Length of hospitalization and intensive care unit stay|Organ dysfunction|Lifestyle changes|The cost of care""}"
"2991","Mortality in Patients With Severe COVID-19 Pneumonia Who Underwent Tracheostomy","","NCT04642703","65/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04642703","Recruiting","2020-03-03","2021-11-30","{""locations"":""Intensive Care Unit, Hospital Cl\u00ednico Universidad de Chile, Santiago, Chile"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""90-days mortality rate|Hospital length of stay|ICU length of stay|Time of mechanical ventilation|Health-care associated infections|Long-term quality of life assessed by Short Form-36 Health Survey, SF-36""}"
"2992","Functional Recovery of Hospitalised Patients With COVID-19: The COREG Extension Study","","NCT04602260","COREG-Extension_14567","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04602260","Recruiting","2020-06-09","2021-09-01","{""locations"":""McMaster University, Hamilton, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""211"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Activity Measure for Post Acute Care (AM-PAC) Basic Mobility Inpatient Version|Change in Activity Measure for Post Acute Care (AM-PAC) Basic Mobility Outpatient Version|Change in Activity Measure for Post Acute Care (AM-PAC) Applied Cognitive Inpatient Version|Change in Activity Measure for Post Acute Care (AM-PAC) Daily Activity|Change in Short Physical Performance Battery (SPPB)|Change in Clinical Frailty Scale (CFS) for participants over 60 years of age|Change in Forced Expiratory Volume (FEV1)|Change in Forced Vital Capacity (FVC)|Change in Forced Expiratory Volume Percentage (FEV1%)|Baseline Dyspnea Index (BDI)|Change in Transition Dyspnea Index (TDI)|Change in Patient Health Questionnaire - 9 (PHQ-9)|Change in Functional Independence Measure (FIM)|Change in Impact of Event Scale - Revised (IES-R)|Change in Health status (EQ-5D-5L)""}"
"2993","Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak","PRPsyCOVID","NCT04351399","2020_29|2020-A00907-32","Other: questionnaire assesment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351399","Completed","2020-04-27","2020-05-04","{""locations"":""Hopital Roger Salengro, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Family-Based|Time Perspective: Cross-Sectional"",""enrollment"":""318"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of RA patients with emotional impact (feeling of isolation)|self-reported questionnaire for painful""}"
"2994","TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients","","NCT04716556","TSUNAMI","Biological: Convalescent plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04716556","Active, not recruiting","2020-07-16","2021-05-01","{""locations"":""SOD Clinica Malattie Infettive Tropicali, Parassitologia, Epatiti Croniche - AOU Ospedali Riuniti di Ancona, Ancona, Italy|Ospedale di Arezzo, Arezzo, Italy|Clinica Malattie Infettive, Universit\u00e0 degli Studi di Bari, Bari, Italy|Ospedale Papa Giovanni XXIII-Dip. emergenza, Urgenza e area critica, Bergamo, Italy|UOC Malattie Infettive - AOU Bologna, Bologna, Italy|UO PID Tossicologia Applicata - Dip. Scienze Biomediche e Biotecnologiche - Universit\u00e0 di Catania - AOU Policlinico Vittorio Emanuele, Catania, Italy|Ospedale Citt\u00e0 di Castello, Citt\u00e0 Di Castello, Italy|Ospedale di Empoli, Empoli, Italy|UOC Malattie Infettive - ASUR Marche Area Vasta 4, Fermo, Italy|UOC Malattie Infettive - AOU Ferrara, Ferrara, Italy|Ospedale Santa Maria Annunziata, Firenze, Italy|SOD Malattie Infettive e Tropicali - AOU Careggi, Firenze, Italy|Dip.Medicina Clinica e Sperimentale - Policlinico \""Riuniti\"" di Foggia, Foggia, Italy|Nuovo Ospedale S. Giovanni Battista Usl Umbria2, Foligno, Italy|U.O.C. Malattie Infettive ASL Frosinone, Frosinone, Italy|U.O. Malattie Infettive IRCCS-Ospedale Policlinico San Martino, Genova, Italy|Ospedale di Grosseto, Grosseto, Italy|ASL 5 Spezzina - SC Malattie Infettive, La Spezia, Italy|ASST Lecco - Malattie Infettive, Lecco, Italy|Ospedale di Livorno, Livorno, Italy|Ospedale di Lucca, Lucca, Italy|S.C. Pneumologia e Utir ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|Ospedale Dell'Angelo - UOC Malattie Infettive, Mestre, Italy|ASST Santi Paolo e Carlo, Milano, Italy|Ospedale Luigi Sacco, Milano, Italy|SC Malattie Infettive ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Ospedale San Gerardo, Monza, Italy|Malattie Infettive - AOU Federico II di Napoli, Napoli, Italy|UOC Malattie Infettive ad indirizzo Respiratorio - PO Cotugno - AORN \""Dei Colli\"", Napoli, Italy|UOC Malattie Infettive e Tropicali - AOU Policlinico, Palermo, Italy|Dip. Medicina Diagnost. e Servizi Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy|UOC Malattie Infettive - Azienda Ospedali Riuniti Marche Nord, Pesaro, Italy|AOU Pisana, Pisa, Italy|Ospedale Pistoia, Pistoia, Italy|Ospedale Prato, Prato, Italy|Malattie Infettive Ravenna, Ravenna, Italy|UOC Malattie Infettive - AUSL Reggio Emilia, Reggio Emilia, Italy|Malattie Infettive - Rimini Forl\u00ec Cesena, Rimini, Italy|Campus Bio Medico - UO Anestesia e Rianimazione, Roma, Italy|ASL 1 Imperiese - SC Malattie Infettive, Sanremo, Italy|ASL 2 Savonese - SC Malattie Infettive, Savona, Italy|Ospedale di Siena, Siena, Italy|Ospedale di Sondrio - dipartimento di Medicina, Sondrio, Italy|AOU di Terni, Terni, Italy|Ospedale Ca Foncello - UOC Malattie Infettive, Treviso, Italy|A.O. Integrata Universit\u00e0 di Verona, Verona, Italy|Ospedale Viareggio, Viareggio, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""474"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients who meet invasive mechanical ventilation or death|Mortality rates|Time to invasive mechanical ventilation or death|Time to virologic recover|Hospitalization time|Adverse events""}"
"2995","ACCESS A Master Digital Surveillance Protocol for COVID-19","ACCESS","NCT04363268","Pro00041635","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363268","Recruiting","2020-04-20","2031-10-01","{""locations"":""Medable Inc., Palo Alto, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of population-based models of disease risk|Relation between disease burden and geolocation|Effect of medications on symptoms of COVID19|Effect of medications on disease severity of COVID19|Rate of COVID19 infection and disease outcomes|Effect of COVID19 on health outcomes|Long-term follow up and recontact""}"
"2996","Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?","","NCT04468802","KSSEAH--0965","Other: Case fatality rate","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468802","Completed","2020-02-01","2020-07-01","{""locations"":""Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Kucukcekmece, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""32"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Case Fatality Rate""}"
"2997","Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","PREP-COVID","NCT04344379","APHP200386|2020-001273-73","Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04344379","Suspended","2020-04-17","2020-07-15","{""locations"":""Hopial Avicenne, Bobigny, France|H\u00f4pital GHU Paris Saclay, Le Kremlin-Bic\u00eatre, France|H\u00f4pital Saint Antoine, Paris, France|H\u00f4pital Broca, Paris, France|H\u00f4pital La Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France|H\u00f4pital Cochin, Paris, France|H\u00f4pital europ\u00e9en Georges Pompidou, Paris, France|H\u00f4pital Necker, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""122"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events""}"
"2998","T Cells Response to SARS COV 2 Peptides","","NCT04573348","PBMC _COVID 19","Diagnostic Test: Savicell's ImmunoBiopsy™","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04573348","Recruiting","2020-10-14","2021-10-10","{""locations"":""Carmel Medical Center, Haifa, North, Israel"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positive and negative diagnosis (scored 0\/1 dichotomously) in accordance with test results (MA\/ELISA\/PCR)|Prevalence of positive for SARS - COV2 - in healthy donors.""}"
"2999","Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.","","NCT04453566","61351342/ 2020-286","Other: Online Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453566","Recruiting","2020-05-27","2020-12-01","{""locations"":""Uskudar University, Istanbul, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""120"",""age"":""18 Years to 35 Years \u00a0 (Adult)"",""outcome_measures"":""Sociodemographic information and training characteristics|The Beck Anxiety Inventory (BAI)|The Visual Analogue Scale (VAS)|Perceived Stress Scale (PSS)|Satisfaction with Life Scale|Brunel mood scale (BRUMS)""}"
"3000","COVID-19 in Immunosuppressed Children","","NCT04511429","062-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04511429","Recruiting","2020-06-30","2021-04-01","{""locations"":""Hospital Federal de Bonsucesso, Rio de Janeiro, RJ, Brazil|Hospital Estadual da Crian\u00e7a, Rio De Janeiro, RJ, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""1 Month to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Serology (IgM, IgG) for COVID-19.|Hospital admission|Intensive care admission|Death|Positive PCR for COVID-19|Clinical characteristics of patients with COVID-19|Proportion of patients with viral excretion in respiratory secretion and faeces on days 3, 7, 14, 21 and 30 after confirmation of covid 19.""}"
"3001","Risk Stratification of COVID-19 Using Urine Biomarkers","","NCT04681040","NCGM-G-003654-00","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04681040","Recruiting","2020-12-19","2022-08-31","{""locations"":""MD Mount Sinai, Baltimore, Maryland, United States|Hospital das Clinicas Ribeirao Preto, Ribeir\u00e3o Preto, San Paulo, Brazil|Danish National Biobank, K\u00f8benhavn, Denmark|Shonan General Hospital, Kamakura, Kanagawa, Japan|National Center Global Health and Medicine, Shinjuku, Tokyo, Japan|Yamanashi Prefectural Central Hospital, K\u014dfu, Yamanashi, Japan|Unilab Group, Manila, Philippines"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Risk Stratification of COVID-19 Participants Using Urine Biomarkers|Prediction of COVID-19 Treatment by Urine L-FABP|Increase of O2 support, hospital days, worsening of chest X-ray and CT, and survival rate, at 14 and\/or 30 days.|Comparison of Risk Stratification with Other Biomarkers""}"
"3002","Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students","","NCT04620798","2008293852","Behavioral: Immediate vs. delayed provision of antibody test results","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04620798","Active, not recruiting","2020-09-14","2020-12-01","{""locations"":""Indiana University, Bloomington, Indiana, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Screening"",""enrollment"":""1700"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of handwashing|Frequency of face touching|Frequency of hand sanitizer use|Frequency of social event avoidance|Frequency of staying home from work\/school|Frequency of mask wearing|Frequency of physical distancing|Frequency of avoiding people at high-risk for severe COVID-19 infections|Proportion of participants with SARS-CoV-2 seroconversion over 8 weeks""}"
"3003","COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study","RICO","NCT04392401","69HCL20_0358|2020-A01079-30","Biological: Collection of blood samples in order to create a biocollection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04392401","Recruiting","2020-05-11","2021-02-01","{""locations"":""H\u00f4pital Pierre Wertheimer, Bron, France|H\u00f4pital Gabriel Montpied, Clermont-Ferrand, France|Centre hospitalier universitaire de Grenoble Alpes, Grenoble, France|H\u00f4pital Edouard Herriot, Lyon, France|H\u00f4pital Edouard Herriot, Lyon, France|H\u00f4pial de la Croix Rousse, Lyon, France|H\u00f4pital Lyon Sud, Pierre-B\u00e9nite, France|CH de St Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Kinetics over time of HLA-DR expression on the surface of monocytes""}"
"3004","Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection","STAUNCH-19","NCT04528888","Staunch-19-1.1-26-04-20","Drug: Enoxaparin|Drug: Methylprednisolone|Drug: unfractionated heparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04528888","Not yet recruiting","2020-09-01","2021-07-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""210"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality at day 28|All-cause mortality at ICU discharge|All-cause mortality at hospital discharge|Need of rescue administration of high-dose steroids or immune-modulatory drugs|New organ dysfunction during ICU stay|Grade of organ dysfunction during ICU stay|ICU free days at day 28|Occurrence of new infections|Ventilation free days at day 28|Vasopressors free-days at day 28|Switch from non-invasive to invasive mechanical ventilation|Delay from start of non-invasive ventilation to switch to invasive ventilation|Occurrence of protocol related adverse events|Occurrence of venous thromboembolism, stroke or myocardial infarction|Occurrence of major bleeding (safety end point)|Occurrence of clinically relevant non-major bleeding (safety end point)""}"
"3005","Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom","","NCT04407156","UHDB/2020/050","Other: acute kidney injury","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407156","Completed","2020-06-01","2020-07-20","{""locations"":""Derby Hospital NHS Foundation Trust, Derby, Derbyshire, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""724"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Acute kidney injury in COVID-19|All-cause mortality in AKI patients""}"
"3006","Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers","TOCIBRAS","NCT04403685","TOCIBRAS","Drug: Tocilizumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04403685","Terminated","2020-05-08","2020-07-21","{""locations"":""UNIFESP, S\u00e3o Paulo, Sao Paulo, Brazil|HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil|HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Benefic\u00eancia Portuguesa de Sao Paulo, Sao Paulo, Brazil|HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil|HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil|HSL - Hospital S\u00edrio Liban\u00eas, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""129"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of clinical status|All-cause mortality|Hospital Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events""}"
"3007","Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia","","NCT04642040","2857","Other: Pulmonary Rehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04642040","Recruiting","2020-06-30","2021-01-01","{""locations"":""Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Dyspnea level as measured by modified Medical Research Council (mMRC) Dyspnea Scale|Change in functional capacity as measured by 30-second sit-to-stand test|Change in physical activity level as measured by International Physical Activity Questionnaire (IPAQ) -Short Form|Change in anxiety and depression as measured by Hospital Anxiety and Depression Scale (HADS)""}"
"3008","A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019","","NCT04346602","130004","Other: all treatment about COVID-2019","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346602","Recruiting","2020-02-01","2020-12-01","{""locations"":""the First Hospital of Jilin University, Chang chun, Jilin, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""132"",""age"":""1 Year to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""fever|cough|diarrhea|anxiety|insomnia|depression""}"
"3009","Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)","","NCT04456088","BAI_COV19_01_CAN","Combination Product: 150 ppm Nitric Oxide delivered through LungFit Delivery System|Combination Product: 80 ppm Nitric Oxide delivered through LungFit Delivery System","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04456088","Withdrawn","2020-07-15","2020-12-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""22 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to deterioration|Time to stable oxygen saturation""}"
"3010","International SARS-CoV-2 (COVID-19) Infection Observational Study","ICOS","NCT04385251","ICOS|75N91019D00024","Other: Data Collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385251","Recruiting","2020-06-18","2021-06-30","{""locations"":""Denver Public Health, Denver, Colorado, United States|Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos, Buenos Aires, Argentina|CHIP Department of Infectious Diseases, Copenhagen, Denmark|University College London Medical School Centre for Sexual Health and HIV Research, London, England, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Hospitalization|Time to Expiration|Rate of Death at 7 Days|Rate of Death at 14 Days|Rate of Death at 28 Days|Rate of Hospitalization at 7 Days|Rate of Hospitalization at 14 Days|Rate of Hospitalization at 28 Days|Participant Health at 7 Days|Participant Health at 14 Days|Participant Health at 28 Days|Modified Borg Dyspnea Scale at 7 Days|Modified Borg Dyspnea Scale at 14 Days|Modified Borg Dyspnea Scale at 28 Days""}"
"3011","Solid Organ Transplant Recipients With SARS-CoV-2 French Registry","TX-COVID","NCT04360707","7766","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04360707","Recruiting","2020-04-08","2021-04-08","{""locations"":""Service de N\u00e9phrologie et Transplantation, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical Presentation and Incidence of Covid-19 Infection in Different Cohorts of Solid Organ Transplant Patients""}"
"3012","Respiratory Mechanics and Gas Exchange Characteristics in Patient With SARS-CoV-2","","NCT04486729","10.202","Other: High PEEP with end inspiratory pause|Other: Low PEEP - FiO2 high|Other: High PEEP without end inspiratory pause|Other: Low PEEP - FiO2 low","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04486729","Recruiting","2020-07-01","2020-10-20","{""locations"":""Sanatorio Anchorena San Martin, San Martin, Buenos Aires, Argentina"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Driving transpulmonary pressure (cmH2O)|Bohr dead space fraction (%)|Shunt fraction (%)""}"
"3013","Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic.","ChoCO-W","NCT04542512","06012020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04542512","Recruiting","2020-10-01","2021-09-01","{""locations"":""Centre Hospitalier Intercommunal Poissy-Saint Germain en Laye, Poissy, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between COVID-19 pneumonia and necrotic cholecystitis|Correlation between coagulopathy and necrotic cholecystitis|Risk factors for necrotic cholecystitis|Outcome necrotic cholecystitis""}"
"3014","Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV","I-GLOBAL","NCT04434417","I-GLOBAL","Device: 2019-nCoV IgG/IgM Rapid Test Cassette","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04434417","Recruiting","2020-04-15","2021-12-31","{""locations"":""Papa Giovanni XXIII Hospital, Bergamo, Italy|Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliera Niguarda C\u00e0 Granda, Milano, Italy|European IO, Division of Early Drug Development for Innovative Therapies, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the rate of SARS-CoV-2 positive cancer patients and health professionals in a comprehensive cancer center or in a cancer setting.|Evaluation of test accuracy|Interleukin-6 quantification|Interleukin-2 quantification|Interleukin-1 quantification|Tumor Necrosis Factor (TNF) quantification|Interferon gamma quantification""}"
"3015","The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients","","NCT04402983","Telerehab_Covid19","Other: Physiotherapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04402983","Completed","2020-05-27","2020-12-01","{""locations"":""University of Health Sciences Turkey, \u0130stanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""34"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Modified Medical Research Council Dyspnea Score|Timed up and go test|Visual analog scale to assess the pain severity|The Short Physical Performance Battery (SPPB)|Visual analog scale to assess the fatigue severity|BECK depression inventory|Saint George Respiratory Questionnaire""}"
"3016","Anxiety and Burnout in Anesthetists and Intensive Care Unit Nurses During Covid-19 Pandemic","","NCT04604119","1577","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04604119","Completed","2020-05-01","2020-06-01","{""locations"":""Sisli Hamidiye Etfal Education and Training Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""104"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety|Burnout""}"
"3017","A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults","","NCT04661839","EBS-CVH-003","Biological: COVID-HIGIV|Other: Placebo (saline)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04661839","Recruiting","2020-12-24","2021-09-01","{""locations"":""Icahn School of Medicine at Mount Sinai, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of Subjects with Adverse Events (AEs) post-dosing|Number of Subjects with Adverse Events that Led to Discontinuation or Temporary Suspension of IV Infusion|Number of Subjects with AEs after a Single IV Infusion|Number of Subjects with SAEs after a Single IV Infusion|Number of Subjects with AEs after a Repeat IV Infusion|Number of Subjects with SAEs after a Repeat IV infusion|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of SARS-CoV-2 antibodies after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of SARS-CoV-2 antibodies plus the additional area extrapolated to infinity (AUC0-inf) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 14 days (AUC0-14d) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 28 days (AUC0-28d) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of maximum observed concentration (Cmax) of SARS-CoV-2 antibodies observed after a single dose of COVID-HIGIV|Pharmacokinetics parameter of time at which Cmax occurs after a single dose of COVID-HIGIV|Pharmacokinetics parameter of trough concentration of SARS-CoV-2 antibodies observed 28 days after a single dose (Cmin28d) of COVID-HIGIV|Pharmacokinetics parameter of terminal elimination constant after a single dose of COVID-HIGIV|Pharmacokinetics parameter of apparent terminal elimination half-life after a single dose of COVID-HIGIV|Pharmacokinetics parameter of systemic clearance after a single dose of COVID-HIGIV|Pharmacokinetics parameter of volume of distribution after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 14 days (AUC0-14d) after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 28 days (AUC0-28d) after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of maximum observed concentration (Cmax) of SARS-CoV-2 antibodies observed after initial dose and repeat dose of COVID-HIGIV.|Pharmacokinetics parameter of time at which Cmax occurs after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of trough concentration of SARS-CoV-2 antibodies observed 28 days after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of accumulation ratios after repeat dose over initial dose of COVID-HIGIV""}"
"3018","Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism","","NCT04558125","ML42522","Drug: TNKase","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04558125","Active, not recruiting","2020-09-08","2022-06-30","{""locations"":""Cedars-Sinai Medical Center, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent improvement in shock index (defined as heart rate divided by systolic blood pressure) 6 hours after the TNK\/placebo bolus.|1. Clinical status at 24 hours after administration of TNK \/ placebo based upon 7-point scale.""}"
"3019","SARS-CoV-2 Disguise Study","Disguise","NCT04395794","CS-COVID-19","Diagnostic Test: SARS-CoV-2-test|Other: SARS-CoV-2 questionnaire survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395794","Recruiting","2020-05-07","2020-11-30","{""locations"":""Meshalkin National Medical Research Center, Novosibirsk, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 positive test|Transformation|Predictors (asymptomatic)|Predictors (symptomatic)|Percentage from different departments""}"
"3020","COVID-19 Pandemic Burden in Severe Mental Disease Patients","PsyCOVID","NCT04357769","152/20","Other: PSS (Perceived Stress Scale)|Other: GAD-7 (7-item Generalized Anxiety Disorder)|Other: PHQ-9 (9-item Patient Health Questionnaire)|Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Other: Zaritt Burden Interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357769","Completed","2020-04-10","2020-04-25","{""locations"":""University of Naples \""Federico II\"", Napoli, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""400"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Perceived Stress Scale (PSS) outcome|Generalized Anxiety Disorder (GAD-7) scale outcome|Patient Health Questionnaire (PHQ-9) scale outcome|Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale outcome|Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale outcome|Caregiver Burden""}"
"3021","Electrical Stimulation for Critically Ill Covid-19 Patients","COVID-19","NCT04685213","H-47781","Device: Electrical Stimulation|Device: Electrical Stimulation - Sham","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04685213","Recruiting","2020-08-18","2021-08-18","{""locations"":""Baylor College of Medicine, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care"",""enrollment"":""20"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in muscle function|muscle fatigue|Change in tissue oxygen saturation|Ankle circumference|Thigh circumference|Foot circumference|Venous Return Flow|Frailty|Length of stay|Major adverse events|instrumental activities of daily living scale|Community engagement Scale|Depression scale|Weight loss|Neuropathy|Change in muscle strength""}"
"3022","Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19","GARDEN","NCT04659109","ACT-CS-006|2020-002733-15","Drug: glenzocimab|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04659109","Not yet recruiting","2020-12-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Progression from moderate to severe respiratory distress assessed at Day 4|All cause mortality at day 40|WHO-COVID-19 Scale|NEWS-2 Scale|Respiratory Rate status (RR)|Hypoxemia status|SpO2 status|CHEST CT-Scan (or in exceptional cases, chest radiogram)|Oxygen-free days|Admission to the ICU|ICU-free days|Hospital-free days|Clinical recovery and Time to Clinical recovery|Cure and Time-to-cure|Incidence, nature and severity of Adverse Events, SAEs, SUSARs and Treatment-Emergent Adverse Events (TEAEs)|Incidence of bleeding-related events|Incidence of hypersensitivity reactions|Changes from baseline on blood pressure|Changes from baseline on heart rate|Changes from baseline on NFS|Changes from baseline on INR\/PTT|Changes from baseline on platelet count|Changes from baseline on plasma fibrinogen level|Changes from baseline on plasma D-Dimers level|Changes from baseline on serum-glucose level|Changes from baseline on urea level|Changes from baseline on creatinemia|Changes from baseline on LFTs (ASAT\/ALAT)|Changes from baseline on CRP level|Changes from baseline on LDH level|Changes from baseline on IL6 level|Changes from baseline on Tnt|Changes from baseline on NT proBNP|Changes from baseline on procalcitonin level|Changes from baseline on ferritin level|ECG over the course of the study versus screening""}"
"3023","The Containing Coronavirus Disease 19 (COVID-19) Trial","ConCorD-19","NCT04552379","200703013","Biological: Peginterferon beta-1a","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04552379","Recruiting","2020-12-01","2021-12-01","{""locations"":""Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1240"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of index cases shedding SARS-CoV-2, at Day 11, in the active arm compared to the standard of care arm.|The proportion of household contacts shedding SARS-CoV-2, at Day 11, in the active arm compared to the standard of care arm.|Duration (in days) of SARS-CoV-2 by PCR of samples taken on study days 1, 6, 11, 16, 21, and 29.|Number of household contacts of participants in the IFN arm with positive upper airway PCR compared to that in the standard of care arm at day 1 & 11, and seroconversion (Ig) over the study period, up to day 29.|The proportion of infected cases in the active arm that are hospitalised or die due to COVID-19, as compared to the proportion in the standard of care arm.|Incidence and severity of reported adverse events in the interferon arm compared to the standard of care arm.""}"
"3024","Immunoregulatory Therapy for 2019-nCoV","","NCT04268537","2020YFC0841300-03","Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04268537","Not yet recruiting","2020-02-10","2020-10-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days""}"
"3025","FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia","FX-COVID","NCT04618042","APHP200495|2020-002056-20","Drug: FX06|Drug: Placebo of FX06","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04618042","Recruiting","2020-11-13","2021-07-01","{""locations"":""Service de M\u00e9decine Intensive R\u00e9animation - CHU Angers, Angers, France|Service de M\u00e9decine Intensive R\u00e9animation - CHI de Poissy, Chambourcy, France|H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in extravascular lung water index (EVLWi)|Evolution of daily extravascular lung water index (EVLWi)|Evolution of daily cardiac index|Evolution of global end-diastolic volume index|Evolution of pulmonary vascular permeability index|Overall survival|Mortality rate in ICU and in hospital|Rate of withdraw or withhold life-sustaining treatments decision|Daily weight|Daily fluid balance|Evolution of albuminemia|Duration of mechanical ventilation|Proportion of participants alive and off invasive mechanical ventilation|Evolution of Murray ARDS severity score|Evolution of radiological Weinberg score|Evolution of pulmonary Sequential Organ Failure Assessment) score.|Rate of rescue therapy with Veino-veinous V-ECMO|Evolution of SOFA (Sequential Organ Failure Assessment) score|Organ failure free days|Renal replacement therapy free days|Duration of renal replacement therapy free days|Nature and frequency of adverse events|Evolution of FX06 concentration|Immunogenicity (antibody against FX06) induced by the drug, performed by ELISA according to manufacturer's procedure""}"
"3026","Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE)","VADER","NCT04375774","2020/15AVR/226","Device: FFP2|Device: Facial mask|Device: MFS","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04375774","Recruiting","2020-05-01","2020-05-01","{""locations"":""Cliniques Universitaires Saint-Luc, Brussels, Belgium"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""10"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Evaluation of airtightness (Fit test)|User Comfort|Breathing easiness|Field of view quality|Ease of use""}"
"3027","Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects","","NCT04523571","BNT162-03","Biological: BNT162b1|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04523571","Active, not recruiting","2020-07-28","2021-08-01","{""locations"":""Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""144"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of solicited local reactions in the subjects (e.g., vaccination sites: pain\/tenderness, erythema\/redness, induration\/swelling) during the 14-days after each dose of BNT162b1 or placebo.|Occurrence of solicited systematic reactions (e.g., nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) during 14-day after each dose of BNT162b1 or placebo.|Occurrence of adverse event (AE) associated with vaccination in subjects during the 21-day period after prime vaccination of BNT162b1 or placebo.|Occurrence of AE associated with vaccination in subjects during the 28-day period after boost dose of BNT162b1 or placebo.|The proportion of subjects experiencing serious adverse events (SAEs), occurring up to Day 21 after prime vaccination and Day 28 after boost vaccination, up to Month 3, 6 and 12.|The proportion of subjects experiencing AE associated with BNT162b1, occurring up to Month 3, 6 and 12.|The proportion of subjects experiencing abnormal markers of hematology, blood chemistry and urine analysis, occurring at Hour 24 and Day 7 after prime vaccination and Day 7 period after boost dose of BNT162b1 or placebo.|Geometric mean titer (GMT) of anti-S1 IgG antibody at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|GMT of anti-receptor binding domain (RBD) immunoglobulin G (IgG) antibody at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|GMT of SARS-CoV-2 neutralizing antibody (including true virus-based SARS-CoV-2 neutralizing test) at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|Fold increase in antibody anti-S1 IgG antibody titers, as compared to baseline, at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|Fold increase in antibody anti-RBD IgG antibody titers, as compared to baseline, at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|Fold increase in SARS-CoV-2 neutralizing antibody titers (virus neutralizing test), as compared to baseline, at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|Seroconversion rates (SCR) defined as a minimum of 4-fold increase of antibody titers, as compared to baseline, at Day 7, Day 21 after prime vaccination, and at Day 7, Day 21 after boost vaccination.""}"
"3028","Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis","Isavu-CAPA","NCT04707703","200639","Drug: Isavuconazonium Injection [Cresemba]|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04707703","Not yet recruiting","2021-01-01","2022-03-01","{""locations"":""University of California Irvine, Orange, California, United States|University of California Davis, Sacramento, California, United States|University of California San Diego, San Diego, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""162"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of SARS-CoV-2-associated invasive aspergillosis at time of ICU discharge|The incidence of SARS-CoV-2-associated non-Aspergillus invasive fungal infections at time of ICU discharge|Survival|Length of ICU stay|Length of Hospital stay|Mortality|Adverse events""}"
"3029","Advanced Endoscopy During COVID-19","","NCT04385147","Global-Endo-COVID","Other: Endoscopic management according to standard of care","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385147","Completed","2020-05-18","2020-07-05","{""locations"":""Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Al-Azhar Univerisity, Cairo, Egypt|University Medicine Greifswald, Greifswald, Germany|2- Hospital Guillermo Kaelin De la Fuente - EsSalud, Lima, Peru|Singapore General Hospital, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""670"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Age, gender, nationality|Indication for procedure, status of SARS-CoV-2 infection|Complete blood count and liver functions tests|procedure related complications|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on staff number""}"
"3030","Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus","COSTA","NCT04355052","7092-20-SMC","Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04355052","Recruiting","2020-04-11","2020-12-11","{""locations"":""Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""250"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death""}"
"3031","Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation","RHUMACOVID","NCT04393233","RHUMACOVID ( 29BRC20.0110)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393233","Recruiting","2020-04-23","2020-05-23","{""locations"":""CHRU de Brest, Brest, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis""}"
"3032","Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment","RHUMAJICOVID","NCT04407923","RHUMAJICOVID (29BRC20.0148)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407923","Recruiting","2020-05-25","2020-11-25","{""locations"":""CH de Belfort, Belfort, France|CHU de Bordeaux, Bordeaux, France|CHRU de Brest, Brest, France|AP-HP H\u00f4pital Kremlin-Bic\u00eatre, Le Kremlin-Bic\u00eatre, France|CHU de Poitiers, Poitiers, France|CHU de Rennes, Rennes, France|CHU de Strasbourg, Strasbourg, France|CHU de Nancy, Vand\u0153uvre les Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis""}"
"3033","Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection","Familles-COVID","NCT04385121","7761","Other: Questionnary","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385121","Recruiting","2020-04-16","2021-03-01","{""locations"":""Les H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Existence of a post-intensive care syndrome-family ((combined score of the HAD ( Hospital Anxiety and D\u00e9pression scale) and IES-R ( Impact of Event Scale-Revised) questionnaires))""}"
"3034","CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms","CANDIDATE","NCT04467918","CANDIDATE study","Drug: Cannabidiol|Other: PLACEBO","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04467918","Active, not recruiting","2020-07-06","2020-12-16","{""locations"":""Servi\u00e7o de Assist\u00eancia M\u00e9dica e Social do Pessoal do Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo, Ribeir\u00e3o Preto, SP, Brazil|Unidade de Pronto Atendimento\/UPA - 13 de Maio\/Dr. Luis At\u00edlio Losi Viana (UPA Covid), Ribeir\u00e3o Preto, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevention of severe\/critical stage of Covid19|Time to CoVid19 symptoms relief and number of participants with negative Clinical CoVid19 symptoms as assessed by CTCAE v5.0|Change in proinflammatory cytokine concentration|Describe the parenchymal lung damage induced by COVID-19 through a qualitative analysis with chest CT|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Time to clinical improvement with CTCAE v5.0 CoVid19 symptoms to 0|Number of participants that need hospitalisation|28-day mortality|Time to positive-to-negative saliva 2019-n-CoV RT-PCR conversion|Reduction in viral load|Brief measure for assessing generalized anxiety disorder and depression|Increment of odor detection sensitivity""}"
"3035","Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019","COVID-19","NCT04609774","1345","Other: Severe Acute Respiratory Syndrome CoronaVirus 2 detection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04609774","Completed","2020-10-08","2020-12-01","{""locations"":""Hospital Italiano de Buenos Aires, Ciudad aut\u00f3noma de Buenos Aires, Argentina"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""8"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Airborne transmission of Severe Acute Respiratory Syndrome CoronaVirus 2""}"
"3036","Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)","COMBAT-19","NCT04397497","COMBAT-19","Drug: Mavrilimumab|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04397497","Not yet recruiting","2020-05-22","2020-11-22","{""locations"":""IRCCS Policlinico San Donato, San Donato, MI, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|IRCCS Istituto Ortopedico Galeazzi, Milano, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in the dependency on oxygen supplementation|Proportion of responders (using the WHO 7-point ordinal scale)|Time to response (using the WHO 7-point ordinal scale)|Proportion of improving patients (using the WHO 7-point ordinal scale)|Time to resolution of fever|Reduction in case fatality|Proportion of patient requiring mechanical ventilation\/deaths|Change in biochemical markers|Median changes in the National Early Warning Score 2 (NEWS2)|Time to clinical improvement as evaluated with the National Early Warning Score 2 (NEWS2)|Variations in radiological findings|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]""}"
"3037","Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic","","NCT04400877","SE2020-02701","Diagnostic Test: Diagnostic examination for venous thromboembolism","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04400877","Completed","2020-06-08","2020-09-30","{""locations"":""University Hospital Link\u00f6ping, Link\u00f6ping, \u00d6sterg\u00f6tland, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""7795"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic?|Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism?|Are there geographic differences in the prevalence of venous thromboembolism within the healthcare system?|Is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities?|How long is the time between symptom onset of the SARS-CoV-2-infection and any subsequent venous thromboembolism?|Is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival?""}"
"3038","The Impact of COVID-19 Outbreak on Trans-population's Health in Italy","","NCT04448418","TRANSCOVID-19","Other: web based survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04448418","Active, not recruiting","2020-05-20","2020-11-20","{""locations"":""1Gynecology and Physiopathology of Human Reproduction, S. Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""300"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of the specific health need of the transpopulation during the COVID-19 pandemic in Italy|Assessment of risk factors for COVID-19 infection in the traspopulation|Evaluation of the satisfaction of this population with telemedicine for hormonal treatment monitoring|Evaluation of the psychological wellbeing of the trans-population during COVID-19 outbreak in Italy|Evaluation of the psychological and physical wellbeing of the trans-population during COVID-19 outbreak in Italy""}"
"3039","NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","NATADEX","NCT04452565","NATADEX","Drug: Drug: NA-831|Combination Product: NA-831 and Atazanavir|Combination Product: NA-831and Dexamethasone|Combination Product: Atazanavir and Dexamethasone","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04452565","Recruiting","2020-10-15","2021-02-15","{""locations"":""Coronavirus Research Institute- Testing Site, Los Angeles, California, United States|Coronavirus Research Institute, Orange, California, United States|Coronavirus Research Institute-Testing Site, Palo Alto, California, United States|Coronavirus Research Institute-Testing Site, Sacramento, California, United States|Coronavirus Research Institute-Testing Site, San Diego, California, United States|Coronavirus Research Testing Site, San Francisco, California, United States|Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States|Coronavirus Research Institute-Testing Site, Fort Lauderdale, Florida, United States|Coronavirus Research Institute-Testing Site, Tampa, Florida, United States|Coronavirus Research Institute- Testing Site, Chicago, Illinois, United States|Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States|Coronavirus Research Institute-Testing Site, Baltimore, Maryland, United States|Coronavirus Research Institute-Testing Site, Bethesda, Maryland, United States|Coronavirus Research Institute-Testing Site, Boston, Massachusetts, United States|Coronavirus Research Institute-Testing Site, Worcester, Massachusetts, United States|Coronavirus Research Institute-Testing Site, Ann Arbor, Michigan, United States|Coronavirus Research Institute-Testing Site, Detroit, Michigan, United States|Coronavirus Research Institute-Testing Site, Newark, New Jersey, United States|Coronavirus Research Institute-Testing Site-, Bronx, New York, United States|Coronavirus Research Institute-Testing Site, New York, New York, United States|Coronavirus Research Institute- Testing Site, Rochester, New York, United States|Coronavirus Research Institute-Testing Site, Durham, North Carolina, United States|Coronavirus Research Institute-Testing Site, Philadelphia, Pennsylvania, United States|Coronavirus Research Institute- Testing Site, Fort Sam Houston, Texas, United States|Coronavirus Research Institute-Testing Site, Galveston, Texas, United States|Coronavirus Research Institute-Testing Site, Houston, Texas, United States|Coronavirus Research Institute-Testing Site, Kirkland, Washington, United States|Coronavirus Research Institute-Testing Site, Seattle, Washington, United States|Coronavirus Research Institute-Testing Site, Tacoma, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""525"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""1. Time (Hours) to recovery|Time fever resolution""}"
"3040","Impact of COVID-19 on Lung Cancer Patients","","NCT04538456","CFTSp189","Other: questionnaire and optional interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04538456","Recruiting","2020-10-15","2021-04-01","{""locations"":""The Christie NHS Foundation, Manchester, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical and Social impact|Psychological impact|prevalence and impact of frailty""}"
"3041","Screening of Cancer Patients to Assess Impact of COVID-19","","NCT04373005","U-DEPLOY: RESPONSE|CAPCR 20-5337","Diagnostic Test: Nasopharyngeal (NP) swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373005","Active, not recruiting","2020-05-11","2021-06-30","{""locations"":""Princess Margaret Cancer Centre, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Rate of asymptomatic COVID-19 infection among cancer patients receiving cancer therapy|Rate of sero-conversion in cancer patients|Describe the clinical course of COVID-19 infection in cancer patients""}"
"3042","Obstructive Sleep Apnea & Covid-19 Outcomes","OSACOVID-19","NCT04363333","2020.140.IRB1.030","Diagnostic Test: Home Sleep Apnea Testing or In-hospital Polysomnography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363333","Active, not recruiting","2020-04-27","2021-07-31","{""locations"":""Marmara University Hospital, Istanbul, Basibuyuk, Turkey|Koc University, Istanbul, Turkey|Koc Healthcare Istanbul American Hospital, \u0130stanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""320"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The rate of clinical improvement|Clinical status - improvement|Clinical status - worsening""}"
"3043","Home Management of Adult Egyptian Mild COVID-19 Cases","COVID-19","NCT04515199","Telemedicine in Mild COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04515199","Recruiting","2020-07-01","2021-03-01","{""locations"":""Faculty of Medicine Cairo University, Cairo, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent of adherence to isolation measures|The incidence of symptoms and their duration|Change in Short Form 35 (SF-36) Questionnaire|Cost- effectiveness of Home Isolation vs hospital admission in mild COVID-19 cases|Identifying the duration of post-COVID-19 symptoms|long-term respiratory complications""}"
"3044","Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19","","NCT04447781","IVI COVID19-001","Biological: INO-4800|Device: CELLECTRA® 2000|Other: Saline-sodium citrate (SSC) buffer","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04447781","Recruiting","2020-07-15","2022-02-22","{""locations"":""Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""160"",""age"":""19 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Primary Outcome Measures""}"
"3045","Cardiac Dysfunction in Critically Ill Patients With COVID-19","CARDYCOVID","NCT04524234","CARDY CRIT COVID","Diagnostic Test: Echocardiography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04524234","Completed","2020-04-20","2020-09-30","{""locations"":""S\u00f6dersjukhuset, Stockholm, Region Stockholm, Sweden|North \u00c4lvsborg County Hospital, Trollh\u00e4ttan, V\u00e4stra G\u00f6talandsregionen, Sweden|Sahlgrenska University Hospital\/M\u00f6lndal, Gothenburg, V\u00e4stra G\u00f6taland, Sweden|Sahlgrenska University Hospital\/\u00d6stra, Gothenburg, V\u00e4stra G\u00f6taland, Sweden|Sahlgrenska University Hospital, Gothenburg, V\u00e4stra G\u00f6taland, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""132"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Left ventricular dysfunction|Right ventricular dysfunction|Risk-factors|Cardiac biomarkers""}"
"3046","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","","NCT04330495","EnCOVID-HidroxiCLOROQUINA","Drug: Hidroxicloroquina|Drug: Control group","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04330495","Not yet recruiting","2020-04-06","2020-11-06","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""800"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence rate of new COVID-19 cases in both arms|Prevalence of COVID-19 cases in both arms|Mortality rate secondary to COVID-19 cases in both groups|Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups|Adverse events""}"
"3047","""Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women""","","NCT04384887","beckcovid","Behavioral: covid-19 positive pregnant women","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384887","Completed","2020-04-25","2020-08-26","{""locations"":""Pinar Yalcin Bahat, Istanbul, \u0130\u0307stanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Evaluation of depression and anxiety score changes of covid-19 positive pregnants""}"
"3048","Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)","HCQPreP","NCT04363450","LSU NO HSC IRB 20-050","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04363450","Recruiting","2020-04-27","2021-06-01","{""locations"":""Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of symptomatic COVID-19 infection in healthcare workers|Absenteeism from work due to COVID-19|Severity of COVID-19 infection""}"
"3049","Long Term Outcomes of Patients With COVID-19","COVID19 LTFU","NCT04360538","20-0538","Other: Quality of Life|Other: Impact Event Score|Other: Hospital anxiety and depression scale","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04360538","Recruiting","2020-04-08","2021-12-30","{""locations"":""University of Chicago Medical Center, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Quality of Life score|cognitive dysfunction|Functional Status Score|Physical Disability|Psychological Sequelae""}"
"3050","Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.","MeCOVID","NCT04353128","MeCOVID","Drug: Melatonin 2mg|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04353128","Recruiting","2020-04-20","2020-12-01","{""locations"":""Hospital Universitario La Paz, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""450"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV 2 infection rate""}"
"3051","Detection of COVID-19 in Saliva Collection","SALICOV","NCT04386551","PI2020_843_0045","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386551","Completed","2020-05-06","2020-08-05","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""501"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Detection of SARS-CoV-2 RNA in the saliva sample|Concordance between the Saliva sample and the nasonasopharyngeal sample SARS-CoV-2 RT-PCR results""}"
"3052","NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis","","NCT04638673","00101270|U54GM104941-08","Device: Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Device: Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04638673","Recruiting","2020-11-19","2021-06-01","{""locations"":""Medical University of South Carolina, Charleston, South Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Score of Patient Health Questionnaire-9""}"
"3053","One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU)","CO-Qo-ICU","NCT04401111","20reamedcovid04","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401111","Recruiting","2020-06-16","2021-06-15","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of recovery of quality of life in first year after ICU discharged in patients hospitalised for severe pneumonia at SARS-CoV2|Evaluation of respiratory function during first year after ICU discharged in population studied|Evaluation at 1 year of evolution of functional exercises capacity in population studied|Evaluation of evolution of renal function during first year after ICU discharged in population studied|Evaluation of evolution of right and left myocardic function during first year after ICU discharged in population studied|Evaluation at 1 year of incidence of psychiatric pathology|Evaluation at 1 year of consequences in professional activity in population studied""}"
"3054","Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)","","NCT04684550","FM-CIE-0824-20","Drug: Stabilized hypochlorous acid|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04684550","Not yet recruiting","2021-02-15","2021-08-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""556"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevention of infection by COVID19|Adverse drug reaction (ADR)|Seroconversion|Hospitalization|ICU""}"
"3055","SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study","","NCT04494776","30631820.0.1001.8098","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04494776","Recruiting","2020-05-21","2022-04-02","{""locations"":""Hospital do Rim, S\u00e3o Paulo, A\u00e3o Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Death|Graft loss|Hospitalization""}"
"3056","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury","","NCT04340921","282289","Biological: COVID-19 exposure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04340921","Recruiting","2020-05-14","2021-11-10","{""locations"":""Barts Health Nhs Trust, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""T-cell immunophenotype|Mortality|ITU admission|Myocardial injury""}"
"3057","NOsocomial Dissemination Risk of SARS-Cov2","NODS-Cov2","NCT04339881","APHP200417","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339881","Completed","2020-04-17","2020-07-12","{""locations"":""Didier Guillemot, Garches, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""2523"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Understanding the dissemination of SARS Cov2 in hospital|Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2""}"
"3058","COVID-19 Immune Repertoire Sequencing","IMSEQ","NCT04368143","IMSEQ","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368143","Recruiting","2020-04-01","2021-12-31","{""locations"":""Universitairy hospital of Antwerp, Antwerp, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""provide proof-of-concept that (longitudinal) B cell repertoire mining allows identification of emerging virus specific B cell receptor variable regions.|study evolutions in B and T cell repertoires to understand COVID-19 specific immune responses fundamentally.|clinical and epidemiological description of UZA hospitalized COVID-19 patients""}"
"3059","Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota","","NCT04473183","SURG-2020-28863","Diagnostic Test: Specimen Collection|Diagnostic Test: Surveys","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473183","Recruiting","2020-07-21","2022-01-01","{""locations"":""University of Minnesota, Minneapolis, Minnesota, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of Symptomatic Infection|Prevalence of Subclinical Infection""}"
"3060","A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19","TriACT","NCT04605588","Pro2020001862","Drug: Nitazoxanide|Drug: Placebo Nitazoxanide|Drug: Ribavirin|Drug: Placebo Ribavirin|Drug: Hydroxychloroquine|Drug: Placebo Hydroxychloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04605588","Recruiting","2020-12-02","2021-04-01","{""locations"":""Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of decline in viral load over the 10 days after randomization""}"
"3061","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","COVID-19-HBO","NCT04327505","COVID-19-HBO|2020-001349-37|K-1199/2020","Drug: Hyperbaric oxygen","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04327505","Recruiting","2020-06-03","2022-12-31","{""locations"":""Bergmannsheil und Kinderklinik Buer GmbH, Gelsenkirchen, Germany|Krankenhaus St. Joesf, Regensburg, Germany|Medical Centre Maria Brasov, Bra\u015fov, Romania|Blekingesjukhuset, Karlskrona, Blekinge, Sweden|Sahlgrenska University hospital, \u00d6stra sjukhuset, Gothenburg, Sweden|Karolinska University Hospital, Stockholm, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU admission|30-day mortality|Time-to-intubation|Time-to-ICU|Inflammatory response|Overall survival""}"
"3062","Rehabilitation in Intensive Care Unit","","NCT04713540","intensive care unit","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04713540","Recruiting","2021-01-01","2021-05-01","{""locations"":""Bakirkor Dr. Sadi Konuk Research and Training hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""58"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Glaskow coma scale|APACHE II|mMRC Dyspnea Scale""}"
"3063","Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic","","NCT04375410","SH042020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375410","Enrolling by invitation","2020-04-22","2020-05-01","{""locations"":""Tine Caroc Warner, Hj\u00f8rring, Nordjylland, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""7000"",""age"":""up to 13 Years \u00a0 (Child)"",""outcome_measures"":""Dermal reaction to frequent hand wash and disinfection in children""}"
"3064","CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals","CORONA","NCT04402879","REB20-0518","Procedure: Prone Positioning (PP)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04402879","Recruiting","2020-11-10","2022-06-01","{""locations"":""Peter Lougheed Centre (PLC), Calgary, Alberta, Canada|Foothills Hospital Intensive Care Unit, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""596"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital mortality or discharge to hospice|Adverse Events and Serious Adverse Events|Change in SpO2|Hospital free days|Admission to ICU|Intubation and mechanical ventilation|Initiation of non-invasive ventilation (NIV) or high-flow nasal oxygen (HFNO).|Oxygen-free days|In-hospital death (time)|Death at 90 days""}"
"3065","Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases","COVID-RIC1","NCT04655612","RECHMPL20_0624","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04655612","Recruiting","2020-12-01","2021-07-30","{""locations"":""Centre hopsitalier universitaire de Montpellier, Montpellier, Occitanie, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis|Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.|Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease|Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics""}"
"3066","COVID19-hematological Malignancies: the Italian Hematology Alliance","","NCT04352556","HM-COVID19-Italy","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04352556","Recruiting","2020-04-07","2021-04-30","{""locations"":""SC Ematologia Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|UOC Ematologia, Ospedali Riuniti, Ancona, Italy|UOC Ematologia e Terapia Cellulare, Ospedale Mazzoni, Ascoli Piceno, Italy|SC Oncologia Medica, CRO, Aviano, Italy|SC Ematologia, Policlinico Bari, Bari, Italy|UOC Ematologia, I.R.C.C.S Istituto Tumori Giovanni Paolo II, Bari, Italy|SSD Ematologia, Ospedale degli Infermi, Biella, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi,, Bologna, Italy|Ematologia e Centro Trapianto Midollo Osseo, Ospedale di Bolzano, Bolzano, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UOC Onco-Ematologia ASST Valle Olona, Busto Arsizio, Italy|SC Ematologia e CTMO AZIENDA OSPEDALIERA \""G. BROTZU\"" - OSPEDALE ONCOLOGICO BUSINCO, Cagliari, Italy|UOC Ematologia, AOU Policlinico Vittorio Emanuele, Catania, Italy|Ematologia, Ospedale Valduce, Como, Italy|UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy|UO Ematologia e CTMO, ASST Cremona, Cremona, Italy|SC Ematologia Ospedale S. Croce, Cuneo, Italy|UOC, Ematologia Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Italy|S.O.D. Ematologia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|UOC Ematologia, Policlinico Ospedali Riuniti, Foggia, Italy|IRST-IRCC di Meldola, Forl\u00ec, Italy|UO Ematologia, Ospedale Policlinico S.Martino IRCCS, Genova, Italy|UO Ematologia, Ospedale Policlinico San Martino, Genova, Italy|UOC di Ematologia e Trapianto di Cellule Staminali, P.O. Vito Fazzi, Lecce, Italy|UOC di Ematologia, Ospedale di Legnano, Legnano, Italy|UO Dipartimento di Ematologia, USL 6, Livorno, Italy|UOC Oncologia ASST Lodi, Lodi, Italy|UOC Ematologia Azienda Ospedaliera Universitaria \""G.Martino\"", Messina, Italy|UO Ematologia, Ospedale dell'Angelo di Mestre, Mestre, Italy|Ematologia, IEO, Milano, Italy|SC Ematologia, Istituto Nazionale dei Tumori, Milano, Italy|SC Ematologia, Ospedale Niguarda, Milano, Italy|UO Ematologia, IRCCS Ospedale San Raffaele, Milano, Italy|UO Servizio di Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Milano, Italy|UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|UO Ematologia Policlinico di Modena, Modena, Italy|UOC Ematologia, Ospedale S. Gerardo, Monza, Italy|SC Ematologia Istituto Nazionale Tumori - IRCCS \""Fondazione G. Pascale\"",, Napoli, Italy|UOC Ematologia e Trapianti di Midollo, AOU Federico II, Napoli, Italy|UOC Ematologia, Ospedale Antonio Cardarelli, Napoli, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, Novara, Italy|Ospedale san Luigi Gonzaga, Orbassano, Italy|Ematologia Azienda Ospedaliera di Padova, Padova, Italy|UO Ematologia, Policlinico Paolo Giaccone, Palermo, Italy|UOC Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|SC Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|SC Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera di Perugia, Perugia, Italy|UO Ematologia e CTMO, Azienda Ospedaliera Ospedali Riuniti, Pesaro, Italy|UOC di Ematologia, Ospedale Civile Spirito Santo, Pescara, Italy|UO Ematologia e CTMO, Presidio Ospedaliero di Piacenza, Piacenza, Italy|UO Ematologia, AOU Pisana- Santa Chiara, Pisa, Italy|UO Ematologia dell'Ospedale Santa Maria delle Croci, Ravenna, Italy|UOC Ematologia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|SC Ematologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|UO Ematologia, Ospedale Infermi, Rimini, Italy|AOU Azienda Ospedaliera Universitaria Sant'Andrea, Roma, Italy|IFO - Ematologia e Trapianto Cellule -Istituto Nazionale del Cancro di Regina Elena, Roma, Italy|SC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UO Ematologia e Trapianti di Cellule Staminali, A.O. S. Camillo-Forlanini, Roma, Italy|UO Ematologia, Policlinico Tor Vergata, Roma, Italy|UOC Ematologia e trapianto di cellule staminali, Policlinico Universitario Campus Bio-Medico, Roma, Italy|UOC Ematologia Policlinico Umberto I, Roma, Italy|UOC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UOC Ematologia- Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy|UO Ematologia, Istituto Clinico Humanitas, Rozzano, Italy|UOC Ematologia e centro trapianti cellule staminali emopoietiche, AOU San Giovanni Di Dio e Ruggi D'aragona, Salerno, Italy|Ematologia ASL Imperiese, Sanremo, Italy|Medicina Interna ed Ematologia, Asl 1, Savona, Italy|UOC Ematologia, Policlinico Santa Maria alle Scotte, Siena, Italy|UOC Ematologia e Trapianto Midollo Osseo, Ospedale S. G. Moscati, Taranto, Italy|SCDU Ematologia e terapie cellulari, Ospedale Mauriziano Umberto I, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Civili Ca' Foncello, Treviso, Italy|SC Ematologia, Azienda sanitaria universitaria Giuliano Isontina, Trieste, Italy|Clinica Ematologia, Azienda Ospedaliera-Universitaria Santa Maria della Misericordia, Udine, Italy|UOC Ematologia, ASST Sette Laghi, Osp. Di Circolo e Fondazione Macchi, Varese, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Ospedale San Bortolo, Vicenza, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate mortality.|To evaluate potential predictive biochemical parameters of mortality.|To evaluate potential predictive HM-related parameters of mortality.|To evaluate COVID severity as predictive parameter of mortality.|Epidemiology of patients with HM infected by SARS-CoV-2with any spectrum of illness severity|Definition of complete clinical picture of COVID-19 in HM|Evolution of HM|To evaluate admission to ICU requiring mechanical ventilation or death per characteristics|Viral dynamics in infected HM patients""}"
"3067","Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar","DOLCI","NCT04425382","MRC-05-069","Drug: Darunavir/Cobicistat|Drug: Lopinavir/Ritonavir","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04425382","Recruiting","2020-03-01","2020-09-01","{""locations"":""Hamad Medical Corporation, Doha, Qatar"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical Improvement and\/or Virological Clearance (Composite Endpoint)|Percentage of Virological Clearance|Percentage of Clinical Deterioration|Incidence of Adverse Events|Length of Hospital Stay|All-cause Mortality""}"
"3068","COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","COVIDOCRECHE","NCT04413968","APHP200587|2020-A01540-39","Diagnostic Test: Rapid detection test|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Stool collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04413968","Completed","2020-06-02","2020-10-02","{""locations"":""Hopital Avicenne, Bobigny, France|H\u00f4pital Jean Verdier - Service de P\u00e9diatrie, Bondy, France|H\u00f4pital Jean Verdier, Bondy, France|H\u00f4pital Antoine b\u00e9cl\u00e8re, Clamart, France|H\u00f4pital Louis Mourier, Colombes, France|CH intercommunal de Cr\u00e9teil, Cr\u00e9teil, France|H\u00f4pital And\u00e9 Mignot, Le Chesnay, France|H\u00f4pital Trousseau, Paris, France|H\u00f4pital Robert debr\u00e9, Paris, France|CHU de Rouen, Rouen, France|H\u00f4pital Annecy Genevois, \u00c9pagny, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""600"",""age"":""1 Month and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Assess the serological status\/rate of past infections in the children of priority staff in the nursery during the containment period""}"
"3069","HEALthy Brain and Child Development Study - COVID-19 Supplement","","NCT04713150","P00035929","Other: No Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04713150","Recruiting","2020-10-05","2021-11-01","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Laboratories of Cognitive Neuroscience, Boston Children's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Maternal stress associated with a SARS-CoV-2 diagnosis in pregnancy.|Maternal mental health associated with a SARS-CoV-2 diagnosis in pregnancy.|Inventory of maternal experience associated with a SARS-CoV-2 diagnosis in pregnancy.|Inventory of maternal experience related to healthcare associated with a SARS-CoV-2 diagnosis in pregnancy.|Global cognitive ability of offspring|Neural networks of offspring|Early structural and functional brain development of offspring""}"
"3070","Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","CORMOR","NCT04388514","CIG: Z7C2CA5837","Procedure: Medical Ozone procedure","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04388514","Recruiting","2020-04-08","2020-10-08","{""locations"":""Dott. Amato De Monte, Udine, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time of respiratory improvement and earlier weaning from oxygen support|The time of respiratory improvement and earlier weaning from oxygen support|Assessment of the length of hospitalization|Assessment of the length of Intensive Care Unit (ICU) stay|Improvment in chest imaging finding|Improvment in cytokine release syndrome""}"
"3071","COVID-19 Testing Sample Acquisition Throughput and Efficiency","HexapodBooth","NCT04532411","QI Initiative","Other: Personal Protective Testing Booth","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04532411","Completed","2020-03-01","2020-09-30","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""28948"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in Testing Throughput After Hexapod Implementation|Change in Isolation Gowns Utilized After Hexapod Utilization|Change in Cost per Test After Hexapod Implementation|Return on Investment|Change in Testing Personnel Cost Per Test|Change in Cost of Isolation Gowns Utilized""}"
"3072","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury","","NCT04445259","283672","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445259","Recruiting","2020-06-20","2021-05-31","{""locations"":""Guy's & St Thomas' Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of any stage of acute kidney injury|Mortality|Renal recovery|Percentage of patients who receive renal replacement therapy|Percentage of participants who are dialysis dependent|Free-days of vasoactive medications and mechanical ventilation|Length of intensive care unit and hospital stay|Number of participants with consequences following AKI|Time from illness onset to need for mechanical ventilator support""}"
"3073","Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease","","NCT04420364","2020P001516","Other: Maintenance or reduction of immunosuppression","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04420364","Not yet recruiting","2021-03-01","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in IL-6 concentration from baseline to day 7|Change in IL-6 concentration from baseline to day 28|Change in T cell response to SARS-CoV-2|Change in titer of serum anti-SARS-CoV-2 antibodies|Change in COVID-19 disease severity score (range 1 to 8; higher worse)|Proportion of patients needing non-invasive ventilation or intubation|Proportion of patients developing ANC < 500 cells per microliter|Proportion of patients developing lymphopenia < 400 cells per microliter|Length of hospital stay|Proportion of patients developing biopsy-proven acute rejection|In-hospital and 28-day mortality|Adverse and serious adverse events""}"
"3074","A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction","","NCT04382534","M20200421","Combination Product: Respiratory rehabilitation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382534","Recruiting","2020-03-10","2020-12-31","{""locations"":""Huarunwugang general hospital, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms and signs|Respiratory function|The body function|ADL""}"
"3075","Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly","CovAged","NCT04414319","20_RIPH3-02","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04414319","Recruiting","2020-04-15","2023-04-15","{""locations"":""University hospital of Rennes, Rennes, France|Va de Lys-Ramsay Gds group Clinic, Tourcoing, France|Hopsital of Valenciennes, Valenciennes, France|University hospital of Guadeloupe, Les Abymes, Guadeloupe|University hospital of Martinique, Fort-de-France, Martinique"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""350"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Loss of autonomy|Hospital readmission|Nursing home admission|All-cause mortality|change in self-rated health""}"
"3076","Renal Biomarkers in AKI and COVID-19","","NCT04517630","C26-20","Diagnostic Test: urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04517630","Recruiting","2020-06-01","2022-09-30","{""locations"":""Centro de Investigacion en Enfermedades Infecciosas, Mexico City, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Urinary levels of renal biomarkers|Incidence of AKI|Urinary levels of renal biomarkers and mortality|Urinary levels of renal biomarkers and severity of the disease.|Risk factors for AKI in severe COVID-19|Evolution renal biomarkers|Evolution of viral load|Evolution of complement pathway|Metabolomic profile|Respiratory changes""}"
"3077","Mindfulness During COVID-19","","NCT04319445","IRB00064587","Behavioral: Mindfulness session(s)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04319445","Active, not recruiting","2020-03-22","2021-06-01","{""locations"":""Wake Forest Health Sciences, Winston-Salem, North Carolina, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""233"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference""}"
"3078","Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)","","NCT04346277","COV02","Biological: IC14, a monoclonal antibody against CD14","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04346277","Available","1970-01-01","1970-01-01","{""locations"":""IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"3079","AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19","AirFLO2","NCT04649775","Pro00105246","Device: AirFLO2","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04649775","Not yet recruiting","2021-01-30","2021-06-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improve hypoxia as measured by change between baseline P:F ratio and repeat P:F ratio|Subject dyspnea symptoms|Subject cough symptoms|Subject respiratory symptoms|Reduced risk progression of respiratory deterioration|Reduced risk of ICU transfer|Reduced risk for intubation|Reduced hospitalization length of stay|Increased patient survival to discharge""}"
"3080","The Prevalence of Pulmonary Hypertension in Patients With COVID-19.","","NCT04459364","20200422PA","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459364","Completed","2020-06-01","2020-07-15","{""locations"":""Karolinska University Hospital, Stockholm, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""67"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence""}"
"3081","Expanded Access to ZofinTM (OrganicellTM Flow) for Patients With COVID-19","","NCT04657406","19881-EA","Drug: ZofinTM","Expanded Access:Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04657406","Available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"3082","Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19","COVLA","NCT04452604","COVLA","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452604","Not yet recruiting","2020-08-01","2023-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical prognostic factors for infection with COVID-19|Biological prognostic factors for infection with COVID-19|Medical care of Coronavirus infection""}"
"3083","Psychosocial Outcomes in Families of COVID-19 ICU Patients","","NCT04498507","Family COVID","Diagnostic Test: HADS questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04498507","Completed","2020-04-16","2020-10-30","{""locations"":""University Hospital of Li\u00e8ge, Li\u00e8ge, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""39"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""occurence of anxiety and depression|occurence of acute stress|occurence of post-traumatic stress disorder|quality of life""}"
"3084","Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients","COVID_OFF","NCT04425317","COVIDOFF001","Diagnostic Test: Blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04425317","Recruiting","2020-06-24","2021-06-15","{""locations"":""Uz Brussels, Brussels, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""20"",""age"":""up to 45 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium|Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometrium""}"
"3085","Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","COVID-Antibody","NCT04334876","2003973826","Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04334876","Not yet recruiting","2020-04-01","2021-01-01","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""340"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy""}"
"3086","COVID-19 Epidemic Response Study","COVeR","NCT04357496","COVER-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357496","Not yet recruiting","2020-12-20","2021-11-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of prognostic parameters for SARS-CoV-2 infected participants.|Investigation of the kinetics of immune activation and antibody production against SARS-CoV-2 and correlation with clinical course""}"
"3087","Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19","STEPCO","NCT04649918","COVID-Rehab","Other: pulmonary rehabilitation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649918","Active, not recruiting","2020-11-25","2021-04-30","{""locations"":""Sch\u00f6n Klinik Berchtesgadener Land, Sch\u00f6nau Am K\u00f6nigssee, Bavaria, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in 6-minute walk distance|change in endurance shuttle walk distance|Change in Diffusion capacity of the lungs for Carbon monoxide|Change in Forced Vital Capacity|Change in total lung capacity|change in Montreal cognitive assessment test|change in short-form 36 question health survey|change in Patient-Reported Outcomes Measurement Information System - 29 (PROMIS-29)|Change in the scale of general anxiety disorder - 7 questionnaire (GAD-7)|Change in the scale of the patient health questionnaire - Depression (PHQ-D)|Change in prevalence of COVID-19 related dyspnea|Change in prevalence of COVID-19 related cough|Change in prevalence of COVID-19 related cognitive impairment|Change in prevalence of COVID-19 related loss of appetite|Change in general perceived well-being|change in D-Dimer level|change in c-reactive protein level|change in leukocytes level|change in hemoglobin level|change in troponin level|change in pro-brain natriuretic peptide level""}"
"3088","Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF","CCF","NCT04344327","2020-02","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344327","Completed","2020-04-10","2020-04-21","{""locations"":""CHU d'Amiens, Amiens, France|CHU Annecy, Annecy, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Cotentin hospital, Cherbourg, France|CHU Dijon, Dijon, France|Elbeuf Louviers Val de Reuil, Elbeuf, France|CHU de Fr\u00e9jus \/ Saint-Raphael, Fr\u00e9jus, France|Lille Catholic Institute Hospital Group, Lille, Lille, France|CHU de Lyon, Lyon, France|APHM, Marseille, France|Jacques Cartier Private Hospital, Massy, Massy, France|CHR d'Orl\u00e9ans, Orl\u00e9ans, France|Bichat (APHP), Paris, France|Georges Pompidou European Hospital (AP-HP), Paris, France|Institut Mutualiste Montsouris, Paris, Paris, France|CHU de Reims, Reims, France|CHU de Rouen, Rouen, France|CHU Saint Etienne, Saint-\u00c9tienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|Saint Gatien hospital, Tours, France|CHU de Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2878"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death rate|Transfer to intensive care unit|Ventilation analysis|Construction of a predictive score for COVID-19 severe form""}"
"3089","Host-pathogen Interactions During SARS-CoV-2 Infection","HPI-COVID-19","NCT04376476","69HCL20_0342|2020-A01102-37","Biological: Blood sample|Biological: Low or upper respiratory tract sample|Biological: Stool collection or fecal swab|Genetic: Blood sample for whole genome sequencing|Other: phone call","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04376476","Recruiting","2020-05-05","2021-06-05","{""locations"":""Groupement Hospitalier Nord-Daupine, Bourgoin-Jallieu, France|H\u00f4pital femme-m\u00e8re-enfant, Bron, France|H\u00f4pital Louis Pradel, Bron, France|H\u00f4pital Louis Mourier, Colombes, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Hopital de la Croix-Rousse, Lyon, France|H\u00f4pital Edouard Herriot, Lyon, France|H\u00f4pital m\u00e8re - enfant Nantes, Nantes, France|Centre Hospitalier Lyon Sud, Pierre-B\u00e9nite, France|H\u00f4pital Nord de Saint Etienne, Saint-Priest-en-Jarez, France|H\u00f4pital Nord-Ouest, Villefranche-sur-Sa\u00f4ne, France|Centre Hospitalier D'Annecy-Genevois, \u00c9pagny, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""450"",""age"":""up to 70 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Initial biological profile of children and adults with COVID-19 infection|Initial immunological profile of children and adults with COVID-19 infection|Clinical worsening|Evolution of the immunological profile of children and adults with COVID-19|Nasopharyngeal swabs SARS-CoV-2 viral loads of children and adults with COVID-19|titers in specific Immunoglobulin G (IgG) antibodies of children and adults with COVID-19|titers in specific Immunoglobulin M (IgM) antibodies of children and adults with COVID-19|titers in specific Immunoglobulin G (IgM) antibodies of children and adults with COVID-19|Genetic profile of adults with COVID-19 infection""}"
"3090","Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","","NCT04611243","2020.229","Drug: Kaletra and beta interferon","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04611243","Recruiting","2020-05-22","2022-05-21","{""locations"":""Prince of Wales Hospital, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""spirometry|Lung volume|6 minute walk distance|quality of life by SF36 questionnaire|serology and T cell response""}"
"3091","Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19","M2C2","NCT04706533","HUM00178971","Diagnostic Test: Biomarkers of inflammation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04706533","Recruiting","2020-03-23","2021-06-01","{""locations"":""University of Michigan, Ann Arbor, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death, need for mechanical ventilation or need for dialysis|All-cause death|Need for mechanical ventilation|Need for dialysis""}"
"3092","Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic","","NCT04565509","202009060","Behavioral: General Communication Message|Behavioral: Focused/Targeted Message|Behavioral: Best Message Alone|Behavioral: Best Message + Augmented Message or Implementation Strategy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04565509","Recruiting","2020-11-20","2022-09-21","{""locations"":""Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Baltimore, Maryland, United States|University of Missouri, Kansas City, Missouri, United States|Special School District, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""2500"",""age"":""5 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Adoption of weekly testing by each participant|Acceptability of Messaging\/Implementation Strategy|Feasibility of Messaging\/Implementation Strategy|Appropriateness of Messaging\/Implementation Strategy|Number of missed school days by students or work days by staff|Students and staff positive SARS-CoV-2 virus|School-based SARS-CoV-2 transmission events""}"
"3093","Assessment of the Psycho-social Impact of COVID-19 Outbreak","COM-COVID","NCT04378452","COM-COVID","Behavioral: COM-COVID anonimous survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04378452","Active, not recruiting","2020-03-31","2021-06-01","{""locations"":""Fundaci\u00f3 Institut Germans Trias i Pujol, Badalona, Catalonia, Spain|Fundaci\u00f3 Lluita contra la Sida (FLS, Fight AIDS Foundation), Badalona, Catalonia, Spain|Anaxomics biotech, Barcelona, Spain|Fundaci\u00f3 Privada per a la Recerca i la Doc\u00e8ncia Sant Joan de D\u00e9u, Esplugues De Llobregat, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""56442"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Psychological impact of the outbreak, total score|Psychological impact of the outbreak: depression questions score|Psychological impact of the outbreak: anxiety questions score|Psychological impact of the outbreak: stress questions score|Psychological impact of the outbreak: PSTD questions score|Descriptive statistics for the non-psychological questions""}"
"3094","Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia","CCAP","NCT04345289","25032020|2020-001367-88","Biological: Convalescent anti-SARS-CoV-2 plasma|Other: Infusion placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04345289","Recruiting","2020-05-01","2021-06-15","{""locations"":""Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Arhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Herning Hospital, Herning, Denmark|Nordsj\u00e6llands Hospital, Hiller\u00f8d, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Vejle Hospital, Vejle, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality or need of invasive mechanical ventilation|Frequency of adverse events|Frequency of severe adverse events|Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|Ventilator-free days|Organ failure-free days|Duration of ICU stay|Mortality rate|Length of hospital stay|Duration of supplemental oxygen""}"
"3095","Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2","EasyCoV","NCT04337424","RECHMPL20_0170","Diagnostic Test: Sampling salivary","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337424","Completed","2020-04-13","2020-10-07","{""locations"":""UCH Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""627"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Specific detection of SARS-CoV-2 specific RNA|Analytical sensitivity of the LAMP test.|The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG \/ SKILLCELL.|Evaluation of the use of saliva samples compared to nasopharyngeal samples""}"
"3096","COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia","COVIDNOCHE","NCT04381923","843124","Device: Helmet Continuous Positive Airway Pressure (CPAP)|Device: High Flow Nasal Oxygen (HFNO)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04381923","Not yet recruiting","2021-02-15","2022-05-15","{""locations"":""University of Pennsylvania, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator-Free Days (VFD)|ICU and Hospital Length of Stay|Intubation|Renal Replacement Therapy (RRT)|Mortality""}"
"3097","Physical Activity Levels of Hypertensive and Healthy Individuals Under Social Isolation During the COVID-19 Pandemic","","NCT04583345","GO 20/610","Behavioral: Questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04583345","Recruiting","2020-06-01","2021-05-01","{""locations"":""Hacettepe University, Ankara, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""32"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical Activity|Quality of Life Assesment|Evaluation of Individuals Healthy Lifestyle Behaviors|Anxiety and Depression Level""}"
"3098","Anti-Androgen Treatment for COVID-19","","NCT04446429","AB-DRUG-SARS-004","Drug: Proxalutamide|Other: Standard of Care","Interventional","Has Results","Not Applicable","https://ClinicalTrials.gov/show/NCT04446429","Completed","2020-09-15","2021-01-21","{""locations"":""Corpometria Institute, Brasilia, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""262"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Hospitalization""}"
"3099","Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections","","NCT04395911","SCD-005","Device: SCD","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04395911","Recruiting","2020-09-10","2021-12-01","{""locations"":""University of Kentucky, Lexington, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality at Day 60|Dialysis Dependency|Ventilation at Day 28|Mortality at Day 28|Urinary output change|P02\/FiO2 change|Safety Assessments|SCD Integrity""}"
"3100","Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases","covid19 fai2r","NCT04353609","NI_2020_03","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04353609","Recruiting","2020-04-18","2020-12-01","{""locations"":""H\u00f4pital Huriez, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""13770"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death|Proportion of patients who die from a severe form of covid-19|Proportion of patients who present an history of diabetes according to medical records|Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg\/cm2)|Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records|Proportion of patients who present an history of Asthma according to medical records|Proportion of patients who present an history of Hypertension according to medical records|Proportion of patients who present an history of cardiac disease according to medical records|Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records|Proportion of patients who present an history of stroke according to medical records|Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records|Proportion of patients who present an history of cancer according to medical records""}"
"3101","COPE - COVID-19 in Pregnancy and Early Childhood","COPE","NCT04433364","2020-02848 0604","Other: biological samples, questionnaires and interviews","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433364","Recruiting","2020-06-02","2041-06-02","{""locations"":""Falu Hospital, Falun, Dalarna, Sweden|Halmstad lasarett, Halmstad, Halland, Sweden|Varbergs sjukhus, Varberg, Halland, Sweden|Helsingborgs lasarett, Helsingborg, Sk\u00e5ne, Sweden|Sk\u00e5ne Universitetssjukhus, Lund, Sk\u00e5ne, Sweden|Eskiltuna hospital, Eskilstuna, S\u00f6dermanland, Sweden|Boras hospital, Boras, VGR, Sweden|Sahlgrenska Univeristy Hospital, Gothenburg, VGR, Sweden|Ryhovs sjukhus, J\u00f6nk\u00f6ping, Sweden|Kalmar Lasarett, Kalmar, Sweden|Karlstad lasarett, Karlstad, Sweden|Kristiandstad l\u00e4nssjukhus, Kristianstad, Sweden|Skaraborgs sjukhus Sk\u00f6vde, Sk\u00f6vde, Sweden|BB Stockholm, Stockholm, Sweden|Danderyd, Stockholm, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska University Hospital- Huddinge, Stockholm, Sweden|S\u00f6dersjukhuset, Stockholm, Sweden|S\u00f6dert\u00e4lje, Stockholm, Sweden|Sundsvall, Sundsvall, Sweden|Ume\u00e5 University Hospital, Ume\u00e5, Sweden|Uppsala University Hospital, Uppsala, Sweden|V\u00e4ster\u00e5s, V\u00e4ster\u00e5s, Sweden|Ystad, Ystad, Sweden|\u00d6rebro University Hospital, \u00d6rebro, Sweden|Link\u00f6ping University Hospital, Link\u00f6ping, \u00d6sterg\u00f6tland, Sweden|Vrinnevisjukhuset, Norrk\u00f6ping, \u00d6sterg\u00f6tland, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Biobank with linkage to registers|Experiences of pregnancy during a pandemic""}"
"3102","Mental Health Outcomes in Healthcare Workers During COVID-19","","NCT04397848","3189","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397848","Completed","2020-05-14","2020-07-03","{""locations"":""University Health Network, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3852"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of Event Scale - Revised (IES-R)|General Anxiety Disorder (GAD-7)|Patient Health Questionnaire (PHQ-9)|Qualitative Data""}"
"3103","Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions","COVID-TRUST","NCT04517136","2020-COVID19-28|2020-A01937-32","Behavioral: Assessment of work-related stress|Biological: Saliva sample collection|Device: Cardiac and electrodermal recordings|Behavioral: Assessment of behavioral response to emotional stimulation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04517136","Recruiting","2020-09-14","2021-03-14","{""locations"":""Groupement Hospitalier R\u00e9gional de Mulhouse Sud Alsace, Mulhouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Professional burnout|Mindfulness level|Perceived stress level following the emotional stimulation|Parasympathetic flexibility evolution during emotional recall|Sympathetic tone at rest|Corticotropic activation at rest|Mood disorders (anxiety \/ depression)|Post-traumatic stress disorder|Sleep quality""}"
"3104","Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora","PROBIOZOVID","NCT04366089","110/2020","Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04366089","Recruiting","2020-03-26","2020-12-31","{""locations"":""Francesco Pugliese, Rome, RM, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""152"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital|delta in the value of interleukin (IL)-1|delta in the value of IL-6|delta in the value of IL-10|delta in the value of Tumor Necrosis Factor (TNF)-alpha|delta in the value of cluster of differentiation (CD)4+ CD38\/ Human Leukocyte Antigen-DR isotype (HLA-DR)|delta in the value of CD8+ CD38\/ HLA-DR|delta in the value of fecal calprotectin|delta in the value of lipopolysaccharide (LPS)|delta in the value of zonulin|delta in the value of alpha1-antitrypsin""}"
"3105","Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)","PROTECT","NCT04363827","IRST100.47","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363827","Active, not recruiting","2020-05-14","2021-09-01","{""locations"":""Irst Irccs, Meldola, FC, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the proportion of subjects of Group 1 who become symptomatic and\/or swab positive in each arm within 1 month from randomization.|the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.|The proportion of subjects with positive swabs in Group 1 within 1 month from randomization in both arms|The proportion of subjects of Group 1 who become symptomatic in each arm within 1 month from randomization|The proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.|The proportion of subjects of Group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population|Absolute and relative frequencies of Serious Adverse Events|Variation in Quality of Life scores in different time points""}"
"3106","COVID-19 Convalescent Plasma","","NCT04340050","IRB20-0523","Biological: anti-SARS-CoV-2 convalescent plasma","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04340050","Completed","2020-04-10","2020-12-23","{""locations"":""University of Chicago Medicine, Chicago, Illinois, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality)""}"
"3107","Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU and COVID-19","CONFIMID","NCT04513561","2020_51|2020_A01596_33","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04513561","Not yet recruiting","2020-12-01","2021-03-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The answer will be considered positive if the patient answers \""totally agree\"", or \""agree\"", or \""slightly agree\"", or \""neither agree nor disagree\"".|Proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered \""Slightly agree\"", \""Agree\"" or \""Totally agree\"" to question 9 of the lock down questionnaire|Proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered \""yes\"" to question 34 of the lock down questionnaire|Proportion of patients (in percentage and numbers) whose response is considered positive if the patient answered \""Slightly agree\"" or \""Agree\"" or \""Strongly agree\"" to question 38 of the lock down questionnaire|Proportion of patients (in percentages and numbers) whose response will be considered positive to questions 13 and 14 of the lock down questionnaire and comparison between the different specialities filled in in question 3.|Proportion of patients (in percent and numbers) whose response will be considered positive to questions 9, 13, 14, 38 or \""Yes\"" to question 34 of the end of lock down and lock down Evaluation Questionnaire.""}"
"3108","A Study to Explore the Role of Gut Flora in COVID-19 Infection","","NCT04359836","PRG-041","Other: There is no intervention in this study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359836","Recruiting","2020-04-16","2021-07-31","{""locations"":""ProgenaBiome, Ventura, California, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing|Validation of Sequencing Methods""}"
"3109","Serological Study of the Exposure of Personnel to Sars-cov-2","SEROPHUGAC","NCT04422977","SEROPHUGAC","Diagnostic Test: Sars-Cov-2 serology","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04422977","Not yet recruiting","2020-06-08","2020-06-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""900"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff""}"
"3110","The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)","","NCT04405739","EIDD-2801-2004","Drug: EIDD-2801|Drug: Placebo (PB0)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04405739","Recruiting","2020-06-16","2021-05-28","{""locations"":""Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cook County Hospital, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|John Hopkins Hospital, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Howard County General Hospital, Columbia, Maryland, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801|Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS|Number of Participants With any Adverse Events(AEs) as assessed by DAIDS""}"
"3111","Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome","","NCT04411459","273/2020/OSS/AUSLBO","Other: Invasive mechanical ventilation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04411459","Completed","2020-02-01","2020-10-16","{""locations"":""Ospedale Santa Maria Annunziata - Anestesia e Rianimazione, Bagno A Ripoli, FI, Italy|A.O. SS. Antonio, Biagio e Cesare Arrigo - Anestesia e Rianimazione, Alessandria, Italy|Anestesia e Rianimazione - Ospedale Civile di Baggiovara, Baggiovara, Italy|Anestesia e Rianimazione - Ospedale di Bentivoglio, Bentivoglio, Italy|Azienda Unit\u00e0 Sanitaria Locale, Bologna, Italy|Anestesia e Rianimazione - Ospedale Bellaria, Bologna, Italy|Anestesia e Rianimazione - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Anestesia e Terapia intensiva dei trapianti addominali e chirurgia epatobiliare - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Anestesia e Terapia Intensiva Polivalente - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Ospedale SS. Trinit\u00e0 - Anestesia e Rianimazione, Borgomanero, Italy|Anestesia e Rianimazione - Ospedale M. Bufalini, Cesena, Italy|Anestesia e Rianimazione - Ospedale degli Infermi, Faenza, Italy|Anestesia e Rianimazione Universitaria - Arcispedale Sant'Anna Ferrara, Ferrara, Italy|Anestesia e Rianimazione - Ospedale Morgagni - Pierantoni, Forl\u00ec, Italy|Anestesia e Rianimazione - Ospedale di Imola S.Maria della Scaletta, Imola, Italy|Ospedale Santo Stefano - Anestesia e Rianimazione, Prato, Italy|Anestesia e Rianimazione - Ospedale S. Maria delle Croci, Ravenna, Italy|Anestesia e Rianimazione - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Anestesia e Rianimazione - Ospedale di Riccione, Riccione, Italy|Anestesia e Rianimazione - Ospedale Infermi, Rimini, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""470"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of mechanical ventilation and 28 days ventilator free days|ICU Mortality|30 days survival after ICU discharge|90 days survival after ICU discharge|Quality of life at 90 days after ICU discharge measured with 15D instrument|Radiologic aspects - structured description of CT and RX data""}"
"3112","Prognostic Impact of the Nutritional Status of Individuals Aged 70 Years and Older With SARS-CoV-2","CodePRONUT","NCT04672343","PUTOT AOIc 2020","Other: Data collection|Other: Querying the INSEE database","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04672343","Recruiting","2020-10-19","2022-01-01","{""locations"":""Chu Dijon Bourogne, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Death""}"
"3113","Physical Activity a Vital Sign? 40 Steps to Safety Test for Patients With COVID-19","","NCT04618835","283998","Diagnostic Test: 40-Steps-test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04618835","Recruiting","2021-01-11","2021-11-03","{""locations"":""Ysbyty Gwynedd, Menai Bridge, Gwynedd, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in decision to discharge|Hospital|Death|Feasibility of the 40-steps test|Change in heart rate|Change in oxygen saturations|Change in respiratory rate|Change in breathlessness""}"
"3114","Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?","","NCT04352699","20urocovid01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04352699","Completed","2020-03-15","2020-05-01","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of UCI admission for surgery-related complication|Rate of surgery-specific death|Rate of coronaviruse positive serologies""}"
"3115","Nebulised Rt-PA for ARDS Due to COVID-19","PACA","NCT04356833","132151","Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04356833","Recruiting","2020-04-22","2021-01-14","{""locations"":""The Royal Free Hospital, London, United Kingdom"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""16 Years to 70 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""treatment efficacy - Percentage change in PaO2\/FiO2 ratio|Safety as measured by bleeds|Safety as measured by other (non-bleed related) adverse events|Safety as measured by fibrinogen levels|Absolute change in PaO2\/FiO2 ratio|Changes in respiratory compliance|Clinical status as determined by a 7 point ordinal scale|Sequential Organ Failure Assessment (SOFA) score|Follow up period - oxygen free days|Follow up period - ventilator free days|Follow up period - intensive care stay|New oxygen via ventilation use - incidence|New oxygen via ventilation use - duration|Incidence of new mechanical ventilation use|Duration of new mechanical ventilation use|In hospital mortality""}"
"3116","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations","","NCT04378881","COVID19-TRHC-2020-002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04378881","Active, not recruiting","2020-06-01","2021-04-30","{""locations"":""Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Calculate the Medication Risk Score of de-identified participants from Medicare\/Medicaid and commercial health insurance plans using their current drug regimen via our proprietary risk stratification process.|Simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen via our proprietary risk stratification process.|Compare the impact (change) on the Medication Risk Score using the calculate before score and simulated after score following the addition of repurposed drugs for COVID-19 to the drug regimens of patients enrolled in the study.|Measure the effects of various repurposed drugs for COVID-19 on each of the five factors computed by algorithms to derive the Medication Risk Score will be calculated via our proprietary risk stratification process.|Comparison of the Medication Risk Score and the effects of the addition of repurposed drugs on the drug regimen between participants with Medicare\/Medicaid vs. commercial health insurance plans will be assessed.|Measure the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used and the impact of various covariables.""}"
"3117","LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)","","NCT04402957","AB002","Drug: LSALT peptide|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04402957","Recruiting","2020-10-14","2021-06-30","{""locations"":""VA San Diego Healthcare System, San Diego, California, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|LSU Health Shreveport, Shreveport, Louisiana, United States|University of Calgary - Foothills Medical Centre, Calgary, Alberta, Canada|University of Calgary - Peter Lougheed Centre, Calgary, Alberta, Canada|Ankara City Hospital, Ankara, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""45 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of Acute Respiratory Distress Syndrome (ARDS) and Other Organ Injuries|Ventilation-free days|Time on nasal cannula or oxygen masks|28 day mortality - all cause and attributable|ICU and hospitalization length of stay (days)|SARS-CoV2 testing|Need and duration for extracorporeal membrane oxygenation (ECMO)|Vasopressor free days|Radiographic pulmonary assessments|Change in modified Medical Research Council (mMRC) dyspnea and Sequential Organ Failure Assessment (SOFA) scores|Incidence of non-lung disorders|Measures of liver dysfunction|Measures of kidney dysfunction|Measures of cardiac dysfunction|Measures of coagulopathies|Changes in immunogenic responses|Healthcare outcomes|Molecular changes in pro-inflammatory pathways|Pharmacokinetics of LSALT peptide""}"
"3118","Acceptability of Telehealth Triage Using Robotic Systems in COVID-19","","NCT04452695","2020P000957","Device: Doctor Spot","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452695","Completed","2020-03-10","2020-08-10","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acceptance of robotic telehealth system|Willingness to interact with robotic telehealth system|Satisfaction of interacting with a robotic telehealth system|Use of robotic system versus in-person triage""}"
"3119","PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis","PROTECT-ASUC","NCT04411784","284030","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04411784","Active, not recruiting","2020-05-20","2020-07-01","{""locations"":""Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust, Hull, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""16 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Primary outcome measure: The need for in-hospital colectomy or rescue therapy|2.1: Duration and type\/route of steroid use|2.2: 30 day colectomy free survival rates|2.3: Covid-19 infection rates|2.4: Rate of Rescue therapy use|2.5: Duration of hospital stay|2.6: Admission severity scoring|2.7: Readmission rates""}"
"3120","DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury","","NCT04447404","C928-020","Drug: DUR-928|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04447404","Recruiting","2020-09-21","2021-10-01","{""locations"":""Site 02, Chicago, Illinois, United States|Site 01, Detroit, Michigan, United States|Site 03, Newark, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite endpoint of alive and free of organ failure|Occurrence of serious adverse events following treatment|Alive at days 28 and 60|Alive and out of ICU|Alive and out of hospital""}"
"3121","COVID-19 Long-Haulers Study","","NCT04678830","CD15_COVID-19","Drug: Placebos|Drug: Leronlimab (700mg)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04678830","Recruiting","2021-03-01","2021-07-23","{""locations"":""Arthritis & Rheumatic Disease Specialties, Aventura, Florida, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""102"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes from baseline in daily COVID-19-related symptom severity score through Day 56.|Duration of COVID-19 associated symptoms from start of study treatment (Day 0) based on self-assessment using daily symptom diary.|Number of symptom-free days of COVID-19 associated symptoms that were present at the start of study treatment (Day 0) based on self-assessment using daily symptom diary.|Progression (or worsening) of COVID-19-associated symptoms through Day 56 compared to baseline.|\u2022 Change from baseline in PROMIS\u00ae Fatigue Score at Days 28 and 56 and 56.|Change from baseline in PROMIS\u00ae Cognitive Function Score at Days 28 and 56|Change from baseline in PROMIS\u00ae Sleep Disturbance Score at Days 28 and 56.|Duration (days) of hospitalization during the treatment phase|Incidence of hospitalization during the treatment phase""}"
"3122","Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients","","NCT04517162","IRE-3412-20-21-1","Drug: Collagen-Polyvinylpyrrolidone","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04517162","Recruiting","2020-08-19","2021-06-19","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico, Cdmx, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical primary Outcome measure|Immunological secondary outcome measure""}"
"3123","A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois","CONTACT","NCT04611230","H20-308","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04611230","Recruiting","2020-11-05","2021-09-24","{""locations"":""Great Lakes Clinical Trials \/ID# 224874, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants With Evidence of Prior SARS-CoV-2 Infection|Percentage of Participants With Current SARS-CoV-2 Infection|Percentage of Participants With Incidence of SARS-CoV-2 Infection|Percentage of Participants With COVID-19 Hospitalization|Percentage of Participants With Influenza and COVID-like Illness|Time to Infection|Time to Symptom Onset|Time to Symptom Resolution|Change in Quality of Life (QOL)""}"
"3124","COVID-19 Diagnostic Self-testing Using Virtual Point-of-care","","NCT04348864","2020/03/18","Diagnostic Test: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04348864","Recruiting","2020-04-16","2021-04-01","{""locations"":""Neuroganics, Northglenn, Colorado, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical accuracy of the antibody and antigen rapid tests compared to LAMP\/PCR-based test result|Clinical accuracy of the antibody and antigen rapid tests based on Clinical diagnosis|Self-test interpretation of result vs expert clinical image interpretation of result|Ease of self-testing procedure""}"
"3125","Neurocognitive Impairment in Patients With COVID-19","NCoV","NCT04359914","COVID-BRAIN","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359914","Recruiting","2020-04-15","2021-04-01","{""locations"":""Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock, Rostock, Mecklenburg-Vorpommern, Germany"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incidence of delirium\/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19|Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19|Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19|Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge|Length of hospital stay in patients with COVID-19 compared to patients without COVID-19|90-day survival in patients with COVID-19 compared to patients without COVID-19""}"
"3126","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia","","NCT04261426","IVIG-001","Drug: Intravenous Immunoglobulin|Other: Standard care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04261426","Not yet recruiting","2020-02-10","2020-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events""}"
"3127","The RIsk Stratification in COVID-19 Patients in the ICU Registry","RISC-19-ICU","NCT04357275","KEK-ZH-req-2020-00322","Other: ICU treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357275","Recruiting","2020-03-13","2022-03-01","{""locations"":""University Hospital of Zurich, Zurich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""ICU mortality|Hospital mortality|ICU length of stay""}"
"3128","Surgery and Lung Ultrasound in COVID-19 Infection","SOUNDS","NCT04661631","1601","Diagnostic Test: Lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04661631","Recruiting","2020-05-08","2021-11-30","{""locations"":""Fundaci\u00f3n Valle del Lili, Cali, Valle Del Cauca, Colombia"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""451"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The best cut-off point for lung ultrasound to discriminate suspected cases of active SARS-CoV-2 infection|Prevalence of active SARS-CoV-2 infection|Operational characteristics of lung ultrasound|Operational characteristics of each of suspicious lung ultrasound findings|Cut-off point resulting from the lung ultrasound score""}"
"3129","Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19","COR-CARDIO","NCT04374110","1860/2020","Other: Clinical data","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374110","Recruiting","2020-05-05","2021-08-24","{""locations"":""National Institute of Cardiology, Warsaw, Poland"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse events|Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke|Ventilation during hospitalization""}"
"3130","Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery","","NCT04169542","PA18-1077|NCI-2019-07463","Other: Questionnaire Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04169542","Recruiting","2019-05-21","2022-03-31","{""locations"":""MD Anderson in The Woodlands, Conroe, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|MD Anderson League City, League City, Texas, United States|MD Anderson in Sugar Land, Sugar Land, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of financial toxicity|Correlation between economic disruption from coronavirus disease 2019 (COVID-19) and financial toxicity|Relationship between financial toxicity and patient reported quality of life|Relationship between financial toxicity and patient reported satisfaction with breast reconstruction""}"
"3131","Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease","COVID-19_LF","NCT04412395","COVID-19_LF","Dietary Supplement: Lactoferrin (Apolactoferrin)|Drug: Placebo of excipient(s) will be administered","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04412395","Not yet recruiting","2021-06-01","2021-09-30","{""locations"":""National Research Center, Egypt (Clinical and Molecular Pharmacology), Cairo, Giza, Egypt|Clinmax CRO (Clinical Research Organization), Cairo, Egypt|Clinical Trial Unit National Research Center, Cairo, Egypt|Egyptian Military Medical Services (Hospitals), Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""516"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival rate.|Rate of disease remission.|The number of patients with PCR negative results.|Mean change in the disease severity (clinical assessment).|Mean change in blood pressure.|Mean change in heart beats.|Mean change in body temperature.|Mean change in body respiratory rate.|Mean change in oxygen saturation.|Mean change in the ratio in arterial oxygen partial pressure to fractional inspired oxygen (PF ratio).|Mean change in complete blood picture (CBC).|Mean change in C reactive protein (CRP).|Mean change in erythrocyte sedimentation rate (ESR).|Mean change in D-dimer.|Mean change in ferritin.|Mean change in liver Albumin.|Mean change in total and direct Bilirubin.|Mean change in prothrombin time (PT) and partial thromboplastin time (PTT ).|Mean change in aspartate aminotransferase (AST).|Mean change in Alanine Aminotransferase (ALT).|Mean change in Blood Urea Nitrogen (BUN).|Mean change in Serum Creatinine.|Mean change in Serum Creatinine clearance.|Mean change in Glomerular filtration rate (GFR ).|The mean change in serum interleukin-1 (IL-1).|The mean change in serum interleukin-6 (IL-6).|The mean change in serum interleukin-10 (IL-10).|The mean change in serum tumor necrosis factor-alpha (TNF alpha).|Mean changes in immunoglobulin G (IgG).|Mean changes in immunoglobulin M (IgM).|The mean change in PCR viral load.|Mean change in lung CT manifestation.|Nature and severity of Adverse Events.|Time for lung recovery.|The number of missed drug doses among each treatment group.""}"
"3132","Characteristics of Patients and Healthcare Workers With COVID-19 in Meta State, Colombia","","NCT04456426","GRIVI_2020_01COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04456426","Not yet recruiting","2020-07-01","2020-08-01","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""up to 120 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality|ICU admission|Mechanical ventilation|ICU length of stay|Hospital length of stay|Days of mechanical ventilation""}"
"3133","Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia","","NCT04597242","CF-301-107","Drug: Exebacase","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04597242","Available","1970-01-01","1970-01-01","{""locations"":""CF-301-107 Study Site, Butte, Montana, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"3134","Understanding Potential Airborne Transmission and the Protective Value of Type II Surgical Masks in SARS-CoV-2","aeroCOVID1","NCT04698837","2020-02768","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04698837","Not yet recruiting","2021-01-01","2021-06-01","{""locations"":""University Hospital Bern, Bern, Switzerland"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""30"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total amount of dummy-inhaled virus copies per 30 minutes sampling per size fraction (>10 \u00b5m, <10 \u00b5m)|Viability of dummy-inhaled viable virus per size fraction (>10 \u00b5m, and <10 \u00b5m)|Reduction of dummy-inhaled virus copies per 30 minutes sampling in a type II-masked setup, as compared to unmasked, per size fraction (>10 \u00b5m, <10 \u00b5m)""}"
"3135","COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","PRIORITY","NCT04323839","20-30410","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04323839","Enrolling by invitation","2020-03-20","2024-03-31","{""locations"":""University of California, San Francisco, San Francisco, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""13 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical presentation|Disease prognosis outcomes|Pregnancy outcomes|Obstetric outcomes|Neonatal outcomes|Modes of transmission of COVID-19""}"
"3136","COVID-19 Infection and Fetal-neonatal Outcomes","","NCT04699578","8453","Diagnostic Test: Covid-19 positive","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04699578","Recruiting","2020-12-28","2022-05-01","{""locations"":""University of Campania Luigi Vanvitelli, Naples, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Preterm birth rate|Gestational age at delivery|Preterm birth rates|Birth weight|Composite adverse neonatal outcomes|Maternal outcomes|Inflammatory markers: coagulation profile, C-reactive protein, glycaemia, ferritinemia""}"
"3137","Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.","","NCT04354779","AUVA SARS-CoV-2 Studie","Diagnostic Test: a specifically designed self-administered questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354779","Completed","2020-05-11","2020-09-28","{""locations"":""Allgemeine Unfallversicherungsanstalt, Vienna, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""3301"",""age"":""15 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Antibody status in HCW|Active virus carriers in HCW|Incubation time|Background incidence rate|Occupation associated infection risk""}"
"3138","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","","NCT04255017","TJ20200128","Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04255017","Recruiting","2020-02-01","2020-07-01","{""locations"":""Department and Institute of Infectious Disease, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA""}"
"3139","Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects","","NCT04547114","IMS COVID-19","Diagnostic Test: Multicapillary column coupled ion mobility spectrometry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04547114","Recruiting","2020-09-14","2021-04-30","{""locations"":""Klinikum Bayreuth\/ Bayreuth General Hospital, Bayreuth, Germany"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""correct classification of SARS-CoV-2 infected and not infected subjects""}"
"3140","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","","NCT04254874","TJ20200131","Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04254874","Recruiting","2020-02-01","2020-07-01","{""locations"":""Department and Institute of Infectious Disease, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA""}"
"3141","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","CYCOV","NCT04324528","CYCOV","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04324528","Recruiting","2020-03-27","2020-11-26","{""locations"":""University Clinic Freiburg, Freiburg, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""interleukin-6 (IL-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate""}"
"3142","Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test","","NCT04689399","COVID-19","Diagnostic Test: Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04689399","Completed","2020-12-26","2020-12-31","{""locations"":""Christian von Buchwald, MD, DMSc, Professor, Copenhagen, Denmark"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""4697"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity and specificity of the rapid antigen test of COVID-19|Economic analyses|PCR analysis on nasopharyngeal swabs""}"
"3143","A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19","OPV-NA831","NCT04540185","OPV-NA831","Biological: Biological: oral polio vaccine|Biological: Comparable Placebo|Drug: NA-831|Drug: Comparable Placebo of drug|Combination Product: Combination of oral polio vaccine and NA-831|Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04540185","Enrolling by invitation","2020-11-01","2022-12-31","{""locations"":""Coronavirus Research Institute- Testing Site, Los Angeles, California, United States|Coronavirus Research Institute, Orange, California, United States|Coronavirus Research Institute-Testing Site, Palo Alto, California, United States|Coronavirus Research Testing Site, San Francisco, California, United States|Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States|Coronavirus Research Institute, Sunnyvale, California, United States|Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States|Coronavirus Research Institute-Testing Site-, Bronx, New York, United States|NeuroActiva-Clinical Research Unit, Auckland, New Zealand|NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland, New Zealand"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""3600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of OPV with or without NA-831|Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal|Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of OPV with or without NA-831|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of OPV with or without NA-831 or Placebo regardless of evidence of prior SARS-CoV-2 Infection""}"
"3144","Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects","","NCT04629703","C-935788-061","Drug: Fostamatinib|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04629703","Recruiting","2021-02-22","2021-10-01","{""locations"":""Sutter Health - Mills Peninsula Medical Center, Burlingame, California, United States|University of California Irvine, Orange, California, United States|Loyola University Medical School, Maywood, Illinois, United States|Harvard Medical School- Bringham and Women's Hospital, Boston, Massachusetts, United States|Ascension Medical Group- St. John Clinic Infectious Disease, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Houston Methodist Research Institute, Houston, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Hospital das Cl\u00ednicas da Universidade Federal de Goi\u00e1s (HC\/UFG), Goi\u00e2nia, Goi\u00e1s, Brazil|Hospital Luxenburgo-Associa\u00e7\u00e3o M\u00e1rio Penna, Belo Horizonte, Minas Gerais, Brazil|Hospital Universitario de Maringa, Maring\u00e1, Parana, Brazil|Irmandade da Santa Casa de Miseric\u00f3rdia de Porto Alegre - ISCMPA, Porto Alegre, Rio Grande Do Sul, Brazil|Complexo de Preven\u00e7\u00e3o, Diagn\u00f3stico, Terapia e Reabilita\u00e7\u00e3o Respirat\u00f3ria LTDA, Blumenau, Santa Catarina, Brazil|Hospital Alem\u00e3o Oswaldo Cruz (HAOC), Bela Vista, Sao Paolo, Brazil|Pontificia Universidade Catolica de Campinas (PUC-CAMP) - Hospital e Maternidade Celso Pierro (HMCP), Campinas, Sao Paolo, Brazil|Hospital Bandeirantes (LeForte), Liberdade, Sao Paolo, Brazil|Clinica de Alergia Martti Antila S\/S Ltda, Sorocaba, Sao Paulo, Brazil|Funda\u00e7\u00e3o Faculdade Reg. de Med de SJRP, S\u00e3o Jos\u00e9 Do Rio Preto, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""308"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Progression to severe\/critical disease within 29 days of first dose of study treatment|Proportion of subjects transferred into the intensive care unit (ICU) or who died prior to Day 29|Total number of calendar days hospitalized through Day 29""}"
"3145","Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome","COVIDIOL","NCT04366908","COVIDIOL","Drug: BAT + Calcifediol|Drug: BAT","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04366908","Recruiting","2020-05-07","2021-06-30","{""locations"":""Hospital Universitario Reina Sof\u00eda, Cordoba, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1008"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Admission to Intensive Care Unit|Death|Time from onset of symptoms to discharge of patients in conventional hospitalization|ICU - Time until admission|ICU - Time mechanical ventilation is removed|Evaluation of the inflammatory markers related with the disease|Vitamin D metabolites|Evolution in SatO2|Evolution in the Sat O2\/FiO2 ratio.|Evolution in the degree of dyspnea|Evolution of the improvement of radiological findings by simple radiology|Incidence of adverse events|Appearance of hemorrhagic or thrombotic phenomena""}"
"3146","Glycine Supplement for Severe COVID-19","","NCT04443673","C40-20","Dietary Supplement: Glycine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04443673","Recruiting","2020-08-20","2021-06-30","{""locations"":""Instituto Nacional de Enfermedades Respiratorias, Mexico DF, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""82"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality|Days under mechanical ventilation|PaO2\/FiO2 ratio|Arterial plasma lactate|Serum IL-1\u03b2|Serum IL-2|Serum IL-4|Serum IL-5|Serum IL-6|Serum IL-7|Serum IL-8|Serum IL-10|Serum IL-12|Serum IL-13|Serum IL-17|Serum G-CSF|Serum GM-CSF|Serum IFN-\u03b3|Serum MCP-1|Serum MIP-1\u03b2|Serum TNF-\u03b1|Serum creatinine|Serum alanine aminotransferase|Serum aspartate aminotransferase|Serum alkaline phosphatase|Serum total bilirubin|Serum unconjugated bilirubin|Serum conjugated bilirubin|Serum C reactive protein|Hemoglobin|Total leukocytes|Neutrophils|Lymphocytes|Monocytes|Eosinophils|Basophils|Platelets|Prothrombin time|Serum PAI-1|SOFA score|APACHE II score""}"
"3147","Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period","","NCT04698044","COVFAIROFALL","Diagnostic Test: Hospital Anxiety Depression Scale","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04698044","Completed","2020-05-08","2020-06-25","{""locations"":""Sultan Abd\u00fclhamid Han Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1107"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""HADS""}"
"3148","COVID-19, bLOod Coagulation and Thrombosis","CLOT","NCT04388657","2020-A00","Diagnostic Test: Echo-Doppler","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388657","Recruiting","2020-05-01","2020-09-01","{""locations"":""H\u00f4pital Ambroise Par\u00e9, Boulogne-Billancourt, IDF, France|H\u00f4pital Priv\u00e9 Jacques Cartier, Massy, IDF, France|Centre Cardiologique du Nord, Saint-Denis, IDF, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""percentage of patients with one or more DVTs.""}"
"3149","Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?","","NCT04522128","2020-9463-15184","Behavioral: Behaviour Change Technique Intervention to Improve Quality of Life","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04522128","Recruiting","2020-05-22","2022-12-31","{""locations"":""University of Manchester - online, Manchester, Cheshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other"",""enrollment"":""969"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in World Health Organisation Quality of Life Combination|Change in The Lubben Social Network Scale|Change in 6-Item Loneliness Scale|Quality of Life Importance Ratings""}"
"3150","Obesity and Mortality of Critically Ill Patients With COVID-19","COV-OB-ICU","NCT04425213","2020PI082","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04425213","Completed","2020-05-12","2020-05-26","{""locations"":""Centre hospitalo-universitaire r\u00e9gional de Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU mortality|Invasive mechanical ventilation|In-hospital mortality""}"
"3151","Pathological Findings of Fatal COVID-19","HISTOCOVID","NCT04675281","MR_HISTOCOVID","Other: 2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04675281","Recruiting","2020-04-24","2021-04-24","{""locations"":""CH Amiens, Amiens, France|Angers University Hospital, Angers, France|CH Angoul\u00eame, Angoul\u00eame, France|CH Annecy, Annecy, France|Hopital Priv\u00e9 d'Antony, Antony, France|CH Argenteuil, Argenteuil, France|CH Belfort, Belfort, France|CHU Bordeaux, Bordeaux, France|Hopital Sainte Camille, Bry-sur-Marne, France|CH Cahors, Cahors, France|CH Cergy Pontoise, Cergy-Pontoise, France|CH Cholet, Cholet, France|CHU Clermont-Ferrand, Clermont-Ferrand, France|CH Compi\u00e8gne-Noyon, Compi\u00e8gne, France|CHD Vend\u00e9e, La Roche-sur-Yon, France|Hopital Lyon Sud, Lyon, France|H\u00f4pital Lyon Sud, Lyon, France|Marseille Hopital Nord APHM, Marseillette, France|CH Melun, Melun, France|CH Mont\u00e9limar, Mont\u00e9limar, France|Nantes University Hospital, Nantes, France|CHU Nice, Nice, France|CHR Orl\u00e9ans, Orl\u00e9ans, France|CH Ambroise Par\u00e9 APHP, Paris, France|GHEF Marne La Vall\u00e9e, Paris, France|Hopital Antoine B\u00e9cl\u00e8re APHP, Paris, France|Hopital Cochin APHP, Paris, France|Hopital Georges Pompidou APHP, Paris, France|Hopital La Piti\u00e9 Salpetri\u00e8re APHP, Paris, France|Hopital Louis Mourier APHP, Paris, France|Hopital Necker APHP, Paris, France|Hopital Saint-Antoine APHP, Paris, France|Hopital Saint-Louis APHP, Paris, France|CH Poissy, Poissy, France|Hopital Priv\u00e9 Claude Galien, Quincy-sous-S\u00e9nart, France|CH Reims, Reims, France|CHU Rennes, Rennes, France|CH Saint-Brieuc, Saint-Brieuc, France|CHU Saint-Etienne, Saint-\u00c9tienne, France|Hopital Foch, Suresnes, France|CHRU Tours, Tours, France|CH Troyes, Troyes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Analysis of the pathological findings of a large cohort of patients who died from COVID-19 in the ICU|Comparison between early (<1 week after ICU admission) and late (\u22651 week) deaths|Analysis of the influence of ARDS severity and length on pathological findings|Analysis of the influence of pharmacological treatments (steroids) on pathological findings|Analysis of the correlation between radiological findings and pathological findings|Association between the primary cause of death and pathological findings|Analysis of the correlation between the ventilator settings and pathological findings|Co-infections""}"
"3152","Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients","","NCT04410471","Sero-Covid19_TH","Diagnostic Test: CLIA of IgG and IgM against SARS-Cov-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04410471","Recruiting","2020-05-29","2021-06-30","{""locations"":""Victor Fernandez Alonso, Madrid, Spain|Victor Fern\u00e1ndez Alonso, Madrid, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of IgG against SARS-CoV-2|titration and evolution of humoral response (IgG) along first 12 months after having Covid-19|Reinfection of Covid-19""}"
"3153","MYocardial DOmmages Related to COVID-19","DOMY COVID","NCT04498065","COTTIN AOIc 2020","Biological: Biological data|Other: Clinical data","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04498065","Active, not recruiting","2020-03-01","2021-07-01","{""locations"":""Chu Dijon Bourgogne, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""characterize the myocardial damage associated with CoV-2 SARS infection""}"
"3154","Predictors of Respiratory Failure in SARS-Cov-2 Infection","","NCT04316949","PREDI-CO","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04316949","Recruiting","2020-03-20","2020-05-31","{""locations"":""University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""350"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Respiratory failure|Occurence of bacterial superinfection""}"
"3155","In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity","","NCT04368897","AB-IVD-CoV-001","Diagnostic Test: CAG length <22|Diagnostic Test: CAG length >=22","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368897","Recruiting","2020-05-01","2021-06-01","{""locations"":""Hospital Universitario Ramon y Cajal, Madrid, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital-free days to Day 28 [ Time Frame: 28 days]|1. Severity of Disease""}"
"3156","COVID-19 Vaccine and Impact on Fertility Study","","NCT04665258","20201451","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04665258","Recruiting","2020-12-14","2021-06-14","{""locations"":""University of Miami, Miami, Florida, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Sperm concentration|Sperm motility""}"
"3157","Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)","AMPoL","NCT04409873","20-30874|R00RG2901","Drug: Oral-B Mouth Sore mouthwash|Drug: Crest Pro-Health Multi-Protection mouthwash|Drug: CloSYS Ultra Sensitive Rinse mouthwash|Drug: Distilled water|Drug: Listerine Zero Mouthwash Product","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04409873","Not yet recruiting","2021-03-22","2021-11-30","{""locations"":""University Of California, San Francisco, San Francisco, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SARS-Cov-2 viral load|Change in self-reported clinical symptom onset|Change in healthcare utilization and hospitalization""}"
"3158","Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients","","NCT04659200","06122020","Diagnostic Test: Venous blood was collected for biochemistry testing.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659200","Completed","2020-09-01","2020-12-07","{""locations"":""Sabahattin Destek, Fatih, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""20"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of thyroid stimulating hormone (TSH) between groups|Comparison of free triiodothyronine (fT3) between groups|Comparison of free thyroxine (fT4) between groups|Comparison of anti-thyroid peroxidase (Anti-TPO) between groups|Comparison of anti-thyroglobulin (Anti-Tg) between groups|White blood cells (WBC) results of Covid 19 patient group|Neutrophil \/ lymphocyte ratio (N\/LO) results of Covid 19 patient group|C-reactive protein (CRP) results of Covid 19 patient group|Fibrinogen results of Covid 19 patient group|Procalcitonin results of Covid 19 patient group|Ferritin results of Covid 19 patient group|D-dimer results of Covid 19 patient group""}"
"3159","Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell","VOLT","NCT04710394","7011897206","Behavioral: Smell Training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04710394","Recruiting","2021-01-11","2022-03-11","{""locations"":""Washington University School of Medicine in Saint Louis, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""University of Pennsylvania Smell Identification Test (UPSIT)|Clinical Global Impression Severity (CGI-S) Scale|Clinical Global Impression Improvement (CGI-I) Scale|Olfactory Dysfunction Outcomes Rating (ODOR)""}"
"3160","Analysis of the Coagulopathy Developed by COVID-19 Infected Patients","COVID-TGT","NCT04356950","PHRC-I/2020/JCG-01","Other: Thrombin generation test assay|Other: Fibrin generation markers assays","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356950","Active, not recruiting","2020-04-28","2022-07-01","{""locations"":""CHU de Bordeaux, Bordeaux, France|CHU de Limoges, Limoges, France|CHU de Montpellier, Montpellier, France|CHU de Nimes, N\u00eemes, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""175"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28-day survival rate|Absolute thrombin generation test latent period|Relative thrombin generation test latent period compared to reference plasma|Absolute thrombin generation test initial velocity|Relative thrombin generation test initial velocity compared to reference plasma|Relative thrombin generation test peak thrombin compared to reference plasma|Absolute thrombin generation test peak thrombin|Absolute thrombin generation test peak thrombin time|Relative thrombin generation test peak thrombin time compared to reference plasma|Absolute thrombin generation test total thrombin generation time|Relative thrombin generation test total thrombin generation time compared to reference plasma|Absolute thrombin generation test endogenous thrombin potential|Relative thrombin generation test endogenous thrombin potential compared to reference plasma|3-month survival rate|Transfer to intensive care unit during hospitalization|Thrombotic complication during hospitalization|Plasma concentrations of D-dimers|Plasma concentrations of soluble fibrin monomers""}"
"3161","Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress","PROVID-19","NCT04363463","CHRO-2020-09","Other: prone position","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363463","Recruiting","2020-08-28","2022-08-28","{""locations"":""CH de Blois, Blois, France|CH de DAX, Dax, France|CHD de VENDEE, La Roche sur Yon, France|CH de LA ROCHELLE, La Rochelle, France|CH Le Mans, Le Mans, France|CH Mont de MArsan, Mont-de-Marsan, France|CHR d'Orl\u00e9ans - Service Pneumologie, Orl\u00e9ans, France|CHR d'Orleans - Service Maladies Infectieuses, Orl\u00e9ans, France|HOPITAL LARIBOISIERE - Service diab\u00e9tologie, endocrinologie, nutrition, Paris, France|Hopital Europ\u00e9en Georges Pompidou, Paris, France|Hopital Lariboisiere - Medecine Interne, Paris, France|Hopital Lariboisiere, Paris, France|CH de PERPIGNAN - Service Maladies infectieuses, Perpignan, France|Centre Hospitalier Intercommunal de Cornouaille - Quimper Concarneau, Quimper, France|CHRU de Tours - Service M\u00e9decine interne et immunologie Clinique, Tours, France|CHRU de Tours - Service Pneumologie, Tours, France|CHRU DE TOURS - Service M\u00e9decine interne et maladies infectieuses, Tours, France|CH Bretagne Atlantique, Vannes, France|centre Hospitalier Princesse Grace, Monaco, Monaco"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""400"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and\/or die, in each of the 2 randomization groups.|Duration in days for the change of 2 points on the WHO ordinal scale|Rate (%) of intubation and invasive ventilation in the 2 randomization groups.|Rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups|Duration of oxygen therapy in the 2 randomization groups.|Duration of hospitalization in the 2 randomization groups.|Hospital mortality and mortality at D28 in the 2 randomization groups|Rate (%) of need for transfer to intensive care unit|Rate (%) of use of non-invasive ventilation at two pressure levels, intubation throughout the entire stay when the stay is longer than 28 days.""}"
"3162","Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""","","NCT04403100","COVID19_AMB_Brasil","Drug: Hydroxychloroquine Sulfate Tablets|Drug: Lopinavir/ Ritonavir Oral Tablet|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04403100","Recruiting","2020-06-03","2021-02-01","{""locations"":""CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Fundo Municipal de Sa\u00fade de Betim, Betim, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1968"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who were hospitalized for progression of COVID-19 disease|Proportion of participants who died due to COVID-19 progression and\/ or complications|Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization|Time to clinical improvement|Time to clinical failure|Hospitalization for any cause|Proportion of participants who died due to pulmonary complications|Proportion of participants who died due to cardiovascular complications|Proportion of participants who presented with adverse events|Time to improvement on respiratory scale symptoms|proportion of non-adherent participants to any of study drugs""}"
"3163","Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection","","NCT04356443","2020P000881","Device: AirGo Respiratory Monitor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356443","Recruiting","2020-04-15","2020-12-31","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Endotracheal intubation during present hospitalization, recorded through chart review|Improvement in hypoxemia as indicated by oxygen saturation and requirement for supplemental oxygen, recorded through chart review|Premature need for removal of the band, recorded through investigator report|In-hospital mortality, recorded through chart review""}"
"3164","Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)","CORIA","NCT04354818","2020-04-CORIA","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354818","Recruiting","2020-05-11","2022-04-27","{""locations"":""St Vincent's Hospital, Darlinghurst, New South Wales, Australia|East Sydney Doctors, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Concord Hospital, Sydney, New South Wales, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, Australia|Melanoma Institute Australia, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died""}"
"3165","Menstrual Cycle Characteristics of Healthcare Professionals","","NCT04413058","HNEAH KAEK 2020/KK/|Ministry of Health","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04413058","Completed","2020-04-10","2020-09-10","{""locations"":""University of Health Sciences Turkey, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Prospective"",""enrollment"":""260"",""age"":""18 Years to 47 Years \u00a0 (Adult)"",""outcome_measures"":""Rate of irregular menstrual cycle|Length of cycle|Rate of prolonged bleeding|Amount of flow|Rate of dysmenorrhea|The number of difference in menstrual cycle length|The number of difference in bleeding days|The number of difference in amount of flow""}"
"3166","Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19","","NCT04376814","IR.BMSU.REC.1399.017","Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04376814","Completed","2020-03-29","2020-05-25","{""locations"":""Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""16 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality|long of hospitalization|Laboratory Treatment Response (Blood cell count)|Laboratory Treatment Response (CRP )|Dyspnea|Oxygen saturation without supplemental oxygen.|Oxygen therapy""}"
"3167","Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic","","NCT04373291","BCG-DENMARK-COVID|2020-001888-90","Biological: BCG-Denmark|Biological: Saline","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04373291","Active, not recruiting","2020-05-18","2021-12-31","{""locations"":""Hvidovre Hospital, Hvidovre, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1293"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days of unplanned absenteeism for any reason|The cumulative incidence of documented COVID|The cumulative incidence of hospital admission for any reason|The number of days of unplanned absenteeism, because of documented COVID|The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2|The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS- CoV-2 infection|The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|The number of days of self-reported fever (\u226538 \u00b0C)|The number of days of self-reported acute respiratory symptoms|The cumulative incidence of self-reported acute respiratory symptoms|The cumulative incidence of death for any reason|The cumulative incidence of death due to documented COVID|The cumulative incidence of Intensive Care Admission for any reason|The cumulative incidence of Intensive Care Admission due to documented COVID|The cumulative incidence of Hospital Admission due to documented COVID""}"
"3168","Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)","","NCT04397692","BAI_COV19_01_US","Device: Nitric Oxide delivered via LungFit™ system","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04397692","Recruiting","2020-06-13","2020-09-30","{""locations"":""Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility"",""enrollment"":""20"",""age"":""22 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to deterioration|Time to NIV|Time to HFNC|Time to intubation|Time to patient having stable oxygen saturation (SpO2) of greater than or equal to 93%""}"
"3169","Effect of COVID-19 Pandemic on Vaccination Compliance","","NCT04618796","Effect of COVID on vaccination","Other: vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04618796","Not yet recruiting","2021-04-01","2022-05-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""1 Year to 2 Years \u00a0 (Child)"",""outcome_measures"":""Measure the vaccination coverage rate among the studied children after the COVID-19 pandemic""}"
"3170","Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19)","COVEN","NCT04497454","CAAE: 30938720800000068","Other: EIT-Group|Other: ARDSNet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04497454","Recruiting","2020-05-08","2021-12-01","{""locations"":""USP Instituto do Cora\u00e7\u00e3o, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""128"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Average daily Modified Lung injury score until day 28|High oxygen dependence free days until day 28|Mechanical ventilation free days until day 28|Incidence of shock or barotrauma|Incidence of acute renal failure requiring renal replacement therapy|28-day mortality""}"
"3171","Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS","AVM0703","NCT04366115","AVM0703-101","Drug: AVM0703|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04366115","Not yet recruiting","2021-01-01","2023-06-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""16"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dose-Limiting Toxicities|28 day all-cause mortality will be a primary end point for Phase 1 and 2""}"
"3172","COVID-19 (SARS-CoV-2) in Urine and Semen","","NCT04446169","17104_oss/2020","Diagnostic Test: SARS-CoV 2 RNA PCR Urine|Diagnostic Test: SARS-CoV 2 RNA PCR Semen|Diagnostic Test: Semen Qualitative Analysis|Diagnostic Test: IIEF-5 questionnaire|Diagnostic Test: Male Sexual Health Questionnaire (MSHQ)|Diagnostic Test: IPSS questionnaire|Diagnostic Test: SECRET questionnaire|Diagnostic Test: Interleukin assessment in semen","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04446169","Active, not recruiting","2020-06-27","2021-03-02","{""locations"":""AOU Careggi, Florence, Tuscany, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""43"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV 2 presence in semen|SARS-CoV 2 presence in urine|Inflammation in Semen|Semen quantitative and qualitative analysis|Erectile Function|Sexual Habits|Urinary function|Sexual and Ejaculatory Function""}"
"3173","ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic","ACORES-2","NCT04329195","APHP200409","Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04329195","Recruiting","2020-04-09","2020-08-09","{""locations"":""Cardiologie, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""554"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge""}"
"3174","Pro-thrombotic Status in Patients With SARS-Cov-2 Infection","ATTAC-Co","NCT04343053","250320","Other: SARS-Cov-2 infection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04343053","Active, not recruiting","2020-04-08","2021-06-09","{""locations"":""Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""54"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""on-treatment platelet reactivity|apoptosis rate in human umbilical vein endothelial cells (HUVEC)|Nitric oxide (NO) intracellular levels|reactive oxygen species (ROS) levels|coagulation factors levels|respiratory function|cardiac function|clinical outcome""}"
"3175","An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection","COVID-19","NCT04522986","ADR-001-1919","Biological: Mesenchymal stem cell","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04522986","Not yet recruiting","2020-09-01","2021-12-01","{""locations"":""Osaka University Hospital, Suita, Osaka, Japan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""6"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety: Adverse Event""}"
"3176","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy","","NCT04339634","COVID-PACE-2020-001","Other: Simulation of Repurposed Drugs for COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339634","Active, not recruiting","2020-04-07","2021-04-06","{""locations"":""Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""12123"",""age"":""55 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.|To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.|To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.|To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.|To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.|To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.""}"
"3177","Double Therapy With IFN-beta 1b and Hydroxychloroquine","","NCT04350281","UW 20-211","Drug: Interferon Beta-1B|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04350281","Completed","2020-04-09","2020-07-07","{""locations"":""The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes""}"
"3178","Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe","Euro-COVIMID","NCT04397237","2020-A01371-38","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397237","Active, not recruiting","2020-06-10","2021-01-01","{""locations"":""Saadoun, Paris, Ile De France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""3100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 seroconversion|COVID-19 infection|Seroconversion rate by disease|Penetration across Europe|COVID-19 severity|COVID-19 mortality rate|COVID-19 impact on immunomodulatory treatment|Patient-reported flares|Patient's fears towards COVID-19|Patient's beliefs in their medicines towards COVID-19""}"
"3179","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","","NCT04261270","ASC09F-CTP-TJ-01","Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04261270","Recruiting","2020-02-01","2020-07-01","{""locations"":""Department and Institute of Infectious Disease, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery""}"
"3180","Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections","SCout","NCT04357938","IDIR-001-2020","Device: CT-imaging","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357938","Active, not recruiting","2020-04-15","2021-04-30","{""locations"":""Jena University Hospital, Jena, Thuringia, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""145"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity and specificity of chest CT in detecting pneumonia in unspecific symptomatic patients who are to be admitted to hospital and who are rt-PCR negative for SARS-CoV-2.|Sensitivity and specificity of chest CT in patients with pulmonary comorbidities|Sensitivity and specificity of chest CT in patients with cardiovascular comorbidities|Sensitivity and specificity of chest CT in patients with malignancy|Sensitivity and specificity of chest CT in patients with immunodeficiency""}"
"3181","Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection","","NCT04491227","000295","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04491227","Enrolling by invitation","2020-05-05","2023-03-31","{""locations"":""University of Alabama, Birmingham, Birmingham, Alabama, United States|University of California, San Diego, San Diego, California, United States|University of Colorado, Aurora, Colorado, United States|St. Peter's Hospital, Albany, New York, United States|Jacobi Medical Center, New York, New York, United States|Hospital Obrero #2, Cochabamba, Bolivia|Hopital Sacre Coeur & Universite de Montreal, Montreal, Quebec, Canada|Universidad de Los Andes, Santiago, Chile|Postgraduate Institute of Research, Chandigarh, Chandigarh, India|Royal Free Hospital, London, United Kingdom|Guy's & St Thomas's Hospital, London, United Kingdom|University of Nottingham, Nottingham, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""AKI incidence|Dialysis requirement|hospital mortality|Renal functional recovery|Functional status|Resource utilization""}"
"3182","Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers","","NCT04681001","COVID-19/CHC_20_04","Device: nasal spray","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04681001","Recruiting","2020-12-20","2021-06-30","{""locations"":""Gesundheitsverbund, Klinik Favoriten, Vienna, Austria|Gesundheitsverbund Klinik Floridsdorf, Vienna, Austria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""300"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of COVID-19 symptoms including symptoms of respiratory viral infection documented in a diary|Nasal swabs for analysis of viruses by PCR|Serology of antibodies against SARS-CoV-2|Number of viral co-infections dedected by PCR""}"
"3183","TARGet Kids! COVID-19 Study of Children and Families","","NCT04449978","1000069701","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04449978","Recruiting","2020-04-09","2022-12-31","{""locations"":""St Michael's Hospital, Toronto, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1082"",""age"":""up to 10 Years \u00a0 (Child)"",""outcome_measures"":""Cumulative Incidence of COVID-19|Risk Factors for COVID-19|Parent-reported probable case definition of COVID-19|Dynamics of COVID-19|Risk to family members|Severity of COVID-19|Longer term effects of COVID-19 on physical health|Longer term effects of COVID-19 on mental health|Longer term effects of COVID-19 on child development|Longer term effects of COVID-19 on family functioning|Longer term effects of COVID-19 on health behaviours|Longer term effects of COVID-19 on healthcare utilization|Effects of preventive measures on infection|Effects of preventive measures on physical health|Effects of preventive measures on mental health|Effects of preventive measures on child development|Effects of preventive measures on family functioning|Effects of preventive measures on health behaviours|Effects of preventive measures on healthcare utilization""}"
"3184","Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)","CARTESIAN","NCT04558450","APHP200762|20.07.24.57438","Diagnostic Test: carotid-femoral pulse-wave velocity","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04558450","Not yet recruiting","2020-09-01","2032-06-01","{""locations"":""CHU Lille, Lille, France|CHRU Nancy, Nancy, France|H\u00f4pital Europ\u00e9en Georges Pompidou - APHP, Paris, France|CHU Rouen, Rouen, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""360"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PWV|PWV change|arterial distensibility|arterial distensibility change|brachial artery FMD|brachial artery FMD change|central blood pressure|central blood pressure (BP) change|wave separation\/wave intensity analysis (WSA\/WIA)|WSA\/WIA change|cardiac diastolic dysfunction|cardiac diastolic dysfunction change|myocardial stiffness|myocardial stiffness change""}"
"3185","TOFAcitinib in SARS-CoV2 Pneumonia","","NCT04332042","TOFACoV","Drug: Tofacitinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04332042","Not yet recruiting","2020-04-10","2020-07-10","{""locations"":""Ospedali Riuniti di Ancona, Ancona, Marche, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events""}"
"3186","A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19","","NCT04380961","CR108820|CNTO136COV2001|2020-003056-32","Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04380961","Recruiting","2020-04-24","2021-09-28","{""locations"":""UCSF Fresno, Fresno, California, United States|MemorialCare Research Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|Sutter Institute for Medical Research, Roseville, California, United States|Sutter Medical Foundation, Sacramento, California, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|The Corporation of Mercer University, Macon, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Illinois College of Medicine at Peoria, Peoria, Illinois, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Health Systems, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Saint Michael's Medical Center - Infectious Disease, Newark, New Jersey, United States|SUNY Upstate Medical University, Syracuse, New York, United States|East Carolina University, Greenville, North Carolina, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor All Saints Medical Center at Fort Worth, Fort Worth, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""270"",""age"":""18 Years to 84 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Percentage of Participants with All-cause Mortality|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of Participants with Related Adverse Events|Percentage of Participants with Severe or Life Threatening Bacterial, Invasive Fungal, Viral or Opportunistic Infections|Percentage of Participants with Grade 3 and 4 Neutropenia|Percentage of Participants with Grade 3 and 4 Lymphocytopenia|Percentage of Participants with Increased Alanine Aminotransferase (ALT) Greater than or equal to 3 Times Upper Limit of Normal (ULN) Combined with Increased Bilirubin > 2 Times ULN|Time to Improvement of at least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Time from Study Intervention to end of Oxygen Supplementation|Time from Study Intervention to Hospital Discharge Among the Surviving Participants|Total Length of Hospitalization|Number of Ventilation Free Days|Participant's Clinical Status at Day 7, 14, 21, 28 as Assessed by 6-Point Ordinal Clinical Recovery Scale|Total Time on Invasive Mechanical Ventilation|Percentage of Participants with a Worse Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale over Time|Percentage of Participants on Extracorporeal Membrane Oxygenation (ECMO) Over Time|Total Time on ECMO|Percentage of Alive Participants at Day 28, Week 8 and Week 16|Percentage of Alive Participants that Required Readmission at Week 8 and Week 16""}"
"3187","Covid-19 Anxiety and Phobia Levels of the Parents","","NCT04631172","farukcicekci","Other: Coronavirus Anxiety Scale , COVID-19 Phobia Scale","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04631172","Completed","2020-05-01","2020-10-15","{""locations"":""Selcuk University, School of Medicine, Konya, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Coronavirus Anxiety Scale (CAS)|COVID 19 phobia scale (C19P-S)""}"
"3188","Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)","COVID-ARA2","NCT04337190","COVID-ARA2","Biological: blood sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337190","Recruiting","2020-04-03","2020-12-06","{""locations"":""University Hospital Angers, Angers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ACE2 level change over time|ACE2 activity over time|Mortality at day 28|ARDS severity|Duration of mechanical ventilation|Need for prone positionning|Need for extracorporeal membran oxygenation|Use of paralytic agents|Need for renal replacement therapy|Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)|Sequential Organ Failure Assessment (SOFA) score|Number of session(s) of prone positionning|Duration of extracorporeal membran oxygenation treatment|Type of vasoactive drugs|Duration of vasoactive treatment""}"
"3189","This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19","","NCT04592549","ADM03820-001","Drug: ADM03820|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04592549","Recruiting","2020-12-04","2021-09-30","{""locations"":""PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|ICON Early Phase Services, LLC, San Antonio, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""The number of participants with Serious Adverse Events following administration of ADM03820 to the final visit|The number of participants with AEs from administration of ADM03820 to the final visit|The assessment of Peak Plasma Concentration (Cmax) for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|The assessment of Tmax for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|The assessment of the Area under the plasma concentration (AUC(0-t)) for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|To assess the anti-drug antibody levels""}"
"3190","The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19","","NCT04357340","99-1-103-47429","Other: Pulmonary Physiotherapy Techniques","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04357340","Completed","2020-04-02","2020-05-30","{""locations"":""Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mixed venous O2 pressure (PVO2)|Mixed venous CO2 pressure (PVCO2)|PH|HCO3|Oxygen saturation (O2 Sat) from VBG|Three minute walk test|O2 Sat after one minute walking|O2 Sat after two minutes use of Partial Rebreather|O2 Sat after two minutes free air breathing|O2 sat\/ Fio2|Mortality rate|Number of participants with Rehospitalization|The Health-Related Quality of Life (HRQOL)|breathlessness""}"
"3191","Observational Study of COVID-19 Treatment Efficacy","","NCT04369989","1589936","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04369989","Enrolling by invitation","2020-04-14","2021-04-14","{""locations"":""OSF HealthCare St Francis Medical Center, Peoria, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality during the COVID-19 treatment hospital encounter|ICU admission during the COVID-19 treatment hospital encounter|Ventilator use during the COVID-19 treatment hospital encounter""}"
"3192","Pediatric Intensive Care and COVID-19","CLOVIS","NCT04544878","PS-PICRN--20001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04544878","Recruiting","2020-03-26","2021-06-01","{""locations"":""Pediatric Intensive Care and Neonatal Medicine, Bic\u00eatre Hospital, AP-HP PAris Saclay University, Le Kremlin-Bic\u00eatre, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patient with secondary infection|Number of patients dying|Description of clinical phenotypes|Description of immunological phenotypes""}"
"3193","The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients","","NCT04321616","118684","Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04321616","Recruiting","2020-03-28","2020-11-01","{""locations"":""Andreas Barratt-Due, Oslo, Norway"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction""}"
"3194","Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells","","NCT04382547","IBCE_MSC2(Covid)","Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04382547","Enrolling by invitation","2020-05-11","2021-06-30","{""locations"":""Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of cured patients|Number of patients with treatment-related adverse events""}"
"3195","Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19","","NCT04407182","IESS-HTMC-JUTD-2020-0305-M","Dietary Supplement: Viusid and Asbrip","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04407182","Completed","2020-05-04","2020-10-01","{""locations"":""Hospital de Especialidades Dr. Teodoro Maldonado Carbo, Guayaquil, Ecuador"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""60"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptom resolution|Cumulative incidence of disease severity|Complementary drugs required|Side effects of supplementation|Duration of SARS-CoV-2 PCR positivity|Concentration of reactive protein c in peripheral blood|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Duration (days) of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate|Time to return to normal activity""}"
"3196","Electrolyte State in Patients With COVID-19","","NCT04539834","(ZU-IRB#: 6328-23-8-2020)","Other: electrolytes","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04539834","Active, not recruiting","2020-05-01","2020-10-01","{""locations"":""Zagazig University, Zagazig, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""52"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""electrolytes disturbances in patients with COVID-19|To asses the relation of the electrolyte disturbances with the severity of COVID-19 infection.""}"
"3197","Clinical Use of Stem Cells for the Treatment of Covid-19","","NCT04392778","Bak. Sadi Konuk-Istinye Uni.","Biological: MSC Treatment|Biological: Saline Control","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04392778","Recruiting","2020-04-01","2020-09-01","{""locations"":""Istinye University, Istanbul, Turkey|SB\u00dc Dr. Sadi Konuk E\u011fitim ve Ara\u015ft\u0131rma Hastanesi, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""40 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Clinical improvement|Lung damage improvement|Sars-Cov-2 viral infection laboratory test|Blood test""}"
"3198","A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine","","NCT04683224","UB-612-301","Biological: UB-612|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04683224","Not yet recruiting","2021-02-01","2023-03-22","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""7320"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of local reactions, solicited systemic events, AEs, MAAEs, SAEs and AESIs|Change in safety chemistry blood lab values for assessment of risk in Phase 3|Change in safety hematology blood lab values for assessment of risk in Phase 3|Prevention of SARS-CoV-2 infection in adults|Change after second dose through the end of study in antibody titers|Prevention of COVID-19 in adults|Reduction in severity of COVID-19 in adults|Prevention of COVID-19 death in adults|Change in SARS CoV-2 shedding|Immunogenicity of UB-612 vaccine in young and older adults, with or without comorbidities, and no serological or virological evidence of past infection with SARS-CoV-2""}"
"3199","Immune Response and Risk of Serious Infection to SARS-Cov2","","NCT04410432","GHESQUIERE AOIc 2020","Biological: Blood sample collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04410432","Recruiting","2020-09-29","2021-08-01","{""locations"":""Chu Dijon Bourogne, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""63"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of circulating Th1 lymphocytes|Serum IFN concentrations-\u03b3, CXCL9, CXCL10, CXCL11""}"
"3200","Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2","DMMETCOV19","NCT04626089","SIL-30000-II(1)","Drug: metformin glycinate|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04626089","Not yet recruiting","2020-11-30","2021-03-31","{""locations"":""Hospital Ju\u00e1rez de M\u00e9xico, OPD, Mexico City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral Load|Days of supplementary oxygen if apply|Days of supplementary mechanical ventilation if apply|Days of Hospitalization|Normalization of fever|Normalization of oxigen saturation|Number of deaths|Change in Serum creatinine levels|Change in serum Troponin I|Change in serum aspartate aminotransferase levels|Change in serum Creatine kinase-MB levels|Incidence of adverse event""}"
"3201","The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations","LEAD COVID-19","NCT04363840","20-063","Drug: Aspirin 81 mg|Dietary Supplement: Vitamin D","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363840","Not yet recruiting","2020-05-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1080"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization""}"
"3202","Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","CYCOV-II","NCT04385771","CYCOV-II","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04385771","Recruiting","2020-09-01","2021-10-31","{""locations"":""University Clinic Freiburg, Freiburg, Germany|Klinikum Ibbenbueren, Ibbenbueren, Germany|Klinikum Ludwigsburg, Ludwigsburg, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IL-6 reduction by 75% or more after 72 hours as compared to the baseline measurement|time to successful ECMO-explantation|Ventilator free days (VFD)|Time to extubation from ventilation and explantation from ECMO|Overall survival time|Days on intensive care unit (ICU)|Vasopressor dosage|Fluid substitution and fluid balance|Serum lactate|Urine output|Willebrand factor|d-dimers|interleukin-6 levels|SOFA-Score|serious adverse device effects|adverse event of special interest: air in the ECMO system|adverse event of special interest: blood-clotting in the ECMO system|adverse event of special interest: bleeding complications""}"
"3203","Tomographic Findings in COVID-19 and Influenza H1N1","","NCT04499378","F-2020-1008-038","Diagnostic Test: Lung CT","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04499378","Not yet recruiting","2020-08-15","2022-04-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oral intubation|Survival""}"
"3204","Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome","ACES","NCT04408326","283005","Drug: Angiotensin II|Drug: Interleukin-1 receptor antagonist","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408326","Recruiting","2020-06-01","2021-05-01","{""locations"":""Guy's & St Thomas' Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportions of patients with mean arterial pressure \u2265 65 mmHg or an increase of mean arterial pressure \u226510 mmHg at 3 hours|Noradrenaline dose|Sequential Organ Failure Assessment (SOFA) score|RRT-free days|RRT discontinuation|Serum creatinine|PaO2\/FiO2 ratio|Mortality|Adverse events|Change in serum C-reactive protein|Change in serum ferritin""}"
"3205","Telerehabilitation After Coronavirus","","NCT04473898","KaratayU2","Other: Aerobic Exercise Training|Behavioral: Patient Education|Other: Respiratory Exercise Training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04473898","Completed","2020-06-19","2021-02-17","{""locations"":""KTO Karatay University, Konya, Karatay, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""35"",""age"":""25 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dyspnoea|Anxiety and Depression|Sleep Quality|Health Related Quality of Life|Kinesiophobia|Patient Satisfaction|Fatigue""}"
"3206","Use of Oxygen Hoods in Patients Failing on Conventional High-flow Oxygen Delivery Systems, Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic COVID-19 Patients. Prospective Cohort Study.","","NCT04407260","HoodStudy701","Device: Oxygen Hood","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407260","Completed","2020-03-06","2020-05-01","{""locations"":""Phelps Hospital, Sleepy Hollow, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""136"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Oxygen saturation|In-hospital Intubation\/Mechanical Ventilation Status|In-hospital Mortality|Length of Hospitalization""}"
"3207","Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection","ONCOVID-19","NCT04363632","ET20-069","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363632","Completed","2020-04-02","2020-06-30","{""locations"":""Institut Bergoni\u00e9, Bordeaux, France|Centre Fran\u00e7ois Baclesse, Caen, France|Centre Hospitalier M\u00e9tropole Savoie, Chamb\u00e9ry, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges Fran\u00e7ois Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|CH Annecy-Genevois, Metz-Tessy, France|Institut de Canc\u00e9rologie de Montpellier, Montpellier, France|Groupement Hospitalier Porte de Provence, Mont\u00e9limar, France|Centre Antoine Lacassagne, Nice, France|Centre Hospitalier Lyon-Sud, Pierre-B\u00e9nite, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Institut de Canc\u00e9rologie de l'Ouest, Saint-Herblain, France|Institut de canc\u00e9rologie Strasbourg Europe (ICANS), Strasbourg, France|Institut Universitaire du Cancer de Toulouse - IUCT Oncopole, Toulouse, France|CH Valence, Valence, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1231"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality of cancer patients under active anticancer treatment|Overall survival|Hospitalizations|Death|Complications|Patients' characteristics""}"
"3208","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia","","NCT04263402","TJ20200201","Drug: Methylprednisolone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04263402","Recruiting","2020-02-01","2020-07-01","{""locations"":""Department and Institute of Infectious Disease, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA""}"
"3209","Respiratory Syncytial Virus Infection May be More Dangerous in Neonate","","NCT04531735","2020/522","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04531735","Active, not recruiting","2020-03-01","2020-08-31","{""locations"":""Beh\u00e7et Uz Children's Hospital, \u0130zmirli, Izmir, Turkey|\u0130zmir Dr. Behcet Uz Training and Research Hospital, \u0130zmir, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""28"",""age"":""up to 1 Month \u00a0 (Child)"",""outcome_measures"":""Oxygen status and evaluation of neonatal intensive care stay""}"
"3210","Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR","","NCT04468217","PRO-02","Diagnostic Test: Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468217","Recruiting","2020-06-02","2020-09-25","{""locations"":""Laboratorio Neurognos, Santiago, Providencia, Chile"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of an alternative method of obtaining viral RNA for the detection of SARS-CoV-2 virus in nasopharyngeal samples.|Evaluation of an alternative method of obtaining viral RNA for the detection of SARS-CoV-2 virus in oropharyngeal, nasal, buccal and saliva samples|Establish a sample bank of nasopharyngeal, oropharyngeal, nasal, buccal and saliva mucosa for future analytical validations of new solutions associated with the detection of the SARS-CoV-2 virus.""}"
"3211","Evaluation of Sedation in COVID-19 ARDS","","NCT04667936","#20-643 -Sed II","Other: Treatment group","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04667936","Recruiting","2020-03-01","2021-01-01","{""locations"":""University Hospital Frankfurt, Frankfurt, Hessen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Position therapy|Agitation and sedation level|Application of opioid analgesic|Change of application of opioid analgesic|Application of sedative|Change in sedative dosage applied|Patient Characteristics|Need for renal replacement therapy|Need for extracorporeal membrane oxygenation (vvECMO)""}"
"3212","Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection","SAR-COVID","NCT04568421","01","Drug: Immunosuppressive Agents","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568421","Recruiting","2020-08-18","2021-12-31","{""locations"":""Sociedad Argentina de Reumatolog\u00eda, Ciudad Aut\u00f3noma de Buenos Aires, Caba, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Hospitalization|SARS-CoV-2 infection presentation|Admission at the intensive care unit|Invasive mechanical ventilation|COVID-19 Complications|Recovery rate""}"
"3213","COVID-19 Associated Coagulopathy in Egypt","","NCT04507230","17300413","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04507230","Completed","2020-08-07","2020-10-31","{""locations"":""Assiut University Hospitals, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""106"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Coagulation screen|Thrombophilia screen|VWF, FVIII""}"
"3214","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","ORCHID","NCT04332991","PETAL 05 Orchid","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04332991","Completed","2020-04-02","2020-07-23","{""locations"":""University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian\/Mercy\/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""479"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28""}"
"3215","Glycaemia and Cardiac Function in Patients With COVID-19","GLYCOVID-19","NCT04410718","H-20024279","Other: Glycaemic levels","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04410718","Recruiting","2020-04-20","2020-11-30","{""locations"":""Herlev and Gentofte Hospital, Hellerup, Please Select, Denmark|Hvidovre Hospital, Hvidovre, Please Select, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Plasma glucose levels and left ventricular ejection fraction|Key secondary outcome: HbA1c, plasma glucose levels and left ventricular systolic function|Plasma glucose levels and strain analysis|Plasma glucose levels and mitral annular systolic velocity|Plasma glucose levels and left ventricular ejection fraction (sub-group analysis)|Plasma glucose levels and strain analysis (sub-group analysis)|Plasma glucose levels and mitral annular systolic velocity (sub-group analysis)|HbA1c, Plasma glucose levels and strain analysis|HbA1c, Plasma glucose levels and mitral annular systolic velocity|Diabetes status and whole blood coagulability and fibrinolysis|Diabetes status and change in whole blood coagulability and fibrinolysis during ICU stay|Prognostic value of TEG analysis|Prognostic value of cardiac function|Diabetes status and high-sensitivity troponins|Diabetes status and change high-sensitivity troponins""}"
"3216","Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants","","NCT04468958","SAB-185-101","Biological: SAB-185|Other: Normal saline","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04468958","Active, not recruiting","2020-08-05","2021-04-01","{""locations"":""Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States|SUNY Upstate Medical University, Syracuse, New York, United States|ICON Early Phase Services, San Antonio, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""28"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of Participants Having Adverse Events|Number of Participants Having Transfusion-Related Adverse Events|Pharmacokinetics from screening to day 90""}"
"3217","REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19, the REHSCU Study","REHSCU","NCT04611425","RC20_0319","Drug: Remimazolam","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04611425","Not yet recruiting","2020-11-01","2021-05-01","{""locations"":""CHU de Nantes, Nantes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""30"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""composite endpoint including a combination of cardio-vascular and sedation events, from baseline (before infusion) to 8 hours, after the beginning of Remimazolam infusion|Adverse Events (all grades), related to Remimazolam.|Heart rate|Arterial pressure|Dose of norepinephrine|Electrocardiogram (ECG)|Sedation.|Other sedatives.|Wake-up time.|Pharmacokinetics of Remimazolam and its metabolites (CNS 7054): Maximum Plasma Concentration.|Pharmacodynamics Remimazolam and its metabolites (CNS 7054): steady state plasma levels and elimination.|Laboratory parameters : blood gas|Laboratory parameters: haemoglobin|Laboratory parameters: platelet count|Laboratory parameters: white blood cell count|Laboratory parameters: ionogram|Laboratory parameters: creatinine|Laboratory parameters: bilirubin|Laboratory parameters: albumin|Laboratory parameters: liver enzymes|Laboratory parameters: phosphorus|Laboratory parameters: magnesium|Extubation failure defined as the need to intubate a patient in the 96 hours following extubation.|Length of Mechanical ventilation.|Death.""}"
"3218","Safety and Tolerability Study of IV ST266 in COVID-19 Subjects","","NCT04720378","ST266-CRS-101","Biological: ST266","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04720378","Recruiting","2021-03-01","2021-08-01","{""locations"":""Innovative Research of West Florida, Clearwater, Florida, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence and Severity of Treatment-Emergent Adverse Events|Pulse Oximetry|Fever|Clinical Status on Ordinal Scale""}"
"3219","Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury","CHARTER-Irl","NCT04511923","NUIG-2020-003","Drug: Nebulised heparin","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04511923","Recruiting","2020-12-23","2022-01-01","{""locations"":""University Hospital Galway, Galway, Ireland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""D-dimer profile|Frequenccy of Severe Adverse Outcomes|Oxygenation Index|Indices of Inflammation|Ratios of Indices of Inflammation|Indices of Coagulation|Quasi-Static Lung Compliance|Time to separation from advanced respiratory support|Number treated with neuromuscular blockers|Number treated with Prone positioning|Number treated with extra-corporeal membrane oxygenation|Number requiring Tracheostomy|Time to separation from invasive ventilation among survivors|Discharge to ward|Discharge to ward in survivors|Patient Survival|Number of patients residing at home or in a community setting at day 60|Number of surviving patients residing at home or in a community|Ventilatory ratio|Number treated with awake prone positioning""}"
"3220","In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers","","NCT04431869","20-1399","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04431869","Recruiting","2020-08-18","2022-07-01","{""locations"":""Children's Hospital Colorado, Aurora, Colorado, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rates of intestinal atresias and limb abnormalities|Rates of preterm labor, fetal growth restriction and spontaneous abortions|Rates of maternal SARS-CoV-2 infection among mothers to infants born with intestinal atresias or limb anomalies""}"
"3221","COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID)","NEOSCREENCOVID","NCT04492410","2020/23","Other: rapid serological test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04492410","Active, not recruiting","2020-07-21","2021-05-01","{""locations"":""Centre Antoine Lacassagne, Nice, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate the prevalence of COVID-19|To evaluate patient's and health care professional's perception about the rapid serological test.|To evaluate the concordance of COVID-19 positivity by the rapid serological test compared to the gold-standard RT-PCR on nasal swab for eligible patients|To evaluate the concordance of COVID-19 positivity by the rapid serological test compared to a classic serological test (ELISA method) from whole blood|To evaluate the proportion of the patients who will have at least one positive testing among all the methods applied.|To evaluate the number of patients who will get at least one new testing after the rapid serological test has been performed.|To compare the clinical and biological characteristics between positive and negative tested COVID-19 patients|To describe the outcome of COVID-19 positive patients|To evaluate the impact of COVID-19 rapid serological test on the anti-cancer treatment schedule""}"
"3222","Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis","NINTECOR","NCT04541680","APHP200527","Drug: Nintedanib 150 MG [Ofev]|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04541680","Recruiting","2020-10-29","2021-12-01","{""locations"":""Pneumologie, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""250"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary objective is to assess whether nintedanib slows the progression of lung fibrosis in COVID-19 survivors as assessed by the decline in the forced vital capacity (FVC) over 12 months compared to placebo.|compare the rate of decline of DLCO over 12 months|compare exercise capacity at 12 months|compare high resolution CT (HRCT) lung opacities extension at 12 months|compare change in health-related quality of life|compare the evolution of dyspnea over time|compare change in Depression and anxiety over time|compare change in lung injury, pulmonary hypertension and inflammation biomarkers|pulmonary hypertension prevalence at inclusion and 12 months|association between genetic susceptibility (MUC5B polymorphism) and lung fibrosis in COVID-19 survivors|safety of nintedanib""}"
"3223","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","ATCO","NCT04332666","P2020/201","Drug: Angiotensin 1-7|Drug: Placebos","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04332666","Not yet recruiting","2020-09-30","2021-06-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ventilator free days|ICU free days|Hospital length of stay|Time to wean from mechanical ventilation|PaO2\/FiO2 changes during drug administration|Deep vein thrombosis incidence|Changes in inflammatory markers|RAS effectors levels|Radiological findings""}"
"3224","Survival Rates and Longterm Outcomes After COVID-19","","NCT04601090","135310","Other: ICU treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04601090","Recruiting","2020-09-16","2022-09-01","{""locations"":""Oslo University Hospital, Oslo, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU Survival rate|Change in Functional Status|Change in Anxiety and Depression|Changes in Cognitive Status|Change in Quality of Life 6 and 12 months after ICU admission""}"
"3225","Anakinra in the Management of COVID-19 Infection","","NCT04643678","MRC-05-140","Drug: Anakinra|Other: Standard of Care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04643678","Recruiting","2020-10-30","2021-10-30","{""locations"":""Hamad Medical Corporation, Doha, Qatar"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment Success at day 14|Change in WHO Clinical Progression Score|Time to ICU admission|Incidence of Adverse Events|Length of hospital stay|All-cause Mortality""}"
"3226","Intravenous Zotatifin in Adults With Mild or Moderate COVID-19","PROPEL","NCT04632381","eFT226-0003","Drug: Zotatifin|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04632381","Not yet recruiting","2020-11-16","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""36"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Safety as assessed by the incidence of Treatment Emergent Adverse Events and Serious Adverse Events|Safety as assessed by the incidence of adverse events of special interest:|Tolerability as assessed by changes in vital signs from baseline (Day 1)|Tolerability as assessed by changes in clinical symptoms from baseline (Day 1)|Tolerability as assessed by changes in clinical laboratory tests from baseline (Day 1)|Time to viral load undetectability;|Proportion of patients with SARS-CoV-2 viral load below the level of detectability;|Mean change in SARS-CoV-2 viral load;|The time to clinical resolution;|Zotatifin plasma concentrations""}"
"3227","Endothelial Damage and Angiogenesis Biomarkers During COVID-19","","NCT04609332","OAIC 1164/20","Diagnostic Test: Endothelial damage and angiogenic biomarkers","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04609332","Recruiting","2020-11-10","2021-11-01","{""locations"":""Hospital Cl\u00ednico de la Universidad de Chile, Independencia, Santiago, Chile"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from Baseline Syndecan-1 concentration at 10th day|Change from Baseline ANG-2 concentration at 10th day|Change from Baseline FGF basic concentration at 10th day|Change from Baseline HGF concentration at 10th day|Change from Baseline IL-8 concentration at 10th day|Change from Baseline PDGF-BB concentration at 10th day|Change from Baseline TIMP-1 concentration at 10th day|Change from Baseline TIMP-2 concentration at 10th day|Change from Baseline TNF\u03b1 concentration at 10th day|Change from Baseline VEGF concentration at 10th day|Change from Baseline Thrombomodulin concentration at 10th day|Major cardiovascular events""}"
"3228","Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU","EpiCoV-Brazil","NCT04378582","31382620.0.0000.0068","Other: risk factors","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04378582","Completed","2020-05-07","2020-08-05","{""locations"":""Hospital das Cl\u00ednicas -HCFMUSP, Sao Paulo, SP, Brazil"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""1589"",""age"":""14 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""ICU survival at 28 days|Hospital survival at 60 days|Duration of mechanical ventilation|Need for renal replacement therapy|Complications during the ICU stay""}"
"3229","Influence Physical Activity Psychological Responses COVID-19 Pandemic","","NCT04352517","3.954.038","Other: Online Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04352517","Completed","2020-03-16","2020-09-30","{""locations"":""Universidade da Sao Paulo, Ribeir\u00e3o Preto, Sao Paulo, Brazil|Universidad Autonoma de Chile, Santiago, Regi\u00f3n Metropolitana, Chile|Universidad de la Rep\u00fablica, Rivera, Uruguay"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""3500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through DASS-21|IImpact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through DASS-21|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through DASS-21""}"
"3230","COVID-19 on Placental Gene Expression and Pathology","PROSPER","NCT04585945","Pro00101090","Diagnostic Test: Positive for SARS-CoV-2 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04585945","Recruiting","2020-08-04","2021-09-30","{""locations"":""Prisma Health Upstate, Greenville, South Carolina, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Inflammatory biomarkers in umbilical cord blood between women with COVID-19 disease in the first, second and third trimester of pregnancy and determine if differences are mediated by severity of the illness.|Differences in placental pathology (inflammatory processes, vasculopathy, and villous maturity) for women with COVID-19 disease and determine of differences are mediated by gestational age at infection or severity of illness.|Differences in gene expression analysis for women with COVID-19 disease and determine if differences are medicated by gestational age at infection or severity of illness.""}"
"3231","Predicting Favorable Outcomes in Hospitalized Covid-19 Patients","","NCT04570488","PAU COVID19 RCT","Other: EPIC risk score display","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04570488","Recruiting","2020-05-15","2021-05-15","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research"",""enrollment"":""1200"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in days from first low-risk score to discharge|Reduction in length of stay (LOS)|Reduction in GTD vs. LOS|No change in 30 day re-ED presentation or hospital admission rate for cohort""}"
"3232","Parkinson's Disease and Experiences Throughout the COVID-19 Pandemic","","NCT04720118","1352","Other: No Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04720118","Recruiting","2021-02-01","2021-05-01","{""locations"":""Towson University, Towson, Maryland, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure of the relationship between Locus of Control and Quality of Life|Measure of secondary control and satisfaction with care""}"
"3233","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry","COVID-19","NCT04323787","20-002610","Other: observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04323787","Recruiting","2020-03-30","2021-04-30","{""locations"":""Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""50000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""ICU and hospital mortality of COVID-19 patients|30 days mortality""}"
"3234","An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.","","NCT04582201","C-1300-01","Drug: agenT-797","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04582201","Recruiting","2020-09-21","2021-10-15","{""locations"":""Weill Cornell Medicine New York Presbyterian, New York, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""55"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events|Number of Dose Limiting Toxicities|To assess time to improvement in pulmonary function.|Amount of virus detected in respiratory tract samples.|To assess longevity of agenT-797 infusion.""}"
"3235","A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer","","NCT04419623","TL-895-202","Drug: Part 1 - TL-895|Drug: Part 2 - TL-895|Drug: Part 2 - Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04419623","Recruiting","2020-07-09","2021-07-01","{""locations"":""University of Miami, Miami, Florida, United States|Georgia Cancer Center, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Barbara Ann Karmanos Cancer Institute - Wertz Clinic, Detroit, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States|OhioHealth - Riverside Methodist Hospital, Columbus, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""146"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Part 1 - Recommended dose of TL-895|Part 2 - Change in the need for artificial ventilation or death|Part 2 - Change in respiratory failure events that require invasive ventilation or death""}"
"3236","A Study of Combination Therapies to Treat COVID-19 Infection","","NCT04459702","PRG-043","Drug: hydroxychloroquine|Drug: Azithromycin|Drug: Ritonavir|Drug: Lopinavir","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04459702","Not yet recruiting","2020-07-01","2021-12-01","{""locations"":""ProgenaBiome, Ventura, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores|Efficacy of Treatment by Time to Non-Infectivity|Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores|Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.|Safety of Dual Therapy as Measured by Complete Blood Count|Safety of Quadruple Therapy as Measured by Complete Blood Count|Safety of Dual Therapy as Measured by Metabolic Panel -Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - A\/G Ratio|Safety of Dual Therapy as Measured by Metabolic Panel A\/G Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT|Safety of Dual Therapy as Measured by Metabolic Panel ALT|Safety of Dual Therapy as Measured by Metabolic Panel BUN\/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel BUN\/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein|Safety of Dual Therapy as Measured by Treatment Related SAE|Safety of Quadruple Therapy as Measured by Treatment Related SAE""}"
"3237","High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study","VitCov","NCT04525820","2020-01401","Drug: Single high dose vitamin D|Drug: Placebo|Drug: Treatment as usual vitamin D","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04525820","Recruiting","2020-12-15","2021-06-30","{""locations"":""Cantonal Hospital Aarau, Aarau, AG, Switzerland|Cantonal Hospital Baselland Liestal, Liestal, BL, Switzerland|Cantonal Hospital St. Gallen, Saint Gallen, SG, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Length of hospitalization|Need of intensive care|Lenght of the Intensive Care Treatment|Overall mortality|Development of vitamin D levels|Development of sepsis""}"
"3238","Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy","THROMBOCOVID","NCT04366752","PI2020_843_0036","Other: venous ultrasound|Other: blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366752","Recruiting","2020-04-22","2020-09-22","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation of thrombin time (in secondes) in Covid-19 patients with pneumonia admitted in ICU.|Variation of factor V concentration (U\/dL) in Covid-19 patients with pneumonia admitted in ICU.|Variation of factor II concentration (U\/dL) in Covid-19 patients with pneumonia admitted in ICU.|Variation of concentration of fibrin and fibrinogen degradation products (\u2265 10 \u00b5gm\/mL) in Covid-19 patients with pneumonia admitted in ICU.""}"
"3239","Biomarkers of Trained Immunity Following MMR Vaccination","","NCT04646239","202011081","Diagnostic Test: Heterologous stimuli","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04646239","Recruiting","2020-12-17","2021-04-01","{""locations"":""Washington University School of Medicine, Saint Louis, Missouri, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cytokine (or chemokine) production in response to heterologous stimuli|The ratio of cytokine (or chemokine) production between day 30 and day 0|The ratio of cytokine (or chemokine) production between MMR and placebo""}"
"3240","Improving Thinking in Everyday Life After Covid-19","","NCT04644172","IRB-300002814C","Behavioral: Speed of Processing Training|Behavioral: Instrumental Activities of Daily Living Shaping|Behavioral: Transfer Package from CI Therapy|Other: Usual Care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04644172","Recruiting","2020-11-01","2024-11-01","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Canadian Occupation Performance Measure (COPM)|Improved and New Cognitive Ability (INCA)|Cognitive Task Activity Log (CTAL) How Well Scale|Cognitive Task Activity Log (CTAL) Independence Scale|Assessment of Motor and Process Skills (AMPS)""}"
"3241","Convalescent Plasma Therapy for COVID-19 Patients","","NCT04565197","LGH008","Biological: convalescent plasma","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04565197","Active, not recruiting","2020-05-01","2020-12-30","{""locations"":""Muhammad Irfan Malik, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""15 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""clinical outcome after plasma therapy|Clinical response to treatment""}"
"3242","Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS","ULSC","NCT04494386","ULSC-CV-01","Biological: Umbilical Cord Lining Stem Cells (ULSC)|Other: Placebo (carrier control)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04494386","Recruiting","2020-07-23","2021-12-30","{""locations"":""Miami Baptist Hospital, Miami, Florida, United States|Sanford Research, Sioux Falls, South Dakota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Dose Limiting Toxicity (DLT)|Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)|Treatment-emergent adverse events (AE) and serious adverse events (SAE)|Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS|Changes from baseline pulse oximetric saturation SpO2\/FiO2 ratio or arterial oxygen pressure pAO2\/FiO2 ratio|Number of ventilator-free days (VFD)|Changes in Complete Blood Count (CBC) with differential from baseline|Changes in levels of blood glucose (mg\/dL) from baseline|Changes in levels of sodium (mEq\/L) from baseline|Changes in levels of potassium (mEq\/L) from baseline|Changes in levels of blood urea nitrogen (BUN; mg\/dL) from baseline|Changes in levels of alanine transaminase (ALT; U\/L) from baseline|Change in Urinalysis (UA) from baseline""}"
"3243","Feasibility, of Tele-rehabilitation Following COVID-19","","NCT04511962","285205","Other: Tele-Pulmonary rehabilitation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04511962","Not yet recruiting","2020-08-12","2022-01-20","{""locations"":""Castle Hill Hospital, Cottingham, East Yorkshire, United Kingdom"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recruitment - contact to consent ratio|Recruitment - screen failure rate|Recruitment rate|Recruitment retention|The Modified Medical Research Council (MMRC) Dyspnoea Scale|Numerical Rating Scale (NRS) of breathlessness|Cough Visual analogue Scale (VAS)|EQ-5D-5L questionnaire|Hospital Anxiety and Depression scale|Sit to stand test""}"
"3244","Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration","EpiSARS2","NCT04627623","2020/ABM /COVID19/0044","Diagnostic Test: IgM and IgG antibodies assay","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04627623","Recruiting","2020-06-22","2021-04-22","{""locations"":""Diagnostyka sp zoo, Katowice, Poland"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""6000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Estimation of prevalence of specific anti-SARS-CoV-2 IgM and IgG antibodies in general population.|Frequency of asymptomatic course of COVID in individuals with anti-SARS-CoV2 antibodies""}"
"3245","Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19","","NCT04343651","CD10_COVID-19","Drug: Placebos|Drug: Leronlimab (700mg)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04343651","Active, not recruiting","2020-04-01","2020-08-31","{""locations"":""University of California, Los Angeles, Los Angeles, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|Eisenhower Health, Rancho Mirage, California, United States|Yale, New Haven, Connecticut, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|White Plains Hospital, White Plains, New York, United States|Novant Health, Charlotte, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""86"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)|Time to clinical resolution (TTCR)|Change from baseline in National Early Warning Score 2 (NEWS2)|Change from baseline in pulse oxygen saturation (SpO2)|Change from baseline in the patient's health status on a 7-category ordinal scale|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Duration (days) of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate|Time to return to normal activity""}"
"3246","Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants","CORhum","NCT04426279","2020_49|2020-A01650-39","Other: questionnaire assesment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04426279","Recruiting","2020-08-18","2021-02-01","{""locations"":""Lille University Hospital, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""analysis of Covid-19-related morbidity and mortality in patients with IRC under IS.|To evaluate the frequency of Covid-19 in patients with IRC under IS.|To compare the morbidity and mortality of patients with IRC under IS during the Covid-19 epidemic wave (March to August 2020) with the six months prior to this wave (September 2019 to February 2020).|Patients' conduct in relation to their treatment during the epidemic wave (maintenance, modification or discontinuation) and the impact on their disease (loss of remission, flare, corticosteroids requirement and need for switch of DMARD therapy)""}"
"3247","RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM","STORM","NCT04433078","The STORM Trial","Drug: Doxycycline|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04433078","Recruiting","2020-06-22","2021-07-01","{""locations"":""Temple University Hospital, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death|NP SARS-CoV-2 PCR|SARS-CoV-2 Serum Quantitative Viral Load|SARS-CoV-2 IgM\/IgG Antibodies|White Blood Cell Count (WBC)|Absolute Lymphocyte Count (ALC)|C-Reactive Protein (CRP)|N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP)|High Sensitivity Troponin I (hsTnT)|Tumor Necrosis Factor Alpha (TNF-a)|IL-1|IL-1B|IL-6""}"
"3248","A Study of a Candidate COVID-19 Vaccine (COV001)","","NCT04324606","COV001","Biological: ChAdOx1 nCoV-19|Biological: MenACWY|Biological: ChAdOx1 nCoV-19 full boost|Biological: ChAdOx1 nCoV-19 half boost|Biological: MenACWY boost|Drug: Paracetamol|Biological: ChAdOx1 nCoV-19 0.5mL boost","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04324606","Active, not recruiting","2020-04-23","2021-10-01","{""locations"":""University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|St Georges University Hospital NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""1090"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by hospital admissions|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by ICU admissions|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by COVID-19 related deaths|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19""}"
"3249","Remote Monitoring of Cancer Patients With Suspected Covid-19","RECAP","NCT04397705","CFTSp186","Device: Patient Status Engine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04397705","Recruiting","2020-10-12","2021-04-01","{""locations"":""The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Device Tolerability (Attrition)|Correlation of physiological data with clinical events|Device Tolerability (Questionnaire)|Device Tolerability (Semi-structured interviews)|Reliability of data transmission""}"
"3250","A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic","","NCT04398277","20-183","Behavioral: Daily Coping Toolkit","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04398277","Recruiting","2020-05-01","2021-04-01","{""locations"":""Akron Children's Hospital, Akron, Ohio, United States|Summa Health Systems, Akron, Ohio, United States|Kent State University, Kent, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire - 4|World Health Organization Well Being Questionnaire|Affective Experience|Treatment Acceptability Questionnaire""}"
"3251","Psychological Impact of COVID-19 Pandemic in Healthcare Workers","PSIMCOV","NCT04506515","COV2-2020","Diagnostic Test: Psychological stress and adaptation at work score (PSAS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04506515","Completed","2020-04-09","2020-04-30","{""locations"":""CHGUV, Valencia, Spain"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""3000"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PSAS (Psychological Stress and Adaptation at work Score) during the crisis|PSAS (Psychological Stress and Adaptation at work Score) in basal conditions""}"
"3252","Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic","","NCT04396210","B6702020000247","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04396210","Completed","2020-05-14","2020-06-18","{""locations"":""Ghent University Hospital, Ghent, Belgium"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""389"",""age"":""18 Years to 47 Years \u00a0 (Adult)"",""outcome_measures"":""Patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire|Patients reproductive behaviour by using a questionnaire|Patients views on resuming fertility treatment by using a questionnaire""}"
"3253","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19","","NCT04285190","T89-NCP-01","Drug: T89","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04285190","Withdrawn","2020-02-26","2020-04-20","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The time to oxygen saturation recovery to normal level (\u226597%)|The proportion of patients with normal level of oxygen saturation(\u226597%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment""}"
"3254","FOUND - Ancillary Study to Smile Protocol NCT03654105","FOUND","NCT04441814","INT 49/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04441814","Enrolling by invitation","2019-07-23","2021-07-01","{""locations"":""Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""960"",""age"":""50 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Temporal variations in the frequency and morphology of SSNs according to the COVID-19 epidemic|Geographical variations in the frequency and morphology of SSNs according to the COVID-19 epidemic|Correlation between sub-solid lesions and individual risk|Correlation between sub-solid lesions and incidence of acute events""}"
"3255","Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS","","NCT04350710","2030/31","Other: PEEP trial","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04350710","Recruiting","2020-03-18","2020-12-31","{""locations"":""CHU, Angers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recruitment-to Inflation ratio (R\/I ratio)|PaO2\/FiO2 (mmHg)|Lung volume recruited (VRec)|Plateau pressure (cm H2O)|Oesophagal pressure (cm H2O)|weight (Kg)|urine output (mL)|serum creatinine (Umo\/L)|Mean arterial pressure (mmHg)|Peak Pressure (cm H2O)|PEEP total (cm H2O)|PEP Set (cm H2O)|Height (cm)|Airway pening pressure (cm H2O)|Expired volume in PEEP setted at 15 cmH2O (mL)|Expired volume in PEEP setted at 5 cmH2O (mL)""}"
"3256","BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization","BISCUIT","NCT04424134","MSU160520","Drug: Bromhexine and Spironolactone|Drug: Base therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04424134","Recruiting","2020-05-16","2020-08-23","{""locations"":""Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline in clinical assessment score COVID 19 (CAS COVID 19)|- Combine endpoint -|C-reactive protein|D-dimer|EuroQol Group. EQ-5D\u2122|EuroQol Group. EQ VAS|HADS|Hospital length of stay""}"
"3257","The Impact of Camostat Mesilate on COVID-19 Infection","CamoCO-19","NCT04321096","2020-001200-42","Drug: Camostat Mesilate|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04321096","Active, not recruiting","2020-04-04","2021-05-01","{""locations"":""Region Hospital North Jutland, Hj\u00f8rring, Region Nord, Denmark|Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hiller\u00f8d, Hiller\u00f8d, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, K\u00f8benhavn, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark|\u00d6rebro Hsopital, \u00d6rebro, \u00d6rebrolan, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""580"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cohort 1: Days to clinical improvement from study enrolment|Cohort 2: Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Cohort 1: Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Cohort 1: Day 30 mortality|Cohort 1: Change in NEW(2) score from baseline to day 30|Cohort 1: Admission to ICU|Cohort 1: Use of invasive mechanical ventilation or ECMO|Cohort 1: Duration of supplemental oxygen (days)|Cohort 1+2: Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30|Cohort 2: Number participant-reported secondary infection of housemates|Cohort 2: Time to hospital admission related to COVID-19 infection""}"
"3258","Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19","","NCT04384380","TYGH109014","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04384380","Completed","2020-04-01","2020-05-31","{""locations"":""Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""33"",""age"":""20 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to negatively RT-PCR|Virologic assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0""}"
"3259","Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients","","NCT04325048","COV001","Device: Cordio App","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04325048","Recruiting","2020-04-23","2021-09-01","{""locations"":""Rambam Medical Center, Haifa, Israel"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Voice anaysis""}"
"3260","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","INCOVPED","NCT04336761","2020_21|2020-A00811-38","Diagnostic Test: nasopharyngeal swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04336761","Completed","2020-04-15","2021-01-01","{""locations"":""CH Louis MOURIER, Colombes, France|H\u00f4pital Jeanne de Flandres, CHU, Lille, France|H\u00f4pital M\u00e8re Enfant CHU, Nantes, France|H\u00f4pitaux P\u00e9diatriques de Nice CHU-Lenval, Nice, France|H\u00f4pital des enfants - CHU, Toulouse, France|CHU de Tours, Tours, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""901"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Prevalence of positivity of COVID-19 virus measured by rt-PCR|Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients|Respiratory signs of children tested within 28 day|Percentage of children hospitalized tested within 28 day|Contact frequency|Prevalence of positivity of other respiratory viruses measured by rt-PCR""}"
"3261","Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box""","","NCT04385576","2020410-8498","Device: Aerosol Box|Device: Intubation Box","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04385576","Recruiting","2020-05-15","2020-12-30","{""locations"":""University Malaya Medical Centre, Kuala Lumpur, Selangor, Malaysia"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""30"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Time to successful intubation|Number of intubation attempts|Evaluation of the intubator's experience using both boxes""}"
"3262","Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia","","NCT04374565","200114","Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04374565","Active, not recruiting","2020-05-05","2021-04-05","{""locations"":""University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""29"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Transfer to ICU|28 day mortality|Cumulative incidence of serious adverse events|Rates and duration of SARS-CoV-2|Serum of plasma antibody titer to SARS-CoV-2|Cellular and humoral immune response|Supplemental oxygen free days|Ventilator free days|ICU free days|Sequential organ failure assessment score|Need for vasopressors|Need for renal replacement therapy|Need for extracorporeal membrane oxygenation (ECMO)|Hospital length of stay (LOS)|ICU LOS|Grade 3 or 4 Adverse Events (AEs)""}"
"3263","Assessment of Chilbains Occuring During Covid-19 Infection","ChilblainCOVID","NCT04344119","20dermatocovid01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344119","Recruiting","2020-04-09","2021-04-30","{""locations"":""CHU de Nice, Nice, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""up to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical skin manifestations|Histology and biological data|Non invasive vascular examination""}"
"3264","Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities","","NCT04377165","Care Collective Study","Behavioral: Gamification|Behavioral: Newsfeed function","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04377165","Terminated","2020-05-06","2020-08-26","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""34"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To compare the hours of sick leave used over the course of the 4-week period post randomisation for each group|To compare handwashing behaviour|To compare self-testing rates|To compare the level of surface wipe down|To compare number of COVID-19 tests completed in Facilities|To compare the number of COVID 19 infections in facilities|To compare the other types of outbreaks (Flu, gastroenteritis)|To compare the awareness of COVID 19 training available to workers in the facilities|To compare the awareness of PPE training available to workers in the facilities|To compare the levels of PPE material used in|To compare the wellbeing and self-efficacy of the two groups""}"
"3265","Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women","","NCT04407572","zinc-dvit-covid19","Other: Serum zinc, vitamin d vitamin b12 levels .","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407572","Completed","2020-04-20","2020-06-14","{""locations"":""Pinar Yalcin Bahat, Istanbul, \u0130\u0307stanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""44"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Serum zinc, vitamin d vitamin b12 deficiency levels""}"
"3266","Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).","VANGARD","NCT04433546","PB1046-PT-CL-0007","Drug: Pemziviptadil (PB1046)|Drug: Low Dose (10 mg) Control","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04433546","Terminated","2020-07-15","2020-12-02","{""locations"":""Baptist Health Research Institute, Jacksonville, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Adventist Healthcare White Oak Medical Center, Silver Spring, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""54"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical recovery from initiation of pemziviptadil (PB1046)|Time to clinical recovery (being well enough for hospital discharge or returning to normal baseline activity level prior to discharge)|Time to hospital discharge|All-cause mortality|Reduction in hospital resource utilization defined as a composite of: total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy|Time to clinical improvement as defined by reduction of at least 2 points on an 8-category ordinal scale of clinical improvement or discharge from hospital, whichever comes first.|Change from baseline in cardiac marker troponin I (TrI)|Change from baseline in cardiac marker NT-proBNP\/BNP|Change from baseline in TNF alpha|Change from baseline in IL-1|Change from baseline in IL-6|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by clinical adverse events (AEs) and their relationship to pemziviptadil (PB1046).|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by vital signs and their relationship to pemziviptadil (PB1046)|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by laboratory results and their relationship to pemziviptadil (PB1046)|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by electrocardiogram (ECG) abnormalities and their relationship to pemziviptadil (PB1046)|Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by incidence of anti-drug antibodies and their relationship to pemziviptadil (PB1046)""}"
"3267","Sevoflurane in COVID-19 ARDS (SevCov)","","NCT04355962","2020-00719","Drug: Sevoflurane|Drug: Intravenous drug","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04355962","Recruiting","2020-04-23","2022-03-31","{""locations"":""Kantonsspital M\u00fcnsterlingen, M\u00fcnsterlingen, Switzerland|Cantonal Hospital of St. Gallen, Sankt Gallen, Switzerland|Stadtspital Triemli, Zurich, Switzerland|University Hospital Zuirch, Zurich, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""64"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28|Length of stay ICU|Plasma Inflammatory markers|Length of stay at hospital|Sex-related differences in complications""}"
"3268","Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19","ECMO-SARS","NCT04397588","35RC20_8979 ECMO-SARS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397588","Recruiting","2020-04-21","2020-10-21","{""locations"":""Angers University Hospital, Angers, France|Besan\u00e7on Hospital, Besan\u00e7on, France|Brest university Hospital, Brest, France|Caen University Hospital, Caen, France|Clermont ferrand University hospital, Clermont-Ferrand, France|APHP Henri Mondor Paris University Hospital, Cr\u00e9teil, France|Dijon University Hospital, Dijon, France|Vend\u00e9e Hospital, La Roche-sur-Yon, France|Grenoble University Hospital, La Tronche, France|APHP Kremli Bicetre Paris University Hospital, Le Kremlin-Bic\u00eatre, France|Marie Lannelongue Hospital, Le Plessis-Robinson, France|Lens Hospital, Lens, France|Lille University Hospital, Lille, France|Limoges University Hospital, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Lyon University Hospital, Lyon, France|Marseille Europ\u00e9en Hospital, Marseille, France|APHM la Timone- Marseille University Hospital, Marseille, France|Clairval Hospital, Marseille, France|Metz University Hospital, Metz, France|Montpellier University Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy University Hospital, Nancy, France|Nantes University Hospital, Nantes, France|Ambroise Par\u00e9 Hospital, Neuilly-sur-Seine, France|Nimes University Hospital, Nimes, France|Institut Mutualiste Montsouris, Paris, France|APHP Hopital Europ\u00e9en Georges Pompidou - Paris University Hospital, Paris, France|APHP necker Paris University Hospital, Paris, France|APHP Bichat - Paris University Hospital, Paris, France|APHP La Piti\u00e9 Salp\u00eatri\u00e8re Paris University Hospital, Paris, France|Bordeaux University Hospital, Pessac, France|Poitiers University hospital, Poitiers, France|Reims University hospital, Reims, France|Rennes University hospital, Rennes, France|Rouen University Hospital, Rouen, France|Saint brieuc Hospital, Saint brieuc, France|La R\u00e9union University Hospital, Saint-Denis, France|Saint Nazaire Hospital, Saint-Nazaire, France|Saint Etienne University Hospital, Saint-\u00c9tienne, France|Strasbourg University Hospital, Strasbourg, France|Toulouse University Hospital - Rangueil Hospital, Toulouse, France|Tours University Hospital, Tours, France|Bretagne Atlantique Hospital, Vannes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Hospital mortality|Mortality Day 28|Mortality Day 90|Ventilator-free days|Intensive care unit-free days|Hospital-free days""}"
"3269","The Covid-19 HEalth caRe wOrkErS (HEROES) Study","HEROES","NCT04352634","HEROES Covid-19","Other: Exposure to the SARS-CoV-2 and its consequences","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04352634","Recruiting","2020-04-26","2021-12-31","{""locations"":""Columbia University, New York, New York, United States|Universidad del Chubut, Rawson, Chubut, Argentina|National Institute of Health Named After Academician S. Avdalbekyan, Yerevan, Armenia|University of Sydney, Sidney, New South Wales, Australia|Salud Global, Sucre, Chuquisaca, Bolivia|University of Chile, Santiago, Chile|Universidad Nacional de Costa Rica, Heredia, Costa Rica|Society for Emergecy and Disaster Medicine CzMA JEP, Kladno, Bohemia, Czechia|Hochschule Emden\/Leer, Emden, Niedersachsen, Germany|Centro de Investigaciones de las Ciencias de la Salud -CICS- Facultad de Ciencias M\u00e9dicas Universidad de San Carlos de Guatemala -USAC-, Guatemala City, Guatemala|University of Cagliari, Cagliari, CA, Italy|University of Cagliari, Cagliari, Italy|The Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon|Logotipo del comercio Instituto Jalisciense De Salud Mental (SALME), Guadalajara, Jalisco, Mexico|Maastricht University, Maastricht, Limburg, Netherlands|University of Ibadan, Ibadan, Oyo State, Nigeria|Ponce Health Sciences University, Ponce, Puerto Rico|King Abdullah International medical research center, Riyadh, Central, Saudi Arabia|Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain|Razi Hospital La Manouba, Tunis, La Manouba, Tunisia|Koc University, Istanbul, Sariyer, Turkey|PNFA Salud Colectiva Instituto de Altos Estudios Dr Arnoldo Gabaldon, Maracay, Aragua, Venezuela"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety and depressive symptoms|Experiences, fears and concerns about the Covid-19|Training and resource prioritization|Suicide ideation (presence)|Suicide ideation (frequency)|Acute stress symptoms|Psycho\/social support and network|Resilience""}"
"3270","RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)","SAMICARE","NCT04453839","RLF-100_EA-1","Drug: RLF-100 (aviptadil)","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04453839","Available","1970-01-01","1970-01-01","{""locations"":""Dignity Health-Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Honor Health Shea Medical Center, Scottsdale, Arizona, United States|Kaiser Permanente, Baldwin Park, California, United States|University of California - Irvine, Irvine, California, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Lakeland Regional Health, Lakeland, Florida, United States|Miller School of Medicine \/ University of Miami Medical Center, Miami, Florida, United States|Baycare St. Joseph Hospital, Tampa, Florida, United States|Southeast Georgia Health system, Brunswick, Georgia, United States|Maui Health Systems, Wailuku, Hawaii, United States|St. Anthony Regional Hospital, Carroll, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|St. Tammany Parish Hospital, Covington, Louisiana, United States|Our Ladies of Lourdes Regional Hospital, Lafayette, Louisiana, United States|St. Joseph Heritage Healthcare, Saint Joseph, Missouri, United States|Great Plains Health, North Platte, Nebraska, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Hendrick Medical Center, Abilene, Texas, United States|Baptist Hospitals of Southeast Texas, Beaumont, Texas, United States|Medical City Denton, Denton, Texas, United States|HR Health Institute for Research & Development, Edinburg, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann Hospital Houston, Houston, Texas, United States|Medical City McKinney, McKinney, Texas, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""12 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""""}"
"3271","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","STROMA-CoV2","NCT04333368","APHP200395|2020-001287-28","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04333368","Active, not recruiting","2020-04-06","2022-04-06","{""locations"":""H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re - APHP, Paris, France|H\u00f4pital Europ\u00e9en Georges Pompidou - APHP, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""47"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Respiratory efficacy evaluated by the increase in PaO2\/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2\/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage""}"
"3272","Tocilizumab in COVID-19 Lahore General Hospital","TC19LGH","NCT04560205","LGH001","Drug: Tocilizumab","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04560205","Recruiting","2020-05-01","2020-12-30","{""locations"":""Lahore General Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""15 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical response after administration|Clinical response to treatment|Duration of hospitalization|Clinical outcome of the treatment|Supplemental Oxygen Requirement from Baseline""}"
"3273","Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)","","NCT04361461","APS000/2020","Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04361461","Withdrawn","2020-04-30","2020-11-04","{""locations"":""Apsen Farmac\u00eautica S.A., S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Individual response rate|All-cause mortality|Duration of mechanical ventilation|Proportion of patients which needed mechanical ventilation during study|World Health Organization (WHO) Ordinal scale|Duration of hospitalization|Rates of drug discontinuation""}"
"3274","Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels","","NCT04438954","2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04438954","Completed","2020-05-05","2020-06-18","{""locations"":""Ankara Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""21 Years to 58 Years \u00a0 (Adult)"",""outcome_measures"":""Fatigue|Physical activity|Sleep quality|Anxiety""}"
"3275","Mental Health Consequences of COVID19 Infection in the French RMD Cohort","MentCovid19RMD","NCT04510467","2020_75|2020-A02058-31","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04510467","Not yet recruiting","2021-01-01","2021-08-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""1313"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of PTSD depending on whether or not autoimmune patients have experienced COVID|Severity of PTSD depending on whether or not autoimmune patients have experienced COVID""}"
"3276","Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19","","NCT04381377","PО-COV-III-20","Drug: azoximer bromide|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04381377","Active, not recruiting","2020-04-29","2021-04-01","{""locations"":""Regional state budgetary institution of public health \""City hospital No. 5 of Barnaul\"", Barnaul, Russian Federation|Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation|The state healthcare institution of the city of Moscow \""City Clinical Hospital No. 15 named after OM Filatov\"" in \""Moscow City Department of Health\"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution \""Infectious Clinical Hospital No. 1 of the Moscow Department of Healthcare\"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution \""City Clinical Hospital No. 24 of the Moscow Department of Healthcare\"", Moscow, Russian Federation|State budgetary institution \""Research Institute of Emergency Care named after N.V. Sklifosovsky in Department of Health of the city of Moscow\"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution \""City Clinical Hospital No. 40 of the Moscow Department of Healthcare\"", Moscow, Russian Federation|State budgetary institution of health care of the Nizhny Novgorod region \""Infectious clinical hospital No. 2 of Nizhny Novgorod\"", Nizhny Novgorod, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""Orenburg State Medical University\"" of the Ministry of Health of the Russian Federation, Orenburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""First St. Petersburg State Medical University named after Academician I.P. Pavlov, Saint Petersburg, Russian Federation|State budgetary health institution of the Vladimir region \""Regional Clinical Hospital\"", Vladimir, Russian Federation|Yaroslavl State Medical University of Ministry of Health of the Russian Federation, Yaroslavl, Russian Federation|Clinics of Infectious Diseases, University Hospital in Nitra, Nitra, Slovakia|Clinics of Infectious Diseases, University Hospital in Trnava, Trnava, Slovakia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""394"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical status of the patient (according to 7-point ordinal scale)|NEWS|Oxygenation|Mechanical Ventilation|Mortality""}"
"3277","The COVID-ICU Healthcare Professional Study","","NCT04372056","136144","Behavioral: Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04372056","Recruiting","2020-05-06","2021-05-06","{""locations"":""Oslo university hospital, Oslo, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2200"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic""}"
"3278","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","TACOS","NCT04306705","WHTJCOVID-19","Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04306705","Recruiting","2020-02-20","2020-06-20","{""locations"":""Tongji Hospital, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""120"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1\u03b2, IL-10, sIL-2R, IL-6, IL-8 and TNF-\u03b1|Change from baseline in proportion of CD4+CD3\/CD8+CD3 T cells""}"
"3279","Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","","NCT04347239","CD12_COVID-19","Drug: Placebos|Drug: Leronlimab (700mg)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04347239","Recruiting","2020-04-15","2021-04-01","{""locations"":""Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|St. Jude Medical Center, Fullerton, California, United States|UCLA, Los Angeles, California, United States|James A. Haley Veterans' Hospital, Tampa, Florida, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|St. Barnabas, Livingston, New Jersey, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|New York Community Hospital of Brooklyn, Brooklyn, New York, United States|Novant Health, Winston-Salem, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""390"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality at Day 28|All-cause mortality at Day 14|Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)|Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)|Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.""}"
"3280","A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19","EQUINOX","NCT04605926","EQ001-20-001","Biological: EQ001|Biological: EQ001 Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04605926","Withdrawn","2020-11-01","2021-06-01","{""locations"":""Inv Site CO01, Medell\u00edn, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects who have recovered at Day 28.|Proportion of subjects deceased or requiring mechanical ventilation at Day 28.|Proportion of subjects deceased at Day 28.""}"
"3281","KIDney Injury in Times of COVID-19 (KIDCOV)","KIDCOV","NCT04705766","KIDCOV2020|R01DK109720","Other: Urine Collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04705766","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":""University of California, San Francisco, California, United States|Rush University, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Continuous, Quantitative KIT Score|Number of participants with a level of Kidney Injury Molecule-1 (KIM1) above 1 ng\/ml|Number of participants with a level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) above 1 ng\/ml|Number of participants with a level of soluble urokinase-type plasminogen activator receptor (suPAR) above 1 ng\/ml""}"
"3282","STerOids in COVID-19 Study","STOIC","NCT04416399","STOIC study","Drug: Budesonide dry powder inhaler","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04416399","Terminated","2020-07-16","2021-01-12","{""locations"":""Oxford Respiratory Trials Unit, Oxford, Oxfordshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""146"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Emergency department attendance of hospitalisation related to COVID-19|Body temperature|Blood oxygen saturation level|Symptoms as assessed by common cold questionnaire|Symptoms as assessed by FluPro questionnaire|Nasal\/throat swab SARS-CoV-2 viral load""}"
"3283","Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals","COVID_2Pro","NCT04349228","ECC2020-03","Drug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04349228","Withdrawn","2020-04-28","2020-07-15","{""locations"":""Eshmoun Clinical Research Centre\/ H\u00f4pital Abderrahmane Mami-Ariana, Tunis, Tunisia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""0"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptomatic COVID(+) infection rate""}"
"3284","The MentalPlus® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19","MP-COVID","NCT04632719","MentalPlus®","Device: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04632719","Recruiting","2020-11-08","2023-12-29","{""locations"":""Livia Stocco Sanches Valentin, S\u00e3o Paulo, SP, Brazil|Livia Stocco Sanches Valentin, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""8 Years to 88 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Assessment of cognitive functions after COVID-19|Rehabilitation of cognitive functions after COVID-19""}"
"3285","Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19","","NCT04374617","PR(AG)213/2020","Diagnostic Test: Duplex ultrasound and Computed Tomography Angiography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374617","Completed","2020-04-01","2020-05-01","{""locations"":""Vall d\u00b4Hebron Research Institute VHIR, Barcelona, Catalunya, Spain|Hospital Germans Trias i Pujol. Universitat Aut\u00f2noma de Barcelona, Badalona, Spain|Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Venous thromboembolisms|Deaths""}"
"3286","COVID-19, Obesity and Lifestyle in Children","COLC","NCT04411511","2020-1330","Other: Exposure to the Dutch measures due to the Covid-19 pandemic.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04411511","Recruiting","2020-05-06","2021-05-06","{""locations"":""Maastricht University Medical Center, Maastricht, Limburg, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""4 Years to 17 Years \u00a0 (Child)"",""outcome_measures"":""Change in weight child|Change in weight parents|Eating behaviour|Symptoms|Day structure|Physical activity|Screentime|Online possibilities|Quality of life in children|Parenting practices""}"
"3287","NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)","","NCT04442230","ALT-601-201","Biological: NasoVAX|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04442230","Recruiting","2020-10-10","2021-02-01","{""locations"":""Miami Dade Medical Research Institute, Miami, Florida, United States|Infinite Clinical Trials, Morrow, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|Columbia University, New York, New York, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Centex Studies, Houston, Texas, United States|Centex Studies, McAllen, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""96"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with clinical worsening|Maximal severity of COVID-19 after treatment|All-cause mortality""}"
"3288","Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)","INSPIRE","NCT04610515","75D30120C08008","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04610515","Recruiting","2020-12-15","2022-11-14","{""locations"":""UCLA, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Yale, New Haven, Connecticut, United States|Rush University Medical Center, Chicago, Illinois, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Texas Southwestern, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Washington, Seattle, Washington, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incident myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS)|Ambulatory care and\/or ED visits post enrollment|Hospitalizations post enrollment|Death during hospital admission|Hospital-free survival|ICU-free survival""}"
"3289","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","HELPCOVID-19","NCT04335084","PRG-042","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04335084","Recruiting","2020-06-22","2021-12-01","{""locations"":""ProgenaBiome, Ventura, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevention of COVID-19 symptoms as recorded in a daily diary|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events""}"
"3290","The Impact of COVID-19 Pandemic on Cancer Care","","NCT04382495","Cancer Care during Covid-19","Other: survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382495","Recruiting","2020-06-15","2021-06-01","{""locations"":""EgyBrit Medical Centre, Cairo, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""patients' and survivors' perspective of their cancer care during COVID-19 pandemic""}"
"3291","National Survey of the Impact of COVID-19 Pandemics","CMDA-SURVEY2","NCT04491201","CMDA-SURVEY2","Other: Customized questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04491201","Recruiting","2020-07-27","2020-09-27","{""locations"":""Lei Li, Beijing, Beijing, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""6000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The changes of workload of physicians during COVID-19 pandemics compared with 2019 year|The changes of education activities during COVID-19 pandemics compared with 2019 year|The changes of research activities during COVID-19 pandemics compared with 2019 year""}"
"3292","Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge","","NCT04368793","2020-22-K17","Behavioral: Remote pulmonary rehabilitation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368793","Recruiting","2020-04-06","2021-12-31","{""locations"":""Wuhan Lung Hospital, Wuhan, Hubei, China|Wuhan Central Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""20 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Six-minute walking distance (6MWD)|Pulmonary function|Respiratory muscle strength|Physical fitness assessment|Symptom|Psychological evaluation|Quality of life|Physical activity|Proportion of returning to society""}"
"3293","Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)","CX4945","NCT04668209","CX4945-AV02-IIT","Drug: Silmitasertib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04668209","Recruiting","2021-01-01","2021-03-31","{""locations"":""Banner University Medical Center Phoenix, Phoenix, Arizona, United States|Banner University Medical Center Tucson, Tucson, Arizona, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]|To compare time to clinical recovery in CX-4945 treatment group evaluated from randomization through Day 28 as compared to the control arm.|To compare changes in clinical status of patients enrolled to CX-4945 treatment arm as compared to the control arm at Day 14 and Day 28.|To evaluate preliminary evidence of anti-viral activity of CX-4945 as compared to the control arm.|Number of Days Hospitalized|To evaluate changes in IL-6 level|To evaluate changes in CRP|To evaluate changes in LDH|To evaluate changes in CPK|To evaluate changes in Ferritin|To evaluate changes in D-dimer|Number of Days of Supplemental Oxygen Use|All-cause Mortality Status|Number of days of on-invasive ventilation\/high flow oxygen|Number of days of invasive mechanical ventilation\/ECMO|Number of patients returned to room air|Change in pulse oxygen saturation|Number of thrombosis events|Changes in EQ-D5-5L""}"
"3294","Cardiac COVID-19 Health Care Workers","CCC","NCT04413071","CCC_2020","Other: Passed infection of SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04413071","Completed","2020-05-25","2020-06-12","{""locations"":""University Hospital of Salamanca, Salamanca, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""142"",""age"":""18 Years to 71 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Myocarditis|Pericarditis|Atrial fibrillation|Ischemic heart disease|Dilatation of right heart chambers|Valvular hear disease|Rhythm disorders""}"
"3295","Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants","","NCT04442152","265A","Behavioral: MenCare+/Bandebereho fathers'/couples' group education","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04442152","Enrolling by invitation","2020-06-01","2020-08-01","{""locations"":""Rwanda Men's Resource Centre (Rwamrec), Kigali, Rwanda"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""26 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Gender division of caregiving\/domestic tasks|Couple communication|Couple conflict|Men's alcohol use|Household economic situation|Stress and frustration""}"
"3296","Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection","","NCT04367883","02-20-161-021","Drug: ACE inhibitor|Drug: ARB","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367883","Recruiting","2020-03-01","2023-08-31","{""locations"":""Hospital de Terrassa, Terrassa, Barcelona, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""2574"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""hospital output|hospital stay""}"
"3297","Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)","","NCT04448756","MS200569_0026|2020-002248-22","Drug: M5049|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04448756","Recruiting","2020-07-29","2021-06-06","{""locations"":""University of Alabama-Birmingham Hospital, Birmingham, Alabama, United States|LAC-USC Medical Center, Los Angeles, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Saint Louis University - Saint Louis University Hospital, Saint Louis, Missouri, United States|Holy Name Hospital - Dept of Multiple Sclerosis Comp Care Center, Teaneck, New Jersey, United States|Christus Spohn Hospital Corpus Christi-Memorial, Corpus Christi, Texas, United States|Santa Casa de Miseric\u00f3rdia de Belo Horizonte, Belo Horizonte, Brazil|Hospital Dia do Pulm\u00e3o, Blumenau, Brazil|Hospital S\u00e3o Jos\u00e9 - Sociedade Liter\u00e1ria e Caritativa Santo Agostinho, Crici\u00fama, Brazil|Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil|HMCG - Hospital e Maternidade Dr. Christov\u00e3o da Gama, Santo Andr\u00e9, Brazil|Pesquisare, Santo Andr\u00e9, Brazil|Hospital Leforte Morumbi, Sao Paulo, Brazil|Hospital Alem\u00e3o Oswaldo Cruz, S\u00e3o Paulo, Brazil|Hospital Bandeirantes \/ Hospital Leforte Liberdade, S\u00e3o Paulo, Brazil|Instituto de Infectologia Em\u00edlio Ribas, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants Alive and not Requiring Supplemental Oxygenation|Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs)|Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings|Clinical Status of Participants on a 9-Point Ordinal Scale|Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours on Room Air|Percentage of Participants With All-Cause Mortality|Clinical Deterioration: Time to Intensive Care Unit (ICU) Admission|Clinical Deterioration: Time to Invasive Mechanical Ventilation|Clinical Deterioration: Time to Non-Invasive Mechanical Ventilation|Total Length of Stay in Intensive Care Unit (ICU)|Total Length of Hospitalization Stay|Percentage Change From Baseline in Inflammatory Biomarkers|Percentage Change From Baseline in Cytokine Biomarkers|Percentage of Participants With Relapse|Percentage of Participants who are Re-Hospitalized|Maximum Observed Concentration (Cmax) of M5049|Time to Reach the Maximum Observed Concentration (tmax) of M5049|Terminal Rate Constant (Lambda z) of M5049|Apparent Elimination Half-Life (t1\/2) of M5049|Area Under the Plasma Concentration-Time Curve From Time of Dosing to the Time of the Last Observation (AUC0-t) of M5049|Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose (AUC0-12h) of M5049|Area Under the Plasma Concentration-Time Curve From Time of Dosing to Infinity (AUC0-Infinity) of M5049|Apparent Total Body Clearance (CL\/F) of M5049|Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz\/F) of M5049|Dose-Normalized Maximum Observed Concentration (Cmax\/Dose) of M5049|Dose-Normalized Area Under the Plasma Concentration-Time Curve From Time of Dosing to the Time of the Last Observation (AUC0-t\/Dose) of M5049|Dose-Normalized Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose (AUC0-12h\/Dose) of M5049|Dose-Normalized Area Under the Plasma Concentration-Time Curve From Time of Dosing to Infinity (AUC0-Infinity\/Dose) of M5049|Accumulation Ratio for Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose [Racc(AUC0- 12h)] of M5049|Accumulation Ratio for Maximum Observed Concentration [Racc(Cmax)] of M5049""}"
"3298","Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection","Coronavirus","NCT04349098","XPORT-CoV-1001|2020-001411-25","Drug: Selinexor|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04349098","Completed","2020-04-17","2020-10-05","{""locations"":""UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""202"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged from Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants \u2264 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Changes from Baseline in Blood Plasma Cytokines Levels|Number of Participants with Adverse Events (AE)""}"
"3299","Covid-19, Acute Myocardial Infarctions and Strokes in France","COVUSI","NCT04542083","RECHMPL20_0513","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04542083","Not yet recruiting","2021-01-20","2021-06-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Daily number of admissions for acute cardio- and neurivascular conditions in France.|Specific mortality rate.""}"
"3300","A Study of ResCure™ to Treat COVID-19 Infection","","NCT04395716","PRG-048","Biological: ResCure™","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04395716","Not yet recruiting","2020-07-01","2021-11-01","{""locations"":""ProgenaBiome, Ventura, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The rate of recovery of mild or moderate COVID-19 in patients using ResCure\u2122|Reduction or progression of symptomatic days|Assess the safety of ResCure\u2122 via pulse|Assess the safety of ResCure\u2122 via oxygen saturation|Assess the safety of ResCure\u2122 via EKG|Assess Tolerability of ResCure\u2122""}"
"3301","Timing of Tracheotomy in Covid-19 Patients","TTCOV19","NCT04412356","HBergquist","Procedure: Tracheotomy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04412356","Recruiting","2020-06-04","2021-02-01","{""locations"":""Sahlgrenska University Hospital, Gothenburg, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation|ICU stay|Oxygen support|Sedation|Adverse events|Mortality""}"
"3302","SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism","COVIRIC","NCT04584541","APHP200598","Biological: blood tests|Biological: Nasopharyngeal swabs|Biological: Stools","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04584541","Recruiting","2020-06-11","2023-12-01","{""locations"":""Cochin hospital, Paris, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs|Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood|Isolation and characterization of B and T lymphocytes in blood""}"
"3303","Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic","","NCT04403438","10840098-604.01.01-E.14697","Other: ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403438","Enrolling by invitation","2020-04-01","2020-06-15","{""locations"":""IstanbulU, Istanbul, Bak\u0131rk\u00f6y, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""45"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IPAQ-SF|Numeric Rating Scale|Short-Form 36 Health Survey (SF-36)|Exercise Stage of Change Questionnaire|Exercise Self-Efficacy Questionnaire|Decisional Balance Questionnaire""}"
"3304","Effect of a Nss to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III","","NCT04507867","202036","Dietary Supplement: Nutritional support system (NSS)|Other: Control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04507867","Not yet recruiting","2020-08-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care"",""enrollment"":""240"",""age"":""30 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygen saturation|Body temperature|Blood pressure|Heart rate|Breathing frequency|Death|Awareness|Hospital stay|qSOFA score|Progression to ventilation|Progression to Intensive Care Unit|Cephalea|Activity level|Anatomic position|Hair hydration|Hair loss|Decalvary patches|Scalp lesions|Itching scalp|Loss of eyelashes|Drooping of eyebrows|Eyelid edema|Vascularity of the sclera|Ocular hydration|Sclera color|Sense of smell|Irritation in the nostrils|Nasal secretions|Cheilitis|Taste buds|Saw edge of the tongue|Changes in the body of the tongue|Thickness of the tongue|Salivation|Taste|Gums|Skin sensitivity|Skin lesions|Skin hydration|Skin texture|Absence of body hair|Cervical pain points|Forearm pain points|Odynophagia|Cough|Sneezing|Respiration rhythm|Abdominal breathing|Use of accessory muscles when breathing|Xiphoid retraction when breathing|Dyspnea|Abdomino-cutaneous reflexes|Rebound sensitivity|Right hypochondrium|Epigastrium|Left hypochondrium|Right flank|Mesogastrium|Left flank|Right iliac fossa.|Hypogastrium|Left iliac fossa.|Vomiting|Appetite|Reflux|Burps|Bristol scale|Hair loss on legs|Sensitivity of the tibial tract|Nail strength|Fungus in the nails of the hands|White stripes on the nails|White spots on the nails|Ridges on the nails|Height|Weight|BMI|Erythrocytes|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean hemoglobin concentration|Mean corpuscular hemoglobin concentration|Erythrocyte distribution width|Hemoglobin distribution index|Leukocytes|Neutrophils (%)|Neutrophils (#)|Lymphocytes (%)|Lymphocytes (#)|Monocytes (%)|Monocytes (#)|Eosinophils (%)|Eosinophils (#)|Basophils (%)|Basophils (#)|Prothrombin time|INR|Control blood sample (100-50) 1|Partial thromboplastin time|Control blood sample (100-50) 2|Platelets|Mean platelet volume|D-dimer|Homocysteine|Vitamin D|Calcium|Phosphorus|Magnesium|Sodium|Potassium|Chlorine|Blood glucose|Total cholesterol|Triglycerides|LDL cholesterol|HDL cholesterol|Aspartate aminotransferase|Alanine aminotransferase|Total bilirubin|Direct bilirubin|Indirect bilirubin|Alkaline phosphatase|Total proteins|Albumin level|Globulin level|A \/ G ratio|Urea nitrogen|Urea|Creatitine|Uric acid|Ferritin|Fibrinogen|C-reactive protein|Adherence to the Nutritional Support System (NSS)|Intake time|Amount of prepared \""NSS\"" he drink|Taking of the \""floratil\"" pill|Neurobion injection|Diet calories|Trans fat in the diet|Saturated fat in the diet.|Monounsaturated fats in the diet|Polyunsaturated fat in the diet|Protein of animal origin in the diet|Plant-based protein in the diet|Fluid balance (income)|Fluid balance (outcome)|Hungry|Abdominal circumference|Arm circumference.|Tricipital fold|Arm area|Biological sex|Age|AB0 system|Rh factor|Use of proton pump inhibitors|Obesity medications|Use of antiepileptic drugs|Use of oral contraceptives|Use of antimitotics|Antibiotics|Analgesics|Corticosteroids|Diuretics|Antihypertensive|Anticoagulants|Other medications|Acute alterations in the absorption of nutrients.|Drug interactions and adverse effects|Oxygen therapy|Mood""}"
"3305","Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19","STOPCOVID19","NCT04718220","202012075","Diagnostic Test: Antibody testing for SARS-CoV-2 IgG|Diagnostic Test: Testing for SARS-CoV-2 RNA|Diagnostic Test: Testing for SARS-CoV-2 IgM/IgG","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04718220","Not yet recruiting","2021-02-01","2022-11-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""420"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Rate of preterm delivery|Rate of preeclampsia|Rate of gestational hypertension|Rate of cesarean section|Rate of stillbirth|Rate of fetal growth restriction|Rate of fetal hydrops|Rate of oligohydramnios|Perinatal death|Rate of premature preterm rupture of membranes|Rate of neonatal intensive care unit (NICU) admission|Rate of neonatal sepsis|Rate of oxygen therapy|Percentage of infants with low 5-minute Apgar|Percentage of infants with abnormal umbilical cord gas|Low birth weight|Confirmed congenital infection|Probable congenital infection|Possible congenital infection""}"
"3306","Prognostic Factors and Outcomes of COVID-19 Cases in Ethiopia","","NCT04584424","EPHI National Cohort","Other: The study does not required","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04584424","Not yet recruiting","2020-10-30","2021-11-14","{""locations"":""Saro Abdella, Addis Ababa, Ethiopia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""6390"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patients survival or death|Rate of recovery time|Viral shedding|Viral loads|Clinical symptoms and signs|Blood pressure|Assess the prevalence of severe forms among hospitalized patients with diab\u00e8tes and COVID-19|Assess the prevalence of severe forms among hospitalized patients with cancer and COVID-19|Lipid Profiles|Assess the prevalence of nutrient intakes|Assess the prevalence of micronutrients deficiencies among hospitalized patients with COVID-19""}"
"3307","Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","CloroCOVID19II","NCT04342650","CAAE: 30504220.5.0000.0005","Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04342650","Completed","2020-04-08","2020-06-08","{""locations"":""Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""152"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with onset of severe acute respiratory syndrome (SARS)|Mortality rate|Number of participants in need of intensive care support|Viral concentration|Cumulative incidence of serious adverse events|Cumulative incidence of grade 3 and 4 adverse events|Proportion of patients with discontinued treatment|Incidence of cardiac lesions|Incidence of cardiac disfunctions|Change in respiratory capacity""}"
"3308","Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity","COVIDORL","NCT04361474","MDL_2020_10","Drug: Budesonide Nasal|Other: Physiological serum","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04361474","Active, not recruiting","2020-05-18","2021-05-25","{""locations"":""Am\u00e9lie YAvchitz, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient with more than 2 points on the ODORATEST""}"
"3309","Liver Injury in Patients With COVID-19","","NCT04358380","CIE N° P 20-011","Other: Liver injury","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04358380","Enrolling by invitation","2020-04-15","2020-12-31","{""locations"":""Universidad Austral, Pilar, Buenos Aires, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""320"",""age"":""17 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Liver injury in patients with COVID-19|Prognostic factors associated with death|Clinical characteristics of patients who developed liver injury""}"
"3310","Impact of the COVID-19 Pandemic in Gynecological Oncology","COVID-GYN","NCT04351139","69HCL20_0346|2020-A01036-33","Other: modification of the planned therapeutic management","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351139","Completed","2020-05-06","2020-11-30","{""locations"":""Service de Gyn\u00e9cologie, HFME, Hospices Civils de Lyon, Bron, France|Service de Gyn\u00e9cologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service Gyn\u00e9cologie, CHLS, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""205"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)""}"
"3311","Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients","","NCT04560413","FSMEAH-KAEK 2020/41","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04560413","Completed","2020-06-01","2020-08-10","{""locations"":""Fatih Sultan Mehmet Training and Research Hospital, \u0130stanbul, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""77"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital Anxiety and Depression Scale|Covid 19 Phobia Scale""}"
"3312","MANAGEMENT OF APPENDICITIS DURING THE COVID-19 PANDEMIC","observational","NCT04615728","PRN8996","Procedure: laparoscopic or open appendicectomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04615728","Completed","2019-11-01","2020-10-06","{""locations"":""Addenbrooke's University Hospital, Cambridge, Cambridgeshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""207"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality|Failure of primary proposed treatment|length of stay|Re-attendance|Imaging|Intra-operative findings during surgery""}"
"3313","SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19)","SUROCO","NCT04458337","19.386","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04458337","Recruiting","2020-03-13","2021-04-13","{""locations"":""Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Quebec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Survival up to 30 days after surgery|Occurrence of postoperative respiratory complications|Occurrence of postoperative non-pulmonary infectious complications|Occurrence of acute kidney injury (AKI)|Occurrence of postoperative thromboembolic complications|The need for a new postoperative ICU admission|Hospital length of stay|30-day mechanical ventilation free-days|30-day organ dysfunction free days|Surgical reinterventions|Any ICU admission during the index hospital stay|Time of room cleaning|6-month survival""}"
"3314","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease","COVIDeHPAD","NCT04337788","87RI20_0013","Other: telehealth applications","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04337788","Not yet recruiting","2020-05-01","2020-09-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""75 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).""}"
"3315","COVID-19 Research in Organ Transplant Recipients","CORONA","NCT04407221","COV-19-SU-TX","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407221","Enrolling by invitation","2020-06-16","2024-05-01","{""locations"":""The Transplant Institute, Gothenburg, Vastra Gotaland, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)|Change in levels of SARS-Cov-2 antibodies (antibody titers)|Cellular response to SARS-Cov-2 (Th4 and Th8 levels)|Change in cellular response to SARS-Cov-2 (Th4 and Th8 levels)|Symptoms and hospitalisations (electronic questionnaire)""}"
"3316","Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","EPICOS","NCT04334928","PrEP COVID-19","Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04334928","Recruiting","2020-04-15","2020-12-31","{""locations"":""Hospital Universitario de Ferrol, Ferrol, A Coru\u00f1a, Spain|Hospital Cl\u00ednico Universitario de Santiago, Santiago De Compostela, A Coru\u00f1a, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de D\u00e9u de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital Mois\u00e8s Broggi, Sant Joan Desp\u00ed, Barcelona, Spain|Hospital Infanta Margarita, Cabra, C\u00f3rdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San Sebasti\u00e1n, Guipuzcoa, Spain|Hospital San Pedro, Logro\u00f1o, La Rioja, Spain|Hospital Principe de Asturias, Alcal\u00e1 De Henares, Madrid, Spain|Hospital Fundaci\u00f3n de Alcorc\u00f3n, Alcorc\u00f3n, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital de Getafe, Getafe, Madrid, Spain|Hospital Severo Ochoa, Legan\u00e9s, Madrid, Spain|Hospital de M\u00f3stoles, M\u00f3stoles, Madrid, Spain|Hospital Rey Juan Carlos, M\u00f3stoles, Madrid, Spain|Hospital Quir\u00f3n Pozuelo, Pozuelo De Alarc\u00f3n, Madrid, Spain|Hospital de Torrej\u00f3n, Torrej\u00f3n De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, M\u00e1laga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Reina Sof\u00eda, Tudela, Navarra, Spain|Hospital Arnau de Vilanova, Ll\u00edria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro M\u00e9dico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital Quir\u00f3n Barcelona, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Cl\u00ednico San Cecilio, Granada, Spain|Hospital Universitario de Le\u00f3n, Le\u00f3n, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Mara\u00f1on, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina Sof\u00eda, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, M\u00e1laga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Se\u00f1ora de Sonsoles, \u00c1vila, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""4000"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days""}"
"3317","Convalescent Plasma for Patients With COVID-19: A Pilot Study","CP-COVID-19","NCT04332380","ABN011-1","Drug: Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04332380","Completed","2020-05-01","2020-07-28","{""locations"":""Universidad del Rosario, Bogota, Cundinamarca, Colombia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality""}"
"3318","Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19","OMNI-Can","NCT03944447","Pro00033337","Drug: Cannabis, Medical","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT03944447","Recruiting","2018-12-01","2025-12-31","{""locations"":""OMNI Medical Services, Boca Raton, Florida, United States|OMNI Medical Services, Bradenton, Florida, United States|OMNI Medical Services, Fort Lauderdale, Florida, United States|OMNI Medical Services, Fort Myers, Florida, United States|OMNI Medical Services, Gainesville, Florida, United States|OMNI Medical Services, Merritt Island, Florida, United States|OMNI Medical Services, Miami, Florida, United States|OMNI Medical Services, Ocoee, Florida, United States|OMNI Medical Services, Pensacola, Florida, United States|OMNI Medical Services, Pompano Beach, Florida, United States|OMNI Medical Services, Tampa, Florida, United States|OMNI Medical Services, Wesley Chapel, Florida, United States|OMNI Medical Services, Beechwood, Ohio, United States|OMNI Medical Services, Bowling Green, Ohio, United States|OMNI Medical Services, Sandusky, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200000"",""age"":""7 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Prevention of COVID-19|Treatment of COVID-19|Treatment of Symptoms|Cannabis Impact on Quality of Life|Cannabis Route and Dosing|Monitoring Adverse Events""}"
"3319","COVID-Impact ""Psychological IMPACT of Covid-19 on AP-HP Staff""","Covid-Impact","NCT04558437","APHP200555","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04558437","Recruiting","2020-06-12","2020-12-31","{""locations"":""Assistance Publique - H\u00f4pitaux de Paris, Paris, Ile De France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of PTSD among APHP staff during the COVID-19 epidemic and at a distance (inclusion, 3 months or 6 months).|Prevalence of Anxiety Disorder among APHP staff during the COVID-19 epidemic and at a distance (inclusion, 3 months and 6 months).|Prevalence of Depressive Disorder among APHP staff during the COVID-19 epidemic and at a distance (inclusion, M3 and M6).""}"
"3320","Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19","","NCT04355676","XPORT-CoV-1002","Drug: Selinexor","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04355676","Withdrawn","2020-04-30","2020-08-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged From Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants \u2264 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Number of Participants with Adverse Events (AE)""}"
"3321","Emotional Intelligence Skills Health Leaders Need During Covid-19","","NCT04694014","IREC/2020/143 AN0003667W500G","Behavioral: EI Open ended Pre-Survey and Semi Structured Interview|Behavioral: Behavioral and Cognitive Assessment|Behavioral: Geneva Emotional Competence Test (GECO)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694014","Enrolling by invitation","2020-10-15","2021-06-30","{""locations"":""Alupe University College, Busia, Kenya"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""25 Years to 67 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Emotional Intelligence Competences Frontline Healthcare Professional need in their Leaders|EI Competence of Participants|Participant Behavioral Analysis""}"
"3322","Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation","COVIDAtoZ","NCT04342728","IRB 20-361","Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04342728","Completed","2020-04-08","2021-02-11","{""locations"":""Cleveland Clinic, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""214"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptom Reduction|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Shortness of Breath|Symptom Resolution: Fatigue|Symptom Resolution: Muscle\/body aches|Symptom Resolution: Headache|Symptom Resolution: New loss of taste|Symptom Resolution: New loss of smell|Symptom Resolution: Congestion\/ runny nose|Symptom Resolution: Nausea|Symptom Resolution: Vomiting|Symptom Resolution: Diarrhea|Day 5 Symptoms|Hospitalizations|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects""}"
"3323","Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation","CAPACoV19","NCT04356378","PO20055","Other: Data record","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356378","Recruiting","2020-06-02","2022-03-02","{""locations"":""Damien JOLLY, Reims, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical functional limitations""}"
"3324","Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19","OPTIMAL","NCT04412330","59097","Other: ICU Recovery + Physical Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04412330","Recruiting","2020-05-01","2021-05-01","{""locations"":""University of Kentucky, Lexington, Kentucky, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse events (safety)|Feasibility (success of consent process, adherence, and attrition)|Six minute walk test|Short Performance Physical Battery|Quality of life (EQ-5DL)|Cognitive function|Anxiety and Depression|PTSD and distress|Return to work|Secondary complication""}"
"3325","Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts","","NCT04652648","BM02332","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04652648","Completed","2020-05-27","2020-11-15","{""locations"":""Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Paoli Hospital, Paoli, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""54"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 symptom development with positive PCR test|Positive coronavirus PCR test without symptoms|Hospital admission for COVID-19|Death by Day 14|HCQ discontinuation or study withdrawal|Symptom severity at specified time points|COVID -19 rate at study entry|EKG changes during study""}"
"3326","App-based Symptom Tracking After Corona Vaccination (CoCoV)","","NCT04686409","CoCoV","Biological: COVID-19 vaccines","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04686409","Not yet recruiting","2021-01-11","2022-08-31","{""locations"":""Universit\u00e4tsklinikum Ulm, Ulm, Germany"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment-related side effects|Distribution and deviation of documented side effects""}"
"3327","Mapping COVID-19 Spread in a Tertiary Hospital","MEDyMAP","NCT04581096","COVID19-MAPA","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581096","Recruiting","2020-10-02","2021-06-15","{""locations"":""CHGUV, Valencia, Spain|CHGUV, Valencia, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""spatiotemporal spread|classification score""}"
"3328","CT Scores Predict Mortality in 2019-nCoV Pneumonia","","NCT04284046","CT2019-nCoV","Other: CT score","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04284046","Completed","2020-01-31","2020-02-18","{""locations"":""Wuhan third hospital, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""39"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""7-day mortality""}"
"3329","Nutritional Assessment of Hospitalized Patients With COVID-19","DenutCOVID","NCT04503525","RC-P00100","Other: Nutritional assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04503525","Recruiting","2020-05-25","2021-06-30","{""locations"":""Saint-Vincent Hospital, Lille, Haut-de-France, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Nutritional status of COVID infected patients|Correlation between the nutritional status and the supplemental oxygen requirement|Correlation between the nutritional status and the prognostic after hospitalization""}"
"3330","RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19","","NCT04531774","BASEC-Nr.2020-00796","Behavioral: RECHARGE|Behavioral: Self Study","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04531774","Recruiting","2020-08-28","2021-06-01","{""locations"":""Klinik f\u00fcr Konsiliarpsychiatrie und Psychosomatik, Z\u00fcrich, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from Baseline in psychological distress Kessler Psychological Distress Scale (K10) at Week 5 and Week 13|Fewer worries in intervention group than in active control group|Less anxiety symptoms in intervention group than in active control group|Fewer depression symptoms in intervention group than in active control group|Lower level of burnout in intervention group than in active control group|Less traumatic stress in intervention group than in active control group|Lower level of distress due to perceived moral injury in intervention group than in active control group|Higher work performance in intervention group than in active control group""}"
"3331","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","AI-COVID-Xr","NCT04313946","0110","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04313946","Recruiting","2020-03-18","2020-08-18","{""locations"":""U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Universit\u00e0 degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Ia\u015fi, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""COVID-19 positive X-Rays|COVID-19 negative X-Rays""}"
"3332","The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs","","NCT04646525","2020/480","Diagnostic Test: Physical examination","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04646525","Recruiting","2020-10-01","2021-02-01","{""locations"":""Selcuk University, Konya, Selcuklu, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""1 Year to 16 Years \u00a0 (Child)"",""outcome_measures"":""The primary outcome of our study was the evaluation of pediatric patients diagnosed with COVID-19 and who had COVID-19 infection in terms of adenoid and tonsillar tissue hypertrophy and the presence of chronic or recurrent infection.""}"
"3333","CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment","Co-PARENT","NCT04431856","20200484","Behavioral: Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|Behavioral: SHG","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04431856","Completed","2020-05-15","2020-11-17","{""locations"":""University of Miami, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure of Anxiety as assessed by the OASIS|Measure of Depression as assessed by the ODSIS|Measure of PTSD as assessed by the PCL-5|Measure of Parenting Overprotection\/Overcontrol as assessed by the S-EMBU|Measure of Parenting Rejection as assessed by the S-EMBU|Measure of Parenting Emotional Warmth as assessed by the S-EMBU|Measure of Parent Accommodation for Child Anxiety as assessed by the FASA""}"
"3334","Follow-up of Critical COVID-19 Patients","FUP-COVID","NCT04474249","EPM-2020-02697","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04474249","Recruiting","2020-06-25","2022-12-01","{""locations"":""Uppsala University Hospital, Uppsala, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Renal recovery|Respiratory recovery|Working capacity|Quality of life score|Cognitive recovery|Frailty|Activities of Daily Life|Anxiety|Depression|Neurological recovery""}"
"3335","Spanish Registry of Pregnant Women With COVID-19","OBS COVID","NCT04558996","55/20|COV20/0021","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04558996","Recruiting","2020-03-01","2021-03-31","{""locations"":""Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""MATERNAL COMPLICATIONS|NEONATAL INFECTION""}"
"3336","Trial of Combination Therapy to Treat COVID-19 Infection","","NCT04482686","PRG-049","Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04482686","Recruiting","2020-12-09","2021-07-01","{""locations"":""ProgenaBiome, Ventura, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Non-Infectivity by RT-PCR|Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)|Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)|Efficacy of Treatment as measured by Titer|Efficacy of Treatment as measured by RT-PCR|Safety of Treatment as Measured by D-Dimer|Safety of Treatment as Measured by Pro-Calcitonin|Safety of Treatment as Measured by C-Reactive Protein|Safety of Treatment as Measured by Ferritin|Safety of Treatment as Measured by Liver Enzymes|Safety of Treatment as Measured by Complete Blood Count|Safety of Treatment as Measured by Electrolyte Levels|Safety of Treatment as Measured by Treatment Related Adverse Events""}"
"3337","Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey","","NCT04344197","s-covid survey","Other: global survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344197","Completed","2020-04-02","2020-04-15","{""locations"":""Tor Vergata Hospital, Rome, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""1200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""overview of surgical management on preventive measures of hospital infection spread during covid 19|testing policies and preventive measures for Covid-19, and their association with asymptomatic cases.""}"
"3338","Early Intervention in COVID-19: Favipiravir Verses Standard Care","PIONEER","NCT04373733","CW002|2020-001449-38","Drug: Favipiravir|Other: Standard of care management","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04373733","Recruiting","2020-05-01","2021-03-31","{""locations"":""Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to improvement by two points on a seven-category ordinal scale|Clinical status on a seven-category ordinal scale (Day 7)|Clinical status on a seven-category ordinal scale (Day 14)|Overall survival|Time to improvement by two points on the NEWS score|Time to improvement by two points on the NEWS element score for temperature|Time to improvement by two points on the NEWS element score for heartrate|Time to improvement by two points on the NEWS element score for respiratory rate|Time to improvement by two points on the NEWS element score for oxygen saturation.|Admission to intensive care|Requirement for mechanical ventilation|Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|Incidence of bacterial or fungal infection|Incidence of adverse events not directly caused by COVID-19 infection.""}"
"3339","Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic","","NCT04362319","54753","Diagnostic Test: Questionnaire forms","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04362319","Completed","2020-05-15","2020-05-31","{""locations"":""Sungai Buloh Hospital, Sungai Buloh, Selangor, Malaysia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""85"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of burnout among anaesthesiology clinicians during Covid-19|Prevalence of depression risk among anaesthesiology clinicians during Covid-19|Prevalence of self-perceived medical errors among anaesthesiology clinicians during Covid-19|Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19""}"
"3340","COVID-19 Brain Injury","","NCT04496076","STUDY20030201","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04496076","Enrolling by invitation","2020-04-02","2021-03-31","{""locations"":""University of Pittsburgh, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital Mortality|30-day mortality|Limitations of patient care- Frequency of care not being provided|Limitations of patient care- Conversion of DNR\/DNI\/CMO status""}"
"3341","Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection","ACTIV-2","NCT04709120","ACTIV-2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04709120","Recruiting","2021-01-11","2021-12-31","{""locations"":""Eurasian Association of Therapists, Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""death|Number of cases of Acute Kidney Injury depending on Coexisting Conditions|Number of cases of Myocarditis and Acute Coronary Events depending on Coexisting Conditions|Number of cases of Cytokine Storm depending on Coexisting Conditions|Number of thrombotic and thromboembolic complications of COVID-19 depending on Coexisting Conditions|Decline in GFR excluding Acute Kidney Injury by the time of discharge depending on Coexisting Conditions|Rate of cases of health status worsening occured during hospitalisation""}"
"3342","Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era","RECIPE","NCT04636021","UPMCP # 20-007","Diagnostic Test: COVID-19 testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04636021","Recruiting","2020-08-01","2022-06-30","{""locations"":""UPMC Pinnacle Harrisburg, Harrisburg, Pennsylvania, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of subjects who contract COVID-19 while hospitalized for elective outpatient procedures|Patient perception of the effect of pre and post procedure COVID-19 testing on risk of contracting COVID-19 while hospitalized for an elective outpatient procedure.""}"
"3343","Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches","MICRO-COV","NCT04410263","2020-00646","Diagnostic Test: Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04410263","Recruiting","2020-04-09","2023-12-31","{""locations"":""University Hospital Zurich, Z\u00fcrich, Zurich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of pro-inflammatory response over the ICU stay as a causative for primary endothelial dysfunction|Time-to-event \""pulmonary bacterial superinfection or death\""|Positive bacteria and\/ or SARS-CoV-2 cultures on handheld devices used in clinical routine and correlation to the adherence to disinfection protocols|Life Quality after COVID-19 Infection""}"
"3344","A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19","","NCT04402060","APL9-COV-201","Drug: APL-9|Other: Vehicle Control","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04402060","Recruiting","2020-05-28","2021-01-01","{""locations"":""University of California at San Francisco - Fresno, Fresno, California, United States|California Pacific Medical Center, San Francisco, California, United States|Baptist Medical Center Beaches, Jacksonville Beach, Florida, United States|Westchester General Hospital, Miami, Florida, United States|Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Lutheran Health Physicians, Fort Wayne, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Audobon Hospital, Louisville, Kentucky, United States|Cambridge Medical Trials, Alexandria, Louisiana, United States|Ascension Providence Hospital, Southfield, Michigan, United States|Rutgers University - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University at Buffalo, Buffalo, New York, United States|Columbia University, New York, New York, United States|Texas A&M College of Medicine - Scott and White, Temple, Texas, United States|Hospital Angelina Caron, Campina Grande Do Sul, Paran\u00e1, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital S\u00e3o Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Estadual Mario Covas, Santo Andr\u00e9, Sao Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clinicos LTDA EPP, S\u00e3o Bernardo Do Campo, Sao Paulo, Brazil|Hospital Alemao Oswaldo Cruz, S\u00e3o Paulo, Sao Paulo, Brazil|Hospital Santa Marcelina, S\u00e3o Paulo, Sao Paulo, Brazil|UPECLIN - Unidade de Pesquisa Cl\u00ednica da Faculdade de Medicina de Botucatu - FMB\/UNESP, Botucatu, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of treatment-emergent serious adverse events and treatment-emergent adverse events.|Hospital length of stay|Any cause of mortality|Sequential Organ Failure Assessment|Total duration of mechanical ventilation and\/or oxygen therapy|Total duration of oxygen therapy""}"
"3345","HIV/COV in Ukraine-NL","","NCT04711954","1990 Study","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04711954","Recruiting","2020-11-01","2022-11-01","{""locations"":""Erasmus MC, Rotterdam, Netherlands|Lviv Regional AIDS Health Center, Lviv, Ukraine"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence COVID19|Incidence COVID-19|WHO categories COVID-19|WHO disease severity COVID-19|Seroprevalence|NPV\/PPV WHO categories COVID19|Treatment|Predictors for COVID-19|Predictors for COVID-19 severity""}"
"3346","Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)","","NCT04665115","ACCRU-LY-2001|NCI-2020-11785|P30CA015083","Drug: Ibrutinib|Other: Quality-of-Life Assessment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04665115","Not yet recruiting","2021-06-30","2025-05-01","{""locations"":""Mayo Clinic in Rochester, Rochester, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""134"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who require hospitalization for their COVID-19 disease or die (Cohort 1)|Proportion of patients who require mechanical ventilation and\/or die (Cohort 2)|Rate of \""flare phenomena\"" (Cohort I)|Patient-reported health and symptom status (Cohort I)|Patterns on ibrutinib therapy during COVID-19 infection (Cohort I)|Reasons for hospitalization (Cohort I)|Mortality (Cohort II)|Time to hospital discharge (Cohort II)|Intubation and oxygen supplementation (Cohort II)|Incidence of \""flare phenomena\"" (Cohort II)|Viral clearance|Development of COVID-19 antibodies|Coagulopathy and thrombosis measures|Cytokine measures|Immune subset measures""}"
"3347","Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients","","NCT04437823","JB&RSC-01","Biological: Intravenous Infusions of Stem Cells","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04437823","Recruiting","2020-06-01","2021-06-30","{""locations"":""Jinnah Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""30 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety and efficacy assessment of infusion associated adverse events|Chest Radiograph or Chest CT Scan|COVID-19 Quantitative Real Time PCR|Sequential Organ Failure Assessment (SOFA) Score|Rate of mortality|Clinical Respiratory Changes""}"
"3348","Psychological Impact of Admission With Covid-19 During the SARS-CoV-2 Pandemic: Naturalistic Cohort Study With a Digital Intervention","FeelGood","NCT04449627","RoyalFreeNHS","Other: Feeling Good Digital App","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04449627","Not yet recruiting","2020-08-31","2021-01-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""125"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety as measured by generalised anxiety disorder score (GAD-7) scale|Depression as measured by the patient health questionnaire 9 (PHQ-9)|Trauma as measured by Trauma screening questionnaire (TSQ)""}"
"3349","COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial","COLORIT","NCT04403243","MSU080520","Drug: Colchicine|Drug: Ruxolitinib 5 MG|Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Other: standard therapy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04403243","Recruiting","2020-05-08","2020-08-23","{""locations"":""Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""change from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline|Combine endpoint: Time to death or mechanical ventilation|C-reactive protein|D-dimer|EuroQol Group. EQ-5D\u2122|exposure area on lung CT""}"
"3350","Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19","","NCT04338802","huilanz Zhang","Drug: Nintedanib 150 MG|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04338802","Not yet recruiting","2020-04-02","2020-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""96"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in forced vital capacity (FVC)|Changes in carbon monoxide dispersion (DLco%)|Changes in the six-minute walk test (6MWT)|Changes in High resolution CT score""}"
"3351","First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.","","NCT04535167","C4611001|2020-003905-73","Drug: PF-07304814|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04535167","Recruiting","2020-09-09","2021-07-05","{""locations"":""El Camino Health, Mountain View, California, United States|Palo Alto Medical Foundation, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|UC Davis Medical Center, Sacramento, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|Multicare Health System-Tacoma General Hospital, Tacoma, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""72"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of treatment-emergent adverse events (TEAEs)|Number of participants who withdraw due to treatment-emergent adverse events (TEAEs)|Frequency of treatment-emergent adverse events (TEAEs), causally related to study intervention|Frequency of treatment-emergent serious adverse events|Frequency of treatment-emergent infusion site reactions|Magnitude of abnormal hematologic laboratory findings|Frequency of abnormal chemistry values|Frequency of abnormal hematologic laboratory findings|Magnitude of abnormal urinalysis findings|Change from baseline in PR values|Change from baseline in RR values|Change from baseline in QTc values|Change from baseline in QTcF values|Change from baseline in QRS values|Change from baseline in pulse rate measurements|Change from baseline in temperature values|Change from baseline in respiratory rate values|Change from baseline in systolic blood pressure|Change from baseline in diastolic blood pressure|Change from baseline in pulse oximetry\/SpO2 measurement|Change in concentration at 24 hours (C24 [end of infusion]) of PF-07304814 and PF-00835231|Change in concentration, dose normalised, at 24 hours (C24 (dn) [end of infusion]) of PF-07304814 and PF-00835231|Change in concentration at 120 hours (C120[end of infusion]) of PF-07304814 and PF-00835231|Change in maximum observed concentration (Cmax) of PF-07304814 and PF-00835231|Change in concentration at steady state (Css) of PF-07304814 and PF-00835231|Cumulative amount of unchanged drug excreted into urine (Ae)|Percent of dose excreted as unchanged drug (Ae%) over dosing period|Change in terminal half life (t1\/2) of PF-07304814 and PF-00835231""}"
"3352","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","REMAP-CAP","NCT02735707","U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab|Drug: Vitamin C|Drug: Therapeutic anticoagulation|Drug: Simvastatin|Biological: Convalescent plasma|Other: Protocolised mechanical ventilation strategy|Drug: Eritoran|Drug: Apremilast|Drug: Aspirin|Drug: Clopidogrel|Drug: Prasugrel|Drug: Ticagrelor","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT02735707","Recruiting","2016-04-11","2023-12-01","{""locations"":""University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - H\u00f4pital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Universit\u00e9 de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Po\u017eega, Po\u017eega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charit\u00e9 - Universit\u00e4tsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charit\u00e9 - Universit\u00e4tsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neuk\u00f6lln, Berlin, Germany|Universit\u00e4tsklinikum K\u00f6ln, Cologne, Germany|Universit\u00e4tsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universit\u00e4tsklinikum Jena, Jena, Germany|Universit\u00e4tsklinikum Leipzig, Leipzig, Germany|Universit\u00e4ts Klinikum T\u00fcbingen, T\u00fcbingen, Germany|Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany|J\u00f3sa Andr\u00e1s County Hospital, Ny\u00edregyh\u00e1za, Hungary|Csolnoky Ferenc K\u00f3rh\u00e1z - Veszprem County Hospital, Veszpr\u00e9m, Hungary|Alm\u00e1si Balogh P\u00e1l K\u00f3rh\u00e1z, \u00d3zd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lus\u00edadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases \""Dr. Victor Babes\"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions M\u00e8diques, Barcelona, Spain|Hospital Universitario Reina Sofia, C\u00f3rdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""7100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Days alive and not receiving organ support in ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome""}"
"3353","Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )","","NCT04357639","COVIP","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357639","Recruiting","2020-05-28","2021-07-31","{""locations"":""CHI Cr\u00e9teil, Cr\u00e9teil, France|CHU Henri Mondor, Cr\u00e9teil, France|Centre hospitalier de Melun (GHSIF), Melun, France|CHI Villeneuve St Georges, Villeneuve-Saint-Georges, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1040"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of the incidence of COVID-19 infection in PLWHIV treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor|Determination of the seroprevalence of COVID-19 infection in both groups of the study|Comparison of the severity of COVID-19 infection symptoms in both groups of the study.|Identification of potential risk factors for COVID-19 infection in HIV patients treated with protease inhibitor or without protease inhibitor""}"
"3354","Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19","","NCT04399252","Pro00105674","Dietary Supplement: Lactobaciltus rhamnosus GG|Dietary Supplement: Lactobaciltus rhamnosus GG Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04399252","Recruiting","2020-06-24","2022-05-25","{""locations"":""Duke University, Durham, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science"",""enrollment"":""1000"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Change in Shannon Diversity|Change in Shannon Diversity in patients that develop COVID-19""}"
"3355","Innovation of Audio-Visual Triage System in Combating the Spread of COVID-19 Infection and Its Efficacy: A Novel Strategy","","NCT04621214","IRBEC/BIH/013-2020","Device: Audio-Visual Triage System (AVT)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04621214","Completed","2020-03-21","2020-04-28","{""locations"":""The University of Lahore, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""20 Years to 38 Years \u00a0 (Adult)"",""outcome_measures"":""Polymerase chain reaction (PCR) to detect SARS-CoV-2 virus|General Anxiety Disorder-7 (GAD-7) scoring system""}"
"3356","COVID-19 Pandemic Impact on Patients With Cancer - a Danish Survey","COPICADS","NCT04389996","OP_1132","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389996","Active, not recruiting","2020-05-14","2023-05-01","{""locations"":""Department of Haemotology, Odense University Hospital, Odense, Region Of Southern Denmark, Denmark|Department of Oncology, Odense University Hospital, Odense C, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""5000"",""age"":""18 Years to 125 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall Quality of Life""}"
"3357","Cereset Research In Healthcare Workers During COVID-19","","NCT04682197","IRB00066997","Device: Cereset Research","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04682197","Not yet recruiting","2021-04-01","2022-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Impact of Event Scale-Revised (IES-R)|Change in Insomnia Severity Index (ISI)|Change in Center for Epidemiologic Studies Depression Scale (CES-D)|Change in Generalized Anxiety Disorder-7 (GAD-7)|Change in PTSD Checklist for Civilians (PCL-C)|Change in Perceived Stress Scale (PSS)|Change in Quality of Life Scale (QOLS)|Change in Interpersonal Support Evaluation List (ISEL-12)|Change in Multiple Ability Self-Report Questionnaire (MASQ)""}"
"3358","Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology","","NCT04365881","REK12345","Other: Cross-sectional observational study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365881","Completed","2020-03-31","2020-04-07","{""locations"":""University of Oslo, Oslo, Norway"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""10084"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""UCLA Loneliness Scale-8 (ULS-8)|Patient Health Questionnaire-9 (PHQ-9)|Generalized Anxiety Disorder-7 (GAD-7)""}"
"3359","Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies","","NCT04694573","CTS Covid-19 Serum Studies","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694573","Recruiting","2020-12-28","2022-12-28","{""locations"":""Nierenzentrum Heidelberg, Heidelberg, DE, Germany"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in dnDSA development (PRE-TX Covid-19 Serum Study)|Change in dnDSA development (POST-TX Covid-19 Serum Study)|Graft Survival (PRE-TX Covid-19 Serum-Study)|Graft Survival (Post-TX Covid-19 Serum-Study)|Incidence of graft rejection (PRE-TX Covid-19 Serum Study)|Incidence of graft rejection (POST-TX Covid-19 Serum Study)""}"
"3360","Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic","","NCT04329533","2003524869","Other: ""Calm"" is a mindfulness meditation mobile app","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04329533","Completed","2020-04-13","2020-11-01","{""locations"":""Banner University Medicine Women's Institute, Phoenix, Arizona, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""101"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire""}"
"3361","Seroprevalence of SARS-Cov-2 Antibodies in Children","","NCT04347408","282617","Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347408","Completed","2020-05-06","2020-12-13","{""locations"":""Royal Belfast Hospital for Sick Children, Belfast, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom|Public Health England, London, United Kingdom|Public Health England, Manchester, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""2 Years to 15 Years \u00a0 (Child)"",""outcome_measures"":""Immunoglobulins (G and M) to SARS-Cov2 in plasma""}"
"3362","The COGCOV Study in ICU Patients","COGCOV","NCT04593069","COGCOV","Behavioral: Neurocognitive assessment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04593069","Recruiting","2020-10-07","2021-02-28","{""locations"":""Ziekenhuis Oost-Limburg, Genk, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Neurocognitive impairment measured by RBANS|Neurocognitive impairment measured by TMT|Neurocognitive impairment by the short IQCODE""}"
"3363","Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic","","NCT04374786","2003524869 [Sub-study]","Device: Calm Meditation App","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04374786","Enrolling by invitation","2020-05-15","2020-10-01","{""locations"":""Banner University Medical Center Phoenix, Phoenix, Arizona, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""328"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Impact of Event Scale-6|Maslach Burnout Inventory|Adherence|Coronavirus Questionnaire|Participant Satisfaction""}"
"3364","A Prospective Clinical Study to Explore Response to Prone Positioning in ARDS Patients","","NCT04692779","ProneARDS","Other: Lung Ultrasound (LUS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04692779","Recruiting","2021-01-31","2021-10-30","{""locations"":""Rush University Medical Center, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygenation and Lung Ultrasound Score (LUS)|COVID-19 ARDS vs non-COVID-19 ARDS""}"
"3365","Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events","iGenes-COVID19","NCT04519398","GTP0051","Genetic: Complete thrombophilic profile testing by multiplex PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04519398","Recruiting","2020-08-18","2021-08-18","{""locations"":""University of Medicine and Pharmacy Gr T. Popa Iasi, Romania, Iasi, Romania"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with thrombophilic profile alterations|Number of patients with RAAS components alterations""}"
"3366","OPV as Potential Protection Against COVID-19","","NCT04445428","77/CNES/INASA/2020","Biological: oral polio vaccine + information|Behavioral: Information","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04445428","Enrolling by invitation","2020-07-15","2021-12-01","{""locations"":""Bandim Health Project, Bissau, Guinea-Bissau"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""3400"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality or infectious disease causing consultation or admission (Composite outcome)|Self-reported morbidity|Suspected COVID-19 infection|Mortality|Hospital admission for infectious disease|Consultations for infectious disease""}"
"3367","Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting","","NCT04621461","20-19","Dietary Supplement: Zinc Sulfate 220 MG|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04621461","Completed","2020-12-20","2021-02-08","{""locations"":""St. Francis Hospital - The Heart Center, Roslyn, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""3"",""age"":""30 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants hospitalized and\/or requiring repeat emergency room visits|Number of participants admitted to the Intensive care unit (ICU)|Number of participants on a ventilator|All-cause mortality|Time to resolution of COVID-19 symptoms|Severity of symptoms""}"
"3368","Serology to Covid for Recording Exposures and Evaluating Needs","SCREEN","NCT04566965","SCREEN","Diagnostic Test: SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04566965","Recruiting","2020-08-18","2023-12-31","{""locations"":""Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The 12-month cumulative incidence of acquired COVID infection in the study cohort.""}"
"3369","Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19","","NCT04371978","0303-20-RMC","Drug: Linagliptin 5 MG","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04371978","Recruiting","2020-10-01","2021-09-30","{""locations"":""Rabin Medical Center, Petah tikva, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical change|Percent of serious adverse events and premature discontinuation of treatment.|Percent of patients with clinical improvement.|Length of hospitalization.|All-cause mortality.|Percent of supplemental oxygen use.|Supplemental oxygen-free days.|Percent of mechanical ventilation use.|Ventilator-free days.|Percent of ICU admissions.|ICU-free days.|Percent of 50% decrease in C-reactive protein (CRP) levels|Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.""}"
"3370","Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas","ICILOLA","NCT04448054","2020-A01216-33","Other: MRI","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04448054","Recruiting","2020-05-20","2021-11-20","{""locations"":""Fondation A De Rothschild, Paris, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients included with at least one sign of neuromeningeal, neurosensory or neurovascular involvement on MRI imaging with the specific sequences used.""}"
"3371","Cyclosporine For The Treatment Of COVID-19(+)","","NCT04492891","H-48163","Drug: Cyclosporine|Other: Standard of Care Treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04492891","Recruiting","2020-11-23","2025-11-23","{""locations"":""Baylor College of Medicine, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""75"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""WHO COVID-19 clinical severity scale""}"
"3372","Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit","","NCT04645433","2854","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04645433","Completed","2020-03-15","2020-05-15","{""locations"":""SisliHamidiye Etfal Education and Training Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality for ICU|hospital stay""}"
"3373","Social Media and COVID-19","","NCT04367363","2020-CERC-001B","Behavioral: Social media & news consumption","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367363","Completed","2020-03-17","2020-05-31","{""locations"":""Yale-NUS College, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""151"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""WhatsApp usage|Changes in fear with regards the COVID-19 situation across 1 week|Changes in amount of thinking about the COVID-19 situation across 1 week""}"
"3374","Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure","","NCT04408222","AAAT0134","Other: Awake proning","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408222","Active, not recruiting","2020-04-16","2021-05-01","{""locations"":""Columbia University Medical Center, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""29"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SpO2|Mean Risk Difference in Intubation Rates""}"
"3375","Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID-19 Infection","RECOP","NCT04371328","RC31/20/0094","Other: RECOP unit patient","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371328","Active, not recruiting","2020-03-13","2021-03-01","{""locations"":""University Hospital of Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1860"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Describe the characteristics of patients admitted to reCOP units according to their virological status vis-\u00e0-vis COVID-19|Develop a predictive model of the risk of being COVID for patients admitted to the emergency room for dyspnea""}"
"3376","Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","CP-COVID-19","NCT04332835","ABN011-2","Drug: Plasma|Drug: Standard Therapy","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04332835","Completed","2020-08-08","2020-11-15","{""locations"":""Universidad del Rosario, Bogota, Cundinamarca, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""92"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Viral Load|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality""}"
"3377","Sequential Oxygen Therapy Strategy for Patients With COVID-19","SOTSPC","NCT04312100","SOT-C","Other: oxygen treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04312100","Recruiting","2020-02-01","2021-02-01","{""locations"":""Henan Provincial People's Hospital, Zhengzhou, Henan, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of respiratory failure|28 day mortality rate""}"
"3378","Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery","CHICANE","NCT04449783","SP0355","Other: pre-operative screening|Other: telephone consult","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04449783","Recruiting","2020-06-25","2020-09-25","{""locations"":""Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""diagnosis of COVID before surgery|diagnosis of COVID after surgery""}"
"3379","Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19","AVICOVID-2","NCT04360096","RLF-100_002","Drug: RLF-100 (aviptadil)|Drug: Placebo|Device: Nebulized administration of RLF-100 or Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04360096","Recruiting","2021-02-15","2021-09-01","{""locations"":""St. Jude Medical Center, Fullerton, California, United States|University of California - Irvine, Irvine, California, United States|University of Louisville Hospital, Louisville, Kentucky, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""288"",""age"":""12 Years to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Progression to Respiratory Failure|Blood oxygenation|RDP Dsypnea Scale|Distance walked in six minutes""}"
"3380","Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection","CO-MY-COVID","NCT04695379","CHUBX 2020/17","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04695379","Recruiting","2020-05-26","2022-11-26","{""locations"":""CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|Hospices Civils de Lyon, Bron, France|APHP - Hopital Raymond Poincarr\u00e9, Garches, France|CHRU de Lille, Lille, France|Assistance Publique H\u00f4pitaux de Marseille, Marseille, France|CHU de Nantes, Nantes, France|APHP GH Piti\u00e9 Salp\u00e9tri\u00e8re, Paris, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""1 Year to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Severity of Myasthenia Gravis evaluated by the Myasthenia Gravis of America (MGFA) score|Severity of Myasthenia Gravis evaluated by the variation of the Myasthenia Gravis of America (MGFA) score|The autonomy of the patients evaluated with the MG-ADL (Myasthenia Gravis-Activities of Daily Living) scale|Risk factors for severe forms of COVID-19|Treatments for MG at the time of the diagnosis of COVID-19|Diagnosis of COVID-19|Severity of COVID-19|Treatments for MG during and after COVID-19""}"
"3381","Losartan for Patients With COVID-19 Requiring Hospitalization","","NCT04312009","SURG-2020-28675|INV-017069","Drug: Losartan|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04312009","Completed","2020-04-13","2021-02-01","{""locations"":""University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Henry Ford Hospital, Detroit, Michigan, United States|M Health Fairview Ridges Hospital, Burnsville, Minnesota, United States|M Health Fairview Southdale Hospital, Edina, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|North Memorial Health Hospital, Robbinsdale, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cooper University Hospital, Camden, New Jersey, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Difference in Estimated (PEEP adjusted) P\/F Ratio at 7 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation \/ Fractional Inhaled Oxygen (F\/S)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea scale|Change in SF-12 Physical Composite Score|Change in SF-12 Mental Composite Score|Disease Severity Rating|Viral Load by Nasopharyngeal Swab Day 9|Viral Load by Nasopharyngeal Swab Day 15|Viral Load by Blood Day 9|Viral Load by Blood Day 15""}"
"3382","Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases","","NCT04690816","10000207|000207-AR","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04690816","Recruiting","2021-02-11","2024-12-31","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""350"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Primary Objective: Characterize how COVID-19 modulates systemic inflammation, autoimmunity features, organ damage and vasculopathy in adult and pediatric patients with a previous diagnosis of systemic autoimmunity. Assess how subjects with syste...|Understand prevalence and severity of COVID-19 in individuals with autoimmune diseases, and the variables that associate\/predict these responses.""}"
"3383","Randomised Evaluation of COVID-19 Therapy","RECOVERY","NCT04381936","NDPHRECOVERY|2020-001113-21|ISRCTN50189673","Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab|Biological: Immunoglobulin|Drug: Synthetic neutralising antibodies|Drug: Aspirin|Drug: Colchicine|Drug: Baricitinib|Drug: Anakinra|Drug: Dimethyl fumarate","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04381936","Recruiting","2020-03-19","2031-12-01","{""locations"":""Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology, Jakarta, Indonesia|Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal|Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""All-cause mortality|Duration of hospital stay|Composite endpoint of death or need for mechanical ventilation or ECMO""}"
"3384","Trial of Treatments for COVID-19 in Hospitalized Adults","DisCoVeRy","NCT04315948","C20-15","Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04315948","Active, not recruiting","2020-03-22","2023-03-01","{""locations"":""Medizinische Universit\u00e4t Innsbruck, Innsbruck, Austria|Kepler Universit\u00e4tsklinikum Linz, Linz, Austria|Landeskrankenhaus Salzburg Universit\u00e4tsklinikum der Paracelsus Medizinischen Privatuniversit\u00e4t, Salzburg, Austria|H\u00f4pital Erasme - Cliniques universitaires de Bruxelles, Brussels, Belgium|H\u00f4pital Saint Luc, Brussels, Belgium|H\u00f4pital La Citadelle, Li\u00e8ge, Belgium|Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France|Centre Hospitalier R\u00e9gional Universitaire de Besan\u00e7on, Besan\u00e7on, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|CHU APHP Ambroise-Par\u00e9, Boulogne-Billancourt, France|Centre Hospitalier Andr\u00e9e Rosemon, Cayenne, France|CHU Clermont-Ferrand, Clermont-Ferrand, France|Hospices Civil, Colmar, France|APHP - h\u00f4pital Henri-Mondor, Cr\u00e9teil, France|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France|Centre Hospitalier Universitaire de Martinique, Fort De France, France|AP-HP H\u00f4pital Bic\u00eatre, Kremlin-Bic\u00eatre, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Groupe Hospitalier de la R\u00e9gion de Mulhouse Sud Alsace, Mulhouse, France|Centre Hospitalier R\u00e9gional et Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalo-Universitaire de Nice, Nice, France|CHU N\u00eemes, N\u00eemes, France|APHP - H\u00f4pital Saint Antoine, Paris, France|APHP - H\u00f4pital Universitaire Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France|APHP - H\u00f4pital Cochin, Paris, France|H\u00f4pital Paris Saint-Joseph et Marie Lannelongue, Paris, France|APHP- H\u00f4pital Europ\u00e9en Georges-Pompidou, Paris, France|APHP - H\u00f4pital Bichat Claude Bernard, Paris, France|CHU Poitiers, Poitiers, France|CH Cornouaille, Quimper, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hopital DELAFONTAINE, Saint-Denis, France|H\u00f4pital d'Instruction des Arm\u00e9es BEGIN, Saint-Mand\u00e9, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-\u00c9tienne, France|Centre Hospitalier R\u00e9gional Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre Hospitalier Universitaire de Tours, Tours, France|CH Bretagne Atlantique, Vannes, France|Centre Hospitalier Annecy Genevois, \u00c9pagny, France|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg|H\u00f4pitaux Robert Schuman, Luxembourg, Luxembourg|Hospital de Abrantes (CHMT), Abrantes, Portugal|Hospital de Cascais, Cascais, Portugal|CHULN- Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, EPE, Porto, Portugal"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""3100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of \u2264 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)""}"
"3385","Losartan for Patients With COVID-19 Not Requiring Hospitalization","","NCT04311177","SURG-2020-28683","Drug: Losartan|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04311177","Completed","2020-04-09","2021-02-01","{""locations"":""Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""580"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospital Admission|Change in PROMIS Dyspnea scale|Change in SF-12 Physical Composite Score|Change in SF-12 Mental Composite Score|Daily Maximum Temperature|Emergency Department\/Clinic Presentations|Disease Severity Rating Day 7|Disease Severity Rating Day 15|Disease Severity Rating Day 28|Viral Load by Oropharyngeal Swab Day 9|Viral Load by Oropharyngeal Swab Day 15|Ventilator-Free Days|Therapeutic Oxygen-Free Days|Need for Hospital Admission at 15 Days|Need for Oxygen Therapy at 15 Days""}"
"3386","A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic","","NCT04375501","284104","Other: Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375501","Completed","2020-02-01","2020-04-15","{""locations"":""Barts Health NHS Trust, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""442"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Morbidity|Discharge""}"
"3387","Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic","","NCT04385238","0002","Other: This is an online survey with no intervention.","Observational","Has Results","","https://ClinicalTrials.gov/show/NCT04385238","Completed","2020-05-15","2020-06-20","{""locations"":""Pregistry, Los Angeles, California, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""6894"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants With Symptoms of Post-traumatic Stress Disorder|Number of Participants With Symptoms of Anxiety and Depression""}"
"3388","Tocilizumab for Patients With Cancer and COVID-19 Disease","","NCT04370834","NCI-2020-02987|TRC-10446","Biological: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04370834","Terminated","2020-05-28","2021-01-14","{""locations"":""National Cancer Institute, Rockville, Maryland, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Valley Medical Center, Renton, Washington, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""1"",""age"":""2 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical outcome as evaluated by the 7-category Clinical Status Ordinal Scale""}"
"3389","Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population","","NCT04426266","PSZ-002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04426266","Completed","2020-05-01","2020-09-28","{""locations"":""University of Szeged Department of Dermatology and Allergology, Szeged, Hungary"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""441"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""sociodemopraphic factors|perceived stress|level of anxiety|self-reported health state|number of complaints|strategies in coping with stressful situations|psychological effects of the coronavirus pandemic on the participants' mood and ways of coping with difficulties arising from the pandemic|level of depression""}"
"3390","Evaluation of Occupational Burnout and Stress Among Dentists in Covid-19 Pandemic","MBI","NCT04605692","KAEK- 590","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04605692","Completed","2020-03-09","2020-05-20","{""locations"":""Akdeniz \u00dcniversitesi, Antalya, Konyaalt\u0131, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""706"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""706 of participants' burnout (MBI) and stress levels during the Covid 19 pandemic process assessed with survey.""}"
"3391","National Study ""AEC COVID-19""","","NCT04573868","AEC-COVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04573868","Recruiting","2020-03-01","2020-09-30","{""locations"":""Salvador Morales-Conde, Sevilla, Spain"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality|Morbidity""}"
"3392","Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients","ACTIV","NCT04492384","ACTIV11062020","Other: non-interventional","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492384","Completed","2020-06-11","2021-01-14","{""locations"":""Eurasian Association of Therapists, Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""3500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""rate of non-infectious diseases|severity of COVID-19 depending on pre-existing diseases|disability registration \/ change of disability status|rate of letal outcomes|rate of letal outcomes depending on pre-existing disease""}"
"3393","Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.","PAIN-COVID","NCT04394169","HCB/2020/0549","Behavioral: Intervention program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04394169","Recruiting","2020-05-25","2021-03-25","{""locations"":""Tom\u00e1s Cu\u00f1at, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention"",""enrollment"":""102"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of intervention program on health-related quality of life (VAS)|Impact of intervention program on health-related quality of life (Index)|Impact of intervention program on chronic pain (intensity)|Impact of intervention program on chronic pain (limitation of daily activities)|Impact of intervention program on chronic pain (Pain catastrophization)|Impact of intervention program on anxiety or depression incidence|Impact of intervention on probable post-traumatic stress syndrome incidence""}"
"3394","PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis","","NCT04513847","Pso-Vac","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04513847","Completed","2020-08-13","2020-10-06","{""locations"":""Dermatrials Research, Hamilton, Ontario, Canada"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""661"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percentage of patients not understanding the interaction of vaccines and their biologic, assessed with voluntary survey.""}"
"3395","Birth Experience During COVID-19 Confinement","CONFINE","NCT04348929","2020-A00881-38","Other: Self-administered questionnaires","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04348929","Recruiting","2020-04-16","2021-10-01","{""locations"":""Centre Hospitalier R\u00e9gional Universitaire de Nancy, Nancy, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""927"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""\""Labor Agentry Scale questionnaire\"" score in immediate post-partum (duration of hospital stay)|\""Labor Agentry Scale questionnaire\"" score at two months after birth|Edinburg Postnatale Depression Scale questionnaire\"" score at two months after birth|\""Impact of Event Scale - Revised questionnaire\"" score at two months after birth|Breastfeeding statement at two months after birth|\""SF-12 Quality of life questionnaire\"" score at two months after birth|\""SF-12 Quality of life questionnaire\"" score in immediate post-partum|Diagnosis of post-natal depression (made by a specialist)""}"
"3396","COVID-19 Biological Samples Collection","COLCOV19-BX","NCT04332016","CHUBX 2020/11","Other: biological samples collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04332016","Recruiting","2020-04-02","2023-03-01","{""locations"":""Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""up to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""COVID-19 desease description""}"
"3397","Cardiovascular Manifestations of COVID-19","","NCT04335630","HSC-MS-20-0286","Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04335630","Recruiting","2020-03-30","2022-03-01","{""locations"":""Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications""}"
"3398","CCP Cancer UK Companion Study","","NCT04603105","C1147","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04603105","Not yet recruiting","2021-02-28","2022-10-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""9000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""To determine the COVID-19 fatality rate overall in the cancer population using the most up to date dataset from the first wave.|To determine the COVID-19 fatality rate in different tumour types.|To describe the clinical features and severity of COVID-19 in different tumour types.|To identify other clinical and laboratory variables that correlate with COVID-19 severity and mortality in different tumour types.|To determine the influence of disease stage, treatment intent and treatment history on severity and COVID-19 fatality rate.|To describe the use of healthcare resources (including intensive care) in the treatment of COVID-19 in different tumour types.|To undertake a matched cohort study using the cancer and non-cancer patients with COVID-19.""}"
"3399","Psychiatric Disturbances and COVID-19 Infection","","NCT04459403","15-2020/1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459403","Completed","2020-06-08","2020-12-30","{""locations"":""15 Mayo Smart Hospital, Cairo, Egypt|National hepatology and tropical medicine research institute, Cairo, Egypt|Students hospital, Giza, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Psychiatric well-being, level of anxiety, symptoms of depression and coping strategies questionnaire|Prevalence and types of Psychiatric disturbances in patients with COVID-19 infection""}"
"3400","Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS","","NCT04391140","PR(AG)198/2020","Other: Prone position","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04391140","Recruiting","2020-05-13","2021-06-01","{""locations"":""Hospital Universitari Vall d'Hebron, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""248"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Therapeutic failure death or intubation|Feasibility and safety of prone position in HFNC patients|Efficacy of prone position in HFNC patients""}"
"3401","Tools for Wellbeing COVID-19 National Study of Undergraduate Students","","NCT04414371","Pro2020000953","Other: Yoga","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04414371","Recruiting","2020-05-20","2020-12-31","{""locations"":""Rutgers University, New Brunswick, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stress|Wellbeing|Anxiety|Depression|Resilience|Positive Affect|Negative Affect""}"
"3402","Dornase Alfa for ARDS in Patients With SARS-CoV-2","DORNASESARS2","NCT04402970","2022206","Drug: Dornase Alfa Inhalation Solution","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04402970","Completed","2020-06-19","2020-12-31","{""locations"":""University of Missouri Hospital and Clinics, Columbia, Missouri, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement in PaO2\/FiO2|Change in static lung compliance|Duration of mechanical ventilation|Length of ICU stay|Length of hospitalization|Secondary bacterial infections|Mortality""}"
"3403","Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians in the Covid-19 Pandemic","","NCT04500652","PMRMentalcovid","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04500652","Recruiting","2020-06-27","2020-10-01","{""locations"":""Dokuz Eylul University, Izmir, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""310"",""age"":""24 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depression, Anxiety and Stress Scales 21 Score|Insomnia severity index score""}"
"3404","Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)","DYADS","NCT04584658","20/NW/0333","Diagnostic Test: Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|Diagnostic Test: Videofluoroscopy|Other: Dysphagia Handicap Index (DHI)|Other: Voice Symptom Scale (VoiSS)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04584658","Recruiting","2020-09-15","2021-12-01","{""locations"":""Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""36"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).|The severity of dysphonia and\/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months)|The severity of dysphonia and\/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only.|Relationship between severity of dysphonia and\/or dysphagia with grade of ARDS|Relationship between severity of dysphonia and\/or dysphagia with length of intubation|Relationship between severity of dysphonia and\/or dysphagia with duration of mechanical ventilation|Relationship between severity of dysphonia on quality of life using Voice Symptom Scale (VoiSS) questionnaire over time at day 0, 1 month and 9 months.|Relationship between severity of dysphagia on quality of life using Dysphagia Handicap Index (DHI) questionnaire over time at day 0, 1 month and 9 months""}"
"3405","Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)","","NCT04478071","HSC-MS-20-0395","Drug: vadadustat|Drug: placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04478071","Recruiting","2020-08-22","2022-08-01","{""locations"":""The University of Texas Health Science Center at Houston, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ECMO), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the NIAID ordinal scale|Number of participants with a total score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) scale""}"
"3406","In-depth Immunological Investigation of COVID-19.","COntAGIouS","NCT04327570","COntAGIouS","Other: Patient sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04327570","Recruiting","2020-03-27","2020-09-30","{""locations"":""UZ Leuven, Leuven, Belgium"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome""}"
"3407","COVID-19 Persistence in Stool","CoPS","NCT04546776","QIB05/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04546776","Enrolling by invitation","2020-09-08","2022-06-01","{""locations"":""Quadram Institute Bioscience, Norwich, Norfolk, United Kingdom|Norfolk and Norwich University Hospital Foundation Trust, Norwich, Norfolk, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence and persistence of the SARS-CoV-2 virus in the faeces, and change in associated health status|Viral strain-specific prevalence, associated with change in health status|Biogeographical viral strain identification, associated with change in health status|Create a SARS-CoV-2 biological sample repository""}"
"3408","Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection","ODYSSI","NCT04466982","REC Ref: 20/SC/0231","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04466982","Recruiting","2020-07-02","2022-01-01","{""locations"":""Addenbrookes Hospital, Cambridge, United Kingdom|Charing Cross Hospital, London, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""UPSIT scores|eQOD scores|SNOT 22 scores""}"
"3409","French Single Centre Experience of Critically Ill Patients With Covid 19","CovidAmiens20","NCT04354558","PI2020_843_0026","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354558","Recruiting","2020-07-01","2021-08-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation of age between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of medical history between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of chronic drug used between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of chest CT scan at admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of respiratory support at ICU admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU""}"
"3410","Methylprednisolone in COVID-19 Patients (Methyl19LGH)","Methyl19LGH","NCT04559113","LGH005","Drug: Methylprednisolone Injectable Product","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04559113","Recruiting","2020-05-01","2020-12-30","{""locations"":""Muhammad Irfan Malik, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical response after administration|Clinical response to treatment|Duration of hospitalization""}"
"3411","ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19","","NCT04367740","20-0937","Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367740","Enrolling by invitation","2020-04-28","2021-04-01","{""locations"":""Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""10000"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection.|Percentage of Asymptomatic patients with viral presence of SARS-CoV-2 infection.""}"
"3412","Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.","","NCT04339686","POWER-COVID_CT","Diagnostic Test: Thoracic CT Scan","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339686","Recruiting","2020-04-20","2020-11-01","{""locations"":""Chu de Poitiers, Poitiers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""56000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diagnostic performance of chest CT in screening for pulmonary lesions in clinical suspicions of COVID.|Compare the diagnostic performance of chest CT and RT-PCR in COVID 19 at the initial consultation (screening).""}"
"3413","Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19","","NCT04701502","COVID_BULG_2020","Dietary Supplement: Viusid|Dietary Supplement: Asbrip|Drug: Standard Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04701502","Completed","2020-11-09","2021-02-15","{""locations"":""MBAL, Sv. Mina, Plovdiv, Bulgaria|MTB Plovdiv, Plovdiv, Bulgaria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Improvement|Time to semirecover|Symptom resolution|Time to recovery|Cumulative assessment of disease severity|Duration of SARS-CoV-2 PCR positivity|Concentration of C-reactive protein in peripheral blood|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate""}"
"3414","RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study","","NCT04659460","1.4","Device: Remote Ischemic Conditioning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04659460","Not yet recruiting","2020-12-15","2021-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Interleukin 1-Beta (IL-1B) (pg\/mL)|Interleukin 6 (IL-6) (pg\/mL)|C-reactive protein (CRP) (mg\/mL)|Tumour Necrosis Factor Alpha (TNFa) (pg\/mL)|Neutrophil to Lymphocyte Ratio (NLR) (absolute neutrophils\/lymphocytes)|Serum Ferritin (ng\/mL)|International Normalized Ratio (INR)|Prothrombin Time (PTT)|Rotational Thromboelastometry (ROTEM)|Total duration of mechanical ventilation (number of days)|Intensive Care Unit Length of Stay (number of days)|Hospital Length of Stay (number of days)""}"
"3415","COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior","","NCT04377581","STUDY00014798","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377581","Completed","2020-04-09","2020-07-10","{""locations"":""Penn State College of Medicine, Hershey, Pennsylvania, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""18251"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Knowledge and Confidence in Knowledge of COVID-19|Beliefs about the effectiveness of public health recommendations|Intent to comply with public health recommendations|Perception of Risk of COVID-19 and other health threats|Perceptions of trust in common health information sources|Single most trusted news source|Intention to change consumption of news because of COVID-19 (yes\/no)|For participants who will change their news consumption, in what way will they change?|Secondary information sources|Concerns about COVID-19""}"
"3416","COVID-19 Detection Test in Oncology","EVIDENCE","NCT04367870","UC-TRA-2002|2020-A01002-37","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367870","Recruiting","2020-05-23","2021-05-01","{""locations"":""Centre Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Hopitaux Civils de Colmar, Colmar, France|Centre Leon Berard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Institut Regional Du Cancer Montpellier Val D Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|H\u00f4pital Universitaire Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut Curie, Saint-Cloud, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate the ability of SARS-CoV-2 immunoassays, following a positive result, to identify patients with very low risk of recurrence of COVID-19 within 3 months.|To estimate the prevalence of patients immunized to the SARS-CoV-2 virus in an oncology population over the whole study duration and within one-month periods.|To estimate the discordance rate between local immunoassay and a centralized ELISA in patients with a positive immunoassay, whatever the immunoassay.|To identify patients with very low risk of recurrence of COVID-19 within 6 months following a positive immunoassay result.|To characterize the evolution over time of the serologic response against SARS-CoV-2 (in a subgroup of patients).""}"
"3417","French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study","FRENCH CORONA","NCT04340466","2020-A00797-32","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04340466","Completed","2020-04-03","2020-07-03","{""locations"":""CHU Nimes, N\u00eemes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1003"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality at day 28|severe complications|Imaging|Delay in Microbiological diagnosis|Antiviral therapy|Antibiotic therapy|Covid-19 treatments|Patients receiving renal replacement therapy|Patients receiving mechanical ventilation|Vital status""}"
"3418","Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;","Plex","NCT04485169","Sultan Mehmood Kamran","Procedure: Therapeutic Plasma Exchange","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04485169","Completed","2020-04-01","2020-07-31","{""locations"":""Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""280"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival|Duration of Hospitalization|Timing of PCR negativity|Time to CRS resolution|Complications""}"
"3419","Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","COVI-DOSE","NCT04373707","2020-001709-21","Drug: Enoxaparin","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04373707","Recruiting","2020-05-13","2021-11-01","{""locations"":""Amiens Academic Hospital, Amiens, France|Besan\u00e7on Academic Hospital, Besan\u00e7on, France|Brest Academic Hospital, Brest, France|Civil Hospital, Colmar, France|Dijon Academic Hospital, Dijon, France|Kremlin Bic\u00eatre Academic Hospital, Le Kremlin-Bic\u00eatre, France|Lille Academic Hospital, Lille, France|Groupe Hospitalier Un\u00e9os, Metz, France|Metz-Thionville Regional Hospital, Metz, France|Montpellier Academic Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy Academic Hospital, Nancy, France|George Pompidou European Hospital, Paris, France|Lariboisi\u00e8re Academic Hospital, Paris, France|St Etienne Academic Hospital, Saint-\u00c9tienne, France|Strasbourg Academic Hospital, Strasbourg, France|Toulouse Academic Hospital, Toulouse, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""602"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Venous thromboembolism|Major bleeding|Major Bleeding and Clinically Relevant Non-Major Bleeding|Net Clinical Benefit|Venous Thromboembolism at other sites|Arterial Thrombosis|All-Cause Mortality|Factors associated with the risk of venous thromboembolism""}"
"3420","Impact of COVID-19 on the Incidence, Characteristics, Management and Outcome of Sepsis","","NCT04698382","BD022384","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04698382","Active, not recruiting","2020-08-01","2021-05-01","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence of hospital and ICU Admission|In-hospital Mortality|Sepsis management quality metrics""}"
"3421","Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;","","NCT04351568","2020A20","Other: quesionnair","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04351568","Recruiting","2020-04-01","2020-08-01","{""locations"":""Assiut, Assiut, Egypt"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""874"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""to evaluate the effect of social media usage in medical practice during covid 19 epidemic""}"
"3422","Impact of COVID-19 on Mental Health of Health Care Workers","COVID-Impact","NCT04382196","BC-07564","Other: Online survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382196","Active, not recruiting","2020-04-17","2022-12-31","{""locations"":""Ghent University Hospital, Ghent, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""497"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Depressive symptoms at baseline|Change in depressive symptoms|Anxiety levels at baseline|Change in anxiety levels|Stress levels at baseline|Change in stress levels|Quality of life at baseline|Change in Quality of life|Covid-19 related psychological distress|Change in Covid-19 related psychological distress|Post traumatic stress symptoms|Change in post traumatic stress symptoms|Perceived social support at baseline|Change in perceived social support""}"
"3423","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients","","NCT04264858","WuhanUH-2019 nCoV-Ig","Drug: Immunoglobulin of cured patients|Drug: γ-Globulin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04264858","Not yet recruiting","2020-03-17","2020-05-31","{""locations"":""Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2\/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality""}"
"3424","Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19","CYNKCOVID","NCT04365101","CYNK-001-COVID-19","Biological: CYNK-001","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04365101","Recruiting","2020-05-13","2022-06-30","{""locations"":""Banner University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arkansas, Little Rock, Arkansas, United States|UC Irvine, Irvine, California, United States|UC Davis Medical Center, Sacramento, California, United States|Scripps Health, San Diego, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Atlantic Health, Morristown, New Jersey, United States|Atlantic Health, Summit, New Jersey, United States|Multicare Health System, Tacoma, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""86"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 1: Frequency and Severity of Adverse Events (AE)|Phase 1 Futility Check for go\/no decision to move to Phase 2: Rate of clinical improvement|Phase 2: Time to Clinical Improvement by Ordinal Scale for Clinical Improvement (OSCI)|Rate of Clearance of SARS-CoV-2|Time to Clearance of SARS-CoV-2|Phase 2: Frequency and Severity of Adverse Events (AE)|Overall Clinical Benefit by time to medical discharge|Overall Clinical Benefit by hospital utilization|Overall Clinical Benefit by measuring mortality rate|Impact of CYNK-001 on sequential organ failure assessment (SOFA) score|Time to Pulmonary Clearance|Rate of Pulmonary Clearance|Supplemental oxygen-free days|Proportion of patients requiring ventilation|Duration of hospitalization|Radiologic Evaluation Score|All-cause mortality rate|Time to clinical improvement by NEWS2 Score|Rate of clinical improvement by NEWS2 Score""}"
"3425","Remdesivir Efficacy in Coronavirus Disease","","NCT04345419","COVID 19 treatment","Drug: Remdesivir|Other: Standard of care treatment","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04345419","Recruiting","2020-06-16","2029-12-01","{""locations"":""Tanta university hospital, Assuit University, Ainshams University, Tanta, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patients with improvement or mortality""}"
"3426","Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","UC-COVID","NCT04373135","UCLA-20-000683","Behavioral: Brief educational video","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04373135","Active, not recruiting","2020-05-08","2021-03-01","{""locations"":""University of California, Los Angeles, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement in knowledge surrounding SRA policy|Improvement in anxiety surrounding SRA policy|Improvement in trust surrounding SRA policy""}"
"3427","COPD in the Time of COVID-19","","NCT04407598","0778","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407598","Active, not recruiting","2020-05-01","2021-06-01","{""locations"":""NIHR Leicester Biomedical Research Centre (Respiratory), Glenfield Hospital, Leicester, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""160"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in COPD Exacerbation Rate|Change in number of Severe AECOPD events during period of interest in 2020 from same period in 2019.|Change in Moderate AECOPD events during period of interest in 2020 from same period in 2019.|Social contact changes during i) pre-lockdown and ii) lockdown period|Household contacts during i) pre-lockdown and ii) lockdown period|Household visitors during i) pre-lockdown and ii) lockdown period|Regular shopping behaviour during i) pre-lockdown and ii) lockdown period|Medication changes during i) pre-lockdown and ii) lockdown period|Reported change in regular medication usage during i) pre-lockdown and ii) lockdown period|Change in physical activity levels during i) pre-lockdown and ii) lockdown period|Change in anxiety levels during i) pre-lockdown and ii) lockdown period|Perceived fear of hospitalisation during COVID-19 period|Patient reported changes in perception of symptoms, need for hospitalisation and availability and safety of healthcare resources thought semi-structured interviews in 20 patients (nested qualitative study)|Association between changes in AECOPD event rate and changes in local air pollution during the COVID-19 lockdown""}"
"3428","Colchicine Counteracting Inflammation in COVID-19 Pneumonia","ColCOVID-19","NCT04322565","ColCOVID-19","Drug: Colchicine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04322565","Recruiting","2020-04-20","2020-12-21","{""locations"":""Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""310"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical ventilhation|Hospitalization|Time from treatment initiation to death|Time to Negativization COVID 19|Fever""}"
"3429","Using BCG to Protect Senior Citizens During the COVID-19 Pandemic","","NCT04542330","BCG-DENMARK-SENIOR","Biological: BCG-Denmark|Biological: Saline","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04542330","Recruiting","2020-09-15","2022-03-01","{""locations"":""Seniorhuset, Odense, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1900"",""age"":""65 Years to 110 Years \u00a0 (Older Adult)"",""outcome_measures"":""Acute infection|SARS-CoV-2 infection|Self-reported respiratory illness""}"
"3430","Neurologic Manifestations of COVID-19","CORONA","NCT04386083","RGAO-2020-0348","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386083","Recruiting","2020-06-10","2021-03-01","{""locations"":""Philippine General Hospital - University of the Philippines Manila, Manila, Philippines"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1342"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality (binary outcome)|Respiratory failure (binary outcome)|Duration of ventilator dependence (continuous outcome)|Intensive care unit (ICU) admission (binary outcome)""}"
"3431","Covid-19 Pandemic and Cerebral Palsy","","NCT04686565","CP-covid","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04686565","Recruiting","2020-02-15","2021-02-28","{""locations"":""Diskapi Education and Research Hospital, Ankara, Alt\u0131ndag, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""3 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""The status of the child to benefit from health-education services|Physical-psychosocial and cognitive state of the child|Caregivers' quality of life|the Covid-19 fear levels of Caregivers""}"
"3432","Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey","PSY_CO_CHU","NCT04358640","LOCAL COVID 2019/JYL-01)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04358640","Completed","2020-04-09","2020-04-27","{""locations"":""Intensive care unit CHU Nimes, N\u00eemes, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1784"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety|Insomnia|Catastrophism""}"
"3433","Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)","","NCT04382131","AC20042","Other: NaCl Solution","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04382131","Recruiting","2020-06-23","2020-10-31","{""locations"":""NHS Lothian, Edinburgh, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""405"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to resolution of symptoms as defined by the single question 'how unwell do you feel today'.|Severity of all symptoms|The length of time for individual symptoms to resolve|Severity of individual symptoms|Contacting healthcare (NHS 24, OOH, GP)|Participants needing GP appointments|Participants attending hospital|Length of stay in hospital if admitted|Number of participants reporting over the counter medication use|Reduction in transmission to household contacts|Number of participants reporting side effects of nasal irrigation|Types and severity of side effects reported|Cost of over the counter medication used""}"
"3434","A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic","RAPID-BRAZIL","NCT04444700","CAAE: 33109220.7.0000.0068","Drug: Therapeutic anticoagulation","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04444700","Recruiting","2020-07-04","2020-12-31","{""locations"":""Hospital das Cl\u00ednicas da FMUSP, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""462"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite main outcome|All-cause death|Composite outcome of ICU admission or all-cause death|Major bleeding|Number of participants who received red blood cell transfusion|Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and\/or fibrinogen concentrate.|Number of hospital-free days alive up to day 28|Number of ICU-free days alive up to day 28|Number of ventilator-free days alive up to day 28|Number of participants with venous thromboembolism|Number of participants with arterial thromboembolism|Number of participants with heparin induced thrombocytopenia""}"
"3435","COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry","","NCT04661657","AAAT0787","Other: Transthoracic echocardiogram (TTE)|Other: Cardiovascular Magnetic Resonance (CMR) Imaging","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04661657","Recruiting","2020-12-28","2022-09-30","{""locations"":""Columbia University Irving Medical Center, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of myocardium demonstrating late gadolinium enhancement|Extracellular Volume (ECV) Fraction|Left Ventricular Ejection Fraction""}"
"3436","Effects of the COVID-19 Health Emergency on Biopsychosocial Health","","NCT04409535","20-266","Other: WHOQOL-BREF survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409535","Active, not recruiting","2020-05-07","2021-03-31","{""locations"":""University of New Mexico Department of Pediatrics, Albuquerque, New Mexico, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""World Health Organization Quality of Life-Brief Scale|Open-ended Interview""}"
"3437","Efficacy and Safety of Ozonised Oil (HOO) in COVID-19 Patients","HOO-COVID","NCT04651387","DEP_052020","Dietary Supplement: Ozonized oil (HOO","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04651387","Not yet recruiting","2021-01-01","2021-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""74"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load of SARS-CoV-2|The temporal profile of viral load of SARS-CoV-2|The proportion of patients with virological clearance|SaO2|hospitalization stay|Intensive care|COVID-19 Severity Score|in-hospital mortality""}"
"3438","Effects of DPP4 Inhibition on COVID-19","","NCT04341935","20200384","Drug: Linagliptin|Drug: Insulin regimen","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04341935","Not yet recruiting","2021-06-30","2021-12-30","{""locations"":""University of Miami, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures""}"
"3439","COVID-19 Pandemic and General Surgery Emergencies","","NCT04686708","Gulhane2020-258","Other: Emergency general surgical admissions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04686708","Completed","2019-03-11","2020-09-11","{""locations"":""Gulhane Training and Research Hospital, Ankara, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""750"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of general surgical emergencies|Complication rate""}"
"3440","Investigating a Vaccine Against COVID-19","","NCT04400838","COV002","Biological: ChAdOx1 nCoV-19 (Abs 260)|Biological: MenACWY vaccine|Biological: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|Biological: Two dose MenACWY vaccine|Biological: ChAdOx1 nCoV-19 (qPCR)|Biological: ChAdOx1 nCoV-19 0.5mL prime plus boost|Biological: Two dose MenACWY vaccine min. 4 weeks apart|Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04400838","Recruiting","2020-05-28","2021-09-01","{""locations"":""University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Castle Hill Hospital, Cottingham, Hull, United Kingdom|St Georges University Hospital NHS Foundation Trust, London, Tooting, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|North Bristol NHS Trust, Bristol, United Kingdom|NIHR Cambridge Clinical Research Facility, Cambridge, United Kingdom|NHS Lothian, Western General Hospital, Edinburgh, United Kingdom|Glasgow University and NHS Greater Glasgow & Clyde, New Lister Building, Glasgow Royal Infirmary & Queen Elizabeth University Hospital, Glasgow, United Kingdom|Liverpool School of Tropical Medicine (LSTM), Accelerator Research Clinic. Clinical Sciences Accelerator, LIverpool, United Kingdom|London North West University Healthcare Trust (LNWUH), Northwick Park Hospital, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, Department of Infection, St Thomas Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|Public Health Wales, Newport, United Kingdom|University of Nottingham Health Service, Cripps Health Centre, University Park, Nottingham, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Sheffield Teaching Hospitals, Royal Hallamshire Hospital, Sheffield, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""12390"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older.|Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited local reactogenicity signs and symptoms for 7 days following|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of unsolicited adverse events (AEs) for 28 days following vaccination|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 through standard blood tests (full blood count, liver and kidney function tests)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: hospital admissions|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: number of deaths|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring incidence of Covid-19|Assess humoral immunogenicity of ChAdOx1 nCoV-19: antibody quantification|Assess humoral immunogenicity of ChAdOx1 nCoV-19: seroconversion|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays (groups 1, 2, 7 and 8 only)|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1, 2, 7 and 8 only): local reactogenicity|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): systemic reactogenicity|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only)|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) through standard blood tests (full blood count, liver and kidney function tests)|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) via seroconversion""}"
"3441","Engaging Patients in Colon Cancer Screening Decisions During COVID-19","","NCT04548531","2020P001579-2","Behavioral: Shared Decision Making","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04548531","Enrolling by invitation","2020-09-10","2021-05-30","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research"",""enrollment"":""800"",""age"":""45 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Shared Decision Making (SDM) Process Scale Score|Decisional Conflict (SURE scale)|Patient's preferred approach to screening|Intention to screen|Colon cancer screening rate""}"
"3442","Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period","AMPCOVID-19","NCT04415359","7789","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04415359","Recruiting","2020-05-20","2021-07-01","{""locations"":""Service Clinico biologique d'Assistance M\u00e9dicale \u00e0 La Procr\u00e9ation, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""700"",""age"":""18 Years to 43 Years \u00a0 (Adult)"",""outcome_measures"":""Study of the evolution of pregnancies in the first trimester following MAR management during a COVD-19 pandemic period""}"
"3443","MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)","MACoVIA","NCT04367077","B04-03","Biological: MultiStem|Biological: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04367077","Recruiting","2020-04-28","2022-08-01","{""locations"":""Athersys Investigational Site 107, Chicago, Illinois, United States|Athersys Investigational Site 103, Akron, Ohio, United States|Athersys Investigational Site 101, Cleveland, Ohio, United States|Athersys Investigational Site 102, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator-Free Days|Safety and Tolerability as measured by the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0.|All-cause mortality|Ranked hierarchical composite outcome of alive and ventilator-free|Ventilator-free days""}"
"3444","Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease","","NCT04569825","1148","Drug: Ophtamesone","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04569825","Recruiting","2020-08-01","2020-10-15","{""locations"":""Raid Muhmid Al-Ani, Ramadi, Anbar, Iraq"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recovery rate of anosmia and shorten recovery time""}"
"3445","Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis","","NCT04644302","FNHK_IGS_8144","Diagnostic Test: microcirculation recording","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04644302","Recruiting","2020-02-01","2021-12-01","{""locations"":""University Hospital Hradec Kralove, Hradec Kr\u00e1lov\u00e9, T\u0159ebe\u0161, Czechia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""change in Proportion of Perfused Vessels (PPV) parameter|change in Syndecan-1 serum concentration|change in albuminuria|mortality in 28 days""}"
"3446","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","BEST-CP","NCT04275414","QLEmer20200214","Drug: Bevacizumab Injection","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04275414","Completed","2020-02-15","2020-05-02","{""locations"":""Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""27"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Rate of improvement of oxygen-support status|The change of areas of pulmonary lesions shown on chest radiological imaging (chest CT or X-ray)|Blood lymphocyte counts|Level of CRP|Level of hs-CRP|All-cause mortality|Discharge rate""}"
"3447","Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea","EPRICOD","NCT04422587","RC31/20/0149","Other: RECOP unit patient","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422587","Completed","2020-03-13","2020-06-07","{""locations"":""University Hospital of Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1860"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Develop a predictive model of the risk of being COVID-19 for patients admitted to the emergency room for dyspnea|Describe the characteristics of patients admitted to reCOP units according to their virological status|Virological status|Mortality status""}"
"3448","A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19","","NCT04415073","SNDX-6352-0505","Drug: SNDX-6352|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04415073","Suspended","2020-05-30","2020-11-15","{""locations"":""HonorHealth, Scottsdale, Arizona, United States|Montefiore Medical Center, Bronx, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""186"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects alive and free of respiratory failure|Secondary clinical improvement outcomes|Time to clinical improvement (TTCI)|To evaluate improvement in oxygenation in hospitalized adults with respiratory signs and symptoms secondary to COVID 19 treated with axatilimab|To evaluate changes in biomarkers following treatment with axatilimab|To evaluate the safety and tolerability of axatilimab in the same population|Ventilation outcomes|To evaluate antiviral effect of axatilimab in hospitalized adults with recently diagnosed SARS CoV-2 infection|To characterize exposure to axatilimab""}"
"3449","COVIDAR - Arrhythmias in COVID-19","COVIDAR","NCT04437901","HCB/2020/0333","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04437901","Not yet recruiting","2020-06-01","2021-12-01","{""locations"":""Antwerp University Hospital, Antwerpen, Belgium|Istituto Auxologico Italiano, IRCCS, Milan, Italy|Amsterdam UMC, Amsterdam, AZ, Netherlands|Hospital Clinic of Barcelona, Barcelona, Spain|St. Georges University Hospitals, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""10000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Arrhythmia|Electrocardiographic changes - Underlying rhythm|Electrocardiographic changes - Atrioventricular conduction|Electrocardiographic changes - QRS duration|Electrocardiographic changes - presence of Brugada QRS pattern|Electrocardiographic changes - QTc duration|Laboratory abnormalities - electrolyte misbalance|Laboratory abnormalities - cardiac biomarkers|Laboratory abnormalities - renal function|Laboratory abnormalities - liver function""}"
"3450","COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020","QTW2020","NCT04399967","QTW 2020","Behavioral: Chat-based support|Behavioral: AWARD plus COVID-specific advice|Behavioral: AWARD advice|Behavioral: COVID-19 related health warning leaflet|Behavioral: Health warning leaflet|Behavioral: SMS-based support|Behavioral: Referral card|Behavioral: COSH Self-help smoking cessation booklet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04399967","Recruiting","2020-06-13","2022-06-30","{""locations"":""Hong Kong Council on Smoking and Health (COSH), Hong Kong, Hong Kong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research"",""enrollment"":""842"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Biochemical validated quit rate|Smoking quit rate change from baseline at 3-month follow-up|Smoking quit rate change from baseline at 6-month follow-up|Smoking reduction rate change from baseline at 3-month follow-up|Smoking reduction rate change from baseline at 6-month follow-up|Smoking quit attempt change from baseline at 3-month follow-up|Smoking quit attempt change from baseline at 6-month follow-up|Use of smoking cessation service|Engagement in chat-based\/SMS-based support""}"
"3451","The Psychological, Social, and Economic Impacts of COVID-19","C19Survey","NCT04369690","2131","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04369690","Recruiting","2020-04-03","2021-04-03","{""locations"":""Southlake Regional Health Centre, Newmarket, Ontario, Canada|CHEO Research Institute, Ottawa, Ontario, Canada|The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|The Centre for Addiction and Mental Health, Ottawa, Ontario, Canada|The University of Ottawa Heart Institute, Ottawa, Ontario, Canada|The Royal's Institute of Mental Health Research, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|H\u00f4pital en sant\u00e9 mentale Rivi\u00e8re-des-Prairies (CIUSSS du Nord-de-l'\u00cele-de-Montr\u00e9al), Montr\u00e9al, Quebec, Canada|McGill University, Montr\u00e9al, Quebec, Canada|University of Montr\u00e9al, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mental health - Stress|Mental health - Anxiety|Mental health - Depression|Moral distress in healthcare workers|Moral resilience in healthcare workers|Social life|COVID-9 symptoms|Adverse health long-term outcome|Health care utilization - Inpatient|Health care utilization - ER|Health care utilization - Outpatient|Sleep""}"
"3452","Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)","Hesperidin","NCT04715932","MHICC-2020-003","Drug: Hesperidin|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04715932","Recruiting","2021-02-18","2021-05-01","{""locations"":""Montreal Heart Institute, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""216"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects with COVID-19 symptoms.|Mean number of COVID-19 symptoms.|Duration of COVID-19 symptoms.|For each COVID-19 symptom listed in the appendix, proportion of subjects with the symptom.""}"
"3453","Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients","","NCT04594330","002/05/2020","Drug: virgin coconut oil (VCO)|Other: placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04594330","Recruiting","2020-06-01","2020-12-31","{""locations"":""Central Public Hospital Dr. Sardjito, Yogyakarta, Indonesia|RSUD Wonosari, Yogyakarta, Indonesia|RSUP Sleman, Yogyakarta, Indonesia|Teaching Hospital of Universitas Gadjah Mada (UGM), Yogyakarta, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ordinal scale for measuring clinical improvement by the World Health Organization (WHO)|Clinical symptoms improvement, determined with interview and examination|Pain as side effects of the drugs, measured by Visual Analog Scale|Allergic reaction severity in mild, moderate, or severe|Laboratory outcome of leucocyte count|Laboratory outcome of lymphocyte count|Laboratory outcome of neutrophil count|Laboratory outcome of neutrophil to lymphocyte ratio, in scale|Laboratory outcome of D-dimer|Laboratory outcome of TNF-alpha|Laboratory outcome of CRP value|Laboratory outcome of IL-6|Laboratory outcome of ferritin|Laboratory outcome of procalcitonin|chest radiology outcome, measured as improvement of infiltrate based on expert assessment""}"
"3454","Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization","","NCT04439006","OSU-20135|NCI-2020-03341|P30CA016058","Other: Best Practice|Drug: Ibrutinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04439006","Recruiting","2020-07-22","2022-12-31","{""locations"":""Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""72"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with diminished respiratory failure and death|Death|Time from study initiation to 48 hours fever-free|Duration of hospitalization|Time in intensive care unit (ICU)|Time to ICU admission|Number of days requiring supplemental oxygen|Total days of mechanical ventilation|Time to mechanical ventilation|Shock and need for pressure support|Incidence of any infection (viral, fungal, bacterial)|Time to clinical resolution|Incidence of grade 3 or higher adverse events|At the end of therapy (day 14)|Time to viral clearance|Survival""}"
"3455","Appendicitis During the National Lockdown During the COVID-19 Pandemic","","NCT04407117","APPCOVID-19","Behavioral: Lock-down and social distancing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407117","Completed","2017-03-23","2020-04-19","{""locations"":""Nordsjaellands Hospital, Hiller\u00f8d, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""6000000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Appendectomy|Postoperative length of stay|Mortality|Incidence of complicated appendicitis""}"
"3456","Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients","","NCT04465552","KCHRF-COVID-19-0001","Other: Patients received standard of care treatment during hospitalization","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04465552","Recruiting","2020-07-10","2021-10-01","{""locations"":""Kansas City Heart Rhythm Institute, Overland Park, Kansas, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""750"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To better characterize arrhythmic manifestations, employed treatment strategies and long- term outcomes in hospitalized COVID-19 patients in the US through a multicenter retrospective chart review.""}"
"3457","Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK","COVID19","NCT04405232","20SM5934","Other: Non-interventional","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04405232","Recruiting","2020-05-25","2021-06-25","{""locations"":""Imperial College Healthcare NHS Trust, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence and characteristics of coagulation abnormalities and their predictive value for respiratory failure requiring ventilation, multiorgan failure and death in patients presenting with COVID 19 infection|Incidence of respiratory failure requiring CPAP or mechanical ventilation|Incidence of thrombosis (clinical or radiological diagnosis) including thrombosis within 90 days after hospital admission (hospital associated thrombosis) 4. Incidence of minor bleeding 5. Heparin induced thrombocytopenia 6. Acute coronary syndrome|Incidence of major bleeding 8. Multiorgan failure 9. Development of DIC 10. Duration of hospital stay (days) 11. Hospital mortality|Incidence of clinically relevant non-major bleeding|Incidence of Heparin induced thrombocytopenia|Incidence of Acute coronary syndrome|Incidence of renal failure requiring renal replacement therapy|Incidence of Multiorgan failure|Incidence of Development of DIC|Duration of hospital stay (days)|Hospital mortality""}"
"3458","Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin","","NCT04378595","2020-004-0019","Other: During COVID-19 Pandemic|Other: After COVID-19 Pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04378595","Recruiting","2020-04-10","2021-07-30","{""locations"":""Dell Medical School, Austin, Texas, United States|CommUnity Care Clinic - Southeast Health and Wellness Clinic, Austin, Texas, United States|CommUnity Care Clinic - Rundberg, Austin, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Food Insecurity Score""}"
"3459","Assessment of Stress, Depression and Anxiety in Healthcare Caring for Patients With COVID-19","","NCT04631497","1072.6120.161.2020","Diagnostic Test: test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04631497","Recruiting","2020-07-01","2021-12-31","{""locations"":""University Hospital in Cracow, Krak\u00f3w, Poland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depression|Stress|Deal with Stress|Stress 2""}"
"3460","Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)","","NCT04421664","2020-6549","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04421664","Terminated","2020-03-25","2020-08-17","{""locations"":""University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Eastern Health, Saint John's, Newfoundland and Labrador, Canada|McMaster University, Hamilton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|Research Institute of the McGill University Health Centre, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ordinal Scale of COVID19 Disease Severity at 14 days|Incidence of Hospitalization|Incidence of COVID-19 related Death|Incidence of all-cause Death|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 days|Overall change in disease severity over 14 days among those who are symptomatic at baseline""}"
"3461","Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use","","NCT04595084","CHA-IRB-1141/05/20|3R33AT010125-03S1","Behavioral: Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|Behavioral: Internet Cognitive Behavioral Therapy plus CHAMindWell|Behavioral: CHAMindWell","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04595084","Not yet recruiting","2021-02-15","2022-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depression Severity (CAT-DI)|Drug Use Rates|Heavy Drinking Days|Televisits""}"
"3462","Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19","","NCT04380818","IPACOVID","Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04380818","Recruiting","2020-06-05","2021-07-01","{""locations"":""Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""106"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1""}"
"3463","COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress","COPING","NCT04379063","NSHA REB#1025690","Other: COVID-19 pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379063","Active, not recruiting","2020-05-13","2022-05-01","{""locations"":""Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""342"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Burnout|Psychological Distress|Post-traumatic stress symptoms|Post-traumatic growth""}"
"3464","Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection","","NCT04694638","20-003191","Other: Body position change","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04694638","Recruiting","2020-05-21","2021-05-01","{""locations"":""Mayo Clinic in Rochester, Rochester, Minnesota, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""24"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of intubation|Incidence of hypotension and cardiac arrhythmias and other nursing-related risks of combining prone positioning with high-flow nasal cannula and non-invasive positive pressure ventilation""}"
"3465","Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong","","NCT04325919","COVID-19 study 2020.076","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04325919","Recruiting","2020-02-24","2021-06-17","{""locations"":""Prince of Wales Hospital, Sha Tin, Hong Kong"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""170"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical|Virological|Microbiological""}"
"3466","Brain Health in the Time of COVID-19","","NCT04438967","MIRO_001_2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04438967","Recruiting","2020-06-16","2021-12-31","{""locations"":""Miro Health, San Francisco, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Test the hypothesis that COVID-19 infection will lead to increased risk of neurological impairment|Determine cognitive and behavioral functional patterns that predict susceptibility to neurological impairment due to COVID-19""}"
"3467","Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease","COVCALL","NCT04345159","GDE_2020_11","Other: Questionnaire by phone call","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04345159","Completed","2020-04-17","2020-11-30","{""locations"":""Fondation Adolphe de Rothschild, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""572"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adjusted Odds Ratio""}"
"3468","Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation","COWAIT","NCT04376775","CHUBX 2020/19","Other: Transplant patient","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376775","Active, not recruiting","2020-05-11","2020-12-11","{""locations"":""Hopital Pellegrin, Bordeaux, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3602"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Compliance precautions with COVID-19|Clinical impact of COVID-19""}"
"3469","Acute Cardiovascular Events Triggered by COVID-19-Related Stress","JoCORE","NCT04368637","JCCG.JoCORE.4.4040","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368637","Recruiting","2020-05-03","2020-08-30","{""locations"":""Istishari Hospital, Amman, Jordan|Abdelhadi Hospital, Amman, Jordan|Farah Hospital, Amman, Jordan|Jordan Hospital, Amman, Jordan|Specialty Hospital, Amman, Jordan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""50"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acute cardiovascular event triggered by COVID-19 stress|Ventricular tachycardia|acute stroke|Implantable cardioverter defibrillator (ICD) shock""}"
"3470","Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)","CARDS","NCT04427280","CCR 5287|20/NE/0139","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04427280","Recruiting","2020-05-26","2021-04-01","{""locations"":""The Royal Marden NHS Foundation Trust, Sutton, Surrey, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients, at each sample timepoint, with a positive detection of IgM and IgG specific antibodies to SARS-CoV-2.|Clinical course of SARS-CoV-2 infection in cancer patients.|Proportion of patients, at each sample timepoint, with SARS-CoV-2 viral clearance by throat\/nose swab by RT-PCR.|Time from start of symptoms to Day 0 testing in the study.|Feasibility of SARS-CoV-2 testing with a lateral flow assay.""}"
"3471","University of Utah COVID-19 Hydrochloroquine Trial","","NCT04342169","IRB_00131893","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04342169","Recruiting","2020-04-04","2022-04-01","{""locations"":""University of Utah, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of viral shedding|Duration of COVID-19-attributable symptoms|Hospitalization|Adult household contact viral acquisition""}"
"3472","COVID-19 Risk Stratification","","NCT04339387","2020P000944","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339387","Completed","2020-03-01","2020-04-26","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1326"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Suitable for discharge""}"
"3473","Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19)","","NCT04456556","ocular infection in covid19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04456556","Completed","2020-04-27","2020-06-30","{""locations"":""Minia university Hospital, Minya, Minia, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""5"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Combined Endophthalmitis and Orbital Cellulitis in patients with Novel Coronavirus Disease (COVID-19)""}"
"3474","Remdesivir in COVID-19 Lahore General Hospital","RC19LGH","NCT04560231","LGH003","Drug: Remdesivir","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04560231","Recruiting","2020-06-01","2020-11-30","{""locations"":""Muhammad Irfan Malik, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""15 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical response after administration|Clinical response to treatment|Duration of hospitalization|Supplemental Oxygen Requirement from Baseline""}"
"3475","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","","NCT04324866","Gisondi 4","Diagnostic Test: Nasopharyngeal swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04324866","Not yet recruiting","2020-04-01","2020-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions""}"
"3476","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","","NCT04327349","IR.MAZUMS.REC.1399.7330|IRCT20181104041551N1","Biological: Convalescent Plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04327349","Enrolling by invitation","2020-03-28","2020-09-30","{""locations"":""Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""30 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-\u03b1|Changes of PaO2\/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4\/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization""}"
"3477","AKI Biomarkers in Coronavirus(COVID)-19","","NCT04408248","283675","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408248","Recruiting","2020-08-20","2021-06-30","{""locations"":""Guy's & St Thomas' Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Any stage of acute kidney injury|need for RRT in first 7 days|Mortality|Duration of mechanical ventilation|Duration of vasopressor support""}"
"3478","COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings","","NCT04371835","2020-04-COHIVE","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371835","Recruiting","2020-08-12","2021-12-31","{""locations"":""Institute of Human Virology, Nigeria (IHVN), Abuja, Nigeria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical features of symptomatic COVID-19 in people living with HIV (PLWH)|Clinical outcomes of symptomatic COVID-19 in PLWH|Seroprevalence of COVID-19 in all parent study participants""}"
"3479","Study on Incidence of Elective Surgery Postponed During COVID-19 Pandemic in Geriatric Population","","NCT04547218","2020623-8801","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04547218","Completed","2020-06-22","2020-12-31","{""locations"":""Department of Anesthesiology & Intensive Care, Faculty of Medicine, University of Malaya, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Incidence of elective surgeries has postponed during COVID-19 pandemic in geriatric population|Incidence of cancer surgeries postponed during COVID-19 pandemic in geriatric population|Physical and psychological impact of postponed elective surgery in geriatric population during COVID-19 pandemic""}"
"3480","Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer: an Ambispective Study Extended Over 2 Time Periods.","CBP-COVID","NCT04366219","CHM-2020/S15/03","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366219","Not yet recruiting","2020-06-01","2022-08-28","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of clinical characteristics|Comparison of diagnostic procedures|Comparison of treatments (according to stage of disease)|Comparison of patients management deadlines|Comparison of survival""}"
"3481","The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong","","NCT04360863","NCT02758028_1","Other: Telephone survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04360863","Recruiting","2020-04-24","2021-12-30","{""locations"":""The University of Hong Kong, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""up to 25 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Smoking behaviors|Knowledge|Readiness to quit""}"
"3482","Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)","PREVICHARM","NCT04400019","COV20/00565","Drug: Hydroxychloroquine Only Product in Oral Dose Form","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04400019","Not yet recruiting","2020-09-01","2021-04-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1930"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of secondary cases of SARS-CoV2 infection among residents at six days|Number of secondary cases of SARS-CoV2 infection among residents at 14 days|Number of secondary cases of SARS-CoV2 infection among residents at 28 days|SARS-CoV-2 infection in nursing home staff who provide direct care at six days|SARS-CoV-2 infection in nursing home staff who provide direct care at 14 days|SARS-CoV-2 infection in nursing home staff who provide direct care at 28 days|Mortality|Compliance with treatment|Symptoms of SARS-CoV-2 infection at six days|Symptoms of SARS-CoV-2 infection at 14 days|Symptoms of SARS-CoV-2 infection at 28 days|Hospitalization|Adverse events at six days|Adverse events at 14 days|Adverse events at 28 days""}"
"3483","Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in the Context COVID-19","HoCoPsy","NCT04417374","RECHMPL20_0320","Other: Description of groups caracteristics","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04417374","Completed","2020-05-01","2020-06-30","{""locations"":""University hospital, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""94"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of hospitalized patients|Cause of hospitalization""}"
"3484","Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection","","NCT04357730","20-0880","Drug: Alteplase 50 MG [Activase]","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04357730","Active, not recruiting","2020-05-14","2021-11-01","{""locations"":""Scripps Memorial Hospital La Jolla, La Jolla, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health, Denver, Colorado, United States|St. Mary's Medical Center, West Palm Beach, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Long Island Jewish Medical Center, New York, New York, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Ben Taub Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PaO2\/FiO2 improvement from pre-to-post intervention|Achievement of PaO2\/FiO2 \u2265 200 or 50% increase in PaO2\/FiO2|National Early Warning Score 2 (NEWS2)|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale|48 hour in-hospital mortality|14 days in-hospital mortality|28 days in-hospital mortality|ICU-free days|In-hospital coagulation-related event-free (arterial and venous) days|Ventilator-free days|Successful extubation|Successful weaning from paralysis|Survival to discharge""}"
"3485","Cardiovascular Complications and COVID-19 (CovCardioVasc-Study)","CovCardioVasc","NCT04335162","20reamedcovid01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04335162","Recruiting","2020-02-28","2021-08-31","{""locations"":""Centre Hospitalier de Cannes, Cannes, France|CHU de Dijon, Dijon, France|Centre Hospitalier de Draguignan, Draguignan, France|Centre Hospitalier de Grasse, Grasse, France|Clinique Ambroise-Par\u00e9, Neuilly, France|CHU de Nice, Nice, France|H\u00f4pitaux Universitaires Paris Centre - H\u00f4pital Cochin, Paris, France|CHU de REIMS, Reims, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine the incidence of cardiomyopathies and venous thromboembolism|Mortality|Duration of mechanical ventilation|Shock|length of stay|Mechanical ventilation|Renal replacement therapy""}"
"3486","The New Silicone N99 Half-Piece Respirator","","NCT04454606","053/2563","Device: Fit test|Device: Filtration Test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04454606","Completed","2020-05-01","2020-05-31","{""locations"":""Bangkok Metroplitan Administration and Vajira Hospital, Bangkok, Thailand"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""43"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Fit test""}"
"3487","Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff","","NCT04320238","Interferon_prophylaxis","Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04320238","Recruiting","2020-01-21","2020-06-01","{""locations"":""Taihe Hospital, Shiyan, Hubei, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2944"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect""}"
"3488","CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.","CRISOL Contigo","NCT04646616","3R21MD012352-02S1","Other: Community popular opinion leader (POL) based intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04646616","Not yet recruiting","2021-01-06","2021-10-31","{""locations"":""Drexel University Dornsife School of Public Health, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Risk of exposure to COVID-19|Access to health care and testing|SAVAME-related factors and access to SAVAME services""}"
"3489","Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.","Ruxo-Sim-20","NCT04348695","Ruxo-Sim-20|2020-001405-23","Drug: Ruxolitinib plus simvastatin|Other: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04348695","Recruiting","2020-04-12","2020-05-13","{""locations"":""Hospital Universitario Madrid Sanchinarro, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""94"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients who develop severe respiratory failure.|Length of ICU stay.|Length of hospital stay|Survival rate at 6 months|Survival rate at 12 months|Survival rate at 28 days|Percentage of patients with each AE by grade|Percentage of patients who discontinued due to AEs""}"
"3490","Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention","COV-ENOX","NCT04520620","20CH089|2020-001823-15","Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe|Device: Ultrasound of the lower limbs","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04520620","Withdrawn","2020-05-02","2020-07-10","{""locations"":""Groupement Hospitalier des portes de Province, Mont\u00e9limar, France|Centre Hospitalier de Roanne, Roanne, France|CHU de Saint-Etienne, Saint-\u00c9tienne, France|Clinique Mutualiste, Saint-\u00c9tienne, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure of anti-Xa activity|Analysis of hemorrhagic risk|Venous thromboembolic events|Analysis individual patient characteristics by the biomarker of Kidney function|Analysis individual patient characteristics by the biomarker of inflammation|Analysis individual patient characteristics by the biomarker of coagulation|Demographic characteristics""}"
"3491","Household Transmission Investigation Study for COVID-19 in Tropical Regions","EPI-COVID-19","NCT04328129","2020-009","Procedure: Human biological samples","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04328129","Recruiting","2020-03-23","2022-03-23","{""locations"":""Centre Hospitalier Andr\u00e9e Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana|Institut Pasteur de Guadeloupe, Les Abymes, Guadeloupe|Institut Pasteur de Nouvelle-Cal\u00e9donie, Noum\u00e9a, New Caledonia"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""1300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Evaluation of the extent of the virus transmission within households|Characterization of the secondary cases|In New-Caledonia, evaluation of the extent of the virus transmission within contact persons""}"
"3492","Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19)","OCTAPUS-AI","NCT04721444","5293","Diagnostic Test: Machine Learning Classification of parenchymal lung change cause|Diagnostic Test: Machine Learning Classification of recurrence and non-recurrence","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04721444","Recruiting","2021-03-01","2023-01-01","{""locations"":""Guys and St. Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Royal Marsden NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Development of a Machine Learning model to distinguish parenchymal lung changes|Development of a Machine Learning model to predict recurrence risk after radical radiotherapy for non-small cell lung cancer""}"
"3493","Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents","COVIDIV","NCT04395859","MMT_2020_15","Procedure: Questionnaire|Other: Data collection up to 1 year","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395859","Recruiting","2020-05-27","2021-12-01","{""locations"":""Centre P\u00f4le Vision du val d'Ouest, Ecully, France|Fondation Adolphe de Rothschild, Paris, France|H\u00f4pital Lariboisi\u00e8re, Paris, France|Centre ophtalmologique Maison Rouge, Strasbourg, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic""}"
"3494","Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases","","NCT04341012","19-001971","Diagnostic Test: Collection of breath sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341012","Recruiting","2019-09-10","2021-12-31","{""locations"":""Mayo Clinic Florida, Jacksonville, Florida, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Breath volatile organic compound profiles|Utility of breath profiles for disease diagnosis or prognosis""}"
"3495","IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","IMPACT","NCT04347798","Pro00100000","Other: Hydroxychloroquine/Chloroquine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04347798","Enrolling by invitation","2020-09-01","2021-04-01","{""locations"":""University of Alberta, Edmonton, Alberta, Canada"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action""}"
"3496","Evaluation of Immune Response in COVID-19 Patients","IMMUNOVID","NCT04438629","IMMUNOVID 2590CESC","Drug: COVID-19 treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04438629","Recruiting","2020-03-26","2020-11-26","{""locations"":""Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 associated immune disorder|COVID-19 associated inflammation|Oxygenation|Diagnostic of COVID disease composite|Changes at the cytokine pattern|Changes at circulating immune cell composition|Intensive Care Unit Admission|Length of hospital stay|Clinical Status|Mortality""}"
"3497","COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)","","NCT04401436","200111|20-I-0111","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401436","Recruiting","2020-05-22","2022-06-30","{""locations"":""MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of lymphocyte subsets in patients with COVID-19 at various stages of disease, including recovery.|Evaluation of inflammatory pathways that may contribute to COVID-19 disease pathogenesis.""}"
"3498","Cross Sectional CFAR HIV/COVID-19 Study","","NCT04514016","20200802","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04514016","Active, not recruiting","2020-08-12","2021-03-31","{""locations"":""Batchelor's Children's Research Institute, Miami, Florida, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""64"",""age"":""3 Years to 25 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Number of participants who tested positive with SARS COV-2 Infection|Number of participants who tested positive with SARS COV-2 antibody""}"
"3499","The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19","","NCT04588441","IRB202002127|OCR39505","Drug: Adenosine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04588441","Not yet recruiting","2021-03-01","2022-12-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 105 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improved COVID-19 symptoms""}"
"3500","Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19","","NCT04316728","VivaDiag-2020","Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04316728","Not yet recruiting","2020-03-01","2020-11-01","{""locations"":""Unit\u00e0' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients""}"
"3501","Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes","CONFI-DIAB","NCT04485351","2020PI137","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04485351","Recruiting","2020-07-01","2020-09-01","{""locations"":""University Regional Hospital of Nancy, Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Compare glycated hemoglobin levels of patients with diabetes from the University Hospital of Nancy between the period preceding and following the lockdown related to the COVID-19 pandemic.|Describe the clinical and biological characteristics of patients with diabetes followed in routine care at the University Hospital of Nancy|Describe the change from baseline of biological and clinical parameters of patients with diabetes followed in routine care at the University Hospital of Nancy between the period preceding and following the lockdown.|Describe the proportion of patients who presented with one or more significant clinical event during the lockdown.|Describe the proportion of patients who forgot and\/or discontinued one or several medication(s) during the lockdown.|Describe the proportion of patients who changed their lifestyle's habits during the lockdown.|Describe healthcare consumption of patients with diabetes during the lockdown.|Describe the proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.""}"
"3502","Convalescent Plasma Therapy in Patients With COVID-19","","NCT04407208","3471041S322342020040800002","Biological: Convalescent plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04407208","Completed","2020-05-01","2020-06-22","{""locations"":""Gatot Soebroto central army presidential hospital, Jakarta Pusat, Indonesia"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Plaque reduction neutralization test (PNRT)|D-dimer|C-Reactive Protein (CRP)|International Normalized Ratio (INR)|Oxygenation Index|Chest X-ray|severe adverse event""}"
"3503","Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)","COVIMAR","NCT04710199","COVIMAR","Drug: Maraviroc experimental group|Other: Standard treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04710199","Not yet recruiting","2021-02-01","2021-10-01","{""locations"":""Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the efficacy of Maraviroc in SARS-CoV-2 infected patients hospitalized for COVID-19 using the Ordinal scale.|Analyze changes in analytical variables: changes in ambient air oxygen saturation (SatO2),related to the progression of COVID-19.|Study the variation in the number of biomarkers of inflammation.|Analyze changes in the number of innate immune activation (monocytes and dendritic cells) and adaptive (T lymphocytes).|Quantify the number of immunomodulatory treatments added to therapy|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Analyze changes in analytical variables:changes in neutrophils, related to the progression of COVID-19.|Analyze changes in analytical variables: changes in platelets, related to the progression of COVID-19.|Analytical variables related to the progression of COVID-19: changes in lactate dehydrogenase (LDH).|Analyze changes in analytical variables: changes in C-reactive protein, related to the progression of COVID-19.""}"
"3504","Electrocardiogram Analysis in COVID-19 Patients","ELCOVID","NCT04367129","385/2020/Oss/AOUFe","Diagnostic Test: ECG","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367129","Recruiting","2020-04-14","2021-04-01","{""locations"":""Arcispedale S. Anna, Ferrara, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1014"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 1: ECG characteristics in patients presenting with severe form of SARS-CoV-2 infection|Phase 2: Correlation between ECG signs and needs for invasive mechanical ventilation and\/or mortality in the acute phase|Phase 3: Correlation between ECG signs and cardiac involvement and mortality in the chronic phase""}"
"3505","Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19","PRoAcT-COVID","NCT04719182","PRoAcT-COVID","Other: Adjunctive therapies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04719182","Active, not recruiting","2020-09-01","2021-07-01","{""locations"":""Amsterdam UMC location AMC, Amsterdam, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|ICU, hospital and 90-day mortality|Ventilator-free days and alive at day 28|ICU length of stay|Hospital length of stay|Proven deep vein thrombosis (DVT)|Incidence of gastrointestinal bleeding|Development of acute kidney injury (AKI)|Incidence of tracheostomy|Use of renal replacement therapy (RRT)|Proven pulmonary embolism (PE)""}"
"3506","Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial","ACTION","NCT04394377","002/2020","Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Drug: Group 2: control group with enoxaparin 40mg/d","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04394377","Recruiting","2020-06-21","2021-03-01","{""locations"":""Centro de Estudos Cl\u00ednicos do Hospital C\u00e1rdio Pulmonar, Salvador, Bahia, Brazil|Instituto de Ensino e Pesquisa do Hospital da Bahia, Salvador, Bahia, Brazil|Santa Casa de Miseric\u00f3rdia da Bahia - Hospital Santa Izabel, Salvador, Bahia, Brazil|Hospital Maternidade S\u00e3o Vicente de Paulo, Barbalha, Cear\u00e1, Brazil|Centro de Ensino e Aperfei\u00e7oamento em Pesquisa - CEAP, Serra, Espirito Santo, Brazil|Centro de Pesquisas Cardiol\u00f3gicas de Goi\u00e2nia do Hospital das Cl\u00ednicas (UFG), Goi\u00e2nia, Goi\u00e1s, Brazil|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|N\u00facleo de Ci\u00eancias de Sa\u00fade - Unidade de Pesquisa - Hospital Fel\u00edcio Rocho, Belo Horizonte, Minas Gerais, Brazil|Centro de Pesquisa Cl\u00ednica do Hospital de Cl\u00ednicas da Universidade Federal de Uberl\u00e2ndia, Uberl\u00e2ndia, Minas Gerais, Brazil|Hospital Universit\u00e1rio da Universidade Estadual de Londrina, Londrina, Paran\u00e1, Brazil|Hospital Agamenon Magalh\u00e3es, Recife, Pernambuco, Brazil|Real Hospital Portugu\u00eas de Benefic\u00eancia em Pernambuco, Recife, Pernambuco, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nereu Ramos, Florian\u00f3polis, Santa Catarina, Brazil|Instituto Baia Sul de Ensino E Pesquisa Dr. Irineu May Brodbeck \/ Hospital Ba\u00eda Sul, Florian\u00f3polis, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Hospital de Amor de Barretos - (Pio XII), Barretos, S\u00e3o Paulo, Brazil|Unidade de Pesquisa Cl\u00ednica da Faculdade de Medicina de Botucatu - Unesp, Botucatu, S\u00e3o Paulo, Brazil|Hospital Universit\u00e1rio S\u00e3o Francisco de Assis, Bragan\u00e7a Paulista, S\u00e3o Paulo, Brazil|Hospital Regional do Litoral Norte, Caraguatatuba, S\u00e3o Paulo, Brazil|Hospital Regional de Registro, Registro, S\u00e3o Paulo, Brazil|Praxis Pesquisa M\u00e9dica, Santo Andr\u00e9, S\u00e3o Paulo, Brazil|Centro Integrado de Pesquisa (CIP) - Hospital de Base de Rio Preto, S\u00e3o Jos\u00e9 Do Rio Preto, S\u00e3o Paulo, Brazil|Hospital Regional de S\u00e3o Jos\u00e9 dos Campos, S\u00e3o Jos\u00e9 Dos Campos, S\u00e3o Paulo, Brazil|Santa Casa de Miseric\u00f3rdia de Votuporanga, Votuporanga, S\u00e3o Paulo, Brazil|Hospital Naval Marc\u00edlio Dias, Rio de Janeiro, Brazil|BP - A Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil|Hcor - Hospital do Cora\u00e7\u00e3o, S\u00e3o Paulo, Brazil|Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil|Hospital Moriah, S\u00e3o Paulo, Brazil|Hospital Samaritano Paulista, S\u00e3o Paulo, Brazil|Hospital Santa Paula, S\u00e3o Paulo, Brazil|Hospital S\u00e3o Paulo, S\u00e3o Paulo, Brazil|Instituto Dante Pazzanese de Cardiologia, S\u00e3o Paulo, Brazil|Instituto de Assist\u00eancia M\u00e9dica ao Servidor P\u00fablico Estadual de S. Paulo, S\u00e3o Paulo, Brazil|Instituto do Cora\u00e7\u00e3o do Hospital das Cl\u00ednicas da Faculdade de Medicina da USP-InCor-HCFMUSP, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.|Incidence of Venous thromboembolism|Incidence of acute myocardial infarction|Incidence of stroke|Number of days using oxygen therapy|Peak of troponin|Peak of D-dimer|Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria""}"
"3507","Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","COVIPREG","NCT04355234","APHP 200448","Diagnostic Test: identify SARS-CoV-2 infection by serology|Biological: collection of biological samples","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04355234","Recruiting","2020-05-04","2021-08-31","{""locations"":""Tsastaris Vassillis, Paris, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""2200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevalence or Number of women who are positive for SARS-CoV-2 in parturient woman|Consequences of SARS-CoV-2 infection in pregnant women and their newborns : Pregnancy outcome, maternal or neonatal complications|Assessment of the vertical transmission of SARS-CoV-2 and the possible routes of this transmission in women who are positive for SARS-CoV-2 during pregnancy|Assessment of susceptibility to infection during the 3 trimesters of pregnancy|Evaluation of the confinement on the risk of exposure to the virus during pregnancy .|collection of biological samples for new investigations in women who are positive for SARS-CoV-2 during pregnancy.|Assessment of the rate of SARS-CoV-2 infection in pregnant women the risk factors for the disease.|Assessment of the rate of SARS-CoV-2 infection in newborns and the risk factors for the disease.""}"
"3508","Mechanisms for Organ Dysfunction in Covid-19","UMODCOVID19","NCT04316884","EPN 2017/043 Covid19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04316884","Recruiting","2020-03-12","2021-12-31","{""locations"":""Uppsala University Hospital, Uppsala, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acute Kidney Injury|ARDS|30 day mortality|1 year mortality|Chronic Kidney Disease|SOFA-score""}"
"3509","Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)","AtTAC","NCT04453371","tPA-2020","Drug: Tissue plasminogen activator|Drug: Ringer solution","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04453371","Not yet recruiting","2020-10-15","2021-02-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""P\/F (PaO2\/FiO2) change during the first 72hrs after the end of the procedure in adult patients with severe atypical ARDS caused by SARS-2-CoV.|Ventilator-free time (days free from MV) for 28 days of observation.""}"
"3510","Effect of Tele-consultation in Addition With Psychiatric Follow-up During COVID-19 in Women Who Have Medical History of Post-partum Depression","COVIDDEPERINAT","NCT04516668","APHP200878","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04516668","Not yet recruiting","2020-11-01","2020-11-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of Hospital anxiety and depression scale (HAD)|Evaluation of Edinburgh Postpartum Depression Scale (EPDS)|Evaluation of HAD score in fathers|Evaluation of EPDS in fathers|Study of the relationship between maternals and paternals symptoms|Study of difficuties in child during the quarantine|Risk and protection factors""}"
"3511","The Effects of Covid-19 Pandemic on The Patients With Fibromyalgia","","NCT04686578","Fibromyalgia-pandemi","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04686578","Recruiting","2020-12-01","2021-02-28","{""locations"":""Diskapi Education and Research Hospital, Ankara, Alt\u0131ndag, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Level of Covid-19 anxiety|Level of Covid-19 fear|The Covid-19 anxiety and fear levels on daily life the patients with fibromyalgia|The Covid-19 anxiety and fear levels on sleep quality the patients with fibromyalgia|The Covid-19 anxiety and fear levels on anxiety-depression the patients with fibromyalgia""}"
"3512","Thromboembolic Events in Severe COVID-19 Patients","COVICLOT","NCT04405869","7779","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04405869","Recruiting","2020-04-29","2021-04-01","{""locations"":""Service d'Anesth\u00e9sie-R\u00e9animation - Nouvel H\u00f4pital Civil, Strasbourg, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Analysis of incidence of thromboembolic events in patients with Sars-CoV-2""}"
"3513","Survey on COVID-19 Airway Management","ISAM-COVID","NCT04487977","ISAM-COVID","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04487977","Recruiting","2020-04-22","2020-09-30","{""locations"":""Consorcio Hospital General Universitario de Valencia, Valencia, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Preferred device""}"
"3514","The REDEEM Pilot Study: A Feasibility RCT of Early ECMO in Severe Acute Respiratory Infection, Including COVID-19, WHO","REDEEM","NCT04708457","ANZIC-RC/AB V3.1","Other: VV-ECMO","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04708457","Not yet recruiting","2021-02-01","2022-01-31","{""locations"":""The Alfred Hospital, Melbourne, Victoria, Australia|Charite Universitatmedizin, Berlin, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants who have SARI and have been mechanically ventilated for at least 5 days.""}"
"3515","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19","","NCT04341480","2020-TJ-COVID-19","Drug: Chemotherapy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341480","Active, not recruiting","2020-07-01","2021-01-10","{""locations"":""Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""305"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection|Tumor response|Safety and tolerability of chemotherapy as measured by the Common Terminology|Quality of Life (QOL) measures using Functional Assessment of Cancer Therapy (FACT- ovarian cancer)""}"
"3516","Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS","","NCT04429555","MN-166-COVID-19-201","Drug: Ibudilast|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04429555","Recruiting","2021-01-11","2021-12-01","{""locations"":""Denver Health and Hospital Authority, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects free from respiratory failure|Mean change from baseline in clinical status using the NIAID 8-point ordinal scale at Day 7|Percentage of patients with improvement in clinical status|Change in cytokine levels from baseline|Adverse event Incidence, severity, relationship to study drug, and study discontinuations|Changes in laboratory values from baseline|Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirement (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Day 14|Mean change from baseline in clinical status|Incidence of mechanical ventilation or intubation|Intensive care unit admission|Plasma concentrations of Ibudilast|All cause mortality""}"
"3517","Immunogenetics Predictors With COVID-19","","NCT04390269","R.20.05.830.R1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04390269","Recruiting","2020-09-10","2022-05-09","{""locations"":""Mansoura Faculty of Medicine, Mansoura, Dakahlyia, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""for the patients""}"
"3518","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","","NCT03808922","DAS181-3-01|2018-004318-16","Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT03808922","Recruiting","2019-05-23","2021-12-28","{""locations"":""City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|University of California Davis Health System, Sacramento, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Louisiana State University, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Universtiy of Michigan, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health, Winston-Salem, North Carolina, United States|The Lindner Center- The Christ Hospital, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Kent Hospital, Warwick, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|Texas Health, Fort Worth, Texas, United States|Therapeutic Concepts, Houston, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert Medical College Pulmonary Clinic, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Auchenflower, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Shanghai Pulmonary Hospital, Yangpu, Shanghai, China|West China Hospital, Chengdu, Sichuan, China|Shulan (Hangzhou) Hospital co., LTD, Hangzhou, Zhejiang, China|The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Rigshospitalet, Copenhagen, Denmark|H\u00f4pital Henri Mondor, Cr\u00e9teil, Ile-de-France, France|Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong|Samsung Medical Center, Gangnam-gu, Seoul, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Gyeonggi-do, Korea, Republic of|National Cheng Kung University Hospital, North District, Tainan, Taiwan|National Taiwan University Hospital, Zhongzheng, Taipei City, Taiwan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""274"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes)""}"
"3519","Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact","COVMUM","NCT04366817","APHP200471","Behavioral: psychological assessment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04366817","Not yet recruiting","2020-04-01","2020-06-01","{""locations"":""Service m\u00e9decine foetale-H\u00f4pital Trousseau, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with postpartum depression defined by an EPDS score >12|Socio-demographic data|Occurrence of a maternal or fetal pathology in a previous pregnancy|Pregnant maternal pathology (hypertension, diabetes, threat of premature delivery)|Presence of psycological maternal risk factor|Dyadic adjustment scale 16 (DAS-16)|Perinatal post traumatic stress disorder questionnaire (PPQ scale)|Mother to infant bonding scale (MIBS) autoquestionnaire|Measure Qualitative Interviews by Grounded theory""}"
"3520","Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19","eCardioCovid19","NCT04325867","GTP0032","Other: Tele-medicine platform","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04325867","Recruiting","2020-03-31","2020-10-01","{""locations"":""Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|Number of patients included in this platform|Number of consultations\/sessions given""}"
"3521","REmotely Monitored, Mobile Health Supported High Intensity Interval Training for Survivors of COVID-19","REMM-HIIT-ICU","NCT04664101","Pro00105798","Behavioral: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04664101","Not yet recruiting","2021-04-01","2023-05-01","{""locations"":""Duke University Medical Center, Durham, North Carolina, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of exercise session completed daily as measured by smart device monitoring.|Percentage of adherence to personal heart rate goal as measured by smart device monitoring.|Change in 6 minute walk distance""}"
"3522","COVID-19 Ad Intervention","","NCT04555122","COVID-Ad","Behavioral: Social Distancing Advertisements","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04555122","Not yet recruiting","2020-09-29","2022-07-28","{""locations"":""UC Irvine, Irvine, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other"",""enrollment"":""52500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mobility""}"
"3523","Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses","","NCT04379453","4094-20","Procedure: Robot Assisted Percutaneous Cardiovascular Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04379453","Recruiting","2020-04-27","2020-04-27","{""locations"":""Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Successful cardiovascular intervention|Performed with the professional team positioned at> 2 meters from the patient for at least 50% of the duration of the intervention|absence of fatal complications caused by the procedure or acute non-fatal vessel occlusion during index admission""}"
"3524","Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt","COVID-19","NCT04339322","COVID-19 in Egypt","Other: Follow up","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339322","Not yet recruiting","2020-05-01","2020-07-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group|Clinical manifestations of Coronavirus Disease 2019 (COVID-19)|Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort|Radiological features of Coronavirus Disease 2019 (COVID-19) cohort|outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group""}"
"3525","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","ELEVATE","NCT04340349","25/20","Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG|Drug: Hydroxychloroquine Sulfate placebo|Drug: Bromhexine 8 MG placebo","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04340349","Enrolling by invitation","2020-05-11","2021-04-15","{""locations"":""National Institute of Rehabilitation, Mexico City, Cdmx, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""280"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.|Polymerase chain reaction assay (PCR) negative at day 30.|Polymerase chain reaction assay (PCR) negative at day 60.""}"
"3526","Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19","PEACE","NCT04637295","768-20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04637295","Recruiting","2021-01-27","2021-06-30","{""locations"":""University of Nebraska Medical Center, Omaha, Nebraska, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical Activity|Psychosocial Function during COVID-19|Self-Efficacy|Sleep Quality|Fatigue|Anxiety|Depression|Loneliness|Global Self-Esteem|Subjective Cognitive Impairment|Social Support|Satisfaction of Life|Stress|Perceptions of Exercise""}"
"3527","COVID-19 and Lactating Mothers","","NCT04558320","STUDY00004889|3U01AI131344-04S1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04558320","Recruiting","2020-07-02","2021-04-01","{""locations"":""University of Rochester Medical Center, Rochester, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""mean change in SARS-Cov-2 viral load in breast milk""}"
"3528","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)","REALIST","NCT03042143","16154DMcA-AS","Biological: Human umbilical cord derived CD362 enriched MSCs|Biological: Placebo (Plasma-Lyte 148)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT03042143","Recruiting","2019-01-07","2022-10-01","{""locations"":""Belfast Health and Social Care Trust, Royal Hospitals, Belfast, Northern Ireland, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""75"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Oxygenation index (OI)|Incidence of Serious Adverse Events (SAEs)|Oxygenation index|Sequential Organ Failure Assessment (SOFA) score|Respiratory compliance (Crs)|Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P\/F ratio)|Driving Pressure|Extubation and reintubation|Ventilation free days at day 28|Length of ICU and hospital stay|28-day and 90-day mortality""}"
"3529","Italian Web-based Cross-sectional Survey on COVID-19","EPICOVID19","NCT04471701","EPICOVID19_2020","Behavioral: Environmental exposure and clinical features","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04471701","Recruiting","2020-04-13","2020-08-31","{""locations"":""Institute of Biomedical Technologies-National Research Council, Segrate, MI, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""200000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants (%) with COVID-19-like symptoms|Number of participants (%) with SARS-CoV-2 nasopharyngeal swab (NPS) test positivity""}"
"3530","Characteristics and Outcomes of Gastrointestinal Manifestations of COVID-19","","NCT04490772","COVID gastro intestinal","Diagnostic Test: Laboratory tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04490772","Not yet recruiting","2020-07-01","2020-09-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical data questionnaire|Tests such as CBC|liver function test""}"
"3531","COVID-19 Wellness Survey","","NCT04394104","Pro2020001009","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04394104","Terminated","2020-05-27","2020-05-31","{""locations"":""Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""593"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health Behavior Change Regression Questionnaire""}"
"3532","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","COVID-19","NCT04256395","RWS-BTCH-002","Other: mobile internet survey on self-test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04256395","Completed","2020-02-01","2020-07-01","{""locations"":""Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""102456"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient""}"
"3533","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","DC-COVID-19","NCT04252274","DC-COVID-19","Drug: Darunavir and Cobicistat","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04252274","Recruiting","2020-01-30","2020-12-31","{""locations"":""Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2""}"
"3534","Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement","NICOR","NCT04476992","8322/1","Drug: Nitric Oxide-Sessions|Drug: Nitric Oxide-Continuous and Sessions","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04476992","Active, not recruiting","2020-07-24","2021-09-17","{""locations"":""Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Methemoglobin level at 48 hours|Change in Methemoglobin level at 96 hours|Improvement in oxygenation between the groups at 48 hours or at discharge if before 48 hours|Improvement in oxygenation between the groups at 96 hours or at discharge if before 96 hours|Rate of positive RT-PCR for SARS-CoV-2 between groups in 5 days, discharge, and 28 days|Time to clinical recovery among groups, defined as time to interruption of oxygen administration for 24 hours or discharge|Reduction in the inflammatory markers among groups|Rate of Acute Kidney Disease (AKI) between groups during hospitalization|Difference in Katz score between groups""}"
"3535","Experience of Orthopaedic and Spine Center Pakistan During COVID-19","","NCT04516824","30","Procedure: Orthopaedic Surgical Procedures","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04516824","Completed","2020-03-19","2020-08-15","{""locations"":""Ghurki trust hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""2160"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical and functional characteristics|Patient's journey""}"
"3536","The Use of Lung Ultrasonography in COVID-19 Patients","","NCT04432051","Gaziosmanpasa","Behavioral: mechanical ventilator settings and position","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04432051","Recruiting","2020-05-26","2020-08-10","{""locations"":""Gazoosmanpasa Education and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""100"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in PO2 values|Change in PCO2 values""}"
"3537","Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19","IDEA","NCT04425863","IDEA","Drug: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|Other: Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|Other: Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.","Observational","Has Results","","https://ClinicalTrials.gov/show/NCT04425863","Completed","2020-05-01","2020-08-30","{""locations"":""Hospital Eurnekian, Buenos Aires, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""167"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Patients Who Improved Their Condition or Did Not Worsen it|ICU-treated Patients After 2-week Treatment|Mortality|Patients Needing Drug Dose Adjustment|Adverse Events""}"
"3538","COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study","","NCT04391816","200115|20-AA-0115","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04391816","Recruiting","2021-03-16","2024-12-31","{""locations"":""NIAAA Section on Human Psychopharmacology, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""AUDIT Score|ADS Score|Life Events Questionnaire (LEQ) Score|UCLA Loneliness Scale (UCLALS) Score|Perceived Stress Scale (PSS) Score""}"
"3539","FilmArray and Management of ICU Patients With Pneumonia in the Covid-19 Context","FAP-REA","NCT04453540","2020PI101","Diagnostic Test: FilmArray PCR on respiratory samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453540","Not yet recruiting","2020-07-01","2020-08-30","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""150"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Therapeutic decision""}"
"3540","COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)","AntiCoV-HB","NCT04416308","35RC20_9716","Diagnostic Test: NG test|Diagnostic Test: Blood test|Behavioral: Self-questionnary","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04416308","Recruiting","2020-05-29","2020-10-10","{""locations"":""CENTRE HOSPITALIER de VITRE_ Saint Jean (La Guerche), La Guerche de Bretagne, La Guerche-de-Bretagne, France|Centre Hospitalier de Fougeres, Foug\u00e8res, France|Centre Hospitalier Grand Fougeray, Grand-Fougeray, France|Centre Hospitalier de La Roche Aux Fees, Janz\u00e9, France|Centre Hospitalier Montfort-Sur-Meu, Montfort sur Meu, France|Centre Hospitalier de Redon Carentoir, Redon, France|Chu Rennes, Rennes, France|Centre Hospitalier St Meen Le Grand, Saint-M\u00e9en-le-Grand, France|CENTRE HOSPITALIER VITRE_Simone Veil, Vitr\u00e9, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic"",""enrollment"":""13000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""rate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M) among employees working in a GHT Haute Bretagne health establishment.|a) Validation of the Biotech NG test:|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgG|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgM.|b) Risk of presence of anti SARS-CoV-2 antibodies in function:|c) Risk of presence of anti SARS-CoV-2 antibodies in function:|d) Description of the experience and behavioral changes related to the epidemic,|e) Evolution of seroprevalence over time:""}"
"3541","Serologic Testing of Household Contacts of Confirmed Cases of COVID-19","","NCT04393142","IF20-00004","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393142","Completed","2020-05-05","2021-02-16","{""locations"":""Hospital Universitario Jos\u00e9 E. Gonzalez, Monterrey, Nuevo Leon, Mexico"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""96"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Identify antibodies|Determine antibody sensitivity|IgM determination|IgG determination""}"
"3542","HFNC and NIV for COVID-19 Complicated by Respiratory Failure","","NCT04452708","2020.203","Device: HFNC","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452708","Recruiting","2020-06-11","2021-06-10","{""locations"":""Prince of Wales Hospital, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""detection of viral RNA from one or more participants' air samples|the nasopharyngeal flocked swab and throat swab viral load (log10 copies\/mL)""}"
"3543","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","NoCovid","NCT04305457","NOgas mildCOVID-19","Drug: Nitric Oxide","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04305457","Active, not recruiting","2020-03-21","2022-04-01","{""locations"":""Providence HealthCare Network, Anchorage, Alaska, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in the incidence of patients with mild\/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery""}"
"3544","Impact Nerium Oleander on Immune Function","","NCT04486144","052020","Other: Proprietary extract of Nerium oleander","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04486144","Completed","2020-05-20","2020-07-23","{""locations"":""KDunn and Associates, PA, dba Healthquilt, Houston, Texas, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""82"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID19 symptoms|Mortality|COVID19 Live Virus|RT-PCR COVID19 Test""}"
"3545","Registry of Patients With Hematologic Disease and COVID-19 in Russia","CHRONOS19","NCT04422470","CHRONOS19","Other: Non-interventional study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422470","Recruiting","2020-06-22","2021-07-22","{""locations"":""Regional Clinical Hospital No1, Ekaterinburg, Russian Federation|Republican Clinical Hospital of Tatarstan, Kazan, Russian Federation|City Hospital n.a. V.V. Veresaev, Moscow, Russian Federation|Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation|National Research Center for Hematology, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod, Russian Federation|Regional Hospital, Novosibirsk, Russian Federation|Regional Clinical Hospital, Omsk, Russian Federation|Republican Clinical Hospital No4, Saransk, Russian Federation|Republic Clinical Hospital n.a. N.A. Semashko, Ulan-Ude, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Regional Clinical Hospital No2, Vladivostok, Russian Federation|Republican Hospital No1, Yakutsk, Russian Federation|Regional Clinical Hospital, Yaroslavl, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""30-day all-cause mortality|COVID-19 complications|ICU admission|Mechanical ventilation \/ O2 requirement|Relapse or progression of hematologic disease|Overall survival|Risk factors""}"
"3546","COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder","COVID-TRAUMA","NCT04401046","COVID-TRAUMA-IPC 2020-026","Other: Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04401046","Recruiting","2020-05-20","2020-10-30","{""locations"":""Institut Paoli-Calmettes, Marseille, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Score of the Impact of Event Scale Revisited scale|Factors associated with post-traumatic stress disorder|Measure of the patient's anxiety|proportion of patients perceiving poorer management of their cancer care since the start of the COVID-19 epidemic.|proportion of patients perceiving the implementation of all necessary measures to reduce the risk of exposure to COVID-19|proportion of patients stating that remote consultation is as useful as a face-to-face consultation|proportion of patients with access to a clinical psychology consultation (at the hospital or on the phone)|Score on the cancer recurrence scale""}"
"3547","Impact of COVID-19 Pandemic in Perinatal Mental Health (RISEUP-PPD-COVID-19)","","NCT04595123","RISEUP-PPD-COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04595123","Recruiting","2020-06-15","2021-06-15","{""locations"":""Beder College University, Tirana, Albania|Universidade Presbiteriana Mackenzie, S\u00e3o Paulo, Brazil|Sofia University, Sofia, Bulgaria|Universidad de Concepci\u00f3n, Concepci\u00f3n, Chile|European University Cyprus, Nicosia, Cyprus|Groupe Hospitalier du Havre, Le Havre, France|University of Athens, Athens, Greece|Bar-Ilan University, Ramat Gan, Israel|University of Malta, Imsida, Malta|Universidade do Minho, Braga, Portugal|Universidad Loyola Andalucia, Sevilla, Spain|K\u0131rklareli \u00dcniversitesi, K\u0131rklareli, Turkey|King'S College London, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depressive symptoms|Posttraumatic Stress Disorder|Anxiety symptoms""}"
"3548","Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device","","NCT04595903","AEMD-2020-02","Device: Hemopurifier","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04595903","Not yet recruiting","2021-01-01","2021-08-01","{""locations"":""Hoag Hospital - Irvine, Irvine, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of treatment emergent adverse events|Incidence of device related adverse events|Incidence of serious adverse events|Length if Stay in ICU|In-hospital mortality|Days free of ventilatory dependency|Vasopressor-free days|Sequential Organ Failure Assessment (SOFA)|Acute Physiology and Chronic Health Evaluation (APACHE)|SARS CoV-2 RNA levels in plasma and nasopharyngeal samples|Total lymphocyte count|C-reactive protein (CRP), IL-1, IL-6, and TNF alpha Tests|D-dimer|Troponin-T|Evaluation of SARS-CoV-2 RNA levels post-treatment Hemopurifier cartridges|Evaluation of viral particle load post-treatment Hemopurifier cartridges""}"
"3549","COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes","","NCT04723550","NO.2020QN80","Device: Hospital telemedicine management system|Other: Usual care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04723550","Recruiting","2021-01-05","2022-01-05","{""locations"":""Department of Endocrinology, Xuzhou NO.1 Peoples Hospital, Xuzhou, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""120"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Glucose control (HbA1c levels)|Change in FBG|Change in Blood glucose 2 hours after breakfast|Change in Blood pressure|Body mass BMI changes|Change in waist-to-hip ratio|Change in biological parameter: TC|Change in biological parameter: TG|Change in biological parameter: HDL-C|Change in biological parameter: BUN|Change in biological parameter: Scr|Change in biological parameter: e-GFR""}"
"3550","COVID-19 Pandemic Lockdown Effect in Adolescents and Young Adults With Type 1 Diabetes: Positive Results of an Unpreceded Challenge for Telemedicine and Patient Self-management","COVIDIABADO","NCT04669912","IDRCB 2020-A02760-39","Other: glucose control and sensor usage","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04669912","Completed","2021-01-15","2021-01-22","{""locations"":""Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""77"",""age"":""13 Years to 25 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Changes in percentage of time spent in range 70-180 mg\/dL after lockdown compared to before lockdown|Changes in percentage of time spent in range 70-180 mg\/dL during first month of lockdown compared to before lockdown|Changes in percentage of time spent in range 70-180 mg\/dL during second month of lockdown compared to before lockdown|Evolution of glucose management indicator (GMI) compared to before lockdown.|Evolution of glucose time spent below range <54 mg\/dL|Evolution of glucose time spent below range 54 - 70 mg\/dL|Evolution of glucose time spent below range 180-250 mg\/dL|Evolution of glucose time spent below range > 250 mg\/dL|Evolution of average glucose in mg\/dL compared to before lockdown.|Evolution of hypoglycaemia frequency compared to before lockdown.|Evolution of glucose sensor use compared to before lockdown.""}"
"3551","Understanding Reactions to Emotional Material in the Media During COVID-19","","NCT04608097","2020-03991","Behavioral: Simple cognitive task intervention|Behavioral: Attention Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04608097","Recruiting","2020-10-28","2021-01-15","{""locations"":""Uppsala University, Uppsala, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science"",""enrollment"":""66"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of intrusive memories related to the trauma film|Characteristics of intrusive trauma memories related to the trauma film|Intrusion questionnaire|Impact of Event Scale - Revised (IES-R): Degree of subjective distress of post-film intrusions|Self-rated functioning associated with intrusive memories|Self-rated concentration disruption associated with intrusive memories|Self-rated sleep ratings|Behavior Change Questionnaire|Intrusion provocation task (IPT)|Verbal recognition memory test|Visual recognition memory test|Time perspective questionnaire|Future self questionnaire|Future Expectancy Scale""}"
"3552","Characteristics of COVID-19 Infection Among PREGnant Women","CCOVID-PREG","NCT04398264","U20-05-4055","Other: COVID-19 positive via testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04398264","Recruiting","2020-07-22","2021-03-31","{""locations"":""INOVA Health System, Falls Church, Virginia, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Asymptomatic COVID-19 positive pregnant women|Asymptomatic Hispanic COVID-19 positive pregnant women|Follow up of asymptomatic COVID-19 positive pregnant women|COVID-19 positive newborns|Severe COVID-19 disease in pregnant women""}"
"3553","Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","ULTRA-COVID","NCT04394182","20.4.1597-GHM","Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04394182","Recruiting","2020-04-21","2021-04-21","{""locations"":""Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""15"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity""}"
"3554","Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU","","NCT04476914","20-1021","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04476914","Recruiting","2020-06-29","2021-12-31","{""locations"":""Eastern Colorado Veterans Affairs Health Care System, University Of Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Brigham and Women's Medical Center, Boston, Massachusetts, United States|South Shore Medical Center, Weymouth, Massachusetts, United States|Columbia Milstein and Allen Hospitals, New York, New York, United States|Penn State Hershey Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Washington, Seattle, Washington, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms of Post-Traumatic Stress Disorder (PTSD)|Symptoms of Anxiety|Symptoms of Depression|Family Satisfaction with Communication and Decision Making""}"
"3555","Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients","","NCT04408378","69","Other: observation of covid 19 pneumonia","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408378","Recruiting","2020-06-05","2020-08-20","{""locations"":""Gaziosmanpa\u015fa TREH, Istanbul, Gaziosmanpa\u015fa, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""156"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""estimation of inflammatory changes in Covid 19 pneumonia by using MVP\/PLT ratio""}"
"3556","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","BARI-COVID","NCT04320277","HPrato-3","Drug: Baricitinib","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04320277","Not yet recruiting","2020-05-16","2020-07-30","{""locations"":""Fabrizio Cantini, Prato, Tuscany, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNF\u03b1 values at baseline and during the treatment course; the number of AEs.""}"
"3557","Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic","","NCT04409743","IRB-55940","Behavioral: Remote Cognitive Behavioral Therapy for Insomnia","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04409743","Recruiting","2020-06-07","2021-11-01","{""locations"":""Stanford University, Palo Alto, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Insomnia Clinical Diagnosis Over Time|Change in Patient Health Questionnaire-9 (PHQ-9) Scale Score as a Measure of Depression Symptoms Over Time|Change in Generalized Anxiety Disorder-7 (GAD-7) Scale Score Over Time|Change in Insomnia Severity Index (ISI) Scale Score Over Time|Change in Quality of Life (SF-36) Scale Score Over Time|Change in Sheehan Suicidality Tracking Scale (S-STS) Score Over Time|Change in UCLA Loneliness Scale Score Over Time|Change in Social Network Index (SNI) Scale Score Over Time|Change in Perceived Stress Scale Score Over Time|Change in Screen Time- Self Report Over Time|Change in International Physical Activity Questionnaire (IPAQ) Scale Score Over Time|Change in Sleep Onset Latency (SOL) as a Measure of Sleep Continuity Over Time|Change in Number of Awakenings as a Measure of Sleep Continuity Over Time|Change in Wake After Sleep Onset (WASO) as a Measure of Sleep Continuity Over Time|Change in Total Sleep Time (TST) as a Measure of Sleep Continuity Over Time|Change in Sleep Efficiency (SE) as a Measure of Sleep Continuity Over Time|Change in Beck Depression Inventory-II (BDI) Scale Score Over Time|Change in Beck Anxiety Inventory (BAI) Scale Score Over Time""}"
"3558","Profiling Recovery of Those Discharged Into the Community With COVID-19","","NCT04649957","COVID-19-UoD&RDH20/21","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649957","Not yet recruiting","2021-01-04","2021-12-17","{""locations"":""University of Derby, Derby, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Post-COVID-19 Functional Status (PCFS) Scale|EQ-5D-5L""}"
"3559","Stress Induced by the COVID-19 Pandemic and Nonconfinement: Study of Anxiety Factors and Potential Effects on Immunity.","SCEI","NCT04491071","20CH129","Diagnostic Test: Generalized Anxiety Disorder-7 (GAD 7)|Diagnostic Test: Background questionnaire|Diagnostic Test: Impact of COVID-19 questionnaire|Diagnostic Test: Confinement and Communication During the COVID-19 Pandemic|Diagnostic Test: Mental Health questionnaire|Diagnostic Test: Patient Health Questionnaire (PHQ-9)|Diagnostic Test: Post Traumatic Stress Disorder questionnaire (PTSD-8)|Diagnostic Test: Experiences in Close Relationship Scale questionnaire (ECR-S)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04491071","Not yet recruiting","2020-09-01","2020-12-01","{""locations"":""Centre Hospitalier Universitaire de Saint-Etienne, Saint-\u00c9tienne, France|Centre de Recherche et d'Innovation Clinique, Glasgow, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""405"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Results of the Generalized Anxiety Disorder (GAD-7)|Results of the Mental Health questionnaire|Results of the Patient Health Questionnaire (PHQ-9)|Results of the Post Traumatic Stress Disorder (PTSD-8)|Results of the Experiences in Close Relationship Scale questionnaire (ECR-S)""}"
"3560","Training Load Management in Three Professional Tennis Players During COVID-19 Lockdown: a Case Series Study","","NCT04602637","TLT01","Other: Training load","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04602637","Active, not recruiting","2019-12-15","2021-01-15","{""locations"":""KIN\u00c9 kinesiolog\u00eda deportiva y funcional, Caba, Argentina"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""3"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Training load""}"
"3561","Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic","","NCT04389463","HEART-19 Study","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389463","Recruiting","2020-05-11","2022-06-30","{""locations"":""University Hospital, Nantes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Highest VIS (Vasoactive-Inotropic Score) in the first 12 hours postoperatively.|Post-operative organ failure|Post-operative outcome""}"
"3562","Fostamatinib for Hospitalized Adults With COVID-19","","NCT04579393","10000110|000110-H","Drug: Placebo|Drug: fostamatinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04579393","Recruiting","2020-01-27","2022-01-31","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States|INOVA Health Systems, Falls Church, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative Incidence of SAEs|Number of days in the ICU|Change in CRP, IL-6, d-dimer, ferritin, fibrinogen, absolute lymphocyte count, absolute neutrophil count, and platelet count from baseline|Ordinal scale|Days of hospitalization|Time to recovery|Number of days free of mechanical ventilation [entire hospitalization cohort 1]|Number of days on oxygen|Change in SOFA score from baseline|Days free of renal failure|Clinically relevant deep vein thrombosis|Relative change in PaO2\/FiO2 or SpO2\/FiO2 ratio""}"
"3563","Evaluating Bubble-PAPR for Healthcare Workers","BubblePAPR","NCT04681365","B00991","Other: Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04681365","Not yet recruiting","2021-02-01","2021-06-02","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""66"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary endpoint is that participating staff rate Bubble PAPR to be more comfortable than current PPE.|Staff rate Bubble PAPR as safer than current PPE|Staff rate Bubble PAPR as easier to communicate with colleagues than existing PPE|Staff rate Bubble PAPR as easier to communicate with patients than existing PPE""}"
"3564","Occupational Balance, Fear and Agoraphobia","OB","NCT04681261","2020/185","Other: this study is not an intervention study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04681261","Completed","2020-05-04","2020-06-04","{""locations"":""\u00d6zg\u00fc \u0130nal, Edirne, Merkez, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""699"",""age"":""19 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occupational Balance Questionnaire""}"
"3565","Evaluation of Aerosol in a Dental Clinic","","NCT04659928","HSC-DB-20-1017","Device: High volume evacuation (HVE)|Device: Extraoral vacuum aspirator (EVA)|Device: External evacuation device (EED)|Drug: Hydrogen Peroxide","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04659928","Not yet recruiting","2020-12-01","2022-12-01","{""locations"":""The University of Texas Health Science Center at Houston, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of bacterial colony forming units (CFUs) .|Change in number of CFUs""}"
"3566","The Doctors for Coronavirus Prevention Project Thanksgiving Messaging Campaign","","NCT04644328","2003000118A010","Behavioral: Facebook Ads on the importance of staying safe during the Thanksgiving holiday","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04644328","Not yet recruiting","2020-11-14","2021-11-26","{""locations"":""JPAL North America, Cambridge, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""20000000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Covid Case Rate|Population count|Facebook mobility rate|Knowledge of COVID-19 thanksgiving prevention message (recall of ad, intent to travel, mask wearing and beliefs about travel)|average number of tiles people occupy (Mobility measure)|percentage of eligible participants only observed in a single level-16 Bing tile (no change in movement)""}"
"3567","COVID-19 Prevalence and Cognitive Deficits in Neurological Patients","Neuro-Covid","NCT04377425","Neuro-Covid-19","Diagnostic Test: COVID-19 swap test PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377425","Withdrawn","2020-05-07","2022-06-30","{""locations"":""Aalborg University Hospital, Aalborg, DK, Denmark|Aarhus University Hospital, Aarhus, DK, Denmark|Regional Hospital West Jutland, Hostebro, Holstebro, DK, Denmark|Regional Hospital Central Jutland, Viborg, Viborg, DK, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID-19 infection in consecutive patients with neurological symptoms|Three months cognitive function of COVID-19 positive patients|Clinical presentation of neurological symptoms in COVID-19 positive patients|Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients|Anosmia in COVID-19 positive patients|Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection|Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients""}"
"3568","Short-term Impact of COVID-19 Lockdown on Metabolic Control of Type 2 Diabetes","","NCT04501991","AS0007","Other: antidiabetic treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04501991","Completed","2020-03-11","2020-06-30","{""locations"":""University of Pisa, Pisa, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""114"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Glucose|HbA1c|Lipid profile""}"
"3569","Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix (NanoDx-CoV-19)","NanoDxCoV19","NCT04597216","38RC20.289","Device: sample of blood and saliva","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04597216","Recruiting","2020-10-15","2021-12-31","{""locations"":""olivier EPAULARD, Grenoble, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of proteomic profile|Interest of proteomic profile|Stability of proteomic profile""}"
"3570","A Clinical Study to Evaluate MW33 Injection","","NCT04533048","MW33-2020-CP101","Combination Product: MW33 injection|Combination Product: MW33 injection placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04533048","Completed","2020-08-07","2020-12-02","{""locations"":""Shanghai Public Health Clinical Center, Shanghai, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Adverse Event|Serious Adverse Event""}"
"3571","Impact of Digital Communication Assist Tools in Endoscopic Team Communication During COVID-19","EndoCom","NCT04680858","122020","Other: DECT","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04680858","Enrolling by invitation","2020-07-01","2021-02-15","{""locations"":""Universit\u00e4tsklinikum Ulm, Ulm, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""500"",""age"":""18 Years to 68 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Communication associated adverse events|Severe adverse events|Subjective Comfort of DECT communication|Endoscopic time""}"
"3572","Impact of Spectacles on Compliance to Mask-wearing Directives","","NCT04501172","ES8/Th5/25-06-2020","Behavioral: Questionnaire completion","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04501172","Completed","2020-06-25","2020-08-14","{""locations"":""University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1214"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Demographic characteristics|Compliance to mask-wearing directives|Questionnaire subscale: Near vision|Questionnaire subscale: Distance vision|Questionnaire subscale: Ocular discomfort|Questionnaire subscale: Driving|Questionnaire subscale: Limitation|Questionnaire subscale: Collaboration|Questionnaire subscale: Need for help|Questionnaire subscale: Emotional impact|Assessment of the relationship between the compliance to mask-wearing directives and the use of spectacles|Assessment of the relationship between the compliance to mask-wearing directives and the other demographic characteristics|Assessment of the relationship between the compliance to mask-wearing directives and the questionnaire items|Assessment of the relationship between demographic characteristics and the 20 questionnaire items""}"
"3573","Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers","","NCT04497519","CARRIED-01","Drug: inhaled hydroxychloroquine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04497519","Completed","2020-09-15","2020-11-01","{""locations"":""University Medical Center Groningen, Groningen, Netherlands"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Local tolerability|Pharmacokinetic parameter""}"
"3574","Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study","","NCT04432870","2020P001579-1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04432870","Enrolling by invitation","2020-06-09","2021-06-30","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""45 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Interest in colon cancer screening|Preference for stool testing|Preference for postponing colonoscopy for one year|Worry about delay|Risk perception on COVID-19""}"
"3575","Intranasal Heparin Tolerability Study","","NCT04490239","Intranasal Heparin","Drug: Intranasal heparin sodium (porcine)","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04490239","Active, not recruiting","2020-10-09","2020-11-01","{""locations"":""The University of Mississippi National Center for Natural Products Research, University, Mississippi, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""6"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""activated partial thromboplastin time (aPTT), acute phase|activated partial thromboplastin time (aPTT), chronic phase|platelet count, acute phase|platelet count, chronic phase|Number of incidents of epistaxis, acute phase|Number of incidents of epistaxis, chronic phase|Other adverse effects, acute phase|Other adverse effects, chronic phase""}"
"3576","Knowledge, Attitude and Practice of Dental Students About COVID-19","","NCT04449081","MelakaMMC","Behavioral: Knowledge, Attitude, Practice, Awareness, Preference","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04449081","Completed","2020-04-25","2020-06-20","{""locations"":""Faculty of Dentistry, Melaka-Manipal Medical College, Melaka Tengah, Melaka, Malaysia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""215"",""age"":""18 Years to 30 Years \u00a0 (Adult)"",""outcome_measures"":""Knowledge, Attitude, Practice of dental students towards COVID-19|Awareness level about Infection control to prevent COVID-19 transmission in clinics|Preference towards online learning.""}"
"3577","Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia","New","NCT04343664","MH-Covid19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04343664","Not yet recruiting","2021-02-01","2021-12-31","{""locations"":""dr. Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""10000"",""age"":""4 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Depression|Anxiety symptoms|Stress related problems|Behavior and emotional problem among children and adolescents""}"
"3578","Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms","AI-COV-19","NCT04510441","20HH5967","Other: Nil intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04510441","Recruiting","2020-05-26","2022-05-01","{""locations"":""London North West University Healthcare NHS Trust, London, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Imperial College London (Hammersmith campus), London, United Kingdom|St Mary's Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Accuracy of machine learning to be able to predict outcome of coronavirus (COVID-19) infection|Accuracy of machine learning to be able to predict prognosis of coronavirus (COVID-19) infection|Accuracy of machine learning to be able to predict cardiac involvement of coronavirus (COVID-19) infection|Accuracy of machine learning vs human assessment to diagnose coronavirus (COVID-19) infection""}"
"3579","Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic","","NCT04406181","COVID-19 Cardiac psy wellbeing","Behavioral: HADS|Behavioral: a survey","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04406181","Recruiting","2020-05-18","2021-01-01","{""locations"":""universitair Ziekenhuis Brussel, Jette, Vlaams Brabant, Belgium"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""200"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety\/depression by means of Hospital Anxiety and Depression Scale (HADS)|Medical problems induced by deferred elective surgery or delayed postoperative ambulatory visit|Reduced access to medical and psychological help""}"
"3580","Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers","","NCT04561076","HLX70-001US-255086","Drug: HLX70|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04561076","Not yet recruiting","2020-12-09","2021-09-18","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""24"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0|Safety evaluation- proportion of subjects undergoing DLT events|PK parameters-Areas under the concentration-time curves|PK parameters-Maximum measured concentration|PK parameters-Time from dosing to maximum measured concentration|PK parameters-Terminal phase elimination rate constant|PK parameters-Terminal phase elimination half life|PK parameters-Clearance|PK parameters-Volume of distribution during terminal phase and at steady state|PK parameters-Mean residence time|Anti-drug antibody""}"
"3581","Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia","","NCT04636554","APT.APS.001","Other: Phage Therapy","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04636554","Available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"3582","ChulaCov19 mRNA Vaccine in Healthy Adults","","NCT04566276","ChulaVac 001","Biological: ChulaCov19 mRNA vaccine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04566276","Not yet recruiting","2021-01-01","2021-06-01","{""locations"":""Chula Vaccine Research Center (ChulaCRC) Faculty of Medicine Chulalongkorn University, Bangkok, Thailand|Center of Excellence for Vaccine Trial (Vaccine Trial Centre), Faculty of Tropical Medicine Mahidol University, Bangkok, Thailand"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""96"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of Adverse Events|Grade of Adverse Events|Frequency of solicited reportable local Adverse Events|Grade of solicited reportable local Adverse Events|Frequency of solicited reportable systemic Adverse Events|Grade of of solicited reportable systemic Adverse Events|Frequency of Serious Adverse Events|Frequency of Medically-Attended Adverse Events|Frequency of New-Onset Chronic Medical Conditions|Measurement of body temperature|measurement of respiratory rate|measurement of pulse rate|measurement of systolic blood pressure (SBP)|measurement of diastolic blood pressure (DBP)|assess if there are any symptoms at the head|assess if there are any symptoms at the ears|assess if there are any symptoms at the nose|assess if there are any symptoms at the throat|assess if there are any symptoms at the lungs|assess if there are any symptoms at the lymph nodes|assess if there are any symptoms at the heart|assess if there are any symptoms at the abdomen|assess if there are any symptoms at the skin|Measurement of haemoglobin (Hb)|Measurement of haematocrit (HCT)|Measurement of red blood cell (RBC)|Measurement of white blood cells (WBC)|Assess the percentage of neutrophil|Assess the number of neutrophil|Assess the percentage of lymphocytes|Assess the number of lymphocytes|Assess the percentage of eosinophil|Assess the number of eosinophil|Assess the percentage of basophil|Assess the number of basophil|Assess the percentage of monocytes|Assess the number of monocytes|Measurement of platelet|Measurement of sodium|Measurement of potassium|Measurement of chloride|Measurement of bicarbonate|Measurement of blood urea nitrogen (BUN)|Measurement of creatinine|Assess total protein|Measurement of albumin|Measurement of lipase|Measurement of phosphorus|Measurement of gamma-glutamyl transferase (GGT)|Measurement of glucose|Measurement of creatinine phosphokinase (CPK)|Measurement of calcium|Measurement of uric acid|Measurement of C-reactive protein (CRP)|Measurement of alanine transaminase (ALT)|Measurement of aspartate transaminase (AST)|Measurement of alkaline phosphatase (ALP)|Assess total bilirubin|Assess estimated glomerular filtration rate (eGFR)|Measurement of prothrombin time (PT)|Measurement of partial thromboplastin time (PTT)|Measurement of international normalized ratio (INR)|Geometric mean titers (GMT) in SARS-CoV-2-specific serum neutralising antibody levels|Proportion of participants who achieved a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2-specific serum neutralising antibody levels|Geometric mean fold rises (GMFR) in SARS-CoV-2-specific serum neutralising titers|Geometric mean titers (GMT) in SARS-CoV-2 surrogate viral neutralising antibody levels|Proportion of participants who achieved a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 surrogate viral neutralising antibody levels|Geometric mean fold rises (GMFR) in SARS-CoV-2 surrogate viral neutralising antibody titers|Geometric mean titers (GMT) of SARS-Cov2-spike protein-binding IgG antibody|Proportion of participants who seroconverted: achieving a greater than or equal to 4-fold rise in SARS-Cov2-spike protein-binding IgG antibody|Geometric mean fold rises (GMFR) in SARS-Cov2-spike protein-binding IgG antibody|Percentage of participants who have positive specific CD4 T-cell IFN\u03b3 ELISpot responses|Percentage of participants who have positive specific CD8 T-cell IFN\u03b3 ELISpot responses|Median number of spot-forming cells (SFC) per 1 million PBMCs|Percentage of participants who shows positive specific Th1 responses|Percentage of participants who shows positive specific Th2 responses|Median percentage specific Th1 responses|Median percentage specific Th2 responses""}"
"3583","Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19","NutriCoviDom","NCT04451694","2020PI097","Other: nutritional intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04451694","Recruiting","2020-04-01","2020-11-30","{""locations"":""Quilliot, VANDOEUVRE LES Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""nutritional evaluation|muscle strenght|food intake|biological nutritional status|anosmia""}"
"3584","Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP","","NCT04340414","Low flow-ECMO by CVVH in NCP","Device: Low flow ECMO driving by CVVH machine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04340414","Recruiting","2020-02-20","2020-10-15","{""locations"":""Yun Long, Beijing, Beijing, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""PaCO2|Driving Pressure|Tidal volume""}"
"3585","Renin Angiotensin System - CoronaVirus","SRA-COV","NCT04337008","2020-16|2020-A00795-34","Other: blood draw","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04337008","Recruiting","2020-04-03","2020-07-31","{""locations"":""ASSISTANCE PUBLIQUE H\u00d6PITAUX de MARSEILLE, Marseille, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""overactivity of the renin \/ aldosterone system""}"
"3586","An Observational Study of Patients With Coronavirus Disease 2019","COVID-19","NCT04331886","TARGET-COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04331886","Recruiting","2020-04-13","2021-03-01","{""locations"":""University of Washington, Seattle, Washington, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Natural history of COVID-19: Characteristics of COVID-19|Natural history of COVID-19: Participant demographics|Natural history of COVID-19: Treatment use|Time point of clinical response""}"
"3587","COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","CoDEX","NCT04327401","CAAE: 30227020.5.1001.0008","Drug: Dexamethasone","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04327401","Terminated","2020-04-13","2020-07-22","{""locations"":""Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Bras\u00edlia, Distrito Federal, Brazil|Funda\u00e7\u00e3o Social Rural de Colatina, Colatina, Eso\u00edrito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Po\u00e7os De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paran\u00e1, Brazil|Eurolatino Natal Pesquisas M\u00e9dicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Crici\u00fama, Santa Catarina, Brazil|Funda\u00e7\u00e3o Pio XII, Barretos, S\u00e3o Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, S\u00e3o Paulo, Brazil|Associacao Beneficente Siria, S\u00e3o Paulo, Brazil|Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da USP - HCFMRP, S\u00e3o Paulo, Brazil|Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, S\u00e3o Paulo, Brazil|Real e Benem\u00e9rita Associa\u00e7\u00e3o Portuguesa de Benefic\u00eancia\/SP, S\u00e3o Paulo, Brazil|Santa Casa de Miseric\u00f3rdia, S\u00e3o Paulo, Brazil|Secretaria de Sa\u00fade do Estado de S\u00e3o Paulo, S\u00e3o Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo, Brazil|Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""299"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score""}"
"3588","Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order","","NCT04536441","U/SERC/62/2020","Behavioral: Ultra Brief Online Mindfulness-based Intervention|Behavioral: Control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04536441","Completed","2020-04-01","2020-06-30","{""locations"":""Universiti Tunku Abdul Rahman, Kampar, Perak, Malaysia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""161"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes of Subjective Unit of Distress|Changes of Anxiety Scores|Changes of Psychological Insecurity|Changes of General Well-being|Fear of COVID-19""}"
"3589","Mental Health and Academic Performance in COVID-19","PANDEMIC","NCT04420416","Mental01","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04420416","Recruiting","2020-04-01","2020-07-30","{""locations"":""Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""720"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Academic Self-Concept Scale Score|PHQ-9 Score|GAD-7 Score|Preference of teaching method|Self perceived academic performance|Academic grades changes""}"
"3590","Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19","SHARP COVID-19","NCT04342156","2020/00402","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04342156","Withdrawn","2020-04-01","2020-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.|Positive serology at day 28.|Symptoms of COVID-19.""}"
"3591","Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients","","NCT04293887","Zhaojp","Drug: Recombinant human interferon α1β","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04293887","Not yet recruiting","2020-03-01","2020-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""328"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.""}"
"3592","Sarilumab COVID-19","","NCT04327388","EFC16844|2020-001162-12","Drug: Sarilumab SAR153191|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04327388","Completed","2020-03-28","2020-09-02","{""locations"":""Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 0760004, S\u00e3o Jos\u00e9 Do Rio Preto, Brazil|Investigational Site Number 0760005, S\u00e3o Paulo, Brazil|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240004, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520001, Talca, Chile|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, K\u00f6ln, Germany|Investigational Site Number 2760001, M\u00fcnster, Germany|Investigational site number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Iruma-Gun, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid \/ Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""420"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale|Percent of patients alive at Day 29|Proportion of patients with one point improvement from baseline in clinical status assessment at days 4, 7, 15, 21, 29 using the 7-point ordinal scale|Mean change in the 7-point ordinal scale from baseline to Days 4, 7, 15, 21, and 29 (or until discharge)|Time to resolution of fever|Time to resolution of fever and improvement in oxygenation|Days with fever|Time to change in NEWS2 from baseline|Time to NEWS2 of <2 and maintained for 24 hours|Mean change from baseline to days 4, 7, 15, 21, and 29 in NEWS2|Time-to-improvement in oxygenation|Alive off supplemental oxygen at day 29|Days of hypoxemia|Days of supplemental oxygen use|Days of resting respiratory rate >24 breaths\/min|Time to saturation \u226594% on room air|Ventilator free days in the first 28 days (to day 29)|The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Proportion of patients requiring rescue medication during the 28-day period|The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Days of hospitalization among survivors|Incidence of serious adverse events|The incidence of major or opportunistic bacterial or fungal infections|The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities""}"
"3593","A Study on the Prospective Cohort Library of COVID-19 in Southeran","","NCT04342702","SAHoWMU-CR2020-NCP-202","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04342702","Active, not recruiting","2020-03-16","2021-03-01","{""locations"":""Wenzhou Medical University, Wenzhou, Zhejiang, China|The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""504"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""36-Item Short Form Survey Instrument (SF-36)|the value of FEV1 by lung function test|the ratio of FEV1 to FVC by lung function test|the predicted value of FEV1 by lung function test|the predicted ratio of FEV1 to FVC by lung function test|Lymphocyte value|Neutrophil value|DDI value|the proportion of applying ACEIs\/ARBs medication|number of clinical symptoms after hospital discharge|number of cases returning to positive result in RT-PCR test|Number of positive outcome of IgG for antibody of COVID-19""}"
"3594","Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19","","NCT04635618","20200213_Treatment","Behavioral: Cognitive Behavioral Brief-Telepsychotherapy|Behavioral: Brief Interpersonal Telepsychotherapy|Behavioral: Telepsychoeducation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04635618","Enrolling by invitation","2020-11-05","2021-07-20","{""locations"":""Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""999"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Symptom Reduction at 1-month|Symptom Reduction at 3 and 6-months follow-up|Remission Levels in distress scales|Service Satisfaction|Improvement in Quality of Life""}"
"3595","COVID-19 and Pregnancy Outcomes","COVID&PREG","NCT04416373","COVID&PREG","Diagnostic Test: RT PCR SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416373","Recruiting","2020-03-22","2023-12-01","{""locations"":""Nova Medical School - UNL, Lisbon, Portugal"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""16 Years to 55 Years \u00a0 (Child, Adult)"",""outcome_measures"":""SARS-CoV-2 Neonatal Infection|Perinatal mortality|ICU maternal admission|5 minute Apgar Score < 7|Preterm labour|PPROM|Miscarriage""}"
"3596","The Status of Parathyroid Hormone Secretion in Covid-19 Patients","","NCT04662437","08122020","Diagnostic Test: Venous blood was collected for biochemistry testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04662437","Completed","2020-09-10","2020-12-09","{""locations"":""Bezmialem VU, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""150"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of parathyroid hormone between groups|Comparison of calcium between groups|Comparison of phosphorus between groups|Comparison of alkaline phosphatase between groups|White blood cells (WBC) results of Covid 19 patient group|Neutrophil \/ lymphocyte ratio (N\/LO) results of Covid 19 patient group|C-reactive protein (CRP) results of Covid 19 patient group|Fibrinogen results of Covid 19 patient group|Procalcitonin results of Covid 19 patient group|Ferritin results of Covid 19 patient group|D-dimer results of Covid 19 patient group""}"
"3597","Study on Kidney Disease and EnviromenTal Chemical","","NCT04679168","SKETCH","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04679168","Recruiting","2020-06-01","2021-12-31","{""locations"":""Seoul National University Boramae Medical Center, Seoul, Korea, Republic of"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""310"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of environmental hazard exposure levels and influencing factors|Relationship between exposure and health related behavior change""}"
"3598","Plasma Adsorption in Patients With Confirmed COVID-19","","NCT04358003","MH-007/B","Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04358003","Recruiting","2020-05-20","2021-12-01","{""locations"":""UNM Health Science Center, Albuquerque, New Mexico, United States|Providence Portland Medical Center, Portland, Oregon, United States|UT Southwestern\/Clements Hospital, Dallas, Texas, United States|UTMB, Galveston, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Change in Sequential Organ Failure Assessment [SOFA] scores""}"
"3599","Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial)","","NCT04361877","20-268 KB","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361877","Recruiting","2020-03-30","2020-04-20","{""locations"":""University Hospital Munich (LMU Klinikum), Munich, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of physical activity|change of nutrition behaviour|semiquantitative change of alcohol intake|change of smoking behaviour|change of stress level|step count""}"
"3600","Yoga Pranayama Adjuvant to Treat Burden COVID-19","YOCO","NCT04413747","2020_COVID-19_YOGA","Behavioral: morning Yoga-based breathing support|Behavioral: pre_lunch Yoga-based breathing support|Behavioral: pre_dinner Yoga-based breathing support","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04413747","Not yet recruiting","2020-08-15","2021-09-30","{""locations"":""Ambulatorio Telemedicina Giardino St Lucia, Massa Lombarda, Ravenna, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""1000"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Mortality-suicide|Incidence of hospitalization for respiratory failure of COVID-19's Patients-|Incidence of al home professional psychiatric-psychological interventions for mental disorder.|Incidence of mental disorder: Beck Depression Inventory-Second Edition (BDI-II).|Incidence od spleep disorder:Pittsburgh Sleep Quality Index (PSQI).""}"
"3601","COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)","","NCT04389385","EruCovid2020","Biological: COVID-19 Specific T Cell derived exosomes (CSTC-Exo)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04389385","Active, not recruiting","2020-05-01","2021-05-31","{""locations"":""GENKOK, Kayseri, Melikgazi, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse reaction (AE) and severe AE (SAE)|Efficacy Assessment|The Rate of Recovery Without Mechanical Ventilator""}"
"3602","Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic","","NCT04387409","VPM1002-DE-3.06CoV","Biological: VPM1002|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04387409","Active, not recruiting","2020-05-25","2021-05-01","{""locations"":""Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Bayern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|SocraTec R&D GmbH, Erfurt, Th\u00fcringen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""59"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection)|Cumulative incidence of documented SARS-CoV-2 infection|Number of days absent from work due to documented SARS-CoV-2 infection|Number of days absent from work due to exposure to person with documented SARS-CoV-2 infection|Number of days absent from work due to symptoms of respiratory disease, documented SARS-CoV-2 infection, or fever (\u2265 38 \u00b0C)|Number of days of self-reported fever (\u2265 38 \u00b0C)|Number of days of self-reported acute respiratory symptoms|Cumulative incidence of self-reported acute respiratory symptoms|Cumulative incidence of death for any reason|Cumulative incidence of death due to documented SARS-CoV-2 infection|Cumulative incidence of ICU admission for any reason|Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection|Cumulative incidence of hospital admission for any reason|Cumulative incidence of hospital admission due to documented SARS-CoV-2 infection""}"
"3603","Intravascular Access of COVID-19 Patient Under Personal Protective Equipment","","NCT04366297","IO_PPE_MS_1","Device: Intravenous access|Device: Intraosseous access","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04366297","Completed","2020-01-12","2020-02-25","{""locations"":""Lazarski Univeristy, Warsaw, Poland"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""41"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""successful rate of first intravascular access attempt|time to successful access|number of attempts to successful access|time to infusion|complication rates|ease of use|Preferred intravascular access method""}"
"3604","CBD Oil for Reducing Emotional Impact of COVID-19","CBDOIL","NCT04603781","2020-07-0138","Dietary Supplement: CBD Isolate|Dietary Supplement: Full Spectrum CBD Oil|Dietary Supplement: Broad-Spectrum CBD Oil|Dietary Supplement: Placebo Oil","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04603781","Recruiting","2020-12-04","2021-12-31","{""locations"":""University of Texas at Austin, Laboratory for the Study of Anxiety Disorders, Austin, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PROMIS Emotional Distress Index|PROMIS Depression Scale|PROMIS Anxiety Scale|PROMIS Anger Scale|PROMIS Alcohol Negative Consequences Scale|PROMIS Sleep Disturbance Scale|COVID-19 Coping Self-Efficacy""}"
"3605","Observational Study for the Evaluation of Tracheal Stenosis in COVID-19 Patients","TS1","NCT04686721","TS1","Diagnostic Test: Chest CT scan + baseline spirometry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04686721","Recruiting","2020-12-20","2021-10-01","{""locations"":""Humanitas Research Hospital, Rozzano, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of tracheal stenosis following either prolonged intubation or tracheostomy in COVID-19 patients|Clinical presentation of tracheal stenosis|Clinical course of tracheal stenosis|Outcome of tracheal stenosis|Identification of demographic factor with a predictive and prognostic value for tracheal stenosis|Identification of clinical factor with a predictive and prognostic value for tracheal stenosis|Identification of radiological factor with a predictive and prognostic value for tracheal stenosis|Identification of instrumental factor with a predictive and prognostic value for tracheal stenosis|Compare COVID-19 and non-COVID-19 patients at risk of developing tracheal stenosis""}"
"3606","Tele-health Enabled Clinical Trial for COVID-19","","NCT04489628","STUDY20200461","Drug: Vitamin D3 or Placebo|Device: Doctella telehealth monitoring","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04489628","Not yet recruiting","2020-08-01","2021-08-01","{""locations"":""Northwestern University, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""110"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients requiring admission to the hospital or experiencing death""}"
"3607","Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients","LAPTRANSCOV","NCT04361396","CHRD 0420","Other: Collection of samples","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04361396","Recruiting","2020-06-16","2021-06-01","{""locations"":""CH Victor Dupouy, Argenteuil, France|CH Intercommunal, Cr\u00e9teil, France|Department of General and Digestive Surgery, Hospital Ren\u00e9 Dubos, Pontoise, France|Department of Gynecology-Obstetrics, Hospital Ren\u00e9 Dubos, Pontoise, France|CH Delafontaine, Saint-Denis, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of the presence of the SARS-COV-2 virus at T4|Assessment of the presence of the SARS-COV-2 virus at T1|Assessment of the presence of the SARS-COV-2 virus in the peritoneal effusion at T2 or T4|Assessment of the presence of the SARS-COV-2 virus at T3|Assessment of the presence of the SARS-COV-2 virus at T5""}"
"3608","Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health","","NCT04453579","UNRomeB","Behavioral: Telephonic interview during the Italian lockdown.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453579","Completed","2020-03-09","2020-05-30","{""locations"":""Michela Campanelli, Rome, RM, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""116"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Psychological conditions""}"
"3609","Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers","","NCT04339790","999920085|20-M-N085","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339790","Active, not recruiting","2020-04-07","2022-04-01","{""locations"":""National Institute of Mental Health (NIMH), Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""NIMH COVID Study survey - adult responses|DSM XC and KS survey""}"
"3610","Short Term Corticosteroids in SARS-CoV2 Patients","","NCT04445506","20-027","Drug: Dexamethasone","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445506","Completed","2020-04-01","2020-05-31","{""locations"":""The Miriam Hospital, Providence, Rhode Island, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Effect on transfers to ICU and escalation of care needing mechanical ventilation|Effect on length of stay|Change in CRP levels""}"
"3611","COVID-19 Burnout Study","","NCT04594278","20-5678","Behavioral: Mindfulness Based Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04594278","Not yet recruiting","2020-11-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Perceived Stress|Burnout|Coping with Stress""}"
"3612","Health Behavior Change During COVID-19 Pandemic","","NCT04367337","3228-1BPSYPSBEH-30","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367337","Active, not recruiting","2020-03-25","2021-03-24","{""locations"":""the University of Melbourne, Melbourne, Australia|University of New Brunswick, Fredericton, Canada|Peking University, Beijing, China|University of Bordeaux, Bordeaux, France|London School of Hygiene and Tropical Medicine (in collaboration with MRC Unit The Gambia at LSHTM), Fajara, Gambia|Freie Universit\u00e4t Berlin, Berlin, Germany|Bar-Ilan University, Ramat Gan, Israel|University of Padova, Padova, Italy|Perdana University, Serdang, Malaysia|SWPS University of Social Sciences and Humanities, Wroclaw, Lower Silezia, Poland|University of Lisbon, Lisbon, Portugal|Babes-Bolyai Unversity, Cluj-Napoca, Romania|Nanyang Technological University, Singapore, Singapore|University of Zurich, Z\u00fcrich, Switzerland"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""6079"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Handwashing adherence|Frequency of handwashing|Self-efficacy|Risk perception|Outcome expectancy|Intention|Planning|Action control|Perceived effectiveness of hand hygiene|Anxiety|Country-level COVID-19 morbidity and mortality rates""}"
"3613","Canakinumab in Patients With COVID-19 and Type 2 Diabetes","CanCovDia","NCT04510493","2020-02008; me20Donath2","Drug: Canakinumab|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04510493","Recruiting","2020-10-23","2023-09-01","{""locations"":""University Medical Clinic Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|University Hospital Bern, Bern, Switzerland|University Hospital Geneva, Geneva, Switzerland|University Hospital Lausanne, Lausanne, Switzerland|Cantonal Hospital Lucerne, Luzern, Switzerland|Cantonal Hospital St Gallen, St. Gallen, Switzerland|University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""116"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""unmatched win ratio after treatment with canakinumab compared to Placebo (composite endpoint)|Time to clinical improvement|Death rate|Admission to intensive care unit (ICU)|Secondary worsening of disease|Prolonged hospital stay|Change in ratio to baseline in the glycated hemoglobin|Change in ratio to baseline in the fasting glucose|Change in ratio to baseline in the fasting insulin|Change in ratio to baseline in the fasting c-peptide|Ratio to baseline in the C-reactive protein (CRP)|Change in ratio to baseline in the D-dimer|Change in ratio to baseline in the Natriuretic peptide (NTproBNP)|Change in ratio to baseline in the Glomerular Filtration Rate Renal (eGFR)|Type of antidiabetic treatment at Day 29|Number of antidiabetic treatment at Day 29|Type of antidiabetic treatment at three months|Number of antidiabetic treatment at three months""}"
"3614","Mental Health Impact of the COVID-19 Pandemic Among Migrants in Chile","STRING-COVID","NCT04497636","170519004","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497636","Recruiting","2020-07-03","2021-01-31","{""locations"":""Pontificia Universidad Catolica de Chile, Santiago, RM, Chile"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1092"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depressive symptoms|Symptoms of anxiety|Symptoms of post-traumatic stress disorder|Change in mental health symptoms, well-being from last 2 weeks before the pandemic to last 2 weeks during COVID-19 pandemic|Loneliness|Change in general physical health|Change in general mental health""}"
"3615","Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)","COVIDOC","NCT04345861","RECHMPL20_168","Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04345861","Terminated","2020-04-11","2020-06-08","{""locations"":""Montpellier University hospital, Montpellier, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""7"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images""}"
"3616","Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","MP-C19","NCT04323592","MP-19 023_2020","Drug: Methylprednisolone|Other: standard care","Observational","Has Results","","https://ClinicalTrials.gov/show/NCT04323592","Completed","2020-03-23","2020-05-10","{""locations"":""Marco Confalonieri, Trieste, TS, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""173"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28|In-hospital Death Within 28 Days|Admission to Intensive Care Unit (ICU)|Endotracheal Intubation (Invasive Mechanical Ventilation)|Change in C-reactive Protein (CRP)|Number of Days Free From Mechanical Ventilation""}"
"3617","Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia","POLYCOR","NCT04453384","RC20_0230","Drug: XAV-19|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04453384","Recruiting","2020-09-01","2021-12-01","{""locations"":""CHU Angers, Angers, France|Hospices Civils Lyon, Lyon, France|CHU Nantes, Nantes, France|H\u00f4pital Saint Antoine, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""414"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 2a: XAV-19 antibody titers|Phase 2a: Adverse events of XAV-19|Phase 2b: Time to weaning of supplemental oxygen.|Phase 2a: Pharmacokinetic analysis|Phase 2a: Antibody titer between the two groups|Phase 2a: Supplemental oxygen|Phase 2a: Evaluation of Transfer to intensive care|Phase 2a: Normalization of Fever|Phase 2a: Biomarkers|Phase 2a: Hospital length of stay|Phase 2b: Efficacy of XAV-19|Phase 2b: National Early Warning Score (NEWS)|Phase 2b: clinical status|Phase 2b: Time to improvement|Phase 2b: fever normalization|Phase 2b: Oxygen therapy|Phase 2b: oxygen requirement|Phase 2b: Time to weaning|Phase 2b: Ventilation|Phase 2b: Hospital length of stay|Phase 2b: mortality|Phase 2b: safety""}"
"3618","Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia","PULCO-19","NCT04422613","RC31/20/0181","Diagnostic Test: pulmonary anomalies 4 months after documented COVID-19 pneumonia","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04422613","Active, not recruiting","2020-05-28","2022-05-01","{""locations"":""University Hospital of Toulouse, Toulouse, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""73"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Alteration of the DLCO|Mechanism of the alteration of gas exchanges|Measurement on lung volumes|mechanism of the alteration of gas exchanges by chest scan|mechanism of the alteration of gas exchanges by scintigraphy|Respiratory symptom|Bronchial or ventilatory anomalies|Persistent respiratory anomalies""}"
"3619","COVID-19 Quarantine on Musculoskeletal Status in Hemophilia","HemoCov","NCT04491318","HemoCov","Other: Observational","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04491318","Recruiting","2020-07-01","2020-07-29","{""locations"":""European University of Madrid, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""27"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline frequency of hemarthrosis after confinement period|Change from baseline joint health after confinement period|Change from baseline joint pain after confinement period|Change from baseline range of motion after confinement period""}"
"3620","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","COVID19-HCW","NCT04318314","130852","Diagnostic Test: COPAN swabbing and blood sample collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04318314","Recruiting","2020-03-18","2021-12-31","{""locations"":""Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroconversion to SARS-CoV-2 positivity""}"
"3621","A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole","","NCT04564040","D8223C00005","Drug: Acalabrutinib Treatment A|Drug: Acalabrutinib Treatment B|Drug: Acalabrutinib Treatment C|Drug: Acalabrutinib Treatment D","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04564040","Completed","2020-10-12","2020-12-11","{""locations"":""Research Site, Berlin, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Part 1 and 2: Area under plasma concentration-time curve from time zero to infinity (AUCinf)|Part 1 and 2: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)|Part 1 and Part 2: Maximum observed plasma concentration (Cmax)|Part 1 and Part 2: Area under the plasma concentration-time curve from time zero to 24 hours post dose (AUC0-24)|Part 1 and 2: Time to reach maximum observed plasma concentration (tmax)|Part 1 and 2: Half-life associated with terminal slope (\u03bbz) of a semi-logarithmic concentrationtime curve (t1\/2)|Part 1 and 2: Mean residence time of the drug in the systemic circulation from zero to infinity (MRT)|Part 1 and 2: Terminal elimination rate constant (\u03bbz)|Part 1 and 2: Apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only (CL\/F)|Part 1 and 2: Apparent volume of distribution during the terminal phase after extravascular administration (acalabrutinib only) (Vz\/F)|Part 1 and 2: Metabolite to parent ratio based on AUCinf and\/or AUClast (M:P[AUC])|Part 1 and 2: Metabolite to parent ratio based on Cmax (M:P[Cmax])|Number of subjects with serious and non-serious adverse events""}"
"3622","Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic","","NCT04373382","20-0084-E","Behavioral: Peer Resilience Champion|Behavioral: Enriched Survey Feedback","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04373382","Active, not recruiting","2020-07-27","2022-02-01","{""locations"":""Sinai Health System, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""882"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in instances of burnout for hospital staff due to the Peer Resilience Champion intervention|Change in instances of burnout for hospital staff due to the Enriched Feedback Survey intervention""}"
"3623","Assessment of Mortality Rates in SARS-CoV-2 Infected Populations Treated With Repurposed Medications","","NCT04432350","COVID-19_TRHCPrescribeWellness","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04432350","Not yet recruiting","2020-06-15","2021-05-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""50000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The rate of mortality in patients with a confirmed (positive test result) COVID-19 infection observed by PrescribeWellness pharmacies will be determined.|The relationship between high-risk cardio-pulmonary and vascular comorbidities (e.g., hypertension, dyslipidemia, diabetes, and chronic lung diseases) and mortality with use of repurposed medications for the treatment of COVID-19 will be investigated.|The MRS\u2122 will be calculated using drug claim data from confirmed COVID-19 patients and explore the predictive value of MRS\u2122 for ADE, LQTS and all-cause of death.|To compare the rates of death in COVID-19 confirmed patients treated with repurposed medications versus COVID-19 confirmed patients not treated with repurposed drugs.|The relationship between medications used to treat these underlying health conditions (e.g. ACE inhibitors, angiotensin type 1 receptor blockers, aliskiren, and mineralocorticoid antagonists) and mortality in patients with a confirmed COVID-19 infection.|To compare the MRS\u2122 and its predictive value for ADE between confirmed COVID-19 patients treated with repurposed drugs and confirmed patients not treated with repurposed drugs.|To examine drug regimen patterns associated with higher risk of MRS\u2122, ADEs, and higher rates of death in confirmed COVID-19 patients with and without repurposed medication.""}"
"3624","The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","","NCT04587219","05-Gam-COVID-Vac-2020","Biological: Gam-COVID-Vac","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04587219","Active, not recruiting","2020-10-22","2021-04-30","{""locations"":""Federal state budgetary institution \""Central clinical hospital with polyclinic\"" Of the office Of the President of the Russian Federation, Moscow, Russian Federation"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""110"",""age"":""60 Years to 111 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changing of antibody levels against the SARS-CoV-2 glycoprotein S in 42 days|Number of Participants With Adverse Events|Changing of of virus neutralizing antibody titer|Changing of antigen-specific cellular immunity level""}"
"3625","Ventilatory Efficiency in Critically Ill COVID-19 Patients","","NCT04694742","VentRatio-19","Other: data collecting","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694742","Recruiting","2020-09-01","2021-04-15","{""locations"":""Arcispedale Sant'Anna, Ferrara, Emilia Romagna, Italy|Ospedale Infermi, Rimini, Emilia Romagna, Italy|ASST Fatebenefratelli Sacco, Milan, Lombardy, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Marche, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilatory ratio correlation|Mortality""}"
"3626","Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19","","NCT04632082","20200213_Prevention","Behavioral: Telepsychoeducation with personalized videos|Behavioral: Telepsychoeducation without personalized videos","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04632082","Enrolling by invitation","2020-11-05","2021-07-20","{""locations"":""Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Incident Cases in 6 months|Incident cases|Service Satisfaction|Improvement in Quality of Life""}"
"3627","Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine","","NCT04025580","190126|19-I-0126","Biological: Flucelvax|Biological: Fluvirin|Biological: Fluzone High Dose","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04025580","Recruiting","2019-10-02","2025-12-31","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Microneutralization titers""}"
"3628","Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19","","NCT04535700","ESCORPIO","Drug: Pioglitazone 30 mg|Other: standard of care","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04535700","Recruiting","2020-09-18","2021-04-10","{""locations"":""Hospital Ram\u00f3n y Cajal, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""76"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients treated with pioglitazone, together with conventional treatment for COVID-19 infection, who during their admission evolve towards the need to receive support with mechanical ventilation, enter the ICU and \/ or die.|Incidence of pioglitazone treatment-Emergent Adverse Events in patients with DM2 and symptomatic SARS-CoV-2 infection.|Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment.""}"
"3629","Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic","COroFet","NCT04360811","RC31/20/0123","Diagnostic Test: COVID 19 diagnostic test by PCR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04360811","Recruiting","2020-04-17","2022-04-01","{""locations"":""University Hospital of Toulouse, Toulouse, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""3600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of positive COVID-19 women""}"
"3630","COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss","COVAYDE","NCT04395144","2021-01","Procedure: Awake Prone Positioning|Procedure: Standard care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04395144","Recruiting","2020-05-15","2021-03-31","{""locations"":""H\u00f4tel-Dieu de Gasp\u00e9, Gasp\u00e9, Quebec, Canada|H\u00f4pital de la Cit\u00e9-de-la-Sant\u00e9, Laval, Quebec, Canada|Montreal General Hospital, McGill University Healthcare Center, Montr\u00e9al, Quebec, Canada|Royal Victory Hospital, McGill University Healthcare Center, Montr\u00e9al, Quebec, Canada|H\u00f4pital de Verdun, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""346"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of Therapeutic failure, defined as a combined outcome of rate of intubation or death|Intubation rate|Mortality|Days spent on mechanical ventilation|Days spent in the ICU|Hospital stay (in days)""}"
"3631","Vaccination Against COVID-19 in Cancer","VOICE","NCT04715438","202000865","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04715438","Recruiting","2021-01-08","2023-04-01","{""locations"":""NKI-AvL, Amsterdam, Netherlands|UMCG, Groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""873"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immune response to vaccination against COVID-19 measured as antibody response expressed as geometric mean concentration: arbitrary units (AU)\/ml|Safety assessment (S)AEs; Incidence and severity of solicited AEs during 7 days after each vaccination with incidence and nature of SAEs reported during 7 days after each vaccination|Safety assessment immune related (ir), with incidence and nature of newly occurring irAEs grade \u2265 3 in cohort B and D reported up to 28 days|Safety assessment AE of special interest (SI)s with Incidence, nature and severity of AESIs graded according to CTCAE v5.0 reported up to 12 months after vaccination|Assessment of immune response: expressed as geometric mean antibody concentration: arbitrary units (AU)\/ml|Assessment of immune response: measured as levels of SARS-CoV-2 specific T-cell responses expressed as number of IFNg producing T cells\/ million peripheral blood mononuclear cells (PBMCs)""}"
"3632","Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","","NCT04519437","R10933-10987-HV-2093","Drug: REGN10933+REGN10987|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04519437","Active, not recruiting","2020-07-26","2021-10-25","{""locations"":""Regeneron Study Site, Tempe, Arizona, United States|Regeneron Study Site, Rogers, Arkansas, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Lincoln, Nebraska, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Austin, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""974"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse event of special interests (AESIs) that occur within 4 days of study drug administration|Concentrations of REGN10933 in serum over time|Concentrations of REGN10987 in serum over time|Proportion of participants with treatment-emergent adverse events (TEAEs)|Severity of TEAEs|Proportion of participants who achieve or exceed target concentration in serum of REGN10933|Proportion of participants who achieve or exceed target concentration in serum of REGN10987|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987""}"
"3633","Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology","VT-Covid-19","NCT04452422","7908","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452422","Recruiting","2020-06-23","2020-09-23","{""locations"":""Service Unit\u00e9 Neurovasculaire, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of cumulated deep venous thrombosis among the hospitalization""}"
"3634","The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19","ENDCOV-I","NCT04619680","GCO 20-2147","Drug: Nintedanib|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04619680","Recruiting","2020-11-18","2021-07-01","{""locations"":""Mount Sinai Beth Israel, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Forced Vital Capacity (FVC)|Number of deaths due to respiratory cause|Chest CT visual score|St. George's Respiratory Questionnaire (SGRQ)|King's Brief Interstitial Lung Disease (KBILD)|King's Brief ILD (KBILD)|Leicester Cough Questionnaire (LCQ)|Leicester Cough Questionnaire|Short Form (SF) 36 Health Survey|SF 36 Health Survey|Hospital Anxiety and Depression Scale (HADS)|Number of participants with Increase in liver transaminases (AST and ALT) > 3 times the upper limit of normal|Number of participants with Thrombotic events|Number of participants with 10% weight loss over 90 days|Number of participants with GI events""}"
"3635","Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19","COVID-19","NCT04613245","Serial 39-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04613245","Recruiting","2020-05-01","2021-03-01","{""locations"":""Egypt, Cairo, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Asthma Control Questionnaire (ACQ)|Mini Asthma Quality of Life Questionnaire|Perceived Stress Scale""}"
"3636","Mindful Prevention of Psychopathology in Healthcare Workers During the COVID-19 Crisis (COVID-19 MindPreP)","","NCT04720404","MFN-COVID-19 2020-22","Behavioral: Mindfulness-Based Stress Reduction|Other: Self-help mindfulness/compassion exercises|Other: Support as usual","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04720404","Recruiting","2020-06-23","2022-02-01","{""locations"":""Radboud university medical center, Nijmegen, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""220"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Somatoform symptoms, Anxiety, Depression|Occurence of psychopathology|Post-traumatic stress symptoms|Severity of insomnia|Alcohol use|Posttraumatic growth|Positive mental health|Health-related quality of life|Costs""}"
"3637","Collaborative Outcomes Study on Health and Functioning During Infection Times During COVID-19 Pandemic","COH-FIT","NCT04383470","COH-FIT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383470","Recruiting","2020-04-26","2022-06-01","{""locations"":""Aristotle University of Thessaloniki, Thessalon\u00edki, Greece"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""100000"",""age"":""6 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mental health symptoms, well-being change from last 2 weeks before the pandemic to last 2 weeks during COVID-19 pandemic|Mental health symptoms, well-being change from last 2 weeks before the pandemic to last 2 weeks 6 months after WHO declares pandemic over COVID-19 pandemic|Mental health symptoms change, well-being change from last 2 weeks before the pandemic to last 2 weeks 12 months after WHO declares pandemic over COVID-19 pandemic|Change in alcohol abuse, as change in units used from last 2 weeks before the pandemic to last 2 weeks during pandemic|Change in cigarettes use, as change in number of cigarettes per day from last 2 weeks before the pandemic to last 2 weeks during pandemic|Change in grams of cannabinoids smoked from last 2 weeks before the pandemic to last 2 weeks during pandemic|Change in general physical health, self-rated, on a VAS scale from 0 to 100.|Change in general mental health, self-rated, on a VAS scale from 0 to 100.|Change in easiness of access to care, self-rated a on a VAS scale from 0 to 100.|Change in medication adherence, self-rated a on a VAS scale from 0 to 100.|Change in functioning in self-care, school\/work, social, and family, self-rated a on a VAS scale from 0 to 100.""}"
"3638","W-SUDs for COVID-19","","NCT04460027","56439","Other: Woebot Substance Use Disorder","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04460027","Completed","2020-06-22","2020-11-30","{""locations"":""Stanford University, Palo Alto, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of number of days drinking|Change of number of days drug use|Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5 (AUDADIS-V)|Short Inventory of Problems - Alcohol and Drugs (SIP-AD)|Drug Abuse Screening Test (DAST-10)|Brief Situational Confidence Questionnaire (BSCQ)|Craving rating|Pain rating|Patient Health Questionnaire-9 (PHQ-9)|General Anxiety Disorder-7 (GAD-7)|CAIR Pandemic Impact Questionnaire (CAIR-PIQ)|Client Satisfaction Questionnaire (CSQ)|Usage Rating Profile Intervention (URPI)""}"
"3639","Serological Diagnostics of COVID-19 in Health Care Workers","KORANIT","NCT04635592","KOAIT-1-2020","Diagnostic Test: SARS-CoV2 nasal swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04635592","Not yet recruiting","2020-11-01","2021-01-31","{""locations"":""University Medical Centre Ljubljana, Ljubljana, Slovenia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""positive nasal swab and serological test|Relation of positive SARS-CoV2 tests to risky contact history""}"
"3640","Evaluation of Novel Diagnostic Tests for COVID-19","COVIDx","NCT04326387","COVIDx","Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04326387","Recruiting","2020-04-06","2021-10-07","{""locations"":""Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""SAMBA COVID-19 POC PCR Test|Patient acceptability|Immune Response Positivity""}"
"3641","COVID-19 RELATED KIDNEY DAMAGE","","NCT04706325","kocaeli derh","Other: ACUTE KIDNEY INJURY","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04706325","Recruiting","2021-01-01","2021-05-15","{""locations"":""Akif \u015eahin, Kocaeli, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""KDIGO""}"
"3642","COVID-19 Health Messaging to Underserved Communities","","NCT04371419","2003000118","Behavioral: Messaging","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04371419","Completed","2020-05-13","2020-05-24","{""locations"":""JPAL North America, Cambridge, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""15475"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Knowledge Beliefs and Practices related to COVID-19|Video Ratings""}"
"3643","Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease","OSCAR","NCT04376684","214094","Biological: Otilimab|Biological: Placebo 1|Biological: Placebo 2|Drug: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04376684","Recruiting","2020-05-28","2021-08-23","{""locations"":""GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, Winfield, Illinois, United States|GSK Investigational Site, Portland, Maine, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Germantown, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Reno, Nevada, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Doylestown, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Roanoke, Virginia, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Munro, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, C\u00f3rdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Argentina|GSK Investigational Site, Cordoba, Argentina|GSK Investigational Site, Corrientes, Argentina|GSK Investigational Site, Brussel, Belgium|GSK Investigational Site, Yvoir, Belgium|GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, S\u00e3o Paulo, Brazil|GSK Investigational Site, S\u00e3o Paulo, Brazil|GSK Investigational Site, S\u00e3o Paulo, Brazil|GSK Investigational Site, S\u00e3o Paulo, Brazil|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Montr\u00e9al, Quebec, Canada|GSK Investigational Site, QC, Quebec, Canada|GSK Investigational Site, St-Jerome, Quebec, Canada|GSK Investigational Site, Talca, Regi\u00f3n Del Maule, Chile|GSK Investigational Site, Quillota, Valpara\u00edso, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Amiens Cedex 1, France|GSK Investigational Site, Angers Cedex 9, France|GSK Investigational Site, Argenteuil, France|GSK Investigational Site, Ars-Laquenexy, France|GSK Investigational Site, La Roche-Sur-Yon, France|GSK Investigational Site, La Tronche, France|GSK Investigational Site, Limoges Cedex, France|GSK Investigational Site, Melun, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pierre-B\u00e9nite, France|GSK Investigational Site, Strasbourg cedex, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Valenciennes Cedex, France|GSK Investigational Site, Aurangabad, India|GSK Investigational Site, Aurangabad, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Kolkata, India|GSK Investigational Site, Kolkata, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Surat, India|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Mexico City, Ciudad De Mexico, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Monterrey, Nuevo Le\u00f3n, Mexico|GSK Investigational Site, DF, Mexico|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Den Bosch, Netherlands|GSK Investigational Site, Enschede, Netherlands|GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Perm, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Ufa, Russian Federation|GSK Investigational Site, Voronezh, Russian Federation|GSK Investigational Site, Benoni, Gauteng, South Africa|GSK Investigational Site, Johannesburg, Gauteng, South Africa|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Middelburg, Mpumalanga, South Africa|GSK Investigational Site, Muckleneuk Pretoria, South Africa|GSK Investigational Site, Panorama,, South Africa|GSK Investigational Site, Tygerberg, South Africa|GSK Investigational Site, Worcester, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Logro\u00f1o, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, San Sebasti\u00e1n De Los Reyes\/Madrid, Spain|GSK Investigational Site, Manchester, Greater Manchester, United Kingdom|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Middlesbrough, United Kingdom|GSK Investigational Site, Newcastle Upon Tyne, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Parts 1 and 2: Proportion of participants alive and free of respiratory failure at Day 28|Parts 1 and 2: Number of deaths due to all causes at Day 60|Part 2: Number of deaths due to all causes at Day 28|Parts 1 and 2: Time to number of deaths due to all causes up to Day 60|Parts 1 and 2: Proportion of participants alive and free of respiratory failure at Days 7, 14, 42 and 60|Parts 1 and 2: Time to recovery from respiratory failure|Parts 1 and 2: Proportion of participants alive and independent of supplementary oxygen at Days 7, 14, 28, 42, and 60|Parts 1 and 2: Time to last dependence on supplementary oxygen|Part 1: Proportion of participants admitted to Intensive Care Unit (ICU)|Parts 1 and 2: Time to final ICU discharge|Part 1: Time to final hospital discharge|Part 2: Time to first discharge from investigator site|Part 2: Time to first discharge to non-hospitalized residence|Parts 1 and 2: Number of participants with Adverse events (AEs) and Serious adverse events (SAEs)""}"
"3644","Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects","","NCT04480957","ARCT-021-01","Biological: ARCT-021 Dose 1|Biological: ARCT-021 Dose 2|Biological: ARCT-021 Dose 3|Biological: ARCT-021 Dose 4|Biological: ARCT-021 Dose Regimen 1|Biological: ARCT-021 Dose Regimen 2|Other: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04480957","Recruiting","2020-08-04","2021-01-01","{""locations"":""SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""92"",""age"":""21 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence, severity and dose-relationship of AEs|Geometric mean titre for SARS-CoV-2-specific serum neutralizing antibody|Mean titre for SARS-CoV-2-specific serum neutralizing antibody levels|Geometric mean fold rise in titre for SARS-CoV-2-spike protein specific neutralizing antibody levels""}"
"3645","Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy","","NCT04588909","73/2020 (Supl 2)","Procedure: Colorectal resections","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04588909","Active, not recruiting","2020-03-23","2020-10-22","{""locations"":""Sher i Kashmir Institute of Medical Sciences, Srinagar, J&K, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Early post operative mortality|Early Post operative complications|Incidence of SARS CoV2 infectivity among health care providers providing direct care to involved patients|Rate of hospital acquired SARS CoV 2 infection among operated patients.""}"
"3646","COVID-19 in People With Primary Ciliary Dyskinesia","","NCT04602481","COVID-PCD","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04602481","Recruiting","2020-05-31","2025-05-31","{""locations"":""Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""SARS-CoV-2|COVID-19|COVID-19 hospitalisation|COVID-19 intensive care|COVID-19 fatal outcome""}"
"3647","Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure","MOM-COPE","NCT04540029","MOM-COPE","Other: Maternal stress","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04540029","Recruiting","2020-05-06","2023-05-31","{""locations"":""IRCCS Mondino Foundation, Pavia, PV, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""up to 12 Months \u00a0 (Child)"",""outcome_measures"":""Infant negative emotionality|Infants' target gene methylation status""}"
"3648","Health cAre woRkers exposeD to COVID-19","HARD-COVID19","NCT04570202","DR200160-HARD-COVID-19|2020-A01642-37|1-20-046 ID 48680","Behavioral: EMDR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04570202","Recruiting","2020-11-20","2022-08-20","{""locations"":""Centre Investigation Clinique 1415, Tours, Centre Val De Loire, France|Bretonneau Regional Universitary Hospital, Tours, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy on symptoms of Post-Traumatic Stress Disorder|Efficacy on symptoms of Burnout|Efficacy on symptoms of Depression|Short-term efficacy on symptoms of PTSD|Short-term efficacy on symptoms of Burnout|Short-term efficacy on symptoms of Depression|Long-term efficacy on symptoms of PTSD|Long-term efficacy on symptoms of Burnout|Long-term efficacy on symptoms of Depression|Efficacy on symptoms of Anxiety|Long-term efficacy on symptoms of Anxiety|Efficacy on suicide attempts""}"
"3649","Simple, Safe, Same: Lung Ultrasound for COVID-19","LUSCOVID19","NCT04322487","0013226/20","Diagnostic Test: Lung ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04322487","Recruiting","2020-04-08","2021-01-15","{""locations"":""Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Lung ultrasound grading system for COVID-19 pneumonia""}"
"3650","A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment","COVIQuest","NCT04359875","2020-CD-COVIQuest (COVID-19)","Behavioral: Phone-call screening and management by a medical student/general practitioner tandem","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04359875","Not yet recruiting","2020-04-01","2020-12-01","{""locations"":""Dibao-Dina, Tours, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""22000"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization(s) at 1 month|Phone-call from the general practitioner (in the experimental group only)|Mortality at 1 month|Use of primary care|Use of secondary care|Number of prescriptions related to the chronic disease dispensed by the pharmacy|Number of hospitalization(s)|Time to hospitalization(s)|Hospitalization(s)' durations|Reasons for hospitalization(s)|Mortality at 6 months|Cardiovascular events (MACE)|Psychotropic drugs""}"
"3651","COVID-19 and the Healthy Minds Program for Educators","CAHMP-ED","NCT04426318","2020-0533|A171600|EDUC/COUNSELING PSYCH|Protocol Approval 10/15/2020","Behavioral: Healthy Minds Program Foundations Training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04426318","Completed","2020-06-14","2021-01-12","{""locations"":""University of Wisconsin, Madison, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""733"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline on an aggregate measure of Psychological distress that averages the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depressive Measures and the NIH Perceived Stress Scale|Change from baseline on the Five Facet Mindfulness Questionnaire Act with Awareness subscale|Change from baseline on the Drexel Defusion Scale (DDS)|Change from baseline on the Meaning in Life Questionnaire|Change from baseline on the NIH Toolbox Loneliness scale|Change from baseline on the Conway COVID Questionnaire|Change from baseline on the Self-Compassion Scale Short Form|Change from baseline on the Perseverative Thought Questionnaire|Change from baseline on the World Health Organization 5-item (WHO-5) well-being scale|Change from baseline on the Neutral Face Rating task|Change from baseline on the Growth Mindset Scale for Well-Being""}"
"3652","SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida","","NCT04596579","MCC-20635","Diagnostic Test: SARS-CoV-2 Antibody Analysis|Diagnostic Test: Weck-cel Swab Collection|Behavioral: Web Based Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04596579","Enrolling by invitation","2020-10-09","2022-10-09","{""locations"":""Moffitt Cancer Center, Tampa, Florida, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants who test positive for SARS-CoV-2 antibodies at first visit|Percentage of Participants who test positive for SARS-CoV-2 antibodies at second visit|Percentage of Participants who test positive for SARS-CoV-2 antibodies at third visit""}"
"3653","SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)","","NCT04487197","COVID-SIERO TRAPIANTI","Procedure: blood sample for seroepidemiological investigation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04487197","Completed","2020-07-15","2021-01-15","{""locations"":""IRCCS San Raffaele, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""282"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serum-prevalence of COVID-19 TX|Serum-prevalence of COVID-19 \/ Age, Gender, Type of transplantation, comorbities, Italian regions-proviences transplanted patients|Asymptomatic or subclinical infections in transplanted patients|Risk factors for infection COVID-19 transplanted patients|Hospitalization rate COVID-19 transplanted patients|Mortality rate COVID-19 transplanted patients""}"
"3654","COVID-19 Related Lockdown Effects On Chronic Diseases","CLEO-CD","NCT04390126","BOULIN AOIc 2020","Other: life questionnaires|Other: questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04390126","Active, not recruiting","2020-04-20","2021-11-07","{""locations"":""CHU Dijon Bourgogne, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""9 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""% adherence to each pharmacological class|number of occurrence of medical events at 1 year|Expressed in %: Non-pharmacological treatment\/lifestyle:|Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication|Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)""}"
"3655","Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2","IC-COVID-19","NCT04665960","NMCSpecialtyH","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04665960","Not yet recruiting","2021-03-01","2021-03-31","{""locations"":""NMC Specialty Hospital, Dubai, United Arab Emirates"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""25 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Consensus using participating experts opinions.""}"
"3656","Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure","COVID-VENT","NCT04445961","COVID-VENT","Diagnostic Test: Respiratory mechanics measurement|Diagnostic Test: Gas exchange measurement","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445961","Completed","2020-05-01","2020-08-14","{""locations"":""Sechenov University Clinic #1, Moscow, Russian Federation|Sechenov University Clinic #3, Moscow, Russian Federation|Sechenov University Clinic #4, Moscow, Russian Federation"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""117"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Optimum positive end-expiratory pressure (PEEP) level|Number of patients with recruitable lung|Change in alveolar dead space|Change in plethysmogram variability during recruitment maneuver|Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2\/FiO2) ratio|Change in driving pressure with different positive end-expiratory pressure (PEEP) levels""}"
"3657","Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients","","NCT04583566","CTM_COVID-19","Genetic: COVID-19 Diagnostic and Assessment Tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04583566","Recruiting","2020-10-04","2022-10-03","{""locations"":""Tanta University Hospital, Tanta, El Gharbia, Egypt|Center of Excellence in Cancer Research, Tanta University Hospital., Tanta, Gharbia, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Differential gene expression profile.|Differential miRNA expression profile.|Multiplex Cytokine assay""}"
"3658","eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19","MySteps-CoV","NCT04587414","MySteps ETL 303/2017","Behavioral: eHealth +counselling contacts|Behavioral: eHealth|Behavioral: Usual care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04587414","Active, not recruiting","2019-03-06","2020-10-31","{""locations"":""North Karelia Hospital District, Joensuu, Finland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""122"",""age"":""20 Years to 69 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in total mean daily step count|Changes in total mean daily time of sedentary, low intensity PA and moderate-to-vigorous PA|Changes in the mean daily number of moderate-to-vigorous PA bouts lasting at least 1, 5 and 10 minutes.""}"
"3659","Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis","APCC-19","NCT04597775","APCC-19","Drug: hydroxychloroquine","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04597775","Not yet recruiting","2020-10-27","2021-01-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""93"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence rate of COVID-19 on day 14 according to positive results of RT-PCR rate at day 14|Safety and adverse events (AEs) incidence rate at day 14|IgM antibodies positive rate for COVID-19 at day 28|Incidence rate of COVID-19 on day 28 according to positive results of RT-PCR rate at day 28|Safety and adverse events (AEs) incidence rate on day 28""}"
"3660","Insomnia After the COVID-19 Pandemic","","NCT04443361","REK125510 (7)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443361","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Bergen insomnia scale (BIS)""}"
"3661","Somerset and South Essex Coronavirus Antigen Testing","SOCRATES","NCT04403906","IRAS283137","Diagnostic Test: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04403906","Not yet recruiting","2020-06-01","2021-08-01","{""locations"":""Musgrove Park Hospital, Taunton, Somerset, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To compare the result of SARS-COV2 PCR test to PCL rapid antigen test|Number of technically failed samples due to test issues.|Time taken for PCL Antigen test result""}"
"3662","SINUS WASH Pilot Study in Adults Testing Positive for COVID-19","","NCT04393792","SPON-AK-0420|2020-001721-31","Drug: Povidone-Iodine|Drug: Normal saline","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04393792","Recruiting","2020-05-01","2020-08-01","{""locations"":""Hampshire Hospitals NHS Foundation Trust, Basingstoke, Hampshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in viral load in the oral and nasopharyngeal cavity|Symptom severity in primary participants and co-residents""}"
"3663","GERAS Frailty Rehabilitation at Home During COVID-19","","NCT04500366","11408","Behavioral: Socialization|Behavioral: Virtual Group Exercise|Combination Product: Nutrition Consult and Protein Supplementation|Behavioral: Medication Review","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04500366","Recruiting","2020-08-26","2021-05-01","{""locations"":""McMaster University - Hamilton Health Sciences (St. Peter's Site), Hamilton, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""70"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Change in Physical Function|Change in Mental Health|Change in Sarcopenia|Change in Frailty|Change in Self-Efficacy|Self-Reported Change in Function, Health and Well-Being|Clinician-Reported Change in Function, Health and Well-Being|Change in Fitness|Program Satisfaction|Change in Health-Related Quality of Life|Change in Nutrition|Change in Emergency Room Visits|Change in Hospitalizations|Change in Number of Calls to 911""}"
"3664","Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients","","NCT04377776","COVID-19 MITRA","Other: Practice details","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377776","Completed","2020-05-04","2020-05-18","{""locations"":""IRCCS San Raffaele, Milano, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""644"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Global Prevalence of COVID-19 TX|Hospitalization rate in COVID-19 TX|Correlation COVID-19 TX and type of transplantation|Prevalence of COVID-19 TX in italian provinces|Symptoms in COVID-19 TX|Correlation COVID-19 TX and comorbidities|COVID-19 TX Therapies|COVID-19 TX in family settings""}"
"3665","A Study of Auxora in Patients With Critical COVID-19 Pneumonia","","NCT04661540","CM4620-205","Drug: CM4620-IE (Injectable Emulsion)|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04661540","Not yet recruiting","2021-02-01","2021-05-01","{""locations"":""Northwestern Memorial Hospital, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decrease in interferon-gamma producing T-cells in Broncoalveolar lavage (BAL) fluid|Number of Days in the Hospital after randomization|Number of Days in the Intensive Care Unit (ICU) after randomization|Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Intensity and relationship of TEAEs and SAEs|Pre-defined changes in cardiac conduction assessed by ECG|Mortality|Plasma Levels of CM4620""}"
"3666","A Study of Auxora in Patients With Severe COVID-19 Pneumonia","","NCT04345614","CM4620-204","Drug: Auxora|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04345614","Recruiting","2020-04-08","2021-06-01","{""locations"":""Long Beach Memorial, Long Beach, California, United States|University of Southern California \/ LA County, Los Angeles, California, United States|Sharp Memorial San Diego, San Diego, California, United States|University of Colorado, Aurora, Colorado, United States|National Jewish Health \/ St. Joseph's Hospital, Denver, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Baton Rouge General, Baton Rouge, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai Grace, Detroit, Michigan, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Temple University, Philadelphia, Pennsylvania, United States|Texas Tech University Medical Center, El Paso, Texas, United States|John Peter Smith Hospital, Fort Worth, Texas, United States|Ben Taub (Baylor), Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Aurora Baycare, Green Bay, Wisconsin, United States|Hospital San Cristobal, Ponce, Puerto Rico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days from the Start of the First Infusion of Study Drug (SFISD) to recovery|Proportion of patients requiring invasive mechanical ventilation or dying|Proportion of patients requiring invasive mechanical ventilation|Differences in outcomes as measured by an 8-point ordinal scale|Proportion of patients who have died at day 30 (mortality)|Number of days in the hospital|Number of days in the Intensive Care Unit (ICU)|Incidence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)|CM4620-IE serum concentration""}"
"3667","General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to COVID-19","","NCT04626050","20-04021913","Behavioral: Medical Music|Behavioral: Narrative Writing|Behavioral: Prolonged Exposure Therapy|Behavioral: Interpersonal Psychotherapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04626050","Not yet recruiting","2021-01-01","2022-01-01","{""locations"":""Weill Cornell Medicine, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility Indicator: Recruitment (Phase I)|Feasibility Indicator: Recruitment (Phase II)|Feasibility Indicator: Enrollment (Phase I)|Feasibility Indicator: Enrollment (Phase II)|Feasibility Indicator: Retention (Phase I)|Feasibility Indicator: Retention (Phase II)|Acceptability Indicator: Satisfaction (Phase I)|Acceptability Indicator: Satisfaction (Phase II)|Preliminary Efficacy as Measured by Change in Clinician-Administered PTSD Scale Score (Phase I)|Preliminary Efficacy as Measured by Change in Clinician-Administered PTSD Scale Score (Phase II)|Change in Anxiety Symptoms measured by the Generalized Anxiety Disorder 7-Item Scale (Phase I)|Change in Anxiety Symptoms measured by the Generalized Anxiety Disorder 7-Item Scale (Phase II)|Change in Depressive Symptoms measured by the Beck Depression Inventory-II (Phase I)|Change in Depressive Symptoms measured by the Beck Depression Inventory-II (Phase II)|Change in score on the Pittsburgh Sleep Quality Index (PSQI) (Phase I)|Change in score on the Pittsburgh Sleep Quality Index (PSQI) (Phase II)|Change in score on the Moral Distress Scale (Phase I)|Change in score on the Moral Distress Scale (Phase II)|Change in score on the Modified Moral Injury Events Scale (Phase I)|Change in score on the Modified Moral Injury Events Scale (Phase II)|Change in score on the PTSD Checklist for DSM-5 (PCL-5) (Phase I)|Change in score on the PTSD Checklist for DSM-5 (PCL-5) (Phase II)|Change in score on the Sheehan Disability Scale (SDS) (Phase I)|Change in score on the Sheehan Disability Scale (SDS) (Phase II)|Change in score on the World Health Organization Quality of Life Scale - Brief (Phase I)|Change in score on the World Health Organization Quality of Life Scale - Brief (Phase II)|Change in score on the Social Adjustment Scale (SAS) (Phase I)|Change in score on the Social Adjustment Scale (SAS) (Phase II)|Change in Score on the Occupational Stress Inventory Revised (OSI-R) (Phase I)|Change in Score on the Occupational Stress Inventory Revised (OSI-R) (Phase II)|Change in Score on the Multidimensional Scale of Perceived Social Support (MSPSS) (Phase I)|Change in Score on the Multidimensional Scale of Perceived Social Support (MSPSS) (Phase II)|Change in score on the Posttraumatic Cognitions Inventory (Phase I)|Change in score on the Posttraumatic Cognitions Inventory (Phase II)|Change in score on the Difficulties in Emotion Regulation Scale (DERS) (Phase I)|Change in score on the Difficulties in Emotion Regulation Scale (Phase II)""}"
"3668","COVID-19 Neurological Disease: A Prospective Study","","NCT04672590","UoL001596","Other: Primary exposure is hypoxia (no intervention)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04672590","Not yet recruiting","2021-01-01","2021-12-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""681"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acute new-onset neurological disease|Admission to a critical (intensive\/high dependency) care unit|Time to discharge from hospital|Severity of stroke using National Institutes of Health Stroke Scale (NIHSS)|Glasgow Outcome Scale Extended|Modified Rankin Score|Montreal Cognitive Assessment (MoCA)|Development of new onset neurological sequelae|European QoL-5D (EQ-5D-3L) overall health utility quality of life score|Death""}"
"3669","Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer","CAPANCOVID-19","NCT04406571","PO20042","Other: Data record","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406571","Recruiting","2020-04-01","2022-04-01","{""locations"":""Damien JOLLY, Reims, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pancreatic adenocarcinoma treatment""}"
"3670","Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment","","NCT04365608","INT_EMS_PPE_1","Procedure: Direct laryngoscopy|Procedure: Vie Scope laryngoscopy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04365608","Completed","2020-03-20","2020-12-10","{""locations"":""Emergency Medical Service, Poznan, Poland|Emergency Medical Service, Warsaw, Poland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intubation success rate during at the first laryngoscopy|Intubation difficulty Scale score|Complications related to tracheal intubation|Time to completion of tracheal intubation (TI) procedure|Duration of the interruption of chest compression during ETI procedure|Laryngeal View during intubation|POGO score""}"
"3671","COVID-19-Related Health and Practices Among Dental Hygienists","","NCT04542915","ADA20-11","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04542915","Active, not recruiting","2020-09-29","2021-10-01","{""locations"":""American Dental Association, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""4776"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 probable or confirmed case|Anxiety|Depression|Dental practice infection control efforts|Personal protective equipment|Employment status""}"
"3672","Perceived Stress Among ICU Medical Staff During COVID-19 Crisis","ICUcovid","NCT04604769","stressICUcovid","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04604769","Completed","2019-06-26","2020-09-01","{""locations"":""University of Li\u00e8ge, Li\u00e8ge, Province De Li\u00e8ge, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""stress at work|stress in a medical unit|hobby activities""}"
"3673","ARDS Caused by COVID-19","","NCT04368975","COVID-19 ARDS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368975","Recruiting","2020-03-12","2020-12-31","{""locations"":""Ricard Mellado, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Discontinuation from mechanical ventilation""}"
"3674","Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak","Sleep&Covid19","NCT04632615","Sleep&Covid19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04632615","Active, not recruiting","2020-05-22","2021-03-31","{""locations"":""IRCCS Istituto Ortopedico Galeazzi, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""84"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Change in Subjective sleep quality|Change in Subjective sleep quantity|Change in Training volume""}"
"3675","Provider Burnout During COVID-19","","NCT04370938","STUDY20040051","Behavioral: Coping strategies video","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04370938","Withdrawn","2020-04-29","2020-10-29","{""locations"":""UPMC, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of undertaking task""}"
"3676","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","CORIPREV-LR","NCT04321174","CORIPREV-1","Drug: Lopinavir/ritonavir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04321174","Recruiting","2020-04-17","2022-03-31","{""locations"":""St. Paul's Hospital, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1220"",""age"":""18 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life""}"
"3677","Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteers","","NCT04594395","10000083|000083-I","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04594395","Not yet recruiting","2021-03-16","2023-12-31","{""locations"":""Cambodian Center for Communicable Disease (CCDC), Ministry of Health (MOH), Phnom Penh, Cambodia|National Malaria Center (CNM), Ministry of Health (MOH), Phnom Penh, Cambodia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2700"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence or absence of SARSCoV-2 immunoglobulin in participant sera by ELISA optical density change.""}"
"3678","Cardiac Rehabilitation and Ongoing Physical Activity During COVID-19","CODIS","NCT04501432","23_CODIS","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04501432","Completed","2020-07-14","2020-10-24","{""locations"":""Institute of Sports Medicine, Prevention and Rehabilitation, Salzburg, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""27"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Work load (W)|Work load % of predicted value|Heart rate (bpm)|Framingham Recurrent Coronary Heart Disease risk score|Metabolic Equivalent (MET) minutes \/ week|Patient Experience""}"
"3679","Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East","OMC-KTR","NCT04542954","2020/1481","Other: Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04542954","Completed","2020-03-01","2020-08-31","{""locations"":""OTC, MOH , Kuwait, Kuwait, Kuwait"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""104"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""patient outcome|Kidney graft outcome|risk factors for getting COVID19 infection""}"
"3680","Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic","ERT-P","NCT04615416","20-269","Behavioral: Emotion Regulation Training via Telehealth","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04615416","Recruiting","2020-05-01","2023-01-01","{""locations"":""Teachers College, Columbia University, New York, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in Anxiety, Depression, and Distress|Changes in Worry|Changes in Rumination|Changes in Functional Impairment|Changes in Life Satisfaction|Semi-Weekly Measures of Treatment Changes in Anxiety|Semi-Weekly Measures of Treatment Changes in Depression|Semi-Weekly Measures of Treatment Changes in Depression Symptoms|Semi-Weekly Measures of Treatment Changes in Distress|Semi-Weekly Measures of Treatment Changes in Worry|Semi-Weekly Measures of Treatment Changes in Rumination|Semi-Weekly Measures of Treatment Changes in Metacognitive Regulation|Semi-Weekly Measures of Treatment Changes in Attentional Regulation|Satisfaction and Usability of Treatment""}"
"3681","Active Pregnancy Against COVID-19","ACPREGCOV","NCT04563065","UPM-2020-32/33","Other: Exercise program|Other: Healthy lifestyle advise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04563065","Recruiting","2020-08-01","2023-12-31","{""locations"":""Facultad de Ciencias de la Actividad F\u00edsica y el Deporte (INEF), Madrid, Spain|Facultad de Ciencias de la Actividad F\u00edsica y el Deporte - INEF, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""280"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Maternal weight gain|blood pressure|OGTT-O'Sullivan test|Urinary Incontinence Questionnaire (ICIQ-SF)|State-Trait Anxiety Inventory (STAI)|depression scale (CES-D)|Behavior of Fetal Heart Rate|gestational age|type of delivery (Vaginal, instrumental or cesarean)|duration of labor|birthweight|child's weight|child's height|mental assessment of the child (depression questionnaire adapted to childhood)|Maternal pains during pregnancy (headache, back pain, pelvic pain, paravertebral, scapular, etc.)|fetal growth and development|Delivery tears|performing episiotomy during childbirth|Apgar Score|length|cranial perimeter|Landau reflexes test|neonatal intensive care unit (NICU)|Postpartum recovery of pre-pregnancy weight|Edinburgh Postpartum Depression Scale (EPDS)""}"
"3682","European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO","EuroECMO-COVID","NCT04366921","METC 2020-1343","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04366921","Recruiting","2020-04-10","2021-04-01","{""locations"":""Universit\u00e4tskliniken Innsbruck, Innsbruck, Austria|Landesklinikum Sankt Polten, St.P\u00f6lten, Austria|Medical University of Vienna, Vienna, Austria|Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium|University Hospital, Antwerp, Antwerp, Belgium|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Chirec, Brussels, Belgium|Erasme University Hospital, Brussel, Belgium|Universitair Ziekenhuis Brussel, Brussel, Belgium|H\u00f4pital Civil Marie Curie de Charleroi, Charleroi, Belgium|University Hospital, Ghent, Ghent, Belgium|La Louvi\u00e8re Hopital, La Louvi\u00e8re, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|CHU de Liege, Li\u00e8ge, Belgium|Charles University, Czech Republic, Praha, Czechia|General University Hospital, Prague, Praha, Czechia|Copenhagen University Hospital at Herlev, Copenhagen, Denmark|University Hospital, Bordeaux, Bourdeaux, France|Hospices Civils de Lyon, Lyon, France|University Hospital, Montpellier, Montpellier, France|Henri Mondor University Hospital, Paris, France|Paris South University Hospitals, Paris, France|Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France|Rennes University Hospital, Rennes, France|University Hospital, Aachen, Aachen, Germany|German Heart Center, Berlin, Germany|Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany|Children's Medical Hospital, University of Essen, Essen, Germany, Essen, Germany|University Hospital, Essen, Essen, Germany|University Heart Center Freiburg - Bad Krozingen, Freiburg, Germany|Hannover Medical School, Hannover, Germany|Klinikum Kassel, Kassel, Germany|Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Germany|Heart Center Leipzig - University Hospital, Leipzig, Germany|Klinikum N\u00fcrnberg, N\u00fcrnberg, Germany|University Hospital Regensburg, Regensburg, Germany|University Hospital Tuebingen, Tuebingen, Germany|University Hospital, Alexandroupolis, Alexandroupolis, Greece|Heim Pal Children's Hospital, Budapest, Hungary|ECMO Centers Israel, Jerusalem, Israel|San Giorgio Clinic, Alessandria, Italy|Ospedali Riuniti Ancona, Ancona, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|St. Orsola Hospital, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Ospedale Maurizio Bufalini, Cesena, Italy|Gaslini Children's Hospital, Genua, Italy|G. Pasquinucci Heart Hospital, Massa, Massa, Italy|Policlinico Hospital Milan, Milano, Italy|Niguarda Hospital, Milan, Italy|Ospedale San Donato, Milan, Italy|San Raffaele University Hospital, Italy, Milan, Italy|San Gerardo Hospital, Monza, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy|GVM Care & Research, Puglia, Italy|Bambino Ges\u00f9 Hospital and Research Institute, Roma, Italy|San Camillo Hospital, Rome, Roma, Italy|A.O.U. Citt\u00e0 della Salute e della Scienza - Molinette Hospital, Turin, Italy|Mauriziano Umberto I Hospital, Turin, Italy|Ospedale S. Giovanni Bosco, Turin, Italy|University Hospital, Udine, Italy, Udine, Italy|Ospedale dell'Angelo, Venezia-Mestre, Venice, Italy|Ospedale San Bortolo di Vicenza, Vicenza, Italy|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|University of Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Medical University of Warsaw, Warsaw, Poland|Hospital Sao Joao, Porto, Portugal|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|City Hospital No 41, Ekaterinburg, Russia, Ekaterinburg, Russian Federation|Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash, Kemerovo, Russian Federation|Krasnodar Regional Hospital no 1, Krasnodar, Russian Federation|City Clinical Hospital No. 67, Moscow, Russia, Moscow, Russian Federation|Novosibirsk City Hospital #2, Novosibirsk, Russian Federation|City Hospital No 40, Saint Petersburg, Russia, Saint Petersburg, Russian Federation|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Miguel Servet, Zaragoza, Spain|Lund University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital, Basel, Switzerland, Basel, Switzerland|University of Bern, Bern, Switzerland|University Hospital, Geneva, Geneva, Switzerland|University of Lausanne Hospitals, Lausanne, Switzerland|Cardiocentro Ticino, Lugano, Switzerland|Klinik Hirslanden, Zurich, Z\u00fcrich, Switzerland|University of Zurich, Z\u00fcrich, Switzerland|Royal Brompton & Harefield NHS Foundation Trust, Brompton, United Kingdom|Paediatric Intensive Care Glasgow, Glasgow, United Kingdom|Leicester Children's Hospital, Leicester, United Kingdom|Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Age|Gender|Weight|Height|BMI|Pre-existing pulmonary disease y\/n|Main co-morbidities y\/n|Date of signs of COVID-19 infection|Date of positive swab|Pre-ECMO length of hospital stay|Pre-ECMO length of ICU stay|Pre-ECMO length of mechanical ventilation days|Use of antibiotics|Use of anti-viral treatment|Use of second line treatment|Indications for ECMO-implant|Type of ECMO-implant|Type of access|Date of ECMO implant|ECMO blood flow rate|ECMO gas flow rate|ECMO configuration change|Date of ECMO configuration change|New ECMO configuration|Indications for ECMO configuration change|Ventilator setting on ECMO|Anticoagulation during ECMO|Frequency of ECMO circuit change|ECMO complications|ECMO Weaning|ICU discharge|Main cause of death|Type of discharge|Alive\/deceased""}"
"3683","Effect of Covid-19 Epidemic on Primary PCI in Patients With STEMI","","NCT04427735","BFH-COVID-19 and Primary PCI","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04427735","Recruiting","2019-01-24","2021-07-24","{""locations"":""Beijing Friendship Hospital, Capital Medical University, Beijing, China"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""MACE (major adverse cardiovascular events)|all-cause death""}"
"3684","Serology COVID-19 From the Cornwall Hospital Union","ROCOCO","NCT04363593","29BRC20.0122","Biological: Serological test|Biological: Serum test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363593","Completed","2020-05-04","2020-11-16","{""locations"":""CH de Cornouaille, Quimper, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""2587"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serological test evaluation|Population seroprevalence""}"
"3685","Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19","CLUSCO","NCT04379544","843008","Other: Observation only","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379544","Active, not recruiting","2020-04-23","2021-12-01","{""locations"":""University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""125"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient requires invasive mechanical ventilation and suffers from acute respiratory failure.|Patient is discharged|Patient is hospitalized, but does not require mechanical ventilation through the duration of hospital stay.|Lung ultrasound findings|Cardiac ultrasound findings""}"
"3686","Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU","RECOVER","NCT04569266","RECOVER","Other: specific exercise rehabilitation treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04569266","Recruiting","2020-08-07","2022-05-07","{""locations"":""Groupe Hospitalier Paris Saint Joseph, Paris, Ile-de-France, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the effect of exercise rehabilitation on post-ICU dyspnea|Evaluate the effect of exercise rehabilitation on functional dyspnea|Evaluate the effect of stress rehabilitation on quality of life""}"
"3687","Assocation Between In-person Instruction and COVID-19 Risk","Campus&Corona","NCT04529421","172155","Behavioral: Online instruction|Behavioral: In-person instruction","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04529421","Enrolling by invitation","2020-09-04","2021-08-01","{""locations"":""Oslo Metropolitan University, Oslo, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""70000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 incidence|Quality of life|Satisfaction with teaching|COVID-19 testing incidence|Learning outcome""}"
"3688","COVID-19 - Implications on Surgeons' Burnout and Career Satisfaction","SURG-SAT-19","NCT04433286","SURG RES COL 1","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433286","Not yet recruiting","2020-06-15","2020-08-31","{""locations"":""Faculty of Medicine Mansoura University, Mansoura, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in Burnout before COVID-19 and during COVID-19|Change in Job satisfaction before COVID-19 and during COVID-19""}"
"3689","Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS)","","NCT04503057","PEx ARDS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04503057","Recruiting","2020-05-01","2024-05-01","{""locations"":""Region Sk\u00e5ne, Lund, Sk\u00e5ne L\u00e4n, Sweden"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""16 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""COVID-19 RT-PCR detection in EBP|Detection of proteins biomarkers in EBP|Particle flow rate as an early indicator for lung injury""}"
"3690","Effects of COVID-19 Pandemic on the Diagnosis and Outcomes of Colorectal Cancer (COVID-CRC)","COVID-CRC","NCT04712292","854/2020/Oss/AOUBo","Procedure: Surgical procedure for cancer","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04712292","Recruiting","2020-09-08","2021-02-28","{""locations"":""Rho Memorial Hospital, Rho, Milan, Italy|Humanitas Research Center, Rozzano, Milan, Italy|Humanitas Gavazzeni Hospital, Bergamo, Italy|Policlinico San Marco, Bergamo, Italy|Maggiore Hospital, Bologna, Italy|Fondazione Poliambulanza, Brescia, Italy|Spedali Civili, Brescia, Italy|Spedali Civili, Brescia, Italy|Istituto Europeo di Oncologia, Milan, Italy|Sacco Hospital, Milan, Italy|San Raffaele Hospital, Milan, Italy|Istituto Nazionale dei Tumori, Milan, Italy|Policlinic of Milan, Milan, Italy|San Paolo Hospital, Milan, Italy|Istituto Oncologico Veneto, Padova, Italy|Padova University Hospital, Padova, Italy|San Matteo Hospital, Pavia, Italy|Citt\u00e0 della salute, Turin, Italy|Mauriziano Hospital, Turin, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Oncologic stage according to TNM classification|30-day outcome""}"
"3691","MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay","MejoraCare_P","NCT04659746","PINV 20-9","Device: MejoraCare","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04659746","Recruiting","2020-12-09","2021-12-09","{""locations"":""Hospital Regional de Encarnaci\u00f3n, Encarnaci\u00f3n, Itap\u00faa, Paraguay"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""96"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change on Health-related Quality of Life|MejoraCare app Usability|Satisfaction with the MejoraCare app|Change in Self-efficacy|Change in Anxiety|Change in Depression|Change in Health Empowerment|Change in Coping with Stress""}"
"3692","Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images","PREDISCAN","NCT04483752","2020-A01322-37","Other: CHEST CT SCAN","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04483752","Recruiting","2020-06-08","2021-11-08","{""locations"":""H\u00f4pital Marie Lannelongue, Le Plessis-Robinson, France|H\u00f4pital Saint Joseph, Paris, France|Institut Gustave Roussy (IGR), Villejuif, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""description of the different types of lesions|quantification of circulating antibodies and correlation between the level of immunization against SARS CoV2, the severity of the initial disease and the existence or not of long-term pulmonary sequelae""}"
"3693","COVID-19 - Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c (Infusion)","","NCT04631666","Uni-Koeln-4288","Biological: human monoclonal antibody DZIF-10c (Group 1A-2D)|Other: Placebo (NaCl 0.9%) (Group 2D)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04631666","Not yet recruiting","2020-11-23","2021-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""69"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Reactogenicity Adverse Events [Safety and Tolerability]|Pharmacokinetic parameter AUC0-672|Pharmacokinetic parameter tmax|Pharmacokinetic parameter AUC0-inf|Pharmacokinetic parameter Cmax|Pharmacokinetic parameter t1\/2|Pharmacokinetic parameter CL|Pharmacokinetic parameter Vss|Pharmacokinetic parameter Vz|Anti-Drug Antibodies|Viral Shedding nasopharyngeal|Viral Shedding oropharyngeal|Viral Shedding Determined by the Isolation of Infectious Virus|Viral Replication Determined by Subgenomic SARS-CoV-2 mRNA|Frequency of COVID-19-related hospitalizations and medically-attended contacts|Duration of COVID-19 symptoms|Activity and Frequency of SARS-CoV-2-reactive immune responses""}"
"3694","Neuro-COVID-19: Neurological Complications of COVID-19","Neuro-COVID","NCT04418609","Neuro-COVID-19","Other: further processing of health data","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04418609","Recruiting","2020-05-01","2022-05-30","{""locations"":""University Hospital Zurich, Z\u00fcrich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of neurological complications|Prevalence and outcome of severe neurological complications|Impact of neurological complications|Characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF)|Brain for pathological changes and histopathological findings (if patient dies).""}"
"3695","COVID-19 - Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c (Inhalation)","","NCT04631705","Uni-Koeln-4370","Biological: human monoclonal antibody DZIF-10c (Group 1A-2D)|Other: Placebo (NaCl 0.9%) (Group 2D)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04631705","Not yet recruiting","2020-11-23","2021-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""69"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Reactogenicity Adverse Events [Safety and Tolerability]|Pharmacokinetic parameter AUC0-672|Pharmacokinetic parameter tmax|Pharmacokinetic parameter AUC0-inf|Pharmacokinetic parameter Cmax|Pharmacokinetic parameter t1\/2|Pharmacokinetic parameter CL|Pharmacokinetic parameter Vss|Pharmacokinetic parameter Vz|Anti-Drug Antibodies|Viral Shedding nasopharyngeal|Viral Shedding oropharyngeal|Viral Shedding Determined by the Isolation of Infectious Virus|Viral Replication Determined by Subgenomic SARS-CoV-2 mRNA|Frequency of COVID-19-related hospitalizations and medically-attended contacts|Duration of COVID-19 symptoms|Activity and Frequency of SARS-CoV-2-reactive immune responses""}"
"3696","Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19","","NCT04352985","SDI-PMX-013","Device: Toraymyxin PMX-20R (PMX Cartridge)","Expanded Access:Intermediate-size Population","No Results Available","","https://ClinicalTrials.gov/show/NCT04352985","Available","1970-01-01","1970-01-01","{""locations"":""University of Connecticut Health Center, Farmington, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|Stony Brook University Hospital, Stony Brook, New York, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"3697","Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia","CONNECTDEM","NCT04385797","CONNECT DEM","Other: Telephone interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385797","Active, not recruiting","2020-05-04","2020-12-31","{""locations"":""Instituto de Investigacion Biomedica de Malaga-IBIMA, M\u00e1laga, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""200"",""age"":""55 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on quality of life in Alzheimer\u00b4s Disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.|Change on caregiver burden prior to, during and after confinement.|Change on healthcare and social support services access prior to, during and after confinement.|Change from health, cognitive, social, informative and entertainment related uses of ICT during and after confinement.""}"
"3698","The Global PCHF-COVICAV Registry","PCHF-COVICAV","NCT04390555","PCHF-COVICAV","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04390555","Recruiting","2020-04-30","2021-07-01","{""locations"":""Zurich Heart Center, Unispital Zurich, Zurich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-hospital mortality.|The length of stay in the intensive care unit.|The duration of hospitalization.|The need and duration of invasive mechanical ventilation.|Hospitalization for cardiovascular causes or cardiovascular deaths within 3 months after hospitalization.|Hospitalization for cardiovascular causes or cardiovascular deaths within 6 months after hospitalization.""}"
"3699","Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic","ASPIRE","NCT04388605","20-30559","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388605","Recruiting","2020-04-21","2022-09-01","{""locations"":""University of California, San Francisco, San Francisco, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""11000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of SARS-CoV-2 infection throughout pregnancy in women|Incidence of SARS-CoV-2 infection throughout pregnancy in women|Risk ratios of adverse obstetric in women infect with SARS-CoV-2 during early pregnancy onward compared to non-infected pregnant women|Risk ratios of adverse neonatal outcomes in women infected with SARS-CoV-2 during early pregnancy onward compared to non-infected pregnant women|Clinical, behavioral, and sociodemographic determinants""}"
"3700","Toclizumam Versus Dexamethasone in Severe Covid-19 Cases","","NCT04519385","SouthVU","Drug: Tocilizumab|Drug: Dexamethasone","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04519385","Completed","2020-03-01","2020-08-05","{""locations"":""Qena faculty medicine, Qin\u0101, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""69"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants with Overall Survival at 14 days|Fio2\/Pao2""}"
"3701","Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial","CPC-SARS","NCT04405310","DI/20/201/04/19","Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04405310","Completed","2020-05-20","2020-12-10","{""locations"":""Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA (sequencial Organ Failure Assesment)""}"
"3702","The COVID-19 Pandemic and Exercise Study","COPE","NCT04400279","H20-01497","Behavioral: Yoga group|Behavioral: High Intensity Interval Training group|Behavioral: Combination","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04400279","Completed","2020-06-01","2020-11-28","{""locations"":""University of British Columbia, Vancouver, British Columbia, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""334"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Changes in depressive symptomology over the course of the exercise intervention|Changes in psychological stress as measured by the SCSQ over the course of the exercise intervention.|Changes in psychological distress as measured by the K10 over the course of the exercise intervention.|Changes in flourishing over the course of the exercise intervention|Changes in resilience over the course of the exercise intervention|Changes in life satisfaction over the course of the exercise intervention|Changes in weekly strain as a result of health problems, financial\/work issues, and relationship trouble using the Chronic Burden Scale over the course of the exercise intervention.|Changes in general affect over the course of the exercise intervention|Changes in leisure time physical activity over the course of the exercise intervention|Changes in physical health symptomology over the course of the exercise intervention|Changes in alcohol habits over the course of the exercise intervention|Tracking the amount of exercise variety participants feel they engage in""}"
"3703","Extracellular Water in Covid 19 Pneumonia","","NCT04416009","76","Device: NİCaS","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416009","Recruiting","2020-07-05","2021-02-20","{""locations"":""Gaziosmanpa\u015fa TREH, Istanbul, Gaziosmanpa\u015fa, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""52"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ECW""}"
"3704","Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)","SequelaeCov","NCT04435327","SequelaeCov","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04435327","Recruiting","2020-08-17","2021-04-01","{""locations"":""San Gerardo Hospital, Monza, MB, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction of Diffusion of Lung CO (DLCO, single breath technique)|Alterations in 6 minute walking test (6MWT)|Alterations of pletismography|Alterations of Arterial Blood Gas Analysis|Abnormal Dyspnea Score|Presence and extension of abnormal pulmonary lung sounds at auscultation|Presence and extension of radiological alterations at chest X-ray|Presence and extension of radiological alterations at chest CT scan""}"
"3705","Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment","","NCT04416919","11887","Other: Assembled mask","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04416919","Active, not recruiting","2020-05-20","2021-07-01","{""locations"":""Oklahoma City VA Health Care System, Oklahoma City, Oklahoma, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Success Percentage|End-tidal CO2 Variation. Description: mmHg.|Oxygen Pulse Oximetry Variation. Description: mmHg.|Mask Visibility. Description: Likert Scale.|Willingness of usage. Description: Likert Scale.""}"
"3706","The COVID-19 and Healthcare Workers: An Active Intervention","","NCT04497415","8032","Other: Video-Based intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04497415","Recruiting","2020-10-21","2021-01-30","{""locations"":""New York State Psychiatric Institute, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research"",""enrollment"":""1200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Help-seeking behavior|GAD-7|PHQ-9|PC-PTSD|Moral Injury""}"
"3707","Influence of the COVId-19 Pandemic on STRESS of Occupational Health Workers","COVISTRESSWork","NCT04619576","2020 COVISTRESS Work","Behavioral: Occupational health workers","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04619576","Recruiting","2020-06-01","2025-12-21","{""locations"":""Clermont-Ferrand University Hospital, Clermont-Ferrand, Aura, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""10 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Stress measures|Sociodemographic characteristics|occupation perception|work conditions|Changes in practices""}"
"3708","Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis","","NCT04475081","PF-1214","Biological: MMR vaccine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04475081","Not yet recruiting","2020-08-17","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Induction of myeloid-derived suppressor cells (MDSCs)|Induction of MDSCs|COVID-19 infection positive|Health questionnaire""}"
"3709","Immunity and Infections in the Psychiatric Population","COVIDIMMUNOPSY","NCT04381845","APHP200553","Diagnostic Test: COVID19 immunization testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04381845","Not yet recruiting","2020-12-10","2021-03-10","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of COVID-positive patients""}"
"3710","Addressing COVID-19 Mental Health Problems Among US Veterans","","NCT04484207","8006","Other: A short video intervention|Other: A vignette intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04484207","Recruiting","2020-07-06","2020-10-26","{""locations"":""New York State Psychiatric Institute, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research"",""enrollment"":""200"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Help seeking behavior|Generalized Anxiety Disorder (GAD-7)|Patient Health Questionnaire-9|The Primary Care PTSD Screen for DSM-5 (PC-PTSD)""}"
"3711","Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQuébec Sub-study","","NCT04371848","2018-042Phase IIA6/09-04-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371848","Completed","2020-04-16","2020-05-07","{""locations"":""Universit\u00e9 Laval, Qu\u00e9bec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2465"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in diet quality|Change in food insecurity|Change in intake of sodium|Change in intake of sugar|Change in intake of saturated fat|Change in intake of vegetables and fruits|Change in intake of dairy products|Change in physical activity|Change in sleep quality|Change in health-related quality of life""}"
"3712","Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry","CONFIDODO","NCT04370210","CHRD 0520","Behavioral: Questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370210","Completed","2020-05-04","2020-06-04","{""locations"":""Centre Hospitalier Ren\u00e9 Dubos, Pontoise, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""247"",""age"":""7 Years to 12 Years \u00a0 (Child)"",""outcome_measures"":""Comparison of sleep quality during COVID-19 containment between children usually followed in child psychiatry and children without follow-up|Assessment of child depression in both groups|Assessment of child anxiety in both groups|Assessment of the influence of socio-demographic factors on sleep in both groups|Measure of the correlation between child sleep quality and parents sleep quality (anxiety level) in both groups|Assessment of sleep disturbance based on psychiatry diagnoses in the group of children usually followed in child psychiatry|Assessment of child anxiety based on psychiatry diagnoses in the group of children usually followed in child psychiatry|Assessment of child depression based on psychiatry diagnoses in the group of children usually followed in child psychiatry""}"
"3713","COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients","COMS-19","NCT04498286","NL74243.029.20","Diagnostic Test: Testing of SARS-CoV-2 antibodies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04498286","Recruiting","2020-08-06","2021-12-01","{""locations"":""VU medical center, Amsterdam, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The correlation of COVID-19 disease course with MS immunomodulatory treatment""}"
"3714","Exercise Influence on COVID-19","","NCT04624048","08112020","Diagnostic Test: COVID-19 survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04624048","Not yet recruiting","2020-12-04","2021-04-04","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Retrospective"",""enrollment"":""30000"",""age"":""17 Years to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Impact of COVID-19|Influence of exercise in COVID-19 infection|Change in the practice of physical exercise after home confinement""}"
"3715","Moral Judgements and Choices of Caregivers in the Time of COVID-19 Pandemic","XPHI-COVID19","NCT04542122","1474","Behavioral: Choices and judgements","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04542122","Not yet recruiting","2020-09-03","2021-08-02","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""500"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxford Utilitarianism Scale""}"
"3716","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases","","NCT04335747","20200401","Other: COVID-19 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04335747","Recruiting","2020-04-23","2021-09-01","{""locations"":""Aalborg University Hospital, Aalborg, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""333"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease activity|Immune modulating treatments|Biomarkers""}"
"3717","Covid-19 Pandemic and Pancreatic Surgery in Italy","PanCOVID","NCT04380766","FPGemelliIRCCS","Procedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380766","Completed","2019-01-01","2020-07-31","{""locations"":""Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma, Roma, Lazio, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""730"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in pancreatic cancer management during the COVID-19 pandemic""}"
"3718","Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America","","NCT04486404","08/04/2020","Other: Online survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04486404","Enrolling by invitation","2020-04-01","2020-11-30","{""locations"":""Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina|Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile|Universidad de Santander, Bucaramanga, Santander, Colombia|Universidad Cat\u00f3lica de Santiago de Guayaquil, Guayaquil, Guayas, Ecuador|Universidad Miguel Hern\u00e1ndez de Elche, Elche, Alicante, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of Acute Stress""}"
"3719","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","ACTCOVID19","NCT04324463","PHRI.ACT.COVID19","Drug: Colchicine|Drug: Interferon-Beta|Drug: Aspirin|Drug: Rivaroxaban","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04324463","Recruiting","2020-04-21","2021-06-30","{""locations"":""Prodal Saude S\/A, Salvador, BA, Brazil|Hospital das Clinicas de Vitoria (Hospital Universitario Cassiano Antonio Moraes), Vitoria, ES, Brazil|Hospital das Clinicas da Universidade Federal de Goias, Goiania, GO, Brazil|Ubermed Servi\u00e7os em Sa\u00fade Eireli - Hospital S\u00e3o Domingos, Uberaba, MG, Brazil|Hospital de Cl\u00ednicas da Universidade Federal de Uberl\u00e2ndia, Uberl\u00e2ndia, MG, Brazil|Hospital Universitario Julio Muller, Cuiab\u00e1, Mount, Brazil|Hospital Universitario da UFPI - Filial EBSERH, Teresina, PI, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, RJ, Brazil|Hospital Universitario Prof. Dr. Horacio Carlos Panepucci da Universidade Federal de Sao Carlos (HU-UFSCar), S\u00e3o Carlos, SP, Brazil|Hospital Alem\u00e3o Oswaldo Cruz, S\u00e3o Paulo, SP, Brazil|Hospital de Doencas Tropicais - HDT\/UFT, Araguaina, TO, Brazil|Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|CIUSSS de L'est-de-l'ile de Montreal, Hopital Maisonneuve-Rosemont, Montreal, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|Halton Healthcare\/Oakville Trafalgar Memorial Hospital, Oakville, Ontario, Canada|Niagara Health System-St. Catharine's, St. Catharines, Ontario, Canada|Toronto Western Hospital Family Health Team, Toronto, Ontario, Canada|Windsor Regional Hospital, Windsor, Ontario, Canada|Woodstock Hospital, Woodstock, Ontario, Canada|Estudios Clinicos Barros Luco Spa, Santiago, Region Metropolitana, Chile|Hospital El Pino, Santiago, Region Metropolitana, Chile|Biomelab SAS, Barranquilla, Atlantico, Colombia|Clinica de la Costa LTDA, Barranquilla, Atlantico, Colombia|Hospital Universidad del Norte, Barranquilla, Atlantico, Colombia|Centro de Diagnostico Cardiologico, Cartagena, Bolivar, Colombia|Clinica de Marly - Sede UniMarly, Bogota, Cundinamarca, Colombia|Fundacion Cometa, Pasto, Narino, Colombia|Fundacion Cardiomet CEQUIN, Armenia, Quindio, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Bucaramanga, Santander, Colombia|Fundacion Centro de Investigaciones Biomedicas Riescard, El Espinal, Tolima, Colombia|Clinica Internacional La Misericordia, Barranquilla, Colombia|Unicormed, Guayaquil, Guayas, Ecuador|Hospital de Especialidades Eugenio Espejo, Quito, Pichincha, Ecuador|Hospital Enrique Garces, Quito, Pichincha, Ecuador|Hospital General Docente de Calderon, Quito, Pichincha, Ecuador|Hospital General Pablo Arturo Suarez, Quito, Pichincha, Ecuador|Giza Chest Hospital, Giza, Cairo, Egypt|Al Rajhi University Hospital, Assiut, Egypt|Abbasia Chest Hospital, Cairo, Egypt|Abbasia Fever Hospital, Cairo, Egypt|National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt|Fayoum General Hospital, Fayoum, Egypt|Fayoum University Hospital, Fayoum, Egypt|CIMS Hospital, Ahmedabad, Gujarat, India|City Plus Hospital, Ahmedabad, Gujarat, India|Sanjivani Hospital, Ahmedabad, Gujarat, India|GMERS Medical College & Hospital, Vadodara, Gujarat, India|Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India|Mazumdar Shaw Medical Centre a Unit of Narayana, Bangalore, Karnataka, India|Bharathi Hospital and Research Center, Pune, Maharashtra, India|Sidhu Hospital Pvt.Ltd, Doraha, Punjab, India|Vijaya Medical & Educational Trust, Chennai, Tamil Nadu, India|SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India|AIG Hospital, Hyderabad, Telangana, India|KIMS, Hyderabad, Telangana, India|Mahavir Hospital & Research Centre, Hyderabad, Telangana, India|Jinnah Postgraduate Medical Center, Karachi, Pakistan|Tabba Heart Institute, Karachi, Pakistan|Philippine General Hospital, Manila, Metro Manila, Philippines|Altai Regional Center for Medical Prevention, Barnaul, Russian Federation|Altai Regional Hospital for War Veterans, Barnaul, Russian Federation|City Clinical Hospital No. 15 named after O.M. Filatova, Moscow, Russian Federation|National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation|City Clinical Hospital No. 10, Nizhny Novgorod, Russian Federation|City Clinical Hospital No. 3, Nizhny Novgorod, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|King Saud Medical City, Riyadh, Saudi Arabia|Thumbay Hospital Dubai, Al Qusais, Dubai, United Arab Emirates|Hatta Hospital, Hatta, Dubai, United Arab Emirates|Rashid Hospital, Dubai Health Authority, Umm Hurair, Dubai, United Arab Emirates"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Outpatient trial - Colchicine vs. control and Aspirin vs. control|Inpatient trial - Interferon-\u03b2 vs. control and Colchicine vs. control|Inpatient trial - Aspirin and rivaroxaban vs. control|Outpatient and Inpatient trials - Colchicine vs. control, Interferon-\u03b2 vs. control|Outpatient and Inpatient trials - Aspirin vs. control, Aspirin and rivaroxaban vs. control""}"
"3720","Determinants of COVID-19 Pneumonia (MC-19)","MC-19","NCT04387799","20200505","Diagnostic Test: Serology for Covid-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387799","Completed","2020-05-13","2020-06-17","{""locations"":""Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""520"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serology|Efficacy of CT scan and Serology|Efficacy of different pharmaceutical treatments""}"
"3721","Parental Stress During the COVID-19 Pandemic and Its Association With Depression and Anxiety","","NCT04377074","REK125510(3)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377074","Completed","2020-03-31","2020-04-07","{""locations"":""University of Oslo, Oslo, Norway"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""2880"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure of parental stress|Patient Health Questionnaire 9|Generalized Anxiety Disorder 7""}"
"3722","COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease","FAMICOV","NCT04511949","CREPATS 012","Diagnostic Test: COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04511949","Completed","2020-07-12","2020-11-30","{""locations"":""Christine KATLAMA, Paris, Ile De France, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""500"",""age"":""3 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Measure of the proportion of contact persons who have developed anti-SARS-CoV-2 antibodies (secondary transmission rate) within the same household of a subject who had a COVID-19 disease assessed by a rapid diagnostic-oriented test""}"
"3723","Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease","ColchiVID","NCT04367168","337420-21-1","Drug: Colchicine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04367168","Recruiting","2020-05-27","2021-04-27","{""locations"":""Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""174"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of patients with improvement in body temperature, myalgia, arthralgia, total lymphocyte count, D-dimer, fibrinogen and ferritin levels|Progression to severe disease""}"
"3724","LIBERATE Trial in COVID-19","LIBERATE","NCT04334629","282009","Drug: Ibuprofen","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04334629","Recruiting","2020-05-26","2021-09-25","{""locations"":""Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease progression|Time to mechanical ventilation|Overall survival|Reduction in proportion of patients who require ventilation|Reduction in length of Critical Care stay|Reduction in length of Hospital stay|Modulation of serum pro- and anti-inflammatory cytokines|Reduction in duration of ventilation|Increase in ventilator-free days""}"
"3725","COVID-19 Health Professional Impact Study","CHIP","NCT04527432","2020COV112","Other: Survey|Diagnostic Test: SARS-CoV-2 antibody test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04527432","Recruiting","2020-12-16","2022-03-31","{""locations"":""The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""3000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The number of employees tested who have evidence of SARS-CoV-2 antibodies|Factors associated with a positive test|Likelihood of clinically relevant (causing illness) infection with SARS-CoV-2 in subjects with both positive and negative SARS-CoV-2 antibody tests""}"
"3726","Influence of the COVId-19 Pandemic on the STRESS of Dental Surgeons (COVISTRESS - Dental Surgery)","","NCT04541472","2020 COVISTRESS Dental Surgery","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04541472","Recruiting","2020-05-01","2020-12-01","{""locations"":""University Hospital, Clermont Ferrand, Clermont-Ferrand, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Stress measures|Sociodemographic characteristics|occupation perception|work conditions|Changes in practices""}"
"3727","COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS)","","NCT04614844","2000029372|1R01HS028340-01","Behavioral: Simulation Intervention|Behavioral: Control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04614844","Recruiting","2021-01-06","2022-11-15","{""locations"":""Yale New Haven Hospital, New Haven, Connecticut, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""84"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in end-of-shift heart rate variability|Change in STAI S-Anxiety|Change in STAI T-Anxiety""}"
"3728","Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)","ISCA","NCT04383730","ISCA Study","Drug: Intravenous sedation|Drug: Inhaled sedation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383730","Recruiting","2020-06-26","2021-05-31","{""locations"":""Beth Israel Deaconess Medical Center, Inc., Boston, Massachusetts, United States|CHU, Brest, France|CHU, Clermont-Ferrand, France|Centre Hospitalier, Dunkerque, France|Piti\u00e9-Salp\u00eatri\u00e8re Hospital - APHP, Paris, France|CH Priv\u00e9 de la Loire, Saint-\u00c9tienne, France|Universit\u00e4tsklinikum, Bochum, Germany|University Medical Center Schleswig-Holstein, Kiel, Germany|Universit\u00e4tsklinikum, Oldenburg, Germany|Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain|Cantonal Hospital, M\u00fcnsterlingen, Switzerland|Universit\u00e4tsspital, Z\u00fcrich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days off the ventilator (VFD28, for ventilator-free days), taking into account death as a competing event|All-cause mortality|Ventilator-free days|ICU-free days|Duration of invasive mechanical ventilation|Duration of controlled mechanical ventilation|Physiological measures of lung function|Development of complications|Duration of vasopressor use|Duration of renal replacement therapy|Duration (in days) of any adjuvant therapies|Duration of continuous neuromuscular blockade|Type of sedation practices|Duration of sedation practices|Modalities of sedation practices""}"
"3729","Physical Activity in University Students Around COVID-19 Confinement","","NCT04361019","Covid_PA2020","Other: On-Line Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04361019","Recruiting","2020-04-16","2020-10-20","{""locations"":""Basque Country University (UPV-EHU),, Bilbao, Bizkaia, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":"": International Physical Activity Questionnaire - Short Form|Pittsburgh Sleep Quality Index: Subjective Sleep Quality and Sleep Duration domains|Short Form 36 Health Survey: Bodily Pain domain|EuroQol 5D: Self rated health""}"
"3730","Attitudes Towards Receiving Mental Health Care Using Telehealth During the COVID-19 Pandemic","","NCT04693052","STU00213696","Other: No interventions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04693052","Enrolling by invitation","2020-12-10","2021-06-30","{""locations"":""Feinberg School of Medicine, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient choosing telehealth as an option for future care|Comparison between in-person and telehealth|Patient Satisfaction with telehealth|Patient Comfort using telehealth|Patient Easy of using telehealth""}"
"3731","Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards","","NCT04544072","2020-163","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04544072","Recruiting","2020-05-01","2021-03-01","{""locations"":""UZ Brussel, Brussel, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total antimicrobial consumption for suspicion of secondary bacterial respiratory infections in hospitalized patients in COVID wards with a clinical or PCR-based COVID diagnosis, expressed as 'Daily defined doses\/hospitalization'.|Total antimicrobial consumption for suspicion of secondary bacterial respiratory infections in hospitalized patients in COVID wards with a clinical or PCR-based COVID diagnosis, expressed as 'Daily defined doses\/1000 hospitalized patient days'.|Total antimicrobial consumption for suspicion of secondary bacterial respiratory infections in hospitalized patients in COVID wards with a clinical or PCR-based COVID diagnosis, expressed as 'Daily doses of administration\/hospitalization'.|Total antimicrobial consumption for suspicion of secondary bacterial respiratory infections in hospitalized patients in COVID wards, expressed as 'Daily doses of administration (DDA)\/1000 hospitalized patient days'.|The degree of appropriateness of antimicrobial prescriptions for presumed respiratory tract (super)infection|The degree of appropriateness of antimicrobial prescriptions for presumed respiratory tract (super)infection, denominator 2|Rate of Clostridioides Difficile infections|Is there a significant difference in age comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|Is there a significant difference in weight comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in amount of comorbidities comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in rate of chronical pulmonary disease as a comorbidity, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in rate of haematological or solid neoplasia as a comorbidity, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in rate of diabetes mellitus as a comorbidity, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in rate of patients with presence or not of at least one suggestive symptom of COVID-19 symptomatology, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in rate of patients with recent AB prescription, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|Is there a significant difference in the rate of patients having had at least one positive significant respiratory germ culture, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|Is there a significant difference in the rate of patients needing oxygen supletion at day 1 of hospitalization, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean duration of hospitalization, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the rate of ICU admission, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|Is there a significant difference in the mean value of oxygen saturation percentage over fractional oxygen percentage, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|Is there a significant difference in qSOFA score level at admission, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|Is there a significant difference in the rate of lymphopenia, comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of C-reactive protein measured at day 1 of hospitalization on a COVID-ward ,comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of white blood cell count measured at day 1 of hospitalization on a COVID-ward ,comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of neutrophil count measured at day 1 of hospitalization on a COVID-ward ,comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of lymphocyte count measured at day 1 of hospitalization on a COVID-ward ,comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of creatinine measured at day 1 of hospitalization on a COVID-ward ,comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of LDH measured at day 1 of hospitalization on a COVID-ward ,comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of bilirubin measured at day 1 of hospitalization on a COVID-ward ,comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of ferritin (first value during hospitalization),comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of troponins (first value during hospitalization),comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?|significant difference in the mean value of D-dimers (first value during hospitalization),comparing the group receiving antibiotics for a suspicion of COVID-19 superinfection and the group without antibiotics?""}"
"3732","Understanding COVID-19 Infection in Pregnant Women and Their Babies","periCOVID","NCT04703270","2020.0276","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04703270","Recruiting","2021-01-04","2023-01-03","{""locations"":""St George's, University of London, London, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody concentrations in maternal and cord blood in pregnant women in England and in infant blood if mothers are rtPCR positive for SARS-COV-2|Antibodies specific to SARS-CoV-2 in breastmilk|Mother-infant pairs who are both rtPCR positive in blood or secretions at birth|Breastmilk samples that are rtPCR positive|Placental samples that are rtPCR positive|Placental samples in whom the virus can be grown in vitro|Breastmilk samples in whom the virus can be grown in vitro.|Mother-infant pairs at six weeks in whom the virus can be grown in vitro""}"
"3733","Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak","","NCT04374097","REK125510(2)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374097","Completed","2020-03-31","2020-04-07","{""locations"":""University of Oslo, Oslo, Norway"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""1778"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PTSD Checklist for DSM-5 (PCL-5)|Patient Health Questionnaire 9 (PHQ-9)|The Generalized Anxiety Disorder 7 (GAD-7)|Health anxiety""}"
"3734","Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)","","NCT04377672","IRB00247557","Biological: Anti-SARS-CoV-2 Human Convalescent Plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04377672","Recruiting","2020-05-28","2022-05-28","{""locations"":""Johns Hopkins Hospitals, Baltimore, Maryland, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""1 Month to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events|Proportion of subjects with disease worsening event|Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers|Proportion of subjects with a natural antibody response to SARS-CoV-2 infection""}"
"3735","Reducing Burnout Among Frontline Healthcare Workers During COVID-19","RESTORE","NCT04474080","11136","Behavioral: Virtual Peer Support Platform|Behavioral: Control Period","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04474080","Not yet recruiting","2021-01-15","2021-07-01","{""locations"":""St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1080"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assess and measure overall burnout|Assess stress|Assess depression|Assess quality of life""}"
"3736","Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.","","NCT04381000","3","Other: Exercise Group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04381000","Completed","2020-04-01","2020-06-10","{""locations"":""Clinical Exercise Physiology and Rehabilitation Laboratory, Lamia, Sterea Ellada, Greece"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""170"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety and Depression|Quality of Life and overall health|Pain Intensity|Quality and patterns of sleep|Patients' illness perceptions|Disability""}"
"3737","COVID-19 and Psychotic Symptoms in France","SCHIZOVID-19","NCT04356885","RECHMPL20_0225","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356885","Completed","2020-04-01","2020-08-01","{""locations"":""UH Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total score of the Cardiff Anomalous Perceptions Scale (CAPS)|Paranoia Scale""}"
"3738","Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic","ONCOVID","NCT04340219","BC-07505-LGE","Other: Survey administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04340219","Completed","2020-03-30","2020-09-18","{""locations"":""University Hospital Gent, Gent, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""394"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs \u2265 29).|Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression); in terms of proportions (0-4 vs \u2265 5).|Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21-Anxiety); in terms of proportions (0-3 vs \u2265 4).|Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21-Stress); in terms of proportions (0-7 vs \u2265 8).|Distress measured at baseline by the CPDI; in terms of continuous values.|Depression at baseline measured by the DASS-21-Depression; in terms of continuous values.|Anxiety at baseline measured by the DASS-21-Anxiety; in terms of continuous values.|Stress at baseline measured by the DASS-21-Stress; in terms of continuous values.|Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREF-Physical health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Psychological health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Social relationships); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Environment); in terms of continuous values.|Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire-in terms of continuous values.|Change from baseline in distress measured by CDPI; in terms of continuous values.|Change from baseline in depression measured by the DASS-21-Depression; in terms of continuous values.|Change from baseline in anxiety measured by the DASS-21-Anxiety; in terms of continues values.|Change from baseline in stress measured by the DASS-21-Stress; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF-Physical health; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF-Psychological health; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF-Social relationship; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF-Environment; in terms of continuous values.|Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.|The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics""}"
"3739","Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC)","","NCT04546581","INSIGHT 013","Drug: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Other: Placebo|Drug: Remdesivir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04546581","Active, not recruiting","2020-10-08","2021-07-01","{""locations"":""Penrose Hospital, Colorado Springs, Colorado, United States|St. Francis Health Services, Colorado Springs, Colorado, United States|St. Anthony Hospital, Lakewood, Colorado, United States|Saint Anthony North Health Campus, Westminster, Colorado, United States|Washington VA Medical Center, Washington, District of Columbia, United States|Redmond Regional Medical Center, Rome, Georgia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Hennepin Healthcare Research Institute\/HCMC, Minneapolis, Minnesota, United States|University of Missouri, Columbia, Missouri, United States|Cox Medical Centers, Springfield, Missouri, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|Ohio Health Research Institute, Columbus, Ohio, United States|Hendrick Medical Center, Abilene, Texas, United States|CHRISTUS Spohn Shoreline Hospital, Corpus Christi, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|CJW Chippenham Medical Center, Richmond, Virginia, United States|Henrico Doctors' Hospital (HCA), Richmond, Virginia, United States|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|CHIP, Department of Infectious Diseases, Section 2100, Copenhagen, Denmark|Herlev-Gentofte Hospital, Hellerup, Denmark|Nordsj\u00e6llands Hospital, Hiller\u00f8d, Hiller\u00f8d, Denmark|Hvidovre University Hospital, Department of Infectious Diseases, Hvidovre, Denmark|Kolding Sygehus, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Democritus University of Thrace, Alexandroupoli, Thrace, Greece|3rd Dept of Medicine, Medical School, NKUA, Athens, Greece|1st Respiratory Medicine Dept, Athens University Medical School, Athens, Greece|Attikon University General Hospital, Athens, Greece|Dept. of Critical Care & Pulmonary Medicine, Evangelismos General Hospital, Athens, Greece|NCGM, Tokyo, Japan|Fujita Health University Hospital, Toyoake, Japan|Institute of Human Virology-Nigeria (IHVN), Abuja, Nigeria|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain|Hospital del Mar, Barcelona, Spain|Hospital Cl\u00ednic de Barcelona, Barcelona, Spain|Royal Free Hospital, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""593"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ordinal Outcome Scale - Day 7|All-cause mortality through Day 28|Ordinal Outcome Scale|Change in National Early Warning Score (NEWS)|Time to Worsening|Discharge Status|Days Alive Outside the Hospital|Pulmonary-only Components of the Primary Ordinal Outcome|Thrombotic Components of the Primary Ordinal Outcome|Time to recovery|Clinical Organ Dysfunction|Safety and Tolerability - Adverse Events|Safety and Tolerability - Infusion Reactions, Interruptions, or Cessation|Safety and Tolerability - Serious Adverse Events|Safety and Tolerability - Prevalence of Adverse Events|Change in Neutralizing Antibody Level""}"
"3740","High Flow Nasal Cannula HFNC In Covid-19 Patients","HFNC19LGH","NCT04560257","LGH004","Device: High flow nasal cannula HFNC","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04560257","Recruiting","2020-05-01","2020-12-30","{""locations"":""Muhammad Irfan Malik, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical response of HFNC|Duration of intervention|Duration of hospitalization|Supplemental Oxygen Requirement from Baseline|Radiological outcome""}"
"3741","Percutaneous Tracheostomy With COVID-19","","NCT04447638","TT17","Procedure: Tracheostomy with aerosol box in COVID-19 positive patients","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04447638","Completed","2020-03-20","2020-06-01","{""locations"":""Canakkale Onsekiz Mart University, Canakkale, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""24"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Complications observed in the cases in which we applied percutaneous tracheostomy with aerosol box""}"
"3742","COVID-19-associated Anxiety of Pregnant Women for Anomalies, Stillbirth and Preterm Labor","CAASP","NCT04568551","UKGEB001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568551","Recruiting","2020-10-01","2021-07-31","{""locations"":""University Hospital of Halle, Halle, Saxony Anhalt, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""anxiety for anomalies during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire)|anxiety for stillbirths during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire)|anxiety for preterm labour during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire)""}"
"3743","Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)","COVER-HCW","NCT04723576","COVID-2020C2-10721","Behavioral: Stress First Aid","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04723576","Recruiting","2020-12-03","2023-11-30","{""locations"":""Clinical Directors Network, Inc, New York, New York, United States|Vizient Inc., Irving, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research"",""enrollment"":""2132"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Posttraumatic Stress Disorder (PTSD)|PTSD|Psychological Distress|Sleep Impairment|Workplace stress|Resilience|Burnout|Moral Distress""}"
"3744","Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic","MindCOVID","NCT04377412","Maternal axiety and COVID-19","Other: Pandemic control measures","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377412","Recruiting","2020-05-01","2020-10-31","{""locations"":""Wayne State University, Detroit, Michigan, United States|University of Medicine Tirana, Tirana, Albania|Royal Prince Alfred Hospital, Sydney, Australia|Charles University, Prague, Czechia|Universit\u00e9 de Paris, Paris, France|Charit\u00e9 - University Medicine Berlin, Berlin, Germany|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Meir Medical Center, Kafr Saba, Israel|University of Brescia, Brescia, Italy|American University of Beirut, Beirut, Lebanon|The Arctic University of Norway, Troms\u00f8, Norway|Nicolaus Copernicus University in Toru\u0144, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland|Pomeranian Medical University, Szczecin, Poland|Centre of Postgraduate Medical Education, Warsaw, Poland|11. Fundaci\u00f3n Para la Investigaci\u00f3n y el Desarrollode la Medicina Materno-Fetal y Neonatal \""iMaterna\"", Madrid, Spain|Karolinska Institutet, Stockholm, Sweden|Taiji Clinic, Taipei, Taiwan"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""8500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety|Depression""}"
"3745","COVID-19 Vaccine Confidence Among Pregnant Women and Mothers","VCCOVID","NCT04694664","0003","Other: This is an online survey with no intervention.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694664","Completed","2020-10-01","2020-12-01","{""locations"":""Pregistry, Los Angeles, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""18000"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of acceptance of a COVID-19 vaccine""}"
"3746","Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection","EasyCov","NCT04583319","ST0194","Diagnostic Test: EasyCov POC","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04583319","Recruiting","2020-10-01","2021-03-01","{""locations"":""Istanbul University Istanbul Faculty of Medicine (ITF), Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positive percent agreement (PPA)|Performance""}"
"3747","The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients","CACOVID-19","NCT04397575","GCO002 CACOVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397575","Active, not recruiting","2020-04-03","2021-12-01","{""locations"":""Ch D'Abbeville, Abbeville, France|CHU - H\u00f4pital Sud, Amiens, France|CHU - H\u00f4tel Dieu, Angers, France|H\u00f4pital Priv\u00e9, Antony, France|CH Victor Dupouy, Argenteuil, France|CH - Metz Thionville Mercy, Ars-Laquenexy, France|H\u00f4pital G\u00e9n\u00e9ral d'Auch, Auch, France|Ch-Ght Unyon Auxerre, Auxerre, France|CH - Henri Duffaut, Avignon, France|PRIVE - Sainte Catherine, Avignon, France|CH, Bayeux, France|CH - C\u00f4te Basque, Bayonne, France|CH, Beauvais, France|CHU - Jean Minjoz, Besan\u00e7on, France|PRIVE - Franche Comt\u00e9, Besan\u00e7on, France|PRIVE - Centre Pierre Curie, Beuvry, France|CH, Blois, France|PRIVE - Tivoli, Bordeaux, France|CH - Duchenne, Boulogne-sur-Mer, France|CHU - Ambroise Par\u00e9, Boulogne, France|CH - Fleyriat, Bourg-en-Bresse, France|CHU - Morvan, Brest, France|CHU - Pierre Wertheimer, Bron, France|CH - Germon et Gauthier - Service de Gastroent\u00e9rologie, B\u00e9thune, France|CH, B\u00e9ziers, France|CHU - C\u00f4te de Nacre, Caen, France|PRIVE - Fran\u00e7ois Baclesse, Caen, France|CH, Calais, France|PRIVE - Infirmerie protestante, Caluire-et-Cuire, France|CH, Cannes, France|PRIVE - M\u00e9dipole de Savoie, Challes-les-Eaux, France|PRIVE - P\u00f4le Sant\u00e9 L\u00e9onard de Vinci, Chambray-l\u00e8s-Tours, France|CH, Charleville-M\u00e9zi\u00e8res, France|CH, Chauny, France|CHP du Cotentin, Cherbourg, France|CH, Cholet, France|CH, Ch\u00e2lons-en-Champagne, France|CH - HIA Percy, Clamart, France|CHU - Estaing, Clermont-Ferrand, France|PRIVE - CAC Jean PERRIN, Clermont-Ferrand, France|CHU - Beaujon, Clichy, France|CH - H\u00f4pitaux civils de Colmar, Colmar, France|CHU - Louis MOURIER, Colombes, France|CH - Compiegne, Compi\u00e8gne, France|PRIVE - Saint C\u00f4me, Compi\u00e8gne, France|CH - Sud Francilien, Corbeil-Essonnes, France|PRIVE - C\u00e9dres, Cornebarrieu, France|PRIVE - Clinique de Flandre, Coudekerque-Branche, France|CH - GHPSO Site de Creil, Creil, France|Ch - C.H.I.C., Cr\u00e9teil, France|CHU - Henri Mondor, Cr\u00e9teil, France|PRIVE - Centre L\u00e9onard de Vinci, Dechy, France|CHU - H\u00f4pital Fran\u00e7ois Mitterand, Dijon, France|PRIVE - CAC GF Leclerc, Dijon, France|PRIVE - Institut de Canc\u00e9rologie de Bourgogne GRReCC, Dijon, France|CH - Louis Pasteur, Dole, France|CH, Douai, France|CH - Victor Jousselin, Dreux, France|PRIVE - Clinique Claude Bernard, Ermont, France|CH - Frejus Saint Raphael, Fr\u00e9jus, France|PRIVE - Forcilles, F\u00e9rolles-Attilly, France|CH, Grasse, France|CHU - Grenoble Alpes, Grenoble, France|PRIVE - GHM Daniel Hollard, Grenoble, France|CH - Marne La Vall\u00e9e\/Jossigny, Jossigny, France|CH - CHD Vend\u00e9e, La Roche-sur-Yon, France|CH - Louis Pasteur, Le Coudray, France|PRIVE - L'Estuaire, Le Havre, France|PRIVE - Centre Jean Bernard, Le Mans, France|CH - Docteur Schaffner, Lens, France|CH - Saint Vincent, Lille, France|CHU - Claude Huriez, Lille, France|PRIVE - CAC Oscar Lambret, Lille, France|PRIVE - La Louvi\u00e8re Institut de Canc\u00e9rologie Lille M\u00e9tropole, Lille, France|CH - Robert Bisson, Lisieux, France|PRIVE - Teissier, Li\u00e9vin, France|CH - GH Nord Essone, Longjumeau, France|CH - CHBS H\u00f4pital du Scrorff, Lorient, France|CHU - Edouard Herriot, Lyon, France|CHU - La Croix Rousse, Lyon, France|PRIVE - La Sauvegarde Lyon, Lyon, France|CH - La Conception, Marseille, France|CH - Saint Joseph, Marseille, France|CHU - La Timone, Marseille, France|CH - GHI de l'Est Francilien Site de Meaux, Meaux, France|CH - Layn\u00e9, Mont-de-Marsan, France|CH - Site du Mittan, Montb\u00e9liard, France|CH, Mont\u00e9limar, France|CH - Emile Muller, Mulhouse, France|CH - Les Chanaux, M\u00e2con, France|PRIVE - Oncologie Gentilly, Nancy, France|PRIVE - Confluent SAS, Nantes, France|PRIVE - Hartmann, Neuilly-sur-Seine, France|CH - Pierre Beregovoy, Nevers, France|CH, Niort, France|CHU - Caremeau, N\u00eemes, France|CHR - Centre Hospitalier R\u00e9gional La Source, Orl\u00e9ans, France|AP - HP - Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France|Bichat, Paris, France|CHU - Cochin, Paris, France|CHU - Lariboisi\u00e8re, Paris, France|CHU - Saint Antoine, Paris, France|CHU - Saint Louis, Paris, France|CHU - Tenon, Paris, France|Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France|H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France|PRIVE - Saint Joseph, Paris, France|Priv\u00e9 - Montsouris, Paris, France|PRIVE - Centre Oncologie Catalan, Perpignan, France|CHU - Haut L\u00e9v\u00eaque, Pessac, France|CHU - Lyon Sud, Pierre-B\u00e9nite, France|PRIVE - Centre Cario HPCA, Pl\u00e9rin, France|CHU - La Miletrie, Poitiers, France|CH - Ren\u00e9 Dubos, Pontoise, France|CH, P\u00e9rigueux, France|PRIVE - Clinique La Croix du Sud, Quint-Fonsegrives, France|CHU - Robert Debr\u00e9, Reims, France|PRIVE - Polyclinique Courlancy, Reims, France|PRIVEE - Jean Godinot, Reims, France|PRIVEE - Polyclinique Courlancy, Reims, France|CHU - Charles Nicolle, Rouen, France|CAC - Institut Curie R. Huguenin, Saint-Cloud, France|PRIVE - Saint Gr\u00e9goire, Saint-Gr\u00e9goire, France|CH - Centre Hospitalier de Saint Malo, Saint-Malo, France|CH - Begin, Saint-Mand\u00e9, France|PRIVE - Clinique Mutualiste de l'Estuaire, Saint-Nazaire, France|CHU - H\u00f4pital Nord CHU Saint Etienne, Saint-Priest-en-Jarez, France|PRIVE - Ramsay Sainte Loire, Saint-\u00c9tienne, France|PRIVE - Trenel, Sainte-Colombe, France|CHU - Hautepierre, Strasbourg, France|ICAN - Institut de Canc\u00e9rologie de Strasbourg Europe, Strasbourg, France|PRIVE - Strasbourg Oncologie Lib\u00e9rale, Strasbourg, France|CH - Foch, Suresnes, France|CH - Maison Sant\u00e9 Protestante, Talence, France|CH - Birgorre, Tarbes, France|CH - Leman, Thonon-les-Bains, France|CH - Sainte Musse, Toulon, France|CAC - Oncopole, Toulouse, France|CHU - Rangueil, Toulouse, France|CH - Gustave Dron, Tourcoing, France|CHU - Bretonneau, Tours, France|CH, Valence, France|CH, Valenciennes, France|PRIVE - Dentelli\u00e8res, Valenciennes, France|CHU - Brabois, Vand\u0153uvre-l\u00e8s-Nancy, France|PRIVE - Robert Schuman, Vantoux, France|CH - Paul Morel, Vesoul, France|CAC - Gustave Roussy, Villejuif, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1509"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of cases of SARS-COV-2 infection and mortality rate directly related to the infection in patients being followed for digestive, thoracic, head and neck, gynecologic, cerebral, urologic or cutaneous cancer|Number of cases of SARS-COV-2 infection|Percentage of severe and fatal forms.of cases of SARS-COV-2 infection|Social characteristics of individuals on treatment|Link between socio-territorial determinants and the characteristics\/severity of SARS-COV-2 infection.""}"
"3748","Post-COVID-19 Epidemic Depression Assessment in Adults in South Punjab Pakistan","","NCT04604080","U1111-1260-1614","Other: service of questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04604080","Completed","2020-11-01","2020-11-18","{""locations"":""The Islamia University of Bahawalpur, Bah\u0101walpur, Punjab, Pakistan|GC University Faisalabad, Faisalabad, Punjab, Pakistan|University of Veterinary and Animal Sciences, Lahore, Lahore, Punjab, Pakistan|Bahauddin Zakriya University Multan, Multan, Punjab, Pakistan|Quaid-i-Azam University Islamabad, Islamabad, Pakistan"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""390"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence estimation of depression in adults""}"
"3749","Community Collaboration to Combat COVID-19 (C-FORWARD)","","NCT04673292","IRB00250298|P30AI094189-09S1","Behavioral: Fixed site standard of care testing|Behavioral: Community-based, mobile van testing|Behavioral: Self-collected, home-based testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04673292","Enrolling by invitation","2021-02-08","2021-08-01","{""locations"":""2212 McElderry Street, Baltimore, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""3000"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Time to receipt of SARS CoV-2 testing results|Acceptance of SARS CoV-2 viral testing assessed by proportion of participants who complete a survey|Uptake of SARS CoV-2 testing as assessed by proportion of participants who complete testing|Time to completion of SARS CoV-2 testing|Time from SARS CoV-2 testing to receipt of results""}"
"3750","The Change of Critical Patient Managements and Subsequent Influences Under Epidemic of Coronavirus Disease 19 (COVID-19)","","NCT04479332","202005094RIND","Procedure: Tracheal intubation and cardiopulmonary resuscitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04479332","Not yet recruiting","2020-08-01","2022-07-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""334"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The success rate of tracheal intubation between resuscitation area and negative pressure isolation rooms|The patient prognosis between resuscitation area and negative pressure isolation rooms|The physical and psychological stress of medical staff|The amount of environmental contamination between resuscitation area and negative pressure isolation rooms""}"
"3751","HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers","","NCT04336748","HCQ prophylaxis for COVID19","Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04336748","Not yet recruiting","2020-04-01","2020-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""440"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR|Viral load during SARS-CoV-2 infection|Seroconversion during the study period|Incidence of any acute respiratory infection|Days of sick leave""}"
"3752","COVID-19 Psychological Wellbeing for Healthcare Students","PoWerS","NCT04429828","PoWerS_June2020","Other: COVID-19 e-package: Psychological wellbeing for healthcare workers","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04429828","Not yet recruiting","2020-06-13","2020-12-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""45"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Qualitative Interviews with Healthcare Students|Warwick-Edinburgh Mental Wellbeing Scale|Single Item Measure of Global Job Stressfulness (Houdmont et al, 2019)|Single Item Global Job Satisfaction Measure (Dolbier et al, 2005)|Single Item Measure of Presenteeism (Aronsson & Gustafsson, 2004)|Single Item Measure of Turnover intentions|Work Engagement (Shaufeli et al, 2006)""}"
"3753","Behavior, Environment And Treatments for Covid-19","BEAT19","NCT04321811","XC-PCOR-COVID19","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04321811","Active, not recruiting","2020-03-21","2022-03-20","{""locations"":""BEAT19.org, San Francisco, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery""}"
"3754","Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf","","NCT04430374","MRC-05-113","Other: No interverntion","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04430374","Recruiting","2020-06-02","2020-12-31","{""locations"":""Hamad Medical Corporation, Doha, Unlisted (UL), Qatar"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The impact of COVID-19 on cardiovascular patient""}"
"3755","HFNC Treatment in COVID-19 Pneumonia","","NCT04424836","5569","Device: high flow nasal cannula device","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424836","Completed","2020-05-15","2020-06-05","{""locations"":""Sisli Etfal Research and Training Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""43"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""short term mortality|icu stay|blood gases""}"
"3756","Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions","","NCT04408027","REB1000070362","Behavioral: Virtual-Care Cognitive Behavioural Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04408027","Recruiting","2020-06-01","2021-06-01","{""locations"":""The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""12 Years to 17 Years \u00a0 (Child)"",""outcome_measures"":""Participation Barriers|Number of Eligible Participants|Number of Participants Approached|Number of Participants Consented|Rates of Refusal|Reasons for Refusal|Number of Sessions Completed in Total|Adherence Index|Amount of time (in weeks) to complete the intervention|Intervention Acceptability|Participant Satisfaction|Working Alliance Inventory after First Intervention Session|Working Alliance Inventory after Sixth Intervention Session|Working Alliance Inventory after Final Intervention Session|Family Impact During a Pandemic at Baseline|Family Impact During a Pandemic after Final Intervention Session|Efficacy of Virtual-Care CBT Intervention|Clinician Virtual Care Experience""}"
"3757","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","","NCT04260594","Abdrcspc202001","Drug: Arbidol|Other: basic treatment","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04260594","Not yet recruiting","2020-02-07","2020-12-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""380"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count""}"
"3758","Surgical Consent During the COVID-19 Pandemic","","NCT04556604","2021.016N","Behavioral: Educational meetings and visual prompts","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04556604","Completed","2020-04-10","2020-08-14","{""locations"":""Medway NHS Foundation Trust, Gillingham, United Kingdom"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""45"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Compliance to consenting practice""}"
"3759","Cerebral Compliance Impairment in COVID-19","","NCT04429477","31750820.1.0000.0068","Device: Cerebral compliance and hemodynamics monitoring","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04429477","Completed","2020-05-01","2020-07-31","{""locations"":""Hospital das Cl\u00ednicas da Faculdade de Medicina da USP., S\u00e3o Paulo, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Detection of cerebral compliance impairment by the B4C sensor|Detection of cerebral hemodynamics impairment by transcranial Doppler|Calculate mortality in this population""}"
"3760","Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia","","NCT04437342","Covid-19 Postpartum depression","Other: PHQ-9 (Patient Health Questionnaire) Depression Scale|Other: GAD-7 (General Anxiety Disorder) scale|Other: 38 questions questionnaire|Other: EPDS (Edinburgh Postnatal Depression Scale)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04437342","Completed","2020-06-30","2020-10-27","{""locations"":""\""Elena Venizelou\"" General and Maternity Hospital of Athens, Athens, Attica, Greece|Aretaieio University Hospital, Athens, Attica, Greece|Alexandra Genaral Hospital Athens, Athens, Greece|University of Ioannina Health Science, Ioannina, Greece|University of Ioannina, Medical School, Ioannina, Greece|University of Thessaly Medical School, Larisa, Greece"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""330"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between the Covid-19 pandemic and postpartum depression with EPDS scale (Edinburgh postnatal depression scale)|Correlation between the Covid-19 pandemic, postpartum depression and type of anaesthesia (general, epidural, spinal, combined, epidural analgesia for vaginal delivery)|Correlation between the Covid-19 pandemic, postpartum depression and postpartum pain""}"
"3761","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","","NCT04449276","CV-NCOV-001|2020-001286-36","Biological: CVnCoV Vaccine|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04449276","Active, not recruiting","2020-06-18","2021-12-01","{""locations"":""Universitair Ziekenhuis Ghent, Ghent, Belgium|Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Bavaria, Germany|Medical University Hannover (MHH), Hannover, Germany|University Hospital T\u00fcbingen Institut f\u00fcr Tropenmedizin, T\u00fcbingen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""280"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination|Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination|Number of Participants with Solicited Local Adverse Events|Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale|Duration of Solicited Local Adverse Events|Number of Participants with Solicited Systemic Adverse Events|Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale|Duration of Solicited Systemic Adverse Events|Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine|Number of Participants with Unsolicited Adverse Events|Intensity of Unsolicited Adverse Events Assessed by the Investigator|Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine|Number of Participants with One or More Serious Adverse events (SAEs)|Number of Participants with One or More Serious Adverse events (SAEs) Considered Related to Trial Vaccine|Number of Participants with One or More Adverse Events of Special Interest (AESIs)|Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine|Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies|Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum|Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies|Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies|Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum|Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies""}"
"3762","3D Telemedicine During COVID-19: Cohort Study","","NCT04444323","GN20HS300","Other: 3D Telemedicine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04444323","Not yet recruiting","2020-09-01","2021-01-01","{""locations"":""Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow, Scotland, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""50"",""age"":""1 Year to 95 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Presence Questionnaire|University Hospital of North Northway Questionnaire|Telehealth Usability Questionnaire|System Usability Scale|Mental Effort Rating Scale|NASA TLX|Range of Motion measurements for elbow joint""}"
"3763","Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients","","NCT04672564","TLKLXG202001","Drug: Carrimycin|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04672564","Not yet recruiting","2021-03-10","2021-06-30","{""locations"":""PharmaTex Research, LLC, Amarillo, Texas, United States|Instituto M\u00e9dico Platense, La Plata, Buenos Aires, Argentina|Cl\u00ednica Monte Grande, Monte Grande, Buenos Aires, Argentina|Instituto Medico Rio Cuarto, Rio Cuarto, C\u00f3rdoba, Argentina|Hospital General de Agudos Donaci\u00f3n F. Santojanni, Buenos Aires, Argentina|Sanatorio Mayo Privado SA, C\u00f3rdoba, Argentina|Instituto Goiano de Oncologia e Hematologia - INGOH, Aparecida de Goi\u00e2nia, Goi\u00e1s, Brazil|Instituto de Pesquisa Cl\u00ednica de Campinas, Campinas, S\u00e3o Paulo, Brazil|Clinica SOMER, Rionegro, Antioquia, Colombia|Hospital Universitario Cl\u00ednica San Rafael, Bogota, Colombia|Paarthiv Lung Care Centre - Internal Medicine, Hyderabad, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Unity Hospital, Surat, Gujarat, India|Rhythm Heart Institute, Vadodara, Gujarat, India|Adichunchanagiri Hospital and Research Centre, Mandya, Karnataka, India|Government Medical College - Department of Internal Medicine, Nagpur, Maharashtra, India|Suretech Hospital and Research Centre - Internal Medicine, Nagpur, Maharashtra, India|Shalinitai Meghe Hospital & Research centre, Nagpur, Maharashtra, India|Universal Hospital, Pune, Maharashtra, India|Sawai Man Singh Medical College & Attached Hospitals, Jaipur, Rajasthan, India|Saveetha Medical College & Hospital, Chennai, Tamil Nadu, India|St.Theresa's Hospital, Hyderabad, Telangana, India|Nuevo Hospital Civil de Guadalajara \""Juan I. Menchaca\"", Guadalajara, Jalisco, Mexico|Hospital Universitario \""Dr. Jose Eleuterio Gonzalez\"", Nuevo Leon, Nuevo Le\u00f3n, Mexico|Kohler & Milstein Research, Merida, Yucat\u00e1n, Mexico|Clinica Ricardo Palma, Lima, Peru|Hospital Central FAP, Lima, Peru|De La Salle Health Sciences Institute, Cavite City, Cavite, Philippines|St. Paul's Hospital of Iloilo, Inc., Iloilo City, Iloilo, Philippines|Makati Medical Center - Infectious Diseases, Makati City, National Capital Region, Philippines|San Juan De Dios Hospital, Pasay City, National Capital Region, Philippines|Veterans Memorial Medical Center, Quezon City, National Capital Region, Philippines|St. Lukes Hospital, Quezon City, National Capital Region, Philippines|Quirino Memorial Medical Center, Quezon, National Capital Region, Philippines|Chernihivska miska likarnia #2, Chernihiv, Chernihivs'ka Oblast', Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ivano-Frankivs'ka Oblast', Ukraine|Oblasnyi klinichnyi ftyziopulmonolohichnyi tsentr, Ivano-Frankivsk, Ivano-Frankivs'ka Oblast', Ukraine|Kyivska miska likarnia #8, Kyiv, Ky\u00efv, Ukraine|Vinnytskyi natsionalnyi medychnyi universytet imeni M.I. Pyr, Vinnytsia, Vinnyts'ka Oblast, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Volyns'ka Oblast', Ukraine"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients alive without need for supplemental oxygen and ongoing in patient-medical care (SOC treatment for COVID-19) at Day 28|Time to recovery|Mean difference from baseline (Days -2 to -1) to Day 28 as per the 8 category ordinal scale|Change in lung imaging|Negative conversion ratio of SARS-CoV-2 RNA in nasopharyngeal samples after treatment.|Improvement in sequential organ failure assessment (SOFA) score|Length of hospital stay (in days)|Number of patients with all cause mortality at Days 14 and 28|Number of patients with adverse event (AEs) and Serious adverse events (SAEs)|Number of patients with changes in routine electrocardiogram (ECG) from Day 1 up to Day 14""}"
"3764","Self-sampling for the Study of COVID-19","","NCT04447495","20-001","Diagnostic Test: iAMP test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04447495","Not yet recruiting","2020-07-01","2020-12-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Validate iAMP testing kit""}"
"3765","Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19)","","NCT04376515","UCaliforniaIrvineSYoung","Behavioral: HOPE intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04376515","Active, not recruiting","2020-03-20","2021-09-01","{""locations"":""UC Irvine, Irvine, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety""}"
"3766","Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome Caused by COVID-19","RE-CoV-ERY","NCT04619368","RC31/20/0219","Other: Follow up calls","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04619368","Recruiting","2020-07-27","2022-07-01","{""locations"":""University Hospital of Toulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Post-traumatic Stress Disorder (PTSD) with the Post-traumatic Checklist-5 (PCL-5) 12 months after intensive-care|psychological disorders measured by QIDS|psychological disorders measured by STAI-YA|quality of life by EQL-5|nutritional status""}"
"3767","Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression","DEPRECOVID","NCT04368208","2020-A01065-34","Other: Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368208","Completed","2020-04-29","2020-11-27","{""locations"":""Bertrand GACHON, Poitiers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""501"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Report postnatal depression between 4 of 6 weeks during the covid 19 pandemia|Report factors associated with postnatal depression between 4 of 6 weeks during the covid 19 pandemia|Describe the experience and the satisfaction about delivery during the covid 19 pandemia""}"
"3768","SARS-CoV-2 (COVID-19) and Surgery","","NCT04368026","1072.6120.103.2020","Other: No intervention (survey study for medical doctors).","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368026","Completed","2020-03-30","2020-12-01","{""locations"":""2nd Department of General Surgery, Jagiellonian University Medical College, Cracovia, Ma\u0142opolska, Poland"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""70"",""age"":""25 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Descriptive data on perceptions of current status of surgical wards during the pandemic and impact of the pandemic on conducting surgery.""}"
"3769","Reducing Food Insecurity During COVID-19","","NCT04652596","H-41052|6007145|AD-1603-34662","Other: Produce prescription program|Other: Grocery store gift cards","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04652596","Enrolling by invitation","2021-02-08","2022-10-01","{""locations"":""Boston Medical Center, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Food Security|Change in fruit & vegetable consumption|Depression Symptoms|Symptom Relief|Changes of behavioral activation for depression|Perceived Stress|Social Support|Medical outcomes social support|Mastery Control|Self-Esteem|Unmet needs|Self-Reported Food Assistance Program Participation|Change in Self-Reported Health Status|Maternal attitudes and safe infant care practices|Impact of COVID-19|Program Experience|Change in adult acute healthcare utilization|Total adult patient-level cost of care|Child healthcare utilization|Child weight|Child height""}"
"3770","Southampton Women's Survey COVID-19 Study","SWS_COVID-19","NCT04666285","56780","Other: Experience of pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666285","Not yet recruiting","2020-12-01","2020-12-01","{""locations"":""MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""12 Years to 57 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Mental Health in women|Mental Health in offspring""}"
"3771","Impact of COVID-19 Lockdown on Obesity and Eating Behaviors","CIO","NCT04431284","69HCL20_0516|2020-A01616-33","Other: Questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04431284","Completed","2020-06-16","2020-12-16","{""locations"":""Centre Int\u00e9gr\u00e9 de l'ob\u00e9sit\u00e9 de Lyon \/ HCL, Pierre-B\u00e9nite, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""37"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of the BMI (kg\/m\u00b2) evolution between the two groups|Score comparison of the Dutch Eating Behavior Questionnaire""}"
"3772","Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19","","NCT04414631","2020-01252; me20Osthoff3","Drug: Conestat alfa","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04414631","Recruiting","2020-08-06","2021-07-01","{""locations"":""Pr\u00e1xis Pesquisa Medica, S\u00e3o Paulo, Brazil|Hospital Universitario \""Dr. Jos\u00e9 Eleiterio Gonz\u00e1lez\"", Colinia Mitras Centro, Monterey, Nuevo Leon Mexico, Mexico|University Hospital Basel, Division of Internal Medicine, Basel, Switzerland|Kantonsspital St. Gallen, Klinik f\u00fcr Infektiologie\/Spitalhygiene, St. Gallen, Switzerland|Stadtspital Triemli, Departement Innere Medizin, Z\u00fcrich, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease severity|Time to clinical improvement|Proportion of participants alive and not having required invasive or non-invasive ventilation|Proportion of subjects with an ALI (defined by PaO2\/FiO2 ratio of <300mmHg)""}"
"3773","Clinical Characteristics and Outcomes of Pediatric COVID-19","PERN-COVID-19","NCT04330261","REB18-0107_MOD9","Other: Exposure (not intervention) - SARS-CoV-2 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04330261","Recruiting","2020-03-18","2022-03-17","{""locations"":""University of Calgary\/Alberta Children's Hospital, Calgary, Alberta, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""12500"",""age"":""up to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies""}"
"3774","Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19","PIC-19","NCT04368377","18275/2020","Drug: Tirofiban Injection|Drug: Clopidogrel|Drug: Acetylsalicylic acid|Drug: Fondaparinux","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04368377","Completed","2020-04-06","2020-04-23","{""locations"":""L. Sacco Hospital, Milano, Lombardia, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""5"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""P\/F ratio|PaO2 difference|A-a O2 difference|CPAP duration|In-hospital change in intensity of the respiratory support|PaCO2 difference|HCO3- difference|Lactate difference|Hb difference|Plt difference|Adverse effects""}"
"3775","Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic","","NCT04464486","IRB_00131892","Other: SCH Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04464486","Enrolling by invitation","2020-04-21","2021-05-31","{""locations"":""Huntsman Cancer Institute, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health Care Utilization Comparison|Patient Social Isolation|COVID-19 Symptoms, Social distancing and Hygiene Practices|Patient Global Health|Patient Anxiety\/Depression|Impact of Pandemic and Health Related Quality of Life|Cancer symptom severity""}"
"3776","Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19","","NCT04380870","01-04-20","Dietary Supplement: Chinese Herbal Medicine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04380870","Recruiting","2020-04-11","2025-04-11","{""locations"":""Seattle Intstitute of East Asian Medicine, Seattle, Washington, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 114 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient reported main complaint|Conduct qualitative analyses of data""}"
"3777","COVID-19 Risk Reduction Among African American Parishioners","","NCT04542343","COVID19Church","Behavioral: Change in knowledge, motivation, skills, resources","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04542343","Recruiting","2020-11-01","2021-09-30","{""locations"":""Charles R. Drew University of Medicine & Science, Los Angeles, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""265"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Percentage of Participants Achieving Improvement of Health Conditions Using the Severity of Medical Chronic Conditions Surveys|Percentage of Participants Achieving Target Levels of Knowledge, Attitude, and Behaviors with NIH Toolbox Surveys|Prevalence of COVID-19 testing using Participant COVID-19 Test History Survey|Prevalence of pneumococcal and influenza vaccinations using Participant Immunization History Survey""}"
"3778","COVID19 and Physical and Emotional Wellbeing of HCP","CoPE-HCP","NCT04433260","284686","Other: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|Other: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Other: Informed consent","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433260","Recruiting","2020-07-25","2021-09-01","{""locations"":""Ajay K Gupta, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1050"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of anxiety at baseline|Presence of depression at baseline|Proportion of those who report a combined outcome of presence of anxiety or depression at the baseline as determined by screening questionnaires used.|Change in proportion of who report a combined outcome of either presence of anxiety or depression from baseline to the end of study|Change in the proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19 from baseline to the end of study|Change in prevalence of anxiety from baseline|Change in prevalence of depression from baseline|Prevalence of sleep-related issues at baseline|Change in prevalence of sleep-related issues from baseline|Prevalence of a combined outcome of presence of anyone of anxiety, depression or sleep related issues at baseline.|Proportion of those with low mental wellbeing at baseline|Change in proportion of those with low mental wellbeing from baseline to the end of study.|Prevalence of those who report concern related to work-place practices.|Change in the prevalence from baseline of those who report concern related to work-place practices.|Change in behavioural habits, such as smoking and alcohol intake from baseline to the end of study|Proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19""}"
"3779","Fibromyalgia During the COVID-19 Pandemic","","NCT04422522","AAGH-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422522","Active, not recruiting","2020-03-15","2020-06-30","{""locations"":""Al-Azhar Faculty of medicine, Rheumatology Department, Cairo, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""45"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of FM patients""}"
"3780","Virtual Reality Study - COVID-19 Protocol","NRVR","NCT04678778","HS17-00354","Behavioral: Physical and Cognitive Activity","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04678778","Recruiting","2019-03-19","2021-02-17","{""locations"":""Mark and Mary Stevens Neuroimaging and Informatics Institute of the University of Southern California, Los Angeles, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""11"",""age"":""50 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Magnetic Resonance Image (MRI) brain scan of hippocampal volume (cubic mm)|Mnemonic Similarity Task for visual memory performance - discrimination index""}"
"3781","Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection","ALI","NCT04526912","VIB7734.P1.S2","Drug: VIB7734|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04526912","Recruiting","2020-08-28","2021-07-01","{""locations"":""Research Site, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of patients who achieve treatment success through Day 28, defined as avoidance of death and critical illness|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent fatal and life-threatening SAEs, Treatment-emergent Serious Adverse Events|Change in safety laboratory parameters""}"
"3782","Renal Outcome in Patients With COVID-19","","NCT04353583","AZ 58/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04353583","Recruiting","2020-04-21","2021-06-30","{""locations"":""University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""GFR loss|Cystatin C as indicator of mortality|Cystatin C as indicator of respiratory illness|Cystatin C as indicator of disease severity|Renal function changes during hospital stay|Incidence of AKI""}"
"3783","LDCT in COVID-19 Pneumonia: a Prospective Moscow Study","LDCTiP","NCT04379531","2020-1","Diagnostic Test: Low-dose Chest CT","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04379531","Completed","2020-04-25","2020-05-22","{""locations"":""Victor Gombolevskiy, Moscow, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the correlation between standard CT and low-dose CT scans for the detection of community-acquired pneumonia.|Threshold value of the infiltration zone size detected by low-dose CT scan compared to standard CT scan.|Number of infiltration zones of pulmonary parenchyma corresponding to viral pneumonia detected by low-dose CT scan in comparison with standard CT scan.""}"
"3784","Physical Activity Level in Patients With OSAS During Covid-19 Pandemic","","NCT04451993","GO 20/540","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04451993","Completed","2020-06-25","2020-09-30","{""locations"":""Trabzon Ahi Evren Thoracic and Cardiovascular Surgery Training and Research Hospital, Trabzon, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""63"",""age"":""19 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical Activity|Sleep Quality|Daytime Sleepiness|Fear of movement|Health literacy""}"
"3785","Inhaled Ibuprofen to Treat COVID-19","CórdobaTrail","NCT04382768","DNL000004","Drug: Inhaled Hypertonic ibuprofen","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04382768","Recruiting","2020-05-01","2021-01-01","{""locations"":""Centro de Excelencia en Productos y Procesos C\u00f3rdoba, C\u00f3rdoba, Argentina"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen.|Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen.|Chage in length of Hospital stay|Chage in duration of ventilation|Chage in length of Critical Care stay|Average score of National Early Warning (NEWS2) between days 1, 7, 14 and 28.|Average change in quick sepsis-related organ failure assessment score (qSOFA) score between day 1, 7, 14 and 28.|Time from first dose to conversion to normal or mild pneumonia|Antibiotic requirement|Glucocorticoids requirement|Incidence of adverse event|Incidence of serious adverse event|Number of deaths from any cause at 28 days|Lymphocyte count""}"
"3786","COVID-19 and Rare Skin Diseases European Observational Study During an Epidemic","","NCT04451902","COVID19-RareSkin","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04451902","Not yet recruiting","2020-06-30","2021-06-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""80"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Analysis of the impact of COVID-19 infection on rare skin diseases: complications|Analysis of the impact of COVID-19 infection on rare skin diseases: potential comorbidity factors|Analysis of the impact of COVID-19 infection on rare skin diseases: impact on the management of chronic conditions (change in treatment)""}"
"3787","How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?","","NCT04348227","KM2020-1","Behavioral: Enhanced hygiene measures","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04348227","Active, not recruiting","2019-01-01","2021-02-04","{""locations"":""Department of anesthesia and intensive care, Fattouma Bourguiba Hospital, Monastir, Tunisia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""120"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""MDR pathogens in endotracheal aspirates|Microorganisms in endotracheal aspirates""}"
"3788","Treating COVID-19 With a Bidirectional Oxygenation Valve","","NCT04326452","COVID19PEEP2020|GO2 PEEP Study","Device: bidirectional oxygenation mouthpiece","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04326452","Recruiting","2020-03-27","2021-03-27","{""locations"":""TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide""}"
"3789","Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial","","NCT04383717","Levamisole and isoprinosine","Drug: Levamisole and isoprinosine|Drug: Azithromycin and hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04383717","Not yet recruiting","2020-05-05","2020-10-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""6 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""COVID 19 induced fever in both groups|COVID 19 induced dyspnea in both groups|COVID 19 viral load in both groups|laboratory clearance in both groups: CRP in mg\/dL""}"
"3790","Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19","","NCT04435353","AstanaMU","Device: VibroLUNG","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04435353","Recruiting","2020-03-22","2021-02-01","{""locations"":""Mukatova Irina, Astana, Nur-Sultan, Kazakhstan|Center of pulmonology Astana, Astana, Kazakhstan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recovery respiratory fail""}"
"3791","Protective Effect of Aspirin on COVID-19 Patients","PEAC","NCT04365309","Xi jingH","Drug: Aspirin 100mg","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04365309","Enrolling by invitation","2020-02-10","2020-06-01","{""locations"":""Cai Yue, Xi'an, Shaanxi, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""128"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""clinical recovery time (TTCR)|the time of SARS-CoV2 overcasting""}"
"3792","3D Telemedicine During COVID-19: Non-clinical Validation","","NCT04444297","GN20HS287","Other: 3D Telemedicine|Other: 2D Telemedicine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04444297","Not yet recruiting","2020-07-31","2021-01-31","{""locations"":""Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow, Scotland, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""16 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Presence Questionnaire|University Hospital of North Northway Questionnaire|Telehealth Usability Questionnaire|System Usability Scale|Mental Effort Rating Scale|NASA TLX|Range of Motion measurements for elbow joint""}"
"3793","Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia","Covid-19","NCT04423315","20200504443","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04423315","Completed","2020-06-08","2020-07-20","{""locations"":""Vital Hospital, Bahcelievler, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""70"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""length of hospital stay""}"
"3794","Clinical and Radiomic Model of COVID-19","","NCT04337502","UM_2020_GY_COVID-19","Diagnostic Test: Machine learning model","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337502","Completed","2019-12-23","2020-03-03","{""locations"":""The central hospital of Wuhan, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Predictive performance""}"
"3795","ASCO Survey on COVID-19 in Oncology (ASCO) Registry","","NCT04659135","Pro00014181","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659135","Recruiting","2020-04-19","2022-12-01","{""locations"":""Anchorage Oncology Center, Anchorage, Alaska, United States|AIS Cancer Center, Bakersfield, California, United States|Long Beach Memorial Medical Center, Fountain Valley, California, United States|Orange Coast Medical Center, Fountain Valley, California, United States|Saddleback Memorial Medical Center, Fountain Valley, California, United States|Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|PIH Health, Whittier, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Hartford HealthCare Cancer Institute, Hartford, Connecticut, United States|Bayhealth Medical Center, Dover, Delaware, United States|Florida Precision Oncology, A Division of 21st Centry Oncology, Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, LLC, Sarasota, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Hawaii Cancer Care, Honolulu, Hawaii, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Joliet Oncology-Hematology Associates, Joliet, Illinois, United States|Edward-Elmhurst Healthcare, Naperville, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Michiana Hematology Oncology, Mishawaka, Indiana, United States|MidAmerica Oncology Associates, Overland Park, Kansas, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Baptist Health Madisonville, Madisonville, Kentucky, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|LifeBridge Health, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Great Lakes Cancer Management Specialists, Grosse Pointe Woods, Michigan, United States|Lakeland Hospitals, Saint Joseph, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Mosaic Cancer Care, Saint Joseph, Missouri, United States|Nebraska Hematology Oncology, Lincoln, Nebraska, United States|Callahan Cancer Center, North Platte, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Bayonne Medical Center, Bayonne, New Jersey, United States|CarePoint Health - Christ Hospital, Jersey City, New Jersey, United States|Penn Medicine, Princeton Health, Plainsboro, New Jersey, United States|Hematology Oncology Associates of Central New York, East Syracuse, New York, United States|Northwell Health Cancer Institute, Lake Success, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Levine Cancer Institute Atrium Health, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Carteret Health Care, Morehead City, North Carolina, United States|CarolinaEast Medical Center, New Bern, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Florida Cancer Specialists, Massillon, Ohio, United States|Columbia Memorial Hospital, Astoria, Oregon, United States|Samaritan Health Services Corvallis, Corvallis, Oregon, United States|Penn Medicine, Lancaster General Health, Lancaster, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Monument Health, Rapid City, South Dakota, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|BSA Harrington Cancer Center, Amarillo, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Changes to Cancer Treatments|All-cause mortality at 30 days|COVID-19 Symptoms|COVID-19 Treatments|Patient vital status|Overall survival|Patient cancer status (for patients who had active cancer at covid-19 dx)|Patient cancer status (for patients who are disease-free at COVID-19 diagnosis)""}"
"3796","Covid-19 Epidemic on Acute Stroke Management","Stroke-Covid19","NCT04370197","7826","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370197","Recruiting","2020-03-03","2020-04-30","{""locations"":""Service de Neuroradiologie Interventionnelle, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Study of the effect of pandemic covid-19 on the management of stroke patients""}"
"3797","Distress in Crisis Situations During COVID-19","","NCT04337047","WefightDistress20","Other: questionnaire assesment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337047","Completed","2020-03-31","2020-05-03","{""locations"":""Wefight, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""quantify and qualify distress over a large population in times of pandemic crisis.|qualify demographic data vs distress over a large population in times of pandemic crisis.""}"
"3798","Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19","","NCT04517422","ABB-COVID19","Dietary Supplement: Probiotics|Other: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04517422","Completed","2020-08-19","2021-02-02","{""locations"":""Hospital General Dr. Manuel Gea Gonzalez, Mexico city, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""300"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Severity progression of COVID-19|Stay at ICU|Mortality ratio|Viral load|Lung abnormalities|Levels of immunoglobulins|Gastrointestinal manifestations, where 0 means good health status and 5 worse status|Fecal microbiome|Adverse events|Change on Serum Biomarkers|Duration of Individual Symptoms""}"
"3799","Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection","Covid-Thelium","NCT04357847","2020/097/OB","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357847","Recruiting","2020-04-09","2021-08-31","{""locations"":""Rouen University Hospital, Rouen, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality|Association of Endothelin-1 plasma level with 28 days mortality|Association of Vascular Endothelial Growth Factor A plasma level with 28 days mortality|Association of soluble Vascular Endothelial Growth Factor Receptor type 1 with 28 days mortality|Association of syndecan -1 plasma level with 28 days mortality|Association of D-dimers plasma levels with thrombotic events|Association of von Willebrandt Factor with thrombotic events|Association of Viscoelastic testing with thrombotic events""}"
"3800","The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's)","","NCT04356365","REK125510","Other: Cross-sectional study investigating the association of NPIs with mental health","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356365","Completed","2020-03-31","2020-04-07","{""locations"":""University of Oslo, Oslo, Norway"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""10084"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire 9|Generalized Anxiety Disorder 7|Measures of adherence""}"
"3801","Virtual Pain Care Management (COVID-19)","VCPM","NCT04539821","C19 20-397","Other: VCPM","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04539821","Recruiting","2020-10-01","2021-06-30","{""locations"":""Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the percent of patients who agree to Buprenorphine transfer|percent of complete tapering or BUP transition""}"
"3802","Capturing MultiORgan Effects of COVID-19","C-MORE","NCT04510025","282608","Diagnostic Test: Magnetic Resonance Imaging","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04510025","Recruiting","2020-05-13","2023-05-01","{""locations"":""University of Oxford, Oxford, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""616"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of damage (quantitative measures of injury) on lung, heart, liver, kidneys and brain MRI.|Prevalence of damage (quantitative measures of injury) on lungs, heart, liver, kidneys and brain on MRI.|Prevalence of acute\/chronic cardiac, renal and liver injury on blood tests.|VO2 max on cardiopulmonary exercise testing|Prevalence of abnormal lung function test (any of the following: Forced expiratory volume in 1 second (FEV1)< 80% of predicted FEV1, or forced vital capacity (FVC)<80% predicted, ratio of FEV1\/FVC >0.7 or diffusion lung capacity (<80% predicted))|Quality of life - Short form-36 SF-36 score|Prevalence of impaired cognitive function on Montreal Cognitive assessment (MoCA<26)|6-minute walk distance|Severity of anxiety on GAD-7 (Score)|Severity of depression on PHQ-9 (Score)|Association between the extent of multi-organ injury (continuous variable) and markers of inflammation (white cell count).|Correlation between the extent of symptoms (dyspnoea-12 score and fatigue score) and multi-organ injury.""}"
"3803","NO Prevention of COVID-19 for Healthcare Providers","NOpreventCOVID","NCT04312243","NOpreCOVID-19","Drug: Inhaled nitric oxide gas","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04312243","Active, not recruiting","2020-04-07","2022-04-07","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""24"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test""}"
"3804","UVA Light Device to Treat COVID-19","","NCT04572399","883","Device: UV Light Treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04572399","Completed","2020-10-30","2020-12-28","{""locations"":""Cedars-Sinai Medical Center, Los Angeles, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""5"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in viral load|Change in bacterial load|Ventilated associated pneumonia|Days to extubation|Days to discharge|Change in C-reactive protein|7-point clinical outcome|Catheter tip assessment""}"
"3805","CMR Findings in COVID-19 Patients Presenting With Myocardial Infarction","","NCT04628104","CMR in myocardial infarction","Radiation: cardiac magnetic resonance","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04628104","Not yet recruiting","2021-01-01","2023-10-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""comparison between COVID-19 and COVID-19 presented with myocardial infarction""}"
"3806","Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","SPIN-CHAT","NCT04335279","2021-2286","Other: SPIN-CHAT Program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04335279","Completed","2020-04-09","2020-07-24","{""locations"":""Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""172"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0|Depression symptoms: Patient Health Questionnaire (PHQ-8)|Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)|Boredom: Multidimensional State Boredom Scale (MSBS-8)|Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)|Adverse Effects|Fear: COVID-19 Fears Questionnaire for Chronic Medical Conditions""}"
"3807","Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement","","NCT04367350","246/2020BO2","Diagnostic Test: laboratory biomarkers|Diagnostic Test: muscle ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04367350","Recruiting","2020-03-20","2022-03-31","{""locations"":""University Hospital Tuebingen, Tuebingen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of elevated creatine kinase in hyperacute phase|Rate of elevated creatine kinase|Rate of two-peak elevation of creatine kinase during acute phase|Rate of myositis-specific antibodies|Rate of antimyocardial antibodies|Area under the curve (AUC) of elevated creatine kinase|Peak-levels of elevated creatine kinase|Peak-levels of troponin|Peak-levels of urine myoglobin|Rate of muscle hyperechogenicity|Peak-muscle hyperechogenicity""}"
"3808","Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare Professionals in India","","NCT04469660","Onco Survey_COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04469660","Recruiting","2020-05-18","2020-09-30","{""locations"":""Max Super Speciality Hospital Saket, New Delhi, Delhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1300"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Therapeutic Sessions emphasizing on Stress|Resilience building and planning""}"
"3809","The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients","","NCT04338672","SMC-20-7078-YZ-CTIL","Other: COVID-19 Pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04338672","Recruiting","2020-04-05","2022-04-01","{""locations"":""Sheba Medical Center, Ramat Gan, Israel"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rates of emergency visits needing surgical consult|The ratio of severe presentations to non-severe presentations|The impact of age on ED attendance rates|Differences in ED surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbidity""}"
"3810","COVID-19 Infection in Patients Infected With HIV and/or on PrEP","COVIDHIVPrEP","NCT04379245","CRC_GHN_2020_002","Other: Data research, database analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379245","Completed","2020-04-30","2020-05-04","{""locations"":""Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""4200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Covid attack rate""}"
"3811","Surfactant Protein Genetic Variants in COVID-19 Infection","","NCT04650191","15456","Other: Identification of genetic variants","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04650191","Recruiting","2020-03-01","2021-12-01","{""locations"":""Milton S. Hershey Medical center, Hershey, Pennsylvania, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""up to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Correlation of surfactant protein genetic variants with severity of COVID-19 infection""}"
"3812","COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being","CoVS","NCT04357041","IRB-2020-91","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357041","Active, not recruiting","2020-04-17","2021-12-01","{""locations"":""Clinical Nutrition Research Center, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Automated Self-Administered 24-Hour Dietary Recall (ASA24)|International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|State trait inventory for cognitive and somatic anxiety (STISA).|Beck Depression inventory (BDI)""}"
"3813","Registry of COVID-19 Patients at AOUI Verona","","NCT04497194","COVID19-VR","Other: not applicable (observational study)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497194","Recruiting","2020-03-01","2020-09-30","{""locations"":""University Hospital of Verona, Verona, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Epidemiological predictors of poor outcomes in COVID-19 patients admitted to University Hospital of Verona|Clinical predictors of poor outcomes in COVID-19 patients admitted to University Hospital of Verona|Body temperature (\u00b0C) on admission in COVID-19 patients admitted to University Hospital of Verona|Blood pressure (mmHg) on admission in COVID-19 patients admitted to University Hospital of Verona|Pulse rate (beats per minute) on admission in COVID-19 patients admitted to University Hospital of Verona|Respiratory rate (breaths per minute) on admission in COVID-19 patients admitted to University Hospital of Verona|Peripheral oxygen saturation (%) on admission in COVID-19 patients admitted to University Hospital of Verona|C reactive protein (CRP, m\/gL) in COVID-19 patients admitted to University Hospital of Verona|Procalcitonin (PCT, ng\/mL) in COVID-19 patients admitted to University Hospital of Verona|White Blood Count (WBC, cell\/mm3) in COVID-19 patients admitted to University Hospital of Verona|Neutrophils (cell\/mm3) in COVID-19 patients admitted to University Hospital of Verona|Lymphocytes (cell\/mm3) in COVID-19 patients admitted to University Hospital of Verona|Platelets (cell\/mm3) in COVID-19 patients admitted to University Hospital of Verona|L-lattato deidrogenasi (LDH, mU\/ml) in COVID-19 patients admitted to University Hospital of Verona|Creatine kinase (CK, U\/L) in COVID-19 patients admitted to University Hospital of Verona|D-dimer (\u03bcg\/L) in COVID-19 patients admitted to University Hospital of Verona|fibrinogen (g\/L) in COVID-19 patients admitted to University Hospital of Verona|ferritin (mcg\/L) in COVID-19 patients admitted to University Hospital of Verona|AST (U\/L) in COVID-19 patients admitted to University Hospital of Verona|ALT (U\/L) in COVID-19 patients admitted to University Hospital of Verona|Creatinine (mg\/dl) in COVID-19 patients admitted to University Hospital of Verona|Arterial blood gas anaysis pH in COVID-19 patients admitted to University Hospital of Verona|Arterial blood gas anaysis pO2 (mmHg) in COVID-19 patients admitted to University Hospital of Verona|Arterial blood gas anaysis pCO2 (mmHg) in COVID-19 patients admitted to University Hospital of Verona|Arterial blood gas anaysis HCO3 (mmol\/l) in COVID-19 patients admitted to University Hospital of Verona|Arterial blood gas anaysis SpO2 (%) in COVID-19 patients admitted to University Hospital of Verona|Host-related factors associated with the pathogenesis of COVID-19|Virological factors associated with the pathogenesis of COVID-19""}"
"3814","Handling Oxygenation Targets in COVID-19","HOT-COVID","NCT04425031","AAUH-ICU-03|2017-000632-34","Drug: Oxygen","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04425031","Recruiting","2020-08-25","2024-03-01","{""locations"":""Dept. of Intensive Care, Aalborg University Hospital, Aalborg, Denmark|Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Herlev Hospital, Herlev, Denmark|Dept. of Intensive Care, Hiller\u00f8d Hospital, Hiller\u00f8d, Denmark|Dept. of Intensive Care, Holb\u00e6k Hospital, Holb\u00e6k, Denmark|Dept. of Intensive Care, Kolding Hospital, Kolding, Denmark|Dept. of Intensive Care, K\u00f8ge Hospital, K\u00f8ge, Denmark|Dept. of Intensive Care, Slagelse Hospital, Slagelse, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""780"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days alive without organ support|90-days mortality|Days alive out of the hospital|Number of patients with one or more serious adverse events|1-year mortality|Quality of life assessement using the EuroQoL EQ-5D-5L telephone interview|Cognitive function 1-year after randomisation as assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score in selected sites|Carbon monoxide diffusion capacity|A health economic analysis""}"
"3815","COVID-19 Serological Status of Hospital Staff Working or Not in the COVID-19 Sector","SEROCO","NCT04481529","87RI20_0049/SEROCO","Other: Health Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04481529","Active, not recruiting","2020-07-29","2021-01-15","{""locations"":""CH Argenteuil - Service de R\u00e9animation, Argenteuil, France|Ch Belfort, Belfort, France|CHU Dijon - Serve de R\u00e9animation, Dijon, France|CHU de Limoges, Limoges, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""1576"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of subjects with a COVID-19 seroconversion""}"
"3816","Sequencing and Tracking of Phylogeny in COVID-19 Study","STOP COVID 19","NCT04359849","PHT/2020/34","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359849","Recruiting","2020-05-01","2022-09-01","{""locations"":""Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""7 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""To produce whole genome sequences for the SARS-CoV-2 virus from viral RNA samples|To develop a phylogenetic map of the SARS-CoV-2 virus""}"
"3817","Viral Specific T-cells for Treatment of COVID-19","","NCT04406064","2020-0353","Biological: Viral Specific T-cells (VSTs)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04406064","Withdrawn","2021-01-01","2025-06-01","{""locations"":""Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Successful production of viral specific T-cells|Presence of viral-specific T-cells""}"
"3818","IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.","IMAGE-19","NCT04357613","P20/05_IMAGE19","Drug: Experimental drug","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04357613","Not yet recruiting","2020-09-01","2021-12-01","{""locations"":""CHU Bordeaux, Bordeaux, France|CH de Versailles, Le Chesnay, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""99"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.|To evaluate the feasibility of imatinib therapy.|To evaluate safety of imatinib therapy|To evaluate the clinical evolution|To evaluate the progression rate to severe COVID-19 disease|To evaluate mortality|To evaluate viral load|To evaluate plasmatic levels of imatinib""}"
"3819","Prognostic Factors Keeping Track for COVID-19 Pneumonia","NIKE_C19","NCT04324684","20202503","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04324684","Completed","2020-03-31","2020-05-07","{""locations"":""Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""198"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""rate of recovery|time to improvement|efficacy of treatments|organ failure""}"
"3820","Scaling Mental Healthcare in COVID-19 With Voice Biomarkers","","NCT04510519","COV-1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04510519","Not yet recruiting","2020-09-01","2021-06-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire (PHQ-9)|Generalized Anxiety Disorder (GAD-7)""}"
"3821","Impact of COVID-19 on Mental Health of Patients With Skin Picking","","NCT04522492","31520820.1.0000.5327","Behavioral: Internet-based Cognitive Behavioral Therapy|Other: Quality of life promotion","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04522492","Active, not recruiting","2020-08-11","2021-06-01","{""locations"":""Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Global Clinical Impression Scale|Change in Beck Anxiety Inventory|Change in Beck Depression Inventory|Change of Skin Picking Impact Scale|Change of emotional regulation|Change in Hamilton Anxiety Scale""}"
"3822","Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study","COVIDHomeless","NCT04408131","2020-32|2020-A01398-31","Biological: Blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04408131","Recruiting","2020-05-28","2021-01-27","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, Paca, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the covid mortality rate""}"
"3823","SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer","","NCT04425616","RHM CRI 0403","Other: Exercise|Behavioral: Psychological and Behaviour Change Support|Other: Nutrition","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04425616","Recruiting","2020-06-04","2022-11-30","{""locations"":""University Hospital Southampton NHS FT, Southampton, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical Function|Emotional Function|Health related quality of life|Health economics analysis|Patient activation|Self-reported physical activity|Nutrition assessment|Self-efficacy for self-management of chronic disease|Distress levels|Functional capacity|The impact of COVID-19 pandemic on psychological functioning|Process Evaluation""}"
"3824","Conséquences of the COVID-19 Lockdown Measures on the CHRU Nancy Pediatric Emergency Services","","NCT04668937","2020PI235","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04668937","Completed","2020-03-18","2020-06-30","{""locations"":""CHRU Nancy's Pediatric Emergencies, Vand\u0153uvre-l\u00e8s-Nancy, Lorraine, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""11000"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""Number of patient who came to Nancy's pediatric emergencies during the study period|Reason of consultation during the study period|Number of children who was send by a General practician|Medical reason to be sending by a General practician""}"
"3825","A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic","","NCT04341922","2020-01719","Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04341922","Active, not recruiting","2020-05-09","2021-09-10","{""locations"":""Karolinska Institutet, Stockholm, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""670"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""\u2022 Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)|Montgomery \u00c5sberg Depression Rating Scale - Self report (MADRS-S)|Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)|Insomnia Severity Index (ISI)|Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)|Intolerance of uncertainty Scale (IUS)|Patient Satisfaction Questionnaire (PSQ)|Adverse events (AE)""}"
"3826","Can the Prediction Market Improve Predictions of COVID-19?","","NCT04410692","SG-COVID","Other: Prediction Market","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04410692","Completed","2020-05-15","2020-05-17","{""locations"":""National University of Singapore, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""560"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictions of COVID-19 Cases and Deaths|Fear""}"
"3827","WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients","NeuroCovid","NCT04643548","NeuroCovid-RNI 2020 GODET","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04643548","Recruiting","2020-10-13","2021-08-13","{""locations"":""CHU, Clermont-Ferrand, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dosage of biomarkers typically explored in intensive care unit delirium|Dosage of neuronal injury markers|Delirium assessment|Coma assessment|Pupils characteristics|Neurological abnormalities""}"
"3828","Blood Donor Recruitment During Epidemic of COVID-19","","NCT04306055","Blood donor recruitment","Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04306055","Completed","2020-03-13","2020-04-03","{""locations"":""Guangzhou Blood Center, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""19491"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks""}"
"3829","Predictors of Mental Well-being During the COVID-19 Pandemic","","NCT04443699","REK125510-12","Behavioral: Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443699","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS)""}"
"3830","Role of Mega Dose of Vitamin C in Critical COVID-19 Patients","","NCT04682574","IRBEC/BIH/09-2020","Drug: Vitamin C","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04682574","Recruiting","2020-11-02","2021-01-10","{""locations"":""Bahria Town International Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Partial pressure of Oxygen in arterial blood to fraction of inspired Oxygen (P\/F ratio)|Hospital stay""}"
"3831","Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection","ImmuCoV","NCT04707820","2020/0100/HP","Diagnostic Test: ELISPOT","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04707820","Recruiting","2020-04-16","2021-06-10","{""locations"":""Rouen University Hospital, Rouen, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""80"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to the S protein|Numbers of T lymphocytes producing IFN in response to other CoV-2-SARS viral|Anti-SARS-CoV-2 IgG and IgM levels|SARS-CoV-2 viral load in nasopharyngeal swab""}"
"3832","Understanding Immunity to the Flu Vaccine in COVID-19 Patients","","NCT04579588","IRB-58356|5U19AI057229-17","Biological: Flu shot","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04579588","Enrolling by invitation","2020-10-29","2022-12-01","{""locations"":""Stanford University, Hospital, and Clinics, Stanford, California, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Testing immunity to the flu vaccine over time""}"
"3833","The Psychological Impact of the COVID-19 on Students.","","NCT04365361","UW20-298","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365361","Recruiting","2020-04-26","2021-03-31","{""locations"":""LAI Agnes, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stress level|Anxiety and depressive symptoms|Insomnia symptoms and the associated daytime impairment|Psychological response to trauma|Resilience|Attitude and practice students regarding preventive measures""}"
"3834","Ozone Therapy in the Prevention of COVID-19 Infection","","NCT04400006","2761","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04400006","Completed","2020-05-06","2020-05-17","{""locations"":""Kardelen Gencer Atalay, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""71"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The survey that was taken by telephone calls""}"
"3835","Taste and Smell Impairment in Critically Ill COVID-19 Patients","","NCT04532632","3334-02","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04532632","Completed","2020-09-01","2020-10-09","{""locations"":""Sisli Etfal Research and Training Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""taste and smell impairment""}"
"3836","Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)","","NCT04334434","002","Other: Telerehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04334434","Completed","2020-07-30","2020-12-15","{""locations"":""Istanbul university Cerrahpasa, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""30"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Physical Activity Scale for the Elderly|Nottingham Health Profile|Loneliness Scale for the Elderly""}"
"3837","Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital","","NCT04430062","Covid19nr1","Procedure: Surgical procedures performed under general anesthesia","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04430062","Completed","2020-05-01","2020-05-30","{""locations"":""Ospedale di Lodi - ASST Lodi, Lodi, Lombardia, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""14"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality""}"
"3838","BIO 300 Oral Suspension in Discharged COVID-19 Patients","","NCT04482595","CL0105-01|272201800011C-P00005-9999-1","Drug: BIO 300 Oral Suspension|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04482595","Recruiting","2020-11-11","2022-05-01","{""locations"":""NYU Langone Health, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""66"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in DLCO|Change in 6 Minute Walk Test|Change in FVC|Change in St. George's Respiratory Questionnaire (SGRQ) Scores|Change in Pulmonary Fibrosis on HRCT Scan|Incidence of Re-Hospitalization|All-Cause Mortality|Change in FEV1|Change in FEV1\/FVC Ratio|Change in Pulse Oximetry at Rest and During the 6MWT|Adverse Events Related to BIO 300 Oral Suspension|Change in Clinical Laboratory Values|Change in Clinical Laboratory Values for Albumin|Change in Clinical Laboratory Values for Serum Enzymes|Change in Complete Blood Counts with Differential""}"
"3839","Use of RDS MultiSense® in Post-ICU Patients in the COVID-19 Era","MONIREA","NCT04661423","20-004","Other: Remote Automated Monitoring System","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04661423","Not yet recruiting","2021-01-01","2022-06-01","{""locations"":""Anesthesia Department, Central Hospital, Nancy, France|Anesthesia, Critical Care & Perioperative Medicine, Hautepierre, Strasbourg, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determination of the quality of measurements of clinical signs provided by MultiSense\u00ae strip in comparison to measurements made with conventional medical devices in the hospital setting, in terms of accuracy.|Determination of the quality of measurements of clinical signs provided by MultiSense\u00ae strip in comparison to measurements made with conventional medical devices in the hospital setting, in terms of connectivity.|Determination of the quality of measurements of clinical signs provided by MultiSense\u00ae strip in comparison to measurements made with conventional medical devices in the hospital setting, in terms of generation of artifactual data.|Determination of the quality of measurements of clinical signs provided by MultiSense\u00ae strip in comparison to measurements made with conventional medical devices in the hospital setting, in terms of stability of data transmission.|Usability of a data acquisition patch by health care providers (HCPs) in the setting of post-ICU, rehabilitation unit assessed via a questionnaire.|User experience of post-ICU rehabilitation patients with the continuous use of the adhesive data acquisition patch during remote monitoring assessed via a patient's final questionnaire.|Assess patients' tolerability to prolonged use of an adhesive patch during remote monitoring.|Assess the correlation between body temperature and skin temperature|Assess the ability of the patch to detect and signal the clinically confirmed excursions of heart rate (high and low) outside predefined thresholds|Assess the ability of the patch to detect and signal the clinically confirmed excursions of SpO2 (low) outside predefined thresholds|Assess the ability of the patch to detect and signal the clinically confirmed excursions of respiratory rate (high and low) outside predefined thresholds""}"
"3840","Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)","COVID-PSL","NCT04402905","CREPATS 011","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04402905","Completed","2020-06-15","2020-08-15","{""locations"":""Yasmine Dudoit, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-PSL Cohort""}"
"3841","Parental Burnout During the COVID-19 Pandemic: Risk Factors and Predictors","","NCT04442386","REK125510-15","Other: Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442386","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The Parental Burnout Inventory (PBI)""}"
"3842","Effects of Fuzheng Huayu Tablets on COVID-19","","NCT04645407","Fzhy-ncp-1","Drug: Fuzheng Huayu tablet","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04645407","Completed","2020-02-01","2020-04-15","{""locations"":""Shuguang Hospital, Shanghai, Shanghai, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""66"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the percentage of patients showing improvement in chest CT|remission rate or progression rate of critical illness|clinical remission rate of respiratory symptoms|routine blood examination|C-reactive protein level|procalcitonin level|oxygen saturation""}"
"3843","Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms","SAVIORII","NCT04382391","2020-132-AGH","Device: gammaCore® Sapphire (non-invasive vagus nerve stimulator)|Other: Standard of care therapies","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04382391","Recruiting","2020-05-08","2022-06-30","{""locations"":""AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|AHN West Penn Hospital, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""summarize and compare the incidence of clinical events in patients randomized to use of gammaCore Sapphire plus standard of care vs standard of care alone in patients hospitalized for CoViD-19.|evaluate cytokine trends|evaluate supplemental oxygen requirements|decrease mortality of CoViD-19 patients|delay onset of ventilation|compare clinical improvement in patients randomized to use of gammaCore Sapphire plus standard of care vs standard of care alone in patients hospitalized for CoViD-19.""}"
"3844","Acupressure for COVID-19 Related Quality of Life and Stress","","NCT04472559","20-000773","Behavioral: Self-acupressure","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04472559","Not yet recruiting","2020-12-25","2021-02-25","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health Related Quality of Life|Perception of stress""}"
"3845","Influence of the COVId-19 Pandemic on STRESS and Eating Habits","COVISTRESSNutr","NCT04621084","2020 COVISTRESS NUTRITION","Behavioral: Eating habits","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04621084","Recruiting","2020-04-01","2025-12-31","{""locations"":""Clermont-Ferrand University Hospital, clermont-Ferrand, Aura, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""10 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Stress measures|Nutrition""}"
"3846","Recruit Blood Donors Via SMS During Epidemic of COVID-19","","NCT04370886","Recruit Blood Donors via SMS","Behavioral: blood donation SMS","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04370886","Completed","2020-04-30","2020-05-10","{""locations"":""Guangzhou Blood Center, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""456517"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Blood donation rate""}"
"3847","An Approach to Screening for COVID-19 at Vancouver Airport","","NCT04665193","H20-03225","Diagnostic Test: Rapid Antigen Test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04665193","Recruiting","2020-11-23","2021-04-30","{""locations"":""Vancouver International Airport, WestJet Domestic Terminal, Level 3, Richmond, British Columbia, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""900"",""age"":""19 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 status""}"
"3848","Obstetric and Perinatal Outcomes of Women With COVID-19","GROCO","NCT04369859","2020-18|ID RCB","Behavioral: Examine the impact of COVID-19 during pregnancy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04369859","Recruiting","2020-04-23","2021-04-22","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, Paca, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Compare the complications rates|Clinical presentation""}"
"3849","STEP: Building Trauma Resilience Among Nurses and Personal Support Workers During COVID-19","","NCT04682561","STP-01","Behavioral: Supportive Trauma Exposure Preparation Program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04682561","Not yet recruiting","2021-01-01","2022-02-01","{""locations"":""St. Michael's Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes from baseline to post-intervention (8 weeks) in healthcare worker burnout using Professional Quality of Life: Compassion Satisfaction and Fatigue Version 5 (ProQOL) burnout subscale|Changes in healthcare worker resilience using Connor-Davidson Resilience Scale 10 item (CD-RISC 10)|Changes in healthcare worker depression symptoms using Patient Health Questionnaire - 9 item (PHQ-9)|Changes in healthcare worker anxiety symptoms using Generalized Anxiety Disorder 7-item scale (GAD-7)|Changes in healthcare worker compassion satisfaction and secondary traumatic stress subscales of the Professional Quality of Life: Compassion Satisfaction and Fatigue Version 5 (ProQOL)|Changes in healthcare worker perceived quality of patient care|Changes in Sheehan Disability Scale (SDS) score|Changes in The Lam Employment Absence and Productivity Scale (LEAPS) score""}"
"3850","Determining the Reproductive Health of Men Post-COVID-19 Infection","","NCT04414904","20HH5998","Other: Exposure: Covid-19 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04414904","Withdrawn","2020-06-10","2020-06-10","{""locations"":""Channa Jayasena, London, Outside U.S.\/Canada, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""0"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Semen parameters|Sperm Parameters|Hormones measurement|Seminal Reactive oxygen species|Sperm DNA fragmentation rate""}"
"3851","Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers","PROVIDE","NCT04371523","3190","Drug: Apo-Hydroxychloroquine|Drug: Matched Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04371523","Not yet recruiting","2020-05-01","2020-08-30","{""locations"":""St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positive for SARS-CoV-2|Hospital admissions|Intensive care unit admissions|Intubation and mechanical ventilation|ICU length of stay|Hospital length of stay|Mortality|Incidence of adverse events""}"
"3852","Living With Sickle Cell Disease in the COVID-19 Pandemic","","NCT04417673","999920125|20-HG-N125","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04417673","Not yet recruiting","2021-03-16","2024-12-31","{""locations"":""National Human Genome Research Institute (NHGRI), Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stress|Anxiety|Depressive symptomology|Pain episodes, and severity|Healthcare utilization (primary care, emergency department, telehealth other)|Receptivity to future health recommendations and medical treatment(s).""}"
"3853","Risk Factors for Community- and Workplace Transmission of COVID-19","","NCT04320732","REK-124170","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04320732","Recruiting","2020-03-27","2030-03-20","{""locations"":""Oslo University Hospital, Oslo, Norway"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""250000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of COVID-19 infection""}"
"3854","Access to Chiropractic Care During the COVID-19 Pandemic","","NCT04666779","CohortChiroCOVID19","Other: Chiropractic care","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666779","Active, not recruiting","2020-12-18","2021-02-28","{""locations"":""Real Centro Universitario Mar\u00eda Cristina, San Lorenzo De El Escorial, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""399"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Pain intensity|Pain duration|Pain frequency|Pain perceived improvement|Pain interference|Pain Catastrophizing Scale|Tampa Scale Kinesiophobia|General Anxiety Disorder scale|Fear of Illness and Virus Evaluation""}"
"3855","Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women","","NCT04420806","ER_ACTLIFE_FU","Other: HIT-exercise|Other: Sham intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04420806","Completed","2020-03-14","2020-10-30","{""locations"":""Institute of Medical Physics, Friedrich-Alexanden University Erlangen-N\u00fcrnberg, Erlangen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""21"",""age"":""48 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Body composition|Hip-\/Leg extension strength|Metabolic Syndrome|Bone Mineral Density (BMD)|Menopausal symptoms|Back and joint pain""}"
"3856","Hydroxychloroquine in Outpatient Adults With COVID-19","","NCT04333654","EFC16855|2020-001269-35|U1111-1249-6168","Drug: Hydroxychloroquine SAR321068|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04333654","Terminated","2020-04-12","2020-05-26","{""locations"":""Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 0561001, Bruxelles, Belgium|Investigational Site Number 0561002, Lodelinsart, Belgium|Investigational Site Number 2501001, Bordeaux Cedex, France|Investigational Site Number 2501002, Paris, France|Investigational Site Number 5281001, Groningen, Netherlands|Investigational Site Number 5281002, Harderwijk, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""8"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events""}"
"3857","Impact of Colchicine in Hospitalized Colombian Patients With COVID-19","(COLCOVID19)","NCT04539873","5175","Drug: Colchicine 0.5 MG|Combination Product: CONTROL GROUP","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04539873","Not yet recruiting","2021-03-15","2021-09-15","{""locations"":""Fundaci\u00f3n Universitaria de Ciencias de La Salud, Bogota, Cundinamarca, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""128"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants who die or require transfer to Intesive care unit|Number of participants who die""}"
"3858","Improving Activity Engagement Among Persons With SCI During COVID-19","","NCT04408287","115929","Other: WebEx Physical Activity Program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04408287","Recruiting","2020-09-15","2021-10-31","{""locations"":""St. Josephs Parkwood Institute, London, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment Satisfaction|Ability to Participate in Social Roles and Activities|Fatigue|Satisfaction with Social Roles and Activities|Positive Affect and Well-Being|Pain Interference|Resilience|Self-Esteem""}"
"3859","Correlation Between Oxidative Stress Status and COVID-19 Severity","","NCT04375137","SBMU.12543","Diagnostic Test: Oxidative Stress ELISA Kit","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375137","Recruiting","2020-04-20","2021-05-30","{""locations"":""Nooshin Dalili, Tehran, Iran, Islamic Republic of"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""MDA concentration|Biopterin concentration|Neopterin rate of increase""}"
"3860","Psychological Symptoms and Families of COVID-19 Patients","","NCT04501445","20071101","Behavioral: Written Summary of Rounds","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04501445","Recruiting","2020-09-14","2021-09-15","{""locations"":""Rush University Medical Center, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms of Post-Traumatic Stress Disorder (PTSD) initial|Symptoms of Anxiety and Depression initial|Surrogate Satisfaction with the Patient's ICU Care:|Symptoms of Post-Traumatic Stress Disorder (PTSD) final|Symptoms of Anxiety and Depression final|Interview initial|Interview final""}"
"3861","Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19","","NCT04386291","7987","Behavioral: Anxiety Reduction Training|Behavioral: Kundalini Yoga and Anxiety Reduction Training|Behavioral: Meditation and Anxiety Reduction Training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04386291","Recruiting","2020-05-25","2022-01-30","{""locations"":""ProofPilot (Virtual Study: https:\/\/proofpilot.com\/covid-anxiety\/), New York, New York, United States|Columbia University Department of Psychiatry, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""360"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""GAD-7|Whiteley 8|PHQ-8|SS-8|Applied Cognition 1.0|PROMIS-4 Sleep Disturbance|ERQ|Perceived Stress Scale|Brief Hypervigilance Scale""}"
"3862","Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology","","NCT04440098","20200446","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04440098","Completed","2020-04-22","2020-05-11","{""locations"":""University of Miami, Miami, Florida, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""1008"",""age"":""18 Years to 35 Years \u00a0 (Adult)"",""outcome_measures"":""Loneliness as evaluated by the UCLA loneliness scale|Alcohol Use as evaluated by the AUDIT|Drug Use as evaluated by the DAST-10|Anxiety as evaluated by GAD-7|Depression as assessed by CES-D-10""}"
"3863","Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise","","NCT04444661","FrOST-FU","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444661","Active, not recruiting","2020-06-10","2020-12-31","{""locations"":""Institute of Medical Physics, Friedrich Alexander University Erlangen-N\u00fcrnberg, Erlangen, Bavaria, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""21"",""age"":""74 Years to 95 Years \u00a0 (Older Adult)"",""outcome_measures"":""SMI|BMD-LS|BMD-hip|Sarcopenia-Z-Score|Fat infiltration thigh muscles|Fat infiltration para-vertebral muscles|Maximum hip-\/leg extensor strength|Metabolic Syndrome Z-Score|Self rated physical performance""}"
"3864","Recovery of Exertion Ability Following COVID-19 Infection in Military Staff","CovEx","NCT04548505","2020-COVID19-30|2020-A02140-39","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04548505","Recruiting","2020-10-05","2023-04-05","{""locations"":""Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, Br\u00e9tigny-sur-Orge, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Magnitude of the decrease in aerobic performance on return to work""}"
"3865","VRQOL in Cataract Patients During the COVID-19 Pandemic","","NCT04468308","VRQOL Cataract COVID-19","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468308","Recruiting","2020-09-08","2021-03-01","{""locations"":""Medical University Innsbruck, Innsbruck, Tyrol, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""116"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement Vision-related quality of life|Delay of Vision-related quality of life|Visual acuity""}"
"3866","External Dead Space in Ventilated COVID-19 Patients","","NCT04424082","Karolinska","Other: Removal of dead space filter","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04424082","Recruiting","2020-06-09","2020-11-07","{""locations"":""Karolinska University Hospital, Stockholm, Sweden"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""40"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""change in carbon dioxide elimination (VCO2) i.e. ml CO2 eliminated\/minute|Changes in alveolar dead space (a Vcap derived parameter)|Changes in arterial carbon dioxide tension (PaCO2).""}"
"3867","Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19","","NCT04373148","IRB-55689|2U19AI057229|20-006-ACTT|1U54CA260517-01","Other: There is no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373148","Recruiting","2020-04-08","2022-04-30","{""locations"":""Stanford Health Care - ValleyCare, Pleasanton, California, United States|Stanford University, Hospital, and Clinics, Stanford, California, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""2 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Testing Immunity to SARS-CoV-2 over time|Testing the virus over time""}"
"3868","Medical Masks vs N95 Respirators for COVID-19","","NCT04296643","20006014","Device: Medical Mask|Device: N95 respirator","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04296643","Recruiting","2020-04-01","2021-04-01","{""locations"":""Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Brantford General Hospital, Brantford, Ontario, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Hopital Montfort, Ottawa, Ontario, Canada|Niagara Health Services, St. Catherines, Ontario, Canada|St. Joe's Unity Health, Toronto, Ontario, Canada|St. Mike's Unity Health, Toronto, Ontario, Canada|Montreal University Health Centre, Montr\u00e9al, Quebec, Canada|The Jewish General Hospital, Montr\u00e9al, Quebec, Canada|Golden Care LTCF, Tzrifin, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""576"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""RT-PCR confirmed COVID-19 infection|Acute respiratory illness|Absenteeism|Lower respiratory infection|Pneumonia|ICU admission|Mechanical ventilation|Death""}"
"3869","Mental Health in Communities Affected by COVID-19 in Uganda","","NCT04616989","Integration of mental health","Behavioral: Psycho-education|Behavioral: Comparator","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04616989","Not yet recruiting","2021-01-01","2021-07-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""840"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in mental health literacy|Burden of anxiety disorders in the community|Burden of PTSD in the community|Burden of substance use disorders in the community|Burden of depression disorders in the community""}"
"3870","Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic","","NCT04431297","GCO 20-1022","Other: Mindfulness Rounds","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04431297","Not yet recruiting","2021-04-01","2022-06-01","{""locations"":""Icahn School of Medicine at Mount Sinai, New York, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Perceived Stress Scale""}"
"3871","MRI Changes of Acute Kidney Injury in COVID-19","MRI-AIDED","NCT04594291","UHDB/2020/077|287571","Procedure: MRI scans","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04594291","Recruiting","2020-10-07","2023-09-01","{""locations"":""University Hospitals of Derby and Burton NHS Foundation Trust, Derby, Derbyshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""MRI assessment of global organ structure at 12 months.|MRI assessment of thrombi (R2*) at 12 months.|MRI assessment of organ perfusion (Arterial spin labelling [ASL]) at 12 months.|MRI assessment of global organ structure.|MRI assessment of thrombi (R2*).|MRI assessment of organ perfusion (ASL)|Correlations between MRI measures with estimated glomerular filtration rate.|Correlations between MRI measures with urine albumin and protein creatinine ratios.|Correlations between MRI measures with mental component score.|Correlations between MRI measures with physical component score.|Correlations between MRI measures with health state score.|Correlations between MRI measures with visual analogue score.|Correlations between MRI measures with fatigue severity.|Correlations between MRI measures with fatigue score.|Correlations with MRI measures with skin autofluorescence levels.|Mean change in mental component score.|Mean change in physical component score.|Mean change in health state score.|Mean change in visual analogue score.|Mean change in fatigue severity scale.|Mean change in fatigue score.|Mean change in skin autofluorescence levels.|Incidence of kidney disease progression.|Incidence of cardiovascular events.|Correlations between MRI measures with all-cause mortality.""}"
"3872","EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19","EPI CV COVID","NCT04498091","Zeller AOIc 2020","Biological: Biological data|Other: Clinical data","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04498091","Active, not recruiting","2020-03-15","2021-07-01","{""locations"":""Chu Dijon Bourgogne, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""35"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection""}"
"3873","COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay","","NCT04452318","R10933-10987-COV-2069","Drug: REGN10933 + REGN10987|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04452318","Recruiting","2020-07-13","2021-08-15","{""locations"":""Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Northridge, California, United States|Regeneron Study Site, Oxnard, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Eatonton, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Sandy Springs, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 2, Chicago, Illinois, United States|Regeneron Study Site 3, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 1, Downers Grove, Illinois, United States|Regeneron Study Site 2, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Metairie, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site 1, Boston, Massachusetts, United States|Regeneron Study Site 2, Boston, Massachusetts, United States|Regeneron Study Site 3, Boston, Massachusetts, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Gulfport, Mississippi, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Hazelwood, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Fayetteville, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Gaffney, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Charlottesville, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Yakima, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucharest, Romania"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""2450"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of participants who have a RT-qPCR confirmed SARS-CoV-2 infection (either symptomatic or asymptomatic) during the EAP|Proportion of participants with treatment-emergent adverse events (TEAEs) and severity of TEAEs|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and absence of signs and symptoms (broad term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and absence of signs and symptoms (strict term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR (based on central lab test) and signs and symptoms (strict term) of SARS-CoV-2 infection during the EAP|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (CDC definition) during the EAP|Number of days of symptomatic SARS-CoV-2 infection (strict-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive SARS-CoV-2 RT-PCR that occurs during the EAP|Number of days of symptomatic SARS-CoV-2 infection (broad-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive SARS-CoV-2 RT-PCR that occurs during the EAP|Time-weighted average of viral load (log10 copies\/mL) from the first positive SARS CoV-2 RT-qPCR Nasopharyngeal (NP) swab sample (that has an onset during the EAP) until the visit within the window including 22 days after the positive test during the EAP|Maximum SARS-CoV-2 RT-qPCR log10 viral copies\/mL in NP swab samples among individuals with \u22651 RT-qPCR positive that has an onset during the EAP|Area under the curve (AUC) in viral load (log10 copies\/mL) from the first positive SARS-CoV-2 RT-qPCR NP swab sample until the first confirmed negative test, that has an onset during the EAP|Number of medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection that has an onset during the EAP|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days missed for daily responsibilities (where applicable) due to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Proportion of subjects who have a positive SARS-CoV-2 RT-qPCR confirmed infection (based on central lab test) during the EAP.|Proportion of baseline seropositive subjects (based on central lab test) with TEAEs and severity of TEAEs|Incidence of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods|Severity of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods|Concentrations of REGN10933 in serum over time and selected PK parameters in seronegative and seropositive participants (based on central lab test)|Concentrations of REGN10987 in serum over time and selected PK parameters in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to REGN10933 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to REGN10987 over time in seronegative and seropositive participants (based on central lab test)|Proportion of participants who subsequently develop signs and symptoms (strict-term) of symptomatic SARS-CoV-2 infection during EAP|Proportion of participants who subsequently develop signs and symptoms (broad-term) of symptomatic SARS-CoV-2 infection during EAP|Proportion of participants who subsequently develop signs and symptoms (CDC definition) of symptomatic SARS-CoV-2 infection during the EAP|Number of days of symptomatic SARS CoV-2 infection (strict-term)|Number of days of symptomatic SARS CoV-2 infection (broad-term)|Time-weighted average change from baseline in viral load (log10 copies\/mL) in NP swab samples until the visit within the window including day 23|Area under the curve (AUC) in viral load (log10 copies\/mL) in NP swab samples until the first confirmed negative test|Maximum SARS-CoV-2 RT-qPCR log10 viral copies\/mL in NP swab samples|Number of medically attended visits in emergency rooms or urgent care centers related to RT-qPCR confirmed SARS-CoV-2 infection|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection|Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection|Number of days missed for daily responsibilities (where applicable) due to a RT-qPCR confirmed SARS-CoV-2 infection|Proportion of participants with TEAEs and severity of TEAEs|Incidence of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods|Severity of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods""}"
"3874","Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases","","NCT04530461","UR17DN02-002","Diagnostic Test: Serological test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04530461","Recruiting","2020-06-01","2021-01-31","{""locations"":""Military Hospital of Tunis, Tunis, Tunisia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serological Profile""}"
"3875","Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19)","","NCT04435106","0123-20- SZMC","Drug: Opaganib|Drug: Standard of Care","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04435106","Completed","2020-04-03","2020-05-15","{""locations"":""Shaare-Zedek Medical Center, Jerusalem, Israel"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""23"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure the time to weaning from high-flow nasal cannula|Measure the time to breathing ambient (room) air|Measure change in lymphocyte count|Measure change in C-reactive protein""}"
"3876","Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE)","","NCT04704544","IRB-300006553","Other: Tele-rheumatology","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04704544","Not yet recruiting","2021-03-01","2022-11-30","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment"",""enrollment"":""320"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient satisfaction|Patient preference""}"
"3877","Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19","MAGIC","NCT04429815","2020-A01681-38","Diagnostic Test: Serological test for COVID-19.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04429815","Not yet recruiting","2020-07-01","2021-04-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""489"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with a positive serological test for COVID-19.""}"
"3878","Surfactant Levels in the Lungs of COVID-19 Patients","","NCT04609488","SJ-859x","Diagnostic Test: Surfactant assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04609488","Not yet recruiting","2020-11-01","2022-10-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Surfactant""}"
"3879","Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)","REMOTE-COVID","NCT04337489","REMOTE-COVID","Device: SensiumVitals wearable sensor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337489","Not yet recruiting","2020-07-28","2021-04-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Deterioration resulting in healthcare review|Hospitalisation|Participant anxiety|Participant depression""}"
"3880","Hesperidin and Diosmin for Treatment of COVID-19","","NCT04452799","1111","Drug: Hesperidin and Diosmin mixture","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04452799","Not yet recruiting","2020-07-01","2020-10-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PCR test|respiratory rate|patients PaO2|serum IL1\u03b2|serum TNF-\u03b1|Mortality rate""}"
"3881","Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients","","NCT04346589","DFPP COVID 19","Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346589","Recruiting","2020-04-15","2020-08-01","{""locations"":""IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy|ASST HPG23 - Unit of Nephrology, Bergamo, Italy|ASST Papa Giovanni XXIII - Microbiology and Virology Unit, Bergamo, Italy|Asst Pg23 - S.I.M.T, Bergamo, Italy|ASST-PG23 - Intensive Care Unit, Bergamo, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of mechanical ventilation days.|Survival|Shift to Continuous Positive Airway Pressure (CPAP) ventilation|Referral to a sub-intensive care unit or discharge|Viral titer|Anti COVID 19 IgG antibodies|Anti COVID 19 IgM antibodies|C5a concentration|C3a concentration|Serum C5b-9 concentration""}"
"3882","C-reactive Protein Levels Among Individuals With COVID-19","","NCT04373798","APPI2-CV-2020-02","Diagnostic Test: C-reactive protein","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373798","Recruiting","2020-05-04","2020-11-30","{""locations"":""The Parker Institute, Frederiksberg Hospital, Copenhagen, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalisation|Death|Transfer to Intensive Care Unit|Oxygen treatment during hospitalisation""}"
"3883","The Impact of COVID-19 Pandemic on Thyroid Surgery in Italy: Results From a Nation-wide Multicentric Study","","NCT04635813","THYCOVIT","Procedure: Thyroidectomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04635813","Completed","2020-03-10","2020-11-12","{""locations"":""AOU Cagliari, Cagliari, CA, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""3800"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Quantify the overall reduction of surgical activity for thyroid disease|Quantify if the number of thyroid cancers operated during COVID-19 pandemic was significant different from the number of patients operated during the same period of the previous year|Quantify the number of aggressive tumors operated during COVID-19 pandemic and the same period of the previous year""}"
"3884","Impact of Isolation in Patients With IBD During the COVID-19 Crisis","","NCT04488471","STH21414","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04488471","Recruiting","2020-06-30","2022-06-30","{""locations"":""Sheffield Teaching Hospitals NHS FT, Sheffield, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""232"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""What impact has the isolation of patients during social isolation had in terms of psychological morbidity?|Have levels of psychological morbidity in young people changed from levels prior to the CoViD pandemic?""}"
"3885","Accurate Classification System for Patients With COVID-19 Pneumonitis","","NCT04302688","COVID-19 WU1","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04302688","Completed","2019-12-10","2020-03-04","{""locations"":""Renmin Hospital of Wuhan University, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""669"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""survival status""}"
"3886","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","STOP-COVID","NCT04343898","2007P000003","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04343898","Active, not recruiting","2020-04-01","2022-08-01","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""5220"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28-Day Mortality|60-Day Mortality|90-Day Mortality""}"
"3887","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","COVID-preg","NCT04319016","145/20","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04319016","Recruiting","2020-01-01","2020-05-01","{""locations"":""Gabriele Saccone, Napoli, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Maternal and perinatal outcomes""}"
"3888","Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide","","NCT04406246","2020-04-682","Drug: Nitazoxanide 500Mg Oral Tablet","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04406246","Recruiting","2020-05-21","2020-12-31","{""locations"":""Materno-Perinatal Hospital \""M\u00f3nica Pretelini\"", Toluca, Mexico"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health workers that require hospitalization""}"
"3889","Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.","","NCT04479280","17300446","Device: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479280","Completed","2020-07-20","2020-08-16","{""locations"":""Assiut university, Assiut, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""70"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""clot rate formation""}"
"3890","Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients","","NCT04686760","IRBEC/BIH/08-2020","Drug: Nitroglycerin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04686760","Recruiting","2020-11-15","2021-01-15","{""locations"":""Bahria Town International Hospital, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen|Oxygen demand|Duration of hospital stay""}"
"3891","Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis","","NCT04384458","HCQ+IVM","Drug: Hydroxychloroquine|Drug: Ivermectin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04384458","Recruiting","2020-07-20","2021-04-01","{""locations"":""Drug Research and Development Center (NPDM), Federal University of Cear\u00e1 (UFC), Fortaleza, Cear\u00e1, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""400"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants in whom there was a positivity for SARS-CoV-2.|Participants who developed mild, moderate, or severe forms of COVID-19.|Measurement of the QT interval.|Widening of the corrected QT interval or with changes in heart rate on the ECG.|Comparison of hematological and biochemical parameters.|Occurrence of adverse events.|Assessment of COVID-19 symptom severity.|Proportion of participants who discontinue study intervention.|Proportion of participants who required hospital care.|Proportion of participants who required mechanical ventilation.""}"
"3892","Intravascular Access in Suspected/Confirmed COVID-19 Patient","","NCT04366947","IO_PPE_1","Device: NIO® (Intraosseous access)|Device: Standard of Care (Intravenous access)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04366947","Completed","2020-04-14","2020-10-30","{""locations"":""Lazarsku University, Warsaw, Masovian, Poland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Success rate of first intravascular access attempt|time to successful access|number of attempts to successful access|time to infusion|complication rates|ROSC""}"
"3893","Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak","","NCT04448704","CCF@EXPO/R001/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04448704","Completed","2020-06-22","2020-10-11","{""locations"":""EXPO, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1011"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""DASS-21 Scores""}"
"3894","The Impact of Information Sources on Mental Health During the COVID-19 Pandemic","","NCT04442360","REK125510-13","Behavioral: Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442360","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire 9|Generalized Anxiety Disorder 7""}"
"3895","Supporting Family Members With Severe Grief Reaction During the COVID-19 Pandemic","","NCT04588415","20200653-01H","Other: Bereavement Virtual Support Group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04588415","Enrolling by invitation","2021-01-03","2022-01-01","{""locations"":""Ottawa Hospital, Ottawa, Ontario, Canada"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The Inventory for Complicated Grief-revised (ICG-r) score at 6 months post-death|The Inventory for Complicated Grief-revised (ICG-r) score at 12 months post-death|Change in ICG-r score from 6 months to 12 months post-death|Qualitative Interviews Post-Virtual Support Group""}"
"3896","Predictors and Mechanisms of Depression and Anxiety During the COVID-19 Pandemic","","NCT04442204","REK125510-10","Other: Prospective study across two time-points examining the impact of viral mitigation protocols on mental health","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442204","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire 9|Generalized Anxiety Disorder 7""}"
"3897","Effects on the Qt Interval of COVID-19 Coronavirus Infection","QT-COVID-19","NCT04422535","QT-COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422535","Recruiting","2020-05-29","2020-12-01","{""locations"":""Servicio de Anestesia, Hospital General Universitario Gregorio Mara\u00f1on, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessing the QT and QTc interval in patients admitted to intensive care units for COVID-19 infection|incidence of arrhythmias and impact of the COVI-drugs administered on QT interval""}"
"3898","The Investigation of the Neonates With or With Risk of COVID-19","","NCT04279899","CHFudanU_NNICU14","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04279899","Recruiting","2020-02-01","2023-12-31","{""locations"":""Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""up to 28 Days \u00a0 (Child)"",""outcome_measures"":""The death of newborns with COVID-19|The SARS-CoV-2 infection of neonates born to mothers with COVID-19|The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19|The small for gestational age newborns in the neonates born to mothers with COVID-19|The preterm delivery of neonates born to mothers with COVID-19|The disease severity of neonates with COVID-19""}"
"3899","Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children","PSICOcs","NCT04475484","PSICOcs_2020","Other: Online questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04475484","Recruiting","2020-06-10","2020-12-31","{""locations"":""h\u00f4pital Femme M\u00e8re Enfant, Bron, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""30000"",""age"":""6 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Proportion of children presenting signs of psychological suffering during confinement.""}"
"3900","Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study","MODIF","NCT04357314","2020-03","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357314","Completed","2020-03-01","2020-05-31","{""locations"":""H\u00f4pital Universitaire Car\u00e9meau, N\u00eemes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""6332"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary endpoint is a composite of death from all causes and mechanical complications of acute myocardial infarction (MI)|Rates of patients presenting with acute myocardial infarction|Patient profile during admission for acute myocardial infarction|Medical care times analysis|Clinical evolution of patients|STEMI (ST Segment Elevation Myocardial Infarction) admissions incidence rates|Proportion of patients who underwent systemic thrombolysis|Proportion of patients infected with COVID-19""}"
"3901","1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study","TMX COVID","NCT04395742","TMX COVID","Other: Data collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395742","Not yet recruiting","2020-05-01","2020-12-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""93"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of vital status|Comparaison of duration of hospital stay|Comparaison of severity|Comparaison of secondary effects (adverse events that needed disruption of treatment (anemia, tachycardia, osteoporosis) : secondary effects of coffee).|Comparaison of use of antibiotics""}"
"3902","sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?","COVIDsFlt1","NCT04394195","PO20043*","Other: measurement of circulating sFlt1 concentration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04394195","Recruiting","2020-03-25","2020-09-01","{""locations"":""Chu Reims, Reims, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Association between concentration of circulating sFlt1 and use of vasopressor""}"
"3903","Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic","","NCT04632368","Pro00106191","Behavioral: Transcendental Meditation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04632368","Recruiting","2020-11-20","2021-04-01","{""locations"":""Duke University health system, Durham, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""change in self reported Stress symptoms|Change in self reported resilience|Change in symptoms of depression|Change in insomnia symptoms|Change in anxiety symptoms|Change in psychological distress|Change in self reported burnout symptoms""}"
"3904","Patient Preference Trial for COVID-19 (PPT-COVID)","PPT-COVID","NCT04418193","20-08","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04418193","Withdrawn","2020-04-06","2021-02-04","{""locations"":""Centre Hospitalier Princesse Grace, Monaco, Monaco"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""0"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the World Health Organisation (WHO) Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) Reverse Transcriptase (RT) - Polymerase Chain Reaction (PCR) on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older""}"
"3905","ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19","","NCT04460677","Pro2020001593","Behavioral: Emotional Support Plan|Behavioral: Daily Monitoring","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04460677","Recruiting","2020-08-12","2021-03-31","{""locations"":""Rutgers University, Piscataway, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decreased distress on Patient Health Questionnaire (PHQ-9)|Decreased distress on EMA reports|Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)|Adult Self Report (ASR)""}"
"3906","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","TOVID-49","NCT04333849","2020/29","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04333849","Completed","2020-03-25","2020-05-11","{""locations"":""Angers University Hospital, Angers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""132"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication.""}"
"3907","Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis","","NCT04315480","TOCICOV-1","Drug: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04315480","Active, not recruiting","2020-03-12","2020-05-01","{""locations"":""Universit\u00e0 Politecnica delle Marche, Ancona, AN, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""38"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death""}"
"3908","Health Care Use During the Covid19 Crisis","US3R","NCT04372030","US3R","Other: Online questionnaire","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04372030","Not yet recruiting","2020-05-01","2021-10-31","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health care use|Postponed heath care use|Foregone health care use""}"
"3909","Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke","","NCT04535297","203/20","Other: exposure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04535297","Completed","2020-05-10","2020-06-30","{""locations"":""Galit Yogev-Seligmann, Haifa, Please Select..., Israel"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""198"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Activation Measure (PAM\u00ae)|Answers to multiple-choice questions""}"
"3910","Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19","","NCT04341493","2020-03-681","Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04341493","Recruiting","2020-04-06","2020-12-30","{""locations"":""Materno-Perinatal Hospital \""M\u00f3nica Pretelini\"", Toluca, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""86"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation requirement""}"
"3911","Distance Learning for Dental Student During COVID-19 Pandemic","","NCT04401371","Distance learning environment","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401371","Completed","2020-05-01","2020-05-10","{""locations"":""Faculty of Dentistry, Cairo, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""418"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""assessment of distance education learning environment experiences among dental students enrolled in pediatric dentistry online course during COVID-19 crisis""}"
"3912","Individual and Institutional Resilience in Migrant Workers During the COVID-19 Pandemic","","NCT04718519","510d2","Behavioral: Factors promoting resilience","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04718519","Completed","2020-06-22","2020-10-11","{""locations"":""Yale NUS, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1288"",""age"":""21 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Self-rated well-being|Demographics""}"
"3913","Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses","","NCT04377100","999920112|20-M-N112","Behavioral: Computer task questionnaires","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04377100","Recruiting","2021-03-16","2022-02-28","{""locations"":""National Institute of Mental Health (NIMH), Bethesda, Maryland, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patterns of neural connectivity as predictors""}"
"3914","Recruit Blood Donors Via SMS During Epidemic of COVID-19 （Repeat Trial）","","NCT04410458","Recruit Blood Donors via SMS 2","Behavioral: blood donation SMS","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04410458","Enrolling by invitation","2020-05-31","2020-06-12","{""locations"":""Guangzhou Blood Center, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""506517"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Blood donation rate""}"
"3915","Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units","","NCT04459975","CoV-AKI_2020","Other: Non interventional study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459975","Recruiting","2020-04-01","2020-11-01","{""locations"":""Intensive care units attached to the Hospices Civils de Lyon (HCL), Lyon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary endpoint is the incidence, the severity and the mortality associated with AKI during COVID-19 severe infection""}"
"3916","The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families","","NCT04365348","UW20-300","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365348","Recruiting","2020-04-27","2021-06-30","{""locations"":""Agnes, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Stress level|Negative emotion|Psychological response to trauma|Severity of insomnia symptoms and the associated daytime impairment|Resilience|Quality of family functioning|Social support|Psychological effects""}"
"3917","Clinical Characteristics of Critically Ill Patients With COVID-19","","NCT04413435","2020-245","Other: File Scanning","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04413435","Completed","2020-10-30","2020-12-25","{""locations"":""Konya Trainig and Research Hospital, Konya, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""105"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Polymerase Chain Reaction (PCR) test|A scoring system for patients to be admitted to the intensive care unit""}"
"3918","Health Care Workers' Perception of Patient Safety During COVID-19 Pandemic","","NCT04576299","2020-09","Other: Group 1","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04576299","Active, not recruiting","2020-09-01","2020-12-15","{""locations"":""Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile|Universidad de Santander, Bucaramanga, Santander, Colombia|Universidad Cat\u00f3lica de Santiago de Guayaquil, Guayaquil, Guayas, Ecuador|Miguel Hern\u00e1ndez University, Elche, Alicante, Spain"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Safety perception.""}"
"3919","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","NOSARSCOVID","NCT04290871","NO-SARS-COVID-19","Drug: Nitric Oxide Gas","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04290871","Withdrawn","2020-03-23","2022-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2\/FiO2 ratio in ambient air""}"
"3920","Mental Health Impact of the COVID-19 Pandemic on Amish and Mennonite Participants in AMBiGen","","NCT04684615","10000038|000038-M","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04684615","Enrolling by invitation","2021-03-16","2022-07-31","{""locations"":""National Institute of Mental Health (NIMH), Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To describe the relationship between stressors related to COVID-19, self-rated measures of mental health symptoms, and distress among a range of participants including various patient populations and healthy volunteers.|Determine if existing mental health concerns moderate the relationship between stressors related to COVID-19, self-rated measures of mental health symptoms, and distress. Identify risk and resilience factors surrounding mental health and behavio...""}"
"3921","Yoga in NHS Health Care Workers With COVID-19 Related Stress","","NCT04481516","DBH 1058/2020/HRAS","Other: Yoga","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04481516","Recruiting","2020-07-01","2021-02-01","{""locations"":""Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, South Yorkshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Alleviated stress 1 - short term|Alleviated stress 2 - short term|Alleviated stress 3 - short term|Alleviated stress 1 - medium term|Alleviated stress 2 - medium term|Alleviated stress 3 - medium term""}"
"3922","Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis","","NCT04451239","COVID-19 keratoconjunctivitis","Drug: topical steroids and cyclosporin-A","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04451239","Not yet recruiting","2020-06-30","2020-07-01","{""locations"":""Farawanyia hospital, Kuwait, Farawanyia, Kuwait"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Symptom improvement|Signs improvement""}"
"3923","Epigenetic Tools as Prognostic Predictors in Covid19","","NCT04411563","2020/143","Other: Taking biological samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04411563","Recruiting","2020-05-21","2020-12-01","{""locations"":""Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""105"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determination of the relationship between the severity of disease and epigenetic factors in COVID 19""}"
"3924","Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.","","NCT04621058","VITD","Drug: Vitamin D|Drug: PLACEBO","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04621058","Recruiting","2020-11-09","2021-11-30","{""locations"":""Joaqu\u00edn Dur\u00e1n Cantolla, Vitoria-Gasteiz, Alava, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""108"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""MORTALITY|Intensive care admissions|Length of hospital stay|Prevalence of vitamin D deficiency|Incremental cost effectiveness ratio (ICER)""}"
"3925","Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic","","NCT04459455","IRB2020-00204","Behavioral: Contain COVID Anxiety SSI|Behavioral: Remain COVID Free SSI","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04459455","Completed","2020-08-19","2020-10-15","{""locations"":""Stony Brook University, Stony Brook, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Anxiety Control Questionnaire (ACQ) from Baseline to Immediately Post-Intervention|Change in Generalized Anxiety Disorder-7 (GAD-7) from Baseline to 2-week follow-up|Change in Activity Social Distancing Intentions - 3 item version (SOC-D) from Baseline to immediately post-intervention|COVID-19 Related Questions|Inventory of Depression and Anxiety Symptoms (IDAS)|Self Hate Scale (SHS)|Comprehension Questions|Everyday Discrimination Scale-Short version|Perceived Changes in generalized anxiety symptoms|Activity Hand Washing Intentions - 3 item version (WASH-I)""}"
"3926","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment","","NCT04337151","RNOH MAGEC","Device: MAGEC Spine Rod|Diagnostic Test: Titanium blood test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337151","Recruiting","2020-04-01","2021-03-01","{""locations"":""Royal National Orthopaedic Hospital, Stanmore, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Titanium level""}"
"3927","Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients","","NCT04344509","PAVM COVID","Other: Bacterial species isolated","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344509","Not yet recruiting","2020-06-01","2020-12-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""10000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of the microorganisms responsible for VAP among patients infected or not by the SARS-CoV-2|Prevalence of multi-drug resistant bacteria responsible for VAP among patients infected or not by the SARS-CoV-2""}"
"3928","Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#","","NCT04431180","Recruit Blood Donors via SMS 3","Behavioral: blood donation SMS","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04431180","Enrolling by invitation","2020-06-13","2020-06-30","{""locations"":""Guangzhou Blood Center, Guangzhou, Guangdong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""403535"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Blood donation rate""}"
"3929","Clinical Characteristics and Prognostic Factors of Patients With COVID-19","","NCT04328454","HBCBH-IEC-2020-101","Other: retrospective analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04328454","Recruiting","2020-01-30","2020-04-15","{""locations"":""Shanghai 10th People's Hospital, Shanghai, Shanghai, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation""}"
"3930","COVID-19: Laser Interferometry for Rapid Single Coronavirus Detection","COLIDE","NCT04401644","RBA20203","Diagnostic Test: Novel laser inferometry test for CORONA virus","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04401644","Not yet recruiting","2020-06-01","2021-12-01","{""locations"":""Somerset NHS Foundation Trust, Taunton, Somerset, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""250"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""kappa value|sensitivity and specificity""}"
"3931","Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)","DECOR-19","NCT04488549","Treviso","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04488549","Completed","2020-05-20","2020-06-10","{""locations"":""Treviso Regional Hospital, Treviso, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1051"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Predictive power of respondents' and hospitals' demographics on delaying colorectal cancer care across 6 geographical regions""}"
"3932","Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19","","NCT04524754","FMASUP46a/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04524754","Recruiting","2020-07-11","2020-11-30","{""locations"":""Ain shams Univesrity, Cairo, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""218"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""olfaction|gustation""}"
"3933","Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic","","NCT04497467","202006225RINA","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04497467","Recruiting","2020-08-01","2020-12-31","{""locations"":""National Taiwan University Hospital, Taipei, Taiwan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1200000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""the number of the out-patient visits""}"
"3934","A Gamified Network for Surgical Education During COVID-19: A Randomized Controlled Trial","","NCT04425499","CERSES 20-068-D","Other: Learning running subcuticular sutures on the Gamified Educational Network","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04425499","Not yet recruiting","2020-06-01","2020-06-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retention of the correct technique for running subcuticular sutures|Technical ability to perform a subcuticular suture|Satisfaction with the GEN platform""}"
"3935","Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic","","NCT04661410","2009008088|R01MH122392-01S1","Behavioral: Reward Re-Training|Behavioral: Supportive Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04661410","Recruiting","2020-12-01","2022-03-30","{""locations"":""Drexel University, Stratton Hall, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Binge eating frequency assessed by the Eating Disorder Examination|Global Eating Pathology|Remission Status|Compensatory behavior frequency assessed by the Eating Disorder Examination (EDE)|Depressive symptoms as assessed by the Beck Depression Inventory-II|Substance Use assessed by the NIDA-Modified ASSIST|Quality of Life assessed by the Quality of Life Inventory (QOLI)""}"
"3936","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","COVID-SER","NCT04341142","69HCL20_0329","Diagnostic Test: Serological tests will be applied on patients blood sampling","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04341142","Recruiting","2020-04-09","2024-04-09","{""locations"":""H\u00f4pital Lyon Sud,Sainte Eug\u00e9nie bat 4M,5, Chemin du Grand Revoyet, Pierre-B\u00e9nite cedex, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""550"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The positivity (Yes\/No) of the serological test.|Measurement of IgM and IgG antibody titer at each sampling of weekly and monthly visits of covid-19+ patients and implementation of the kinetics of mean appearance.|- Among the symptomatic PCR negative patients recruited into the study at the first visit, the measurement of the IgM antibody and IgG titer will be performed in serum at D28, and the positive results will then constitute the false-negative PCR results.|- Measurement of IgM and IgG antibody titer at each sampling of late patient visits.|- The neutralizing capacity of the antibodies will be determined by in vitro serum neutralization tests on seropositive serum. A group of 50 patients made up of seropositive and asymptomatic caregivers at the time of infection will represent this group.""}"
"3937","Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry","ISACS-STEMI","NCT04412655","115/20","Device: Percutaneous Coronary Revascularization for STEMI","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412655","Active, not recruiting","2020-05-05","2020-06-02","{""locations"":""Giuseppe De Luca, Novara, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""6609"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of patients undergoing primary angioplasty|Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset;|Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission|In-hospital mortality""}"
"3938","Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge","","NCT04417270","20-0455","Device: Freestyle Libre 14 day CGM system|Device: Accuchek Inform II platform","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04417270","Completed","2020-06-12","2020-11-30","{""locations"":""Lenox Hill Hospital, New York, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""52"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of values between two devices""}"
"3939","A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19","COVSurf","NCT04362059","RHM CRI0399","Device: COVSurf Drug Delivery System|Other: Standard of Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04362059","Recruiting","2020-06-18","2021-11-16","{""locations"":""University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygenation Improvement|Pulmonary ventilation Improvement|Safety Assessment of Frequency and Severity of Adverse Events""}"
"3940","Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial","BREATH","NCT04399798","2020-001185-11","Drug: Baricitinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04399798","Not yet recruiting","2020-05-15","2020-11-15","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""13"",""age"":""18 Years to 74 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Response to treatment: absence of moderate to severe oxygenation impairment (Berlin criteria)|Response to treatment: survival|To quantify the rate of each of: moderate or severe oxygenation impairment within 8 days|To quantify the rate of each of: moderate or severe oxygenation impairment within 15 days|Mortality|Peripheral capillary oxygen saturation (SpO2)|Partial pressure of oxygen\/fraction inspired oxygen (PaO2\/FiO2)|To assess the rate of patients admitted to the intensive care unit|To measure the length of hospital stay|28-day mortality|To quantify the rate of re-admission within 28 days|To quantify the cumulative incidence and severity of adverse events|Interleukin (IL)-1; IL-2; IL-10; IL-6; IL-8; IL-17; IL-2 receptor levels;|TNFalpha; vascular endothelial growth factor (VEGF); interferon gamma (IFNgamma) levels|Viral load analyses""}"
"3941","Status of Management of Surgery in Beijing During COVID-19","","NCT04401124","BFH-SurgeryCovid","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04401124","Not yet recruiting","2020-05-25","2020-06-07","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""treatment of fevers at arrival|treatment of post-operative fevers|assorted surgical parameters|hospitals' protection measures and extent of implementation""}"
"3942","Prediction of the Patient Pathway in Emergency Room in an Exceptional Sanitary Situation","3PU-SSE","NCT04665778","PI2020_843_0055","Other: hospital bedroom booking","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04665778","Recruiting","2020-12-04","2021-03-01","{""locations"":""CHU Amiens, Amiens, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""1516"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation of the length of stay between high probability of hospitalization group and not high risk of hospitalization group.""}"
"3943","Telematic Monitoring Through a Mobile Application of Patients With COVID-19","","NCT04423289","PR(AG)182-2020","Other: Farmalarm","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04423289","Completed","2020-03-31","2020-05-18","{""locations"":""Vall d'Hebron Hospital Universitari, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Re-consultation|Telephone calls""}"
"3944","Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases","","NCT04693975","PIDS-PC","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04693975","Recruiting","2020-10-16","2022-10-01","{""locations"":""Laboratory of Reasearch in Respiratory Physiotherapy, State University of Londrina, Londrina, Paran\u00e1, Brazil"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""94"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Physical activity in daily life|Patient's perception of physical activity in daily life|Dyspnoea sensation in daily living|Acute exacerbation|Hospitalization|Functional status|Health-related Quality of life|Sleep quality|Anxiety and depression""}"
"3945","Knowledge, Attitude and Practice of Gastrointestinal Endoscopists Toward PPE in COVID-19 Era","","NCT04479345","COVID endoscopy","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04479345","Not yet recruiting","2020-07-01","2020-09-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""25 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The knowledge and attitude toward PPE during endoscopy""}"
"3946","Impact of Cancellation of Non-urgent Surgical Cases on Patients During the COVID-19 Pandemic","","NCT04433312","SURG RES COL 2","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433312","Not yet recruiting","2020-07-01","2020-12-01","{""locations"":""Mansoura Faculty of Medicine, Mansoura, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""10000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Quality of Life of the patients""}"
"3947","The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.","","NCT04345640","ILBS-COVID-01","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04345640","Recruiting","2020-04-10","2020-12-31","{""locations"":""Institute of Liver and Biliary Sciences, New Delhi, Delhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Spontaneous recovery or death in both groups|Severity of prior as well as present decompensation in both groups|Duration of prior as well as present decompensation in both groups|Improvement in severity assessment Indices Model for End Stage Liver Disease (MELD) scores in both groups|Improvement in severity assessment Indices Child-Turcotte-Pugh (CTP) scores in both groups|Improvement in severity assessment Indices Sequential Organ Failure Assessment (SOFA) scores in both groups|Improvement in severity assessment Indices Acute Physiology And Chronic Health Evaluation (APACHE) scores II in both groups|Improvement in severity assessment Indices Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF SOFA) scores in both groups.""}"
"3948","Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19","","NCT04542226","Covid_v_1.0","Drug: Polyoxidonium","Observational","Has Results","","https://ClinicalTrials.gov/show/NCT04542226","Completed","2020-03-31","2020-10-30","{""locations"":""Healthcare Institution \""Grodno Regional Infectious Clinical Hospital\"", Grodno, Belarus|State-Funded Healthcare Institution \""Emergency Hospital\"" of Ministry of Health of Chuvash Republic, Cheboksary, Chuvashia, Russian Federation|State-Funded Healthcare Institution \""Infectious Disease Hospital No.3\"" of Ministry of Health of Krasnodar Krai, Novorossiysk, Krasnodar Krai, Russian Federation|State-Funded Institution of Mari El Republic \""Yoshkar-Ola City Hospital\"", Yoshkar-Ola, Mari El Republic, Russian Federation|State-Funded Healthcare Institution of Voronezh Region \""Novaya Usman District Hospital\"", Novaya Usman, Voronezh Region, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""81"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Status of the Patient (According to 7-point Ordinal Scale)|Time to Improvement in Clinical Status of the Patient (According to Ordinal Scale) by 1 Point for Each OS Score|Clinical Status of the Patient (According to National Early Warning Score (NEWS Scale))|Number of Patients Requiring Supplementary Oxygen|Hospitalisation Duration|Mortality|The Number of Participants With Serious Adverse Events|The Number of Participants With Adverse Events|Number of Participants With Discontinuation of Drug Administration""}"
"3949","Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain","","NCT04573361","ChiroCOVID19","Other: Chiropractic care (one visit)|Other: Chiropractic care (more than one visit)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04573361","Completed","2020-05-02","2020-05-27","{""locations"":""Real Centro Universitario Mar\u00eda Cristina, San Lorenzo De El Escorial, Madrid, Spain"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""723"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Pain intensity|Pain frequency|Pain evolution|Pain interference|Pain Catastrophizing Scale|Tampa Scale Kinesiophobia|General Anxiety Disorder scale|Intolerance of Uncertainty Scale|General Self-Efficacy scale|Fear of Illness and Virus Evaluation""}"
"3950","Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic","","NCT04453514","Tibbitts_TIYoga_COVID","Behavioral: Trauma-informed yoga video recording","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04453514","Recruiting","2020-07-21","2020-10-01","{""locations"":""National University of Natural Medicine, Portland, Oregon, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants enrolled over 3 months|Number of participants enrolled per week over 3 months|Proportion of participants who enroll in the study over 3 months|Proportion of participants who complete the study over 3 months|Proportion of missing data over 3 months|Proportion of participants who complete the 45-minute video over 3 months|Mean change in state anxiety from immediately before to immediately after yoga using the State Trait Anxiety Scale - 6 item short form|Mean change in state mindfulness from immediately before to immediately after yoga using the State Mindfulness Scale (State Mindfulness of Mind subscale)|Mean change in body awareness from immediately before to immediately after yoga using the State Mindfulness Scale (State Mindfulness of Body subscale)""}"
"3951","Incidence of Covid-19 in School Children","COVIDECOLE","NCT04377737","20-HPNCL-02","Diagnostic Test: RT-PCR Covid-19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04377737","Withdrawn","2020-05-15","2020-09-01","{""locations"":""H\u00f4pitaux P\u00e9diatrique de Nice CHU Lenval, Nice, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""0"",""age"":""3 Years to 10 Years \u00a0 (Child)"",""outcome_measures"":""evaluation of the prevalence of positive real-time-polymerase chain reaction (rt-PCR) in school children during the pandemic period in Nice|evaluation of the serological prevalence of the Covid-19 infection|evaluation of the COVID-19 reinfection among seropositive children at the inclusion time|evaluation of the prevalence of positive rt-PCR of other respiratory viruses (including others coronavirus)|comparison of inflammatory response level between different coronavirus strains|Estimation of medico-social risk factors associated with COVID-19 infection""}"
"3952","Oncology Care Pathway's Modifications Impact During COVID-19 Pandemic : the ONCOCARE-COV Study","ONCOCARE-COV","NCT04445870","2020Ao001*","Other: data record","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445870","Recruiting","2020-05-01","2020-12-01","{""locations"":""Chu Reims, Reims, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""data record""}"
"3953","COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19","COMBATCOVID19","NCT04363437","2020-04-12","Drug: Colchicine|Drug: Usual Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04363437","Recruiting","2020-04-26","2020-06-14","{""locations"":""Maimonides Medical Center, Brooklyn, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Patients requiring supplemental oxygen beyond 8L nasal cannula|Percentage of patients who will require mechanical ventillation|Hospital length of stay|Mortality|Maximum CRP|Maximum troponin elevation""}"
"3954","Endoscopy-related Phone Consultation During the COVID-19 Outbreak","","NCT04344964","38839","Other: None - NA","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344964","Completed","2020-04-15","2020-07-03","{""locations"":""Austin Health, Melbourne, Victoria, Australia"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""186"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Failed to attend patients|Patient satisfaction with the phone consult|Consultant satisfaction with the phone consult""}"
"3955","Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic","","NCT04360850","STUDY00010090","Behavioral: online survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04360850","Recruiting","2020-04-24","2025-10-01","{""locations"":""University of Washington, Seattle, Washington, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""responses to the survey questions""}"
"3956","Evaluation of Newborns Presenting With Suspected COVID 19","","NCT04519307","2020/251","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04519307","Active, not recruiting","2020-03-01","2020-08-31","{""locations"":""\u0130zmir Dr. Behcet Uz Training and Research Hospital, \u0130zmir, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""72"",""age"":""up to 1 Month \u00a0 (Child)"",""outcome_measures"":""General Characteristics of the infants with respiratory infection at the NICU admission""}"
"3957","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS","","NCT04325906","COVID-19-HFNC+PP","Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04325906","Recruiting","2020-04-02","2021-06-30","{""locations"":""Rush University Medical Center, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""346"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment failure|Intubation rate|Efficacy of PP""}"
"3958","COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs","COVIDRIC 2","NCT04530682","RECHMPL20_0409|UF8074","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04530682","Recruiting","2021-03-05","2024-07-01","{""locations"":""Centre hopsitalier universitaire de Montpellier, Montpellier, Occitanie, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevalence of COVID-19 in patients with inflammatory rheumatisms|Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion""}"
"3959","Extended Post Anaesthetic Care in PACU During COVID-19: Multi-perspective Value-based Analysis","","NCT04717089","TMH-ExRR-001","Other: overnight intensive recovery / extended post anaesthetic care in PACU","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04717089","Recruiting","2020-02-10","2021-06-30","{""locations"":""Operation Theatre, Tuen Mun Hospital, Tuen Mun, Hong Kong"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""total number of ICU bed days spared|amount of healthcare expenditures based on bed occupancy and manpower|number of unanticipated intensive care unit admission within 48 hours upon discharge to general ward|rate of elective discharge to the intensive care unit|length of hospital stays""}"
"3960","MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support","","NCT04611399","MIND-VR/Besta","Behavioral: VR for psychoeducation and relaxation|Behavioral: Text material for psychoeducation and audio for relaxation techniques","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04611399","Recruiting","2021-02-03","2021-11-01","{""locations"":""Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""90"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in score at the State-Trait Anxiety Inventory -Y2|Change in score at the Perceived Stress Scale|Change in score at the Depression, Anxiety ans Stress Scale-21 items|Change in score of knowledge on stress and anxiety|Change in score at the EQ-5D-5L|Change in score at the Impact of Event Scale - Revised""}"
"3961","Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19)","COVAL-NANCY","NCT04448769","2020PI128","Biological: Anti-SARS-CoV-2 IgT seropositivity","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04448769","Completed","2020-06-26","2020-07-24","{""locations"":""Chru Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""2006"",""age"":""5 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Anti-SARS-CoV-2 IgT (IgM\/IgA\/IgG) seropositivity|Proportion of asymptomatic, symptomatic cases among seropositive people|Proportion of asymptomatic cases among seropositive people|Identification of risk groups - Anti-SARS-CoV-2 IgT seropositivity by age, sex and as a function of weight status, smoking status, work activity and social status.|Proportion of seropositive subjects according to the level of social disadvantage measured by the EPICES score|Proportion of infected households|Anti-SARS-CoV-2 IgT seropositivity in the household|Clinical expression patterns of infection by symptom\/antibody association|Serological Response to Infection|Anti-SARS-CoV-2 IgT seropositivity|\u2022 Evaluation of serum neutralisation of persons positive for anti-SARS-CoV-2 antibodies, of the infectivity of viral strains in cell culture: percentage neutralisation compared to a viral strain not exposed to seropositive serum.""}"
"3962","Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19","ZnCOVID-19","NCT04551339","20-004637","Dietary Supplement: PreserVision AREDS formulation soft gels or tablets|Dietary Supplement: Multivitamin with 11mg of zinc","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04551339","Enrolling by invitation","2020-09-28","2021-09-14","{""locations"":""Mayo Clinic in Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic in Jacksonville, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""4500"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 illness requiring hospitalization|Illness without hospitalization|Supplemental oxygen therapy during hospitalization|Invasive ventilation during hospitalization|Mortality""}"
"3963","A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research","","NCT04327804","20-002","Diagnostic Test: Odd/Even birth year intervention groups","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04327804","Recruiting","2020-03-25","2020-04-10","{""locations"":""Everett Clinic, Seattle, Washington, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development""}"
"3964","Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19","EN-COVID-19","NCT04602832","University of British Columbia","Other: Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04602832","Enrolling by invitation","2020-10-14","2020-12-01","{""locations"":""University of British Columbia, Kelowna, British Columbia, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""350"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Beck Depression Inventory - II (BDI-II)|Satisfaction With Life Scale (SWLS)|Generalized Anxiety Disorder - 7 (GAD-7)|Patient Health Questionnaire (PHQ-9)|Perceived Stress Scale (PSS)|Positive and Negative Affect Scale (PANAS)|Health Anxiety Inventory Short-Form (HAI-SF)|World Health Organization Quality of Life (WHOQOL - BREF)|Meaning In Life Questionnaire (MLQ)|Sleep Disorder Questionnaire (SDQ)|Measure of Attachment Qualities (MAQ)|University of California, Los Angeles Loneliness Scale (UCLA Loneliness Scale)|Insomnia Severity Index (ISI)|Paffenbarger Physical Activity Questionnaire (PPAQ)|PTSD Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (PCL-5)|European Quality of Life Group - 5 Dimensions - 5 Levels (EQ-5D-5L)""}"
"3965","Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic","","NCT04384965","059/2020","Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04384965","Recruiting","2020-05-12","2022-11-01","{""locations"":""CAMH, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)|Change in HRSD-24|Response on HRSD-24|Remission on Patient Health Questionnaire (PHQ-9)|Response on PHQ-9|Change in PHQ-9|Remission on General Anxiety Disorder 7 item (GAD-7)|Response on GAD-7|Change in GAD-7|Remission on Beck Depression Inventory (BDI-II)|Response on BDI-II|Change on BDI-II|Remission on Beck Scale for Suicidal Ideation (SSI)|Change on SSI|Change in WHO Disability Assessment Schedule (WHODAS)|Proportion of Patients Maintaining Response During Relapse Prevention""}"
"3966","Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study","COVID-WELL","NCT04410016","COVID-WELL_May20","Other: Staff Wellbeing Centres","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04410016","Recruiting","2020-05-25","2020-11-30","{""locations"":""Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""45"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Warwick-Edinburgh Mental Wellbeing Scale|Single Item Measure of Global Job Stressfulness (Houdmont et al, 2019)|Single Item Global Job Satisfaction Measure (Dolbier et al, 2005)|Single Item Measure of Presenteeism (Aronsson & Gustafsson, 2004)|Single Item Measure of Turnover intentions (Ryan et al, 2017)|Work Engagement (Shaufeli et al, 2006)""}"
"3967","Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients","","NCT04372576","57/2020.","Diagnostic Test: Assessment of ventilator-associated pneumonia criteria","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04372576","Recruiting","2020-04-16","2020-08-01","{""locations"":""Semmelweis University, Budapest, Hungary"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28-day all-cause mortality|Days of mechanical ventilation|ICU length-of-stay|Antibiotic utilization|Ventilator-associated pneumonia rate""}"
"3968","Evaluation of the Sleep Hygiene in the Lebanese Population During the COVID-19 Confinement Period.","","NCT04372043","CEHDF1650","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04372043","Not yet recruiting","2020-04-30","2020-09-30","{""locations"":""Saint Joseph University, Beirut, Lebanon"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sleep Hygiene""}"
"3969","Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic","","NCT04548934","CPR PPE","Device: Personal protective equipment (PPE)|Device: No Personal protective equipment (PPE)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04548934","Completed","2020-09-13","2021-01-31","{""locations"":""Headquarter of \""Croce Bianca\"" EMS organization, Bolzano, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""34"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Depth of chest compression|Chest compression rate|Relaxation""}"
"3970","A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19","","NCT04524598","Limbix Spark 02","Device: Limbix Spark|Other: Psychoeducation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04524598","Recruiting","2020-07-20","2020-12-31","{""locations"":""Limbix Health, Inc., San Francisco, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""410"",""age"":""13 Years to 21 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Change in depressive symptoms|Change in anxiety symptoms|Change in parent report of child depressive symptoms""}"
"3971","Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic","","NCT04427137","071-2020","Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04427137","Recruiting","2020-06-09","2022-12-01","{""locations"":""CAMH, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)|Change in Hamilton Rating Scale for Depresion 24-it (HRSD-24)|Response on Hamilton Rating Scale for Depresion 24-it (HRSD-24)|Change in Young Mania Rating Scale (YMRS)|Remission on Patient Health Questionnaire (PHQ-9)|Response on Patient Health Questionnaire (PHQ-9)|Change in Patient Health Questionnaire (PHQ-9)|Remission on General Anxiety Disorder 7 item (GAD-7)|Response on General Anxiety Disorder 7 item (GAD-7)|Change in General Anxiety Disorder 7 item (GAD-7)|Remission on Beck Depression Inventory (BDI-II)|Response on Beck Depression Inventory (BDI-II)|Change on Beck Depression Inventory (BDI-II)|Remission on Beck Scale for Suicidal Ideation (SSI)|Change on Beck Scale for Suicidal Ideation (SSI)|Change in WHO Disability Assessment Schedule (WHODAS) Range 0-38|Proportion of Patients Maintaining Response During Relapse Prevention""}"
"3972","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","HYCOVID","NCT04325893","49RC20_0071","Drug: Hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04325893","Terminated","2020-04-01","2020-06-18","{""locations"":""CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Auxerre, Auxerre, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Chalon Sur Sa\u00f4ne, Chalon Sur Sa\u00f4ne, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|CH Compi\u00e8gne, Compi\u00e8gne, France|APHP Henri Mondor, Cr\u00e9teil, France|CH Intercommunal Cr\u00e9teil, Cr\u00e9teil, France|CHU Dijon, Dijon, France|APHP Joffre Dupuytren, Draveil, France|CHD Vend\u00e9e, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CH Emile Roux, Le Puy-en-Velay, France|APHP Emile ROUX, Limeil-Brevannes, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|H\u00f4pital Europ\u00e9en - Marseille, Marseille, France|H\u00f4pital Saint-Joseph, Marseille, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|H\u00f4pital Priv\u00e9 du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orl\u00e9ans, Orl\u00e9ans, France|APHP Saint-Antoine, Paris, France|GH Croix Saint Simon, Paris, France|La Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-\u00c9tienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""259"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older""}"
"3973","One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19","","NCT04457505","CIBERESUCICOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04457505","Recruiting","2020-05-08","2021-05-31","{""locations"":""Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Matar\u00f3, Matar\u00f3, Barcelona, Spain|Hospital General de Catalu\u00f1a, Sant Cugat Del Vall\u00e8s, Barcelona, Spain|Hospital Infanta Margarita de Cabra, Cabra, C\u00f3rdoba, Spain|Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain|Hospital Son Llatzer, Palma De Mallorca, Mallorca, Spain|Hospital \u00c1lvaro Cunqueiro, Vigo, Pontevedra, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|Hospital Universitario Sant Joan d'Alacant, Alicante, Spain|Cl\u00ednica Sagrada Fam\u00edlia, Barcelona, Spain|Hospital Sagrat Cor, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Burgos, Burgos, Spain|Hospital San Pedro de Alcantara, C\u00e1ceres, Spain|Hospital de Le\u00f3n, Le\u00f3n, Spain|Hospital Arnau de Vilanova Lleida, Lleida, Spain|Hospital Infanta Leonor de Madrid, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Complexo Hospitalario Universitario de Ourense, Ourense, Spain|Complejo Asistencial Universitario de Palencia, Palencia, Spain|Hospital Montecelo, Pontevedra, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitari Virgen de Valme, Sevilla, Spain|Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain|Hospital Cl\u00ednic Universitari de Val\u00e8ncia, Valencia, Spain|Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain|Hospital Universitario Valladolid, Valladolid, Spain|Hospital Nuestra Se\u00f1ora de Gracia, Zaragoza, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""One year mortality|Six month mortality""}"
"3974","Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19","","NCT04666493","0240","Other: Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04666493","Recruiting","2020-12-04","2021-11-30","{""locations"":""Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""8 Years to 13 Years \u00a0 (Child)"",""outcome_measures"":""Screen for Child Anxiety Related Emotional Disorders (SCARED), Parent version|Screen for Child Anxiety Related Emotional Disorders (SCARED), Child version""}"
"3975","Impact of the Change in Hospital Service of Caregivers During COVID-19 Health Crisis on Operational Strain","CovIdeDocS","NCT04667962","2020-COVID19-33|2020-A02932-37","Other: Online questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04667962","Recruiting","2020-12-23","2021-09-01","{""locations"":""Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, Br\u00e9tigny-sur-Orge, France|Ecole du Val-de-Gr\u00e2ce, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""302"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Burn-out Assessment tool (BAT) score at enrollment.""}"
"3976","The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19","COVRehab","NCT04505761","COVRehab","Device: Virtual Reality","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04505761","Recruiting","2020-08-01","2021-01-01","{""locations"":""Radboud university medical center, Nijmegen, Gelderland, Netherlands"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Semi-structured interview with 15 patients on their experiences of VR for rehabilitation from COVID-19.|Use of VR|Semi-structured interviews with physiotherapists on their experiences of VR for rehabilitation from COVID-19.|Change in baseline performance test (guidelines KNGF) - Patient specific complaints.|Change in baseline performance test (guidelines KNGF) - 6 minute walk test|Change in baseline performance test (guidelines KNGF) - one-repetition maximum test|Change in baseline performance test (guidelines KNGF) - 30 sec sit to stand|Change in baseline performance test (guidelines KNGF) - Borgscale for fatigue|Change in activities of daily life.|Change in HADS.|Change in CFQ.|Change in SF12.|Change in positive health.""}"
"3977","Quality of Life and Long-term Outcomes After Hospitalization for COVID-19","","NCT04376658","Coalition COVID-19: Long-term","Other: COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04376658","Recruiting","2020-07-15","2022-07-15","{""locations"":""Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""One-year utility score of health-related quality of life|Incidence of all-cause mortality|Incidence of rehospitalizations|Percentage of return to work or study|Score of Instrumental Activities of Daily Living|Score of dyspnea|Percentage of long-term ventilatory support need|Symptoms of anxiety and depression|Symptoms of posttraumatic stress disorder|Utility score of health-related quality of life at 3, 6, and 9 months|Score of self-rated health""}"
"3978","Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic","","NCT04391166","200826","Other: Non invasive visual acuity testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04391166","Active, not recruiting","2020-05-20","2022-05-01","{""locations"":""Vanderbilt Eye Institute, Nashville, Tennessee, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Best Corrected Visual Acuity (BCVA) Per Eye""}"
"3979","Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19","","NCT04412551","LUS-Covid001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412551","Recruiting","2020-05-20","2020-12-31","{""locations"":""Falun Hospital, Falun, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identification of requirement of mechanical ventilation|Prediction of requirement of mechanical ventilation|Association of LUS to clinical parameters|Description of findings on LUS""}"
"3980","A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19","","NCT04622332","SIR365-US-101","Drug: SIR1-365|Drug: Matching Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04622332","Not yet recruiting","2020-12-15","2021-12-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with any TEAEs during the treatment period|Proportion of patients with any AEs, SAEs and drug-related AEs during the study|Proportion of patients with clinically significant abnormality in clinical laboratory tests and ECG during the study|Change from Baseline to Day 7 and Day 14 in PaO2\/FiO2 ratio|Time to improvement of oxygenation defined as oxygen saturation (pulse oximetry) >93% and increased \u22651% from Baseline breathing only room air in the 48 hours preceding the measurement during the study|Number of days without oxygen use during the study|Proportion of patients with clinical improvement defined as a reduction of 2 points in the WHO ordinal scale during the study|Number of days hospitalized during the study|Proportion of patients free of respiratory failure during the study|All-cause mortality rate during the study|Change from Baseline to Day 7 and to Day 14 in plasma CRP level|Time to reach 50% reduction from Baseline in plasma CRP level during the treatment period|Number of the patients to reach 50% reduction from Baseline in plasma CRP level during the treatment period|Change from Baseline to Day 7 and Day 14 in serum cytokine levels|Change from Baseline to Day 7 and Day 14 in plasma pRIP1 and pMLKL levels|Change from Baseline to Day 7 and Day 14 in urine NGAL and KIM-1 levels|Plasma drug levels""}"
"3981","Status and Predictors of Mental Health Symptoms Among Migrants and Refugees During the COVID-19 Pandemic","","NCT04443764","REK125510 (8)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443764","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""287"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire 9|Generalized Anxiety Disorder 7|Health Anxiety Symptoms""}"
"3982","Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure","COVID-PLEX","NCT04634422","H-20041716","Procedure: Plasma exchange and convalescent plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04634422","Recruiting","2020-11-16","2022-06-30","{""locations"":""Rigshospitalet, Copenhagen, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Alive at Day 90th|Day 8 serious adverse events|Day 28 all cause mortality|Days alive without life support at day 90""}"
"3983","Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia","","NCT04326725","2020-2/1","Drug: Plaquenil 200Mg Tablet","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04326725","Active, not recruiting","2020-03-20","2020-09-01","{""locations"":""Istinye University Medical School, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""20 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Protection against COVID-19""}"
"3984","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19","","NCT04292340","Anti-SARS-CoV-2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04292340","Recruiting","2020-02-01","2020-12-31","{""locations"":""Shanghai Public Health Clinical Center, Shanghai, Shanghai, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0""}"
"3985","Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19","","NCT04468893","VIU-PP","Behavioral: Online Intervention Mental Health COVID-19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04468893","Recruiting","2020-05-20","2021-01-15","{""locations"":""Universidad Aut\u00f3noma de Ciudad Ju\u00e1rez, Juarez, Chihuahua, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""128"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decrease in the score of Anxiety symptoms|Change in the symptoms of depression|Change in the symptoms of General Anxiety Disorder|Change in the score of Posttraumatic stress symptoms|Changes in the Widespread fear Scale|Change in the score of The Pittsburgh Sleep Quality Index.|Change on the Suicidal Thoughts Scale""}"
"3986","Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak","","NCT04346082","online-mind","Behavioral: online mindfulness group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346082","Not yet recruiting","2020-08-01","2021-07-30","{""locations"":""School of public health and primary care, Hong Kong, Hong Kong"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""rate of recruitment|rate of attendence|Depression, Anxiety and Stress Scale (DASS-21)|Sense of Coherence Scale""}"
"3987","COVID-19 Prevalence in HIV-infected Patients","SeCoVIHA","NCT04515225","7947","Other: Blood Sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04515225","Not yet recruiting","2020-09-15","2020-09-15","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevalence of SARS-CoV-2""}"
"3988","Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV","AAIM-High","NCT04661813","03-18-16-S1|U01HL142099","Other: EXTRA-CVD Virtual Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04661813","Not yet recruiting","2021-02-01","2022-08-01","{""locations"":""Duke Health, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of eligible participants who agree to participate|Average of home blood pressure values assessed over a 2-week period at 0-, 4-, 8-, and 12-months.|Number of days with at least 1 home blood pressure measurement assessed over a 2-week period at 0-, 4-, 8-, and 12-months.""}"
"3989","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection","","NCT04251871","2020001D","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04251871","Recruiting","2020-01-22","2021-01-22","{""locations"":""The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""14 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""The incidents of acute respiratory distress syndrome (ARDS) development|The time to fever resolution rate|Time to recovery of lung injury""}"
"3990","Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic","","NCT04456062","1804","Other: Caring Contacts","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04456062","Recruiting","2020-08-04","2021-03-01","{""locations"":""Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hopkins Symptom Checklist-25 (HSCL-25)""}"
"3991","Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students","","NCT04558411","Pro2020002008","Behavioral: Dialectical Behavioral Therapy (DBT) Skills","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04558411","Recruiting","2020-09-12","2020-12-15","{""locations"":""Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Distress|Emotion regulation|Distress (within-person change)|Maintenance of improvement in emotion regulation""}"
"3992","Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic","","NCT04458246","31314220.5.0000.0068","Other: Exercise training group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04458246","Recruiting","2020-07-01","2021-06-01","{""locations"":""Univsersity of Sao Paulo, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""140"",""age"":""10 Years to 19 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Safety and efficacy of a home-based exercise training program|Patients perceptions during social isolation|Adolescents quality of life|Disease activity|Disease overall assessment|Strengths and difficulties""}"
"3993","A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19","IFORS","NCT04431466","IFORS","Drug: Ivermectin|Other: Standard treatment for COVID-19","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04431466","Recruiting","2020-07-01","2021-07-01","{""locations"":""Hospital Univerist\u00e1rio da Universidade Federal de S\u00e3o Carlos (HU-UFSCar), S\u00e3o Carlos, S\u00e3o Paulo, Brazil|Hospital Universit\u00e1rio da Universidade Federal de S\u00e3o Carlos (HU-UFSCar), S\u00e3o Carlos, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""64"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Viral load variation in the nasopharyngeal swab.|Proportion of patients with undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Proportion of patients with clinical improvement.""}"
"3994","Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients","","NCT04379518","I 659920|NCI-2020-02317|P30CA016056","Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04379518","Recruiting","2020-09-04","2021-09-04","{""locations"":""Roswell Park Cancer Institute, Buffalo, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""44"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events (AEs)|Kinetics of viral load in nasopharyngeal swabs|Kinetics of viral load in the peripheral blood and nasopharyngeal swabs|Kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood|30-day mortality|Hospitalization due to infection|Determine known mediators of antiviral immunity""}"
"3995","Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19","","NCT04326114","Covid_ISCIII 20/265-E_BS","Device: Inspiratory training device|Device: Expiratory training device","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04326114","Not yet recruiting","2020-07-26","2020-12-20","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""240"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 disease diagnosis|COVID-19 disease symptoms severity|Adverse effects""}"
"3996","The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19","","NCT04403009","YLS2020(112)","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403009","Recruiting","2020-02-01","2020-06-20","{""locations"":""The First Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China|Hankou Hospital, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""20 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Lymphocyte cell|d-dimer|PLT|CRP|LDH|CK|PT|ALT|AST|NK cell|PCT|IL-6|the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases""}"
"3997","Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients","","NCT04441424","CPT-COVID-19","Biological: Convalescent plasma|Drug: Hydroxychloroquin with Azithromycin","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04441424","Completed","2020-04-03","2020-06-01","{""locations"":""Akarkh Healt hdirectorate, Baghdad, Iraq"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""49"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death versus survival of treated patients|The length of stay in hospitals""}"
"3998","Evaluation of the Fluid Response of SARS-CoV-2 (COVID-19) Patients in Intensive Care; Pleth Variability Index","","NCT04373213","EBYU COVİD PVI","Diagnostic Test: Pleth variability index","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04373213","Not yet recruiting","2020-05-05","2020-06-15","{""locations"":""Erzincan University, Erzincan, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pleth variability index""}"
"3999","Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19","","NCT04385186","CT01","Drug: Inactivated convalescent plasma|Drug: Support treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04385186","Not yet recruiting","2020-06-20","2020-12-30","{""locations"":""Cl\u00ednica Antioqu\u00eda, Medell\u00edn, Antioqu\u00eda, Colombia|Cl\u00ednica Sagrado Coraz\u00f3n, Medell\u00edn, Antioqu\u00eda, Colombia|IPS Universitaria, Medell\u00edn, Antioqu\u00eda, Colombia|Universidad de Antioqu\u00eda, Medell\u00edn, Antioqu\u00eda, Colombia|National Blood Center Foundation, Hemolife\/Fundaci\u00f3n Banco Nacional de Sangre Hemolife, Bogot\u00e1, Cundinamarca, Colombia|Cl\u00ednica Rosales, Pereira, Risaralda, Colombia|Clinica Nuestra, Cali, Valle, Colombia|Cl\u00ednica Corpas, Bogot\u00e1, Colombia|E.S.E Hospital San Rafael Facatativa, Facatativa, Colombia|Cl\u00ednica la Estancia, Popay\u00e1n, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality reduction in CoViD-19 patients treated with inactivated convalescent plasma + support treatment|Clinical evolution|Clinical evolution by seven-parameter ordinal scale|Multi-organ failure progression|Change in hemoglobin concentration|Change in blood cell count|Change in serum creatinine level|Change in aspartate aminotransferase level|Change in alanin aminotransferase level|Change in bilirubin level|Change in lactate dehydrogenase level|Change in creatine kinase level|Change in creatine kinase MB level|Change in C reactive protein concentration|Change in D Dimer concentration|Change in Procalcitonin concentration|Change in IL6 level|Radiography imaging|Tomography imaging|Assessment of oxygenation|Viral Load|Antibody titer|Oxygen-free days through Day 60|Mechanical ventilation-free days through Day 28|Intensive Care Unit (ICU)-free days through Day 28|Hospital-free days through Day 60""}"
"4000","Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19","SAMILCOV","NCT04550390","2020-COVID19-36|2020-A02536-33","Diagnostic Test: Saliva collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04550390","Completed","2020-09-15","2020-10-19","{""locations"":""H\u00f4pital d'Instruction des Arm\u00e9es Percy, Clamart, France|H\u00f4pital d'Instruction des Arm\u00e9es Laveran, Marseille, France|H\u00f4pital d'Instruction des Arm\u00e9es B\u00e9gin, Saint-Mand\u00e9, France|H\u00f4pital d'Instruction des Arm\u00e9es Sainte-Anne, Toulon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""329"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Qualitative result of molecular tests for the SARS-CoV-2 virus.""}"
"4001","Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients","PredictCovidT","NCT04369456","20-PP-09","Other: blood sample","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04369456","Recruiting","2020-04-22","2020-10-22","{""locations"":""Lyon Univerity Hospital, Lyon, France|APHM, Marseille, France|Montpellier University Hospital, Montpellier, France|University Nice Hospital, Nice, France|APHP, Paris, France|Saint Etienne University Hospital, Saint-\u00c9tienne, France|Strasbourg Univeristy Hospital, Strasbourg, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""115"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation""}"
"4002","Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic","","NCT04341714","GREEN GRC01","Other: Satisfaction evaluation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341714","Recruiting","2020-03-16","2020-06-15","{""locations"":""Department of Neuro- Urology, H\u00f4pital Tenon, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""450"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficiency of the telephone consultation|Satisfaction of the telephone consultation""}"
"4003","Breastfeeding Education in the Time of COVID-19","","NCT04519216","1613611-2","Behavioral: Telesimulation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04519216","Recruiting","2020-07-31","2021-09-30","{""locations"":""University of California - Davis, Sacramento, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""39"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in practice patterns|Self efficacy|Satisfaction with simulation""}"
"4004","Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19","PRAISE@COVID","NCT04388579","046i/17","Other: Pulmonary Rehabilitation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388579","Completed","2020-03-20","2020-03-27","{""locations"":""Nippon Gases Portugal Unipessoal Lda, Maia, Porto, Portugal|Universidade de Lisboa, Faculdade de Medicina, Instituto de Sa\u00fade Ambiental (ISAMB), Lisboa, Portugal|Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital Pulido Valente, Unidade de Reabilita\u00e7\u00e3o Respirat\u00f3ria, Lisboa, Portugal"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years to 88 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient's self-efficacy|Respiratory exercises|Physical activity""}"
"4005","Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals","","NCT04321369","20-001","Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04321369","Completed","2020-03-09","2020-03-23","{""locations"":""Everett Clinic, Seattle, Washington, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""533"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Accuracy of patient administered tests""}"
"4006","Improving Wellbeing and Health for Care Home Residents During COVID-19","COVIDWHELD","NCT04590469","20-21-10","Other: COVID WHELD","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04590469","Not yet recruiting","2020-11-20","2022-01-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""2880"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dementia Quality of Life - DEMQOL proxy|Neuropsychiatric Inventory|Psychotropic medications|Confidence in Dementia (CODE) Scale|Sense of Competence in Dementia Care Staff (SCIDS) scale|Patient Health Questionnaire (PHQ-9)|EQ5D (Euroquol 5D - 5 dimensions)|Client Service Receipt Inventory""}"
"4007","Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","REP-COVID","NCT04374539","2020-001722-66","Biological: Plasma exchange|Drug: Standar medical treatmen","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04374539","Recruiting","2020-04-29","2021-08-29","{""locations"":""Hospital Clinic i Provincial de Barcelona, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""116"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of plasma exchange""}"
"4008","Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff","VINCI","NCT04538469","20/ANAES/02","Other: COVID visitation restrictions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04538469","Not yet recruiting","2020-09-01","2021-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of delirium|Incidence of delirium|Length of critical care stay|Length of hospital stay|Doses of specified drugs during ICU admission|Length of time ventilated|Mortality""}"
"4009","Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic","","NCT04406844","Onco_Covid-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406844","Recruiting","2020-05-09","2021-06-30","{""locations"":""Max Superspeciality hospital, A Unit of Balaji Medical and Diagnostic Centre, New Delhi, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""12 Years to 98 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Oncology patients""}"
"4010","Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic","","NCT04389333","nc-MCE pilotRCT","Device: non-contact magnetically-controlled capsule endoscopy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04389333","Completed","2020-03-26","2020-05-20","{""locations"":""Changhai Hospital, Shanghai, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""40"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Maneuverability score|Gastric examination time(GET)|the comfort and acceptability of patients|diagnostic yield""}"
"4011","COVID-19 Pandemic Response Network","","NCT04320862","Pro00105189","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04320862","Recruiting","2020-04-03","2021-12-31","{""locations"":""Duke University Medical Center, Durham, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of participants who experience inpatient admission|Number of participants admitted to the intensive care unit|Number of participants requiring mechanical ventilation|Number of deceased participants""}"
"4012","Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors","COVIDICA","NCT04389684","2020-A01301-38","Other: Psycho-Social Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389684","Recruiting","2020-05-27","2021-07-27","{""locations"":""MOULIN Val\u00e9rie, La Rochelle, France|BOURGEOIS Hugues, Le Mans, France|RANDRIAN Violaine, Poitiers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival of patients with metastatic colorectal cancer or metastatic pancreatic cancer""}"
"4013","PTSD Symptoms Among Health Workers and Public Service Providers After the COVID-19 Outbreak: A 3 Month Follow up","","NCT04442243","REK125510 (4)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442243","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""889"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PTSD Checklist for DSM-5 (PCL-5)|Patient Health Questionnaire 9 (PHQ-9)|Generalized Anxiety Disorder 7 (GAD-7)|The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)""}"
"4014","Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure","ProneSpontCov","NCT04632602","2020-17","Other: physiological effects of awake prone position in COVID 19 patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04632602","Recruiting","2020-04-04","2021-01-31","{""locations"":""Assistance Publique H\u00f6pitaux de Marseille, Marseille, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Global Inhomogeneity Index variations (expressed in percentage) between baseline, supine and prone position periods.""}"
"4015","Upper Limb Robotic Rehabilitation During COVID-19 Outbreak","","NCT04392453","FDG_Icone","Device: Robotic therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04392453","Recruiting","2020-10-26","2021-12-01","{""locations"":""Fondazione Don Carlo Gnocchi, Rome, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""System Usability Scale (SUS)|Technology Acceptance Model (TAM)|Likert Scale|Fugl-Meyer Assessment for upper extremity (FMA-UE)|Motricity Index for the upper extremity (MI-UE)|Modified Ashworth Scale (MAS)|Numeric Pain Rating Scale (NPRS)|Modified Barthel Index (mBI)|Montreal Cognitive Assessment (MoCA)|Kinematic parameters""}"
"4016","A Novel School-clinic-community Online Model of Child Obesity Treatment in Singapore During COVID-19","","NCT04395430","20190049","Behavioral: Usual Care|Behavioral: online KKH Sports Singapore Program with Usual Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04395430","Recruiting","2020-09-18","2021-10-01","{""locations"":""KK Women's and Children's Hospital, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""4 Years to 7 Years \u00a0 (Child)"",""outcome_measures"":""Intensity of intervention|Change in cardiorespiratory fitness|Change in quality of life|Change in BMI|Change in self-esteem|Change in eating behaviour|Change in gross motor skills|Change in caloric intake|Change in physical activity|Change in blood pressure|Change in waist circumference|Change in servings of fruits and vegetables""}"
"4017","Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients","COVID-DEX","NCT04358627","SPEC-M|SPEC-M COVID-19","Drug: Dexmedetomidine Injectable Product","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04358627","Not yet recruiting","2020-04-15","2020-06-30","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation|Duration of mechanical ventilation|Delirium on recovery from sedation""}"
"4018","Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic","COVIDPROBLEM","NCT04677270","COVIDPROBLEM","Behavioral: Digital problem solving tool","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04677270","Completed","2020-08-31","2020-11-30","{""locations"":""Centrum f\u00f6r Psykiatriforskning, Stockholm, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""397"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""System Usability Scale|Treatment Credibility Scale|Use of intervention""}"
"4019","The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19","OCAT","NCT04367636","EC/2019/0841","Behavioral: Behavioral: OCAT-sham|Behavioral: Behavioral: OCAT|Other: psycho-education video","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04367636","Recruiting","2020-04-30","2021-09-01","{""locations"":""Ghent University, Gent, Oost-Vlaanderen, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""100"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in depression-, anxiety- and psychosomatic stress symptoms|Changes in rumination.|Changes in cognitive emotion regulation strategies.|Changes in emotional attention""}"
"4020","Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children","","NCT04371315","COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371315","Recruiting","2020-04-27","2022-06-30","{""locations"":""St. Jude Children's Research Hospital, Memphis, Tennessee, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""up to 24 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Characteristics and outcomes of acute respiratory infections due to COVID-19 in children.|Clinical risk factors of acute respiratory infection due to COVID-19 in children.|Immunologic response to acute respiratory infection due to COVID-19 in children.|Duration of viral shedding and evolution in children longitudinally.""}"
"4021","Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic","","NCT04517006","00039312","Behavioral: Self-focused acts|Behavioral: Prosocial acts","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04517006","Not yet recruiting","2021-01-01","2021-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""1542"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in happiness from baseline using the subjective happiness scale|Change in valued life assessment from baseline using 4-item scale|Change in depression from baseline using the CESD (8-item)|Change in anxiety from baseline using the HADS-A""}"
"4022","COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)","","NCT04344041","2020-001602-34","Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04344041","Recruiting","2020-04-15","2021-05-01","{""locations"":""CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Lille, Lille, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""260"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Number of death of any cause, during the 14 days following the inclusion and intervention.|Number of death of any cause, during the 28 days following the inclusion and intervention.|Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19|Rate of patients with at least one severe adverse event at day 28, according to the regulations|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol\/L) at baseline|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol\/L) at baseline|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD <25nmol\/L) at baseline|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol\/L) at baseline|Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol\/L or 25-OHD\u226575nmol\/L)|Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol\/L or 25-OHD\u226575nmol\/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol\/L or 25-OHD\u226575nmol\/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol\/L or 25-OHD\u226575nmol\/L)|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol\/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol\/L or \u226575nmol\/L)|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol\/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol\/L or \u226575nmol\/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol\/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol\/L or \u226575nmol\/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol\/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol\/L or \u226575nmol\/L)|Number of death of any cause during the 14 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 28 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 14 days following the inclusion and intervention, compared to mortality data in French hospital geriatric units from the current national survey by the French Society of Geriatrics and Gerontology""}"
"4023","Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama","","NCT04604743","MISP #60590","Behavioral: Intervention, TBN","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04604743","Not yet recruiting","2021-05-01","2023-06-30","{""locations"":""University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""4"",""age"":""15 Years to 17 Years \u00a0 (Child)"",""outcome_measures"":""HPV Vaccination|Reduction in Vaccine Hesitancy""}"
"4024","Impact of Social Distancing on Bariatric Versus Non-Surgical Obese Patients During COVID-19 Pandemic","","NCT04633941","HenryLew","Other: Standard Care","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04633941","Completed","2020-06-01","2020-07-30","{""locations"":""Singapore General Hospital, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""272"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Weight|Blood Sugar Control|Medical Adherence|Stress level|Physical Activity Level""}"
"4025","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)","Coalition-I","NCT04322123","Brazil COVID Coalition I Trial","Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04322123","Active, not recruiting","2020-04-01","2020-08-30","{""locations"":""Hospital Geral Cl\u00e9riston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN\/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vit\u00f3ria Da Conquista, BA, Brazil|Hospital Geral de Vit\u00f3ria da Conquista, Vit\u00f3ria Da Conquista, BA, Brazil|Hospital de Bras\u00edlia, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Bras\u00edlia, DF, Brazil|Hospital Maternidade S\u00e3o Jos\u00e9 - UNESC - Funda\u00e7\u00e3o Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Miseric\u00f3rdia de S\u00e3o Jo\u00e3o Del Rei, S\u00e3o Jo\u00e3o Del Rei, MG, Brazil|Associa\u00e7\u00e3o Evang\u00e9lica Beneficente de Londrina - Hospital Evang\u00e9lico de Londrina, Londrina, PR, Brazil|Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital S\u00e3o Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital S\u00e3o Jos\u00e9, Criciuma, SC, Brazil|Hospital Ba\u00eda Sul - Ba\u00eda Sul Medical Center, Florian\u00f3polis, SC, Brazil|Hospital Nereu Ramos, Florian\u00f3polis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Funda\u00e7\u00e3o PIO XII), Barretos, SP, Brazil|Casa de Sa\u00fade Santa Marcelina, S\u00e3o Paulo, SP, Brazil|Hospital Albert Einstein, S\u00e3o Paulo, SP, Brazil|Hospital Benefic\u00eancia Portuguesa - Real e Benem\u00e9rita Associa\u00e7\u00e3o Portuguesa de Benefic\u00eancia, S\u00e3o Paulo, SP, Brazil|Hospital BP Mirante - Real e Benem\u00e9rita, S\u00e3o Paulo, SP, Brazil|Hospital das Cl\u00ednicas da FMUSP, S\u00e3o Paulo, SP, Brazil|Hospital do Servidor P\u00fablico Estadual - HSPE - IAMSPE, S\u00e3o Paulo, SP, Brazil|Hospital S\u00e3o Paulo - UNIFESP, S\u00e3o Paulo, SP, Brazil|Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo, SP, Brazil|Hospital SEPACO, S\u00e3o Paulo, S, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""630"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days""}"
"4026","A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults","","NCT04668339","ARCT-021-04","Biological: ARCT-021 single dose priming|Biological: ARCT-021 two lower dose priming|Biological: ARCT-021 two higher dose priming|Biological: Placebo (two doses), priming|Biological: Randomized booster|Biological: Placebo booster","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04668339","Recruiting","2021-01-07","2022-04-30","{""locations"":""Arcturus Investigational Site 103, Chandler, Arizona, United States|Arcturus Investigational Site 107, Tucson, Arizona, United States|Arcturus Investigational Site 112, San Diego, California, United States|Arcturus Investigational Site 104, Melbourne, Florida, United States|Arcturus Investigational Site 105, Orlando, Florida, United States|Arcturus Investigational Site 106, Pinellas Park, Florida, United States|Arcturus Investigational Site 109, The Villages, Florida, United States|Arcturus Investigational Site 101, Peoria, Illinois, United States|Arcturus Investigational Site 110, Rockville, Maryland, United States|Arcturus Investigational Site 102, Anderson, South Carolina, United States|Arcturus Investigational Site 111, Austin, Texas, United States|Arcturus Investigational Site 108, Dallas, Texas, United States|Arcturus Investigational Site 204, Singapore, Singapore|Arcturus Investigational Site 201, Singapore, Singapore|Arcturus Investigational Site 203, Singapore, Singapore"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentages of participants reporting solicited local adverse events|Percentages of participants reporting solicited systemic adverse events|Percentages of participants reporting adverse events|Percentages of participants reporting serious adverse events|Percentages of participants reporting medically attended adverse events|Percentages of participants reporting new onset of chronic disease|Percentages of participants with abnormal chemistry and hematology values|SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs|Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs|Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels|SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels, expressed as GMCs|Changes in SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs|Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels""}"
"4027","Difficulties in Emotion-regulation and Interpersonal Problems During and After the COVID-19 Pandemic","","NCT04442282","REK125510 (5)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442282","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""5041"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire 9 (PHQ-9)|The Generalized Anxiety Disorder - 7|Difficulties in Emotion Regulation Scale|Interpersonal problems""}"
"4028","Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19","","NCT04381819","20-04072","Diagnostic Test: SARS-CoV-2 PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04381819","Recruiting","2020-03-02","2023-12-31","{""locations"":""Vestre Viken Drammen Hospital, Drammen, Viken, Norway|Haukeland University Hospital, Bergen, Norway|\u00d8stfold Hospital Trust, Fredrikstad, Norway|Akershus University Hospital, L\u00f8renskog, Norway|Oslo University Hospital, Oslo, Norway|University Hospital North Norway, Troms\u00f8, Norway|St Olavs Hospital, Trondheim, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death|Recovery from COVID-19|Progression to ICU care or ventilation|Clearance of SARS-CoV-2 from respiratory specimen|Immune response to COVID-19""}"
"4029","Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)","","NCT04346953","002","Behavioral: Video based exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346953","Not yet recruiting","2020-08-20","2020-11-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""128"",""age"":""40 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""International Physical Activity Questionnaire - Short Form|Nottingham Health Profile|Beck Depression Inventory|Beck Anxiety Inventory|Pittsburgh Sleep Quality Index|Timed Get Up and Go Test|Flamingo Balance Test""}"
"4030","A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period","","NCT04394013","180320201","Behavioral: Mindfulness intervention|Behavioral: Non-Mindfulness intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04394013","Completed","2020-08-26","2020-12-31","{""locations"":""Monash University Malaysia, Subang Jaya, Selangor, Malaysia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""70"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Loneliness (UCLA-8 Loneliness Scale)|Mindfulness (FFMQ)|Quality of life (EQ-5D-5L Questionnaire)""}"
"4031","Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation","","NCT04448782","RT COVID-19","Diagnostic Test: Asynchronies detection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04448782","Completed","2020-03-09","2020-06-30","{""locations"":""Candelaria de Haro, Sabadell, Barcelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""32"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence and pattern of presentation of Reverse triggering in COVID-19 patients under invasive mechanical ventilation|Incidence of Reverse Triggering related to the level of sedation in COVID-19 patients under invasive mechanical ventilation|Reverse triggering and secondary asynchronies in COVID-19 patients under invasive mechanical ventilation|Incidence and pattern of presentation of asynchronies in COVID-19 patients under invasive mechanical ventilation|Influence of asynchronies in different outcomes in in COVID-19 patients under invasive mechanical ventilation""}"
"4032","Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)","","NCT04516837","ITP-PKU020","Drug: Eltrombopag|Drug: rhTPO","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04516837","Recruiting","2020-08-31","2022-08-01","{""locations"":""Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Complete response|Response|No response|Relapses|Early response|Initial response|Durable response|TOR (time to response)|DOR (duration of response)|Treatments associated adverse events|Reduction in bleeding symptoms""}"
"4033","Factors Associated With Adherence to Hygiene-related Behaviors and Viral Mitigation Protocols During the COVID-19 Pandemic","","NCT04442217","REK125510-11","Behavioral: Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442217","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adherence to WHO-advised hygiene-related|Adherence to viral mitigation protocols""}"
"4034","Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection","","NCT04443868","COVID-IND-02","Drug: Nitric Oxide-Releasing Drug","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04443868","Not yet recruiting","2021-01-01","2021-07-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To Measure the efficacy of NONI compared to saline placebo control to shorten the duration of COVID-19 viral infectivity|To Measure the virucidal effect of NONI compared to placebo in the nasal cavity in subjects with mild COVID-19 infection|To Measure the efficacy of NONI in prevention of progression of COVID-19|To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life (QoL) in subjects with COVID-19|To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19|To measure the tolerance of NONI compared to saline placebo in participants with mild COVID-19 infection""}"
"4035","Information Sources and Their Relationship to Depressive and Anxiety Symptoms During the COVID-19 Pandemic: A Network Study","","NCT04444336","REK125510-16","Behavioral: Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444336","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The Patient Health Questionnaire 9|Generalized Anxiety Disorder 7""}"
"4036","Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT","","NCT03183570","IRB Protocol: 40450","Drug: [18F]FP-R01-MG-F2","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT03183570","Recruiting","2017-11-08","2023-04-14","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SUV max comparison : IPF versus Healthy Lung, PSC versus Healthy Liver, COVID19 versus Healthy Lung|Time Activity Measurements|Incidence of Study Completion (Safety and Tolerability)""}"
"4037","Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health","","NCT04344834","Covid-19 mental health","Diagnostic Test: Online questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04344834","Not yet recruiting","2020-05-01","2020-10-01","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Depression|Anxiety|Obsessive compulsive disorder""}"
"4038","Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19","","NCT04530136","C1 6201","Drug: Ruconest","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04530136","Recruiting","2020-11-30","2021-11-30","{""locations"":""The Valley Hospital, Ridgewood, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease Severity on the 7-Point WHO Ordinal Scale|Clinical improvement|Invasive or non-invasive ventilation|Acute Lung Injury""}"
"4039","Healthcare Renunciation During the Confinement Period in Connection With the COVID-19 Epidemic in Adult Emergency Departments","","NCT04460196","49RC20_0155","Other: survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04460196","Completed","2020-07-08","2020-09-18","{""locations"":""CHU Angers, Angers, France|CH Le Mans, Le Mans, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""rate of patients who gave up consulting in the emergency department""}"
"4040","Impact in the Medical Care Among the Rheumatic Diseases Patients in a Tertiary Hospital in México During the COVID-19 Pandemic","","NCT04557358","IRE-3467","Other: COVID-19 survey|Other: RAPID-3|Other: WHOQOL-BREF|Other: DASS-21 instrument (depression and anxiety)|Other: IER-R (posttraumatic stress)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04557358","Enrolling by invitation","2020-10-01","2022-12-31","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Tlalpan, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""346"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the pattern of the usual medical care among the rheumatic disease patients|Change in the patient's activity disease|Change in the patient's activity disease measures by their rheumatologist|Change in patient\u00b4s quality of life|Change in patient\u00b4s depression and anxiety|Change in patient\u00b4s posttraumatic stress""}"
"4041","Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial","Cov-EMERALD","NCT04455360","Protocol version 1.2","Other: Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04455360","Recruiting","2020-10-01","2021-09-01","{""locations"":""University Hospital Southampton NHS Foundation Trust, Southampton, Hamphsire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""26"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of recruitment, intervention adherence, incidence of treatment related adverse events and trial completion to final assessment timepoints|Post-Traumatic stress disorder|Anxiety and depression|Cognitive function|Health Related Quality of Life|Health and disability|Physical activity|Nutritional status""}"
"4042","A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19","","NCT04469621","PDY16879|2020-002104-39|U1111-1250-1185","Drug: SAR443122|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04469621","Completed","2020-07-17","2020-10-23","{""locations"":""Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, S\u00e3o Jos\u00e9 Do Rio Preto, Brazil|Investigational Site Number 0760002, S\u00e3o Paulo, Brazil|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Talca, Chile|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""68"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Relative change from baseline in CRP level|Time to 50% decrease from baseline in CRP level|Time to improvement of oxygenation|Change from baseline in SPO2\/FiO2 ratio|Number of Days without need for oxygen support and alive|Numbers of Ventilator-free days and alive|Change from baseline in markers of inflammation: white blood cell count and differential blood lymphocytes|Change from baseline in marker of inflammation: neutrophil to lymphocyte ratio|Change from baseline in marker of inflammation: interleukin 6 (IL-6)|Change from baseline in D-Dimer|Incidence of Deaths|Percentage of participants receiving thrombolytic treatment|Percentage of participants receiving vasopressor treatment|Incidence of serious adverse events (SAEs), adverse events of special interest (AESI) and treatment-emergent adverse events (TEAEs) leading to treatment discontinuation|Incidence of TEAEs leading to study discontinuation (primary reason)|Numbers of Respiratory Failure-Free Days (RFFD) and alive""}"
"4043","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","CORIMUNO-19","NCT04324047","APHP200375|2020-001246-18","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04324047","Recruiting","2020-03-27","2021-12-31","{""locations"":""Kremlin Bictre APHP, Le Kremlin-Bic\u00eatre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival|WHO progression scale COVID 19""}"
"4044","Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19","","NCT04445324","2021-2281","Behavioral: Transitional Online Peer Support Group (n=20)|Other: Control Group (pharmacotherapy and/or psychotherapy, n=10)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04445324","Active, not recruiting","2020-08-25","2020-12-01","{""locations"":""CR-IUSMM, Montreal, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Supportive Care"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of patients' current status : recovery (personal recovery)|Assessment of patients' current status : citizenship (personal recovery)|Assessment of patients' current status : COVID-19 Stress Scales|Assessment of patients' current status : anxiety (clinical recovery)|Assessment of patients' current status : depression (clinical recovery)|Assessment of patients' current status : alcohol dependence (clinical recovery)|Assessment of patients' current status : drug dependence (clinical recovery)|Assessment of patients' current status : psychosis (clinical recovery)|Assessment of patients' current status : social functioning (clinical recovery)""}"
"4045","Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","NOCOVID","NCT04337918","COVID-CTP-01","Drug: NORS (Nitric Oxide Releasing Solution)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04337918","Completed","2020-05-08","2021-02-02","{""locations"":""BC Diabetes, Vancouver, British Columbia, Canada|LMC Manna, Pointe-Claire, Quebec, Canada|Diex Recherche Qu\u00e9bec, Qu\u00e9bec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-Borrom\u00e9e, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""143"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms|Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2""}"
"4046","Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen","SeroCOV","NCT04707833","2020/0126/HP","Diagnostic Test: Serological testing for COVID-19 infection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04707833","Recruiting","2020-11-26","2023-12-01","{""locations"":""Rouen University Hospital, Rouen, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""385"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of immunological Abbott Architect SARS-CoV-2 IgG Assay|Evaluation of immunological of EUROIMMUN SARS-CoV-2(IgA) ELISA, EUROIMMUN SARS-CoV-2 (IgG) ELISA, WANTAI SARS-CoV-2 Ab ELISA, WANTAI SARS-CoV-2 IgM ELISA, Diasorin LIAISON SARS CoV-2 S1\/S2 IgG, Roche ECL anti-SARS-Cov-2 (combined IgG IgA)""}"
"4047","Psychological Impact of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders","","NCT04410835","32-363 ex 19/20","Diagnostic Test: Online Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04410835","Recruiting","2020-04-28","2021-04-28","{""locations"":""Medical University Graz, Department of Psychiatry and Psychotherapeutic Medicine, Graz, Styria, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Global symptom load (Anxiety, Somatisation, Depression, Global Symptom Index)|Depressive symptoms|Sleep disorders and Sleep Quality|Life style changes|Food Craving|COVID-19 associated fears and emotional responses to the pandemic""}"
"4048","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","I-COVID","NCT04315870","5/20","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04315870","Recruiting","2020-01-01","2020-04-30","{""locations"":""University of Naples Federico II, Napoli, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""20"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Maternal and perinatal outcomes""}"
"4049","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","GARM-COVID19","NCT04326036","GARM COVID19","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04326036","Recruiting","2020-03-25","2021-12-31","{""locations"":""Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry""}"
"4050","Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina","","NCT04673279","3545","Diagnostic Test: serology","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04673279","Recruiting","2020-12-02","2021-07-01","{""locations"":""Hospital de Ni\u00f1os Ricardo Gutierrez, Buenos Aires, Ciudad De Buenos Aires, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""189"",""age"":""14 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""to estimate the proportion of people with positive IgG antibodies for COVID-19 who have positive IgG antibodies after 5 month of the first measurement|to estimate the proportion of people with positive IgG antibodies for dengue""}"
"4051","Convalescent Antibodies Infusion in COVID 19 Patients","","NCT04418531","DFPP COVID 19 Early","Biological: Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04418531","Not yet recruiting","2020-06-01","2020-09-01","{""locations"":""ASST - Papa Giovanni XXIII - Unit of Nephrology, Bergamo, BG, Italy|Asst Hpg23 - Eas, Bergamo, BG, Italy|ASST HPG23 - Intensive Care Unit, Bergamo, BG, Italy|ASST HPG23 - Microbioly and Virology Unit, Bergamo, BG, Italy|Sst Hpg23 - S.I.M.T., Bergamo, BG, Italy|IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to weaning of oxygen support|Chest XR or CT scan evaluation|Survival,|Viral titer|Anti COVID 19 IgG antibodies|Anti COVID 19 IgM antibodies|C5a concentration|C3a concentration|Serum C5b-9 concentration Marker of complement activation|Serum IL-6 levels|Serum IL-1b levels|Serum IFN\u03b3 levels|Serum MCP-1 levels|Serum TNF\u03b1 levels|Serum IL-10 levels|Serum IL-2 levels|Serum IL-7 levels""}"
"4052","STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers","","NCT04488796","116127","Behavioral: Assigned Strategies: Opt-in|Behavioral: Assigned Strategies: Active Choice|Behavioral: Assigned Strategies: Enhanced Active Choice|Behavioral: Choice of Assignment: Opt-in|Behavioral: Choice of Assignment: Active Choice|Behavioral: Choice of Assignment: Enhanced Active Choice","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04488796","Recruiting","2020-09-07","2020-12-01","{""locations"":""University of Western Ontario, London, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""145"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in sedentary behaviour break frequency|Change in sedentary behaviour break duration|Change in work-related quality of life|Change in Health outcomes|Change in sitting time|Change in standing time|Change in moving time|Change in prolonged sitting bouts|Change in percentage of time spent sitting|Change in percentage of time spent standing|Change in percentage of time spent moving|Change in sedentary break frequency|Change in sedentary break duration""}"
"4053","Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome","","NCT04351906","AZ 63/20","Device: ECCO2R","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04351906","Recruiting","2020-05-03","2021-10-01","{""locations"":""University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Delta change in arterial partial pressure of carbon dioxide during ECCO2R treatment|Change in vasopressor use during ECCO2R|Assessment of changes in tidal volume during ECCO2R|Assessment of changes in pH during ECCO2R|Assessment of changes in Positive End-Expiratory Pressure during ECCO2R|Number of participants with adverse events directly related to ECCO2R|Rate of technical adverse events related to ECCO2R|Delta change in venous partial pressure of carbon dioxide before and after ECCO2R membrane""}"
"4054","Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT","","NCT04460014","2020-03085","Behavioral: Simple cognitive task intervention|Behavioral: Attention Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04460014","Recruiting","2020-09-30","2021-08-01","{""locations"":""Hospital units across Sweden (e.g. FO Akut, Karolinska University Hospital Huddinge), Huddinge, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""164"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of intrusive memories of traumatic event(s)|Intrusion questionnaire - frequency item|Intrusion questionnaire - characteristics|Impact of Event Scale - Revised (IES-R): Degree of subjective distress of post-trauma intrusion and avoidance symptoms|Posttraumatic Stress Disorder Checklist 5 (PCL-5) short version|Characteristics of intrusive trauma memories""}"
"4055","ASC Therapy for Patients With Severe Respiratory COVID-19","ASC COVID-19","NCT04341610","EudraCT number: 2020-001330-36","Drug: Stem Cell Product","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04341610","Withdrawn","2020-04-20","2021-04-30","{""locations"":""2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in clinical critical treatment index|Days of respirator treatment|Improvement of clinical symptoms including duration of fever and respiratory need|Mortality|Marker of Immunological function -CD4+ and CD8+ T cell count|C-reactive protein and leucocyte|Cytokine profile|Glomerular Filtration Rate|Duration of hospitalization""}"
"4056","A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19","","NCT04548544","19-29083 (b)","Behavioral: Training for Awareness, Resilience, and Action (TARA)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04548544","Completed","2019-10-18","2020-05-20","{""locations"":""UCSF, San Francisco, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science"",""enrollment"":""21"",""age"":""14 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Change in Emotional Problems""}"
"4057","Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19","","NCT04638842","VIU-Grief-COVID","Behavioral: Online Intervention Grief COVID-19","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04638842","Recruiting","2020-12-24","2021-06-01","{""locations"":""Universidad Aut\u00f3noma de Ciudad Ju\u00e1rez, Ju\u00e1rez, Chihuahua, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Decrease in the scores of the Center for Epidemiologic Studies Depression (CES-D) scale|Change in the score of Anxiety Symptoms in the Depression Anxiety Stress Scale (DASS-21)|Decrease in the score of The Pittsburgh Sleep Quality Index.|Decrease in the scores of the Post-Traumatic Stress Disorder Symptom Scale|Increase in Satisfaction with Life Scale|Decrease in the symptoms of General Anxiety Disorder|Decrease in the Plutchik Suicide Risk Scale|Decrease in Grief symptoms""}"
"4058","Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic","AUTONOMIC","NCT04365335","2020-COVID19-11|2020-A01058-31","Behavioral: Assessment of work-related stress|Biological: Saliva sample collection|Other: Cardiac and electrodermal recordings|Behavioral: Assessment of behavioral response to emotional stimulation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365335","Completed","2020-04-25","2020-06-12","{""locations"":""El\u00e9ment Militaire de R\u00e9animation (EMR), Mulhouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Professional burnout|Mindfulness level|Perceived stress level following the emotional stimulation|Parasympathetic flexibility evolution during emotional recall|Sympathetic tone at rest|Corticotropic activation at rest|Mood disorders (anxiety \/ depression)|Post-traumatic stress disorder|Sleep quality""}"
"4059","The Validity of Modern Mobile Applications in Management of COVID-19 Home Isolation Patients: a Survey for Health Care Professionals","","NCT04548492","75 / 2020","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04548492","Not yet recruiting","2020-09-14","2021-01-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Prospective"",""enrollment"":""175"",""age"":""35 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""rate of reassurance delivered from doctors to patients through Whatsapp""}"
"4060","An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies","","NCT04581187","GIMEMA-ALLIANCE Platform","Other: Quality of life assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581187","Not yet recruiting","2020-10-01","2024-10-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""HRQOL in adult patients with hematologic malignancies|Symptoms in adult patients with hematologic malignancies|Adherence to therapy in adult patients with hematologic malignancies|Prevalence of clinically relevant functional limitations and symptoms|Factors associated with physical and mental health concerns|Financial and social impact imposed by the COVID-19 pandemic on patient health outcomes|Limitations in accessing routine medical care services imposed by the COVID-19 pandemic on patient health outcomes|Clinical strategies adopted by physicians""}"
"4061","Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents","NH-Shingrix","NCT04523246","OUHSC IRB#12394","Biological: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|Drug: Normal Saline","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04523246","Recruiting","2020-09-01","2021-09-01","{""locations"":""Fran and Earl Ziegler College of Nursing, Oklahoma City, Oklahoma, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science"",""enrollment"":""250"",""age"":""65 Years to 100 Years \u00a0 (Older Adult)"",""outcome_measures"":""Evidenced of active and trained innate immunity|Respiratory Disease Severity (6 month)""}"
"4062","Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19","COVID19_LLC-MW","NCT04391946","FILO-COVID19_LLC-MW","Behavioral: Data registry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04391946","Recruiting","2020-03-14","2022-12-31","{""locations"":""Chu Angers, Angers, France|CHU Jean Minjoz - H\u00e9matologie, Besan\u00e7on, France|H\u00f4pital Avicenne - Centre de Recherche Clinique, Bobigny, France|CHU Estaing - H\u00e9matologie Clinique Adulte, Clermont-Ferrand, France|Chu Creteil, Cr\u00e9teil, France|CHU Grenoble - H\u00e9matologie, Grenoble, France|Chd Vendee, La Roche-sur-Yon, France|Centre Hospitalier du Mans, Le Mans, France|H\u00f4pital Saint Vicent de Paul, Lille, France|Centre L\u00e9on B\u00e9rard - H\u00e9matologie, Lyon, France|Institut Paoli Calmette, Marseille, France|Hopital E.Muller, Mulhouse, France|CHU DE NANTES - Hematologie clinique, Nantes, France|Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent, Paris, France|Centre Hospitalier Lyon Sud, Pierre-B\u00e9nite, France|H\u00f4pital de la Mil\u00e9trie - H\u00e9matologie et Th\u00e9rapie Cellulaire, Poitiers, France|H\u00f4pital Robert Debr\u00e9 - H\u00e9matologie Clinique, Reims, France|Centre Henri Becquerel - Service H\u00e9matologie Clinique, Rouen, France|H\u00f4pital Hautepierre - H\u00e9matologie, Strasbourg, France|IUCT ONCOPOLE - H\u00e9matologie, Toulouse, France|H\u00f4pital Bretonneau - H\u00e9matologie et Th\u00e9rapie Cellulaire, Tours, France|CHU Nancy Brabois, Vand\u0153uvre-l\u00e8s-Nancy, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prognostic factors for healing of COVID-19 infection|Medical care of Coronavirus infection|national epidemiological monitoring""}"
"4063","Study of Resilience and Loneliness in Youth (18 - 25 Years Old) During the COVID-19 Pandemic Lock-down Measures.","","NCT04371250","SRB2020_158","Other: Survey and Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371250","Active, not recruiting","2020-04-30","2020-12-30","{""locations"":""Erasme University Hospital, Brussels, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years to 25 Years \u00a0 (Adult)"",""outcome_measures"":""Self-rated measure of Resilience|Self-rated measure of Loneliness""}"
"4064","COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic","COMPASS","NCT04535778","20347","Behavioral: COMPASS|Behavioral: Standard charity resources","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04535778","Recruiting","2020-11-16","2021-06-01","{""locations"":""Health Psychology Section, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)|Change in Work and social adjustment scale (WSAS)|Change in EQ-5D-3L|Change in Illness perception questionnaire - revised (IPQ-R), emotional subscale""}"
"4065","Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients","COVID-19_EIT","NCT04359407","2020-00896","Other: Prone positioning","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04359407","Recruiting","2020-04-27","2021-01-31","{""locations"":""University Hospitals of Geneva, Geneva, Switzerland"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""16"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Tidal electrical Impedance|Intrapulmonary shunt|Volumetric capnography""}"
"4066","Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19","AFFORD COVID","NCT04613739","IHS-1602-34331","Behavioral: insurance navigation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04613739","Recruiting","2020-12-08","2023-01-31","{""locations"":""Harvard Pilgrim Health Care, Wellesley, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""430"",""age"":""4 Years to 64 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Insurance coverage|Medication adherence|Financial burden|Delayed\/forgone care due to cost""}"
"4067","Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.","CoVEX","NCT04402827","EC 162/20","Diagnostic Test: Susceptibility to infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04402827","Recruiting","2020-08-01","2021-01-30","{""locations"":""Hospital Ramon y Cajal, Madrid, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Susceptibility to SARS CoV-2 infection according to ACE2 receptor|Cellular immune response to SARS CoV-2 infection|Susceptibility to infections according to KIR phenoytpes|Characteristics of exposure in time and intensity of HCW with SARS CoV-2 infection|Cellular immune response in HCW with positive IgG against SARS CoV-2""}"
"4068","Management of Acute Appendicitis at District General Hospital","","NCT04707339","3810","Procedure: Appendicectomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04707339","Recruiting","2020-01-30","2021-01-30","{""locations"":""The Princess Alexandra Hospital NHS Trust, Harlow, Essex, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Negative Appendicectomy Rate|Outcomes of Conservative vs Operative Management|Increased Open Appendicectomy Rate|Surgical site infection in patients on antibiotics|Length of Stay""}"
"4069","Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19","ProPAC-COVID","NCT04322396","KronLungesyg_COVID_19_protokol","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04322396","Completed","2020-04-06","2021-02-02","{""locations"":""Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsj\u00e6llands Hospital, Hiller\u00f8d, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""117"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement \""LTOT\"")""}"
"4070","Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients","COCARDE","NCT04358952","RC31/20/0117|2020-A00852-37","Diagnostic Test: Global Longitudinal Strain","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04358952","Recruiting","2020-04-04","2021-04-04","{""locations"":""UHToulouse, Toulouse, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Left ventricular function|inflammatory biological parameters""}"
"4071","An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19","","NCT04346693","DAL-05-04-2020","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04346693","Completed","2020-04-08","2020-11-20","{""locations"":""Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""320"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study""}"
"4072","Physical Activity, Exercise Capacity and Coronavirus Phobia of Adult Cystic Fibrosis Patients During COVID-19 Pandemic","","NCT04673331","GO 20/794","Other: exercise capacity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04673331","Recruiting","2020-11-04","2021-11-04","{""locations"":""Hacettepe University, Ankara, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""24"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical Activity Level-International Physical Activity Questionnaire|Coronavirus Phobia-Coronavirus-19 Phobia Scale|Exercise Capacity|Weekly Average Steps|Cognitive Function-Standardized Mini Mental State Examination|Quality Of Life-Nottingham Health Profile""}"
"4073","Adapting and Adopting Highly Specialized Pediatric Eating Disorder Treatment to Virtual Care: Implementation Research for the COVID-19 Context and Beyond","vFBT","NCT04678843","12722","Behavioral: Virtual Family-Based Treatment","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04678843","Enrolling by invitation","2021-02-09","2021-12-01","{""locations"":""Southlake Regional Health Centre, Newmarket, Ontario, Canada|St. Joseph's Care Group, Thunder Bay, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|CMHA Waterloo Wellington, Waterloo, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""36"",""age"":""10 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Key components of FBT|Fidelity|Qualitative experience of participants|Change in Weight|Change in Number of Binge\/Purge Episodes|Therapists' Change in Readiness|Therapists' Change in Attitudes about Evidence Based Practice|Therapists' Change in Confidence related to the Intervention""}"
"4074","Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19","","NCT04645368","DISSOLVE","Drug: bovhyaluronidase azoxymer","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04645368","Recruiting","2020-07-01","2021-07-01","{""locations"":""Federal State Budgetary Educational Institution of Higher Education \""Astrakhan State Medical University\"" of the Ministry of Health of the Russian Federation, Astrakhan, Astrakhan Region, Russian Federation|Municipal autonomous health care institution \""City Clinical Polyclinic No. 8\"", Chelyabinsk, Chelyabinsk Region, Russian Federation|State Budgetary Healthcare Institution \""Regional Clinical Hospital No. 3\"", Chelyabinsk, Chelyabinsk Region, Russian Federation|Municipal budgetary institution \""Central city clinical hospital number 6 \"", Ekaterinburg, Ekaterinburg Region, Russian Federation|Medical center \""Clinic South\"", Krasnodar, Krasnodar Region, Russian Federation|Federal State Budgetary Scientific Institution \""Federal Research Center\"" Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences \"" Scientific Research Institute of Medical Problems of the North, Krasnoyarsk, Krasnoyarsk Region, Russian Federation|Institute of Clinical Immunology LLC, Krasnoyarsk, Krasnoyarsk Region, Russian Federation|St. Petersburg State Budgetary Healthcare Institution \""City Consultative and Diagnostic Center No. 1\"", Saint Petersburg, Leningrad Region, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, Novosibirsk Region, Russian Federation|CJSC \""Medical Center\"" Philosophy of Beauty and Health \"", Perm, Perm Region, Russian Federation|State budgetary institution of health care Republican clinical hospital named after G.G. Kuvatova, Ufa, Ufa Region, Russian Federation|State health care institution \""Clinical Hospital No. 4\"", Volgograd, Volgograd Region, Russian Federation|Federal State Budgetary Educational Institution of Higher Education \""Volgograd State Medical University\"" of the Ministry of Health of the Russian Federation Volgograd State Medical University of the Ministry of Health of Russia, Volgograd, Volgograd Region, Russian Federation|FSBI \""Main Military Clinical Hospital named after Academician N.N.Burdenko\"" of the Ministry of Defense of the Russian Federation, Moscow, Russian Federation|State Budgetary Institution of Healthcare of the City of Moscow \""City Polyclinic No. 180 of the Department of Healthcare of the City of Moscow\"", Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""160"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The severity of lung tissue lesions with fibrosis and interstitial changes on day 75|The severity of lung tissue damage by fibrosis and interstitial changes (%) on day 180|The severity of lung tissue lesions with fibrosis and interstitial changes (%) on day 75 and day 180|The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) images analyzed by the Botkin.AI program (artificial intelligence)|Change in forced vital capacity (FVC)|Change in the diffusion capacity of the lungs|Change in the degree of dyspnea on the MMRC scale|Changes in capillary blood oxygen saturation (SpO2)|Changes in the covered footage in the 6-minute walk test|Changes in capillary blood saturation (SpO2) after a 6-minute walk test|Change in the residual volume of the lungs|Change in the total lung capacity|Change in inspiratory capacity""}"
"4075","Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients","","NCT04674410","BD022383","Drug: Antibiotic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04674410","Active, not recruiting","2020-03-01","2021-02-28","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In-Hospital Mortality or discharge to hospice|Rates of Mechanical Ventilation|Rates of C. difficile infection|Length of stay for survivors|Rates of ICU Admission|Rates of Acute Kidney Injury|Days free of antibiotics|Rates of secondary infections due to antibiotic resistant pathogens""}"
"4076","Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19","ECMO-COVID-19","NCT04343404","7772","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04343404","Completed","2020-04-01","2020-04-15","{""locations"":""Service de Chirurgie Thoracique Nouvel H\u00f4pital Civil H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them""}"
"4077","Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","BURDENCOV","NCT04341519","APHP200389","Behavioral: PTSD|Behavioral: Burnout","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04341519","Recruiting","2020-04-06","2021-12-31","{""locations"":""Saint-Louis Hospital, Paris, Ile De France, France|Cochin, Paris, France|Piti\u00e9 Salpetri\u00e8re, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1464"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PTSD Family members sup 22|PTSD Family members|PTSD Patients|PTSD healthcare providers|HADS Family members|HADS Patients|SF36 Patients|Questionnaire Family members|Questionnaire Patients|Questionnaire healthcare providers|MBI healthcare providers|Karasec instrument healthcare providers""}"
"4078","""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""","COVID-19","NCT04400305","05-281983","Behavioral: Digital Health Online Platform","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04400305","Recruiting","2020-05-20","2021-03-31","{""locations"":""Behavioural Medicine Lab, University of Victoria, Victoria, British Columbia, Canada|University of Victoria, Victoria, British Columbia, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Recruitment rate (monthly)|Participant retention|Participant intervention satisfaction\/evaluation|Change in self-reported physical activity from baseline to 6 weeks|Change in physical activity beliefs, attitudes, barriers, and motivation from baseline to 6 weeks.|Change in physical activity behaviour regulation from baseline to 6 weeks.|Change in physical activity habits from baseline to 6 weeks|Change in physical activity identity from baseline to 6 weeks|Change in life satisfaction measured using the Short Form 12 questionnaire from baseline to 6 weeks""}"
"4079","Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).","Masq-Aute","NCT04427176","20CH073|2020-A00817-32","Device: ARFC mask","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04427176","Completed","2020-04-29","2020-05-28","{""locations"":""CHU Saint-Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the feasibility of the use of an ARFC mask by nursing staff, in terms of tolerance|Evaluate the feasibility of the use of an ARFC mask by nursing staff, in terms of compatibility with technical gestures.|Assess the acceptability of the wearing of an ARFC mask by nursing staff|To assess the minor complications of wearing the ARFC mask .""}"
"4080","Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic","","NCT04378257","12/2020","Behavioral: Therapist Guided E-Therapy|Behavioral: Self-Help Therapy","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04378257","Not yet recruiting","2020-06-01","2020-10-20","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""70"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Depressive symptoms measured by Patient Health Questionnaire-9|Change in Anxiety symptoms measured by Generalized Anxiety Disorder-7|Proportion of subjects with Significant Depression|Proportion of subjects with Significant Anxiety""}"
"4081","Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic","MUCONFIN","NCT04463628","MUCONFIN","Behavioral: Questionnaire|Behavioral: Interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04463628","Recruiting","2020-05-15","2021-06-30","{""locations"":""Intercommunal hospital of Cr\u00e9teil, Creteil, IDF, France|TROUSSEAU Hospital, Paris, IDF, France|FOCH Hospital, Suresnes, IDF, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Cancellation or postponement of consultations by the health professional or patient,|Patient cancellation of teleconsultations\/telecare replacement,|Cancellation or postponement by the health care institution or by the patient of hospitalizations (scheduled or unscheduled),|Change in the modalities of administration of antibiotics cures (oral instead of intravenous administration).|The reduction of each of the elements of care provision and health care utilization:|The change of modality of administration of antibiotic cures|Compliance|Anxiety and stress (at risk of being affected by COVID-19 or at risk of being treated less well)|Presence or absence of toxic consumption (drug, alcohol) during the lockdown|Evaluation of the knowledge, experience and social representations of the risk of Covid-19|Assessing the role of social inequalities in the consequences of lockdown|Suspected and\/or confirmed Covid-19 in patients with cystic fibrosis.""}"
"4082","Electrical Impedance Tomography: Collapse in Dependent Areas as a Predictor of Response to Prone Position Ventilation in COVID-19 Acute Respiratory Distress Syndrome","COVIDEIT","NCT04603755","2020-COVID19-16|2020-A02823-36","Device: Electrical Impedance tomography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04603755","Recruiting","2020-10-26","2022-04-01","{""locations"":""H\u00f4pital d'Instruction des Arm\u00e9es Sainte-Anne, Toulon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Coefficient of correlation between the percentage of derecruitment of dependent areas (measured with Electrical Impedance Tomography) and the response to prone position""}"
"4083","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool","","NCT04274322","COV_NUTRIC","Other: Nutrition support","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04274322","Active, not recruiting","2020-02-19","2020-07-01","{""locations"":""Peking University Third Hospital, Beijing, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""117"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation""}"
"4084","To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic","Coronavirus19","NCT04412239","NO, F6-2017/NTP-ADMIN","Behavioral: Patient-centred advice on Telephone Consultation in TB Patients:","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04412239","Recruiting","2020-04-20","2020-12-20","{""locations"":""Dhq Bannu Kpk, Bannu, KPK, Pakistan|District Bannu TB Control Center, Bannu, KPK, Pakistan"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficiency of the telephone consultation,|Patient satisfaction|Adherence Rate""}"
"4085","Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19","RECOVER","NCT04470544","CAM20CV","Drug: Camostat Mesilate|Other: Standard of Care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04470544","Recruiting","2020-07-28","2022-09-15","{""locations"":""Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Tucson Medical Center, Tucson, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""264"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the proportion of patients alive and free from respiratory failure|Change in the proportion of patients alive and free of ventilator use or ECMO|Mortality Rate|Clinical Change|Adverse Events""}"
"4086","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","CORIMUNO-SARI","NCT04324073","APHP200375-2","Drug: Sarilumab","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04324073","Active, not recruiting","2020-03-27","2021-12-31","{""locations"":""Kremlin Bicetre hospital APHP, Le Kremlin-Bic\u00eatre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""239"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2\/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge""}"
"4087","Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic","","NCT04559074","283209","Drug: Amlodipine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04559074","Recruiting","2020-10-23","2021-07-31","{""locations"":""Queen Mary University London, London, United Kingdom"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reductions in blood pressure in participants with primary hypertension and inadequate BP control by up-titration of amlodipine in 1-2 mg increments.|Mean change in daily DBP|Difference between mean changes of blood pressure|Collect data on tolerability \/ side effects""}"
"4088","Covid-19 and Diabetes in West of Algeria","COVIDIAB-13","NCT04412746","COVIDIAB-13","Drug: MANAGEMENT OF COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04412746","Recruiting","2020-04-01","2020-06-30","{""locations"":""Department of Internal Medicine, Acedemic Hospital of Tlemcen, Tlemcen, Algeria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Prevalence of diabetes among all hospitalized COVID-19|Diabetes-related factors risk""}"
"4089","A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19","TRISTARDS","NCT04640194","0135-0347|2020-002913-16","Drug: Alteplase|Procedure: Standard of care","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04640194","Recruiting","2020-12-16","2022-09-01","{""locations"":""LKH Klagenfurt am Woerthersee, Klagenfurt, Austria|Wiener Gesundheitsverbund Klinik Favoriten, Vienna, Austria|ULB Hopital Erasme, Bruxelles, Belgium|Centre Hospitalier Universitaire de Li\u00e8ge, Li\u00e8ge, Belgium|Ottignies - HOSP St-Pierre, Ottignies, Belgium|Hvidovre Hospital, Hvidovre, Denmark|HOP Europ\u00e9en G. Pompidou, Paris cedex 15, France|HOP Cochin, Paris, France|HOP Pierre B\u00e9nite, Pierre B\u00e9nite, France|HOP Civil, Strasbourg cedex, France|Universit\u00e4tsklinikum Essen A\u00f6R, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany|Universit\u00e4tsklinikum Leipzig, Leipzig, Germany|Klinikum der Universit\u00e4t M\u00fcnchen - Campus Gro\u00dfhadern, M\u00fcnchen, Germany|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Ospedali Riuniti di Ancona, Torrette Di Ancona (AN), Italy|Gelre Ziekenhuizen Apeldoorn, Apeldoorn, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Canisius-Wilhelmina ziekenhuis, Nijmegen, Netherlands|CHLO, EPE - Hospital Egas Moniz, Lisboa, Portugal|Centro Hospitalar Universit\u00e1rio do Porto, EPE - Hospital de Santo Ant\u00f3nio, Porto, Portugal|ULSAM, EPE - Hospital de Santa Luzia, Viana do Castelo, Portugal|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Puerta del Mar, C\u00e1diz, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""270"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement or hospital discharge|All cause mortality|Number of ventilator-free days|Improvement of Sequential (sepsis-related) Organ Failure Assessment (SOFA) score by \u22652 points|Number of major bleeding events (MBE)|Daily average PaO2\/FiO2 ratio (or inferred PaO2\/FiO2 ratio from SpO2) change|All-cause mortality or on mechanical ventilation""}"
"4090","Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19","","NCT04453657","IRB00250864","Device: FamilyChildCare (provisional name of app)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04453657","Enrolling by invitation","2021-02-04","2021-09-01","{""locations"":""Johns Hopkins School of Nursing, Baltimore, Maryland, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""270"",""age"":""3 Years to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Change in Perceived Level of Stress as assessed by the Perceived Stress Scale|Change in Perceived Level of Informational Support as assessed by the PROMIS Informational Support Short Form|Change in Awareness of the Maryland Early Childhood Family Engagement Framework and Toolkit as assessed by a survey question|Change in Social, Emotional, and Behavior Functioning in Children as assessed by the Social Competence and Behavior Evaluation for Children|Change in Quality of the Parent-Child Care Relationship as assessed by the Supportive Parent-Caregiver Relationship Subscale""}"
"4091","Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers","COVID-BCG","NCT04384549","APHP200462|2020-001678-31","Biological: BCG GROUP|Other: PLACEBO GROUP","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04384549","Recruiting","2020-05-20","2021-02-20","{""locations"":""I-REIVAC\/CIC 1417 Cochin Hospital, APHP, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""1120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of documented COVID-19 among health care workers exposed to SARS CoV2 and vaccinated with BCG compared to placebo.|Numbers of COVID-19 patients requiring hospitalization in ICU and O2, artificial ventilation or extracorporal membrane oxygenation, or deaths in BCG-vaccinated health care workers compared to placebo|Incidence of asymptomatic SARS CoV2 seropositive subjects among BCG-vaccinated health care workers compared to placebo.|Incidence of subjects with any respiratory infection among BCG-vaccinated health care workers compared to placebo.|Numbers of sick days and numbers of sick leaves among BCG-vaccinated health care workers compared to placebo.|Numbers of subjects with BCG-related advers events among BCG-vaccinated health care workers compared to placebo.|Numbers and intensity of changes in innate immune markers after SARS CoV2 infection among BCG-vaccinated health care workers compared to placebo.""}"
"4092","Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near","","NCT04407663","Telemedicine","Other: Telemedicine to remote outpatient visit in bariatric patient","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407663","Completed","2020-03-03","2020-05-04","{""locations"":""University of Campania \""Luigi Vanvitelli\"", Naples, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""138"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of feasibility of telemedicine in outpatient visit in bariatric patients""}"
"4093","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)","","NCT04321278","30155020.5.1001.0071","Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04321278","Completed","2020-03-28","2020-06-14","{""locations"":""Hospital de Urg\u00eancia e Emerg\u00eancia de Rio Branco, Rio Branco, AC, Brazil|Hospital e Cl\u00ednica S\u00e3o Roque, Ipia\u00fa, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Maternidade S\u00e3o Vicente de Paulo, Barbalha, CE, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil|Hospital Evang\u00e9lico de Vila Velha, Vila Velha, ES, Brazil|Secretaria de Estado de Sa\u00fade de Goias, Goi\u00e2nia, GO, Brazil|Santa Casa de Miseric\u00f3rdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil|Hospital Santa Paula, Passos, MG, Brazil|Santa Casa da Misericordia - UTI (S\u00e3o Jo\u00e3o Del Rey), S\u00e3o Jo\u00e3o Del Rei, MG, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Po\u00e7os De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paran\u00e1, Brazil|Hospital Adventista de Bel\u00e9m, Bel\u00e9m, Par\u00e1, Brazil|Hospital Adventista de Belem, Belem, PA, Brazil|Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil|Liga Paranaense de Combate ao C\u00e2ncer, Curitiba, PR, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Naval Marc\u00edlio Dias, Rio de Janeiro, RJ, Brazil|Hospital S\u00e3o Lucas, Rio De Janeiro, RJ, Brazil|Hospital Maternidade PROMATER, Natal, RN, Brazil|Associa\u00e7\u00e3o Dr. Bartholomeu Tacchini, Bento Gon\u00e7alves, RS, Brazil|Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital S\u00e3o Vicente de Paulo, Passo Fundo, RS, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Crici\u00fama, Santa Catarina, Brazil|Hospital Nereu Ramos, Florian\u00f3polis, SC, Brazil|Hospital Universit\u00e1rio Polydoro Ernani de S\u00e3o Thiago\/HU - UFSC, Florian\u00f3polis, SC, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital Municipal Sao Jose, Joinville, SC, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil|Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil|nstituto de Pesquisa Cl\u00ednica de Campinas, Campinas, SP, Brazil|Funda\u00e7\u00e3o do ABC (Hospital Estadual M\u00e1rio Covas), Santo Andr\u00e9, SP, Brazil|AC Camargo Cancer Center - Funda\u00e7\u00e3o Antonio Prudente, S\u00e3o Paulo, SP, Brazil|Casa de Saude Santa Marcelina, S\u00e3o Paulo, SP, Brazil|Hospital Alem\u00e3o Oswaldo Cruz, S\u00e3o Paulo, SP, Brazil|Hospital Moriah, S\u00e3o Paulo, SP, Brazil|Hospital Nove de Julho, S\u00e3o Paulo, SP, Brazil|Hospital Santa Paula, S\u00e3o Paulo, SP, Brazil|Hospital S\u00e3o Camilo Pompeia, S\u00e3o Paulo, SP, Brazil|Funda\u00e7\u00e3o Pio XII, Barretos, S\u00e3o Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, S\u00e3o Paulo, Brazil|Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil|A Benefic\u00eancia Portuguesa de S\u00e3o Paulo - BP, S\u00e3o Paulo, Brazil|Associacao Beneficente Siria, S\u00e3o Paulo, Brazil|Hospital Vila Santa Catarina, S\u00e3o Paulo, Brazil|Real e Benem\u00e9rita Associa\u00e7\u00e3o Portuguesa de Benefic\u00eancia\/SP - 1, S\u00e3o Paulo, Brazil|Secretaria de Sa\u00fade do Estado de S\u00e3o Paulo, S\u00e3o Paulo, Brazil|Serv Social da Industria do papel, papel\u00e3o e corti\u00e7a do estado de SP, S\u00e3o Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo, Brazil|Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""440"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype""}"
"4094","Sparing in Neuromuscular Blockade in COVID 19 ICU","TOF-COVID","NCT04459533","2020_TOF-COVID","Device: TOF protocol","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04459533","Completed","2020-06-01","2020-06-01","{""locations"":""Department of Anesthesiology and Intensive Care Medicine, H\u00f4pital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""NMB agents consumption""}"
"4095","COVID-19 and SARS-CoV-2 Detection in Saliva","","NCT04517682","COV_20_001","Diagnostic Test: RT-PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04517682","Enrolling by invitation","2020-05-21","2020-12-30","{""locations"":""Ambry Genetics, Aliso Viejo, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Detection of COVID-19 SARs-CoV-2 in saliva samples versus nasopharyngeal samples""}"
"4096","Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness","","NCT04570384","CIT-COVID19-002-01","Drug: L-Citrulline|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04570384","Recruiting","2020-10-15","2021-12-28","{""locations"":""University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Biochemical Objective to measure levels of citrulline and arginine in the Blood|The primary safety objective is a beneficial effect of intravenous L-Citrulline on hemodynamic status.|Primary Clinical Objective|Evaluate the Safety of L-Citrulline|Evaluate the effect of intravenous L-Citrulline compared to placebo as measured by the total length of all mechanical ventilation|Evaluate the Effect of IV L-Citrulline to Placebo for Hospital all cause mortality|Evaluate the Effect of IV L-Citrulline to Placebo on length of ICU and Hospital Stay|Evaluate overall difference in intubation rates|Evaluate overall duration of mechanical ventilation from consent and post-infusion""}"
"4097","""COVID-19 and Diabetes Outcomes""","CORONADO","NCT04324736","RC20_0148","Other: no interventional study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04324736","Completed","2020-03-10","2020-12-31","{""locations"":""CHU Nantes, Nantes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""5309"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Assess the prevalence of severe forms among hospitalized patients with diab\u00e8tes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19""}"
"4098","An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic","","NCT04395508","AL42478","Drug: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)","Expanded Access:Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04395508","Available","1970-01-01","1970-01-01","{""locations"":""Beverly Hills Cancer Center, Beverly Hills, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|Stanford Univ School of Med; Oncology, Stanford, California, United States|University Of Colorado, Aurora, Colorado, United States|MedStar Washington Hosp Center, Washington, District of Columbia, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States"",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"4099","PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine","","NCT04353037","2020-0003","Drug: Group A HCQ|Drug: Group B Control","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04353037","Recruiting","2020-04-07","2021-06-15","{""locations"":""ProHealth New York, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""850"",""age"":""50 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sub Study 1: Patients|Sub Study 2: Health Care Workers|Sub Study 1: Patients: Rate of secondary infection of co-inhabitants|Sub Study 1: Patients: Adverse Events|Sub Study 1: Patients: Negative for COVID-19|Sub Study 2:Health Care Workers:Number of shifts missed|Sub Study 2:Health Care Workers:Rate of adverse events|Sub Study 2:Health Care Workers:Rate of hospitalization""}"
"4100","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection","NoCovid","NCT04290858","COVID19 NOgas mild","Drug: Nitric Oxide","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04290858","Withdrawn","2020-03-01","2022-02-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery""}"
"4101","Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure","QUANTICO-RETRO","NCT04534400","7888","Radiation: thoracic CT-scan","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04534400","Recruiting","2020-09-01","2021-01-15","{""locations"":""GHR MULHOUSE-SUD ALSACE, H\u00f4pital Emile Muller, Service de Radiologie, Mulhouse, France|H\u00d4PITAUX UNIVERSITAIRES DE STRASBOURG, H\u00f4pital de Hautepierre, Service de R\u00e9animation M\u00e9dicale, Strasbourg, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between altered pulmonary volume and ordinal severity scale""}"
"4102","The Provider Insurance Revenue Study in Healthcare Providers in the United States of America","","NCT04587245","PIRStudy","Other: Online questionnaire and interviews","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04587245","Recruiting","2020-10-01","2021-10-15","{""locations"":""University of California Irvine Beall Applied Innovation, Irvine, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in monthly income of healthcare Providers from baseline to 6, 9 and 12 months after the beginning of the COVID-related events|Differences in Accounts Receivable (AR) due to claim denials over 4 quarters: Differences in recoveries of AR.""}"
"4103","Covid-19 and Vitamin D in Nursing-home","COVIT-EHPAD","NCT04435119","2020/67","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04435119","Completed","2020-03-15","2020-05-15","{""locations"":""Angers University Hospital, Angers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""96"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Number of deaths of any cause in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19|Clinical severity score of COVID19 in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19""}"
"4104","Covid-19 Triage Using Camera-based AI","","NCT04383457","U1111-1251-4114","Device: RIA-device (Remote Investigation and Assessment)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383457","Completed","2020-06-15","2020-10-08","{""locations"":""\u00d6stra Sjukhuset, Gothenburg, Sweden"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""214"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Agreement between the new camera based method and reference standard to estimate body temperature|Agreement between the new camera based method and reference standard to estimate heart rate|Agreement between the new camera based method and reference standard to estimate blood oxygen saturation|Agreement between the new camera based method and reference standard to estimate systolic blood pressure|Agreement between the new camera based method and reference standard to estimate diastolic blood pressure|Agreement between the new camera based method and reference standard to estimate respiratory rate|Prediction of hospital admission using vital signs estimated using reference standard methods|Prediction of death using vital signs estimated using reference standard methods|Prediction of hospital admission using vital signs estimated using the new camera based method|Prediction of death using vital signs estimated using the new camera based method|Prediction of hospital admission using raw camera data|Prediction of death using raw camera data""}"
"4105","Effect of Liver Injury on Mortality in Coronavirus Disease-2019 Patients Admitted to Intensive Care Unit","","NCT04669509","CKKacar","Diagnostic Test: Liver function tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04669509","Completed","2020-04-01","2020-12-14","{""locations"":""Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital, Diyarbak\u0131r, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""532"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""7 and 28 day mortality""}"
"4106","Feasibility of a Telematics Pre-operative Assessment in a Bariatric Surgery During Covid-19","","NCT04486417","66.2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04486417","Recruiting","2020-06-01","2020-07-31","{""locations"":""Gianfranco Silecchia, Latina, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rejection rate (%)|Drop out rate|Excess Weight Loss percentage (EWL%)|Satisfaction degree""}"
"4107","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19)","","NCT04320056","21909","Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04320056","Recruiting","2020-04-20","2021-10-31","{""locations"":""Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec - Universit\u00e9 Laval, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""216"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The number of interventions|Duration of interventions|Mean oxygen flow|Time within theSpO2 target|Time with hypoxemia|Time with hyperoxemia|Rate of ICU admission|Rate of needed non invasive respiratory support|Rate of intubation|NEWS 2 score evolution|EWSO2 score evolution|Cost-effectiveness|length of stay""}"
"4108","Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak","CLIECO","NCT04416360","RC31/20/0151","Other: Interview by psychologists","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04416360","Recruiting","2020-05-05","2021-01-01","{""locations"":""University hospital of Toulouse, Toulouse, Occitanie, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Esquirol, Limoges, France|H\u00f4pital Robert-Debr\u00e9 (AP-HP), Paris, France|Maison de Solenn (H\u00f4pital Cochin AP-HP), Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""6 Years to 17 Years \u00a0 (Child)"",""outcome_measures"":""Interview of the parents : contextual data|Interview of the children\/adolescents\/ parents : Experience of the confinement in general|Interview of the referring caregiver : data relating to disease and management of care""}"
"4109","Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases","MYOCOVID","NCT04375748","RC31/20/0139","Diagnostic Test: Performing routine care (clinical and paraclinical tests)|Diagnostic Test: Examinations for the research:","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04375748","Recruiting","2020-04-15","2021-10-15","{""locations"":""Cardiology, Aix-en-Provence, France|Reanimation, Amiens, France|Cardiology, Angers, France|Reanimation, Angers, France|Cardiology, Avignon, France|Cardiology, Bordeaux, France|Pediatric cardiology, Bordeaux, France|Reanimation, Bordeaux, France|Cardiology, Brest, France|Cardiology, Caen, France|Pediatric Cardiology, Caen, France|Cardiology, Clermont-Ferrand, France|Pediatric cardilogy, Clermont-Ferrand, France|Reanimation, Clermont-Ferrand, France|Pediatric cardiology, Dijon, France|Cardiology, Grenoble, France|Pediatric cardiology, Grenoble, France|Reanimation, Grenoble, France|Cardiology, Lille, France|Pediatric cardiology, Lille, France|Pediatric cardiology, Limoges, France|Cardiology, Lyon, France|Pediatric cardiology, Lyon, France|Cardiology, Marseille, France|Pediatric cardiology, Marseille, France|Cardiology, Metz, France|Cardiology, Montpellier, France|Mill\u00e9naire Clinical - Cardiology, Montpellier, France|Pediatric cardiology, Montpellier, France|Reanimation, Montpellier, France|Cardiology, Nancy, France|Cardiology, Nancy, France|Pediatric cardiology, Nancy, France|Cardiology, Nantes, France|Pediatric cardiology, Nantes, France|Cardiology, Nice, France|Pediatric cardiology, Nice, France|Cardiology, N\u00eemes, France|Cardiology, Henri Mondor Hospital, Paris, France|Cardiology, Paris, France|Cardiology, Paris, France|Henri Mondor Hospital Reanimation, Paris, France|Marie Lannelongue Hospital - Pediatric Cardiology, Paris, France|Marie Lannelongue Hospital Cardiology, Paris, France|Reanimation, Paris, France|Reanimation, Paris, France|Robert Debr\u00e9 Hospital - Pediatric cardiology, Paris, France|Saint Antoine Hospital - Cardiology, Paris, France|Cardiology, Poitiers, France|Reanimation, Poitiers, France|Pediatric cardiology, Reims, France|Cardiology, Rennes, France|Pediatric reanimation, Rennes, France|Cardiology, Rouen, France|Pediatric cardiology, Rouen, France|P\u00e9diatric cardiology, Strasbourg, France|Reanimation, Strasbourg, France|CHU de TOULOUSE, Toulouse, France|Croix du Sud Clinical, Toulouse, France|Pasteur Clinical - Cardiology, Toulouse, France|Pasteur Clinical - Pediatric cardiology, Toulouse, France|Pediatric Cardiology, Toulouse, France|Cardiolgy, Tours, France|Pediatric Cardiology, Tours, France|Cardiology, Valenciennes, France|Cardiology, Martinique, Martinique|Cardiology, Mamoudzou, Mayotte|P\u00e9diatric cardiology, R\u00e9union, R\u00e9union"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Evolution of the proportion of positive SARS-COV-2 cases.|Ultrasound characteristics.|Assess prognosis of the acute myocarditis .|The factors associated with acute myocarditis cases .|Biological characteristics|Describe at the admission and during the treatment cardiac MRI parameters""}"
"4110","Nursing Perspective on Burnout and Medical Errors in the Intensive Care Unit During Covid-19 Pandemic","","NCT04371302","54843","Diagnostic Test: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04371302","Not yet recruiting","2020-05-01","2020-06-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""145"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of burnout among ICU nurses during Covid-19|Prevalence of depression among ICU nurses during Covid-19|Prevalence of self-perceived medical errors among ICU nurses during Covid-19|Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19""}"
"4111","Asymptomatic COVID-19 Infection Among Healthcare Workers","","NCT04354792","N-31-2020","Diagnostic Test: Serum SARs COV 2 IGg screening in health care workers","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354792","Completed","2020-05-01","2020-06-10","{""locations"":""Cairo University Hospital, Cairo, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""500"",""age"":""25 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of IGg seropositive health care workers|Differentiation between low risk and high risk HCWs""}"
"4112","Effectiveness of a Novel Respirator With Chitosan Nanoparticles","","NCT04490200","VESTA Trial|32862320.0.0000.0030","Device: VESTA respirator|Device: Conventional N95 respirator","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04490200","Recruiting","2021-03-01","2022-02-15","{""locations"":""HRAN (Hospital Regional da Asa Norte), Bras\u00edlia, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""20 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of laboratory-confirmed COVID-19|Ability of the filtering element to inactivate the SARS-Cov-2|Usability and comfort of the respirator|Adherence to the use of the Respirator|Stress|Burnout|Self-reported quality of life|Musculoskeletal discomfort|Work ability|Incidence of acute respiratory illness""}"
"4113","Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study","COVIDOR","NCT04387968","2020-A01414-35","Diagnostic Test: Covid-19 presto test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387968","Recruiting","2020-08-24","2021-03-24","{""locations"":""Unit\u00e9 de Recherche PARADICT-O - Service de M\u00e9decine - Orl\u00e9ans M\u00e9tropole, Orl\u00e9ans, France|Unit\u00e9 de Recherche PARADICT-O - Service de M\u00e9decine - Orl\u00e9ans M\u00e9tropole, Orl\u00e9ans, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Study the prevalence of Covid-19 infection, coronavirus (SARS coronavirus-2) in territorial agents in the 3 structures : CCTVL, Loire Valley Region Centre, Orleans Metropolitan city|Determine if there is a relationship between the profession carried out by the agents of the territorial community of Orleans metropolitan city, the Loire Valley Region, the CCTVL and contamination by covid-19""}"
"4114","Eculizumab (Soliris) in Covid-19 Infected Patients","SOLID-C19","NCT04288713","COVID19","Drug: Eculizumab","Expanded Access:Individual Patients|Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04288713","Available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"4115","NK Cells Treatment for COVID-19","","NCT04280224","xinxiangM","Biological: NK Cells","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04280224","Recruiting","2020-02-15","2020-12-30","{""locations"":""The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Improvement of clinical symptoms including duration of fever|Improvement of clinical symptoms including respiratory frequency|Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0|Time of virus nucleic acid test negative|CD4+ and CD8+ T cell count|Rate of mortality within 28-days|Size of lesion area by thoracic imaging""}"
"4116","Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia","COP-COVID-19","NCT04358783","IF20-00002","Biological: Plasma|Other: Best Available Therapy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04358783","Active, not recruiting","2020-04-27","2021-05-30","{""locations"":""Hospital Universitario Jos\u00e9 E. Gonzalez, Monterrey, Nuevo Leon, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Early all-cause mortality|Time in days for SARS-CoV-2 RT-PCR negatives|The serum anti-SARS-CoV-2 antibody titres|Detection of serum antibodies""}"
"4117","COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","NOSO-COR","NCT04290780","69HCL20_0214","Other: nosocomial infection/hospital acquired infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04290780","Recruiting","2020-03-09","2021-12-31","{""locations"":""Service Hygi\u00e8ne, Epid\u00e9miologie et Pr\u00e9vention, Lyon, France|Service Hygi\u00e8ne, Epid\u00e9miologie et Pr\u00e9vention, Lyon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""nosocomial infection""}"
"4118","GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)","","NCT04590547","GLS27-005","Drug: GLS-1027|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04590547","Not yet recruiting","2021-02-01","2021-11-01","{""locations"":""Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""132"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of serious adverse events relative to treatment group|Incidence of progression to WHO Classification of \u22656 to include intubation with mechanical ventilation, need for ECMO, or death relative to treatment group|Assess the number of days requiring ICU care relative to treatment group|Assess the number of days of mechanical ventilation relative to treatment group""}"
"4119","Exploring Interventions for Glue Ear During Covid-19","BIG-C","NCT04427631","262816","Device: Bone conduction headphones","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04427631","Not yet recruiting","2020-06-22","2021-06-01","{""locations"":""Peacock Children's centre. Brookfields Hospital, Cambridge, Cambridgeshire, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""3 Years to 11 Years \u00a0 (Child)"",""outcome_measures"":""acceptability of management strategy, questionnaire|quality of life questionnaire OMQ-14""}"
"4120","Antimalarial and Covid 19 in Rheumatoid Arthritis","","NCT04389320","covid 19 in RA","Drug: Hydroxychloroquine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04389320","Completed","2020-03-15","2020-05-01","{""locations"":""Manal Hassanien, Assiut, Yes, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""20 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""immunoglobulin mesurement""}"
"4121","COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111","","NCT04388826","V0211901","Drug: Veru-111","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04388826","Active, not recruiting","2020-06-18","2021-02-08","{""locations"":""HonorHealth, Scottsdale, Arizona, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Inspira Medical Center, Vineland, New Jersey, United States|Memorial Hermann Memorial City Hospital, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects that are alive without respiratory failure at Day 29.|WHO clinical Improvement|Normalization of Fever and Oxygen|Discharge from Hospital|Patients alive and free of respiratory failure""}"
"4122","Biomarkers for Identification of COVID-19 Infection","B-DT-COV2","NCT04322513","covid-19 biomarkers","Diagnostic Test: Biomarkers expression","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04322513","Recruiting","2020-03-24","2020-12-30","{""locations"":""Luca Gallelli, Catanzaro, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""110"",""age"":""14 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, Neuron-Specific Enolase, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment""}"
"4123","COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO)","","NCT04637867","69HCL20_0761","Other: Collection of blood, salivary and nasopharyngeal samples.","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04637867","Recruiting","2020-11-23","2021-11-01","{""locations"":""hopital Edouard Herriot, Lyon, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroprevalence of SARS-CoV-2 antibodies in laboratory confirmed SARS-CoV-2 patients""}"
"4124","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","COVID-BioB","NCT04318366","COVID-BioB/OSR","Other: Observational Study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04318366","Recruiting","2020-03-19","2022-03-19","{""locations"":""Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Universit\u00e0 Vita-Salute San Raffaele, Milano, Mi, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response""}"
"4125","Pharmacy Education During Covid-19 Outbreak","","NCT04409951","Educational process & Covid-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409951","Not yet recruiting","2020-11-01","2021-09-01","{""locations"":""Damanhour university, Beheira, Damanhour, Egypt"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""16 Years to 40 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Impact of Covid-19 on pharmacy Education study in Egypt""}"
"4126","Use of Angiotensin-(1-7) in COVID-19","","NCT04633772","RBR-35734p","Drug: Angiotensin-(1-7)|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04633772","Recruiting","2020-08-05","2021-02-28","{""locations"":""Hospital Eduardo de Menezes, Belo Horizonte, Minas Gerais, Brazil|Hospital Mater Dei, Belo Horizonte, Minas Gerais, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""130"",""age"":""17 Years to 81 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""supplemental oxygen-free days (SOFDs)|Hospital length of stay|ventilator free days|ICU free days|RAS effectors levels|CT scan findings|Changes in inflammatory markers: C reactive protein|Changes in clinical state: vasopressors usage|Chest X ray findings|Changes in inflammatory markers: chemokines|Changes in inflammatory markers: troponin|Changes in thrombotic markers: D-Dimer|Changes in clinical state: secondary infections|Changes in clinical state: deep venous thrombosis""}"
"4127","Effect of COVID19-related COntainment in ChildreN","E-COCCON","NCT04615195","RC31/20/0205","Other: cries 13 questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04615195","Recruiting","2020-06-10","2020-11-30","{""locations"":""UHToulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""8 Years to 15 Years \u00a0 (Child)"",""outcome_measures"":""Signs of post traumatic stress disorder""}"
"4128","ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection","","NCT04326426","VLY-686-3501","Drug: Tradipitant|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04326426","Enrolling by invitation","2020-04-13","2020-08-31","{""locations"":""Lenox Hill Hospital Northwell Health, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to improvement on a 7-point ordinal scale as compared to baseline|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough|Reduction from baseline of NRS for nausea|Time to normalization of fever for at least 48 hours|Time to improvement in oxygenation for at least 48 hours""}"
"4129","Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)","","NCT04374474","Anosmia_CoVID 19","Other: Olfactory retraining|Drug: corticosteroid nasal irrigation|Other: smell household Items|Other: Nasal Irrigation","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04374474","Withdrawn","2021-01-10","2022-03-10","{""locations"":""St. Joseph's Health Care, London, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from Baseline Snap and Sniff Threshold Test at 3 months|Change from baseline Smell Identification Test (SIT) at 3 months|Change from Baseline Snap and Sniff Threshold Test at 6 months|Change from baseline Smell Identification Test (SIT) at 6 months|Change from baseline QOD-NS at 3 months|Change from baseline SF-36 health survey at 3 months|Change from baseline QOD-NS at 6 months|Change from baseline SF-36 health survey at 6 months|Adherence to the Study Protocol|Recovery""}"
"4130","PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic","PREPARE IBD","NCT04410484","284920","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04410484","Active, not recruiting","2020-05-22","2020-08-01","{""locations"":""Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust, Hull, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""1500"",""age"":""16 Years to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Flare of IBD needing change in therapy or surgery""}"
"4131","Knowledge About Covid-19 Infection in Pregnant Women","","NCT04423692","Knowledge about covid 19","Other: labs","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04423692","Recruiting","2020-06-01","2020-08-20","{""locations"":""Aljazeera( Al Gazeera) hospital, Giza, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years to 42 Years \u00a0 (Adult)"",""outcome_measures"":""The number of pregnant women who have knowledge about covid-19""}"
"4132","Covid -19 Pandemic: Economic Burden on Patients Operated for Traumatic Close Fractures","","NCT04482205","akupde","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04482205","Completed","2020-03-16","2020-05-31","{""locations"":""Aga Khan University Hospital, Karachi, Sindh, Pakistan"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""840"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""the effect of Covid -19 on the total costs of inpatient care|drop in the collective revenue generated in covid era""}"
"4133","Covid-19 Lockdown and Deviant Sexual Fantasies","","NCT04448405","RECHMPL20_0341","Behavioral: Questionnaire for evaluation of confinement on deviant sexual fantasies","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04448405","Completed","2020-06-18","2020-10-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of confinement on deviant fantasies|Intensity of deviant fantasies|Frequency of deviant fantasies|Paraphilic type impacted|Occurrence of sexual act|Access mode for deviant fantasies|Use of support during confinement|Evaluating anxiety\/depression level""}"
"4134","Spironolactone in Covid-19 Induced ARDS","","NCT04345887","10042020","Drug: Spironolactone 100mg|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04345887","Not yet recruiting","2020-04-21","2020-10-21","{""locations"":""Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""p\/f ratio|SOFA""}"
"4135","Non-contact Endoscopy at Covid-19 Outbreak","","NCT04320953","ncMCE1","Device: Non-contact MCE system","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04320953","Completed","2020-03-16","2020-04-09","{""locations"":""Changhai Hospital, Shanghai, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""5"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Technical success|Clinical success|Adverse events""}"
"4136","COVID 19 Viral Clearance Among the Infected Healthcare Workers In Assiut University Hospitals","","NCT04409574","COVID19 among HCWs","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409574","Not yet recruiting","2020-06-01","2021-06-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""31"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""the time of Covid 19 viral clearance in medical healthcare workers and its relation to clinical presentation, severity among and resolution of symptoms.|knowledge and practice of infection control measures""}"
"4137","Social Media and Covid19 Pandemic","","NCT04378738","AcibademU social media","Behavioral: survey","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04378738","Enrolling by invitation","2020-05-01","2020-05-08","{""locations"":""Bahar Yuksel, Istanbul, Turkey|Haseki Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""212"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the role of social media""}"
"4138","Characteristics in Post Covid-19 Patients","","NCT04514705","F110820","Other: Exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04514705","Recruiting","2020-08-11","2021-12-31","{""locations"":""Universidade do Estado do Par\u00e1, Bel\u00e9m, Par\u00e1, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Characteristics of lung|Respiratory muscle strength""}"
"4139","Psychological Impairment Due to Covid-19","","NCT04368312","TEMP553914-BO","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368312","Not yet recruiting","2020-05-06","2020-05-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""PCL5 Questionnaire|BSI - Brief symptom inventory|PHQD|WHO - QoL BREF|STAXI|AUDIT questionnaire""}"
"4140","COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection","","NCT04444674","ChAdOx1 nCoV-19_ZA_phI/II v4.1","Biological: ChAdOx1 nCoV-19|Biological: Normal saline 0.9%","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04444674","Active, not recruiting","2020-06-24","2021-12-01","{""locations"":""PHRU Kliptown, Johannesburg, Gauteng, South Africa|Soweto Clinical Trials Centre, Johannesburg, Gauteng, South Africa|Wits RHI Shandukani Research Centre, Johannesburg, Gauteng, South Africa|Setshaba Research Centre (SRC), Soshanguve, Gauteng, South Africa|Chris Hani Baragwanath Academic Hospital - DST\/NRF VPD RMPRU, Soweto, Gauteng, South Africa|FAMCRU, Cape Town, Western Cape, South Africa|Groote Schuur hospital, Lung infection and immunity unit, UCT, Cape Town, Western Cape, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""2130"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assess the incidence of adverse events (intervention-related and intervention-unrelated) in HIV-negative adults aged 18-65 year receiving candidate ChAdOx1 nCoV-19 vaccine or placebo (safety)|Determine if there is a reduction of severe and non-severe COVID-19 disease in HIV-negative adults who receive candidate vaccine ChAdOx1 nCoV-19 compared to placebo recipients (efficacy)|Assess the incidence of adverse events (intervention-related and intervention-unrelated) in HIV-positive adults aged 18-65 year receiving candidate ChAdOx1 nCoV-19 vaccine or placebo (safety)|Assess cellular Immunogenicity of ChAdOx1 nCoV-19 in people living with HIV (immunogenicity)|Assess humoral immunogenicity of ChAdOx1 nCoV-19 in people living with HIV|Assess humoral Immunogenicity of ChAdOx1 nCoV-19 in HIV-negative adults (immunogenicity)|Assess cellular Immunogenicity of ChAdOx1 nCoV-19 in HIV-negative adults (immunogenicity)""}"
"4141","ERN ReCONNET Study on COVID-19 Vaccination in Rare and Complex Connective Tissue Disease (VACCINATE)","VACCINATE","NCT04702295","UPISA2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04702295","Not yet recruiting","2021-02-01","2023-08-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events (any type)|COVID-19 incidence in patients with and without evidence of past SARS-CoV-2 infection before and during vaccination regimen - cases confirmed \u22657 days after the last dose|Incidence of disease flare post-vaccination|Incidence of serious adverse events|Incidence of life-threatening adverse events and deaths|Incidence of adverse events of special interest for COVID-19|Clinical variables (age, sex, underlying disease, ongoing treatment, comorbidities) associated with COVID-19 occurrence during the post-vaccination follow-up|Comparison of the incidence of COVID-19 among different types of vaccines|Significant anti COVID 19 antibodies titer at 3 and 6 months""}"
"4142","The Seniors COvid-19 Pandemic and Exercise Study","SCOPE","NCT04412343","H20-01515","Behavioral: Virtual Group Intervention|Behavioral: Personal Exercise Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04412343","Completed","2020-05-23","2020-10-05","{""locations"":""University of British Columbia, Vancouver, British Columbia, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""241"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Well-Being (Psychological Flourishing)|Life Satisfaction|Stress|Depression|Resilience|Social Identification|Social and Emotional Lonliness|Chronic Illness (Physical Health)|Weekly Somatic Symptoms (Physical Health)|Leisure-time physical activity|Alcohol Habits|Physical Adherence|Affective Attitudes|Demographics""}"
"4143","Acute kIDnEy Injury in coviD-19","AIDED","NCT04583293","UHDB/2020/076","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04583293","Recruiting","2020-12-08","2022-10-01","{""locations"":""University Hospitals of Derby and Burton NHS Foundation Trust, Derby, Derbyshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""220"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of kidney disease progression at 12 months.|Incidence of albuminuria at 6-9 months.|Incidence of albuminuria at 12-15 months.|Incidence of combined kidney disease progression and albuminuria at 6-9 months.|Incidence of combined kidney disease progression and albuminuria at 12-15 months.|Factors associated with all-cause mortality at 6-9 months.|Factors associated with all-cause mortality at 12-15 months.|Incidence of hospital readmissions at 6-9 months|Incidence of hospital readmissions at 12-15 months""}"
"4144","CoViD-19 Patient in Reims University Hospital in March to April 2020","COVID-Reims","NCT04553575","PO20124*","Biological: serology","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04553575","Recruiting","2020-09-25","2022-09-01","{""locations"":""Chu Reims, Reims, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""499"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Health status in the 2 years after CoViD-19 diagnosis""}"
"4145","The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology","","NCT04694482","COVID-19-psychiatry","Other: Psychometric scale administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04694482","Recruiting","2020-11-12","2021-01-31","{""locations"":""University of Milan Bicocca - Ospedale San Gerardo, Monza, MB, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Brief Psychiatric Rating Scale (BPRS)|Clinical Global Impression (CGI) severity subscale|Clinical Global Impression (CGI) improvement subscale|Hamilton Anxiety Scale (HAM-A)|Impact of Event Scale - Revised version (IES-R)|Disability Scale (DISS)|Hamilton Depression Rating Scale (HAM-D)|Montgomery and Asberg Depression Rating Scale (MADRS)|Young Mania Rating Scale (YMRS)|Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)""}"
"4146","Acute Respiratory Failure and COVID-19 in Real Life","","NCT04307459","17263/2020","Other: standard operating procedures","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04307459","Recruiting","2020-03-19","2020-12-31","{""locations"":""Luigi Sacco University Hospital, Milan, Lombardia, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management""}"
"4147","Hemodynamic Characteristics of Patients With SARS-CoV-2","PiCCOVID","NCT04337983","2020-A00793-36","Device: Transpulmonary thermodilution|Device: Echocardiography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04337983","Recruiting","2020-03-13","2021-04-01","{""locations"":""Bicetre Hospital, Paris, Val-de-Marne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Body temperature|Blood pressure|Pulse (heart rate)|Respiratory rate|Data provided by transpulmonary thermodilution-CI|Data provided by transpulmonary thermodilution-GEDV|Data provided by transpulmonary thermodilution-EVLW|Data provided by transpulmonary thermodilution-PVPI|Incidence of abnormal laboratory test results|Incidence of new-onset or reversible systolic left ventricular dysfunction|Changes of extravascular lung water measured by transpulmonary thermodilution|Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution|Correlation between the hemodynamic characteristics and 90-day mortality""}"
"4148","Sexual Function During COVID 19 Pandemic","","NCT04395885","SFCOV","Other: Electronic questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04395885","Completed","2020-06-01","2020-09-15","{""locations"":""Ahmed Abbas, Assiut, Cairo, Egypt|Assiut Faculty of Medicine, Assiut, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""306"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""The percentage of study participants diagnosed with sexual dysfunction""}"
"4149","Parental Stress After the Covid-19 Pandemic","","NCT04442308","REK125510 (6)","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442308","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1440"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Parental stress""}"
"4150","Study of the Incidence of SARS-CoV-2 Infection (COVID-19)","CovImmune 2","NCT04429594","20-PP-14","Other: blood sampling","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04429594","Recruiting","2020-07-28","2025-12-31","{""locations"":""University Nice Hospital, Nice, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""positive serologies""}"
"4151","Role of Children in Transmission of COVID-19 to Immunocompromised Patients","","NCT04407546","20-000517|NCI-2020-03669","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04407546","Recruiting","2020-05-27","2023-05-28","{""locations"":""University of California at Los Angeles, Los Angeles, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""To define the role of household contact with children or siblings in the transmission of SARS-CoV-2 to immunocompromised patients.|To characterize secondary cases of SARS-CoV-2 in immunocompromised participants|To describe the exposure factors such as pets and travel and how those factors are related to immunocompromised patients to estimate risk profiles by household characteristics""}"
"4152","Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study","","NCT04471831","CMUL/HREC/06/20/742","Other: Rehabilitation exercise protocol","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04471831","Not yet recruiting","2020-07-13","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cycle Threshold (CT) values as recorded from the series of the qRT-PCR|Nucleic acid values as calculated from the Cycle Threshold recorded from the series of the qRT-PCR|Quality of Life perception|Exercise capacity|Exercise endurance""}"
"4153","Covid-19 and Prevention of Malnutrition After Confinement by Dentists","","NCT04386460","20odontocovid-02","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386460","Recruiting","2020-05-11","2021-05-11","{""locations"":""University Nice Hospital, Nice, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Body Mass Index|Weight changes during confinement|prescription of nutritional supplements and observance""}"
"4154","Outcomes in Hospitalized Older Patients With COVID-19","","NCT04385212","2020-00819","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385212","Completed","2020-03-13","2020-04-14","{""locations"":""Department of Rehabilitation and Geriatrics, Geneva, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""230"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""To evaluate the relative contributions of comorbidities on intra-hospitalized death|To evaluate the relative contributions of functional characteristics on intra-hospitalized death|To explore specific clinical profiles that may influence COVID-19 disease outcomes in the elderly based on geriatrics syndromes""}"
"4155","Etiology of Lymphopenia in Covid19 Infection","","NCT04404608","201920008.2","Diagnostic Test: Complete blood picture, bone marrow aspiration cytology","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04404608","Not yet recruiting","2020-06-01","2021-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Death or recovery""}"
"4156","Influence of the COvid-19 Epidemic on STRESS","COVISTRESS","NCT04308187","2020 COVISTRESS","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04308187","Not yet recruiting","2020-03-11","2022-03-01","{""locations"":""University Hospital, Clermont-Ferrand, Clermont-Ferrand, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""50000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Stress|Perception and knowledge of the epidemic|Feeling of information on the part of companies \/ establishments \/ governments|Means of protection|Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|Sociodemographic factors and lifestyle habits""}"
"4157","Student-delivered Telehealth Program for COVID-19 Education and Health Promotion","","NCT04492527","COACH","Behavioral: Telehealth coaching sessions","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04492527","Recruiting","2020-07-28","2021-07-31","{""locations"":""University of British Columbia, Vancouver, British Columbia, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""75"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Change from baseline: Health Directed Behaviour at 2 months|Depression, Anxiety, Stress Scale|Medical Outcomes Study (MOS): Social Support Survey|Medical Outcomes Study (MOS): Short Form-36|Self-Rated Abilities for Health Practices Scale|Self-management""}"
"4158","Technology-enabled Collaborative Care for Diabetes Management During COVID-19","","NCT04607915","104-2020","Behavioral: Intervention for TECC Model","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04607915","Not yet recruiting","2021-02-05","2021-03-31","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility - Recruitment Numbers|Feasibility - Participant characteristics|Feasibility - Participant Engagement (retention rate)|Feasibility - Participant Engagement (intensity)|Feasibility - Participant Engagement (drop out)|Feasibility - Delivery of Intervention (Time with coach)|Feasibility - Delivery of Intervention (Mode of interaction)|Feasibility - Delivery of Intervention (Coach strategies)|Study Participant experience and satisfaction via semi-structured interview|Care Coordinator experience and satisfaction via semi-structured interview|Virtual Care Team experience and satisfaction via semi-structured interview""}"
"4159","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.","Cov-CONTACT","NCT04259892","C20-06|2020-A00280-39","Biological: 2019-nCoV PCR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04259892","Recruiting","2020-02-04","2021-02-04","{""locations"":""Service de maladies infectieuses et tropicales H\u00f4pital Jean Minjoz CHRU Besan\u00e7on, Besan\u00e7on, France|Service des Maladies infectieuses et tropicales, P\u00f4le Sp\u00e9cialit\u00e9s m\u00e9dicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses H\u00f4pital Gabriel Montpied CHU de Clermont Ferrand, Clermont-Ferrand, France|Centre d'investigation clinique 1432 H\u00f4pital Fran\u00e7ois Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre Investigation Clinique 1433 CHRU de NANCY, Nancy, France|Centre d'investigation clinique Infectiologie H\u00f4tel-Dieu CHU Nantes, Nantes, France|Centre d'Investigation Clinique H\u00f4pital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, H\u00f4pital Bichat Claude Bernard, Paris, France|Centre Investigation Clinique 1417 H\u00f4pital Cochin B\u00e2timent Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes H\u00f4pital Pontchaillou, Rennes, France|Centre Hospitalier F\u00e9lix Guyon Ile de la R\u00e9union CHU nord, Saint Denis, France|Centre d'Investigation Clinique Ile de la R\u00e9union CHU sud, Saint-Pierre, France|D\u00e9partement maladie infectieux CHU Saint Etienne, Saint-\u00c9tienne, France|Centre Investigation Clinique 1415 CHRU Tours - H\u00f4pital Bretonneau, Tours, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""345"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Time to SARS-CoV-2 nasopharyngeal excretion, from the day of the first high\/moderate risk contact to 12 days after the last high\/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Time to apparition of any symptom suggestive of SARS-CoV-2 from the day of the first high\/moderate risk contact to 12 days after the last high\/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Factors associated with the time to SARS-CoV-2 nasopharyngeal excretion|Factors associated with the time to apparition of any symptom suggestive of SARS-CoV-2 infection|Proportion of contact subjects with apparition of any symptom suggestive of SARS-CoV-2 infection|Proportion of contact subjects with positive serology defined as the presence of SARS-CoV-2 IgM or IgG at day 30 (+\/-7) following last contact|Host genetic variants|The time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.""}"
"4160","Escin in Patients With Covid-19 Infection","add-on-COV2","NCT04322344","covid-19 add-on therapy","Drug: Escin|Drug: standard therapy","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04322344","Recruiting","2020-03-23","2020-12-30","{""locations"":""Luca Gallelli, Catanzaro, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care"",""enrollment"":""120"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function""}"
"4161","The Get Outside Study","GO","NCT04685681","STUDY00005101","Behavioral: Hiking challenge|Other: Activity list","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04685681","Not yet recruiting","2021-01-01","2021-03-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of lower-risk activities|Frequency of higher-risk activities|Frequency of social activities|Frequency of physical activities|Frequency of hiking\/nature walks|Frequency of restaurant dining|Stress|Sleep""}"
"4162","Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19)","REACOVIM","NCT04365166","2020-COVID19-05|2020-A00898-31","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04365166","Recruiting","2020-04-21","2022-04-21","{""locations"":""Percy Military Teaching Hospital, Clamart, France|B\u00e9gin Military Teaching Hospital, Saint-Mand\u00e9, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Immune response - Plasma cytokine profile|Immune response - Phenotype of circulating cells|Severity criteria - Duration of stay in intensive care unit|Severity criteria - Duration of hospitalization stay|Severity criteria - Duration of period out of hospital|Severity criteria - Duration without mechanical ventilation|Severity criteria - Duration without ventilation|Severity criteria - Duration without intubation|Severity criteria - Number of transfusions|Severity criteria - Duration of the period without cathecholamines|Severity criteria - Duration of the period without dialysis|Severity criteria - SOFA|Severity criteria - LIS|SARS-Cov2 viral load|Emergence of concomitant infections|Emergence of concomitant infections - Phenotype of circulating cells|Stress physiological profile - Sympathetic tone|Stress physiological profile - Temperature|Stress physiological profile - Glucocorticoids|Angiotensin converting enzyme type II (ACE2) polymorphism - ACE|Angiotensin converting enzyme type II (ACE2) polymorphism - ACE2\/ACE1|Comorbidities - diabetes|Comorbidities - Heart disease|Comorbidities - organ failure|Plasma concentrations of several metabolic pathways - GABA|Plasma concentrations of several metabolic pathways - Glucocorticoid|Plasma concentrations of several metabolic pathways - Tryptophan|Plasma concentrations of several metabolic pathways - Serotonin|Plasma concentrations of several metabolic pathways - Dopamin|Plasma concentrations of several metabolic pathways - Cathecholamines|Plasma concentrations of several metabolic pathways - Arachidonic acid derivatives|Plasma concentrations of several metabolic pathways - Endocannabinoids""}"
"4163","Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19","","NCT04299152","2020-TH-001","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04299152","Not yet recruiting","2020-11-10","2021-11-10","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Determine the number of Covid-19 patients who were unable to complete SCE Therapy|Examine the percentage of activated T cells after SCE therapy by flow cytometry|Assess the percentage of Th17 cells after SCE therapy by flow cytometry|Chest imaging changes by computed tomography (CT) scan of the chest|Quantification of the SARS-CoV-2 viral load by real time RT-PCR""}"
"4164","PREdiction of DIagnosed Covid-19 infecTion in IUC Patients","PREDICT","NCT04327180","2020_20|2020-A00763-36","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04327180","Recruiting","2020-03-30","2021-09-01","{""locations"":""H\u00f4pital Roger Salengro, ICU, CHU Lille, Lille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU|Coinfections|Respiratory dysfunction requiring mechanical ventilation|Sequential Organ Failure Assessment (SOFA) Score|SAPS II score|Disseminated Intravascular Coagulation (DIC) score|Number of days on vasopressive amines|Occurrence of an event of venous or arterial thromboembolic disease|Number of days with extra renal treatment (ERA)|Number of patients alive after ICU stay less than 28 days will be tracked|Short Form 36|Hospital anxiety and depression scale (HADS)|Impact of Event Scale - revised (IES-R)|Post-traumatic stress disorder Checklist version DSM-5 (PSL-5)|Modified Medical Research Council (MMRC) Dyspnea Scale|Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters|Viral clearance""}"
"4165","Functional Exhaustion of T Cells in COVID19 Patients","","NCT04470323","T cells","Diagnostic Test: Flow cytometry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04470323","Recruiting","2020-07-22","2020-11-01","{""locations"":""Faculty of Medicine, Assiut, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""CD4+ (T-helper cells) in COVID 19 patients and healthy volunteers.|CD8+ (T-cytotoxic cells) in COVID 19 patients and healthy volunteers.|Detect PD-1 on CD8+ and CD4+ cells in COVID 19 patients and healthy volunteers .|Detect CD28+ and CD3+ cells in COVID 19 patients and healthy volunteers.""}"
"4166","Pilot Feasibility Study of Remote Problem Management Plus for Adults Affected by COVID-19","PM+","NCT04617262","2020-91-PM+","Behavioral: Remote Problem Management Plus","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04617262","Recruiting","2021-01-05","2021-09-01","{""locations"":""The New School, New York, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Psychological Outcomes Profile; Unabbreviated scale title \""Psychological Outcomes Profile\""|Patient Health Questionnaire; Unabbreviated scale title \""Patient Health Questionnaire\""|Generalized Anxiety Disorder Scale; Unabbreviated scale title \""Generalized Anxiety Disorder 7-item Scale\""|World Health Organization Disability Assessment Scale 2.0; Unabbreviated scale title \""World Health Organization Disability Assessment Scale 2.0\""|World Health Organization Quality of Life Questionnaire-BREF; Unabbreviated scale title \""World Health Organization Quality of Life Questionnaire-BREF\""|EuroQoL 5-dimension 5-level; Unabbreviated scale title \""EuroQoL 5-dimension 5-level\""|Pittsburgh Sleep Quality Index; Unabbreviated scale title \""Pittsburgh Sleep Quality Index\""|Somatic Symptom Scale-8; Unabbreviated scale title \""Somatic Symptom Scale-8\""""}"
"4167","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","NOSARSCOVID","NCT04306393","NO-SARS-COVID-19","Drug: Nitric Oxide Gas","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04306393","Recruiting","2020-03-21","2022-03-21","{""locations"":""University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment""}"
"4168","Psychological Impact of COVID19 Among Doctors in Assiut University Hospitals","","NCT04363229","pshycological impact COVID19","Other: maslach burnout inventory questionnair","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363229","Not yet recruiting","2020-07-01","2021-06-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""250"",""age"":""22 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The MBI-HSS (MP) addresses three scales:Emotional Exhaustion ,Depersonalization and Personal Accomplishment|GHQ-12 questionnaire for measuring of current mental health""}"
"4169","Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19","","NCT04416464","QoL_ICU_COVID","Other: COVID-19 Pneumonia","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04416464","Not yet recruiting","2020-06-15","2022-10-01","{""locations"":""Centro Hospitalar Universit\u00e1rio do Algarve, Faro, Algarve, Portugal|Hospital de S\u00e3o Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, Porto, Portugal|Centro Hospitalar Universit\u00e1rio do Porto - Hospital de Santo Ant\u00f3nio, Porto, Portugal"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health-related quality of life.|Length of stay at the ICU.|Incidence of all-cause mortality|Rehospitalization.|Percentage of long-term ventilatory support need.|Percentage of renal replacement therapy need.|Symptoms of anxiety and depression.|Score of functional independence.|Score of cognitive function.|Percentage of major cardiac events.|Score of Chronic obstructive pulmonary disease (COPD)|Symptoms of posttraumatic stress disorder|Utility score of health-related quality of life at 3, 6, and 9 months.|Score of self-rated health.""}"
"4170","The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People","","NCT04476745","2020-PHA-16","Dietary Supplement: Vitamin D3","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04476745","Enrolling by invitation","2020-10-05","2021-02-20","{""locations"":""Mahmoud S Abu-Samak, Amman, Jordan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""30 Years to 66 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IL-1 beta|IL-6|TNF|serum concentrations of 25-hydroxyvitamin D""}"
"4171","Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19","","NCT04567927","2020-01266","Other: Ultrasonography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04567927","Completed","2020-03-03","2020-05-28","{""locations"":""Ospedale Regionale di Bellinzona e Valli, Bellinzona, Ticino, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Period prevalence of deep vein thrombosis (DVT)""}"
"4172","At Home Monitoring for Patients With Covid19","","NCT04453774","3185","Device: Covidfree@home","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04453774","Not yet recruiting","2020-10-16","2023-04-01","{""locations"":""Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of participants with an unplanned hospital admissions|Number of participants with planned hospital admissions that are found to be necessary|Number of participants with an emergency department visits not resulting in hospital admission|Number of planned hospital admissions which are found to be unnecessary""}"
"4173","Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)","","NCT04361552","STUDY00000419|NCI-2020-02314|WINSHIP4998-20|P30CA138292","Other: Best Practice|Biological: Tocilizumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04361552","Withdrawn","2020-04-07","2020-06-02","{""locations"":""Emory University Hospital\/Winship Cancer Institute, Atlanta, Georgia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""7-day length of invasive mechanical ventilation (MV)|30-day mortality rate|Rate of intensive care (ICU) transfer|Rate of invasive mechanical ventilation|Rate of tracheostomy|Length of ICU stay|Length of hospital stay""}"
"4174","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","TOCIVID","NCT04322773","APPI2-CV-2020-01","Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04322773","Terminated","2020-04-05","2020-10-08","{""locations"":""Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hiller\u00f8d Hospital, Hiller\u00f8d, Denmark"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events""}"
"4175","Psychological Impact of COVID19 Among Women Undergoing Infertility Treatment","PsyCovART","NCT04496869","69HCL20_0577","Other: Online questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04496869","Not yet recruiting","2020-07-01","2020-12-01","{""locations"":""H\u00f4pital Femme M\u00e8re Enfant, Bron, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""18 Years to 43 Years \u00a0 (Adult)"",""outcome_measures"":""Psychological impact assessed by scores of PSS10 scales.|Psychological impact assessed by scores of HADS scales.""}"
"4176","A Comparison of 3D and 2D Telemedicine During Covid 19","","NCT04359225","GN20HS182","Other: 3D Telemedicine|Other: 2D Telemedicine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04359225","Not yet recruiting","2020-06-30","2021-12-31","{""locations"":""Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow, Scotland, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""80"",""age"":""1 Year to 95 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""University Hospitals of North Northway questionnaire|Mental effort rating scale|Telehealth Usability Questionnaire|Subjective feedback interview""}"
"4177","Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection","","NCT04445454","TJT2012","Biological: Mesenchymal stromal cells","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04445454","Recruiting","2020-06-12","2022-09-30","{""locations"":""CHU de Li\u00e8ge, Li\u00e8ge, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)""}"
"4178","Effect of COvid-19 on Mental Health in Syrian and Turkish Maintenance HemoDialysis Patients: COST-HD Study","COST-HD","NCT04444557","200620","Other: Beck Depression Inventory (BDI)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444557","Completed","2020-04-17","2020-05-01","{""locations"":""Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""97"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Score of Beck Depression Inventory""}"
"4179","Evaluation of Systemic and Oral Conditions of Pregnant Women and Their Babies, With Exposure to COVID-19 Infection","(COVID-19","NCT04492449","FOBpregnat","Other: congenital malformation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492449","Not yet recruiting","2021-01-01","2022-12-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""260"",""age"":""16 Years to 40 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Periodontal status|Quality of life of pregnants""}"
"4180","Orthopaedic Conservative Treatment in the Time of Covid-19 Pandemic","","NCT04623346","Treatment in the time of Covid","Procedure: Observation for study group","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04623346","Active, not recruiting","2020-03-11","2020-12-01","{""locations"":""SBU Prof. Cemil Tascioglu City Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""262"",""age"":""85 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Comparison of the two groups in terms of bony union""}"
"4181","Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","","NCT04336410","COVID19-001","Drug: INO-4800|Device: CELLECTRA® 2000","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04336410","Active, not recruiting","2020-04-03","2022-01-01","{""locations"":""Central Kentucky Research Associates, Lexington, Kentucky, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Administration (Injection) Site Reactions|Percentage of Participants with Adverse Events of Special Interest (AESIs)|Change from Baseline in SARS-CoV-2 Spike Glycoprotein Antigen-Specific Binding Antibody Titers|Change from Baseline in Antigen-Specific Cellular Immune Response""}"
"4182","Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?","HEROs","NCT04374942","HEROs Protocol 1.5|ISRCTN14326006","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04374942","Enrolling by invitation","2020-04-30","2022-01-30","{""locations"":""University Health Network, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""988"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Microbiologically confirmed COVID-19 (SARS-CoV-2 infection)|Adverse events|Symptom duration of COVID-19|Days of hospitalization attributable to COVID-19|Respiratory failure requiring ventilatory support attributable to COVID-19|Mortality|Impact on work eligibility|Seropositivity|Short-term psychological impact""}"
"4183","Evaluation of Dental Emergency Treatments During COVID19 Crisis","URGDENTCOVID","NCT04354272","APHP200464","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04354272","Completed","2020-04-21","2020-06-29","{""locations"":""Service d'odontologie, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""503"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable|Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable|welcoming quality from hospital staff|anxiety score|perception of the technical quality of the emergency treatment""}"
"4184","Mask Usage and Exercise During the COVİD-19 Pandemic","","NCT04498546","KaratayU3","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04498546","Recruiting","2020-07-20","2021-09-30","{""locations"":""KTO Karatay University, Konya, Karatay, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Resting Heart Rate|Peak Heart Rate|Recovery Heart Rate|Resting systolic blood pressure|Recovery systolic blood pressure|Resting diastolic blood pressure|Recovery diastolic blood pressure|Peripheral oxygen saturation|VO2max|Dyspnoea Severity""}"
"4185","SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study","SeroCOVIDial","NCT04420338","2020-34|2020-A01515-34","Biological: Blood sample|Biological: Serum tube collection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04420338","Recruiting","2020-06-05","2020-12-15","{""locations"":""Assistance Publique H\u00f4pitaux de Marseille, Marseille, Paca, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The prevalence of SARS-COV2 seroconversion in chronic hemodialysis patients|The prevalence of SARS-COV2 seroconversion in dialysis caregivers""}"
"4186","Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia","","NCT04355637","TACTIC-COVID|2020-001616-18","Drug: Inhaled budesonide","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04355637","Recruiting","2020-04-21","2021-08-31","{""locations"":""Hospital de Infecciosas \""Francisco Javier Mu\u00f1iz\"", Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|CEMIC (Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas \""Norberto Quirno\""), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital de Rehabilitaci\u00f3n Respiratoria \""Mar\u00eda Ferrer\"", Ciudad Aut\u00f3noma de Buenos Aires, Buenos Aires, Argentina|Hospital Donaci\u00f3n \""Francisco Santojanni\"", Ciudad Aut\u00f3noma de Buenos Aires, Buenos Aires, Argentina|Cl\u00ednica Monte Grande, Monte Grande, Buenos Aires, Argentina|Hospital Centro de Salud Zen\u00f3n J. Santill\u00e1n, San Miguel De Tucum\u00e1n, Tucum\u00e1n, Argentina|Hospital San Juan de Dios, La plata, Argentina|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sabadell-Parc Tauli, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients in both arms fulfilling the criteria for treatment failure|ICU admission|ICU refusal|Occurrence of complications|lactate dehydrogenase (LDH)|C Reactive Protein (CRP)|ferritin|D-dimer|leukocyte counts""}"
"4187","SARS-CoV 2 in Personal Protective Equipment","","NCT04398043","rt PCR en EPP","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04398043","Not yet recruiting","2020-05-15","2020-07-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""16"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Asses surface contamination personel protective equipment|Virus charge cuantification|Place in PPE contamination""}"
"4188","Ayurveda for Flu Like Illness During Covid-19 Outbreak","","NCT04351542","AU09","Dietary Supplement: Ayurveda|Other: Usual Care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04351542","Completed","2020-03-06","2020-04-12","{""locations"":""Aarogyam, Leicester, United Kingdom"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care"",""enrollment"":""32"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Time to achieve afebrile|Severity of symptom score|Patient reported improvement""}"
"4189","The Impact of Covid-19 Pandemic on Colorectal Cancer Prevention Due to Delays in Diagnosis: a Global Study","COVID_CRC","NCT04637893","100","Other: Colonoscopy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04637893","Not yet recruiting","2020-12-16","2021-03-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Colorectal Cancer prevention""}"
"4190","Demographics and Outcomes of COVID 19 in Pregnancy at a Community Based Hospital","","NCT04385914","1595116-1","Other: COVID positive via testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385914","Not yet recruiting","2020-05-01","2020-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Pregnancy Outcome""}"
"4191","Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study","CoDDYC","NCT04447209","2020410-8500","Other: Dietary counselling on Food Groups according to IYC Feeding practices, WHO","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04447209","Recruiting","2020-06-06","2021-05-31","{""locations"":""University of Malaya Medical Center, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""6 Months to 6 Years \u00a0 (Child)"",""outcome_measures"":""Minimal Dietary Diversity (MDD) of more than 5 food groups in 24 hours|Height|Weight|Meal frequencies in past 24 hours|Blood hemoglobin in children at the start of study and 4 months later|Serum ferritin in children at the start of study and 4 months later|Consumption of sugar and processed foods|Food Aids received""}"
"4192","Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults","","NCT04590430","HFB30132A-101","Drug: HFB30132A|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04590430","Active, not recruiting","2020-10-20","2021-07-01","{""locations"":""Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Number of participants with treatment emergent serious adverse events (TESAEs)|Number of participants with treatment emergent adverse events (TEAE) of special interest|Number of participants with treatment-emergent adverse events (TEAE)|Maximum observed serum concentration (Cmax)|Minimum observed serum concentration (Cmin)|Time of maximum serum concentration (Tmax)|Area under the concentration vs. time curve (AUC0-last), AUC0-\u221e)|Terminal half-life (T1\/2)|Systemic clearance (CL)|Steady-state volume of distribution (Vss)|Number of participants with treatment-emergent adverse events (TEAEs)|Number of participants with treatment-emergent serious adverse events (TESAEs)|Maximum observed serum HFB30132A concentration (Cmax) in nasal and oral secretions|Minimum observed serum HFB30132A concentration (Cmin) in nasal and oral secretions|Time of maximum serum HFB30132A concentration (Tmax) in nasal and oral secretions|Area under the concentration vs. time curve (AUC0-last), AUC0-\u221e) in nasal and oral secretions|Terminal half-life (T1\/2) of HFB30132A in nasal and oral secretions|Systemic clearance (CL) of HFB30132A in nasal and oral secretions|Steady-state volume of distribution (Vss) of HFB30132A in nasal and oral secretions|HFB30132A Anti-drug antibodies""}"
"4193","RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19","P20/09","NCT04397666","P20/09_COVEYES","Diagnostic Test: conjunctival RT PCR","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04397666","Recruiting","2020-05-15","2020-11-15","{""locations"":""Centre Hospitalier de versailles, Le Chesnay, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""68"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the SARS-Cov-2 positivity rate in patients with Covid-19 with or without signs of conjunctivitis""}"
"4194","A Survey to Assess Effects of Covid-19 on Cardiovascular Patients","","NCT04508920","20-1156","Other: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04508920","Recruiting","2019-05-15","2021-07-15","{""locations"":""Centro de Insuficiencia Cardiaca Instituto Nacional de Cardiologia, Mexico City, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""76"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""NYHA class deterioration|Dyspnea deterioration|Paroxysmal nocturnal dyspnea deterioration|Edema|Daily activities In the last four weeks? Please, mention if you a perceived limitation on : Walking deterioration""}"
"4195","GlobalSurg-CovidSurg Week","","NCT04509986","GS-CSWeek.20200713","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04509986","Not yet recruiting","2020-10-01","2020-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Post-operative mortality|In-patient mortality|Post-operative pulmonary complications|Post-operative venous thromboembolism|Post-operative complications""}"
"4196","Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19","TOCIDEX","NCT04476979","APHP200375-TOCIDEX|2020-001246-18","Drug: Tocilizumab|Drug: Dexamethasone","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04476979","Recruiting","2020-07-16","2021-12-31","{""locations"":""CH Andr\u00e9e Rosemon, Cayenne, French Guiana"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival without needs of ventilator utilization at day 14|WHO progression scale at day 7 and 14|Overall survival at 14, 28, 60 and 90 days|Cumulative incidence of discharge alive at 14 and 28 days|Survival without needs of mechanical ventilation at day 1|Cumulative incidence of oxygen supply independency at 14 and 28 days""}"
"4197","Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut University Hospital","","NCT04481360","Presentation of COVID19 in AUH","Device: CT of the chest","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04481360","Not yet recruiting","2020-08-01","2021-09-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical evaluation""}"
"4198","Maternal Telemental Health Interventions in Response to Covid-19*","CoronaVirus","NCT04594525","MRC-05-087","Other: Low-Intensity Psychosocial Interventions through Telemental health","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04594525","Not yet recruiting","2021-06-01","2022-06-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""58"",""age"":""18 Years to 49 Years \u00a0 (Adult)"",""outcome_measures"":""Baseline (T0) perinatal depression through the 10-points Edinburgh Postnatal Depression (Scale (EPDS-10)|Change (T1-T0) from baseline perinatal depression on the 10-points Edinburgh Postnatal Depression Scale (EPDS-10) at third trimester (T1)|Change (T2-T1) from third trimester perinatal depression on the 10-points Edinburgh Postnatal Depression Scale (EPDS-10) at 3-5 weeks postnatal (T2)|Change (T3-T2) in perinatal depression on the 10-points Edinburgh Postnatal Depression Scale (EPDS-10) at 2-4 months postnatal (T3)|Change (T4-T3) in perinatal depression on the 10-points Edinburgh Postnatal Depression Scale (EPDS-10) at 5-7 months postnatal (T4)|Change (T5-T4) in perinatal depression on the 10-points Edinburgh Postnatal Depression Scale (EPDS-10) at 8-10 months postnatal (T5)|Baseline (T0) Covid-19 Specific phobia through the Covid-19 Specific phobia questionnaire|Change (T1-T0) in Covid-19 Specific phobia through the Covid-19 Specific phobia questionnaire at third trimester (T1)|Change (T2-T1) in Covid-19 Specific phobia through the Covid-19 Specific phobia questionnaire at 3-5 weeks after birth (T2)|Change (T3-T2) in Covid-19 Specific phobia through the Covid-19 Specific phobia questionnaire at 2-4 months after birth (T3)|Change (T4-T3) in Covid-19 Specific phobia through the Covid-19 Specific phobia questionnaire at 5-7 months after birth (T4)|Change (T5-T4) in Covid-19 Specific phobia through the Covid-19 Specific phobia questionnaire at 8-10 months after birth (T5)|Baseline (T0) perinatal anxiety through a subscale of Edinburgh Postnatal Depression Scale (EPDS-3)|Change (T1-T0) in perinatal anxiety through a subscale of Edinburgh Postnatal Depression Scale (EPDS-3) at third trimester (T1)|Change (T2-T1) in perinatal anxiety through a subscale of Edinburgh Postnatal Depression Scale (EPDS-3) at 3-5 weeks after birth (T2)|Change (T3-T2) in perinatal anxiety through a subscale of Edinburgh Postnatal Depression Scale (EPDS-3) at 2-4 months after birth (T3)|Change (T4-T3) in perinatal anxiety through a subscale of Edinburgh Postnatal Depression Scale (EPDS-3) at 5-7 months after birth (T4)|Change (T5-T4) in perinatal anxiety through a subscale of Edinburgh Postnatal Depression Scale (EPDS-3) at 8-10 months after birth (T5)""}"
"4199","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","","NCT04322786","ISAC17_205R","Drug: ACE inhibitor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04322786","Active, not recruiting","1998-01-01","2021-03-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""1302508"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of influenza""}"
"4200","SARS-CoV-2 Donor-Recipient Immunity Transfer","","NCT04666025","20153|NCI-2020-11156|P30CA033572","Procedure: Biospecimen Collection|Other: Diagnostic Laboratory Biomarker Analysis|Other: Electronic Health Record Review|Other: Questionnaire Administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666025","Recruiting","2020-09-23","2022-09-23","{""locations"":""City of Hope Medical Center, Duarte, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Severe acute respiratory syndrome (SARS)-Coronavirus 2 (CoV-2) Spike protein (S)-specific IgG concentration and T cell levels|SARS-CoV-2 nucleocapsid protein (N) -specific IgG concentration and T cell levels|SARS-CoV-2 neutralizing antibodies|SARS-CoV-2 IgA concentration""}"
"4201","Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak","","NCT04342208","GPA1347","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04342208","Not yet recruiting","2020-04-10","2020-07-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The Rapid Office Strain Assessment (ROSA)|The Standardised Nordic Questionnaries (NMQ)""}"
"4202","Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric","","NCT04425005","21056813.3.0000.0068","Other: Home-based exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04425005","Completed","2020-05-10","2020-12-07","{""locations"":""Univsersity of Sao Paulo, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""55"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline on waist circumference at 3 months of follow-up.|Change from baseline on cardiometabolic risk factor at 3 months of follow-up.|Change from baseline on cardiopulmonary fitness at 3 months of follow-up.|Change from baseline on quality of life at 3 months of follow up.|Change from baseline on Physical activity levels at 3 months of follow up.|Change from baseline on dietary intake at 3 months of follow up.""}"
"4203","Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study","ProCov","NCT04344106","20202703-2","Procedure: Prone positioning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04344106","Recruiting","2020-04-01","2020-05-01","{""locations"":""CHI Aix-Pertuis, Aix-en-Provence, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of \""responder\"" patients to prone position|proportion of \""persistent responders\"" patients after prone position|Evolution of PaO2|Duration of prone positioning and PaO2 evolution|Evolution of Spo2|EVA Dyspnea|Intolerance to prone positioning|Tolerance to prone positioning""}"
"4204","Evaluation of Lymphedema Patients Status During Covid-19 Pandemic","","NCT04568005","feyzaakanbegoglu","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04568005","Completed","2020-06-01","2020-08-01","{""locations"":""Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Ata\u015fehir, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Coronavirus Phobia Scale|Lymphedema Quality of Life Arm|Lymphedema Quality of Life Leg|Hospital Anxiety and Depression Scale""}"
"4205","Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability","FatCovid-19","NCT04363606","20CH085|2020-A00982-37","Other: Questionnaires|Biological: blood test|Other: Maximal effort test|Device: actigraphy|Device: Neuromuscular evaluation|Other: stool analysis|Other: food diary","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363606","Recruiting","2020-05-27","2021-12-01","{""locations"":""CHU de Grenoble, Grenoble, France|Clinique de la Sauvegarde - Lyon, Lyon, France|H\u00f4pital Croix Rousse - HCL, Lyon, France|Centre Hospitalier de Lyon Sud, Pierre-benite, France|Chu Saint-Etienne, Saint Etienne, France|Clinique Mutualiste Saint Etienne, Saint Etienne, France|H\u00f4pital Henry Gabrielle, Saint-Genis-Laval, France|H\u00f4pital priv\u00e9 de la Loire, Saint-\u00c9tienne, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""82"",""age"":""35 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""voluntary maximum force reduction|Neuromuscular function : cortical activity|Neuromuscular function : Peripheral function|Maximal oxygen uptake (VO2max)|quality of sleep|muscle volume|metabolic fatigue|microbiote intestinal""}"
"4206","Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic","","NCT04435379","VPM1002-DE-3.07CoV|2020-001675-33","Biological: VPM1002|Biological: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04435379","Active, not recruiting","2020-06-18","2021-09-30","{""locations"":""Hautarztpraxis Dres. Leitz & Kollegen, Stuttgart, Baden-W\u00fcrttemberg, Germany|MECS Cottbus GmbH, Cottbus, Brandenburg, Germany|Studienzentrum Dr. Keller, Frankfurt, Hessen, Germany|Klinische Forschung Hannover Mitte GmbH, Hannover, Niedersachsen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Medizentrum Essen Borbeck, Essen, Nordrhein-Westfalen, Germany|BAG Dres. med. Quist PartG, Mainz, Rheinland-Pfalz, Germany|SIBAmed GmbH & Co. KG, Leipzig, Sachsen, Germany|SocraTec R&D GmbH, Erfurt, Th\u00fcringen, Germany|emovis GmbH, Berlin, Germany|Klinische Forschung Berlin GbR, Berlin, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""2038"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days with severe respiratory disease at hospital and\/or at home|Cumulative incidence of hospital admissions|Cumulative incidence of documented SARS-CoV-2 infection|Number of days with self-reported fever (\u2265 38 \u00baC)|Number of days with self-reported acute respiratory symptoms|Cumulative incidence of self-reported acute respiratory symptoms|Cumulative incidence of death for any reason|Cumulative incidence of death due to documented SARS-CoV-2 infection|Cumulative incidence of ICU admission for any reason|Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection|Cumulative incidence of hospital admission due to documented SARSCoV- 2 infection""}"
"4207","Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak","","NCT04345549","AU08","Other: Individualised Ayurveda","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04345549","Completed","2020-02-26","2020-03-30","{""locations"":""Aarogyam, Leicester, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""18"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Time to achieve afebrile|Severity of influenza symptom score""}"
"4208","Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center","SurgiCovid","NCT04379232","CRC_GHN_2020_001","Biological: Screening test for covid ( RT PCR and CT Chest)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04379232","Completed","2020-03-19","2020-04-25","{""locations"":""Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""112"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptoms of Covid after surgery""}"
"4209","Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown","","NCT04466605","AU/NMP/0921","Other: Tele-yoga therapy|Other: Primary care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04466605","Completed","2020-03-30","2020-07-06","{""locations"":""NMP Medical Research Institute, Jaipur, Rajasthan, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""64"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Severity of pain|Interference of pain|Global rating of change in pain|Intervention specific satisfaction""}"
"4210","Feasibility and Benefits of Digital Services During the COVID19 Pandemic","AnhandCOV19","NCT04453475","Anhand-COVID19","Behavioral: Training session adressing information and health literacy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04453475","Recruiting","2020-07-01","2021-12-31","{""locations"":""Jacobs University Bremen gGmbH, Bremen, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""1230"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Interest in digital interventions (attitudes, behavioral intentions, behavioral experiences)|Usability and effectiveness of digital interventions|Stressors and barriers due to Covid-19""}"
"4211","Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients","COVIDSOT","NCT04319172","COVIDSOT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04319172","Recruiting","2020-03-12","2021-04-01","{""locations"":""Hospital Universitario Virgen del Rocio, Seville, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Incidence of coronavirus infection in Solid Organ Transplant Recipients|Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients|Presence of other risk factors|Establish the frequency and type of complications related to the net state of the patient immunosuppression|Frequency of co-infections|Mortality|Laboratory characteristics|Determination of coronavirus viral load|Microbiological testing""}"
"4212","ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation","ROCO","NCT04380909","2020-00990","Behavioral: Internet-based self-help|Behavioral: Internet-based self-help after 3 weeks","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04380909","Active, not recruiting","2020-05-06","2021-04-01","{""locations"":""Universit\u00e4t Bern, Bern, Switzerland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""107"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire (L\u00f6we et al., 2002)|Suicide Behavior Questionnaire Revised (Glaesmer et al., 2018)|DASS-21: Depression, Angst, Stress-Skala (Lovibond & Lovibond, 1995)|SF-12: Short Form Health Survey (Ware et al., 1996)|LOT-R: Revised Life Orientation Test (Herzberg et al., 2006)|Berner Verbitterungsinventar Kurzversion (Znoj, 2008)|Emotion regulation skills SEK-27 (Berking & Znoj, 2008)|SWE: Skala zur Allgemeinen Selbstwirksamkeit (Jerusalem & Schwarzer, 2003)|UCLA Loneliness Scale (D\u00f6ring & Bortz, 1993)|Connor-Davidson Resilience Scale (Sarubin et al., 2015)|ZUF-8: Zufriedenheitsfragebogen (Attkisson & Zwick, 1982)|SUS: System Usability Scale (Brooke, 1996)""}"
"4213","Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic","","NCT04369378","27-126","Behavioral: Meditation app usage","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04369378","Recruiting","2020-08-19","2021-04-30","{""locations"":""LECOM, Erie, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety|Well-being|Future outlook & hopefulness|Sleep habits|Nutrition habits|Meditation app continued usage""}"
"4214","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection","","NCT04327479","20-9213-BO","Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04327479","Recruiting","2020-03-26","2026-03-25","{""locations"":""University Hospital Essen, Essen, NRW, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""728"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|30-day mortality|Major adverse cardiovascular events""}"
"4215","Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders","CLASSIC","NCT04581577","286495","Other: Semi-structured telephone questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581577","Recruiting","2020-09-11","2021-04-30","{""locations"":""Royal Brompton Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""75"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Qualitative evaluation of the perceived clinical and psychosocial impact of the Covid-19 pandemic in patients with neuromuscular and neurological disorders|Quantification of the proportion of patients with NMD who have had suspected or confirmed Covid-19 infection during the pandemic|Qualitative evaluation of the social environment of patients with NMDs|Qualitative evaluation of the social activities of patients with NMDs|Qualitative evaluation of the professional activities of patients with NMDs|Qualitative evaluation of the impact of the Covid-19 pandemic on families of patients with neuromuscular and neurological disorders|Qualitative evaluation of concerns regarding medical care from the perspective of patients with NMDs and their families during the Covid-19 pandemic""}"
"4216","Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19","CoviDep","NCT04508868","2020-02079","Behavioral: Brief Behavioral Activation with Mental Imagery|Behavioral: Minimal Attention Control Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04508868","Terminated","2020-08-31","2020-12-23","{""locations"":""Adult Psychiatric Clinic, V\u00e4ster\u00e5s, V\u00e4stmanland, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""41"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Change from baseline in depressive symptoms using the Montgomery-Asberg Depression Rating Scale, MADRS-S|Change from baseline in depressive symptoms using the Geriatric Depression Rating Scale 15, GDS-15|Change from baseline in depressive symptoms using the Patient Health Questionnaire 9, PHQ-9|Change in depression diagnosis assessed using the Mini International Neuropsychiatric Interview, MINI|Change from baseline in anxiety symptoms using the Generalized Anxiety Disorder 7-item, GAD-7|Change from baseline in behavioral activation using The Behavioral Activation for Depression Scale - Short Form, BADS-SF|Change from baseline in health and disability using The WHO Disability Assessment Schedule 12-item, WHODAS|Adverse and unwanted effects of the experimental intervention using the Negative Effects Questionnaire, NEQ|Mental imagery is assessed at baseline using the Plymouth Sensory Imagery Questionnaire, Psi-Q""}"
"4217","Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency","MOHC","NCT04410536","MOH","Drug: Symptomatic drugs|Drug: Bridge therapy|Behavioral: Mindfulness program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04410536","Recruiting","2020-06-15","2022-07-01","{""locations"":""Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit, Milano, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""25"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Drop out rates|Absence of Medication Overuse Headache (MOH)""}"
"4218","Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study","","NCT04537962","4172-20","Other: Colgate periogard mouthwash|Other: Colgate Peroxyl mouthwash|Other: Colgate Total mouthwash|Other: Placebo mouthwash (water)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04537962","Enrolling by invitation","2020-06-11","2021-08-30","{""locations"":""Hospital israelita Albert Einstein, Sao Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""70"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load of SARS-CoV-2 in the oral mucosa, oropharynx and saliva of hospitalized patients already considered positive for the virus""}"
"4219","Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease","PTT-Online","NCT04422353","PTT-Parkinson/COVID19","Other: Video Dance classes|Other: Unsupervised physical activities","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04422353","Recruiting","2020-05-01","2024-12-30","{""locations"":""Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""50 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Quality of life (QoL)|Depressive symptoms - Geriatric Depression Scale - 15 item|Physical Activity - International Physical Activity Questionnaires (IPAQ)|Cognitive function - Montreal Cognitive Assessment by telephone|Falls - Falls Efficacy Scale - International|Functional lower extremity strength -Five Times Sit to Stand Test""}"
"4220","Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure","","NCT04385823","HLM_JDR9","Device: patients receiving nasal high flow","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385823","Completed","2020-03-01","2020-05-04","{""locations"":""H\u00f4pital Louis Mourier, Assistance Publique - H\u00f4pitaux de Paris, Colombes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""62"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in ROX index|NHF failure|NHF flow|NHF inspired fraction in oxygen|oxygenation|respiratory status|prediction of intubation|prediction of NHF success""}"
"4221","Experience of Lock Down Related to the Covid-19 Epidemic and Its Impact on the Project of Parenthood","CONFIN-AMP","NCT04556630","2020_65|2020-A01810-39","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04556630","Not yet recruiting","2020-10-01","2020-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""360"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Level of anxiety and\/or depression of MPA patients (male and female couples) by Hospital Anxiety and Depression Scale (HAD) score.""}"
"4222","Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity During the COVID19 Pandemic","","NCT04419870","200120|20-HG-0120","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04419870","Recruiting","2021-03-16","2025-05-01","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""2 Months and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""We will perform whole blood transcriptomic analysis, humoral response profiling and soluble mediator profiling.|Patient Medical Records for Data Abstraction|Patient centered outcomes data via questionnaires""}"
"4223","Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)","DeathPercep","NCT04384419","RECHMPL20_0276","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384419","Recruiting","2020-05-29","2021-06-01","{""locations"":""UH Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of perception distortions|Recall number of deaths""}"
"4224","A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis","COMET20d","NCT04397471","COMET20d","Procedure: Bone Marrow Harvest","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04397471","Not yet recruiting","2020-05-01","2021-12-01","{""locations"":""Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""10"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Determine feasibility of recruiting healthy volunteers in a clinically useful timeframe.|Manufacture a cell-based product suitable for clinical use|Establishment of a robust process of production|Production of stability data to be used in the MHRA dossier for the COMET clinical trial.|Production of cell-based products to be administered to COVID-19 patients with severe pneumonitis.|Analysis of cells for understanding production, manufacture and related research.""}"
"4225","Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic","","NCT04690400","39305720.9.0000.5313","Other: Experimental: Active care group|Other: Active Comparator: Self-care group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04690400","Not yet recruiting","2021-01-18","2021-04-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""28"",""age"":""30 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Changes in the Widespread Pain Index|Changes in Sleep Quality|Symptom Severity Scale|Impact of fibromyalgia on daily activities|Depressive symptoms|Physical activity level|Functionality \/ Flexibility|Painful intensity at rest and movement|Subjective perception of well-being""}"
"4226","Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?","FERTICOVID","NCT04487639","RNI 2020 BRUGNON|2020-A01409-30","Diagnostic Test: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04487639","Recruiting","2020-07-10","2021-07-01","{""locations"":""AP-H\u00f4pitaux de Paris - H\u00f4pital Jean Verdier - Service de Biologie de la reproduction, Bondy, France|AP-H\u00f4pitaux de Paris - H\u00f4pital Antoine B\u00e9cl\u00e9re - Service de Biologie de la reproduction et AMP DPI CECOS, Clamart, France|CHU de Clermont-Ferrand - Laboratoire de Virologie, Clermont-Ferrand, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Dijon - Laboratoire de Biologie de la Reproduction-CECOS, Dijon, France|CHU de Grenoble - Laboratoire d'Aide \u00e0 la Procr\u00e9ation CECOS, Grenoble, France|Hospices Civils de Lyon - Service AMP-CECOS, Lyon, France|H\u00f4pital de la Conception - AP-H\u00f4pitaux de Marseille - Service AMP-CECOS, Marseille, France|CHU de Nancy - Laboratoire de biologie de la reproduction - CECOS, Nancy, France|AP-H\u00f4pitaux de Paris - H\u00f4pital Tenon - Service de Biologie de la reproduction - CECOS, Paris, France|AP-H\u00f4pitaux de Paris - H\u00f4pital Cochin - Service d'Histologie-Embryologie-Biologie de la reproduction, Paris, France|Centre Hospitalier intercommunal (CHI) de Poissy Saint Germain en Laye, Poissy, France|CHU de Reims - Service de Biologie de la Reproduction - CECOS Champagne-Ardenne de Reims, Reims, France|CHU de Rouen Normandie - Service Biologie de la Reproduction-CECOS, Rouen, France|CHU de Strasbourg - Service de Biologie de la reproduction, Strasbourg, France|CHU de Toulouse - CECOS Midi-Pyr\u00e9n\u00e9es, Toulouse, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""250"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Detection of SARS-CoV-2 in sperm during fertility preservation procedures by RT-qPCR|To correlate the presence of SARS-CoV-2 in the seminal fluid and the spermatozoa fractions of the same ejaculate|To determine if the presence of this virus in sperm is associated with its presence in nasal swabs|To determine if the presence of this virus in sperm is associated with COVID symptoms|To determine if the presence of this virus in sperm is associated with specific serological profiles|To determine if the presence of this virus in sperm is associated with particular oncological pathologies\/treatments|To determine if the presence of this virus in sperm could impair its quality""}"
"4227","Registry of the Evolution of Diagnosed and/or Hospitalized Patients for Pulmonary Embolism During the Covid-19 Pandemic","COVID-EP","NCT04465656","2020-05-01","Diagnostic Test: Serology test for COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04465656","Recruiting","2020-07-07","2021-04-30","{""locations"":""H\u00f4pital Saint Joseph Marseille, Marseille, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""% of patients for each group presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 6 months after PE diagnosis.|% of patients for each group and subgroup presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 12 months after PE diagnosis.|% of patients in each group presenting the occurrence of each of the following events at each follow-up (3 months, 6 months and 12 months after PE diagnosis).|% of patients diagnosed COVID - at M0 by RT-PCR on nasopharyngeal swab and diagnosed COVID + by serology 3 months after PE diagnosis|Effectiveness of the different category of treatments used in all patients and in the groups: % of occurrence of PE complications for each categories of treatments|Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with occurrence of bleeding complications for each categories of treatments|Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with no occurrence of complications for each categories of treatments|Effectiveness of the different category of treatments used in all patients and in the groups: duration of Heparin treatment (number of day)""}"
"4228","Assessment of the Psychological Impact of the COVID19 (SARS-CoV-2) Pandemic on Patients With Chronic Inflammatory Rheumatism","RICOVID19","NCT04723407","87RI20_0062 /RICOVID19","Other: questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04723407","Not yet recruiting","2021-02-01","2022-03-01","{""locations"":""D\u00e9partement de Rhumatologie, Limoges, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""950"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""post-traumatic stress""}"
"4229","Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi","","NCT04422418","CPRA-2020-034","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422418","Recruiting","2020-07-01","2020-12-31","{""locations"":""Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates|Mediclinic, Abu Dhabi, United Arab Emirates|Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates|Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from Baseline Burnout at 2-3 months and 6 months|Change from Baseline Cardiovascular Risk Cardiovascular Risk Through Heart Rate Variability Markers at 2-3 months and 6 months|Change from Baseline Through Actigraphy at 2-3 months and 6 months|Change from Baseline Through Sleep Quality at 2-3 months and 6 months|Change from Baseline Cardiovascular Risk Through Fuster-BEWAT score at 2-3 months and 6 months|Change from Baseline Immune Dysfunction at 2-3 months and 6 months|Change from Baseline Cardio-Respiratory Fitness at 2-3 months and 6 months""}"
"4230","Evaluation of Changes in Weight, Sleep, and Other Psycho-behavioural Parameters During Covid-19 Confinement in Subjects Monitored by the RNPC Network","CO-RNPC","NCT04409197","38RC20.150","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409197","Completed","2020-05-08","2020-07-11","{""locations"":""CHU Grenoble Alpes, Grenoble, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4789"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Analyse the variation in weight loss kinetics before, during and after confinement in patients enrolled in a weight reduction programme (RNPC) in France|Define the effects of containment on the variation in the kinetics of anthropometric parameters other than weight|Evolution of blood pressure before versus after confinement|Characterize clusters (homogeneous groups of patients) associated with particular dynamics of weight kinetics during confinement|Evaluate the impact of teleconsultation monitoring during containment on weight loss""}"
"4231","A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19","","NCT04347031","FL-01/20","Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04347031","Completed","2020-04-08","2020-11-20","{""locations"":""Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""320"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2""}"
"4232","Quality of Life of Very Preterm Children With Dysexecutive Disorders at Elementary School Age During the Confinement-deconfinement Period of Covid-19 Pandemic","GPE-QolVID","NCT04696679","2020-38|2020-A01631-38","Other: Patient Quality of life assessment|Other: Control group Quality of life assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04696679","Completed","2020-06-19","2020-12-31","{""locations"":""Assistance Publique des Hopitaux de Marseille, Marseille, France"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""170"",""age"":""7 Years to 9 Years \u00a0 (Child)"",""outcome_measures"":""Assessment of the quality of life using the questionnaire Kidscreen 10 Index|Assessment of the quality of life using The VSP-A questionnaire (Life and Perceived Health of the Adolescent and the Child)|Specific data concerning the period of confinement-deconfinement|Data on children behavioral disorders:|Data concerning the anxiety symptoms of the parent completing the survey questionnaire:""}"
"4233","Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19","PsyCovid_App","NCT04393818","COVID-19/06","Behavioral: Intervention App","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04393818","Completed","2020-05-05","2020-08-24","{""locations"":""Ignacio Ricci-Cabello, Palma De Mallorca, Balearic Islands, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""560"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depression, anxiety and stress|Post-traumatic stress syndrome|Insomnia|Self Efficacy""}"
"4234","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations","","NCT04279795","PL11","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04279795","Recruiting","2020-01-20","2021-02-28","{""locations"":""The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Positive rate of 2019 Novel Coronavirus RNA|Survival rate""}"
"4235","BCG Vaccine for Health Care Workers as Defense Against COVID 19","BADAS","NCT04348370","2020-0432F","Biological: BCG Vaccine|Biological: Placebo Vaccine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04348370","Recruiting","2020-04-20","2021-11-01","{""locations"":""Cedars-Sinai Medical Center, Los Angeles, California, United States|Texas A&M Family Care Clinic, Bryan, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Harris Health System - Ben Taub Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""1800"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID 19 Infection|Disease Severity""}"
"4236","HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital","H-Cov-Run","NCT04384705","2020/CHU/08","Other: research specific blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04384705","Recruiting","2020-06-17","2021-07-01","{""locations"":""Centre Hospitalier Universitaire R\u00e9union, Saint-Denis, France|Centre Hospitalier Universitaire de la R\u00e9union, Saint-Pierre, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of lipid profile during exposure to SARS-Cov-2|HDL-cholesterol size|circulating plasma cytokine levels|ACE2 gene polymorphisms""}"
"4237","Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic","REST","NCT04362358","7799","Behavioral: Online cognitive behavioral therapy (CBT)|Behavioral: Online bibliotherapy programme","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04362358","Not yet recruiting","2020-05-01","2021-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""120"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Significant score reduction at the Perceived Stress Scale""}"
"4238","Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19","","NCT04390152","BIOXSOMCOV001","Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04390152","Recruiting","2020-01-13","2022-04-01","{""locations"":""BioXcellerator, Medellin, Antioquia-CO, Colombia|Clinical Somer, Rionegro, Antioquia, Colombia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between \""Sequential Organ Failure Assessment\"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.""}"
"4239","Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID","","NCT04387253","GYNE-COVID","Diagnostic Test: Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04387253","Recruiting","2020-05-23","2021-07-23","{""locations"":""CHU de Poitiers, Poitiers, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic"",""enrollment"":""80"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Estimate the prevalence of SARS-CoV-2 infection in women with late fetal loss of unexplained cause.""}"
"4240","Measurement of Airway Opening Pressure (AOP) in Patients With Acute Respiratory Distress Syndrom and With or Without Covid 19.","POVA-TIE","NCT04386720","CHUBX 2020/15","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04386720","Recruiting","2020-05-25","2021-05-25","{""locations"":""HOPITAL HAUT-LEVEQUE - Service R\u00e9animation thoracique, Pessac, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of the PV curves|Comparison of regional AOP|Comparison of the different AOPs with the level of PEEP""}"
"4241","Ethical and Psychological Support for Health Care Professions in Intensive Care Units in the COVID19 Pandemic Context: Adequacy With Needs and Psychological Impact Crisis and Post-crisis","PsyCOVID","NCT04441476","QUENOT SERI 2020","Other: Questionnaires|Other: psychological and sociological interviews","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04441476","Active, not recruiting","2020-04-21","2021-11-01","{""locations"":""Chu Dijon Bourgogne, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PS-ICU Scale Score""}"
"4242","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection","","NCT04279782","XWX3","Other: Comprehensive treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04279782","Recruiting","2020-01-20","2021-02-28","{""locations"":""The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Survival rate|Chest computed tomography|Recovery Time|Depression evaluation""}"
"4243","Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU","COVIDOP-DVT","NCT04363528","P20/08_COVIDOP-DVT","Other: Doppler Echo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363528","Recruiting","2020-04-24","2020-10-30","{""locations"":""Centre Hospitalier de Versailles, Le Chesnay, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU""}"
"4244","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers","","NCT04461353","PUL-01","Drug: Aerolized Hydroxychloroquine Sulfate|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04461353","Completed","2020-06-25","2020-08-17","{""locations"":""The Rockefeller University, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""12"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidences of treatment-emergent adverse events (TEAEs) as assessed by TGSHAAV (September 2007) or CTCAE version 5.0|Change from baseline in clinical laboratory test results for CBC with differential|Incidence of abnormal laboratory test results for CBC with differential at Screening|Incidence of abnormal laboratory test results for CBC with differential - Day 8|Changes from baseline for blood glucose|Incidence of abnormal laboratory test results for chemistry -Screening|Incidence of abnormal laboratory tests results for chemistry - Day 8|Incidence of abnormal laboratory tests results for urinalysis - Screening|Incidence of abnormal laboratory tests results for urinalysis- Day 8|Changes in vital signs from baseline (pre-dose) - respiratory rate|Changes in vital signs from baseline (pre-dose)- temperature|Changes in vital signs from baseline (pre-dose) - seated blood pressure|Changes in vital signs from baseline (pre-dose) - pulse|Changes in vital signs from baseline (pre-dose) - O2 saturation|Incidence of abnormal and physical examinations findings during Screening- general appearance|Incidence of abnormal and physical examinations findings on Day 1 - general appearance|Incidence of abnormal and physical examinations findings on Day 2- general appearance|Incidence of abnormal and physical examinations findings on Day 8- general appearance|Incidence of abnormal and physical examinations findings during Screening- neurological|Incidence of abnormal and physical examinations findings on Day 1- neurological|Incidence of abnormal and physical examinations findings on Day 2- neurological|Incidence of abnormal and physical examinations findings on Day 8- neurological|Incidence of abnormal and physical examinations findings during Screening - heart\/cardiovascular|Incidence of abnormal and physical examinations findings on Day 1 - heart\/cardiovascular|Incidence of abnormal and physical examinations findings on Day 2 - heart\/cardiovascular|Incidence of abnormal and physical examinations findings on Day 8 - heart\/cardiovascular|Incidence of abnormal and physical examinations findings during Screening - lungs|Incidence of abnormal and physical examinations findings on Day 1 - lungs|Incidence of abnormal and physical examinations findings on Day 2 - lungs|Incidence of abnormal and physical examinations findings on Day 8 - lungs|Incidence of abnormal and physical examinations findings during Screening- abdomen|Incidence of abnormal and physical examinations findings on Day 1 - abdomen|Incidence of abnormal and physical examinations findings on Day 2- abdomen|Incidence of abnormal and physical examinations findings on Day 8- abdomen|Incidence of abnormal and physical examinations findings during screening- endocrine|Incidence of abnormal and physical examinations findings on Day 1 - endocrine|Incidence of abnormal and physical examinations findings on Day 2- endocrine|Incidence of abnormal and physical examinations findings on Day 8- endocrine|Incidence of abnormal and physical examinations findings during Screening- extremities|Incidence of abnormal and physical examinations findings on Day 1- extremities|Incidence of abnormal and physical examinations findings on Day 2- extremities|Incidence of abnormal and physical examinations findings on Day 8- extremities|Incidence of abnormal and physical examinations findings during Screening- lymphatic|Incidence of abnormal and physical examinations findings on Day 1- lymphatic|Incidence of abnormal and physical examinations findings on Day 2 - lymphatic|Incidence of abnormal and physical examinations findings on Day 8- lymphatic|Incidence of abnormal and physical examinations findings during screening - skin|Incidence of abnormal and physical examinations findings on Day 1 - skin|Incidence of abnormal and physical examinations findings on Day 2 - skin|Incidence of abnormal and physical examinations findings on Day 8 - skin|Changes from baseline for pulmonary function tests (PFTs) - FEV1|Changes from baseline for pulmonary function tests (PFTs) - FVC|Changes from baseline for pulmonary function tests (PFTs) - FEV1\/FVC|Changes from baseline for ECG readings - QT interval|Changes from baseline for ECG readings - QTcB Interval|Changes from baseline for ECG readings - QRS duration|Changes from baseline for ECG readings - PR interval|Changes from baseline for ECG readings - heart rate|Incidence of abnormal ECG - Screening|Incidence of abnormal ECG- Day 1|Incidence of abnormal ECG - Day 2|Incidence of abnormal ECG - Day 8|HCQ concentration in whole blood versus time profiles""}"
"4245","Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 in Healthy Volunteers","","NCT04679493","COVID-XC7-01","Drug: XC7 100 mg single|Drug: XC7 200 mg single|Drug: Placebo single|Drug: XC7 200 mg multiple|Drug: Placebo multiple","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04679493","Not yet recruiting","2020-12-01","2021-02-01","{""locations"":""Federal State Autonomous Educational Institution of Higher Education \""The First Moscow State Medical University named after I.M. Sechenov\"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""16"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Number of Adverse events (AEs) per treatment arm|Pharmacokinetics of XC7 by assessing AUC0-inf|Pharmacokinetics of XC7 by assessing Cmax|Pharmacokinetics of XC7 by assessing AUC0-t|Pharmacokinetics of XC7 by assessing Tmax|Pharmacokinetics of XC7 by assessing T1\/2""}"
"4246","Anosmia and / or Ageusia and Early Corticosteroid Use","","NCT04528329","PR0013","Drug: Early-Dexamethasone|Drug: Late dexamethazone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04528329","Recruiting","2020-08-30","2021-04-15","{""locations"":""Asalam, Maadi, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to recovery""}"
"4247","COVID-19 - No Health Without Mental Health","Co-COVID-19","NCT04421612","126376","Behavioral: Co-mestring (co-coping)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04421612","Recruiting","2020-04-02","2021-12-31","{""locations"":""Haukeland University Hospital, Bergen, Norway"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The Patient Health Questionnaire|The Generalized Anxiety Disorder Scale|Positive and negative affect|Perceived Stress Scale|Client Satisfaction Scale""}"
"4248","Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)","PREDICT-ILI","NCT04664075","20SM6170","Biological: Respiratory infections","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04664075","Not yet recruiting","2021-01-01","2021-06-30","{""locations"":""Imperial College London, London, United Kingdom"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Describe the aetiology of influenza-like illness in hospitalised adults|Describe the clinical outcomes of influenza-like illness in hospitalised adults|Identify changes in cytokine levels during influenza-like illness in hospitalised adults""}"
"4249","Stay Well at Home: a Text-messaging Study Social Distancing","","NCT04473599","2020-04-13162","Behavioral: Uniform random message delivery|Behavioral: Reinforcement learning message delivery","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04473599","Recruiting","2020-04-17","2021-04-01","{""locations"":""University of California Berkeley, Berkeley, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depression scores|Anxiety scores|Self reported mood ratings""}"
"4250","Turkish of the SARS-CoV-2 Anxiety Scale","","NCT04490473","DSAYIK2|Ayfer AÇIKGÖZ|ERTUĞRUL ÇOLAK|DENİZ YİĞİT|ÖZLEM MUMCU","Other: survey work","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04490473","Recruiting","2020-07-24","2021-04-24","{""locations"":""Eskisehir Osmangazi University, Eskisehir, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""300"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Anxiety in SARS-CoV-2|Ratio of SARS-CoV-2 anxiety scale to beck anxiety scale""}"
"4251","Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19","MetCOVID","NCT04343729","CAEE: 30615920.2.0000.0005","Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04343729","Completed","2020-04-18","2020-10-20","{""locations"":""Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""416"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate at day 28|Mortality rate on days 7, 14 and 28|Incidence of orotracheal intubation|Change in oxygenation index""}"
"4252","Finding Wellness in the Pandemic","","NCT04615741","2020-096","Behavioral: Trauma Informed Yoga|Behavioral: Trauma Informed Psychotherapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04615741","Active, not recruiting","2020-11-09","2021-04-30","{""locations"":""University of Lethbridge, Lethbridge, Alberta, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""187"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in Tobacco Use|Changes in Alcohol Use|Changes in Drug Use|Changes in Gambling|Changes in Post-Traumatic Stress Symptoms|Changes in Depression Symptoms|Changes in Anxiety Symptoms|Changes in Eating Behaviour|Changes in Sleeping Behaviour|Changes in Physical Activity|Changes in Resilience|Changes in Self-Esteem|Changes in Loneliness|Changes in Dissociative Experiences""}"
"4253","Mask Adhesive Institutional Study","","NCT04644276","SRCHRCMask Adhesive 2020_11130","Device: Mask with Mask Adhesive/Arm 1|Device: Mask without Mask Adhesive / Arm 2","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04644276","Recruiting","2021-02-17","2021-03-19","{""locations"":""Sleep Disorder Center of Alabama, Birmingham, Alabama, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Medical Adhesive-Related Skin Injury (MARSI) and Ease of Use|Leak Change""}"
"4254","A Research Platform to Screen Healthcare Workers","RESPECT","NCT04574765","OZUHN-001|20-5289","Diagnostic Test: Nasopharyngeal swab|Other: Questionnaire collection|Other: Optional blood completion|Other: Optional questionnaire completion","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04574765","Recruiting","2020-04-16","2021-04-16","{""locations"":""University Health Network, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of healthcare workers who are asymptomatic and COVID-19 positive""}"
"4255","Study of Descartes-30 in Acute Respiratory Distress Syndrome","","NCT04524962","DC30-1A","Biological: Descartes 30","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04524962","Recruiting","2020-09-15","2022-09-25","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California-Irvine, Irvine, California, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Maryland Medical Center Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS.""}"
"4256","Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial","COVI-PRONE","NCT04350723","2154","Procedure: Awake Proning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04350723","Recruiting","2020-06-10","2021-08-30","{""locations"":""St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Hamilton General Hospital, Hamilton, Canada|Juravinski Hospital, Hamilton, Canada|St. Catharine's General -, St. Catharines, Canada|King Fahad Hospital of the University, Khobar, Eastern Province, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Endotracheal intubation|Mortality|Invasive mechanical ventilation free days|Non-invasive ventilation free days|ICU length of stay|Hospital length of stay|Change in oxygenation|Complications from proning,""}"
"4257","Containment Measures and Eating Disorders","COVITA","NCT04492189","RECHMPL20_0220","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492189","Completed","2020-04-01","2020-06-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Variation in eating disorders|Vision of the bodily aspect|Variation in physical activity|Identify the clinical factors modulating the psychological state during confinement""}"
"4258","Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population","PsyConfPop","NCT04374643","RECHMPL20_0197","Other: Slef questionnaires fulfilment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374643","Recruiting","2020-04-01","2021-12-30","{""locations"":""University hospital, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depressive Symptomatology""}"
"4259","Inflammatory Bowel Disease (IBD) and Covid-19 Infection","MICI-Covid-19","NCT04492267","7930","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04492267","Recruiting","2020-07-07","2021-01-07","{""locations"":""Service H\u00e9pato-Gastroent\u00e9rologie et Assistance Nutritive H\u00f4pitaux Univesitaires de Strasbourg, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Retrospective analysis of severity and specific needs in case of SARS-CoV-2 infection in IBD patients""}"
"4260","imPROving prenaTal carE During ConfinemenT","PROTECT","NCT04368832","2020-A01023-36","Other: Remote consultation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04368832","Active, not recruiting","2020-04-25","2021-09-30","{""locations"":""Maternit\u00e9 R\u00e9gionale Universitaire de Nancy, Nancy, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""108"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Score of perceived quality of prenatal care|Level of stress during pregnancy|level of health and digital literacy|Obstetrical outcomes|Characteristics of medical supervision during pregnancy""}"
"4261","Social Media Use During COVID-19","","NCT04305574","2020-CERC-001","Behavioral: Use of social media during COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04305574","Completed","2020-03-07","2020-04-21","{""locations"":""Yale-NUS College, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1145"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depression, Anxiety and Stress Scale""}"
"4262","Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)","","NCT04679909","ALT-501-101","Biological: AdCOVID|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04679909","Recruiting","2021-02-01","2022-02-01","{""locations"":""Optimal Research, Melbourne, Florida, United States|Optimal Research, Peoria, Illinois, United States|Optimal Research, Rockville, Maryland, United States|Optimal Research, Austin, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""180"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Reactogenicity|Adverse Events (AEs)|Anti-SARS-CoV-2 spike IgG antibody levels|Neutralizing antibody titer against live and\/or pseudotyped SARS-CoV-2 virus""}"
"4263","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","CORIMUNO-ANA","NCT04341584","APHP200375-5","Drug: Anakinra","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04341584","Completed","2020-04-08","2020-07-25","{""locations"":""H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris, Le Kremlin-Bic\u00eatre, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""161"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival without needs of ventilator utilization at day 14|WHO progression scale \u2264 5|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2\/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge""}"
"4264","Neurological Features During COVID19","NeuroSARS","NCT04460599","Brain COVID","Other: Observation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04460599","Recruiting","2020-03-08","2020-09-30","{""locations"":""Hopital Raymond Poincare, Garches, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary|Secondary""}"
"4265","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","2019-nCoV","NCT04292327","KY-2020-24.01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04292327","Active, not recruiting","2020-01-01","2020-07-31","{""locations"":""Fujian Provincial Hospital, Fuzhou, Fujian, China"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""400"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|The time interval of Nucleic acid detection become negative""}"
"4266","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia","","NCT04269525","2020002","Biological: UC-MSCs","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04269525","Recruiting","2020-02-06","2020-12-30","{""locations"":""Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""16"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygenation index|28 day mortality|Hospital stay|2019-nCoV antibody test|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-10|tumor necrosis factor(TNF)-\u03b1|\u03b3-interferon(IFN)|C-reactive protein(CRP)|CD4+ T-Lymphocytopenia|CD8+ T-Lymphocytopenia|natural killer cell(NK)""}"
"4267","Convalescent Plasma Collection and Treatment in Pediatrics and Adults","","NCT04376034","2004965705","Biological: Convalescent Plasma 1 Unit|Biological: Convalescent Plasma 2 Units|Other: Standard of Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04376034","Recruiting","2020-04-16","2021-03-30","{""locations"":""WVU Medicine, Morgantown, West Virginia, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""31 Days and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Plasma Donor|Plasma Recipient""}"
"4268","Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic","canSEROcov","NCT04517097","2020-A00877-32","Biological: blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04517097","Completed","2020-05-12","2020-06-30","{""locations"":""Centre Georges-Fran\u00e7ois LECLERC, Dijon, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1680"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""seroprevalence of SARS-CoV-2""}"
"4269","Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations","Heart Up!","NCT03907891","2018-1485|R01NR017649|3R01NR017649-04S1","Behavioral: Motivational social support from nurse|Behavioral: Motivational social support from nurse with additional support from significant other|Behavioral: Attention control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT03907891","Recruiting","2019-08-01","2023-05-01","{""locations"":""Spectrum Health, Grand Rapids, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""225"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ActiGraph GT9X Link Accelerometer|State-Trait Hopelessness Scale|Exercise Self-Regulation Questionnaire|ENRICHD Social Support Inventory""}"
"4270","Tocilizumab in Coronavirus-19 Positive Patients","","NCT04423042","REB20-0713","Biological: Tocilizumab","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04423042","Not yet recruiting","2020-07-30","2021-06-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|Ordinal Scale for evaluating subject clinical status at days 3, 8, 15, 30, 60 post treatment.""}"
"4271","Regional COVID Epidemiology in England (RECEDE)","RECEDE","NCT04579562","UHDB/2020/075","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04579562","Not yet recruiting","2020-11-01","2021-10-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""5000"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause mortality|acute kidney injury|Mechanical ventilation""}"
"4272","Haemoglobin Concentration on COVID-19","","NCT04377607","145/2020","Other: File scanning","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04377607","Recruiting","2020-11-01","2020-12-30","{""locations"":""Konya Training and Research Hospital, Konya, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Relationship between severity of disease and values of erythrocyte indices|Sensitivity of haemoglobin concentration on severity of the disease""}"
"4273","Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions","","NCT04462848","IRB#20-001263","Biological: anti-SARS-CoV-2 human convalescent plasma","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04462848","Not yet recruiting","2020-08-01","2024-12-01","{""locations"":""University of California, Los Angeles (UCLA), Los Angeles, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""1 Month to 17 Years \u00a0 (Child)"",""outcome_measures"":""Cumulative incidence of Grade 3 and Grade 4 adverse events|Cumulative incidence of serious adverse events|Proportion of participants with disease worsening event.|Serum concentration at baseline, Day 7, Day 14, and Day 28 for anti-SARS-CoV-2 antibodies|Percentage of participants with a natural antibody response to SARS-CoV-2 infection""}"
"4274","Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols","","NCT04467112","COVID-Breath","Device: Breath Biopsy face masks with removable filters and fitted PVA strip","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04467112","Recruiting","2020-07-30","2020-12-01","{""locations"":""Cambridge University Hospital NHS, Cambridge, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Detection of nCOVID-19 using a face mask|Independent Patient use of face mask""}"
"4275","A Study of a Candidate COVID-19 Vaccine (COV003)","","NCT04536051","COV003","Biological: ChAdOx1 nCoV-19 single dose + paracetamol|Biological: MenACWY single dose + paracetamol|Biological: ChAdOx1 nCoV-19 two dose + paracetamol|Biological: MenACWY prime & saline placebo boost + paracetamol","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04536051","Recruiting","2020-06-02","2021-09-01","{""locations"":""Instituto D'Or de Pesquisa e Ensino - I'Dor, Salvador, Bahia, Brazil|Centro de Pesquisas Clinicas de Natal (CPCLIN), Natal, Rio Grande Do Norte, Brazil|Hospital das Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Universidade Federal de Santa Maria (UFSM), Santa Maria, Rio Grande Do Sul, Brazil|Instituto D'Or de Pesquisa e Ensino - I'Dor, Rio de Janeiro, Brazil|CRIE, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""10300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against COVID-19 disease confirmed with PCR|Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination|Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of serious adverse events|Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of episodes; intensified disease|Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: hospitalization for COVID-19 disease confirmed by PCR|Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: COVID-19 serious disease confirmed by PCR|Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: death associated with COVID-19 disease|Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates)|Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: antibodies against the SARS-CoV-2 spike protein (serum conversion rates)|Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: virus neutralizing antibodies (NAb) against live and\/or pseudotyped SARS-CoV-2 virus|Assess the cellular immunogenicity of ChAdOx1 nCoV-19 candidate vaccine""}"
"4276","Viral Infections in Healthy and Immunocompromised Hosts","","NCT01306084","110109|11-I-0109","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT01306084","Recruiting","2011-03-15","1970-01-01","{""locations"":""National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Sample collection, analysis of immune function, or review of tissue bx or clinical rpts from outside labs in designated pop. w\/ viral, suspected, or recovered from a viral infection or a close contact of people w\/or suspected to have a viral inf...""}"
"4277","Intensive Care Anxiety in SARS-CoV-2 Patients","","NCT04715477","derince TRH 2","Behavioral: Hospital Anxiety Depression Measure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04715477","Recruiting","2021-01-17","2021-04-15","{""locations"":""\u0130lke K\u00fcpeli, \u0130\u0307zmi\u0307t, Kocaeli\u0307, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""intensive care Anxiety""}"
"4278","Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection","","NCT04340557","COVID-ARB|2003902","Drug: Losartan","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04340557","Recruiting","2020-03-27","2020-12-31","{""locations"":""Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mechanical ventilation|ICU transfer|Oxygen therapy""}"
"4279","Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.","","NCT04322279","C20-16|2020-A00609-30","Diagnostic Test: Serology|Genetic: Sequencing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04322279","Recruiting","2020-03-09","2021-06-01","{""locations"":""Service de maladies infectieuses et tropicales H\u00f4pital Jean Minjoz CHRU Besan\u00e7on, Besan\u00e7on, France|Service des Maladies infectieuses et tropicales, P\u00f4le Sp\u00e9cialit\u00e9s m\u00e9dicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses H\u00f4pital Gabriel Montpied CHU de Clermont Ferrand, Clermont Ferrand, France|Centre d'investigation clinique 1432 H\u00f4pital Fran\u00e7ois Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre d'investigation clinique Infectiologie H\u00f4tel-Dieu CHU Nantes, Nantes, France|Centre d'Investigation Clinique H\u00f4pital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, H\u00f4pital Bichat Claude Bernard, Paris, France|H\u00f4pital Cochin CIC 1417 B\u00e2timent Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes H\u00f4pital Pontchaillou, Rennes, France|Centre Hospitalier F\u00e9lix Guyon Ile de la R\u00e9union CHU nord, Saint Denis, France|D\u00e9partement maladie infectieux CHU Saint Etienne, Saint Etienne, France|Centre d'Investigation Clinique Ile de la R\u00e9union CHU sud, Saint-Pierre, France|Centre Investigation Clinique 1415 CHRU Tours - H\u00f4pital Bretonneau, Tours, France|Centre Investigation Clinique 1433 CHRU de NANCY, Vand\u0153uvre-l\u00e8s-Nancy, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of subjects with SARS-CoV-2 positive serology at day 30 following the last high\/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Factors associated with a SARS-CoV-2 positive serology at day 30 (+\/-7);|Time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.""}"
"4280","SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)","","NCT04344184","HM20018977","Drug: L-ascorbic acid|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04344184","Recruiting","2020-12-18","2021-05-01","{""locations"":""Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in COVID disease status|Renal safety biomarkers - serum oxalate|Renal safety biomarkers - urine oxalate stones|Renal safety biomarkers - 24-hour urine oxalate levels|Acute Kidney Injury-free days|Number of deaths|Change in plasma ferritin levels|Change in plasma D-dimer levels|Change in serum lactate dehydrogenase (LDH) levels|Change in plasma IL-6 levels|Proportion of patients alive and free of respiratory failure|Proportion of patients alive and free of invasive mechanical ventilation""}"
"4281","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection","","NCT04261907","ASC09F-CTP-ZY-01","Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04261907","Not yet recruiting","2020-02-07","2020-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""160"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal""}"
"4282","Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population","","NCT04561102","COVD-B07-002","Diagnostic Test: Diagnostic test for detection of SARS-CoV-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04561102","Enrolling by invitation","2020-09-11","2021-04-30","{""locations"":""Rollins College Alfonds Sports Center, Winter Park, Florida, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positive percent agreement (PPA) and negative percent agreement (NPA) between the COVIDSeq Test and a comparator EUA test for the detection of SARS-CoV-2 RNA""}"
"4283","Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel","","NCT04561089","COVD-B07-001","Diagnostic Test: COVIDSeq Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04561089","Enrolling by invitation","2020-02-13","2021-04-30","{""locations"":""Illumina Laboratory Services, Foster City, California, United States|Illumina Hayward, Hayward, California, United States|Illumina Laboratory Services, San Diego, California, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positive percent agreement (PPA) and negative percent agreement (NPA) between the COVIDSeq Test and a comparator EUA test for the detection of SARS-CoV-2 RNA""}"
"4284","Using PRP and Cord Blood in Treatment of Covid -19","","NCT04393415","covid -19","Combination Product: stem cells","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04393415","Recruiting","2020-05-25","2020-09-01","{""locations"":""Aljazeera( Al Gazeera) hospital, Giza, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""100"",""age"":""20 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the number of patients with positive covid 19 who will improve after receiving stem cells""}"
"4285","Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome","Resistir","NCT04403061","EC128/20","Diagnostic Test: Cytokines measurement|Diagnostic Test: Cellular response|Diagnostic Test: TLRs activation measurement|Diagnostic Test: KIR phenotype evaluation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04403061","Completed","2020-05-22","2021-01-10","{""locations"":""Hospital Ramon y Cajal, Madrid, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""106"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in cytokines associated with SARS CoV-2 infection|Evaluation of cellular response|TLRs activation|KIR phenotype determination""}"
"4286","The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection","","NCT04433754","UsakU-Cevdet2","Other: biochemical analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04433754","Completed","2020-03-01","2020-06-12","{""locations"":""Usak University Training and Research Hospital, Usak, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""to compare presence of fever in patients with and without pancreatic injury|to compare presence of dyspnea in patients with and without pancreatic injury|To compare cRP levels in patients with and without pancreatic injury|To compare d-dimer levels in patients with and without pancreatic injury""}"
"4287","Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome","ACROCOVID","NCT04590209","APHP200884|N° IDRCB 2020-A0181336","Other: Blood sampling|Other: Skin biopsy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04590209","Not yet recruiting","2020-10-01","2020-12-01","{""locations"":""Department of Dermatology, Tarnier hospital, AP-HP, Paris, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Detection of SARS-CoV-2 by real-time PCR and serological test|Detection of SARS-CoV-2 by metagenomics analysis|Detection of acrosyndrome by transcriptomic analysis of skin samples""}"
"4288","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia","","NCT04264533","2020001","Drug: VC|Drug: Sterile Water for Injection","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04264533","Terminated","2020-02-14","2020-03-29","{""locations"":""Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores""}"
"4289","COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents","","NCT04542395","COVID19testingvacc","Behavioral: Increasing Willingness and Uptake of COVID-19 Testing and Vaccination","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04542395","Not yet recruiting","2021-06-01","2022-11-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""310"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of COVID-19 testing, pneumococcal and influenza vaccinations Using Test History Self-Report|Percentage of Participants Achieving Decreased Levels of COVID-19 Risk Using the NIH Toolbox Surveys on COVID-19|Percentage of Participants Achieving Decreased Levels of COVID-19 Mistrust and Barriers Using the NIH Toolbox Surveys on COVID-19""}"
"4290","Assessment of Lung Recruitablity of Acute Respiratory Distress Syndrome With SARS-CoV-2 Pneumonia by Electrical Impedance Tomography","","NCT04473300","ASPEIT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04473300","Recruiting","2020-05-11","2020-08-31","{""locations"":""Osaka University Hospital, Suita, Osaka, Japan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The distribution of ventilation|Silent spaces|Respiratory system compliance|Oxygenation|Dead space ventilation ratio""}"
"4291","The PREPARE for COVID Trial","","NCT04392115","","Behavioral: The PREPARE program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04392115","Not yet recruiting","2020-06-15","2021-09-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research"",""enrollment"":""372"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Patient-reported disability 90 days after enrollment|Mental Health|Function|Health-related quality of life|Frailty|All-cause mortality.|Health System - Emergency Department Visits|Health System - Re-admission|Health System - Transfer to Long-Term Care|COVID-19 test results|Safety [Adverse Events]""}"
"4292","Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID","","NCT04639349","P.T.REC/012/002897","Behavioral: exercise group|Other: control group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04639349","Recruiting","2020-11-19","2021-03-01","{""locations"":""Faculty of Physical Therapy Cairo University, Giza, Dokki, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""50 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""cortisol|hospital anxiety and depression scale|pulmonary function test|Interleukin-8|body mass index|six minute walking test|St. George's respiratory questionnaire""}"
"4293","CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19)","","NCT04659252","CCR5361","Other: n/a - samples collected along routine care samples only","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04659252","Recruiting","2021-03-04","2021-12-01","{""locations"":""The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""70"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Validated FLC""}"
"4294","Sero-epidemiological Survey of England in 2019/2020","STORY","NCT04061382","ID 263097","Procedure: Venepuncture|Procedure: Oral fluid swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04061382","Recruiting","2019-10-15","2021-06-30","{""locations"":""Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""2800"",""age"":""up to 24 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Feasibility of developing an England based sero-epidemiological programme in 0-24 year olds|Feasibility of developing an England based sero epidemiological survey in 0-24 year olds|Recruitment rate|Cost|To assess, in relevant age groups and different ethnicities antibody concentrations against infections and vaccine preventable diseases|Sera collection|Exploratory""}"
"4295","HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection","HOME-CoV","NCT04338841","2020-A00831-38","Other: HOME-CoV rule implementation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04338841","Completed","2020-04-09","2020-06-17","{""locations"":""Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Li\u00e8ge, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|H\u00f4pital Bichat, Paris, France|H\u00f4pital Lariboisi\u00e8re, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""3133"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the composite rate of adverse outcomes|The rate of hospitalization""}"
"4296","MR-Evaluation of Renal Function In Septic Patients","MERSEP","NCT02765191","MERSEP-523-2014-2569","Other: Plasma expansion with Ringer's Acetate","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT02765191","Recruiting","2016-04-01","2025-10-01","{""locations"":""Uppsala University Hospital, Uppsala, Sweden"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in renal blood flow and renal oxygenation after standardized plasma expansion with fluid bolus|Descriptive renal oxygenation and blood flow in critical illness due to sepsis|Descriptive renal oxygenation and blood flow in critical illness in no\/low grade AKI or high grade AKI.""}"
"4297","A Study of Ad26.COV2.S in Adults (COVID-19)","","NCT04436276","CR108828|2020-001483-28|VAC31518COV1001","Biological: Ad26.COV2.S|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04436276","Active, not recruiting","2020-07-15","2024-02-02","{""locations"":""Optimal Research, San Diego, California, United States|Optimal Research, Melbourne, Florida, United States|Optimal Research, Peoria, Illinois, United States|Optimal Research, Rockville, Maryland, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States|Optimal Research, Austin, Texas, United States|SGS Life Science Services, Antwerpen, Belgium|Center for Vaccinology (CEVAC), Gent, Belgium|UZ Leuven, Leuven, Belgium|Clinical Pharmacology Unit, Merksem, Belgium|Universiteit Antwerpen, Wilrijk, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other"",""enrollment"":""1085"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination|Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination|Cohort 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 1 Year after the Second Vaccination|Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination|Cohorts 1, 2, and 3: Number of Participants With SARS-CoV-2 Neutralizing Antibody Titers as Assessed by Virus Neutralization Assay (VNA)|Cohorts 1, 2, and 3: Number of Participants with SARS-CoV-2 Binding Antibodies Assessed by ELISA|Cohorts 1, 2, and 3: Number of Participants with T-helper (Th)-1 and Th-2 Immune Responses as Assessed by Flow Cytometry""}"
"4298","The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients","VITDALIZE","NCT03188796","VITDALIZE 1.0","Drug: Cholecalciferol|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT03188796","Recruiting","2017-10-10","2023-02-01","{""locations"":""LKH Hochsteiermark Standort Bruck, Bruck An Der Mur, Austria|LKH Enzenbach, Enzenbach, Austria|LKH Feldbach, Feldbach, Austria|LKH F\u00fcrstenfeld, F\u00fcrstenfeld, Austria|Medical University of Graz, Graz, Austria|Medical University Innsbruck, Innsbruck, Austria|Klinikum am W\u00f6rthersee, Klagenfurt, Austria|LKH Hochsteiermark Standort Leoben, Leoben, Austria|Barmherzige Br\u00fcder Konventhospital Linz, Linz, Austria|Barmherzige Schwestern, Linz, Austria|Kepler Universit\u00e4tsklinikum Linz, Linz, Austria|Krankenhaus Schwarzach, Schwarzach Im Pongau, Austria|Barmherzige Br\u00fcder, Vienna, Austria|Medical University of Vienna, Vienna, Austria|LKH Villach, Villach, Austria|Kaiser Franz Josef Spital Wien, Wien, Austria|Erasme Hospital, Brussel, Belgium|CHU de Charleroi, Charleroi, Belgium|CHR Citadelle, Li\u00e8ge, Belgium|CHU Ambroise Pare, Mons, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""2400"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""28-day mortality|Hospital Length of stay|Hypercalcemia at day 5|Hospital readmissions""}"
"4299","Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.","Resi-CoV","NCT04349163","2020-A00831-39","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04349163","Completed","2020-05-10","2020-06-25","{""locations"":""CHU, Angers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""280"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.""}"
"4300","To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects","","NCT04525079","CT-P59 1.1|2020-003065-19","Drug: CT-P59|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04525079","Recruiting","2020-07-18","2020-11-30","{""locations"":""Chungnam National University Hospital, Daejeon, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening"",""enrollment"":""32"",""age"":""19 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Primary safety outcome|To evaluate the safety of CT-P59|To evaluate the Pharmacokinetic(PK) of CT-P59""}"
"4301","A Clinical Trial of COVAC Vaccines in Healthy Adults","","NCT04702178","COVAC-001","Biological: COVAC-2|Biological: Saline Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04702178","Recruiting","2021-01-01","2023-02-01","{""locations"":""Canadian Center for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""108"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of adverse events (AEs) from the first injection to Day 28, in all participants, in all groups|Occurrence of AEs from the second injection to Day 56 (28 days post injection), in all participants, in all groups|Specific antibody response induced by the vaccine against the SARS-CoV-2 S protein as measured by ELISA|Specific cell-mediated immunity (CMI) response induced by the vaccine against the SARS-CoV-2 virus""}"
"4302","Study of the Consequences of Infection on Compliance of Modalities of Decisions of Limitations and Stops of Treatments (COVID-19-LAT)","COVID-19-LAT","NCT04452487","2020_GUASTELLA_COVID-19-LAT","Behavioral: decisions of limitations and stop processing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04452487","Recruiting","2020-06-01","2021-06-01","{""locations"":""CHU de Clermont-Ferrand, Clermont-Ferrand, France|Hospices Civiles de Lyon, Lyon, France|CH de Vichy, Vichy, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""decisions of limitations and therapeutic stops|Characteristics of the notification of LAT procedure|Characteristics of the LAT procedure (persons who participated to the collegial discussion)|Characteristics of consultant's reasoned opinion for the LAT procedure|Characteristics of the LAT procedure|Characteristics of units|Age of physicians|gendrer of physicians|Exparience of physicians|Characteristics of physicians|Age of patients|patient's history|COVID-19 patient's status|Characteristics of hospitalization's patients|Characteristics of affected organ|Characteristics of patients|final patient status|patient's environnement""}"
"4303","Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2","CloroCOVID19","NCT04323527","CAAE: 30152620.1.0000.0005","Drug: Chloroquine diphosphate","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04323527","Completed","2020-03-23","2020-06-07","{""locations"":""Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""278"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate reduction of 50% by day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable)""}"
"4304","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia","","NCT04275388","QF-XYP2001-1","Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04275388","Not yet recruiting","2020-05-15","2021-12-14","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""426"",""age"":""up to 100 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia""}"
"4305","A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults","","NCT04380701","BNT162-01|2020-001038-36|U1111-1249-4220","Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04380701","Recruiting","2020-04-23","2023-04-01","{""locations"":""Contract Research Organization, Berlin, Germany|Universit\u00e4ts Klinikum, Frankfurt am Main, Germany|Universit\u00e4ts Klinikum, Heidelberg, Germany|Contract Research Organization, Kiel, Germany|Contract Research Organization, Mannheim, Germany"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""456"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Solicited local reactions at the injection site (pain, tenderness, erythema\/redness, induration\/swelling) recorded up to 7 days after each immunization.|Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7 days after each immunization.|The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):|For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P\/B):|For BNT162c2 (SD):""}"
"4306","Less Frequency Hemodialysis and COVID-19","","NCT04374058","coronavirus","Other: less-frequency hemodialysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04374058","Active, not recruiting","2020-03-20","2021-03-01","{""locations"":""Dialisis Madariaga, General Juan Madariaga, Buenos Aires, Argentina"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Anemia, Nutrition, Adequation of dialysis, total ultrafiltration, ultrafiltration rate,|Hospitalization|Vascular Access""}"
"4307","Convalescent Plasma to Stem Coronavirus (CSSC-001)","CSSC-001","NCT04323800","IRB00245634","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04323800","Recruiting","2020-06-10","2023-01-01","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for American Indian Health - Chinle Office, Chinle, Arizona, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Network, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Netowrk, Norwalk Hospital, Norwalk, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Miami, Coral Gables, Florida, United States|Lee Memorial Health System, Fort Myers, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan\/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of treatment at Day 28|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2|Cumulative incidence of disease severity""}"
"4308","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","","NCT04245631","DTXY022","Diagnostic Test: Recombinase aided amplification (RAA) assay","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04245631","Recruiting","2020-01-01","2020-12-31","{""locations"":""Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""1 Year to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%""}"
"4309","Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU","PR-Covid-19","NCT04385004","7815","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04385004","Recruiting","2020-04-27","2020-07-01","{""locations"":""Service Reanimation Medicale, Strasbourg, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Other"",""enrollment"":""320"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Analysis of Clinical, Biological and Histological Pulmonary and Renal Impairment Related to SARS-CoV-2""}"
"4310","Covid Radiographic Images Data-set for A.I","CORDA","NCT04419545","CORDA","Diagnostic Test: Neural network diagnosis algorithm","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04419545","Recruiting","2020-03-24","2021-03-31","{""locations"":""Azienda Ospedaliero Universitaria Citt\u00e0 della Salute e della Scienza, Torino, Turin, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""2500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""sensibility and specificity of neural network diagnosis""}"
"4311","Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products","","NCT00571389","BioCytics 0001|WIRB Protocol # 20070969","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT00571389","Recruiting","2007-11-01","2025-02-01","{""locations"":""Carolina BioOncology Institute, Huntersville, North Carolina, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""""}"
"4312","COVID - 19 and Advanced Gastro-intestinal Cancer Treatment","COVID - AGICT","NCT04686747","MH - COVID - AGICT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04686747","Enrolling by invitation","2021-01-01","2021-06-30","{""locations"":""Department of General and Emergency Surgery. Misericordia Hospital. Director: Coratti Andrea, MD, Grosseto, Tuscany, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2000"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of advanced Esophageal, Gastric, Pancreatic and Colorectal cancer in 2020 compared to 2019.|Rate of neo-adjuvant therapy in 2020 compared to 2019|Rate of palliative procedure in 2020 compared to 2019|Rate of preoperative chemo or radiotherapy in 2020 compared to 2019 for metastatic disease.|Rate of patient unable to performer adjuvant treatment in 2020 compared to 2019""}"
"4313","Sequelae of Sars-CoV-2 Infections","","NCT04442789","SECOV","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04442789","Recruiting","2020-05-20","2023-12-31","{""locations"":""Department of Internal Medicine II, Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig-University, Giessen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sequelae after COVID-19""}"
"4314","COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020","","NCT04723290","SERO-SARS-CoV-2 GHdC","Diagnostic Test: Serological tests for SARS Cov-2","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04723290","Completed","2020-06-20","2020-12-31","{""locations"":""Grand H\u00f4pital de Charleroi, Charleroi, Hainaut, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serological tests to know the level of antibodies against SARS CoV-2""}"
"4315","Body Weight Regulation, Disordered Eating Behaviour, and Experiences of Sexual Harassment in Female Martial Art Athletes","FMAB","NCT04559542","20/00378","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04559542","Recruiting","2020-09-10","2021-12-31","{""locations"":""Norwegian school of sport sciences, Oslo, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""16 Years to 40 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Low energy availability for females questionnaire (LEAF-Q)|Eating disorder examination questionnaire (EDE-q)|Body Weight regulation strategies, selfreported|Body appreciation scale (BAS-2)|Exercise frequency, selfreported according to a designed questionnaire|Exercise duration, selfreported according to a designed questionnaire|Exercise motivation, selfreported according to a designed questionnaire|Exercise program variation, selfreported according to a designed questionnaire|Physical activity level, objectively measured|Four day weighed diet registration; energyintake|Four day weighed diet registration; nutrient intake|Experiences of sexual harassment|Effects from Covid-19 pandemic on exercise- and eating routines, designed questionnaire""}"
"4316","Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19)","CAVIARDS","NCT03963622","1765","Other: Respiratory Mechanics|Other: Standard Ventilation Strategy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT03963622","Recruiting","2020-11-23","2022-11-01","{""locations"":""St. Michael's Hospital, Toronto, Ontario, Canada|CH Victor Dupouy, Argenteuil, France|CH de Beauvais, Beauvais, France|CHU Bordeaux - Haut Leveque, Bordeaux, France|Hopital de la Cavale Blanche - CHRU Brest, Brest, France|CH de Cholet, Cholet, France|Hopital Intercommunal de Creteil, Creteil, France|CHU Grenoble-Alpes, Grenoble, France|Hopital Roger Salengro - CHU Lille, Lille, France|Hopital de l'Archet 1 - CHU de Nice, Nice, France|Hopital Europeen Georges-Pompidou, Paris, France|CHU de Poitiers - La Miletrie, Poitiers, France|CH Bretagne Atlantique Vannes-Auray, Vannes, France|HIA Robert Picque, Villenave-d'Ornon, France|Vall d'Hebron University Hospital, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""740"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause 60-day mortality|Duration of ventilation|Duration of ICU and hospital stay|Number of patients with organ dysfunction|Number of patients with barotrauma|Mortality at ICU discharge, 28 days, and hospital discharge""}"
"4317","Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in Tübingen Children","Coro-Buddy","NCT04581889","Coro-Buddy","Other: Diagnostic test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04581889","Recruiting","2020-07-02","2021-12-01","{""locations"":""Institute of Tropical Medicine, T\u00fcbingen, Deutschland, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2380"",""age"":""1 Year to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Incidence of SARS-CoV-2 infection in infants, children and adolescents|Incidence of SARS-CoV-2""}"
"4318","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","COVID-19","NCT04322682","MHIPS-2020-001|3R01HL146206-02S1","Drug: Colchicine|Drug: Placebo oral tablet","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04322682","Completed","2020-03-23","2021-01-21","{""locations"":""Mayo Clinic - Arizona, Phoenix, Arizona, United States|Yuma Regional Medical Center Cancer Center, Yuma, Arizona, United States|University of Arkansas for medical Sciences, Little Rock, Arkansas, United States|Centric Health Resources Inc., Bakersfield, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Rancho Research Institute, Downey, California, United States|University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|South Florida Research Organization, Medley, Florida, United States|Miami Center for Advanced Cardiology, Miami Beach, Florida, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|New York University School of Medecine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Prisma Health, Greenville, South Carolina, United States|Baylor Scott & White Research Institute - Pharmacy, Dallas, Texas, United States|University of Texas(UT) Southwestern Medical Center, Dallas, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Heart Institute (inCor), Scholl of Medecine, University of Sao Paulo, S\u00e3o Paulo, Sao Paulo, Brazil|Montreal Heart Institute, Montreal, Quebec, Canada|Tread Research, Tygerberg Hospital, Cape Town, South Africa|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""4506"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation""}"
"4319","The COVID-19 ICU PRAYER Study","","NCT04361838","Covid Prayer Study","Behavioral: prayer","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04361838","Recruiting","2020-05-21","2021-08-31","{""locations"":""Research Medical Center, Kansas City, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care"",""enrollment"":""1000"",""age"":""18 Years to 110 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of multi-denominational prayer on clinical outcomes of critically ill COVID-19 patients in the Intensive Care Unit on mortality.|Difference in patient outcomes - Acute Physiology and Chronic Health Enquiry. APACHE II score.|Difference in patient outcomes - Sequential Organ Failure Assessment - SOFA Score|Difference in patient outcomes - Length of stay in ICU.|Difference in patient outcomes - Length of ventilator support|Difference in patient outcomes - length of vasopressor support""}"
"4320","2019-nCoV Outbreak and Cardiovascular Diseases","","NCT04255940","2019nCoV-CVD","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04255940","Recruiting","2020-01-20","2020-04-30","{""locations"":""Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""12000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety""}"
"4321","Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease","COVIDEP","NCT04479540","2020_0058","Radiation: Angiography scanner","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04479540","Recruiting","2020-05-26","2021-08-31","{""locations"":""H\u00f4pital Foch, Suresnes, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of patients with pulmonary embolism|Prothrombin level measurement|activated partial thromboplastin time measurement|Fibrinogen measurement|D-dimers measurement|Protein C measurement|Willebrand antigen measurement|Soluble tissue factor measurement|Soluble thrombomodulin measurement|E-selectin measurement|Thrombin-antithrombin complex measurement|Assessment of clot formation curve|Assessment of thrombin generation|Assessment of fibrinolysis|Mortality""}"
"4322","Skeletal Muscle Wasting in SARS-CoV-2","SMW","NCT04698798","SMW-CoV-2","Procedure: Muscle Biopsy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04698798","Recruiting","2021-01-02","2021-05-01","{""locations"":""Jessa Ziekenhuis, Hasselt, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""16"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Skeletal muscle biopsy|Electrophysiological test|Blood sample analyses|Mechanical ventilation and oxygen therapy|Dietary intake|concommitted medication|APACHE II score|Comorbidities|Duration from hospital admission to ICU admission|Symptoms of disease onset and myalgia""}"
"4323","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","","NCT03331445","NTM-CTP-01: H17-02107","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT03331445","Recruiting","2017-10-24","2021-03-31","{""locations"":""Nitric Solutions-Mobile Unit, Vancouver, British Columbia, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects|Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects|Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum|Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score""}"
"4324","COV2Base-A Rare Disease by COVID Study","","NCT04564274","10000091|000091-H","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04564274","Recruiting","2021-03-16","2021-09-01","{""locations"":""National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""5000"",""age"":""1 Month and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""To quantify the frequency and severity of COVID infection in patients with rare and common diseases, looking for conditions that increase risk of severe outcomes.|To identify gene-, tissue- or sociodemographic level features that increase risk of severe COVID outcomes that may inform future genetic modifier studies.""}"
"4325","Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP)","ASAP","NCT04474444","ASAP01","Other: attendance by ambulance crew","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04474444","Recruiting","2019-03-23","2021-03-23","{""locations"":""University of Lincoln, Lincoln, United Kingdom"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""55000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Attendances for alcohol and drug use""}"
"4326","COVID-19 Sero-prevalence Health Care Workers Kinshasa","PRESTACOV","NCT04699058","B3002020000144","Diagnostic Test: COVID-antibody test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04699058","Active, not recruiting","2020-07-17","2021-04-30","{""locations"":""Institut Nationale de recherche Biom\u00e9dicale, Kinshasa, Congo, The Democratic Republic of the"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""1650"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""COVID antibody prevalence in Health care workers (serological test)|COVID antibody prevalence in Household members (serological test)|Seroconversion COVID Health care workers (serological test)|Seroconversion COVID household members (serological test)|work-related exposure evaluated through a questionnaire and summarized as a score|behavioural risk factors (questionnaire), summarized as a score""}"
"4327","Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling","","NCT04282135","IMS 1","Diagnostic Test: MCC IMS","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04282135","Completed","2020-02-15","2020-06-30","{""locations"":""Klinikum Bayreuth, Bayreuth, Germany"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""76"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cluster Analysis of MCC IMS spectra.""}"
"4328","Sexual Health and Problems During the Covid -19 Infection","","NCT04427813","marital health","Behavioral: questionaire to husband and wife","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04427813","Not yet recruiting","2020-06-11","2020-07-12","{""locations"":""Algazeerah, Giza, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""the number of partners that have unusual behaviour""}"
"4329","Emotional Freedom Technique (EFT) Effect on Nurses","","NCT04393077","2020\0192","Behavioral: Emotional Freedom Technique","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04393077","Completed","2020-05-10","2020-05-20","{""locations"":""Medeniyet University, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""80"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The subjective units of distress scale|The State Anxiety|Burnout""}"
"4330","LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION","INC-CVD-202001","NCT04409275","INC-CVD-2020-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04409275","Recruiting","2020-05-21","2021-07-31","{""locations"":""Pulmonary Department. Hospital Clinico., Valencia, Spain"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pulmonary fibrotic changes, short and medium term|Degree of lung function impairment|Biological markers""}"
"4331","A New Screening Strategy for 2019 Novel Coronavirus Infection","","NCT04281693","307-nCoV","Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04281693","Not yet recruiting","2020-02-01","2020-03-01","{""locations"":""the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""230"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Screening accuracy|Cost-effectiveness analysis""}"
"4332","Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)","APICS","NCT03738774","IRB181120","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT03738774","Recruiting","2019-01-02","2022-07-01","{""locations"":""Johns Hopkins Hospital, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Vanderbilt University, Nashville, Tennessee, United States|Intermountain Medical Center, Murray, Utah, United States|George Wahlen Salt Lake City Veterans Administration Hospital, Salt Lake City, Utah, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of deaths or hospital readmissions within three months of discharge|Number of ER visits|Healthcare utilization|Cognitive Functional outcome as assessed by Montreal Cognitive Assessment (MoCA) - Blind Instrument|Physical function outcome as assessed by Activity of Daily Living (ADL-Katz Index)|Physical function outcome as assessed by Instrumental Activity of Daily Living (IADL-Lawton)|Mental health Functional outcome as assessed by Hospital Anxiety and Depression Scale (HADS)|Functional outcomes-Post Traumatic Stress Disorder (PTSD)|Coping or social support|Health related quality of life|Number of deaths within 6 Months after discharge|Return to work""}"
"4333","Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.","COVID-19","NCT04388631","2020-S073","Other: Coronavirus Disease 2019","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388631","Recruiting","2020-05-10","2021-05-01","{""locations"":""Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Sperm density|Sperm activity|Erection hardness and duration|IIEF-5\/QEQ questionnaire score|Detection rate of SARS-CoV-2 in male genitourinary system|Semen volume|Sperm survival rate|Serum testosterone\/luteinizing hormone (LH)\/follicle stimulating hormone (FSH) level|SCL-90 questionnaire score""}"
"4334","COVID-19 - SARS-CoV-2 Community Contamination in Children and Adults (Dyn3CEA_Nosocor)","","NCT04664296","69HCL20_1100","Other: Review of medical patient file|Other: Phone call interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04664296","Recruiting","2020-12-21","2021-03-21","{""locations"":""Service de Reanimation Pediatrique, Lyon, Rhone, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""75"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percentage of possible contaminants, adults, adolescents and children with Covid-19""}"
"4335","Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR","","NCT04604145","FWH20200198H","Diagnostic Test: SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04604145","Recruiting","2021-02-03","2021-06-01","{""locations"":""David Grant U.S. Airforce Medical Center, Travis Air Force Base, California, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""65"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percent positive agreement between self-collected saliva samples and healthcare-worker collected nasopharyngeal samples|Percent negative agreement between self-collected saliva samples and healthcare-worker collected nasopharyngeal samples|Percent overall agreement between self-collected saliva samples and healthcare-worker collected nasopharyngeal samples""}"
"4336","Behavior During and After COVID-19 Crisis","","NCT04502108","BFH Corona","Behavioral: Covid19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04502108","Recruiting","2020-04-01","2022-12-31","{""locations"":""Bern University of Applied Sciences, Department of Health Professions, Bern, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical activity 2020|Physical activity 2021|Nutrition 2020|Nutrition 2021|Alcohol 2020|Alcohol 2021|Sleep 2020|Sleep 2021""}"
"4337","Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19","","NCT04486521","RAC # 2201053","Drug: Interleukin 6 (IL6) Antagonist|Drug: Interleukin 6 (IL6) Antagonist and corticosteroids|Drug: corticosteroid alone","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04486521","Recruiting","2020-07-22","2021-07-22","{""locations"":""King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""860"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Ventilator-Free Days|Median duration of ventilation|Median change in the PaO2\/FiO2|Vasopressor-Free days|Duration of ICU Stay|Duration of Hospital Stay|Mortality Rate|Percentage of participants with adverse events [transaminitis, hyperglycemia]|Concentration of Ferritin, IL6, D dimer, fibrinogen, C-reactive protein (CRP), Lactate dehydrogenase (LDH) and absolute lymphocyte count and their correlation with the effectiveness of the treatment|Rate of superinfection (bacterial, viral, invasive fungal infections)|Time to the first COVID 19 test negative""}"
"4338","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia","","NCT04260308","IRBID:TJ-C 20200107","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04260308","Recruiting","2020-02-03","2020-04-20","{""locations"":""Tongji Hospital\uff0cTongji Medical College Affiliated\uff0cHuazhong University of Science \uff06 Technology, Wuhan, Hubei, China"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""30000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)""}"
"4339","Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy","","NCT04540939","HUM00152509-COVID Substudy|1R61AT009867","Behavioral: Mindfulness-Based Cognitive Therapy|Behavioral: Muscle Relaxation Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04540939","Recruiting","2020-10-19","2021-12-01","{""locations"":""University of Michigan, Ann Arbor, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 72 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient-Reported Outcomes Measurement Information System (PROMIS-adult short form level 2) Anxiety survey|Penn State Worry Questionnaire (PSWQ-16) Worry survey|PROMIS (adult short form) Emotional Depression survey|Working Alliance Inventory- short revised (WAI-SR)|Patient-Reported Outcomes Measurement Information System (PROMIS-adult short form level 2) Anxiety survey group differences (MBCT and PMR)|Penn State Worry Questionnaire (PSWQ-16) Worry survey group differences (MBCT and PMR)|PROMIS (adult short form) Emotional Depression survey group differences (MBCT and PMR)|Working Alliance Inventory- short revised (WAI-SR) group differences (MBCT and PMR)""}"
"4340","Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","","NCT04385836","4-0520- 076-K-02-H","Drug: alpha one antitrypsin inhalation","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04385836","Recruiting","2020-06-01","2020-09-01","{""locations"":""Ministry of Health, Mecca, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""clinical improvement""}"
"4341","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","","NCT04275245","20200101","Drug: Meplazumab for Injection","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04275245","Recruiting","2020-02-03","2020-12-31","{""locations"":""Tangdu Hospital, Xi'an, Shaanxi, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT \/ chest film changes|PaO2 \/ FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status""}"
"4342","Convalescent Plasma to Limit Coronavirus Associated Complications","","NCT04325672","20-002864","Biological: Convalescent Plasma","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04325672","Withdrawn","2020-04-01","2022-12-31","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""0"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support""}"
"4343","First Responder Resiliency Program During COVID-19","","NCT04536376","20-005017","Behavioral: Resilience Program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04536376","Recruiting","2021-01-15","2021-12-31","{""locations"":""Mayo Clinic, Rochester, Minnesota, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""changes in biometric trends""}"
"4344","A Study of Ad26.COV2.S in Adults (COVID-19)","","NCT04509947","CR108871|VAC31518COV1002","Biological: Ad26.COV2.S|Biological: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04509947","Active, not recruiting","2020-08-11","2021-12-08","{""locations"":""Souseikai Hakata Clinic, Fukuoka, Japan|SOUSEIKAI PS Clinic, Fukuoka, Japan|Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""250"",""age"":""20 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants with Solicited Local Adverse Events (AEs) for 7 days after First Vaccination|Number of Participants with Solicited Local AEs for 7 days after Second Vaccination|Number of Participants with Solicited Systemic AEs for 7 days after First Vaccination|Number of Participants with Solicited Systemic AEs for 7 days after Second Vaccination|Number of Participants with Unsolicited AEs for 28 days after First Vaccination|Number of Participants with Unsolicited AEs for 28 days after Second Vaccination|Number of Participants with Serious Adverse Events (SAEs)|Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Neutralization as measured by Virus Neutralization Assay (VNA)|SARS-CoV-2-Binding Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)""}"
"4345","COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","","NCT04392219","EIDD-2801-1001|2020-001407-17","Drug: EIDD-2801|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04392219","Completed","2020-04-10","2020-08-11","{""locations"":""Covance Leeds Clinical Research Unit, Leeds, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""130"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Safety and Tolerability of Single Ascending Dose (SAD) of EIDD-2801 (Part 1): Adverse Events|Safety and Tolerability of Multiple Ascending Dose (MAD) of EIDD-2801 (Part 3): Adverse Events|Pharmacokinetics (PK) of EIDD-2801 when given as Single Doses (Part 2): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Single Ascending Dose (SAD) (Part 1): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Multiple Ascending Dose (MAD) (Part 3): Maximum observed concentration Cmax|Safety and Tolerability of Single Doses of EIDD-2801 (Part 2): Adverse Events""}"
"4346","Personal Protective Equipment for the Prevention of SARS-Cov-2 During Neonatal Resuscitation","","NCT04666233","SARS-CoV-2-NEO-Res-01","Procedure: Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|Procedure: Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04666233","Not yet recruiting","2021-03-01","2021-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Initiation of positive pressure ventilation|Duration of intubation procedure|Correct use of personal protective equipment|Participant's opinion on discomfort using personal protective equipment|Time of initiation of chest compressions""}"
"4347","Variation in Acute Appendicitis During COVID-19 Pandemic in Italy","","NCT04649996","Appendicitis-pandemic","Procedure: Appendectomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04649996","Completed","2020-09-01","2020-11-30","{""locations"":""Policlinico San Pietro, Ponte San Pietro, BG, Italy|Ospedale Manzoni, Lecco, LC, Italy|ASST Monza, Monza, MB, Italy|Ospedale San Raffaele, Milano, Mi, Italy|ASST Lodi, Lodi, Italy|Azienda ospedaliero-universitaria Pisana,Ospedale Cisanello, Pisa, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""532"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""complicated appendicitis""}"
"4348","Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","WU352","NCT04341727","202003188","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04341727","Suspended","2020-04-04","2021-08-01","{""locations"":""Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hours to recovery|Time fever resolution""}"
"4349","Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress","CoronaStress","NCT04394403","coronastress","Behavioral: Internet-based guided self-help based on CBT principles","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04394403","Recruiting","2020-05-14","2022-06-30","{""locations"":""Hebrew University of Jerusalem, Jerusalem, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The CoRonavIruS Health Impact Survey (CRISIS)|Depression, Anxiety, and Stress Scale- 21 item version: DASS-21""}"
"4350","Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19","","NCT04363047","282566","Other: 40ml blood sample","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363047","Enrolling by invitation","2020-10-01","2021-05-01","{""locations"":""Universit of Manchester, Manchester, Greater Manchester, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""125"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence and abundance of CD4+ T lymphocytes""}"
"4351","An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso","CHLORAZ","NCT04445441","IRSS-URCN-CM 001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04445441","Completed","2020-04-24","2020-11-30","{""locations"":""Sourou Sanon University Hospital, Bobo-Dioulasso, Burkina Faso|Tingadogo University Hospital, Ouagadougou, Burkina Faso"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""153"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clearance of viral load|Safety of the treatment""}"
"4352","Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.","","NCT04406545","#CAAE 31237220.1.0000.5272","Other: evaluation of skin microvascular flow and reactivity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406545","Recruiting","2020-05-15","2021-12-01","{""locations"":""National Institute of Cardiology, Rio de Janeiro, Brazil"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate, through laser doppler, the presence of changes in systemic microvascular endothelial function in patients in the acute phase of COVID-19.""}"
"4353","Psychological Impact of Institutional Quarantine as a Precautionary Measure Against COVID-19","","NCT04552392","COVID","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04552392","Not yet recruiting","2020-09-20","2020-10-20","{""locations"":""ITBP Chawala, Delhi, India"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""depression|anxiety|perceived stress|impact of life events""}"
"4354","Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic","","NCT04382560","ESPCOV1","Other: Deep Breathing training|Other: Compassion focused intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04382560","Completed","2020-05-02","2020-05-31","{""locations"":""Sapienza University of Rome, Rome, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""69"",""age"":""20 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Dispositional questionnaire 1|Dispositional questionnaire 2|Dispositional questionnaire 3|Dispositional questionnaire 4|Heart rate|Cardiac vagal modulation""}"
"4355","QoL and the Emotional-affective Sphere o in Rehabilitation Setting During COVID-19 Quarantine","","NCT04408196","FDG_socialdistancing_COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04408196","Completed","2020-05-26","2021-02-22","{""locations"":""Don Gnocchi Foundation, Rome, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""121"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Short Form-36 Health Survey (SF36)|Short Form (36) Health Survey (SF36)|Beck Anxiety Inventory (BAI)|Beck Depression Inventory-II (BDI-II)|modified Barthel Index (mBI)""}"
"4356","Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19","","NCT04634903","1505797-3","Behavioral: Supportive Therapy SSI|Behavioral: Behavioral Activation SSI|Behavioral: Growth Mindset SSI","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04634903","Active, not recruiting","2020-11-19","2021-07-31","{""locations"":""Stony Brook University, Stony Brook, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""2409"",""age"":""13 Years to 16 Years \u00a0 (Child)"",""outcome_measures"":""Change in adolescent depressive symptom severity|Change in Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF)|Change in Behavioral Activation for Depression Scale - Short Form|Change in State Hope Scale|Change in Beck Hopelessness Scale - 4 Item Version|Change in Implicit Personality Theory Questionnaire|Program Feedback Scale""}"
"4357","Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access","TMD","NCT04420273","STU00212165","Behavioral: SSE educational intervention|Other: Home sample collection of concerning mole with physician supervision|Behavioral: Active control:Healthy Living","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04420273","Completed","2020-07-02","2021-03-01","{""locations"":""Northwestern University Feinberg School of Medicine Department of Dermatology, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SSE performance|Identification of concerning mole|Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma|Change in skin self-examination anxiety|Change in confidence performing mole checks|Number of physician visits for concerning moles|Number of biopsies of concerning moles""}"
"4358","Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention","","NCT04388644","TCHIRB-10904015-E","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04388644","Recruiting","2020-02-20","2020-05-30","{""locations"":""Branch of Chinese Medicine, Taipei City Hospital, Taipei, Taiwan|Branch of Linsen Chinese Medicine and Kunming, Taipei City Hospital, Taipei, Taiwan|Taipei City Hospital, Taipei, Taiwan"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""20 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""the number confirmed COVID-19 cases|The person with COVID-19 like symptoms|The improving rate of COVID-19 like symptoms|The satisfaction% to taking JGF""}"
"4359","To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19","","NCT04524052","DWJ1516101_India","Drug: DWRX2003|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04524052","Not yet recruiting","2020-08-01","2020-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events|pharmacokinetic changes of niclosamide from baseline in each dose group: Cmax|pharmacokinetic changes of niclosamide from baseline in each dose group: Tmax|pharmcodynamic analysis of niclosamide from baseline in each dose group and time point: CRP""}"
"4360","Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey","","NCT04357886","60350273-605.99-","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357886","Not yet recruiting","2020-05-01","2020-06-01","{""locations"":""Istanbul University-Cerrahpasa, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""15 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""COVID-19 Awareness Survey""}"
"4361","Physiotherapist-led Exercise Within Cardiac Rehabilitation and Paroxysmal Atrial Fibrillation and COVID-19.","","NCT04600713","273293","Other: PT-X and IMT","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04600713","Not yet recruiting","2021-01-01","2025-10-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""40 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health-related quality of life|N-terminal pro-B type natriuretic peptide (NT-proBNP)|Antibodies for SARS-CoV-2|Inspiratory and expiratory muscle strength|Exercise capacity|Muscle function|Physical activity|Self reported physical activity|Self-reported anxiently and depression|Handheld ECG heart rhythm|Direct hospital costs related to AF""}"
"4362","Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia","RELEASE","NCT04578210","RELEASE","Biological: T memory cells and NK cells","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04578210","Recruiting","2020-09-04","2021-03-01","{""locations"":""Hospital Universitario La Paz, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""58"",""age"":""up to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Occurrence of DLTs in all patients during the study treatment, until 21 days after cell infusion and the MTD""}"
"4363","CoCo-20: a Longitudinal Follow-up Study of the French Paediatric Population During and After the Coronavirus Pandemic COVID-19","CoCo-20","NCT04498416","20-HPNCL-05","Diagnostic Test: Quantitative and qualitative assessments of mental health","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04498416","Recruiting","2020-04-27","2021-07-01","{""locations"":""H\u00f4pitaux P\u00e9diatriques de Nice CHU-Lenval, Nice, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""70"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""diagnosis of possible psychological and psychiatric difficulties at baseline|follow up of psychological and psychiatric difficulties at V2|follow up of psychological and psychiatric difficulties at V3|follow up of psychological and psychiatric difficulties at V4|impact of traumatic history prior to confinement|impact of other previous psychiatric disorders|parental reaction""}"
"4364","Implementation of the Integrated Care of Older People App and ICOPE Monitor in Primary Care (ICOPE)","ICOPE","NCT04413877","GerULiege/SG/DSR/ICOPE","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04413877","Not yet recruiting","2020-10-01","2021-11-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Incidence of frailty""}"
"4365","A 3-month Cycle of Virtual Guided Tours to Promote Health in Older Community Members in a Context of COVID-19 Induced Social Isolation: a Pilot Study","VGV","NCT04593433","2021-2604","Other: Museum virtual guided tours","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04593433","Not yet recruiting","2021-03-04","2021-09-04","{""locations"":""Jewish General Hospital, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Well-being|Quality of life|frailty|social isolation|socio-geriatric vulnerability|Incident planned and unplanned visits to physicians, Emergency Department (ED) and hospitalization|compliance""}"
"4366","Obesity Surgery During 2020 Italian Pandemic","","NCT04480034","008758/27.05.2020","Procedure: Bariatric procedures","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04480034","Recruiting","2020-07-15","2021-05-30","{""locations"":""University La Sapienza of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Latina, LT, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1600"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Postoperative COVID-19 infection|Complications related to bariatric surgery""}"
"4367","Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome","ARDS-MSC-205","NCT04447833","2020-02238","Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04447833","Active, not recruiting","2020-06-17","2025-06-30","{""locations"":""Uppsala University Hospital, Uppsala, Sweden"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""7"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of pre-specified treatment related adverse events of interest (TRAEIs).|Safety; All-cause mortality|Changes in Leucocytes|Changes in Trombocytes|Changes in plasma concentration of C-reactive protein (CRP)|Changes in plasma concentration of Prothrombin complex (PK)|Changes in plasma concentration of Creatinine|Changes in plasma concentration of Aspartate amino transferase (ASAT)|Changes in plasma concentration of Alanine amino transferase (ALAT)|Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)|Changes in Blood pressure|Changes in Body temperature|Efficacy; Changes in pulmonary compliance|Efficacy; Changes in driving pressure (Plateau pressure- PEEP)|Efficacy; Changes in oxygenation (PaO2\/FiO2)|Efficacy; Duration of ventilator support|Efficacy; Pulmonary bilateral infiltrates|Efficacy; Sequential Organ Failure Assessment (SOFA) score|Efficacy; Hospital stay|Lung function|Lung fibrosis|Six minutes walk test|Changes in Quality of life|Blood biomarkers|Sensitisation test""}"
"4368","A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device","","NCT04357977","KBS005","Diagnostic Test: RBA-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04357977","Not yet recruiting","2020-04-01","2020-12-01","{""locations"":""Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|AdventHealth Tampa, Tampa, Florida, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Covid +""}"
"4369","Evaluation of the Physical Activity Level of the Elderly in Social Isolation","","NCT04480606","008","Behavioral: Home exercise program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04480606","Not yet recruiting","2020-08-01","2020-11-20","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""88"",""age"":""65 Years to 80 Years \u00a0 (Older Adult)"",""outcome_measures"":""Physical Activity Scale for the Elderly|Nottingham Health Profile|Short Physical Performance Battery|Beck anxiety inventory|Beck depression inventory|Contentment With Life Scale""}"
"4370","Vitamin D3 Supplementation to Prevent Respiratory Tract Infections","","NCT04596657","20-455","Dietary Supplement: Vitamin D supplementation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04596657","Recruiting","2020-10-27","2021-11-01","{""locations"":""Cooper University Hospital, Camden, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2099"",""age"":""52 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Respiratory tract infection""}"
"4371","Effect on paO2 of Adding an Aerosol Mask Above the Nasal Canulas","","NCT04715854","lmcondorcet","Device: Mask","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04715854","Active, not recruiting","2021-02-19","2021-07-01","{""locations"":""Epicura, Hornu, Hainaut, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in PaO2 and PaCO2|Respiratory frequency""}"
"4372","RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study","RASCALS","NCT04233268","277039","Diagnostic Test: Rapid Pathogen Detection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04233268","Recruiting","2020-04-06","2025-02-28","{""locations"":""Addenbrooke's Hospital, Cambridge, Cambs, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""up to 16 Years \u00a0 (Child)"",""outcome_measures"":""Performance of the novel pathogen detection assay|Time to results|Negative cultures|Antibiotic therapy|Prevalence of COVID19 in children admitted to PICU""}"
"4373","Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects","","NCT04160975","IRB19-1424","Behavioral: Video about safety and effectiveness of adult seasonal flu vaccination|Behavioral: Message directing subjects to information on COVID-19 vaccine safety and efficacy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04160975","Completed","2019-12-20","2021-02-19","{""locations"":""Harvard University, Cambridge, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research"",""enrollment"":""2902"",""age"":""18 Years to 51 Years \u00a0 (Adult)"",""outcome_measures"":""Posterior beliefs about the risk\/benefits of the flu shot|Demand for information about a COVID-19 vaccine|Willingness-to-pay (WTP) for a free flu shot coupon|Level of attention and recall from the infomercial video during Baseline survey|Level of attention and recall from the infomercial video during Endline survey|Redemption of said coupon""}"
"4374","How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample)","","NCT04602286","2019000347-S4P","Other: Meditation (1 x 20-minute guided audio training)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04602286","Recruiting","2020-10-28","2021-03-01","{""locations"":""Health and Behavioural Sciences, Brisbane, Queensland, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""292"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Pain intensity|Pain Unpleasantness|Pain Catastrophizing""}"
"4375","A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)","","NCT03648372","TAK-981-1002|U1111-1214-4537|2020-003947-27","Drug: TAK-981|Drug: Standard of care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT03648372","Recruiting","2018-10-01","2023-10-01","{""locations"":""University of California San Diego Moores Cancer Center, La Jolla, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""242"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase 1: Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)|Phase 1: Number of Participants Based on Severity of TEAEs|Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)|Phase 1: Number of Participants With Clinically Significant Laboratory Values|Phase 2: Overall Response Rate (ORR)|COVID-19 Expansion: Number of Participants With Greater Than or Equal to (>=) 2 log Reduction From Baseline in Viral Load or Below Level of Detection (Negative) in Nasopharyngeal or Oropharyngeal Samples|Phase 2: Number of Participants Reporting one or More TEAEs|Phase 2: Number of Participants Based on Severity of TEAEs|Phase 2, Cmax: Maximum Observed Plasma Concentration for TAK-981|Phase 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981|Phase 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-981|Phase 2, AUC\u221e: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-981|Phase 2, Terminal Disposition Phase Half-life (t1\/2z) for TAK-981|Phase 2, Total Clearance (CL) After Intravenous Administration for TAK-981|Phase 2, Volume of Distribution at Steady State After Intravenous Administration (Vss) for TAK-981|Phase 2: ORR|Phase 2: Duration of Response (DOR)|Phase 2: Disease Control Rate (DCR)|Phase 2: Time to Response (TTR)|Phase 2: Time to Progression (TTP)|Phase 2: Progression-free Survival (PFS)|Phase 2: Overall Survival (OS)|Phase 2: Number of Participants With TAK-981-Small Ubiquitin-like Modifier (TAK-981-SUMO) Adduct Formation and SUMO Pathway Inhibition in Skin\/Blood|COVID-19 Expansion: Number of Participants Reporting one or More TEAEs|COVID-19 Expansion: Number of Participants Based on Severity of TEAEs|COVID-19 Expansion: Duration of TEAEs|COVID-19 Expansion: Change from Baseline in National Early Warning Score (NEWS)|COVID-19 Expansion: Percentage of Participants Reporting Each Hospitalization Severity Rating|COVID-19 Expansion: Change From Baseline in SARS-CoV-2 Viral Load in Nasopharyngeal or Oropharyngeal Samples|COVID-19 Expansion: Percentage of Participants Requiring Oxygen Supplementation; Assisted or Positive Pressure Non-invasive Ventilation; and Invasive Ventilation, on Days 3, 5, 8, 11, 15, and 30|COVID-19 Expansion: Percentage of Participants That met Intensive Care Unit (ICU) Criteria|COVID-19 Expansion: Duration of Hospitalization|COVID-19 Expansion: Time to Viral Ribonucleic Acid (RNA) Negativity in Nasopharyngeal or Oropharyngeal Samples|COVID-19 Expansion: Time to Discharge or to a NEWS of Less Than or Equal to (<=) 3 and Maintained for 24 Hours|COVID-19 Expansion: Number of Deaths in Hospital due to any Cause in First 30 Days and in 90 Days""}"
"4376","Expanded Access Remdesivir (RDV; GS-5734™)","","NCT04302766","S-20-01","Drug: Remdesivir","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","No Results Available","","https://ClinicalTrials.gov/show/NCT04302766","No longer available","1970-01-01","1970-01-01","{""locations"":"""",""study_designs"":"""",""enrollment"":"""",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""""}"
"4377","A Patient-Centered PaTH to Addressing Diabetes","","NCT02788903","PCORI|NEN-1509-32304","Other: Weight Counseling|Other: Telemedicine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT02788903","Active, not recruiting","2016-03-01","2021-05-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""2000000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Weight change|Diabetes Incidence|Hospitalization|Intubation|Death""}"
"4378","CoV-ICU Score, Intensive Care Unit, SARS-CoV-2","","NCT04383483","BYIEAH-202005","Other: COVICU","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383483","Recruiting","2020-06-15","2020-08-31","{""locations"":""Bursa Y\u00fcksek Ihtisas Training and Research Hospital, Bursa, Yildirim, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVICU score|Values""}"
"4379","Nurse Leadership for Hospital Infection Control","","NCT04603079","NurseLeadership","Behavioral: Intervention for COVID-19 preventive protocols","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04603079","Not yet recruiting","2021-04-01","2021-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Core competencies in nurses for infection control and prevention (Min and Sil 2014)""}"
"4380","Pre-exposure Prophylaxis for SARS-Coronavirus-2","","NCT04328467","STUDY00009414","Drug: Hydroxychloroquine|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04328467","Active, not recruiting","2020-04-06","2020-08-01","{""locations"":""Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects""}"
"4381","imPulse™ Una Full-spectrum, Over Clothing E-stethoscope","","NCT04556149","00110011","Device: imPulse™ Una e-stethoscope|Device: Philips Lumify Ultrasound System","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04556149","Completed","2020-10-01","2020-12-02","{""locations"":""Johns Hopkins School of Medicine, Baltimore, Maryland, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""34"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diagnostic performance characteristics""}"
"4382","Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease","RAID-CoV-2","NCT04476680","1062MODREC20","Dietary Supplement: Vitamin D 1000 IU|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04476680","Not yet recruiting","2020-09-01","2021-04-28","{""locations"":""Headingley and City campuses, Leeds Beckett University, Leeds, Yorkshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""4400"",""age"":""18 Years to 30 Years \u00a0 (Adult)"",""outcome_measures"":""Seroconversion|Interim analysis - seropositivity at 12 weeks|Dried Blood Spot performance|Salivary IgA performance|Prevalence of SARS-CoV-2|Change in seropositivity|Change in seroconversion rate""}"
"4383","French COVID Cohort","FrenchCOVID","NCT04262921","C20-05|2020-A00256-33","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04262921","Recruiting","2020-02-08","2023-08-07","{""locations"":""CHG Agen, Agen, France|Centre Hospitalier Du Pays D'aix, Aix-en-Provence, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Annecy Genevois, Annecy, France|Hopital priv\u00e9 d'Antony, Antony, France|H\u00f4pital de Mercy. CHR METZ-THIONVILLE, Ars-Laquenexy, France|Centre Hospitalier Henri Duffaut, Avignon, France|Chu Jean Minjoz, Besan\u00e7on, France|H\u00f4pital Avicenne AP-HP, Bobigny, France|CHU Pellegrin, Bordeaux, France|CHU Ambroise Par\u00e9, Boulogne-Billancourt, France|Ch Fleyriat, Bourg-en-Bresse, France|Chru Hopital Cavale Blanche, Brest, France|CHU Brest, Brest, France|Centre hospitalier de B\u00e9ziers, B\u00e9ziers, France|CH Cahors, Cahors, France|Chms Chambery Nh, Chamb\u00e9ry, France|Centre Hospitalier De Cholet, Cholet, France|CHU Gabriel Montpied, Clermont-Ferrand, France|CH Colmar - Hopital Pasteur, Colmar, France|Centre hospitalier Alpes Leman, Contamine-sur-Arve, France|Centre hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France|H\u00f4pital Henri Mondor, Cr\u00e9teil, France|Centre Hospitalier Dax, Dax, France|CHU Dijon Bourgogne, Dijon, France|Hopital Raymond Poincare, Garches, France|CHU Grenoble, Grenoble, France|Grand Hopital de l'Est Francilien site Marne-la-Vall\u00e9e, Jossigny, France|Chd Les Oudairies, La Roche-sur-Yon, France|H\u00f4pital Universitaire Bic\u00eatre, Le Kremlin-Bic\u00eatre, France|Centre Hospitalier Emile Roux, Le Puy-en-Velay, France|Centre Hospitalier Universitaire de Lille, Lille, France|CHRU Lille, H\u00f4pital Salengro, Lille, France|CHU de Lille, Lille, France|H\u00f4pital de la Croix-Rousse, Lyon, France|H\u00f4pital Louis Raffalli, Manosque, France|Assistance publique hopitaux de Marseille, hopital Nord, Marseille, France|H\u00f4pital Conception, Marseille, France|Groupe Hospitalier Sud Ile De France, Melun, France|CH de Mont Marsan, Mont de Marsan, France|CHU Montpellier, Montpellier, France|CHU Nantes, Nantes, France|Hopital Am\u00e9ricain de Paris, Neuilly-sur-Seine, France|CHU de Nice, Nice, France|CHU Caremeau, N\u00eemes, France|APHP Bichat, Paris, France|APHP Tenon, Paris, France|CH Lariboisi\u00e8re, Paris, France|Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France|Hopital Cochin-CIC1417, Paris, France|Hopital Europ\u00e9en Georges Pompidou, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Saint Louis, Paris, France|La piti\u00e9 salpetri\u00e8re, Paris, France|Centre Hospitalier de Pau, Pau, France|CH de Perpignan, Perpignan, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier de P\u00e9rigueux, P\u00e9rigueux, France|Ch Cornouaille, Quimper, France|Chu Reims, Reims, France|H\u00f4pital Pontchaillou, Rennes, France|CHU Rouen Normandie, Rouen, France|Hopital d'instruction des arm\u00e9es Begin 69, Saint-Mand\u00e9, France|Centre hospitalier Louis Constant Fleming, Saint-Martin, France|CHU de Saint-Etienne, Saint-\u00c9tienne, France|CH de Saintonge, Saintes, France|Centre Hospitalier de Soissons, Soissons, France|N.H.C. - Nouvel Hopital Civil, Strasbourg, France|Hopital Foch, Suresnes, France|CHR Metz-Thionville -Hopital Bel Air, Thionville, France|Hopitaux du Leman, Thonon-les-Bains, France|Centre Hospitalier Universitaire de Rangueil, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU Toulouse IUCT Institut Universitaire de Cancer de Toulouse, Toulouse, France|H\u00f4pital Gustave Dron, Tourcoing, France|Centre Hospitalier R\u00e9gional Universitaire de Tours, Tours, France|CHRU de Tours, Tours, France|CHU Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France|Centre Hospitalier Intercommunal, Villeneuve Saint Georges, France|CH Annecy Genevois, \u00c9pagny, France"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants""}"
"4384","Corona Virus Infection Among Liver Transplant Recipients","","NCT04565782","17300475","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04565782","Recruiting","2020-09-15","2020-12-31","{""locations"":""Assiut University, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""The occurrence of corona virus infection (confirmed or suspected) among liver transplant recipients|The presence of Neutralizing Ab against SARS-Corona virus 2 among liver transplant recipients whether who give symptoms for corona virus or asymptomatic and who accept to give blood sample""}"
"4385","Brain Imaging in Babies Study","BIBS","NCT04443179","IRAS: 108997, REC 12/LO/2017","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443179","Recruiting","2013-04-05","2023-12-01","{""locations"":""King's College London, London, United Kingdom"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""790"",""age"":""16 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Neurodevelopmental Outcomes""}"
"4386","Needle Stick Injuries in Emergency Medical Service Practice","","NCT04363788","OH_PPE_1","Procedure: double gloves","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04363788","Completed","2020-02-28","2020-04-24","{""locations"":""Lazarski Univeristy, Warsaw, Poland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of visible puncture|WLT""}"
"4387","Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System","PostCOVID19","NCT04353245","UAP107","Other: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04353245","Not yet recruiting","2020-06-01","2021-09-30","{""locations"":""Instituto do Cora\u00e7\u00e3o - Hospital das Cl\u00ednicas - Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""130"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fibrosis|Ergospirometers""}"
"4388","OUR Stress/ Emotion Management for Black/African American Women With Hypertension","OUR-Project","NCT04526145","2020B0182","Behavioral: Stress and emotion management","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04526145","Not yet recruiting","2021-01-31","2022-01-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""30"",""age"":""45 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine the feasibility of a synchronous web-based health education program, of OUR project.|Determine the acceptability of a synchronous web-based health education program, of OUR project.|Change from baseline at 3 months weight.|Change from baseline at 3 months waist circumference.|Change from baseline at 3 months blood pressure.|Change from baseline stress at 3 months.|Change from baseline emotional regulation at 3 months.|Change from baseline dietary approaches to stop hypertension knowledge at 3 months.|Change from baseline resilience at 3 months.|Describe participant experience and health during the COVID-19 pandemic.""}"
"4389","International Lung UltraSound Analysis (ILUSA) Study","ILUSA","NCT04353141","COVID-19: ILUSA (S63988)","Diagnostic Test: standardized Lung Ultrasound (LUS) examination","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04353141","Recruiting","2020-04-28","2020-12-31","{""locations"":""University Hospitals Leuven, Leuven, Belgium|University of Brescia, Brescia, Italy|University of Foggia, Foggia, Italy|University of Milan, Milan, Italy|University of Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Queen Charlotte's & Chelsea Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1850"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Diagnostic performance of LUS to predict poor outcome""}"
"4390","Effect of Positive Attitudes on Behavior and Wellness","TEAM-ICU","NCT04441632","STUDY00000786","Behavioral: Positive feedback","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04441632","Completed","2020-06-15","2020-07-30","{""locations"":""Cedars-Sinai Medical Center, Los Angeles, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Teamwork climate, as measured by selected items from the validated Safety Attitude Questionnaire (SAQ)|Resiliency, as measured by the validated Brief Resilience Scale (BRS)|Burnout, as validated by the single-item burnout scale inventory""}"
"4391","The Impact of a Societal Lockdown on Those With Spinal Cord and Brain Injuries","","NCT04426071","115999","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04426071","Recruiting","2020-06-01","2021-12-01","{""locations"":""Lawson Health Research Institute, London, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""142"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Fear of COVID-19|Change in ability to participate in social roles and activities|Change in depressive symptoms|Change in positive affect and well-being|Change in anxiety|Change in fatigue|Change in emotional and behavioural dyscontrol|Change in satisfaction with social roles and activities|Change in sleep disturbance|Change in stigma|Change in cognitive function|Change in social distancing strategies used|Change in thoughts and feelings about social distancing""}"
"4392","Clinical Outcomes of Patients With COVID19","","NCT04280913","GZHZ-COVID19","Other: retrospective analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04280913","Withdrawn","2020-02-22","2020-03-31","{""locations"":""HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""0"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation""}"
"4393","Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19)","","NCT04502433","CLI-050000-04|2020-002632-75","Drug: CUROSURF® (poractant alfa)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04502433","Recruiting","2021-01-06","2021-07-31","{""locations"":""UCLH and UCL 250 Euston Road, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""85"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""number of ventilator-free days|Number of free days from invasive ventilation|Number of free days from non-invasive ventilation (NIV)|Change from baseline in PaO2\/FiO2 ratio measured at 6 hours and 12 hours following administration of each dose in the treated group and at the similar timepoints in the control group|Change from baseline in PaO2\/FiO2 ratio at additional timepoints|Length of ICU stay (days)|Mortality at Day 28|Change from baseline in ventilatory parameter (Tidal volume (TV))|Delta Sequential Organ Failure Assessment (SOFA) Score|Incidence of all the AEs, AEs related to poractant alfa (treated cohort) (ADRs), serious AEs (SAEs) and AEs leading to death|Change from baseline in blood gas analysis acid-base balance parameter (pH)|Percentage of patients with PaO2\/ FiO2 improvement of >20% following administration of each dose in the treated group and at similar timepoints in the control group|Number of Extracorporeal Membrane Oxygenation (ECMO)-free days- (only for cohort 2 of patients in ECMO)|Change from baseline in FiO2|Change from baseline in ventilatory parameter (respiratory rate (RR))|Change from baseline in ventilatory parameter (dynamic compliance (Cdyn))|Change from baseline in ventilatory parameter (static compliance (Cstat))|Change from baseline in ventilatory parameter (positive end-expiratory pressure (PEEP)|Change from baseline in ventilatory parameter (peak inspiratory pressure (PIP))|Change from baseline in ventilatory parameter (plateau pressure (Pplat))|Change from baseline in blood gas analysis acid-base balance parameter (pCO2)|Change from baseline in blood gas analysis acid-base balance parameter (pO2)|Change from baseline in blood gas analysis acid-base balance parameter (HCO3)|Change from baseline in blood gas analysis acid-base balance parameter (lactate)""}"
"4394","Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures","","NCT04370678","ArthrocancellationSUH2020","Behavioral: Change in preference to surgery under COVID-19 pandemic.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04370678","Completed","2020-04-17","2020-04-24","{""locations"":""Zealand University Hospital, K\u00f8ge, Zealand Region, Denmark"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""79"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in preference|Change in preference between groups""}"
"4395","Telerehabilitation in Oncology Patients","","NCT04547634","Teleclub_cam","Other: Therapeutic Exercise and Education","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04547634","Enrolling by invitation","2020-07-01","2020-12-01","{""locations"":""Antonio Cuesta Vargas, M\u00e1laga, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Suitability of exercise intensity|Verification of exercise intensity|Total attendance|Absence type|Attendance type|Change from Cancer-Related Fatigue (CRF)|Change from Functional capacity|Change from Upper limb functionality (%)|Change from Lower limb functionality (%)|Change from Quality of life (self-reported questionnaire)|Change from specific Breast Cancer Quality of life (self-reported questionnaire)""}"
"4396","Post-Pandemic Perception of Public Space in Singapore","","NCT04394039","NUS-IRB_S-20-12","Other: Public space exposure","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04394039","Not yet recruiting","2020-06-01","2020-12-31","{""locations"":""Institute for Health Innovation & Technology (iHealthtech), Singapore, Singapore"",""study_designs"":""Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""34"",""age"":""21 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""EEG power in alpha band|EEG power in beta band|fNIRS haemodynamics|Profile of mood states|landscape preference measured with self-assessment manikin scale""}"
"4397","Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living'","","NCT04495543","BSL-01","Behavioral: Brief Skills for Safer Living","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04495543","Recruiting","2020-12-01","2021-08-01","{""locations"":""St. Michael's Hospital, Toronto, Ontario, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in suicidal ideation using Beck Scale for Suicide Ideation|Change in depression symptoms using the Quick Inventory of Depressive Symptoms self-report scale (QIDS-SR)|Change in anxiety symptoms using the Generalized Anxiety Disorder 7-item scale (GAD-7)|Change in Acquired Capability of Suicide Scale (ACSS)|Change in Interpersonal Needs Questionnaire score|Change in Dimensional Anhedonia Rating Scale (DARS) score|Change in Sheehan Disability Scale (SDS) score|Change in Treatment Utilization""}"
"4398","Psychological Impact of the Health Measures Generated by the COVID19 in Adolescents","COVADO","NCT04406558","COVADO","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04406558","Recruiting","2020-05-27","2021-04-01","{""locations"":""Camille JUNG, Creteil, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""11 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Anxiety score from the Generalized Anxiety Disorder 7 (GAD-7) questionnaire|Depression score from the Adolescent Depression Rating Scale (ADRS) questionnaire|Post traumatic score questionnaire: Children's Revised Impact of Events Scales -CRIES13|Presence or absence of difficulty in falling asleep, sleeping|Presence or absence of feeding difficulty|Presence or absence of difficulty performing physical activity|Presence or absence of toxic consomption (drug, acohol) during the lockdown|Mean duration time in front of screen (hours per day)|Presence or absence of difficulties with social interactions|Presence or absence of difficulties with familial interactions""}"
"4399","Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis","TB TRIAGE+","NCT04666311","P1685-20A","Diagnostic Test: Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB|Diagnostic Test: CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666311","Not yet recruiting","2020-12-01","2022-05-01","{""locations"":""Butha-Buthe District Hospital, Butha-Buthe, Lesotho|Caluza Clinic, Pietermaritzburg, KwaZulu-Natal, South Africa"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine CAD4TB cut-off value|Determine Afinion CRP assay cut-off value|Evaluate CAD4TB ROC against reference standard|Evaluate Afinion CRP assay ROC against reference standard|Evaluate CAD4COVID and COVID-19 RDT ROC against reference standard""}"
"4400","Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults","","NCT04480112","H-26786","Behavioral: Technology based social interactions|Other: No research related technology based social interactions","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04480112","Enrolling by invitation","2020-06-02","2021-05-01","{""locations"":""Boston University Alzheimer Disease Center, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""150"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in memory performance|Change in cognition|Change in phonemic fluency|Social isolation|Loneliness|Depressive symptoms|Misinformation about Covid-19""}"
"4401","The Professional Peer Resilience Initiative","PPRI","NCT04396600","PSYCH-2020-28762","Behavioral: MinnRAP Peer Support Program","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04396600","Enrolling by invitation","2020-06-08","2022-05-25","{""locations"":""University of Minnesota, Minneapolis, Minnesota, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in professional quality of life|Change in mental health symptoms and resilience markers""}"
"4402","The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19","","NCT04453527","PHT/2020/37","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04453527","Recruiting","2020-05-28","2021-09-01","{""locations"":""Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Complement Activation|Leukotrienes Measure|Coagulation Measure|Hyperinflammation Measure|Cell Count|Cytokines and Chemokine Measure|Endothelial dysfunction measures:""}"
"4403","Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness","BREATH","NCT04368676","115855","Other: Sudarshan Kriya Yoga (SKY)|Other: Health Enhancement Program","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04368676","Recruiting","2020-06-25","2021-06-30","{""locations"":""London Health Sciences Centre, London, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of participant recruitment|Rate of retention|Completeness of data entry|Cost of interventions|Unexpected costs|Change in Athens Insomnia Scale|Change in Generalized Anxiety Disorder 7-item scale|Change in Patient Health Questionnaire 9|Change in Connor-Davidson Resilience Scale""}"
"4404","The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm","","NCT04483271","2020-PHA-18","Dietary Supplement: 300 mg of omega3-FA","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04483271","Enrolling by invitation","2020-10-02","2021-02-10","{""locations"":""Mahmoud S Abu-Samak, Amman, Jordan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""30 Years to 66 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""IL-1 beta|IL-6|TNF alpha|Lipid profile|Fasting blood glucose""}"
"4405","European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol","EPPICC","NCT04677842","EPPICC","Drug: ART Therapy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04677842","Active, not recruiting","2013-01-01","2025-01-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""10000"",""age"":""up to 17 Years \u00a0 (Child)"",""outcome_measures"":""CD4 count in adulthood of young people with HIV assessed using routine clinical data|2. Viral suppression in adulthood of young people with HIV assessed using routine clinical data|Viral suppression defined as <50 copies, <400 copies and 1000 copies\/mL) upto 144 weeks.|CD4 change from drug start up to 144 weeks|Cumulative incidence of virological failure (>1000 copies\/mL)|From start of novel drug of interest through to earliest date of the following: death, loss to follow-up, discontinuation of drug or last visit""}"
"4406","CoV-PICS: A Virtual Post-ICU Clinic","","NCT04490278","202007053","Other: Medical Record Review - Inpatient Treatment|Other: Online Questionnaires","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04490278","Recruiting","2020-09-29","2021-07-30","{""locations"":""Washington University School of Medicine\/Barnes-Jewish Hospital, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""80"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Acceptance with virtual CoV-PICS Visits - AIM|Acceptance with virtual CoV-PICS Visits - IAM|Acceptance with virtual CoV-PICS Visits - FIM|PICS Symptoms - Daily living|PICS Systems - Cognitive|PICS Systems - Nutrition|PICS Systems - PROMIS|PICS Symptoms - Memory""}"
"4407","Brief Video Interventions for Depression","","NCT04643964","2020B0326","Behavioral: Entrée: Cognitive skills|Behavioral: Entrée: Behavioral skills|Behavioral: Entrée: Interpersonal skills|Behavioral: Sampler skills","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04643964","Recruiting","2020-11-01","2020-11-01","{""locations"":""Department of Psychology, Columbus, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""501"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR)|Change in the Ways of Responding Questionnaire (WOR)|Change in the Styles of Emotion Response Questionnaire (SERQ)|Change in the University of California, Los Angeles (UCLA) Loneliness Scale, Version 3""}"
"4408","Mindfulness Training for Seniors","","NCT04378803","20200443","Behavioral: Mindfulness training (MT) Connect","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04378803","Completed","2020-05-13","2020-08-04","{""locations"":""University of Miami, Coral Gables, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""53"",""age"":""60 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in mindfulness skills as measured by Five-Facet Mindfulness Questionnaire (5FMQ)|Change in mindfulness skills as measured by decentering - Experiences Questionnaire (EQ).|Change in psychological health as measured by Patient Health Questionnaire 4 items (PHQ4).|Change in positive affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).|Change in negative affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).|Change in loneliness measured by the loneliness questions from the social isolation battery.|Change in loneliness measured by a loneliness question.|Change in attention|Change in well-being as measured by the Perseverative Thought Questionnaire (PTQ)|Change in well-being as measured by the Experience of Intrusions Scale (EIS)|Change in well-being as measured by the short version of the perceived stress scale (PSS).|Change in well-being as measured by the PERMA-Profiler""}"
"4409","Sleep Quality Among HCWs","","NCT04549350","2020/1464","Other: PSQI","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04549350","Completed","2020-05-19","2020-09-05","{""locations"":""Zagazig University, Zagazig, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""217"",""age"":""25 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Presence of poor sleep quality or not|reported medical errors""}"
"4410","A Clinical Study of Online Active Play Program With Adolescents","","NCT04618341","RAP/003","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04618341","Completed","2020-03-30","2020-07-28","{""locations"":""Revival Active, Leicester, Leicestershire, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""32"",""age"":""11 Years to 17 Years \u00a0 (Child)"",""outcome_measures"":""Anxiety|Depression""}"
"4411","Needs of Persons With Spinal Cord Injury (SCI)","","NCT04422769","202005026","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04422769","Active, not recruiting","2020-05-22","2021-03-31","{""locations"":""Washington University School of Medicine, Saint Louis, Missouri, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""NIH Toolbox Instrumental Support Survey - change in instrumental support|UCLA (University of California - Los Angeles) 3-item Loneliness Scale - change in social isolation""}"
"4412","Digital vs Analog Impression in Cases of All-on-4 - Prosthesis","","NCT04475913","5","Other: DIG Axial|Other: DIG Tilted|Other: CIG Axial|Other: CIG Tilted","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04475913","Completed","2018-07-11","2020-08-20","{""locations"":""OctoberUMSA, Giza, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""50 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""implant loss|crestal bone loss""}"
"4413","Music Therapy in Frontline Healthcare Workers","","NCT04551274","H20-02015","Behavioral: Music Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04551274","Not yet recruiting","2020-10-01","2020-11-30","{""locations"":""Simon Fraser University, Burnaby, British Columbia, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""20"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Perceived Stress score - NIH Emotion Toolbox|Change in General Life Satisfaction score - NIH Emotion Toolbox|Change in Positive Affect score - NIH Emotion Toolbox|Change in Anger score - NIH Emotion Toolbox|Change in Fear score - NIH Emotion Toolbox|Change in Meaning & Purpose score - NIH Emotion Toolbox|Change in Sadness score - NIH Emotion Toolbox|Change in Emotional Support score - NIH Emotion Toolbox|Change in Loneliness score - NIH Emotion Toolbox|EEG - Change in power in the Delta band|EEG - Change in power in the Beta band|EEG - Change in power in the Alpha band|EEG - Change in power in the Theta band""}"
"4414","Telemedical Risk Assessment and Preoperative Evaluation (TAPE)","","NCT04518514","19-174","Device: TAPE-Software","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04518514","Recruiting","2020-04-20","2020-11-30","{""locations"":""RWTH Aachen University Hospital, Aachen, Germany"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Feasibility (as defined below) of telemedical risk assessment and preoperative evaluation in anesthesiology as assessed by a questionnaire.|Patient acceptance of a telemedical preanesthesia evaluation as assessed by a questionnaire.|Patient satisfaction with a telemedical preanesthesia evaluation as assessed by a questionnaire.|Time saving for the patient|Time saving for the physician|Adverse events""}"
"4415","Group CST Using Zoom: A Proof of Concept Study","","NCT04695743","17127/002","Other: Online Cognitive Stimulation Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04695743","Recruiting","2020-09-01","2022-09-01","{""locations"":""University College London, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""ADAS-Cog (adapted for virtual use) - change is being assessed|MOCA blind- change is being assessed|Geriatric Depression Scale- change is being assessed|QoL-AD- change is being assessed|Post intervention interviews""}"
"4416","Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study","Tele-RehaB","NCT04658979","21983","Other: Pulmonary tele-rehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04658979","Recruiting","2020-12-01","2022-01-01","{""locations"":""Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Qu\u00e9bec, Quebec, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""20 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasability - Patients\u00b4 satisfaction with the program between baseline and the up to 12 weeks follow-up|Feasability - Health care professionals' receptivity|Feasibility - Patients' satisfaction with the health care received|Quality of life by questionnaire|Dyspnea level|Exercise capacity|Functionnal capacity|Anxiety|Depression""}"
"4417","Comparative Effectiveness of Telemedicine in Primary Care","","NCT04684836","20-12023014","Other: Exposure to telemedicine, after the onset of the pandemic","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04684836","Not yet recruiting","2021-02-01","2023-12-01","{""locations"":""University of Florida, Gainesville, New York, United States|Mount Sinai, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""216000"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of avoidable emergency department (ED) admissions|Number of unplanned hospital admissions from the ED|Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index|Continuity of care as assessed by the Breslau Usual Provider of Care measure|Continuity of care as assessed by attendance at follow-up appointment|Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)|Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure|Days at home|Patient experiences based on the Patient Satisfaction Questionnaire (PSQ-18)|Ease of use and access to telemedicine based on Telehealth Usability Questionnaire (TUQ)""}"
"4418","Effects of a Face Mask on Oxygenation During Exercise","","NCT04557605","2201","Other: Progressive cycling exercise test to exhaustion","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04557605","Completed","2020-09-14","2020-10-15","{""locations"":""University of Saskatchewan, Saskatoon, Saskatchewan, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""14"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to exhaustion during exercise|Change from baseline in peak power output|Change from baseline in blood oxygen saturation|Change from baseline in quadriceps tissue oxygenation index|Change from baseline in rating of perceived exertion|Change from baseline in heart rate""}"
"4419","Effects of Wearing a Face Mask During CrossFit Exercise","","NCT04688502","2431","Other: High intensity interval training|Other: Continuous exercise training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04688502","Not yet recruiting","2021-01-11","2021-03-15","{""locations"":""University of Saskatchewan, Saskatoon, Saskatchewan, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline in box jumps|Change from baseline in pull-up, push-up, and squat repetitions|Change from baseline in rating of perceived exertion|Change from baseline in heart rate|Change from baseline in dyspnea""}"
"4420","Smartphone Application: A Possible Solution for Follow up of Patients With Hip Arthroplasty","","NCT04688840","TantaH","Procedure: hip arthropalsty","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04688840","Completed","2020-01-01","2020-12-01","{""locations"":""Ahmed Samy, Tanta, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""167"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Western Ontario McMaster Universities Osteoarthritis Index (WOMAC)|Short Form Health Survey Clinical care (SF12)|Self-Administered Patient Satisfaction Scale (SAPS)""}"
"4421","Video-Based Exercises and Well-Being During Social Isolation","","NCT04335851","Physical Activity Project","Other: Video based aerobic exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04335851","Completed","2020-04-06","2020-06-03","{""locations"":""Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""68"",""age"":""18 Years to 35 Years \u00a0 (Adult)"",""outcome_measures"":""World Health Organization Quality of Life Questionnaire Bref|Rapid Assessment of Physical Activity|Global Rating of Change Scale""}"
"4422","The Efficacy Comparing Daily and After-each-case Room Disinfection.","","NCT04399005","DACD-HuY-2005","Other: after-each-case room disinfection|Other: daily room disinfection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04399005","Completed","2020-05-25","2020-06-10","{""locations"":""First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""240"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Qualified rate of room disinfection|The number of colony-forming units (CFU)""}"
"4423","Effectiveness of Convalescent Immune Plasma Therapy","","NCT04442958","2020.05.2.14.070","Other: Convalescent Immune Plasma","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04442958","Completed","2020-05-15","2020-06-17","{""locations"":""Istanbul Bagc\u0131lar Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Plasma ferritin level|Lymphocyte count|D-Dimer level|C-Reactive protein level|Plasma procalcitonin level|Plasma fibrinogen level|Fractional Inspired Oxygen Level|Partial Oxygen Saturation level|Arterial Oxygen level""}"
"4424","Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019","RISC","NCT04383899","CHUBX 2020/13","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04383899","Withdrawn","2020-09-30","2020-11-30","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""0"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Describe medications used prior to admission associated with worse infection in COVID-19 patients in France.|Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France.|Describe other patient characteristics with worse infection in COVID-19 patients in France.|Quantify other patient characteristics with worse infection in COVID-19 patients in France.""}"
"4425","PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics","","NCT04609371","SMHC-20-10","Behavioral: self-care tools|Behavioral: lay telephone coaching","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04609371","Enrolling by invitation","2020-10-21","2021-05-01","{""locations"":""St Mary's Hospital Research Centre, Montr\u00e9al, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care"",""enrollment"":""176"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Consent rate|Data completion rate|Fidelity of intervention completion|Severity of depression symptoms|Severity of anxiety symptoms|Use of health care services|Use of the self-care materials""}"
"4426","Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial","PVC-RAM","NCT04344665","v5.0, 2020.09.12","Other: Virtual Care and Remote Automated Monitoring","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04344665","Active, not recruiting","2020-04-23","2021-01-01","{""locations"":""University of Alberta Hospital, Edmonton, Alberta, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Hamilton General Hospital, Hamilton, Canada|Juravinski Hospital, Hamilton, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Kingston Health Sciences Centre, Kingston, Canada|London Health Sciences Centre, London, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""905"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Days alive at home|Hospital re-admission|Emergency Department visit|Urgent Care centre visit|Brief acute hospital care|Medication error detection|Medication error correction|Death|Participant Pain|Acute hospital care|All-cause hospital days""}"
"4427","Tele-Yoga Therapy for Chronic Pain","","NCT04457388","AU/018","Other: Tele-Yoga Therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04457388","Completed","2020-03-25","2020-06-15","{""locations"":""Aarogyam UK, Leicester, Leicestershire, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""18"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Pain Intensity|Pain Disability|Anxiety|Depression""}"
"4428","A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults","MITIGATE","NCT04505098","1597940","Drug: Icosapent ethyl","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04505098","Recruiting","2020-08-07","2023-02-28","{""locations"":""Kaiser Permanente Northern California, Oakland, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""16500"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with moderate or severe confirmed viral URIs|Worst clinical status due to a confirmed viral URI""}"
"4429","The Impact of Lifestyle Changes on Non-COVID Deaths","","NCT04550312","XYFY2020-KL142-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04550312","Recruiting","2020-09-01","2020-10-01","{""locations"":""Xuzhou Medical University affiliated Hospital, Xuzhou, Jiangsu, China"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""80000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Numeric values of all-cause death and the death rates of non-COVID diseases""}"
"4430","Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program","iREACH","NCT04514900","Pro00101006","Behavioral: Video Chat +Personalized Feedback|Behavioral: Video Chat + Basic Feedback|Behavioral: Discussion Board for Social Support +Basic Feedback|Behavioral: Discussion Board for Social Support+Personalized Feedback","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04514900","Active, not recruiting","2020-09-23","2021-09-15","{""locations"":""University of South Carolina, Columbia, South Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Weight loss|Change in body weight from baseline calculated as % of body weight lost|Treatment Engagement: daily weighing|Treatment Engagement: weekly food journal submissions|Treatment Engagement: completion of the 16 weekly interactive online modules|Treatment Engagement: Attendance at Video Chat condition""}"
"4431","Telemedicine in HIV Care in Buenos Aires","","NCT04513496","TM HIV BA","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04513496","Not yet recruiting","2020-09-01","2022-07-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Telemedicine Reach. RE-AIM framework|Telemedicine Effectiveness. RE-AIM framework|Telemedicine Adoption. RE-AIM framework|Telemedicine Implementation.RE-AIM framework|Telemedicine Manteinance. RE-AIM framework""}"
"4432","Telerehabilitation for Patients Diagnosed With Coronavirus","COVID-19","NCT04346927","009","Other: Telerehabilitation|Other: exercise brochure","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346927","Not yet recruiting","2020-08-10","2020-11-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Visual Analogue Scale|Modified Borg Scale|Leicester Cough Questionnaire|Timed Up and Go|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory""}"
"4433","Chat-based Support for Preventing Smoking Relapse","","NCT04409496","UW 20-356","Behavioral: Chat-based instant messaging support|Behavioral: SMS message support|Behavioral: Self-help booklet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04409496","Completed","2020-06-02","2021-01-22","{""locations"":""Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""108"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Biochemically-validated tobacco abstinence|Self-reported 6-month prolonged tobacco abstinence|Self-reported 7-day point-prevalence tobacco abstinence|Self-reported relapse rate""}"
"4434","Feasibility and Quality of TeleConsultation in Pediatric Anesthesia","TéléCCCAP","NCT04583865","RC31/20/0220|2020-A02275-34","Other: teleconsultation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04583865","Active, not recruiting","2020-10-07","2022-03-14","{""locations"":""UHToulouse, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""1 Month to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""assess the feasibility of teleconsultation (TLC) in pediatric anesthesia in France in the context of the COVID 19 pandemic.""}"
"4435","Telemedicine for Follow-up of Systemic Lupus Erythematosus","","NCT04368299","TeleSLE","Other: Telemedicine|Other: Standard care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04368299","Recruiting","2020-05-01","2021-12-31","{""locations"":""The Chinese University of Hong Kong, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The percentage of patients in remission or LLDAS at one year.|Direct and indirect costs after one year.|The change of Lupus Quality of Life (LupusQoL) at one year.|Patient confidence and satisfaction score at one year.|Rates of adverse reaction and severe adverse reaction, including contracting COVID-19 infection, after one year.|Numbers of clinic visits, hospitalization, overall in-person hospital visits in one year.|The change of (Health Assessment Questionnaire Disability Index HAQ-DI) at one year.|The change of (Hospital Anxiety and Depression Scale) HADS at one year.""}"
"4436","Specimen Collection Study Protocol","","NCT04468386","CV19-Col-004","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468386","Active, not recruiting","2020-07-07","2021-03-30","{""locations"":""Biomerica, Inc., Irvine, California, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Matrix Equivalency""}"
"4437","Digital Cardiac Counseling Trial: DCC Trial","DCC","NCT04393636","NL72754.068.20","Other: Digital cardiac Counseling","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04393636","Recruiting","2020-06-05","2022-12-31","{""locations"":""Maastricht University Medical Center, Maastricht, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""394"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""MACEs|Mortality|Cardiovascular-related mortality|Covid-19 related mortality|Health-related quality of life|NYHA Functional classification|CCS (Canadian Cardiovascular Society grading of angina pectoris)|Perioperative complications|Hospital length of stay|Time on mechanical ventilation|Smoking status|Anxiety and Depression|Participation in postoperative cardiac rehabilitation|Body-Mass Index (BMI)|Number of participants with unplanned visits|Healthcare costs""}"
"4438","Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations","","NCT04687488","S64237","Other: Fluorescein|Other: Particle measurement","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04687488","Completed","2020-07-23","2020-11-09","{""locations"":""TARGID, Leuven, Vlaams-Brabant, Belgium"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of droplets spread on the investigator and their location on gown or goggles, by the end of the procedure of naso-gastric intubation for gastrointestinal motility investigations.|Generation of aerosol particles by insertion and by removal of the naso-gastric motility or pH monitoring probe.""}"
"4439","Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse","ChroMig-Smart","NCT04389372","Chro-Mig-Smart","Behavioral: Mindfulness","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04389372","Recruiting","2020-03-15","2021-12-01","{""locations"":""UOC Neurologia 3, Milano, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy of Mindfullness by Smartphone|Change of Disability Score|Change in Quality of life""}"
"4440","Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat","NIC-002","NCT04644705","201767","Drug: Niclosamide|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04644705","Recruiting","2020-11-02","2021-05-31","{""locations"":""Charit\u00e9 Research Organisation GmbH, Berlin, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""28"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Treatment emergent number of Adverse Events|Maximum plasma concentration of niclosamide (\u00b5g\/ml)|Area Under the Plasma Concentration Time Curve from predose until last detectable concentration of niclosamide(AUC0-last) of niclosamide [\u00b5g\/ml*h]|Food effect on maximum plasma concentration of niclosamide (\u00b5g\/ml)|Food effect on Area Under the Plasma Concentration Time Curve from predose until last detectable concentration of niclosamide (AUC0-last) [\u00b5g\/ml*h]|Maximum plasma concentration of niclosamide (\u00b5g\/ml) at steady state after multiple dosing|Area Under the Plasma Concentration Time Curve between two dosing intervals (AUC tau ss) of niclosamide [\u00b5g\/ml*h] at steady state after multiple dosing""}"
"4441","Virtual Parental Presence on Induction","VPPIA","NCT04574219","2020-0371","Other: Use of Facetime with child and parents during induction","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04574219","Recruiting","2020-11-03","2022-12-01","{""locations"":""Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Hospital for Sick Children, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""184"",""age"":""4 Years to 12 Years \u00a0 (Child)"",""outcome_measures"":""Virtual presence cause delays in operating room|Parent satisfaction with virtual presence|Operating room provider satisfaction|Operating room induction nurse satisfaction|Assessment of parental presence with either Facetime, Skype or Teams|Anxiety of child|Child behavior induction compliance|Parent anxiety|Patient previous induction experience|Parental Coaching - Prior|Parental Coaching - Day""}"
"4442","Determining the Physical Activity Level of Healthy Adults During Pandemic","","NCT04555954","2020/8/318","Other: surveys and questionnaires","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04555954","Completed","2020-04-11","2020-08-20","{""locations"":""Afyonkarahisar Health Science University, Afyonkarahisar, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""205"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""physical activity level""}"
"4443","Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions","DEXA-REFINE","NCT04545242","ICI20-00062","Drug: Dexamethasone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04545242","Not yet recruiting","2021-02-08","2023-12-30","{""locations"":""Hospital Universitario Mutua Terrassa (ICU), Terrassa, Barcelona, Spain|Hospital General La Mancha Centro (ICU), Alcazar de San Juan, Ciudad Real, Spain|Complejo Hospitalario Universitario de Santiago (Anesthesia), Santiago De Compostela, La Coru\u00f1a, Spain|Hospital General El Bierzo (ICU), Ponferrada, Le\u00f3n, Spain|Hospital Universitario del Henares (ICU), Coslada, Madrid, Spain|Hospital Universitario de Getafe (ICU), Getafe, Madrid, Spain|Hospital Universitario Severo Ochoa (ICU), Legan\u00e9s, Madrid, Spain|Hospital Universitario Puerta de Hierro (ICU), Majadahonda, Madrid, Spain|Hospital Nuestra Se\u00f1ora del Prado (ICU), Talavera De La Reina, Toledo, Spain|Hospital Universitario de Cruces (Anesthesia), Barakaldo, Vizcaya, Spain|Hospital Universitario de Cruces (ICU), Barakaldo, Vizcaya, Spain|Complejo Hospitalario Universitario de Albacete (ICU), Albacete, Spain|Hospital Clinic de Barcelona (AVI), Barcelona, Spain|Hospital Clinic de Barcelona (Cardiac ICU), Barcelona, Spain|Hospital Cl\u00ednic (Hepatic ICU), Barcelona, Spain|Hospital Cl\u00ednic de Barcelona (Anesthesia), Barcelona, Spain|Hospital General de Ciudad Real (ICU), Ciudad Real, Spain|Hospital Virgen de la Luz (ICU), Cuenca, Spain|Hospital Universitario de A Coru\u00f1a (ICU), La Coru\u00f1a, Spain|Complejo Asistencial Universitario de Le\u00f3n (ICU), Le\u00f3n, Spain|Hospital Universitario La Princesa (ICU), Madrid, Spain|Hospital Universitario Ram\u00f3n y Cajal (Anesthesia), Madrid, Spain|Hospital Cl\u00ednico Universitario San Carlos (ICU), Madrid, Spain|Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz (ICU), Madrid, Spain|Hospital Universitario Doce de Octubre (ICU), Madrid, Spain|Hospital Universitario La Paz (Anesthesia), Madrid, Spain|Hospital Universitario La Paz (ICU), Madrid, Spain|Hospital Universitario Virgen de Arrixaca (Anesthesia), Murcia, Spain|Hospital Universitario Virgen de Arrixaca (ICU), Murcia, Spain|Hospital Universitario Regional de Malaga Carlos Haya (ICU), M\u00e1laga, Spain|Cl\u00ednica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Montecelo (Anesthesia), Pontevedra, Spain|Hospital Universitario Nuestra Se\u00f1ora de Candelaria (ICU), Santa Cruz De Tenerife, Spain|Hospital General de Segovia (ICU), Segovia, Spain|Hospital Clinico Universitario de Valencia (Anesthesia), Valencia, Spain|Hospital Clinico Universitario de Valencia (ICU), Valencia, Spain|Hospital Cl\u00ednico Universitario de Valladolid (Anesthesia), Valladolid, Spain|Hospital Universitario R\u00edo Hortega (Anesthesia), Valladolid, Spain|Hospital Universitario R\u00edo Hortega (ICU), Valladolid, Spain|Hospital Virgen de la Concha (ICU), Zamora, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""980"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""60-day mortality|Ventilator-free days""}"
"4444","Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine","Be-Home-Kids","NCT04604977","Be-Home-Kids","Behavioral: Mindfulness","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04604977","Recruiting","2020-09-15","2021-12-01","{""locations"":""Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit, Milano, Italy"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""25"",""age"":""12 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""reduction of headache days|reduction of headache days until last follow up|disability score|catastrophising attitude|depression symptoms|trait-state anxiety symptoms (STAI X1-X2)""}"
"4445","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","COVID-19","NCT04319211","EAvcil|İpek Yeldan","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04319211","Not yet recruiting","2020-03-25","2020-07-20","{""locations"":""Istanbul University Cerrahpasa, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|Beck Depression Scale""}"
"4446","Auricular Stimulation for Relief of Stress and Anxiety","AA_COVID","NCT04703907","BB 324/20","Other: Auricular stimulation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04703907","Recruiting","2020-12-03","2021-08-01","{""locations"":""University Medicine of Greifswald, Greifswald, Germany"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""19 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Anxiety|Trait anxiety|Sleep quality""}"
"4447","Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Vent","","NCT04369274","2020P001051","Device: Mechanical ventilation with the automated BVM compressor","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04369274","Not yet recruiting","2021-03-01","2021-11-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Arterial oxygenation|Expired pressure of carbon dioxide.|Airway pressure|Heart rate|Blood pressure|Airway flow""}"
"4448","Online Culture for Mental Health in People Aged 16-24","O-ACEPOP","NCT04663594","0009275","Other: WofB|Other: Ashmolean Website","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04663594","Recruiting","2020-12-04","2021-03-01","{""locations"":""Ashmolean Museum Website, Oxford, Oxfordshire, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""400"",""age"":""16 Years to 24 Years \u00a0 (Child, Adult)"",""outcome_measures"":""PANAS|K10|Facial expression recognition task|Probabilistic Incentive Learning Task|Flourishing|Loneliness""}"
"4449","Brief Mindfulness Based Intervention to Improve Psychological Wellbeing","","NCT04656626","Mindfullness during a pandemic","Behavioral: brief mindfulness based intervention|Behavioral: Progressive muscle relaxation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04656626","Completed","2020-07-07","2020-09-05","{""locations"":""Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""146"",""age"":""22 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""reduction of anxiety symptom severity|change in the level of psychological resilience|mental wellbeing|and functional status""}"
"4450","Project Resurgence Communication Trial","","NCT04418947","843220","Other: Communication type","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04418947","Completed","2020-06-15","2020-07-17","{""locations"":""University of Pennsylvania, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""11120"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percent with visit or procedure with provider|Percent with scheduled visit or procedure with provider|Percent with completed telemedicine visit with provider""}"
"4451","TRACERx Renal CAPTURE Sub-study","TRACERxRenal","NCT03226886","CCR 3723","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT03226886","Recruiting","2012-02-05","2023-09-01","{""locations"":""Edinburgh Western General Hospital, Edinburgh, Scotland, United Kingdom|Guy's & St Thomas Hospital, London, UK, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Royal Free Hospital, London, United Kingdom"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""360"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To validate ITH index and WGII as stage and grade independent prognostic markers of progression free survival in patients with ccRCC mutation in a gene of interest|CAPTURE Sub-study: Describe the population characteristics between SARS-CoV-2 positive and negative cancer patients""}"
"4452","DigiVis: Self-testing Vision App for Telephone Consultations","","NCT04482387","IRAS196573","Device: DigiVis visual acuity app","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04482387","Recruiting","2020-07-24","2021-07-01","{""locations"":""Cambridge University Hospitals NHS Trust, Cambridge, Cambs, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""250"",""age"":""5 Years to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Comparison of visual acuity measurement using DigiVis testing and standard visual acuity testing|Levels of Agreement between DigiVis testing and standard visual acuity testing|DigiVis test repeatability""}"
"4453","Point of Care Artificial Intelligence Tool for Heart Failure Diagnosis","DUO-EF-19","NCT04601415","285417","Diagnostic Test: ECG from handheld device","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04601415","Not yet recruiting","2021-02-01","2022-10-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Area under receiver operating curve""}"
"4454","Self-compassion for Chronic Pain Virtual Group Treatment Program","","NCT04413006","sccpvgtbsas2020","Behavioral: Self-Compassion for Chronic Pain Virtual Group Treatment Program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04413006","Recruiting","2020-05-25","2021-03-31","{""locations"":""University of Manitoba, Winnipeg, Manitoba, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""28"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change over time in Scores on the Self-Compassion Scale (SCS)|Change over time in Scores on the Pain Disability Index|Change over time in Scores on the Chronic Pain Acceptance Questionnaire - 8|Change over time in Scores on the Pain Catastrophizing Scale -6|Change over time in Scores on the Pain Self-Efficacy Questionnaire-4|Change over time in Pain Intensity|Change over time in Depression Symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)|Changes over time in Anxiety Symptoms as measured by the Generalized Anxiety Scale-7|Change over time in Quality of Life as measured by the PROMIS GLOBAL- 10|Changes over time in Mindfulness""}"
"4455","PH94B in the Treatment of Adjustment Disorder With Anxiety","","NCT04404192","PH94B-CL-029","Drug: PH94B","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04404192","Not yet recruiting","2020-11-01","2021-09-01","{""locations"":""The Medical Research Network, New York, New York, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hamilton Anxiety Scale|Sheehan Disability Scale|Adjustment Disorder New Module (ADNM)|Clinical Global Impression - Improvement rating (CGI-I)""}"
"4456","Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement","(COVID-19)","NCT04372693","FON170133","Other: impliminting Online Distance Learning","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04372693","Enrolling by invitation","2020-09-01","2021-02-28","{""locations"":""Cairo University, Cairo, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Students' Learning Perception Questionnaire (SLPQ),|students' scholar achievement.""}"
"4457","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","CORIMUNO-TOC","NCT04331808","APHP200375-1","Drug: Tocilizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04331808","Active, not recruiting","2020-03-30","2021-12-31","{""locations"":""APHP- Hopital Tenon, Paris, France|APHP - Beaujon, Paris, France|APHP - Bichat, Paris, France|APHP - Hopital Necker, Paris, France|APHP - Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France|APHP - Saint Louis, Paris, France|CHU Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""228"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2\/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge""}"
"4458","Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression","","NCT04428099","RMD01","Behavioral: Lifestyle change promotion program|Behavioral: Mindfullness based cognitive program|Behavioral: Written Information","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04428099","Recruiting","2020-01-13","2022-07-12","{""locations"":""Universitat Illes Balears, Palma de Mallorca, Illes Balears, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""186"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Depression severity|Health-related quality of life""}"
"4459","Prednisolone in Early Diffuse Systemic Sclerosis","PRedSS","NCT03708718","119220","Drug: Prednisolone 5 mg|Drug: Placebo oral capsule; From August 2020 'no additional treatment'","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT03708718","Recruiting","2017-12-21","2021-09-01","{""locations"":""Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, Aberdeenshire, United Kingdom|Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom|Salford Royal NHS Foundation Trust, Salford, Greater Manchester, United Kingdom|Glasgow Royal Infirmary -, Glasgow, Lanarkshire, United Kingdom|Aintree University Hospitals NHS Foundation Trust, Liverpool, Merseyside, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom|Royal National Hospital For Rheumatic Diseases - Royal United Hospitals Bath NHS Foundation Trust, Bath, Somerset, United Kingdom|Royal Hallamshire Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom|Freeman Hospital - The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom|Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, United Kingdom|Southmead Hospital Bristol - North Bristol NHS Trust, Bristol, United Kingdom|Ninewells Hospital and Medical School - NHS Tayside, Dundee, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""72"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health Assessment Questionnaire Disability Index (HAQ-DI)|modified Rodnan Skin Score (mRSS)|Quality of life and functional ability - Assessed by Questionnaire|Pain and disability|Functional ability - Assessed by Questionnaire|Pain associated with itch - Assessed by Questionnaire|Hand function - Assessed by Questionnaire|Fatigue - Assessed by Questionnaire|Anxiety and depression - Assessed by questionnaire|Health related quality of life - Assessed by Questionnaire|Health related quality of Life - Assessed by Questionnaire|Assessment of pain - Clinician assessment|Pain and disability - Assessed by Questionnaire""}"
"4460","Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety","","NCT04662021","12-2020","Other: Aerobic Exercises","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04662021","Enrolling by invitation","2020-12-10","2021-02-25","{""locations"":""Marwa Eid, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 25 Years \u00a0 (Adult)"",""outcome_measures"":""DASS 21""}"
"4461","Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms","","NCT04394455","1503202018052020242912","Behavioral: Brief cognitive behavioral therapy|Behavioral: Crisis intervention therapy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04394455","Enrolling by invitation","2020-06-30","2020-12-30","{""locations"":""Universidad Nacional Aut\u00f3noma de Honduras, Tegucigalpa, Francisco Moraz\u00e1n, Honduras"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""236"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate reduction in Depressive symptoms|Rate reduction in Anxiety symptoms|Rate reduction in Post traumatic Stress symptoms|Rate reduction in Perceived stress level""}"
"4462","A Study of Opaganib in Coronavirus Disease 2019 Pneumonia","COVID-19","NCT04414618","ABC-110","Drug: Opaganib|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04414618","Completed","2020-07-02","2020-12-23","{""locations"":""HonorHealth Research Institute, Scottsdale, Arizona, United States|Miami Cancer Institute, Miami, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Albany Medical Center, Albany, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Memorial Herman Southeast Hospital, Houston, Texas, United States|Memorial Hermann, Memorial City Medical Center, Houston, Texas, United States|Ziv Medical Center, Safed, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measurement of the oxygen requirement|Measurement of the reduction in oxygen requirement.|Eliminating supplemental oxygen|Elimination of fever|Time to negative swabs for SARS-CoV-2 by PCR post treatment|Time to negative swabs for SARS-CoV-2 by PCR at Day 14|Intubation and mechanical ventilation requirements|Evaluation of the time to mechanical ventilation|Evaluation the proportion of patients, with at least one measurement of fever at baseline who are afebrile at Day 14|Evaluation of mortality 30 days post-baseline""}"
"4463","Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia","","NCT04657809","S85insu23fdf","Combination Product: Insulin film|Device: Fast dissolving film","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04657809","Active, not recruiting","2020-10-01","2021-02-20","{""locations"":""Soad, Minya, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Smell sensation improvement""}"
"4464","Effectiveness of Basic Body Awareness Therapy in Post-traumatic Stress Disorders: A Randomized Clinical Trial","BATEP","NCT04396314","UL-002","Behavioral: Basic Body Awareness Therapy|Behavioral: Psychological treatment","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04396314","Not yet recruiting","2021-02-01","2021-09-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""54"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Davidson Trauma Scale (DTS)|Change in Beck Depression Inventory (BDI)|Change in State-Trait Anxiety Inventory (STAI)|Change in Short Form 36 (SF36)|Change in Visual Analogue Scale (VAS)|Change in Pittsburgh Sleep Quality Index (PSQI)""}"
"4465","Evaluation of Six-month HIV Treatment Dispensing in South Africa","","NCT04468789","H-40512|OPP1192640","Other: Six-month ARV dispensing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468789","Not yet recruiting","2021-04-01","2022-12-01","{""locations"":""Health Economics and Epidemiology Research Office, Johannesburg, Gauteng, South Africa"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150945"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Uptake of 6MMD|Retention in care|Viral suppression|Provider acceptability of 6MMD before intervention|Provider acceptability of 6MMD after intervention|Patient acceptability at baseline|Patient acceptability at 6 months|Provider costs""}"
"4466","Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy","","NCT04435028","1890-1-2019","Drug: Ketotifen 1 MG","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04435028","Completed","2019-01-14","2019-08-13","{""locations"":""Horus University, Damietta, Damiete Governonate, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""111"",""age"":""30 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""prophylaxis effect of Ketotifen on patient's hearts during the treatment of anthracyclines""}"
"4467","Do Network Centrality Predict Overall Depression Symptom Reduction With Lifting of Social Distancing Protocols?","","NCT04444713","802810-2","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04444713","Not yet recruiting","2020-06-22","2020-07-13","{""locations"":"""",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""10084"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire-9 (PHQ-9)|Cognitive-Attentional Syndrome-1 (CAS-1)""}"
"4468","The Effect of Clear Masks in Improving Patient Relationships","","NCT04595695","20-2229","Behavioral: Transparent mask|Behavioral: Typical surgical covered mask","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04595695","Completed","2020-09-03","2020-12-14","{""locations"":""University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Mask Preference Quantitative|Patient Mask Preference Qualitative|Patient Survey Scores Evaluating Surgeon Communication Skills|Patient Survey Scores Describing Trust in the Surgeon""}"
"4469","A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy","","NCT04148430","19-168","Drug: Anakinra","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04148430","Recruiting","2019-10-30","2022-10-01","{""locations"":""Memorial Sloan Kettering Cancer Center, New York, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities|Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation""}"
"4470","Safety and Effectiveness Assessment of the MakAir Artificial Ventilator","COVRESP","NCT04475185","RC20_0173","Device: MakAir","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04475185","Recruiting","2020-07-20","2020-12-01","{""locations"":""CHRU Brest, Brest, Finist\u00e8re, France|CHU Nantes, Nantes, Loire-Atlantique, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""117"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of dysfunctions""}"
"4471","A Smartphone Intervention for Relational and Mental Well Being","","NCT04629755","STUDY00009897","Behavioral: Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04629755","Completed","2020-04-04","2020-08-03","{""locations"":""University of Washington, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1765"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in depressed mood|Change in loneliness|Change in relationship quality""}"
"4472","Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.","","NCT04424355","2020-2","Diagnostic Test: Chest MRI","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04424355","Recruiting","2020-05-19","2021-12-20","{""locations"":""Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department, Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""115"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of zones of pulmonary parenchyma corresponding to viral pneumonia detected by chest MRI in comparison with CT scan""}"
"4473","Intracorporeal Anastomosis in Laparoscopic Left Colectomy. Cohort Comparative Study","RIAL-COLECTOMY","NCT04456933","HEMI-E-INTRACORPOREA-2020","Procedure: Extracorporeal left hemicolectomy anastomosis|Procedure: Intracorporeal left hemicolectomy anastomosis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04456933","Recruiting","2020-06-29","2022-02-28","{""locations"":""Hospital Universitario Parc Tauli de Sabadel, Sabadell, Barceelona, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""148"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of anastomotic leak (AL)|Rate of global morbidity|Rate of Surgical site infection|Rate of Re-interventions""}"
"4474","Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.","OLAF","NCT04470869","RC31/20/0190","Other: Phone call","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04470869","Recruiting","2020-06-12","2021-10-12","{""locations"":""University Hospital Toulouse, Toulouse, Occitanie, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""130"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""incidence of PTSD observed 6 months after patient's discharge from the intensive care unit|incidence of PTSD observed 6 months after patient's death in the intensive care unit|PTSD incidence at month 3|PTSD incidence at month 12|Symptoms incidence at month 3|Symptoms incidence at month 6|Symptoms incidence at month 12|incidence of persistent complicated grief at month 3|incidence of persistent complicated grief at month 6|incidence of persistent complicated grief at month 12""}"
"4475","Study Testing Convalescent Plasma vs Best Supportive Care","","NCT04333251","020-123","Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04333251","Not yet recruiting","2020-04-01","2022-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""115"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""reduction in oxygen and ventilation support""}"
"4476","Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids","ACE2-AVG","NCT04640610","APHP201032","Other: Storage of operating waste","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04640610","Not yet recruiting","2020-12-01","2021-09-01","{""locations"":""H\u00f4pital Mondor, Cr\u00e9teil, France|H\u00f4pital Bic\u00eatre, Le Kremlin-Bic\u00eatre, France|H\u00f4pital Lariboisi\u00e8re, Paris, France|H\u00f4pital Armand Trousseau, Paris, France|H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France|HEGP, Paris, France|H\u00f4pital Necker-Enfants Malades, Paris, France|H\u00f4pital Bichat, Paris, France|H\u00f4pital Tenon, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Expression of ACE 2 receptor and TMPRSS2 serine protease|Location of ACE 2 receptor and TMPRSS2 serine protease""}"
"4477","Proper Nutrition And Its Relation To Oral Diseases In Covid -19 Era","","NCT04434014","12345678","Dietary Supplement: proper diet","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04434014","Recruiting","2020-06-08","2020-06-28","{""locations"":""October university of modern sciences and arts, Giza, Egypt"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""20 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""regeneration of taste""}"
"4478","Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)","","NCT04550351","LKM-2020-NCV03","Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04550351","Active, not recruiting","2020-08-19","2021-12-31","{""locations"":""Hunan Provincial Center for Disease Control and Prevention, Xiangtan, Changsha, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""50"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The number of adverse events after intramuscular injection|Immunogenic end point""}"
"4479","A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults","","NCT04464460","TAK-671-1501|U1111-1252-9426","Drug: TAK-671|Drug: TAK-671 Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04464460","Withdrawn","2020-09-25","2020-10-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Markedly Abnormal Laboratory Values|Number of Participants With Markedly Abnormal Values of Vital Signs|Number of Participants With Markedly Abnormal 12-lead Electrocardiograms|Number of Participants With Adverse Events (AEs) Related to Physical Examination Findings|Ceoi: Serum Concentration at the end of Infusion for TAK-671|T1\/2z: Terminal Disposition Serum Half-life for TAK-671|AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-671|AUC\u221e: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-671|Percentage of Participants With Sustained Clinical Improvement or Live Discharge at Day 28|Percentage of Participants With Sustained Clinical Recovery|Percentage of Participants With Sustained Remission of Respiratory Symptoms|Mortality Rate|Time to Sustained Clinical Improvement or Discharge From Hospital|Time to Sustained Clinical Recovery|Percentage of Participants With Any Form of New Ventilation Use|Number of Days of New Ventilation Use|Number of Ventilation-free Days|Number of Days Free of Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Time to Sustained Remission of Respiratory Symptoms|Percentage of Participants Admitted to Intensive Care Unit (ICU)|Number of Days of ICU Stay|Change From Baseline in Sequential Organ Failure Assessment (SOFA) Score at Days 7, 14, and 28""}"
"4480","Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization","","NCT04530448","WVU Protocol #2005006707","Drug: Sodium bicarbonate|Other: Standard of Care","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04530448","Recruiting","2020-10-05","2021-03-01","{""locations"":""WVU Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""pH|Number of Days Alive Free of Stage 2-3 AKI|Stage 2-3 AKI|Vent-Free|Hospital-Free""}"
"4481","Telerehabilitation in Lung Surgery Patients","","NCT04568564","PostopTele","Other: Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|Other: Exercise booklet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04568564","Recruiting","2020-10-01","2021-05-01","{""locations"":""Istanbul University-Cerrahpa\u015fa, Cerrahpa\u015fa Faculty of Medicine Thoracic Surgery Clinic, \u0130stanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Major complication rate|The six-minute walking test|Modified Medical Research Council Dyspnea Scale|Visual analog scale|Duration of tube thoracostomy drainage|Forced expiratory volume one second (FEV1)|Forced vital capacity (FVC)|Diffusion Capacity|Lung Capacities|Lung V\/Q Scintigraphy|Procalcitonin (PCT)|C-Reactive Protein (CRP)|Ferritin|Lactate dehydrogenase|D'dimer test|Partial Carbon monoxide Pressure (PaCO2)|Partial Oxigen Pressure (PaO2)|Arterial blood oxygen saturation level (SaO2)|Anxiety inventory""}"
"4482","Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress","AGMFMSS","NCT04443075","XJTU1AF2020LSK-022","Device: faecal sample collector","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04443075","Completed","2020-06-24","2020-12-24","{""locations"":""First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""180"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Gut microbiome composition of exposed group|Gut microbiome composition of non-exposed group|The Impact of Event Scale-Revised (IES-R) of exposed group|The Impact of Event Scale-Revised (IES-R) of non-exposed group|The 15-item Patient Health Questionnaire (PHQ-15) of exposed group|The 15-item Patient Health Questionnaire-15 (PHQ-15) of non-exposed group|The 9-item Patient Health Questionnaire (PHQ-9) of exposed group|The 9-item Patient Health Questionnaire (PHQ-9) of non-exposed group|The 7-item Generalized Anxiety Disorder Scale (GAD-7) of exposed group|The 7-item Generalized Anxiety Disorder Scale (GAD-7) of non-exposed group|The Pittsburgh Sleep Quality Index (PSQI) of exposed group|The Pittsburgh Sleep Quality Index (PSQI) of non-exposed group|The Symptom Check List 90 (SCL-90) of exposed group|The Symptom Check List 90 (SCL-90) of non-exposed group""}"
"4483","Lockdown Impact on Spontaneous Premature Birth in a Level III NICU","CONFINéo","NCT04605172","2020PI168","Other: hospitalization for premature birth","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04605172","Enrolling by invitation","2020-11-02","2021-05-01","{""locations"":""Maternite Regionale Universitaire CHRU NANCY, Nancy, Lorraine, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""up to 28 Days \u00a0 (Child)"",""outcome_measures"":""Evaluate the impact of confinement on the rate of spontaneous prematurity at the Regional University Maternity Hospital of Nancy (MRUN)|Evaluate the impact of confinement on the type of prematurity rate: spontaneous or not|Evaluate the impact of confinement on the outborn rate managed by the Regional Neonatal transport team for prematurity|Evaluate the type of prematurity over the period of confinement""}"
"4484","Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections","","NCT04356144","TGA-TM-Critical-2019","Diagnostic Test: Thrombin Generation Assay (TGA)|Diagnostic Test: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04356144","Recruiting","2020-04-15","2020-12-01","{""locations"":""Medical University Vienna, Vienna, Austria"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ETP (AUC) without rhThrombomodulin (rhTM)|ETP (AUC) with rhThrombomodulin (rhTM)|ETP-ratio|ETP-Normalisation""}"
"4485","First Level Socio-geriatric Evaluation: ESOGER Databank","","NCT04393649","MP-05-2021-2308","Other: ESOGER","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04393649","Recruiting","2020-04-20","2021-04-19","{""locations"":""Jewish General Hospital, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""20000"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""COVID-19 symptoms|issues related to medication and food delivery and access to home care|physical frailty|psychological frailty|Caregiver burden""}"
"4486","Mobile Mental Health Apps for Suicide Prevention","","NCT04536935","STUDY00010842","Behavioral: Mobile Mental Health App - 1|Behavioral: Mobile Mental Health App - 2|Behavioral: Mobile Mental Health App - 3|Behavioral: Mobile Mental Health App - 4","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04536935","Enrolling by invitation","2021-01-01","2021-02-01","{""locations"":""University of Washington, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient Health Questionnaire (PHQ-9)|Generalized Anxiety Disorder (7-Item) Scale (GAD-7)|Brief Difficulties with Emotional Regulation Scale (DERS)|Acceptability of Intervention Measure (AIM)|Intervention Appropriateness Measure (IAM)|Feasibility of Intervention Measure (FIM)""}"
"4487","Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis","AS DEFER","NCT04333875","2020-00672","Device: TAVR or SAVR","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04333875","Active, not recruiting","2020-03-20","2020-12-01","{""locations"":""Department of Cardiology, Bern University Hospital, Bern, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""71"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure""}"
"4488","Norwegian Coronavirus Disease 2019 Study","NO COVID-19","NCT04316377","REC 121446","Drug: Hydroxychloroquine Sulfate","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04316377","Active, not recruiting","2020-03-25","2025-03-03","{""locations"":""Akershus University Hospital, L\u00f8renskog, Norway"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""53"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status|Change in C-reactive protein concentrations|Change in alanine aminotransferase concentrations|Change in aspartate aminotransferase concentrations|Change in bilirubin concentrations|Change in estimated glomerular filtration rate|Change in cardiac troponin concentrations|Change in natriuretic peptide concentrations""}"
"4489","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","","NCT04276688","UW-20-074","Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04276688","Completed","2020-02-10","2020-03-31","{""locations"":""University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""127"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens""}"
"4490","Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction","","NCT04439825","BTX-PST-COVID","Drug: Botulinum Neurotoxin|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04439825","Not yet recruiting","2020-07-15","2020-10-15","{""locations"":""DeNova Research, Chicago, Illinois, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""10 Years to 75 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Self- perception of mood before treatment and after achieving an optimal cosmetic result as determined by the PI.|Happiness levels before treatment and after achieving an optimal cosmetic result as determined by the PI.|Measurement of the Glabellar Wrinkle Severity Scores before treatment. The onset of effect and maximum efficacy compared to previous BOTOX Cosmetic injections will also be assessed by questionnaires.""}"
"4491","Heal-Me Personalized Online Nutrition and Exercise Routines","PiONEeR","NCT04666558","Pro00103715","Other: Exercise & Nutrition","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04666558","Recruiting","2020-11-30","2021-12-17","{""locations"":""University of Alberta, Edmonton, Alberta, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""216"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Lower Extremity Functional Scale (LEFS)|Upper Extremity Functional Index (UEFI)|6-Minute Walk Test (6MWT) Distance|Timed Sit-to-Stand (60 & 30 seconds)|Timed One-Legged Stance|2-Minute Step Test (2MST)|Sit-and-Reach|Step Count & Activity Minutes|Overall Well-Being (The World Health Organization-5 [WHO-5] Well-Being Index)|Resilience (10-Item Connor Davidson Resilience Scale)|General health-related quality of life (36-Item Short Form Survey [SF-36])|General health-related quality of life (5-Level EQ-5D [EQ-5D-5L])""}"
"4492","Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform","","NCT04663776","P00036213","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04663776","Recruiting","2020-11-04","2021-12-08","{""locations"":""Boston Children's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of in\ufb02uenza-like illness (ILI) and COVID-like illness (CLI) in a study participant.|Incidence of COVID-like illness (CLI) in a study participant.|Disease Prevalence""}"
"4493","Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation","PROACTIVE","NCT04467086","776228483","Drug: Propranolol Hydrochloride","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04467086","Recruiting","2020-12-11","2021-05-01","{""locations"":""Hamilton Health Sciences Centre - Hamilton General Hospital, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""108"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary sedative dose change|Sedation scores|Primary sedative dose|Total sedative daily dose change|Total opioid daily dose change|Adverse event - bradycardia|Adverse event - hypotension|Adverse event - bronchospasm|Adverse event - ECG conduction delays""}"
"4494","Virtual White Boards for Patient Satisfaction","","NCT04497922","2020P002382","Device: e-ink screen|Behavioral: Treatment as usual","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04497922","Recruiting","2021-01-25","2021-05-15","{""locations"":""Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""emergency department satisfaction: likert scale|Quality of emergency department stay: likert scale|Preference for virtual white board""}"
"4495","Global Mental Health of Urban Mothers","MUM","NCT04363177","P2SKP3_187728","Behavioral: Web-based psychosocial peer-to-peer support","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363177","Not yet recruiting","2020-11-01","2023-06-01","{""locations"":""Shanghai Women's and Children's Health Center, Shanghai, Shanghai, China|Chinese University Hong Kong, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Edinburgh Postnatal Depression Scale (EPDS)|Mental health status and COVID-19|Socio-economic status (education level, income, marital status, profession, nationality)|Elective CS""}"
"4496","Lessening Organ Dysfunction With VITamin C","LOVIT","NCT03680274","MP-31-2019-2945","Drug: Vitamin C|Other: Control","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT03680274","Recruiting","2018-11-08","2022-12-31","{""locations"":""Research Center of the CHUS, Sherbrooke, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration""}"
"4497","Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia","","NCT03852537","18-010925","Drug: Methylprednisolone|Other: Usual Care","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT03852537","Active, not recruiting","2019-12-02","2021-03-15","{""locations"":""Mayo Clinic in Rochester, Rochester, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""44"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation|Mortality|Progression of disease|Evolution of respiratory failure|Evolution of kidney failure|Evolution of shock|Length of stay|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Hyperglycemia|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Delirium|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Secondary Infection|Need for Vasopressors and Inotropes|Duration of Vasopressors and Inotropes|New onset and worsening cardiac arrhythmias|Re-hospitalization for a primary cardiovascular diagnosis|Myocardial Injury|Oxygen Use|Need for Non Invasive and Invasive Mechanical Ventilation|Duration of Non Invasive and Invasive Mechanical Ventilation|Discharge Disposition""}"
"4498","The Effectiveness of Telerehabilitation-Based Exercises in Elderly People","","NCT04346940","007","Other: Telerehabilitation|Other: Exercise brochure","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346940","Not yet recruiting","2020-08-10","2020-11-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Standardized Mini Mental Test|Mini Nutritional Assesment|Short Physical Performance Test|Single Leg Stance Test|Charlson Comorbidity Index|Clinic Fragility Scale|Pittsburgh Sleep Quality Index|Social Isolation Survey|Quality of life scale in the elderly|The Physical Activity Scale for the Elderly|Timed Up and Go Test|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory""}"
"4499","Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of Medical University of Warsaw","","NCT04569019","AKBE/118/2020","Other: Vacciantion status in health care workers","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04569019","Recruiting","2020-09-01","2022-07-01","{""locations"":""Warsaw Medical Uniwerity, Warsaw, Poland"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assesment of vaccination indeks in the hsopital by using questionare""}"
"4500","Inhaled NO for the Treatment of Viral Pneumonia in Adults","","NCT04606407","BA_VPLF_01","Device: LungFit™","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04606407","Recruiting","2020-11-25","2021-09-07","{""locations"":""Shaare Zedek Medical Center, Jerusalem, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""incidence of Serious Adverse Events|fever resolution|ICU admission|Oxygen support|Stable room air saturation""}"
"4501","Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831","NEUROSIVIR","NCT04480333","NEUROSIVIR","Drug: Drug: NA-831 - 0.10 mg/kg|Drug: Placebo- 0.10 mg/kg|Drug: Drug: NA-831 - 0.20 mg/kg|Drug: Placebo- 0.20 mg/kg|Drug: Drug: GS-5734 - 1.00 mg/kg|Drug: Placebo- 1.00 mg/kg|Drug: Drug: GS-5734 - 2.00 mg/kg|Drug: Placebo- 2.00 mg/kg|Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|Combination Product: Placebo 0.10 mg + 1.00 mg/kg|Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|Combination Product: Placebo 0.20 mg + 2.00 mg/kg","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04480333","Recruiting","2020-09-15","2021-03-31","{""locations"":""Coronavirus Research Institute, Sunnyvale, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""45"",""age"":""21 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-\u221e)|Half-Life (t1\/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment""}"
"4502","Advance Care Planning: Communicating With Outpatients for Vital Informed Decision","ACP-COVID","NCT04660422","20-600|UH3AG060626-03S1","Other: VitalTalk communication skills training|Other: ACP Decisions Video Program|Other: Intervention training:|Other: Medical Record Review","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04660422","Recruiting","2020-12-15","2021-05-14","{""locations"":""Northwell Health, New Hyde Park, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""13150"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Rate for Advanced Care Planning (ACP) documentation|Rate of orders for resuscitation preferences|Rate of palliative care consultation|Rate of referral to hospice|Advanced Care Planning (ACP) documentation rates among under-represented minority groups.""}"
"4503","Audio Data Collection for Identification and Classification of Coughing","","NCT04326309","HM070102","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04326309","Recruiting","2020-03-25","2022-09-25","{""locations"":""Virtual Facility, Bronx, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dataset size|Cough sound identification|Improvement of the existing model|Evaluate the usability of the application""}"
"4504","Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.","ImmunoCOVID","NCT04382508","RHM CHI1061","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04382508","Enrolling by invitation","2020-03-22","2021-03-21","{""locations"":""University Hospital Southampton NHS FT, Southampton, Hampshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""To describe COVID19 infection in children\/adults who are vulnerable for infection in an outpatients setting|Number of children\/adults tested positive for COVID19|Number of children\/adults admitted in hospital because of COVID19|To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children""}"
"4505","PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock","PLACCSEPS","NCT04107402","PLACCSEPS|2018/11DEC/469","Other: Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04107402","Recruiting","2019-03-15","2024-03-15","{""locations"":""Cliniques Universitaires St Luc, Bruxelles, Belgium"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Platelets Acetyl-CoA Carboxylase phosphorylation rate|Sepsis severity|Mortality rate|Platelet function assessment|Thrombin generation marker rate|Tubulin acetylation rate|Total platelets lipid content and composition|Neutrophils extracellular trap formation|Platelets activation|Respiratory failure""}"
"4506","SELF-BREATHE RCT for Chronic Breathlessness","","NCT04574050","IRAS 285303|20/LO/1108","Other: SELF-BREATHE","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04574050","Not yet recruiting","2020-12-03","2022-06-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility: the number of patients recruited into this study over a 12-month period""}"
"4507","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","POPS or POP02","NCT04278404","Pro00103838","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04278404","Recruiting","2020-03-05","2024-04-24","{""locations"":""Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|University of California, Los Angeles, California, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania State University--Hershey Children's Hospital, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|University of Texas-Southwestern Medical Center, Dallas, Texas, United States|University of Texas--Memorial Hermann Texas Medical Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""up to 20 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Clearance (CL) or apparent oral clearance (CL\/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V\/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1\/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling""}"
"4508","Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study","PSI-RECORd-XP","NCT04348552","RC20_0183","Other: Primary care professionals reports of potential patient safety incidents, non-COVID-19 related","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04348552","Recruiting","2020-04-28","2020-06-28","{""locations"":""University Hospital, Nantes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Describe patient safety incidents (types, severity, contributing and correcting factors) - 1000 PSI required|Describe patient safety incidents (types, severity, contributing and correcting factors) - 100 PSI required""}"
"4509","Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis","PSI-RECORd-GP","NCT04346121","RC20_0182","Other: GPs reports of potential patient safety incidents, non-COVID-19 related","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04346121","Completed","2020-04-28","2020-06-29","{""locations"":""University Hospital, Nantes, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""132"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Describe patient safety incidents (types, severity, contributing and correcting factors) - 1000 PSI required|Describe patient safety incidents (types, severity, contributing and correcting factors) - 100 PSI required""}"
"4510","Coronavirus Smell Therapy for Anosmia Recovery","Co-STAR","NCT04422275","PA-18-334","Drug: Budesonide|Behavioral: High-Concentration Essential Oil|Drug: Placebo|Behavioral: Low-Concentration Essential Oil","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04422275","Withdrawn","2021-06-01","2023-12-31","{""locations"":""Washington University, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""0"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""University of Pennsylvania Smell Identification Test (UPSIT)|Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS).|Global Rating of Smell.|Global Rating of Smell Change.""}"
"4511","Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health","","NCT04573062","10000089|000089-N","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04573062","Recruiting","2021-03-16","2024-12-31","{""locations"":""National Institutes of Health Clinical Center, Bethesda, Maryland, United States"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Screening Phase""}"
"4512","Universal Anti-Viral Vaccine for Healthy Elderly Adults","ALLOPRIME","NCT04441047","MBI-001-ALLOPRIME","Drug: AlloStim","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04441047","Not yet recruiting","2021-03-06","2022-12-31","{""locations"":""Florida Medical Clinic, LLC, Zephyrhills, Florida, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""40"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""frequency of vaccine events|Proportion of subjects with positive T-cell response|Proportion of subjects able to suppress viral propagation""}"
"4513","The Effectiveness of Video-Based Exercises in Young Adults","","NCT04346966","001","Other: Study Group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346966","Not yet recruiting","2020-08-20","2020-11-20","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""128"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""International Physical Activity Questionnaire (Short Form)|Short Form-36 (SF-36)|The Pittsburgh Sleep Quality Index|Distress Tolerance Scale|Beck Anxiety Inventory|Nottingham Health Profile|Sit And Reach Test|Shoulder Flexibility Test|Curl-Up Test|Repetitive Squat Test|Side Plank Test|Timed Up and Go Test|Single Leg Stance Test""}"
"4514","Characteristics of TraceTogether Users","","NCT04468581","510d","Behavioral: Use of mobile application","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04468581","Completed","2020-04-03","2020-07-17","{""locations"":""Yale NUS, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""505"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Demographic information""}"
"4515","Remote Blood Pressure Monitoring With the Wearable SENBIOSYS Photoplethysmographic Device","","NCT04379986","SENBIOSYS trial","Device: Sensbiosys","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04379986","Not yet recruiting","2020-05-01","2020-06-01","{""locations"":""University and hospital Fribourg, Fribourg, Switzerland"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of non-invasive BP monitors: blood pressure|Percentage of signal with artefact,""}"
"4516","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GOTCHA","NCT04473274","IRB20-042","Drug: Pioglitazone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04473274","Completed","2020-05-21","2020-12-01","{""locations"":""Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse events outcomes without attribution|Adverse events attributable|Clinical improvement|Levels of treatment|d-Dimer|C Reactive Protein|Ferritin|Lactate dehydrogenase|A1c""}"
"4517","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","COVID-19 PEP","NCT04308668","MED-2020-28673","Drug: Hydroxychloroquine|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04308668","Completed","2020-03-17","2020-05-20","{""locations"":""Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1309"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID19 Disease among those who are asymptomatic at baseline|Overall change in disease severity over 14 days among those who are symptomatic at baseline|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 days|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry""}"
"4518","Analysis of the Impact on Surgical Residency Programs in Times of Pandemic in Argentina","","NCT04703400","0817040","Other: anonymous survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04703400","Completed","2020-08-15","2021-01-03","{""locations"":""Ren\u00e9 M. Palacios Huatuco, C\u00f3rdoba, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""195"",""age"":""20 Years to 30 Years \u00a0 (Adult)"",""outcome_measures"":""Demographic variables|type of hospital|type and year of training program|attendance at your institution and surgical practices""}"
"4519","Acceptance and Commitment Therapy Delivered by Automated Software Messaging","","NCT04329897","201412701-1","Behavioral: Software Messaging","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04329897","Completed","2020-04-05","2020-06-01","{""locations"":""University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.""}"
"4520","Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study","","NCT04657471","2020-A03067-32","Other: revised HOME-CoV score","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04657471","Recruiting","2020-12-08","2021-06-08","{""locations"":""CHU Angers, Angers, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The safety of the revised HOME-CoV score strategy for home treatment|The efficacy of the revised HOME-CoV score strategy for home treatment|The applicability of the revised HOME-CoV score strategy for home treatment|The reliability of the revised HOME-CoV score strategy for home treatment|The predictive performances of the revised HOME-CoV score of evolution towards a COVID-19 with a WHO-OSCI\u22655.|The predictive performances of the revised HOME-CoV score of evolution towards a COVID-19 with a WHO-OSCI\u22656|The predictive performances of the revised HOME-CoV score of evolution towards a fatal COVID-19|Subgroup analysis in patients with confirmed COVID-19 (positive SARS-CoV2 RT-PCR) of the predictive performances of the revised HOME-CoV score|The predictive performances of the revised HOME-CoV score as compared to those of other prognostic scores for COVID-19|Venous thrombo-embolism in COVID-19 patients (ancillary study)""}"
"4521","Care in Patients Hospitalized for Anorexia Nervosa at the Time of the Coronavirus-19 Epidemic (QUALICOVID)","QUALICOVID","NCT04387708","RIPH 2020-01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04387708","Not yet recruiting","2020-05-14","2020-06-08","{""locations"":"""",""study_designs"":""Observational Model: Family-Based|Time Perspective: Cross-Sectional"",""enrollment"":""18"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Content analysis concerning the reorganization of care for children or adolescent and thier parents""}"
"4522","Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness","","NCT04414826","2020-04-0088","Behavioral: Mindfulness Alone (MO) Intervention|Behavioral: Mindfulness + Compassion Intervention (MC)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04414826","Recruiting","2020-05-25","2021-05-01","{""locations"":""Laboratory for the Study of Anxiety Disorders, University of Texas at Austin, Austin, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Revised University of California Los Angeles Loneliness Scale - 8 (ULS-8)|Perceived Stress Scale (PSS)""}"
"4523","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","","NCT03452774","SYNERGY-AI","Other: Clinical Trial Matching","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT03452774","Recruiting","2018-01-01","2022-12-01","{""locations"":""Massive Bio, Inc, New York, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of patients Eligible for CTE versus Actual CTE|Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Identification of Barriers to CTE|Real World Data Analytics|Virtual Tumor Board Utilization|Time from Intervention to Actual CTE (months)""}"
"4524","Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions","","NCT04444986","NOV2020/01919","Drug: FAVIR 200 MG FT|Drug: AVIGAN 200 mg FT","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04444986","Completed","2020-06-05","2020-06-13","{""locations"":""Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Gaziantep, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""AUC0-tlast of favipiravir|Cmax of favipiravir|AUC0-inf of favipiravir|tmax of favipiravir""}"
"4525","Comparison of VieScope vs. Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions","","NCT04363775","INT_PPE_2020_1","Device: The standard Macintosh laryngoscope|Device: The Vie Scope laryngoscope","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04363775","Completed","2020-01-20","2020-02-25","{""locations"":""Lazarski Univeristy, Warsaw, Poland"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""35"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""time to intubation|success of intubation|Number of optimalization maneuvers|Procedure Ease of use|the degree of visibility of the glottis|Cormack - Lehane grade""}"
"4526","Healthy Lifestyle or Pro-health Obsession During the Pandemic","","NCT04432038","GdanskUPES","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04432038","Recruiting","2020-06-19","2021-06-30","{""locations"":""Gdansk University of Physical Education and Sport, Gda\u0144sk, Poland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Levels of Physical Activity|Eating Attitudes|Psychological wellbeing|Physical wellbeing|Obligatory Exercise|Attitudes Towards Body|Body Image Disturbance""}"
"4527","ICBT for Mental Health Problems Related to the Coronavirus Pandemic","","NCT04424212","CoronaCope","Behavioral: Intervention group CoronaCope","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04424212","Active, not recruiting","2020-06-10","2021-08-01","{""locations"":""Link\u00f6ping University, Link\u00f6ping, \u00d6sterg\u00f6tland, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Becks Depression Inventory-II|Brunnsviken Brief Quality of Life Scale|Patient Health Questionnaire|Alcohol Use Disorder Identification Test|Insomnia Severity Index|The CoRonavIruS Health Impact Survey|Impact of Event Scale-Revised|Perceived Stress Scale|Dimensions of Anger Reactions (DAR-5) Questionnaire""}"
"4528","Pilot Study to Evaluate the Revoxa™ System in Hypoxic Patients","","NCT04699942","6031410","Device: Conventional (low flow) oxygen delivery via nasal cannula|Device: Revoxa Oxygen Rebrearther","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04699942","Not yet recruiting","2021-01-04","2021-07-01","{""locations"":""Kingston Health Sciences Centre, Kingston, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""23"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygen flow required to achieve SpO2 >96%.|Average oxygen consumption|Peak SpO2|Patient-reported dyspnea (Modified Borg Scale)|Patient-reported comfort (Visual Analogue Scale)""}"
"4529","Telehealth Intervention Program for Older Adults","TIP-OA","NCT04523610","TIP-OA","Behavioral: Telehealth phone calls|Other: Volunteer of TIP-OA Program|Other: Stakeholder of TIP-OA Program","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04523610","Recruiting","2020-10-02","2022-10-01","{""locations"":""Institute of Community and Family Psychiatry, Montreal, Quebec, Canada"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""258"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Perceived Stress Scale (PSS)|Patient Health Questionnaire-9 (PHQ-9)|Generalized Anxiety Disorder-7 (GAD-7)|Fear of COVID-19 Scale|Mental Healthcare Utilization|Interviews and Focus Groups with Volunteers|Interviews and Focus Groups with Stakeholders|Interviews with Program Users""}"
"4530","Telerehabilitation-based Yoga and Mindfulness Home Program in Postmenopausal Women Having Social Isolation","","NCT04346979","0001","Other: Telerehabilitation-Based|Other: Video-Based","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04346979","Not yet recruiting","2020-08-01","2020-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""45 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The Brief Resilience Scale|Nottingham Health Profile|Mindful Attention Awareness Scale|The Body Awareness Questionnaire|Richard-Campbell Sleep Questionnaire|Lateral bridge test|Functional reach test|Beck Depression Scale""}"
"4531","Responsible Gambling Telephone Intervention to High-risk Gamblers by a State-owned Gambling Operator in Sweden.","","NCT04646421","omsorgssamtal","Behavioral: Motivational telephone intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04646421","Recruiting","2020-11-30","2021-11-30","{""locations"":""Lund University, Lund, Sweden"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Other"",""enrollment"":""3626"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in gambling frequency.|Change in money wagered|Change in money lost|Occurrence of any self-limiting intervention post-intervention|Change in wagering frequency in both the own operator and other operators|Change in wagering amounts in both the own operator and other operators|Change in gambling losses in both the own operator and other operators, in prospective study part|Occurrence of any self-limiting intervention after the intervention in prospective study part|Gambler's immediate perception of the call|Gambler's perception of the intervention|Gambler's perception of the intervention's effects on gambling""}"
"4532","Using Telemedicine to Optimize Teamwork and Infection Control of Critical and Highly-infectious Patients in an Emergency Department","","NCT04591873","202007114RINA","Other: telemedicine|Other: traditional communication tools","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04591873","Not yet recruiting","2020-10-10","2021-10-30","{""locations"":""National Taiwan University Hospital, Taipei, Taiwan"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""20 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""time to complete intubation|teamwork score|exposure time in isolation rooms""}"
"4533","Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions","","NCT04651959","NOV2020/01941","Drug: AVICOD 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04651959","Active, not recruiting","2020-11-13","2020-12-20","{""locations"":""Novagenix Drug R&D Center, Akyurt, Ankara, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Favipiravir AUC0-tlast|Favipiravir Cmax|tmax of Favipiravir|t1\/2 of Favipiravir""}"
"4534","Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions","Favipiravir","NCT04406194","NOV2020/1917","Drug: FAVICOVIR 200 mg Film Tablet|Drug: AVIGAN 200 mg Film Tablets","Interventional","Has Results","Phase 1","https://ClinicalTrials.gov/show/NCT04406194","Completed","2020-05-14","2020-06-19","{""locations"":""Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""20 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""AUC0-tlast of Favipiravir|Cmax of Favipiravir|AUC0-inf of Favipiravir|Tmax of Favipiravir""}"
"4535","Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions","Favipiravir","NCT04400682","NOV2020/1923|FARGE 367","Drug: FAVIRA 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets","Interventional","Has Results","Phase 1","https://ClinicalTrials.gov/show/NCT04400682","Completed","2020-05-28","2020-06-18","{""locations"":""Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""20 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""AUC0-tlast|Favipiravir Cmax|AUC0-inf of Favipiravir|Tmax of Favipiravir""}"
"4536","Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds","AEGIS","NCT04240886","APX001-202|2019-001386-33","Drug: fosmanogepix","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04240886","Recruiting","2020-01-04","2021-10-01","{""locations"":""Clinical Trial Site, Duarte, California, United States|Clinical Trial Site, Sacramento, California, United States|Clinical Trial Site, San Diego, California, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Brussels, Belgium|Clinical Trial Site, Brussels, Belgium|Clinical Trial Site, Leuven, Belgium|Clinical Trial Site, Yvoir, Belgium|Clinical Trial Site, Koeln, Germany|Clinical Trial Site, Mainz, Germany|Clinical Trial Site, Haifa, Israel|Clinical Trial Site, Tel Aviv, Israel|Clinical Trial Site, Tel HaShomer, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-Cause Mortality|Global Response""}"
"4537","Novelty, Conformity and Trust in Vaccines","","NCT04693689","SG-Trust in Vaccines","Other: RNA vaccine|Other: 20% adoption rate|Other: 40% adoption rate|Other: 60% adoption rate|Other: 80% adoption rate|Other: Conventional vaccine|Other: 0% adoption rate","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04693689","Recruiting","2021-02-01","2021-03-30","{""locations"":""SurveyMonkey, San Mateo, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research"",""enrollment"":""32400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Willingness to receive COVID-19 vaccine|Belief in how much COVID-19 vaccine should be subsidized by the government|Belief in importance of vaccinating children|Belief in safety of vaccines|Belief in effectiveness of vaccines|Dishonesty index""}"
"4538","Who Benefits More? Optimising Mindfulness Based Interventions for Improved Psychological Outcomes","","NCT04417153","S-19-176","Behavioral: Mindfulness Based Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04417153","Recruiting","2019-09-20","2022-06-30","{""locations"":""National University Singapore, Singapore, Singapore"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Subjective measures of Sleep quality: Pittsburgh Sleep Quality Index total Score|Change in subjective measures of Stress: Perceived Stress Scale (PSS)|Change in Subjective Time in Bed (TIB)|Change in Subjective Total Sleep Time (TST)|Change in Subjective Sleep Onset Latency (SOL)|Change in Subjective Wake After Sleep Onset (WASO)""}"
"4539","Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation","","NCT04683744","2012926551|CDR-2018C3-14715","Other: Semi-structured interviews-Patients|Other: Semi-structured interviews-Health system","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04683744","Recruiting","2021-01-01","2023-07-01","{""locations"":""Indiana University, Indianapolis, Indiana, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Identify facilitators and barriers to implementing decision aids, provider notifications, and personal risk calculation using an electronic health record to promote colorectal cancer screening.|Identify the challenges and facilitators of effective cancer screening and prevention in primary care during the COVID-19 pandemic among leadership, providers, and staff.|Identify patient knowledge, attitudes, and beliefs that influence decisions to engage in cancer screening and prevention during the COVID-19 pandemic, and barriers to uptake""}"
"4540","The Cognitive and spOrt Virtual EPIC Training Study for Cardiovascular Diseases","COVEPICARDIO","NCT04661189","ICM 2020-2785","Behavioral: Physical exercise training|Behavioral: Cognitive training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04661189","Recruiting","2020-05-18","2022-12-01","{""locations"":""Preventive medicine and physical activity centre (centre EPIC), Montreal Heart Institute, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""122"",""age"":""50 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in general cognitive functioning|Change in executive functions|Change in processing speed|Change in episodic memory|Change in Walking speed|Change in Functional mobility|Change in Balance performance|Change in Lower limb muscles strength|Change in Cardiorespiratory fitness""}"
"4541","Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients","","NCT04502368","SRB2020-289|P2020/375","Procedure: Fiberoptic Bronchoscopy (FOB)|Procedure: Bronchoalveolar Lavage (BAL)|Diagnostic Test: Electrical Impedance Tomography (EIT)|Diagnostic Test: Arterial Blood Gas test (ABG)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04502368","Recruiting","2020-09-01","2021-04-30","{""locations"":""Erasme University Hospital - Intensive Care Unit, Brussels, Belgium"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Regional Compliance Variation|Regional Resistance Variation|Regional Compliance and FOB duration|Regional Compliance and PaO2|Atelectasis areas and BAL flooded areas|PaO2 and PaO2\/FiO2 ratio|PaCO2|Endotracheal tube size and Fiberscope size|Hemodynamic variations""}"
"4542","Virtual Simulation for Woven EndoBridge Device Sizing","VS-WEB","NCT04621552","RECHMPL20_0601","Device: WEB embolization","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04621552","Completed","2015-01-01","2020-10-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""186"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Median duration of the intervention|Median radiation dose|Need of corrective interventions|number of WEBs opened|Overall rate of complications|morbidity rate|Rate of Aneurysm occlusion|WEB-shape change""}"
"4543","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia","","NCT04276987","MEXCOVID","Biological: MSCs-derived exosomes","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04276987","Completed","2020-02-15","2020-07-31","{""locations"":""Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality""}"
"4544","Eating Habits of Adults During the Quarantine","","NCT04339842","Nutr2020","Other: Assessment of Dietary Changes in Adults in the Quarantine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04339842","Completed","2020-04-10","2020-05-31","{""locations"":""Online, Nicosia, Cyprus"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""673"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in the Eating Habits of Adults during the Quarantine""}"
"4545","The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions","Umifenovir","NCT04476719","NOV2020/01918","Drug: ATAFENOVIR 200 MG KAPSUL|Drug: ARBIDOL 100 MG KAPSUL","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04476719","Active, not recruiting","2020-07-09","2020-08-20","{""locations"":""Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""18"",""age"":""20 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Primary PK Endpoint|Secondary PK Endpoint""}"
"4546","Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions","Favipiravir","NCT04407000","NOV2020/01925","Drug: Test: Favipiravir 200 mg (LOQULAR)|Drug: Reference: Favipiravir 200 mg (Avigan)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04407000","Completed","2020-06-23","2020-08-08","{""locations"":""Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""20 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Primary PK End Points AUC0-tlast|Primary PK End Points Cmax|Secondary PK End Points AUC0-inf|Secondary PK End Points tmax""}"
"4547","Pandemic-adapted Caries Care Multicentre Case Series","","NCT04666597","IRB00010617","Procedure: Modified CariesCare International management","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04666597","Recruiting","2020-11-15","2022-03-02","{""locations"":""Indiana University, Indianapolis, Indiana, United States|Tufts University, Boston, Massachusetts, United States|Universidad de Buenos Aires, Buenos Aires, Argentina|Universidad Nacional de C\u00f3rdoba, C\u00f3rdoba, Argentina|University of Sao Paulo, S\u00e3o Paulo, Brazil|Universidad El Bosque, Bogot\u00e1, Bogot\u00e1 DC, Colombia|Viva 1A IPS Health Provider, Barranquilla, Colombia|Fundaci\u00f3n Universitaria de Colegios de Colombia, Bogot\u00e1, Colombia|Corporaci\u00f3n Universitaria Rafael N\u00fa\u00f1ez, Cartagena, Colombia|Universidad de Cartagena, Cartagena, Colombia|ACFF Colombian Chapter Manizales Demonstration Territory, Manizales, Colombia|Universidad Cooperativa de Colombia, Medell\u00edn, Colombia|Universidad Iberoamericamericana, Santo Domingo, Dominican Republic|Universite Cote d' Azur, Nice, France|Universidad de Guadalajara, Guadalajara, Mexico|ACTA, Amsterdam, Netherlands|Universidad Peruana Cayetano Heredia, Lima, Peru|University of Porto, Porto, Portugal|University of Moscow, Moscow, Russian Federation|University of Sheffield, Sheffield, United Kingdom|Universidad Cat\u00f3lica de Uruguay, Buenos aires, Sanmartin, Uruguay"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""420"",""age"":""3 Years to 8 Years \u00a0 (Child)"",""outcome_measures"":""Outcome at the tooth surface and at the individual level|Parents' satisfaction and dentists' process acceptability|Children behaviour change related with oral health caring""}"
"4548","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","","NCT04684602","ICSS-2020-032","Biological: PrimePro™/ PrimeMSK™","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04684602","Recruiting","2020-07-09","2030-12-09","{""locations"":""Southern California Hospital at Culver City \/ Southern California Hospital at Hollywood \/ Multiple US-based Sub-Investigator Sites, Culver City, California, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of quality of life (QOL) via 36-Item Short Form Survey (SF-36) change from baseline at 6 and 12 months.|Assessment of disabilities of arm, shoulder, hand via DASH Questionnaire change from baseline at 6 and 12 months.|Assessment of erectile function via International Index of Erectile Function (IIEF-5) change from baseline at 6 and 12 months.|Assessment of COPD via Clinical Chronic Obstructive Pulmonary Disease Questionnaire change from baseline at 6 and 12 months.|Assessment of mental state via Mini Mental State Examination (MMSE) change from baseline at 6 and 12 months.|Assessment of interstitial cystitis via O'Leary\/Sant Questionnaire change from baseline at 6 and 12 months.|Assessment of back pain via Oswestry Low Back Pain Disability Questionnaire change from baseline at 6 and 12 months.|Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.""}"
"4549","The VISION-Acute Study","","NCT04589923","PHT/2020/50","Device: Lifelight® Data Collect Blood Pressure Group|Device: Lifelight® Data Collect Oxygen Saturation Group","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04589923","Recruiting","2020-09-14","2022-01-01","{""locations"":""Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Objective|Secondary Objective 1|Secondary Objective 2|Secondary Objective 3|Secondary Objective 4""}"
"4550","Azithromycin-Prevention in Labor Use Study (A-PLUS)","","NCT03871491","CP Azithromycin","Drug: Azithromycin|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT03871491","Recruiting","2020-09-01","2023-09-01","{""locations"":""ICDDRB, Dhaka, Bangladesh|Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the|Institute for Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala|Jawaharlal Nehru Medical College, Belagavi, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""34000"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.|Neonatal: Incidence of intrapartum\/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group|Incidence of chorioamnionitis|Incidence of endometritis|Incidence of other infections|Incidence of use of subsequent maternal antibiotic therapy|Maternal initial hospital length of stay|Incidence of maternal readmissions|Incidence of maternal admission to special care units|Incidence of maternal unscheduled visit for care|Incidence of maternal GI symptoms|Incidence of maternal death due to sepsis|Incidence of other neonatal infections (e.g. eye infection, skin infection)|Neonatal initial hospital length of stay|Incidence of neonatal readmissions|Incidence of neonatal admission to special care units|Incidence of neonatal unscheduled visit for care|Incidence of neonatal death due to sepsis|Incidence of pyloric stenosis within 42 days of delivery""}"
"4551","Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients","","NCT03474965","CSEG101B2201|2017-001747-12","Drug: Crizanlizumab","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT03474965","Recruiting","2018-10-01","2024-11-20","{""locations"":""University of Alabama 1600 7th ave, Birmingham, Alabama, United States|Phoenix Childrens Hospital CVAL489A2302, Phoenix, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|Children s National Hospital, Washington, District of Columbia, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Joe DiMaggio Childrens Hospital, Hollywood, Florida, United States|Childrens Healthcare of Atlanta, Atlanta, Georgia, United States|Ann and Robert H Lurie Childrens Hospital of Chicago CTBM100C2407, Chicago, Illinois, United States|University of Chicago Hospital, Chicago, Illinois, United States|Childrens Hospital Boston, Boston, Massachusetts, United States|Institute for Pediatric Cancer and Blood Disorders, Hackensack, New Jersey, United States|UMDNJ, New Brunswick, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Duke University Medical Center Oncology, Durham, North Carolina, United States|East Carolina University SC, Greenville, North Carolina, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina Medical Uni of South Carolina, Charleston, South Carolina, United States|St. Jude Children's Research Hosptial, Memphis, Tennessee, United States|Cook Childrens Medical Center Oncology, Fort Worth, Texas, United States|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Laeken, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, S\u00e3o Paulo, SP, Brazil|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Paris cedex 15, France|Novartis Investigative Site, Heidelberg, Baden Wuerttemberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Vellore, India|Novartis Investigative Site, Modena, Italy|Novartis Investigative Site, Orbassano, Italy|Novartis Investigative Site, Padova, Italy|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Tripoli, Lebanon|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Aarau, Aargau, Switzerland|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""6 Months to 17 Years \u00a0 (Child)"",""outcome_measures"":""PK (AUCd15) after 1st dose|PD (AUCd15) after 1st dose|PK (AUCtau) after multiple dose|PD (AUCtau) after multiple dose|PK (Cmax) after 1st dose and multiple dose|PK pre-dose concentrations|Frequency of any adverse events (AEs) as a measure of safety and tolerability|Annualized rate Vaso Occusive Crisis (VOC) events leading to healthcare visit in clinic\/ER\/hospital|Annualized rate Vaso Occusive Crisis (VOC) events treated at home (based on documentation by health care provider following phone contact with the patient)|Annualized rate each subcategory of VOC event (uncomplicated pain crisis, acute chest syndrome, hepatic sequestration, splenic sequestration, priapism)|Annualized rate hospitalizations and ER visits (both overall and VOC-related)|Annualized rate days of ER\/hospitalization (both overall and VOC-related)|Annualized rate of dactylitis events|Number, seriousness, severity, and causality assessments of treatement emergent adverse events and other data as considered appropiate.|Absolute change from baseline in hemoglobin|Immunogenicity: measurement of anti-drug antibodies (ADA) to crizanlizumab|Electrocardiogram (ECGs) at relevant PK time points|Growth and sexual maturation assessments (Tanner stage)|PK pre-dose concentrations prior to each study drug dose.|Percentage P-selectin inhibition prior to dosing""}"
"4552","Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions","Orvical","NCT04386876","NOV2020/01911|FARGE365","Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04386876","Completed","2020-04-30","2020-06-11","{""locations"":""Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""30"",""age"":""20 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Primary PK End Points""}"
"4553","DiaBetter Together for Young Adults With Type 1 Diabetes","DiaBetter","NCT04247620","H-45360|1R01DK119246","Behavioral: DiaBetter Together|Behavioral: Peer Mentor Delivery","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04247620","Enrolling by invitation","2020-12-15","2024-06-01","{""locations"":""Baylor College of Medicine, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""186"",""age"":""17 Years to 35 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Glycemic Control (HbA1c)|Time to First Adult Care Visit|Diabetes Self-Management\/Adherence (Self-Care Inventory-Revised, Short Form)|Health-Related Quality of Life (Type 1 Diabetes and Life)|Diabetes Strengths (Diabetes Strengths and Resilience measure)|Social Support (Brief 2-Way Social Support Scale)|Diabetes Distress (Diabetes Distress Scale for Adults with T1D)|Depressive Symptoms (PROMIS Short Form Depression 4a)|Emotional Support (PROMIS Short Form Emotional Support 4a)|Informational Support (PROMIS Short Form Informational Support 4a)|Social Isolation (PROMIS Short Form Social Isolation item)|Transition Readiness (Readiness Assessment of Emerging Adults With Type 1 Diabetes Diagnosed in Youth)|General Quality of Life (Satisfaction with Life Scale)|Subjective Sleep Experiences (Pittsburgh Sleep Quality Index - Revised)|COVID-19 Protective Behaviors (Oelsner MESA COVID-19 - Revised)|COVID-19 Experiences (COVID-19 Experiences Questionnaire for Young Adults with T1D)|Stressful Events (Stressful Event Questionnaire)""}"
"4554","Disability Following Hospitalization in People of Working-age Surviving SARS-CoV-2 Infection - COVID-19","DisCOVID","NCT04724395","P200601","Other: Hospitalization","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04724395","Not yet recruiting","2021-01-01","2023-01-01","{""locations"":""Cochin Hospital, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Post-acute COVID-19 disability from the care provider's perspective, 9 months after hospitalization|Post-acute COVID-19 disability from the care provider's perspective, 18 months after hospitalization|Post-acute COVID-19 disability from the care provider's perspective, 24 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 9 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 18 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 24 months after hospitalization|Type of treatments|Acceptable symptom state (questionnaire self-administered on ComPARe IT dedicated platform)|Health-related quality of life (questionnaire self-administered on ComPARe IT dedicated platform)|Pain (questionnaire self-administered on ComPARe IT dedicated platform)|Impairments, activity limitations and participation restrictions, health-related quality of life Fatigue (questionnaire self-administered on ComPARe IT dedicated platform)|Impairments, activity limitations and participation restrictions, health-related quality of life (questionnaires self-administered on ComPARe IT dedicated platform)|Urinary symptoms, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Female sexual dysfunction, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Erectile dysfunction, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Global activity limitations and participation restrictions (questionnaire self-administered on ComPARe IT dedicated platform)|Work Ability (questionnaire self-administered on ComPARe IT dedicated platform)|Work productivity (questionnaire self-administered on ComPARe IT dedicated platform)|Comorbidities (score completed by the investigator during a face-to-face visit)|Impairments, activity limitations and participation restrictions (checklist completed by the investigator during a face-to-face visit)|Mobility test to assess the consequences of neurological, cardiorespiratory, osteoarticular or respiratory impairments (clinical assessment by the investigator during a face-to-face visit)|Locomotor impairments (clinical assessment by the investigator during a face-to-face visit)|Upper extremities impairments (clinical assessment by the investigator during a face-to-face visit)|Respiratory impairment (clinical assessment by the investigator during a face-to-face visit)|Cognitive impairments (clinical assessment by the investigator during a face-to-face visit)|Muscular impairments (clinical assessment by the investigator during a face-to-face visit)|Respiratory impairments (clinical assessment by the investigator during a face-to-face visit)|Total costs|Costs drivers|Estimated Years lived with Disability|Burden of post-acute COVID-19 on participant's close relative|Resource utilization|Symptoms of anxiety and\/or depression of participant's close relative|Symptoms of post-traumatic stress""}"
"4555","Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19","","NCT04724720","20-1155","Drug: Famotidine|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04724720","Recruiting","2021-01-19","2021-12-01","{""locations"":""Northwell Health, Lake Success, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""84"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative incidence of symptom resolution|Relative change of symptoms|Assessment of Serious Adverse Events|Clinical improvement|Improvement in peripheral oxygen saturation|Mortality|Comparative proportions of hospitalized patients|Change in systemic inflammation""}"
"4556","A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection","","NCT04725097","20-011415","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04725097","Recruiting","2020-12-10","2021-08-30","{""locations"":""Mayo Clinic, Rochester, Minnesota, United States|Sri Jayadeva, Bengaluru, Karnataka, India|Gregorio Mara\u00f1on Hospital, Madrid, Spain|Imperial College, London, England, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years to 89 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID 19 Detection""}"
"4557","Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)","STRUCK","NCT04724629","402422/2020-1","Biological: Ixekizumab|Biological: Aldesleukin|Drug: Colchicine|Drug: Standard of care (SOC)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04724629","Recruiting","2021-01-05","2021-07-30","{""locations"":""Faculdade de Medicina de Ribeir\u00e3o Preto - USP, Ribeir\u00e3o Preto, SP, Brazil|Hospital e Maternidade Christov\u00e3o da Gama, Santo Andr\u00e9, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ordinal scale of seven World Health Organization (WHO) categories of IL-17 inhibitor versus low dose IL-2 versus indirect IL-6 inhibitor (colchicine) versus standard treatment in the treatment of severe COVID-19|Time until independence from oxygen therapy in days|Ventilator free days (in days)|Assessment of worsening pulmonary involvement, defined as the presence of one of these criteria (absence or presence)|In patients who needed mechanical ventilation, time to indicate mechanical ventilation|Duration of hospitalization, in survivors|Analysis of in-hospital mortality|Analysis of general mortality""}"
"4558","Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19","","NCT04724538","RNT COVID-19","Radiation: 99mTc-pertechnetate|Radiation: 99mTc-pertechnetate aerosol|Drug: 99mTc-pertechnetate aerosol","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04724538","Recruiting","2020-10-15","2021-03-15","{""locations"":""P. Hertsen Moscow Oncology Research Institute, Moscow, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""15"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dosimetry. Transition coefficients calculation of count rate to absolutely activity of 99mTc-pertechnetate in ROI.|Dosimetry. Evaluation of the accumulated dose in human lungs with internal irradiation with 99mTc in a group of healthy volunteers with different body weights.|Safety of inhalation 99mTc-pertechnetate aerosol in patients with COVID-19 viral pneumonia through Adverse Event Monitoring.|Evaluation treatment standard related adverse events as assessed by CTCAE v5.0 of patients with COVID-19 viral pneumonia without inhalation procedure.""}"
"4559","Russian Cardiovascular Registry of COVID-19","","NCT04724707","0509-20-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04724707","Recruiting","2020-09-11","2022-12-01","{""locations"":""Almazov National Medical Research Centre, Saint Petersburg, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death|Hospitalization for cardiovascular reasons|Hospitalization for any reason|Time to death|Mechanical support or heart transplant|ICD or CRT|Quality of life|Cardiac pacing or catheter ablation|Syncope or presyncope|Arrythmias""}"
"4560","Follow-up Study of COVID-19 Patients in the District Konstanz","FSC19-KN","NCT04724434","20-1020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04724434","Enrolling by invitation","2020-12-04","2026-06-01","{""locations"":""Hegau-Bodensee-Klinikum Singen, Singen, Baden-W\u00fcrttemberg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of Hospitalization|EQ-5D-5L|KCCQ-12""}"
"4561","Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome","SONIC-19","NCT04725084","2021-CHITS-001","Other: Use of High Flow Nasal Cannula alone|Other: Use of Non-invasive Ventilation|Other: Use of Continuous Positive Airway Pressure","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04725084","Completed","2020-07-01","2020-12-15","{""locations"":""Centre Hospitalier de Bethune, B\u00e9thune, Nord-Pas-de-Calais, France|Grand H\u00f4pital de l'Est Francilien, Jossigny, Seine-et-Marne, France|Groupe Hospitalier Sud Ile de France, Melun, Seine-et-Marne, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, Var, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Refractory hypoxemia|Mechanical Ventilation free days|Survival at ICU discharge|ICU length of stay|Complications during ICU stay|Delay between admission and intubation""}"
"4562","CARTOON: CoronAviRus (COVID-19) educaTional prOgram fOr childreN","CARTOON","NCT04724616","2128/2020","Other: Educational Program (CARTOON)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04724616","Recruiting","2021-01-06","2021-06-01","{""locations"":""Medical University of Vienna, Vienna, Austria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""3 Years to 6 Years \u00a0 (Child)"",""outcome_measures"":""Change of Emotional Outcome|Change of Knowledge Outcome|Baseline Behavior of the Participants|Nationality of parents|First language of parents|Highest degree of school education|Profession of the parents|Financial standing of the parents|Housing conditions of the family|Psychological or physical illness in the family""}"
"4563","Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome","","NCT04725110","ARDS","Drug: Instilled T3|Other: Placebo Therapy","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04725110","Not yet recruiting","2021-03-01","2024-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""250"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change Extravascular Lung Water Index|Length of ICU Stay|Number of Ventilator-Free Days|30-day Survival|Creatinine Concentration|Glomerular Filtration Rate|New York Heart Association (NYHA) Functional Classification""}"
"4564","Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients","","NCT04723706","14632","Diagnostic Test: COVID-19 serology IgG","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04723706","Not yet recruiting","2021-02-01","2022-03-01","{""locations"":""Henry Ford Health System, Detroit, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""estimate range for COVID-19 serology IgG in SCT and CART patients post vaccine""}"
"4565","COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency","","NCT04724642","1067-20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04724642","Recruiting","2020-12-28","2021-12-28","{""locations"":""Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""110"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of side effects in patients|Prevalence of severe adverse reactions""}"
"4566","Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura","COVIXTREM","NCT04724850","1/2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04724850","Not yet recruiting","2021-02-01","2023-07-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""To determine the effectiveness of the pharmacological treatments used for hospitalized patients with COVID-19 in clinical practice assessed in terms of mortality.|To determine the effectiveness of the pharmacological treatments used in the clinical practice for hospitalized patients with SARS-Cov2 infection assessed by time until death.|To determine the effectiveness of the pharmacological treatments used in the clinical practice for hospitalized patients with SARS-Cov2 infection assessed in terms of recovery.|To evaluate the influence of the age on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of the gender on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of the arterial hypertension on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of the diabetes on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of the dyslipidemia on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of myocardial infarction on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of angina on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of chronic heart disease on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of peripheral arterial disease the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of ictus on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To influence of dementia on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of neuromuscular disease on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of chronic obstructive pulmonary disease on the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of asthma the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate de influence of chronic kidney disease the effectiveness of the pharmacological treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice.|To evaluate the influence of the severity of the disease on the effectiveness of the pharmacologic treatments used for hospitalized patients with SARS-Cov2 infection in clinical practice assessed in terms of mortality.|To evaluate the influence of taking non-steroidal anti-inflammatory drugs on the effectiveness of the pharmacological treatments used for SARS-Cov2 infection in hospitalized patients in clinical practice.|To evaluate the influence of taking angiotensin II receptor antagonists on the effectiveness of the pharmacological treatments used for SARS-Cov2 infection in hospitalized patients in clinical practice.|To evaluate the influence of taking oral anti-diabetics drugs on the effectiveness of the pharmacological treatments used for SARS-Cov2 infection in hospitalized patients in clinical practice.|To evaluate the influence of administration of insulin on the effectiveness of the pharmacological treatments used for SARS-Cov2 infection in hospitalized patients in clinical practice.|To obtain information on the dosage of the pharmacologic treatments used for the treatment of the SARS-Cov2 infection in hospitalized patients and outpatients in clinical practice.|To obtain information on the duration of the pharmacologic treatments used for the treatment of the SARS-Cov2 infection in hospitalized patients and outpatients in clinical practice.|To identify and quantity the side effects of the pharmacologic treatments used for the treatment of the SARS-Cov2 infection in hospitalized patients and outpatients in clinical practice.|To analyze the effectiveness of the pharmacologic treatments used for SARS-Cov2 infection in hospitalized patients in clinical practice assessed by time of hospitalization.|To analyze the effectiveness of the pharmacologic treatments used for SARS-Cov2 infection in hospitalized patients in clinical practice assessed by the need to stay in the intensive care unit.|To analyze the effectiveness of the pharmacologic treatments used for SARS-Cov2 infection in hospitalized patients in clinical practice assessed by the maximum severity reached during admission.|To determine the evolution of patients with a positive diagnostic test for SARS-Cov2 who have not been treated with some of the specific drugs for this disease used for hospitalized patients in clinical practice.|To describe the symptoms presented by the hospitalized patient for COVID-19 in the Community of Extremadura during the entire epidemic period|To describe the temperature presented during admission by patients hospitalized for COVID-19 in the community of Extremadura during the entire period of the pandemic.|To describe the heart rate presented during admission by patients hospitalized for COVID-19 in the community of Extremadura during the entire period of the pandemic.|To describe the oxygen saturation breathing ambient air presented during admission by patients hospitalized for COVID-19 in the community of Extremadura during the entire period of the pandemic.|To describe the blood pressure presented during admission by patients hospitalized for COVID-19 in the community of Extremadura during the entire period of the pandemic.|To describe the symptoms presented by the outpatients diagnosed with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the temperature presented by the outpatients diagnosed with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe heart rate presented by the outpatients diagnosed with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the respiratory rate presented by the outpatients diagnosed with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the oxygen saturation breathing ambient air presented by the outpatients diagnosed with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the blood pressure presented by the outpatients diagnosed with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the radiological findings in hospitalized patients with CIVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the radiological findings in outpatients with CIVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the ferritin levels in the blood of hospitalized patients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the D-dimer levels in the blood of hospitalized patients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the interleukin 6 levels in the blood of hospitalized patients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the lymphocyte count in the blood of hospitalized patients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the c-reactive protein level in the blood of hospitalized patients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the results of SARS-CoV2 diagnostic test performed in hospitalized patients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the ferritin levels in the blood of outpatients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the D-dimer levels in the blood of outpatients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the interleukin 6 levels in the blood of outpatients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the lymphocyte count in the blood of outpatients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the c-reactive protein level in the blood of outpatients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To describe the results of SARS-CoV2 diagnostic test performed in outpatients with COVID-19 in the Community of Extremadura during the entire epidemic period.|To assess the health-related quality of life perceived by hospitalized patients after recovery.""}"
"4567","Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection","WARD COVID-19","NCT04724681","H-20025357","Device: WARD CSS","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04724681","Recruiting","2021-02-01","2021-12-31","{""locations"":""Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative duration of deviating vital signs: SpO2 < 85% min-1|Cumulative duration of deviating vital signs, respiratory rate \u2264 5 min-1|Cumulative duration of deviating vital signs, respiratory rate > 24 min-1|Cumulative duration of deviating vital signs, heart rate > 130 min-1|Cumulative duration of deviating vital signs, heart rate \u2264 30 min-1|Cumulative duration of deviating vital signs, ScO2|Frequency of predefined microevents (deviating vital signs)|Change in vital parameters|The frequency of events with desaturation as defined below and the simultaneous values of ScO2|Events with ScO2 < 60% for \u2265 1 min""}"
"4568","Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults","","NCT04723602","Sabin 001","Biological: cAd3-Marburg|Biological: cAd3-EBO-S","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04723602","Recruiting","2021-01-06","2021-12-06","{""locations"":""Oklahoma Blood Institute (OBI), Oklahoma City, Oklahoma, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""32"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Safety of Ebola and Marburg vaccines assessed by clinical observation.|Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Complete Blood Count (CBC).|Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Creatinine.|Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Alanine Transaminase (ALT).|Safety of Ebola and Marburg vaccines assessed by adverse experiences.|Safety of Ebola and Marburg vaccines assessed by serious adverse experiences.|Evaluation of antibody response to cAd3-EBO-S and cAd3 Marburg vaccines|Collection of sufficient post-vaccination plasma to support further development of filovirus assays.""}"
"4569","COVID-19 Pandemic and Medical Students","","NCT04726865","Jordan Universities","Other: Naser Al-Husban","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04726865","Completed","2020-10-01","2020-12-31","{""locations"":""Al-Husban University Naser, Amman, Jordan"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""415"",""age"":""18 Years to 24 Years \u00a0 (Adult)"",""outcome_measures"":""psychological stress and academic results""}"
"4570","COVID-19 and Pregnancy: Placental and Immunological Impacts","MaterCov","NCT04726111","2020_0170","Other: Specimens specific for the study","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04726111","Recruiting","2020-12-30","2021-08-30","{""locations"":""Hopital Foch, Suresnes, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Placental histological evaluation|Cellular analysis on maternal blood and cord blood: phenotyping from PBMCs and NFS with the characterization of lymphocyte populations by the CytodiffTM technique|Cellular analysis on maternal blood and cord blood: functional activities from PBMCs and NFS with the characterization of lymphocyte populations by the CytodiffTM technique|Number of cytokines in maternal blood and cord blood|Number of immunoglobulins in maternal and fetal blood|Maternal clinical evaluation then neonatal on medical file and telephone questionnaire 1 month after childbirth. Comparison of results between groups.|Foetal clinical evaluation then neonatal on medical file and telephone questionnaire 1 month after childbirth. Comparison of results between groups.""}"
"4571","Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19","HIGHLOWDEXA","NCT04726098","HIGHLOWDEXA-COVID|2020-005702-25","Drug: Dexamethasone high dose|Drug: Dexamethasone low dose","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04726098","Recruiting","2021-01-15","2022-12-31","{""locations"":""University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, A Coru\u00f1a, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""198"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of patients with treatment failure at day 11|Percentage of patients without the need for oxygen support at day 11.|28-days mortality|90-days mortality|Clinical status of patients using the World Health Organization 7-point Ordinal Scale for clinical improvement during 10 days of treatment|Percentage of patients needing Intensive Care Unit admission|Percentage of patients needing invasive mechanical ventilation or extracorporeal membrane oxygenation|Percentage of patients needing non-invasive ventilation or nasal high-flow oxygen therapy|Length of stay in the hospital|Infectious complications during hospital admission|Adverse drug reactions""}"
"4572","Repurposed Approved Therapies for Outpatient Treatment of Patients With Early-Onset COVID-19 and Mild Symptoms","","NCT04727424","TOGETHER_2","Drug: Fluvoxamine Maleate 100 MG [Luvox]|Drug: Metformin Extended Release Oral Tablet|Drug: Ivermectin Tablets|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04727424","Recruiting","2021-01-19","2022-03-01","{""locations"":""Coity of Ibirit\u00e9, Ibirit\u00e9, MG, Brazil|City of Sete Lagoas, Sete Lagoas, MG, Brazil|CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""2724"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To evaluate the effect of fluvoxamine, ivermectin and metformin in reducing need for emergency care AND observation for more than 12 hours due to the worsening of COVID-19;|To evaluate the effect of fluvoxamine, ivermectin and metformin in reducing need for Hospitalization due to lower respiratory tract infection (LRTI) related to COVID-19|Change in viral load on day 03 and 07 after randomization (first 600 enrolled participants)|Time to clinical improvement (up to 28 days of randomization), defined as improvement greater than 50% in reference to baseline symptoms)|Time to clinical failure, defined as time to need for hospitalization due to the clinical progression of COVID-19|Number of days with respiratory symptoms since randomization|All-cause hospitalizations|COVID-19 related hospitalizations|All-Cause Death|Cardiovascular death|Respiratory death|Promis Global-10 scale|WHO ordinal scale for clinical improvement|Adverse Events|Adherence of Study drug""}"
"4573","COVID-19 and the Brain","","NCT04726176","1432020000338","Biological: Exposure to COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04726176","Recruiting","2021-01-30","2021-07-01","{""locations"":""Vrije Universiteit Brussel, Brussels, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""40 Years to 76 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Brain scans|Neurocognitive test battery|Emotion regulation task|Mental fatigue Visual Analogue Scale (M-VAS)|Physical fatigue Visual Analogue Scale (P-VAS)|Return to work questionnaire|Profile of Mood States (POMS)""}"
"4574","European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) SARS-CoV-2 Antibody Study Protocol. Covid-19","SARS-Cov2","NCT04726137","17493/002","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04726137","Not yet recruiting","2021-03-30","2022-04-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1150"",""age"":""up to 24 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Number of participants with presence of SARS-CoV-2 antibodies assessed by serology tests""}"
"4575","Effect of CoVid-19 (CoronaVirusDisease-19) and Exercise on Myocardial Fibrosis and Ventricular Arrhythmias","CoViDEx","NCT04726150","1499","Other: ILR implantation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04726150","Not yet recruiting","2021-04-01","2026-04-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of athletes with LGE on CMR|Arrhythmic Burden on ILR|Arrhythmic Burden on 5d Holter|Occurrence of (pre)syncope or SCD|Long-term evolution of cardiac function on echo\/CMR: ejection fraction""}"
"4576","Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings","","NCT04726371","2020P003803, 2020P003957","Behavioral: Generic Best Practices|Behavioral: Tailored Best Practices","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04726371","Recruiting","2021-01-08","2022-10-01","{""locations"":""Massachusetts General Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""5350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""New COVID-19 Group Home Incidence at Baseline|New COVID-19 Group Home Incidence at 3 Months|New COVID-19 Group Home Incidence at 6 Months|New COVID-19 Group Home Incidence at 9 Months|New COVID-19 Group Home Incidence at 12 Months|New COVID-19 Group Home Incidence at 15 Months|Best Practices Fidelity at Baseline|Best Practices Fidelity at 3 Months|Best Practices Fidelity at 6 Months|Best Practices Fidelity at 9 Months|Best Practices Fidelity at 12 Months|Best Practices Fidelity at 15 Months""}"
"4577","Social Acceptability of COVID-19 Vaccines in Pakistan","","NCT04727372","Living amongst the fear","Other: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04727372","Completed","2021-01-23","2021-02-23","{""locations"":""Islamabad City, Islamabad, Capital Territory, Pakistan|Bahawalpur Rural and Urban Areas, Bahawalpur, Punjab, Pakistan|Faisalabad city, Faisal\u0101bad, Punjab, Pakistan|Lahore City, Lahore, Punjab, Pakistan"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""986"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Demographics (Age)|Demographics (Weight)|Demographics (Gender)|Demographics (Education)|Demographics (Family set up)|Demographics (Residence)|Attitude, knowledge and behavior about COVID-19 Vaccine and its acceptance or rejection|Correlation of Age with a particular behavior|Correlation of Weight with a particular behavior|Correlation of Gender with a particular behavior|Correlation of Education level with a particular behavior|Correlation of Family set up with a particular behavior|Correlation of Residence with a particular behavior|Respondents Attitude, knowledge and behavior about COVID-19 Vaccine and its acceptance or rejection""}"
"4578","MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey","","NCT04727294","MM/COVID-19 part II","Behavioral: Questionnaire","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04727294","Recruiting","2021-01-22","2021-12-01","{""locations"":""HealthTree.org (Online), Lehi, Utah, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Diagnosis and Treatment|Changes to Myeloma Treatment and Care|Health and Fitness|Quality of Life (QOL) Distress Screening tool|Clinical Trial Familiarity""}"
"4579","Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection","COVIDEX","NCT04726163","8078","Device: Continuous blind glucose measurement device (Free style Pro)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04726163","Recruiting","2021-01-29","2021-06-14","{""locations"":""Hopitaux Universitaires de Strasbourg, Strasbourg, France"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of time spent in the range 70-180 mg \/ dl (TIR)|Mortality|Intensive Care Unit Transfers|Cardiovascular and infectious complications|Acute metabolic complications: keto acidosis, severe hypoglycaemia|Duration of hospitalization and treatments administered|Mean glucose|Time spent above glycaemia > 180mg\/dl|Time spent bellow glycaemia < 70mg\/dl""}"
"4580","Antiviral Drugs on the Treatment of SARS-CoV-2","FavRem","NCT04727775","AMU","Drug: Favipiravir|Drug: Remdesivir","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04727775","Recruiting","2020-11-25","2021-03-20","{""locations"":""Aidos Konkaev, Nur-Sultan, Kazakhstan|Semey Medical University, Semey, Kazakhstan"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Outcome without comlications|Heart rate|SpO2|Blood pressure|Respiratory rate""}"
"4581","Use of the Mask and Current Pandemic","Mask","NCT04727762","ID0031","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04727762","Recruiting","2021-02-04","2021-03-30","{""locations"":""Gemma Victoria Esp\u00ed-L\u00f3pez, Valencia, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Generic health|Global well-be-ing|Headache Impact|Oral health|Dyspnea disability|Quantification of dyspnea|Level of Physical activity|Insomnia Symptom""}"
"4582","An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization","","NCT04729140","COVIVER-OUT PLUS","Drug: Ivermectin Tablets|Drug: Doxycycline Tablets|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04729140","Recruiting","2020-12-28","2022-03-28","{""locations"":""MAX HEALTH, Subsero Health 2055 Wood Street, Suite 100, Sarasota, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decreased admission rate to the hospital secondary to respiratory illness related to COVID-19|Decrease in total duration of symptoms secondary to respiratory illness related to COVID-19|Assessment of White Blood Cell Count|Assessment of Hemoglobin level|Assessment of Hematocrit level|Assessment of Platelet Count|Assessment of Sodium level|Assessment of Potassium level|Assessment of Chloride level|Assessment of Carbon Dioxide level|Assessment of Blood Urea Nitrogen level|Assessment of Creatinine level|Assessment of Calcium level|Assessment of Glucose level|Assessment of Total Bilirubin level|Assessment of Total Protein level|Assessment of Albumin level|Assessment of Aspartate Aminotransferase level|Assessment of Alanine Aminotransferase level|Assessment of Alkaline Phosphatase level|Assessment of Ferritin|Assessment of D-dimer|Assessment of Creatine Phosphokinase|Assessment of C-Reactive Protein|Assessment of Prothrombin Time and International Normalized Ratio|Assessment of activated Partial Thromboplastin Time|Assessment of Fibrinogen Activity|Mortality|Measurement of Participants with Medication Side Effects|Measurement of Participants with new onset Shortness of Breath or Changes in Shortness of Breath Severity|Measurement of Participants Pulse Oximetry readings on room air|Measurement of Participants with new onset Red Eyes or Changes in Red Eyes Severity|Measurement of Participants with new onset Chills or Changes in Chills Severity|Measurement of Participants with new onset Runny Nose or Changes in Runny Nose Severity|Measurement of Participants with new onset Sore Throat or Changes in Sore Throat Severity|Measurement of Participants with new onset Loss of Smell or Changes in Severity of in Loss of Smell|Measurement of Participants with new onset Loss of Taste or Changes in Severity of Loss of Taste|Measurement of Participants with new onset Body Aches or Body Pains or Changes in Body Aches or Body Pains Severity|Measurement of Participants with new onset Diarrhea or Changes in Diarrhea Severity|Measurement of Participants with new onset Headaches or Changes in Headaches Severity|Measurement of Participants with new onset Anxiety or Changes in Anxiety Severity|Measurement of Participants with new onset Fatigue or Changes in Fatigue Severity|Measurement of Participants with new onset Trouble Concentrating or Changes in Trouble Concentrating Severity|Measurement of Participants with new onset Cough or Changes in Cough Severity|Measurement of Participants with new onset Vomiting or Changes in Vomiting Severity|Measurement of Participants with new onset Nausea or Changes in Nausea Severity|Measurement of Participants with new onset Feelings of Hopelessness or Changes in Feelings of Hopelessness severity|Measurement of Participants with new onset feelings of Depression or Changes in feelings of Depression severity|Measurement of Participants with new onset Fever or Changes in Fever Severity|Measurement of Participants with new onset Moving Slowly or Changes in the Severity of Moving Slowly|Measurement of Participants with new onset Speaking Slowly or Changes in the Severity of Speaking Slowly|Measurement of Participants with new onset Feelings of Restlessness or Changes in the Severity of Feelings of Restlessness|Measurement of Participants with new onset Thoughts of Better Off Being Dead or Changes in the Severity of Thoughts of Better Off Being Dead|Measurement of Participants with new onset Thoughts of Hurting Yourself or Changes in the Severity of Thoughts of Hurting Yourself|Measurement of Participants with new onset Loss of Interest in Doing Things or Changes in the Severity of Loss of Interest in Doing Things|Measurement of Participants with new onset Loss of Pleasure in Doing Things or Changes in the Severity of Loss of Pleasure in Doing Things|Measurement of Participants with new onset Trouble Falling Asleep or Changes in the Severity of Trouble Falling Asleep|Measurement of Participants with new onset Trouble Staying Asleep or Changes in the Severity of Trouble Staying Asleep|Measurement of Participants with new onset Unmentioned Negative Impacts of COVID 19 infection or Changes in the Severity of these Negative Impacts of COVID 19 infection""}"
"4583","COVADIAL - Immunogenicity of COVID-19 Vaccine in Hemodialysis Patients","COVADIAL","NCT04728828","COVADIAL","Biological: Serological COVID-19 vaccine immunogenicity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04728828","Recruiting","2021-01-25","2023-08-15","{""locations"":""Centre Hospitalier de Quimper, Quimper, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""antibody synthesis induced after Covid-19 vaccination (positive or negative)|Lack of immunogenicity|COVID-19 incidence|Death during follow up|measure antibody response to vaccines in patient subgroup (diabetic patients, patients with auto-immune disease, patients with cancer, patients with an history of solid organ transplantation)|Longevity of the antibody synthesis induced after Covid-19 vaccination|antibody synthesis induced after one injection of Covid-19 vaccine""}"
"4584","Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity","","NCT04729153","DAADs and covid-19","Drug: DAAD Compound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04729153","Not yet recruiting","2021-02-01","2022-03-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the effect of DAADs on covid -19""}"
"4585","Study to Evaluate Tempol (MBM-02) to Help Prevent Hospitalizations in COVID-19 Patients.","","NCT04729595","APC400-03","Drug: Tempol|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04729595","Not yet recruiting","2021-05-01","2022-01-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""310"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Outcome Measure|Secondary Outcome Measure""}"
"4586","Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress","","NCT04728698","MSC-COV-201","Drug: COVI-MSC|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04728698","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":""Fresno Community Hospital, Fresno, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality at Day 28|Mortality at Days 60 and 90|Number of ventilator-free days|Improvement in oxygenation|SOFA score at Day 28""}"
"4587","Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection","","NCT04728919","R200090","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04728919","Recruiting","2021-01-15","2024-01-15","{""locations"":""Tampere University Hospital, Tampere, Finland"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""80"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Viral load of SARS-CoV-2 from different sample sites|Upper respiratory tract viruses|FeNO|FnNO|Change in FeNO|CHange in FnNO|Airway resistance at 20Hz, R20|Airway resistance at 5Hz, R5|Airway resistance at 20 Hz, R20|Change in R20|Change in R5|Reactance at 5Hz (X5)|Change in X5|Resonant frequency (Fres)|Change in Fres|Reactance area (A\u0425)|Change in AX|FEV1|FVC|VC|FEV1\/FVC|FEV1\/VC""}"
"4588","Characterisation of the Immune Response to SARS-CoV-2","","NCT04729452","CT 269506","Other: blood test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04729452","Recruiting","2020-06-01","2023-12-01","{""locations"":""Cwm Taf Morgannwg University Health board, Llantrisant, Rhondda Cynon Taf, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determination of key protective cellular immune parameters|Determination of public T-cell receptor response to SARS-CoV-2""}"
"4589","Proxalutamide Treatment for Hospitalized COVID-19 Patients","","NCT04728802","KP-DRUG-SARS-003","Drug: Proxalutamide|Drug: Standard of Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04728802","Not yet recruiting","2021-02-01","2021-12-30","{""locations"":""Centro Cl\u00ednico Advance, SGAS 915, Lote 69\/70, Sala 262, Bras\u00edlia, DF, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment efficacy of Proxalutamide relative to standard of care arm as assessed by the COVID-19 ordinal scale""}"
"4590","EAT-DUTA AndroCoV Trial","","NCT04729491","CORPO-AB-DRUG-SARS-004B","Drug: Dutasteride 0.5 mg|Drug: Azithromycin|Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04729491","Completed","2020-06-30","2020-10-07","{""locations"":""Corpometria Institute, Bras\u00edlia, DF, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""138"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Positivity rate of rtPCR-SARS-CoV-2 (qualitative analysis)|World Health Organization (WHO) Clinical Progression Scale [0 to 10; 0 = uninfected; 10 = death]|World Health Organization (WHO) COVID=19 Ordinal Scale for Clinical Improvement [1 to 8; 1 = not hospitalized, no limitation on activities; 8 = death]|Time-to-recovery|SARS-CoV-2 viral load|Duration of fatigue|Duration of anosmia|Overall duration of clinical manifestations|Proportion of subjects needing additional drugs or interventions|Proportion of subjects needing oxygen use|Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation|Proportion of hospitalizations|Proportion of mechanical ventilation use|Proportion of vasopressors use|Proportion of deaths|Duration of new oxygen use|Duration of hospitalization|Duration of mechanical ventilation|Proportion of increased ultrasensitive C-reactive protein (usCRP) (defined as usRCP > 7 mg\/L)|Proportion of decrease in erythrocyte sedimentation rate (ESR) (defined as ESR decrease > 50% compared to baseline (Day 0))|Proportion of increase in eosinophils (defined as eosinophils increase > 50% compared to baseline (Day 0))|Proportion of increased d-dimer (defined as d-dimer > 500 mg\/dL)|Variation in oxygen saturation compared to baseline (Day 0)|Disease duration|Change in viral load from baseline to Day 5|Proportion of post-COVID mental symptoms|Proportion of post-COVID physical symptoms|Proportion of post-COVID overall symptoms""}"
"4591","Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset","NorthCARDS","NCT04729075","19-0598","Other: ARDS and COVID19 treatments","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04729075","Completed","2021-01-19","2021-01-19","{""locations"":""Feinstein Institutes for Medical Research, Manhasset, New York, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""1800"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Index Hospital Survival|Time to Mechanical Ventilator Liberation|Hospital Readmission""}"
"4592","COVID-19 Vaccine Induced Adaptive Immune Responses","","NCT04729374","NJGLVAC-001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04729374","Recruiting","2021-01-27","2023-12-31","{""locations"":""Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 59 Years \u00a0 (Adult)"",""outcome_measures"":""Concentration of anti-SARS-CoV-2 neutralizing antibody in serum|Concentration of serum anti-SARS-CoV-2 binding antibody|Rate of anti-SARS-CoV-2 T cell response|The rate of SARS-CoV-2 infection|Rate of anti-SARS-CoV-2 B cell response""}"
"4593","Emails Promoting COVID-19 Vaccination Among Healthcare Workers","","NCT04728594","2021-0128","Behavioral: Social Proof|Behavioral: Reframing|Behavioral: Scarcity Message","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04728594","Completed","2021-01-15","2021-01-20","{""locations"":""Geisinger, Danville, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention"",""enrollment"":""9656"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of employees who scheduled vaccination appointments after 2 days|Number of emails opened after 2 days|Number of scheduling links clicked after 2 days""}"
"4594","Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience","","NCT04728880","R.20.11.1097","Drug: Remdesivir","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04728880","Recruiting","2021-01-26","2021-05-30","{""locations"":""Mansoura University Hospital, Mansoura, Dakahliya, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from baseline in Pulse rate|Change from baseline in respiratory rate|Change from baseline in body core temperature|Change from baseline in blood pressure|Change from baseline in arterial blood gas analyses|Change from baseline in Spo2 \/ FIO2 ratio|Change from baseline in White blood cell count|Change from baseline in lymphocyte count|Change from baseline in lactate dehydrogenase|Change from baseline in D-dimer|Change from baseline in procalcitonin|Change from baseline in Interleukin-6|Change from baseline in Serum ferretin|Change from baseline in prothrombin time|Change from baseline in serum creatinine|Change from baseline in liver enzyme ALT|Change from baseline in creatinine kinase|Change from baseline in cardiac troponin|Change from baseline in The Sequential Organ Failure Assessment score (SOFA score)|Duration of hospitalization|Supplemental Oxygen Requirement from Baseline|Duration without mechanical ventilation|Mortality""}"
"4595","Heart Patch for Myocardial Infarction COVID-19","","NCT04728906","120/KEPK-RSB/X/20","Device: Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04728906","Not yet recruiting","2021-03-05","2021-12-19","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""40 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Change of the ischemic burden (%)|Change in the regional heart wall motion abnormality|Change of the electrocardiographic wave|Change of the ejection fraction""}"
"4596","Reflective Tasks With Healthcare Workers During COVID-19","","NCT04728958","170732","Behavioral: Gratitude","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04728958","Not yet recruiting","2021-07-01","2022-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""219"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Anxiety Level|Change in Depression Level|Change in Stress Level|Change in Subjective Happiness Level|Change in Satisfaction with Life|Change in State Gratitude|State Gratitude Score|Change in Trait Gratitude|Trait Gratitude score""}"
"4597","Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021","","NCT04728347","ARCT-021-02","Biological: ARCT-021","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04728347","Recruiting","2021-01-04","2022-06-01","{""locations"":""SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital, Singapore, Singapore"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""106"",""age"":""21 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentages of participants reporting solicited local adverse events|Percentages of participants reporting solicited systemic adverse events|Percentages of participants reporting adverse events|Percentages of participants reporting serious adverse events|Percentages of participants reporting medically attended adverse events|Percentages of participants reporting new onset of chronic disease|Percentages of participants with abnormal safety laboratory test values|Percentages of participants with abnormal vital sign assessments|SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs|SARS-CoV-2 binding antibody levels, expressed as GMCs""}"
"4598","Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection","","NCT04731116","0245-20-RMC","Drug: Cannabidiol","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04731116","Recruiting","2021-01-10","2022-04-30","{""locations"":""Rabin Medical Center, Petach Tikva, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serum C-reactive protein (CRP) level|Serum ferritin level|Serum Interferon gamma-induced protein 10 (IP10) level|Serum IL-6 level|Serum TNF-related apoptosis-inducing ligand (TRAIL)|Study drug related adverse events|Patient adherence to the study protocol|Ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2) ratio (PaO2\/FiO2 ratio) for ventilated patients|Length of ventilation for ventilated patients|Length of stay in the ICU|Survival by day 28|Remission of respiratory symptoms|Documented infections up to discharge|Sequential organ failure assistance (SOFA) score""}"
"4599","TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience","","NCT04730323","IRB# FMH-05-2020-IRB-75","Drug: Tocilizumab","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04730323","Completed","2020-05-12","2020-06-12","{""locations"":""Fatima Memorial Hospital College of Medicine & Dentistry, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""93"",""age"":""16 Years to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Decreased Mortality in Participants|Hospital & ICU stay in days""}"
"4600","Convalescent Plasma in the Treatment of Covid-19","CP_COVID-19","NCT04730401","Plasma_Covid-19","Biological: Convalescent plasma from COVID-19 donors|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04730401","Recruiting","2021-01-27","2021-12-31","{""locations"":""Helsinki University Central Hospital, Helsinki, Uusimaa, Finland"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""390"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Safety (SAE)|Rate of intubation|Number of participants initiating systemic corticosteroids|Hospital stay|Mortality|ICU stay|Ventilator days|Severity of respiratory failure|Viral load|Antibody measurements|Thrombotic complication|The rate of participants presenting with coagulopathy disorders|Number of participants with laboratory change|Adverse effects|Convalescent plasma efficacy|Convalescent plasma high vs low titer efficacy|Convalescent plasma efficacy according to donor status""}"
"4601","Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19","","NCT04730427","GX-I7-COV-009","Drug: GX-I7|Drug: GX-I7 vehicle","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04730427","Recruiting","2021-01-01","2022-04-01","{""locations"":""Borame Medical Center, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence rate, characteristics, and severity of adverse reactions|Shift from baseline of vital sign|Shift from baseline of physical examination|Shift from baseline of hematology|Shift from baseline of blood chemistry|Dose limiting toxicity (DLT)|Absolute lymphocyte count (ALC)|RT-PCR for COVID-19|Assessment of clinical improvement by modified early warning score (MEWS)|Ordinal scale for clinical improvement (WHO) in each visit|The proportion of subjects who have progressed to death or a critical illness|Immune repertoire""}"
"4602","The DAWN Camostat Trial for Ambulatory COVID-19 Patients","DAWN","NCT04730206","S6445","Drug: Camostat|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04730206","Not yet recruiting","2021-03-01","2023-05-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1306"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""All-cause unplanned hospital admission for at least 24 hours or death|All-cause unplanned hospital admission for at least 24 hours|All-cause mortality|Time to recovery|Health status|Oxygen administration in the home setting|All-cause mortality at 1 year after randomization|Cardiovascular and thromboembolic complications|Symptom duration for each individual symptom|Duration of hospital admission for those admitted to hospital|Health services usage|Consumption of antibiotics|Participants' quality of life""}"
"4603","Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)","","NCT04730856","PROTHROMCOVID","Drug: Tinzaparin","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04730856","Not yet recruiting","2021-01-29","2021-07-31","{""locations"":""Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Infanta Sof\u00eda, Madrid, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital \u00c1lvaro Cunqueiro, Vigo, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction of suspicion of systemic thrombotic symptomatic events|Use of Mechanical ventilation|Progression on the WHO Progression Scale during follow-up.|Overall survival at 30 days.|Length of hospital stay (days)|Length of ICU stay (days)|Number of bleedings and adverse reactions""}"
"4604","The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients","","NCT04731051","HYDR0121/CCO","Drug: HCQ01|Drug: standard of care (SOC) for COVID-19","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04731051","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":""King Hussein Cancer Center, Amman, Jordan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""28"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who improve by at least one level lower on the 11-point World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI), where patients are scored on a scale of 0-10 with 0 being uninfected and 10 being dead .|Proportion of participants who improve by at least one level lower on the 11-point WHO-OSCI|Change in condition measured using the 11-point WHO-OSCI|All-cause mortality|Hydroxychloroquine (HCQ) concentration in plasma versus time profiles|Change from Baseline Oxygenation as determined by the SpO2 \/ FiO2 ratio|Treatment-related adverse events of HCQ|Rate of Transfer to the Intensive Care Unit|Time to Clinical Improvement|Duration of hospitalization|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of \u2264 2 maintained for 24 hrs|Status of discharged or not requiring supplemental oxygen|Rates of Intensive Care Unit mortality|Intensive Care length of stay|Oxygenation free days|Ventilator free days|Incidence & duration of new oxygen use|Incidence and duration of new mechanical ventilation use|Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia|Cardiac Arrhythmia - Ventricular Tachycardia|Cardiac Arrhythmia - Lengthening QTc""}"
"4605","Isotretinoin (13- Cis-Retinoic Acid) Versus Spike Protein Based Vaccine for Providing Complete Protection Against COVID-19 and Preventing the Expected Long Term Serious Side Effects Which May Caused by Spike Protein Based Vaccine-An Urgent Protective Clinical Trial","Isotretinoin","NCT04730895","COVID vaccine","Drug: Oral 13 cis retinoic acid|Drug: Aerosolized 13 cis retinoic acid|Combination Product: 13 cis retinoic acid doses orally in combination with spike protein based vaccine|Combination Product: Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|Biological: Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04730895","Not yet recruiting","2021-02-01","2023-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""360"",""age"":""18 Years to 40 Years \u00a0 (Adult)"",""outcome_measures"":""Assess the efficacy of the candidate oral and aerosolized isotretinoin for providing complete protection against COVID-19 in adults aged 18 years and older.|Assess the safety of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in adults aged 18 years and older.|Assess the efficacy of the candidate vaccine spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine for providing complete protection against COVID-19 in adults aged 18 years and older.|Assess the efficacy of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 combined with oral and aerosolized isotetinoin in adults aged 18 years and older. for providing complete protection against COVID-19|Assess the safety of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in combination with oral or aersolized 13 cis retinoic acid in adults aged 18 years and older.|Assess efficacy of the candidate oral and aerosolized isotretinoin against COVID-19|Assess efficacy of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine against COVID-19|Assess safety of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine combined with oral and aerosolized isotetinoin in vaccinated participants|Assessment the expression of MDAP-5 , RIG-1 , IFN1, TLR3 and IFN1 in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Absolute lymphocyte counts (CD4,CD8 and CD25+FOXP3+ Regulatory T cells ) in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Assessment the generated IgA antibodies in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Thrombin|Assessment the expression of Transe membrane protease ,serine II (TMPRSS2) changes over time in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Assessment the expression of Angiotensin-converting enzyme II (ACE2) changes over time in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Platelet aggregation in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|ACE2 autoantibodies IgG and IgM""}"
"4606","Evaluation of a Synbiotic Formula in Patient With COVID-19","","NCT04730284","COVSyn","Other: Health supplements","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04730284","Recruiting","2020-08-25","2022-03-31","{""locations"":""Chinese University of Hong Kong, Hong Kong, Hong Kong"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in gut microbiome|Changes in fecal bacteria metabolites|Change in plasma cytokines including IL-6, IL-IB, TNF-a and CXCL-10|Trend in symptom score|Change in Quality of life measured by EQ-5D-5L|Change in Quality of life measured by SF-12|Duration of gastrointestinal symptoms|Adverse event assessment""}"
"4607","Effects of the COVID-19 Pandemic on Fibromyalgia Patients","","NCT04730934","2020/43-01","Other: Perceived stress scale|Other: Fibromyalgia impact questionnaire|Other: The drugs used before and during the pandemic, the patient's job status, physical activity conditions, pain status","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04730934","Completed","2021-01-01","2021-02-25","{""locations"":""\u00c7am and Sakura City Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1360"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical activity|Occupation conditions|General health condition|General pain condition|Perceived stress scale|Fibromyalgia impact questionnaire""}"
"4608","Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19","SITCOV","NCT04730661","2020/0339/HP","Diagnostic Test: Sit to stand test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04730661","Recruiting","2020-12-21","2021-12-28","{""locations"":""Rouen university hospital, Rouen, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""146"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of late hospitalizations, within 48 hours of first discharge from emergency department, and motivated by worsening symptoms secondary to SARS-Cov2 infection.|Proportion of immediate hospitalizations after the 1st admission at emergency department.|Proportion of adverse events related to SARS-Cov2 infection within 7 days of patient inclusion.|Establish the correlation between the number of chair rises performed on STST and the occurrence of an adverse event.|Correlation between SpO2 and the occurrence of an adverse event|Correlation between heart rate (HR) and the occurrence of an adverse event|Correlation between dyspnea score and the occurrence of an adverse event""}"
"4609","Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers","","NCT04731324","ZYIL1 1001|CTRI/2020/12/030045","Drug: ZYIL1 capsule","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04731324","Recruiting","2021-01-05","2021-12-30","{""locations"":""Zydus Research Centre, Ahmedabad, Gujarat, India"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""42"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence and Severity of Adverse event of ZYIL1 following a single oral dose in healthy subjects|Maximum plasma concentration (Cmax)""}"
"4610","Educational Interventions for Surgeons During COVID-19 Pandemic: Cross-sectional, E-survey","EDUCOVID","NCT04732858","APHP201297","Other: Cross sectional e-Survey on surgeons exposed to any educational intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04732858","Active, not recruiting","2020-03-01","2021-06-01","{""locations"":""Assistance Publique H\u00f4pitaux de Paris - GHU AP-HP H\u00f4pitaux Universitaires Henri-Mondor, Cr\u00e9teil, France"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional"",""enrollment"":""50"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Kirkpatrick level 3 on a 5-modalities Likert scale""}"
"4611","Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19","SPRINTER","NCT04732949","SG018|2020-004743-83","Drug: SNG001|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04732949","Recruiting","2021-01-12","2021-09-01","{""locations"":""PharmaTex Research, LLC, Amarillo, Texas, United States|Hull Royal Infirmary, Hull, North Humberside, East Riding Of Yorkshire, United Kingdom|Royal Victoria Infirmary, Newcastle, Newcastle, England, United Kingdom|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom|The Royal Bournemouth & Christ, Bournemouth, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|Plymouth Hospitals NHS Trust, Plymouth, United Kingdom|Morriston Hospital Swansea NHS, Swansea, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""610"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to hospital discharge|Time to recovery|Progression to severe disease or death|Progression to intubation or death|Death within 35 days of first dose|Recovery as analysed at Days 7, 14, 21 and 28|Hospital discharge at days 7, 14, 21 and 28|Number of patients with improvement based on entire OSCI score at days 7, 14, 21 and 28|Change in total score according to the breathlessness, cough and sputum scale (BCSS) and disaggregated breathlessness and cough scores|Changes in National Early Warning Score (NEWS2) during the hospitalisation period|Number of patients with presence of COVID-19 symptoms based on daily assessment|Number of patients with limitations of usual activities based on daily assessment|Quality of life measured using EuroQol 5-dimension 5-level (EQ-5D-5L)|Number of patients with long-COVID-19 symptoms based on General Anxiety Disorder 7 Questionnaire (GAD-7)|Number of patients with long-COVID-19 symptoms based on FACIT Fatigue Scale (Version 4)|Number of patients with long-COVID-19 symptoms based on Patient Health Questionnaire-9 (PHQ-9)|Number of patients with long-COVID-19 symptoms based on Brief Pain Inventory (Short Form)|Number of patients with adverse events (AEs) and serious adverse events (SAEs)""}"
"4612","COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA","","NCT04732468","COVID-4.005","Biological: hAd5-S-Fusion+N-ETSD (Suspension for injection)|Drug: hAd5-SFusion+ N-ETSD (Oral capsule)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04732468","Recruiting","2021-02-24","2022-04-01","{""locations"":""Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""65"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of MAAEs and SAEs|Incidence and severity of solicited local reactogenicity AEs|Incidence and severity of solicited systemic reactogenicity AEs|Incidence and severity of unsolicited AEs|Incidence of changes of laboratory safety examinations|Vital Sign - Temperature|Vital Sign - Heart rate|Vital Sign - Blood Pressure|Vital Sign - Respiratory Rate|GMFR in IgG titer|GMT of S-specific, RBD-specific, and N-specific antibodies|Percentage of subjects who seroconverted|GMFR in neutralizing antibody|GMT of neutralizing antibody|Seroconversion rate of neutralizing antibody|CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein|CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein""}"
"4613","Clinical Performance Evaluation of KnowNow SARS-CoV-2 Test for the Detection of COVID-19 Antigen","","NCT04733170","VATIC-0101","Diagnostic Test: KnowNow SARS-CoV-2 Rapid Antigen Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04733170","Not yet recruiting","2021-02-15","2021-08-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assess clinical diagnostic performance of the KnowNow SARS-CoV-2 Rapid Antigen Test|Efficacy to assess the test compared to the reference test method|Usability Questionnaire to evaluate the use of the test with 2 saliva collection methods""}"
"4614","Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19","","NCT04732663","Pro00107436","Other: No Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04732663","Recruiting","2021-03-04","2023-12-01","{""locations"":""Clinical Physiology Laboratory, Edmonton, Alberta, Canada"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""225"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Peak Oxygen Uptake (VO2peak)|Peak Cardiac Output (Qpeak)|Pulmonary Capillary Blood Volume (Vc)|Ventilatory Efficiency (VE\/VCO2)|Dyspnea|Membrane Diffusion Capacity (Dm)|Pulmonary Artery Systolic Pressure (PASP)|Right Ventricular Function|Left Ventricular Stiffness""}"
"4615","Concordance Between Buccal Cavity Swab and Nasopharyngeal Swab for SARS-CoV-2 (COVID-19) Detection by RT-PCR and ELISA","","NCT04732637","U1111-1264-2742","Diagnostic Test: Test At Home's Proprietary ""Lollipop"" Buccal Cavity Swab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04732637","Not yet recruiting","2021-02-26","2021-08-31","{""locations"":""Datar Cancer Genetics, Nashik, Maharashtra, India"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Concordance between buccal cavity swab and contemporary nasal swab.""}"
"4616","Improving COVID-19 Vaccine Uptake in Nursing Homes","","NCT04732819","2012002872|3U54AG063546-02S2|Pro00048627","Behavioral: High touch multi-pronged behavioral intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04732819","Recruiting","2021-01-04","2021-04-19","{""locations"":""Mission Health, Tampa, Florida, United States|Nexion Health, Sykesville, Maryland, United States|Vetter Senior Living, Elkhorn, Nebraska, United States|Genesis HealthCare, Kennett Square, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research"",""enrollment"":""22500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Patient vaccine counts|Staff vaccine counts""}"
"4617","Evaluation of COVID-19 IgG Antibodies in Maternal and Cord Blood Samples","","NCT04732767","08-20-20E","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04732767","Not yet recruiting","2021-01-20","2021-06-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of COVID-19 IgG antibodies by immunoassay in maternal and cord blood samples.""}"
"4618","Pronostic Value of Type I ANTi-Interferon Antibodies in Patients With COVID-19 Acute Respiratory Failure","ANTICOV","NCT04733105","APHP201254","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04733105","Recruiting","2020-11-19","2022-02-20","{""locations"":""Assistance Publique H\u00f4pitaux de Paris - CHU HENRI MONDOR, Cr\u00e9teil, France"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""530"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""day-28 mortality|rate of positivity of type I anti-IFN antibodies|Factors associated with type I anti-IFN antibody positivity|hospital mortality""}"
"4619","Exploring Vaccine Confidence and Uptake of Potential COVID-19 Vaccines","","NCT04731870","60622","Other: Survey research","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04731870","Not yet recruiting","2021-02-01","2023-01-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""632"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Covid-19 vaccine confidence (survey to be developed by study team)|Covid-19 vaccine messaging (messages to be developed by study team & focus group participants)|Covid-19 vaccine uptake (survey to be developed by study team)|Covid-19 vaccine trust (survey to be developed by study team)|Covid-19 vaccine recommendation practices (survey to be developed by study team)""}"
"4620","Effects of Contact Restrictions During the COVID-19 Pandemic on Newborns and Their Parents","","NCT04732702","20-1440","Other: no intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04732702","Recruiting","2020-10-29","2021-04-30","{""locations"":""University hospital of Cologne, Department of Neonatology, Cologne, Northrhine-westfalia, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""6 Months to 9 Months \u00a0 (Child)"",""outcome_measures"":""Analysis of the mother-child-interaction|Analysis of expression and methylation of candidate genes of stress signaling pathways from mucosal epithelial cells (buccal swab)|parental depression|parental subjective distress caused by traumatic events|Social support|parental stress|parental bonding|breastfeeding""}"
"4621","Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms","","NCT04734860","AMG-COV-201","Biological: COVI-AMG|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04734860","Not yet recruiting","2021-03-01","2021-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects who have remained out of the hospital or emergency room through Day 29|Viral load reduction from baseline to Day 8, 15, 29, 43, and 70|Proportion of subjects who have remained out of the hospital or emergency room through Day 43 and 70|Proportion of subjects who have 50%, 70%, and 90% reduction in PRO instrument score|Time to resolution of fever""}"
"4622","Antibodies Response to mRNA Vaccine Against Covid-19","SABREVAC","NCT04733807","Max-2821","Biological: BNT162b2 mRNA Covid-19 Vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04733807","Recruiting","2021-01-28","2022-02-01","{""locations"":""ICOT-Sapienza University Hospital, Latina, LT, Italy"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serum IgM and IgG antibodies levels in response to vaccine|Sars-Cov2 infection in vaccinated subjects|Covid-19 disease in vaccinated subjects""}"
"4623","A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19","","NCT04733833","VB-201-019","Drug: VB-201 + Standard of care|Drug: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04733833","Recruiting","2021-01-26","2022-06-30","{""locations"":""Chaim Sheba Medical Center, Ramat Gan, Israel"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assess the safety and tolerability of VB-201""}"
"4624","CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients","","NCT04734873","CPI-006-003","Drug: CPI-006 2 mg/kg + SOC|Drug: CPI-006 1 mg/kg + SOC|Drug: Placebo + SOC","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04734873","Recruiting","2021-02-25","2022-01-30","{""locations"":""Sharp Chula Vista Medical Center, Chula Vista, California, United States|El Centro Regional Medical Center, El Centro, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Cambridge Medical Trials, Alexandria, Louisiana, United States|MedPharmics, Metairie, Louisiana, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Cl\u00ednica Adventista Belgrano, Estomba, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Clinica Independencia, Munro, Buenos Aires, Argentina|Instituto M\u00e9dico R\u00edo Cuarto, R\u00edo Cuarto, C\u00f3rdoba, Argentina|Centro de Investigaci\u00f3n Cl\u00ednica - Cl\u00ednica Viedma, Viedma, R\u00edo Negro, Argentina|Centro M\u00e9dico IPAM, Rosario, Santa Fe, Argentina|Hospital Provincial Del Centenario, Rosario, Santa Fe, Argentina|Clinica Mayo de U.M.C.B. S.R.L, San Miguel de Tucum\u00e1n, Tucum\u00e1n, Argentina|Hospital de Cl\u00ednicas Presidente Dr. Nicol\u00e1s Avellaneda, San Miguel De Tucum\u00e1n, Tucum\u00e1n, Argentina|Fundaci\u00f3n Sanatorio G\u00fcemes, Ciudad Aut\u00f3noma de Buenos Aires, Argentina|Hospital Rawson, C\u00f3rdoba, Argentina|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Hospital Agamenon Magalh\u00e3es, Recife, Pernambuco, Brazil|Santa Casa de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Dia do Pulm\u00e3o, Blumenau, Santa Catarina, Brazil|Cl\u00ednica Supera, Chapec\u00f3, Santa Catarina, Brazil|Hospital Municipal de Barueri Dr. Francisco Moran, Barueri, S\u00e3o Paulo, Brazil|Centro Hospitalar Nossa Sa\u00fade, Curitiba, Brazil|Hospital Anchieta, S\u00e3o Paulo, Brazil|Hospital de Base Da Faculdade de Medicina de S\u00e3o Jos\u00e9 Do Rio Preto, S\u00e3o Paulo, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, S\u00e3o Paulo, Brazil|Toronto General Hospital, Toronto, Ontario, Canada|Rodrigo Botero S.A.S, Medell\u00edn, Antioquia, Colombia|Fundacion Santa Fe de Bogota, Bogot\u00e1, Cundinamarca, Colombia|Cl\u00ednica Universidad De la Sabana, Ch\u00eda, Cundinamarca, Colombia|Fundacion Centro de Excelencia en Enfermedades Cronicas No Transmisibles, Monteria, C\u00f3rdoba, Colombia|Cl\u00ednica de la Mujer S.A.S., Bogot\u00e1, Colombia|Hospital Universitario Clinica San Rafael, Bogot\u00e1, Colombia|Fundacion Hospitalaria San Vicente de Paul, Medell\u00edn, Colombia|Promotora Medica Las Am\u00e9ricas S.A- Cl\u00ednica Las Am\u00e9ricas, Medell\u00edn, Colombia|Fundaci\u00f3n Valle Del Lili, Santiago de Cali, Colombia|CHRU Dijon, Dijon, C\u00f4te-d'Or, France|H\u00f4pital Saint-Andr\u00e9, Bordeaux, Gironde, France|Amiens University Hospital, Dreuil-l\u00e8s-Amiens, Somme, France|Centre Hospitalier Departemental de Vendee, La Roche-sur-Yon, Vend\u00e9e, France|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Tel-Aviv, Israel|Edith Wolfson Medical Center, Holon, Tel-Avov, Israel|Shamir Medical Center Assaf Harofeh, Be'er Ya'aqov, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|ZIV Medical Center, Safed, Israel|Sheba Medical Center, Tel HaShomer, Israel|Azienda Ospedaliera Cotugno, Napoli, Campania, Italy|Azienda Ospedaliero Universitaria Di Modena Policlinico, Modena, Emilia-Romagna, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milano, Lombardia, Italy|ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo, Milano, Lombardia, Italy|Ospedale San Raffaele S.r.l., Milano, Lombardia, Italy|ASST di Monza - Azienda Ospedaliera San Gerardo, Monza, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Lombardia, Italy|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonz\u00e1lez, Monterrey, Nuevo Leon, Mexico|Hospital Civil de Culiac\u00e1n, Culiac\u00e1n, Sinaloa, Mexico|Hospital General de Culiac\u00e1n, Culiac\u00e1n, Sinaloa, Mexico|Hospital Nacional Sergio E. Bernales, Comas, Lima, Peru|Hospital Chancay y Servicios Basicos de Salud, Huaral, Lima, Peru|Hospital Central Fuerza A\u00e9rea del Per\u00fa, Miraflores, Lima, Peru|Hospital Mar\u00eda Auxiliadora, San Juan De Miraflores, Lima, Peru|Cl\u00ednica Providencia, San Miguel, Lima, Peru|Cl\u00ednica San Pablo, Santiago De Surco, Lima, Peru|Hospital Nacional Adolfo Guevara Velasco Essalud, Cusco, Peru|Hospital Militar Central, Lima, Peru|Merc SiReN - MeDiNova Clinical Research, Johannesburg, Gauteng, South Africa|Peermed Clinical Trial Centre, Kempton Park, Gauteng, South Africa|Dr JM Engelbrecht Trial Site, Cape Town, Western Cape, South Africa|Excellentis Clinical Trial Consultants, George, Western Cape, South Africa|Task Eden Research Centre, George, Western Cape, South Africa|Clinical Projects Research SA Pty Ltd, Worcester, Western Cape, South Africa|Hospital Costa del Sol, Marbella, M\u00e1laga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Spain|Municipal Institution City Clinical Hospital #6 of Dnipropetrovsk Regional Council, Dnipro, Dnipropetrovs'ka Oblast, Ukraine|Kharkiv Regional Clinical Infectious Diseases Hospital, Kharkiv, Kharkivs'ka Oblast, Ukraine|Poltava Regional Clinical Infectious Hospital, Poltava, Poltavs'ka Oblast, Ukraine|Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1, Vinnytsya, Vinnytsia Oblast, Ukraine|Municipal enterprise Volyn Regional Clinical Hospital of Volyn Regional Council, Lutsk, Volyn Oblast, Ukraine|MNPE City Hospital No. 6 of Zaporizhzhia City Council, Zaporizhzhia, Zaporiz'ka Oblast, Ukraine|Municipal Institution City Hospital #7, Zhaporizhzhya, Zaporiz'ka Oblast, Ukraine"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To compare the proportion of participants alive and respiratory failure free of CPI-006 plus SOC versus placebo plus SOC|To compare the time to recovery of CPI-006 plus SOC versus placebo plus SOC|To compare the time to clinical improvement of CPI-006 plus SOC versus placebo plus SOC|To compare the change from baseline in the level of antibodies targeting the receptor binding domain (RBD) of SARS-CoV-2""}"
"4625","Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19","","NCT04733651","22-2021","Drug: Hospital standard of care for COVID-19|Drug: Isoquercetin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04733651","Not yet recruiting","2021-02-20","2021-08-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Disease progression, defined as WHO Clinical Progression Scale score of \u2265 6, at any time from day 1 to day 28|Disease recovery, defined as WHO Progression Scale score of \u2264 2, at day 28""}"
"4626","The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19","","NCT04734886","Provid","Dietary Supplement: L. reuteri DSM 17938 + vitamin D|Dietary Supplement: Placebo + vitamin D","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04734886","Recruiting","2020-11-27","2021-12-31","{""locations"":""\u00d6rebro University, \u00d6rebro, \u00d6rebro L\u00e4n, Sweden"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science"",""enrollment"":""400"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""SARS-CoV-2 specific antibodies|Maintenance of SARS-CoV-2 seroconversion in seropositive individuals|Duration of COVID-19 symptoms measured by a weekly symptom questionnaire|Severity of COVID-19 symptoms measured by Ordinal Scale for Clinical Improvement|Secretory IgA (sIgA) antibodies|Blood group A antigen antibodies|Blood group B antigen antibodies|Tn antigen antibodies|Innate immune system activation|Cytokines|Total antibodies|T cell activation|B cell activation|Intestinal inflammation|Intestinal barrier function|Indirect marker of intestinal permeability""}"
"4627","Covid-19 in Hematological Malignancies","EPICOVIDEHA","NCT04733729","EHA-IDWG","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04733729","Recruiting","2020-03-01","2021-12-31","{""locations"":""ASST-Spedali Civili, Brescia, Italy|AOU Policlinico Federico II, Napoli, Italy|Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy|Istituto Nazionale Tumori Regina Elena IFO, Rome, Italy|Osp. di Circolo-Fondazione Macchi, Varese, Italy|AOUI Verona, Verona, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""3000"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Epidemiology of COVID-19 infection in patients with hematological malignancies""}"
"4628","Social Activity, Loneliness and Stigma During COVID-19 Outbreak","","NCT04734171","AAAT0067","Behavioral: Digital social activity video intervention|Behavioral: Informational sheet|Behavioral: Stigma awareness video intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04734171","Completed","2020-04-02","2020-04-16","{""locations"":""Columbia University, New York, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1200"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in total stigma score 2 weeks after the intervention|Change in total fear score 2 weeks after the intervention|Change in loneliness ordinal score 2 weeks after the intervention|Change in fear of people COVID-19+ ordinal score 2 weeks after the intervention|Change in time spent on internet ordinal score 2 weeks after the intervention|Change in social activity ordinal score 2 weeks after the intervention""}"
"4629","Neuroimaging Findings in Patients With COVID-19","","NCT04734223","09.25.2020/587","Diagnostic Test: Neuroimaging Findings in Patients With COVID-19","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04734223","Completed","2020-04-01","2020-12-31","{""locations"":""Sa\u011flik Bilimleri \u00dcniversitesi Training and Research Hospital, Di\u0307yarbakir, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""436"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of acute thromboembolism in COVID-19 patients undergoing neuroimaging""}"
"4630","Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome","","NCT04734678","COVID-Infliximab","Drug: Tocilizumab|Drug: Infliximab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04734678","Recruiting","2020-12-01","2021-06-01","{""locations"":""Teachers Hospital, Cairo, Please Select, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""84"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients' clinical status improvement using six category scale|Time to improvement in oxygenation|Duration of hospitalization|Mortality rate|Incidence of non-invasive mechanical ventilation|Duration of non-invasive mechanical ventilation|Incidence of invasive mechanical ventilation|Duration of invasive mechanical ventilation|Occurrence of Secondary infections|Monitoring of adverse events|Occurrence of cardiovascular events""}"
"4631","Coordination and Locomotor Problems in Patients With Covid-19 Virus","","NCT04734717","IKEB2021/02","Diagnostic Test: Neurology test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04734717","Enrolling by invitation","2021-01-12","2021-04-12","{""locations"":""Dr. J\u00f3zsef Toll\u00e1r, Kaposv\u00e1r, Somogy, Hungary"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment"",""enrollment"":""2"",""age"":""20 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""EQ5D-5L|Berg test|SPPB test (gait, balance, leg stregth)|6MWT""}"
"4632","The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection","","NCT04733625","KA-2020/151","Drug: Cholecalciferol|Drug: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04733625","Completed","2020-09-15","2020-12-17","{""locations"":""Cairo university hospitals, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death or need for intubation""}"
"4633","Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease","","NCT04734561","20/715-E_BS","Other: Inspiratory muscle training group|Other: Inspiratory muscle training placebo group|Other: Inspiratory + expiratory muscle training group|Other: Inspiratory + expiratory muscle training placebo group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04734561","Not yet recruiting","2021-02-08","2022-07-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""88"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Health-related quality of life|Exercise tolerance|Maximum respiratory pressures|Inspiratory muscle endurance|Upper limb muscle strength|Lung function (forced spirometry)|Cognitive factors|Lower limb muscle strength|Psychological factors""}"
"4634","User Experience of the OSR M-1","","NCT04733677","IRB00070715","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04733677","Not yet recruiting","2021-03-01","2021-07-01","{""locations"":""Wake Forest Baptist Health, Winston-Salem, North Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percentage of Successful Fits|Quality of Fit Score|Percentage of Participants that Fit in a Small Size Mask|Percentage of Participants that fit in a Medium Size Mask|Percentage of Participants that fit in a Large Size Mask|User Acceptance Percentage|Percentage of Impression Change""}"
"4635","Corneal Wounds Repair Emergencies During COVID-19 : 10/0 Absorbable Polyglactin Sutures as a Valuable Strategy","","NCT04733846","IRBN202021","Other: data collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04733846","Not yet recruiting","2021-02-01","2021-03-01","{""locations"":""CHU Saint-Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""9"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Visual acuity (Snellen scale)|Visual acuity (Paarinaud) scale|Astigmatism (diopter)|Number of postoperative external consultations|Adverse events""}"
"4636","Evaluation of Transnasal Endoscopy During COVID-19 Pandemic","","NCT04734912","ETNE v1.0","Other: gastroscopy in transnasal techique","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04734912","Recruiting","2021-01-13","2021-12-31","{""locations"":""University Hospital Mainz, Mainz, Rhenanie-Palatinate, Germany"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""500"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Questionnaire""}"
"4637","The IRCM POST-COVID-19 (IPCO) Clinic","IPCO","NCT04736732","2021-1092","Other: Medical follow-up","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04736732","Recruiting","2021-01-01","2023-12-12","{""locations"":""Montreal Clinical Research Institute, Montr\u00e9al, Quebec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""570"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the short- and long-term end-organ complications post-COVID-19 in relation to the severity of the acute COVID-19 infection.|Establish a post-COVID-19 biobank.|The development of any end-organ complication that can plausibly be related to COVID-19. We will evaluate the following end-organ systems: neurological, cardiovascular, pulmopnary, renal, endocrine and metabolic, gastro-intestinal (GI).""}"
"4638","Hearts of Athletes","","NCT04736004","Pro00106943","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04736004","Not yet recruiting","2021-03-15","2022-04-30","{""locations"":""Duke University, Durham, North Carolina, United States"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 30 Years \u00a0 (Adult)"",""outcome_measures"":""Rate of Definite Myocarditis as measured by CMR (Cardiac Magnetic Resonance Imaging)|Rate of Possible Myocarditis as measured by CMR (Cardiac Magnetic Resonance Imaging)|Number of abnormal ECGs as measured by medical record abstraction|Number of abnormal Troponin as measured by medical record abstraction|Number of abnormal echocardiogram as measured by medical record abstraction""}"
"4639","Effects of COVID-19 Infection and Critical Illness on Diaphragm Tissue Characteristics and Movement, Visualized With MRI","","NCT04735757","NL 72271.029.20","Other: Contrast-enhanced MRI|Other: Measurement of respiratory muscle force","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04735757","Recruiting","2021-02-03","2023-01-19","{""locations"":""Amsterdam UMC, location VUmc, Amsterdam, Noord-Holland, Netherlands"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Tissue characteristics of the diaphragm|Movement of the diaphragm|Quantitative dynamic contrast enhanced imaging of the diaphragm|Correlation of movement and tissue characteristics of the diaphragm with measurements of maximum inspiratory and expiratory pressure|Correlation of movement and tissue characteristics of the diaphragm with clinical parameters""}"
"4640","Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome","","NCT04737161","56248","Biological: T regulatory cells","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04737161","Not yet recruiting","2021-03-01","2022-09-01","{""locations"":""Stanford University, Stanford, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The number of participants that experience the occurrence of infusion associated adverse events (AEs)|The number of patients that experience treatment emergent AEs|The number of patients who receive the target dose for one or more intravenous infusions|The ratio of average daily partial pressure of oxygen (PaO2) to average fraction of inspired oxygen (FiO2) (PaO2:FiO2) over time|World Health Organization (WHO) COVID-19 ordinal scale score for clinical improvement|Change in Sequential Organ Failure Assessment (SOFA) Score over time|Mortality following initial infusion""}"
"4641","Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19","","NCT04736901","COVID-Anticoagulants","Drug: Enoxaparin|Drug: Rivaroxaban|Drug: Apixaban","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04736901","Recruiting","2020-12-01","2021-06-01","{""locations"":""Teachers Hospital, Cairo, Please Select, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""90"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in clotting factors level|Change in gas exchange over time|Time to increase in oxygenation|Duration of hospitalization|Monitoring of adverse events|In hospital mortality rate|Monitoring of hemoglobin levels.|Monitoring of platelets levels""}"
"4642","Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP","","NCT04735588","ITP1021","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04735588","Not yet recruiting","2021-04-01","2023-10-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of ITP patients in which COVID-19 occurs|Number of COVID-19 patients developing ITP""}"
"4643","Evaluation of Allied Healthcare in Patients Recovering From COVID-19","ParaCOV","NCT04735744","ParaCOV","Other: Patients recovering from COVID19 receive usual care by allied health professionals","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04735744","Not yet recruiting","2021-02-15","2024-01-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1315"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participation|Quality of life measured with EQ-5D-5L|Fatigue|Physical functioning|Costs|Patient Specific Activities|Nutritional Status|Global Assessment|Voice Problems|Swallowing Problems|Activities|Exercise capacity|Quadriceps strength|Hand grip strength|Bioimpedance (BIA|VAS-appetite, taste and smell|Dietary goal attainment|Liquid medical nutrition|Sarcopenia|Types of Stool|Physical Functioning|Cognitive Functioning""}"
"4644","Pediatric Virtual Visits as a Strategy for Access to Care During the COVID-19 Pandemic in a Pediatric Hospital","","NCT04736680","2392","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04736680","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""667"",""age"":""1 Month to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Prevalence of missed appointments|Clinical and administrative characteristics""}"
"4645","Immune Response Following COVID-19 Vaccination","IFVAC","NCT04736524","TCAI_IFVAC","Other: Rapid antibody test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04736524","Recruiting","2021-01-15","2022-03-01","{""locations"":""Texas Cardiac arrhythmia Institute, St. David's Hospital, Austin, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""16 Years to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Post-vaccination immune response""}"
"4646","Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19","","NCT04738175","AMG-COV-201-BR","Biological: COVI-AMG|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04738175","Not yet recruiting","2021-04-01","2021-11-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""209"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events by type, frequency, severity, and causality (safety)|Changes in viral shedding from Baseline to Day 15|Changes in viral shedding from Baseline to Day 8, 29, 43, and 70|Time to viral RNA negativity|Time to resolution of symptoms""}"
"4647","Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients","","NCT04739410","IRB#FMH-07-2020-IRB-766-M","Drug: Ivermectin","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04739410","Completed","2020-05-01","2020-06-30","{""locations"":""Aijaz Zeeshan Khan Chachar, Lahore, Punjab, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Resolution of symptoms|Progression of the disease""}"
"4648","Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia","","NCT04738136","SAMi-05-1-01","Drug: S-1226","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04738136","Not yet recruiting","2021-02-15","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment Emergent Adverse Effects|Change in use of supplemental oxygen therapy|Normalization of body temperature, measured in degrees Celsius.|Evaluation of changes in an SpO2\/FiO2 ratio|Mean change on a 7-point ordinal scale|Proportion of patients that progress to levels 6-7 of the 7-point Ordinal Scale|Time to progression to levels 6-7 of the 7-point Ordinal Scale|Normalization of oxygen saturation, SpO2 > 90%, while breathing room air, sustained minimum 24 hours|Time to normalization of oxygen saturation, SpO2 > 90%, while breathing room air sustained minimum 24 hours.|Change in daily symptom monitoring assessed by yes or no questions to a list of symptoms.|Days of hospitalization attributable to COVID-19 disease""}"
"4649","Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients","","NCT04738045","REC-H-PhBSU-21001","Drug: Remdesivir|Drug: Lopinavir/ Ritonavir and Remdesivir combination","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04738045","Recruiting","2020-11-01","2021-04-01","{""locations"":""Beni-suef University, Ban\u012b Suwayf, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of cured patients in the interventional group versus the proportion of cured patients in the control group|Monitoring of adverse events.""}"
"4650","SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19)","SCOPE","NCT04738695","BC-08719","Diagnostic Test: Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04738695","Recruiting","2021-02-01","2022-03-31","{""locations"":""Ghent University, Ghent, Oost-Vlaanderen, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3036"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of seroprevalence of anti-SARS-CoV-2 antibodies among nursing home residents and staff in Belgium|Change in SARS-CoV-2 seroconversion among nursing home residents and staff in Belgium|Assess the risk of getting symptomatically SARS-CoV-2 infected between the seropositive and seronegative group at baseline|Assess the proportion of deaths within 10 months between sero-positive and -negative participants at baseline visit for NH residents.|Assess the seroconversion time in the group of sero-negative participants at baseline visit in relation to observed risk factors such as care dependency scale (for NH residents),type of job assignment and flu vaccination (for staff)|Assess the duration of SARS-CoV-2 antigen specific seropositivity among NH residents and staff in Belgium.|Assess the time until death within 10 months between sero-positive and -negative participants at baseline visit for NH residents""}"
"4651","Respiratory Aerosols in Patients With COVID-19 and Healthy Controls","","NCT04739020","20-1001","Diagnostic Test: Resp-Aer-Meter|Diagnostic Test: Spirometry|Diagnostic Test: Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04739020","Recruiting","2021-01-18","2021-12-31","{""locations"":""Johann Wolfgang Goethe University Hospital, Frankfurt, Hessen, Germany"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""525"",""age"":""6 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Aerosol concentration in PCR SARS-CoV-2 positive and negative participants|Change in aerosol concentration over time in PCR SARS-CoV-2 positive participants|Aerosol concentration in children and adults|Qualitative and quantitative virus detection in respiratory secretions of patients with high aerosol concentrations.|Cofounder Analysis|Aerosol concentration and clinical symptoms in PCR SARS-CoV-2 positive participants""}"
"4652","Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database","CovPCR","NCT04738331","RECHMPL21_0051","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04738331","Recruiting","2021-02-01","2022-06-30","{""locations"":""Uh Montpellier, Montpellier, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""10000000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Detecting co-factors associated with Ct values|Detecting associations with epidemic spread""}"
"4653","New Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection","","NCT04739345","COVID-IL-6","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04739345","Recruiting","2020-12-01","2021-07-01","{""locations"":""Teachers Hospital, Cairo, Please Select, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""50"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in patients' clinical status|Time to increase in oxygenation|Duration of hospitalization|In hospital mortality|Incidence of non-invasive mechanical ventilation|Duration of non-invasive mechanical ventilation|Incidence of invasive mechanical ventilation|Duration of invasive mechanical ventilation|Occurrence of secondary infection""}"
"4654","'4C' Intervention to Reduce SARS-CoV-2 (Covid-19) Transmission","","NCT04739449","HUM00186126|3P30AG024824-16S1","Behavioral: Coaching, Cleaning, Communication, Collaboration","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04739449","Not yet recruiting","2021-04-05","2022-01-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Surface contamination with SARS-CoV-2""}"
"4655","Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients","","NCT04738760","COVID-VIT-D","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04738760","Recruiting","2020-12-01","2021-06-01","{""locations"":""Teachers Hospital, Cairo, Please Select, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""150"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Duration of hospitalization|In-hospital mortality|Clinical status improvement using six category ordinal scale|Change in gas exchange|Time to increase in oxygenation|Change in Lactate dehydrogenase (LDH) levels|Change in C-reactive protein (CRP) levels|Change in serum ferritin levels|Occurrence of secondary infection|Occurrence of at least one severe adverse event|Need for mechanical ventilator or intensive care unit (ICU) support""}"
"4656","Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina","COVID-19","NCT04738435","3876","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04738435","Recruiting","2021-01-05","2021-03-01","{""locations"":""Hospital Italiano de Buenos Aires, Buenos Aires, Caba, Argentina"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of events supposedly attributed to vaccines and immunizations after Sputnik V""}"
"4657","SMS Maama Project COVID-19","","NCT04739462","STUDY00010582","Behavioral: mHealth Platform","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04739462","Recruiting","2021-02-03","2022-02-01","{""locations"":""University of Minnesota, Minneapolis, Minnesota, United States|Makerere University, Kampala, Uganda"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""248"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Pre- to Post-Intervention Knowledge|Change in Knowledge on COVID-19|Rate of COVID Testing|Change in Pregnancy Risk Knowledge|Change in Breastfeeding Knowledge|Antenatal Care Rate|Skilled Birth Attendance Rate|Rate of Negative Pregnancy Outcomes""}"
"4658","Physical Activity and Physical Fitness Parameters in COVID-19 Quarantine","","NCT04738721","E-10840098-772.02-2685","Behavioral: Evaluation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04738721","Recruiting","2021-02-05","2021-04-15","{""locations"":""Istanbul Medipol University, Istanbul, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""87"",""age"":""18 Years to 22 Years \u00a0 (Adult)"",""outcome_measures"":""Physical activity|Physical fitness|Flexibility|Body composition""}"
"4659","Stories for Change: Digital Storytelling Intervention for Diabetes Self-Management in the COVID-19 Pandemic","S4C - COVID-19","NCT04738032","20-006354","Other: Digital Storytelling Intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04738032","Completed","2020-08-26","2021-01-07","{""locations"":""Mountain Park Health Center, Phoenix, Arizona, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""76"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Diabetes self-management behaviors""}"
"4660","A First-in-Human Study of AV-001 in Healthy Subjects","","NCT04737486","AV001-PK-001","Drug: AV-001|Other: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04737486","Recruiting","2020-12-16","2021-06-01","{""locations"":""Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participants experiencing drug-related adverse events|Cmax: Maximum plasma AV-001 concentration|Tmax: Time of maximum plasma AV-001 concentration|AUClast: AUC from predose (time 0) to the time of the last quantifiable concentration|AUCinf: AUC from predose (time 0) extrapolated to infinite time|AUCtau: AUC over the dose interval time|\u03bbz: The terminal elimination rate|T\u00bd: Terminal elimination half-life|CL: Total body clearance|Vz: Apparent volume of distribution|Ctau: Trough plasma concentration|Rac(AUCtau), Rac(Cmax), Rac(Ctau): Accumulation ratios assessment|LM: Time-invariance ratio calculation""}"
"4661","COVID-19 SARS-CoV-2 Screening Protocol","","NCT04740320","20IC6378","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04740320","Recruiting","2020-12-15","2021-05-01","{""locations"":""hVIVO Services Ltd, QMB Bioenterprise building, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years to 30 Years \u00a0 (Adult)"",""outcome_measures"":""Participants enrolled""}"
"4662","Pulmonary Tele-rehabilitation and Progressive Muscle Relaxation on Discharged Covid-19 Patients","","NCT04741282","18225","Other: Pulmonary telerehabilitation|Other: progressive muscle relaxation training","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04741282","Not yet recruiting","2021-02-15","2021-06-15","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""52"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Functional capacity|dyspnea|Sleep quality|anxiety and depression""}"
"4663","Organizational Measures to Prevent and Control COVID-19 Infection in Nursing Homes on the Risk of Death of Residents","PIANO-COVID-19","NCT04740658","RC31/20/0300","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04740658","Not yet recruiting","2021-02-01","2021-07-01","{""locations"":""University Hospital Toulouse - G\u00e9rontop\u00f4le, Toulouse, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""9600"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Death occurrence within one year of follow up|deaths related to COVID during the one-year follow-up""}"
"4664","The REnal Patients COVID-19 VACcination Immune Response (RECOVAC IR) Study","RECOVAC-IR","NCT04741386","NL76215.042.20","Biological: SARS-CoV-2 vaccination","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04741386","Not yet recruiting","2021-02-01","2022-12-31","{""locations"":""Radboud university medical center, Nijmegen, Gelderland, Netherlands|Amsterdam University Medical Center, Amsterdam, Noord-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Groningen, Groningen, Netherlands"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""850"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The antibody based immune response to vaccination against COVID-19 as compared to controls|Longevity of the antibody based immune response|SARS-CoV2 specific T and B cell response|Incidence and severity of solicited adverse events""}"
"4665","Development of an International COVID-19 Specific Quality of Life Questionnaire, Phase III. The OSLO COVID-19 QLQ","","NCT04740372","REK Norway: 171640","Other: No intervention. Method study. Psychometric testing","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04740372","Recruiting","2020-11-20","2021-11-01","{""locations"":""Oslo University Hospital, Oslo, Norway"",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Validated COVID-19 specific questionnaire""}"
"4666","PAtterns and Extension in COVID-19 Related Interstitial Pneumonia: CT Analysis","Paesi-COV-19","NCT04741178","Paesi-COV-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04741178","Recruiting","2020-03-20","2021-12-31","{""locations"":""Morgagni Pierantoni Hospital, Forl\u00ec, FC, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""600"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""CT evidence of peculiar patterns in Covid-19 pneumonia""}"
"4667","Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light","SPUTNIK-LIGHT","NCT04741061","01 - Sputnik Light - 2021","Biological: Sputnik Light|Other: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04741061","Recruiting","2021-02-19","2022-01-31","{""locations"":""Federal State Autonomous Educational Institution for Higher Education \""Immanuel Kant Baltic Federal University\"", Kaliningrad, Russian Federation|State Budgetary Healthcare Institution, Moscow, Consultation and Diagnosis Polyclinic No. 121, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 210, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 219, Moscow Healthcare Department, Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""diagnostic centre \u2116 5 associated with policlinic department of Moscow Healthcare Department\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""diagnostic clinical centre \u2116 1 Moscow Healthcare Department \"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""Municipal Polyclinic \u2116 2 Moscow Healthcare Department\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""Municipal Polyclinic \u2116 36 Moscow Healthcare Department\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""Municipal Polyclinic \u2116 6 Moscow Healthcare Department\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""Municipal Polyclinic \u2116 62 Moscow Healthcare Department\"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow \""Municipal Polyclinic \u2116 64 Moscow Healthcare Department\"", Moscow, Russian Federation|St. Petersburg's state budgetary health care Institution \""Municipal hospital \u2116 40 of Kurortniy area\"", Saint Petersburg, Russian Federation|St. Petersburg's state budgetary health care Institution \""Municipal hospital \u2116117\"", Saint Petersburg, Russian Federation|Federal state budgetary educational Institution for Higher Education \""Saratov State Medical University named after V.I. Razumovskiy\"" Ministry of Health of Russian Federation, Saratov, Russian Federation|LLC \""Uromed\"", Smolensk, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""6000"",""age"":""18 Years to 111 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence and severity of adverse events in study subjects|Percentage of study subjects with COVID-19 cases developed after vaccination|Humoral immunogenicity (Quantitative IgG antibodies to SARS-CoV-2 S Protein)|Humoral immunogenicity (IgG SARS-CoV-2 N-antibodies)""}"
"4668","Pediatric SARS-CoV-2 Infections: Course of COVID-19, Immune Responses, Complications and Long-term Consequences","PEDCOVID-19","NCT04741412","212_20 B","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04741412","Recruiting","2020-06-03","2021-05-31","{""locations"":""University Hospital Erlangen, Erlangen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""230"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""age-dependence of SARS-CoV-2 infection|percentage of household members infected by SARS-CoV-2|duration of primary COVID-19 symptoms|frequency of late-onset cardiovascular complications|frequency of postviral fatigue|frequency of noticeable temporary hair loss after COVID-19""}"
"4669","SURVEY ABOUT STRESS-COVID IN HEALTH CARE WORKERS IN NORTH AFRICA COUNTRY","COVID-STRESS","NCT04740125","UR17DN05SURVEY","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04740125","Completed","2020-05-01","2020-11-30","{""locations"":""Military Hospital of Tunis, Tunis, Montfleury, Tunisia"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""368"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""STRESS-COVID""}"
"4670","The Effects of Telerehabilitation on Muscle Function, Physical Activity and Sleep in Cystic Fibrosis During Pandemic","","NCT04742049","KA-20058","Other: Telerehabilitation-based|Other: Follow-up based","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04742049","Recruiting","2020-12-28","2021-03-01","{""locations"":""Hacettepe University, Ankara, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""8 Years to 14 Years \u00a0 (Child)"",""outcome_measures"":""1 minute sit to stand test (STS) repetitions|crunch repetitions|squat repetitions|push-up repetitions|plank duration|sleep quality assessment|physical activity level""}"
"4671","The Impact of Covid-19 on Cardiac Rehabilitation Participants and Staff","","NCT04740489","005","Behavioral: Phase 3 Cardiac rehabilitation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04740489","Not yet recruiting","2021-02-01","2022-06-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Psychosocial health and wellbeing|Acceptability to Participants|Feasible to Participants|Physical activity|Loneliness|Heart rate|Blood pressure|Disease management""}"
"4672","Wearable Diagnostic for Detection of COVID-19 Infection","","NCT04742569","1294415","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04742569","Recruiting","2020-12-21","2021-12-01","{""locations"":""ClinOne, Inc, Greenwood Village, Colorado, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2352"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.|The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms.|The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19.|The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms.""}"
"4673","Telerehabilitation in Covid-19 After Hospital Discharge","TRCovidA","NCT04742946","TRCovidAndalucía","Other: Standard Physiotherapy program|Other: Telerehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04742946","Not yet recruiting","2021-02-15","2021-09-30","{""locations"":""Facultad Ciencias de la Salud, Melilla, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""237"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Functional Capacity|Functional Capacity (SPBB) short performance physical battery test|The Short Form Health Survey SF-12|The Short Form Health Survey SF-12 Quality of Live|European Quality of Life-5 Dimensions EQ-5D|Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)|Cost-effectiveness of the telerehabilitation intervention""}"
"4674","A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","","NCT04742725","TAL-PRO-001","Drug: Placebo|Drug: Prothione™ (6g)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04742725","Not yet recruiting","2021-02-15","2021-03-26","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of subjects reporting each severity rating on an 8-point ordinal Scale on Day 29 Clinical Status is assessed by the Investigator using an 8-Category Ordinal Scale|Time to clinical resolution (TTCR)|\u2022 Clinical Improvement as assessed by change in total symptom score from baseline (for fever, myalgia, dyspnea and cough).|Change from baseline to Day 29 in RBC intracellular GSH concentration|Change from baseline to Day 29 in RBC in 8-OHdG level|Change from baseline to Day 29 in pulse oxygen saturation (SpO2)|Change from baseline to Day 29 in Quantitative C-Reactive Protein level|Change from baseline to Day 29 in Lymphocyte Count|Change from baseline to Day 29 in Sars-Cov2 viral load|Duration (days) of hospitalization|Duration (days) of mechanical ventilation supply|Duration (days) of oxygen use|Duration (days) of Intensive Care Unite admission|Mortality at Day 29""}"
"4675","Community Network-driven COVID-19 Testing of Vulnerable Populations in the Central US","C3","NCT04743908","20-1494","Other: Social Network Strategy + COVID-19 messaging","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04743908","Not yet recruiting","2021-02-01","2023-12-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Total number of tests among network members referred for COVID testing (network tested)""}"
"4676","Enriched Heparin Anti COVID-19 Trial","EnHanCed","NCT04743011","UPECLIN-MB-2","Drug: Heparin sodium|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04743011","Not yet recruiting","2021-02-15","2021-12-31","{""locations"":""School of Medicine at Botucatu- Paulista State University- UNESP, S\u00e3o Paulo, Brazil, Botucatu, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in activated partial thromboplastin time (APTT) > 1.5|Viral load in nasal swab reverse transcription polymerase chain reaction (RT-PCR).|Number of participants needing supplemental oxygen therapy|Number of participants needing mechanical pulmonary ventilation|Number of hospitalization days|Number of participants that develop renal failure|Number of participants that develop major cardiovascular events|Number of participants transferred to the intensive care unit (ICU)|Number of participants presenting secondary pulmonary bacterial infections|Number of participants that develop deep vein thrombosis (DVT)|Number of participants that develop pancreatitis|Number of participants that need corticosteroid therapy|Number of deaths among participants|Number of participants with increased white blood cell count|Number of participants with increased C reactive protein test|Number of participants with deterioration of arterial blood gas paO2\/pFiO2 ratio|Number of participants with altered sodium|Number of participants with altered potassium|Number of participants with increased pulmonary area compromised (%)""}"
"4677","Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients","","NCT04743401","F3731-P|42402","Other: Tele-exergaming Tablet","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04743401","Not yet recruiting","2021-04-01","2023-03-31","{""locations"":""Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Exercise dropout rate|Katz Activities of Daily Living Scale""}"
"4678","Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)","","NCT04742738","GBP510_001","Biological: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|Other: Normal saline (0.9% sodium chloride solution) - Stage 1|Biological: GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|Biological: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|Biological: GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|Other: Normal saline (0.9% sodium chloride solution)- Stage 2","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04742738","Recruiting","2021-01-20","2022-04-01","{""locations"":""Korea University Ansan Hospital, Ansan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""260"",""age"":""19 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of immediate systemic reactions - Stage 1|Occurrence of solicited local Adverse Events (AEs) during 7 days post each vaccination - Stage 1|Occurrence of solicited systemic AEs during 7 days post each vaccination - Stage 1|Occurrence of unsolicited AEs during 28 days post each vaccination - Stage 1|Occurrence of Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs) and Adverse Events of Special Interest (AESIs) during the whole study period - Stage 1|(Only in Sentinel group) Occurrence of out-of-normal range clinical laboratory test results (including change from baseline values) during 7 days post 1st vaccination - Stage 1|GMT of IgG antibody to the SARS-CoV-2 RBD measured by Enzyme-linked Immunosorbent Assay (ELISA) - Stage 2|GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA - Stage 2|Percentage of participants with \u2265 4-fold rise from baseline in ELISA IgG titer - Stage 2|GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays - Stage 2|GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays - Stage 2|Percentage of participants with \u2265 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer - Stage 2|Cell-mediated response for both Th1 and Th2 (e.g. INF-\u03b3, IL-4 using Enzyme-linked ImmunoSpot (ELISpot) or other system) - Stage 2|GMT of IgG antibody to the SARS-CoV-2 RBD measured by ELISA - Stage 1|GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA - Stage 1|Percentage of participants with \u2265 4-fold rise from baseline in ELISA IgG titer - Stage 1|GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays - Stage 1|GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays - Stage 1|Percentage of participants with \u2265 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer - Stage 1|Cell-mediated response for both Th1 and Th2 (e.g. INF-\u03b3, IL-4 using ELISpot or other system) - Stage 1|Occurrence of immediate systemic reactions - Stage 2|Occurrence of solicited local AEs during 7 days post each vaccination - Stage 2|Occurrence of solicited systemic AEs during 7 days post each vaccination - Stage 2|Occurrence of unsolicited AEs during 28 days post each vaccination - Stage 2|Occurrence of SAEs, MAAEs and AESIs during the whole study period - Stage 2""}"
"4679","Steam Inhalations in COVID-19 Patients","Steam-COVID","NCT04743349","Steam-COVID","Procedure: Steam inhalations","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04743349","Recruiting","2021-01-26","2021-10-31","{""locations"":""Meyer Children's Hospital, Florence, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in viral shedding|Clinical outcome|Negativization rate""}"
"4680","Vaccination Against COVID-19 in Chronic Kidney Disease","","NCT04743947","2020-1237","Other: No intervention; observational study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04743947","Recruiting","2020-12-21","2025-12-31","{""locations"":""MVZ DaVita Rhein-Ruhr, D\u00fcsseldorf, Germany|KfH Kuratorium f\u00fcr Dialyse und Nierentransplantation e.V., D\u00fcsseldorf, Germany|University Hospital D\u00fcsseldorf, Heinrich Heine University, D\u00fcsseldorf, Germany|Nephrocare Mettmann, Mettmann, Germany|Hospital Solingen, Solingen, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2- antibody- titer""}"
"4681","The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers","COVALIA","NCT04742842","COV101","Biological: COVIGEN 0.8 mg ID or Placebo ID|Biological: COVIGEN 2.0 mg IM or Placebo IM|Biological: COVIGEN 4.0 mg IM or Placebo IM","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04742842","Not yet recruiting","2021-02-15","2022-12-31","{""locations"":""Scientia Clinical Research, Randwick, New South Wales, Australia|Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Adelaide, South Australia, Australia|Wesfarmers Centre of Vaccines and Infectious Diseases Telethon Kids Institute, Perth, Western Australia, Australia"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""150"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of solicited local reactogenicity AEs|Frequency of solicited systemic reactogenicity AEs|Frequency of any unsolicited AEs|Frequency of any serious adverse events (SAEs)|Frequency of any medically attended adverse events (MAAES)|Change in safety laboratory values from baseline|GMTs for serum neutralizing antibody response|GMFR from baseline for serum neutralizing antibody response|Seroconversion rate for serum neutralizing antibody response|GMTs for serum S1- and RBD-specific IgG antibody responses|GMFR from baseline for serum S1- and RBD-specific IgG antibody responses|Seroconversion rate serum S1- and RBD-specific IgG antibody responses|Geometric means of T-cells (spot-forming cells) producing IFN\u03b3, IL-2, or both for S protein specific IFN-\u03b3 and IL-2 T-cell responses|Fold rise of T-cells (spot-forming cells) producing IFN\u03b3, IL-2, or both for S protein specific IFN-\u03b3 and IL-2 T-cell responses|Proportion of participants with significant T-cell responses for S protein specific IFN-\u03b3 and IL-2 T-cell responses""}"
"4682","SARS-CoV-2 Specific Cytotoxic T Lymphocytes for the Treatment of COVID-19 in Patients With Cancer","","NCT04742595","2020-0759|NCI-2020-13875","Biological: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes","Interventional","No Results Available","Early Phase 1","https://ClinicalTrials.gov/show/NCT04742595","Recruiting","2020-12-18","2022-03-31","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""16"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients who receive at least one severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) specific cytotoxic T lymphocytes infusion|Incidence of adverse events|Response to cytotoxic T lymphocytes|Overall survival|Relapse free survival (original malignancy)|Cumulative incidence of coronavirus disease 2019 pneumonia resolution after therapy|Cumulative incidence of grade 2-4 or 3-4 graft versus host disease (GVHD), and chronic GVHD|All-cause mortality|Proportion of subjects alive and free of respiratory failure|Reconstitution of anti-virus immunity""}"
"4683","Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System","","NCT04743388","900/24-12-2020","Biological: BNT162b2|Biological: Other vaccine against SARS-Cov-2","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04743388","Recruiting","2021-01-04","2022-04-01","{""locations"":""Department of Clinical Therapeutics, General Hospital of Athens ALEXANDRA, Athens, Greece"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Neutralizing antibodies against SARS-CoV-2|Development of anti-S-RBD antibodies against SARS-CoV-2|Number of memory B-cells against SARS-CoV-2|Number of memory T-cells against SARS-CoV-2|Number of monocytes (CD14+, CD16+)|Interleukin 6 (IL-6), Interleukin 3 (IL-3), Interleukin 1b (IL-1b) levels|TNF-a levels|CRP levels""}"
"4684","COVID-19 Resuscitation Plans and Decisions on Escalation and Limitation of Treatment","CORDEAL","NCT04743232","NL76435","Other: Decision tool for clinicians","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04743232","Recruiting","2021-03-01","2022-01-31","{""locations"":""OLVG, Amsterdam, Noord-Holland, Netherlands|Maasstad Ziekenhuis, Rotterdam, Zuid-Holland, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|Rijnstate, Arnhem, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Radboud UMC, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""ICU-admissions|Mortality|Health care professionals' satisfaction|Patient satisfaction""}"
"4685","A Feasibility Study Using the CoronaCheck Device to Identify Incident Cases of SARS CoV-2 Covid-19","","NCT04742712","PHT/2020/57","Device: CoronaCheck Device","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04742712","Recruiting","2020-10-27","2021-12-01","{""locations"":""Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Presence of SARS-CoV-2 infection in those with high clinical suspicion and\/or a positive RT-PCR swab.""}"
"4686","RSV Burden in Outpatient Settings","Oursyn","NCT04743609","2020-A02876-33","Diagnostic Test: nasopharyngeal samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04743609","Not yet recruiting","2021-02-01","2023-01-11","{""locations"":""ACTIV, Cr\u00e9teil, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1600"",""age"":""up to 24 Months \u00a0 (Child)"",""outcome_measures"":""RSV proven|Proportion of Respiratory Tract Infections by RSV Status|Proportion of Respiratory Tract Infections with SARS-CoV-2|Proportion of associated complications by RSV status|Proportion of AOM by RSV status|Proportion of pneumonia by RSV status|Score of Quality of life|Caracteristic of tests""}"
"4687","Effect of Covid-19 Affliction on Psychological and Mental Health Among College Going Students: Cross-Sectional Survey","","NCT04746443","ECM#2020-2501","Other: NOT APPLICABLE (NA)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04746443","Recruiting","2020-12-08","2021-03-08","{""locations"":""King Khalid University, Abha, Aseer, Saudi Arabia"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Cross-Sectional"",""enrollment"":""40"",""age"":""18 Years to 30 Years \u00a0 (Adult)"",""outcome_measures"":""EVENT IMPACT SCALE - REVISED""}"
"4688","AGILE (Early Phase Platform Trial for COVID-19)","","NCT04746183","UoL001542","Drug: CST-2: EIDD-2801|Drug: CST-2: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04746183","Recruiting","2020-07-03","2021-12-31","{""locations"":""Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Master Protocol: Dose-finding\/Phase I|Master Protocol: Efficacy evaluation\/Phase II - Severe patients (Group A)|Master Protocol: Efficacy evaluation\/Phase II - Mild to moderate patients (Group B)|CST-2 Phase I: To determine the safety and tolerability of multiple ascending doses of EIDD-2801 to recommend dose for phase II.|CST-2 Phase II: To determine the ability of EIDD-2801 to reduce serious complications of COVID-19 including hospitalization, reduction in SAO2<92%, or death.|Master Protocol: Safety|Master Protocol: To evaluate clinical improvement|Master Protocol: To evaluate clinical improvement using WHO clinical progression scale|Master Protocol: To evaluate clinical improvement using SpO2\/FiO2|Master Protocol: To evaluate discharge|Master Protocol: To evaluate admission to ICU|Master Protocol: To evaluate safety further (WCC)|Master Protocol: To evaluate safety further (Hg)|Master Protocol: To evaluate safety further (platelets)|Master Protocol: To evaluate safety further (creatinine)|Master Protocol: To evaluate safety further (ALT)|Master Protocol: To evaluate overall mortality|Master Protocol: To evaluate the number of oxygen-free days|Master Protocol: To evaluate ventilator-free days|Master Protocol: To evaluate incidence of new mechanical ventilation use|Master Protocol: To evaluate National Early Warning Score (NEWS)2\/qSOFA|Master Protocol: To evaluate translational outcomes (Viral Load)|Master Protocol: To evaluate translational outcomes (Baseline SARS-COV-2)|CST-2 Additional: Pharmacokinetic Objective: To define PK of EIDD-2801 and EIDD-1931 in plasma following multiple doses administered to patients with COVID-19.|CST-2 Additional: Virologic Objective: To assess the difference in viral clearance (time to negative PCR) between EIDD-2801 and control.|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (FLU-PRO)|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (WHO Scale).|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (NEWS2)|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (mortality)|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (death)""}"
"4689","Ivermectin Role in Covid-19 Clinical Trial","IRICT","NCT04746365","1029076|2101001","Drug: ivermectin|Drug: hydroxychloroquine|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04746365","Completed","2020-12-06","2021-02-06","{""locations"":""Shebin-Elkom teaching hospital, Shib\u012bn Al Kawm, Menoufia, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reduction in the WHO ordinal scale of clinical status by at least two points|Time to discharge|Mortality""}"
"4690","Cellular-Mediated Immunity in COVID-19","DEMETRA","NCT04746521","L. Vanvitelli","Diagnostic Test: Multitest 6 color TBNK and BD Lyotubes","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04746521","Recruiting","2021-03-01","2022-12-01","{""locations"":""U.O.C. Division of Clinical Immunology, Immunohematology, Transfusion Medicine and Transplant Immunology, Regional Reference Laboratory of Transplant Immunology, Department of Internal and Specialty Medicine, A.O.U., UniversityofCampania \""Luigi Vanvitelli, Napoli, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Detection of Cellular-Mediated Immune Response|Detection of T cell subpopulation maturation""}"
"4691","Neurological and Neuropsychological Sequelae of COVID-19 Infection","NeNeSCo","NCT04745611","NL75102.068.20","Diagnostic Test: MRI|Diagnostic Test: Neuropsychological assessment|Diagnostic Test: Questionnaires Patient|Diagnostic Test: Questionnaires Family","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04745611","Recruiting","2020-12-12","2021-09-01","{""locations"":""Maastricht University, Maastricht, Limburg, Netherlands|Amsterdam Universitair Medische Centra, Amsterdam, Netherlands|Universitair Medische Centra Utrecht, Utrecht, Netherlands"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in participation|Change in patient quality of life|Presence of MRI abnormalities|Neurological symptoms|Deficits in cognition|Deficits in memory|Deficits in visual attention & task switching|Deficits in selective attention, cognitive flexibility & processing speed|Deficits in working memory, attention & executive function|Change in subjective cognitive complaints|Change in depression\/anxiety|Change in post-traumatic stress symptoms|Change in family burden|Change in family quality of life|MRI abnormalities (specific)""}"
"4692","Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)","","NCT04745351","GS-US-540-5912|2020-005416-22","Drug: Remdesivir|Drug: RDV Placebo|Drug: Standard of Care","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04745351","Recruiting","2021-03-01","2021-09-01","{""locations"":""Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""1116"",""age"":""12 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Composite of All-Cause Mortality or Invasive Mechanical Ventilation (IMV) Through Day 29|All-Cause Mortality Through Day 29|Invasive Mechanical Ventilation Through Day 29|Time to Recovery|Clinical Status Assessed by an 8-Point Ordinal Scale on Day 15|Clinical Status Assessed by an 8-Point Ordinal Scale on Day 29|Renal Replacement Therapy (RRT)-Free Days (Among Those Without End-Stage Kidney Disease [ESKD] at Randomization) Through Day 29|Recovery Through Day 29|Percentage of Participants Experiencing Serious Adverse Events (SAEs)|Percentage of Participants who Permanently Discontinue Investigational Drug due to Adverse Events (AEs)""}"
"4693","Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19","APOLLO","NCT04746339","004/2020","Drug: Apixaban 2.5 MG|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04746339","Not yet recruiting","2021-02-01","2021-12-01","{""locations"":""Hospital Israelita Albert Einstein, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of days alive and out of hospital or emergency department|Hospitalization due to bleeding|Hospitalizations for cardiopulmonary causes|All-cause hospitalization|All-cause death|Days free of venous thromboembolism|Major cardiovascular events (MACE)""}"
"4694","COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study","COPPER","NCT04746430","GPRI-21001-COV|2021-000235-30","Drug: Dexamethasone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04746430","Not yet recruiting","2021-02-01","2022-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""2000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Hospitalization\/death|Recovery|Disease severity|HCRU""}"
"4695","Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic","","NCT04745923","GO 21/127","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04745923","Recruiting","2021-01-20","2021-03-30","{""locations"":""Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Ankara, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""28"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fear of COVID-19|Physical activity|Qol|Anxiety and depression|Fear of movement""}"
"4696","Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19","","NCT04745442","ANTITROMBINA","Drug: Antithrombin + best available treatment|Drug: Best available treatment","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04745442","Completed","2020-04-27","2021-01-15","{""locations"":""Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Combined variable: mortality or worsening rate with need for non-invasive mechanical ventilation or with need for invasive mechanical ventilation|Time to clinical improvement (decreased risk of developing SARS or death)|Evaluate the improvement of the oxygenation index - PaO2 \/ FiO2- at 24 and 48 hours.|Improvement of the analytical parameters: time (in days) until the tendency to normalization (decrease >= 20%) of DD, ferritin, LDH, PCR and IL-6; the criteria reached before will be used.|Time (in days) until improvement in oxygenation: - Time until the SpO2 \/ FiO2 ratio exceeds the worst SpO2 \/ FiO2 prior to AT treatment.|Time to radiological improvement in radiological report.|Time (in days) of non-invasive mechanical ventilation.|Time (in days) of invasive mechanical ventilation.|Mortality rate in hospital and one month after pharmacological intervention.|Percentage of patients who suffer any adverse effect related to pharmacological intervention.|Incidence of adverse events related to medication and its administration.|Incidence in the appearance of allergic type hypersensitivity|Incidence of B19 parvovirus infection|Bleeding""}"
"4697","Clinical Characteristics of Patients With Leukemia and COVID-19","","NCT04745416","DECS/JPO-CT-400-2020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04745416","Completed","2020-01-01","2021-01-25","{""locations"":""Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, State Of Mexico, Mexico|Hospital General de M\u00e9xico \""Dr. Eduardo Liceaga\"", Mexico City, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival|Progression free survival|Number of relapses|Complete Remission|COVID-19 confirmed""}"
"4698","Responses to COVID-19 Vaccination in Patients With Cancer","ReCOVer","NCT04745377","HE_42C/21 ReCOVer study","Diagnostic Test: IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04745377","Recruiting","2021-01-12","2022-01-31","{""locations"":""Metropolitan Hospital, Athens, Attica, Greece"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical outcome post vaccination|Serological outcome post vaccination, immune response to vaccination against COVID-19 (measured as antibody titre 1 month after completion of vaccination|Serological outcome post vaccination, immune response to vaccination against COVID-19 (measured as antibody titre 3 months after completion of vaccination|Safety and Tolerance assessment - AEs; Incidence and severity of Adverse Events post vaccination|Correlation of factors that might affect immune response in patients with cancer compared to individuals without cancer""}"
"4699","COVID-19 Contact Study by Antigen Detection Test","DETAC","NCT04745533","12/2020","Diagnostic Test: Antigen detection test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04745533","Not yet recruiting","2021-02-15","2021-06-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity of the antigen detection test used in the study of contacts of COVID-19 patients.|Specificity of the antigen detection test used in the study of contacts of COVID-19 patients.|Positive predictive value of the antigen detection test used in the study of contacts of COVID-19 patients.|Negative predictive value of the antigen detection test used in the study of contacts of COVID-19 patients.|Positive likelihood ratio of the antigen detection test used in the study of contacts of COVID-19 patients.|Negative likelihood ratio of the antigen detection test used in the study of contacts of COVID-19 patients.|Change in the pretest probability when the antigen detection test result is positive in a COVID-19 patient contact.|Change in the pretest probability when the antigen detection test result is negative in a COVID-19 patient contact.|Cut-off point of the cycle threshold of the polymerase chain reaction test that discriminates infectivity.|Risk of SARS-CoV2 infection in close contacts of COVID-19 patients with a positive polymerase chain reaction test depending on whether the antigen detection test is positive or negative.|To predict a positive result of the polymerase chain reaction test based on the appearance of symptoms during quarantine|The percentage of COVID-19 patient contacts with symptoms during the quarantine.""}"
"4700","The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19","","NCT04746092","1068-20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04746092","Recruiting","2021-01-06","2022-05-24","{""locations"":""Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""550"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Capability of Haemato-oncology patients to generate antibodies against COVID-19 after infection and vaccination.|Assess COVID19 morbidity rates|Documentation of the vaccine side effects|Comparison of antibody formation to COVID19 between haemato-oncology patients and healthy participants""}"
"4701","Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19","","NCT04746066","EMO AER COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04746066","Active, not recruiting","2020-03-31","2030-12-01","{""locations"":""Ospedali Galliera - S.S.D. Microcitemia, anemie congenite e dismetabolismo del ferro, Genova, Italy"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""10000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Number of Patients with Covid 19 infection""}"
"4702","Hospitalizations During Pandemia in the Italian Coronary Care Unit Network","BLITZ-COVID19","NCT04744415","K22","Other: Epidemiology of admissions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04744415","Recruiting","2020-11-09","2021-02-09","{""locations"":""Ospedale Santo Spirito - Sc Cardiologia, Casale Monferrato, AL, Italy|Istituto Scientifico Inrca - Uo Cardiologia\/Utic\/Telecardiologia, Ancona, AN, Italy|Ospedale Generale Regionale-Po U. Parini - U.O. Cardiologia E Cure Intensive Card., Aosta, AO, Italy|Po Sant'Ottone Frangipane - U.O.C. Cardiologia - Utic, Ariano Irpino, AV, Italy|Aorn San Giuseppe Moscati - U.O. Cardiologia\/Utic 'D. Rotiroti', Avellino, AV, Italy|Ospedale Miulli - U.O.C. Cardiologia - Utic, Acquaviva Delle Fonti, BA, Italy|Aou Policlinico - Uoc Cardiologia Ospedaliera, Bari, BA, Italy|Ospedale Di Venere - U.O.C. Di Cardiologia, Bari, BA, Italy|Ospedale San Paolo - Cardiologia-Utic, Bari, BA, Italy|Ospedale Di Bentivoglio - U.O. Di Cardiologia, Bentivoglio, BO, Italy|Ospedale Maggiore - U.O. Di Cardiologia, Bologna, BO, Italy|Asst Spedali Civili - Cardiologia, Brescia, BS, Italy|Ospedale L. Bonomo - Cardiologia - Utic, Andria, BT, Italy|Ospedale Generale Regionale - Divisione Di Cardiologia, Bolzano, BZ, Italy|Arnas G. Brotzu - Cardiologia Con Utic, Cagliari, CA, Italy|A.O.U. Cagliari Policlinico Monserrato - Sc Cardiologia Utic Emodinamica, Monserrato, CA, Italy|Ospedale A. Cardarelli - U.O. Cardiologia E Utic, Campobasso, CB, Italy|Presidio Ospedaliero Moscati - U.O.C. Cardiologia-Utic, Aversa, CE, Italy|Az. Ospedaliera S. Anna E S. Sebastiano - U.O. Cardiologia-Utic, Caserta, CE, Italy|Ospedale Civile Ave Gratia Plena - U.O. Di Cardiologia E Utic, Piedimonte Matese, CE, Italy|Ospedale San Giuseppe E Melorio - U.O.C. Cardiologia Utic, Santa Maria Capua Vetere, CE, Italy|Presidio Ospedaliero San Rocco - U.O.C. Cardiologia - Utic, Sessa Aurunca, CE, Italy|Ospedale San Pio Da Pietrelcina - Cardiologia, Vasto, CH, Italy|Ospedale Regina Montis Regalis - U.O. Cardiologia-Utic, Mondov\u00ec, CN, Italy|Ospedale Maggiore Ss. Annunziata - Sc Cardiologia, Savigliano, CN, Italy|Ospedale Moriggia Pelascini - Unita' Operativa Di Cardiologia, Gravedona, CO, Italy|Ospedale S. Anna - U.O.C. Di Cardiologia, San Fermo Della Battaglia, CO, Italy|P.O. Garibaldi Centro - U.O.C. Cardiologia, Catania, CT, Italy|Centro Cuore Morgagni - U.F. Utic Ed Emodinamica, Pedara, CT, Italy|Arcispedale Sant'Anna - U.O. Cardiologia - Utic, Ferrara, FE, Italy|Ospedali Riuniti - S.C. Di Cardiologia Univ.-Utic, Foggia, FG, Italy|Ospedale Casa Sollievo Della Sofferenza - Cardiologia - Utic - Riabil Cardiologica, San Giovanni Rotondo, FG, Italy|Presidio Ospedaliero T. Masselli Mascia - S.C. Cardiologia - Utic - Riabil. Card., San Severo, FG, Italy|Ospedale Santa Maria Annunziata - Cardiologia, Bagno A Ripoli, FI, Italy|Ospedale San Giuseppe - Cardiologia, Empoli, FI, Italy|Aou Careggi - Cardiologia Interventistica, Firenze, FI, Italy|Ospedale San Giovanni Di Dio - Cardiologia, Firenze, FI, Italy|Ospedale Santa Maria Nuova - Hdu Cardiologica\/Utic, Firenze, FI, Italy|E.O. Ospedali Galliera - S. C. Cardiologia, Genova, GE, Italy|Presidio Ospedaliero - U.O. Cardiologia, Sanremo, IM, Italy|Ospedale Civile Sacro Cuore Di Gesu' - Uo Cardiologia Utic, Gallipoli, LE, Italy|Ospedale Ignazio Veris Delli Ponti - Uoc Cardiologia-Utic, Scorrano, LE, Italy|Azienda Osp. Cardinale G. Panico - U.O. Cardiologia - Utic, Tricase, LE, Italy|Ospedali Riuniti - U.O.C. Cardiologia E Utic, Livorno, LI, Italy|Nuovo Ospedale Versilia - Sc Cardiologia, Lido Di Camaiore, LU, Italy|Ospedale San Gerardo - U.O. Cardiologia-Utic, Monza, MB, Italy|Aor Papardo - U.O. Cardiologia Con Utic, Messina, ME, Italy|Ospedale Piemonte - Cardiologia E Utic, Messina, ME, Italy|Centro Cardiologico Monzino - Terapia Intensiva Cardiologica (Utic), Milano, MI, Italy|Irccs Policlinico Multimedica - Uo Di Cardiologia, Sesto San Giovanni, MI, Italy|Ospedale Civile Di Baggiovara - U.O. Di Cardiologia, Modena, MO, Italy|Ospedale San Francesco - Cardiologia - Utic, Nuoro, NU, Italy|Fondazione G. Giglio - U.O. Cardiologia E Utic, Cefal\u00f9, PA, Italy|Aor Villa Sofia-Cervello P.O. Cervello - U.O. Cardiologia - Cervello, Palermo, PA, Italy|Aor Villa Sofia-Cervello Po Villa Sofia - U.O.C. Cardiologia E Utic - Villa Sofia, Palermo, PA, Italy|Ospedale Civile 'Guglielmo Da Saliceto' - Uo Cardiologia, Piacenza, PC, Italy|Ospedale Civile Dello Spirito Santo - Utic E Cardiologia Interventistica, Pescara, PE, Italy|Presidio Ospedaliero Citta' Di Castello - U.O. Di Cardiologia, Citt\u00e0 Di Castello, PG, Italy|Ospedale Gubbio-Gualdo Tadino - U.O. Di Utic E Cardiologia, Gubbio, PG, Italy|Ospedale Generale Provinciale Lotti - U.O. Malattie Cardiovascolari Vde E Avc, Pontedera, PI, Italy|Ospedale Di Pordenone - S.O.C. Cardiologia, Pordenone, PN, Italy|Ospedale Ss. Cosma E Damiano - U. O. Cardiologia - Utic, Pescia, Point, Italy|Ospedale Santo Stefano - U.O. Cardiologia, Prato, PO, Italy|Ospedale Generale Di Zona - U.O. Cardiologia - Utic, Lagonegro, PZ, Italy|Azienda Ospedaliera San Carlo - Ssd Utic, Potenza, PZ, Italy|Ospedale Per Gli Infermi - U.O. Cardiologia - Utic, Faenza, RA, Italy|Ospedale Civile Santa Maria Delle Croci - U.O. Di Cardiologia, Ravenna, RA, Italy|P.O. San Camillo de Lellis - U.O.C. Cardiologia, Rieti, RI, Italy|Ospedale Civile San Paolo - U.O. Cardiologia - Utic, Civitavecchia, RM, Italy|Ospedale S. Maria Goretti - Uoc Malattie Cardiovascolari, Latina, RM, Italy|Aurelia Hospital - U.O.C Cardiologia, Roma, RM, Italy|Clinica Citta' Di Roma - Cardiologia-Utic, Roma, RM, Italy|European Hospital - U.O. Cardiologia Interventistica, Roma, RM, Italy|Ospedale Fatebenefratelli - U.O.C. Cardiologia, Roma, RM, Italy|Ospedale San Camillo - Uoc Cardiologia, Roma, RM, Italy|Ospedale Sandro Pertini - Uoc Cardiologia, Roma, RM, Italy|Ospedale Sant'Andrea Di Roma - U.O.C. Cardiologia, Roma, RM, Italy|Ospedale Santa Maria Della Misericordia - U.O.C. Cardiologia, Rovigo, RO, Italy|Presidio Osped. S. Maria Della Speranza - U.O. Di Cardiologia, Battipaglia, SA, Italy|P.O. Nocera-Pagani - Osp. Umberto I - Uoc Cardiologia - Utic, Nocera Inferiore, SA, Italy|Presidio Ospedaliero Luigi Curto - Uo Cardiologia-Utic, Polla, SA, Italy|Aou S. Giovanni Di Dio-Ruggi D'Aragona - U.O.C. Utic, Salerno, SA, Italy|Ospedale San Luca - U.O. Utic - Cardiologia, Vallo Della Lucania, SA, Italy|Ospedale Dell'Alta Val D'Elsa - Uosd Cardiologia-Utic, Poggibonsi, SI, Italy|Aou Senese Ospedale S. Maria Alle Scotte - U.O.C. Cardiologia Clinico-Chirurg. Utic, Siena, SI, Italy|Ospedale Civile - U.O. Cardiologia, Sondrio, SO, Italy|Ospedale S. Andrea - S.C. Cardiologia, La Spezia, SP, Italy|Ospedale E. Muscatello - U.O. Di Cardiologia - Utic, Augusta, SR, Italy|Ospedale G. Di Maria - Cardiologia Utic, Avola, SR, Italy|P.O. Lentini - U.O. Di Cardiologia Con Utic, Lentini, SR, Italy|Ospedale Nostra Signora Di Bonaria - U.O.C. Cardiologia E Utic, San Gavino Monreale, SU, Italy|Ospedale Santa Maria Del Carmine - Cardiologia, Rovereto, TN, Italy|Ospedale Santa Chiara - Divisione Di Cardiologia, Trento, TN, Italy|Po S. Antonio Abate Di Trapani - U.O.C. Di Cardiologia E Utic, Erice, TP, Italy|Ospedale Santa Maria Dei Battuti - U.O. Di Cardiologia, Conegliano, TV, Italy|Pou Santa Maria Della Misericordia - S.O.C. Cardiologia, Udine, UD, Italy|Presidio Ospedaliero Di Saronno - U.O.C. Di Cardiologia, Saronno, VA, Italy|Ospedale Civile - U.O. Cardiologia, Mirano, VE, Italy|Ospedale Civile - U.O.C. Cardiologia, Arzignano, VI, Italy|Ospedale Civile San Bortolo - U.O.C. Cardiologia, Vicenza, VI, Italy|Ospedale Mater Salutis - U.O.C. Cardiologia, Legnago, VR, Italy|Casa Di Cura Dr. Pederzoli - Servizio Di Cardiologia, Peschiera Del Garda, VR, Italy|Ospedale Ss. Trinita' - S.C. Di Cardiologia, Borgomanero, Italy|Ospedale San Leonardo - U.O. Di Cardiologia-Utic, Castellammare Di Stabia, Italy|Ospedale San Giovanni Di Dio - Uo Cardiologia - Utic, Frattamaggiore, Italy|Ospedale Generale Di Zona - U.O. Cardiologia - Utic, Giugliano In Campania, Italy|Ospedale Anna Rizzoli - Cardiologia-Utic, Lacco Ameno, Italy|Aorn Cardarelli - U.O. Cardiologia Con Utic, Napoli, Italy|Clinica Mediterranea - U.O. Di Cardiologia, Napoli, Italy|Ospedale Dei Pellegrini - Uoc Cardiologia-Utic, Napoli, Italy|Ospedale Del Mare - U.O. Cardiologia Con Utic, Napoli, Italy|Pres. Ospedaliero S. Maria Della Pieta' - U.O. Cardiologia E Utic, Nola, Italy|Aou Maggiore Della Carita' - Cardiologia Ii, Novara, Italy|PO San Filippo neri - ASL Roma1, Roma, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""4000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact that COVID-19 infection may have had on the in-hospital mortality|Epidemiology and management of patients admitted to ICU""}"
"4703","COVID-19. CT-Scan Modeling in COVID19 Sequelae","SILICOVILUNG","NCT04747769","APHP210006","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04747769","Not yet recruiting","2021-02-01","2021-10-01","{""locations"":""H\u00f4pital Avicenne APHP, Bobigny, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Qualitative and quantitative parameters obtained by in silico modeling of intra-pulmonary vascular remodeling in 3D at 2-4 months.|Specific mechanical parameters of pulmonary parenchymal stiffness\/localized compliances obtained by dynamic poromechanical modeling at 2-4 months.""}"
"4704","An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine","Projeto S","NCT04747821","COV-04-IB","Biological: Adsorbed COVID-19 (Inactivated) Vaccine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04747821","Enrolling by invitation","2021-02-17","2022-02-01","{""locations"":""Hospital Estadual de Serrana, Serrana, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""30000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID-19 cases after two-doses immunization schedule in clusters in the first quarter of study|Incidence of COVID-19 cases after two-doses immunization schedule in clusters up to one year of study|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization status|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to pre-existing SARS-CoV-2 antibodies|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization coverage|Incidence of hospitalization and death due to COVID-19 after two-doses immunization schedule in clusters|Change in average number of reported COVID-19 cases in the study area in comparison to other neighboring cities|Medically-attended adverse reactions to the study vaccine|Frequency of severe COVID-19 cases|Frequency of adverse events of special interest after immunization|Acceptability of the study vaccine|Adherence to vaccination schedule""}"
"4705","COVID-19 Convalescent Plasma Therapy","TPCC","NCT04747158","PINV20-388","Biological: Convalescent plasma","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04747158","Completed","2020-08-10","2021-01-10","{""locations"":""Facultad de Ciencias M\u00e9dicas - Universidad Nacional de Asunci\u00f3n, Asunci\u00f3n, Paraguay"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""350"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival (30-day mortality)|Median length of hospital stay|Change in clinical status|Change in inflammatory marker: ferritin|Change in inflammatory marker: D dimer|Change in inflammatory marker: leukocytes|Serum Antibody Titers|Transfer to ICU|Transfusion related events""}"
"4706","Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity","","NCT04747366","NAPKON-HAP","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04747366","Recruiting","2020-11-06","2025-11-30","{""locations"":""University Medical Center Freiburg Department of Internal Medicine II Department of Infectiology, Freiburg, Baden-W\u00fcrttemberg, Germany|University Hospital Heidelberg Clinic for Gastroenterology, Infections, Poisoning, Heidelberg, Baden-W\u00fcrttemberg, Germany|Clinic of the University of Munich Medical Clinic and Polyclinic III, Munich, Bayern, Germany|University Hospital Frankfurt Medical Clinic II Department of infectiology, Frankfurt, Hessen, Germany|University Hospital Giessen (+Marburg) Medical Clinic II Pneumology and internal intensive care medicine Infectiology, Gastroenterology, Nephrology, Gie\u00dfen, Hessen, Germany|Hanover Medical School Clinic for Pneumology, Hannover, Niedersachsen, Germany|University Hospital Cologne Internal Medicine I and Hematology and Oncology, Infectiology, additional qualification in Emergency Medicine, Cologne, Nordrhein-Westfalen, Germany|University Medical Center Schleswig-Holstein (Campus Kiel): Internal medicine, gastroenterology, pneumology, allergology, sleep medicine, emergency medicine, intensive care, Kiel, Schleswig-Holstein, Germany|University Medical Center Schleswig-Holstein (Campus L\u00fcbeck): Internal medicine, gastroenterology, pneumology, allergology, sleep medicine, emergency medicine, intensive care, L\u00fcbeck, Schleswig-Holstein, Germany|University Hospital Jena Department of Internal Medicine IV, Jena, Th\u00fcringen, Germany|Charit\u00e9 University Hospital Berlin Medical Clinic Infectiology and Pneumology CCM\/CVK, Berlin, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""750"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in Patient-reported Quality of life recorded with the help of the European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l) questionnaire|Changes in Patient-reported Quality of life recorded with the help of the Short Form Health 36 (Sf36)|Changes in Patient-reported Quality of life recorded with the help of the Patient-Reported Outcomes Measurement Information System (PROMIS Profile)|Changes in Patient-reported Quality of life recorded with the help of the Neuropathy Questionnaire (Mnsi)|Changes in Patient-reported Quality of life recorded with the help of the Trauma Patient Health Questionnaire|Changes in Patient-reported Quality of life recorded with the help of the PTSD (Post-traumatic stress disorder) Checklist for Diagnostic and Statistical Manual of Mental Disorders 5 (PCL-5).|Changes in Patient-reported Quality of life recorded with the help of the National Eye Institute Visual Function Questionnaire (NEI-VFQ)|Changes in Patient-reported Quality of life recorded with the help of the St. George's Respiratory Questionnaire (SGRQ)|Changes in neruocognitive testing with Cambridge Neuropsychological Test Automated Battery (CANTAB)|Changes in neruocognitive testing with Montreal Cognitive Assessment Test (MOCA)|Changes in blood pressure measured during spiroergometry testing|Changes in sensomotory testing with the questionnaire for peripheral neuropathy (Michigan Neuropathy Screening Instrument, MNSI)|Changes in sensomotory testing with the questionnaire (painDETECT-questionnaire, pDQ)|Changes in Quantitative sensory testing (QST)|Changes in Point-of-care neurography|Changes in pulmonary function assessed by body plethysmography|Changes in pulmonary function assessed by single breath CO (carbon monoxide) diffusion capacity (DLCO)|Changes in heart rate measured with ECG (Electrocardiogram) during spiroergometry testing|Changes in the oxygen saturation of the blood measured during spiroergometry testing|Changes in the total concentration of carbon dioxide (ctCO2) of the blood measured during spiroergometry testing|Changes in the pH value of the blood measured during spiroergometry testing|Changes in the bicarbonate content of the blood measured during spiroergometry testing|Changes in the blood lactate levels during spiroergometry testing|Changes in the partial pressure of carbon dioxide (pCO2) of the blood measured during spiroergometry testing|Changes in heart rhythm type measured with ECG (Electrocardiogram) during spiroergometry testing|Changes in time intervals of PQ measured with ECG (Electrocardiogram) during spiroergometry testing|Changes in time intervals of QRS measured with ECG (Electrocardiogram) during spiroergometry testing|Changes in time intervals of QT measured with ECG (Electrocardiogram) during spiroergometry testing|Deviations in the ST segment depicted with the use of ECG (Electrocardiogram) during spiroergometry testing|Changes in body temperature|Changes in blood pressure|Changes in heart rate|Changes in breath frequency (respiratory rate)|Changes in peripheral oxygen saturation|Changes in the clinical score SOFA (sequential organ failure assessment)|Changes in the clinical score Berlin ARDS (acute respiratory distress syndrome) severity score (if provided)|Changes in the clinical score APACHE (Acute Physiology and Chronic Health Evaluation) Score|Changes in the clinical score NEWS (National Early Warning Score)|Changes in the clinical score qSOFA Score (quick sequential organ failure assessment)|Changes in the Barthel Index|Changes in the Frailty score|Changes in the clinical score Murray Score|Changes in the clinical score Glasgow Coma Scale (GCS)|Changes in the clinical score RASS (Richmond Agitation Sedation Scale)|Changes in the clinical score CAM-ICU (Score Confusion Assessment Method for Intensive Care Unit)|Changes in the clinical score SAPSII (Simplified acute physiology Score II)|Changes in the clinical score NRS (numeric rating scale) pain score|Changes in the clinical score BPS (behavioural pain scale) pain score|Changes in the clinical score CPOT (Critical Care Pain Observation tool)|Changes in the clinical score DDS (Delirium detection score)|Changes in the checked items on the ICDSC (Intensive Care Delirium Screening checklist)|Changes in the heart time volume|Changes in the cardiac index|Changes in EVLWI (Extravascular Lung Water Index)|Changes in Systemic Vascular Resistance Index (SVRI)|Changes in ITBVI (Intrathoracic Blood Volume Index)|Changes in the score WHO (World Health Organisation) clinical ordinal scale|Changes in the NYHA (New York Heart Association) score|Changes in the Post-COVID-19 Functional Status (PCFS) scale|Changes in the National Institutes of Health Stroke Scale (NIHSS)|Changes in the Katz Index|Changes in the Rose Dyspnea Scale""}"
"4707","Treatment of Nosocomial COVID-19","CATCO-NOS","NCT04748588","REB21-0096","Drug: Bamlanivimab","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04748588","Not yet recruiting","2021-02-01","2023-03-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""648"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Requirement for mechanical ventilation or in-hospital death|In-hospital death|Need for mechanical ventilation|Need for new intensive care admission|Need for new oxygen administration""}"
"4708","Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection","","NCT04747574","0254-20-TLV","Drug: EXO-CD24","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04747574","Recruiting","2020-09-25","2021-03-25","{""locations"":""Tel Aviv Medical Center, Tel Aviv, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""35"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary safety endpoint: Adverse events|Exploratory Endpoint: Alive at Day 5 without bronchospasms, unexpected infections, or clinical deterioration|Exploratory Endpoint: Proportion of patients with respiratory rate \u2264 23\/min for 24 hours|Exploratory endpoint: Change in respiratory rate from baseline to Day 5|Exploratory endpoint: Proportion of patients with SpO2 saturation \u226594% for at least 24 hours|Exploratory endpoint: Change in SpO2 saturation from baseline to Day 5|Exploratory endpoint: Proportion of patients with no artificial ventilation after 5 days of treatment|Exploratory endpoint: Proportion of patients with a change in absolute lymphocyte count, sustained for \u226548 hours after 5 days of treatment|Exploratory endpoint: Change in the absolute lymphocyte count from baseline to Day 5|Exploratory endpoint: Change in neutrophil-to-lymphocyte ratio (NLR), sustained for \u226548 hours after 5 days of treatment|Exploratory endpoint: Change in neutrophil-to-lymphocyte ratio (NLR) from baseline to Day 5""}"
"4709","COVID-19 Longitudinal Biomarkers in Lung Injury","COLOBILI","NCT04747782","COLOBILI v4.2","Other: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04747782","Recruiting","2020-03-23","2021-12-31","{""locations"":""St Michael's Hospital, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death in ICU|Days in ICU|Mechanical ventilation days|Days of mechanical ventilation rescue measures|APACHE II score on admission|SOFA score|In hospital death""}"
"4710","Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19","COVIPACT 2","NCT04747249","2020-A03234-35","Other: Psychological support","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04747249","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":""Centre Francois Baclesse, Caen, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""115"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with improvement in post-traumatic stress symptoms|Resilience Scores""}"
"4711","Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19","COL","NCT04748783","20-3046|COL Study","Other: Water|Other: Peroxyl|Drug: Periogard|Other: Colgate Total Zero","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04748783","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":""Adams School of Dentistry, Chapel Hill, North Carolina, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""180"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Reverse Transcription Polymerase Chain Reaction (RT-PCR) Baseline to 15 min|Change in Reverse Transcription Polymerase Chain Reaction (RT-PCR) from Baseline to 30 Minutes|Change in Reverse Transcription Polymerase Chain Reaction (RT-PCR) from Baseline to 45 Minutes|Change in Reverse Transcription Polymerase Chain Reaction (RT-PCR) from Baseline to 60 Minutes|Change in Reverse Transcription Polymerase Chain Reaction (RT-PCR) from Baseline to 1-week.|Change in Saliva Cytokine Concentration|Change in Blood Cytokine Concentration|Change in Saliva Chemokine Concentration|Change in Blood Chemokine Concentration""}"
"4712","Adverse Effects of Ivermectin Used in Egypt During COVID-19","","NCT04747678","ahmed19782020","Drug: Ivermectin","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04747678","Enrolling by invitation","2021-02-03","2021-03-01","{""locations"":""Ahmed Mansour, Shib\u012bn Al Kawm, Menoufia, Egypt"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""16 Years to 80 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""all adverse effects will be collected from people used Ivermectin in between September 2020 to December 2020|all data will be arranged according to time and dose manner""}"
"4713","Evaluation of Psychological Impact of Group Therapy for Patients Who Have Been Hospitalized in Intensive Care During COVID-19 Pandemic: Exploratory Study","GPR COVID","NCT04747405","CHMS20009","Other: therapy group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04747405","Not yet recruiting","2021-02-22","2022-08-22","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""prevalence of post traumatic stress syndrome""}"
"4714","Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)","CoviCompareM","NCT04748471","APHP201504|2020-005889-34","Biological: mRNA-1273","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04748471","Not yet recruiting","2021-02-10","2023-01-25","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Titers of anti-SARS-CoV-2 Spike IgG Immunoglobulin in sera|Anti SARS-CoV -2 IgG, IgA and IgM (total and subclasses IgG1-4) as measured by ELISA.|Anti-SARS-CoV-2 neutralizing antibody (in vitro neutralisation assay.|Anti-SARS-CoV-2 -specific neutralizing antibody (Pseudo neutralisation assay using lentiviral phenotypes carrying specific SARS-Cov-2 proteins.|Fluorospot assays (TH1, TH2, TH17, Cytotoxicity). Phenotyping of antigen specific T-Cells via Mass cytometry, B cell repertoire and memory|Mucosal SARS-CoV-2 -specific antibody via measure of sIgA, sIgM and IgG in saliva by specific home-made and commercially available ELISA assays.|Functionality of mucosal sIgA and sIgM by Antibody Dependent Cellular Cytotoxicity (ADCC) assay specific for SARS-CoV-2 mucosal IgA and IgM|Local and systemic reactogenicity|Determination of autoimmunity markers such as antibodies Anti-nuclear (unit measure: titers)|Determination of autoimmunity markers such as antibodies Anti-ACL, Anti-\u03b22-GP1, Rheumatoid factor (unit measure: U\/L)|Determination of autoimmunity markers such as antibodies Anti-GM1, Anti-MAG ( unit measure: pos\/ne)""}"
"4715","Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients","","NCT04748120","20-525","Procedure: Operative management|Procedure: Non-operative management","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04748120","Enrolling by invitation","2020-12-28","2021-09-28","{""locations"":""Cleveland Clinic Foundation, Cleveland, Ohio, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of pulmonary complications|Rate of pulmonary complications following operative management|Rate of pulmonary complications following non-operative management|Rate of post-intervention ICU admission|Mortality (all cause)|Rate of all complications as measured by the Clavien-Dindo classification|Median length of hospital stay|Rate of emergency room visits\/readmission""}"
"4716","COVID-19 Vaccine and Ovarian Reserve","","NCT04748172","8121-21-SMC","Biological: SARS-CoV-2 virus vaccines|Diagnostic Test: AMH sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04748172","Recruiting","2021-02-01","2022-02-01","{""locations"":""Sheba Medical Center, Ramat-Gan, Israel"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years to 42 Years \u00a0 (Adult)"",""outcome_measures"":""Delta in AMH levels""}"
"4717","Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency","","NCT04747132","SALUD-2021-Telegeria","Other: Telegeriatric intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04747132","Completed","2020-07-20","2020-11-16","{""locations"":""Universidad Iberoamericana, Ciudad de Mexico, Ciudad De M\u00e9xico, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research"",""enrollment"":""110"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Visual analog scale of the European quality of life questionnaire|Physical performance.|Depressive symptoms|Symptoms of anxiety.|Body composition|Anthropometric measures|Dietary intake""}"
"4718","Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies","","NCT04748185","20-012589","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04748185","Recruiting","2021-01-18","2023-01-30","{""locations"":""Mayo Clinic, Rochester, Minnesota, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""650"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Humoral Immunogenicity|Cellular Immunogenicity""}"
"4719","Annexin A5 in Patients With Severe COVID-19 Disease","AX-COVID","NCT04748757","REDA-10122","Drug: recombinant human annexin A5|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04748757","Not yet recruiting","2021-03-01","2022-12-01","{""locations"":""London Health Sciences Centre, London, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""19 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Enrollment|Protocol adherence|Data completeness|Organ failure|Organ function at end of treatment measured with SOFA|Organ function at end of treatment measured with Multiple Organ Dysfunction Score (MODS)|Individual organ function scores at EOT measured with SOFA|Individual organ function scores at 30 days measured with SOFA|Individual organ function scores at EOT measured with MODS|Individual organ function scores at 30 days measured with MODS|Plasma annexin A5 levels daily days 1-8 (treatment period) and on day 14|Mortality at 60 days|Hospital mortality|Ventilator-free days|ICU-free days|Number of participants with persistent organ dysfunction|Number of serious adverse events (SAE)|Maximum plasma concentration (Cmax) of annexin A5 (SY-005)|Elimination half-life of annexin A5 (SY-005)|Number of participants with anti-annexin A5 antibodies""}"
"4720","Creating a Virtual Village for People Aging With HIV During COVID-19","","NCT04747756","60304","Other: Virtual Village","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04747756","Not yet recruiting","2021-03-01","2022-12-01","{""locations"":""UC Riverside, Riverside, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""80"",""age"":""50 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in depression after pilot testing virtual village""}"
"4721","Analysis Before and After COVID 19","","NCT04748614","Ilke-ICU","Other: Cost","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04748614","Not yet recruiting","2021-02-15","2021-03-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cost of ICU""}"
"4722","Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)","SCV-KTx-imm","NCT04747522","227626","Drug: SARS-CoV-2 vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04747522","Recruiting","2021-01-22","2021-06-30","{""locations"":""Oslo University Hospital, Oslo, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cellular immunological response|Humoral immunological response|Vaccine related side effects""}"
"4723","Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers","","NCT04748536","C1104-003","Drug: IRL201104|Drug: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04748536","Recruiting","2021-01-29","2021-04-05","{""locations"":""Hammersmith Medicines Research, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""18"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of subjects with TEAEs and number of events will be summarised by treatment|Number of subjects with potentially clinically important (PCI) abnormal haematology variables will be summarised by treatment|Number of subjects with PCI abnormal clinical chemistry variables will be summarised by treatment|Number of subjects with PCI and\/or abnormal electrocardiogram variables will be summarised by treatment|Number of subjects with PCI abnormal vital sign variables will be summarised by treatment|Pharmacokinetics of IRL201104: Trough blood concentration (Ctrough)|PK of IRL201104: Maximum (peak) blood concentration (Cmax)|PK of IRL201104: Terminal half life (t1\/2)|PK of IRL201104: Area under the curve from time zero to last quantifiable concentration of IRL201104 (AUCt)|PK of IRL201104: Apparent total body clearance from blood (CLss)|PK of IRL201104: steady state volume of distribution (Vz)""}"
"4724","coMpliAnce With evideNce-based cliniCal Guidelines in the managemenT of Acute biliaRy pancreAtitis","MANCTRA-1","NCT04747990","Biliary Pancreatitis","Procedure: Early Definitive Treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04747990","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Mortality|Early Cholecystectomy or ERCP and Sphincterotomy|Hospital re-admission|Morbidity|Hospital readmission""}"
"4725","Integrated Platform for Multimodal Patient Monitoring and Therapy Support in ICU Patients","ICUCockpitAp","NCT04748289","2020-02177","Device: ICU Cockpit software testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04748289","Not yet recruiting","2021-02-01","2023-01-31","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""1000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Verification of ICU Cockpit software for remote monitoring of isolated patients|Verification of ICU Cockpit software ICU Cockpit Stable State|Verification of ICU Cockpit software Cerebral Ischemia|Adverse events, complaints and use-errors reporting|Usability testing""}"
"4726","Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection","ABCOVID","NCT04750720","CHRO-2020-12","Other: Sampling by venipuncture","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04750720","Recruiting","2020-08-27","2023-12-01","{""locations"":""Centre Hospitalier R\u00e9gional d'Orl\u00e9ans, France, Orl\u00e9ans, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""170"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of specific anti-SARS-CoV-2 antibodies|Presence of specific anti-SARS-CoV-2 antibodies in subgroups|Neutralizing capacity of anti-SARS-CoV-2 antibodies|Measurement of activated CD8 (CD38+DR+) in culture|Measurement of activated CD4 in culture|Measurement of activated B lymphocytes in culture""}"
"4727","Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection","mtDNA-COVID","NCT04750330","COVIDmtDNA1.0","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04750330","Not yet recruiting","2021-04-01","2022-03-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 Severity|Overall survival of the hospitalized population""}"
"4728","Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia","TOFA-COV-2","NCT04750317","107892","Drug: Tofacitinib","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04750317","Completed","2020-05-11","2020-09-01","{""locations"":""Sechenov First Moscow State Medical University (Sechenov University) - University Clinical Hospital, Moscow, Russian Federation"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""414"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Death|Mechanical ventilation""}"
"4729","Enhanced Triage for COVID-19","ETC-19","NCT04750369","20-5225","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04750369","Recruiting","2020-04-01","2021-03-31","{""locations"":""University Health Network, Toronto, Ontario, Canada"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictive Accuracy of Biomarkers for Risk Stratification|Performance of Biomarkers as Indicators of Clinical Severity: Disposition post-ED visit (admitted vs discharged home vs discharged home and readmitted)|Performance of Biomarkers as Indicators of Clinical Severity: Hospital and ICU length of stay|Performance of Biomarkers as Indicators of Clinical Severity: Need for artificial respiratory support or hemodynamic support (mechanical ventilation, ECLS)""}"
"4730","Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)","","NCT04750343","GBP510_002","Biological: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|Biological: GBP510 (RBD 10μg/dose) - Stage 1|Other: Normal saline (0.9% sodium chloride solution) - Stage 1|Biological: GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|Biological: GBP510 (RBD 25μg/dose) - Stage 1|Biological: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|Biological: GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|Biological: GBP510 (RBD 25μg/dose)- Stage 2|Other: Normal saline (0.9% sodium chloride solution)- Stage 2","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04750343","Recruiting","2021-02-03","2022-06-01","{""locations"":""Korea University Ansan Hospital, Ansan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""320"",""age"":""19 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of immediate systemic reactions - Stage 1|Occurrence of solicited local Adverse Events (AEs) during 7 days post each vaccination - Stage 1|Occurrence of solicited systemic AEs during 7 days post each vaccination - Stage 1|Occurrence of unsolicited AEs during 28 days post each vaccination - Stage 1|Occurrence of Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs) and Adverse Events of Special Interest (AESIs) during the whole study period - Stage 1|(Only in Sentinel group) Occurrence of out-of-normal range clinical laboratory test results (including change from baseline values) during 7 days post 1st vaccination - Stage 1|GMT of IgG antibody to the SARS-CoV-2 RBD measured by Enzyme-linked Immunosorbent Assay (ELISA) - Stage 2|GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA - Stage 2|Percentage of participants with \u2265 4-fold rise from baseline in ELISA IgG titer - Stage 2|GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays - Stage 2|GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays - Stage 2|Percentage of participants with \u2265 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer - Stage 2|Cell-mediated response for both Th1 and Th2 (e.g. INF-\u03b3, IL-4 using Enzyme-linked ImmunoSpot (ELISpot) or other system) - Stage 2|GMT of IgG antibody to the SARS-CoV-2 RBD measured by ELISA - Stage 1|GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA - Stage 1|Percentage of participants with \u2265 4-fold rise from baseline in ELISA IgG titer - Stage 1|GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays - Stage 1|GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays - Stage 1|Percentage of participants with \u2265 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer - Stage 1|Cell-mediated response for both Th1 and Th2 (e.g. INF-\u03b3, IL-4 using ELISpot or other system) - Stage 1|Occurrence of immediate systemic reactions - Stage 2|Occurrence of solicited local AEs during 7 days post each vaccination - Stage 2|Occurrence of solicited systemic AEs during 7 days post each vaccination - Stage 2|Occurrence of unsolicited AEs during 28 days post each vaccination - Stage 2|Occurrence of SAEs, MAAEs and AESIs during the whole study period - Stage 2""}"
"4731","To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.","","NCT04749173","DW_DWJ1516101","Drug: DWRX2003","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04749173","Recruiting","2020-11-21","2021-06-30","{""locations"":""Chungnam National university hospital, Daejeon, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""19 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of Treatment-Emergent Adverse Events""}"
"4732","A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)","","NCT04750278","FP02C-20-001","Drug: FP-025 100 mg|Drug: FP-025 300 mg|Drug: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04750278","Not yet recruiting","2021-02-01","2022-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""403"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of patients alive and not requiring non-invasive or invasive ventilation|Proportion of patients on invasive mechanical ventilation|Proportion of patients alive|Proportion of patients alive and not requiring non-invasive or invasive ventilation""}"
"4733","Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 CoviDx™ Rapid Antigen Test","CoviDx","NCT04750629","21 0115","Device: POC CoviDx™ Rapid Antigen Test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04750629","Not yet recruiting","2021-02-08","2021-03-26","{""locations"":""Comprehensive Clinical Research, West Palm Beach, Florida, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""1 Year and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Sensitivity of SARS-CoV-2 antigen in nasal swab as compared to a high-sensitive SARS-CoV-2 RT-PCR granted Emergency Use Authorization (EUA) by the FDA""}"
"4734","Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat","NICCAM","NCT04750759","201741","Drug: Niclosamide + Camostat|Other: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04750759","Recruiting","2021-02-03","2021-06-30","{""locations"":""Charit\u00e9 Research Organisation GmbH, Berlin, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Treatment emergent number of Adverse Events""}"
"4735","Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators","","NCT04749121","059/63","Device: UVC Irradiation|Drug: UVC Irradiation|Device: Fit test|Device: Tensile strength","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04749121","Completed","2020-04-01","2021-02-05","{""locations"":""Faculty of Medicine ,Vajira hospital,Navamindradhiraj University, Bangkok, Thailand"",""study_designs"":""Allocation: N\/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""20"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Fit test|Colony count of microorganisms|Load of Tensile strength""}"
"4736","Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19","","NCT04750265","ROBEM II","Device: Robotic assisted early mobilization","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04750265","Recruiting","2021-02-11","2021-09-01","{""locations"":""Charit\u00e9 - Univiversit\u00e4tsmedizin Berlin, Berlin-Mitte, Berlin, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Level of mobilization|Frequency of Mobilization|Initiation of first Mobilization|Mobilization duration|Depth of sedation|Days of sedation|Days of mechanical ventilation|Days of Intubation|Days of Delirium|MRC Score|Muscle wasting|Number of Health care provider|Mortality|Length of stay|Global function|Health care provider assessment|Safety events|Functional status|DRG workplace data""}"
"4737","Influence of Co-Vid 19 Pandemic on Screening Mammography Single Institution","","NCT04750018","KSVGH20-CT7-26","Other: surgery","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04750018","Recruiting","2020-07-03","2021-06-01","{""locations"":""Radiology depart, Kaohsiung, Taiwan"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""600"",""age"":""30 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""breast cancer""}"
"4738","SARS-CoV-2 (COVID-19) Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity (Legacy Study)","","NCT04750356","UCLH 134617","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04750356","Recruiting","2021-01-27","2024-12-31","{""locations"":""The Francis Crick Institute, London, United Kingdom|UCLH, London, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""6000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 susceptibility in healthcare workers and patients|SARS-CoV-2 transmission in healthcare workers and patients|SARS-CoV-2 severity in healthcare workers and patients""}"
"4739","Oxidative Stress Parameters, Trace Element and Quality of Life in Women Before and After Covid-19 Vaccines","","NCT04751721","2021-01-173","Biological: CoronoVac Vaccine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04751721","Not yet recruiting","2021-02-01","2021-04-01","{""locations"":""Kadirhan Ozdemir, \u0130zmir, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""20"",""age"":""35 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of the levels of Oxidative Stress Parameter 1|Change of the levels of Oxidative Stress Parameter 2|Change of the levels of Oxidative Stress Parameter 3|Change of the levels of Oxidative Stress Parameter 4|Change of the levels serum trace element 1|Change of the levels serum trace element 2|Change of the levels serum trace element 3|Change of the levels serum trace element 4|Change of the levels serum trace element 5|Change of the levels serum trace element 6|Change of the levels serum trace element 7|Change of the levels of quality of life""}"
"4740","Pulmonary Rehabilitation of Patients With a History of COVID-19","","NCT04751617","Rehabilitation after COVID-19","Procedure: Pulmonary rehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04751617","Enrolling by invitation","2021-01-01","2021-03-31","{""locations"":""University of Rzesz\u00f3w \/ Podkarpackie Center for Lung Diseases in Rzesz\u00f3w, Rzesz\u00f3w, Poland"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the quality of life|Change in lung volume parameters (spirometry)|Change in respiratory flow parameters (spirometry)|Change in lung diffusing capacity|Change in Body Mass Index (BMI)|Change in the body composition (bioelectrical impedance analysis)|Change in C-reactive protein (CRP) values (blood sample)|Change in D-Dimer values (blood sample)|Change in white blood cell (WBC) values (blood sample)|Change in gasometry (blood sample)|Change in the percentage of opacity (chest computed tomography)""}"
"4741","Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19","COVit-2","NCT04751604","A 107/20","Dietary Supplement: Nicotinamide|Dietary Supplement: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04751604","Recruiting","2021-02-01","2021-12-01","{""locations"":""University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""840"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of complete symptom resolution after 2 weeks of dietary supplementation|Frequency of complete symptom resolution after 4 weeks of dietary supplementation|Time from diagnosis to complete symptom resolution [days]|Frequency of freedom from fatigue after 2 weeks of dietary supplementation|Frequency of severe COVID-19 (examination in an emergency department \/ hospitalisation with requirement for oxygen (at least 24 h), intensive care or ventilation \/ death by COVID-19)""}"
"4742","Efficacy of a Dietary Supplementation in Reducing Hospital Admissions for COVID-19. Randomized Clinical Trial","CoVIT","NCT04751669","CoVIT Clinical Trial","Dietary Supplement: Vitamin and trace elements|Dietary Supplement: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04751669","Not yet recruiting","2021-04-01","2021-12-31","{""locations"":""Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""300"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need for hospital admission|Micronutrient basal status|Micronutrient status at hospital admission|Micronutrient status at end of study|Inflammatory parameters|Thromboembolic disease|Oxygen supplementation|High-Flow oxygen supplementation|Invasive mechanical ventilation|Tracheostomy|Renal replacement|Death|Intensive Care Unit Admission|Cumulative hospital admission|Hospitalization needs (days)|Survival|Adverse events|Serious Adverse Events""}"
"4743","Impact of Maternal COVID-19 Vaccines on Breast Milk","MilkCorona","NCT04751734","IATA-CSIC","Biological: Covid vaccines","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04751734","Enrolling by invitation","2021-01-16","2021-12-01","{""locations"":""Fundacion Investigacion Sanitaria INCLIVA, Valencia, Spain|Hospital Universitario y Politecnico la Fe, Valencia, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibodies|breast milk bioactive composition|infant microbiota|infant growth and development""}"
"4744","Oxidative Stress Parameters, Trace Element and Quality of Life in Men Before and After Covid-19 Vaccines","","NCT04751695","2021-01-174","Biological: CoronoVac Vaccine","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04751695","Not yet recruiting","2021-02-01","2021-04-01","{""locations"":""Kadirhan Ozdemir, \u0130zmir, Turkey"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""20"",""age"":""35 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change of the levels of Oxidative Stress Parameter 1|Change of the levels of Oxidative Stress Parameter 2|Change of the levels of Oxidative Stress Parameter 3|Change of the levels of Oxidative Stress Parameter 4|Change of the levels serum trace element 1|Change of the levels serum trace element 2|Change of the levels serum trace element 3|Change of the levels serum trace element 4|Change of the levels serum trace element 5|Change of the levels serum trace element 6|Change of the levels serum trace element 7|Change of the levels of quality of life""}"
"4745","Prognosis and Course of COVID-19 Infection in Hospitalised Patients","","NCT04752085","03-21","Diagnostic Test: Chitotriosidase activity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04752085","Active, not recruiting","2020-11-01","2021-09-30","{""locations"":""University Hospital #1, Moscow, Russian Federation|University Hospital #4, Moscow, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""345"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Need in biological therapy or\/and respiratory support|Number of days spent in hospital|All-cause death""}"
"4746","Effects of COVID-19 Hospitalization on Physical Performance","","NCT04751630","CBAS-21-22","Other: Therapeutic Exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04751630","Not yet recruiting","2021-05-01","2022-02-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""78"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Upper limb strength change|Physical Performance change|Walking speed change|lower limb strength change|Fraility change""}"
"4747","Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections","CovidEP","NCT04751643","69HCL20_0518|2020-A03039-30","Other: Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|Other: Usual treatments in intensive care unit according to the current state of knowledge","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04751643","Not yet recruiting","2021-02-01","2022-11-01","{""locations"":""Centre Hospitalier William Morey, Chalon-sur-Sa\u00f4ne, France|H\u00f4pital Edouard Herriot, Lyon, France|H\u00f4pital Edouard Herriot, Lyon, France|H\u00f4pital Croix Rousse, Lyon, France|Clinique de la Sauvegarde, Lyon, France|Groupement Hospitalier Porte de Valence - Mont\u00e9limar, Montelimar, France|H\u00f4pital Piti\u00e9 Salp\u00e9tri\u00e8re - Assistante Publique des H\u00f4pitaux de Paris, Paris, France|Centre Hospitalier Lyon Sud, Pierre-B\u00e9nite, France|Medipole Villeurbanne, Villeurbanne, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""132"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Use of intubation and invasive ventilation (IV) between Day 0 (Inclusion Visit) and Day 10|Assess the adverse events according to CTCAE v5.0|PaO2\/FIO2 (Partial Pressure of Oxygen\/Fraction of Inspired Oxygen) (mmHg) at day 4 after inclusion (PaO2\/FiO2 is a usual parameter for assessing evolution of ARDS)|Percentage of patients weaned from non invasive ventilation|Survival at day 10|Survival at 2 months|Percentage of patients without any increase in inflammatory parameters (analysis of C-reactive protein, Fibrinogen,D-Dimers, procalcitonin, Ferritin)|Variation in cytokine and chemokine levels in the cytokine storm|Percentage of patients with improved phenotype (decreased phenotype of exhausted cells) and improved function (improved proliferation)|Percentage of patients with decreased platelet activation|Change in anti-IFN auto-antibodies type I (\u03b1 and \u03c9) level""}"
"4748","Evaluation of the Psychosocial Impact on Health Professionals Exposed During COVID 19 Coronavirus Pandemic","","NCT04752839","IIBSP-COV-2020-40","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04752839","Not yet recruiting","2021-02-01","2021-05-01","{""locations"":""Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""General Anxiety Disorder (GAD7) score.|Insomnia severity Index (ISI)|Patient Health Questionaire (PHQ-9)|Perceived Stress Scale|Impact of Event Scale Revised (IES-R)""}"
"4749","Modafinil for Wakefulness in the Critical Care Units","","NCT04751227","RAC # 2201230","Drug: Modafinil","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04751227","Completed","2020-11-22","2021-01-30","{""locations"":""King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""8"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Median change in of Glasgow Coma Scale (GCS)|adverse drug reactions (ADRs)|Duration of Mechanical Ventilation|ICU Length of stay (LOS)|Hospital Length of Stay (LOS)|Mortality rate""}"
"4750","Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19","","NCT04751682","BBIL/BBV154/2020","Biological: BBV154 Vaccine","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04751682","Not yet recruiting","2021-03-01","2021-11-30","{""locations"":""Apollo Hospitals, Chennai, Tamil Nadu, India|Dr.Lal Babu Prasad, Noida, Uttar Pradesh, India|Dr.A.Venkateshwar Rao, Hyderabad, India|Dr.Vilas Panchbhai, Nagpur, India"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""175"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence of immediate adverse events.|The incidence of solicited local and systemic adverse events|The incidence of serious adverse events (SAEs)|The incidence of unsolicited adverse events|To evaluate the humoral immune responses of BBV154|To compare the humoral responses between single dose group and double dose group.|To evaluate the immune responses against spike protein of SARS-CoV-2 virus and Adenovirus vector|Vaccine induced cell mediated antigen specific T-cell responses across the three groups.|Vaccine induced cell mediated antigen specific cytokines across the three groups. To evaluate the vaccine induced Cell mediated immune response.|To evaluate the vaccine secretory IgA antibody response.|To evaluate the safety of the vaccine in terms of assessing adverse event of special interest (AESI)""}"
"4751","The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction","","NCT04751474","2021/47-31","Other: Motivational messages","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04751474","Active, not recruiting","2021-02-01","2021-03-31","{""locations"":""Elif Gezginci, Istanbul, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""93"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Optimistic level assessed by the Life Orientation Test|Hopelessness level assessed by the Beck Hopelessness Scale|Life satisfaction assessed by the Satisfaction with Life Scale""}"
"4752","Effect of Prone Position onV/Q Matching in Non-intubated Patients With COVID-19","","NCT04754113","COVID-19 PPV","Other: prone position","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04754113","Not yet recruiting","2021-02-07","2021-02-27","{""locations"":""Ling Liu, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Ventilation-perfusion (V\/Q) mismatch|Regional ventilation|regional perfusion|The Global Inhomogeneity (GI) index|PF raio""}"
"4753","Comparison of Cardiopulmonary Fitness Level With Normal Values After COVID-19","","NCT04753346","I11-670-20","Other: Physical Activity Level|Other: Anxiety and Depression Assessment|Diagnostic Test: Exercise Capacity|Diagnostic Test: Pulmonary Function Test|Diagnostic Test: Cardiopulmonary Fitness Level","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04753346","Not yet recruiting","2021-02-15","2023-01-01","{""locations"":""Ankara University, Faculty of Medicine, Physical Medicine and Rehabilitation Department, Ankara, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""240"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Peak oxygen uptake|Oxygen uptake at anaerobic threshold|Borg rating of perceived exertion scale|Walk distance|Borg dyspnea scale|Anxiety score|Depression score""}"
"4754","Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management","","NCT04753619","PRO2021070003","Drug: Niclosamide Oral Tablet","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04753619","Recruiting","2021-01-03","2021-05-03","{""locations"":""Ahmed S. Abdulamir, Baghdad, Baghdada, Iraq"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of Cure of the patient|Time to recovery|The percentage of Progressive patients|Rate of mortality|Side effects""}"
"4755","Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia","","NCT04753476","SCCR_Secretome","Biological: Injection of Secretome-MSCs|Drug: Standard treatment of Covid-19","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04753476","Recruiting","2020-06-08","2021-08-08","{""locations"":""Sultan Imanuddin Hospital, Kalimantan, Central Borneo, Indonesia|Charlie Hospital, Kendal, Central Java, Indonesia|RS PKU Muhammadiyah Yogyakarta, Yogyakarta, Central Java, Indonesia|Bhayangkara Hospital, Makassar, South Celebes, Indonesia|Gatot Soebroto Army Hospital, Jakarta, Indonesia|Dr. Esnawan Antariksa Air Force Hospital, Jakarta, Indonesia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""48"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Change in patients clinical manifestation|Need for a ventilator|Duration of using a ventilator|Length of stay|Routine blood profile|CRP|D-dimer|Blood Gas Analisis (BGA)|Photo thorax|Survival""}"
"4756","Psychosocial Care During the COVID-19 Pandemic in Acute Hospitals","","NCT04753242","Req-2020-00861; th21Schaefert","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04753242","Recruiting","2020-12-08","2021-07-31","{""locations"":""Medical University of Graz, Graz, Steiermark, Austria|Klinikum N\u00fcrnberg, Department of Psychosomatic Medicine and Psychotherapy, N\u00fcrnberg, Bayern, Germany|Universit\u00e4tsklinikum K\u00f6ln, Polyclinic for Psychosomatics and Psychotherapy, K\u00f6ln, Nordrhein-Westfalen, Germany|University Hospital Basel, Department for Psychosomatics, Basel, Basel-City, Switzerland|University of Basel, Department of Psychiatry (UPK), Basel, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Structural and process quality of COVID-19 related psychosocial consultation and liaison (CL) services s""}"
"4757","Assessment of the Impact of COVID-19 Pandemic on Residents Training and Mental Health in Poland","","NCT04753463","1775","Other: Survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04753463","Not yet recruiting","2021-03-15","2021-04-15","{""locations"":""Medical University, Bia\u0142ystok, Poland|Ophthalmology Clinic Medical University of Bialystok, Bia\u0142ystok, Poland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""130"",""age"":""25 Years to 35 Years \u00a0 (Adult)"",""outcome_measures"":""questionnaire assessing the incidence of disturbance of COVID-19 pandemic on ophthalmology training programs among residents|questionnaire assessing the negative impact of COVID-19 pandemic on mental health among ophthalmology residents|questionnaire assessing the attitude on COVID-19 vaccination of ophthalmology residents""}"
"4758","Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection","IMACovid","NCT04753762","2020PI086","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04753762","Recruiting","2020-03-01","2022-11-01","{""locations"":""Laura FILIPPETTI, Vand\u0153uvre-l\u00e8s-Nancy, France"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""50"",""age"":""18 Years to 79 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To Characterize cardiac involvement by cardiac TTE imaging during 4 months after confirmed COVID-19 infection|To Characterize cardiac involvement by cardiac MRI during 4 months after confirmed COVID-19 infection|To characterize cardiac evolution at 12 +\/-2 months from COVID-19 infection|To evaluate Cardiac events at 12 +\/-2 months from COVID-19 infection|To evaluate all cause deaths at 12 +\/-2 months from COVID-19 infection""}"
"4759","Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","","NCT04754594","C4591015|2020-005444-35","Biological: BNT162b2|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04754594","Recruiting","2021-02-16","2022-06-27","{""locations"":""Arrowhead Hospital, Glendale, Arizona, United States|Abrazo West Campus Hospital, Goodyear, Arizona, United States|St. Joseph Hospital, Phoenix, Arizona, United States|MedPharmics, LLC, Phoenix, Arizona, United States|Chemidox Clinical Trials Inc., Lancaster, California, United States|Axcess Medical Research, Loxahatchee Groves, Florida, United States|Idaho Falls Pediatrics, Ammon, Idaho, United States|Idaho Falls Pediatrics, Idaho Falls, Idaho, United States|Clinical Research Prime, Idaho Falls, Idaho, United States|Eastern Idaho Regional Medical Center, Idaho Falls, Idaho, United States|Mountain View Hospital, Idaho Falls, Idaho, United States|ASR, LLC, Nampa, Idaho, United States|Medpharmics, LLC, Covington, Louisiana, United States|Women's Health & Wellness, Covington, Louisiana, United States|MedPharmics LLC, Lafayette, Louisiana, United States|MedPharmics, LLC, Metairie, Louisiana, United States|MedPharmics, LLC, Gulfport, Mississippi, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Boeson Research (BUT), Butte, Montana, United States|SCL St. James Healthcare Hospital, Butte, Montana, United States|Marcus Daly Memorial Hospital, Hamilton, Montana, United States|Providence St. Patrick Hospital, Missoula, Montana, United States|The Birth Center, Missoula, Montana, United States|Boeson Research, Missoula, Montana, United States|Community Medical Center, Missoula, Montana, United States|Community Physicians Group-Maternal Fetal Medicine (Medical Practice), Missoula, Montana, United States|St. Luke Community Healthcare Hospital, Ronan, Montana, United States|Meridian Clinical Research, LLC, Grand Island, Nebraska, United States|Meridian Clinical Research, LLC, Hastings, Nebraska, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Allegheny Health and Wellness Pavilion, Erie, Pennsylvania, United States|OBGYN Associates of Erie, Erie, Pennsylvania, United States|Liberty Family Practice, Erie, Pennsylvania, United States|Saint Vincent Hospital, Erie, Pennsylvania, United States|Tekton Research, Inc., Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|Memorial Hermann Memorial City - Labor and Delivery Unit, Houston, Texas, United States|UT Physicians Women's Center at Memorial City, Houston, Texas, United States|UTHealth Women's Research Program at Memorial City, Houston, Texas, United States|The University of Texas Medical School at Houston, Houston, Texas, United States|Ventavia Research Group, LLC, Plano, Texas, United States|Tekton Research, Inc., San Antonio, Texas, United States|Ventavia Research Group, LLC, Weatherford, Texas, United States|Weatherford OBGYN, Weatherford, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention"",""enrollment"":""4000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percentage of maternal participants reporting: Local reactions|Percentage of maternal participants reporting systemic events|Percentage of maternal participants reporting adverse events|Percentage of maternal participants reporting serious adverse events|Demonstrate non inferiority of immune response in pregnant women compared to nonpregnant female participants from the C4591001 study without evidence of past SARS-CoV-2 infection.|Demonstrate non inferiority of immune response in pregnant women compared to nonpregnant female participants from the C4591001 study with and without evidence of prior SARS-CoV-2 infection|Confirmed COVID 19 in participants without evidence of infection prior to vaccination|Confirmed COVID 19 in participants with and without evidence of infection prior to vaccination.""}"
"4760","Comparison of Chest CT Findings Related to COVID-19 With RSNA and BSTI Guidelines","","NCT04754633","2020/588","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04754633","Completed","2020-07-01","2020-07-20","{""locations"":""Sa\u011flik Bilimleri \u00dcniversitesi Training and Research Hospital, Diyarbak\u0131r, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""764"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Current study evaluating the success of the guidelines recommended by RSNA and BSTI in detecting COVID-19 disease""}"
"4761","Status of People With Cerebral Palsy and Their Caregivers During COVID-19 Pandemic","","NCT04753632","DF0095UG","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04753632","Not yet recruiting","2021-03-01","2021-06-15","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Questionnaire of Knowledge, attitudes and practice towards COVID-19|Caregiver COVID-19 limitation scale|Fear of Coronavirus-19 Scale|Covid-19 Stress Scale (CSS)|Coronavirus Anxiety Scale (CAS)|Connor-Davidson Resilience Scale-10|COPE|Medical Outcomes Study-Social Support Survey|Zarit Burden Inventory|Euroqol-5D|Hospital Anxiety and Depression Scale|Pittsburgh Sleep Quality Index|International Physical Activity Questionnaire|Functional independence measure|Gross motor function classification system|Manual Agility Classification System""}"
"4762","BRAC Institute of Governance and Development-Hygiene Behavioural Change and Coalition","(BIGD-HBCC)","NCT04753645","BIGD2021","Behavioral: Handwashing stations at the public places|Behavioral: No activities of the HBCC project","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04753645","Active, not recruiting","2020-09-19","2021-05-01","{""locations"":""BRAC, Bangladesh, Dhaka, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""3840"",""age"":""10 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Daily handwashing frequency|Likelihood of using soap when handwashing|Prevalence of transmissible diseases in the past 15 days|Knowledge of handwashing practices|Attitudes|Handwashing at the public places|Mask usage""}"
"4763","COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS","CoronavRheum","NCT04754698","42566621.0.0000.0068","Biological: CoronaVac","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04754698","Recruiting","2021-02-09","2023-03-01","{""locations"":""University of Sao Paulo General Hospital, S\u00e3o Paulo, SP, Brazil"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""2067"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immunogenicity""}"
"4764","Monitoring Health Care Workers at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology","","NCT04756869","HUM00180076","Other: COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04756869","Active, not recruiting","2020-04-28","2023-01-01","{""locations"":""Michigan Medicine, Ann Arbor, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""226"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of Wearing Fitbit Watch|Feasibility of Wearing TempTraq Patch|Survey Completion Rate""}"
"4765","Impact of Colchicine and Low-dose Naltrexone on COVID-19","COLTREXONE","NCT04756128","X2103400","Drug: Colchicine 0.6 mg|Drug: Naltrexone","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04756128","Enrolling by invitation","2021-01-25","2021-12-31","{""locations"":""Park Nicollet Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""164"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Progression of COVID-19 from \""moderate\"" classification to \""severe\/critical\""|Total duration of hospitalization|Total duration of hospitalization (from first dose of study drug to discharge)|Composite in-hospital mortality|Total duration of ICU Admission|Total duration of intubation|Total duration of time spent on HFNC or NIPPV from first dose of study drug to discharge|Total duration of time above baseline oxygen requirements from first dose of study drug to discharge|In hospital days with a fever >\/= 38 degrees Celsius (00:00 to 23:59:59) from first dose of study drug to discharge (or anticipated first dose if in standard of care arm)|Incidence of adverse events associated with the study drug|Incidence of significant adverse outcomes associated with\/attributable to COVID-19|Cumulative dose of corticosteroids received in ED\/Hospital|Cumulative dose of remdesivir received in ED\/Hospital|Discharge Anticoagulation Needs|Continuous lab results - B-Type Natriuretic Peptide|Continuous lab results - C-Reactive Protein|Continuous lab results - D-Dimer|Continuous lab results - Ferritin|Continuous lab results - Procalcitonin|Continuous lab results - Serum Creatinine|Continuous lab results - Troponin|Continuous lab results - Hepatic Function Panel (ALT\/AST\/Alkaline Phosphotase)|Continuous lab results - Hepatic Function Panel (Bilirubin)|Continuous lab results - Hepatic Function Panel (Protein\/Albumin)|Continuous lab results - Complete Blood Count with Differential Part 1|Continuous lab results - Complete Blood Count with Differential Part 2|Continuous lab results - Complete Blood Count with Differential Part 3""}"
"4766","A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19","","NCT04756830","IDOR_VAC_01","Biological: Adsorbed COVID-19 (inactivated) Vaccine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04756830","Not yet recruiting","2021-02-01","2023-06-01","{""locations"":""Hospital Gloria D'Or - Hospitais Integrados da Gavea S\/A, Rio De Janeiro, Brazil|D'Or Institute for Research and Education, Rio De Janeiro, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of local and systemic adverse reactions in the first 7 days after immunization|Seroconversion rates|Frequency of adverse reactions up to 28 days after immunization|Frequency of severe adverse events|Frequency of adverse events of special interest|Cell-mediated immune response|Frequency of detection of antibodies against SARS-CoV-2|Geometric mean titer of neutralizing antibodies""}"
"4767","COVID-19 Infection and Machine Learning Using Artificial Intelligence (AI)","","NCT04756518","20/053","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04756518","Recruiting","2020-07-06","2021-07-01","{""locations"":""East Suffolk and North Essex NHS Foundation Trust, Ipswich, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""785"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Specificity and sensitivity of using AI-based image analytical modelling for diagnosis of COVID-19.|Risk stratification modelling""}"
"4768","A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)","","NCT04756323","2020L001-1B","Biological: medium dosage inactivated SARS-CoV-2 vaccine|Biological: high dosage inactivated SARS-CoV-2 vaccine|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04756323","Active, not recruiting","2020-10-27","2022-02-28","{""locations"":""Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The seropositive rates of SARS-CoV-2 neutralizing antibody|The seropositive level of SARS-CoV-2 neutralizing antibody|The seropositive rates of SARS-CoV-2 IgG antibody (tested by ELISA)|Incidence of adverse reactions\/events|Serious Adverse Events (SAE)|Level of SARS-CoV-2 IgG antibody (tested by ELISA)|The seropositive level of SARS-CoV-2 IgG antibody (tested by ELISA)""}"
"4769","CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))","","NCT04756141","20-010816","Device: Continuous Glucose Monitor (CGM)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04756141","Recruiting","2021-03-03","2022-01-28","{""locations"":""Mayo Clinic in Florida, Jacksonville, Florida, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""20"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""CGM accuracy - mean absolute relative difference (MARD)|Incidence of CGM recorded hypoglycemia episodes|Incidence of CGM recorded hyperglycemia episodes|CGM accuracy in hypotensive patients|CGM accuracy in patients with hypoxemia|CGM accuracy in lactic acidosis.|Hospitalization length of stay|Number of CGM alarms and clinical result of these alarms|Patient satisfaction|Reducing staff exposure to patients with COVID19""}"
"4770","Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly","","NCT04756466","P055","Dietary Supplement: Placebo|Dietary Supplement: Lactobacillus","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04756466","Active, not recruiting","2021-01-01","2021-12-31","{""locations"":""Residencia San Marcos, Santiago De Compostela, A Coru\u00f1a, Spain|Residencia Santa Olalla, Santiago De Compostela, A Coru\u00f1a, Spain|Residencia San Simon de Ons, Santiago De Compostela, A Coru\u00f1a, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""201"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of SARS CoV-2 infection.|Incidence of hospital admissions caused by SARS-CoV-2 infection .|Incidence of ICU admissions caused by SARS-CoV-2 infection|Incidence of pneumonia caused by SARS-CoV-2 infection .|Incidence of need for oxygen support due to SARS-CoV-2 infection..|Incidence of gastrointestinal symptoms due to SARS-CoV-2 infection.|Days with body temperature> 37.5\u00baC.|Days of persistent cough.|Days of persistent feeling of fatigue.|Use of pharmacological treatments.|Serum levels of IgG antibody against SARS-CoV-2|Serum levels of IgA antibody against SARS-CoV-2""}"
"4771","Mortality Due to COVID-19 in the COVID-AGEBRU Study","COVID-AGEBRU","NCT04756479","COVID-19 AGE-BRUGMANN 2022/111","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04756479","Completed","2020-03-01","2020-06-30","{""locations"":""CHU Brugmann, Brussels, Belgium"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""160"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""All-cause mortality during hospital admission (admission up to discharge time)|Prevalence of medical diseases and geriatric syndromes""}"
"4772","Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound","","NCT04756193","20.0836","Diagnostic Test: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04756193","Recruiting","2021-04-01","2022-12-31","{""locations"":""University of Louisville Health, Louisville, Kentucky, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Echocardiographic strain measurements of the left, right heart|Lung ultrasound measurements""}"
"4773","The Impact of Covid-19 on Skeletal Muscle","","NCT04756674","Cov-Mi|Sponsor ID: 20065","Other: No intervetion will be used","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04756674","Not yet recruiting","2021-02-09","2023-04-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""36"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The difference in mitochondrial function between COVID-19 infection and control group|The difference in mitochondrial function between levels of ventilation support required in COVID-19 patients|The changes in mitochondrial function during the recovery period from COVID-19|The difference in muscle macroscopic structure between the groups|Difference in the neurological supply of skeletal muscle|Difference in muscle function""}"
"4774","Muscle-targeted Nutritional Therapy for the Recovery From COVID-19","RE-COVID","NCT04756856","20210006520","Other: Muscle-target oral nutritional supplementation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04756856","Not yet recruiting","2021-03-01","2021-12-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Physical performance - chair-stand|Total body muscle mass|Appendicular muscle mass|Functional status - muscle strength|Fatigue|Energy intake|Self-perceived quality of life|Body weight|Serum levels of 25-hydroxy-vitamin D""}"
"4775","Systematic Offer of Nurse-Driven Screening for COVID-19 in Emergency Departments in the Paris Metropolitan Area, DEPIST-COVID","DEPIST-COVID","NCT04756609","APHP201625|IDRCB: 2020-A03532-37","Procedure: Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|Other: Usual emergency department practice with physician-directed diagnostic testing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04756609","Not yet recruiting","2021-02-12","2021-06-01","{""locations"":""URC-EST, H\u00f4pital saint-Antoine, Paris, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""104000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients tested positive for SARS-CoV2 amongst the flow of consulting adults|Proportion of positive patients amongst asymptomatic patients and in the Paris Metropolitan area at the same period (these proportions will be compared amongst each ED geographic area, amongst symptomatic patients and amongst the tested population)|Feasibility of screening strategy : proportion of patients having completed the questionnaire, proportion of tests offered , accepted and performed, proportion of patients notified of the result and staff involved|Description of patients tested in both periods (proportion of positive tests and of asymptomatic patients)|For symptomatic patients: description of the symptomatology|Description of patients tested in both periods: patient exposure factors with the DEPIST-COVID questionnaire|Sociodemographic, behavioural factors and habits associated with SARS-Cov2 infection in patients tested in the following schemes: DEPIST-COVID, ComCor and COVISAN .|Incidence of SARS-Cov2 infections in Paris Metropolitan area : proportion of positive patients and their profiles. To estimate the under-detection of cases in the region, and compare with results from the model experiment .|Number of close contact persons who have been tested for SARS-Cov2, who have been tested positive and who have been isolated over both periods.""}"
"4776","Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece","GREVAXIMO","NCT04756817","2/27.1.2021","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04756817","Recruiting","2021-02-13","2021-09-30","{""locations"":""G. Gennimatas General Hospital, Thessalon\u00edki, Thessaloniki, Greece"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""85 Years to 100 Years \u00a0 (Older Adult)"",""outcome_measures"":""Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine|Immunogenicity after the second dose of the BNT162b2 mRNA Covid-19 vaccine|Immunogenicity after the second dose of the BNT162b2 mRNA Covid-19|PCR-confirmed cases of SARS-CoV-2 infection anytime after the first dose.""}"
"4777","Safety and Immunogenicity of Inactivated Vaccine Against COVID-19 Infection","","NCT04756271","6738-14-2-21","Biological: SARS-Cov-2 neutralizing antibody titer","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04756271","Recruiting","2021-02-11","2021-08-01","{""locations"":""Zagazig University Faculty of Medicine, Zagazig, Sharkia, Egypt"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse reactions|Seroconversion rate of neutralizing antibody""}"
"4778","Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2","","NCT04755972","2181-147-01/06/M.S.-20-02","Other: Inhalation of N-acetylcysteine|Other: Inhalation of 5% sodium chloride|Other: Inhalation of 8,4% sodium bicarbonate","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04755972","Recruiting","2021-01-29","2021-08-29","{""locations"":""Clinical Hospital Centre Split, Split, Croatia"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Difference between 4 arms regarding ventilator-associated pneumonia rate|Number of ventilator-free days|Mortality""}"
"4779","Strados System at Center of Excellence","","NCT04485741","SL-RS-AEMC01","Device: RESP","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04485741","Recruiting","2020-09-23","2021-08-31","{""locations"":""Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical utility as assessed by the PI|Clinical utility as assessed by other clinicians|Correlation of RESP data with other measures of patient status.""}"
"4780","Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU","","NCT04757792","RC1-2-2021","Other: File inquiry","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04757792","Completed","2020-06-06","2021-02-11","{""locations"":""Faculty of Medicine, Banh\u0101, Qalubia, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""475"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Mortality rate""}"
"4781","COVID-19 Antithrombotic Rivaroxaban Evaluation","CARE","NCT04757857","36066320.5.1001.0070","Drug: Rivaroxaban 10 mg","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04757857","Recruiting","2020-09-29","2021-04-30","{""locations"":""Cl\u00ednica Senhor do Bonfim, Feira de Santana, Bahia, Brazil|Hospital Maternidade S\u00e3o Vicente de Paulo, Barbalha, Cear\u00e1, Brazil|Hospital de Base do Distrito Federal, Bras\u00edlia, Distrito Federal, Brazil|Hospital de Campanha Covid-19 Goi\u00e2nia\/Sesgo, Goi\u00e2nia, Goias, Brazil|Hospital Estadual de Urg\u00eancias de Trindade\/SESGO, Trindade, Goias, Brazil|N\u00facleo de Pesquisa Cl\u00ednica do Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Hospital S\u00e3o Lucas, Belo Horizonte, Minas Gerais, Brazil|Santa Casa de Miseric\u00f3rdia de Passos, Passos, Minas Gerais, Brazil|Hospital Universit\u00e1rio Regional de Maring\u00e1, Maring\u00e1, Paran\u00e1, Brazil|Beneficencia Nipo Brasileira Da Amazonia, Bel\u00e9m, Para, Brazil|Hospital Adventista de Bel\u00e9m, Bel\u00e9m, Para, Brazil|Associa\u00e7\u00e3o Dr. Bartholomeu Tacchini, Bento Gon\u00e7alves, Rio Grande Do Sul, Brazil|Hospital S\u00e3o Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital das Cl\u00ednicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Universitario de Santa Maria, Santa Maria, Rio Grande Do Sul, Brazil|Cl\u00ednica Proc\u00e1rdio Ltda, Blumenau, Santa Catarina, Brazil|H&W Cardiologia LTDA, Joinville, Santa Catarina, Brazil|Irmandade santa Casa de Araras, Araras, S\u00e3o Paulo, Brazil|Alphacor Cardiologia Cl\u00ednica e Diagn\u00f3stica LTDA, Barueri, S\u00e3o Paulo, Brazil|Maestri e Kormann Consultoria Medico-Cientifica LTDA - EPP, Blumenau, S\u00e3o Paulo, Brazil|Hospital Regional do Litoral Norte - Instituto S\u00f3crates Guanaes, Caraguatatuba, S\u00e3o Paulo, Brazil|Hospital Santos Dumont Litoral Norte, Caraguatatuba, S\u00e3o Paulo, Brazil|Hospital de Corderiopolis, Cordeiropolis, S\u00e3o Paulo, Brazil|Hospital Regional Jorge Rossman - Instituto S\u00f3crates Guanaes, Itanha\u00e9m, S\u00e3o Paulo, Brazil|Hospital Carlos Fernando Malzoni, Mat\u00e3o, S\u00e3o Paulo, Brazil|Hospital Moinhos de Vento, Porto Alegre, S\u00e3o Paulo, Brazil|Hospital Regional de Registro - Instituto S\u00f3crates Guanaes, Registro, S\u00e3o Paulo, Brazil|Hospital Unimed Ribeir\u00e3o Preto, Ribeir\u00e3o Preto, S\u00e3o Paulo, Brazil|Kaiser Clinica e Hospital Dia, S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Paulo, Brazil|Braile Hospital Dia Ltda, S\u00e3o Jos\u00e9 Do Rio Preto, S\u00e3o Paulo, Brazil|Hospital Policlin, S\u00e3o Jos\u00e9 Dos Campos, S\u00e3o Paulo, Brazil|Hospital Regional de S\u00e3o Jos\u00e9 dos Campos - Instituto S\u00f3crates Guanaes, S\u00e3o Jos\u00e9 Dos Campos, S\u00e3o Paulo, Brazil|Santa Casa de Miseric\u00f3rdia de Votuporanga, Votuporanga, S\u00e3o Paulo, Brazil|International Research Center - Hospital Alem\u00e3o Oswaldo Cruz, S\u00e3o Paulo, Brazil|Hospital Leforte Liberdade, S\u00e3o Paulo, Brazil|Incor - Instituto do Cora\u00e7\u00e3o do Hospital das Cl\u00ednicas da FMUSP, S\u00e3o Paulo, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Venous thromboembolic events (VTE)|Mechanical ventilation free-survival|Major Adverse Cardiovascular Events (MACE)|Out-of-hospital death not attributed to major injury|Time from randomization to hospitalization|Length of Hospitalization|Hospitalization in Intensive Care Unit|Clinical requirement of mechanical ventilation|Clinical duration of mechanical ventilation|Composite vascular endpoint I|Composite vascular endpoint II|Major Bleeding|Mortality""}"
"4782","Macro-scale Estimators of Covid-19's Worldwide Cases and Deaths","","NCT04757870","KCU_16022021","Other: frequency","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04757870","Not yet recruiting","2021-03-01","2021-12-31","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""1790"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Occurence|Mortality""}"
"4783","COVID-19 Treatment Cascade Optimization Study","","NCT04757298","UIUC-NJCRI 102497-18274-267805|3R01MD010629-04S2","Behavioral: Navigation Services|Behavioral: Critical Dialogue|Behavioral: Brief Counseling|Behavioral: Referral and Digital Brochure","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04757298","Recruiting","2021-02-12","2022-12-31","{""locations"":""North Jersey Community Research Initiative, Newark, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""670"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Completion of COVID-19 test""}"
"4784","Coronavirus-19 (COVID-19) and Related Outcomes in School Aged Children (ABC Health Outcomes in Children)","","NCT04757831","Pro00107647","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04757831","Not yet recruiting","2021-02-15","2026-02-15","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1000000"",""age"":""up to 21 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Describe the incidence of non-severe and severe COVID-19, including Multisystem Inflammatory Syndrome in Children (MIS-C).|Describe risk factors of non-severe and severe COVID-19.|Characterize outcomes associated with COVID-19 in children.|Describe characteristics of participants who attend in-person versus virtual classes.|Describe the duration of in-person school attendance.""}"
"4785","A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)","","NCT04758273","2020L001-1A","Biological: medium dosage inactivated SARS-CoV-2 vaccine|Biological: high dosage inactivated SARS-CoV-2 vaccine|Biological: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04758273","Active, not recruiting","2020-10-07","2022-02-28","{""locations"":""Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""180"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse reactions\/events|Serious Adverse Events (SAE)|Incidence of abnormal indicators of laboratory safety examinations(including blood routine, blood biochemistry, urine routine and coagulation function)|The seropositive rates of SARS-CoV-2 neutralizing antibody|The seropositive level of SARS-CoV-2 neutralizing antibody|The seropositive rates of SARS-CoV-2 IgG antibody(tested by ELISA)|The seropositive level of SARS-CoV-2 IgG antibody(tested by ELISA)|The proportion of IFN-\u03b3 positive cells (by ELISpot)|Level of IL-2\u3001IL-4\u3001IL-5\u3001IL-6\u3001TNF\u03b1\u3001IFN-\u03b3 (by ELISA)""}"
"4786","Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19","","NCT04758286","RC2-2-2021","Procedure: Emergency surgical procedures","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04758286","Completed","2020-07-01","2021-02-11","{""locations"":""Faculty of Medicine, Banh\u0101, Qalubia, Egypt"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""209"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Questionnaire|Physiologic assessment|Surgical follow-up""}"
"4787","Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits","","NCT04758299","STUDY2020_501","Other: decision science-based design","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04758299","Not yet recruiting","2021-02-01","2021-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""choice of action to take with negative test|Likelihood of COVID-19 infection (qualitative)|Likelihood of COVID-19 infection (quantitative)|safe practices|ease of use of information rating|usefulness of information rating|helpfulness of information for what to do given positive test result|helpfulness of information for what to do given negative test result|Assess effect of the FDA authorized description of test accuracy""}"
"4788","Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.","CPC COVID","NCT04757818","CPC COVID","Other: 0.07% cetylpyridinium chloride (CPC) in mouthwash|Other: Distilled water with the same colorant as the experimental product","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04757818","Recruiting","2021-02-04","2021-03-25","{""locations"":""CAP Gorg, Badalona, Barcelona, Spain|CAP Gran Sol, Badalona, Barcelona, Spain|CAP St Roc, Badalona, Barcelona, Spain|CAP Dr Barraquer, Sant Adri\u00e0 De Bes\u00f2s, Barcelona, Spain|CAP Barri Llat\u00ed, Santa Coloma De Gramenet, Barcelona, Spain|CAP Fondo, Santa Coloma De Gramenet, Barcelona, Spain|CAP Santa Rosa, Santa Coloma De Gramenet, Barcelona, Spain|CAP Singuerlin, Santa Coloma De Gramenet, Barcelona, Spain|CAP Dr Robert, Badalona, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 viral load|In Vitro Infectivity|Sensitivity and specificity of rapid SARS-CoV-2 antigen tests in saliva samples compared to RT-qPCR""}"
"4789","Clinical Characteristics and In-hospital Death of a Chilean COVID-19 Prospective Cohort","","NCT04758039","OAIC N° 1119/20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04758039","Completed","2020-03-13","2020-07-10","{""locations"":""Hospital Clinico de la Universidad de Chile, Santiago, Regi\u00f3n Metropolitana, Chile"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""395"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""In hospital Mortality|Admission to an intensive care unit (ICU)|Use of invasive mechanical ventilation (IMV)|Presence of thromboembolic disease (deep vein thrombosis, pulmonary embolism or both)|Acute kidney injury (AKI)|Renal replacement therapy (RRT).""}"
"4790","Copeptin and Psychological Stress of Medic During COVID-19 Pandemic","COVID-19","NCT04757285","0304842","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04757285","Completed","2020-05-10","2020-10-30","{""locations"":""Alexandria University Faculty of Medicine, Alexandria, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""90"",""age"":""24 Years to 37 Years \u00a0 (Adult)"",""outcome_measures"":""evaluation of psychological stress|determine stress hormones in serum cortisol and copeptin|correlation of psychological stress with stress hormone copeptin""}"
"4791","Pandemia And Exercise in Turkey in University Students of Turkey","","NCT04757207","60116787-020/76132","Other: survey","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04757207","Not yet recruiting","2021-02-22","2021-05-01","{""locations"":""Pamukkale University, Denizli, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1000"",""age"":""17 Years to 40 Years \u00a0 (Child, Adult)"",""outcome_measures"":""International Physical Activity Score (short form) MEt-min\/week|Energy expenditure while stepping|Energy expenditure while exercising""}"
"4792","Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients","COVATRHUS","NCT04757883","8135","Other: Study of the synthesis of antibodies directed against SARS","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04757883","Not yet recruiting","2021-03-01","2023-03-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The primary endpoint will be the rate of kidney transplant patients with neutralizing Antibodies directed against the Spike protein of the SARS CoV-2 virus after the 2nd injection of the vaccine.""}"
"4793","A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults","","NCT04758962","214525","Biological: 1 µg CoV2 SAM (LNP)|Biological: 3 µg CoV2 SAM (LNP)|Biological: 10 µg CoV2 SAM (LNP)|Biological: 30 µg CoV2 SAM (LNP)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04758962","Recruiting","2021-02-15","2022-05-09","{""locations"":""GSK Investigational Site, Rochester, New York, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""40"",""age"":""18 Years to 50 Years \u00a0 (Adult)"",""outcome_measures"":""Number of participants with at least 1 solicited administration site event during 7-day follow-up period after first vaccination (first vaccination occurs on Day 1)|Number of participants with at least 1 solicited administration site event during 7-day follow-up period after second vaccination (second vaccination occurs on Day 31)|Number of participants with at least 1 solicited systemic event during 7-day follow-up period after first vaccination (first vaccination occurs on Day 1)|Number of participants with at least 1 solicited systemic event during 7-day follow-up period after second vaccination (second vaccination occurs on Day 31)|Number of participants with any unsolicited adverse event (AE) during 30-day follow-up period after first vaccination (first vaccination occurs on Day 1)|Number of participants with any unsolicited AE during 30-day follow-up period after second vaccination (second vaccination occurs on Day 31)|Number of participants with any hematological and biochemical laboratory abnormality at screening|Number of participants with any hematological and biochemical laboratory abnormality at Day 1|Number of participants with any hematological and biochemical laboratory abnormality at Day 2|Number of participants with any hematological and biochemical laboratory abnormality at Day 8|Number of participants with any hematological and biochemical laboratory abnormality at Day 31|Number of participants with any hematological and biochemical laboratory abnormality at Day 32|Number of participants with any hematological and biochemical laboratory abnormality at Day 38|Number of participants with at least 1 medically attended AE (MAE) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31)|Number of participants with at least 1 serious adverse event (SAE) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31)|Number of participants with at least 1 adverse event of special interest (AESI) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31)|Number of participants with at least 1 MAE from first administered dose up to study conclusion|Number of participants with at least 1 SAE from first administered dose up to study conclusion|Number of participants with at least 1 AESI from first administered dose up to study conclusion|Humoral immune response in terms of SARS-CoV-2 Anti-Spike immunoglobulin G (IgG) antibody geometric mean concentrations (GMCs) at pre-vaccination, first dose (first vaccination occurs on Day 1)|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at pre-vaccination, second dose (second vaccination occurs on Day 31)|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at 1 month after last dose (second vaccination occurs on Day 31)|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at pre-vaccination, first dose (first vaccination occurs on Day 1)|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at pre-vaccination, second dose (second vaccination occurs on Day 31)|Humoral immune response in terms of Anti-Nucleocapsid IgG antibody GMCs at 1 month after last dose (second vaccination occurs on Day 31)|Humoral immune response in terms of SARS-CoV-2 neutralizing antibody Geometric Mean Titers (GMTs) at pre-vaccination, first dose (first vaccination occurs on Day 1)|Humoral immune response in terms of SARS-CoV-2 neutralizing antibody GMTs at pre-vaccination, second dose (second vaccination occurs on Day 31)|Humoral immune response in terms of SARS-CoV-2 neutralizing antibody GMTs at 1 month after last dose (second vaccination occurs on Day 31)|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Day 8|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Day 15|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Day 38|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Day 45|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Day 8|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Day 15|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Day 38|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Day 45|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Month 4|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Month 7|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Month 10|Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Month 13|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Month 4|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Month 7|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Month 10|Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Month 13|Humoral immune response in terms of SARS-CoV-2 neutralizing antibody GMTs at Month 4|Humoral immune response in terms of SARS-CoV-2 neutralizing antibody GMTs at Month 7|Humoral immune response in terms of SARS-CoV-2 neutralizing antibody GMTs at Month 10|Humoral immune response in terms of SARS-CoV-2 neutralizing antibody GMTs at Month 13|Cell mediated immune (CMI) response in terms of frequency of SARS-CoV-2 Spike-specific Cluster of Differentiation (CD) 4+ and CD8+ T-cells secreting at least 2 cytokines at pre-vaccination, first dose (first vaccination occurs on Day 1)|CMI response in terms of frequency of SARS-CoV-2 Spike-specific CD4+ and CD8+ T-cells secreting at least 2 cytokines at pre-vaccination, second dose (second vaccination occurs on Day 31)|CMI response in terms of frequency of SARS-CoV-2 Spike-specific CD4+ and CD8+ T-cells secreting at least 2 cytokines at Day 61|CMI response in terms of frequency of SARS-CoV-2 Spike-specific CD4+ and CD8+ T-cells secreting at least 2 cytokines at Day 121|CMI response in terms of frequency of SARS-CoV-2 Spike-specific CD4+ and CD8+ T-cells secreting at least 2 cytokines at Day 391""}"
"4794","Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?","","NCT04757272","6733","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04757272","Completed","2020-05-01","2021-01-30","{""locations"":""Zagazig University Hospitals, Zagazig, Sharkia, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""753"",""age"":""21 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""incidence of chronic hepatitis C among COVID-19 hospitalized patients.|the impact of previous exposure to different HCV management protocols on the clinical characteristics and outcome of COVID-19 among COVID-19 hospitalized patients""}"
"4795","Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)","","NCT04760730","CV03872091","Biological: AZD1222|Biological: rAd26-S","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04760730","Not yet recruiting","2021-03-17","2021-12-31","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention"",""enrollment"":""100"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody seroconversion rate (\u2265 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination|Incidence of local and systemic solicited Adverse Events (AEs) for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination)|Incidence of unsolicited AEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) through 29 days post each vaccination|Incidence of SAEs and AESIs after first vaccination until study end (Day 180)|Antibody seroconversion rate (\u2265 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post first vaccination|Antibody seroconversion rate (\u2265 4 fold increase from baseline) against Receptor Binding Domain (RBD) antigen|Geometric Mean Titre (GMT) and Geometric Mean Fold Rise (GMFR) of immunogenicity against Spike and RBD antigens at the day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).|Antibody seroconversion rate (\u2265 4 fold increase from baseline) SARS-CoV-2 neutralising antibodies|GMT and GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180)""}"
"4796","COVID Breath Test - Ancon","","NCT04760639","Pro00102970","Diagnostic Test: Breath test","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04760639","Recruiting","2020-12-16","2021-04-16","{""locations"":""Medical University of South Carolina, Charleston, South Carolina, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Provide an adequate sample and compare the signals given from the two groups.""}"
"4797","Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)","","NCT04760743","NBP2001_001","Biological: NBP2001 adjuvanted with alum (RBD 30μg/dose)|Biological: NBP2001 adjuvanted with alum (RBD 50μg/dose)|Other: Normal Saline","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04760743","Active, not recruiting","2020-12-17","2022-04-01","{""locations"":""Seoul National University Bundang Hospital, Seongnam-si, Bundang, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""50"",""age"":""19 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Occurrence of immediate systemic reactions|Occurrence of solicited local Adverse Events (AEs) during 7 days post each vaccination|Occurrence of solicited systemic AEs during 7 days post each vaccination|Occurrence of unsolicited AEs during 28 days post each vaccination|Occurrence of Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs) and Adverse Events of Special Interest (AESIs) during the whole study period|GMT of IgG antibody to the SARS-CoV-2 RBD measured by Enzyme-linked Immunosorbent Assay (ELISA)|GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA|Percentage of participants with \u2265 4-fold rise from baseline in ELISA IgG titer|GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays|GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays|Percentage of participants with \u2265 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer|Cell-mediated response for both Th1 and Th2 (e.g. INF-\u03b3, IL-4 using Enzyme-linked ImmunoSpot (ELISpot) or other system""}"
"4798","Covid-19 Vaccine Response in Elderly Subjects","MONITOCOVAGING","NCT04760704","2021_02|2021-A00119-32","Biological: Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04760704","Not yet recruiting","2021-02-01","2023-05-01","{""locations"":""CHU lille, Lille, France"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Comparison of specific cellular response after anti-SARS-CoV-2 BNT162b2 mRNA vaccine|Specific CD4+ and CD8+ T cell response|Total anti-S and neutralizing antibody levels|Specific immune response according to presence\/absence of pre-vaccine antibodies|Specific immune response after COVID-19 vs after BNT162b2 mRNA vaccine|Specific immune response according to nutritional status|Correlation between number of T cells, total anti-S antibody and neutralising antibody at 3 and 9 months, and basal levels of proinflammatory cytokines (interleukin-6, TNF-alpha) in elderly subjects|Peripheral blood mononuclear cells and serum collection""}"
"4799","A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.","MS COVID-19","NCT04760990","2020-02604; me20Mehling","Other: data collection|Other: analysis of blood samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04760990","Recruiting","2021-02-01","2023-12-01","{""locations"":""Kantonsspital Aarau, Aarau, Switzerland|University Hospital Basel, Department of Neurology and Department of Biomedicine, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|H\u00f4pitaux Universitaires Gen\u00e8ve, Gen\u00e8ve, Switzerland|Lausanne University Hospital (CHUV), Lausanne, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of severe COVID-19 as defined by the WHO clinical progression scale (Score 6-9)|COVID-19 related death defined by the WHO clinical progression scale (Score 10)|Proportion of patients with Anti-SARS-CoV-2 seroconversion|Change in mean titers of IgM- and IgG-antibodies against SARS-CoV-2|Change in individual titers of IgM- and IgG-antibodies against SARS-CoV-2|Proportion of total confirmed SARS-CoV-2-infections (independent of WHO clinical progression scale Score).""}"
"4800","Impact of COVID-19 on GU Disease","","NCT04761107","GCO 20-1053|STUDY-20-01467","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04761107","Recruiting","2021-02-01","2026-02-01","{""locations"":""Icahn School of Medicine at Mount Sinai, New York, New York, United States"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""15240"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients with a new diagnosis of GU|Proportion of GU cancer patients, with active disease or in remission|Proportion of patients with the benign urologic condition""}"
"4801","Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden","AutoCOVID-19","NCT04760184","2020-03433","Other: Autologous stem cell transplantation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04760184","Not yet recruiting","2021-04-01","2021-12-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Overall survival|COVID-19 related mortality|Time of COVID-19 infection|Hospitalization|Oxygen treatment|High-flow oxygen therapy|Non-invasive ventilation|Intensive care|Invasive mechanical ventilation|ECMO|Occurence of ARDS|Occurence of arterial thrombosis|Occurence of venous thrombosis|Occurence of arrhythmias|Occurence of acute cardiac injury|Occurence of secondary infection|Occurence of cytokine release syndrome|Comorbidities|Disease status|Previous disease modifying treatment|Conditioning treatment|Time of infection|Neutropenia|Elevated CRP|Elevated leukocyte count|Lymphocytopenia|Elevated liver enzymes|Elevated lactate dehydrogenase|Elevated ferritin|Elevated d-dimer|Prolonged aPTT|Elevated troponin|Elevated creatinine""}"
"4802","Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19","PREMIER","NCT04760821","SDC5100/20/129","Drug: Trimetazidine","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04760821","Recruiting","2020-12-10","2021-04-30","{""locations"":""Heart Institute (InCor-HCFMUSP), Sao Paulo, SP, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""80"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""High-sensitivity cardiac troponin|All-cause mortality assessed at 30 days following randomization|Admission in ICU assessed at 30 days following randomization|Mechanical respiratory support assessed at 30 days following randomization|ICU-free days assessed at 30 days following randomization|Hospital-free days assessed at 30 days following randomization""}"
"4803","National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)","ENFORCE","NCT04760132","ENFORCE","Biological: COMIRNATY - BioNTech Manufacturing GmbH|Biological: COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|Biological: COVID-19 Vaccine AstraZeneca suspension for injection","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04760132","Recruiting","2021-02-08","2024-12-31","{""locations"":""Aarhus Universitetshospital, Skejby, Aarhus, Aarhus N, Denmark|Aalborg Universityhospital Syd, Aalborg, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universityhospital, Odense, Denmark|Sj\u00e6llandsuniversitetshospital, Roskilde, Denmark"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of the effectiveness of citizens being vaccinated with one of the SARS-CoV-2 vaccines|Number of breakthrough infections in the 24 months period will be used to compare the effectiveness between the vaccines|Assessment of the safety of the vaccines will be compared between groups|Assessment of any Adverse Event from the vaccines will be compared between groups""}"
"4804","Self-prone Positioning for Awake Non-intubated Patients With COVID-19","","NCT04760561","proning for COVID-19 patients","Procedure: prone position group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04760561","Not yet recruiting","2021-02-20","2021-04-20","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""82"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Oxygenation index|SpO2|ROX index|PaO2mmHg|PCO2mmHg|SaO2|pH|Respiratory Rate (RR) (bpm)|Heart Rate (HR) (bpm)|Blood Pressure (BP) mmHg|Positive response to prone positioning|Prone position adverse events""}"
"4805","Stress, Personality, Attachment and Coping During the Covid Crisis.","STERACOVID","NCT04760795","IRBN922020","Other: PTSD Check List (PCL) scale|Other: Brief COPE scale|Other: GAD-7 (Generalized Anxiety Disorder) scale (during containment)|Other: Analog scale|Other: GAD-7 (Generalized Anxiety Disorder) scale (post containment)|Other: Big Five Inventory (BFI) scale|Other: Relationship Scales Questionnaire (RSQ)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04760795","Recruiting","2020-11-15","2021-06-01","{""locations"":""CH Le Vinatier, Bron, France|Chu Saint-Etienne, Saint-\u00c9tienne, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""118"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Analysis post traumatic stress disorder measured by PTSD Check List (PCL) results|Analysis usual coping strategies measured by brief COPE (dispositional version) results|Analysis of situation of patients|Analysis usual coping strategies during containment measured by brief COPE (dispositional version) results|Analysis anxiety during containment measured by GAD-7 (Generalized Anxiety Disorder) results|Analysis anxiety related to the containment context measured by analogue scale|Analysis anxiety post containment measured by GAD-7 (Generalized Anxiety Disorder) results|Analysis of personalities by Big Five Inventory (BFI) scale|Analysis attachment measured by Relationship Scales Questionnaire (RSQ) scale results|presence of traumatic life events""}"
"4806","Trauma and Trauma-Focused Therapy in the University of Kentucky SMART Clinic","","NCT04760418","64485","Behavioral: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04760418","Not yet recruiting","2021-03-01","2022-08-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""6"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PTSD Checklist for DSM-5 (PCL-5)|Recovery Update Form""}"
"4807","Protecting Native Families From COVID-19","","NCT04765475","IRB00014147","Behavioral: Motivational Interviewing|Behavioral: COVID-19 Symptom Monitoring System|Behavioral: Motivational Interviewing and COVID-19 Symptom Monitoring System|Other: Supportive Services","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04765475","Not yet recruiting","2021-02-01","2022-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""TESTING: Proportion tested for COVID-19|TESTING: Time to Test from Symptom Onset|CHANGE IN PROTECTIVE BEHAVIORS Over time - Recommended Practices|PROTECTIVE BEHAVIORS - Days quarantined in the past month|PROTECTIVE BEHAVIORS - Vaccine Acceptance|Cultural Identity and Connectedness|Substance Use|Depression|Anxiety|Demographic""}"
"4808","Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients","SaiseiCovUKR","NCT04762628","SaiseiMAF supplements COVID","Dietary Supplement: MAF capsules 148 mg|Dietary Supplement: M capsules 148 mg|Other: Standard of care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04762628","Active, not recruiting","2020-10-27","2022-01-10","{""locations"":""The Central Hospital of Rubizhne, Infection Disease Department, Rubizhne, Luhansk Region, Ukraine|Municipal Kharkiv Regional Infectious Diseases Clinical Hospital, Kharkiv, Ukraine"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The time to basic clinical improvement and to recovery defined as the following|14-day Participant Mortality|29-day Participant Mortality|Percentage of Participants in Each Clinical Status Category as Assessed by a 9-Point Ordinal Scale on Day 14|Time to an improvement of one category from admission on 9-Point Ordinal Scale|Time to an improvement of two categories from admission on 9-Point Ordinal Scale|Percentage of Participants in Each Clinical Status Category as Assessed by a 9-Point Ordinal Scale on Day at days 3, 5, 8, 11,14 and 29|Mean change in the ranking on 9-Point Ordinal Scale from baseline to days 3, 5, 8, 11, 14 and 29|Duration of conventional oxygen therapy Use|Duration of new conventional oxygen therapy Use|Duration of Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of Mechanical Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Oxygen Use|Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use|Percentage of Participants Requiring Ventilator or ECMO Use|Incidents of post-COVID-19 related symptoms at Day 29|Incidents of post-COVID-19 related symptoms at Day 60|Percentage of participants with post-COVID-19 related symptoms at Day 29|Percentage of participants with post-COVID-19 related symptoms at Day 60|Percentage of Participants Reporting Grade 3 and 4 Clinical and\/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Percentage of Participants Discontinued or Temporarily Suspended From Investigational dietary supplements|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Total Bilirubin|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Lymphocytes""}"
"4809","Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection","","NCT04765449","21P.015","Drug: Cytotoxic T Lymphocytes","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04765449","Not yet recruiting","2021-03-30","2024-02-29","{""locations"":""Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Safety of COVID-19-specific CTLs: Infusion Reactions|Safety of COVID-19-specific CTLs: Grade 4 AEs|Safety of COVID-19-specific CTLs: GVHD|Safety of COVID-19-specific CTLs: Marrow Aplasia|Safety of COVID-19-specific CTLs: Neurotoxicty|Safety of COVID-19-specific CTLs: CRS""}"
"4810","Effectiveness of Convalescent Plasma in Hospitalized Patients With COVID-19","","NCT04764747","CP in COVID-19 patients","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04764747","Recruiting","2020-11-01","2021-04-01","{""locations"":""Al-Amal Hospital, Najaf, Iraq|Al-Hakeem Hospital, Najaf, Iraq"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""400"",""age"":""18 Years to 95 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to clinical improvement|Find the prediction factors associated with good outcome of patients on CP therapy|Time to negative PCR|Mortality rate|Hospital stay time|Adverse effect of plasma therapy""}"
"4811","Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Subjects With a History of Severe COVID","TEP-COV","NCT04764721","A2021-01-01","Device: 18F-FDG PET-CT","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04764721","Not yet recruiting","2021-04-12","2022-05-12","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""50"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To characterize the changes in brain metabolism in 18F-FDG PET-CT in patients enrolled in Neurocog-Study in the hospital of Nancy|To compare the sensitivity of detection of cerebral abnormalities in MRI and 18F-FDG PET-CT in patients included in Neurocog-Covid study at the hospital of Nancy|To correlate the brain functions impacted on the neuropsychological assessment to the brain metabolism in 18F-FDG PET-CT in patients included in the Neurocog-Covid study at the Nancy Hospital|Correlating brain metabolism to the volume of damage to the lung sequelae of Covid-19.""}"
"4812","PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","","NCT04765436","PRO-CL-001","Biological: PTX-COVID19-B|Biological: Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04765436","Recruiting","2021-01-14","2022-02-14","{""locations"":""Manna Research, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""Occurrence of adverse events (AEs) during the follow-up after each vaccination|Assessments of AEs|Assessment of Safety|Immunogenicity analysis""}"
"4813","Adoptive SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19","ACT-COVID-19","NCT04762186","Uni-Koeln-4480","Drug: IMP 1,000 plus SoC|Drug: IMP 5,000 plus SoC|Drug: IMP RP2D plus SoC|Drug: SoC","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04762186","Not yet recruiting","2021-04-01","2022-12-01","{""locations"":""Department I for Internal Medicine University Hospital of Cologne, Cologne, NRW, Germany"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""51"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Phase I: Dose-limiting toxicities|Phase II:|Safety outcome measures|Acute graft- vs. -host disease""}"
"4814","Covid-19 Epidemic Lockdown Impact on Psychomotor Performance","","NCT04761718","Covid-19 Epidemic impact","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04761718","Not yet recruiting","2021-03-01","2021-05-30","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""300"",""age"":""6 Years to 18 Years \u00a0 (Child, Adult)"",""outcome_measures"":""pre lockdown assessment for physical activity|post lockdown assessment for physical activity""}"
"4815","CPAx for Assessing Functional Status of COVID-19 Patients After Intensive Care Unit Discharge","","NCT04762056","1","Other: Chelsea Critical Care Physical Assessment Tool","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04762056","Not yet recruiting","2021-02-20","2021-05-30","{""locations"":""Ko\u00e7 Univercity Hospital, Istanbul, None Selected, Turkey|Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""26"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Chelsea Critical Care Physical Assessment Tool (CPAx)|Barthel Index|Katz Index|Medical Research Council sum score (MRC-SS)|30 seconds sit to stand|5 times sit to stand test|modified Medical Research Council (mMRC) dyspnea scale|Modified Borg scale""}"
"4816","Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older","VAT00002","NCT04762680","VAT00002|U1111-1251-4616","Biological: SARS-CoV-2 recombinant protein vaccine Formulation 1|Biological: SARS-CoV-2 recombinant protein vaccine Formulation 2|Biological: SARS-CoV-2 recombinant protein vaccine Formulation 3","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04762680","Active, not recruiting","2021-02-24","2022-09-01","{""locations"":""Investigational Site Number 8400251, Chandler, Arizona, United States|Investigational Site Number 8400220, Los Angeles, California, United States|Investigational Site Number 8400094, Rolling Hills Estates, California, United States|Investigational Site Number 8400173, San Diego, California, United States|Investigational Site Number 8400239, New Haven, Connecticut, United States|Investigational Site Number 8400212, Washington, District of Columbia, United States|Investigational Site Number 8400089, Hollywood, Florida, United States|Investigational Site Number 8400057, Melbourne, Florida, United States|Investigational Site Number 8400179, Orlando, Florida, United States|Investigational Site Number 8400201, Decatur, Georgia, United States|Investigational Site Number 8400187, Peoria, Illinois, United States|Investigational Site Number 8400048, Rockville, Maryland, United States|Investigational Site Number 8400199, Boston, Massachusetts, United States|Investigational Site Number 8400030, Omaha, Nebraska, United States|Investigational Site Number 8400230, New York, New York, United States|Investigational Site Number 8400203, New York, New York, United States|Investigational Site Number 8400207, Rochester, New York, United States|Investigational Site Number 8400233, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400097, North Charleston, South Carolina, United States|Investigational Site Number 8400191, Austin, Texas, United States|Investigational Site Number 3400002, Municipio Del Distrito Central, Honduras|Investigational Site Number 3400001, San Pedro Sula, Honduras"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""722"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Presence of immediate adverse events|Presence of solicited injection site or systemic reactions|Presence of unsolicited adverse events|Presence of serious adverse events|Presence of adverse events of special interest|Presence of medically-attended adverse events|Neutralizing antibody titer at Day 1|Neutralizing antibody titer at Day 36|Neutralizing antibody titer fold-rise post-vaccination|2-fold rise and 4-fold-rise in neutralization antibody titer|Responders, as determined by neutralizing antibody titers at Day 36|Neutralizing antibody titer at all pre-defined time points|Neutralizing antibody titer fold-rise post-vaccination at all pre-defined time points|2-fold rise and 4-fold-rise in neutralization antibody titer at all pre-defined time points|Responders, as determined by neutralizing antibody titers at each pre-defined time point|Binding antibody concentrations|Binding antibody fold-rise|2-fold-rise and 4-fold rise in binding antibody concentration|Responders, as determined by binding antibody concentrations|Occurrences of laboratory-confirmed symptomatic COVID-19|Occurrences of symptomatic COVID-19 episodes associated with hospitalization|Occurrences of severe symptomatic COVID-19|Occurrences of death associated with symptomatic COVID-19|Occurrences of serologically-confirmed SARS-CoV-2 infection""}"
"4817","Right Ventricular Dysfunction in Ventilated Patients With COVID-19","COVID-RV","NCT04764032","20/COVID/17","Diagnostic Test: Echocardiography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04764032","Recruiting","2020-09-02","2021-04-30","{""locations"":""Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Univeristy Hospital, Ayr, Ayr, United Kingdom|Golden Jubilee National Hospital, Clydebank, United Kingdom|Dumfries and Galloway Royal Infirmary, Dumfries, United Kingdom|University Hospital Hairmyres, East Kilbride, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|University Hospital, Crosshouse, Kilmarnock, United Kingdom|Royal Alexandra hospital, Paisley, United Kingdom|University Hospital, Wishaw, Wishaw, United Kingdom"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""17 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""The prevalence of RV dysfunction in ventilated patients with COVID-19|Association of RV dysfunction with 30-day mortality.|Association of ARDS and RV dysfunction|Association of micro\/macro thrombi and RV dysfunction|The association of direct myocardial injury and RV dysfunction|The association of ventilation and RV dysfunction|Association of ARDS and 30-day mortality|Association of micro\/macro thrombi and 30-day mortality|Association of direct myocardial injury and 30-day mortality|Association of ventilation and 30-day mortality|The difference in NP levels between patients with, and patients without, RV dysfunction.|The difference in hsTn between patients with, and patients without, RV dysfunction.|Association between hsTn and 30-day mortality in patients with, and patients without, RV dysfunction|Association between NP levels and 30-day mortality in patients with, and patients without, RV dysfunction""}"
"4818","Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)","Colheart-19","NCT04762771","152247","Drug: Colchicine","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04762771","Recruiting","2020-12-01","2021-11-01","{""locations"":""Baptist Hospital of Miami, Miami, Florida, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""75"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality|Mechanical Ventilation|Mechanical Circulatory Support|Time (days) to the primary end point|Peak and delta (change from baseline) troponin level|Baseline BNP level|Inflammatory biomarkers|Hospital length of stay|Need for re-hospitalization""}"
"4819","Paediatric Inflammatory Multisystem Syndrome During COVID-19 Pandemic","","NCT04761913","19/20/048","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04761913","Not yet recruiting","2021-04-01","2021-12-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""3 Months to 16 Years \u00a0 (Child)"",""outcome_measures"":""Blood biomarker associated with a cytokine storm - Pro-Beta Natriuretic Peptide (measured in pg\/mL).|Blood biomarker associated with a cytokine storm - Ferritin (measured in \u00b5g\/L)|Blood Biomarker associated with a cytokine storm - C-Reactive Protein (measured in mg\/L)|Demographic characteristics including age, sex, ethnicity and pre-existing morbidities|Hospital stay data|Cytokine storm biomarker measured in mg\/L (CRP)|Cytokine storm biomarkers measured in pg\/mL (pro-beta natriuretic peptide, IL-6, IFN-gamma, IL-10, TNF-alpha)|Full blood count measures in 10^9\/L (white cell count - neutrophil and lymphocyte count and platelet)|Full blood count measures in L\/L (haematocrit)|Haemoglobin in g\/L or g\/dL (measured as part of full blood count and blood gas analysis)|Blood gas analysis measured in KPa (pCO2, pO2)|Blood gas analysis measured in mmol\/l (glucose, lactate, Na, K and Cl)|Blood gas analysis measured in mmol\/l or mEq\/L (HCO3, BE)|Liver function tests measured in g\/L (protein, albumin, globulin)|Liver function tests measured in U\/L (ALP\/ALT)|Liver function tests measured in \u00b5mol\/L (bilirubin)|Troponin measured in ng\/ml or ng\/L|vitamin D measured in nmol\/L|Amylase, CK, LDH measured in U\/L|Glucose and triglycerides measured in mmol\/L|Urea and electrolytes measured in mmol\/L (Na, K, urea)|Urea and electrolytes measured in \u00b5mol\/L (creatinine)|ferritin measured in \u00b5g\/L|fibrinogen measured in g\/L|D-dimer measured in ng\/ml|PT and APTT measured in seconds|INR as a ratio (Patient PT\/Control PT)|Acute Kidney Injury graded as no AKI or stage of AKI (1-3)|Positive or negative COVID-19 antibody test|Presence or absence of clinical conditions as assessed by ECG\/echocardiography|Presence or absence of clinical conditions as assessed by chest x-ray\/chest CT|Presence or absence of clinical conditions as assessed by abdominal ultrasound|Proteinuria as assessed by urinalysis graded as no protein, protein ++ or protein +++|Positive or negative COVID swab result as assessed by PCR|Positive or negative NPA or throat swab result for respiratory panel as assessed by PCR|Vaccination status""}"
"4820","COVID-19 Infection in Diabetic Patients","","NCT04765254","ITH00131","Other: no intervention as it is an observational study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04765254","Recruiting","2021-02-20","2021-04-10","{""locations"":""Cairo University teaching hospitals, Cairo, Kasr Al Ainy, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""30 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Investigation of bad prognosis cause for covid-19 diabetic patients""}"
"4821","Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)","","NCT04764981","OLFATO001","Other: Essence oils","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04764981","Enrolling by invitation","2021-05-01","2024-05-01","{""locations"":""Unidade de Ensino E Assist\u00eancia Em Fisioterapia E Terapia Ocupacional, Bel\u00e9m, PA, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""350"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To Assess the effectiveness of olfactory training therapy in the treatment of persistent olfactory dysfunctions after COVID-19|To Investigate by means of skull nuclear magnetic resonance (MRI) exams for possible neural correlates of olfactory dysfunctions present in post-COVID-19 patients|To Measure by means of a standardized olfactory test the olfactory dysfunctions present in post-COVID-19 patients|Propose an olfactory training protocol appropriate to the demands of patients with post-COVID-19 olfactory dysfunction and in accordance with the reality of Brazilian public health services""}"
"4822","Liver Function Test Abnormalities in COVID-19","COVID-19","NCT04763395","Soh-Med-21-02-27","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04763395","Recruiting","2021-01-29","2021-03-01","{""locations"":""Mona Mohammed Abdelrhman, Sohag, Egypt"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""100"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percentage of liver function tests abnormalities in Egyptian patients who infected with COVID19 -To evaluate if liver function test abnormalities are related to the severity of the Covid19.|Risk factors of Liver function test abnormalities|Liver function test abnormalities among patients with severe and non-severe disease""}"
"4823","Persistence of Symptoms After Improvement of Acute COVID-19","COVID-19","NCT04764773","Soh-Med-21-02-46","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04764773","Recruiting","2020-05-01","2021-03-31","{""locations"":""Mona Mohammed Abdelrahman, Sohag, Egypt"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""250"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Percentage of patient who had persistent symptoms after recovery of acute covid19|Type of persistent symptom after acute covid19|Risk factors for persistent symptoms after recovery of acute covid19""}"
"4824","Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks","","NCT04762693","DASRD","Device: Hyfe cough tracker","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04762693","Recruiting","2020-11-11","2021-11-01","{""locations"":""Universidad de Navarra, Pamplona, Navarra, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""13 Years to 99 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Correlation between registered coughs per person-hour and incidence of respiratory diseases|Uptake of the surveillance system|Barriers and facilitators affecting uptake of the surveillance system""}"
"4825","Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19","COPreDex","NCT04765371","CHRD1520|2020-005883-78","Drug: DEXAMETHASONE|Drug: PREDNISOLONE","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04765371","Not yet recruiting","2021-03-01","2021-10-01","{""locations"":""Department of Emergency, Hospital Victor Dupouy, Argenteuil, France|Department of Pneumology and Infectious Medicine, Hospital Carnelle Portes de l'Oise, Beaumont, France|Department of Infectious and Tropical Diseases, Hospital Simone Veil, Eaubonne, France|Department of Infectious Medicine, Hospital of Gonesse, Gonesse, France|Department of Infectious and Tropical Diseases, Hospital Ren\u00e9 Dubos,, Pontoise, France|Department of Infectious and respiratory Diseases, Hospital Delafontaine, Saint-Denis, France"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality assessment at D28|Assessment of clinical course in both groups (arms)|Measurement of evolution of respiratory symptoms in both groups (arms)|Assessment of patient satisfaction towards the treatment|Comparison betwween D1 and D28 of patient quality of life evolution between randomization groups (arms)|Comparison betwween D1 and D28 of adverse events and adverse effects between randomization groups (arms)""}"
"4826","Self-Help for Stress Related to COVID-19","","NCT04762173","STUDY00015766","Device: Online self-help intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04762173","Active, not recruiting","2020-11-06","2021-06-03","{""locations"":""The Pennsylvania State University, University Park, Pennsylvania, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""585"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in stress|Change in anxiety|Change in depression|Change in perceived stress|Change in coronavirus-related stress""}"
"4827","Increasing COVID-19, Influenza, and Pneumonia Vaccine Uptake","","NCT04761692","vaccineinc","Behavioral: Full VEPMP Intervention|Behavioral: Partial VEPMP Intervention|Behavioral: Delayed VEPMP Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04761692","Not yet recruiting","2021-10-01","2026-12-31","{""locations"":""Charles R. Drew University of Medicine & Science, Los Angeles, California, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""570"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report|Percentage of Participants Achieving Adherence to COVID-19, influenza, and pneumonia vaccination schedules Risk Using the NIH Toolbox Surveys on COVID-19|Percentage of Participants Achieving Decreased Vaccine Hesitancy Levels of COVID-19, influenza, and pneumonia Using the NIH Toolbox Surveys on COVID-19, influenza, and pneumonia|Percentage of Participants Achieving Decreased Levels of COVID-19, influenza, and pneumonia Mistrust and Barriers Using the NIH Toolbox Surveys on COVID-19, influenza, and pneumonia""}"
"4828","Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic","TELECAST-CSC","NCT04761874","TC0002","Other: Telestroke","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04761874","Completed","2019-12-01","2020-09-29","{""locations"":""M Health Fairview Southdale Hospital, Edina, Minnesota, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""296"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Guideline-Based Inpatient Stroke Care|Stroke Recurrence|Readmission Rate""}"
"4829","COVID-19: SARS Vaccination","SARS","NCT04761822","DAIT COVID-19-004|NIAID CRMS ID#: 38814","Biological: Moderna COVID-19 Vaccine|Biological: Pfizer-BioNTech COVID-19 Vaccine|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04761822","Not yet recruiting","2021-03-01","2021-06-01","{""locations"":""Mayo Clinic in Arizona, Phoenix, Arizona, United States|The University of Arizona Health Sciences, College of Medicine Tucson, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Tucson, Arizona, United States|Arkansas Children's, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of California, Los Angeles Medical Center, Los Angeles, California, United States|Stanford Medicine, Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States|National Jewish Health, Denver, Colorado, United States|University Health, University of Miami Health System, Miami, Florida, United States|University of South Florida, Division of Allergy and Immunology, Morsani College of Medicine, Tampa, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|The Sinus and Allergy Center of Northwestern University, Chicago, Illinois, United States|NorthShore Medical Group, Skokie, Illinois, United States|University of Iowa Health Care, Iowa City, Iowa, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan Health, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Saint Louis University Care, Center for Specialized Medicine, Saint Louis, Missouri, United States|The Mount Sinai Hospital, Department of Medicine, Division of Clinical Immunology, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Rochester Regional Health, Rochester, New York, United States|University of North Carolina Center for Environmental Medicine, Asthma & Lung Biology, Chapel Hill, North Carolina, United States|Cleveland Clinic, Allergy & Clinical Immunology, Cleveland, Ohio, United States|Penn State Health Allergy, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|University of Virginia Health System: Department of Medicine, Division of Allergy and Immunology, Charlottesville, Virginia, United States|Virginia Commonwealth University, Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, Richmond, Virginia, United States|University of Wisconsin Asthma Allergy Pulmonary Research, Madison, Wisconsin, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""3400"",""age"":""18 Years to 69 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of participants who experience a systemic allergic reaction to either dose of the Pfizer-BioNTech COVID-19 Vaccine|Proportion of participants who experience a systemic allergic reaction to either dose of the Moderna COVID-19 Vaccine|Proportion of participants who experience a severe (\u2265 Grade 3) systemic allergic reaction to either dose of each vaccine|Proportion of participants who experience an anaphylactic reaction per Brighton Collaboration Criteria to either dose of each vaccine|Proportion of participants who experience a systemic allergic reaction \u2265Grade 2 to the first dose|Proportion of participants who experience a systemic allergic reaction \u2265Grade 2 to the second dose conditional on no systemic allergic reaction to the first dose|Proportion of participants who experience a systemic allergic reaction \u2265Grade 2 to the first dose after adjusting for placebo administration""}"
"4830","The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh","","NCT04765540","2020091","Behavioral: Low Intensity Nudges|Behavioral: High Intensity Activities|Behavioral: BRAC's business-as-usual","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04765540","Active, not recruiting","2021-01-03","2021-05-30","{""locations"":""BRAC, Dhaka, Bangladesh|BRAC Khulna, Khulna, Bangladesh|BRAC Mymensingh, Mymensingh, Bangladesh"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""860"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Average handwashing station soap pedal presses per day (in weeks 1 to 3)|Average handwashing station soap pedal presses per day (in weeks 4 to 6)""}"
"4831","Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand","","NCT04764422","GPO NDV-HXP-S","Biological: Normal Saline|Biological: NDV-HXP-S vaccine","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04764422","Not yet recruiting","2021-03-01","2023-04-01","{""locations"":""Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""460"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of solicited reportable local adverse event after first vaccination|Frequency of solicited reportable local adverse event after second vaccination|Frequency of solicited reportable systemic adverse event after first vaccination|Frequency of solicited reportable systemic adverse event after second vaccination|Measurement of hemoglobin changed from baseline at 7 days after first vaccination|Measurement of hemoglobin changed from baseline at 7 days after second vaccination|Measurement of white blood cells changed from baseline at 7 days after first vaccination|Measurement of white blood cells changed from baseline at 7 days after second vaccination|Measurement of platelet count changed from baseline at 7 days after first vaccination|Measurement of platelet count changed from baseline at 7 days after second vaccination|Measurement of creatinine changed from baseline at 7 days after first vaccination|Measurement of creatinine changed from baseline at 7 days after second vaccination|Measurement of AST changed from baseline at 7 days after first vaccination|Measurement of AST changed from baseline at 7 days after second vaccination|Measurement of ALT change from baseline at 7 days after first vaccination|Measurement of ALT change from baseline at 7 days after second vaccination|Measurement of total bilirubin changed from baseline at 7 days after first vaccination|Measurement of total bilirubin changed from baseline at 7 days after second vaccination|Frequency of all unsolicited AEs|Frequency of SAEs|Frequency of medically-attended adverse event (MAAEs)|Frequency of AESI|GMT Neutralizing antibody titer 50 changed from baseline at 28 days after the first vaccination|GMT Neutralizing antibody titer 50 changed from baseline at 14 days after the second vaccination|GMT Neutralizing antibody titer 50 changed from baseline at 6 months after the second vaccination|GMT Neutralizing antibody titer 50 changed from baseline at 12 months after the second vaccination|GMT Neutralizing antibody titer 80 changed from baseline at 28 days after the first vaccination|GMT Neutralizing antibody titer 80 changed from baseline at 14 days after the second vaccination|GMT Neutralizing antibody titer 80 changed from baseline at 6 months after the second vaccination|GMT Neutralizing antibody titer 80 changed from baseline at 12 months after the second vaccination|NT50 seroresponses changed from baseline at 28 days after the first vacccination|NT50 seroresponses changed from baseline at 14 days after the second vaccination|NT50 seroresponses changed from baseline at 6 months after the second vaccination|NT50 seroresponses changed from baseline at 12 months after the second vaccination|NT80 seroresponses changed from baseline at 28 days after the first vaccination|NT80 seroresponses changed from baseline at 14 days after the second vaccination|NT80 seroresponses changed from baseline at 6 months after the second vaccination|NT80 seroresponses changed from baseline at 12 months after the second vaccination|GMT Anti-S IgG at 28 days after the first vaccination|GMT Anti-S IgG at 14 days after the second vaccination|GMT Anti-S IgG at 6 months after the second vaccination|GMT Anti-S IgG at 12 months after the second vaccination|GMFR changed from baseline in anti-S IgG GMT at 28 days after the first vaccination|GMFR changed from baseline in anti-S IgG GMT at 14 days after the second vaccination|GMFR changed from baseline in anti-S IgG GMT at 6 months after the second vaccination|GMFR changed from baseline in anti-S IgG GMT at 12 months after the second vaccination|Anti-S IgG Seroresponses changed from baseline at 28 days after the first vaccination|Anti-S IgG Seroresponses changed from baseline at 14 days after the second vaccination|Anti-S IgG Seroresponses changed from baseline at 6 months after the second vaccination|Anti-S IgG Seroresponses changed from baseline at 12 months after the second vaccination""}"
"4832","Couple HOPES (Helping Overcome PTSD and Enhance Satisfaction)","HOPES","NCT04763681","2019-475|173098|CIHR-IRSC:0525007697|W7714-207266","Behavioral: Couple HOPES Guided, Internet-Delivered, Self-Help Intervention","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04763681","Recruiting","2021-01-01","2021-08-31","{""locations"":""York University, Toronto, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""140"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 (PCL-5) with change measured as mean change from baseline|Couple Satisfaction Index (CSI-4) with change measured as mean change from baseline|Significant Others' Responses to Trauma Scale with change measured as mean change from baseline|Mean change from baseline on Ineffective Arguing Inventory""}"
"4833","A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)","HORIZON 1","NCT04765384","CR108962|2020-005330-14|VAC31518COV2004","Biological: Ad26.COV2.S","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04765384","Not yet recruiting","2021-02-26","2023-06-20","{""locations"":""Central Research Associates, Inc., Birmingham, Alabama, United States|SEC Clinical Research, Dothan, Alabama, United States|University of Southern California, Los Angeles, California, United States|Stanford Health Care - Positive Care Clinic, Stanford, California, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|Emory University, Atlanta, Georgia, United States|Spectrum Health System, Grand Rapids, Michigan, United States|Medpharmics, LLC, Gulfport, Mississippi, United States|Meridian Clinical Research, LLC, Grand Island, Nebraska, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Medpharmics, LLC, Albuquerque, New Mexico, United States|Columbia University Medical Center, New York, New York, United States|Monroe Biomedical Research, Monroe, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Columbus, Ohio, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|Tekton Research Inc., Austin, Texas, United States|Baylor College of Medicine and Texas Childrens Hospital, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Maximos OB\/GYN, League City, Texas, United States|Women's and Children's Hospital, North Adelaide, Australia|Murdoch Children's Research Institute, Parkville, Australia|Mater Hospital Brisbane, South Brisbane, Australia|Hospital de Clinicas da Universidade Federal De Minas Geraisnas Gerais, Belo Horizonte, Brazil|HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil|Centro de Estudos e Pesquisas em Mol\u00e9stias Infecciosas, Natal, Brazil|Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil|Hospital Geral de Nova Iguacu - HGNI DST\/AIDS, Rio De Janeiro, Brazil|Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Brazil|University of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|CMPC - Consultoria M\u00e9dica e Pesquisa Cl\u00ednica, Sorocaba, Brazil|Universidade Municipal de Sao Caetano do Sul, S\u00e3o Caetano do Sul, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo, S\u00e3o Paulo, Brazil|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|Helsinki University Hospital, Helsinki, Finland|Kokkolan rokotetutkimusklinikka, Kokkola, Finland|Oulun rokotetutkimusklinikka, Oulu, Finland|Sein\u00e4joen rokotetutkimusklinikka, Sein\u00e4joki, Finland|Tampereen rokotetutkimusklinikka, Tampere, Finland|Turun rokotetutkimusklinikka, Turku, Finland|Shandukani Research Centre, Johannesburg, South Africa|Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa|Setshaba Research Centre, Soshanguve, South Africa|Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa|Vaccines and Infectious Diseases Analytics Research Unit (VIDA), Formely RMPRU, Soweto, South Africa|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Univ. Pta. de Hierro Majadahonda, Majadahonda, Spain|Hosp. Puerta Del Sur, Mostoles, Spain|Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcon, Spain|Hosp. Clinico Univ. de Santiago, Santiago de Compostela, Spain|University Hospitals Bristol NHS Trust, Bristol, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds,, United Kingdom|Barts Health NHS Trust, Royal London Hospital, London, United Kingdom|University College London Hospitals NHSFT, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Chelsea and Westminster NHS Foundation Trust, London, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""400"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Number of Participants with Solicited Local Adverse Events (AEs)|Number of Participants with Solicited Systemic AEs|Number of Participants with Unsolicited AEs|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Medically-attended Adverse Events (MAAEs)|Number of Participants with MAAEs leading to Discontinuation|Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination|Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After First Vaccination|Serological Response to Vaccination as Measured by ELISA 28 Days After Second Vaccination|Number of Participants with Antibody GMC 28 Days After Second Vaccination|Number of Participants with Pregnancy Outcomes|Number of Participants with Pregnancy Related AEs|Number of Neonates and Infants with any Complications, Anomalies and Deaths|Number of Neonates and Infants with SAEs|Number of Neonates and Infants with MAAEs|Number of Neonates and Infants with MAAEs leading to Study Discontinuation|Serological Response to Vaccination as Measured by ELISA|Number of Neonates and Infants with Antibody GMC""}"
"4834","New Predictors in Determining the Need for Invasive Treatment in Non-STEMI","non-STEMI","NCT04763213","05.08.2020-2020/15/10","Diagnostic Test: Coronary Angiography","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04763213","Completed","2018-01-01","2019-12-31","{""locations"":""Ekrem Aksu, Kahramanmara\u015f, Turkey"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""276"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Predictive factors for Non ST elevated MI Blood prarameters Predictive factors for Non ST eleveted MI""}"
"4835","Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.","","NCT04765215","CHEMOCOVAC","Biological: CoronoVAC","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04765215","Not yet recruiting","2021-03-31","2022-03-31","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""291"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody levels above the defined cut-off""}"
"4836","Self-contamination Following Removal of Two Personal Protective Equipment Suits: a Crossover Trial","","NCT04763304","5646","Other: Gown personal protective equipment (PPE-G) suit|Other: Coverall personal protective equipment (PPE-C) suit","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04763304","Completed","2020-09-01","2020-11-18","{""locations"":""Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mean within-participant difference in self-contamination between PPE-G and PPE-C suits|Correlation between self-contamination and adherence to the PPE removal protocol""}"
"4837","Mindfulness-SOS: Stress Reduction for Refugees","","NCT04761510","Mindfulness-SOS for Refugees","Behavioral: Mindfulness-SOS for Refugees","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04761510","Completed","2020-09-14","2021-01-14","{""locations"":""Assaf, Tel Aviv, Merkaz, Israel"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Harvard Trauma Questionnaire according to DSM-5 (HTQ-5)|Brief Patient Health Questionnaire (PHQ-9)|Beck's Anxiety Inventory (BAI)|Post-Migration Living Difficulties Checklist (PMLD)|Brief Inventory of Thriving (BIT)|Dimensions of Anger Reactions-5 (DAR-5)|Parenting Scale (PS)|Modified 5-item Extended-Hurt\/Insult\/Threaten\/Scream (Modified E-HITS)|Positive and Negative Affect Schedule (PANAS)|Brief assessment of mindful awareness|Brief assessment of self-compassion|Brief weekly assessment of formal and informal mindfulness practice|Brief weekly assessment of post-traumatic stress|Brief weekly assessment of depression|Brief weekly assessment of anxiety""}"
"4838","The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection","","NCT04766931","FB2001-102","Drug: FB2001|Drug: FB2001 Placebo","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04766931","Not yet recruiting","2021-03-01","2021-12-01","{""locations"":""Frontage Clinical Services, Inc., Secaucus, New Jersey, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""18 Years to 60 Years \u00a0 (Adult)"",""outcome_measures"":""The Maximum Tolerable Dose (MTD)|Number of participants with treatment-related adverse events as assessed by CTCAE V4.0|Pharmacokinetic parameters(Cmax)|Pharmacokinetic parameters(AUC)""}"
"4839","Honey and Nigella Sativa in COVID-19 Prophylaxis","HNS-COVID-PK","NCT04767087","SZMC/IRB/Internal/273/2021","Drug: Honey|Drug: Nigella sativa seed|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04767087","Recruiting","2021-02-05","2021-07-15","{""locations"":""Shaikh Zayed Post-Graduate Medical Institute, Lahore, MA, Pakistan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 infection rate""}"
"4840","An Exploratory Study to Describe Virological Effect, Safety, and Pharmacokinetics of VIR-7831 Monoclonal Antibody in Hospitalized Participants With COVID-19","COMET-ACE","NCT04766671","214366","Biological: VIR-7831|Biological: Placebo|Drug: Standard of care","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04766671","Not yet recruiting","2021-04-14","2022-06-08","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from Baseline in viral load as measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) from nasopharyngeal (NP) swabs|Change from Baseline in viral load as measured by qRT-PCR from tracheal aspirate (TA) or endotracheal tube aspirate (ET) or spontaneous sputum (SS) samples and saliva samples|Change from Baseline in viral load as measured by quantitative culture from NP swabs|Time (in days) to achieve undetectable Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) from TA or ET or SS samples, NP swabs and saliva samples using qRT-PCR|Maximum observed serum concentration (Cmax) of VIR-7831|Area under the plasma concentration-time curve from time 0 to Day 29 (AUC 0-Day 29) of VIR-7831|Number of participants with adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)|Number of participants with clinically significant changes in vital signs, laboratory parameters and 12-lead electrocardiogram (ECG) findings""}"
"4841","Studying Students at Risk for COVID-19","","NCT04766788","HUM00185391","Other: Wearable devices, saliva samples, survey measures","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04766788","Active, not recruiting","2020-09-03","2021-08-01","{""locations"":""Michigan Medicine, Ann Arbor, Michigan, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""2494"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Feasibility of wearing Fitbit device|Survey completion""}"
"4842","Macrophage Activation Markers in COVID-19 Patients","COVID-19","NCT04766294","Soh-Med-21-02-20","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04766294","Recruiting","2020-04-25","2021-04-01","{""locations"":""Faculty of medicine - sohag university, Sohag, Egypt"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""70"",""age"":""19 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measurement of matrix metalloproteinase-7 \""MMP-7\"" serum level (pg\/ml) as a biomarker of macrophage activation|Measurement of matrix metalloproteinase-9 \""MMP-9\"" serum level (pg\/L) as a biomarker of macrophage activation|Measurement of transforming growth factor B \""TGF-B\"" serum level ( pg\/ml) as a biomarker of macrophage activation|Measurement of platelet derived growth factor \""PDGF\"" serum level (ng\/ml) as a biomarker of macrophage activation""}"
"4843","The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing","RAPID COVID","NCT04767958","20200858-01T","Diagnostic Test: Spartan COVID-19 Platform","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04767958","Not yet recruiting","2021-02-16","2022-07-31","{""locations"":""University of Ottawa Heart Institute, Ottawa, Ontario, Canada"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""2500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Sensitivity of POC testing as compared to core lab testing|Incidence in which decision making would have been altered by POC testing""}"
"4844","Incidence of VAP in Patients With Severe COVID-19","CoV-AP","NCT04766983","20/01/2021-0002005-U","Diagnostic Test: bronchoalveolar lavage","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04766983","Recruiting","2021-01-22","2022-04-30","{""locations"":""IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, MI, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of VAP|number of episodes with concordance in bacterial isolates between BAL and ETA performed on VAP suspicion|number of episodes with concordance in bacterial isolates between BAL performed on VAP suspicion and the preceding surveillance ETA|number of episodes with concordance in cellular phenotype between BAL and peripheral blood on VAP suspicion|number of episodes with concordance in lymphocyte-monocyte activation between BAL and peripheral blood on VAP suspicion|number of episodes with concordance in SARS-CoV-2 viral quantification between BAL, ETA and nasopharyngeal swab on VAP suspicion|number of episodes with concordance in SARS-CoV-2 sequencing between BAL, ETA and nasopharyngeal swab on VAP suspicion""}"
"4845","Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors","","NCT04767477","CR and TR","Other: Face-to-face rehabilitation|Other: Telerehabilitation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04767477","Not yet recruiting","2021-03-28","2021-08-01","{""locations"":""Universidade Federal de Pernambuco, Recife, PE, Brazil"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Maximum functional capacity|Submaximal functional capacity|Intensity and impact of fatigue|Spirometry|Quality of life assessment: Short Form-36 questionnaire""}"
"4846","New Jersey Healthcare Essential Worker Outreach and Education Study - Testing Overlooked Occupations","","NCT04766333","2020002549","Behavioral: Healthcare Worker Focused Outreach|Behavioral: Community Organization Led Outreach","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04766333","Not yet recruiting","2021-03-01","2022-08-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""2000"",""age"":""4 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Number of participants who complete COVID-19 testing""}"
"4847","Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations","CERC","NCT04765839","21-000205","Other: Educational, culturally appropriate COVID-19 messages","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04765839","Active, not recruiting","2021-02-12","2021-03-22","{""locations"":""Mayo Clinic, Rochester, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care"",""enrollment"":""90"",""age"":""18 Years to 101 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 attitudes""}"
"4848","Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients","IVCOM","NCT04768179","IVCOM PROTOCOL VERSION 03","Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04768179","Not yet recruiting","2021-02-19","2021-09-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""490"",""age"":""18 Years to 64 Years \u00a0 (Adult)"",""outcome_measures"":""SARS COV 2 Viral clearance|World Health Organization COVID-19 ordinal improvement score|Clinical recovery|Spectrum and severity of adverse events|Maximum Plasma concentration|Minimum Plasma concentration|Area Under the Curve""}"
"4849","Physical Activity Post COVID-19","PA-COVID19","NCT04768257","CEID/HU/2020/51","Behavioral: Physical activity","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04768257","Not yet recruiting","2021-04-01","2022-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""195"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in Physical activity (PA) patterns (steps\/day) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (time spent in moderate-to-vigorous PA) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (time spent in moderate-to-vigorous PA, in bouts of 10 minutes) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (Mean duration of bouts of moderate-to-vigorous PA) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (total time in sedentary behaviour -lying or sitting-) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (mean duration of a sedentary bout) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in functional capacity (six-minutes walking test) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in functional capacity (one-minute sit-to-stand test) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in isometric quadriceps strength from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in handgrip force from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in maximal inspiratory and expiratory pressures from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in health-related quality of life from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in dyspnea symptom from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in fatigue symptom from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in anxiety and depression symptoms from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Forced expiratory volume in the first second (FEV1) assessed using spirometry at baseline (at hospital discharge or patient's home)|Forced vital capacity (FVC) assessed using spirometry at baseline (at hospital discharge or patient's home)|Ratio between Forced expiratory volume in the first second and Forced vital capacity (FEV1\/FVC) assessed using spirometry at baseline (at hospital discharge or patient's home)|Sociodemographics (age) at baseline (at hospital discharge or patient's home)|Sociodemographics (sex) at baseline (at hospital discharge or patient's home)|Anthropometrics (height) at baseline (at hospital discharge or patient's home)|Change in anthropometrics (weight) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Relevant clinical history (diagnosis with lung or cardiovascular disease) at baseline""}"
"4850","The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection","","NCT04769245","Acibadem Healthcare Group","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04769245","Recruiting","2021-02-18","2021-06-01","{""locations"":""Ac\u0131badem Labcell Cellular Therapy Laboratories, Istanbul, Turkey|Acibadem Altunizade Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Retrospective"",""enrollment"":""40"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality Rate|Length of Hospitalization|Side Effects""}"
"4851","Impact of Maternal COVID-19 Disease on Breast Milk and Infant Health","MilkCorona","NCT04768244","covid1","Other: maternal SARS-CoV-2 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04768244","Recruiting","2020-04-01","2021-12-01","{""locations"":""Fundacion Investigacion Sanitaria INCLIVA, Valencia, Spain|Hospital Universitario y Politecnico la Fe, Valencia, Spain"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""SARS-CoV-2 RNA|breast milk immune|breast milk microbiota|breast milk metabolite|infant microbiota|infant growth and development""}"
"4852","Post-partum Depression, Breastfeeding Adherence and Fear in COVID-19","","NCT04769700","Lactancia1","Behavioral: Edinburgh Postnatal Depression Scale|Behavioral: Breast Feeding Adherence|Behavioral: Fear of Covid-19 Scale","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04769700","Recruiting","2021-01-01","2021-06-01","{""locations"":""Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""250"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Post-Partum Depression Frequency|Breast Feeding Adherence and behavior.|Fear of Covid-19 severity""}"
"4853","Airway Management in the Intensive Care and Regular Hospital Units During COVID-19 Pandemic","","NCT04769154","BIO-2020-0049","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04769154","Not yet recruiting","2021-02-01","2023-02-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The success rate of endotracheal intubation at first attempt|Adverse events (Hypoxemia)|Adverse events (Hypotension)""}"
"4854","Psychological State of Students of Health Sciences During COVID-19","","NCT04769284","Mental health student","Other: Mental health student","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04769284","Completed","2021-02-12","2021-02-21","{""locations"":""Faculty of Health Sciences. Zaragoza's University, Zaragoza, Spain"",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""332"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Modified version of EPP-10 related to COVID-19 (EPP-10-C)|Abbreviated Goldberg Anxiety Scale EADG|Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).|Short International Physical Activity Questionnaire (IPAQ)""}"
"4855","Effectiveness of Supportive Housing on COVID-19 Related Outcomes for People Experiencing Homelessness","","NCT04769349","UP-20-01081","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04769349","Recruiting","2021-01-29","2022-12-15","{""locations"":""Los Angeles Homeless Services Authority (LAHSA), Los Angeles, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""800"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Life Satisfaction|Quality of physical health|Degree of mental health symptomatology|Social Isolation|Housing Environment|COVID-19 Prevention practices|Healthcare Utilization""}"
"4856","Prioritising Prevention of COVID-19 in Persons With Cancer in the French West Indies","RESILIENCE","NCT04768153","20_RIPH3_04","Biological: Serology","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04768153","Recruiting","2020-06-29","2021-12-29","{""locations"":""CHU Martinique, Fort-de-France, Martinique"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""700"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of Psychiatric disorders""}"
"4857","Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic","","NCT04769297","LM-LDK-001","Drug: Sublingual Micro-Dose Ketamine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04769297","Active, not recruiting","2020-04-15","2021-04-01","{""locations"":""Limbic Medical, Toluca Lake, California, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patient self-reported outcome measure""}"
"4858","Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD)","ESCAPE-IBD","NCT04769258","IGIBD001","Biological: Pfizer Comirnaty vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04769258","Not yet recruiting","2021-03-01","2022-06-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""1380"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Quantitative serum titer of IgM and IgG against SARS-CoV-2|Rate of COVID-19 occurrence|Rate of adherence to the vaccination|Rate of adverse events of the different vaccines|Rate of IBD flare-ups|Predictors of effectiveness of COVID-19 vaccine|Differences of effectiveness between patients|Differences of effectiveness between the several vaccines""}"
"4859","Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)","SUEP-NAPKON","NCT04768998","01KX2021","Other: Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04768998","Recruiting","2020-11-04","2023-09-01","{""locations"":""RWTH Aachen, Aachen, Germany|University Hospital Augsburg, Augsburg, Germany|Charit\u00e9 Berlin, Berlin, Germany|Klinikum Bielefeld, Bielefeld, Germany|University Hospital Ruhr-University Bochum, Bochum, Germany|University Hospital Bonn, Bonn, Germany|University Hospital Cologne, Cologne, Germany|University Hospital Carl Gustav Carus Dresden, Dresden, Germany|University Hospital Dusseldorf, Dusseldorf, Germany|University Hospital Erlangen, Erlangen, Germany|University Hospital Essen, Essen, Germany|Johann Wolfgang Goethe University, Frankfurt am Main, Germany|University Hospital Freiburg, Freiburg, Germany|University Hospital Greifswald, Greifswald, Germany|University Hospital G\u00f6ttingen, G\u00f6ttingen, Germany|University Hospital Halle, Halle\/Saale, Germany|University Hospital Hamburg-Eppendorf, Hamburg, Germany|University Hospital MMH Hannover, Hannover, Germany|University Hospital Heidelberg, Heidelberg, Germany|University Hospital UKS Homburg, Homburg, Germany|University Hospital Jena, Jena, Germany|University Hospital UKSH Schleswig-Holstein, Kiel, Germany|University Hospital Leipzig, Leipzig, Germany|University Hospital UKSH Schleswig-Holstein, L\u00fcbeck, Germany|University Hospital Mannheim, Mannheim, Germany|University Hospital Giessen\/Marburg, Marburg, Germany|University Hospital LMU Munich, Munich, Germany|University Hospital TUM Munich, Munich, Germany|University Hospital M\u00fcnster, M\u00fcnster, Germany|Klinikum Oldenburg, Oldenburg, Germany|University Hospital Regensburg, Regensburg, Germany|University Hospital T\u00fcbingen, T\u00fcbingen, Germany|University Hospital Ulm, Ulm, Germany|University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""6550"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Longitudinal collection of data and biomaterial|Number of cases of SARS-CoV-2 infection|Changes in concentration of inflammatory parameters.|Changes in concentration of cardiac parameters.|Changes in concentration of urine parameters.|Changes in Patient-reported Quality of life recorded with the help of the European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l) questionnaire.|Changes in body temperature.|Changes in blood pressure.|Changes in heart rate.|Changes in breath frequency.|Changes in peripheral oxygen saturation.""}"
"4860","Evaluation of a Non-face to Face Multidisciplinary Health Care Model in a Population With Rheumatoid Arthritis","","NCT04768413","5171","Other: Teleconsultation either by phone or by computer consultation. Quantitative and qualitative approaches to analysis|Other: Care modalities. Quantitative and qualitative approaches to analysis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04768413","Recruiting","2020-06-01","2021-06-30","{""locations"":""BIOMAP IPS Centro de Atenci\u00f3n Integral en Artritis Reumatoide, Bogota, Cundinamarca, Colombia|Colombia Fundaci\u00f3n Universitaria de Ciencias de la Salud-FUCS, Bogota, Cundinamarca, Colombia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluation of the implementation of a non-face-to-face multidisciplinary consultation model in a population of rheumatoid arthritis|Epidemiological characterization|Proportion of individuals infected|Risk factors for infection|Risk factors for hospitalization|Risk factors for mortality|Average change from baseline in Disease Activity Score with 28-joint counts [DAS28] in face-to-face consultation group|Average change from baseline in Patient Activity Scale scores in both groups tele-assisted consultation and face-to-face consultation|Evaluation of participant's pain using visual analogue scale [VAS] in both groups tele-assisted consultation and face-to-face consultation|Evaluation of the disease activity by Doctor using visual analogue scale [VAS] in both groups tele-assisted consultation and face-to-face consultation|Absolute and percent change in the Health Assessment Questionnaire (HAQ) in both groups tele-assisted consultation and face-to-face consultation|Average change from baseline in European Quality of Life 5 Dimensions (EQ-5D) questionnaire in both groups tele-assisted consultation and face-to-face consultation|Evaluation of the level of therapeutic adherence using a specific Scale in both groups tele-assisted consultation and face-to-face consultation|Evaluation of the self-care capacity using the Appraisal of Self-care Agency Scale -Revised (ASA-R) in both groups tele-assisted consultation and face-to-face consultation""}"
"4861","Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19","","NCT04771351","AMG-COV-202","Biological: COVI-AMG|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04771351","Not yet recruiting","2021-03-01","2021-09-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""280"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of subjects who are alive and free of respiratory failure at Day 29|Viral load reduction|Time to sustained clinical improvement|Proportion of subjects with clinical improvement|All-cause mortality at Day 29""}"
"4862","A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19","","NCT04770467","BRII-196-198-002","Drug: BRII-196 and BRII-198|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04770467","Not yet recruiting","2021-02-01","2022-10-01","{""locations"":""Investigative Site 1, Hong Kong, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""56"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Change from pre-dose baseline in RBC count|Change from pre-dose baseline in WBC count|Change from pre-dose baseline in Platelets count|Change from pre-dose baseline in Hemoglobin result|Change from pre-dose baseline in Creatine kinase result|Change from pre-dose baseline in Alanine aminotransferase (ALT) result|Time-weighted average changes in SARSCoV-2 RNA levels in nasopharyngeal swabs from baseline to Day 8|Duration of COVID-19 related symptoms through Day 29 among subjects with mild-moderate COVID-19|Proportion of subjects who have mild-moderate COVID-19 and develop severe COVID-19 after randomization|Assessment of PK parameters: maximum serum concentration observed (Cmax)""}"
"4863","Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras","","NCT04771013","AEC-01-2021|COM-2020-01","Biological: Thymic peptides","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04771013","Recruiting","2021-02-10","2021-05-01","{""locations"":""Hospital de Santa B\u00e1rbara Integrado, Santa B\u00e1rbara, Honduras"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""20"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to Participant Response|Number of Participants with Treatment Related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)|Number of Participants with Treatment Related Side Effects as Assessed by the General Assessment of Side Effects (GASE)|Hospital Average Length of Stay (ALOS) as Measured by the Mean Participants' Inpatient Days|Overall Survival Defined as the Time From the Start of Treatment until Death due to any Reason""}"
"4864","Breathing Exercise After COVID-19 Pneumonia","","NCT04771598","123458","Other: Breathing exercise with the phone application|Other: Breathing exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04771598","Not yet recruiting","2021-02-25","2021-07-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""52"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""6 minute walking test|FEV-1|FVC|FEV1\/FVC|MVV|St. George's Respiratory Questionnaire""}"
"4865","Minimizing the Effects of COVID-19 Hospitalization With the COVID Rehabilitation Program for the Elderly","CORE","NCT04771052","MP-31-2021-3770","Other: COVID Rehabilitation Program for the Elderly (CORE)","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04771052","Enrolling by invitation","2020-09-01","2021-04-01","{""locations"":""CIUSSS de l'Estrie-Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada|Centre hospitalier affili\u00e9 universitaire r\u00e9gional (CHAUR), Trois-Rivi\u00e8res, Quebec, Canada"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""128"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Length of stay|Post-discharge destination|Readmission rate 30 days after discharge|Change in patient prognosis|Change in functional capacity (lower limb function)|Change in functional capacity (handgrip strength)""}"
"4866","Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19","KOVIT","NCT04770740","KOVIT","Dietary Supplement: Vitamin K2 in the form of Menaquinone-7 (MK-7)|Dietary Supplement: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04770740","Recruiting","2021-02-22","2021-10-01","{""locations"":""Canisius Wilhelmina Hospital, Nijmegen, Gelderland, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Plasma desmosine levels|Plasma dp-ucMGP levels|Safety|Serum PIVKA-II levels""}"
"4867","Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients","","NCT04771559","132620","Other: COVID-19 antibody test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04771559","Not yet recruiting","2021-03-01","2021-07-01","{""locations"":""Bezmialem University, Istanbul, Fatih, Turkey|Okmeydani Research Hospital, Istanbul, Fatih, Turkey|Acibadem University, Istanbul, Turkey|Medeniyet University, Istanbul, Turkey|Medipol University, Istanbul, Turkey"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody levels|Side effects""}"
"4868","COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications","COVFIS-HOME","NCT04771611","20-009705","Drug: Fisetin","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04771611","Not yet recruiting","2021-03-01","2023-06-01","{""locations"":""Mayo Clinic, Rochester, Minnesota, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Serious Adverse Events|Long Hauler Syndrome""}"
"4869","Assessment of Executive Functions After Covid-19","","NCT04771624","21022021","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04771624","Recruiting","2020-10-30","2021-07-30","{""locations"":""Sa\u011fl\u0131k Bilimleri \u00dcniversitesi Gazi Ya\u015fargil Training and Research Hospital, Diyarbak\u0131r, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Neuropsychological test scores|Severity of the disease""}"
"4870","A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19","","NCT04771000","N-003-CRD008","Drug: Ambrisentan|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04771000","Recruiting","2021-02-08","2021-10-31","{""locations"":""University Hospital 12 de Octubre, Madrid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""50 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in SpO2\/FiO2 from baseline to the time-weighted average obtained on Day 3|Proportion of subjects alive and not having developed respiratory failure from randomization to Day 14|Change in SpO2\/FiO2 from baseline to the time-weighted average obtained on Day 1|Change in SpO2\/FiO2 from baseline to the time-weighted average obtained on Day 2|Proportion of subjects alive and not requiring oxygen supplementation or higher respiratory support at Day 14.|Proportion of subjects alive and free of respiratory failure at Day 14|Time until weaning from oxygen therapy (up to Day 30)|Time until weaning from respiratory support other than low-flow oxygen supplementation for subjects having developed respiratory failure (up to Day 30)|Time to hospital discharge (up to Day 30)|Time to death due to any cause (up to Day 30)|Proportion of subjects admitted to the Intensive Care Unit or High-Dependency Unit (up to Day 30)|Proportion of subjects experiencing at least one event of venous thrombosis (specifically deep venous thrombosis or pulmonary embolism) (up to Day 30).|Proportion of subjects by clinical status reported on a 11-point ordinal scale at Day 14 and Day 30""}"
"4871","Defiances to Face COVID-19 Pandemic in Mexico","","NCT04771117","Fear5","Behavioral: Fear of Covid-19 Scale","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04771117","Completed","2020-05-01","2020-12-01","{""locations"":""Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico"",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""4004"",""age"":""16 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Risk Factors|Fear of Covid-19""}"
"4872","Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19","QUELLE","NCT04771585","20-14 QUELLE","Other: Community Mask|Other: Surgical Mask|Other: FFP2 respirator|Other: FFP3 respirator","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04771585","Recruiting","2021-03-15","2022-01-31","{""locations"":""Fraunhofer ITEM, Hannover, Niedersachsen, Germany"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""30"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""To compare the emitted small particle fraction between various respiratory activities.|To assess the influence of different face masks on the emitted small particle fraction of various respiratory activities.|To assess the emitted particle size distribution of various respiratory activities.|To assess the reproducibility of exhaled particle quantification.|To assess the influence of different face masks on the emitted particle size distribution of various respiratory activities.""}"
"4873","Computer Assisted Lessening of Intrusive Memories in the Emergency Department","CALM-ED","NCT04769999","R64738/RE001","Behavioral: Simple cognitive task","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04769999","Completed","2020-06-04","2020-10-30","{""locations"":""South Central Ambulance Service NHS Foundation Trust, Bicester, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|Royal Berkshire NHS Foundation Trust, Reading, United Kingdom"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""14"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in the number of intrusive memories of traumatic event|Changes in ratings of intrusive memory characteristics|Impact of Events Scale-Revised score (IES-R; Weiss & Marmar, 1997)|The Patient Health Questionnaire Depression scale (PHQ-9; Kroenke, Spitzer, & Williams, 2001)|The Generalised Anxiety Disorder scale (GAD-7; Spitzer, Kroenke, Williams & L\u00f6we, 2006)|The Pittsburgh Sleep Quality Index (PSQI; Buysse, 1989)|Change in retrospective ratings of intrusive memory characteristics over the last week""}"
"4874","Vaccine Observation to Include All Communities for Equitable Science","VOICES","NCT04770649","PB-2021-01","Biological: COVID-19 vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04770649","Recruiting","2021-04-01","2023-12-01","{""locations"":""Persephone Biosciences, Inc., San Diego, California, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determine whether the microbiome composition can predict effectiveness of vaccine.|Identify correlations between microbiome composition and immune system response to the vaccine|Track coronavirus variants of any individuals infected|Build a library of samples and data for future research""}"
"4875","Spanish Study to Analyze the Histopathological, Ultrastructural and Microbiological Findings Obtained in Autopsies of Patients Who Died Due to COVID-19","","NCT04772833","NECROVID","Other: Autopsy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04772833","Recruiting","2020-06-05","2021-12-31","{""locations"":""Marqu\u00e9s de Valdecilla University Hospital, Santander, Cantabria, Spain|Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain|Navarra University Hospital, Pamplona, Navarra, Spain|Barcelona Clinic University Hospital, Barcelona, Spain|Reina Sof\u00eda University Hospital, C\u00f3rdoba, Spain|Ram\u00f3n y Cajal University Hospital, Madrid, Spain|Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain|12 de Octubre University Hospital, Madrid, Spain|Virgen del Roc\u00edo University Hospital, Sevilla, Spain|Araba University Hospital, Vitoria, \u00c1lava, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Histopathological and ultra-structural findings|Molecular characterization|Hidden pulmonary superinfections|Histopathological \/ ultra-structural findings and clinical \/ biological expression correlation""}"
"4876","Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a)","","NCT04773665","VBI-2902a-CT01","Biological: VBI-2902a|Biological: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04773665","Not yet recruiting","2021-03-01","2022-06-01","{""locations"":""Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|LMC Manna - Bayview CPU, Toronto, Ontario, Canada|Manna Toronto, Toronto, Ontario, Canada|Manna Montreal, Montreal, Quebec, Canada|Manna Research Quebec, Quebec City, Quebec, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""780"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate and severity of local and systemic solicited adverse events|Rate and severity of unsolicited adverse events|Rate and severity of medically attended adverse events|Rate of serious adverse events|Adverse events leading to discontinuation of study vaccination|Adverse events leading to study discontinuation|Rate and severity of laboratory abnormalities (hematology, biochemistry, urinalysis)|Geometric Mean Titer (GMT) and the geometric mean fold increase in serum virus-neutralizing activity in a subset of participants post-vaccination over baseline|GMT and the geometric mean fold increase in serum receptor binding domain (RBD) antibody titers measured by ELISA post-vaccination over baseline|GMT and the geometric mean fold increase in serum virus-neutralizing activity in a subset of participants post-vaccination over baseline|GMT and the geometric mean fold increase in serum RBD antibody titers measured by ELISA post-vaccination over baseline|GMT and the geometric mean fold increase in serum spike protein antibody binding titers measured by ELISA post-vaccination over baseline""}"
"4877","A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","","NCT04773067","V-205","Biological: UB-612|Biological: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04773067","Recruiting","2021-01-30","2022-06-30","{""locations"":""Changhua Christian Hospital, Changhua, Taiwan|Chang-Geng Medical Foundation Kaoshiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Far Eastern Memorial Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital, Taoyuan, Taiwan"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""3850"",""age"":""12 Years to 85 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody|Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody|Safety evaluation|SCR of anti-S1-RBD antibody|GMT of SARS-CoV-2 neutralizing antibody|GMT of anti-S1-RBD antibody|Geometric mean fold increase in anti-S1-RBD and SARS-CoV-2 neutralizing antibodies|Evaluation of lot to lot consistency""}"
"4878","COVID-19 Associated Endothelial Dysfunction Study","CAUSED","NCT04773899","2021-A00330-41","Diagnostic Test: Procedure : Multimodal microvascular assessment at study inclusion","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04773899","Not yet recruiting","2021-04-09","2022-06-09","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Endothelial function measured by Near-infrared spectroscopy (NIRS)|Endothelial function measured by perfusion index|Microvascular reactivity measured laser speckle contrast imaging|Morphological analysis by Sublingual videomicroscopy|Inflammatory status|Prothrombotic condition|Thrombotic events|Severity of lung disease|Mortality|Organ failure""}"
"4879","DNA Damage in Critically Ill COVID-19 Patients","","NCT04772703","CVV_COVID-19_DNA","Diagnostic Test: COMET ASSAY","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04772703","Recruiting","2020-11-23","2021-07-30","{""locations"":""University Hospital Hradec Kralove, Hradec Kr\u00e1lov\u00e9, T\u0159ebe\u0161, Czechia"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""single-stranded DNA breaks|oxidation of DNA bases|Mortality""}"
"4880","Sarcopenia and Mechanical Ventilation in Older Patients Admitted Due to COVID-19","SARCO-V","NCT04772586","SARCO-V_2021/110","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04772586","Recruiting","2020-09-01","2022-03-01","{""locations"":""Brugmann university hospital, Brussels, Belgium"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""120"",""age"":""60 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Indication of mechanical ventilation|Evaluate difficult-to-wean in mechanical ventilation|All-cause mortality""}"
"4881","Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt","","NCT04773756","0305032","Drug: Sofosbuvir 400 MG/ Daclatasvir 60mg","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04773756","Completed","2020-11-01","2020-12-12","{""locations"":""Amr Aly Abd elmoety, Alexandria, Egypt"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""54"",""age"":""12 Years to 90 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""evaluate the combined effect of Sofosbuvir and Daclatasvir in treatment of patients with mild-moderate Covid-19.""}"
"4882","Evaluation of an Online Lifestyle Intervention in Mexican School Children During COVID-19 Pandemic","","NCT04772859","Lifestyle intervention","Behavioral: Online Lifestyle Intervention|Other: Control Group","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04772859","Recruiting","2021-02-01","2021-07-01","{""locations"":""Rolando Giovanni Diaz Zavala, Hermosillo, Sonora, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""54"",""age"":""9 Years to 12 Years \u00a0 (Child)"",""outcome_measures"":""Change in BMI Z-score|Change in weight|Change in height|Change in waist circumference|Change in body fat percentage|Change in relative fat mass|Change in nutrition knowledge|Change in food frequency consumption Food consumption frequency questionnaire|Change in physical activity and sedentary behaviors|Change in quality of life|Retention|Attendance|Acceptability""}"
"4883","Repercussion of the COVID-19 Pandemic on Physical Activity, Psychological State and Sleep","","NCT04772404","DF0094UG","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04772404","Not yet recruiting","2021-03-01","2021-06-15","{""locations"":""Department of Physical Therapy, Granada, Spain"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Knowledge of COVID|Fear of COVID-19 Scale|COVID-19 Anxiety Scale (CAS)|COVID Stress Scales|Burn-Out de Maslach Inventory|Steps per day|International physical activity questionnaire|Barriers to being active quiz|Questionnaire of the transtheoretical model of change of physical exercise|Hospital Anxiety and Depression Scale|Connor-Davidson Resilience Scale|COPE-28|Pittsburgh Sleep Quality Index|Morningness-eveningness questionnaire (MEQ)|Epworth sleepiness Scale|Insomnia severity index|EuroQoL-5D|Charlson Comorbidity Index""}"
"4884","Feasibility of Remote Home Support Coaches (SOCIAL Study)","","NCT04772820","2020P004113|3P30AG031679-10S2","Behavioral: Telephone-based coaching","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04772820","Not yet recruiting","2021-03-01","2022-06-30","{""locations"":""University of Maryland School of Medicine, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""60"",""age"":""75 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Physical Activity - Self-report survey to measure engagement in activities|Loneliness assessment - 20 item, self-report assessment to measure loneliness|Physical Activity - step activity monitor to track daily steps walked|PROMIS Short form to measure level 2 adult depression|PROMIS short-form to measure anxiety in adults|Late Life Function Instrument to assess functionality in elderly|Late Life Function Instrument to access disability in elderly|Duke Social Support short scale to measure social support among older people|Mini-nutritional assessment to determine if there is risk of malnourishment|Likert 0-7 rating scale of participants satisfaction with the program""}"
"4885","COVID-19 Vaccine Hesitancy Among Rheumatic Diseases Patients","","NCT04775563","IRE-3639","Other: COVID-19 vaccine hesitancy scale in rheumatic diseases|Other: COVID-19 vaccine hesitancy associated factors","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04775563","Recruiting","2021-02-01","2021-10-01","{""locations"":""Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""740"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Measure the phenomenon of vaccine hesitancy among rheumatic diseases patients|Identify factors associated with COVID-19 vaccine hesitancy among rheumatic diseases patients""}"
"4886","Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19","RESPIRE","NCT04776044","ATR-002-202","Drug: ATR-002|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04776044","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":""Atriva study site 49001, Berlin, Germany|Atriva study site 49003, Frankfurt, Germany|Atriva study site 49002, Hemer, Germany|Atriva study site 49005, Homburg, Germany|Atriva study site 49004, M\u00fcnster, Germany|Atriva study site 91002, Ahmedabad, India|Atriva study site 91001, Al\u012bgarh, India|Atriva study site 91003, New Delhi, India|Atriva study site 91004, Raipur, India|Atriva study site 31001, Eindhoven, Netherlands|Atriva study site 31002, Tilburg, Netherlands|Atriva study site 27005, Benoni, South Africa|Atriva study site 27002, Cape Town, South Africa|Atriva study site 27003, George, South Africa|Atriva study site 27001, Mpumalanga, South Africa|Atriva study site 27004, Vereeniging, South Africa|Atriva study site 34001, Barcelona, Spain|Atriva study site 34002, Madrid, Spain|Atriva study site 34005, Madrid, Spain|Atriva study site 34004, Valencia, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""220"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical severity status on a 7-point ordinal scale|Time from randomization to discharge from hospital|Time to discharge from hospital or to score of \u22642 maintained for 24 hours in NEWS2, whichever occurs first|Time to resolution of fever, defined as \u226436.6\u00b0C (axilla), \u226437.2\u00b0C (oral) or \u226437.8\u00b0C (rectal or tympanic) for at least 24 hours without antipyretics for 24 hours|Time to SpO2 >94% on room air maintained for 24 hours|Clinical severity status over the hospital period calculated as AUC from the 7-point ordinal scale at Days 3, 5, 8, 11, 15 and 30""}"
"4887","A Study to Evaluate Vaccines Against COVID-19 in the Real World","","NCT04775056","APASL_COVID-19 Vaccine_Ab","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04775056","Not yet recruiting","2021-03-15","2022-03-31","{""locations"":""Humanity & Health Medical Group, Hong Kong, Hong Kong"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""30000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immunogenicity index-seroconversion rates of neutralizing antibody|Safety index-incidence of adverse reactions|Immunogenicity index-seropositive rates of neutralizing antibody""}"
"4888","Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma (After SARS-CoV-2 Infection or COVID-19)","REASSURE","NCT04775134","S64988","Diagnostic Test: Lung biopsy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04775134","Recruiting","2021-01-31","2022-01-31","{""locations"":""UZ Leuven, Leuven, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""75"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Reverse transcriptase-PCR|Fluorescence immunohistochemistry (IHC)|Single molecule fluorescence in situ hybridization (smFISH)|Viral culture""}"
"4889","Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults","","NCT04776317","20-0034|5UM1AI148684-02","Biological: ChAdV68-S|Biological: ChAdV68-S-TCE|Biological: SAM-LNP-S|Biological: SAM-LNP-S-TCE|Other: Sodium Chloride, 0.9%","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04776317","Not yet recruiting","2021-03-15","2022-09-19","{""locations"":""Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""130"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency by grade of solicited local reactogenicity adverse events (AEs)|Frequency by grade of solicited systemic reactogenicity adverse events (AEs)|Frequency by grade of unsolicited adverse events (AEs)|Frequency of Adverse Events of Special Interest (AESIs)|Frequency of clinical safety laboratory adverse events by severity grade|Frequency of Serious Adverse Events (SAEs)|Geometric mean fold rise from baseline in titer measured by a SARS-CoV-2 neutralization assay, for wild-type virus and emergent viral strains|Geometric mean fold rise from baseline in titer of receptor-binding domain (RBD) specific Immunoglobulin G (IgG)|Geometric mean fold rise from baseline in titer of Spike-specific Immunoglobulin G (IgG)|Geometric mean titer measured by a SARS-CoV-2 neutralization assay, for wild-type virus and emergent viral strains|Geometric mean titer of receptor-binding domain (RBD) specific Immunoglobulin G (IgG)|Geometric mean titer of Spike-specific Immunoglobulin G (IgG)|Percent of cells expressing a cytokine by cell type (CD4+ or CD8+), cytokine set (Th1 or Th2 cytokine for CD4+ and CD8+ cytokine for CD8+ or other combinations of interest) and peptide pool (covering spike and T cell epitope regions)|Percentage of subjects who seroconverted, for RBD from wild-type virus and emergent viral strains|Percentage of subjects who seroconverted, for spike protein from wild-type virus and emergent viral strains|Percentage of subjects who seroconverted, for wild-type virus and emergent viral strains|Rate of spot-forming cell per million cells by peptide pool (covering spike and T cell epitope regions)|Responder status, derived from the intracellular cytokine staining (ICS) cell counts for each set of applicable cytokines and each peptide pool|Responder status, determined by interferon (IFN) gamma Enzyme Linked Immunospot Assay (ELISpot) for each peptide pool|Th1\/Th2 cytokine balance of T cell response""}"
"4890","COVID-19 Serological Testing of Patients With a Mental Disorder From the Catchment Area of the Capital Region of Denmark","","NCT04775407","COVID-19 RHP","Procedure: blood sampling","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04775407","Recruiting","2021-01-18","2022-09-01","{""locations"":""Psychiatric Centre Copenhagen, Copenhagen, Denmark"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The incidence of positive serological COVID-19 test result|Registered death (number), hospital admissions (number), changes in out-patients clinic contacts (number), changes in suicidal behavior (score on medical scale) and changes in psychopharmacological treatment (registered changed in medial journal).""}"
"4891","Delirium in Covid-19: Germany-wide Covid-19 Intensive Register","","NCT04775017","COVID-19-Delirium","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04775017","Recruiting","2021-01-01","2021-12-01","{""locations"":""Department of Anesthesiology and Operative Intensive Care Medicine Campus Virchow-Klinikum, Berlin, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of delirium|Risk factors for severe COVID-19|Patient characteristics|Blood gas analysis|Enteral nutrition|Parenteral nutrition|Serum albumin|Total protein|Phosphate|Triglyceride|Caloric intake|Respiratory setting|Inflammatory laboratory parameter 1|Inflammatory laboratory parameter 2|Inflammatory laboratory parameter 3|Inflammatory laboratory parameter 4|Toxic-drug factors|Sociodemographic factors|Breathing hours|Length of intensive care unit stay|Length of hospital stay|Adverse events|Post Intensivecare Unit Syndrome (PICS)|In-hospital mortality|Mortality""}"
"4892","Determination of COVID-19 Related Virus in Central Nervous System","","NCT04775784","NCH08-2020","Diagnostic Test: Determination of SARS-CoV2 presence in CNS","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04775784","Recruiting","2020-12-17","2022-12-20","{""locations"":""IRCCS San Raffaele Scientific Institute, Milan, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Determination of SARS-CoV-2 presence in the CNS""}"
"4893","Efficacy and Tolerance of Telerobotic vs Standard Ultrasound Exam in Children","","NCT04776174","CHILDMELODY","Device: Ultrasound using the telerobotic Melody system","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04776174","Not yet recruiting","2021-03-01","2022-01-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""40"",""age"":""1 Year to 10 Years \u00a0 (Child)"",""outcome_measures"":""Number of normal and abnormal standard and telerobotic ultrasound examinations|Age of participants|Number of anomalies found|Parent satisfaction|Medical assistant satisfaction|Sonographer satisfaction""}"
"4894","CPAP Observance During the COVID-19 (SARS-CoV-2) Pandemic","COVADENE","NCT04775966","RECHMPL21_0067","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04775966","Completed","2021-01-15","2021-02-15","{""locations"":""Adene Group, Montpellier, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""8477"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in positive airway pressure(PAP)-adherence during the first lockdown versus corresponding 2019 weeks (h\/days)|Change in positive airway pressure(PAP)-adherence during the second lockdown versus corresponding 2019 weeks (h\/days)|Change in PAP-adherence 2020 versus 2019 (h\/days\/weeks)|Change in the percentage of adherent patients (adherence > 4h\/day\/week) during the first lockdown versus corresponding 2019 weeks (h\/days)|Change in the percentage of adherent patients (adherence > 4h\/day\/week) during the second lockdown versus corresponding 2019 weeks (h\/days)|Change in patient adherence 2020 versus 2019 (%).""}"
"4895","Antibody Response to COVID-19 Vaccines in Liver Disease Patients","","NCT04775069","HHCTC_COVID-19_VACCINE_Ab","Biological: BNT162b2|Biological: CoronaVac|Biological: AZD1222","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04775069","Not yet recruiting","2021-03-15","2022-03-31","{""locations"":""Humanity & Health Medical Group Limited, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""900"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody response""}"
"4896","COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies","COVIDVAC OH","NCT04776005","20210204","Other: Data collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04776005","Not yet recruiting","2021-03-01","2022-12-01","{""locations"":""Saint-Louis Hospital, AP-HP, Paris, France|Bichat Hospital, AP-HP, Paris, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""SARS-CoV-2 vaccine response at 12 months|Seroprevalence of antibodies against Sarc-CoV-2 S-protein before vaccination|Seroprevalence of antibodies against Sarc-CoV-2 N-protein before vaccination|SARS-CoV-2 vaccine response after first dose of vaccine|SARS-CoV-2 vaccine response at 3 months|SARS-CoV-2 vaccine response at 6 months|SARS-CoV-2 vaccine safety in the study population""}"
"4897","High Resolution Micro OCT Imaging","","NCT03256773","F160125001","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT03256773","Recruiting","2016-04-15","2022-12-31","{""locations"":""University of Alabama at Birmingham, Birmingham, Alabama, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""14 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""feasibility of uOCT probe""}"
"4898","International COVID-19 Clinical Evaluation Registry -2 (HOPE-2)","HOPE-2","NCT04778020","21/128-E","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04778020","Not yet recruiting","2021-03-01","2022-01-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""10000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""DEATH|Any POSTCOVID-19 symptom""}"
"4899","(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC","","NCT04777981","1001","Dietary Supplement: CBDRA60 supplement|Dietary Supplement: Placebo","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04777981","Not yet recruiting","2021-04-01","2021-05-28","{""locations"":""Anewsha Therapeutics \/ Comco R&D, Hanover, Michigan, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Decreased hospitalization|Resolution of COVID-19 symptoms""}"
"4900","Semen Analysis Parameters Following Pfizer's COVID-19 Vaccine","","NCT04778033","SHEBA - 21 - 8079- JH - CTIL","Other: Sperm collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04778033","Recruiting","2021-02-09","2021-05-01","{""locations"":""Sheba medical center, Ramat Gan, Israel"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""75"",""age"":""18 Years to 45 Years \u00a0 (Adult)"",""outcome_measures"":""Sperm Concentration (10^6\/ml)|Sperm Motility (%)|White Blood Cells (10^6\/ml) in Semen|Sperm Morphology (%)|Sperm Vitality (%)|Semen Liquefaction (normal\/abnormal)|Semen Viscosity (normal\/abnormal)|Semen Color|Semen PH|Semen Volume (ml)""}"
"4901","Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19","","NCT04778059","USB002-2020-001","Drug: USB002|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04778059","Not yet recruiting","2021-04-01","2022-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""184"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with treatment emergent adverse events (TEAE)""}"
"4902","Expressive Writing for the Management of Stress in Cancer Survivors","","NCT04776941","2020-0538|NCI-2021-00218","Behavioral: Behavioral Intervention|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04776941","Recruiting","2020-08-07","2021-12-31","{""locations"":""M D Anderson Cancer Center, Houston, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care"",""enrollment"":""120"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participant response rate|Study completion rate|Intervention adherence rate|Change in stress|Change in quality of life|Change in physical health (sleep, fatigue, and cancer related morbidities)|Change in psychological health (depressive symptoms, anxiety, and fear of cancer recurrence)""}"
"4903","Clinical Study in the Treatment of Patients With COVID-19","","NCT04780672","MNCV-III/2-2020","Drug: Molixan|Drug: Placebo","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04780672","Not yet recruiting","2021-03-05","2021-10-19","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"",""enrollment"":""330"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""WHO Ordinal Scale for Clinical Improvement|Mortality|Duration of hospitalization|Mechanical ventilation|Time to cancellation of oxygen support|Invasive mechanical ventilation|Stay in the intensive care unit|The transition of the disease to an extremely severe course|Fever|The dynamics of the National Early Warning Score (NEWS)|The dynamics of changes in the level of C-reactive protein|The dynamics of residual symptoms|The dynamics of blood biochemical parameters|The dynamics of CT signs""}"
"4904","DCI COVID-19 Surveillance Project","","NCT04780698","27042","Diagnostic Test: SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04780698","Recruiting","2021-03-01","2022-03-01","{""locations"":""Dialysis Clinic, Inc., Philadelphia, Pennsylvania, United States"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening"",""enrollment"":""160"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of COVID-19 infection in the cohort|Link the presence of COVID-19 infection to COVID-19 antibody formation (seroconversion) from quantitative and qualitative testing|Incidence of COVID-19 reinfection|Presence of antibodies in cases of reinfection""}"
"4905","Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19","COMET-PEAK","NCT04779879","VIR-7831-5006|GSK Study 216912","Biological: VIR-7831 (Gen1)|Biological: VIR-7831 (Gen2)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04779879","Recruiting","2021-02-18","2021-09-01","{""locations"":""Investigative Site, Anniston, Alabama, United States|Investigative Site, Bakersfield, California, United States|Investigative Site, Fort Pierce, Florida, United States|Investigative Site, Winfield, Illinois, United States|Investigative Site, Rockville, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Occurrence of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of adverse events of special interest (AESIs)|Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) readings|Occurrence of disease progression events (not classified as AEs)|Cmax|Clast|Tmax|Tlast|AUCD0-28|AUCinf|AUClast|%AUCexp|t1\/2|Vz|Vss|CL|Occurrence of SAEs|Occurrence of AESIs|Occurrence of clinically significant abnormalities on 12-lead ECG readings""}"
"4906","COvid-19 REgistry on THROMBOSIS Complications","CORE-THROMB","NCT04780295","CTH C010|DRKS00022277","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04780295","Recruiting","2020-04-15","2021-12-01","{""locations"":""Unicamp (Universidade Estadual de Campinas; University of Campinas), Campinas, Brazil|Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo, Brazil|Hospital de Campanha Anhembi, S\u00e3o Paulo, Brazil|Amager and Hvidovre Hospital, Hvidovre, Denmark|DRK Kliniken Berlin K\u00f6penick, Berlin K\u00f6penick, Germany|DRK Kliniken Berlin Westend, Berlin Westend, Germany|Universit\u00e4tsklinikum Koeln, Cologne, Germany|Augusta-Krankenhaus Duesseldorf, Duesseldorf, Germany|Universit\u00e4ts-Herzzentrum Freiburg, Freiburg, Germany|Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes, Homburg, Germany|Universit\u00e4tsmedizin Mainz, Mainz, Germany|Krankenhaus Neuwittelsbach, Munich, Germany|Paracelsus Medizinische Privatuniversit\u00e4t am Klinikum Nuernberg, Nuremberg, Germany|Mater Misericordiae University Hospital, Dublin, Ireland|University of Bologna, Bologna, Italy|Azienda Socio Sanitaria Territoriale (ASST) Lariana, Como, Italy|Ospedale Sacra Famiglia Fatebenefratelli, Erba, Italy|Presidio Ospedaliero Santa Croce di Fano, Fano, Italy|IRCCS Ospedale Policlinico San Martino, Genova, Italy|Ospedale Civile di Guastalla - Azienda Unit\u00e0 Sanitaria Locale (AUSL) Reggio Emilia, Guastalla, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Ospedale Maggiore di Parma - Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Ospedale Maggiore di Parma - Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Civile di Castel San Giovanni - Azienda Unit\u00e0 Sanitaria Locale (AUSL) di Piacenza, Piacenza, Italy|Santa Maria Nuova Hospital - Azienda Unit\u00e0 Sanitaria Locale (AUSL) IRCCS di Reggio Emilia, Reggio Emilia, Italy|IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy|Universit\u00e0 degli studi dell' Insubria (University of Insubria), Varese, Italy|Instituto Nacional de Cardiologia Ignacio Chavez (National Institute of Cardiology Igancio Chavez), Mexico City, Mexico|Hospital Quir\u00f3nsalud, M\u00e1laga, Spain|Erdem Medical Center, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""5000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fatal or non-fatal venous thromboembolism (VTE)|Fatal or non-fatal cardiovascular events, encompassing stroke and myocardial infarction|All-cause death|Prevalence of cardiovascular risk factors|Length of hospitalization|Prevalent use of in-hospital thromboprophylaxis|In-hospital course of D-dimer (\u03bcg\/mL)|In-hospital course of Troponin (ng\/ml)""}"
"4907","COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","COVAXID","NCT04780659","2021-000175-37","Biological: Comirnaty (COVID-19, mRNA vaccine)","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04780659","Recruiting","2021-02-23","2022-12-31","{""locations"":""Karolinska University Hospital, Stockholm, Huddinge, Sweden"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""540"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessment of seroconversion, defined as development of immunoglobulin G (IgG) antibodies against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) after vaccination of 2 doses in seronegative individuals.|Assessment of any Adverse Events (AE) of the given vaccine [Safety and tolerability].|Frequency of SARS-CoV-2 infection documented by positive polymerase chain reaction (PCR) test.|Assessment of humoral and cellular immune responses in blood and saliva.|Assessment of escape mutations of sequencing SARS-CoV-2 at breakthrough infection.|Assessment of graft versus host disease in allogenic stem cell transplanted persons after given vaccine.|Assessment of biopsy verified rejection in solid organ transplanted persons after given vaccine.|Assessment of viremia, defined as HIV ribonucleic acid (RNA) > 50 copies\/milliliter after vaccination in HIV infected persons.|Assessment of HIV deoxyribonucleic acid (DNA) levels after given vaccine in HIV infected persons.|Assessment of oral and gut microbiota in immunosuppressed and controls, in relation to immune response to vaccination.""}"
"4908","Dietary Supplements for COVID-19","","NCT04780061","20210072-01H","Drug: Vitamin D3 50,000 IU|Dietary Supplement: Vitamin C/Zinc|Dietary Supplement: Vitamin K2/D|Other: Microcrystalline Cellulose Capsule|Other: Medium Chain Triglyceride Oil","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04780061","Not yet recruiting","2021-04-01","2021-12-01","{""locations"":""The Centre for Health Innovation, Ottawa, Ontario, Canada"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Participant-reported overall health|Effect of COVID-19 on the health status of participants|Symptom Severity of common COVID-19 symptoms|Total symptom duration|Incidence of delayed return to usual health|Frequency of Hospitalizations|Hospital Length of Stay|All-cause mortality""}"
"4909","Pregnancy Outcomes According to the Gestational Age of Acquiring COVID-19","","NCT04779749","PregOutCOV","Other: Data extraction from medical files","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779749","Recruiting","2020-12-08","2021-12-01","{""locations"":""CHU Brugmann, Brussels, Belgium|Antoine B\u00e9cl\u00e8re Hospital, Clamart, France|H\u00f4pital Louis Mourier, Colombes, France|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Retrospective"",""enrollment"":""10000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Preterm delivery|Preeclampsia|Eclampsia|Hemolysis Elevated Liver enzymes Low Platelets Syndrome (HELLP)|Number of participants with Cesarean delivery (CD)|Percentage of participants with Cesarean delivery (CD)|Deep venous thrombosis|Pulmonary embolism|Pregnancy loss at less than 24 weeks' gestation|Intrauterine Fetal Demise (IUFD)|Maternal death|Low birth weight|Number of participants with Neonatal intensive care unit (NICU) admission|Percentage of participants with Neonatal intensive care unit (NICU) admission|Number of participants with APGAR score (Activity, Pulse, Grimace, Appearance, Respiration score) at 5 minutes < 7:|Percentage of participants with APGAR score (Activity, Pulse, Grimace, Appearance, Respiration score) at 5 minutes < 7:|Number of participants with Respiratory distress at birth|Percentage of participants with Respiratory distress at birth|Neonatal death|Number of participants with Delivery < 32 weeks|Percentage of participants with Delivery < 32 weeks|Number of participants with Spontaneous delivery < 37 weeks|Percentage of participants with Spontaneous delivery < 37 weeks|Number of participants with Fetal distress|Percentage of participants with Fetal distress|Number of participants with Unscheduled cesarean delivery|Percentage of participants with Unscheduled cesarean delivery|Postpartum hemorrhage|Number of participants with Intraventricular hemorrhage|Percentage of participants with Intraventricular hemorrhage|Umbilical cord pH|Small for gestational age (SGA)|Large for gestational age (LGA)""}"
"4910","Evaluation of Musculoskeletal System Symptoms and Biochemical Parameters in COVID-19","","NCT04780555","AIBU-FTR-EY-02","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04780555","Not yet recruiting","2021-03-01","2021-06-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""150"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Neutrophil-lymphocyte ratio (NLR)|D-dimer|Fibrinogen""}"
"4911","Comparison of Remdesivir and Tocilizumab Versus Hydroxychloroquine and Tocilizumab Combination in COVID-19 Patients","","NCT04779047","REC-H-PhBSU-21011","Drug: Remdesivir|Drug: Hydroxychloroquine|Drug: Tocilizumab","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04779047","Recruiting","2020-10-01","2021-04-05","{""locations"":""Beni-suef University, Ban\u012b Suwayf, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 88 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of clinical cure in each arm""}"
"4912","A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19","","NCT04780685","STEM-107-COVID-19","Biological: hMSC","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04780685","Recruiting","2021-03-20","2021-12-31","{""locations"":""Providence Saint John's Health Center - Saint John's Cancer Institute, Santa Monica, California, United States|PRX Research, Dallas Regional Medical Center, Mesquite, Texas, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""40"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Survival|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0""}"
"4913","JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects","","NCT04780321","JS016-002-Ib/II","Biological: Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|Drug: Placebo","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04780321","Recruiting","2020-10-30","2021-06-30","{""locations"":""Beijing Ditan Hospital affiliated to Capital Medical University, Beijing, China|Huashan Hospital affiliated to Fudan University, Shanghai, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Efficacy Measurs(Time to negative conversion in viral nucleic acid test(by RT-PCR) for diagnostic samples)|Safety Measurements : 90 of participants with treatment-related adverse events as assessed byCTCAE v5.0|PK Measures:AUC0-tau|PK Measures\uff1aCmax|PK Measures\uff1aTmax|PK Measures\uff1at1\/2|PK Measures\uff1aCL|PK Measures\uff1aVd|Proportions of participants with negative conversion in viral nucleic acid test|Viral load change from baseline|Pulmonary CT\uff08observe by imaging reports to degree of pulmonary inflammation, degree of vitreous fibrosis)""}"
"4914","Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","","NCT04780035","COV/pept-03/20","Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|Other: Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04780035","Active, not recruiting","2020-11-18","2021-09-01","{""locations"":""State Budgetary Healthcare Institution of the Moscow region - Krasnogorsk City Hospital # 1 (short name: SBHI MR KCH # 1), Krasnogorsk, Moscow Region, Russian Federation|Federal State Autonomous Educational Institution of Higher Education - Immanuel Kant Baltic University (short name: FSAEIHE- I. Kant Baltic Federal University), Kaliningrad, Russian Federation|State Autonomous Healthcare Institution - Clinical City Hospital # 7 of Kazan (short name: SAHI CCH # 7), Kazan, Russian Federation|Federal State Budgetary Institution - N.I. Pirogov National Medical and Surgical Center, Ministry of Health of the Russian Federation (short name: FSBI - N.I. Pirogov NMSC, Ministry of Health of the Russian Federation), Moscow, Russian Federation|Federal State Budgetary Research Institution - Academician B.V. Petrovsky Russian Research Center for Surgery (short name: FSBRI - Academician B.V. Petrovsky RRCS), Moscow, Russian Federation|Research Center: Federal State Budgetary Institution - Central Clinical Hospital with Polyclinic, Administrative Office of the President of the Russian Federation (short name: FSBI Central Clinical Hospital with Polyclinic), Moscow, Russian Federation|State Budgetary Healthcare Institution of the Moscow region - M.F. Vladimirsky Moscow Regional Research Clinical Institute (short name: M.F. Vladimirsky SBHI MRRCI), Moscow, Russian Federation|State Budgetary Educational Institution of Higher Professional Education - Tyumen State Medical University, Ministry of Health of the Russian Federation (short name: SBEIHPE - Tyumen State Medical University, Ministry of Health of Russian Federation), Tyumen, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""3000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of vaccinated volunteers with no laboratory confirmed symptoms caused by SARS-CoV-2, within 6 months post vaccination versus a placebo|The prophylactic efficacy of the vaccine|The proportion of volunteers with increased levels of the immune response in terms of geometric mean titers of specific antibodies|The proportion of volunteers with increased levels of the immune response in terms of specific neutralizing antibody titers|The frequency of severe cases of COVID-19 following a single \/ double vaccination|Duration of disease|The incidence of asymptomatic COVID-19 following a single \/ double vaccination""}"
"4915","Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease","","NCT04779359","COVID-19 Disease","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779359","Not yet recruiting","2021-04-01","2021-12-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Cross-Sectional"",""enrollment"":""1"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Correlation of CD4+ and CD8+ T cell absolute counts to disease outcomes""}"
"4916","Sarco-COVID Study: Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19","SARCO-COVID","NCT04780126","21/090-E_COVID","Other: Sarcopenia diagnosis","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04780126","Recruiting","2021-02-26","2021-05-31","{""locations"":""Hospital de Emergencias Isabel Zendal, Madrid, Spain"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""64"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Loss of muscle mass|Prevalence of sarcopenia|Normal values of muscle ultrasound thickness|C reactive protein (CRP) correlated to the presence of sarcopenia|Therapy with corticosteroids impact on muscle thickness|Normal values of medial gastrocnemius pennation angle in all patients|Ferritin correlated to the presence of sarcopenia|Fibrinogen correlated to the presence of sarcopenia""}"
"4917","National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units","VACOVID-SENIOR","NCT04779541","2021-028|ar20-0031v1","Other: observation","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779541","Recruiting","2021-02-08","2021-04-08","{""locations"":""Angers University Hospital, Angers, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1000"",""age"":""75 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Acceptance rate of the SARS-CoV-2 vaccine among people living in nursing homes and long-term care units|Symptoms related to vaccination against COVID-19""}"
"4918","Prevalence and Incidence of Antibodies Against SARS-CoV-2 Among Primary Healthcare Providers in Belgium (COVID-19)","CHARMING","NCT04779424","OZ8478","Other: POCT","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779424","Active, not recruiting","2020-11-15","2022-06-30","{""locations"":""Niels Adriaenssens, Wilrijk, Antwerp, Belgium"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T1|Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T2|Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T3|Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T4|Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T5|Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T6|Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T7|Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T8|Prevalence of antibodies against SARS-CoV-2 in primary health care providers - T9|Monthly incidence of antibodies against SARS-CoV-2 in primary health care providers|Annual incidence of antibodies against SARS-CoV-2 in primary health care providers|Longevity of antibodies against SARS-CoV-2 in primary health care providers|Proportion of asymptomatic cases among primary health care providers with antibodies against SARS-CoV-2|Determinants of of SARS-CoV-2 infection among primary health care providers|Validation of a self-administered and self-reported serological point of care test in a primary care setting|Familiarisation with a self-administered and self-reported serological point of care test among primary health care providers""}"
"4919","Best Practices in Perinatal Mental Health During COVID-19","","NCT04779775","RISEUP-PPD-DEVOTION- COVID-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779775","Not yet recruiting","2021-03-15","2021-06-30","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""70"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Changes in perinatal best practices|Changes in perinatal mental health protocols""}"
"4920","Prognostic Score in Covid-19","","NCT04780373","prot. N. 71726","Other: data collection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04780373","Completed","2020-02-27","2020-05-15","{""locations"":""University of L'Aquila, L'Aquila, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Data collection of clinical and demographical parameters of patients affected by COVID-19|Application of statistical analysis on data of patients affected by COVID-19""}"
"4921","Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept","COR-DIAL-S","NCT04780334","2021_0063|2021-A00387-34","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: Biosensor","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04780334","Not yet recruiting","2021-04-01","2022-04-01","{""locations"":"""",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Sensitivity and specificity of CorDial-S based on the first nasopharyngeal swab taken on patient admission, compared to the final positive or negative diagnosis of COVID-19 by the medical team|Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and CorDial-S based on nasopharyngeal swabs taken at patient admission.|Sensitivity and specificity of CorDial-S based on the first saliva sample taken at patient admission compared to the final positive or negative diagnosis of COVID-19 by the medical team.|Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and CorDial-S based on saliva samples taken at patient admission.""}"
"4922","Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department","","NCT04779021","21infectiocovid01","Other: Hospitalisation for SARS-COV2 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779021","Recruiting","2020-02-15","2022-12-31","{""locations"":""CHU de NICE - Infectiologie, Nice, France|CHU de NICE - Urgences, Nice, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical characteristics|Biological characteristics|Radiological characteristics|Number of patient hospitalised for Covid-19|Overall Inpatient Mortality|Requirement for mechanical ventilation|ICU Length of Stay (LOS)|Evolution of patient general state during hospitalisation|Biological tests""}"
"4923","Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University Hospital","","NCT04780594","COVID19 surgical impact","Procedure: The study evaluates all surgical patients operated, both elective scheduled and emergent cases","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04780594","Completed","2020-02-13","2020-12-09","{""locations"":""Marta Caballero, Hospitalet de Llobregat, Barcelona, Spain"",""study_designs"":""Observational Model: Case-Crossover|Time Perspective: Retrospective"",""enrollment"":""2530"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Register the post-surgical complications|Register the rate of surgical reintervention|Register the ICU admission|Register the Hospital stay|Register the Mortality""}"
"4924","Impact of SARS-CoV-2 Pandemic on Psychological State of Health Care Workers","","NCT04779944","AssiutU1235","Other: other","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779944","Completed","2020-04-07","2020-08-15","{""locations"":""heba Yassa, Assiut, Egypt"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""25 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Questionnaire to assess the psychological impacts of SARS-CoV-2 on health care workers""}"
"4925","Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment","","NCT04779996","CCAM 21-01","Diagnostic Test: Laboratory Samples","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779996","Recruiting","2021-02-16","2022-02-28","{""locations"":""Auxilio Mutuo Cancer Center, San Juan, Puerto Rico"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Cross-Sectional"",""enrollment"":""250"",""age"":""21 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Primary Objective|Secondary objective 1|Secondary objective 2""}"
"4926","Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks","","NCT04779827","827141","Behavioral: Online Social Network and Collective Intelligence Intervention|Behavioral: Independent Control","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04779827","Not yet recruiting","2021-03-15","2022-12-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science"",""enrollment"":""1920"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""COVID-19 vaccination attitude|COVID-19 vaccination intention|COVID-19 vaccine belief""}"
"4927","Immunity Against SARS-CoV-2 Corona Virus in the Oncology Outpatient Setting","COVIDOUT","NCT04779346","2020-10275-BO-ff","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04779346","Recruiting","2020-12-21","2022-12-31","{""locations"":""Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Rate of SARS-CoV-2 antibody positive patients|Rate of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 antibody positive patients|Rate of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 vaccinated patients|Rate of unknown prior COVID19 disease in SARS-CoV-2 antibody positive patients|Rate of cancer entities in SARS-CoV-2 antibody positive patients|Rate of therapy modalities in SARS-CoV-2 antibody positive patients|Subgroup analysis of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 vaccinated patients|Rate of re-infection in SARS-CoV-2 antibody positive patients""}"
"4928","TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic","","NCT04780152","54/20","Device: Transcranial Direct Current Stimulation|Device: Placebo-simulation of transcranial direct current stimulation|Drug: Fluoxetine Tablets","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04780152","Recruiting","2021-03-01","2022-09-01","{""locations"":""Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, Mexico City, Ciudad De M\u00e9xico, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""172"",""age"":""10 Years to 17 Years \u00a0 (Child)"",""outcome_measures"":""Change of Children Depression Inventory score from the beginning to the end of the study|Change of Columbia-Suicide Severity Rating Scale score from the beginning to the end of the study|Change of Young Mania Rating Scale score from the begining to the end of the study""}"
"4929","Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients","","NCT04780581","MP3-pulses-COVID-19","Drug: Dexamethasone|Drug: Methylprednisolone","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04780581","Recruiting","2021-02-01","2021-12-31","{""locations"":""Complejo Asistencial Universitario de Burgos, Burgos, Spain|Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario R\u00edo Hortega, Valladolid, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""290"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate in COVID-19 patients after high-dose methylprednisolone bolus administration versus mortality rate intermediate-dose dexamethasone pattern (RECOVERY trial)|Admission in Intensive Unit Care (ICU)|Evaluation of respiratory support requirements|Days in hospital|Evaluation of presence of adverse events related with use of high dose of glucocorticoids.|Evaluation of other immunosuppressors requirements.|Status according to the World Health Organization (WHO) 10-category scale.""}"
"4930","Evolution of Perceived Stress in General Practice Residents During COVID-19 Sanitary Crisis","","NCT04780113","2020-A03283-36|CHES N°20/01","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04780113","Recruiting","2021-02-25","2021-10-25","{""locations"":""CH Eure-Seine, \u00c9vreux, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""285"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evolution of perceived stress during the epidemic wave of COVID19 vs. at the end of the epidemic wave of COVID19|Description of general characteristics of residents and their feelings and experiences with the sanitary crisis|Assessment of residents' profile stress according to their socio-demographic and working characteristics""}"
"4931","Effect of Telemonitoring on Upper Limb Function, Quality of Life and Risk of Lymphedema During and After Pandemic COVID-19 in Women Submitted to Treatment for Breast Cancer","","NCT04779450","Telemonitoring BCS","Other: Kinesiotherapy protocol|Other: Usual orientations","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04779450","Recruiting","2021-03-01","2021-12-01","{""locations"":""Santa Catarina State University, Florian\u00f3polis, Santa Catarina, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""30"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Upper Limb Functionality|Assessment of quality of life|Arm circumference|Level of satisfaction""}"
"4932","Increasing Vaccine Uptake in Underresourced Public Housing Areas","","NCT04779138","vaccinehousing","Behavioral: Increasing Willingness and Uptake of COVID-19 Vaccination","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04779138","Not yet recruiting","2021-09-11","2023-11-30","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""600"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report|Percentage of Participants Achieving Decreased Vaccine Hesitancy Levels of COVID-19 vaccine Using the NIH Toolbox Surveys on COVID-19|Percentage of Participants Achieving Increased Level of Behavior Change toward COVID-19 Vaccination Using the NIH Toolbox Surveys on COVID-19""}"
"4933","Structured Diabetes Self-Management Education and Care Outcomes in Adults liVIng With Type 2 Diabetes in Accra, Ghana","SMSCOVID","NCT04780425","KBTH-IRB 100017512020","Behavioral: DESMOND|Other: usual care","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04780425","Active, not recruiting","2021-01-26","2021-05-31","{""locations"":""Korle Bu Teaching Hospital, Accra, Ghana|Weija Gbawe Municipal Hospital, Accra, Ghana"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care"",""enrollment"":""206"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in mean glaciated heamoglobin (HbA1c) at three months|Change in mean summary of diabetes self-care activities (SDSCA) score at three months|Change in mean WHO quality of life (WHOQoL BREF) score at three months|Change in mean fasting plasma glucose (FPG) at three months|Change in mean fasting blood glucose (FBG) at three months|Change in mean blood pressure (BP) at three months|Change in waist circumference (WC) at three months|Change in neck circumference (NC) at three months|Change in body weight (BW) at three months|Change in problem areas in diabetes (PAID-5) scores""}"
"4934","A Blended Gaming COVID-19 Training System (BGCTS) With WHO Guidelines for Staff in Residential Care Homes","BGCTS","NCT04783025","HSEARS20200903007","Behavioral: Blended Gaming COVID-19 Training System (BGCTS)|Behavioral: Usual care, infection control briefing","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04783025","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":""The Hong Kong Polytechnic University, Hong Kong, Hong Kong"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research"",""enrollment"":""188"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Changes in unobtrusive observational-based compliance rate of infection control practices|Knowledge and attitudes towards respiratory infection (KARI)|Self-reported Infection Control Practice (SICP)|Demographic data|Data on experience""}"
"4935","P-Co-Li (Pulmonary Covid-19 Study)","","NCT04782700","IRB # 21-0076","Other: Steroid Taper (Prednisone)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04782700","Recruiting","2021-03-15","2025-03-03","{""locations"":""Northwell Health, Manhasset, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""522"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Worsened pulmonary function test (PFT) (FVC or DLCO)|Hypoxemia|6 Minute-Walk Test (6MWT)|mBorg Dyspnea Scale|PROMIS Short Forms Outcomes Survey|Lower Extremity Functional Scale|EQ-5D-5L outcomes survey|Changes over time in CT chest sans|Other pulmonary function test (PFT) changes over time""}"
"4936","Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test","INFORM","NCT04782336","S-CLIN-PROT-00018","Other: Group A (Sample Collection)|Other: Group B (Sample Collection)|Diagnostic Test: On-Site Testing (LumiraDx)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04782336","Recruiting","2020-12-12","2022-05-31","{""locations"":""Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Homerton University Hospital NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|St George's University Hospitals NHS Foundation, London, United Kingdom"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""3500"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Collection of Nasal Swabs, Throat Swabs and Saliva Samples across a range of demographics.""}"
"4937","COVID-19 Infections and Mortality in Long-term Care Facilities During the First Wave","","NCT04782427","CentreSuddeMontréal","Other: COVID-19 infection","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04782427","Active, not recruiting","2021-01-01","2021-05-13","{""locations"":""CIUSSS Centre-Sud-de-l'\u00cele-de-Montr\u00e9al, Montreal, Quebec, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Death""}"
"4938","Evaluation of the Impact of the COVID-19 Pandemic on Provision and Uptake of Services for the Prevention of Mother-to-child Transmission of HIV and Syphilis in Zimbabwe","","NCT04782739","MRCZ/A/2682","Other: None - Descriptive study","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04782739","Not yet recruiting","2021-03-01","2022-04-19","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Other"",""enrollment"":""30"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Proportion of pregnant women seen in antenatal care who are tested for HIV and syphilis|Proportion of HIV-positive pregnant women seen in antenatal care who are on antiretroviral therapy|Proportion of HIV-exposed infants seen in antenatal care who are tested for HIV by 6 weeks of age|Number of HIV-exposed neonates admitted to Sally Mugabe Central Hospital|Among neonates admitted to Sally Mugabe Central Hospital, number receiving HIV testing and prophylaxis|Case fatality rate per 1,000 HIV-exposed neonates admitted to Sally Mugabe Central Hospital|Number of pregnant women who experienced interruptions to PMTCT service delivery|Qualitative evaluation of the impact of COVID-19 on provision and uptake of PMTCT services""}"
"4939","ABC Science Collaborative Registry Study","","NCT04781218","Pro00107036","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04781218","Not yet recruiting","2021-03-15","2026-03-15","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""1000000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Participants who enroll in the ABC Registry""}"
"4940","Bidirectional, Upbeat Communication and Differentiated, Distanced Care for Young People","BUDDY","NCT04781400","448/2020","Behavioral: Mobile phone support|Behavioral: Remote service delivery model","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04781400","Recruiting","2021-02-08","2022-02-08","{""locations"":""Gugulethu Community Health Centre, Cape Town, Western Cape, South Africa"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research"",""enrollment"":""600"",""age"":""13 Years to 24 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Acceptability of a remote service delivery and mobile support intervention assessed by the number of participants opting in to receive courier delivery of ART.|Engagement in HIV care assessed by serial measurements of HIV Viral load.|Changes in Gender Based Violence (GBV) incidence as a result of COVID lock-down measures as assessed by self reported surveys.|Incidence of COVID-19 infection by assessing participant IgG antibody levels.|Qualitative themes assessed from in-depth individual interview data""}"
"4941","Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot","","NCT03262051","2016-02232","Diagnostic Test: CYP phenotyping","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT03262051","Recruiting","2017-09-01","2021-09-01","{""locations"":""Geneva University Hospitals, HUG, Gen\u00e8ve, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""106"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the impact of IL6 levels on the activity of CYPs in patients with acute (post orthopaedic surgery -hip or post SARS-CoV-2 infection) and chronic (rheumatoid arthritis) inflammation.|Evaluate the correlation between the activity of CYPs and CRP levels|Evaluate the correlation between the activity of CYPs and TNF-\u03b1 levels|Evaluate the correlation between the activity of CYPs and IL-1\u03b2 levels|Evaluate the correlation between the activity of CYPs and IFN-\u03b3 levels|Assess if tocilizumab reverse the activity of CYP in patients with RA after 3 months of treatment|Assess if SARS-CoV-2 infection modify pharmacokinetic parameters of concomitant medications which are CYPs substrates|Evaluate the correlation between inflammatory markers, CYP function and intensity of fatigue (MFI) and pain (NRS)""}"
"4942","Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19","","NCT04784754","UBMELCOVID19-P|UL1TR001412","Drug: Melatonin|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04784754","Not yet recruiting","2021-04-01","2021-12-31","{""locations"":""University at Buffalo, Buffalo, New York, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Cumulative Incidence of Treatment-Emergent Adverse Events|Incidence of COVID-19 related hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality""}"
"4943","A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19","","NCT04784897","IPI-BRIc-201","Drug: Brilacidin|Drug: Placebo|Drug: Standard of Care (SoC)","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04784897","Recruiting","2021-02-22","2021-07-01","{""locations"":""IPI Investigator Site, Winfield, Illinois, United States|IPI Investigator Site, Metairie, Louisiana, United States|IPI Investigator Site, Toledo, Ohio, United States|IPI Investigator Site, Barnaul, Russian Federation|IPI Investigator Site, Moscow, Russian Federation|IPI Investigator Site, Moscow, Russian Federation|IPI Investigator Site, Moscow, Russian Federation|IPI Investigator Site, Moscow, Russian Federation|IPI Investigator Site, Nizniy Novgorod, Russian Federation|IPI Investigator Site, Pushkin, Russian Federation|IPI Investigator Site, Saint Petersburg, Russian Federation|IPI Investigator Site, Saint Petersburg, Russian Federation|IPI Investigator Site, Saint Petersburg, Russian Federation|IPI Investigator Site, Saint Petersburg, Russian Federation"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Time to sustained recovery through Day 29|Proportion of subjects achieving recovery status scores at Day 29|Proportion of subjects that die or develop respiratory failure by Day 29|Subject Clinical status|Proportion of subjects achieving at least one category improvement in clinical status|Proportion of subjects achieving at least two category improvement in clinical status|Time to at least one category improvement in clinical status|Time to at least two category improvement in clinical status|Time to a National Early Warning Score 2 (NEWS2) of <\/= 2 and maintained for 24 hours|Change from baseline in National Early Warning Score 2 (NEWS2)|Incidence of treatment-emergent adverse events|Incidence of treatment-emergent graded laboratory abnormalities""}"
"4944","Evaluation of Muscle Strength, Functional Independence, Myalgia, Fatigue and Dyspnea in COVID-19 Infection","","NCT04784546","Gazi University PMR INF","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04784546","Recruiting","2021-03-01","2022-01-01","{""locations"":""Gazi University Faculty of Medicine, Physical Medicine and Rehabilitation Department, Ankara, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""60"",""age"":""18 Years to 85 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change from Baseline Muscle Strength at 1st week, 3rd week and 12th week.|Change from Baseline '5 Times Sit to Stand Test' at 1st week, 3rd week and 12th week.|Change from Baseline Modified Borg Scale at 1st week, 3rd week and 12th week.|Change from Baseline Barthel Index for Activities of Daily Living at 1st week, 3rd week and 12th week.|Change from Baseline Visual Analog Scale at 1st week, 3rd week and 12th week.""}"
"4945","DNA Damage and Oxidative Stress in Hospitalized COVID-19 Patients","ABCD","NCT04784468","UNIVIE_Covid_Oxstress","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04784468","Recruiting","2020-11-19","2021-09-30","{""locations"":""Klinik Donaustadt, Vienna, Austria"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""135"",""age"":""40 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""DNA damage|The investigators will consider further DNA damage parameter|The investigators will consider oxidative stress marker|The investigators will consider inflammatory marker|The investigators will consider the phenotypic age marker|The investigators will consider RDA and DNA gene expression|The investigators will consider clinical biochemistry marker""}"
"4946","Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults","","NCT04783311","EuSNAP_COV101","Biological: EuCorVac-19|Other: Normal Saline","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04783311","Recruiting","2021-02-23","2023-01-01","{""locations"":""The Catholic University of Eunpyeong St.Mary's Hospital, Seoul, Korea, Republic of"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""280"",""age"":""19 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Immediate AEs|Solicited local and systemic AEs|Unsolicited AEs|SAEs|AESIs""}"
"4947","Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection","Neptuno","NCT04784559","APL-D-003-20","Drug: Plitidepsin|Drug: Dexamethasone|Drug: Remdesivir","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04784559","Not yet recruiting","2021-03-01","2021-08-01","{""locations"":""Hospital General de Agudos, Buenos Aires, Argentina|Hospital Mu\u00f1iz, Ciudad aut\u00f3noma de Buenos Aires, Argentina|Hospital Fel\u00edcio Rocho, Belo Horizonte, Brazil|CEMEC - Centro Multidisciplinar de Estudos Cl\u00ednicos, S\u00e3o Bernardo Do Campo, Brazil|University Multiprofile Hospital for Active Treatment Sveta Ekaterina EAD, Dimitrovgrad, Bulgaria|Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases - Haskovo, Haskovo, Bulgaria|SHATPPD Dr. Dimitar Gramatikov, Ruse Ltd., Ruse, Bulgaria|\""MHAT \""Sveta Anna\""\"" - Sofia AD, Sofia, Bulgaria|Azienda Ospedaliera di Rilievo Nazional Santobono Pausilipon, Napoli, Italy|Istituto Nazionale per le Malattie Infettive IRCCS \""Lazzaro Spallanzani\"", Roma, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Hospital Central Universitario de Chihuahua, Chihuahua, CHH, Mexico|Sanatorio Palmore, A.C., Chihuahua, CHH, Mexico|Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, DIF, Mexico|niversidad Autonoma de Nuevo Leon - Hospital Universitario \""Dr. Jose Eleuterio Gonzalez\"", Monterrey, NL, Mexico|Hospital Alberto Sabogal Sologuren, Bellavista, Lima, Peru|Hospital de Chancay, Chancay, Lima, Peru|Hospital Militar Central, Lima, Peru|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario HM Montepr\u00edncipe, Boadilla Del Monte, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Quir\u00f3n Madrid, Pozuelo De Alarc\u00f3n, Madrid, Spain|Hospital Civil de Guadalajara, Guadalajara, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain|Hospital Cl\u00ednico San Carlos, Madrid, Spain|Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""609"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The percentage of patients who achieve complete recovery|Changes in Chest Imaging|Clinical Status|Time to clinical recovery|Percentages of patients requiring different types of oxygen therapy""}"
"4948","Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults","","NCT04785144","21-0002","Biological: mRNA-1273|Biological: mRNA-1273.351","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04785144","Not yet recruiting","2021-03-10","2022-08-31","{""locations"":""Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States|Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""210"",""age"":""18 Years to 99 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of solicited reactogenicity adverse events (AEs)|Frequency of unsolicited adverse events (AEs)|Grade of solicited reactogenicity adverse events (AEs)|Grade of unsolicited adverse events (AEs)|Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers|Response rate of SARS-CoV-2 specific antibody binding and neutralization titers""}"
"4949","Ivermectin Reproposing for Mild Stage COVID-19 Outpatients","IVER-Leve","NCT04784481","5077-410-CH2020","Drug: Ivermectin","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04784481","Completed","2020-09-20","2021-01-18","{""locations"":""SI.PRO.SA, Ministerio de Salud P\u00fablica, Tucum\u00e1n, Argentina"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""240"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion test|Odd Ratio|Odd Ratio and logistic regression test""}"
"4950","SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults","","NCT04784767","S-20-03|WRAIR # 2847|EID030|IND 27301","Biological: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|Drug: Sodium chloride, USP, for injection (0.9% NaCl)|Biological: 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)","Interventional","No Results Available","Phase 1","https://ClinicalTrials.gov/show/NCT04784767","Not yet recruiting","2021-04-05","2023-10-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""72"",""age"":""18 Years to 55 Years \u00a0 (Adult)"",""outcome_measures"":""Number of participants with local and systemic reactions|Incidents of treatment-adverse events as assessed by FDA Toxicity grading scale.|Number of participants with humoral immune response at Study Day 43 (+\/- 2).|Number of participants with binding antibody response rate|Number of participants with neutralizing antibody response rate|Number of participants with ACE-2 binding inhibition""}"
"4951","Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium.","BRAINSTORM","NCT04785157","RC31/20/0441|2020-005827-35","Biological: serology testing profiles description|Biological: immune response characterization|Other: in vivo brain PET-TSPO acquisitions|Other: brain MRI assessment|Behavioral: neurocognitive assessment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04785157","Not yet recruiting","2021-04-01","2022-08-01","{""locations"":""University Hospital of Toulouse, Toulouse, France|CHRU Tours, Tours, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""PET imaging examination|SARS-CoV-2 quasispecies detection in acute delirium phase in blood specimen|SARS-CoV-2 quasispecies detection 3 month after the acute delirium phase in blood specimen|SARS-CoV-2 quasispecies detection in acute delirium phase in cerebrospinal fluid specimen|SARS-CoV-2 quasispecies detection 3 month after the acute delirium phase in cerebrospinal fluid specimen|multimodal MRI in acute delirium phase|multimodal MRI 3 months after the acute delirium phase""}"
"4952","SCREENING AND SEROEPIDEMIOLOGY OF SARS-CoV-2 INFECTION AT THE UNIVERSITY OF BARCELONA: A CROSS-SECTIONAL STUDY","UB-GTMS-COVID","NCT04784403","UB-EPI-2020-01","Diagnostic Test: SARS-CoV-2 PCR and serology tests","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04784403","Completed","2020-12-14","2021-02-24","{""locations"":""Francisco Ciruela Alf\u00e9rez, L'Hospitalet De Llobregat, Barcelona, Spain"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""3356"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of people with a positive SARS-CoV-2 PCR.|Incidence of people with a positive SARS-CoV-2 PCR.|Number of people with a positive total immunoglobulin titer and positive IgG for SARS-CoV-2.|Prevalence of people with a positive total immunoglobulin titer and positive IgG for SARS-CoV-2.|Number of people with a positive SARS-CoV-2 Ig total titer and a negative IgG.""}"
"4953","Host Immune Response to Novel RNA COVID Vaccination","","NCT04784689","CTMS 21-0012","Biological: COVID-19 Vaccine","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04784689","Recruiting","2021-02-24","2024-01-01","{""locations"":""Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Antibody response level in patients with cancer to the COVID-19 vaccination.""}"
"4954","Virtual Lifestyle Program Evaluation During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","","NCT04784624","HS24424(H2020:495)","Behavioral: Lifestyle program","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04784624","Not yet recruiting","2021-03-01","2022-03-31","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Impact of COVID-19 survey|Program adherence|Physical activity level - International Physical Activity Questionnaire-Long (IPAQ-L)|Physical activity level - International Physical Activity Questionnaire-Short (IPAQ-S)|Dietary intake|Dietary behavior|Dietary habits|Sleep|Stress|High-density lipoprotein Cholesterol (HDL-C)|Total cholesterol|Low-density lipoprotein cholesterol (LDL-C)|Triglycerides|Total cholesterol\/HDL ratio|Fasting blood glucose|Insulin|Hemoglobin A1C|Body weight|BMI|Systolic blood pressure|Diastolic blood pressure|Medication intake|Cardiovascular assessment|Impact of COVID-19-focus groups|Program acceptability - exit survey|Program acceptability - focus groups""}"
"4955","Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay","COVID-IDNow","NCT04785898","COVID-IDNow","Diagnostic Test: ID Now™ COVID-19 Screening Test","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04785898","Active, not recruiting","2020-11-09","2021-04-30","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, Ile De France, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""1000"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the diagnostic performance of the ID Now \u2122 COVID-19 test carried out by nurses in an emergency department in comparison with the reference PCR test: Simplexa \u2122 COVID-19 Direct""}"
"4956","Impact of Rapid Screening for COVID-19 in Delocalized Biology in the Emergency Department","DELOCOVID","NCT04786249","DELOCOVID","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04786249","Recruiting","2021-02-24","2021-04-30","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, Ile De France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""2400"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the impact of a short delay in delivering results in delocalized biology on the emergency medical care time, in comparison with the reference method by RT-PCR at the central laboratory of microbiology|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the final orientation of the patient|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the bed management|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the number of additional examinations carried out and their deadline|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the prescriptions and the timeframe for the implementation of specific therapies against Covid-19 in hospitalized patients|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the prescription of antibiotic treatments|Compare the primary endpoint for two subgroups of patients according to their treatment schedule|Evaluate the level of satisfaction and the feelings of the medical and paramedical teams of the Emergency Department regarding the DMBE Test ID Now \u2122 COVID-19 and its impact""}"
"4957","the Impact of COVID-19 Pandemic on the Incidence and Outcome of Complicated Appendicitis","","NCT04786041","MMC-0223-20","Procedure: laparoscopic appendectomy","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04786041","Completed","2020-03-01","2020-05-30","{""locations"":""Meir medical center, Kfar Saba, Israel"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""complicated appendicitis""}"
"4958","Long COVID Kids DK - Investigating Long-term Covid-19","","NCT04786353","Long COVID-19 Kids DK","Other: LongCOVIDkidsDK","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04786353","Not yet recruiting","2021-04-01","2023-04-01","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Other"",""enrollment"":""300000"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Contacts to the general practitioner|Hospitalizations|Diagnoses|Prescribed drugs""}"
"4959","COVID-19 Infection and Epithelial Cell Markers","","NCT04787588","11033-T","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04787588","Recruiting","2021-02-14","2022-02-01","{""locations"":""McMaster Cardio-Respiratory Research Lab, Hamilton, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""235"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""TSLP expression in nasal epithelium|TSLP expression in endobronchial biopsies|IL-33 expression in endobronchial biopsies|ACE-2 receptor expression in endobronchial biopsies""}"
"4960","A Phase 2 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","","NCT04787211","BRII-196-198-004","Drug: BRII-196 and BRII-198|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04787211","Not yet recruiting","2021-03-01","2021-12-01","{""locations"":""Investigative Site 1, Beijing, Beijing, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""24"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Change from pre-dose baseline in RBC count|Change from pre-dose baseline in WBC count|Change from pre-dose baseline in Platelets count|Change from pre-dose baseline in Hemoglobin result|Change from pre-dose baseline in Creatine kinase result|Change from pre-dose baseline in Alanine aminotransferase (ALT) result|Time-weighted average changes in SARSCoV-2 RNA levels in nasopharyngeal swabs from baseline to Day 8|Duration of COVID-19 related symptoms through Day 29 among subjects with mild-moderate COVID-19|Proportion of subjects who have mild-moderate COVID-19 and develop severe COVID-19 after randomization|Assessment of PK parameters (Group A and B): maximum serum concentration observed (Cmax)""}"
"4961","Detection of SARS-CoV-2 (COVID-19) by SERS Spectroscopy Combined With Artificial Intelligence","Kaïssa Covid","NCT04786197","Kaïssa Covid","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04786197","Recruiting","2020-12-17","2021-12-31","{""locations"":""Groupe Hospitalier Paris Saint-Joseph, Paris, Ile De France, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""603"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Evaluate the performance in terms of sensitivity and specificity of the technique by spectral analysis combined with artificial intelligence for the SARS-CoV-2 virus versus to the reference technique by RT-qPCR|Evaluate the detection limit of the technique by spectral analysis combined with artificial intelligence""}"
"4962","COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection","","NCT04787510","895/23-12-2020","Drug: low molecular weight Heparin as standard of care treatment","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04787510","Recruiting","2020-12-23","2021-06-23","{""locations"":""University General Hospital of Ioannina, Io\u00e1nnina, Epirus, Greece"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""50"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""EFFECT OF COVID-19 DISEASE IN CLOTTING FACTORS""}"
"4963","Risk Factors for COVID-19 Mortality","RF-COVID","NCT04786808","RF-COVID-AUSLPC","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04786808","Recruiting","2021-01-15","2021-12-31","{""locations"":""Azienda USL di Piacenza, Piacenza, Emilia-Romagna, Italy"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Mortality rate|Need of invasive ventilation""}"
"4964","STRESS From in Charge Relative Facing the Announcement of Decisions Limiting or Stopping Treatments in Emergency Room During the COVID-19 Epidemic","COVER ACC","NCT04785807","69HCL20_0678","Other: Post traumatic, Anxiety and depression evaluation","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04785807","Not yet recruiting","2021-03-01","2022-01-01","{""locations"":"""",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""140"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Post traumatic syndrome evaluated thanks to the Revised impact event scale (IES-R)|Anxiety level at day 7, assessed using the Hospitalized Anxiety and Depression Scale-(HADS)|Depression level at day 7, assessed using the Hospitalized Anxiety and Depression Scale|Anxiety level at day 30, assessed using the Hospitalized Anxiety and Depression Scale (HADS)|Depression level at day 30, assessed using the Hospitalized Anxiety and Depression Scale (HADS)|Description of socio-demographic factors|Description of clinical factors""}"
"4965","Effects of Face Masks on Cardiopulmonary Capacity in Healthy Individuals","","NCT04785781","pamukkaleU:","Other: without masks|Other: Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|Other: FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04785781","Recruiting","2021-02-01","2021-04-15","{""locations"":""Pamukkale University, Denizli, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research"",""enrollment"":""16"",""age"":""18 Years to 30 Years \u00a0 (Adult)"",""outcome_measures"":""time to exhaustion|Mask comfort\/discomfort|heart rate|oxygen saturation|respiratory frequency""}"
"4966","The Effect of Laughter Therapy on Students in the COVID-19 Pandemic","","NCT04786483","2021/06","Other: Laughter Theraphy","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04786483","Active, not recruiting","2020-11-01","2021-05-10","{""locations"":""Zonguldak B\u00fclent Ecevit University, Zonguldak, Turkey"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research"",""enrollment"":""80"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""psychological well-being|life satisfaction|Psychological Well-being""}"
"4967","2019 NSECE COVID-19 Follow-up","","NCT04787614","HHSP233201500048I-CF","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04787614","Enrolling by invitation","2020-11-01","2021-06-30","{""locations"":""NORC at the University of Chicago, Chicago, Illinois, United States"",""study_designs"":""Observational Model: Ecologic or Community|Time Perspective: Prospective"",""enrollment"":""15200"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Impact of the COVID-19 pandemic on pre-pandemic supply of center-based care|Impact of the COVID-19 pandemic on pre-pandemic supply of paid home-based care""}"
"4968","Supporting Parents & Kids Through Lockdown Experiences (SPARKLE).","SPARKLE","NCT04786080","SPARKLE; REC #:HR-20/21-21451","Behavioral: Parent Positive","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04786080","Not yet recruiting","2021-03-15","2021-11-30","{""locations"":""King's College London, London, United Kingdom"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""616"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997) Conduct Problems|SDQ Conduct Problems|SDQ Emotional Problems|Parental child-related stress and worries levels|Family conflict|Depression, Anxiety and Stress Scale (DASS-21) parental psychological distress""}"
"4969","Perioperative Cognitive Trajectories in Deferred Surgery (CoTELE-SURGE)","CoTELE-SURGE","NCT04787536","10829","Procedure: Non-cardiac surgery","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04787536","Recruiting","2020-06-10","2022-12-31","{""locations"":""McMaster University, Hamilton, Ontario, Canada"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""300"",""age"":""65 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Change in perioperative cognitive trajectories assessed using the Cogstate Brief Battery (CBB)|Pain trajectories using the Numeric Pain Rating Scale|Depressive symptoms trajectories using the Geriatric Depression Scale (short form) (GDS)""}"
"4970","Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Law Enforcement Professionals With Risk Factors for Severity","COVACMANAUS","NCT04789356","CAAE: 44076721.5.0000.0005","Biological: Adsorbed SARS-CoV-2 (inactivated) vaccine","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04789356","Not yet recruiting","2021-03-15","2022-03-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""10156"",""age"":""18 Years to 49 Years \u00a0 (Adult)"",""outcome_measures"":""Incidence density of moderate and severe clinical cases of COVID-19|Incidence density of moderate and severe clinical cases of COVID-19 after first dose|Incidence density of moderate and severe clinical cases of COVID-19 after second dose|Incidence density of severe clinical cases of COVID-19 after second dose|Median of clinical progression scores between moderate and severe cases|Incidence density of clinical cases virologically confirmed as COVID-19|Mortality confirmed as COVID-19|Incidence density of hospitalizations for any cause|Mortality from any cause|Adverse events|Humoral and cell-mediated immune response|Detection of antibodies against SARS-CoV-2 in samples""}"
"4971","The Relationship Between Laboratory Features of Covid-19 Patients in the Hospital With Prognosis","","NCT04789460","COLAMOR","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04789460","Not yet recruiting","2021-03-05","2021-03-28","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality rate|need for intensive care unit rate|length stay in hospital""}"
"4972","Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","","NCT04788459","COV-1/2-01|2020-003734-20","Biological: COVID-eVax|Device: Cliniporator® and EPSGun","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04788459","Recruiting","2021-02-25","2022-06-01","{""locations"":""San Gerardo Hospital, Monza, Italy|Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy|INMI Lazzaro Spallanzani, Rome, Italy"",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention"",""enrollment"":""160"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Incidence of solicited local Adverse events (AEs) at the injection site (for Phase 1)|Incidence of solicited systemic AEs (for Phase 1)|Incidence of unsolicited AEs (for Phase 1)|White Blood Cell (WBC) levels (for Phase 1)|Red Blood Cell (RBC) levels (for Phase 1)|Platelets levels (for Phase 1)|Alanine Transaminase (ALT) levels (for Phase 1)|Aspartate Transaminase (AST) levels (for Phase 1)|Creatine Phosphokinase (CPK) levels (for Phase 1)|Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 2)|SARS-CoV-2 neutralizing antibody titer (for Phase 2)|Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 2)|Percentage of subjects who seroconverted (for Phase 2)|Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 1)|SARS-CoV-2 neutralizing antibody titer (for Phase 1)|Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 1)|Percentage of subjects who seroconverted (for Phase 1)|Incidence of solicited local AEs at the injection site (for Phase 2)|Incidence of solicited systemic AEs (for Phase 2)|Incidence of unsolicited AEs (for Phase 2)|White Blood Cell (WBC) levels (for Phase 2)|Red Blood Cell (RBC) levels (for Phase 2)|Platelets levels (for Phase 2)|Alanine Transaminase (ALT) levels (for Phase 2)|Aspartate Transaminase (AST) levels (for Phase 2)|Creatine Phosphokinase (CPK) levels (for Phase 2)""}"
"4973","Respiratory Muscle Strength in Volleyball Players Suffering From Covid-19","","NCT04789512","2021-189","Other: Respiratory functions","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04789512","Recruiting","2021-03-01","2021-03-20","{""locations"":""Gazi University, Ankara, \u00c7ankaya, Turkey"",""study_designs"":""Observational Model: Case-Control|Time Perspective: Prospective"",""enrollment"":""40"",""age"":""15 Years to 35 Years \u00a0 (Child, Adult)"",""outcome_measures"":""Respiratory muscle strength|FEV1|FVC|FEV1\/FVC|PEF|FEF2575|Fat mass|Fat mass percent|Fat-free mass|Body mass index|Predicted muscle mass|Symptom severity perceptions|Performance situations perceptions""}"
"4974","Psychological Impact of Covid-19 Assiut University Hospital Experience","","NCT04789226","Psychology and covid 19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04789226","Not yet recruiting","2021-03-01","2022-03-01","{""locations"":"""",""study_designs"":""Observational Model: Other|Time Perspective: Prospective"",""enrollment"":""239"",""age"":""18 Years to 90 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Symptom Checklist 90 \""SCL 90\""|post traumatic stress disorder \""PTSD\""|Pittsburgh Sleep Quality Index \""PSQI\""|The 36- items Short Form\""SF 36\""""}"
"4975","Evaluation of Prognosis of COVID-19 Patients With Only CT Findings, Only RT-PCR Positivity and Both of Them Positive","","NCT04789447","COP-19","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04789447","Recruiting","2021-03-04","2021-03-28","{""locations"":""Sultan Abd\u00fclhamid Han Training and Research Hospital, Istanbul, Turkey|Sultan Abd\u00fclhamid Han Training and Research Hospital, Istanbul, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""1200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""mortality|need for intensive care|length stay""}"
"4976","Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts","PENTZ","NCT04788407","FH-53","Drug: Nitazoxanide|Drug: Placebo","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04788407","Recruiting","2020-12-01","2021-04-30","{""locations"":""Fundaci\u00f3n Hu\u00e9sped., Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"",""enrollment"":""456"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""The proportion of subjects with laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study|Proportion of adverse events (AE) and serious AE (SAE) related to research product.|Incidence of all causes of study drug withdrawal or discontinuation.""}"
"4977","Evaluation of Post-covid 19 Patients Who Receive Ozonetheraphy With Thorax CT","","NCT04789395","08.092.r1.125","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04789395","Recruiting","2020-09-02","2021-12-20","{""locations"":""Gaziosmanpa\u015fa TREH, Istanbul, Gaziosmanpa\u015fa, Turkey"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""25"",""age"":""18 Years to 80 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""prevention of pulmonary fibrosis in covid 19 pneumonia patients with ozone therapy""}"
"4978","Effects of Using Mask During the 6-minute Walking Test in Times of COVID-19","","NCT04789603","CBAS-2020-03","Other: 6-min-walk surgical mask|Other: 6-min-walk Fpp2|Other: 6-min-walk without mask","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04789603","Not yet recruiting","2021-03-09","2021-04-10","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research"",""enrollment"":""50"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""6 minutes walk test (minutes)|Dyspnea using the visual analogue scale (VAS) (cms)|Heart Rate (b\/min)|Transcutaneous oxygen saturation (% of saturation)|Frequency Muscle tone with MyotonePRO device (Hz)|Dynamic Stiffness Muscle tone with MyotonePRO device (N\/m)|Muscle viscoelasticy with MyotonePRO device (ms)""}"
"4979","Renal Involvement in Hospitalized Children With COVID-19","RIHCC","NCT04788394","MRC01-21-089","Other: To determine the prevalence of renal dysfunction in hospitalized children with COVID19 in Qatar.","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04788394","Recruiting","2021-03-01","2021-12-31","{""locations"":""Hamad General corporation, Doha, Qatar"",""study_designs"":""Observational Model: Other|Time Perspective: Retrospective"",""enrollment"":""500"",""age"":""up to 14 Years \u00a0 (Child)"",""outcome_measures"":""determine the prevalence of renal dysfunction in hospitalized children with COVID19 in Qatar.""}"
"4980","Smell in Covid-19 and Efficacy of Nasal Theophylline","SCENT2","NCT04789499","202101190","Drug: Nasal Irrigation","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04789499","Recruiting","2021-03-01","2021-12-01","{""locations"":""Washington University School of Medicine in Saint Louis, Saint Louis, Missouri, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""50"",""age"":""18 Years to 70 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical Global Impression Scale|University of Pennsylvania Smell Identification Test (UPSIT)|Questionnaire for Olfactory Dysfunction (QOD)|36-Item Short Form Health Survey (SF-36)|Olfactory Dysfunction Outcomes Rating (ODOR)""}"
"4981","Prevention of Complications (SARS-CoV-2): Clinical Study","","NCT04788355","HA and A COVID 19","Drug: Control group (standard hospital treatment)|Drug: Group Hydroxychloroquine|Drug: Group Hydroxychloroquine and apixaban|Drug: Group Apixaban","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04788355","Completed","2020-07-01","2020-12-23","{""locations"":""Univ\u00e1s, Pouso Alegre, Minas Gerais, Brazil"",""study_designs"":""Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""176"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Patients in home isolation will be followed for (telemedicine) 14 days. The Beck scale will assess anxiety. Questions will be asked to patients about their health conditions. The answers will be tabulated in a spreadsheet composed of the following result|Assessment of the presence or absence of secondary complications for patients in home isolation or hospitalized, after using the drugs.""}"
"4982","Registry of Coronavirus Complications - CORRELATION WITH GLYCOMIC PROFILE","ROCCO","NCT04788433","ROCCO-197/2020","Diagnostic Test: glycomic analysis|Other: Phone interview","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04788433","Recruiting","2021-03-04","2022-03-31","{""locations"":""Aast Papa Giovanni Xxiii, Bergamo, Italy"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""615"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Glycomic profile as predictor of long-term morbidity""}"
"4983","Physical Training and Diet for Childhood Obesity","","NCT04789525","Obesity","Other: High-intensity aerobic training with high protein diet","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04789525","Completed","2020-03-10","2020-12-25","{""locations"":""Marwa Eid, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment"",""enrollment"":""76"",""age"":""5 Years to 12 Years \u00a0 (Child)"",""outcome_measures"":""Body mass index""}"
"4984","Evaluation of Monoclonal Antibodies in COVID-19","","NCT04790786","STUDY21020179","Biological: Lilly Bamlanivimab|Biological: Regeneron Casirivimab + Imdevimab|Biological: Lilly Bamlanivimab + Etesevimab","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04790786","Not yet recruiting","2021-03-01","2022-12-30","{""locations"":""UPMC, Pittsburgh, Pennsylvania, United States"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""5000"",""age"":""18 Years to 120 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Alive and Free from Hospitalization|All-location mortality at 90 days|All-location mortality at 28 days|All-cause mortality at 28 days|All-cause mortality at 90 days|Organ-support free days at day 28|SARS-CoV-2 nasopharyngeal viral loads|SARS-CoV-2 plasma viral loads|SARS-CoV-2 antibody titers|SARS-CoV-2 antibody neutralization|SARS-CoV-2 immune responses|Detection of SARS-CoV-2 variants through next-generation sequencing|Duration of SAR-CoV-2 infectivity|Non-culture surrogates for SARS-CoV-2 infectivity""}"
"4985","COVID-19 Prevalence in UNIVI Geriatric Institutions: Epidemiological Study of Immunological Status With Rapid Serological Tests","","NCT04790994","2020-A01838-31","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04790994","Active, not recruiting","2020-07-24","2021-04-16","{""locations"":""CentreM\u00e9dicalPorteVerte, Versailles, France"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""1145"",""age"":""Child, Adult, Older Adult"",""outcome_measures"":""Among asymptomatic residents and caregivers in French nursing homes and geriatric healthcare institutions belonging to the UNIVI Group: prevalence of covid 19|Exposure to SARS Cov-2 Among asymptomatic residents and caregivers in French nursing homes and geriatric healthcare institutions belonging to the UNIVI Group|Recurrence of Covid-19 at 1, 3 and 6 months among residents and caregivers who had at least on positive test at inclusion (RT-PCR test or NB Biotech rapid serological test)|Risk factors for Covid-19 infection in caregivers|Covid-19 symptoms among residents|Prevalence of Covid-19 at 3 months""}"
"4986","Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)","COVID","NCT04790240","CHM2282395-1","Dietary Supplement: Inflammation (I)|Dietary Supplement: Inflammation (II)|Dietary Supplement: Inflammation (III)|Drug: Standard of care","Interventional","No Results Available","Phase 1|Phase 2","https://ClinicalTrials.gov/show/NCT04790240","Recruiting","2021-02-01","2023-03-01","{""locations"":""All Natural Medicine Clinic, LLC, Rockville, Maryland, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""120"",""age"":""10 Years to 70 Years \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""recovering damaged organ|inhibiting inflammation|preventing the antibody depositing on antigen|monitoring the antibody level|correcting reversed immunity ratio|tracking the COVID virus marks""}"
"4987","Tele-coaching in Patients With COVID-19","","NCT04791072","IKCSS","Other: Exercise","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04791072","Not yet recruiting","2021-03-01","2021-03-01","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""36"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Exercise Capacity|Dyspnea Assessment|Quality of Life Assessment|Anxiety and Depression""}"
"4988","Study of GRAd-COV2 for the Prevention of COVID-19 in Adults","COVITAR","NCT04791423","RT-CoV-2_01","Biological: GRAd-COV2|Other: Placebo","Interventional","No Results Available","Phase 2|Phase 3","https://ClinicalTrials.gov/show/NCT04791423","Not yet recruiting","2021-02-28","2022-04-30","{""locations"":""Istituto per le Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, RM, Italy|A.O. Sant'Anna E San Sebastiano Caserta, Caserta, Italy|Asst Di Cremona, Cremona, Italy|Azienda Ospedaliero-Universitaria Di Ferrara, Ferrara, Italy|Ao Ospedali Riuniti - Foggia, Foggia, Italy|E.O. Ospedali Galliera, Genova, Italy|Presidio Ospedaliero Nord-Ospedale Santa Maria Goretti Latina, Latina, Italy|Fondaz.Irccs Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|Asst Fatebenefratelli Sacco, Milano, Italy|Ospedale S.Gerardo - Monza, Monza, Italy|Azienda Ospedaliera Dei Colli - P Cotugno, Napoli, Italy|Azienda Ospedaliera Universitaria Della Universita' Vanvitelli I Di Napoli, Napoli, Italy|Az.Osp.Univ.P.Giaccone, Palermo, Italy|Azienda Ospedaliero-Universitaria Di Parma, Parma, Italy|Policlinico S. Matteo - Pavia, Pavia, Italy|Azienda Usl Di Piacenza, Piacenza, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Policlinico A. Gemelli E C.I.C.- Policlinico Universitario A. Gemelli, Roma, Italy|Ospedale Amedeo Di Savoia, Torino, Italy|Azienda Sanitaria Universitaria Integrata Di Trieste, Trieste, Italy|Asst Dei Sette Laghi, Varese, Italy|Ospedale Unico Del Vercellese - Ospedale Sant'Andrea, Vercelli, Italy|Az.Osp.Universitaria Integrata Verona, Verona, Italy"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""10300"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Number of participants with symptomatic laboratory confirmed COVID-19|Incidence of AEs, SAEs, MAAEs, and AESI|Incidence of local and systemic solicited AEs|Post-treatment GMTs in SARS-CoV2 S and\/or RBD antibodies|Post-treatment GMFRs in SARS-CoV2 S and\/or RBD antibodies|Proportion of participants with post-treatment seroresponse (> 4-fold rise in titers) to the S and\/or RBD antigens of GRAd-COV2|Time to first SARS-CoV2 RT-PCR positive severe or critical symptomatic illness|Proportion of participants who have a post-treatment response for SARS-COV2 Nucleocapside antibodies|Time to first case of SARS-COV2 RT-PCR positive symptomatic illness using CDC criteria|Time to first COVID-19 related Emergency Department admission|Time to COVID-19 related death|Post-treatment GMTs in SARS-CoV-2 S and\/or RBD antibodies|Post-treatment GMFRs in SARS-CoV-2 S and\/or RBD antibodies|Proportion of participants who have a post-treatment seroresponse (\u2265 4-fold rise in titers) in S and\/or RBD antigens of GRAd-COV2.|Post-treatment GMTs in SARS-CoV2 S neutralizing antibodies|Post-treatment GMFRs in SARS-CoV2 S neutralizing antibodies|Proportion of participants with post-treatment seroresponse (> 4-fold rise in titers) in SARS-COV2 neutralizing antibodies""}"
"4989","Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients","","NCT04792021","N-acetylcysteine in COVID 19","Drug: N-acetylcysteine","Interventional","No Results Available","Phase 3","https://ClinicalTrials.gov/show/NCT04792021","Recruiting","2021-03-09","2021-11-01","{""locations"":""Al Assema Hospital, Cairo, Egypt"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in TNF alfa level from baseline|Change in IL-6 level from baseline|Change in glutathione peroxidase level from baseline|Length of hospital stay|Need for mechanical ventilation""}"
"4990","Investigation of Stress Levels and Lifestyle of a Sample of Greek General Surgeons in Covid-19","","NCT04791085","1183/17.02.21","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04791085","Recruiting","2021-02-08","2021-05-08","{""locations"":""Sismanoglio-Amalia Fleming Hospital, Athens, Melissia, Greece"",""study_designs"":""Observational Model: Other|Time Perspective: Cross-Sectional"",""enrollment"":""200"",""age"":""23 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Perceived Stress Scale (PSS)|DASS-21|PITTSBURGH (GR-PSQI)|Healthy Lifestyle and Personal Control Questionnaire|Multi dimensional Health Locus of Control (MHLC)|COVID-19-Anxiety Questionnaire (C-19-A)""}"
"4991","Oral and Olfactory Complications of Recovered COVID-19 Patients","","NCT04791436","OORCV","Diagnostic Test: Gustatory and olfactory function test|Diagnostic Test: Molecular assessment of saliva","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04791436","Not yet recruiting","2021-03-01","2022-02-28","{""locations"":"""",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""402"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Periodontal health|Oral mucocutaneous lesions|Gustatory function|Olfactory function""}"
"4992","COVID-19 in Osteoarthritis Patients","","NCT04791462","RECHMPL21_0109","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04791462","Not yet recruiting","2021-03-10","2021-12-30","{""locations"":""Uhmontpellier, Montpellier, France"",""study_designs"":""Observational Model: Case-Only|Time Perspective: Prospective"",""enrollment"":""500"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Assessing the state of post-traumatic stress|To evaluate the level of anxiety\/depression|To evaluate the level of stress perceived|To evaluate the level of physical activity|Assess demographic influencing perceived stress, anxiety\/depression, physical activity, post-traumatic stress disorder""}"
"4993","Disease Containment Measures Among Older Adults During the Covid-19 Pandemia","Co-AiT","NCT04792086","COVID19-AIT","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04792086","Recruiting","2021-02-18","2024-12-31","{""locations"":""Norwegian National Advisory Unit of Ageing and Health, T\u00f8nsberg, Norway"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""12000"",""age"":""70 Years and older \u00a0 (Older Adult)"",""outcome_measures"":""Use of Health care services|Use of psychotropic medications|Montreal Cognitive Assessment scale|CERAD Ten-words test|Incidence of dementia diagnosis|Incidence of mild cognitive impairment""}"
"4994","Evaluation of Immunogenicity and Safety of Combined Immunization of COVIV and PPV23 / IIV4","","NCT04790851","COVIV-PPV23-IIV4-Combine","Biological: COVIV+IIV4; COVIV+PPV23|Biological: COVIV only (1st and 2nd dose)|Biological: IIV4 for the 1st dose and PPV23 for the 2nd dose","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04790851","Recruiting","2021-02-23","2021-12-01","{""locations"":""Sichuan Center for Disease Control and Prevention, Chengdu, China|Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China|Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""1152"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Seroconversion rate (COVIV)|Neutralizing antibody level (COVIV)|Seroconversion rate (IIV4)|Neutralizing antibody level (IIV4)|Seroconversion rate (PPV23)|Adverse events following vaccination""}"
"4995","A Check-list Including Lung Ultrasound for ED Patients With ARF","CHECKIRA-COVID","NCT04791241","CHMS20005","Other: check-list including lung ultrasound","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04791241","Recruiting","2021-03-03","2021-05-04","{""locations"":""CH Annecy Genevois, Annecy, France|Centre Hospitalier Metropole Savoie, Chamb\u00e9ry, France|CHUGA, Grenoble, France"",""study_designs"":""Allocation: N\/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic"",""enrollment"":""105"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Agreement between the etiology retained after using the checklist and the diagnosis retained by an adjudication committee after analysis of the entire patient file.|Analysis of the diagnosis retained after the checklist in patients with a final diagnosis of COVID-19; analysis of the final diagnosis in patients with a diagnosis of COVID-19 evoked after the checklist|Collection of treatments started only after completion of the checklist and verification of its suitability for the diagnosis selected|Collection of additional examinations possibly performed in the emergency unit after the completion of the checklist|Comparison of treatments introduced after completion of the checklist and after the other additional examinations performed at the emergency room|Delay between completion of the checklist and obtaining the results of any other examinations""}"
"4996","Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico","","NCT04793243","CI-07620","Dietary Supplement: Vitamin D3","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04793243","Completed","2020-08-17","2020-10-24","{""locations"":""Universidad de Guadalajara, Guadalajara, Jalisco, Mexico"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care"",""enrollment"":""42"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Baseline levels of serum vitamin D in COVID-19 patients|Correlation between D-dimer and vitamin D serum levels in COVID-19 patients|Correlation between transferrin and vitamin D serum levels in COVID-19 patients|Correlation between ferritin and vitamin D serum levels in COVID-19 patients|Effects of vitamin D3 supplementation on COVID-19 patients""}"
"4997","Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients","","NCT04793984","COVID-19/TCP_20_05","Device: Carragelose|Device: NaCl","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04793984","Recruiting","2021-03-08","2021-10-30","{""locations"":""Gesundheitsverbund, Klinik Floridsdorf, Vienna, Austria"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"",""enrollment"":""228"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Clinical status of subjects as expressed on the WHO-8-Category ordinal scale:|Cycle threshold of SARS-CoV-2 PCR\u00b7|multiplex viral examination|supplemental oxygen requirement|modified 10 point BORG scale""}"
"4998","Characteristics of Long COVID-19 Syndrome","","NCT04793269","2021-00280","Other: No intervention","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04793269","Recruiting","2021-02-23","2024-04-30","{""locations"":""University Hospital Zurich, Zurich, Switzerland"",""study_designs"":""Observational Model: Cohort|Time Perspective: Retrospective"",""enrollment"":""200"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Dyspnea|self-addressed Quality of life|Thoracic pain|Medical history|Fibrosis|Myocardial damage""}"
"4999","Myocardial Injury and Quality of Life After COVID-19","","NCT04794062","08092020","","Observational","No Results Available","","https://ClinicalTrials.gov/show/NCT04794062","Recruiting","2020-09-16","2021-12-31","{""locations"":""Voronezh Region Clinical, Consultative and Diagnostic Center, Voronezh, Voronezh Region, Russian Federation"",""study_designs"":""Observational Model: Cohort|Time Perspective: Prospective"",""enrollment"":""100"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Proportion of patients (%) recovered from COVID-19 with signs of myocardial injury on cardiac magnetic resonance imaging.|Proportion of patients (%) recovered from COVID-19 with signs of myocardial injury on echocardiography.|Evaluation of quality of life of the patients recovered from the COVID-19 by the means of EQ-5D questionnaire.|Evaluation of quality of life of the patients recovered from the COVID-19 by the means of EQ-5D visual analogue scale.|Evaluation of quality of life of the patients recovered from the COVID-19 by the Duke Activity Status Index.""}"
"5000","Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients","INVENT COVID","NCT04794088","INVENT COVID","Drug: Imatinib Mesylate intravenous solution|Drug: Placebo","Interventional","No Results Available","Phase 2","https://ClinicalTrials.gov/show/NCT04794088","Not yet recruiting","2021-03-01","2022-02-01","{""locations"":""Amsterdam Universitair Medische Centra, location VUmc, Amsterdam, Noord-Holland, Netherlands|Amsterdam Universitair Medische Centra, location AMC, Amsterdam, Noord-Holland, Netherlands"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""90"",""age"":""18 Years and older \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in extravascular lung water index|Pulmonary vascular permeability|PaO2\/FiO2 ratio as measure of gas-exchange|Oxygenation index as measure of gas-exchange|Driving pressure as an indicator of global lung strain|Compliance as a measure of respiratory mechanics|Mechanical power as quantification of the energy load delivered to the lung per positive pressure breath|Pro-inflammatory cytokines|Matrix metalloproteinases as markers of inflammation|D-dimer as an inflammatory biomarker|Angiopoietin-1 and -2 as biomarkers of endothelial activation and injury|Soluble thrombomodulin as a biomarker of endothelial activation and injury|Surfactant as biomarker of lung epithelial injury|Protein biomarkers of lung epithelial injury|SOFA score as organ function and outcome measure|WHO ordinal scale for clinical improvement as functional outcome measure|Morbidity and mortality outcomes|28-day mortality|Hemoglobin cell count as drug safety parameter|Blood cell count as drug safety parameter|Serum creatinine as measure of kidney function|Estimated glomerular filtration rate as measure of kidney function|Electrolytes as drug safety parameters|Liver enzymes as drug safety parameter|Serum bilirubin as drug safety parameter|NT-proBNP as drug safety parameter|Reporting of adverse and serious adverse events|Corrected QT interval on ECG|Total concentration as a pharmacokinetic measure of imatinib|Free fraction as a pharmacokinetic measure of imatinib|Imatinib metabolite AGP|Imatinib metabolite albumin|Thoracic ultrasound""}"
"5001","Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patient","","NCT04794036","COVID-19_TRHB","Other: Asynchronous telerehabilitation programme|Other: Rehabilitation programme","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04794036","Not yet recruiting","2021-03-08","2021-09-30","{""locations"":"""",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""32"",""age"":""18 Years to 75 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Fatigue Severity Level|Adherence|Satisfaction level|Incidents|Maximum Leg Strength Endurance|Maximum Arm Strength Endurance|Maximum Aerobic Capacity Walking|Post-COVID-19 Functional Status|Depression, Anxiety and Stress|Self-efficacy|Quality of Life Assessment""}"
"5002","Microbiome Therapy in Covid-19 Primary Care Support","MiCel","NCT04793997","B3002021000018","Biological: Microbiome spray|Biological: Placebo spray","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04793997","Recruiting","2021-02-01","2022-02-01","{""locations"":""Veronique Verhoeven, Antwerp, Belgium"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"",""enrollment"":""150"",""age"":""18 Years to 65 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Change in severity of COVID-19 infection symptoms after using microbiome spray|Change in duration of COVID-19 infection symptoms after using microbiome spray|Change in absolute numbers of SARS-CoV-2 after using microbiome spray|Change in absolute numbers of specific bacterial pathogens after using microbiome spray|Change in microbiome of nose\/throat region after using microbiome spray.|Prevalence of antibodies against SARS-CoV-2 in the index patients' household members|Prevalence of COVID-19 in the index patients' household members""}"
"5003","Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","AMA-VACC","NCT04792567","CBAF312ADE03|2020-005752-38","Drug: BAF312|Drug: Baseline disease modifying therapies (DMTs)","Interventional","No Results Available","Phase 4","https://ClinicalTrials.gov/show/NCT04792567","Not yet recruiting","2021-03-15","2022-04-01","{""locations"":"""",""study_designs"":""Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"",""enrollment"":""60"",""age"":""18 Years to 100 Years \u00a0 (Adult, Older Adult)"",""outcome_measures"":""Percentage of participants achieving seroconversion after receiving a modRNA vaccine|SARS-CoV-2 serum functional antibody levels over time|T-cell response to modRNA vaccines over time|Number of treatment emergent adverse events, serious adverse events and COVID-19 infections""}"
"5004","Healthy Oregon: Together We Can","OSJP","NCT04793464","10032020.002|P50DA048756-02S2","Behavioral: Promotores de Salud|Behavioral: Services as usual","Interventional","No Results Available","Not Applicable","https://ClinicalTrials.gov/show/NCT04793464","Recruiting","2021-02-04","2021-08-31","{""locations"":""University of Oregon, Eugene, Oregon, United States"",""study_designs"":""Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention"",""enrollment"":""3600"",""age"":""3 Years and older \u00a0 (Child, Adult, Older Adult)"",""outcome_measures"":""Latinx testing engagement|COVID-19 Prevention Health Behaviors|COVID-19 Knowledge and Attitudes|Attitudes Towards COVID-19 Vaccines""}"